PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Apte, SS; Fukai, N; Beier, DR; Olsen, BR				Apte, SS; Fukai, N; Beier, DR; Olsen, BR			The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE; MOLECULAR-CLONING; PROGELATINASE-A; ACTIVATION; SURFACE; 72-KDA; CELLS; FIBROBLASTS; LOCATION; DOMAIN	The matrix metalloproteinases (MMPs) are a family of zinc-containing matrix degrading endopeptidases. A subfamily of membrane type (MT) -MMPs has been described recently. We have determined the structure of the gene (Mmp14) encoding the first MT-MMP to be described, MT1-MMP (MMP-14), and mapped it to mouse chromosome 14. The mouse MMP-14 protein is encoded by ten exons. The novel C-terminal peptide domains of MMP-14 are encoded by a single large exon that also encodes the 3'-untranslated region, The structure of the exons encoding the catalytic domain and pro domain of MMP-14 is distinct from previously described MMP genes, whereas the exons encoding the hemopexin-like domains are similar to those of most other MMP genes. Mmp14 and the gene for tissue inhibitor of metalloproteinases-2 (Timp2) show a temporally and spatially coregulated expression during mouse development. They are co-expressed during vascular and urogenital development and during the development of osteocartilaginous and musculotendinous structures. The stringent co-expression of these two genes suggests common regulatory pathways that may have important functional implications for the activation of pro-gelatinase A in health and disease.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Apte, SS (corresponding author), CLEVELAND CLIN FDN,DEPT BIOMED ENGN,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR 44436, AR36819, AR36820] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036819, R01AR036820, R01AR044436, R29AR044436, R37AR036820, R01AR036819, R56AR036819] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BLAVIER L, 1997, IN PRESS MOL BIOL CE, V8; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; COLLIER IE, 1988, J BIOL CHEM, V263, P10711; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; FUKAI N, 1994, METHOD ENZYMOL, V245, P3; GAIRE M, 1994, J BIOL CHEM, V269, P6600; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Imai K, 1996, CANCER RES, V56, P2707; KIDWELL JF, 1961, J HERED, V52, P145, DOI 10.1093/oxfordjournals.jhered.a107050; KONOH H, 1996, J CELL SCI, V109, P953; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mattei MG, 1997, GENOMICS, V40, P168, DOI 10.1006/geno.1996.4559; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PENDAS AM, 1995, GENOMICS, V26, P615, DOI 10.1016/0888-7543(95)80186-P; PENDAS KAM, 1997, GENOMICS, V40, P222; Puente XS, 1996, CANCER RES, V56, P944; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; REPONEN P, 1992, J BIOL CHEM, V267, P7856; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, GENOMICS, V39, P412, DOI 10.1006/geno.1996.4496; Sato T, 1997, J CELL SCI, V110, P589; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Taylor B.A, 1978, ORIGINS INBRED MICE; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Yang MZ, 1996, J BIOL CHEM, V271, P25548, DOI 10.1074/jbc.271.41.25548	41	115	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25511	25517		10.1074/jbc.272.41.25511	http://dx.doi.org/10.1074/jbc.272.41.25511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325265	hybrid			2022-12-27	WOS:A1997YA35800020
J	Blain, SW; Montalvo, E; Massague, J				Blain, SW; Montalvo, E; Massague, J			Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) with cyclin A-Cdk2 and cyclin D2-Cdk4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; FIBROBLAST CELL-CYCLE; GROWTH-FACTOR-BETA; G1 PHASE; TGF-BETA; POTENTIAL MEDIATOR; ACTIVATING KINASE; MAMMALIAN-CELLS; MICE LACKING; P21	Although p27(Kip1) has been considered a general inhibitor of G(1) and S phase cyclin-dependent kinases, we report that the interaction of p27 with two such kinases, cyclin A-Cdk2 and cyclin D-Cdk4, is different. In Mv1Lu cells containing a p27 inducible system, a 6-fold increase over the basal p27 level completely inhibited Cdk2 and cell cycle progression. In contrast, the same or a larger increase in p27 levels did not inhibit Cdk4 or its homologue Cdk6, despite extensive binding to these kinases. A p27-cyclin A-Cdk2 complex formed in vitro was essentially inactive, whereas a p27-cyclin D2-Cdk4 complex was active as a retinoblastoma kinase and served as a substrate for the Cdk-activating kinase Cak. High concentrations of p27 inhibited cyclin D2 Cdk4, apparently by conversion of active complexes into inactive ones by the binding of additional p27 molecules. In contrast to their differential interaction, cyclin A-Cdk2 and cyclin D2-Cdk4 were similarly inhibited by bound p21(Cip1/Waf1). Roles of cyclin A-Cdk2 as a p27 target and cyclin D2-Cdk4 as a p27 reservoir may result from the differential ability of bound p27 to inhibit the kinase subunit in these complexes.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	73	241	268	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25863	25872		10.1074/jbc.272.41.25863	http://dx.doi.org/10.1074/jbc.272.41.25863			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325318	hybrid			2022-12-27	WOS:A1997YA35800073
J	GarciaCardena, G; Martasek, P; Masters, BSS; Skidd, PM; Couet, J; Li, SW; Lisanti, MP; Sessa, WC				GarciaCardena, G; Martasek, P; Masters, BSS; Skidd, PM; Couet, J; Li, SW; Lisanti, MP; Sessa, WC			Dissecting the interaction between nitric oxide synthase (NOS) and caveolin - Functional significance of the NOS caveolin binding domain in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCULAR-DYSTROPHY; ESCHERICHIA-COLI; PROTEIN; CELLS; PALMITOYLATION; PURIFICATION; ASSOCIATION; EXPRESSION; SARCOLEMMA; MEMBRANES	Endothelial nitric oxide synthase (eNOS) is a dually acylated peripheral membrane protein that targets to the Golgi region and caveolae of endothelial cells. Recent evidence has shown that eNOS can co-precipitate with caveolin-1, the resident coat protein of caveolae, suggesting a direct interaction between these two proteins, To test this idea, we examined the interactions of eNOS with caveolin-1 in vitro and in vivo. Incubation of endothelial cell lysates or purified eNOS with glutathione S-transferase (GST)-caveolin-1 resulted in the direct interaction of the two proteins. Utilizing a series of GST-caveolin-1 deletion mutants, we identified two cytoplasmic domains of caveolin-1 that interact with eNOS, the scaffolding domain (amino acids 61-101) and to a lesser extent the C-terminal tail (amino acids 135-178). Incubation of pure eNOS with peptides derived from the scaffolding domains of caveolin-1 and -3, but not the analogous regions from caveolin-2, resulted in inhibition of eNOS, inducible NOS (iNOS), and neuronal NOS (nNOS) activities. These results suggest a common mechanism and site of inhibition. Utilizing GST-eNOS fusions, the site of caveolin binding was localized between amino acids 310 and 570. Site-directed mutagenesis of the predicted caveolin binding motif within eNOS blocked the ability of caveolin-1 to suppress NO release in co-transfection experiments. Thus, our data demonstrate a novel functional role for caveolin-1 in mammalian cells as a potential molecular chaperone that directly inactivates NOS. This suggests that the direct binding of eNOS to caveolin-1, per se, and the functional consequences of eNOS targeting to caveolae are likely temporally and spatially distinct events that regulate NO production in endothelial cells. Additionally, the inactivation of eNOS and nNOS by the scaffolding domain of caveolin-3 suggests that eNOS in cardiac myocytes and nNOS in skeletal muscle are likely subject to negative regulation by this muscle-specific caveolin isoform.	YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT PHARMACOL, NEW HAVEN, CT 06536 USA; UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA	Yale University; University of Texas System; University of Texas Health San Antonio; Yeshiva University; Albert Einstein College of Medicine			Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011; Lisanti, Michael/B-6131-2018; Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013; Martasek, Pavel/G-6622-2017	Sessa, William C/0000-0001-5759-1938; Lisanti, Michael/0000-0003-2034-1382; Li, Shengwen Calvin/0000-0002-9699-9204; Couet, Jacques/0000-0001-5409-8689; Martasek, Pavel/0000-0001-6165-4444	NCI NIH HHS [F32 CA071326] Funding Source: Medline; NHLBI NIH HHS [HL57665, HL51948] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R29HL051948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FREY C, 1994, J BIOL CHEM, V269, P26083; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, CELL MOL BIOL, V43, P293; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	27	667	687	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25437	25440		10.1074/jbc.272.41.25437	http://dx.doi.org/10.1074/jbc.272.41.25437			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325253	hybrid			2022-12-27	WOS:A1997YA35800008
J	Heimburg, T; Esmann, M; Marsh, D				Heimburg, T; Esmann, M; Marsh, D			Characterization of the secondary structure and assembly of the transmembrane domains of trypsinized Na,K-ATPase by Fourier transform infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; SARCOPLASMIC-RETICULUM; SQUALUS-ACANTHIAS; RECTAL GLANDS; ATPASE; NA+,K+-ATPASE; PROTEINS; SEQUENCE; SODIUM; (NA++K+)-ATPASE	Fourier transform infrared spectroscopy has been used to compare native Na,K-ATPase-containing membranes with those trypsinized in the presence of either Rb+ or Na+ ions to remove the extramembranous parts of the protein, The protein secondary structure content deduced from the amide I band is approximately 30-35% alpha-helix, 37-40% beta-structure, and 13-15% random coli for native membranes from shark rectal gland and from pig kidney, in both the Na- and K-forms. Trypsinization in either Rb+ (a K+ congener) or Na+ removes approximately 35% of the amide I band intensity of native membranes from shark rectal gland. The protein secondary structural content of the trypsinized membranes lies in the range of approximately 23-32% alpha-helix, 37-46% beta-structure, and 12-18% random coil for the shark and kidney enzymes. The distribution of intensity between the bands corresponding to protonated and deuterium-exchanged alpha-helices, and between the component bands attributed to beta-structure, changes considerably on trypsinization, in the direction of a greater proportion of protonated alpha-helix and a broader range of frequencies for beta-structure. The kinetics of deuteration of the slowly exchanging population of protein amide groups is also changed on trypsinization, The mean rate constant for deuteration of trypsinized membranes is approximately half that for native membranes, whereas the proportion of amides contributing to this population increases on trypsinization. The temperature dependence of the amide I band in the Fourier transform infrared spectra indicates that the onset of thermal denaturation occurs at 58 degrees C for native membranes (in either Na+ or K+) and for membranes trypsinized in Rb+, but the major denaturation event for membranes trypsinized in Na+ occurs at approximately 84 degrees C. These results correlate with the functional properties of the intramembranous section of the enzyme.	MAX PLANCK INST BIOPHYS CHEM,ABT SPECKTROSKOPIE,D-37077 GOTTINGEN,GERMANY; AARHUS UNIV,DEPT BIOPHYS,DK-8000 AARHUS C,DENMARK	Max Planck Society; Aarhus University			Heimburg, Thomas/AAA-7726-2022; Heimburg, Thomas R/I-5064-2014	Heimburg, Thomas R/0000-0003-4599-4582				ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHETVERIN AB, 1985, J BIOL CHEM, V260, P7817; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; CORBALANGARCIA S, 1994, BIOCHEMISTRY-US, V33, P8247, DOI 10.1021/bi00193a011; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; ESMANN M, 1988, BIOCHIM BIOPHYS ACTA, V940, P71, DOI 10.1016/0005-2736(88)90009-0; ESMANN M, 1987, BIOCHEMISTRY-US, V26, P8675, DOI 10.1021/bi00400a028; ESMANN M, 1994, BIOCHEMISTRY-US, V33, P3693, DOI 10.1021/bi00178a028; ESMANN M, 1994, BIOCHEMISTRY-US, V33, P8044, DOI 10.1021/bi00192a008; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HEIMBURG T, 1993, BIOPHYS J, V65, P2408, DOI 10.1016/S0006-3495(93)81299-2; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAUNSBACH AB, 1989, PROG CLIN BIOL RES, V268, P39; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MUGA A, 1990, BIOCHEMISTRY-US, V29, P2925, DOI 10.1021/bi00464a006; SKOU JC, 1979, BIOCHIM BIOPHYS ACTA, V567, P436, DOI 10.1016/0005-2744(79)90129-3; SKRIVER E, 1992, J STRUCT BIOL, V108, P176, DOI 10.1016/1047-8477(92)90017-5; SUREWICZ WK, 1990, BIOCHEMISTRY-US, V29, P8106, DOI 10.1021/bi00487a017; SUREWICZ WK, 1993, BIOCHEMISTRY-US, V32, P389, DOI 10.1021/bi00053a001; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VIGNERON L, 1995, J BIOL CHEM, V270, P17685, DOI 10.1074/jbc.270.30.17685	32	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25685	25692		10.1074/jbc.272.41.25685	http://dx.doi.org/10.1074/jbc.272.41.25685			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325292	hybrid, Green Submitted			2022-12-27	WOS:A1997YA35800047
J	Shimkets, RA; Lifton, RP; Canessa, CM				Shimkets, RA; Lifton, RP; Canessa, CM			The activity of the epithelial sodium channel is regulated by clathrin-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIDDLES SYNDROME; BETA-SUBUNIT; NA+ CHANNEL; BREFELDIN-A; MISSENSE MUTATION; HYPERTENSION; ACTIVATION; SEQUENCE	Activity of the epithelial sodium channel (ENaC) is a key determinant of sodium homeostasis and blood pressure, Liddle's syndrome, an inherited form of hypertension, is caused by mutations that delete or alter PY domains in the carboxyl termini of beta or gamma ENaC subunits, leading to increased channel activity. In this study we investigated the mechanism of this effect by analysis of wild-type and mutant ENaC activity in Xenopus oocytes, By inhibiting insertion of new channels into the plasma membrane with brefeldin A, we demonstrate that the half-life of the activity of channels containing Liddle's mutations is markedly prolonged compared with wild type channels (t(1/2) of 30 h in mutant versus 3.6 in wild type, p < 0.001), We investigated the involvement of clathrin-coated pit-mediated endocytosis by co-expressing a dominant-negative dynamin mutant with wildtype ENaC in oocytes. Expression of this specific inhibitor of endocytosis leads to a large increase in the activity of wild-type channels, demonstrating that normal turnover of this channel is through the clathrin-coated pit pathway, In contrast, co-expression of Liddle's mutations and dynamin mutants leads to no further increase in channel activity, consistent with one of the effects of Liddle's mutations being the loss of endocytosis of these channels, These findings demonstrate the normal mechanism of turnover of ENaC from the cell surface and demonstrate a mechanism that can account for the increased number of channels in the plasma membrane seen in Liddle's syndrome.	YALE UNIV,DEPT CELLULAR & MOL PHYSIOL,SCH MED,NEW HAVEN,CT 06520; YALE UNIV,DEPT GENET,SCH MED,NEW HAVEN,CT 06520	Yale University; Yale University								CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Ismailov II, 1996, AM J PHYSIOL-CELL PH, V270, pC214, DOI 10.1152/ajpcell.1996.270.1.C214; JUNPING L, 1995, ENDOCR REV, V16, P590; MULNERLORILLON O, 1995, DEV BIOL, V170, P223, DOI 10.1006/dbio.1995.1209; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P56699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	24	237	239	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25537	25541		10.1074/jbc.272.41.25537	http://dx.doi.org/10.1074/jbc.272.41.25537			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325269	hybrid			2022-12-27	WOS:A1997YA35800024
J	Simmons, T; Newhouse, YM; Arnold, KS; Innerarity, TL; Weisgraber, KH				Simmons, T; Newhouse, YM; Arnold, KS; Innerarity, TL; Weisgraber, KH			Human low density lipoprotein receptor fragment - Successful refolding of a functionally active ligand-binding domain produced in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-E; CYSTEINE-RICH REPEAT; HUMAN-PLASMA-LIPOPROTEINS; AMINO-ACID-SEQUENCE; HUMAN-E APOPROTEIN; LDL-RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; 3-DIMENSIONAL STRUCTURE; MULTIFUNCTIONAL RECEPTOR; MONOCLONAL-ANTIBODIES	The low density lipoprotein (LDL) receptor plays a key role in cholesterol homeostasis, mediating cellular uptake of Lipoprotein particles by high affinity binding to its ligands, apolipoprotein (ape) B-100 and apoE. The ligand-binding domain of the LDL receptor contains 7 cysteine-rich repeats of approximately 40 amino acids; each repeat contains 6 cysteines, which form 3 intra-repeat disulfide bonds, As a first step toward determining the structure of the LDL receptor, both free and bound to its ligands, we produced in Escherichia coli a soluble fragment containing the Ligand-binding domain (residues 1-292) as a thrombin-cleavable, heat-stable thioredoxin fusion, Modest amounts (5 mg/liter) of partially purified but inactive fragment were obtained after cell lysis, heat treatment, thrombin cleavage, and gel filtration under denaturing conditions, We were able to refold the receptor fragment to an active conformation with approximately 10% efficiency, The active fragment was isolated and purified with an LDL affinity column, The refolded receptor fragment was homogeneous, as determined by sodium dodecyl sulfate or non-denaturing polyacrylamide gel electrophoresis and isoelectric focusing, The purified fragment did not react with fluorescein-5-maleimide, indicating that all 42 cysteines were disulfide linked, In addition, the refolded fragment exhibited properties identical to those of the intact native receptor: Ca2+-dependent binding and isoform-dependent apoE binding (apoE2 binding <5% of apoE3). Furthermore, antibodies to the fragment recognized native receptors and inhibited the binding of I-125-LDL to fibroblast LDL receptors, We conclude that we have produced a properly folded and fully active receptor fragment that can be used for further structural studies.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,DEPT PATHOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes					NCRR NIH HHS [RR00083] Funding Source: Medline; NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNOLD KS, 1992, LIPOPROTEIN ANAL PRA, P145; AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V2; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1984, SCI AM, V251, P58, DOI 10.1038/scientificamerican1184-58; Creighton TE, 1997, TRENDS BIOCHEM SCI, V22, P6, DOI 10.1016/S0968-0004(96)20030-1; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; INNERARITY TL, 1978, J BIOL CHEM, V253, P6289; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; McLachlin DT, 1996, PROTEIN EXPRES PURIF, V7, P275, DOI 10.1006/prep.1996.0039; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RALL SC, 1982, J BIOL CHEM, V257, P4171; RALL SC, 1984, LATENT DYSLIPOPROTEI, P157; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER WJ, 1985, METHOD ENZYMOL, V109, P405; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	40	37	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25531	25536		10.1074/jbc.272.41.25531	http://dx.doi.org/10.1074/jbc.272.41.25531			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325268	hybrid			2022-12-27	WOS:A1997YA35800023
J	Vilei, EM; Calderara, S; Anagli, J; Berardi, S; Hitomi, K; Maki, M; Carafoli, E				Vilei, EM; Calderara, S; Anagli, J; Berardi, S; Hitomi, K; Maki, M; Carafoli, E			Functional properties of recombinant calpain I and of mutants lacking domains III and IV of the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; CYSTEINE PROTEINASES; MOLECULAR DIVERSITY; MU-CALPAIN; INVOLVEMENT; CALPASTATIN; EXPRESSION; BINDING; RECONSTITUTION	The catalytic subunit (L-mu CANP) of human calpain I (mu CANP, the high Ca2+ affinity form) and two of its mutants were expressed in Escherichia coli or using the baculovirus Sf9 system. The mutants lacked domain III (L-mu CANP Delta 3) and the calmodulin-like domain IV (L-mu CANP Delta 4), respectively. The bacterially expressed proteins were solubilized from the inclusion bodies and refolded with polyethylene glycol. In Sf9 cells, co-expression of the inhibitor calpastatin was necessary to prevent autolysis of L-mu CANP, whereas co-expression of the regulatory subunit enhanced it. Only very low levels of mRNA of the truncated form L-mu CANP Delta 4 were found in bacmid-transfected Sf9 cells, and it proved impossible to isolate this mutant using the baculovirus expression system. While the apparent K-m(Ca2+) of freshly isolated human erythrocyte mu CANP was about 60 mu M, the recombinant monomeric forms L-mu CANP and L-mu CANP Delta 3 required 65-215 and 400-530 mu M Ca2+, respectively. Bacterially expressed L-mu CANP Delta 4 was Ca2+-independent; the presence of inhibitors during its renaturation was necessary to prevent its autolysis. A chimeric form (L-mu mCANP) composed by domains I-III of mu CANP and domain IV of calpain II (mcANP, the low Ca2+ affinity form) was also expressed in Sf9 cells. This mutant required less Ca2+ (about 50 mu M) than native erythrocyte calpain for half-maximal activity and had the highest specific activity of all calpains tested. Domain III proved unnecessary for the activity of the recombinant catalytic subunit, but its absence raised the K-m(Ca2+) and removed its inactivation at high Ca2+ concentrations. All recombinant proteins were active as monomers in polyethylene glycol-containing buffers; the in vitro association with the regulatory subunit enhanced only slightly the V-max and the Ca2+ dependence of the expressed proteins. Activation by Ca2+ promoted the separation of the two subunits of the expressed recombinant proteins.	ETH ZURICH, INST BIOCHEM, CH-8092 ZURICH, SWITZERLAND; HENRY FORD HOSP, DEPT PATHOL, DIV BIOCHEM RES, DETROIT, MI 48202 USA; UNIV ZURICH HOSP, DEPT INTERNAL MED, DIV CLIN PHARMACOL & TOXICOL, CH-8091 ZURICH, SWITZERLAND; NAGOYA UNIV, SCH AGR SCI, DEPT APPL BIOL SCI, NAGOYA, AICHI 46401, JAPAN	Swiss Federal Institutes of Technology Domain; ETH Zurich; Henry Ford Health System; Henry Ford Hospital; University of Zurich; University Zurich Hospital; Nagoya University			Carafoli, Ernesto/K-5192-2016; Vilei, Edy/A-6138-2009; Maki, Masatoshi/AAM-6839-2021	Carafoli, Ernesto/0000-0002-7826-0094; Maki, Masatoshi/0000-0001-9144-5491				Anagli J, 1996, EUR J BIOCHEM, V241, P948, DOI 10.1111/j.1432-1033.1996.00948.x; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; COTTIN P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P139, DOI 10.1016/0167-4838(91)90118-J; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; CROALL DE, 1984, BIOCHIM BIOPHYS ACTA, V788, P348, DOI 10.1016/0167-4838(84)90048-7; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DELUCA CI, 1993, BIOCHIM BIOPHYS ACTA, V1216, P81, DOI 10.1016/0167-4781(93)90040-K; GRAHAMSIEGENTHALER K, 1994, J BIOL CHEM, V269, P30457; HATHAWAY DR, 1982, J BIOL CHEM, V257, P9072; Higuchi R., 1989, PCR TECHNOLOGY, P61; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIKUCHI T, 1984, ARCH BIOCHEM BIOPHYS, V234, P639, DOI 10.1016/0003-9861(84)90314-X; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WJ, 1992, J BIOL CHEM, V267, P8437; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; Meyer SL, 1996, BIOCHEM J, V314, P511, DOI 10.1042/bj3140511; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; RUSSELLHARDE D, 1995, J INTERF CYTOK RES, V15, P31, DOI 10.1089/jir.1995.15.31; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAIDO TC, 1993, INNOVATION PROTEASES, P197; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; Zhang WL, 1996, BIOCHEM BIOPH RES CO, V227, P890, DOI 10.1006/bbrc.1996.1601; ZIMMERMAN UJP, 1984, PROG NEUROBIOL, V23, P63, DOI 10.1016/0301-0082(84)90012-1	42	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25802	25808		10.1074/jbc.272.41.25802	http://dx.doi.org/10.1074/jbc.272.41.25802			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325309	hybrid			2022-12-27	WOS:A1997YA35800064
J	Werner, I; Bacher, A; Eisenreich, W				Werner, I; Bacher, A; Eisenreich, W			Retrobiosynthetic NMR studies with C-13-labeled glucose - Formation of gallic acid in plants and fungi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOBACTERIUM-THERMOAUTOTROPHICUM; BIOSYNTHESIS	The biosynthesis of gallic acid was studied in cultures of the fungus Phycomyces blakesleeanus and in leaves of the tree Rhus typhina. Fungal cultures were grown with [1-C-13]gluose or with a mixture of unlabeled glucose and [U-C-13(6)]glucose. Young leaves of R. typhina were kept in an incubation chamber and were supplied with a solution containing a mixture of unlabeled glucose and [U-C-13(6)]glucose via the leaf stem. Isotope distributions in isolated gallic acid and aromatic amino acids were analyzed by one-dimensional H-1 and C-13 NMR spectroscopy. A quantitative analysis of the complex isotopomer composition of metabolites was obtained by deconvolution of the (CC)-C-13-C-13 coupling multiplets using numerical simulation methods. This approach required the accurate analysis of heavy isotope chemical shift effects in a variety of different isotopomers and the analysis of long range (CC)-C-13-C-13 coupling constants. The resulting isotopomer patterns were interpreted using a retrobiosynthetic approach based on a comparison between the isotopomer patterns of gallic acid and tyrosine. The data show that both in the fungus and in the plant all carbon atoms of gallic acid are biosynthetically equivalent to carbon atoms of shikimate. Notably, the carboxylic group of gallic acid is derived from the carboxylic group of an early intermediate of the shikimate pathway and not from the side chain of phenylalanine or tyrosine. It follows that the committed precursor of gallic acid is an intermediate of the shikimate pathway prior to prephenate or arogenate, most probably 5-dehydroshikimate. A formation of gallic acid via phenylalanine, the lignin precursor, caffeic acid, or 3,4,5-trihydroxycinnamic acid can be ruled out as major pathways in the fungus and in young leaves of R. typhina. The incorporation of uniformly C-13-labeled glucose followed by quantitative NMR analysis of isotopomer patterns is suggested as a general method for biosynthetic studies. As shown by the plant experiment, this approach is also applicable to systems with low incorporation rates.	TECH UNIV MUNICH,DEPT ORGAN CHEM & BIOCHEM,D-85747 GARCHING,GERMANY	Technical University of Munich			Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				BRUCKER W., 1962, BER DEUTSCH BOT GES, V75, P3; BRUCKER W, 1957, PLANTA, V48, P627, DOI 10.1007/BF01945032; BRUCKER W, 1958, ARCH MIKROBIOL, V30, P396, DOI 10.1007/BF00411234; CONN EE, 1961, CHEM IND-LONDON, P592; CORNTHWAITE D, 1965, J CHEM SOC, P3008, DOI 10.1039/jr9650003008; DEWICK PM, 1968, CHEM COMMUN, P673, DOI 10.1039/c19680000673; DEWICK PM, 1969, BIOCHEM J, V113, P537, DOI 10.1042/bj1130537; Dixon RA, 1996, GENE, V179, P61, DOI 10.1016/S0378-1119(96)00327-7; Eisenreich W, 1997, J BIOL CHEM, V272, P867, DOI 10.1074/jbc.272.2.867; EISENREICH W, 1991, J BIOL CHEM, V266, P23840; Eisenreich W, 1996, P NATL ACAD SCI USA, V93, P6431, DOI 10.1073/pnas.93.13.6431; EISENREICH W, 1991, J BIOL CHEM, V266, P9622; Gilchrist D. G., 1980, The biochemistry of plants. A comprehensive treatise. Volume 5. Amino acids and derivatives., P507; GROSS GG, 1992, BASIC LIFE SCI, V59, P43; HASLAM E, 1961, J CHEM SOC, P1854, DOI 10.1039/jr9610001854; HASLAM E, 1992, BASIC LIFE SCI, V59, P169; ISHIKURA N, 1975, EXPERIENTIA, V31, P1407, DOI 10.1007/BF01923213; ISHIKURA N, 1984, BOT MAG TOKYO, V97, P355, DOI 10.1007/BF02488668; KATO N, 1968, BOT MAG TOKYO, V81, P506; MARIGO G, 1969, CR ACAD SCI D NAT, V269, P1852; NEISH AC, 1964, PHYTOCHEMISTRY, V3, P485; SAIJO R, 1983, AGR BIOL CHEM TOKYO, V47, P455, DOI 10.1080/00021369.1983.10865673; STRAUSS G, 1992, EUR J BIOCHEM, V205, P853, DOI 10.1111/j.1432-1033.1992.tb16850.x; TATEOKA TN, 1968, BOT MAG TOKYO, V81, P103; ZAPROMETOV M N, 1968, Biokhimiya, V33, P383; ZENK MH, 1964, Z NATURFORSCH PT B, VB 19, P83	26	77	84	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25474	25482		10.1074/jbc.272.41.25474	http://dx.doi.org/10.1074/jbc.272.41.25474			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325260	hybrid			2022-12-27	WOS:A1997YA35800015
J	Samson, M; LaRosa, G; Libert, F; Paindavoine, P; Detheux, M; Vassart, G; Parmentier, M				Samson, M; LaRosa, G; Libert, F; Paindavoine, P; Detheux, M; Vassart, G; Parmentier, M			The second extracellular loop of CCR5 is the major determinant of ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR GENE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; HIV-1 INFECTION; INTERLEUKIN-8 RECEPTOR; CELLS; ENTRY; MIP-1-ALPHA; MIP-1-BETA; RANTES	The chemokine receptor CCR5 binds macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and regulated on activation, normal T-cell expressed and secreted (RANTES), and constitutes the major co-receptor allowing infection of CD4(+) T lymphocytes, macrophages, and microglial cells by macrophage-tropic strains of human and simian immunodeficiency virus, CCR5 is most closely related to CCR2b, another chemokine receptor that responds to monocyte chemoattractant protein (MCP)-1, MCP-2, MCP-3, and MCP-4, We have investigated by mutagenesis the regions of CCR5 and CCR2b involved in the specificity of binding and functional response to their respective ligands, We demonstrate that the key region of CCR5 involved in its specific interaction with MIP-1 alpha, MIP-1 beta, and RANTES, and its subsequent activation, lies within the second extracellular loop (and possibly the adjacent transmembrane segments), Conversely, the NH2-terminal domain of CCR2b is responsible for the high affinity binding of MCP-1, but is not sufficient to confer activation of the intracellular cascades. Extracellular loops of the receptor, among which the second loop plays a prominent role, are necessary to achieve efficient signaling of the receptor, These data complement our previous mapping of CCR5 domains functionally involved in the fusion process with the human immunodeficiency virus envelope, and will help in the development of agents able to interfere with the early steps of viral infection.	ULB,IRIBHN,SERV GENET MED,B-1070 BRUSSELS,BELGIUM; EUROSCREEN SA,INST INTERDISCIPLINARY RES,BRUSSELS,BELGIUM; LEUKOSITE INC,CAMBRIDGE,MA 02142	Universite Libre de Bruxelles			Samson, Michel/F-8356-2013	Parmentier, Marc/0000-0001-8081-4685				Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHESEBRO B, 1990, J VIROL, V64, P215, DOI 10.1128/JVI.64.1.215-221.1990; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANCI C, 1995, J IMMUNOL, V154, P651; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhao-Hai Lu, 1995, Journal of Biological Chemistry, V270, P26239	37	165	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24934	24941		10.1074/jbc.272.40.24934	http://dx.doi.org/10.1074/jbc.272.40.24934			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312096	hybrid			2022-12-27	WOS:A1997XY97000035
J	Vandana, S; Raje, M; Krishnasastry, MV				Vandana, S; Raje, M; Krishnasastry, MV			The role of the amino terminus in the kinetics and assembly of alpha-hemolysin of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-FORMING PROTEIN; ESCHERICHIA-COLI; TRANSMEMBRANE PORE; KEY RESIDUES; MEMBRANE; TOXIN; MUTAGENESIS; EXPRESSION; BACTERIA; SEQUENCE	The nature of the involvement of an intact NH2 terminus in the assembly of alpha-hemolysin of Staphylococcus aureus was reinvestigated, For the first time, a deletion of the first four amino acids at the NH2 terminus of alpha-hemolysin yielded a novel mutant that undergoes all of the conformational changes to form a lytic pore, The experimental evidence shows unequivocally that the mutant toxin forms heat and sodium dodecyl sulfate-stable heptameric oligomers. The concentration required to achieve 50% lysis of red blood cells is around 58-116 ng/ml, and the time taken to achieve lysis to the same extent as that of intact toxin is considerably longer. Transmission electron microscopic studies also suggest that the pores formed by this deletion mutant are similar to those by the full-length toxin, This is in contrast to the previously reported 2- and 11 amino acid deletions that failed to proceed further from a presumed prefinal nonlytic pore to a lytic pore, Studies on the kinetics of assembly indicate that this mutant can form heat-and sodium dodecyl sulfate-stable oligomers as fast as full-length alpha-hemolysin but that pore opening is slowed down. The data strongly suggest that these amino acids (Ala-Asp-Ser-Asp) are involved in the final stages of assembly of alpha-hemolysin in target membranes.	INST MICROBIAL TECHNOL, CHANDIGARH 160036, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)								Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; ARBUTHNOTT JP, 1967, J BACTERIOL, V94, P1170, DOI 10.1128/JB.94.4.1170-1177.1967; CHAZIN WJ, 1995, NAT STRUCT BIOL, V2, P707, DOI 10.1038/nsb0995-707; Engelman DM, 1996, SCIENCE, V274, P1850, DOI 10.1126/science.274.5294.1850; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; IKIGAI H, 1984, FEMS MICROBIOL LETT, V24, P319, DOI 10.1111/j.1574-6968.1984.tb01327.x; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LATHROP BK, 1992, PROTEIN EXPRES PURIF, V3, P512, DOI 10.1016/1046-5928(92)90069-9; LEMA MW, 1994, J MICROBIOL METH, V19, P167, DOI 10.1016/0167-7012(94)90066-3; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; OLOFSSON A, 1990, J MOL BIOL, V214, P299, DOI 10.1016/0022-2836(90)90162-F; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; WALKER B, 1993, J BIOL CHEM, V268, P5285; WALKER B, 1992, J BIOL CHEM, V267, P10902; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655	26	29	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24858	24863		10.1074/jbc.272.40.24858	http://dx.doi.org/10.1074/jbc.272.40.24858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312085	hybrid			2022-12-27	WOS:A1997XY97000024
J	Burfoot, MS; Rogers, NC; Watling, D; Smith, JM; Pons, S; Paonessaw, G; Pellegrini, S; White, MF; Kerr, IM				Burfoot, MS; Rogers, NC; Watling, D; Smith, JM; Pons, S; Paonessaw, G; Pellegrini, S; White, MF; Kerr, IM			Janus kinase-dependent activation of insulin receptor substrate 1 in response to interleukin-4, oncostatin M, and the interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; SIGNAL-TRANSDUCTION PATHWAY; STIMULATED GENE FACTOR-3; GROWTH-FACTOR-I; TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; GAMMA RECEPTOR; JAK KINASES; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING	In addition to a role in response to insulin and insulinlike growth factors, insulin receptor substrate 1 (IRS-1) is phosphorylated in response to IL-4, the interferons (IFNs) and oncostatin M (OSM). Here mutant cell lines lacking JAK1, JAK2, or Tyk2 were used to determine the role(s) of the Janus kinase (JAK) family of protein-tyrosine kinases in IRS-1 phophorylation. 32D cells, which do not express IRS proteins, were analyzed for any requirement for these proteins in response to the IFNs. For the mutant human fibrosarcoma cell lines, phospho rylation of IRS-1 through the insulin-like growth factor receptor is independent of JAK1, JAK2, or Tyk2. In contrast, phosphorylation of IRS-1 mediated by the Type I IFNs, IL-4, and OSM is JAK-dependent. For the alpha beta-IFNs, activation of IRS-1 is dependent on JAK1 and Tyk2, consistent with the interdependence of these kinases in the IFN-alpha beta response. Neither IRS-1 nor IRS-2 was detectably activated by IFN-gamma. Consistent with this, activation of neither IRS proteins appears to be an absolute requirement for an antiproliferative or an antiviral response to the IFNs. For IL-4 and OSM phosphorylation of IRS-1 in the human fibrosarcoma cells is largely dependent on JAK1 but can also be mediated through Tyk2 or JAK2. Activation of phosphatidylinositol 3'-kinase in response to IL-4 and OSM, at least, was also JAK-dependent. The JAKs are, therefore, required not only for STAT activation but also for the activation through a variety of different types of cytokine receptor, of an additional signaling pathway(s) through IRS-1 and phosphatidylinositol S'-kinase.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; IRBM,I-00040 POMEZIA,ROMA,ITALY; INST PASTEUR,UNITE INSERM 276,F-75724 PARIS 15,FRANCE	Cancer Research UK; Harvard University; Joslin Diabetes Center, Inc.; Merck & Company; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Pellegrini, Sandra -/G-5546-2015; Pellegrini, Sandra/Y-6351-2019; PONS, SEBASTIAN/K-7794-2014	Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; Rogers, Neil/0000-0001-8977-7585; PONS, SEBASTIAN/0000-0003-1027-0621				AGUET G, 1988, CELL, V56, P273; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; COLAMONICI OR, 1995, J BIOL CHEM, V270, P8188, DOI 10.1074/jbc.270.14.8188; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; Murata T, 1996, J IMMUNOL, V156, P2972; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PAUL WE, 1991, BLOOD, V77, P1859; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PONS S, 1995, MOL CELL BIOL, V15, P4453; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schnyder B, 1996, BIOCHEM J, V315, P767, DOI 10.1042/bj3150767; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang HY, 1997, J IMMUNOL, V158, P1037; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	62	103	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24183	24190		10.1074/jbc.272.39.24183	http://dx.doi.org/10.1074/jbc.272.39.24183			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305869	hybrid			2022-12-27	WOS:A1997XY51500020
J	ElHadri, K; Courtalon, A; Gauthereau, X; ChambautGuerin, AM; Pairault, J; Feve, B				ElHadri, K; Courtalon, A; Gauthereau, X; ChambautGuerin, AM; Pairault, J; Feve, B			Differential regulation by tumor necrosis factor-alpha of beta(1)-, beta(2)-, and beta(3)-adrenoreceptor gene expression in 3T3-F442A adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-RESISTANCE; TYROSINE KINASE-ACTIVITY; MESSENGER-RNA CONTENT; ADIPOSE-TISSUE; 3T3-L1 CELLS; BETA-3-ADRENERGIC RECEPTOR; LIPOPROTEIN-LIPASE; BETA(3)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; GLYCEROPHOSPHATE DEHYDROGENASE	Modulation of beta-adrenoreceptor expression by tumor necrosis factor-alpha (TNF-alpha) was investigated in murine 3T3-F442A adipocytes. TNF-alpha treatment of mature adipocytes decreased beta(3)-adrenoreceptor mRNA content in a time-and concentration-dependent manner, with a 8.5-fold decrease observed after a 6-h exposure to 300 pM TNF-alpha. beta(1)-Adrenoreceptor mRNA abundance was slightly decreased by TNF-alpha treatment, while beta(2)-adrenoreceptor mRNA levels were potently induced (6-fold increase at 6 h), (-)-[I-125]Iodocyanopindolol saturation and competition binding experiments indicated that TNF-alpha induced a 2-fold decrease in beta(3)-adrenoreceptor number, a nonsignificant reduction in beta(1)-subtype population, and a similar to 4.5-fold increase in beta(2)-adrenoreceptor density, This correlated with a lower EC value measured for epinephrine in stimulating adenylyl cyclase, whereas the EC50 value for norepinephrine increased. Nuclear run-on assays on isolated nuclei and mRNA stability measurements showed that TNF-alpha increased both beta(2)-adrenoreceptor gene transcription and beta(2)-adrenoreceptor mRNA half-life, while beta(1)- and beta(3)-adrenoreceptor gene expression was modulated only at the transcriptional level by the cytokine. These findings demonstrate a differential modulation by TNF-alpha of the three beta-adrenoreceptor subtypes in adipocytes, which may contribute to metabolic disorders induced by the cytokine in the adipocyte.	HOP HENRI MONDOR,INSERM UNITE 282,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)				Feve, Bruno/0000-0001-6577-9009; EL HADRI, KHADIJA/0000-0002-1275-9861				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; Barbe P, 1996, BRIT J PHARMACOL, V117, P907, DOI 10.1111/j.1476-5381.1996.tb15279.x; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BLIN N, 1993, MOL PHARMACOL, V44, P1094; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; Charon C, 1995, BIOCHEM J, V312, P781, DOI 10.1042/bj3120781; CHAUDHRY A, 1994, J PHARMACOL EXP THER, V271, P1253; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; ElHadri K, 1996, EUR J BIOCHEM, V239, P519; ElHadri K, 1996, EUR J PHARMACOL, V297, P107, DOI 10.1016/0014-2999(95)00723-7; ENOCKSSON S, 1995, J CLIN INVEST, V95, P2239, DOI 10.1172/JCI117914; FEINGOLD KR, 1992, ENDOCRINOLOGY, V130, P10, DOI 10.1210/en.130.1.10; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1992, J BIOL CHEM, V267, P15909; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; GRANNEMAN JG, 1994, ENDOCRINOLOGY, V135, P1025, DOI 10.1210/en.135.3.1025; GRANNEMAN JG, 1993, MOL PHARMACOL, V44, P264; GREEN A, 1994, ENDOCRINOLOGY, V134, P2581, DOI 10.1210/en.134.6.2581; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GRUNFELD C, 1991, TRENDS ENDOCRIN MET, V2, P213, DOI 10.1016/1043-2760(91)90027-K; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KRIEF S, 1994, J BIOL CHEM, V269, P6664; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LANG CH, 1993, AM J PHYSIOL, V264, pR984, DOI 10.1152/ajpregu.1993.264.5.R984; LIN ECC, 1960, J BIOL CHEM, V235, P1820; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NAKADA MT, 1989, BIOCHEM J, V260, P53, DOI 10.1042/bj2600053; NANTEL F, 1994, J BIOL CHEM, V269, P13148; PAIRAULT J, 1987, J CELL PHYSIOL, V132, P279, DOI 10.1002/jcp.1041320212; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; PETRUSCHKE T, 1993, J CLIN ENDOCR METAB, V76, P742, DOI 10.1210/jc.76.3.742; PRICE SR, 1986, BIOCHEM J, V240, P601, DOI 10.1042/bj2400601; REVELLI JP, 1993, J MOL ENDOCRINOL, V10, P193, DOI 10.1677/jme.0.0100193; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; STERN L, 1988, J BIOL CHEM, V263, P15876; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; WEINER FR, 1991, J BIOL CHEM, V266, P23525; WILLIAMS PM, 1992, MOL ENDOCRINOL, V6, P1135, DOI 10.1210/me.6.7.1135; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	71	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24514	24521		10.1074/jbc.272.39.24514	http://dx.doi.org/10.1074/jbc.272.39.24514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305915	hybrid			2022-12-27	WOS:A1997XY51500066
J	Masson, D; Duverger, N; Emmanuel, F; Lagrost, L				Masson, D; Duverger, N; Emmanuel, F; Lagrost, L			Differential interaction of the human cholesteryl ester transfer protein with plasma high density lipoproteins (HDLs) from humans, control mice, and transgenic mice to human HDL apolipoproteins - Lack of lipid transfer inhibitory activity in transgenic mice expressing human apoA-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; A-I; SIZE DISTRIBUTION; EXCHANGE; BINDING; ACYLTRANSFERASE; ATHEROGENESIS; TRIGLYCERIDE; METABOLISM; PARTICLES	Plasma high density lipoproteins (HDLs) from humans, from transgenic mice to human apolipoprotein A-I (HuAITg mice), from transgenic mice to human apolipoprotein A-II (HuAIITg mice), from transgenic mice to human apolipoproteins A-I and A-II (HuAIAIITg mice), and from C57BL/6 control mice were isolated, and their ability to interact with the human cholesteryl ester transfer protein (CETP) was studied, Whereas cholesteryl ester transfer rates were gradually enhanced by the addition of moderate amounts of HDL from the different sources, striking differences appeared when HDL levels kept increasing beyond a maximal transfer value. Indeed, while a plateau value corresponding to maximal CETP activity was maintained when raising the concentration of HuAITg HDL and HuAIAIITg HDL, inhibitions could be observed with the highest levels of human, control mouse, and HuAIITg mouse HDL. The concentration-dependent inhibition of CETP activity could be reproduced by the addition of delipidated HDL apolipoproteins from control mice, but it was abolished by a l-h preheating treatment at 56 degrees C, In contrast, no significant inhibition of CETP activity was observed with the delipidated protein moiety of HuAITg HDL, and cholesteryl ester transfer rates remained unchanged before and after a l-h, 56 degrees C preheating step. Finally, the CETP-mediated transfer of radiolabeled cholesteryl esters from human low density lipoprotein to human HDL was significantly higher in the presence of lipoprotein-deficient plasma from HuAITg mice than in the presence of lipoprotein-deficient plasma from control mice, Interestingly, cholesteryl ester transfer rates measured with both control and HuAITg lipoprotein deficient plasmas became remarkably similar following a 1-h, 56 degrees C preheating treatment. It is concluded that human, control mouse, and HuAIITg mouse HDL contain a heat-labile lipid transfer inhibitory activity that is absent from HDL of HuAITg and HuAIAIITg mice, Alterations in CETP-lipoprotein binding did not account for differential lipid transfer inhibitory activities.	FAC MED,INSERM CJF9310,LAB BIOCHIM LIPOPROT,F-21033 DIJON,FRANCE; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,GENCELL DIV,ATHEROSCLEROSIS DEPT,F-94403 VITRY SUR SEINE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Sanofi-Aventis; Sanofi France			Masson, David/R-6633-2019; MASSON, David/AAC-8896-2022; MASSON, David/R-4557-2017	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699				AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BARTER PJ, 1980, J LIPID RES, V21, P238; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V1085, P209; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; BRUCE C, 1995, J BIOL CHEM, V270, P11532, DOI 10.1074/jbc.270.19.11532; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; CHAM BE, 1976, J LIPID RES, V17, P176; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; EPPS DE, 1995, BIOCHEMISTRY-US, V34, P12560, DOI 10.1021/bi00039a010; Florentin E, 1996, EUR J BIOCHEM, V240, P699, DOI 10.1111/j.1432-1033.1996.0699h.x; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; GONG EL, 1994, BBA-LIPID LIPID MET, V1213, P335, DOI 10.1016/0005-2760(94)00062-X; GUYARDDANGREMONT V, 1994, CLIN CHIM ACTA, V231, P147, DOI 10.1016/0009-8981(94)90199-6; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; IHM J, 1982, J LIPID RES, V23, P1328; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; JIANG XC, 1995, BIOCHEMISTRY-US, V34, P7258, DOI 10.1021/bi00021a042; KUSHWAHA RS, 1993, J LIPID RES, V34, P1285; LAGROST L, 1994, J BIOL CHEM, V269, P3189; Lagrost L, 1996, J BIOL CHEM, V271, P19058, DOI 10.1074/jbc.271.32.19058; LAGROST L, 1994, BBA-LIPID LIPID MET, V1215, P209, DOI 10.1016/0005-2760(94)90047-7; LAGROST L, 1991, BIOCHIM BIOPHYS ACTA, V1085, P209, DOI 10.1016/0005-2760(91)90096-Z; LAGROST L, 1994, J LIPID RES, V35, P825; Masson D, 1996, J LIPID RES, V37, P1579; MORTON RE, 1985, J BIOL CHEM, V260, P2593; MORTON RE, 1994, J LIPID RES, V35, P836; MORTON RE, 1994, J LIPID RES, V35, P2094; MORTON RE, 1993, ARTERIOSCLER THROMB, V13, P1843, DOI 10.1161/01.ATV.13.12.1843; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MOULIN P, 1994, J LIPID RES, V35, P793; NISHIDA HI, 1993, J BIOL CHEM, V268, P16352; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; NISHIDE T, 1989, J LIPID RES, V30, P149; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; Roy P, 1996, J LIPID RES, V37, P22; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; RYE KA, 1992, J LIPID RES, V33, P215; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SON YSC, 1984, BIOCHIM BIOPHYS ACTA, V795, P473; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1989, J LIPID RES, V30, P1491; TALL AR, 1995, J INTERN MED, V237, P5, DOI 10.1111/j.1365-2796.1995.tb01133.x; TALL AR, 1993, J LIPID RES, V34, P1255; TALL AR, 1985, J BIOL CHEM, V259, P9587; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE984; TREMP GL, 1995, GENE, V156, P199, DOI 10.1016/0378-1119(95)00010-4; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	49	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24287	24293		10.1074/jbc.272.39.24287	http://dx.doi.org/10.1074/jbc.272.39.24287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305883	hybrid			2022-12-27	WOS:A1997XY51500034
J	Ng, J; Cantrell, D				Ng, J; Cantrell, D			STAT3 is a serine kinase target in T lymphocytes - Interleukin 2 and T cell antigen receptor signals converge upon serine 727	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC ANTIBODIES; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION STATE; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; ACTIVATION; TYROSINE; PROTEINS; DISTINCT	Interleukin 2 (IL-2) induces tyrosine phosphorylation of STATs 3 and 5 (signal transducer and activator of transcription). We now show that IL-2 regulation of STAT3 proteins in T cells is a complex response involving activation of two forms of STAT3: 90-kDa STAT3 alpha and an 83-kDa carboxyl-terminal truncated STAT3 beta. The phosphorylation of STAT proteins on serine residues is also required far competent STAT transcription, A critical serine phosphorylation site in STAT3 alpha is at position 727. In this study we have produced an antisera specific for STAT3 alpha proteins phosphorylated on serine 727 and used this to monitor the phosphorylation of this residue during T lymphocyte activation, Our results show that phosphorylation of STAT3 alpha on serine 727 is not constitutive in quiescent T cells but can be induced by the cytokine IL-2. Interestingly, triggering of the T cell antigen receptor complex or activation of protein kinase C with phorbol esters also induces phosphorylation of serine 727 but without simultaneously inducing STAT3 tyrosine phosphorylation or DNA binding, Hence, the present results show that STAT3 serine phosphorylation call be regulated independently of the tyrosine phosphorylation of this molecule, IL-2 and T cell antigen receptor complex induction of STAT3 alpha serine 727 phosphorylation is dependent; on the activity of the MEK/ERK pathway, Previous studies have identified H-7-sensitive kinase pathways that regulate STAT3 DNA binding, We show that H-7-sensitive pathways regulate STAT3 DNA binding in T cells. Nevertheless, we show that H-7-sensitive kinases do not regulate STAT3 tyrosine phosphorylation or phosphorylation of serine 727. These results thus show that STAT3 proteins are targets for multiple kinase pathways in T cells and can integrate signals from both cytokine receptors and antigen receptors.	IMPERIAL CANC RES FUND, LYMPHOCYTE ACTIVAT LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Ng, Julian/C-5747-2009	Ng, Julian/0000-0002-1908-4414				AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BRUNN GJ, 1995, J BIOL CHEM, V270, P11628, DOI 10.1074/jbc.270.19.11628; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Cho SS, 1996, J IMMUNOL, V157, P4781; COGHLAN MP, 1994, BIOCHEM J, V303, P893, DOI 10.1042/bj3030893; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORI T, 1987, BLOOD, V70, P1069; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MERIDA I, 1991, J IMMUNOL, V147, P2202; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PATTON BL, 1993, MOL BIOL CELL, V4, P159, DOI 10.1091/mbc.4.2.159; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAWAMI H, 1992, J CELL PHYSIOL, V151, P367, DOI 10.1002/jcp.1041510218; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	44	129	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24542	24549		10.1074/jbc.272.39.24542	http://dx.doi.org/10.1074/jbc.272.39.24542			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305919	hybrid			2022-12-27	WOS:A1997XY51500070
J	Onions, J; Hermann, S; Grundstrom, T				Onions, J; Hermann, S; Grundstrom, T			Basic helix-loop-helix protein sequences determining differential inhibition by calmodulin and S-100 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; CALCIUM MESSENGER SYSTEM; KINASE-II; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; RAT S100-ALPHA; GENE FAMILY; MYOD FAMILY; PHOSPHORYLATION; E47	Basic helix-loop-helix (bHLH) proteins are a group of transcription factors that are involved in differentiation and numerous other cellular processes. The proteins include the widely expressed class A bHLH proteins (E proteins) and the tissue specific class E proteins. Previous studies have shown that calmodulin can inhibit the DNA binding activity of certain E proteins but not their heterodimers with class B proteins. Here we show that calmodulin binds to the DNA-interacting basic sequence within the bHLH domain of E proteins. The strength of the binding of bHLH proteins to calmodulin correlates directly with the calmodulin sensitivity of their DNA binding, The basic sequence of MyoD, a class B protein, can also interact with calmodulin. This interaction, however, is blocked by MyoD sequences directly N-terminal of the basic sequence. We further demonstrate that S-100 proteins can interact with and differentially inhibit the DNA binding of bHLH proteins through interaction with the basic sequence, Both the binding to the basic sequence and the effect of the directly N-terminal sequence vary for different 5-100 proteins and bHLH proteins, The results suggest the involvement of both calmodulin and S-100 proteins in the differential regulation of bHLH proteins.	UMEA UNIV,DEPT APPL CELL & MOL BIOL,DIV TUMOUR BIOL,S-90187 UMEA,SWEDEN	Umea University								ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BABIYCHUK EB, 1995, BIOCHEMISTRY-US, V34, P6366, DOI 10.1021/bi00019a015; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAUDIER J, 1982, FEBS LETT, V147, P165, DOI 10.1016/0014-5793(82)81033-8; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; BAUDIER J, 1987, BIOCHEMISTRY-US, V26, P2886, DOI 10.1021/bi00384a033; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRODIN P, 1989, PROTEIN ENG, V2, P353, DOI 10.1093/protein/2.5.353; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EDMONDSON DG, 1990, GENE DEV, V4, P1450, DOI 10.1101/gad.4.8.1450; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; FARMER K, 1992, J BIOL CHEM, V267, P5631; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAIMOTO H, 1987, LAB INVEST, V57, P489; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOPAN R, 1994, DEVELOPMENT, V120, P2385; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAUE TM, 1995, P NATL ACAD SCI USA, V92, P11824, DOI 10.1073/pnas.92.25.11824; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MITSUI K, 1993, J BIOL CHEM, V268, P24415; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1094; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1164; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; TAKEDA T, 1987, P NATL ACAD SCI USA, V84, P3580, DOI 10.1073/pnas.84.11.3580; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232; ZIMMER DB, 1987, AM J PHYSIOL, V252, pC285, DOI 10.1152/ajpcell.1987.252.3.C285; ZIMMER DB, 1991, BRAIN RES BULL, V27, P157, DOI 10.1016/0361-9230(91)90061-N	54	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23930	23937		10.1074/jbc.272.38.23930	http://dx.doi.org/10.1074/jbc.272.38.23930			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295343	hybrid			2022-12-27	WOS:A1997XX38100068
J	Vonakis, BM; Chen, HX; HaleemSmith, H; Metzger, H				Vonakis, BM; Chen, HX; HaleemSmith, H; Metzger, H			The unique domain as the site on Lyn kinase for its constitutive association with the high affinity receptor for IgE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; BASOPHILIC LEUKEMIA-CELLS; ACTIVATION MOTIF ITAM; IMMUNOGLOBULIN-E; MAST-CELLS; 2-HYBRID SYSTEM; 2 FORMS; BINDING; HISTAMINE; SUBUNITS	Aggregation of the high affinity receptor for IgE (Fc epsilon RI) leads to the phosphorylation of tyrosines on the beta and gamma chains of the receptor by the Src family kinase Lyn. We have studied the interaction between Lyn and the Fc epsilon RI in vivo using a transfection-based approach. Fc epsilon RI were stably transfected into Chinese hamster ovary cells. The small amount of endogenous Src family kinase was sufficient to phosphorylate receptor tyrosines upon extensive aggregation of Fc epsilon RI but not after addition of dimers of IgE. Upon stable co-transfection of Lyn kinase into the cells, dimers were now able to stimulate receptor phosphorylation and the response to more extensive aggregation was enhanced. In contrast, co-transfection with catalytically inactive Lyn inhibited the aggregation-induced phosphorylation by the endogenous kinase, and a quantitatively similar inhibition was observed in cells transfected with the SH4-containing unique domain of Lyn. Consistent with the results of others using alternative approaches, our additional studies using a yeast two-hybrid system detected a direct interaction between intact Lyn or its unique domain and the C-terminal cytoplasmic domain of the beta chain but not with the receptor's other cytoplasmic domains.			Vonakis, BM (corresponding author), NIAMSD,ARTHRIT & RHEUMATISM BRANCH,NIH,BLDG 10-RM 9N-258,10 CTR DR MSC 1520,BETHESDA,MD 20892, USA.			Vonakis, Becky/0000-0003-4174-6514				ALBER G, 1992, J IMMUNOL, V149, P2428; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BAZIN H, 1974, IMMUNOLOGY, V26, P713; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; EISEMAN E, 1992, NATURE, V355, P78; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Gauen LKT, 1996, J CELL BIOL, V133, P1007, DOI 10.1083/jcb.133.5.1007; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; LIU FT, 1980, J IMMUNOL, V124, P2728; MATTHYSSENS GE, 1975, MOL CELL BIOCHEM, V7, P119, DOI 10.1007/BF01792078; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; RIDER LG, 1994, GENE, V138, P219, DOI 10.1016/0378-1119(94)90811-7; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SUMMERS MD, 1988, TEX AGR EXPT STN B, V1555; TAUROG JD, 1977, J IMMUNOL, V119, P1757; Torigoe C, 1997, P NATL ACAD SCI USA, V94, P1372, DOI 10.1073/pnas.94.4.1372; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	39	102	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24072	24080		10.1074/jbc.272.38.24072	http://dx.doi.org/10.1074/jbc.272.38.24072			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295361	hybrid			2022-12-27	WOS:A1997XX38100086
J	Makino, Y; Yamano, K; Kanemaki, M; Morikawa, K; Kishimoto, T; Shimbara, N; Tanaka, K; Tamura, T				Makino, Y; Yamano, K; Kanemaki, M; Morikawa, K; Kishimoto, T; Shimbara, N; Tanaka, K; Tamura, T			SUG1, a component of the 26 S proteasome, is an ATPase stimulated by specific RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE; BINDING PROTEIN; HELICASE ACTIVITY; YEAST; DEGRADATION; EXPRESSION; UBIQUITIN; POLYMERASE; COMPLEX; CLONING	SUG1 is an integral component of the 26 S proteasome, Belonging to a novel putative ATPase family, it shares four conserved motifs characteristic of ATP-dependent DNA/RNA helicases, Recombinant rat SUG1 (rSUG1) produced in Escherichia coli was highly purified and characterized in terms of its biochemical properties. The rSUG1 exhibited a Mg2+-dependent ATPase activity. The K-m for ATP and V-max of rSUG1 were 35 mu M and 7 pmol of ATP/min/mu g of protein, respectively. Both ATPase activity to release [P-32]monophosphate and [P-32]ATP-labeling activity were coordinately affected by cold ATP severely, GTP and UTP moderately, and CTP little, Interestingly, the rSUG1 ATPase activity was stimulated by poly(U) and poly(C), but not by poly(A), poly(G), or by any forms of DNAs tested. A UV crosslinking assay also indicated poly(U)- and poly(C)-stimulated labeling of rSUG1 with [alpha-P-32]ATP. Moreover, the ATPase activity was facilitated by cellular poly(A)(+) RNA, but not by poly(A)(-) RNA. RNA transcribed in vitro from cDNA encoding a b-Zip protein could stimulate the ATPase activity, This is the first report to demonstrate a specific RNA requirement for ATPase with respect to the proteasomal ATPases. Our present work suggests that SUG1 can specifically interact with protein-coding RNA (mRNA) and play some roles in mRNA metabolism.	CHIBA UNIV, FAC SCI, DEPT BIOL, INAGE KU, CHIBA 263, JAPAN; SUMITOMO ELECT IND LTD, BIOMED R&D DEPT, SAKAE KU, YOKOHAMA, KANAGAWA 244, JAPAN; TOKYO METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN	Chiba University; Sumitomo Electric Industries; Tokyo Metropolitan Institute of Medical Science			Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556				AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; ARMON T, 1990, J BIOL CHEM, V265, P20723; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GOYER C, 1992, DNA CELL BIOL, V11, P579, DOI 10.1089/dna.1992.11.579; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HIRTZLIN J, 1994, EUR J BIOCHEM, V226, P673, DOI 10.1111/j.1432-1033.1994.tb20095.x; Kishimoto T, 1996, BIOCHEM BIOPH RES CO, V223, P746, DOI 10.1006/bbrc.1996.0962; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LUCERO HA, 1995, J BIOL CHEM, V270, P9178, DOI 10.1074/jbc.270.16.9178; MA CP, 1994, J BIOL CHEM, V269, P3539; Makino Y, 1996, BIOCHEM BIOPH RES CO, V220, P1049, DOI 10.1006/bbrc.1996.0530; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	37	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23201	23205		10.1074/jbc.272.37.23201	http://dx.doi.org/10.1074/jbc.272.37.23201			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287326	hybrid			2022-12-27	WOS:A1997XV74400037
J	Sepp, A; Skacel, P; Lindstedt, R; Lechler, RI				Sepp, A; Skacel, P; Lindstedt, R; Lechler, RI			Expression of alpha-1,3-galactose and other type 2 oligosaccharide structures in a porcine endothelial cell line transfected with human alpha-1,2-fucosyltransferase cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOLICHOS-BIFLORUS AGGLUTININ; XENOREACTIVE NATURAL ANTIBODIES; HYPERACUTE XENOGRAFT REJECTION; COMPLEMENT-MEDIATED CYTOLYSIS; ALPHA-GALACTOSYL EPITOPES; COLLECTING DUCT CELLS; HAMSTER OVARY CELLS; ANTI-GAL ANTIBODY; LEWIS-Y ANTIGEN; DISCORDANT XENOGRAFTS	The binding of xenoreactive natural antibodies to the Gal alpha 1-3Gal beta 1-4GlcNAc (alpha-galactose) oligosaccharide epitope on pig cells activates the recipient's complement system in pig to primate xenotransplantation, Expression of human alpha-1,2-fucosyltransferase in pigs has been proposed as a strategy for reducing the expression level of the alpha-galactose epitope thereby rendering the pig organs more suitable for transplantation into humans. The aim of this study was to examine how the cell surface expression of alpha-galactose, H, and related fucosylated and sialylated structures on a pig liver endothelial cell line is affected by transfection of human alpha-1,2-fucosyltransferase cDNA. Nontransfected and mock-transfected cells expressed alpha-galactose, alpha-2,3-sialylated, and alpha-2,6-sialylated epitopes strongly, with low level expression of type 2 H and Lewis(X). By contrast, expression of the H epitope was increased 5-8-fold in transfected cells with a 40% reduction in the expression of alpha-galactose epitope and a 50% decrease in sialylation, as measured by binding of Maackia amurensis and Sambuccus nigra agglutinins. Lewis(X) expression was reduced to background levels, while the Lewis(Y) neoepitope was induced in human alpha-1,2-fucosyltransferase-expressing pig cells. The activities of endogenous alpha-1,3-galactosyltransferase, alpha-1,3-fucosyltransferases, and alpha-2,3- and alpha-2,6-sialyltransferases acting on lactosamine were unaffected, Our results show that a reduction in alpha-galactose epitope expression in porcine endothelial cells transfected with human alpha-1,2-fucosyltransferase cDNA may be achieved but at the expense of considerable distortion of the overall cell surface glycosylation profile, including the appearance of carbohydrate epitopes that are absent from the parent cells.	ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND; ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London								ASHFORD DA, 1993, J BIOL CHEM, V268, P3260; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; Cairns T, 1995, TRANSPLANTATION, V60, P1202; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cooper D K, 1993, Transpl Immunol, V1, P198, DOI 10.1016/0966-3274(93)90047-C; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; DARR D, 1990, J CUTAN PATHOL, V17, P9, DOI 10.1111/j.1600-0560.1990.tb01671.x; DELAU WBM, 1993, J IMMUNOL, V150, P4911; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GRUPP CT, 1990, KIDNEY INT, V37, P1163; HAYASHI S, 1994, TRANSPLANT P, V26, P1243; HecklOstreicher B, 1995, CLIN EXP IMMUNOL, V102, P589; HELLER D S, 1990, Pediatric Pathology, V10, P681; HENDRICKS SP, 1990, J BIOL CHEM, V265, P17621; HOKKE CH, 1994, EUR J BIOCHEM, V221, P491, DOI 10.1111/j.1432-1033.1994.tb18762.x; HOLTHOFER H, 1987, CELL TISSUE RES, V249, P481; HOLZKNECHT ZE, 1995, J IMMUNOL, V154, P4565; INOUE M, 1990, VIRCHOWS ARCH A, V416, P221, DOI 10.1007/BF01678981; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; KANEKO T, 1993, J BIOCHEM-TOKYO, V113, P114, DOI 10.1093/oxfordjournals.jbchem.a123993; KENNEDY SP, 1994, TRANSPLANTATION, V57, P1494; KIRK AD, 1992, TRANSPLANT P, V24, P602; KIRK AD, 1993, TRANSPLANTATION, V55, P924, DOI 10.1097/00007890-199304000-00043; KROSHUS TJ, 1995, J SURG RES, V59, P43, DOI 10.1006/jsre.1995.1130; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEVENTHAL JR, 1994, TRANSPLANTATION, V57, P974; Lowe J B, 1991, Semin Cell Biol, V2, P289; MARTENSSON S, 1995, HUM PATHOL, V26, P735, DOI 10.1016/0046-8177(95)90220-1; MCCORMACK KM, 1987, CLIN RES, V35, pA702; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; McKenzie I F, 1994, Transpl Immunol, V2, P81, DOI 10.1016/0966-3274(94)90032-9; MIYAGAWA S, 1994, TRANSPLANTATION, V58, P834, DOI 10.1097/00007890-199410150-00015; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MYERS RB, 1995, J UROLOGY, V153, P1572, DOI 10.1016/S0022-5347(01)67464-0; NEETHLING FA, 1994, TRANSPLANTATION, V57, P959, DOI 10.1097/00007890-199403270-00032; OGAWA J, 1995, ANN THORAC SURG, V59, P412, DOI 10.1016/0003-4975(94)00866-6; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PARKER W, 1994, J IMMUNOL, V153, P3791; PLATT JL, 1994, TRANSPLANTATION, V57, P327, DOI 10.1097/00007890-199402150-00003; PLATT JL, 1990, IMMUNOL TODAY, V11, P450, DOI 10.1016/0167-5699(90)90174-8; PLATT JL, 1991, TRANSPLANTATION, V52, P1037, DOI 10.1097/00007890-199112000-00019; PLENDL J, 1992, ANAT HISTOL EMBRYOL, V21, P118, DOI 10.1111/j.1439-0264.1992.tb00328.x; PRUITT SK, 1991, TRANSPLANTATION, V52, P868, DOI 10.1097/00007890-199111000-00022; ROSE AG, 1991, J HEART LUNG TRANSPL, V10, P223; ROSENGARD AM, 1995, TRANSPLANT P, V27, P326; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; Sepp A, 1996, J IMMUNOL METHODS, V196, P175, DOI 10.1016/0022-1759(96)00112-3; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; SHIOJIRI N, 1988, ANAT EMBRYOL, V178, P15, DOI 10.1007/BF00305009; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SOARES M, 1994, TRANSPLANTATION, V57, P1003; TERADA T, 1995, AM J PATHOL, V146, P67; THALL A, 1991, ACTA ENDOCRINOL-COP, V124, P692, DOI 10.1530/acta.0.1240692; VAUGHAN HA, 1993, TRANSPLANT P, V25, P2919; WAKABAYASHI M, 1995, CANCER, V75, P2827, DOI 10.1002/1097-0142(19950615)75:12<2827::AID-CNCR2820751207>3.0.CO;2-Z; YANNOUTSOS N, 1995, TRANSPLANT P, V27, P324	63	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23104	23110		10.1074/jbc.272.37.23104	http://dx.doi.org/10.1074/jbc.272.37.23104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287311	hybrid			2022-12-27	WOS:A1997XV74400022
J	Vance, BA; Wu, WY; Ribaudo, RK; Segal, DM; Kearse, KP				Vance, BA; Wu, WY; Ribaudo, RK; Segal, DM; Kearse, KP			Multiple dimeric forms of human CD69 result from differential addition of N-glycans to typical (Asn-X-Ser/Thr) and atypical (Asn-X-Cys) glycosylation motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION ANTIGEN CD69; ASPARAGINE-LINKED OLIGOSACCHARIDES; NATURAL-KILLER-CELLS; LYMPHOCYTE-ACTIVATION; AMINO-ACID; ENDOPLASMIC-RETICULUM; PROTEIN-C; RECEPTOR; EXPRESSION; SEQUENCE	CD69 is expressed on the surface of all hematopoietically derived leukocytes and is suggested to function as a multipurpose cell-surface trigger molecule important in the development and activation of many different cell types. Human CD69 contains only a single consensus sequence for N-linked oligosaccharide addition within its extracellular domain (Asn-Val-Thr), yet exists as two distinct glycoforms that are assembled together into disulfide-linked homodimers and heterodimers. The molecular basis for human CD69 heterogeneity has remained elusive. In the current report we show that human CD69 glycoforms are generated before the egress of CD69 proteins from the endoplasmic reticulum to the Golgi and are synthesized under conditions where Golgi processing is inhibited, effectively ruling out the possibility that CD69 heterogeneity results from the differential processing of a single glycosylation site in the Golgi complex. Importantly, these data demonstrate that contrary to current belief, not one but two sites for N-glycan addition exist within the human CD69 extracellular do main and identify the second, ''cryptic'' CD69 N-glycan attachment site as the atypical Cys-containing glycosylation motif, Asn-Ala-Cys. The results in this study provide a molecular basis for human CD69 heterogeneity and show that multiple dimeric forms of human CD69 result from the variable addition of N-glycans to atypical and typical glycosylation motifs within the CD69 extracellular domain.	E CAROLINA UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, GREENVILLE, NC 27858 USA; NCI, EXPT IMMUNOL BRANCH, NIH, BETHESDA, MD 20892 USA; NCI, LAB IMMUNE CELL BIOL, NIH, BETHESDA, MD 20892 USA	University of North Carolina; East Carolina University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Ribaudo, Randall/AAH-7094-2021; Vance, Barbara/GYA-0940-2022					BAJORATH J, 1994, J BIOL CHEM, V269, P32457; Balow JP, 1996, J IMMUNOL METHODS, V189, P251, DOI 10.1016/0022-1759(95)00255-3; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; Bause E, 1995, BIOCHEM J, V312, P979, DOI 10.1042/bj3120979; BEZOUSKA K, 1995, BIOCHEM BIOPH RES CO, V208, P68, DOI 10.1006/bbrc.1995.1306; DEMARIA R, 1994, J EXP MED, V180, P1999, DOI 10.1084/jem.180.5.1999; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FRANKLIN RA, 1994, J CLIN INVEST, V93, P2134, DOI 10.1172/JCI117209; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HAMANN J, 1993, J IMMUNOL, V150, P4920; HART GW, 1979, J BIOL CHEM, V254, P9747; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; KEARSE KP, 1994, EMBO J, V13, P4504, DOI 10.1002/j.1460-2075.1994.tb06772.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANIER LL, 1988, J EXP MED, V167, P1572, DOI 10.1084/jem.167.5.1572; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; Marshall R D, 1974, Biochem Soc Symp, P17; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; MORETTA A, 1991, J EXP MED, V174, P1393, DOI 10.1084/jem.174.6.1393; SANCHEZMATEOS P, 1991, EUR J IMMUNOL, V21, P2317, DOI 10.1002/eji.1830211005; SANTIS AG, 1994, EUR J IMMUNOL, V24, P1692, DOI 10.1002/eji.1830240735; STENFLO J, 1982, J BIOL CHEM, V257, P2180; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TESTI R, 1990, J EXP MED, V172, P701, DOI 10.1084/jem.172.3.701; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; TESTI R, 1989, J IMMUNOL, V143, P1123; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZEIGLER SF, 1994, J IMMUNOL, V152, P1228; ZIEGLER SF, 1993, EUR J IMMUNOL, V23, P1643, DOI 10.1002/eji.1830230737; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502	34	61	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23117	23122		10.1074/jbc.272.37.23117	http://dx.doi.org/10.1074/jbc.272.37.23117			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287313	hybrid			2022-12-27	WOS:A1997XV74400024
J	Waters, SB; DAuria, M; Martin, SS; Nguyen, C; Kozma, LM; Luskey, KL				Waters, SB; DAuria, M; Martin, SS; Nguyen, C; Kozma, LM; Luskey, KL			The amino terminus of insulin-responsive aminopeptidase causes Glut4 translocation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED MEMBRANE AMINOPEPTIDASE; GLUCOSE-TRANSPORTER; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; MAJOR PROTEIN; VESICLES; LOCALIZATION; FIBROBLASTS; TRAFFICKING; MUSCLE	The insulin-responsive aminopeptidase (IRAP) is a constituent of the vesicles that contain the insulin-regulated glucose transporter (Glut4). Like Glu4, IRAP translocates to the cell surface in response to insulin, Microinjection into 3T3-L1 adipocytes of a glutathione S-transferase (GST) fusion protein containing the cytosolic portion of IRAP (GST-IRAP-(1-109)), resulted in translocation of Glut4 to the cell surface, Immunostaining of 3T3-L1 adipocytes for Glut4 showed that the percentage of cells with substantial cell surface Glut4 was 10% in unstimulated cells, 8% following injection of GST, and 27% following injection of GST-IRAP-(1-109). Increased cell surface Glut4 occurred within 5-10 min following injection and was maintained for at least 4 h, A fusion protein containing only 28 amino acids from IRAP (GST-IRAP-(55-82)) was as effective in increasing cell surface Glut4 as stimulation with 100 nM insulin (44% versus 43%, respectively), In contrast to insulin-stimulated Glut4 translocation, the redistribution of Glut4 following injection of GST-IRAP-(55-82) was not blocked by wortmannin or co-injection with a SH2 domain from the regulatory subunit of phosphatidylinositol 3-kinase. These data suggest that the amino terminus of IRAP interacts with a retention/sorting protein that also regulates the distribution of Glut4 in insulin-responsive cells.	METABOLEX INC, HAYWARD, CA 94545 USA; UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; VERHEY KJ, 1994, J BIOL CHEM, V269, P2353; YEH JI, 1995, BIOCHEMISTRY-US, V34, P15523, DOI 10.1021/bi00047a018	24	102	105	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23323	23327		10.1074/jbc.272.37.23323	http://dx.doi.org/10.1074/jbc.272.37.23323			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287343	hybrid			2022-12-27	WOS:A1997XV74400054
J	Davis, DA; Newcomb, FM; Starke, DW; Ott, DE; Mieyal, JJ; Yarchoan, R				Davis, DA; Newcomb, FM; Starke, DW; Ott, DE; Mieyal, JJ; Yarchoan, R			Thioltransferase (glutaredoxin) is detected-within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; OXIDATIVE STRESS; S-THIOLATION; ESCHERICHIA-COLI; VIRAL INFECTIVITY; CYSTEINE RESIDUES; RESPIRATORY BURST; VACCINIA VIRUS; TYPE-1; PROTEINS	Previous studies have suggested that the two conserved cysteines of the HIV-1 protease may be involved in regulating protease activity, Here, we examined diglutathionylated wild type protease (Cys-67-SSG, Cys-95-SSG) and the monoglutathionylated protease mutants (C67A, Cys-95-SSG and C95A, Cys-67-SSG) as potential substrates for thioltransferase (glutaredoxin). Time-dependent changes in the extent of deglutathionylation of each protein were assayed by reverse phase-high performance liquid chromatography. Glutathione alone was not an effective reductant, whereas thioltransferase displayed differential catalysis toward the Cys-95-SSG and Cys-67-SSG sites. At low thioltransferase concentrations (5 nM), deglutathionylation occurred almost exclusively at Cys-95-SSG. With substantially more thioltransferase (100 nM) Cys-67-SSG was partially deglutathionylated but only at 20% of the rate of Cys-95-SSG reduction, Treatment of the diglutathionylated protease with thioltransferase not only restored protease activity but generated an enzyme preparation that had a 3- to 5-fold greater specific activity relative to the fully reduced form, Immunoblot analysis of HIV-1(MN) virus with an antibody to thioltransferase detected a band co-migrating with recombinant thioltransferase that persisted following subtilisin treatment, indicating the presence of thioltransferase within HIV-1. Our results implicate thioltransferase in the regulation and/or maintenance of protease activity in HIV-1 infected cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; SCI APPLICAT INT CORP,AIDS VACCINE PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Davis, DA (corresponding author), NCI,HIV & AIDS MALIGNANCY BRANCH,NIH,BETHESDA,MD 20892, USA.							AHN BY, 1992, P NATL ACAD SCI USA, V89, P7060, DOI 10.1073/pnas.89.15.7060; ARAD G, 1995, J GEN VIROL, V76, P1917, DOI 10.1099/0022-1317-76-8-1917; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; AUKRUST P, 1995, BLOOD, V86, P258, DOI 10.1182/blood.V86.1.258.bloodjournal861258; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BUHL R, 1989, LANCET, V2, P1294; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; DARKE PL, 1994, BIOCHEMISTRY-US, V33, P98, DOI 10.1021/bi00167a013; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; DETTORRE C, 1994, ARCH BIOCHEM BIOPHYS, V313, P71, DOI 10.1006/abbi.1994.1360; DONALD LJ, 1991, J BIOL CHEM, V266, P20709; Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; GRASSER FA, 1992, ONCOGENE, V7, P1005; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRIERSON AW, 1994, J GEN VIROL, V75, P2761, DOI 10.1099/0022-1317-75-10-2761; Gvakharia BO, 1996, VIROLOGY, V226, P408, DOI 10.1006/viro.1996.0669; Gvakharia BO, 1996, J BIOL CHEM, V271, P15307, DOI 10.1074/jbc.271.26.15307; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; Humphrey RW, 1997, ANTIMICROB AGENTS CH, V41, P1017, DOI 10.1128/AAC.41.5.1017; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KARLSTROM AR, 1993, ARCH BIOCHEM BIOPHYS, V304, P163, DOI 10.1006/abbi.1993.1334; KARLSTROM AR, 1991, P NATL ACAD SCI USA, V88, P5552, DOI 10.1073/pnas.88.13.5552; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; KRAUSSLICH HG, 1992, J VIROL, V66, P150; Kurata SI, 1996, J BIOL CHEM, V271, P21798, DOI 10.1074/jbc.271.36.21798; LUNDSTROMLJUNG J, 1995, J BIOL CHEM, V270, P7822, DOI 10.1074/jbc.270.14.7822; MEEK TD, 1989, P NATL ACAD SCI USA, V86, P1841, DOI 10.1073/pnas.86.6.1841; MERGENER K, 1992, VIROLOGY, V186, P25, DOI 10.1016/0042-6822(92)90058-W; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MYERS G, 1995, HUMAN RETROVIRUSES A; OTT DE, 1995, AIDS RES HUM RETROV, V11, P1003, DOI 10.1089/aid.1995.11.1003; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; PACE GW, 1995, FREE RADICAL BIO MED, V19, P523, DOI 10.1016/0891-5849(95)00047-2; PIETTE J, 1994, CHEM-BIOL INTERACT, V91, P79, DOI 10.1016/0009-2797(94)90028-0; RAJAGOPAL I, 1995, J BIOL CHEM, V270, P27415, DOI 10.1074/jbc.270.46.27415; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; ROKUTAN K, 1991, J IMMUNOL, V147, P260; ROSE JR, 1995, J VIROL, V69, P2751; ROZELL B, 1993, EUR J CELL BIOL, V62, P314; SALTO R, 1994, J BIOL CHEM, V269, P10691; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; TERADA T, 1992, J BIOCHEM-TOKYO, V111, P688, DOI 10.1093/oxfordjournals.jbchem.a123819; WEBSTER A, 1994, J VIROL, V68, P7292, DOI 10.1128/JVI.68.11.7292-7300.1994; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500	55	129	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25935	25940		10.1074/jbc.272.41.25935	http://dx.doi.org/10.1074/jbc.272.41.25935			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325327	hybrid			2022-12-27	WOS:A1997YA35800082
J	Gerton, JL; Brown, PO				Gerton, JL; Brown, PO			The core domain of HIV-1 integrase recognizes key features of its DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA-VIRUS; SITE-DIRECTED MUTAGENESIS; CARBOXYL-TERMINAL DOMAINS; TYPE-1 INTEGRASE; CATALYTIC DOMAIN; RETROVIRAL DNA; ESCHERICHIA-COLI; PROTEIN INVITRO; IN-VITRO	We investigated which features of the substrate specificity of human immunodeficiency virus type 1 (HIV-1) integrase could be assigned to the central domain of the 288-residue HIV-1 integrase protein, composed of amino acids 50-212. This domain contains the active site and shares structural homology with a large family of polynucleotidyl transferases. Using model substrates with defined alterations in critical features we found that this domain alone is sufficient for recognition of: 1) the phylogenetically conserved CA/TG base pairs near the viral DNA end; 2) the 5'-terminal dinucleotide that is left unpaired after end processing; and 3) target DNA flanking the site of joining. Future efforts aimed at identifying specific amino acids involved in recognition of these key substrate features can now be targeted at this domain.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University								BOR YC, 1995, P NATL ACAD SCI USA, V92, P10334, DOI 10.1073/pnas.92.22.10334; Brown P.O., 1997, RETROVIRUSES; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHOW SA, 1994, J VIROL, V68, P3896, DOI 10.1128/JVI.68.6.3896-3907.1994; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CHOW SA, 1994, J VIROL, V68, P7869, DOI 10.1128/JVI.68.12.7869-7878.1994; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGLEMAN A, 1992, J VIROL, V66, P6361; HAGINOYAMAGISHI K, 1987, J VIROL, V61, P1964, DOI 10.1128/JVI.61.6.1964-1971.1987; JENKINS TM, 1995, P NATL ACAD SCI USA, V92, P6057, DOI 10.1073/pnas.92.13.6057; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; KATZMAN M, 1995, J VIROL, V69, P5687, DOI 10.1128/JVI.69.9.5687-5696.1995; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; MULLER HP, 1994, EMBO J, V13, P4707; PAHL A, 1995, J BIOL CHEM, V270, P2957, DOI 10.1074/jbc.270.7.2957; PRUSS D, 1994, J BIOL CHEM, V269, P25031; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; PURASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; ROTH MJ, 1989, CELL, V58, P47, DOI 10.1016/0092-8674(89)90401-7; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; Shibagaki Y, 1997, J BIOL CHEM, V272, P8361, DOI 10.1074/jbc.272.13.8361; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419	45	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25809	25815		10.1074/jbc.272.41.25809	http://dx.doi.org/10.1074/jbc.272.41.25809			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325310	hybrid			2022-12-27	WOS:A1997YA35800065
J	Michel, JB; Feron, O; Sase, K; Prabhakar, P; Michel, T				Michel, JB; Feron, O; Sase, K; Prabhakar, P; Michel, T			Caveolin versus calmodulin - Counterbalancing allosteric modulators of endothelial nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; BINDING; MUTAGENESIS; RECOGNITION; EXPRESSION; ACYLATION; TARGETS	Nitric oxide is synthesized in diverse mammalian tissues by a family of calmodulin-dependent nitric oxide synthases, The endothelial isoform of nitric oxide synthase (eNOS) is targeted to the specialized signal-transducing membrane domains termed plasmalemmal caveolae, Caveolin, the principal structural protein in caveolae, interacts with eNOS and leads to enzyme inhibition in a reversible process modulated by Ca2+-calmodulin (Michel, J. B., Feron, O., Sacks, D., and Michel, T. (1997) J. Biol. Chem. 272, 15583-15586). Caveolin also interacts with other structurally distinct signaling proteins via a specific region identified within the caveolin sequence (amino acids 82-101) that appears to subserve the role of a ''scaffolding domain.'' We now report that the co-immunoprecipitation of eNOS with caveolin is completely and specifically blocked by an oligopeptide corresponding to the caveolin scaffolding domain, Peptides corresponding to this domain markedly inhibit nitric oxide synthase activity in endothelial membranes and interact directly with the enzyme to inhibit activity of purified recombinant eNOS expressed in Escherichia coli, The inhibition of purified eNOS by the caveolin scaffolding domain peptide is competitive and completely reversed by Ca2+-calmodulin. These studies establish that caveolin, via its scaffolding domain, directly forms an inhibitory complex with eNOS and suggest that caveolin inhibits eNOS by abrogating the enzyme's activation by calmodulin.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CARDIOVASC DIV, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School			FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCONI L, 1995, MOL PHARMACOL, V47, P655; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; HANSON PI, 1992, J BIOL CHEM, V267, P17216; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Michel JB, 1997, FEBS LETT, V405, P356, DOI 10.1016/S0014-5793(97)00222-6; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; NATHAN C, 1994, J BIOL CHEM, V269, P13725; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Sase K, 1997, TRENDS CARDIOVAS MED, V7, P28, DOI 10.1016/S1050-1738(96)00121-1; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435	24	268	273	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25907	25912		10.1074/jbc.272.41.25907	http://dx.doi.org/10.1074/jbc.272.41.25907			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325323	hybrid			2022-12-27	WOS:A1997YA35800078
J	TorresRamos, CA; Prakash, S; Prakash, L				TorresRamos, CA; Prakash, S; Prakash, L			Requirement of yeast DNA polymerase delta in post-replicational repair of UV-damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INDUCED MUTAGENESIS; ESCHERICHIA-COLI; RAD18; PROTEINS; MUTATIONS; MUTANTS; EPSILON; BYPASS; GENOME	DNA lesions in the template strand pose a block to the replication machinery, Replication across such lesions may occur by a mutagenic bypass process in which a wrong base is inserted opposite the lesion or may involve processes that are relatively error-free. Genetic studies in the yeast Saccharomyces cerevisiae have indicated the requirement of REV3-encoded DNA polymerase in mutagenic bypass, The DNA polymerase responsible for error-free bypass, however, has not been identified, but genetic studies implicating proliferating cell nuclear antigen in this process have suggested that either DNA polymerase delta or DNA polymerase epsilon may be involved, Here, we use temperature sensitive (ts) conditional lethal mutations of the S. cerevisiae POL2 and POL3 genes, which encode DNA polymerase epsilon and delta, respectively, and show that post-replicational bypass of UV-damaged DNA is severely inhibited in the pol3-3 mutant at the restrictive temperature, By contrast, the pol2-18 mutation has no adverse effect on this process at the restrictive temperature, From these observations, we infer a requirement of DNA polymerase delta in post-replicative bypass of UV-damaged DNA.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NIGMS NIH HHS [GM19261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARMSTRONG JD, 1994, MUTAT RES-DNA REPAIR, V315, P281, DOI 10.1016/0921-8777(94)90039-6; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; CONRAD MN, 1983, MOL CELL BIOL, V3, P1000, DOI 10.1128/MCB.3.6.1000; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FRIEDBERG EC, 1995, DNA REPAIR; GIBBS PEM, 1995, NUCLEIC ACIDS RES, V23, P1919, DOI 10.1093/nar/23.11.1919; GIBBS PEM, 1993, J BACTERIOL, V175, P2607, DOI 10.1128/JB.175.9.2607-2612.1993; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; LAWRENCE CW, 1982, ADV GENET, V21, P173, DOI 10.1016/S0065-2660(08)60299-0; LAWRENCE CW, 1985, MOL GEN GENET, V200, P86, DOI 10.1007/BF00383317; LEMONTT JF, 1970, GENETICS, V68, P21; Longley MJ, 1997, J BIOL CHEM, V272, P10917; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TorresRamos CA, 1996, P NATL ACAD SCI USA, V93, P9676, DOI 10.1073/pnas.93.18.9676; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	27	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25445	25448		10.1074/jbc.272.41.25445	http://dx.doi.org/10.1074/jbc.272.41.25445			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325255	hybrid			2022-12-27	WOS:A1997YA35800010
J	Zhou, YT; Shimabukuro, M; Lee, Y; Koyama, K; Trieu, F; Unger, RH				Zhou, YT; Shimabukuro, M; Lee, Y; Koyama, K; Trieu, F; Unger, RH			Leptin normalizes the impaired response of proinsulin mRNA to long chain fatty acids in heterozygous Zucker diabetic fatty rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLETS; RECEPTOR; OBESITY; MUTATION; WEIGHT; LIPOTOXICITY; PATHOGENESIS; GLUCOSE; GENE	To determine if underleptinization of islets of Zucker diabetic fatty (ZDF) rats is the proximal cause of their inability to compensate for obesity, we compared the proinsulin/beta-actin mRNA ratio in heterozygous (fa/+) ZDF rats with that of wild-type (+/+) and homozygous (fa/fa) ZDF rats. In +/+ islets cultured with 2 mM free fatty acids (FFA) the proinsulin mRNA ratio rose 2.4-fold at 12 h. In fa/+ islets, the ratio rose only 65% above normal. There was no change in fa/fa islets. The presence of leptin (20 ng/ml) in the culture medium increased the FFA-induced response of proinsulin mRNA of fa/+ islets to that of +/+ islets while reducing FFA incorporation into triglycerides. The leptin-induced improvement in the proinsulin mRNA response was independent of any changes in glucose usage. These findings support a causal relationship between diminished leptin action on islets and the impaired beta-cell response to FFA in ZDF rats.	UNIV TEXAS,SW MED CTR,CTR DIABET RES,DEPT INTERNAL MED,GIFFORD LABS,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CTR DIABET RES,DEPT BIOCHEM,GIFFORD LABS,DALLAS,TX 75235; DEPT VET AFFAIRS MED CTR,DALLAS,TX 75216	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Shimabukuro, Michio/0000-0001-7835-7665	NIDDK NIH HHS [DK02700-37] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK002700, R01DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MATCHINSKY FM, 1980, DIABETES 1979, P154; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1276, DOI 10.1210/endo-100-5-1276; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1	20	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25648	25651		10.1074/jbc.272.41.25648	http://dx.doi.org/10.1074/jbc.272.41.25648			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325287	hybrid			2022-12-27	WOS:A1997YA35800042
J	McPhie, DL; Lee, RKK; Eckman, CB; Olstein, DH; Durham, SP; Yager, D; Younkin, SG; Wurtman, RJ; Neve, RL				McPhie, DL; Lee, RKK; Eckman, CB; Olstein, DH; Durham, SP; Yager, D; Younkin, SG; Wurtman, RJ; Neve, RL			Neuronal expression of beta-amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid beta and cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE; CELLS; IDENTIFICATION; BRAIN; NEUROTOXICITY	Five different Alzheimer mutations of the beta-amyloid precursor protein (APP) were expressed in neurons via recombinant herpes simplex virus (HSV) vectors, and the levels of APP metabolites were quantified, The predominant intracellular accumulation product was a C-terminal fragment of APP that co-migrated with the protein product of an HSV recombinant expressing the C-terminal 100 amino acids (C100) of APP, which is known to cause neurodegeneration. Fractionation studies revealed that the C-terminal fragment generated by expression of the Alzheimer mutations, Like C100, partitioned into membrane fractions and was particularly enriched in synaptosomes. The processing abnormality caused by expression of the Alzheimer mutations occurs predominantly in neurons. Expression of these mutations or of C100 alone in neurons caused increased secretion of A beta relative to that of neurons infected with wild type APP recombinant vectors, These data show that expression of APP mutations that cause familial Alzheimer's disease increases the intracellular accumulation of potentially amyloidogenic and neurotoxic C-terminal fragments of APP in neurons.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MAYO CLIN JACKSONVILLE,JACKSONVILLE,FL 32224	Massachusetts Institute of Technology (MIT); Mayo Clinic	McPhie, DL (corresponding author), HARVARD UNIV,MCLEAN HOSP,SCH MED,DEPT GENET,BELMONT,MA 02178, USA.				NATIONAL INSTITUTE ON AGING [R01AG012954] Funding Source: NIH RePORTER; NIA NIH HHS [AG12954] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CITRON M, 1996, NEURON, V17, P1471; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DYRKS T, 1992, J BIOL CHEM, V267, P18210; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FELSENSTEIN KM, 1993, NEUROSCI LETT, V152, P185, DOI 10.1016/0304-3940(93)90514-L; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N; FUKUCHI KI, 1994, EXP NEUROL, V127, P253, DOI 10.1006/exnr.1994.1101; GARDELLA JE, 1993, BIOCHEM J, V294, P667, DOI 10.1042/bj2940667; GRAY EG, 1962, J ANAT, V96, P79; HAASS C, 1991, J NEUROSCI, V11, P3783; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; LEVISON SW, 1991, CULTURING NERVE CELL, P310; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; NEVE RL, 1992, P NATL ACAD SCI USA, V89, P3448, DOI 10.1073/pnas.89.8.3448; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; NEVE RL, 1995, METH NEUROSCI, V25, P163; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SOPHER BL, 1994, MOL BRAIN RES, V26, P207, DOI 10.1016/0169-328X(94)90092-2; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TATE B, 1992, P NATL ACAD SCI USA, V89, P7090, DOI 10.1073/pnas.89.15.7090; Tjernberg LO, 1997, J BIOL CHEM, V272, P1870, DOI 10.1074/jbc.272.3.1870; VANBROECKHOVEN CL, 1995, EUR NEUROL, V35, P8, DOI 10.1159/000117083; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	33	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24743	24746		10.1074/jbc.272.40.24743	http://dx.doi.org/10.1074/jbc.272.40.24743			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312066	hybrid			2022-12-27	WOS:A1997XY97000005
J	Motevalli, M; GoldschmidtClermont, PJ; Virgil, D; Kwiterovich, PO				Motevalli, M; GoldschmidtClermont, PJ; Virgil, D; Kwiterovich, PO			Abnormal protein tyrosine phosphorylation in fibroblasts from hyperapobetalipoproteinemia subjects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYLATION STIMULATING PROTEIN; CORONARY-ARTERY DISEASE; SERUM BASIC-PROTEIN; ORAL FAT LOAD; HYPERAPOB FIBROBLASTS; KINASE; LIPOPROTEIN; INSULIN; PURIFICATION; PHOSPHATASES	The stimulatory effects of three normal human serum basic proteins (EP), BP I (M-r 14,000, pI 9.10), BP II (M-r 27, 500, pI 8.48), and BP III (M-r 55,000, pI 8.73) on cellular triglyceride and cholesterol formation require intact protein-tyrosine kinase phosphorylation (TKP). Here we examined whether there is an abnormality in TKP in cultured fibroblasts from 11 patients with hyperapobetalipoproteinemia (hyperapoB) that manifest two acylation-stimulatory defects, decreased stimulation of triglyceride synthesis by BP I but enhanced formation of cholesterol by BP II. Soluble and insoluble proteins in Triton X-100 extracts were isolated by immunoprecipitation with a monoclonal anti-phosphotyrosine antibody (MAPA) bound to agarose beads and by ultracentrifugation, respectively, from confluent fibroblasts after incubation for 24 h in supplemented serum-free and lipid-free medium (DMEM/F12). Western blots of insoluble proteins showed that group (Gp) II (M-r 36,000-55,000) and Gp III (M-r 14,000-35,000) from hyperapoB cells, grown in DMEM/F12 medium without BP, had significantly decreased reactivity to MAPA. No significant differences in reactivity to MAPA were detected between normal and hyperapoB cells for Gp I (M-r 97-120,000). BP II, but not BP I or BP III, reversed the decreased reactivity of Gp II and Gp III to MAPA in hyperapoB cells. Sodium vanadate, an inhibitor of phosphotyrosine phosphatases, did not reverse the deficiency in TKP or the 50% deficiency in the stimulation of mass triglyceride by BP I in hyperapoB cells. Tyrosine-phosphorylated Erk-2, a mitogen-activated protein kinase, identified as one of the proteins in Gp II, was significantly decreased in hyperapoB cells. These results provide further evidence for abnormal protein TKP in hyperapoB cells and suggest a possible link between atherosclerotic changes in hyperapoB patients and growth factors upstream from mitogen-activated protein kinase.	JOHNS HOPKINS UNIV HOSP,LIPID RES ATHEROSCLEROSIS UNIT,DEPT PEDIAT,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,LIPID RES ATHEROSCLEROSIS UNIT,DEPT MED,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,DIV CARDIOL,DEPT MED,BERNARD LAB,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV HOSP,DIV CARDIOL,DEPT PEDIAT,BERNARD LAB,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032193] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047212, P50HL052315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52315-03, 1P50HL-47212-05] Funding Source: Medline; NICHD NIH HHS [R01HD-32193-03] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABLER A, 1992, J BIOL CHEM, V267, P3946; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AMOROSA LF, 1984, BIOCHIM BIOPHYS ACTA, V792, P192, DOI 10.1016/0005-2760(84)90222-4; BACHORIK PS, 1996, CIRCULATION S1, V94, P347; BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BOLEN JB, 1993, ONCOGENE, V8, P2025; CIANFLONE K, 1989, J LIPID RES, V30, P1727; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; CORESH J, 1993, J LIPID RES, V34, P1687; DISE KR, 1993, ECL HIGHLIGHTS, V1, P4; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GENEST J, 1986, ARTERIOSCLEROSIS, V6, P297, DOI 10.1161/01.ATV.6.3.297; GERMINARIO R, 1993, METABOLISM, V40, P574; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HRESKO RC, 1990, J BIOL CHEM, V265, P21075; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KWITEROVICH P, 1990, P NATL ACAD SCI USA, V87, P8980, DOI 10.1073/pnas.87.22.8980; Kwiterovich Peter O. Jr., 1993, Current Opinion in Lipidology, V4, P133, DOI 10.1097/00041433-199304000-00009; KWITEROVICH PO, 1993, AM J CARDIOL, V71, P631, DOI 10.1016/0002-9149(93)91002-Y; KWITEROVICH PO, 1994, ARTERIOSCLER THROMB, V14, P1, DOI 10.1161/01.ATV.14.1.1; KWITEROVICH PO, 1995, ARTERIOSCL THROM VAS, V15, P1195, DOI 10.1161/01.ATV.15.8.1195; KWITEROVICH PO, 1991, CLIN CHEM, V37, P317; KWITEROVICH PO, 1995, CIRCULATION, V92, P426; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONTESANO R, 1988, J CELL PHYSIOL, V134, P460, DOI 10.1002/jcp.1041340318; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; SNIDERMAN A, 1987, NIH872646 US DEP HLT, P293; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; TENG B, 1988, CAN J PHYSIOL PHARM, V66, P239, DOI 10.1139/y88-040; TOMASKA L, 1993, BIOCHEM J, V293, P215, DOI 10.1042/bj2930215; YASRUEL Z, 1991, LIPIDS, V26, P495, DOI 10.1007/BF02536592	34	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24703	24709		10.1074/jbc.272.39.24703	http://dx.doi.org/10.1074/jbc.272.39.24703			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305942	hybrid			2022-12-27	WOS:A1997XY51500093
J	Rosendahl, MS; Ko, SC; Long, DL; Brewer, MT; Rosenzweig, B; Hedl, E; Anderson, L; Pyle, SM; Moreland, J; Meyers, MA; Kohno, T; Lyons, D; Lichenstein, HS				Rosendahl, MS; Ko, SC; Long, DL; Brewer, MT; Rosenzweig, B; Hedl, E; Anderson, L; Pyle, SM; Moreland, J; Meyers, MA; Kohno, T; Lyons, D; Lichenstein, HS			Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIMERIC MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; TNF RECEPTOR; CELL; INHIBITOR; MEMBRANE; DISINTEGRIN; CLEAVAGE; CA2	Tumor necrosis factor-alpha (TNF) is initially expressed as a 26-kDa membrane-bound precusor protein (pro-TNF) that is shed proteolytically from the cell surface, releasing soluble 17-kDa TNF. We have identified human ADAM 10 (HuAD10) from THP-1 membrane extracts as a metalloprotease that specifically clips a peptide substrate spanning the authentic cleavage site between Ala(76) and Val(77) in pro-TNF. To confirm that HuAD10 has TNF processing activity, we cloned, expressed, and purified an active, truncated form of HuAD10. Characterization of recombinant HuAD10 (rHuAD10) suggests that this enzyme has many of the properties (i.e. , substrate specificity, metalloprotease activity, cellular location) expected for a physiologically relevant TNF-processing enzyme.			Rosendahl, MS (corresponding author), AMGEN INC,8200 WALNUT ST,BOULDER,CO 80301, USA.		Hedl, Erik/F-3479-2011	Hedl, Erik/0000-0002-9419-4648				Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; MAEDA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P115, DOI 10.1016/0005-2736(83)90404-2; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MouradaSilva AM, 1996, EUR J IMMUNOL, V26, P2000, DOI 10.1002/eji.1830260905; MULLBERG J, 1995, J IMMUNOL, V155, P5198; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; ROBACHEGALLEA S, 1995, J BIOL CHEM, V270, P23688, DOI 10.1074/jbc.270.40.23688; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	22	172	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24588	24593		10.1074/jbc.272.39.24588	http://dx.doi.org/10.1074/jbc.272.39.24588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305925	hybrid			2022-12-27	WOS:A1997XY51500076
J	Severinov, K; Mooney, R; Darst, SA; Landick, R				Severinov, K; Mooney, R; Darst, SA; Landick, R			Tethering of the large subunits of Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; FUNCTIONAL TOPOGRAPHY; BETA-SUBUNIT; TRANSCRIPTION; ELONGATION; GENOME; PURIFICATION; TERMINATION; EXPRESSION; EVOLUTION	The rpoB and rpoC genes of eubacteria and archaea, coding, respectively, for the beta and beta'-like subunits of DNA-dependent RNA polymerase, are organized in an operon with rpoB always preceding rpoC, Here, we show that in Escherichia coli the two genes can be fused and that the resulting 2751-amino acid beta::beta' fusion polypeptide assembles into functional RNA polymerase in vivo and in vitro, The results establish that the C terminus of the beta subunit and the N terminus of the beta' subunit are in close proximity to each other on the surface of the assembled RNA polymerase during all phases of the transcription cycle and also suggest that RNA polymerase assembly in vivo may occur co-translationally.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	Rockefeller University; University of Wisconsin System; University of Wisconsin Madison			Severinov, Konstantin/C-8545-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053759, R29GM038660, R01GM038660, R37GM038660] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38660, GM53759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Buhler J.M., 1987, RNA POLYM REGULATION, P25; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Dykxhoorn DM, 1996, MOL MICROBIOL, V19, P483, DOI 10.1046/j.1365-2958.1996.384913.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GODOVIKOVA TS, 1987, EUR J BIOCHEM, V166, P611, DOI 10.1111/j.1432-1033.1987.tb13557.x; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; Ishihama A, 1981, Adv Biophys, V14, P1; Jansma DB, 1996, NUCLEIC ACIDS RES, V24, P4543, DOI 10.1093/nar/24.22.4543; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; LANDICK R, 1990, J BACTERIOL, V172, P2844, DOI 10.1128/jb.172.6.2844-2854.1990; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; LU J, 1996, GENES CELLS, V1, P819; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; RIDLEY SP, 1982, J BACTERIOL, V152, P736; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WILSON DW, 1988, NUCLEIC ACIDS RES, V16, P8097; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	27	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24137	24140		10.1074/jbc.272.39.24137	http://dx.doi.org/10.1074/jbc.272.39.24137			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305860	hybrid			2022-12-27	WOS:A1997XY51500011
J	Culotta, VC; Klomp, LWJ; Strain, J; Casareno, RLB; Krems, B; Gitlin, JD				Culotta, VC; Klomp, LWJ; Strain, J; Casareno, RLB; Krems, B; Gitlin, JD			The copper chaperone for superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; SACCHAROMYCES-CEREVISIAE; CANDIDATE GENE; WILSON DISEASE; MENKES DISEASE; YEAST; ENCODES; PROTEIN; CLONING	Copper is distributed to distinct localizations in the cell through diverse pathways. We demonstrate here that the delivery of copper to copper/zinc superoxide dismutase (SOD1) is mediated through a soluble factor identified as Saccharomyces cerevisiae LYS7 and human CCS (copper chaperone for SOD). This factor is specific for SOD1 and does not deliver copper to proteins in the mitochondria, nucleus, or secretory pathway. Yeast cells containing a lys7 Delta null mutation have normal levels of SOD1 protein, but fail to incorporate copper into SOD1, which is therefore devoid of superoxide scavenging activity. LYS7 and CCS specifically restore the biosynthesis of holoSOD1 in vivo. Elucidation of the CCS copper delivery pathway may permit development of novel therapeutic approaches to human diseases that involve SOD1, including amyotrophic lateral sclerosis.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	Culotta, VC (corresponding author), JOHNS HOPKINS UNIV, SCH PUBL HLTH,DEPT ENVIRONM HLTH SCI, DIV TOXICOL SCI,615 N WOLFE ST, RM 7032, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044464, R01DK044464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050016, R01GM050016] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44464] Funding Source: Medline; NIGMS NIH HHS [GM 50016] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BEEM KM, 1974, J BIOL CHEM, V249, P7298; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1994, SCIENCE, V266, P1586, DOI 10.1126/science.7985031; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; NULPE C, 1993, NAT GENET, V3, P7; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Petrovic N, 1996, J BIOL CHEM, V271, P28331, DOI 10.1074/jbc.271.45.28331; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHERMAN F, 1978, METHODS YEAST GENETI, P163; SIKORSKI RS, 1989, GENETICS, V122, P19; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	43	667	682	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23469	23472		10.1074/jbc.272.38.23469	http://dx.doi.org/10.1074/jbc.272.38.23469			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295278	hybrid			2022-12-27	WOS:A1997XX38100003
J	Matsunaga, I; Yokotani, N; Gotoh, O; Kusunose, E; Yamada, M; Ichihara, K				Matsunaga, I; Yokotani, N; Gotoh, O; Kusunose, E; Yamada, M; Ichihara, K			Molecular cloning and expression of fatty acid alpha-hydroxylase from Sphingomonas paucimobilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; OXIDATION; METABOLISM; SEQUENCE; SYNTHASE; LOCALIZATION; PEROXISOMES; PRODUCT; PROTEIN; SYSTEM	Fatty acid alpha-hydroxylase (FAAH) catalyzes the initial reaction in alpha-oxidation of fatty acid to produce 2-hydroxy fatty acid, FAAH activity has been detected in a wide range of organisms from prokaryotes to eukaryotes. Here, we describe cloning of the FAAH gene from Sphingomonas paucimobilis, a sphingolipid- and 2-hydroxyristic acid-rich bacterium, The isolated gene encoded 415 amino acids, A homology search revealed that amino acid sequences highly conserved in cytochrome P450 (P450) were present in FAAH, Although the heme-bindimg cysteine was recognizable at position 361, the consensus in the heme-binding region was modified by an insertion. Overall, FAAH has no significant identity to the known P450s, CO difference spectrum of recombinant FAAH showed the characteristic one of P450, except this peak was at 445 nm. These results suggest bacterial FAAH is a novel member of the P450 superfamily.	SAITAMA CANC CTR,RES INST,DEPT BIOCHEM,INA,SAITAMA 362,JAPAN		Matsunaga, I (corresponding author), OSAKA CITY UNIV,SCH MED,TONEYAMA INST TB RES,SECT MOL REGULAT,5-1-1 TONEYAMA,TOYONAKA,OSAKA 560,JAPAN.			Matsunaga, Isamu/0000-0001-9541-350X				AKANUMA H, 1978, J NEUROCHEM, V30, P1051, DOI 10.1111/j.1471-4159.1978.tb12398.x; AOYAMA T, 1989, J BIOL CHEM, V264, P10388; Borge GIA, 1997, BBA-LIPID LIPID MET, V1344, P47; CASTELFRANCO PAUL, 1955, JOUR BIOL CHEM, V214, P567; Croes K, 1996, EUR J BIOCHEM, V240, P674, DOI 10.1111/j.1432-1033.1996.0674h.x; Davis LG, 1994, BASIC METHODS MOL BI; FULCO AJ, 1967, J BIOL CHEM, V242, P3608; Gotoh O, 1996, J MOL BIOL, V264, P823, DOI 10.1006/jmbi.1996.0679; Gotoh O., 1993, CYTOCHROME P450, P255; HITCHCOC.C, 1966, BIOCHIM BIOPHYS ACTA, V116, P413, DOI 10.1016/0005-2760(66)90112-3; HORIUCHI T, 1993, CYTOCHROME P 450, P186; HOSHI M, 1973, J BIOL CHEM, V248, P4123; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARKOVETZ AJ, 1972, LIPIDS, V7, P159, DOI 10.1007/BF02533056; Matsui K, 1996, FEBS LETT, V394, P21, DOI 10.1016/0014-5793(96)00924-6; Matsunaga I, 1996, FEBS LETT, V386, P252, DOI 10.1016/0014-5793(96)00451-6; MATSUNAGA I, 1994, BIOCHEM BIOPH RES CO, V201, P1554, DOI 10.1006/bbrc.1994.1881; MIHALIK SJ, 1995, EUR J BIOCHEM, V232, P545, DOI 10.1111/j.1432-1033.1995.tb20842.x; MIYATA A, 1994, BIOCHEM BIOPH RES CO, V200, P1728, DOI 10.1006/bbrc.1994.1652; MURAD S, 1975, J BIOL CHEM, V250, P5841; MURALIDHARAN FN, 1987, INT J BIOCHEM, V19, P663, DOI 10.1016/0020-711X(87)90078-4; MURALIDHARAN VB, 1984, J BIOL CHEM, V259, P3021; NARHI LO, 1986, J BIOL CHEM, V261, P7160; OHASHI K, 1992, J BIOL CHEM, V267, P789; OMURA T, 1964, J BIOL CHEM, V239, P2379; Pahan K, 1995, FEBS LETT, V377, P213, DOI 10.1016/0014-5793(95)01341-5; PAHAN K, 1993, FEBS LETT, V333, P154, DOI 10.1016/0014-5793(93)80395-B; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; SAWAMURA A, 1993, BIOCHIM BIOPHYS ACTA, V1168, P30; SINGH I, 1979, J BIOL CHEM, V254, P7698; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Steinberg D, 1989, METABOLIC BASIS INHE, P1533; STUMPF PK, 1956, J BIOL CHEM, V223, P643; TSAI SC, 1969, J BIOL CHEM, V244, P2682; YABUUCHI E, 1990, MICROBIOL IMMUNOL, V34, P99, DOI 10.1111/j.1348-0421.1990.tb00996.x; YANO I, 1971, BIOCHIM BIOPHYS ACTA, V239, P513	36	57	58	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23592	23596		10.1074/jbc.272.38.23592	http://dx.doi.org/10.1074/jbc.272.38.23592			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295298	hybrid			2022-12-27	WOS:A1997XX38100023
J	Newlon, MG; Roy, M; Hausken, ZE; Scott, JD; Jennings, PA				Newlon, MG; Roy, M; Hausken, ZE; Scott, JD; Jennings, PA			The A-kinase anchoring domain of type II alpha cAMP-dependent protein kinase is highly helical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; FOLDING INITIATION SITES; GROUP HYDROGEN-EXCHANGE; CHEMICAL-SHIFT INDEX; NMR-SPECTROSCOPY; IMPROVED SENSITIVITY; SECONDARY STRUCTURE; LARGER PROTEINS; CIRCULAR-DICHROISM; LINEAR PEPTIDES	Subcellular localization of the type II cAMP-dependent protein kinase is controlled by interaction of the regulatory subunit with A-Kinase Anchoring Proteins (AKAPs). This contribution examines the solution structure of a 44-residue region that is sufficient for high affinity binding to AKAPs. The N-terminal dimerization domain of the type II alpha regulatory subunit of cAMP-dependent protein kinase was expressed to high levels on minimal media and uniformly isotopically enriched with N-15 and C-13 nuclei. Sequence-specific backbone and side chain resonance assignments have been made for greater than 95% of the amino acids in the free dimerization domain using high resolution multidimensional heteronuclear NMR techniques. Contrary to the results from secondary structure prediction algorithms, our analysis indicates that the domain is :highly helical with a single 3-5-residue sequence involved in a beta-strand. The assignments and secondary structure analysis provide the basis for analyzing the structure and dynamics of the dimerization domain both free and complexed with specific anchoring proteins.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; OREGON HLTH SCI UNIV, VOLLUM INST, HOWARD HUGHES MED INST, PORTLAND, OR 97201 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NCI NIH HHS [CA09523] Funding Source: Medline; NIDDK NIH HHS [DK44239] Funding Source: Medline; NIGMS NIH HHS [GM07313] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURELL L, 1977, THROMB RES, V11, P595, DOI 10.1016/0049-3848(77)90018-4; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAHMACHARI SK, 1982, BIOPOLYMERS, V21, P1107, DOI 10.1002/bip.360210608; BURGERING MJM, 1994, BIOCHEMISTRY-US, V33, P15036, DOI 10.1021/bi00254a012; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1991, J BIOMOL NMR, V1, P99; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MANNING MC, 1989, BIOCHEMISTRY-US, V28, P8609, DOI 10.1021/bi00447a051; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MCCOY MA, 1992, J MAGN RESON, V98, P674, DOI 10.1016/0022-2364(92)90023-Z; MCCOY MA, 1992, J AM CHEM SOC, V114, P2108, DOI 10.1021/ja00032a026; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Newton AC, 1996, CURR BIOL, V6, P806, DOI 10.1016/S0960-9822(02)00600-0; PATT SL, 1992, J MAGN RESON, V96, P94, DOI 10.1016/0022-2364(92)90289-J; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCHLEUCHER J, 1993, ANGEW CHEM, V105, P1518; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6348, DOI 10.1021/bi00076a007; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6356, DOI 10.1021/bi00076a008; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; STARICH MR, 1996, J MOL BIOL, V33, P15036; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Venyaminov SY, 1996, DETERMINATION PROTEI; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAO J, 1994, J MOL BIOL, V243, P736, DOI 10.1016/0022-2836(94)90044-2	73	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23637	23644		10.1074/jbc.272.38.23637	http://dx.doi.org/10.1074/jbc.272.38.23637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295304	hybrid, Green Submitted			2022-12-27	WOS:A1997XX38100029
J	Owczarek, CM; Zhang, Y; Layton, MJ; Metcalf, D; Roberts, B; Nicola, NA				Owczarek, CM; Zhang, Y; Layton, MJ; Metcalf, D; Roberts, B; Nicola, NA			The unusual species cross-reactivity of the leukemia inhibitory factor receptor alpha-chain is determined primarily by the immunoglobulin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; MOLECULAR-CLONING; EXPRESSION CLONING; HUMAN HOMOLOG; GENE FAMILY; BINDING; MURINE; GP130; COMPLEX	Human leukemia inhibitory factor (hLIF) binds to both human and mouse LIF receptors (LIFRs), while mouse LIF (mLIF) binds only to mouse LIFRs. Furthermore, hLIF binds with much higher affinity to the mouse LIFR (mLIFR) alpha-chain than does mLIF itself. To define the structural elements of the mLIFR alpha-chain conferring high affinity binding of hLIF and the species-specific interaction with mLIF, we first constructed C-terminally truncated extracellular domains of both the mLIFR and the human LIFR (hLIFR) alpha-chains, which contained only the two hemopoietin domains separated by an immunoglobulin-like domain. These recombinant truncated LIFR alpha-chains had identical binding and biological characteristics to either their naturally occurring or transfected counterparts. On the basis of this, we have generated eight interspecies receptor chimeras by combining different regions of the mouse and human LIFR sequence. Surprisingly, the immunoglobulin-like domain of the mLIFR, alpha-chain played the predominant role in receptor-ligand interactions. Moreover, both high affinity binding for hLIF and the species-specific binding for mLIF mapped to the same domain of mLIFR molecule, These findings should enable the development of a ''humanized'' mouse LIFR that could act as a potent antagonist of hLIF biological activities in vivo.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; COOPERAT RES CTR CELLULAR GROWTH FACTORS, MELBOURNE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Layton, Meredith/E-9171-2014; Nicola, Nicos/D-2989-2011	Nicola, Nicos/0000-0003-1054-7889	NCI NIH HHS [CA22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GOUGH NM, 1988, P NATL ACAD SCI USA, V85, P2623, DOI 10.1073/pnas.85.8.2623; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; MCPHERSON GA, 1985, KINETIC EBDA LIGAND; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TOMIDA M, 1993, FEBS LETT, V334, P193, DOI 10.1016/0014-5793(93)81710-H; TOMIDA M, 1994, J BIOCHEM-TOKYO, V115, P557, DOI 10.1093/oxfordjournals.jbchem.a124375; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WARE CB, 1995, DEVELOPMENT, V121, P1283; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348	47	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23976	23985		10.1074/jbc.272.38.23976	http://dx.doi.org/10.1074/jbc.272.38.23976			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295349	hybrid			2022-12-27	WOS:A1997XX38100074
J	Ohta, T; Kinoshita, T; Naito, M; Nozaki, T; Masutani, M; Tsuruo, T; Miyajima, A				Ohta, T; Kinoshita, T; Naito, M; Nozaki, T; Masutani, M; Tsuruo, T; Miyajima, A			Requirement of the caspase-3/CPP32 protease cascade for apoptotic death following cytokine deprivation in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; POLY(ADP-RIBOSE) POLYMERASE; ICE/CED-3 PROTEASE; EXPRESSION; FAS; ICE; RECEPTOR; ACTIVATION; SURVIVAL; IMMUNE	Hematopoietic cytokines transduce cell survival signals, which are distinct from the signals necessary for the stimulation of DNA synthesis, Recently, the Ras and phosphatidylinositol 3-kinase pathways have been shown to play important roles in preventing apoptosis in various cell types, e.g. hematopoietic cells and neuronal cells, Withdrawal of cytokine(s), in turn, results in rapid inactivation of these survival pathways and eventually leads to cell death accompanied by the hallmarks of apoptosis, However, the mechanism of cell death caused by cytokine deprivation has not been fully elucidated, In this study, we demonstrate that caspase-3/CPP32, a member of the caspase/interleukin-1 beta-converting enzyme family, is activated upon interleukin (IL)-3 deprivation in IL-3-dependent cells as well as IL-2 deprivation in IL-2-dependent cells, In addition, poly(ADP-ribose) polymerase, a cellular substrate for the caspase family proteases, was degraded into apoptotic fragments in both cell lines after cytokine removal, Furthermore, inhibition of a caspase family protease by synthetic peptides suppressed apoptotic death, These results indicate that the activation of a caspase-like protease(s) is required for the progression of apoptosis following cytokine deprivation. However, readdition of IL-3 did not restore the proliferative potential of the cells that survived in the presence of the peptide inhibitor after IL-3 depletion, Therefore, cellular commitment to apoptosis appears to precede the activation of a caspase-like protease(s).	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,LAB CELLULAR BIOSYNTH,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BIOMED RES LAB,BUNKYO KU,TOKYO 113,JAPAN; NATL CANC CTR,RES INST,DIV BIOCHEM,CHUO KU,TOKYO 104,JAPAN	University of Tokyo; University of Tokyo; National Cancer Center - Japan								ALLEN PD, 1993, BLOOD REV, V7, P63, DOI 10.1016/0268-960X(93)90025-Y; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDERSON MW, 1992, ENVIRON HEALTH PERSP, V98, P13, DOI 10.2307/3431243; ANDREA K, 1997, NATURE, V385, P544; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; IKEJIMA M, 1989, BIOCHEM BIOPH RES CO, V163, P739, DOI 10.1016/0006-291X(89)92285-7; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KINOSHITA T, 1997, IN PRESS ONCOGENE, V14; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VASILAKOS JP, 1995, J IMMUNOL, V155, P3433; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	39	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23111	23116		10.1074/jbc.272.37.23111	http://dx.doi.org/10.1074/jbc.272.37.23111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287312	hybrid			2022-12-27	WOS:A1997XV74400023
J	Alenius, M; Bohm, S				Alenius, M; Bohm, S			Identification of a novel neural cell adhesion molecule-related gene with a potential role in selective axonal projection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY OLFACTORY PROJECTION; GROWTH CONE GUIDANCE; FASCICLIN-II; N-CAM; EXPRESSION; SYSTEM; ORGANIZATION; EPITHELIUM; PROTEINS; MOUSE	We describe here the cloning of mouse complementary DNAs encoding a novel protein, Rb-8 neural cell adhesion molecule (RNCAM), with a predicted extracellular region of five immunoglobulin Ca-type domains followed by two fibronectin type III domains, Alternative splicing is likely to generate two RNCAM isoforms, which are differently attached to the cell membrane, These structural features and overall sequence identity identify this protein as a novel member of a cell adhesion molecule subgroup together with vertebrate neural cell adhesion molecule, Aplysia cell adhesion molecule, and Drosophila fasciclin II, In insects, fasciclin II is present on a restricted subset of embryonic central nervous system axons where it controls selective axon fasciculation. Intriguingly, RNCAM likewise is expressed in subsets of olfactory and vomeronasal neurons with topographically defined axonal projections, The spatial expression RNCAM corresponds precisely to that of certain odorant receptor expression zones of the olfactory epithelium. These expression patterns thus render RNCAM the first described cell adhesion molecule with a potential regulatory role in formation of selective axonal projections important for olfactory sensory information coding.	UMEA UNIV,DEPT CELL & MOL BIOL,S-90187 UMEA,SWEDEN	Umea University								BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; Berghard A, 1996, J NEUROSCI, V16, P909; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; Chen H, 1996, GENOME RES, V6, P747, DOI 10.1101/gr.6.8.747; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Goridis C, 1992, Semin Cell Biol, V3, P189; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWOB JE, 1988, J NEUROSCI, V8, P3470; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; SHINOHARA H, 1992, J NEUROSCI, V12, P1275; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; TESSIERLAVIGNE M, 1996, SCIENCE, V274, P1128; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M	26	82	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26083	26086		10.1074/jbc.272.42.26083	http://dx.doi.org/10.1074/jbc.272.42.26083			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334170	hybrid			2022-12-27	WOS:A1997YB13900004
J	Bonifer, C; Jagle, U; Huber, MC				Bonifer, C; Jagle, U; Huber, MC			The chicken lysozyme locus as a paradigm for the complex developmental regulation of eukaryotic gene loci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSGENIC MICE; TRANSCRIPTION FACTORS; HYPERSENSITIVE SITES; CHROMATIN DOMAIN; IN-VIVO; EXPRESSION; DROSOPHILA		UNIV FREIBURG, INST BIOL 3, D-79104 FREIBURG, GERMANY	University of Freiburg			Bonifer, Constanze/B-3000-2009	Bonifer, Constanze/0000-0002-4267-0825; Huber, Matthias C./0000-0003-3034-793X				BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BONIFER C, 1994, NUCLEIC ACIDS RES, V22, P4202, DOI 10.1093/nar/22.20.4202; FRITTON HP, 1984, NATURE, V311, P163, DOI 10.1038/311163a0; FRITTON HP, 1983, NUCLEIC ACIDS RES, V11, P3467, DOI 10.1093/nar/11.11.3467; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hauser H, 1981, Haematol Blood Transfus, V26, P175; Hempel K, 1996, J CELL SCI, V109, P1459; Huber MC, 1997, NUCLEIC ACIDS RES, V25, P2992, DOI 10.1093/nar/25.15.2992; Huber MC, 1996, NUCLEIC ACIDS RES, V24, P1443, DOI 10.1093/nar/24.8.1443; HUBER MC, 1995, DNA CELL BIOL, V14, P397, DOI 10.1089/dna.1995.14.397; HUBER MC, 1994, NUCLEIC ACIDS RES, V22, P4195, DOI 10.1093/nar/22.20.4195; Jagle U, 1997, J BIOL CHEM, V272, P5871, DOI 10.1074/jbc.272.9.5871; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; Roque MC, 1996, MOL CELL BIOL, V16, P3138; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SCHUTZ G, 1977, COLD SPRING HARB SYM, V42, P617, DOI 10.1101/SQB.1978.042.01.064; Sippel A E, 1987, Results Probl Cell Differ, V14, P255; SIPPEL AE, 1993, COLD SPRING HARB SYM, V58, P37, DOI 10.1101/SQB.1993.058.01.007; SIPPEL AE, 1988, ARCHITECTURE EUKARYO, P355; STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	28	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26075	26078		10.1074/jbc.272.42.26075	http://dx.doi.org/10.1074/jbc.272.42.26075			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334168	Green Published, hybrid			2022-12-27	WOS:A1997YB13900002
J	Strickland, E; Qu, BH; Millen, L; Thomas, PJ				Strickland, E; Qu, BH; Millen, L; Thomas, PJ			The molecular chaperone Hsc70 assists the in vitro folding of the N-terminal nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; DELTA-F508 MUTATION; PROTEIN; HSP70; COMMON; PROTEASOME; STABILITY; PATHWAY; PEPTIDE; ATPASE	The most common disease-causing mutation in the cystic fibrosis transmembrane conductance regulator is a single amino acid deletion (Delta F508) in the N-terminal cytosolic nucleotide-binding domain (NBD1), This mutation has previously been shown to be a temperature-sensitive folding mutation that alters the folding pathway but not the native state stability of the isolated domain (Qu, B.-H., and Thomas, P. J. (1996) J. Biol. Chem, 271, 7261-7264), Here we provide evidence that the molecular chaperone Hsc70 productively interacts with NBD1 to increase the folding yield of the domain and inhibit off-pathway associations leading to the formation of high molecular weight aggregates, Furthermore, we have sublocalized a region within NBD1 where Hsc70 binds, Notably, inhibition of NBD1 aggregation is not dependent upon the presence of Hsc70 in the early stages of folding, indicating that the chaperone may act on a folding intermediate. In the presence of K+ and Mg2+-ATP, conditions where Hsp70 binds substrate rapidly and can release it, Hsc70 is less effective at inhibiting NBD1 aggregation, Thus, the rate of release of unfolded substrate is an important factor in preventing aggregation and promoting folding of the domain, These results demonstrate that Hsc70 promotes the otherwise inefficient folding of Delta F-NBD1 and provide insight into the mechanisms by which molecular chaperones assist proteins in folding.	UNIV TEXAS,SW MED CTR,GRAD PROGRAM MOL BIOPHYS,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Thomas, Philip J/F-7115-2012		NIDDK NIH HHS [NIDDK49835] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049835, R01DK049835] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Bercovich B, 1997, J BIOL CHEM, V272, P9002; BLONDELGUINDI S, 1993, CELL, V75, P1; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; GREENE LE, 1990, J BIOL CHEM, V265, P6682; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; JACOB U, 1996, J BIOL CHEM, V271, P10035; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; QU BH, 1997, IN PRESS J BIOENERG; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480	32	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25421	25424		10.1074/jbc.272.41.25421	http://dx.doi.org/10.1074/jbc.272.41.25421			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325249	hybrid			2022-12-27	WOS:A1997YA35800004
J	Tiruppathi, C; Song, W; Bergenfeldt, M; Sass, P; Malik, AB				Tiruppathi, C; Song, W; Bergenfeldt, M; Sass, P; Malik, AB			Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY MODIFIED ALBUMINS; SRC SH2 DOMAIN; CAPILLARY-PERMEABILITY; SIGNAL-TRANSDUCTION; BINDING PROTEINS; RECEPTOR; ENDOCYTOSIS; TRANSPORT; CAVEOLAE; SURFACE	We investigated the function of gp60, an endothelial cell membrane 60-kDa albumin-binding protein localized in caveolae, and the mechanism of its activation in regulating endothelial permeability of albumin, Gp60 organization on the bovine pulmonary microvessel endothelial cell (BPMVEC) surface was punctate as shown by immunofluorescence using an anti-gp60 antibody (Ab) conjugated with bisfunctional, N-hydroxysuccinimidyl fluorophore (Cy3), Addition of a secondary Ab to anti-gp60 Ab-treated BPMVEC induced cross-linking of gp60 as evident by increased size of fluorescent particles and cell surface gp60 clustering, Gp60 cross-linking also produced 2-3-fold increases in the endothelial cell uptake and the luminal to abluminal permeability of I-125-albumin as well as the fluid-phase tracer, horseradish peroxidase, The increased transendothelial permeability of macromolecules was the result of transcytosis as it was not associated with an increase in the paracellular pathway, Incubation of anti-gp60 Ab with BPMVEC at 37 degrees C caused internalization of gp60, and thereby reduced the uptake of the macromolecules. Activation of gp60 by either albumin (the gp60 ligand) or gp60 crosslinking induced the phosphorylation of both gp60 and caveolin-1 (the major structural caveolar protein) on tyrosine residues, Gp60 activation also phosphorylated the Src family tyrosine kinases pp60(c-Src) and Fyn. The activated pp60(c-Src) and Fyn co-immunoprecipitated with caveolin-1 in BPMVEC membrane, Protein tyrosine kinase (PTK) inhibitors, herbimycin A and genistein, prevented gp60-activated macromolecule uptake and transcytosis in a concentration-dependent manner, indicating the functional significance of the PTK pathway in activating albumin transcytosis, These findings indicate that activation of gp60 stimulates the Src PTK signaling pathway, and thus regulates the transcytosis of albumin across the endothelial cell monolayer.			Tiruppathi, C (corresponding author), UNIV ILLINOIS, COLL MED, DEPT PHARMACOL MC 868, 835 S WOLCOTT AVE, CHICAGO, IL 60612 USA.			Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL27016] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027016, R37HL027016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CURRY FE, 1980, MICROVASC RES, V20, P96, DOI 10.1016/0026-2862(80)90024-2; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DELVECCHIO PJ, 1992, IN VITRO CELL DEV-AN, V28A, P711; FORKER EL, 1983, J CLIN INVEST, V72, P1764, DOI 10.1172/JCI111136; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GORDEN P, 1982, METABOLISM, V31, P664, DOI 10.1016/0026-0495(82)90196-2; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Li SW, 1996, J BIOL CHEM, V271, P3863; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU XQ, 1993, ONCOGENE, V8, P1119; MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; PARDRIDGE WM, 1979, ENDOCRINOLOGY, V105, P605, DOI 10.1210/endo-105-3-605; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; Putnam E., 1975, 3 SERUM ALBUMIN, VSecond, P133, DOI [10.1016/B978-0-12-568401-9.50010-4, DOI 10.1016/B978-0-12-568401-9.50010-4]; RESINK TJ, 1990, MOL PHARMACOL, V38, P244; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHLESSINGER J, 1980, TRENDS BIOCHEM SCI, V5, P210, DOI 10.1016/S0968-0004(80)80010-7; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, BIOCHEM BIOPH RES CO, V199, P11, DOI 10.1006/bbrc.1994.1185; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SIFLINGERBIRNBOIM A, 1991, J CELL PHYSIOL, V149, P575, DOI 10.1002/jcp.1041490329; SIFLINGERBIRNBOIM A, 1987, J CELL PHYSIOL, V132, P111, DOI 10.1002/jcp.1041320115; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TIRUPPATHI C, 1992, AM J PHYSIOL, V263, pL595, DOI 10.1152/ajplung.1992.263.5.L595; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WALZOG B, 1994, J LEUKOCYTE BIOL, V56, P625, DOI 10.1002/jlb.56.5.625; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	278	281	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25968	25975		10.1074/jbc.272.41.25968	http://dx.doi.org/10.1074/jbc.272.41.25968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325331	hybrid			2022-12-27	WOS:A1997YA35800086
J	Tseng, WC; Haselton, FR; Giorgio, TD				Tseng, WC; Haselton, FR; Giorgio, TD			Transfection by cationic liposomes using simultaneous single cell measurements of plasmid delivery and transgene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; GENE DELIVERY; FLOW-CYTOMETRY; DNA; MECHANISM; THERAPY; HUMANS; SERIES	Cationic liposomes are potentially important gene transfer vehicles, although their application has been limited by relatively low efficiency of transgene expression. Single cell, quantitative methods, such as those used in this study, should permit a more detailed understanding of the relationships between delivered plasmid and transgene expression, Intracellular plasmid delivery and transgene expression were measured simultaneously using photoconjugated ethidium monoazide as an intracellular plasmid delivery marker and green fluorescent protein (GFP(S65T)) as a transgene expression marker, Quantitative flow cytometry was used to estimate plasmid copy number and GFP(S65T) molecules in single cells, The plasmid was delivered to HeLa cells with a cationic liposome vehicle containing 1,2-dioleoyloxy-3-trimethylammonium-propane and dioleoylphosphatidylethanolamine (1:1 mol/mol). Treatment was carried out continuously for 24 h. Flow cytometry measurements on 20,000 cells were performed during treatment and for 48 h post-treatment. On a single cell basis, transgene expression efficiency and average GFP(S65T) expression level increased with intracellular plasmid copy number. After 3-h exposure to the liposomal vector, more than 95% of the cells were positive for plasmid entry, but none had detectable transgene expression, Maximum transgene expression was achieved at 24 h and remained unchanged at the 72-h measurement. At 24 h, the average positive cell contained 1.6 x 10(5) plasmid copies and 2.3 x 10(6) GFP(S65T) molecules, importantly, the measurement strategies revealed that transgene expression varied widely within the entire cell population. Although only 30% of all cells expressed transgene, the subpopulation of cells that rapidly incorporated the vector demonstrated 100% efficiency in transgene expression. This study identifies parameters that modulate highly efficient transgene expression from plasmid delivery by cationic liposomes.	VANDERBILT UNIV, DEPT CHEM, NASHVILLE, TN 37235 USA; VANDERBILT UNIV, DEPT BIOMED ENGN, NASHVILLE, TN 37235 USA	Vanderbilt University; Vanderbilt University								BAGWELL CB, 1993, ANN NY ACAD SCI, V677, P167, DOI 10.1111/j.1749-6632.1993.tb38775.x; Barak Z, 1996, J MOL BIOL, V256, P676, DOI 10.1006/jmbi.1996.0117; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Friend DS, 1996, BBA-BIOMEMBRANES, V1278, P41, DOI 10.1016/0005-2736(95)00219-7; Fritz JD, 1996, HUM GENE THER, V7, P1395, DOI 10.1089/hum.1996.7.12-1395; Gao X, 1996, BIOCHEMISTRY-US, V35, P1027, DOI 10.1021/bi952436a; GuyCaffey JK, 1995, J BIOL CHEM, V270, P31391, DOI 10.1074/jbc.270.52.31391; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; Lee RJ, 1996, J BIOL CHEM, V271, P8481, DOI 10.1074/jbc.271.14.8481; Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; ROPP JD, 1995, CYTOMETRY, V21, P309, DOI 10.1002/cyto.990210402; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHREIER H, 1994, J BIOL CHEM, V269, P9090; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; Stephan DJ, 1996, HUM GENE THER, V7, P1803, DOI 10.1089/hum.1996.7.15-1803; Tseng WC, 1996, BIOTECHNOL BIOENG, V50, P548, DOI 10.1002/(SICI)1097-0290(19960605)50:5<548::AID-BIT9>3.0.CO;2-F; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	27	133	141	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25641	25647		10.1074/jbc.272.41.25641	http://dx.doi.org/10.1074/jbc.272.41.25641			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325286	hybrid			2022-12-27	WOS:A1997YA35800041
J	Chihara, K; Amano, M; Nakamura, N; Yano, T; Shibata, M; Tokui, T; Ichikawa, H; Ikebe, R; Ikebe, M; Kaibuchi, K				Chihara, K; Amano, M; Nakamura, N; Yano, T; Shibata, M; Tokui, T; Ichikawa, H; Ikebe, R; Ikebe, M; Kaibuchi, K			Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; SERINE-THREONINE KINASE; ACTIN STRESS FIBERS; ADP-RIBOSYLATION; SMOOTH-MUSCLE; FOCAL ADHESIONS; MAMMALIAN-CELLS; PUTATIVE TARGET; PHOSPHORYLATION; INVOLVEMENT	The small GTPase Rho is implicated in cytoskeletal rearrangements including stress fiber and focal adhesion formation and in the transcriptional activation of c-fos serum response element. In vitro, Rho-kinase, which is activated by Rho, phosphorylates not only myosin light chain (MLC) (thereby activating myosin ATPase) but also myosin phosphatase, thus inactivating myosin phosphatase. Rho-kinase is involved in the formation of stress fibers and focal adhesions in fibro blasts. Here we show that the expression of constitutively active Rho-kinase increased the level of MLC phosphorylation, The activity of Rho-kinase was necessary for maintaining the vinculin-containing focal adhesions, whereas organized actin stress fibers were not necessary for this, The microinjection of constitutively active Rho-kinase into fibroblasts induced the forma tion of focal adhesions to some extent under the conditions where organized actin stress fibers were disrupted, The expression of constitutively active Rho-kinase also stimulated the transcriptional activity of c-fos serum response element. These results suggest that Rho-kinase has distinct roles in divergent pathways downstream of Rho, which include MLC phosphorylation leading to stress fiber formation, focal adhesion formation, and gene expression.	NARA INST SCI & TECHNOL, DIV SIGNAL TRANSDUCT, IKOMA 63001, JAPAN; UNIV MASSACHUSETTS, MED CTR, DEPT PHYSIOL, WORCESTER, MA 01655 USA; MED & BIOL LABS, INA, SAITAMA 396, JAPAN	Nara Institute of Science & Technology; University of Massachusetts System; University of Massachusetts Worcester			Amano, Mutsuki/M-4820-2014	Amano, Mutsuki/0000-0002-0662-1524	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047530, P50HL037117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37117, HL47530] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BARSAGI D, 1995, METHOD ENZYMOL, V255, P436; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kolega J., 1993, Bioimaging, V1, P136, DOI 10.1002/1361-6374(199309)1:3<136::AID-BIO2>3.3.CO;2-4; Kosako H, 1997, J BIOL CHEM, V272, P10333; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; ZHANG J, 1993, J BIOL CHEM, V268, P22251	45	161	162	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25121	25127		10.1074/jbc.272.40.25121	http://dx.doi.org/10.1074/jbc.272.40.25121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312122	hybrid			2022-12-27	WOS:A1997XY97000061
J	Li, DX; Lin, HH; McMahon, M; Ma, HY; Ann, DK				Li, DX; Lin, HH; McMahon, M; Ma, HY; Ann, DK			Oncogenic Raf-1 induces the expression of non-histone chromosomal architectural protein HMGI-C via a p44/p42 mitogen-activated protein kinase-dependent pathway in salivary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; MOBILITY-GROUP PROTEIN; SIGNAL-TRANSDUCTION PATHWAY; MAP-KINASE; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION SITES; IN-VITRO; RECEPTOR; CASCADE	The enzyme activity of mitogen-activated protein kinase (MAP kinase) increases in response to agents acting on a variety of cell surface receptors, including receptors linked to heterotrimeric G proteins, In this report, we demonstrated that Raf-1 protein kinase activity in the mouse parotid glands was induced by chronic isoproterenol administration in whole animals, To investigate the molecular nature underlying cellular responses to Raf-1 activation, we have stably transfected rat salivary epithelial Pa-4 cells with human Raf-1-estrogen receptor fusion gene (Delta Raf-1:ER) and used mRNA differential display in search of messages induced by Delta Raf-1:ER activation, Through this approach, the gene encoding non-histone chromosomal protein HMGI-C was identified as one of the target genes activated by oncogenic Raf-1 kinase, Activation of Raf-1 kinase resulted in a delayed and sustained increase of HMGI-C expression in the Pa-4 cells, The induction of HMGI-C mRNA level is sensitive to both the protein synthesis inhibitor cycloheximide and transcription inhibitor actinomycin D, The role of the extracellular signal-related kinase (ERK) signaling pathway in the HMGI-C induction was highlighted by the result that the MAP kinase kinase (MEK) inhibitor, PD 98059, blocked Delta Raf-1:ER-and 12-O-tetradecanoylphorbol-13-acetate-stimulated HMGI-C induction, Altogether, these findings support the notion that the Raf/MEK/ERK signaling module, at least in part, regulates transcriptional activation of the chromosomal architectural protein HMGI-C.	UNIV SO CALIF,DEPT MOL PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; DNAX RES INST MOL & CELLULAR BIOL INC,PALO ALTO,CA 94304	University of Southern California; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE10742] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ann DK, 1997, CRIT REV ORAL BIOL M, V8, P244, DOI 10.1177/10454411970080030101; ASHAR HR, 1995, CELL, V82, P57; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BUSCHER D, 1993, ONCOGENE, V8, P3323; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; French SW, 1996, MOL CELL BIOL, V16, P5393; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Holt KH, 1996, MOL CELL BIOL, V16, P577; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG TH, 1994, AM J RESP CELL MOL, V10, P192, DOI 10.1165/ajrcmb.10.2.7509163; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEGER H, 1995, MOL CELL BIOL, V15, P3738; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Manfioletti G, 1995, GENE, V167, P249, DOI 10.1016/0378-1119(95)00666-4; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PORRAS A, 1994, J BIOL CHEM, V269, P12741; PURUSHOTHAM KR, 1994, BIOCHEM BIOPH RES CO, V202, P743, DOI 10.1006/bbrc.1994.1993; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TRAVERSE S, 1993, ONCOGENE, V8, P3175; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; Zhou XJ, 1996, NUCLEIC ACIDS RES, V24, P4071, DOI 10.1093/nar/24.20.4071	65	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25062	25070		10.1074/jbc.272.40.25062	http://dx.doi.org/10.1074/jbc.272.40.25062			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312114	hybrid			2022-12-27	WOS:A1997XY97000053
J	Pellegrino, S; Zhang, SY; Garritsen, A; Simonds, WF				Pellegrino, S; Zhang, SY; Garritsen, A; Simonds, WF			The coiled-coil region of the G protein beta subunit - Mutational analysis of G gamma and effector interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; DIEKER LISSENCEPHALY GENE; GCN4 LEUCINE-ZIPPER; CRYSTAL-STRUCTURE; COMPLEX-FORMATION; KINASE PATHWAY; DOMAIN; ACTIVATION; BINDING; MITOGEN	The beta and gamma subunits of the heterotrimeric G proteins remain tightly associated throughout the signaling cycle as the beta gamma dimer interacts with G alpha, receptors, and effecters, A coiled coil structure involving alpha-helical segments at the N termini of the beta and gamma subunits contrib- utes to the dimerization interface and has been implicated in effector signaling in yeast, Scanning mutagenesis of the coiled-coil region of the mammalian beta(1) subunit was performed to examine the effect of point mutations on py assembly and effector signaling in COS cell cotransfection assays, In addition to the E10K mutation described previously mutations A11E, L14E, and I18E in beta(1) were found to block beta gamma association, as evidenced by the failure of the G beta mutants to undergo cytosolic translocation with cotransfected nonisoprenylated G gamma, Although none of 14 beta(1) point mutations prevented the beta gamma-dependent activation of the c-Jun N-terminal kinase (JNK) effector pathway, the D20K point mutation enhanced JNK but not phospholipase C-beta 2 activation, These findings implicate the coiled-coil region of G beta in JNK signaling, provide further evidence that the structural features of the beta gamma complex mediating effector regulation may differ among effecters, and identify single codons in the mammalian beta subunit where mutation might yield a phenotype of defective signal transduction.	NIDDK,METAB DIS BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COETZER TL, 1991, J CLIN INVEST, V88, P743, DOI 10.1172/JCI115371; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FAURE M, 1994, J BIOL CHEM, V269, P7851; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRISHIN AV, 1994, GENETICS, V138, P1081; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; Hirschman JE, 1997, J BIOL CHEM, V272, P240; HOVNANIAN A, 1993, NAT GENET, V3, P327, DOI 10.1038/ng0493-327; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; Kim DU, 1996, MOL GEN GENET, V252, P20, DOI 10.1007/BF02173201; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Offermanns S, 1996, CANCER SURV, V27, P177; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PARK D, 1992, J BIOL CHEM, V267, P16048; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	63	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25360	25366		10.1074/jbc.272.40.25360	http://dx.doi.org/10.1074/jbc.272.40.25360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312156	hybrid			2022-12-27	WOS:A1997XY97000095
J	Wang, DZ; Zamorano, J; Keegan, AD; Boothby, M				Wang, DZ; Zamorano, J; Keegan, AD; Boothby, M			HMG-I(Y) phosphorylation status as a nuclear target regulated through insulin receptor substrate-1 and the I4R motif of the interleukin-4 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-3 JANUS KINASE; P70 S6 KINASE; GENE-EXPRESSION; B-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; PROTEIN HMG-I(Y); EPSILON-PROMOTER	Interleukin (IL)-4 is a cytokine that regulates both the growth and differentiation of hematopoietic cells. Its ligand binding specificity and important signal transduction mechanisms are conferred by the IL-4 receptor alpha chain (IL-4R alpha). The I4R is a tyrosine containing motif within IL-4R alpha that is critical for proliferative responses to IL-4. Although the I4R also contributes to gene regulation, nuclear targets directly regulated by this motif have not been described, It is shown here that the tyrosine at position 497 in the I4R is critical for regulation of the phosphorylation status of a set of nuclear proteins that includes HMG-I(Y), small non-histone chromosomal proteins involved in the control of gene expression in hematopoietic cell lines. Moreover, IL-4 is unable to induce HMG-I(Y) phosphorylation in insulin receptor substrate-1-deficient cells, and the inhibitor wortmannin completely blocks IL-4 regulation of HMG-I(Y) phosphorylation status but not activation of an IL-4 Stat protein. Taken together, these data indicate that HMG-I(Y) is a nuclear target whose phosphorylation status is regulated through the I4R motif via insulin receptor substrate proteins, independent of activation of the Stat pathway.	VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; AMER RED CROSS,DEPT IMMUNOL,HOLLAND LAB,BETHESDA,MD 20855	Vanderbilt University; American Red Cross			Zamorano, Jose/Q-2514-2017	Zamorano, Jose/0000-0002-4271-3741	NIAID NIH HHS [AI 38985] Funding Source: Medline; NIGMS NIH HHS [GM42550] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038985, R01AI038985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042550, R01GM042550] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOTHBY M, 1988, SCIENCE, V242, P1559, DOI 10.1126/science.3144043; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; Dahl J, 1996, MOL CELL BIOL, V16, P2728; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ikizawa K, 1996, CELL IMMUNOL, V170, P134, DOI 10.1006/cimm.1996.0143; JANSEN JH, 1990, BLUT, V60, P269, DOI 10.1007/BF01736226; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kaplan M. H., 1997, Journal of Allergy and Clinical Immunology, V99, pS484; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KIM J, 1995, EUR J IMMUNOL, V25, P798, DOI 10.1002/eji.1830250326; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; MYERS MG, 1994, J BIOL CHEM, V269, P28783; PAUL WE, 1991, BLOOD, V77, P1589; PERNIS A, 1995, P NATL ACAD SCI USA, V92, P7971, DOI 10.1073/pnas.92.17.7971; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; RICHARDS ML, 1994, J IMMUNOL, V152, P3453; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Snapper CM, 1996, J IMMUNOL, V156, P183; STACK RM, 1994, J IMMUNOL, V152, P5723; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Wang DZ, 1996, INT IMMUNOL, V8, P977, DOI 10.1093/intimm/8.7.977; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG Y, 1995, INSECT MOL BIOL, V4, P113, DOI 10.1111/j.1365-2583.1995.tb00015.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zamorano J, 1996, J IMMUNOL, V157, P4926; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	64	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25083	25090		10.1074/jbc.272.40.25083	http://dx.doi.org/10.1074/jbc.272.40.25083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312117	hybrid			2022-12-27	WOS:A1997XY97000056
J	Desai, SD; Liu, LF; VazquezAbad, D; DArpa, P				Desai, SD; Liu, LF; VazquezAbad, D; DArpa, P			Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA CLEAVABLE COMPLEXES; PROTEOLYTIC PATHWAY; REPLICATION FORKS; CELL-CYCLE; MULTIUBIQUITIN CHAIN; SCLERODERMA PATIENTS; CONJUGATING ENZYMES; PROTEASOME PATHWAY; ACTIVATING ENZYME; TRANSCRIPTION	y Topoisomerase I (TOP1) relaxes superhelical DNA through a breakage/rejoining reaction in which the active site tyrosine links covalently to a 3' phosphate at the break site as a transient intermediate, The antitumor drug camptothecin (CPT) and its analogs inhibit the rejoining step of the breakage/rejoining reaction, which traps the enzyme in covalent linkage with DNA (the cleavable complex), Little is known about the fate of cellular TOP1 trapped in the cleavable complex, We have analyzed TOP1 in mammalian cell lines treated with CPT, When CPT-treated cells were lysed with either SDS or alkali and analyzed by Western blotting, greater than 90% of the TOP1 was linked to DNA, Nuclease treatment of the cell lysate to remove the covalently linked DNA from TOP1 revealed a distinct ladder of higher molecular weight bands having properties indicative of multi-ubiquitin (Ub) conjugates of TOP1, Approximately 5-10% of TOP1 was present as these conjugates within minutes of CPT treatment. Consistent with ubiquitination, TOP1 was not modified in ts85 cells at the restrictive temperature for its thermolabile ubiquitin activating enzyme (El), Because conjugation with ubiquitin can mark proteins for destruction by the 26S proteasome, we analyzed TOP1 protein levels during prolonged CPT treatment, TOP1 protein levels were reduced to about 25% during CPT treatments of 2-4 h resulting from increased destruction, with the half-life dropping from 10-16 h down to 1-2 h. The destruction of TOP1, like the formation of Ub-TOP1 conjugates, was not observed in ts85 cells at the restrictive temperature, The destruction of TOP1 was also prevented in cells treated with MG-132 and lactacystin, specific inhibitors of the 26S proteasome. Finally, the multi-Ub conjugates of TOP1 were observed whether or not aphidicolin was included in cotreatment with CPT, indicating that replication fork activity was not involved in making TOP1 a substrate for ubiquitination, These results demonstrate that independent of DNA replication, the TOP1 cleavable complex is ubiquitinated and destroyed in cells treated with antitumor drugs that block the religation step of the TOP1 reaction.	UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM & MOL BIOL,BETHESDA,MD 20814; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854; CANC INST NEW JERSEY,NEW BRUNSWICK,NJ 08901; UNIV CONNECTICUT,SCH MED,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06030	Uniformed Services University of the Health Sciences - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Connecticut				D'Arpa, Peter/0000-0002-0562-0263; Liu, Leroy/0000-0001-9396-763X	NATIONAL CANCER INSTITUTE [R01CA059750, R01CA039662, R29CA059750] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662, CA59750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BEIDLER DR, 1995, MOL PHARMACOL, V47, P907; BENDIXEN C, 1990, BIOCHEMISTRY-US, V29, P5613, DOI 10.1021/bi00475a028; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1992, J BIOL CHEM, V267, P16467; DARPA P, 1995, EXP CELL RES, V217, P125, DOI 10.1006/excr.1995.1071; DARPA P, 1990, CANCER RES, V50, P6919; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DARPA P, 1990, ARTHRITIS RHEUM-US, V33, P1501, DOI 10.1002/art.1780331007; DAVIE JR, 1990, BIOCHEMISTRY-US, V29, P4752, DOI 10.1021/bi00472a002; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; ERICSSON C, 1986, EXP CELL RES, V167, P127, DOI 10.1016/0014-4827(86)90210-7; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; GILMOUR DS, 1987, MOL CELL BIOL, V7, P141, DOI 10.1128/MCB.7.1.141; GILMOUR DS, 1986, CELL, V44, P401, DOI 10.1016/0092-8674(86)90461-7; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; GRANT EP, 1995, J IMMUNOL, V155, P3750; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; HOLM C, 1989, CANCER RES, V49, P6365; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; LEE DH, 1996, J BIOL CHEM, V271, P23720; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Maniatis T., 1982, MOL CLONING; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; PORTER SE, 1989, MOL CELL BIOL, V9, P541, DOI 10.1128/MCB.9.2.541; RYAN AJ, 1994, CARCINOGENESIS, V15, P823, DOI 10.1093/carcin/15.5.823; SADIS S, 1995, MOL CELL BIOL, V15, P4086; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; SQUIRES S, 1993, CANCER RES, V53, P2012; TSAO YP, 1993, CANCER RES, V53, P5908; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU RS, 1971, P NATL ACAD SCI USA, V68, P3009, DOI 10.1073/pnas.68.12.3009; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	51	218	227	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24159	24164		10.1074/jbc.272.39.24159	http://dx.doi.org/10.1074/jbc.272.39.24159			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305865	hybrid			2022-12-27	WOS:A1997XY51500016
J	Mannick, JB; Miao, XQ; Stamler, JS				Mannick, JB; Miao, XQ; Stamler, JS			Nitric oxide inhibits Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1-BETA CONVERTING ENZYME; MEDIATED APOPTOSIS; T-CELLS; LYMPHOPROLIFERATIVE SYNDROME; MONOCLONAL-ANTIBODY; SIGNALING COMPLEX; HIV-INFECTION; LPR/LPR MICE	The Fas antigen (CD95, APO-1) is a transmembrane cell surface receptor that mediates apoptosis of many cell types when bound by Fas ligand or cross-linked by agonist antibody. The cellular factors regulating Fas-induced apoptosis have not been well defined. Here we show that basal nitric-oxide synthase (NOS) activity in human leukocytes inhibits Fas-induced apoptosis via a cGMP-independent mechanism. Further, NOS inhibits Fas-induced cleavage of poly(ADP-ribose) polymerase by members of the caspase family of cysteine proteases. These data suggest that Fas activity is under the control of the NO signaling pathway. NOS regulating the function of this member of the tumor necrosis factor receptor family suggests a new role for nitric oxide (or related molecules) in the human immune response.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DIV RESP,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DIV CARDIOVASC MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University	Mannick, JB (corresponding author), DANA FARBER CANC INST,DIV INFECT DIS,JFB 422,44 BINNEY ST,BOSTON,MA 02115, USA.			Stamler, Jonathan/0000-0002-6866-1572				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALBINA JE, 1993, J IMMUNOL, V150, P5080; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BLANCO FJ, 1995, AM J PATHOL, V146, P75; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; DANIEL PT, 1994, J IMMUNOL, V152, P5624; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; EVANS TG, 1994, CLIN EXP IMMUNOL, V97, P83; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; IZUI S, 1984, J IMMUNOL, V133, P227; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; Kohno T, 1996, J IMMUNOL, V156, P4722; KONDO E, 1994, AM J PATHOL, V145, P330; MACIEJEWSKI JP, 1995, J CLIN INVEST, V96, P1085, DOI 10.1172/JCI118094; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MONCADA S, 1991, PHARMACOL REV, V43, P109; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NERI A, 1991, BLOOD, V77, P1092; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, BIOL NITRIC OXIDE, V1, P20; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TORRE D, 1995, AIDS, V9, P979, DOI 10.1097/00002030-199508000-00027; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANDENDOBBELSTE.DJ, 1996, J BIOL CHEM, V271, P14520; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEINBERG JB, 1994, J EXP MED, V179, P651, DOI 10.1084/jem.179.2.651; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	64	277	280	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24125	24128		10.1074/jbc.272.39.24125	http://dx.doi.org/10.1074/jbc.272.39.24125			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305857	hybrid			2022-12-27	WOS:A1997XY51500008
J	Tepper, AD; BoesendeCock, JGR; deVries, E; Borst, J; vanBlitterswijk, WJ				Tepper, AD; BoesendeCock, JGR; deVries, E; Borst, J; vanBlitterswijk, WJ			CD95/Fas-induced ceramide formation proceeds with slow kinetics and is not blocked by caspase-3/CPP32 inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CELL-DEATH; ICE/CED-3 PROTEASE; SIGNALING COMPLEX; SPHINGOMYELINASE; RECEPTOR; PATHWAY; CYTOTOXICITY; BIOSYNTHESIS; INVOLVEMENT	The current confusion regarding the relevance of endogenous ceramide in mediating GD95/Fas-induced apoptosis is based mainly on (i) discrepancies in kinetics of the ceramide response between different studies using the same apoptotic stimulus and (ii) the observation that late ceramide formation (hours) often parallels apoptosis onset, We investigated CD95-induced ceramide formation in Jurkat cells, using two methods (radiolabeling/thin layer chromatography and benzoylation/ high performance liquid chromatography), which, unlike the commonly used diglyceride kinase assay, discriminate between ceramide species and de novo formed dihydroceramide. We demonstrate that ceramide accumulates after several hours, reaching a I-fold increase after 8 h, kinetics closely paralleling apoptosis induction, No fast response was observed, not even in the presence of inhibitors of ceramide metabolism. The majority (similar to 70%) of the ceramide response remained unaffected when apoptosis was completely inhibited at the level of caspase-3/CPP32 processing by the inhibitor peptide DEVD-CHO. Exogenous cell-permeable C-2-ceramide induced the proteolytic processing of caspase-3, albeit viith somewhat slower kinetics than with CD95, DEVD-CHO dose-dependently inhibited C-2-ceramide- or exogenous sphingomyelinase-induced apoptosis, The results support the idea that ceramide acts in conjunction with the caspase cascade in CD95-induced apoptosis.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Borst, Jannie/0000-0002-8043-5009				Abe A, 1996, J BIOL CHEM, V271, P14383, DOI 10.1074/jbc.271.24.14383; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cabot MC, 1996, FEBS LETT, V394, P129, DOI 10.1016/0014-5793(96)00942-8; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CIFONE MG, 1993, J EXP MED, V177, P1547; DHAIBO GS, 1997, J EXP MED, V185, P481; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Gamen S, 1996, FEBS LETT, V390, P233, DOI 10.1016/0014-5793(96)00666-7; GOTTSCHALK AR, 1995, EUR J IMMUNOL, V25, P1032, DOI 10.1002/eji.1830250426; GROSS SK, 1980, ANAL BIOCHEM, V102, P429, DOI 10.1016/0003-2697(80)90178-5; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; IWAMORI M, 1974, J LIPID RES, V20, P86; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LOUIE K, 1988, BIOCHEMISTRY-US, V27, P9014, DOI 10.1021/bi00425a020; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Previati M, 1996, ANAL BIOCHEM, V233, P108, DOI 10.1006/abio.1996.0014; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	42	113	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24308	24312		10.1074/jbc.272.39.24308	http://dx.doi.org/10.1074/jbc.272.39.24308			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305886	hybrid			2022-12-27	WOS:A1997XY51500037
J	Lacorte, JM; Ktistaki, E; Beigneux, A; Zannis, VI; Chambaz, J; Talianidis, I				Lacorte, JM; Ktistaki, E; Beigneux, A; Zannis, VI; Chambaz, J; Talianidis, I			Activation of CAAT enhancer-binding protein delta (C/EBP delta) by interleukin-1 negatively influences apolipoprotein C-III expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-SPECIFIC EXPRESSION; HUMAN APOCIII GENE; ACUTE-PHASE GENES; NUCLEAR FACTOR; TRANSCRIPTION FACTOR; RESPONSE ELEMENT; TRANSGENIC MICE; DNA-BINDING; I GENE	Tissue specific transcription of the apolipoprotein C-III (apoC-III) gene is mainly regulated by synergistic interactions between the liver-enriched transcription factor HNF-4, which binds to the proximal promoter, and ubiquitous factors, which bind to the upstream enhancer region, Here we show that apoC-III expression in HepG2 cells is negatively regulated in response to interleukin-1 (IL-1), and this inhibition is mainly due to transcriptional repression, CAAT enhancer-binding protein delta (C/EBP delta) was found to be the main mediator of IL-1-induced suppression. Analysis of the apoC-III promoter revealed two IL-1 response elements, The first is located in the proximal promoter region D and the second in the distal enhancer region I, Proximal element D is a high affinity binding site for C/EBP delta, while the enhancer element I is not directly recognized by this transcription factor, Functional analysis of different combinations of homologous and heterologous promoter constructs revealed that indirect interaction of C/EBP delta with site I, in the context of the full promoter, leads to repression. C/EBP delta is activated by phosphorylation during IL-1-induced signal transduction pathway, This modification is important for bath DNA binding activity and indirect transrepression of the apoC-III promoter.	FDN RES & TECHNOL HELLAS,INST MOL BIOL & BIOTECHNOL,IRAKLION 71110,CRETE,GREECE; INST BIOMED CORDELIERS,CNRS,URA 1283,F-75006 PARIS,FRANCE	Foundation for Research & Technology - Hellas (FORTH); Centre National de la Recherche Scientifique (CNRS)			Talianidis, Iannis/F-7556-2016	Talianidis, Iannis/0000-0002-1209-3609				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Aldred A.R., 1993, ACUTE PHASE PROTEINS, V1st ed., P21; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FEINGOLD KR, 1989, ENDOCRINOLOGY, V125, P267, DOI 10.1210/endo-125-1-267; FEY G, 1990, PROGR LIVER DIS, P89; FEY GH, 1987, MOL BIOL MED, V4, P323; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JOHNSON PF, 1994, TRANSCRIPTIONAL REGU, P143; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KRITIS AA, 1993, NUCLEIC ACIDS RES, V21, P5882, DOI 10.1093/nar/21.25.5882; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1990, MOL CELL BIOL, V10, P6624, DOI 10.1128/MCB.10.12.6624; LI XX, 1991, J BIOL CHEM, V266, P15192; MAEDA N, 1994, J BIOL CHEM, V269, P23610; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAJJELO B, 1990, EMBO J, V9, P457; MORRONE G, 1989, EMBO J, V8, P3767, DOI 10.1002/j.1460-2075.1989.tb08553.x; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; OGAMI K, 1990, J BIOL CHEM, V265, P9808; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; POLI V, 1994, TRANSCRIPTIONAL REGU, P84; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; WALSH A, 1993, J LIPID RES, V34, P617; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181	59	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23578	23584		10.1074/jbc.272.38.23578	http://dx.doi.org/10.1074/jbc.272.38.23578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295296	hybrid			2022-12-27	WOS:A1997XX38100021
J	Sano, T; Ohyama, K; Yamano, Y; Nakagomi, Y; Nakazawa, S; Kikyo, M; Shirai, H; Blank, JS; Exton, JH; Inagami, T				Sano, T; Ohyama, K; Yamano, Y; Nakagomi, Y; Nakazawa, S; Kikyo, M; Shirai, H; Blank, JS; Exton, JH; Inagami, T			A domain for G protein coupling in carboxyl-terminal tail of rat angiotensin II receptor type 1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BETA-2-ADRENERGIC RECEPTOR; CYTOPLASMIC DOMAINS; PHOSPHOLIPASE-C; IDENTIFICATION; BINDING; EXPRESSION; SEQUENCE; CELLS; INTERNALIZATION	To delineate domains essential for G(q) protein coupling in the C-terminal region (C-tail) of rat angiotensin II (Ang II) receptor type 1A (AT(1A)), we modified the putative cytosolic regions of the receptor by truncation or alanine substitution and determined resultant changes in the guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) effect on Ang II binding and inositol trisphosphate production by the agonist, Independently, we studied the effect of synthetic C-tail peptides (P-5) and its alanine substitution analogs on [S-35]GTP gamma S binding to G(q), Effects of GTP gamma S on Ang II binding (shift to a low affinity form) and inositol trisphosphate production in the deletional mutant receptor 1-317 AT(1A) was similar to wild type AT(1A), whereas in shorter C-terminal deletion mutants 1-309, 1-311, 1-312, 1-313 AT(1A), and substitutional mutants Y312A, F313A, and L314A these activities were markedly reduced. The binding of [S-35]GTP gamma S to G(q) was promoted by the synthetic C-terminal peptide P-5 but not when mutated at Tyr(312), Phe(313), or Leu(314). Results indicate that Tyr(312), Phe(313), and Leu(314) in cytosolic carboxyl-terminal region of rat AT(1A) are essential for coupling and activation of G(q).	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOL BIOPHYS,NASHVILLE,TN 37232; YAMANASHI MED COLL,DEPT PEDIAT,YAMANASHI 40938,JAPAN; TOTTORI UNIV,FAC AGR,DEPT MET BIOCHEM,TOTTORI 680,JAPAN	Vanderbilt University; Vanderbilt University; University of Yamanashi; Tottori University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL058205, R01HL058205, P50HL014192, R01HL035323] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14192, HL58205, HL-35323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAKI S, 1992, BIOCHEM BIOPH RES CO, V182, P388, DOI 10.1016/S0006-291X(05)80157-3; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CRAWFORD KW, 1992, MOL PHARMACOL, V41, P154; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HESCHELER J, 1988, EMBO J, V7, P619, DOI 10.1002/j.1460-2075.1988.tb02855.x; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; INAGAMI T, 1992, J HYPERTENS, V10, P713; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARIE J, 1994, J BIOL CHEM, V269, P20815; MITCHELL J, 1991, END SOC ABSTR, V199; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SHIRAI H, 1995, HYPERTENSION, V25, P726, DOI 10.1161/01.HYP.25.4.726; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677	27	102	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23631	23636		10.1074/jbc.272.38.23631	http://dx.doi.org/10.1074/jbc.272.38.23631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295303	hybrid			2022-12-27	WOS:A1997XX38100028
J	Vora, AC; Chiu, R; McCord, M; Goodarzi, G; Stahl, SJ; Mueser, TC; Hyde, CC; Grandgenett, DP				Vora, AC; Chiu, R; McCord, M; Goodarzi, G; Stahl, SJ; Mueser, TC; Hyde, CC; Grandgenett, DP			Avian retrovirus U3 and U5 DNA inverted repeats - Role of nonsymmetrical nucleotides in promoting full-site integration by purified virion and bacterial recombinant integrases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOBLASTOSIS VIRUS INTEGRASE; IN-VITRO; CONCERTED INTEGRATION; VIRAL-DNA; PROTEIN INVITRO; SEQUENCES; BINDING; WATER; CLEAVAGE; TERMINI	The U3 and U5 termini of linear retrovirus DNA contain imperfect inverted repeats that are necessary for the concerted insertion of the termini into the host chromosome by viral integrase. Avian myeloblastosis virus integrase can efficiently insert the termini of retrovirus-like DNA donor substrates (480 base pairs) by a concerted mechanism (full-site reaction) into circular target DNA in vitro. The specific activities of virion-derived avian myeloblastosis virus integrase and bacterial recombinant Rous sarcoma virus (Prague A strain) integrase (similar to 50 nM or less) appear similar upon catalyzing the full-site reaction with 3'-OH recessed wild type or mutant donor substrates, We examined the role of the three nonsymmetrical nucleotides located at the 5th, 8th, and 12th positions in the U3 and U5 15-base pair inverted repeats for their ability to modify the full-site and simultaneously, the half-site strand transfer reactions. Our data suggest that the nucleotide at the 5th position appears to be responsible for the 3-5-fold preference for wild type U3 ends over wild type U5 ends by integrase for concerted integration. Additional mutations at the 5th or 6th position, or both, of U3 or U5 termini significantly increased (similar to 3 fold) the full-site reactions of mutant donors over wild type donors.	ST LOUIS UNIV,HLTH SCI CTR,INST MOL VIROL,ST LOUIS,MO 63110; NIAMS,NIH,BETHESDA,MD 20892	Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)					NATIONAL CANCER INSTITUTE [R01CA016312] Funding Source: NIH RePORTER; NCI NIH HHS [CA16312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Balakrishnan M, 1997, J VIROL, V71, P1025, DOI 10.1128/JVI.71.2.1025-1035.1997; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; FITZGERALD ML, 1992, J VIROL, V66, P6257, DOI 10.1128/JVI.66.11.6257-6263.1992; FITZGERALD ML, 1994, J VIROL, V68, P4314, DOI 10.1128/JVI.68.7.4314-4321.1994; FITZGERALD ML, 1991, ANAL BIOCHEM, V196, P19, DOI 10.1016/0003-2697(91)90111-6; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; GRANDGENETT DP, 1993, J VIROL, V67, P1628; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10205, DOI 10.1021/bi00032a014; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; REICIN AS, 1995, J VIROL, V69, P5904, DOI 10.1128/JVI.69.9.5904-5907.1995; Robinson CR, 1996, PROTEIN SCI, V5, P2119, DOI 10.1002/pro.5560051019; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; Sidorova NY, 1996, P NATL ACAD SCI USA, V93, P12272, DOI 10.1073/pnas.93.22.12272; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VARMUS HE, 1983, MOBILE GENETIC ELEME, P411; VINK C, 1994, J VIROL, V68, P1468, DOI 10.1128/JVI.68.3.1468-1474.1994; VINK C, 1993, TRENDS GENET, V9, P4333; VORA AC, 1995, J VIROL, V69, P7483, DOI 10.1128/JVI.69.12.7483-7488.1995; VORA AC, 1994, NUCLEIC ACIDS RES, V22, P4454, DOI 10.1093/nar/22.21.4454	30	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23938	23945		10.1074/jbc.272.38.23938	http://dx.doi.org/10.1074/jbc.272.38.23938			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295344	hybrid			2022-12-27	WOS:A1997XX38100069
J	Zugaza, JL; Waldron, RT; SinnettSmith, J; Rozengurt, E				Zugaza, JL; Waldron, RT; SinnettSmith, J; Rozengurt, E			Bombesin, vasopressin, endothelin, bradykinin, and platelet-derived growth factor rapidly activate protein kinase D through a protein kinase C-dependent signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; FOCAL ADHESION KINASE; STRUCTURALLY RELATED PEPTIDES; TYROSINE PHOSPHORYLATION; PHORBOL ESTERS; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; RAT-BRAIN; D PKD; DIACYLGLYCEROL	Protein kinase D (PKD) is a serine/threonine protein kinase that is activated by phorbol esters via protein kinase C in intact cells. To assess the physiological significance of this putative pathway, we examined the regulation of PKD in living cells by mitogenic regulatory peptides and by platelet-derived growth factors (PDGF). Our results demonstrate that bombesin rapidly induces PKD activation in Swiss 3T3 cells, as shown by autophosphorylation and syntide-2 phosphorylation assays, Maximum PKD activation (14-fold above base-line levels) was obtained 90 s after bombesin stimulation, Bombesin also induced PBD activation in Rat-1 cells stably transfected with the bombesin/gastrin releasing peptide (GRP) receptor and in COS-7 cells transiently co-transfected with PKD and bombesin/GRP receptor expression constructs, No inducible kinase activity was demonstrated when COS-7 cells were transfected with a kinase-deficient PKD mutant. Bombesin-mediated PKD activation was prevented by treatment of Swiss 3T3 cells with the protein kinase C inhibitors GF 1092030X and Ro 31-8220. In contrast, these compounds did not inhibit PKD activity when added directly in vitro. Vasopressin, endothelin, and bradykinin also activated PKD in Swiss 3T3 cells through a PRC-dependent pathway. Platelet-derived growth factor-stimulated PKD activation in Swiss 3T3 cells and in porcine aortic endothelial cells stably transfected with PDGF-beta receptors. Treatment with GF 1092030X or ro 31-8220 inhibited PKD activation induced by PDGF. Thus, our results indicate that PKD is activated by multiple signaling peptides through a protein kinase C-dependent signal transduction pathway in a variety of cell types.	IMPERIAL CANC RES FUND, GROWTH REGULAT LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Waldron, Richard Taliesin/ABF-2773-2020; Bustelo, Xose R./A-9526-2010	Waldron, Richard Taliesin/0000-0003-3151-6002; Bustelo, Xose R./0000-0001-9398-6072; ZUGAZA GURRUCHAGA, JOSE LUIS/0000-0003-2287-6671				BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; Charlesworth A, 1996, ONCOGENE, V12, P1337; COY DH, 1992, PEPTIDES, V13, P775, DOI 10.1016/0196-9781(92)90186-7; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; HUBBARD SR, 1991, SCIENCE, V254, P1776; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ISSANDOU M, 1989, BIOCHEM BIOPH RES CO, V163, P201, DOI 10.1016/0006-291X(89)92121-9; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MORRIS C, 1988, FEBS LETT, V231, P311, DOI 10.1016/0014-5793(88)80840-8; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STADDON JM, 1991, J BIOL CHEM, V266, P4840; TAKUWA N, 1987, J BIOL CHEM, V262, P182; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; Withers DJ, 1997, J BIOL CHEM, V272, P2509; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	63	156	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23952	23960		10.1074/jbc.272.38.23952	http://dx.doi.org/10.1074/jbc.272.38.23952			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295346	hybrid			2022-12-27	WOS:A1997XX38100071
J	Davidson, D; Cloutier, JF; Gregorieff, A; Veillette, A				Davidson, D; Cloutier, JF; Gregorieff, A; Veillette, A			Inhibitory tyrosine protein kinase p50(csk) is associated with protein-tyrosine phosphatase PTP-PEST in hemopoietic and non-hemopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTES; SH2 DOMAIN; ZETA-CHAIN; C-SRC; V-SRC; CSK; ACTIVATION; CLONING; GENE; PHOSPHORYLATION	p50(csk) is a cytosolic tyrosine protein kinase expressed in all cell types, Accumulating data show that it inhibits multiple cellular processes, as a consequence of its ability to repress the enzymatic activity of Src family tyrosine protein kinases, We previously demonstrated that, via its Src homology 3 (SH3) domain, Csk is tightly bound to PEP, a protein-tyrosine phosphatase (PTP) exclusively expressed in hemopoietic cells, In this report, we have tested the possibility that Csk also interacts with PTP-PEST, a ubiquitous PTP sharing structural homology with PEP, Our studies revealed that Csk was associated with PTP-PEST in a variety of cell types, including non-hemopoietic cells, This interaction involved the SH3 region of p50(csk) and a proline-rich region (PPPLPERTPESFVLADM) outside the catalytic region of PTP-PEST. Even though both PTP PEST and PEP were associated with Csk, significant differences were noted between these two PTPs. PTP-PEST, but not PEP, was also complexed with She, an adaptor molecule implicated in the has pathway, Moreover, PTP-PEST and PEP were found to accumulate primarily in distinct intracellular compartments in cell fractionation studies, In combination, these findings indicated that, like PEP, PTP-PEST is probably involved in Csk-mediated functions in mammalian cells, Moreover, they suggested that the roles of Csk-PTP-PEST and Csk-PEP are likely to be different.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University			Cloutier, Jean-François/K-2003-2012					ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; FLORES E, 1994, MOL CELL BIOL, V14, P4938, DOI 10.1128/MCB.14.7.4938; FORD CE, 1994, J BIOL CHEM, V269, P30378; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; HABIB T, 1994, J BIOL CHEM, V269, P25243; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Huang K, 1996, ONCOGENE, V13, P1567; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Kim YW, 1996, ONCOGENE, V13, P2275; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NADA S, 1993, CELL, V73, P125; NEET K, 1995, MOL CELL BIOL, V15, P4908; OETKEN C, 1994, ONCOGENE, V9, P1625; PERI KG, 1993, ONCOGENE, V8, P2765; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; ROZDZIAL MM, 1994, J IMMUNOL, V153, P1563; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SupertiFurga G, 1996, NAT BIOTECHNOL, V14, P600, DOI 10.1038/nbt0596-600; Tobe K, 1996, MOL CELL BIOL, V16, P4765; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEIL R, 1994, J BIOL CHEM, V269, P22830; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274; YANG Q, 1993, J BIOL CHEM, V268, P6622	44	94	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23455	23462		10.1074/jbc.272.37.23455	http://dx.doi.org/10.1074/jbc.272.37.23455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287362	hybrid			2022-12-27	WOS:A1997XV74400073
J	DiMarco, A; Gloaguen, I; Demartis, A; Saggio, I; Graziani, R; Paonessa, G; Laufer, R				DiMarco, A; Gloaguen, I; Demartis, A; Saggio, I; Graziani, R; Paonessa, G; Laufer, R			Agonistic and antagonistic variants of ciliary neurotrophic factor (CNTF) reveal functional differences between membrane-bound and soluble CNTF alpha-receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; EPIDERMAL GROWTH-FACTOR; LOW-AFFINITY RECEPTORS; ONCOSTATIN-M; EQUILIBRIUM BINDING; PROTEIN; INTERLEUKIN-6; CELLS; ACTIVATION; CYTOKINES	Ciliary neurotrophic factor (CNTF) drives the sequential assembly of a receptor complex containing the ligand-specific alpha-receptor subunit (CNTFR) and the signal-transducing beta-subunits gp130 and leukemia inhibitory factor receptor-beta (LIFR). CNTFR can function in either membrane-bound or soluble forms. The membrane-bound form mediates the neuronal actions of CNTF, whereas the soluble form serves to confer cytokine responsiveness to non-neuronal cells expressing gp130 and LIFR. The objective of this work was to analyze whether the two receptor isoforms differ in their ability to interact functionally with CNTF and related proteins. Two new types of CNTF variants, characterized by weakened interactions with either CNTFR or both LIFR and gp130, were developed, and the biological activities of these and other mutants were determined in non-neuronal versus neuronal cells, as well as in nonneuronal cells transfected with an expression vector for CNTFR. Membrane anchoring of CNTFR was found to render the CNTF receptor complex relatively insensitive to changes in agonist affinity for either alpha-or beta-receptor subunits and to promote a more efficient interaction with a gp130-depleting antagonistic variant of CNTF. As a result of this phenomenon, which can be rationalized in terms of the multivalent nature of CNTF receptor interaction, CNTF variants display striking changes in receptor selectivity.	IRBM,I-00040 POMEZIA,ROME,ITALY	Merck & Company			Saggio, Isabella/H-2417-2015; Laufer, Ralph/H-9336-2013	saggio, isabella/0000-0002-9497-7415				BAUMANN G, 1994, J CLIN ENDOCR METAB, V78, P1113, DOI 10.1210/jc.78.5.1113; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; CONOVER JC, 1993, DEVELOPMENT, V119, P559; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Demartis A, 1996, CANCER RES, V56, P4213; DEMBO M, 1978, J IMMUNOL, V121, P345; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; DiMarco A, 1996, P NATL ACAD SCI USA, V93, P9247, DOI 10.1073/pnas.93.17.9247; DiStefano PS, 1996, J BIOL CHEM, V271, P22839, DOI 10.1074/jbc.271.37.22839; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; DOWER SK, 1981, BIOCHEMISTRY-US, V20, P6326, DOI 10.1021/bi00525a007; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Halvorsen SW, 1996, NEUROPHARMACOLOGY, V35, P257, DOI 10.1016/0028-3908(95)00168-9; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HUBER J, 1993, EUR J BIOCHEM, V218, P1031, DOI 10.1111/j.1432-1033.1993.tb18462.x; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; INOUE M, 1995, P NATL ACAD SCI USA, V92, P8579, DOI 10.1073/pnas.92.19.8579; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Manthorpe M, 1993, NEUROTROPHIC FACTORS, P443; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007; PANAYOTATOS N, 1993, J BIOL CHEM, V268, P19000; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SAGGIO I, 1995, EMBO J, V14, P3045, DOI 10.1002/j.1460-2075.1995.tb07307.x; SAGGIO I, 1994, ANAL BIOCHEM, V221, P387, DOI 10.1006/abio.1994.1430; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; SCHOOLTINK H, 1992, FEBS LETT, V314, P280, DOI 10.1016/0014-5793(92)81489-9; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; Sun RX, 1997, EUR CYTOKINE NETW, V8, P51; THOMA B, 1994, J BIOL CHEM, V269, P6215; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZHANG XG, 1994, J EXP MED, V177, P1337; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	46	9	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23069	23075		10.1074/jbc.272.37.23069	http://dx.doi.org/10.1074/jbc.272.37.23069			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287306	hybrid			2022-12-27	WOS:A1997XV74400017
J	Ishii, TM; Maylie, J; Adelman, JP				Ishii, TM; Maylie, J; Adelman, JP			Determinants of apamin and d-tubocurarine block in SK potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED K+ CHANNELS; RAT-BRAIN; INWARD RECTIFIER; SKELETAL-MUSCLE; AFTER-HYPERPOLARIZATION; FUNCTIONAL EXPRESSION; HIPPOCAMPAL-NEURONS; SMALL-CONDUCTANCE; MAMMALIAN BRAIN; BINDING-SITE	Small conductance calcium-activated potassium channels show a distinct pharmacology. Some, but not all, are blocked by the peptide toxin apamin, and apamin-sensitive channels are also blocked by d-tubocurarine. Cloned SK channels (small conductance calcium-activated potassium channel) recapitulate these properties, We have investigated the structural basis for these differences and found that two amino acid residues on either side of the deep pore are the primary determinants of sensitivity to apamin and differential block by d-tubocurarine. Therefore, the pharmacology of SK channels compared with other potassium channels correlates with structural differences in the outer pore region, However, introduction of a tyrosine residue in the position analogous to that which determines sensitivity to external tetraethylammonium for voltage-gated potassium channels endows SK channels with an equivalent tetraethylammonium sensitivity, indicating that the outer vestibules of the pores are similar, The pharmacology of channels formed in oocytes coinjected with SK1 and SK2 mRNAs, or with SK1-SK2 dimer mRNA, show that SK subunits may form heteromeric channels.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT OBSTET & GYNECOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; BEHRENS MI, 1994, MUSCLE NERVE, V17, P1264, DOI 10.1002/mus.880171104; BEHRENS MI, 1992, AM J PHYSIOL, V263, pC794, DOI 10.1152/ajpcell.1992.263.4.C794; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; DUN NJ, 1986, J PHYSIOL-LONDON, V375, P499, DOI 10.1113/jphysiol.1986.sp016130; FOSSET M, 1984, P NATL ACAD SCI-BIOL, V81, P7228, DOI 10.1073/pnas.81.22.7228; Gandolfo G, 1996, BRAIN RES, V736, P344, DOI 10.1016/0006-8993(96)00690-7; GEHLERT DR, 1993, NEUROSCIENCE, V52, P191, DOI 10.1016/0306-4522(93)90192-I; GOH JW, 1987, J PHYSIOL-LONDON, V394, P315, DOI 10.1113/jphysiol.1987.sp016872; GRANIER C, 1978, EUR J BIOCHEM, V82, P293, DOI 10.1111/j.1432-1033.1978.tb12023.x; HARVEY AL, 1985, PHARMACOL THERAPEUT, V31, P33, DOI 10.1016/0163-7258(85)90036-1; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEURTEAUX C, 1993, MOL BRAIN RES, V18, P17, DOI 10.1016/0169-328X(93)90169-P; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOTSON JR, 1980, J NEUROPHYSIOL, V43, P409, DOI 10.1152/jn.1980.43.2.409; HUGUES M, 1982, EMBO J, V1, P1039, DOI 10.1002/j.1460-2075.1982.tb01293.x; HURST RS, 1992, J BIOL CHEM, V267, P23742; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LABBEJULLIE C, 1991, EUR J BIOCHEM, V196, P639, DOI 10.1111/j.1432-1033.1991.tb15860.x; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LANG DG, 1990, J PHYSIOL-LONDON, V425, P117, DOI 10.1113/jphysiol.1990.sp018095; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MCCOWN TJ, 1990, EUR J PHARMACOL, V187, P49, DOI 10.1016/0014-2999(90)90339-8; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MESSIER C, 1991, BRAIN RES, V551, P322, DOI 10.1016/0006-8993(91)90950-Z; MOURRE C, 1984, EUR J PHARMACOL, V100, P135, DOI 10.1016/0014-2999(84)90329-7; NEWLAND CF, 1992, NEURON, V8, P975, DOI 10.1016/0896-6273(92)90212-V; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; PEASE JHB, 1988, BIOCHEMISTRY-US, V27, P8491, DOI 10.1021/bi00422a029; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; RENAUD JF, 1986, NATURE, V319, P678, DOI 10.1038/319678a0; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SANDBERG BEB, 1979, INT J PEPT PROT RES, V13, P327; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCHMIDANTOMARCHI H, 1985, P NATL ACAD SCI USA, V82, P2188, DOI 10.1073/pnas.82.7.2188; STUHMER W, 1988, FEBS LETT, V242, P199, DOI 10.1016/0014-5793(88)81015-9; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; VINCENT JP, 1975, BIOCHEMISTRY-US, V14, P2521, DOI 10.1021/bi00682a035; YAROM Y, 1985, NEUROSCIENCE, V16, P719, DOI 10.1016/0306-4522(85)90090-9; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P661, DOI 10.1113/jphysiol.1995.sp020998	53	228	234	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23195	23200		10.1074/jbc.272.37.23195	http://dx.doi.org/10.1074/jbc.272.37.23195			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287325	hybrid			2022-12-27	WOS:A1997XV74400036
J	Antonenkov, VD; VanVeldhoven, PP; Waelkens, E; Mannaerts, GP				Antonenkov, VD; VanVeldhoven, PP; Waelkens, E; Mannaerts, GP			Substrate specificities of 3-oxoacyl-CoA thiolase A and sterol carrier protein 2/3-oxoacyl-CoA thiolase purified from normal rat liver peroxisomes - Sterol carrier protein 2/3-oxoacyl-CoA thiolase is involved in the metabolism of 2-methyl-branched fatty acids and bile acid intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; COENZYME-A THIOLASE; BETA-OXIDATION; 3-KETOACYL-COA THIOLASE; KINETIC MECHANISM; 58-KDA PROTEIN; PURIFICATION; CDNA; SEQUENCE; IDENTIFICATION	The two main thiolase activities present in isolated peroxisomes from normal rat liver were purified to near homogeneity. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the first enzyme preparation displayed a single band of 41 kDa that was identified as 3-oxoacyl-CoA thiolase A (thiolase A) by N-terminal amino acid sequencing, The second enzyme preparation consisted of a 58- and a 46-kDa band, The 58-kDa polypeptide reacted with antibodies raised against either sterol carrier protein 2 or the thiolase domain of sterol carrier protein 2/3-oxoacyl-CoA thiolase (SCP-2/thiolase), formerly also called sterol carrier protein X, whereas the 46-kDa polypeptide reacted only with the antibodies raised against the thiolase domain, Internal peptide sequencing confirmed that the 58-kDa polypeptide is SCP-2/thiolase and that the 46-kDa polypeptide is the thiolase domain of SCP-2/thiolase. Thiolase A catalyzed the cleavage of short, medium, and long straight chain 3-oxoacyl-CoAs, medium chain 3-oxoacyl-CoAs being the best substrates, The enzyme was inactive with the 2-methyl-branched 3-oxo-2-methylpalmitoyl-CoA and with the bile acid intermediate 24-oxo-trihydroxycoprostanoyl-CoA. SCP-2/thiolase was active with medium and long straight chain 3-oxoacyl-CoAs but also with the 2-methyl-branched 3-oxoacyl-CoA and the bile acid intermediate. In peroxisomal extracts, more than 90% of the thiolase activity toward straight chain 3-oxoacyl-CoAs was associated with thiolase A. Kinetic parameters (K-m and V-max) were determined for each enzyme with the different substrates. Our results indicate the following: 1) the two (main) thiolases present in peroxisomes from normal rat liver are thiolase A and SCP-2/thiolase; 2) thiolase A is responsible for the thiolytic cleavage of straight chain 3-oxoacyl-CoAs; and 3) SCP-2/thiolase is responsible for the thiolytic cleavage of the 3-oxoacyl-CoA derivatives of 2-methyl-branched fatty acids and the side chain of cholesterol.	UNIV CATHOLIQUE LOUVAIN, DEPT MOL CELLBIOL, AFDELING FARMACOL, B-3000 LOUVAIN LA NEUVE, BELGIUM; UNIV CATHOLIQUE LOUVAIN, DEPT MOL CELLBIOL, AFDELING BIOCHEM, B-3000 LOUVAIN LA NEUVE, BELGIUM	Universite Catholique Louvain; Universite Catholique Louvain			, Van Veldhoven Paul/U-6359-2019	, Van Veldhoven Paul/0000-0002-4478-2564				Baumgart E, 1996, P NATL ACAD SCI USA, V93, P13748, DOI 10.1073/pnas.93.24.13748; BODNAR AG, 1990, GENE, V91, P193, DOI 10.1016/0378-1119(90)90088-9; BOUT A, 1991, BIOCHIM BIOPHYS ACTA, V1090, P43, DOI 10.1016/0167-4781(91)90035-K; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINKENBEARD KD, 1973, J BIOL CHEM, V248, P2275; DieuaideNoubhani M, 1997, BIOCHEM J, V321, P253, DOI 10.1042/bj3210253; DieuaideNoubhani M, 1996, EUR J BIOCHEM, V240, P660, DOI 10.1111/j.1432-1033.1996.0660h.x; DieuaideNoubhani M, 1997, BIOCHEM J, V325, P367, DOI 10.1042/bj3250367; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; GEHRING U, 1972, ENZYMES, V7, P391; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; HUTH W, 1973, H-S Z PHYSIOL CHEM, V354, P635, DOI 10.1515/bchm2.1973.354.1.635; HUTH W, 1975, EUR J BIOCHEM, V59, P475, DOI 10.1111/j.1432-1033.1975.tb02476.x; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; Leenders F, 1996, J BIOL CHEM, V271, P5438, DOI 10.1074/jbc.271.10.5438; Mannaerts GP, 1996, ANN NY ACAD SCI, V804, P99, DOI 10.1111/j.1749-6632.1996.tb18611.x; MIDDLETON B, 1983, CLIN CHIM ACTA, V128, P291, DOI 10.1016/0009-8981(83)90329-7; MIDDLETON B, 1973, BIOCHEM J, V132, P717, DOI 10.1042/bj1320717; MIDDLETON B, 1974, BIOCHEM J, V139, P109, DOI 10.1042/bj1390109; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; MIYAZAWA S, 1981, J BIOCHEM, V90, P511, DOI 10.1093/oxfordjournals.jbchem.a133499; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; NOVIKOV DK, 1994, J BIOL CHEM, V269, P27125; OHBA T, 1995, BIOCHEMISTRY-US, V34, P10660, DOI 10.1021/bi00033a042; Ossendorp BC, 1996, ARCH BIOCHEM BIOPHYS, V334, P251, DOI 10.1006/abbi.1996.0453; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITZ W, 1995, EUR J BIOCHEM, V231, P815, DOI 10.1111/j.1432-1033.1995.0815d.x; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; SEUBERT W, 1968, BIOCHIM BIOPHYS ACTA, V164, P498, DOI 10.1016/0005-2760(68)90180-X; STAACK H, 1978, J BIOL CHEM, V253, P1827; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Vanhooren JCT, 1997, BIOCHEM J, V325, P593, DOI 10.1042/bj3250593; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VanVeldhoven PP, 1996, FEBS LETT, V388, P80, DOI 10.1016/0014-5793(96)00508-X; VanVeldhoven PP, 1997, BBA-LIPID LIPID MET, V1347, P62, DOI 10.1016/S0005-2760(97)00053-2; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P24676; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; VERHEYDEN K, 1992, BIOCHIM BIOPHYS ACTA, V1109, P48, DOI 10.1016/0005-2736(92)90185-O; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; Xu RF, 1996, BIOCHEM BIOPH RES CO, V221, P271, DOI 10.1006/bbrc.1996.0585	49	126	130	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26023	26031		10.1074/jbc.272.41.26023	http://dx.doi.org/10.1074/jbc.272.41.26023			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325339	hybrid			2022-12-27	WOS:A1997YA35800094
J	Duchateau, PN; Pullinger, CR; Orellana, RE; Kunitake, ST; NayaVigne, J; OConnor, PM; Malloy, MJ; Kane, JP				Duchateau, PN; Pullinger, CR; Orellana, RE; Kunitake, ST; NayaVigne, J; OConnor, PM; Malloy, MJ; Kane, JP			Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas - Identification, cloning, characterization, and plasma distribution of apolipoprotein L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER TRANSFER; I-CONTAINING LIPOPROTEINS; SEPHAROSE AFFINITY-CHROMATOGRAPHY; CELL-DERIVED CHOLESTEROL; APOPROTEIN-A-I; POLYACRYLAMIDE GELS; HEART-DISEASE; PROTEINS; ACYLTRANSFERASE; IMMUNOSORPTION	In this study, we have identified and characterized a new protein present in human high density lipoprotein that we have designated apolipoprotein L. Using a combination of liquid-phase isoelectrophoresis and high resolution two-dimensional gel electrophoresis, apolipoprotein L was identified and partially sequenced from immunoisolated high density lipoprotein (Lp(A-I)). Expression was only detected in the pancreas, The cDNA sequence encoding the full-length protein was cloned using reverse transcription-polymerase chain reaction, The deduced amino acid sequence contains 383 residues, including a typical signal peptide of 12 amino acids, No significant homology was found with known sequences, The plasma protein is a single chain polypeptide with an apparent molecular mass of 42 kDa, Antibodies raised against this protein detected a truncated form with a molecular mass of 39 kDa, Both forms were predominantly associated with immunoaffinity-isolated apoA-I-containing lipoproteins and detected mainly in the density range 1.123 < d < 1.21 g/ml. Free apoL was not detected in plasma. Anti-apoL immunoaffinity chromatography was used to purify apoL-containing lipoproteins (Lp(L)) directly from plasma. Nondenaturing gel electrophoresis of Lp(L) showed two major molecular species with apparent diameters of 12.2-17 and 10.4-12.2 nm. Moreover, Lp(L) exhibited both pre-beta and alpha electromobility. Apolipoproteins A-I, A-II, A-IV, and C-III were also detected in the apoL-containing lipoprotein particles.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NHLBI NIH HHS [HL-50792, HL-50779, HL-31210] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL031210, R01HL031210, R01HL050779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAUPOVIC P, 1980, HDB ELECTROPHORESIS, V1, P27; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BOJANOVSKI D, 1985, J LIPID RES, V26, P185; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1986, J LIPID RES, V27, P1135; CHEUNG MC, 1988, J LIPID RES, V29, P15; EDELSTEIN C, 1983, J BIOL CHEM, V258, P1430; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1980, P NATL ACAD SCI-BIOL, V77, P3327, DOI 10.1073/pnas.77.6.3327; FRANCONE OL, 1990, EUR HEART J, V11, P218, DOI 10.1093/eurheartj/11.suppl_E.218; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON T, 1977, JAMA-J AM MED ASSOC, V238, P497, DOI 10.1001/jama.238.6.497; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JAMES RW, 1988, J LIPID RES, V29, P1557; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KUNITAKE S, 1987, NATL I HLTH WORKSH L, V87, P419; KUNITAKE ST, 1985, J LIPID RES, V26, P549; KUNITAKE ST, 1982, J LIPID RES, V23, P936; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; KUNITAKE ST, 1994, BIOCHEMISTRY-US, V33, P1988, DOI 10.1021/bi00174a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCEL YL, 1981, J LIPID RES, V22, P1198; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; MILLER GJ, 1975, LANCET, V1, P16; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OHTA T, 1989, FEBS LETT, V257, P435, DOI 10.1016/0014-5793(89)81590-X; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROFATTER JA, 1995, GENOME RES, V5, P214, DOI 10.1101/gr.5.3.214; WEISGRABER KH, 1980, J LIPID RES, V21, P316; WIELAND H, 1982, J LIPID RES, V23, P893; WILSON HM, 1992, BIOCHEM J, V284, P477, DOI 10.1042/bj2840477; ZEHR BD, 1989, ANAL BIOCHEM, V182, P157, DOI 10.1016/0003-2697(89)90734-3	39	165	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25576	25582		10.1074/jbc.272.41.25576	http://dx.doi.org/10.1074/jbc.272.41.25576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325276	hybrid			2022-12-27	WOS:A1997YA35800031
J	Mantey, SA; Weber, HC; Sainz, E; Akeson, M; Ryan, RR; Pradhan, TK; Searles, RP; Spindel, ER; Battey, JF; Coy, DH; Jensen, RT				Mantey, SA; Weber, HC; Sainz, E; Akeson, M; Ryan, RR; Pradhan, TK; Searles, RP; Spindel, ER; Battey, JF; Coy, DH; Jensen, RT			Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING PEPTIDE; SWISS 3T3 CELLS; PANCREATIC ACINAR-CELLS; LUNG-CARCINOMA CELLS; ANTAGONIST ACTIVITY; ANTIMITOTIC ACTIVITY; LIGAND-BINDING; POTENT; ANALOGS; INTERNALIZATION	An orphan receptor discovered in 1993 was called bombesin receptor subtype 3 (BRS-3) because of 47-51% amino acid identity with bombesin (Bn) receptors. Its pharmacology is unknown, because no naturally occurring tissues have sufficient receptors to allow studies. We made two cell lines stably expressing the human BRS-3 (hBRS-3). hBRS-3 was overexpressed in the human non-small cell lung cancer cells, NCI-H1299, and the other was made in Balb 3T3 cells, which lack endogenous BRS-3. [D-Phe(6),beta-Ala(11),Phe(13),Nle(14)]Bn-(6-14) (where Nle represents norleucine) was discovered to have high potency for stimulating inositol phosphate formation in both cell lines. [I-125-D-Tyr(6),beta-Ala(11),Phe(13),Nle(14)]Bn-(6-14) bound to both cell lines with high affinity. Neither Bn nor 14 other naturally occurring Bn peptides bound to hBRS-3 with a K-d <1000 nM. Twenty-six synthetic peptides that are high affinity agonists or antagonists at other bombesin receptors had an affinity >1000 nM. Guanosine 5'-(beta,gamma-imido)triphosphate inhibited binding to both cells due to a change in receptor affinity. These results demonstrate hBRS-3 has a unique pharmacology. It does not interact with high affinity with any known natural agonist or high affinity antagonist of the Bn receptor family, suggesting the natural ligand is either an undiscovered member of the Bn peptide family or an unrelated peptide. The availability of these cell lines and the hBRS-3 ligand should facilitate identification of the natural ligand for BRS-3, its pharmacology, and cell biology.	NIDDK, NIH, DDB, BETHESDA, MD 20892 USA; NIDOCD, NIH, ROCKVILLE, MD 20850 USA; TULANE UNIV, PEPTIDE RES LABS, NEW ORLEANS, LA 70117 USA; OREGON REG PRIMATE RES CTR, DIV NEUROSCI, BEAVERTON, OR 97006 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Tulane University; Oregon Health & Science University; Oregon National Primate Research Center				Weber, Horst Christian/0000-0001-9005-6988				BENYA RV, 1992, MOL PHARMACOL, V42, P1058; BENYA RV, 1994, MOL PHARMACOL, V46, P235; BENYA RV, 1995, MOL PHARMACOL, V47, P10; CAMBLE R, 1989, LIFE SCI, V45, P1521, DOI 10.1016/0024-3205(89)90417-7; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; COY D, 1990, EUR J PHARMACOL, V190, P31, DOI 10.1016/0014-2999(90)94109-B; COY DH, 1988, J BIOL CHEM, V263, P5056; COY DH, 1989, J BIOL CHEM, V264, P14691; Davis LG, 1994, BASIC METHODS MOL BI; FATHI Z, 1993, J BIOL CHEM, V268, P5979; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; GORBULEV V, 1994, FEBS LETT, V340, P260, DOI 10.1016/0014-5793(94)80150-9; HEIMBROOK DC, 1989, J BIOL CHEM, V264, P11258; HEINZERIAN P, 1987, AM J PHYSIOL, V252, pG439, DOI 10.1152/ajpgi.1987.252.3.G439; JENSEN RT, 1991, TRENDS PHARMACOL SCI, V12, P13, DOI 10.1016/0165-6147(91)90483-9; JENSEN RT, 1978, P NATL ACAD SCI USA, V75, P6139, DOI 10.1073/pnas.75.12.6139; JENSEN RT, 1984, NATURE, V309, P61, DOI 10.1038/309061a0; KUSUI T, 1994, BIOCHEMISTRY-US, V33, P12968, DOI 10.1021/bi00248a005; LADENHEIM EE, 1993, METHODS NEUROSCI, V11, P283; LEBAN JJ, 1993, P NATL ACAD SCI USA, V90, P1922, DOI 10.1073/pnas.90.5.1922; LEVITZKI A, 1984, RECEPTORS QUANTITATI; MANTEY S, 1993, MOL PHARMACOL, V43, P762; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; ORBUCH M, 1993, MOL PHARMACOL, V44, P841; Pansky A, 1997, EUR J CLIN INVEST, V27, P69, DOI 10.1046/j.1365-2362.1997.900616.x; ROZENGURT E, 1988, ANN NY ACAD SCI, V547, P277, DOI 10.1111/j.1749-6632.1988.tb23896.x; SAEED ZA, 1989, PEPTIDES, V10, P597, DOI 10.1016/0196-9781(89)90149-6; SASAKI Y, 1987, PEPTIDES, V8, P119, DOI 10.1016/0196-9781(87)90174-4; SHAPIRA H, 1993, METHODS NEUROSCI, V13, P220; SIMMACO M, 1990, PEPTIDES, V11, P299, DOI 10.1016/0196-9781(90)90086-K; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VIGNA SR, 1991, METHODS NEUROSCIENCE, P301; VONSCHRENCK T, 1990, AM J PHYSIOL, V259, pG468, DOI 10.1152/ajpgi.1990.259.3.G468; WANG LH, 1990, BIOCHEMISTRY-US, V29, P616, DOI 10.1021/bi00455a004; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N; WANG LH, 1990, J BIOL CHEM, V265, P15695; WECHSELBERGER C, 1992, P NATL ACAD SCI USA, V89, P9819, DOI 10.1073/pnas.89.20.9819; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; Wu JM, 1996, MOL PHARMACOL, V50, P1355; ZHANG L, 1988, BIOCHIM BIOPHYS ACTA, V972, P37, DOI 10.1016/0167-4889(88)90100-0	41	146	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26062	26071		10.1074/jbc.272.41.26062	http://dx.doi.org/10.1074/jbc.272.41.26062			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325344	hybrid			2022-12-27	WOS:A1997YA35800099
J	Atfi, A; Buisine, M; Mazars, A; Gespach, C				Atfi, A; Buisine, M; Mazars, A; Gespach, C			Induction of apoptosis by DPC4, a transcriptional factor regulated by transforming growth factor-beta through stress-activated protein kinase c-Jun N-terminal kinase (SAPK/JNK) signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; CELL-DEATH; RECEPTORS; FAMILY; JNK; TRANSDUCTION; DOMAIN; ERK	Many of the actions of serine/threonine kinase receptors for the transforming growth factor-beta (TGF beta) are mediated by DPC4, a human MAD-related protein identified as a tumor suppressor gene in pancreatic carcinoma. Overexpression of DPC4 is sufficient to induce the activation of gene expression and cell cycle arrest, characteristic of the TGF beta response. The stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) is also one of the downstream targets required for TGF beta-mediated signaling, Here we report that expression of the dominant-interfering mutant of various components of the SAPK/JNK. cascade specifically blocked both TGF beta and DPC4-induced gene expression, These dominant-interfering mutants also inhibited TGF beta-stimulated DPC4 transcriptional activity. Moreover, we find that overexpression of DPC4 causes transfected cells to undergo the morphological changes typical of apoptosis, These findings define a mechanism whereby TGF beta signals mediated by DPC4 and SAPK/JNK cascade are integrated in the nucleus to activate gene expression and identify a new cellular function for DPC4.	HOP ST ANTOINE,INSERM,U55,F-75571 PARIS 12,FRANCE; HOP ST ANTOINE,CTR HOSP UNIV ST ANTOINE,INST FEDERATIF RECH,IFR 65,F-75571 PARIS 12,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite								Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Frey RS, 1997, CANCER RES, V57, P628; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RAPP UR, 1994, ONCOGENE, V9, P3493; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	31	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24731	24734		10.1074/jbc.272.40.24731	http://dx.doi.org/10.1074/jbc.272.40.24731			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312063	hybrid			2022-12-27	WOS:A1997XY97000002
J	Holland, PM; Suzanne, M; Campbell, JS; Noselli, S; Cooper, JA				Holland, PM; Suzanne, M; Campbell, JS; Noselli, S; Cooper, JA			MKK7 is a stress-activated mitogen-activated protein kinase kinase functionally related to hemipterous	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ACTIN POLYMERIZATION; BINDING PROTEIN; C-JUN; DROSOPHILA; PATHWAY; RAC; PHOSPHORYLATION; IDENTIFICATION; MORPHOGENESIS	Exposure of mammalian cells to stressful stimuli results in activation of the c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinases (SAPKs), a family of protein kinases related to mitogen-activated protein (MAP) kinase, JNK/SAPKs are activated by specific MAP kinase kinases (MKKs), one of which, MKK4/SEK1, has been characterized extensively, In Drosophila, the JNK/SAPK Basket (Bsk) and the MKK Hemipterous (Hep), are important for embryonic development, Loss of function of either gene inhibits dorsal closure, a morphogenetic movement in which the edges of the embryonic ectoderm move together over the amnioserosa. There is evidence that the Rho GTPases Rac and Cdc42 are also required for dorsal closure, suggesting that Rac or Cdc42 may regulate Hep and Bsk, We have identified MKK7, a murine homolog of Hep. MKK7 functionally rescues hep mutant flies, In fibroblasts, MKK7 is activated by stress and by the GTPase Rac1. MKK7 directly phosphorylates and activates JNK/SAPK. Thus, MKK7 is a homolog of hep and functions in a conserved signaling pathway involving JNK/SAPK and the GTPase Rac1.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98109; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; CTR DEV BIOL,CNRS,UNITE MIXTE RECH 5547,F-31062 TOULOUSE,FRANCE	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)				Noselli, stephane/0000-0002-7296-324X; Campbell, Jean/0000-0002-9187-2204				AHN NG, 1990, J BIOL CHEM, V265, P11487; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; HARDEN N, 1995, DEVELOPMENT, V121, P903; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1992, J BIOL CHEM, V267, P25628; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Thummel CS, 1992, DROS INF SERV, V71, P150; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	32	151	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24994	24998		10.1074/jbc.272.40.24994	http://dx.doi.org/10.1074/jbc.272.40.24994			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312105	hybrid			2022-12-27	WOS:A1997XY97000044
J	Molinari, M; Galii, C; Norais, N; Telford, JL; Rappuoli, R; Luzio, JP; Montecucco, C				Molinari, M; Galii, C; Norais, N; Telford, JL; Rappuoli, R; Luzio, JP; Montecucco, C			Vacuoles induced by Helicobacter pylori toxin contain both late endosomal and lysosomal markers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLATING CYTOTOXIN; CAMPYLOBACTER-PYLORI; ENDOCYTIC PATHWAY; VIRULENCE FACTORS; GASTRIC LYMPHOMA; PEPTIC-ULCER; DISEASE; INFECTION; RECEPTORS; STRAINS	Intoxication of mammalian cells with the vacuolating toxin (VacA) released by Helicobacter pylori causes the formation of large acidic vacuoles containing the vacuolar ATPase proton pump and Rab7, a late endosome marker. Here, we describe a novel subcellular fractionation procedure, and we show that nanomolar concentrations of VacA induce a clear redistribution of lysosomal membrane glycoproteins among endocytic compartments. This redistribution is an early event in the process of cellular intoxication by VacA and precedes the formation of macroscopic vacuoles. The absence of the cation independent mannose 6-P receptor and the presence of Rab7 and of lysosomal membrane proteins in the newly formed compartment suggest that the vacuolating toxin induces the accumulation of a post-endosomal hybrid compartment presenting both late endosomal and lysosomal features.	UNIV PADUA,DIPARTIMENTO SCI BIOMED,I-35100 PADUA,ITALY; CTR RIC IRIS,BIOCINE CHIRON,I-53100 SIENA,ITALY; UNIV CAMBRIDGE,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	University of Padua; University of Cambridge	Molinari, M (corresponding author), UNIV PADUA,CTR CNR,VIA G COLOMBO 3,I-35100 PADUA,ITALY.		Molinari, Maurizio/N-2587-2019; Telford, John Laird/ABG-8144-2020	Molinari, Maurizio/0000-0002-7636-5829; 				ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; COVER TL, 1994, J BIOL CHEM, V269, P10566; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; DESJARDINS M, 1995, TRENDS CELL BIOL, V5, P183, DOI 10.1016/S0962-8924(00)88989-8; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FernandezBorja M, 1996, INT IMMUNOL, V8, P625, DOI 10.1093/intimm/8.5.625; FIOCCA R, 1992, VIRCHOWS ARCH A, V420, P489, DOI 10.1007/BF01600253; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GOODWIN CS, 1988, LANCET, V2, P1467; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P615, DOI 10.1016/S0016-5085(89)80057-5; Griffiths G, 1996, PROTOPLASMA, V195, P37, DOI 10.1007/BF01279185; ISAACSON PG, 1994, NEW ENGL J MED, V330, P1310, DOI 10.1056/NEJM199405053301812; LEUNK RD, 1991, REV INFECT DIS S, V13, P686; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MERESSE S, 1995, J CELL SCI, V108, P3349; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; PAPINI E, 1993, MOL MICROBIOL, V7, P323, DOI 10.1111/j.1365-2958.1993.tb01123.x; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PAPINI E, 1996, BACTERIAL PROTEIN TO, V28, P181; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Reaves BJ, 1996, J CELL SCI, V109, P749; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; TOMPKINS LS, 1995, SCIENCE, V267, P1621, DOI 10.1126/science.7886448; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	36	165	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25339	25344		10.1074/jbc.272.40.25339	http://dx.doi.org/10.1074/jbc.272.40.25339			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312153	hybrid			2022-12-27	WOS:A1997XY97000092
J	Ueda, H; Siani, MA; Gong, WH; Thompson, DA; Brown, GG; Wang, JM				Ueda, H; Siani, MA; Gong, WH; Thompson, DA; Brown, GG; Wang, JM			Chemically synthesized SDF-1 alpha analogue, N33A, is a potent chemotactic agent for CXCR4/Fusin/LESTR-expressing human leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-3 MCP3 INTERACTS; MOLECULAR-CLONING; CHEMOKINE RECEPTORS; HIV-1 ENTRY; LYMPHOCYTE CHEMOATTRACTANT; CHROMOSOMAL LOCALIZATION; 7-TRANSMEMBRANE; RANTES; SDF-1; GENE	Stromal cell-derived factor (SDF) 1 is a potent chemoattractant for leukocytes through activation of the receptor CXCR4/Fusin/LESTR, which is a fusion co-factor for the entry of T lymphocytotropic human immunodeficiency virus type 1 (HIV-1), This CXCR4-mediated HIV-1 fusion can be inhibited by SDF-1, Because of its importance in the study of immunity and AIDS, large scale production of SDF-1 is desirable, In addition to recombinant technology, chemical synthesis provides means by which biologically active proteins can be produced not only in large quantity but also with a variety of designed modifications, In this study, we investigated the binding and function of an SDF-1 alpha analogue, N33A, synthesized by a newly developed native chemical ligation approach, Radioiodinated N33A showed high affinity binding to human monocytes, T lymphocytes, as well as neutrophils, and competed equally well with native recombinant SDF-1 alpha for binding sites on leukocytes. N33A also showed equally potent chemoattractant activity as native recombinant SDF-1 alpha for human leukocytes. Further study with CXCR4/Fusin/LESTR transfected HEK 293 cells showed that N33A binds and induces directional migration of these cells in vitro. These results demonstrate that the chemically synthesized SDF-1 alpha analogue, N33A, which can be produced rapidly in large quantity, possesses the same capacity as native SDF-1 alpha to activate CXCR4-expressing cells and will provide a valuable agent for research on the host immune response and AIDS.	NCI,FREDERICK CANC RES & DEV CTR,MOL IMMUNOREGULAT LAB,DIV BASIC SCI,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,INTRAMURAL RES SUPPORTPROGRAM,SAIC FREDRICK,FREDERICK,MD 21702; GRYPHON SCI,S SAN FRANCISCO,CA 94080; NEN LIFE SCI PROD,IODINAT GRP,BILLERICA,MA 01862	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Thompson, Darren/0000-0002-3725-7112				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; CANNE LE, 1995, TETRAHEDRON LETT, V36, P1217, DOI 10.1016/0040-4039(95)00037-D; CANNE LE, 1995, J AM CHEM SOC, V117, P2998, DOI 10.1021/ja00116a005; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; JIANG W, 1994, EXP CELL RES, V215, P284, DOI 10.1006/excr.1994.1344; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Maeda Y, 1996, PROTEIN ENG, V9, P95, DOI 10.1093/protein/9.1.95; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Oppenheim Joost J., 1996, P187; Robson B, 1996, NAT BIOTECHNOL, V14, P892, DOI 10.1038/nbt0796-892; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; XU LL, 1995, J LEUKOCYTE BIOL, V57, P335, DOI 10.1002/jlb.57.2.335	33	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24966	24970		10.1074/jbc.272.40.24966	http://dx.doi.org/10.1074/jbc.272.40.24966			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312101	hybrid			2022-12-27	WOS:A1997XY97000040
J	Kai, M; Wada, I; Imai, S; Sakane, F; Kanoh, H				Kai, M; Wada, I; Imai, S; Sakane, F; Kanoh, H			Cloning and characterization of two human isozymes of Mg2+-independent phosphatidic acid phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-D; RAT-LIVER; PHOSPHOHYDROLASE ACTIVITY; DIACYLGLYCEROL KINASE; ENDOPLASMIC-RETICULUM; SPHINGOSINE 1-PHOSPHATE; MOLECULAR-CLONING; ESCHERICHIA-COLI; IDENTIFICATION	We obtained two human cDNA clones encoding phosphatidic acid phosphatase (PAP) isozymes named PAP-2a (M-r = 32,158) and -2b (M-r = 35, 119), both of which contained six putative transmembrane domains, Both enzymes were glycosylated and cleaved by N glycanase and endo-beta-galactosidase, thus suggesting their post-Golgi localization. PAP-Za and -2b shared 47% identical sequence and were judged to be the human counterparts of the previously sequenced mouse 35-kDa PAP(83% identity) and rat Dri42 protein (94% identity), respectively, Furthermore, the sequences of both PAPs were 34-39% identical to that of Drosophila Wunen protein. In view of the functions ascribed to Wunen and Dri42 in germ cell migration and epithelial differentiation, respectively, these findings unexpectedly suggest critical roles of PAP isoforms in cell growth and differentiation, Although the two PAPs hydrolyzed lysophosphatidate and ceramide-l-phosphate. in addition to phosphatidate, the hydrolysis of sphingosine-l-phosphate was detected only for PAP-2b, PAP-2b was expressed almost ubiquitously in all human tissues examined, whereas the expression of PAP-2a was relatively variable, being extremely low in the placenta and thymus, In HeLa cells, the transcription of PAP-2a was not affected by different stimuli, whereas PAP-2b was induced (up to 3-fold) by epidermal growth factor. These findings indicate that despite structural similarities, the two PAP isozymes may play distinct functions through their different patterns of substrate utilization and transcriptional regulation.	SAPPORO MED UNIV,SCH MED,DEPT BIOCHEM,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	Sapporo Medical University			Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377; Wada, Ikuo/0000-0001-5668-6994				ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Barila D, 1996, J BIOL CHEM, V271, P29928, DOI 10.1074/jbc.271.47.29928; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; EGAWA K, 1995, FEBS LETT, V372, P74, DOI 10.1016/0014-5793(95)00957-B; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HII CST, 1991, J BIOL CHEM, V266, P20238; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; Jiang YW, 1996, J BIOL CHEM, V271, P29529, DOI 10.1074/jbc.271.47.29529; Kai M, 1996, J BIOL CHEM, V271, P18931, DOI 10.1074/jbc.271.31.18931; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1992, J BIOL CHEM, V267, P25309; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; KANOH H, 1997, IN PRESS BIOCH BIOPH; KOLESNICK R, 1994, CELL, V77, P326; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; Neuwald AF, 1997, PROTEIN SCI, V6, P1764, DOI 10.1002/pro.5560060817; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PERRY DK, 1993, J BIOL CHEM, V268, P25302; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Siess EA, 1996, FEBS LETT, V381, P169, DOI 10.1016/0014-5793(96)00111-1; SMITH SW, 1957, J BIOL CHEM, V228, P915; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Stukey J, 1997, PROTEIN SCI, V6, P469; TRUETT AP, 1992, FASEB J, V6, P2720, DOI 10.1096/fasebj.6.9.1612297; WADA I, 1994, J BIOL CHEM, V269, P7464; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WALSH JP, 1986, J BIOL CHEM, V261, P6239; XIE MS, 1994, ARCH BIOCHEM BIOPHYS, V312, P254, DOI 10.1006/abbi.1994.1307; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0	45	136	147	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24572	24578		10.1074/jbc.272.39.24572	http://dx.doi.org/10.1074/jbc.272.39.24572			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305923	hybrid			2022-12-27	WOS:A1997XY51500074
J	Lauber, AH; Barrett, TJ; Subramaniam, M; Schuchard, M; Spelsberg, TC				Lauber, AH; Barrett, TJ; Subramaniam, M; Schuchard, M; Spelsberg, TC			A DNA-binding element for a steroid receptor-binding factor is flanked by dual nuclear matrix DNA attachment sites in the c-myc gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							OVIDUCT PROGESTERONE-RECEPTOR; ESTROGEN-INDUCED EXPRESSION; CHROMOSOMAL LOOP ANCHORAGE; CHROMATIN ACCEPTOR SITES; BREAST-CANCER-CELLS; AVIAN OVIDUCT; JUN PROTOONCOGENE; FACTOR-I; TRANSCRIPTION FACTORS; HORMONE ACTION	The receptor-binding factor (RBF) for the avian oviduct progesterone (Pg) receptor (PR) has previously been shown to be a unique 10-kDa nuclear matrix protein that generates high affinity PR-binding sites on avian DNA. This paper describes the use of Southwestern blot and DNA gel shift analyses with RBF protein to identify a minimal 54-base pair RBF-binding element in the matrix-associated region (MAR) of the Pg-regulated c-myc gene promoter, This element contains a 5'-GC-rich domain and a 3'-AT-rich domain, the latter of which has a homopurine/homopyrimidine structure. The gel shift assays required the generation of an RBF-maltose fusion protein (RBF-MBP), which specifically binds this element and is supershifted when the anti-RBF polyclonal antibody is added. Computer analysis of the full-length amino acid sequence for RBF predicts a DNA-binding motif involving a beta-sheet structure at the N-terminal domain. Southern blot analyses using nuclear matrix DNA suggests that there are dual MAR sites in the c-myc promoter, which flank an intervening domain containing the RBF element. The co-transfection of this MAR sequence, containing the RBF element and cloned into a luciferase reporter vector, together with an RBF expression vector construct, into steroid treated human MCF-7 cells, results in a decrease of the c-myc promoter activity relative to control transfections containing only the parent vector of the RBF expression construct. These data suggest that a unique chromatin/nuclear matrix structure, composed of the RBF-DNA element complex which is flanked by nuclear matrix attachment sites, serves to bind the PR and repress the c-myc promoter.	MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, MAYO MED VENTURES, ROCHESTER, MN 55905 USA; SIGMA CHEM CO, ELECTROPHORESIS DEPT, ST LOUIS, MO 63118 USA	Mayo Clinic; Mayo Clinic					NCI NIH HHS [CA90441] Funding Source: Medline; NICHD NIH HHS [HD09140, HD07108] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140, T32HD007108] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA090441, R56CA090441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; AGUTTER PS, 1979, EXP CELL RES, V124, P453, DOI 10.1016/0014-4827(79)90224-6; ALEXANDER RB, 1987, ENDOCRINOLOGY, V120, P1851, DOI 10.1210/endo-120-5-1851; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BAGCHI MK, 1992, ENDOCR REV, V13, P525, DOI 10.1210/er.13.3.525; BARRACK ER, 1987, J STEROID BIOCHEM, V27, P115, DOI 10.1016/0022-4731(87)90302-5; BARRACK ER, 1980, J BIOL CHEM, V255, P7265; BARRACK ER, 1983, BIOCHEM ACTION HORM, V10, P23; BARRACK ER, 1982, RECENT PROG HORM RES, V38, P133; BARRACK ER, 1987, STEROID HORMONE RECE, P86; Barrack ER, 1987, RECENT ADV STEROID H, P85; Barrett TJ, 1996, BIOCHEMISTRY-US, V35, P9746, DOI 10.1021/bi960058j; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BEREZNEY R, 1984, CHROMOSOMAL NONHISTO, V4, P120; BEREZNEY R, 1995, INT REV CYTOLOGY CEL; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Bode J, 1995, INT REV CYTOL, V162A, P389; BOULIKAS T, 1993, J CELL BIOCHEM, V53, P1, DOI 10.1002/jcb.240530102; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; CHUKNYISKA RS, 1984, ENDOCRINOLOGY, V115, P836, DOI 10.1210/endo-115-2-836; CIEJEK EM, 1983, NATURE, V306, P607, DOI 10.1038/306607a0; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLVARD DS, 1984, BIOCHEMISTRY-US, V23, P3479, DOI 10.1021/bi00310a015; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Coutts AS, 1996, J CELL BIOCHEM, V63, P174, DOI 10.1002/(SICI)1097-4644(19961101)63:2<174::AID-JCB5>3.0.CO;2-V; DEBOER W, 1984, J STEROID BIOCHEM, V20, P387, DOI 10.1016/0022-4731(84)90239-5; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DUBIK D, 1987, CANCER RES, V47, P6517; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; ELLIOTT TS, 1993, BIOCHEM BIOPH RES CO, V190, P167, DOI 10.1006/bbrc.1993.1026; EPPERLY M, 1984, J STEROID BIOCHEM, V20, P691, DOI 10.1016/0022-4731(84)90072-4; FINK KL, 1988, P NATL ACAD SCI USA, V85, P1796, DOI 10.1073/pnas.85.6.1796; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GOLDBERGER A, 1988, BIOCHEMISTRY-US, V27, P2103, DOI 10.1021/bi00406a043; GOLDBERGER A, 1986, ENDOCRINOLOGY, V118, P2235, DOI 10.1210/endo-118-6-2235; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HAGER GL, 1991, NUCLEAR HORMONE RECE, P217; HIGUTI T, 1992, BIOCHEMISTRY-US, V31, P12451, DOI 10.1021/bi00164a022; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; HORA J, 1986, P NATL ACAD SCI USA, V83, P8839, DOI 10.1073/pnas.83.23.8839; JOST JP, 1984, P NATL ACAD SCI-BIOL, V81, P429, DOI 10.1073/pnas.81.2.429; KLYZSEJKOSTEFANOWICZ L, 1976, P NATL ACAD SCI USA, V73, P1954, DOI 10.1073/pnas.73.6.1954; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LANDERS JP, 1991, ANN NY ACAD SCI, V637, P26, DOI 10.1111/j.1749-6632.1991.tb27299.x; LANDERS JP, 1994, J CELL BIOCHEM, V55, P241, DOI 10.1002/jcb.240550211; LAU CK, 1990, ENDOCRINOLOGY, V127, P2595, DOI 10.1210/endo-127-5-2595; LAU CK, 1991, P NATL ACAD SCI USA, V88, P829, DOI 10.1073/pnas.88.3.829; Lauber Andrea H., 1995, V162B, P337; METZGER DA, 1990, ENDOCRINOLOGY, V126, P2190, DOI 10.1210/endo-126-4-2190; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; OGLE TF, 1987, ENDOCRINOLOGY, V121, P28, DOI 10.1210/endo-121-1-28; PAVLIK EJ, 1986, ENDOCRINOLOGY, V118, P1924, DOI 10.1210/endo-118-5-1924; PHILLIPS SEV, 1993, NUCLEIC ACIDS MOL BI, V7, P28; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; PIENTA K J, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P355; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; REJMAN J, 1991, J PROTEIN CHEM, V10, P651, DOI 10.1007/BF01025717; RORIES C, 1989, MOL ENDOCRINOL, V3, P991, DOI 10.1210/mend-3-6-991; RORIES C, 1989, ANNU REV PHYSIOL, V51, P653, DOI 10.1146/annurev.physiol.51.1.653; RUH TS, 1983, BIOCHEM J, V210, P905, DOI 10.1042/bj2100905; RUH TS, 1981, BIOCHEM J, V200, P133, DOI 10.1042/bj2000133; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SARKAR G, 1988, NUCLEIC ACIDS RES, V16, P5197, DOI 10.1093/nar/16.11.5197; SCHUCHARD M, 1991, BIOCHEMISTRY-US, V30, P9516, DOI 10.1021/bi00103a019; SCHUCHARD M, 1991, BIOCHEMISTRY-US, V30, P4535, DOI 10.1021/bi00232a024; SCHUCHARD M, 1993, ENDOCR REV, V14, P659, DOI 10.1210/er.14.6.659; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SPELSBERG TC, 1976, J STEROID BIOCHEM, V7, P1091, DOI 10.1016/0022-4731(76)90039-X; Spelsberg TC, 1996, RECENT PROG HORM RES, V51, P63; SPELSBERG TC, 1988, J STEROID BIOCHEM, V31, P579, DOI 10.1016/0022-4731(88)90009-X; SPELSBERG TC, 1983, RECENT PROG HORM RES, V39, P463; SPELSBERG TC, 1971, J BIOL CHEM, V246, P4188; SPELSBERG TC, 1972, J BIOL CHEM, V247, P1368; SPELSBERG TC, 1984, BIOCHEMISTRY-US, V23, P5103, DOI 10.1021/bi00317a004; SPELSBERG TC, 1987, J STEROID BIOCHEM, V27, P133, DOI 10.1016/0022-4731(87)90304-9; SPELSBERG TC, 1987, RECENT ADV STEROID H, P31; STEIN GS, 1994, J CELL BIOCHEM, V55, P4, DOI 10.1002/jcb.240550103; SUBRAMANIAM M, 1993, ENDOCRINOLOGY, V133, P2049, DOI 10.1210/en.133.5.2049; TOYODA H, 1985, P NATL ACAD SCI USA, V82, P4722, DOI 10.1073/pnas.82.14.4722; TRAVERS MT, 1987, FEBS LETT, V211, P27, DOI 10.1016/0014-5793(87)81267-X; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI SY, 1991, NUCLEAR HORMONE RECE, P103; VANSTEENSEL B, 1991, FEBS LETT, V292, P229, DOI 10.1016/0014-5793(91)80873-2; VIG E, 1994, MOL ENDOCRINOL, V8, P1336, DOI 10.1210/me.8.10.1336; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WALKER JE, 1991, BIOCHEMISTRY-US, V30, P5369, DOI 10.1021/bi00236a007; WEBB DK, 1990, BIOCHEM BIOPH RES CO, V168, P721, DOI 10.1016/0006-291X(90)92381-9; ZHUANG YH, 1993, J CELL BIOCHEM, V53, P383, DOI 10.1002/jcb.240530416	102	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24657	24665		10.1074/jbc.272.39.24657	http://dx.doi.org/10.1074/jbc.272.39.24657			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305935	hybrid			2022-12-27	WOS:A1997XY51500086
J	Nagendra, SN; Faiman, MD; Davis, K; Wu, JY; Newby, X; Schloss, JV				Nagendra, SN; Faiman, MD; Davis, K; Wu, JY; Newby, X; Schloss, JV			Carbamoylation of brain glutamate receptors by a disulfiram metabolite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATORY AMINO-ACIDS; TOXICITY; SUBUNITS	S-Methyl-N,N-diethylthiolcarbamate sulfoxide (DETC-MeSO), a metabolite of the drug disulfiram, is a selective carbamoylating agent for sulfhydryl groups, Treatment of glutamate receptors isolated from mouse brain with DETC-MeSO blocks glutamate binding, In vivo, carbamoylated glutathione, administered directly to mice or formed by reaction of DETC-MeSO with glutathione in the blood, also blocks brain glutamate receptors, Carbamoyl groups appear to be delivered to brain glutamate receptors or to liver aldehyde dehydrogenase in vivo by a novel glutathione-mediated mechanism. Seizures caused by the glutamate analogs N-methyl-D-aspartate and methionine sulfoximine, or by hyperbaric oxygen, are prevented by DETC-MeSO, indicating that carbamoylation of glutamate receptors gives an antagonist effect, These observations offer an explanation for some of the previously reported neurological effects of disulfiram, such as its ability to prevent O-2-induced seizures, Furthermore, some of the physiology of the disulfiram-ethanol reaction, that could not be accounted for based on the known inhibition of aldehyde dehydrogenase alone, may be explained by disulfiram's effect on glutamate receptors.	UNIV KANSAS,DEPT MED CHEM,LAWRENCE,KS 66045; UNIV KANSAS,DEPT PHARMACOL & TOXICOL,LAWRENCE,KS 66045; UNIV KANSAS,DEPT PHYSIOL & CELL BIOL,LAWRENCE,KS 66045	University of Kansas; University of Kansas; University of Kansas			WU, JANG-YEN/I-6424-2013	Schloss, John/0000-0002-6586-7508				BONHAUS DW, 1989, MOL PHARMACOL, V36, P273; BRANCHEY L, 1987, AM J PSYCHIAT, V144, P1310; BURNASHEV N, 1993, CELL PHYSIOL BIOCHEM, V3, P318, DOI 10.1159/000154696; CINCOTTA M, 1989, ANAL BIOCHEM, V177, P150, DOI 10.1016/0003-2697(89)90030-4; ENEANYA DI, 1981, ANNU REV PHARMACOL, V21, P575, DOI 10.1146/annurev.pa.21.040181.003043; FAIMAN MD, 1974, AEROSPACE MED, V45, P29; FAIMAN MD, 1971, BIOCHEM PHARMACOL, V20, P3059, DOI 10.1016/0006-2952(71)90110-9; FAIMAN MD, 1979, BIOCH PHARMACOLOGY E, V2, P325; FISHER CM, 1989, ARCH NEUROL-CHICAGO, V46, P798, DOI 10.1001/archneur.1989.00520430094024; Follesa P, 1996, J BIOL CHEM, V271, P13297, DOI 10.1074/jbc.271.23.13297; GOZLAN H, 1995, TRENDS PHARMACOL SCI, V16, P368, DOI 10.1016/S0165-6147(00)89077-X; HALD J, 1948, LANCET, V252, P1001, DOI 10.1016/S0140-6736(48)91514-1; HALEY TJ, 1979, DRUG METAB REV, V9, P319, DOI 10.3109/03602537908993897; HART BW, 1992, BIOCHEM PHARMACOL, V43, P403, DOI 10.1016/0006-2952(92)90555-W; HOTSON JR, 1976, ARCH NEUROL-CHICAGO, V33, P141, DOI 10.1001/archneur.1976.00500020069012; JIN LX, 1994, CHEM RES TOXICOL, V7, P526, DOI 10.1021/tx00040a008; LAMAR C, 1968, BIOCHEM PHARMACOL, V17, P636, DOI 10.1016/0006-2952(68)90280-3; LEE YH, 1995, J NEUROSCI RES, V40, P797, DOI 10.1002/jnr.490400611; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lipton SA, 1996, NEUROCHEM INT, V29, P111, DOI 10.1016/0197-0186(95)00150-6; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MADAN A, 1995, DRUG METAB DISPOS, V23, P1153; MOKRI B, 1981, NEUROLOGY, V31, P730, DOI 10.1212/WNL.31.6.730; NEVO I, 1995, NEUROCHEM INT, V26, P305, DOI 10.1016/0197-0186(94)00139-L; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; POTTER DW, 1993, TOXICOL APPL PHARM, V120, P186, DOI 10.1006/taap.1993.1102; RAO SLN, 1972, BIOCHEMISTRY-US, V11, P1123, DOI 10.1021/bi00757a001; SCATTON B, 1994, LIFE SCI, V55, P2115, DOI 10.1016/0024-3205(94)00392-0; SCHOEPP DD, 1994, NEUROCHEM INT, V24, P439, DOI 10.1016/0197-0186(94)90092-2; THOMAS RJ, 1995, J AM GERIATR SOC, V43, P1279, DOI 10.1111/j.1532-5415.1995.tb07407.x	30	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24247	24251		10.1074/jbc.272.39.24247	http://dx.doi.org/10.1074/jbc.272.39.24247			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305877	hybrid			2022-12-27	WOS:A1997XY51500028
J	Cote, HCF; Pratt, KP; Davie, EW; Chung, DW				Cote, HCF; Pratt, KP; Davie, EW; Chung, DW			The polymerization pocket ''a'' within the carboxyl-terminal region of the gamma chain of human fibrinogen is adjacent to but independent from the calcium-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLY-HIS-ARG; SYNTHETIC PEPTIDES; ALPHA-CHAIN; FRAGMENTS-D; PRO-ARG; LOCALIZATION; COMPLEMENTARY; COAGULATION; AGGREGATION; DEGRADATION	The carboxy terminal region of the gamma chain of fibrinogen is involved in calcium binding, fibrin polymerization, factor XIIIa-mediated cross-linking, and binding to the platelet fibrin(ogen) receptor, Protein fragments encoding amino acids Val(143) to Val(411) (rFbg gamma C30) or Val(143) to Leu(427) (gamma'C30) from the carboxyl end of the gamma or gamma' chains, respectively, of human fibrinogen were expressed in yeast (Pichia pastoris) and characterized as to their cross-linking by factor XIIIa, polymerization pocket, and calcium-binding site, rFbg gamma C30 and gamma'C30 were both readily cross-linked by factor XIIIa, but only rFbg gamma C30 was capable of inhibiting thrombin-induced platelet aggregation. Two mutants, gamma C30-Q329R and gamma C30-D364A, which were based on the three-dimensional structure of the polymerization pocket within rFbg gamma C30 and on information derived from naturally occurring mutant fibrinogens, were also expressed and characterized, rFbg gamma C30 inhibited (desAA)fibrin polymerization in a dose-dependent manner, while the two mutant forms did not, Similarly, rFbg gamma C30 and gamma'C30 were protected from plasmin degradation by the presence of Ca2+ or the peptide Gly-Pro-Arg-Pro, indicating that a functional Ca2+-binding site and polymerization pocket are contained within each of these fragments. The mutant fragments, however, were protected from plasmin only by metal ions, while net protective effect was conferred by GPRP or by any other peptide tested. These results indicate that the polymerization pocket ''a'', which binds the peptide GPRP, functions independently from the nearby calcium-binding site and that amino acids Gln(329) and Asp(364) play a crucial role in fibrin polymerization.			Cote, HCF (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195, USA.		Sessum, Rachel/F-7312-2015; Cote, Helene/K-7896-2012; Pratt, Kathleen P/E-9489-2019	Sessum, Rachel/0000-0002-2444-7056; Pratt, Kathleen/0000-0001-6837-6133; Chung, Dominic/0000-0002-2645-5703	NHLBI NIH HHS [HL-16919] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; Bentolila S, 1995, ANN MED INTERNE, V146, P575; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BOYER MH, 1972, BLOOD-J HEMATOL, V39, P382, DOI 10.1182/blood.V39.3.382.382; CHEN R, 1971, BIOCHEMISTRY-US, V10, P4486, DOI 10.1021/bi00800a021; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; CIERNIEWSKI CS, 1993, EUR J BIOCHEM, V218, P321, DOI 10.1111/j.1432-1033.1993.tb18380.x; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; Doolittle RF, 1996, FASEB J, V10, P1464, DOI 10.1096/fasebj.10.13.8940292; DOOLITTLE RF, 1980, PROTIDES BIOL FLUIDS, V28, P311; Ebert RF., 1994, INDEX VARIANT HUMAN; ENDRES GF, 1972, ARCH BIOCHEM BIOPHYS, V153, P266, DOI 10.1016/0003-9861(72)90445-6; EVERSE SJ, 1995, PROTEIN SCI, V4, P1013; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FORNACE AJ, 1984, J BIOL CHEM, V259, P2826; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FURLAN M, 1983, BIOCHIM BIOPHYS ACTA, V742, P25, DOI 10.1016/0167-4838(83)90354-0; Furlan M, 1996, THROMB HAEMOSTASIS, V76, P377; FURLAN M, 1992, THROMB HAEMOSTASIS, V47, P118; HASEGAWA N, 1990, THROMB RES, V57, P183, DOI 10.1016/0049-3848(90)90318-7; HAVERKATE F, 1977, THROMB RES, V10, P803, DOI 10.1016/0049-3848(77)90137-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARRIEU MJ, 1972, BRIT J HAEMATOL, V22, P719, DOI 10.1111/j.1365-2141.1972.tb05717.x; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LAUDANO AP, 1981, SCIENCE, V212, P457, DOI 10.1126/science.7209542; LAUDANO AP, 1983, ANN NY ACAD SCI, V408, P315, DOI 10.1111/j.1749-6632.1983.tb23254.x; LORAND L, 1993, METHOD ENZYMOL, V222, P22; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; MARGUERIE G, 1982, BIOCHIM BIOPHYS ACTA, V701, P410, DOI 10.1016/0167-4838(82)90246-1; MARGUERIE G, 1977, BIOCHIM BIOPHYS ACTA, V490, P94, DOI 10.1016/0005-2795(77)90109-X; Medved L, 1997, BIOCHEMISTRY-US, V36, P4685, DOI 10.1021/bi962795l; MEDVED LV, 1993, FEBS LETT, V320, P239, DOI 10.1016/0014-5793(93)80594-K; MIYATA T, 1989, J BIOCHEM, V105, P10, DOI 10.1093/oxfordjournals.jbchem.a122601; MOSESSON MW, 1972, J BIOL CHEM, V247, P5223; NIEUWENHUIZEN W, 1983, ANN NY ACAD SCI, V408, P92, DOI 10.1111/j.1749-6632.1983.tb23236.x; Okumura N, 1996, THROMB HAEMOSTASIS, V75, P887; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; PRATT KP, 1997, P NATL ACAD SCI USA, V95, P7176; SCORER CA, 1994, BIO-TECHNOL, V12, P181, DOI 10.1038/nbt0294-181; SHAINOFF JR, 1979, SCIENCE, V204, P200, DOI 10.1126/science.155308; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893; YAMAZUMI K, 1992, PROTEIN SCI, V1, P1719, DOI 10.1002/pro.5560011220; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8	49	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23792	23798		10.1074/jbc.272.38.23792	http://dx.doi.org/10.1074/jbc.272.38.23792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295325	hybrid			2022-12-27	WOS:A1997XX38100050
J	Schwarz, M; Lund, EG; Lathe, R; Bjorkhem, I; Russell, DW				Schwarz, M; Lund, EG; Lathe, R; Bjorkhem, I; Russell, DW			Identification and characterization of a mouse oxysterol 7 alpha-hydroxylase cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID BIOSYNTHESIS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; MESSENGER-RNA; REGULATION INVIVO; ENZYME; LIVER; CLONING; GENE; MICE; DISRUPTION	The synthesis of essential 7 alpha-hydroxylated bile acids in the liver is mediated by two pathways that involve distinct 7 alpha-hydroxylases. One pathway is initiated in the endoplasmic reticulum by cholesterol 7 alpha-hydroxylase, a well studied cytochrome P450 enzyme. A second pathway is initiated by a less well defined oxysterol 7 alpha-hydroxylase. Here, we show that a mouse hepatic oxysterol 7 alpha-hydroxylase is encoded by Cyp7b1, a cytochrome P450 cDNA originally isolated from the hippocampus. Expression of a Cyp7b1 cDNA in cultured cells produces an enzyme with the same biochemical and, pharmacological properties as those of the hepatic oxysterol 7 alpha-hydroxylase. Cyp7b1 mRNA and protein are induced in the third week of life commensurate with an increase in hepatic oxysterol 7 alpha-hydroxylase activity. In the adult mouse, dietary cholesterol or colestipol induce cholesterol 7 alpha-hydroxylase mRNA levels but do not affect oxysterol 7 alpha-hydroxylase enzyme activity, mRNA, or protein levels. Cholesterol 7 alpha-hydroxylase mRNA is reduced to undetectable levels in response to bile acids, whereas expression of oxysterol 7 alpha-hydroxylase is modestly decreased, The liver thus maintains the capacity to synthesize 7 alpha-hydroxylated bile acids regardless of dietary composition, underscoring the central role of 7 alpha-hydroxylated bile acids in lipid metabolism.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; HUDDINGE HOSP,KAROLINSKA INST,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Edinburgh; Karolinska Institutet				Russell, David/0000-0002-0277-403X; Lathe, Richard/0000-0001-9698-9834; Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1992, J BIOL CHEM, V267, P1701; BJORKHEM I, 1992, J LIPID RES, V33, P455; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; DUELAND S, 1993, J LIPID RES, V34, P923; DUMASWALA R, 1989, J LIPID RES, V30, P847; HASLEWOOD GA, 1967, J LIPID RES, V8, P535; Hylemon P B, 1994, Prog Liver Dis, V12, P99; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; LI YC, 1990, J BIOL CHEM, V265, P12012; MARTIN KO, 1993, J LIPID RES, V34, P581; Martin KO, 1997, J LIPID RES, V38, P1053; MATSCHINER JT, 1971, BILE ACIDS CHEM PHYS, V1, P11; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; PAYNE DW, 1995, J BIOL CHEM, V270, P1888; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; RUDLING M, 1992, J LIPID RES, V33, P493; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SHEFER S, 1991, J BIOL CHEM, V266, P2693; SKREDE S, 1986, J CLIN INVEST, V78, P729, DOI 10.1172/JCI112633; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; TOLL A, 1994, EUR J BIOCHEM, V224, P309, DOI 10.1111/j.1432-1033.1994.00309.x; TURLEY SD, 1994, J LIPID RES, V35, P328; WACHTEL N, 1968, J BIOL CHEM, V243, P5207	29	138	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23995	24001		10.1074/jbc.272.38.23995	http://dx.doi.org/10.1074/jbc.272.38.23995			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295351	hybrid			2022-12-27	WOS:A1997XX38100076
J	Mezgrhani, H; Mziaut, H; Courageot, J; Oughideni, R; Bastiani, P; Miquelis, R				Mezgrhani, H; Mziaut, H; Courageot, J; Oughideni, R; Bastiani, P; Miquelis, R			Identification of the membrane receptor binding domain of thyroglobulin - Insights into quality control of thyroglobulin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE SYNTHESIS; AMINO-ACID-SEQUENCE; DEHYDROALANINE RESIDUES; HORMONOGENIC SITES; RECOGNITION; IODINATION; THYROCYTES; PROTEINS; BOVINE	The last stages of thyroglobulin maturation occur in the thyroid follicular lumen and include thyroid hormone formation and glycan completion, In this compartment, newly secreted thyroglobulins interact with a thyrocyte membrane receptor that prevents their premature lysosomal transfer and degradation. Both GlcNAc moieties and thyroglobulin peptide determinants are involved in receptor interaction, Here me used monoclonal antibodies (mAbs) directed against human thyroglobulin either to inhibit (mAb78) or to enhance (mAb240) the thyroglobulin binding and to identify the region of the thyroglobulin involved in the receptor recognition. Peptides containing the mAb epitopes were obtained by immunoscreening cyanogen bromide-derived native human thyroglobulin peptides and a cDNA thyroglobulin expression library. Three peptides, localized in the thyroglobulin N-terminal domain, were obtained. Peptides N1 (Ala(1148)-Gln(1295)) and N2 (Ser(789)-Met(1008)) were recognized by mAb240 and mAb78, respectively. None of them bound the receptor. The third peptide, N3 (Ser(789)-Met(1172)), (i) overlapped all or part of the N1 and N2 peptide sequences and was recognized by both mAbs, (ii) carried two complex glycans at Asn(797) and Asn(928), of which a subset presented accessible GlcNAc residues, and (iii) inhibited the thyroglobulin binding to FRTL5 cell membrane preparations. The N3 peptide includes tyrosine residues that have been reported to be involved in hormone formation. These results suggest that structural modifications closely associated with hormone formation within this domain act as sensors for the receptor interaction and thus for the intrafollicular retention or lysosomal homing of the prohormone.	FAC MED NORD,INST FED JEAN ROCHE,LAB BIOCHIM INGN PROT,UMR 6660,F-13916 MARSEILLE 20,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite								BASTIANI P, 1977, ACTA ENDOCRINOL-COP, V85, P357, DOI 10.1530/acta.0.0850357; BASTIANI P, 1995, ENDOCRINOLOGY, V136, P4204, DOI 10.1210/en.136.10.4204; BJORKMAN U, 1990, BIOCH THYROID HORMON, P83; DUNN JT, 1987, J BIOL CHEM, V262, P16948; EDELHOCH H, 1985, THYROGLOBULIN PROTHY, P1; EKHOLM R, 1975, ENDOCRINOLOGY, V97, P1432, DOI 10.1210/endo-97-6-1432; FASSLER CA, 1988, J BIOL CHEM, V263, P17366; GAVARET JM, 1981, J BIOL CHEM, V256, P9167; GAVARET JM, 1980, J BIOL CHEM, V255, P5281; GENTILE F, 1993, EUR J BIOCHEM, V218, P603, DOI 10.1111/j.1432-1033.1993.tb18414.x; HENRY M, 1990, J IMMUNOL, V145, P3692; IMBERTY A, 1995, PROTEIN ENG, V8, P699, DOI 10.1093/protein/8.7.699; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMAS L, 1989, J BIOL CHEM, V264, P13541; MALLET B, 1995, J BIOL CHEM, V270, P29881; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MARRIQ C, 1986, FEBS LETT, V207, P302, DOI 10.1016/0014-5793(86)81509-5; MERKEN L, 1985, EUR J BIOCHEM, V147, P59; MIQUELIS R, 1993, J CELL BIOL, V123, P1695, DOI 10.1083/jcb.123.6.1695; MIQUELIS R, 1987, J BIOL CHEM, V262, P15291; MIQUELIS R, 1980, ACTA ENDOCRINOL-COP, V95, P489, DOI 10.1530/acta.0.0950489; Molina F, 1996, EUR J BIOCHEM, V240, P125, DOI 10.1111/j.1432-1033.1996.0125h.x; Molina F, 1996, FEBS LETT, V391, P229, DOI 10.1016/0014-5793(96)00708-9; Mziaut H, 1996, ENDOCRINOLOGY, V137, P1370, DOI 10.1210/en.137.4.1370; OHMIYA Y, 1990, J BIOL CHEM, V265, P9066; PARMA J, 1987, J MOL BIOL, V196, P769, DOI 10.1016/0022-2836(87)90403-7; RAWITCH AB, 1983, J BIOL CHEM, V258, P2079; ROE MT, 1989, ENDOCRINOLOGY, V124, P1327, DOI 10.1210/endo-124-3-1327; SHIFRIN S, 1981, J BIOL CHEM, V256, P600; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; WITHEHEART SW, 1989, METHOD ENZYMOL, V179, P82; XIO S, 1995, ARCH BIOCHEM BIOPHYS, V320, P96; Yamashita M, 1996, J BIOL CHEM, V271, P1282, DOI 10.1074/jbc.271.3.1282	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23340	23346		10.1074/jbc.272.37.23340	http://dx.doi.org/10.1074/jbc.272.37.23340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287346	hybrid			2022-12-27	WOS:A1997XV74400057
J	Tapping, RI; Tobias, PS				Tapping, RI; Tobias, PS			Cellular binding of soluble CD14 requires lipopolysaccharide (LPS) and LPS-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; MURINE SPLENOCYTES; ENDOTHELIAL-CELLS; CROSS-LINKING; 70Z/3 CELLS; ENDOTOXIN; RECOGNITION; MACROPHAGES; COMPLEXES; RESPONSES	The stimulation of nonmyeloid cells by lipopolysaccharide (LPS) is mediated by the serum protein, soluble CD14 (sCD14), We have examined the interaction of sCD14 with whole cells using a biologically active radio labeled sCD14 molecule as a ligand, Specific binding of sCD14 to nonmyeloid cells is detected only when it is first incubated with both LPS and the serum LPS-binding protein (LBP), Through the use of an anti-CD14 monoclonal antibody, we demonstrate that sCD14 must interact with LPS in order for cellular binding to occur. Although LBP is traditionally known to function as a catalyst in the transfer of LPS to sCD14, our results reveal that LBP is actually a physical part of sCD14-c ontaining, cell-associating complexes. The LPS- and LBP-dependent cell surface binding of sCD14 appears to be distinct from events leading to cell stimulation, since certain anti-CD14 and anti-LBP monoclonal antibodies have different effects on cellular binding versus cellular activation, Bound sCD14 is internalized, indicating that the LBP- and LPS dependent binding of sCD14 may represent a novel general mechanism by which nonmyeloid cells clear LPS.	Scripps Res Inst, DEPT IMMUNOL, IMM12, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [HL23584] Funding Source: Medline; NIAID NIH HHS [AI32021] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL023584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032021] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; FUNG HF, 1986, METHOD ENZYMOL, V119, P296; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GOLENBOCK DT, 1995, J LAB CLIN MED, V125, P662; GRUBE BJ, 1994, J BIOL CHEM, V269, P8477; Grunwald U, 1996, J IMMUNOL, V157, P4119; GRUNWALD U, 1992, J IMMUNOL METHODS, V155, P225, DOI 10.1016/0022-1759(92)90289-6; Hailman E, 1996, J IMMUNOL, V156, P4384; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAZIOT A, 1995, J IMMUNOL, V154, P6529; HAZIOT A, 1994, J IMMUNOL, V152, P5868; HAZIOT A, 1993, J IMMUNOL, V151, P1500; JACK RS, 1995, EUR J IMMUNOL, V25, P1436, DOI 10.1002/eji.1830250545; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; KIRKLAND TN, 1990, J BIOL CHEM, V265, P9520; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEI MG, 1988, J IMMUNOL, V141, P996; LEI MG, 1988, J IMMUNOL, V141, P1006; LETURCQ D, 1992, J CELL BIOCHEM, V16, P161; LUCHI M, 1993, J IMMUNOL, V151, P959; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SCHLETTER J, 1995, INFECT IMMUN, V63, P2576, DOI 10.1128/IAI.63.7.2576-2580.1995; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SCHUTT C, 1992, RES IMMUNOL, V143, P71, DOI 10.1016/0923-2494(92)80082-V; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P14; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Tobias PS, 1992, J CELL BIOCHEM, V16C, P151; Troelstra A, 1997, J LEUKOCYTE BIOL, V61, P173, DOI 10.1002/jlb.61.2.173; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vita N, 1997, J IMMUNOL, V158, P3457; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yu B, 1996, J BIOL CHEM, V271, P4100	45	88	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23157	23164		10.1074/jbc.272.37.23157	http://dx.doi.org/10.1074/jbc.272.37.23157			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287319	hybrid			2022-12-27	WOS:A1997XV74400030
J	Ann, K; Kowalchyk, JA; Loyet, KM; Martin, TFJ				Ann, K; Kowalchyk, JA; Loyet, KM; Martin, TFJ			Novel Ca2+-binding protein (CAPS) related to UNC-31 required for Ca2+-activated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROENDOCRINE CELLS; VESICLE FUSION; SECRETION; CA2+; SEQUENCES; RELEASE; SITE; STEP	Exocytotic secretion in neuroendocrine cells is activated by cytoplasmic Ca2+ increases. Late post-docking events in dense core vesicle exocytosis in permeable PC12 cells require cytosolic factors for sequential ATP-dependent priming and Ca2+-dependent triggering steps. The cytosolic proteins phosphatidylinositol transfer protein and phosphatidylinositol (4)-phosphate 5-kinase, as well as membrane-bound N-ethylmaleimide-sensitive factor, are required for the ATP dependent priming step. Following priming, the Ca2+-dependent triggering of vesicle fusion requires an additional cytosolic factor, CAPS, which was purified as a 145-kDa protein. To clarify late Ca2+-dependent events in vesicle fusion, the sequence of rat CAPS cDNA was determined and found to encode a novel protein that is the vertebrate homologue of the Caenorhabditis elegans UNC-31 protein shown genetically to be required for neurosecretion. Recombinant CAPS substituted for cytosol in the Ca2+ triggering step in permeable PC12 cells and exhibited moderate affinity (K-d = 270 mu M) Ca2+ binding (2 mol Ca2+/mol CAPS dimer), consistent with a role at a Ca2+-regulated step in exocytosis.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040428, R37DK025861, R01DK025861] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25861, DK40428] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Avery Leon, 1993, Genetics, V134, P455; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; Calakos N, 1996, PHYSIOL REV, V76, P1; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HARTMANN J, 1995, FEBS LETT, V363, P217, DOI 10.1016/0014-5793(95)00318-4; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; LIVINGSTONE D, 1991, STUDIES UNC 31 GENE; LOMNETH R, 1991, J NEUROCHEM, V57, P1413, DOI 10.1111/j.1471-4159.1991.tb08308.x; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9	29	143	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19637	19640		10.1074/jbc.272.32.19637	http://dx.doi.org/10.1074/jbc.272.32.19637			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9289490	hybrid			2022-12-27	WOS:A1997XQ05900002
J	Higashita, R; Li, LY; VanPutten, V; Yamamura, Y; Zarinetchi, F; Heasley, L; Nemenoff, RA				Higashita, R; Li, LY; VanPutten, V; Yamamura, Y; Zarinetchi, F; Heasley, L; Nemenoff, RA			G alpha(16) mimics vasoconstrictor action to induce smooth muscle alpha-actin in vascular smooth muscle cells through a Jun-NH2-terminal kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GTPASE-DEFICIENT G-ALPHA(16); SIGNAL-TRANSDUCTION PATHWAYS; MAP KINASE; ANGIOTENSIN-II; GROWTH-FACTOR; C-JUN; ARGININE VASOPRESSIN; PHORBOL ESTERS; DIFFERENTIATION	Prolonged exposure of vascular smooth muscle cells (VSMC) to vasoconstrictors such as vasopressin or angiotensin II induces hypertrophy and increases expression of muscle-specific genes including smooth muscle alpha-actin (SM-alpha-actin). These vasoconstrictors signal through G-proteins, including members of the Gq family. To further investigate the role of Gq family members, VSMC were transfected with a constitutively active mutant of a G(q) family member, G alpha(16) (G alpha(16)Q212L). Stable expression of G alpha(16)Q212L persistently stimulated phospholipase C, resulting in increased basal levels of inositol phosphates. These cells were hypertrophied and expressed elevated levels of SM-alpha-actin compared with wild-type VSMC or cells transfected with a control plasmid (Neo), SM-alpha-actin promoter activity was markedly increased in cells stably or transiently expressing G alpha(16)Q212L. Basal c-Jun-NH2-terminal kinase (JNK) activity was increased 3-9-fold in cells stably expressing G alpha(16)Q212L, while basal activity of the p42/44 mitogen-activated protein kinases (ERKs) was unaffected, Transient expression of a kinase inactive JNK kinase partially inhibited induction of SM-alpha-actin promoter activity in response to vasoconstrictors or expression of G alpha(16)Q212L. These results indicate that expression of constitutively active G alpha(16) in VSMC mimics the effects of vasoconstrictors on hypertrophy and muscle-specific gene expression, and activation of JNK may play a role in these responses.	UNIV COLORADO,HLTH SCI CTR,DIV RENAL DIS & HYPERTENS,DEPT MED,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Higashita, Ryuji/AAN-6273-2020		NHLBI NIH HHS [HL 09039] Funding Source: Medline; NIDDK NIH HHS [DK 39902, DK 19928] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928, R01DK039902] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARAMELO C, 1988, BIOCHEM J, V254, P625, DOI 10.1042/bj2540625; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; Heasley LE, 1996, J BIOL CHEM, V271, P349, DOI 10.1074/jbc.271.1.349; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KARIYA K, 1987, ATHEROSCLEROSIS, V63, P251, DOI 10.1016/0021-9150(87)90128-6; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KRIBBEN A, 1993, AM J PHYSIOL, V265, pC939, DOI 10.1152/ajpcell.1993.265.4.C939; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LI XM, 1994, J BIOL CHEM, V269, P19653; OWENS GK, 1995, PHYSIOL REV, V75, P487; QIAN NX, 1994, J BIOL CHEM, V269, P17417; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; THIBONNIER M, 1992, REGUL PEPTIDES, V38, P1, DOI 10.1016/0167-0115(92)90067-5; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VANPUTTEN V, 1994, CIRC RES, V75, P1126, DOI 10.1161/01.RES.75.6.1126; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	36	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25845	25850		10.1074/jbc.272.41.25845	http://dx.doi.org/10.1074/jbc.272.41.25845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325315	hybrid			2022-12-27	WOS:A1997YA35800070
J	Keranen, LM; Newton, AC				Keranen, LM; Newton, AC			Ca2+ differentially regulates conventional protein kinase Cs' membrane interaction and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT ACTIVATION; C2 DOMAIN; DIACYLGLYCEROL; BINDING; PHOSPHATIDYLSERINE; PHOSPHOLIPIDS; COOPERATIVITY; SPECIFICITY; SUBSTRATE	The regulation of conventional protein kinase Cs by Ca2+ was examined by determining how this cation affects the enzyme's 1) membrane binding and catalytic function and 2) conformation. In the first part, we show that significantly lower concentrations of Ca2+ are required to effect half-maximal membrane binding than to half-maximally activate the enzyme, The disparity between binding and activation kinetics is most striking for protein kinase C beta II, where the concentration of Ca2+ promoting half-maximal membrane binding is approximately 40-fold higher than the apparent K-m for Ca2+ for activation, In addition, the Ca2+ requirement for activation of protein kinase C beta II is an order of magnitude greater than that for the alternatively spliced protein kinase C beta I; these isozymes differ only in 50 amino acids at the carboxyl terminus, revealing that residues in the carboxyl terminus influence the enzyme's Ca2+ regulation, In the second part, we use proteases as conformational probes to show that Ca2+-dependent membrane binding and Ca2+-dependent activation involve two distinct sets of structural changes in protein kinase C beta II. Three separate domains spanning the entire protein participate in these conformational changes, suggesting significant interdomain interactions, A highly localized hinge motion between the regulatory and catalytic halves of the protein accompanies membrane binding; release of the carboxyl terminus accompanies the low affinity membrane binding mediated by concentrations of Ca2+ too low to promote catalysis; and exposure of the amino-terminal pseudosubstrate and mashing of the carboxyl terminus accompany catalysis. In summary, these data reveal that structural determinants unique to each isozyme of protein kinase C dictate the enzyme's Ca2+-dependent affinity for acidic membranes and show that, surprisingly, some of these determinants are in the carboxyl terminus of the enzyme, distal from the Ca2+-binding site in the amino-terminal regulatory domain.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMADEO LS, 1993, RECEPTOR CHANNEL, V1, P1; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; JEAN T, 1986, J BIOL CHEM, V261, P6414; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LUO JH, 1993, J BIOL CHEM, V268, P23580; MAURER MC, 1992, BIOCHEMISTRY-US, V31, P7714, DOI 10.1021/bi00148a036; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5	32	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25959	25967		10.1074/jbc.272.41.25959	http://dx.doi.org/10.1074/jbc.272.41.25959			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325330	hybrid			2022-12-27	WOS:A1997YA35800085
J	Koshiba, M; Kojima, H; Huang, S; Apasov, S; Sitkovsky, MV				Koshiba, M; Kojima, H; Huang, S; Apasov, S; Sitkovsky, MV			Memory of extracellular adenosine A(2A) purinergic receptor-mediated signaling in murine T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DEAMINASE DEFICIENCY; EFFECTOR FUNCTIONS; LYMPHOCYTES-T; DNA CLEAVAGE; ANTIGEN; CYTOTOXICITY; ACTIVATION; INHIBITOR; PHARMACOLOGY	Accumulation of extracellular and intracellular adenosine (Ado) under hypoxic conditions or in the absence of adenosine deaminase results in lymphocyte depletion and in severe combined immunodeficiency, which are currently explained by direct intracellular lymphotoxicity of Ado metabolites. In support of the alternative, ''signaling'' mechanism, we show that extracellular Ado (extAdo) suppresses all tested T cell receptor (TCR)triggered effector functions of T Lymphocytes including the TCR-triggered Fast mRNA up-regulation in cytotoxic T lymphocytes. Strong evidence against the intracellular lymphotoxicity of Ado (and in support of the signaling model) is provided by abrogation of TCR-triggered growth inhibition in Ado exposed T cells. The brief exposure to Ado was sufficient to observe inhibition of TCR-triggered effector functions. The ''memory'' of T cells to exposure to extAdo is best explained by sustained increases in cAMP. Selective agonist (CGS21680) and antagonist (ZM241385) of A(2A) adenosine receptor were used in functional assays and cDNA probes for different sybtypes of adenosine receptors were used in Northern blot studies. A(2A) receptors are identified as the predominantly expressed subtype of G(s)-coupled Ado receptors in T cells, The demonstration of cross-talk between the A(2A) receptors and TCR in both directions support the possible role of A(2A) receptors in mechanisms of extAdo-mediated immunosuppression in vivo under adenosine deaminase deficiency and hypoxic conditions in, e.g., solid tumors.	NIAID,IMMUNOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/j.1600-065X.1995.tb00680.x; Apasov SG, 1997, J IMMUNOL, V158, P5095; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BLACKBURN MR, 1996, J BIOL CHEM, V271, P15208; CRONSTEIN BN, 1995, ARTHRITIS RHEUM, V38, P1040, DOI 10.1002/art.1780380804; GIBLETT ER, 1972, LANCET, V2, P1067; HENKART PA, 1992, CYTOTOXIC CELLS RECO, P153; Hershfield MS, 1995, METABOLIC MOL BASES, V2, P1725; HIRSCHHORN R, 1995, CLIN IMMUNOL IMMUNOP, V76, pS219, DOI 10.1016/S0090-1229(95)90288-0; HOSKIN DW, 1994, INT J CANCER, V59, P854, DOI 10.1002/ijc.2910590625; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; HUTCHISON AJ, 1990, J MED CHEM, V33, P1919, DOI 10.1021/jm00169a015; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; JACOBSON KA, 1993, FEBS LETT, V323, P141, DOI 10.1016/0014-5793(93)81466-D; JACOBSON KA, 1992, J MED CHEM, V35, P407, DOI 10.1021/jm00081a001; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; Kataoka T, 1996, J IMMUNOL, V156, P3678; KIZAKI H, 1988, J IMMUNOL, V141, P1652; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KOJIMA H, 1994, IMMUNITY, V1, P357, DOI 10.1016/1074-7613(94)90066-3; Koshiba M, 1997, P NATL ACAD SCI USA, V94, P831, DOI 10.1073/pnas.94.3.831; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARQUARDT DL, 1994, J IMMUNOL, V152, P4508; MARTZ E, 1993, CYTOTOXIC CELLS RECO, P9; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; Mizumura T, 1996, CIRC RES, V79, P415, DOI 10.1161/01.RES.79.3.415; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; POUCHER SM, 1995, BRIT J PHARMACOL, V115, P1096, DOI 10.1111/j.1476-5381.1995.tb15923.x; RATNER A, 1993, CYTOTOXIC CELLS RECO, P487; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; STAERZ UD, 1985, NATURE, V314, P628, DOI 10.1038/314628a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGIYAMA H, 1992, J BIOL CHEM, V267, P25256; TAFFS RE, 1991, J IMMUNOL, V147, P722; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TAKAYAMA H, 1991, INT IMMUNOL, V3, P1149, DOI 10.1093/intimm/3.11.1149; TAKAYAMA H, 1987, J EXP MED, V166, P725, DOI 10.1084/jem.166.3.725; TOES RE, 1996, INT J CANCER, V29, P686; vanderPloeg I, 1996, N-S ARCH PHARMACOL, V353, P250, DOI 10.1007/BF00168626	41	154	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25881	25889		10.1074/jbc.272.41.25881	http://dx.doi.org/10.1074/jbc.272.41.25881			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325320	hybrid			2022-12-27	WOS:A1997YA35800075
J	Bienkowska, J; Cruz, M; Atiemo, A; Handin, R; Liddington, R				Bienkowska, J; Cruz, M; Atiemo, A; Handin, R; Liddington, R			The von Willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-2-BETA-1 VLA-2; I-DOMAIN; VONWILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; BINDING-SITE; FACTOR VWF; CD49B/CD29; COLLAGENS; PROTEIN; PROGRAM	von Willebrand factor (vWF) is a multimeric plasma protein that mediates platelet adhesion to exposed subendothelium at sites of vascular injury, The A3 domain of vWF (vWF-A3) forms the principal binding site for collagens type I and III, We report here the crystal structure of the vWF A3 domain at 2.2-Angstrom resolution, As expected, the structure is similar to the integrin I domain but with several novel features, Sequence alignments had suggested that the domain contained an integrin metal ion-dependent adhesion site (MIDAS) motif, but the crystal structure shows that the motif is modified and that no metal ion is bound, We have introduced mutations into the vestigial MIDAS motif and report that, unlike the I domain of integrin (alpha 2 beta 1, vWF-A3 continues to bind collagen after disruption of the motif. We conclude that collagen recognition by vWF-A3 occurs by a mechanism different from that of the integrin alpha 2 beta 1.	UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND; BRIGHAM & WOMENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; BOSTON UNIV, BIOMED ENGN RES CTR, BOSTON, MA 02115 USA	University of Leicester; Harvard University; Brigham & Women's Hospital; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054876] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL54876] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P43; BRUNGER AT, 1992, XPLOR MANUAL VERSION; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; EWENSWTEIN BM, 1994, BLEEDING, P1069; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nicholls A., 1992, GRASP GRAPHICAL REPR; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SLAYTER H, 1985, J BIOL CHEM, V260, P8559; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TUCKWELL D, 1995, J CELL SCI, V108, P1629; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x	27	104	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25162	25167		10.1074/jbc.272.40.25162	http://dx.doi.org/10.1074/jbc.272.40.25162			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312128	hybrid			2022-12-27	WOS:A1997XY97000067
J	Wang, Y; Malenbaum, SE; Kachel, K; Zhan, HJ; Collier, RJ; London, E				Wang, Y; Malenbaum, SE; Kachel, K; Zhan, HJ; Collier, RJ; London, E			Identification of shallow and deep membrane-penetrating forms of diphtheria toxin T domain that are regulated by protein concentration and bilayer width	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL MEMBRANES; TRANSMEMBRANE DOMAIN; REFINED STRUCTURE; PARALLAX ANALYSIS; NORMAL-ALKANES; PH; CHANNELS; TRANSLOCATION; DEPTH; INTOXICATION	The alpha-helix-rich, hydrophobic transmembrane (T) domain of diphtheria toxin is believed to play a central role in membrane insertion by the toxin and in the translocation of its catalytic domain across membranes, In this report, T domain structure was studied using site-directed single-Cys mutants. The residues chosen, 322 (near the amino-terminal end of helix TH8), 333 (within helix TH8), and 356 (within helix TH9) were substituted with Cys and labeled with the fluorescent probe bimane, (Residues 333 and 356 should be located within the bilayer in the transmembrane state, and residue 322 should not penetrate the bilayer,) After insertion of T domain into model membrane vesicles, the location of bimane label relative to the lipid bilayer was characterized by its fluorescence emission and by its quenching with nitroxide-labeled phospholipids. It was found that when the T domain is added to dioleoylphosphatidylcholine-containing vesicles, all three residues reside close to the outer surface, However, at high T domain concentration or in thinner dimyristoleoylphosphatidylcholine-containing vesicles, a large fraction of residues 333 and 356 penetrate deeply into the membrane, In contrast, residue 322 remains exposed to aqueous solution under these conditions, These conclusions were confirmed by a novel antibody binding method, Antibodies that quench the fluorescence of 4,4-difluoro-5,7-dimethyl-4-bora-3 a,4a-diaza-3-indacene (BODIPY) groups were used to evaluate the exposure of BODIPY-labeled 322, 333, and 356, Maximum exposure of residues 333 and 356 to externally added antibody was only observed under conditions in which bimane fluorescence showed that these residues do not penetrate the bilayer, In contrast, residue 322 remained exposed under all conditions, We propose that the deeply penetrating T domain conformation represents a transmembrane or near-transmembrane state, The regulation of the transmembrane/nontransmembrane equilibrium should be a key to understanding diphtheria toxin membrane insertion and translocation. Our results suggest that toxin-toxin interactions may play an important role in regulating this behavior.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Harvard Medical School					NIAID NIH HHS [AI-22021] Funding Source: Medline; NIGMS NIH HHS [GM 31986] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022021, R01AI022021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; ASUNCIONPUNZALAN E, 1995, BIOCHEMISTRY-US, V34, P11460, DOI 10.1021/bi00036a019; BELL CE, 1997, BIOCHEMISTRY-US, V36, P181; BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; CABIAUX V, 1994, MOL MICROBIOL, V11, P43, DOI 10.1111/j.1365-2958.1994.tb00288.x; CAFFREY M, 1981, BIOCHEMISTRY-US, V20, P1949, DOI 10.1021/bi00510a034; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; Collier RJ, 1982, ADP RIBOSYLATION REA, P575; HAYDON DA, 1977, BIOCHIM BIOPHYS ACTA, V470, P17, DOI 10.1016/0005-2736(77)90058-X; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; JIANG JX, 1990, J BIOL CHEM, V265, P8636; JOHANNSSON A, 1981, J BIOL CHEM, V256, P1643; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; LONDON E, 1992, MOL MICROBIOL, V6, P3277, DOI 10.1111/j.1365-2958.1992.tb02195.x; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; MILNE JC, 1994, J BIOL CHEM, V269, P20607; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P45; MINDELL JA, 1994, J MEMBRANE BIOL, V137, P29; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; SILVERMAN JA, 1994, J MEMBRANE BIOL, V137, P17; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TORTORELLA D, 1995, J BIOL CHEM, V270, P27439, DOI 10.1074/jbc.270.46.27439; WALKER B, 1992, J BIOL CHEM, V267, P21782; ZALMAN LS, 1984, P NATL ACAD SCI-BIOL, V81, P3341, DOI 10.1073/pnas.81.11.3341; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	33	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25091	25098		10.1074/jbc.272.40.25091	http://dx.doi.org/10.1074/jbc.272.40.25091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312118	hybrid			2022-12-27	WOS:A1997XY97000057
J	Ying, GG; Arsura, M; Introna, M; Golay, J				Ying, GG; Arsura, M; Introna, M; Golay, J			The DNA binding domain of the A-MYB transcription factor is responsible for its B cell-specific activity and binds to a B cell 110-kDa nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYB; BURKITTS-LYMPHOMA; ONCOGENE FAMILY; GENE; EXPRESSION; PROLIFERATION; COACTIVATOR; ACTIVATOR; DIFFERENTIATION; LYMPHOCYTES	Expression studies as well as the use of transgenic animals have demonstrated that the A-MYB transcription factor plays central and specific role in the regulation of mature B cell proliferation and/or differentiation, Furthermore, it is highly expressed in Burkitt's lymphoma cells and may participate in the pathogenesis of this disease, We have therefore investigated the transcriptional activity of A-MYB and its regulation in several human lymphoid cell lines using co-transfection assays and show that A-MYB is transcriptionally active in all the B cell lines studied, but not in T cells. In particular the best responder cell line was the Burkitt's cell line Namalwa. The activity of A-MYB in B and not T cells was observed when either an artificial construct or the c-MYC promoter was used as a reporter. Furthermore, the functional domains responsible for DNA binding, transactivation, and negative regulation, previously characterized in a fibroblast context, were found to have similar activity in B cells, The region of A-MYB responsible for the B cell specific activity was defined to be the N-terminal 218 amino acids containing the DNA binding domain. Finally, a 110-kDa protein has been identified in the nuclei of all the B, but not T, cell lines that specifically binds to this A-MYB N-terminal domain, We hypothesize that this 110-kDa protein may be a functionally important B cell-specific co-activator of A-MYB.	MARIO NEGRI INST PHARMACOL RES,DEPT IMMUNOL & CELL BIOL,MOL IMMUNOHEMATOL LAB,I-20157 MILAN,ITALY; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Boston University			Golay, Josee/AAA-4085-2022; Introna, Martino/AAA-5823-2019	Golay, Josee/0000-0002-7932-909X; Introna, Martino/0000-0001-6216-0892				ARSURA M, 1992, BLOOD, V79, P2708; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DeRocco SE, 1997, P NATL ACAD SCI USA, V94, P3240, DOI 10.1073/pnas.94.7.3240; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; Golay J, 1996, INT J CLIN LAB RES, V26, P24, DOI 10.1007/BF02644770; Golay J, 1996, BLOOD, V87, P1900; GOLAY J, 1994, ONCOGENE, V9, P2469; GOLAY J, 1994, J IMMUNOL, V153, P543; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1992, ONCOGENE, V7, P1005; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lipsick JS, 1996, ONCOGENE, V13, P223; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARHAMATI DJ, 1997, IN PRESS MOL BIOL CE; MartinezValdez H, 1996, J EXP MED, V183, P971, DOI 10.1084/jem.183.3.971; METTUS RV, 1994, ONCOGENE, V9, P3077; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SEED B, 1988, GENE AMST, V67, P270; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TONG X, 1995, MOL CELL BIOL, V15, P4735; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3	33	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24921	24926		10.1074/jbc.272.40.24921	http://dx.doi.org/10.1074/jbc.272.40.24921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312094	hybrid			2022-12-27	WOS:A1997XY97000033
J	Raju, U; Lu, RS; Noel, F; Gumin, GJ; Tofilon, PJ				Raju, U; Lu, RS; Noel, F; Gumin, GJ; Tofilon, PJ			Failure of a second x-ray dose to activate nuclear factor kappa B in normal rat astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION INDUCES EXPRESSION; IONIZING-RADIATION; TRANSCRIPTIONAL ACTIVATION; INDUCTION; ALPHA; GROWTH; IRRADIATION; INJURY; CELLS; IMMUNOSUPPRESSION	Induced gene expression and subsequent cytokine production have been implicated in the normal tissue injury response to radiotherapy. However, studies of radiation-induced gene expression have used single radiation doses rather than the fractionated exposures typical of the clinical situation. To study the effects of multiple radiation doses oil gene expression, we investigated nuclear factor kappa B (NF kappa B) DNA binding activity in primary astrocyte cultures after one and two exposures to x-rays. After a single dose of x-rays (3.8-15 gray (Gy)), NF kappa B binding activity in astrocytes increased in a dose-dependent manner, reaching a maximum by 2-4 h and returning to control levels by 8 h after irradiation, In split-dose experiments, when an interval of 24 h was used between two doses of 7.5 Gy, the second 7.5 Gy exposure failed to induce NF kappa B activation, The period of desensitization induced by the first radiation exposure was dose-dependent, persisting approximately 72 h after 7.5 Gy compared with 24 h after 1.5 Gy. No changes in I kappa B alpha protein levels were detected, However, the presence of a transcription inhibitor prevented the desensitizing effect of the initial irradiation. Irradiation also prevented NF kappa B activation in astrocytes by a subsequent exposure to H2O2, but it had mo effect on the activation induced by tumor necrosis factor-alpha. These data indicate that an initial x-ray exposure can desensitize astrocytes to the NF kappa B-activating effects of a subsequent radiation exposure, Furthermore, they suggest that this desensitization depends on gene transcription and may have some specificity for NF kappa B activation mediated by reactive oxygen species.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EXPT RADIAT ONCOL 66,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT NEUROSURG,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA-16672, CA-72156] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072156, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BRACH MA, 1993, J BIOL CHEM, V268, P8466; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; FUKS Z, 1992, INT J RADIAT ONCOL, V24, P183, DOI 10.1016/0360-3016(92)91041-K; HALL EJ, 1994, RADIOBIOLOGY RADIOLO, P29; Hallahan D, 1995, BIOCHEM BIOPH RES CO, V217, P784, DOI 10.1006/bbrc.1995.2841; Hensold JO, 1996, J CELL PHYSIOL, V168, P105; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; MCBRIDE WH, 1995, INT J RADIAT ONCOL, V33, P233, DOI 10.1016/0360-3016(95)02019-8; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER HW, 1995, PHARMACOL THERAPEUT, V65, P1, DOI 10.1016/0163-7258(94)00047-7; Noel F, 1997, RADIAT RES, V147, P484, DOI 10.2307/3579506; RUBIN P, 1992, INT J RADIAT ONCOL, V24, P93, DOI 10.1016/0360-3016(92)91027-K; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tolentino PJ, 1996, MOL BRAIN RES, V39, P89, DOI 10.1016/0169-328X(96)00004-6; Weill D, 1996, J INTERF CYTOK RES, V16, P395, DOI 10.1089/jir.1996.16.395; WILSON RE, 1993, ONCOGENE, V8, P3229; WITTE L, 1989, CANCER RES, V49, P5066	30	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24624	24630		10.1074/jbc.272.39.24624	http://dx.doi.org/10.1074/jbc.272.39.24624			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305931	hybrid			2022-12-27	WOS:A1997XY51500082
J	Cappelli, E; Taylor, R; Cevasco, M; Abbondandolo, A; Caldecott, K; Frosina, G				Cappelli, E; Taylor, R; Cevasco, M; Abbondandolo, A; Caldecott, K; Frosina, G			Involvement of XRCC1 and DNA ligase III gene products in DNA base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELL EXTRACTS; POLYMERASE-BETA; IN-VITRO; PROTEIN	DNA ligase III and the essential protein XRCC1 are present at greatly reduced levels in the xrcc1 mutant CHO cell line EM-C11, Cell-free extracts prepared from these cells were used to examine the role of the XRCC1 gene product in DNA base excision repair is vitro. EM-C11 cell extract was partially defective in ligation of base excision repair patches, in comparison to wild type CHO-9 extracts, Of the two branches of the base excision repair pathway, only the single nucleotide insertion pathway was affected; no ligation defect was observed in the proliferating cell nuclear antigen-dependent pathway. Full complementation of the ligation defect in EM-C11 extracts was achieved by addition to the repair reaction of recombinant; human DNA ligase III but not by XRCC1. This is consistent with the notion that XRCC1 acts as an important stabilizing factor of DNA ligase III. These data demonstrate for the first time that xrcc1 mutant cells are partially defective in ligation of base excision repair patches and that the defect is specific to the polymerase beta-dependent single nucleotide insertion pathway.	IST NAZL RIC CANC, DNA REPAIR UNIT, CSTA LAB, I-16132 GENOA, ITALY; UNIV MANCHESTER, SCH BIOL SCI, ZENECCA LAB CELL & MOL BIOL, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV GENOA, CHAIR GENET, GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST; University of Manchester; University of Genoa			Caldecott, Keith/S-4245-2019; Frosina, Guido/Z-2382-2019; cappelli, enrico/K-7954-2016	Frosina, Guido/0000-0002-6717-5097; Caldecott, Keith/0000-0003-4255-9016; cappelli, enrico/0000-0001-5910-9260				Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CAPPELLI E, 1995, CARCINOGENESIS, V16, P2267, DOI 10.1093/carcin/16.9.2267; DEMURCIA G, 1996, WORKSH PROC DNA DAM; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; FRASAD R, 1996, J BIOL CHEM, V271, P16000; FRIGENT C, 1994, MOL CELL BIOL, V14, P310; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; SAPORITO SM, 1989, J BACTERIOL, V171, P2542, DOI 10.1128/jb.171.5.2542-2546.1989; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; THOMPSON LH, 1982, MUTAT RES, V95, P247; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; ZDZIENICKA MZ, 1992, MUTAGENESIS, V7, P265, DOI 10.1093/mutage/7.4.265	18	265	275	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23970	23975		10.1074/jbc.272.38.23970	http://dx.doi.org/10.1074/jbc.272.38.23970			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295348	hybrid			2022-12-27	WOS:A1997XX38100073
J	Taylor, GS; Liu, Y; Baskerville, C; Charbonneau, H				Taylor, GS; Liu, Y; Baskerville, C; Charbonneau, H			The activity of Cdc14p, an oligomeric dual specificity protein phosphatase from Saccharomyces cerevisiae, is required for cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; DNA-REPLICATION; STRUCTURAL BASIS; YEAST; PURIFICATION; KINASE; RECOGNITION; MUTATIONS; SEQUENCE; CLONING	The essential CDC14 gene of the budding yeast, Saccharomyces cerevisiae, encodes a 62-kDa protein containing a sequence that conforms to the active site motif found in all enzymes of the protein tyrosine phosphatase superfamily. Genetic studies suggest that Cdc14p may be involved in the initiation of DNA replication, but its precise cell cycle function is unknown. Recombinant Cdc14p was produced in bacteria, characterized, and shown to be a dual specificity protein phosphatase. Polyanions such as polyglutamate and double-stranded and single-stranded DNA bind to Cdc14p and affect its activity, Native molecular weights of 131,000 and 169,000 determined by two independent methods indicate that recombinant Cdc14p self-associates in vitro to form active oligomers, The catalytically inactive Cdc14p C283S/ R289A mutant is not able to suppress the temperature sensitivity of a cdc14-1(ts) mutant nor replace the wild type gene in vivo, demonstrating that phosphatase activity is required for the cell cycle function of Cdc14p, A distinctive COOH-terminal segment (residues 375-551) is rich in Asn and Ser residues, carries a net positive charge, and contains two tandem 21-residue repeats. This COOH-terminal segment is not required for activity, for oligomerization, or for the critical cell cycle function of Cdc14p.	PURDUE UNIV, DEPT BIOCHEM 1153, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA59935, CA23168] Funding Source: Medline; NIDDK NIH HHS [DK20542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059935, P30CA023168, R01CA059935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beavo J A, 1974, Methods Enzymol, V38, P299; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CIGAN AM, 1987, GENE, V59, P1; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Eki T, 1996, YEAST, V12, P177; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Freifelder D, 1973, Methods Enzymol, V27, P140; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Harlow E., 1988, ANTIBODIES LAB MANUA; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kaiser C., 1994, METHODS YEAST GENETI; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Kroll ES, 1996, GENETICS, V143, P95; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHILD D, 1980, GENETICS, V96, P859; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shirayama M, 1996, MOL GEN GENET, V251, P176; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1994, MOL GENETICS YEAST P, P97; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WAN J, 1992, J BIOL CHEM, V267, P11274; Wiland AM, 1996, J BIOL CHEM, V271, P33486, DOI 10.1074/jbc.271.52.33486; WOOD JS, 1982, J CELL BIOL, V94, P718, DOI 10.1083/jcb.94.3.718; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	48	95	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24054	24063		10.1074/jbc.272.38.24054	http://dx.doi.org/10.1074/jbc.272.38.24054			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295359	hybrid			2022-12-27	WOS:A1997XX38100084
J	Tsuji, M; Ezumi, Y; Arai, M; Takayama, H				Tsuji, M; Ezumi, Y; Arai, M; Takayama, H			A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; TYROSINE PHOSPHORYLATION; HUMAN-MONOCYTES; EPSILON-RI; U937 CELLS; AGGREGATION; MEMBRANE; ACTIVATION; PATIENT; SUBUNIT	The mechanism by which occupancy of collagen receptors is coupled to platelet activation has been uncertain, Our group previously demonstrated that glycoprotein (GP) VI, an uncharacterized platelet membrane protein, is specifically required for collagen-platelet interaction leading to activation of protein-tyrosine kinase Syk. Since collagen stimulation of platelets has recently been found to induce tyrosine phosphorylation of Fc receptor (FcR) gamma-chain, a signal-generating subunit of FcR, we further investigated She relationships between FcR gamma-chain and GPVI in human platelets. Our present study revealed the following. FcR gamma-chain was physically and stably associated with GPVI in human platelets; both FcR gamma-chain and GPVI were proportionally absent in GPVI-deficient platelets; GPVI cross-linking or collagen stimulation of platelets resulted in tyrosine phosphorylation of GPVI-associated FcR gamma-chain accompanied by Syk association and activation. These findings strongly suggest that the associated complex of GPVI and FcR gamma-chain is a collagen receptor featuring the signaling through immune receptors.	KYOTO UNIV,DEPT HEMATOL & ONCOL,GRAD SCH MED,SAKYO KU,KYOTO 60601,JAPAN; TOKYO MED COLL,DEPT CLIN PATHOL,TOKYO 160,JAPAN	Kyoto University; Tokyo Medical University								ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; CHIANG TM, 1982, J BIOL CHEM, V257, P7581; DECKMYN H, 1992, BLOOD, V79, P1466, DOI 10.1182/blood.V79.6.1466.bloodjournal7961466; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HYNES RO, 1992, CELL, V69, P1; Ichinohe T, 1997, J BIOL CHEM, V272, P63; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; LOONEY RJ, 1986, J IMMUNOL, V136, P1641; MASUDA M, 1993, J IMMUNOL, V151, P7188; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SANTOSO S, 1989, HUM IMMUNOL, V25, P237, DOI 10.1016/0198-8859(89)90086-4; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKAYAMA H, 1983, PROSTA LEUKOTR MED, V12, P261, DOI 10.1016/0262-1746(83)90004-5; TANDON NN, 1989, J BIOL CHEM, V264, P7576; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; Zipser Y, 1996, BIOCHEM J, V314, P881, DOI 10.1042/bj3140881	31	229	237	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23528	23531		10.1074/jbc.272.38.23528	http://dx.doi.org/10.1074/jbc.272.38.23528			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295288	hybrid			2022-12-27	WOS:A1997XX38100013
J	Diaz, JF; Sillen, A; Engelborghs, Y				Diaz, JF; Sillen, A; Engelborghs, Y			Equilibrium and kinetic study of the conformational transition toward the active state of p21(Ha-ras), induced by the binding of BeF3- to the GDP-bound state in the absence of GTPase-activating proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-RAS P21; REGULATORY COMPONENT; ADENYLATE-CYCLASE; FLUORIDE COMPLEXES; PHASE FLUOROMETRY; FLUORESCENCE; RESOLUTION; GUANOSINE; ALUMINUM; MICROTUBULES	Hitherto ras-related GTP-binding proteins have been considered not to hind phosphate analogs (Kahn, R, A, (1991) J, Biol. Chem. 266, 15595-15597), at least in the absence of activating proteins (Mittal, R., Reza, M., Goody, R., and Wittinghofer, A, (1996) Science 273, 115-117), in this work, we have used a fluorescent active mutant (Y32W) of p21(Ha-ras) to demonstrate that BeF3- binds to the GDP . p21(Ha-ras) complex in the absence of activating proteins, It induces a conformational change leading to a state with fluorescence properties similar tee those of the active state, The binding has a low affinity (K-d at 25 degrees C = 8.1 +/- 0.3 mM) and is endothermic (Delta H = 22.3 +/- 1.6 kJ mol(-1)). The similarity between the GTP-bound form and the GDP . BeF3--bound form has been confirmed using lifetime analysis of the tryptophan fluorescence, The kinetic analysis of the process indicates that the binding can be divided into a first bimolecular step, which accounts for the association of the anion with its binding site, and a second step, which corresponds to an internal conformational transition of the GDP . BeF3-. p21(Ha-ras) complex to its final state. Both steps are endothermic (Delta H-1 = 15 +/- 2 kJ mol(-1) and Delta H-2 = 8 +/- 2 kJ mol(-1)). The kinetically determined enthalpy change of 23 +/- 4 kJ mol(-1) is in excellent agreement with the equilibrium analysis.	KATHOLIEKE UNIV LEUVEN,LAB CHEM & BIOL DYNAM,B-3001 LOUVAIN,BELGIUM	KU Leuven			Díaz, J. Fernando/U-3532-2017; Díaz, J. Fernando/M-6853-2019	Díaz, J. Fernando/0000-0003-2743-3319; Díaz, J. Fernando/0000-0003-2743-3319				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALCALA JR, 1987, BIOPHYS J, V51, P587, DOI 10.1016/S0006-3495(87)83383-0; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; Diaz JF, 1997, PROTEINS, V28, P434; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1986, J BIOL CHEM, V261, P963; HOWLETT AC, 1979, J BIOL CHEM, V254, P2287; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; LIWO A, 1994, J PROTEIN CHEM, V13, P237, DOI 10.1007/BF01891982; MESMER RE, 1969, INORG CHEM, V8, P618, DOI 10.1021/ic50073a042; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PETERMAN BF, 1979, ANAL BIOCHEM, V93, P442, DOI 10.1016/S0003-2697(79)80176-1; RALL TW, 1958, J BIOL CHEM, V232, P1065; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; Sillen A, 1996, PHOTOCHEM PHOTOBIOL, V64, P785, DOI 10.1111/j.1751-1097.1996.tb01835.x; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STREHLOW H, 1977, FUNDAMENTALS CHEM RE, P101; STREHLOW H, 1977, FUNDAMENTALS CHEM RE, P47; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VINCENT M, 1988, BIOCHEMISTRY-US, V27, P8752, DOI 10.1021/bi00424a010; VOS R, 1997, J FLUORESC, V7, pS33; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	34	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23138	23143		10.1074/jbc.272.37.23138	http://dx.doi.org/10.1074/jbc.272.37.23138			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287316	hybrid			2022-12-27	WOS:A1997XV74400027
J	Kanda, S; Hodgkin, MN; Woodfield, RJ; Wakelam, MJO; Thomas, G; ClaessonWelsh, L				Kanda, S; Hodgkin, MN; Woodfield, RJ; Wakelam, MJO; Thomas, G; ClaessonWelsh, L			Phosphatidylinositol 3'-kinase-independent p70 S6 kinase activation by fibroblast growth factor receptor-1 is important for proliferation but not differentiation of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; POINT MUTATION; BINDING-SITE; LATE PHASE; RAPAMYCIN; P70(S6K); INHIBITION; TARGET	p70(s6k) has a role in cell cycle progression in response to specific extracellular stimuli. The signal transduction pathway leading to activation of p70(s6k) by fibroblast growth factor receptor-1 (FGFR-1) was examined in FGF-2-treated rat L6 myoblasts. p70(s6k) was activated in a biphasic and rapamycin-sensitive manner. Although phosphatidylinositol 3'-kinase was not activated in the FGF-2 treated cells, as judged from in vitro and in vivo analyses, wortmannin and LY294002 treatment inhibited p70(s6k) activation. Inhibition of protein kinase C (PKC), by bisindolylmaleimide or by chronic phorbol ester treatment of the FGFR-1 cells, suppressed but did not block p70(s6k) activation. In cells expressing a point-mutated FGFR-1, Y766F, unable to mediate PKC activation, p70(s6k) was still activated, in a bisindolylmaleimide- and phorbol ester-resistant manner. The involvement of S6 kinase in FGFR-1-dependent biological responses was examined in murine brain endothelial cells. In response to FGF-2, these cells differentiate to form tubelike structures in collagen gel cultures and proliferate when cultured on fibronectin. p70(s6k) was not activated in endothelial cells on collagen, whereas activation was observed during proliferation on fibronectin. In agreement with this finding, rapamycin inhibited the proliferative but not the differentiation response. Our results indicate that FGFR-1 mediates p70(s6k) activation by a phosphatidylinositol 3'-kinase-independent mechanism that does not require PKC activation and, furthermore, proliferation, but not differentiation of endothelial cells in response to FGF-2, is associated with p70(s6k) activation.	LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; QUEEN ELIZABETH HOSP,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Ludwig Institute for Cancer Research; University of Birmingham; Friedrich Miescher Institute for Biomedical Research				Wakelam, Michael/0000-0003-4059-9276; Claesson-Welsh, Lena/0000-0003-4275-2000				BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HARA K, 1995, BIOCHEM BIOPH RES CO, V208, P735, DOI 10.1006/bbrc.1995.1399; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KAHAN C, 1992, J BIOL CHEM, V267, P13369; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; SUSA M, 1992, J BIOL CHEM, V267, P6905; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; WAKELAM MJO, 1995, RECEPTOR TRANSDUCTIO, P271; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	51	85	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23347	23353		10.1074/jbc.272.37.23347	http://dx.doi.org/10.1074/jbc.272.37.23347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287347	hybrid			2022-12-27	WOS:A1997XV74400058
J	Zhang, L; Kelley, J; Schmeisser, G; Kobayashi, YM; Jones, LR				Zhang, L; Kelley, J; Schmeisser, G; Kobayashi, YM; Jones, LR			Complex formation between junction, triadin, calsequestrin, and the ryanodine receptor - Proteins of the cardiac junctional sarcoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; BINDING 30-KDA PROTEIN; AMINO-ACID SEQUENCE; SKELETAL-MUSCLE; BIOCHEMICAL-CHARACTERIZATION; GLYCOPROTEIN TRIADIN; VESICLES; PURIFICATION; CDNA; PHOSPHOLAMBAN	Several key proteins have been localized to junctional sarcoplasmic reticulum which are important for Ca2+ release. These include the ryanodine receptor, triadin, and calsequestrin, which may associate into a stable complex at the junctional membrane. We recently purified and cloned a fourth component of this complex, junctin, which exhibits homology with triadin and is the major I-125-calsequestrin-binding protein detected in cardiac sarcoplasmic reticulum vesicles (Jones, L. R., Zhang, L., Sanborn, K., Jorgensen, A. O., and Kelley, J. (1995) J. Biol. Chem. 270, 30787-30796). In the present study, we have examined the binding interactions between the cardiac forms of these four proteins with emphasis placed on the role of junctin. By a combination of approaches including calsequestrin-affinity chromatography, filter overlay, immunoprecipitation assays, and fusion protein binding analyses, we find that junctin binds directly to calsequestrin, triadin, and the ryanodine receptor. This binding interaction is localized to the lumenal domain of junctin, which is highly enriched in charged amino acids organized into ''KEKE'' motifs. KEKE repeats are also found in the common lumenal domain of triadin, which likewise is capable of binding to calsequestrin and the ryanodine receptor (Guo, W., and Campbell, K. P. (1995) J. Biol. Chem. 270, 9027-9030). It appears that junctin and triadin interact directly in the junctional sarcoplasmic reticulum membrane and stabilize a complex that anchors calsequestrin to the ryanodine receptor. Taken together, these results suggest that junctin, calsequestrin, triadin, and the ryanodine receptor form a quaternary complex that may be required for normal operation of Ca2+ release.	INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AlSeikhan BA, 1997, BIOPHYS J, V72, pTU185; Cala S E, 1990, Semin Cell Biol, V1, P265; CALA SE, 1983, J BIOL CHEM, V258, P1932; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; Chen W, 1996, J BIOL CHEM, V271, P7398, DOI 10.1074/jbc.271.13.7398; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; DAMIANI E, 1990, BIOCHEM BIOPH RES CO, V172, P1253, DOI 10.1016/0006-291X(90)91584-F; Donoso P, 1996, BIOCHEMISTRY-US, V35, P13419, DOI 10.1021/bi9616209; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; Harlow E, 1988, ANTIBODIES LABORATOR, P521; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; IKEMOTO N, 1971, BIOCHEM BIOPH RES CO, V44, P1510, DOI 10.1016/S0006-291X(71)80257-7; JOHNSON EA, 1967, J CELL BIOL, V33, P103, DOI 10.1083/jcb.33.1.103; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; Kagari T, 1996, BIOCHEM BIOPH RES CO, V227, P700, DOI 10.1006/bbrc.1996.1572; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RARDON DP, 1989, CIRC RES, V64, P779, DOI 10.1161/01.RES.64.4.779; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1995, J BIOL CHEM, V270, P29664; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; YAMAGUCHI N, 1995, BIOCHEM BIOPH RES CO, V210, P648, DOI 10.1006/bbrc.1995.1709; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961	42	439	451	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23389	23397		10.1074/jbc.272.37.23389	http://dx.doi.org/10.1074/jbc.272.37.23389			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287354	hybrid			2022-12-27	WOS:A1997XV74400065
J	Huang, YD; Schwendner, SW; Rall, SC; Sanan, DA; Mahley, RW				Huang, YD; Schwendner, SW; Rall, SC; Sanan, DA; Mahley, RW			Apolipoprotein E2 transgenic rabbits - Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HERITABLE HYPERLIPIDEMIC RABBITS; INCREASED MESSENGER-RNA; FAMILIAL HYPERCHOLESTEROLEMIA; ANIMAL-MODEL; WHHL-RABBIT; LIPOLYTIC CONVERSION; REMNANT CLEARANCE; HEPATIC LIPASE; E DEFICIENCY	Transgenic rabbits were produced that expressed high plasma levels (30-70 mg/dl) of human apolipoprotein (ape) E2(Cys-158), an apoE variant associated with the human genetic disorder type III hyperlipoproteinemia (HLP), Male transgenic rabbits fed normal chow had up to 8-fold (289 +/- 148 mg/dl) and 15-fold (697 +/- 452 mg/dl) increases in plasma total cholesterol and triglycerides, respectively, compared with nontransgenic males, Female transgenic rabbits had only a modest hyperlipidemia (total cholesterol, 140 +/- 46 mg/dl; total triglycerides, 174 +/- 66 mg/dl). Both sexes displayed the hallmarks of type III HLP: beta-migrating very low density lipoproteins (beta-VLDL) (intestinal and hepatic remnant lipoproteins) and significantly increased VLDL and intermediate density lipoproteins. Apolipoprotein E2-containing VLDL particles were cleared from the circulation more slowly and were more resistant to lipoprotein lipase-mediated lipolysis than normal VLDL, Only females had increased high density lipoproteins (HDL) (40%), which were shifted from typical small HDL to larger HDL1. Plasma apoE2 was predominantly associated with beta-VLDL in males and with HDL in females, To ascertain reasons for the phenotypic gender difference, we treated the male transgenic rabbits with 17 alpha-ethinyl estradiol, Estrogen treatment for 10 days dramatically decreased total cholesterol (73%) and triglycerides (89%) and converted beta-VLDL to pre-beta-migrating VLDL. Concomitantly, lipoprotein lipase and hepatic lipase activities increased by 90%, low density lipoprotein receptor activity was stimulated significantly, apoE2 was redistributed to HDL, and HDL were converted to HDL1, Conversely, ovariectomy in female transgenic rabbits significantly increased total cholesterol (75%), triglycerides (117%), and beta-VLDL, while decreasing lipoprotein! lipase and hepatic lipase activities by 35% and redistributing apoE2 to the beta-VLDL, Thus, estrogen status appears to be responsible for much of the gender difference of the lipoprotein phenotype, mainly by modulating both lipase and low density lipoprotein receptor activities, Furthermore, transgenic rabbits fed normal chow for 11 months developed fatty streaks, and some had more advanced atherosclerotic lesions, especially around the aortic arch and proximal abdominal aorta, The lesions were more extensive in males, roughly correlating with the magnitude of the hyperlipidemia Therefore, high plasma levels of human apoE2 in transgenic rabbits result in a type III HLP phenotype, in which males have both more severe hyperlipidemia and more extensive atherosclerosis than females.	UNIV CALIF SAN FRANCISCO, INST CARDIOVASC RES, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Huang, YD (corresponding author), UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, POB 419100, SAN FRANCISCO, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS CWM, 1982, ATHEROSCLEROSIS, V44, P1, DOI 10.1016/0021-9150(82)90047-8; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; CHUNG BH, 1983, J LIPID RES, V24, P1148; CLARK G, 1981, STAINING PROCEDURES, P189; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; CORNHILL JF, 1985, ARTERIOSCLEROSIS, V5, P415, DOI 10.1161/01.ATV.5.5.415; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; DEMACKER PNM, 1977, CLIN CHEM, V23, P1238; DEMACKER PNM, 1991, ARTERIOSCLER THROMB, V11, P1652, DOI 10.1161/01.ATV.11.6.1652; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FAN JL, 1995, ARTERIOSCL THROM VAS, V15, P1889, DOI 10.1161/01.ATV.15.11.1889; FAZIO S, 1992, J BIOL CHEM, V267, P6941; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOMORI G, 1950, AM J CLIN PATHOL, V20, P661, DOI 10.1093/ajcp/20.7_ts.661; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Hoeg JM, 1996, J BIOL CHEM, V271, P4396; HORIE Y, 1992, J BIOL CHEM, V267, P1962; Huang YD, 1996, J BIOL CHEM, V271, P29146, DOI 10.1074/jbc.271.46.29146; HUETTINGER M, 1984, J CLIN INVEST, V74, P1017, DOI 10.1172/JCI111469; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1995, J BIOL CHEM, V270, P8578, DOI 10.1074/jbc.270.15.8578; IVERIUS PH, 1972, J BIOL CHEM, V247, P6610; Johnson FB, 1992, LAB METHODS HISTOTEC, P177; KITA T, 1981, P NATL ACAD SCI-BIOL, V78, P2268, DOI 10.1073/pnas.78.4.2268; KOVANEN PT, 1979, J BIOL CHEM, V254, P1367; MA PTS, 1986, P NATL ACAD SCI USA, V83, P792, DOI 10.1073/pnas.83.3.792; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; MAHLEY RW, 1985, CIRCULATION, V72, P943, DOI 10.1161/01.CIR.72.5.943; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1985, ANN NY ACAD SCI, V454, P209, DOI 10.1111/j.1749-6632.1985.tb11860.x; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; MCLEAN JW, 1984, J BIOL CHEM, V259, P6498; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P797, DOI 10.1161/01.ATV.11.4.797; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; Sacks Frank M., 1994, Current Opinion in Lipidology, V5, P236, DOI 10.1097/00041433-199405030-00012; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SHIOMI M, 1995, ARTERIOSCL THROM VAS, V15, P1938, DOI 10.1161/01.ATV.15.11.1938; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TANZAWA K, 1980, FEBS LETT, V118, P81, DOI 10.1016/0014-5793(80)81223-3; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; VANVLIJMEN BJM, 1996, ARTERIOSCL THROM VAS, V271, P30595; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	56	44	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22685	22694		10.1074/jbc.272.36.22685	http://dx.doi.org/10.1074/jbc.272.36.22685			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9312550	hybrid			2022-12-27	WOS:A1997XV49200047
J	Beckman, KB; Ames, BN				Beckman, KB; Ames, BN			Oxidative decay of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CULTURED HUMAN FIBROBLASTS; NUCLEAR-DNA; ELECTROCHEMICAL DETECTION; MITOCHONDRIAL-DNA; NITRIC-OXIDE; IN-VIVO; DAMAGE; 8-HYDROXYDEOXYGUANOSINE; 8-HYDROXY-2'-DEOXYGUANOSINE; CHROMATOGRAPHY		UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NCI NIH HHS [CA33910] Funding Source: Medline; NIEHS NIH HHS [ES01896] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADACHI S, 1995, CARCINOGENESIS, V16, P253, DOI 10.1093/carcin/16.2.253; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Asami S, 1996, CANCER RES, V56, P2546; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Baik SC, 1996, CANCER RES, V56, P1279; Ballinger SW, 1996, CANCER RES, V56, P5692; BALLMAIER D, 1995, CARCINOGENESIS, V16, P335, DOI 10.1093/carcin/16.2.335; Beckman K B, 1996, Methods Enzymol, V264, P442, DOI 10.1016/S0076-6879(96)64040-3; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chen Q, 1996, CARCINOGENESIS, V17, P2525, DOI 10.1093/carcin/17.11.2525; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; CZENE S, 1995, MUTAT RES-DNA REPAIR, V336, P235, DOI 10.1016/0921-8777(94)00058-E; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dennog C, 1996, MUTAGENESIS, V11, P605, DOI 10.1093/mutage/11.6.605; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DOUKI T, 1994, CHEM RES TOXICOL, V7, P511, DOI 10.1021/tx00040a006; Douki T, 1996, CHEM RES TOXICOL, V9, P3, DOI 10.1021/tx950126n; Douki T, 1996, FREE RADICAL RES, V24, P369, DOI 10.3109/10715769609088035; Douki T, 1996, CARCINOGENESIS, V17, P347, DOI 10.1093/carcin/17.2.347; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; Driggers WJ, 1996, CANCER RES, V56, P1262; Enright H, 1996, CARCINOGENESIS, V17, P1175, DOI 10.1093/carcin/17.5.1175; EPE B, 1994, METHOD ENZYMOL, V234, P122; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Finnegan MTV, 1996, FREE RADICAL BIO MED, V20, P93, DOI 10.1016/0891-5849(95)02003-9; Fraga CG, 1996, MUTAT RES-FUND MOL M, V351, P199, DOI 10.1016/0027-5107(95)00251-0; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; Goldman M, 1996, SCIENCE, V271, P1821, DOI 10.1126/science.271.5257.1821; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; HASEGAWA R, 1995, FOOD CHEM TOXICOL, V33, P961, DOI 10.1016/0278-6915(95)00064-9; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Hiraku Y, 1996, CANCER RES, V56, P5172; HIRANO T, 1995, BIOCHEM BIOPH RES CO, V214, P1157, DOI 10.1006/bbrc.1995.2407; Hirano T, 1996, J GERONTOL A-BIOL, V51, pB303, DOI 10.1093/gerona/51A.5.B303; Ichinose T, 1997, CARCINOGENESIS, V18, P185, DOI 10.1093/carcin/18.1.185; INOUE S, 1995, FEBS LETT, V371, P86, DOI 10.1016/0014-5793(95)00873-8; Jacob Robert A., 1996, American Journal of Clinical Nutrition, V63, p985S; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; KANEKO T, 1996, KUTAT RES, V316, P277; KASPRZAK KS, 1995, CANCER INVEST, V13, P411, DOI 10.3109/07357909509031921; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kim HS, 1996, MUTAT RES-DNA REPAIR, V363, P115, DOI 10.1016/0921-8777(96)00006-7; Lee YS, 1996, MUTAT RES-DNA REPAIR, V364, P227, DOI 10.1016/S0921-8777(96)00038-9; LIU L, 1995, FREE RADICAL BIO MED, V19, P639, DOI 10.1016/0891-5849(95)00082-9; Liu L, 1996, MUTAT RES-GENET TOX, V370, P145, DOI 10.1016/S0165-1218(96)00048-1; Liu PK, 1996, J NEUROSCI, V16, P6795; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/BF00207507; LOFT S, 1992, CARCINOGENESIS, V13, P2241, DOI 10.1093/carcin/13.12.2241; MIRSALIS JC, 1995, ANNU REV PHARMACOL, V35, P145; Nagashima M, 1997, MUTAT RES-DNA REPAIR, V383, P49, DOI 10.1016/S0921-8777(96)00045-6; NAKAE D, 1995, CANCER LETT, V97, P233, DOI 10.1016/0304-3835(95)03980-B; Nakajima M, 1996, ENVIRON HEALTH PERSP, V104, P1336, DOI 10.2307/3432971; Nakajima M, 1996, CARCINOGENESIS, V17, P787, DOI 10.1093/carcin/17.4.787; Randerath E, 1996, CARCINOGENESIS, V17, P2563, DOI 10.1093/carcin/17.12.2563; RAVANAT JL, 1995, CHEM RES TOXICOL, V8, P1039, DOI 10.1021/tx00050a007; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHEN CC, 1995, MUTAT RES-DNA REPAIR, V337, P19, DOI 10.1016/0921-8777(95)00008-8; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; SHEN HM, 1995, CARCINOGENESIS, V16, P419, DOI 10.1093/carcin/16.2.419; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Spencer JPE, 1996, BIOCHEM BIOPH RES CO, V224, P17, DOI 10.1006/bbrc.1996.0977; Takeuchi T, 1996, CARCINOGENESIS, V17, P1543, DOI 10.1093/carcin/17.8.1543; Teixeira HD, 1996, BIOCHEM J, V315, P821, DOI 10.1042/bj3150821; TOYOKUNI S, 1995, INT J CANCER, V62, P309, DOI 10.1002/ijc.2910620313; Tsou TC, 1996, CARCINOGENESIS, V17, P103, DOI 10.1093/carcin/17.1.103; Umemura T, 1996, JPN J CANCER RES, V87, P882, DOI 10.1111/j.1349-7006.1996.tb02115.x; Uppu RM, 1996, FREE RADICAL BIO MED, V21, P407, DOI 10.1016/0891-5849(96)00220-1; WISEMAN H, 1995, CANCER LETT, V93, P113, DOI 10.1016/0304-3835(95)03792-U; Wolff S, 1996, MUTAT RES-FUND MOL M, V358, P135, DOI 10.1016/S0027-5107(96)00114-5; Woodall AA, 1997, PREVENTIVE NUTR COMP, P373; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yamaguchi R, 1996, CARCINOGENESIS, V17, P2419, DOI 10.1093/carcin/17.11.2419; Yang CS, 1996, REDOX REP, V2, P379, DOI 10.1080/13510002.1996.11747078; Yarborough A, 1996, CANCER RES, V56, P683; Zastawny TH, 1997, FREE RADICAL BIO MED, V22, P101, DOI 10.1016/S0891-5849(96)00270-5	87	787	808	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19633	19636		10.1074/jbc.272.32.19633	http://dx.doi.org/10.1074/jbc.272.32.19633			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9289489	hybrid			2022-12-27	WOS:A1997XQ05900001
J	Lin, HC; Barylko, B; Achiriloaie, M; Albanesi, JP				Lin, HC; Barylko, B; Achiriloaie, M; Albanesi, JP			Phosphatidylinositol (4,5)-bisphosphate-dependent activation of dynamins I and II lacking the proline/arginine-rich domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACTIVITY; BINDING-SITE; ACIDIC PHOSPHOLIPIDS; SH3 DOMAINS; MICROTUBULES; BRAIN; PHOSPHOINOSITIDES; ENDOCYTOSIS; PROTEINS	Dynamins comprise a family of GTPases that participate in the early stages of endocytosis. The GTPase activity of neuronal specific dynamin I is stimulated by microtubules, negatively charged phospholipid vesicles, and Src homology 3-containing proteins, including Grb2. These activators were previously shown to bind to a proline/arginine-rich domain (PRD) in the carboxyl-terminal region of the enzyme. Dynamin II, which is ubiquitously expressed, had not been purified or characterized previously. In this study, the enzymatic properties of rat dynamin II and of D746, a dynamin II truncation mutant lacking the PRD, have been characterized. Dynamin II has a higher basal activity than dynamin I, but the two types of dynamin are stimulated similarly by microtubules, Grb2, and phospholipids. D746 is not activated by microtubules or Grb2, highlighting the significance of the PRD for these interactions, but it is activated by phospholipid vesicles containing phosphatidylserine or phosphatidylinositol-4,5-bisphosphate. Moreover, in contrast to previous reports, the PRD appears not to be required for phospholipid-stimulated self-assembly of dynamin, which is a key element in the regulation of its activity. Similar results were obtained with bovine brain dynamin I that had been subjected to limited proteolytic digestion to remove the PRD. Our data highlight the potential involvement of dynamin pleckstrin homology domains in the regulation of GTPase activity by phospholipids.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM38567, 2-T32 GM07062-22, GM 34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R37GM034497, R01GM034497, R01GM038567] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], ALLOSTERIC ENZYMES K; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Earnest S, 1996, FEBS LETT, V396, P62, DOI 10.1016/0014-5793(96)01074-5; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KORN ED, 1982, METHOD ENZYMOL, V85, P357; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	31	71	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25999	26004		10.1074/jbc.272.41.25999	http://dx.doi.org/10.1074/jbc.272.41.25999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325335	hybrid			2022-12-27	WOS:A1997YA35800090
J	Nastri, HG; Evans, PD; Walker, IH; Riggs, PD				Nastri, HG; Evans, PD; Walker, IH; Riggs, PD			Catalytic and DNA binding properties of P upsilon uII restriction endonuclease mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ECORI ENDONUCLEASE; CRYSTAL-STRUCTURE; AMINO-ACID; MUTATIONAL ANALYSIS; PVUII ENDONUCLEASE; PROTEUS-VULGARIS; ESCHERICHIA-COLI; COGNATE DNA; ACTIVE-SITE	The role of particular residues of the PvuII endonuclease in DNA binding and cleavage was studied by mutational analysis using a number of in vivo and in vitro approaches. While confirming the importance of residues predicted to be involved directly in function by the crystal structure, the analysis led to several striking results. Aspartate 34, which contacts the central base pair of the PvuII site (5'-CAGCTG-3') through the minor groove, plays a critical role in binding specificity. A D34G mutant binds with high affinity to any of the sequences in the set CANNTG, although its low level of cleavage activity acts only on the wild-type site. In addition, a His to Ala mutation at the residue that contacts the central G and is predicted to be blocked by PvuII methylation still requires the PvuII methylase to be maintained in vivo, arguing against this hypothesis as the only mechanism for methylation protection. Finally, four of the five mutations that reduce cleavage activity while still exhibiting binding in the gel shift assay are at residues that form DNA- or subunit-subunit contacts rather than in the catalytic center. This provides further evidence for a strong linkage between specific binding and catalysis.	NEW ENGLAND BIOLABS INC, BEVERLY, MA 01915 USA									AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K; ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BALENDIRAN K, 1994, PROTEINS, V19, P77, DOI 10.1002/prot.340190110; BLUMENTHAL RM, 1985, J BACTERIOL, V164, P501, DOI 10.1128/JB.164.2.501-509.1985; Bozic D, 1996, J MOL BIOL, V255, P176, DOI 10.1006/jmbi.1996.0015; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; DORNER LF, 1994, NUCLEIC ACIDS RES, V22, P1068, DOI 10.1093/nar/22.6.1068; ELLEDGE SJ, 1989, GENE DEV, V3, P185, DOI 10.1101/gad.3.2.185; FLORES H, 1995, GENE, V157, P295, DOI 10.1016/0378-1119(94)00863-N; FOMENKOV A, 1994, NUCLEIC ACIDS RES, V22, P2399, DOI 10.1093/nar/22.12.2399; GINGERAS TR, 1981, NUCLEIC ACIDS RES, V9, P4525, DOI 10.1093/nar/9.18.4525; Grabowski G, 1996, FEBS LETT, V381, P106, DOI 10.1016/0014-5793(96)00075-0; GRABOWSKI G, 1995, GENE, V157, P113, DOI 10.1016/0378-1119(94)00714-4; HEITMAN J, 1991, GENE, V103, P1, DOI 10.1016/0378-1119(91)90383-M; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; HOLTZ JK, 1994, J BIOL CHEM, V269, P27286; JELTSCH A, 1992, FEBS LETT, V304, P4, DOI 10.1016/0014-5793(92)80576-3; Jeltsch A, 1996, TRENDS BIOTECHNOL, V14, P235, DOI 10.1016/0167-7799(96)10030-5; JELTSCH A, 1993, J MOL BIOL, V229, P221, DOI 10.1006/jmbi.1993.1019; JenJacobson L, 1996, EMBO J, V15, P2870, DOI 10.1002/j.1460-2075.1996.tb00648.x; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KING K, 1989, J BIOL CHEM, V264, P11807; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; NEEDELS MC, 1989, P NATL ACAD SCI USA, V86, P3579, DOI 10.1073/pnas.86.10.3579; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; OTWINOWSKI Z, 1988, NATURE, V366, P178; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; Stahl F, 1996, P NATL ACAD SCI USA, V93, P6175, DOI 10.1073/pnas.93.12.6175; THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; THOMAS M, 1992, BIOTECHNIQUES, V13, P533; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1701, DOI 10.1021/bi952391d; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Wenz C, 1996, J BIOL CHEM, V271, P5565, DOI 10.1074/jbc.271.10.5565; WENZ C, 1994, BBA-GENE STRUCT EXPR, V1219, P73, DOI 10.1016/0167-4781(94)90248-8; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; XU SY, 1991, J BIOL CHEM, V266, P4425; XU SY, 1991, J BACTERIOL, V173, P5030, DOI 10.1128/jb.173.16.5030-5035.1991; [No title captured]	46	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25761	25767		10.1074/jbc.272.41.25761	http://dx.doi.org/10.1074/jbc.272.41.25761			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325303	hybrid			2022-12-27	WOS:A1997YA35800058
J	Subramaniam, VN; Loh, E; Hong, WJ				Subramaniam, VN; Loh, E; Hong, WJ			N-ethylmaleimide-sensitive factor (NSF) and alpha-soluble NSF attachment proteins (SNAP) mediate dissociation of GS28-syntaxin 5 Golgi SNAP receptors (SNARE) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; CIS-GOLGI; FUSION; YEAST; FAMILY; SED5; ER	Golgi soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) GS28 and syntaxin 5 can be reciprocally coimmunoprecipitated from Golgi extracts, suggesting that they exist in a protein complex. When Golgi extract is preincubated with soluble NSF attachment proteins (alpha-SNAP) and N-ethylmaleimide-sensitive factor (NSF) under conditions that allow ATP hydrolysis by NSF, GS28 and syntaxin 5 become dissociated, GS28 and syntaxin 5 remain in a protein complex when Golgi extract is preincubated with similar amounts of alpha-SNAP and NSF under conditions that prevent ATP hydrolysis by NSF, suggesting that ATP hydrolysis by NSF is necessary for dissociating the GS28-syntaxin 5 complex. Since preincubation of Golgi extract with either alpha-SNAP or NSF alone has no effect on the GS28-syntaxin 5 complex, a concerted action of alpha-SNAP and NSF therefore mediates the dissociation of the GS28-syntaxin 5 complex. Furthermore, GS28 but not syntaxin 5 is capable of binding to immobilized alpha-SNAP when the GS28-syntaxin 5 complex is dissociated.	INST MOL & CELL BIOL, MEMBRANE BIOL LAB, SINGAPORE 119076, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)			HONG, Wanjin/E-9927-2010; Subramaniam, V. Nathan/A-1901-2010	Subramaniam, V. Nathan/0000-0002-4583-7790				BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1994, J BIOL CHEM, V269, P29363; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Harlow E., 1988, ANTIBODIES LAB MANUA; Lowe SL, 1996, J CELL SCI, V109, P209; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5	21	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25441	25444		10.1074/jbc.272.41.25441	http://dx.doi.org/10.1074/jbc.272.41.25441			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325254	Green Published, hybrid			2022-12-27	WOS:A1997YA35800009
J	Vertessy, BG; Orosz, F; Kovacs, J; Ovadi, J				Vertessy, BG; Orosz, F; Kovacs, J; Ovadi, J			Alternative binding of two sequential glycolytic enzymes to microtubules - Molecular studies in the phosphofructokinase/aldolase/microtubule system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE PHOSPHOFRUCTOKINASE; TUBULIN INTERACTIONS; ALDOLASE; CALMODULIN; ASSOCIATION; TERMINALS; PROTEINS	Simultaneous binding of two sequential glycolytic enzymes, phosphofructokinase and aldolase, to a microtubular network was investigated. The binding of the phosphofructokinase to microtubules and its bundling activity has been previously characterized (Lehotzky, A., Telegdi, M., Liliom, K., and Ovadi, J. (1993) J. Biol. Chem. 268, 10888-10894). Aldolase binding to microtubules at near physiological ionic strength is weak (K-d = 20 mu M) as compared with that of the kinase (K-d = 1 mu M). The interactions of both enzymes with microtubules are modulated by their common intermediate, fructose-1,6-bisphosphate. Pelleting and electron microscopic measurements have revealed that the aldolase binding interferes with that of phosphofructokinase, although they have distinct binding domains on microtubules. The underlying molecular mechanism responsible for this finding is that in the solution phase aldolase and phosphofructokinase form a bienzyme complex that does not bind to the microtubule. The bienzyme complex formation does not influence the catalytic activity of aldolase, however, it inhibits the dissociation-induced inactivation of the kinase by stabilizing a catalytically active molecular form, The present data suggest the first experimental evidence that two sequential glycolytic enzymes do not associate simultaneously to microtubules, but their complexation in solution provides kinetic advantage for glycolysis.	HUNGARIAN ACAD SCI, INST ENZYMOL, BIOL RES CTR, H-1518 BUDAPEST, HUNGARY; EOTVOS LORAND UNIV, FAC SCI, DEPT GEN ZOOL, H-1445 BUDAPEST, HUNGARY	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University			Vertessy, Beata G/H-6202-2012	Ovadi, Judit/0000-0002-3420-682X; Vertessy, Beata G./0000-0002-1288-2982				Bershadsky AD., 1988, CYTOSKELETON, V1st; BISZKU E, 1964, ACTA PHYSIOL HUNG, V25, P161; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1982, T AM SOC NEUROCHEM, V13, P226; CARR D, 1993, BIOCHEM BIOPH RES CO, V195, P289, DOI 10.1006/bbrc.1993.2043; CLARKE FM, 1985, CELL MOTILITY MECHAN, P235; DURRIEU C, 1987, ARCH BIOCHEM BIOPHYS, V252, P32, DOI 10.1016/0003-9861(87)90005-1; HESTERBERG LK, 1982, BIOCHEMISTRY-US, V21, P216, DOI 10.1021/bi00531a003; HOWARD WD, 1988, J BIOL CHEM, V263, P1342; KNULL HR, 1992, CURR TOP CELL REGUL, V33, P15; KNULL HR, 1990, UCLA SYM BI, V133, P215; LEHOTZKY A, 1994, BIOCHEM BIOPH RES CO, V204, P585, DOI 10.1006/bbrc.1994.2499; LEHOTZKY A, 1993, J BIOL CHEM, V268, P10888; MACRAE TH, 1992, BIOCHIM BIOPHYS ACTA, V1160, P145, DOI 10.1016/0167-4838(92)90001-T; MALAMUD D, 1978, ANAL BIOCHEM, V86, P620, DOI 10.1016/0003-2697(78)90790-X; MASTERS C, 1992, INT J BIOCHEM, V24, P405, DOI 10.1016/0020-711X(92)90031-U; MASTERS CJ, 1981, CRC CR REV BIOCH MOL, V11, P105, DOI 10.3109/10409238109108700; MAYR GW, 1984, EUR J BIOCHEM, V143, P513, DOI 10.1111/j.1432-1033.1984.tb08400.x; Na C.N., 1986, BIOCHEMISTRY-US, V25, P6214; OBLINGER MM, 1988, J NEUROSCI RES, V21, P25, DOI 10.1002/jnr.490210105; OROSZ F, 1986, EUR J BIOCHEM, V160, P615, DOI 10.1111/j.1432-1033.1986.tb10082.x; OROSZ F, 1987, BIOCHEM BIOPH RES CO, V147, P1121, DOI 10.1016/S0006-291X(87)80186-9; Orosz F, 1997, BRIT J PHARMACOL, V121, P947, DOI 10.1038/sj.bjp.0701189; OROSZ F, 1988, BIOCHIM BIOPHYS ACTA, V957, P293, DOI 10.1016/0167-4838(88)90286-5; OVADI J, 1992, CURR TOP CELL REGUL, V33, P105; OVADI J, 1995, CELL ARCHITECTURE ME; ROBERTS SJ, 1987, BIOCHEMISTRY-US, V26, P3437, DOI 10.1021/bi00386a028; SACKETT DL, 1986, J BIOL CHEM, V261, P9070; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; Vertessy BG, 1997, BIOCHEMISTRY-US, V36, P2051, DOI 10.1021/bi9623441; Vertessy BG, 1996, FEBS LETT, V379, P191, DOI 10.1016/0014-5793(95)01510-8; Volker KW, 1997, ARCH BIOCHEM BIOPHYS, V338, P237, DOI 10.1006/abbi.1996.9819; VOLKER KW, 1993, J MOL RECOGNIT, V6, P167, DOI 10.1002/jmr.300060405	34	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25542	25546		10.1074/jbc.272.41.25542	http://dx.doi.org/10.1074/jbc.272.41.25542			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325270	hybrid			2022-12-27	WOS:A1997YA35800025
J	Gregoire, CJ; Gautheret, D; Loret, EP				Gregoire, CJ; Gautheret, D; Loret, EP			No tRNA(3)(Lys) unwinding in a complex with HIV NCp7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TERMINAL ZINC-FINGER; NUCLEOCAPSID PROTEIN NCP7; PRIMER TRANSFER-RNA; IN-VITRO; REVERSE-TRANSCRIPTASE; REPLICATION PRIMER; CIRCULAR-DICHROISM; ANNEALING ACTIVITIES; BINDING-SITE	The nucleocapsid protein NCp7 of the human immunodeficiency virus (HIV) type 1 is important for the annealing of HIV RNA and tRNA(3)(Lys), the tRNA acting as a primer during reverse transcription of HIV RNA, A wild type NCp7 and a Cys(23) mutant having a disrupted zinc finger were analyzed with far UV circular dichroism (CD), CD data analysis revealed that NCp7 has a high content of extended structures in aqueous buffer, decreasing in Cys(23) NCp7 and in NCp7 in the absence of zinc, An increase in beta-turn structures is observed in NCp7 bound to tRNA(3)(Lys). Furthermore, CD data shows that Cys(23) NCp7 binds tRNA(3)(Lys). The CD spectrum of tRNA(3)(Lys) is typical of an A-form helix and retains this structure after binding of NCp7, which demonstrates that NCp7 does not induce tRNA(3)(Lys) unwinding, CD spectra of tRNA(3)(Lys) were measured from 5 to 80 degrees C to observe CD changes resulting from tRNA(3)(Lys) melting. Molecular modeling of the complex identifies two potential tRNA anticodon binding sites in the NCp7 N-terminal region and first zinc finger, In this model, both binding sites can interact with 12 nucleotides in the anticodon domain without requiring a base specificity.	CNRS, LAB INGN SYST MACROMOL, F-13402 MARSEILLE 20, FRANCE; CNRS, INST BIOL STRUCT & MICROBIOL, F-13402 MARSEILLE 20, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)				Gautheret, Daniel/0000-0002-1508-8469				Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460; BARAT C, 1993, J MOL BIOL, V231, P185, DOI 10.1006/jmbi.1993.1273; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; JULIAN N, 1993, FEBS LETT, V331, P43, DOI 10.1016/0014-5793(93)80294-5; KHAN R, 1992, J BIOL CHEM, V267, P6689; LAM WC, 1994, BIOCHEMISTRY-US, V33, P10693, DOI 10.1021/bi00201a017; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MATHEWS CK, 1990, BIOCHEMISTRY-US, P133; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MELY Y, 1995, J BIOL CHEM, V270, P1650, DOI 10.1074/jbc.270.4.1650; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; PRINZ H, 1974, BIOCHEMISTRY-US, V13, P1322, DOI 10.1021/bi00704a003; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; SANGER F, 1963, BIOCHIM BIOPHYS ACTA, V71, P468, DOI 10.1016/0006-3002(63)91108-9; Schmalzbauer E, 1996, J VIROL, V70, P771, DOI 10.1128/JVI.70.2.771-777.1996; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SOUTH TL, 1993, PROTEIN SCI, V2, P3; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; WAKEFIELD JK, 1995, J VIROL, V69, P6021, DOI 10.1128/JVI.69.10.6021-6029.1995; WESTHOF E, 1988, ACTA CRYSTALLOGR A, V44, P112, DOI 10.1107/S010876738700446X; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15	37	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25143	25148		10.1074/jbc.272.40.25143	http://dx.doi.org/10.1074/jbc.272.40.25143			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312125	hybrid			2022-12-27	WOS:A1997XY97000064
J	Zwick, E; Daub, H; Aoki, N; YamaguchiAoki, Y; Tinhofer, I; Maly, K; Ullrich, A				Zwick, E; Daub, H; Aoki, N; YamaguchiAoki, Y; Tinhofer, I; Maly, K; Ullrich, A			Critical role of calcium-dependent epidermal growth factor receptor transactivation in PC12 cell membrane depolarization and bradykinin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GENE-EXPRESSION; MAP KINASE; TYROSINE KINASE; ACTIVATION; RAS; SRC; NEURONS; INFLUX; STIMULATION	PC12 cells respond to a variety of external stimuli such as growth factors, neurotransmitters, and membrane depolarization by activating the Ras/mitogen-activated protein kinase pathway, Here we demonstrate that both depolarization-induced calcium influx and treatment with bradykinin stimulate tyrosine phosphorylation of the epidermal growth factor receptor (EGFR). Using a tetracycline-controlled expression system in conjunction with a dominant-negative EGFR mutant, we demonstrate that depolarization and bradykinin triggered signals involve EG;FR function upstream of SHC and MAP kinase, Furthermore, bradykinin-stimulated EGFR transactivation is critically dependent on the presence of extracellular calcium, and when triggered by ionophore treatment, calcium influx is already sufficient to induce EGFR tyrosine phosphorylation, Taken together, our results establish calcium-dependent EGFR transactivation as a signaling mechanism mediating activation of the Ras/mitogen-activated protein kinase pathway in neuronal cell types.	UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA; MAX PLANCK INST BIOCHEM, DEPT MOL BIOL, D-82152 MARTINSRIED, GERMANY	University of Innsbruck; Max Planck Society				Tinhofer, Ingeborg/0000-0002-0512-549X				BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haller T, 1996, CELL CALCIUM, V19, P157, DOI 10.1016/S0143-4160(96)90084-6; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; TUCKER MS, 1993, BRAIN RES, V631, P65, DOI 10.1016/0006-8993(93)91187-W; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309	24	184	186	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24767	24770		10.1074/jbc.272.40.24767	http://dx.doi.org/10.1074/jbc.272.40.24767			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312072	hybrid			2022-12-27	WOS:A1997XY97000011
J	Tailor, RH; Acland, DP; Attenborough, S; Cammue, BPA; Evans, IJ; Osborn, RW; Ray, JA; Rees, SB; Broekaert, WF				Tailor, RH; Acland, DP; Attenborough, S; Cammue, BPA; Evans, IJ; Osborn, RW; Ray, JA; Rees, SB; Broekaert, WF			A novel family of small cysteine-rich antimicrobial peptides from seed of Impatiens balsamina is derived from a single precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT ANTIFUNGAL PROTEINS; LIPID TRANSFER PROTEINS; CDNA SEQUENCE; RADISH; BARLEY; INHIBITORS; MAGAININS; MECHANISM; DEFENSE	Four closely related peptides were isolated from seed of lmpatiens balsamina and were shown to be inhibitory to the growth of a range of fungi and bacteria, while not being cytotoxic to cultured human cells, The peptides, designated Ib-AMP1, Ib-AMP2, Ib-AMP3, and Ib-AMP4, are 20 amino acids long and are the smallest plant-derived antimicrobial peptides isolated to date, The Ib-AMPs (I. balsaminn antimicrobial peptides) are highly basic and contain four cysteine residues which form two intramolecular disulfide bonds. Searches of protein data bases have failed to identify any proteins with significant homology to the peptides described here, Characterization of isolated cDNAs reveals that all four peptides are encoded within a single transcript, The predicted Ib-AMP precursor protein consists of a prepeptide followed by 6 mature peptide domains, each flanked by propeptide domains ranging from 16 to 35 amino acids in length, Such a primary structure with repeated alternating basic mature peptide domains and acidic propeptide domains has, to date, not been reported in plants.	ZENECA AGROCHEM, JEALOTTS HILL RES STN, BRACKNELL RG42 6EY, BERKS, ENGLAND; KATHOLIEKE UNIV LEUVEN, FA JANSSENS LAB GENET, B-3001 HEVERLEE, BELGIUM	KU Leuven			Cammue, Bruno/M-9575-2013					ATKINSON AH, 1993, PLANT CELL, V5, P203, DOI 10.1105/tpc.5.2.203; Belknap WR, 1996, TRENDS PLANT SCI, V1, P331; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; BROEKAERT WF, 1992, BIOCHEMISTRY-US, V31, P4308, DOI 10.1021/bi00132a023; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; CAMMUE BPA, 1992, J BIOL CHEM, V267, P2228; CAMMUE BRUNO PA, 1995, PLANT PHYSIOL, V109, P445, DOI 10.1104/pp.109.2.445; CASTEELSJOSSON K, 1993, EMBO J, V12, P1569, DOI 10.1002/j.1460-2075.1993.tb05801.x; COLILLA FJ, 1990, FEBS LETT, V270, P191, DOI 10.1016/0014-5793(90)81265-P; DUVICK JP, 1992, J BIOL CHEM, V267, P18814; Garcia-Olmedo F., 1989, OXFORD SURV PLANT MO, V6, P31; GRAY WR, 1981, J BIOL CHEM, V256, P4734; Jepson I., 1991, PLANT MOL BIOL REP, V9, P131; KIYOMASU T, 1991, J VIROL, V65, P4539, DOI 10.1128/JVI.65.8.4539-4542.1991; KOVARIK A, 1987, FOLIA BIOL-PRAGUE, V33, P253; Marcus JP, 1997, EUR J BIOCHEM, V244, P743, DOI 10.1111/j.1432-1033.1997.00743.x; MENDEZ E, 1990, EUR J BIOCHEM, V194, P533, DOI 10.1111/j.1432-1033.1990.tb15649.x; MOLINA A, 1993, FEBS LETT, V316, P119, DOI 10.1016/0014-5793(93)81198-9; OHTANI S, 1977, J BIOCHEM-TOKYO, V82, P753; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; PARDI A, 1989, BIOCHEMISTRY-US, V28, P5494, DOI 10.1021/bi00439a026; TERRAS FRG, 1993, FEBS LETT, V316, P233, DOI 10.1016/0014-5793(93)81299-F; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TERRAS FRG, 1992, PLANT PHYSIOL, V100, P1055, DOI 10.1104/pp.100.2.1055; TERRAS FRG, 1995, PLANT CELL, V7, P573, DOI 10.1105/tpc.7.5.573; TERRY AS, 1988, J BIOL CHEM, V263, P5745; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	29	140	162	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24480	24487		10.1074/jbc.272.39.24480	http://dx.doi.org/10.1074/jbc.272.39.24480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305910	hybrid			2022-12-27	WOS:A1997XY51500061
J	Herbert, JM; Lamarche, I; Carmeliet, P				Herbert, JM; Lamarche, I; Carmeliet, P			Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HUMAN-ENDOTHELIAL CELLS; RAT CAROTID-ARTERY; EXTRACELLULAR-MATRIX; THROMBIN RECEPTOR; EXPRESS UROKINASE; GENE-EXPRESSION; INHIBITOR; INDUCTION; MICE	The present study was undertaken to evaluate in vitro the relative importance of tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA) in the mitogenic and chemotactic potential of bovine fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF)-BB for smooth muscle cells (SMC), Aortic SMC were isolated from transgenic mice showing single inactivations of the t-PA, u-PA, plasminogen activator inhibitor-1, or urokinase-type plasminogen activator receptor (u-PAR) genes. With regard to serum-induced proliferation, all cell types showed similar responses, However, SMC isolated from t-PA-deficient mice did not proliferate or migrate in response to PDGF, whereas SMC isolated from u-PA-deficient animals appeared to be much less sensitive to bFGF than the cells isolated from the other animals, Supplementation of cells from deficient animals with exogenous murine t-PA or u-PA restored the normal response of the growth factors with regard to both migration and proliferation, The mitogenic and chemotactic responses of bFGF were specifically inhibited in u-PAR-deficient cells or in wild-type SMC, cultured in the presence of antibodies to u-PAR, The role of u-PA and t-PA in bFGF and PDGF-induced growth and migration of SMC was not dependent on plasmin generation and activity as demonstrated by the inactivity of epsilon-aminocaproic acid and aprotinin, A 4-5-fold increase in the steady-state levels of u-PA and t-PA mRNA and proteins were observed after 24 h of incubation of the cell cultures with bFGF and PDGF-BB, respectively, These results therefore indicate that, at least in vitro, t-PA is an important element of the activity of PDGF-BB with regard to the proliferation and migration of SMC whereas u-PA is a key factor in the effect of bFGF on SMC.	KATHOLIEKE UNIV LEUVEN,CTR TRANSGENE TECHNOL & GENE THERAPY,B-3000 LOUVAIN,BELGIUM	KU Leuven	Herbert, JM (corresponding author), SANOFI RECH,HAEMOBIOL RES DEPT,195 ROUTE ESPAGNE,F-31036 TOULOUSE,FRANCE.		Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821				AU YPT, 1992, J BIOL CHEM, V267, P3438; BERK BC, 1991, BIOCHEM J, V274, P799, DOI 10.1042/bj2740799; BJORKERUD S, 1988, CIRC RES, V62, P1011, DOI 10.1161/01.RES.62.5.1011; Carmeliet P, 1996, FIBRINOLYSIS, V10, P195, DOI 10.1016/S0268-9499(96)80017-8; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CARMELIET P, 1997, IN PRESS J CLIN INVE; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1992, CIRC RES, V70, P1128, DOI 10.1161/01.RES.70.6.1128; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; DECLERCK PJ, 1995, J BIOL CHEM, V270, P8397, DOI 10.1074/jbc.270.15.8397; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FISHEL RS, 1995, J CLIN INVEST, V95, P377, DOI 10.1172/JCI117666; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GOLDSMITH GH, 1981, EXP MOL PATHOL, V35, P257, DOI 10.1016/0014-4800(81)90065-4; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; HERBERT JM, 1994, J BIOL CHEM, V269, P3076; HERBERT JM, 1992, FEBS LETT, V301, P155, DOI 10.1016/0014-5793(92)81237-G; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KORNER G, 1993, J CELL PHYSIOL, V154, P456, DOI 10.1002/jcp.1041540303; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; LEVIN EG, 1978, THROMB RES, V15, P869; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MIMURO J, 1987, BLOOD, V70, P721; MORE RS, 1995, CARDIOVASC RES, V29, P22, DOI 10.1016/0008-6363(96)88541-5; MORIOKA S, 1987, J INVEST DERMATOL, V88, P418, DOI 10.1111/1523-1747.ep12469754; NODAHEINY H, 1995, ARTERIOSCL THROM VAS, V15, P37, DOI 10.1161/01.ATV.15.1.37; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PAUL R, 1987, THROMB RES, V46, P793, DOI 10.1016/0049-3848(87)90071-5; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; REILLY CF, 1991, J BIOL CHEM, V266, P9419; REUNING U, 1994, BLOOD, V84, P3700, DOI 10.1182/blood.V84.11.3700.bloodjournal84113700; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SCHOLLMANN C, 1992, J BIOL CHEM, V267, P18032; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; STAHL A, 1994, CANCER RES, V54, P3066; TAIJI M, 1992, MOL CELL BIOL, V12, P2193, DOI 10.1128/MCB.12.5.2193; TODD RF, 1995, LEUKOCYTE TYPING, V5, P111; vanLeeuwen RTJ, 1996, FIBRINOLYSIS, V10, P59, DOI 10.1016/S0268-9499(96)80081-6; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WATANABE Y, 1994, ARTERIOSCLER THROMB, V14, P1000, DOI 10.1161/01.ATV.14.6.1000; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WEISS RH, 1993, J BIOL CHEM, V268, P5724	60	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23585	23591		10.1074/jbc.272.38.23585	http://dx.doi.org/10.1074/jbc.272.38.23585			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295297	hybrid			2022-12-27	WOS:A1997XX38100022
J	Perez, PJ; RamosFranco, J; Fill, M; Mignery, GA				Perez, PJ; RamosFranco, J; Fill, M; Mignery, GA			Identification and functional reconstitution of the type 2 inositol 1,4,5-trisphosphate receptor from ventricular cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNELS; RYANODINE RECEPTOR; INSP3 RECEPTOR; TRISPHOSPHATE; BINDING; HEART; EXPRESSION; MECHANISM; MITOCHONDRIAL; CEREBELLUM	The inositol 1,4,5-trisphosphate receptor (InsP(3)R) is an intracellular Ca2+ release channel that mediates the rise in cytoplasmic calcium in response to receptor-activated production of InsP(3). The InsP(3)R-mediated signaling pathway appears to be ubiquitous and is involved in many cellular processes including cell division, smooth muscle contraction, and neuronal signaling. Different regions of the heart also express InsP(3) receptors, We report here that acutely dissociated ventricular myocytes from ferret and rat hearts express significant levels of InsP(3)R as indicated by immunoblotting with a receptor consensus antibody, InsP(3) binding experiments (K-D = 23.6 nM and B-max = 0.46 pmol/mg) suggest the myocytes contain the high affinity type 2 InsP(3) receptor. Exhaustive mRNA screening by polymerase chain reaction, RNase protection, and subsequent DNA sequencing positively identify the InsP(3)R as type 2, The type 2 receptor from ferret heart was then incorporated into planar lipid bilayers and formed Ca2+-selective, InsP(3)-activated, heparin-blocked ion channels. We conclude that the predominant InsP(3) receptor isoform expressed in cardiac myocytes is type 2 and that it forms a functional InsP(3)-gated Ca2+ channel when reconstituted in planar lipid bilayers.	LOYOLA UNIV,STRITCH SCH MED,DEPT PHYSIOL,MAYWOOD,IL 60153; LOYOLA UNIV,STRITCH SCH MED,CARDIOVASC INST,MAYWOOD,IL 60153; LOYOLA UNIV,STRITCH SCH MED,PROGRAM MOL BIOL,MAYWOOD,IL 60153; INST NACL CARDIOL IGNACIO CHAVEZ,DEPT PHYSIOL,MEXICO CITY 14080,DF,MEXICO	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; National Institute of Cardiology - Mexico				Ramos-Franco, Josefina/0000-0001-5404-9481	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH053367] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29 AR41197] Funding Source: Medline; NIMH NIH HHS [R29 MH53367] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BASSANI RA, 1992, J PHYSIOL-LONDON, V453, P591, DOI 10.1113/jphysiol.1992.sp019246; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1994, J GEN PHYSIOL, V104, P821, DOI 10.1085/jgp.104.5.821; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BORGATTA L, 1991, P NATL ACAD SCI USA, V88, P2486, DOI 10.1073/pnas.88.6.2486; BROWN J H, 1986, P245; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GO LO, 1995, J CLIN INVEST, V95, P888, DOI 10.1172/JCI117739; GORZA L, 1993, J CELL BIOL, V121, P345, DOI 10.1083/jcb.121.2.345; GORZA L, 1995, ANN NY ACAD SCI, V752, P141, DOI 10.1111/j.1749-6632.1995.tb17417.x; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HIRATA M, 1984, BIOCHEM J, V223, P229, DOI 10.1042/bj2230229; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; KIJIMA Y, 1992, BIOCHEM BIOPH RES CO, V189, P728, DOI 10.1016/0006-291X(92)92262-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MIGNERY GA, 1993, METH NEUROSCI, V18, P247; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Sambrook J, 1989, MOL CLONING LAB MANU, P382; SCHOLZ H, 1986, J MOL CELL CARDIOL, V18, P79, DOI 10.1016/S0022-2828(86)80463-1; SMITH JS, 1989, J GEN PHYSIOL, V92, P1; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5	34	137	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23961	23969		10.1074/jbc.272.38.23961	http://dx.doi.org/10.1074/jbc.272.38.23961			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295347	hybrid			2022-12-27	WOS:A1997XX38100072
J	Schroder, I; Rech, S; Krafft, T; Macy, JM				Schroder, I; Rech, S; Krafft, T; Macy, JM			Purification and characterization of the selenate reductase from Thauera selenatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPLASMIC NITRATE REDUCTASE; JOAQUIN DRAINAGE WATER; ELEMENTAL SELENIUM; ANAEROBIC RESPIRATION; BIOREMEDIATION; CALIFORNIA; SEDIMENTS; SYSTEM	Thauera selenatis is one of two isolated bacterial species that can obtain energy by respiring anaerobically with selenate as the terminal electron acceptor. The reduction of selenate to selenite is catalyzed by a selenate reductase, previously shown to be located in the periplasmic space of the cell. This study describes the purification of the enzyme from T. selenatis grown anaerobically with selenate. The enzyme is a trimeric alpha beta gamma complex with an apparent M-r of 180,000. The alpha, beta, and gamma subunits are 96 kDa, 40 kDa, and 23 kDa, respectively, in size. The selenate reductase contains molybdenum, iron, and acid-labile sulfur as prosthetic group constituents. UV-visible absorption spectroscopy also revealed the presence of one cytochrome b per alpha beta gamma complex, The K-m for selenate was determined to be 16 mu M, and the V-max was 40 mu mol/min/mg of protein. The enzyme is specific for the reduction of selenate; nitrate, nitrite, chlorate, and sulfate were not reduced at detectable rates, These studies constitute the first description of a selenate reductase, which represents a new class of enzymes. The significance of this enzyme in relation to cell growth and energy generation is discussed.	LA TROBE UNIV,SCH MICROBIOL,BUNDOORA,VIC 3083,AUSTRALIA; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOL GENET,LOS ANGELES,CA 90095	La Trobe University; University of California System; University of California Los Angeles								BERKS BC, 1994, EUR J BIOCHEM, V220, P117, DOI 10.1111/j.1432-1033.1994.tb18605.x; BODE C, 1969, Z KLIN CHEM KLIN BIO, V6, P419; Brumby P.E., 1967, METHOD ENZYMOL, V10, P463, DOI DOI 10.1016/0076-6879(67)10078-5; BYRNE MD, 1987, BIOCHIM BIOPHYS ACTA, V915, P120, DOI 10.1016/0167-4838(87)90131-2; Cantafio AW, 1996, APPL ENVIRON MICROB, V62, P3298, DOI 10.1128/AEM.62.9.3298-3303.1996; DEMOLLDECKER H, 1993, ARCH MICROBIOL, V160, P241; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Garbisu C, 1995, BIOFACTORS, V5, P29; Hanlon SP, 1996, EUR J BIOCHEM, V239, P391, DOI 10.1111/j.1432-1033.1996.0391u.x; KING TE, 1967, METHOD ENZYMOL, V10, P634; LAWSON S, 1995, APPL MICROBIOL BIOT, V43, P762, DOI 10.1007/BF00164785; LORTIE L, 1992, APPL ENVIRON MICROB, V58, P4042, DOI 10.1128/AEM.58.12.4042-4044.1992; MACY JM, 1993, APPL MICROBIOL BIOT, V40, P588; MACY JM, 1993, INT J SYST BACTERIOL, V43, P135, DOI 10.1099/00207713-43-1-135; MACY JM, 1989, FEMS MICROBIOL LETT, V61, P195, DOI 10.1111/j.1574-6968.1989.tb03577.x; MACY JM, 1993, ARCH MICROBIOL, V160, P295, DOI 10.1007/BF00292080; OREMLAND RS, 1991, APPL ENVIRON MICROB, V57, P615, DOI 10.1128/AEM.57.2.615-617.1991; OREMLAND RS, 1994, APPL ENVIRON MICROB, V60, P3011, DOI 10.1128/AEM.60.8.3011-3019.1994; OREMLAND RS, 1989, APPL ENVIRON MICROB, V55, P2333, DOI 10.1128/AEM.55.9.2333-2343.1989; OREMLAND RS, 1990, ENVIRON SCI TECHNOL, V24, P1157, DOI 10.1021/es00078a001; OREMLAND RS, 1993, SELENIUM ENV, P389; Osborn M J, 1974, Methods Enzymol, V31, P642; RECH SA, 1992, J BACTERIOL, V174, P7316, DOI 10.1128/jb.174.22.7316-7320.1992; Reyes F, 1996, MOL MICROBIOL, V19, P1307, DOI 10.1111/j.1365-2958.1996.tb02475.x; SAIKI MK, 1987, ARCH ENVIRON CON TOX, V16, P657, DOI 10.1007/BF01055416; SCHRODER I, 1994, J BACTERIOL, V176, P4985, DOI 10.1128/jb.176.16.4985-4992.1994; SIDDIQUI RA, 1993, J BACTERIOL, V175, P5867, DOI 10.1128/JB.175.18.5867-5876.1993; Smith L, 1978, Methods Enzymol, V53, P202; STEINBERG NA, 1990, APPL ENVIRON MICROB, V56, P3550, DOI 10.1128/AEM.56.11.3550-3557.1990; TOMEI FA, 1992, CAN J MICROBIOL, V38, P1328, DOI 10.1139/m92-219; WERES O, 1989, APPL GEOCHEM, V4, P543, DOI 10.1016/0883-2927(89)90066-8	31	170	177	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23765	23768		10.1074/jbc.272.38.23765	http://dx.doi.org/10.1074/jbc.272.38.23765			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295321	hybrid			2022-12-27	WOS:A1997XX38100046
J	Ramamurthy, V; Oliver, D				Ramamurthy, V; Oliver, D			Topology of the integral membrane form of Escherichia coli SecA protein reveals multiple periplasmically exposed regions and modulation by ATP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN TRANSLOCASE; PLASMA-MEMBRANE; INNER MEMBRANE; ESSENTIAL COMPONENT; SECRETORY PROTEIN; TERMINAL REGION; PHOSPHOLIPIDS; SUBUNIT; INSERTION; DOMAINS	SecA insertion and integration into the Escherichia coli inner membrane is a critical step for the catalysis of protein translocation across this layer, To understand this step further, SecA topology was investigated, To determine which regions of SecA are periplasmically exposed, right-side out membrane vesicles were prepared from strains synthesizing monocysteine SecA variants produced by mutagenesis and probed with a membrane-impermeant sulfhydryl-labeling reagent, To determine which regions of SecA contain membrane-integration determinants, inverted inner membrane vesicles were subjected to proteolysis, and integral-membrane fragments of SecA were identified with region-specific antibodies, The membrane association properties of various truncated SecA species produced in vivo were also determined, Our analysis indicates that the membrane topology of SecA is complex with amino-terminal, central, and carboxyl-terminal regions of SecA integrated into the membrane where portions are periplasmically accessible, Furthermore, the insertion and penetration of the amino-terminal third of SecA, which includes the proposed preprotein binding domain, is subject to modulation by ATP binding, The importance of these studies to the cycle of membrane insertion and de-insertion of SecA that promotes protein translocation and SecA's proximity to the preprotein channel are discussed.	WESLEYAN UNIV, DEPT MOL BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA	Wesleyan University					NIGMS NIH HHS [GM42033] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; COLE ST, 1982, EUR J BIOCHEM, V122, P479; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; HANADA M, 1994, J BIOL CHEM, V269, P23625; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KIM YJ, 1994, CELL, V78, P845; KIM YJ, 1994, FEBS LETT, V339, P175, DOI 10.1016/0014-5793(94)80410-9; KIMURA E, 1991, J BIOL CHEM, V266, P6600; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Miller J. H., 1972, EXPT MOL GENETICS, P431; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RAJAPANDI T, 1991, J BACTERIOL, V173, P7092, DOI 10.1128/jb.173.22.7092-7097.1991; Randall LL, 1997, P NATL ACAD SCI USA, V94, P802, DOI 10.1073/pnas.94.3.802; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Snyders S, 1997, J BIOL CHEM, V272, P11302; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAMATSU H, 1994, J BIOCHEM-TOKYO, V116, P1287, DOI 10.1093/oxfordjournals.jbchem.a124677; TRAXLER B, 1993, J MEMBRANE BIOL, V132, P1; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	54	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23239	23246		10.1074/jbc.272.37.23239	http://dx.doi.org/10.1074/jbc.272.37.23239			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287332	hybrid			2022-12-27	WOS:A1997XV74400043
J	Kahyaoglu, A; Haghjoo, K; Guo, FS; Jordan, F; Kettner, C; Felfoldi, F; Polgar, L				Kahyaoglu, A; Haghjoo, K; Guo, FS; Jordan, F; Kettner, C; Felfoldi, F; Polgar, L			Low barrier hydrogen bond is absent in the catalytic triads in the ground state but is present in a transition-state complex in the prolyl oligopeptidase family of serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CYTOSOLIC ASPARTATE-AMINOTRANSFERASE; N-15 NMR-SPECTROSCOPY; ENZYME CATALYSIS; ESCHERICHIA-COLI; HISTIDINE-RESIDUES; 10-18-PPM RANGE; H-1 RESONANCES; ACTIVE-SITE; CHYMOTRYPSIN	High frequency proton NMR spectra for two members of the prolyl oligopeptidase class of serine proteases, prolyl oligopeptidase and oligopeptidase B, showed that resonances corresponding to the active center histidine (NH)-H-delta 1 and (NH)-H-epsilon 2 generally observed in this region, are absent in these enzymes, However, for both enzymes, as well as with the H652A and H652Q active center variants of oligopeptidase B, there are two resonances observed in this region that could be assigned to two protonated histidines with a noncatalytic function, The results indicate that these two histidines participate in strong hydrogen bonds, The absence of resonances pertinent to the active center histidine resonances suggests the absence of a low barrier hydrogen bond between the Asp and His in these two enzymes in their ground states, Addition of the peptide boronic acid t-butoxycarbonyl-(D)Val-Leu-(L)boroArg to oligopeptidase B resulted in potent, slow binding inhibition of the enzyme and the appearance of a new resonance at 15.8 ppm, whose chemical shift is appropriate for a tetrahedral boronate complex and a low barrier hydrogen bond. The results demonstrate important dissimilarities between the active centers of the prolyl oligopeptidase class of serine proteases and the pancreatic and subtilisin classes both in the ground state and in the transition-state analog complexes.	RUTGERS STATE UNIV, DEPT CHEM, NEWARK, NJ 07102 USA; DUPONT MERCK PHARMACEUT CO, WILMINGTON, DE 19880 USA; HUNGARIAN ACAD SCI, BIOL RES CTR, INST ENZYMOL, H-1113 BUDAPEST, HUNGARY	Rutgers State University Newark; Rutgers State University New Brunswick; DuPont; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences								ADEBODUN F, 1989, J CELL BIOCHEM, V40, P249, DOI 10.1002/jcb.240400213; BACHOVCHIN WW, 1985, P NATL ACAD SCI USA, V82, P7948, DOI 10.1073/pnas.82.23.7948; BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BACHOVCHIN WW, 1988, BIOCHEMISTRY-US, V27, P7689, DOI 10.1021/bi00420a018; CLELAND WW, 1995, SCIENCE, V269, P104, DOI 10.1126/science.269.5220.104; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; FREY PA, 1995, SCIENCE, V269, P104, DOI 10.1126/science.269.5220.104-a; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; HAGHJOO K, 1996, THESIS RUTGERS NEWAR; Halkides CJ, 1996, BIOCHEMISTRY-US, V35, P15941, DOI 10.1021/bi961805f; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HORE PJ, 1983, J MAGN RESON, V55, P283, DOI 10.1016/0022-2364(83)90240-8; JORDAN F, 1981, BIOCHEMISTRY-US, V20, P6366, DOI 10.1021/bi00525a013; Kahyaoglu A, 1997, BIOCHEM J, V322, P839, DOI 10.1042/bj3220839; KANATANI A, 1991, J BIOCHEM-TOKYO, V110, P315, DOI 10.1093/oxfordjournals.jbchem.a123577; KETTNER CA, 1984, J BIOL CHEM, V259, P5106; KINTANAR A, 1991, J BIOL CHEM, V266, P17222; LIANG TC, 1987, BIOCHEMISTRY-US, V26, P7603, DOI 10.1021/bi00398a011; Markley JL, 1996, BIOCHEMISTRY-US, V35, P11092, DOI 10.1021/bi961366k; MARKLEY JL, 1978, BIOCHEMISTRY-US, V17, P4648, DOI 10.1021/bi00615a010; METZLER DE, 1994, J BIOL CHEM, V269, P28027; METZLER DE, 1994, J BIOL CHEM, V269, P28017; POLGAR L, 1992, FEBS LETT, V311, P281, DOI 10.1016/0014-5793(92)81120-B; POLGAR L, 1994, METHOD ENZYMOL, V244, P188; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; ROBILLAR.G, 1974, J MOL BIOL, V86, P519, DOI 10.1016/0022-2836(74)90178-8; ROBILLAR.G, 1974, J MOL BIOL, V86, P541, DOI 10.1016/0022-2836(74)90179-X; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; STRONGIN AY, 1978, J BACTERIOL, V133, P1401, DOI 10.1128/JB.133.3.1401-1411.1978; TOBIN JB, 1995, BIOCHEMISTRY-US, V34, P6919, DOI 10.1021/bi00021a002; TONG HX, 1995, BIOCHEMISTRY-US, V34, P3362, DOI 10.1021/bi00010a027; TSURU D, 1994, METHOD ENZYMOL, V244, P201; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x; ZHONG S, 1995, J AM CHEM SOC, V117, P7048, DOI 10.1021/ja00132a002; ZHONG S, 1991, THESI SRUTGERS NEWAR	36	28	28	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25547	25554		10.1074/jbc.272.41.25547	http://dx.doi.org/10.1074/jbc.272.41.25547			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325271	hybrid			2022-12-27	WOS:A1997YA35800026
J	Peppel, K; Boekhoff, I; McDonald, P; Breer, H; Caron, MG; Lefkowitz, RJ				Peppel, K; Boekhoff, I; McDonald, P; Breer, H; Caron, MG; Lefkowitz, RJ			G protein-coupled receptor kinase 3 (GRK3) gene disruption leads to loss of odorant receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAILING HUMAN HEART; BETA-ARRESTIN; FAMILY; EXPRESSION; ACTIVATION; RHODOPSIN; MEMBER	G protein-coupled receptor kinases (GRKs) 2 and 3 (beta-adrenergic receptor kinases 1 and 2 (beta ARK1 and -2)) mediate the agonist dependent phosphorylation and uncoupling of many G protein-coupled receptors, These two members of the GRK family share a high degree of sequence homology and show overlapping patterns of substrate specificity in vitro. To define their physiological roles in vivo we have generated mice that carry targeted disruption of these genes. In contrast to GRK2-deficient mice, which die in utero (Jaber, M., Koch, W. J., Rockman, H., Smith, B., Bond, R. A., Sulik, K. K., Boss, J. JR., Lefkowitz, R. J. Caron, M. G., and Giros, B. (1996) Proc. Natl. Acad, Sci, U. S. A. 93, 12974-12979), GRK3 deletion allows for normal embryonic and postnatal development, GRK3 is expressed to a high degree in the olfactory epithelium, where GRK2 is absent, Here we report that cilia preparations derived from GRK3-deficient mice lack the fast agonist-induced desensitization normally seen after odorant stimulation, Moreover, total second messenger (cAMP) generation in these cilia preparations following odorant stimulation is markedly reduced when compared with preparations from wildtype littermates, This reduction in the ability to generate cAMP is evident even in the presence of nonodorant receptor stimuli (GTP gamma S and forskolin), suggesting a compensatory dampening of the G protein-adenylyl cyclase system in the GRK3 (-/-) mice in the olfactory epithelium, These findings demonstrate the requirement of GRK3 for odorant-induced desensitization of cAMP responses.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,HOWARD HUGHES MED INST,DURHAM,NC 27710; UNIV HOHENHEIM,DEPT PHYSIOL,D-70593 STUTTGART,GERMANY	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; University Hohenheim			Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANHOLT RRH, 1986, J NEUROSCI, V6, P1403; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOLLER BH, 1989, P NATL ACAD SCI USA, V86, P8932, DOI 10.1073/pnas.86.22.8932; KRIEGER J, 1994, EUR J BIOCHEM, V219, P829, DOI 10.1111/j.1432-1033.1994.tb18564.x; LEFKOWITZ RJ, 1993, HDB EXP PHARM, V46, P33; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; NIH, 1985, NIH PUBL; PERSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Yamamoto S, 1997, NAT GENET, V15, P175, DOI 10.1038/ng0297-175	25	129	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25425	25428		10.1074/jbc.272.41.25425	http://dx.doi.org/10.1074/jbc.272.41.25425			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325250	hybrid			2022-12-27	WOS:A1997YA35800005
J	Rivas, S; Bolland, S; Cabezon, E; Goni, FM; delaCruz, F				Rivas, S; Bolland, S; Cabezon, E; Goni, FM; delaCruz, F			TrwD, a protein encoded by the IncW plasmid R388, displays an ATP hydrolase activity essential for bacterial conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; PULLULANASE SECRETION; CYTOPLASMIC MEMBRANE; OUTER-MEMBRANE; BINDING SITE; DNA TRANSFER; PURIFICATION; SYSTEM; ORGANIZATION	A 1.7-kilobase pair segment from the conjugative transfer region of plasmid R388 DNA was cloned and sequenced, It contained trwD, a gene essential for plasmid R388 conjugation, for expression of the conjugative W-pilus and for sensitivity to phage PRD1. The deduced amino acid sequence of TrwD showed homology to the PulE/VirB11 superfamily of potential ATPases involved in various types of transport processes, A fusion of trwD with the glutathione S-transferase (GST) was constructed, and the resulting fusion protein was purified from overproducing bacteria. Factor X-a hydrolysis of GST-TrwD and further purification rendered TrwD protein with more than 95% purity, Antibodies raised against TrwD localized it both in the soluble fraction and in the outer membrane of Escherichia coli. TrwD is probably a peripheral outer membrane protein because it could be solubilized by increasing salt concentration to 0.5 M NaCl in the lysis buffer, Both purified GST-TrwD and TrwD could hydrolize ATP, ATPase activity increased 2-fold in the presence of detergent-phospholipid mixed micelles, To study the importance of the nucleotide-binding site, Walker box A (GXXGXGK(T/S)), present in TrwD, the conserved lysine residue was replaced by glutamine, The mutant protein, expressed and purified under the same conditions as the wild type, did not exhibit ATPase activity, TrwD(K203Q) was not able to complement the mutation in trwD of the R388 mutant plasmid, suggesting the essentiality of the ATPase activity of the protein in the conjugative process. Further more, the dominant character of this mutation suggested that GST-TrwD(K432Q) was still able to interact either with itself or with other component(s) of the conjugative machinery.	UNIV CANTABRIA, DEPT BIOL MOL, SANTANDER 39011, SPAIN; UNIV BASQUE COUNTRY, DEPT BIOQUIM,CSIC,GRP BIOMEMBRANES,UNIDAD ASOCIADA, E-48080 BILBAO, SPAIN	Universidad de Cantabria; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country			Goni, Felix M/M-5425-2015; Cabezon, Elena/K-5874-2014; de la Cruz, Fernando/L-2812-2014	Goni, Felix M/0000-0001-6270-9216; de la Cruz, Fernando/0000-0003-4758-6857; Cabezon, Elena/0000-0002-6177-5016				ATSCHUL SF, 1990, J MOL BIOL, V215, P403; BAKELS RHA, 1994, BIOCHEM BIOPH RES CO, V201, P487, DOI 10.1006/bbrc.1994.1728; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BOLLAND S, 1990, J BACTERIOL, V172, P5795, DOI 10.1128/jb.172.10.5795-5802.1990; BOLLAND S, 1991, THESIS U CANTABRIA S; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CHRISTIE PJ, 1989, P NATL ACAD SCI USA, V86, P9677, DOI 10.1073/pnas.86.24.9677; DATTA N, 1972, J GEN MICROBIOL, V72, P349, DOI 10.1099/00221287-72-2-349; DEMAAGD RA, 1986, J BACTERIOL, V167, P1083, DOI 10.1128/jb.167.3.1083-1085.1986; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Harlow E., 1988, ANTIBODIES LAB MANUA; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; LLOSA M, 1994, J MOL BIOL, V235, P448, DOI 10.1006/jmbi.1994.1005; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; Maniatis T., 1982, MOL CLONING; MOTALLEBIVESHAREH M, 1992, MOL MICROBIOL, V6, P907, DOI 10.1111/j.1365-2958.1992.tb01541.x; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; POSSOT O, 1992, MOL MICROBIOL, V6, P95, DOI 10.1111/j.1365-2958.1992.tb00841.x; POSSOT O, 1994, MOL MICROBIOL, V12, P287, DOI 10.1111/j.1365-2958.1994.tb01017.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SADLER JR, 1980, GENE, V8, P279, DOI 10.1016/0378-1119(80)90005-0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENS KM, 1995, J BACTERIOL, V177, P27, DOI 10.1002/path.1711770106; TURNER LR, 1993, J BACTERIOL, V175, P4962, DOI 10.1128/JB.175.16.4962-4969.1993; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEISSBACH A, 1959, J BIOL CHEM, V234, P705; WHITCHURCH CB, 1991, GENE, V101, P33, DOI 10.1016/0378-1119(91)90221-V; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	38	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25583	25590		10.1074/jbc.272.41.25583	http://dx.doi.org/10.1074/jbc.272.41.25583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325277	hybrid			2022-12-27	WOS:A1997YA35800032
J	Ascoli, GA; Luu, KX; Olds, JL; Nelson, TJ; Gusev, PA; Bertucci, C; Bramanti, E; Raffaelli, A; Salvadori, P; Alkon, DL				Ascoli, GA; Luu, KX; Olds, JL; Nelson, TJ; Gusev, PA; Bertucci, C; Bramanti, E; Raffaelli, A; Salvadori, P; Alkon, DL			Secondary structure and Ca2+-induced conformational change of calexcitin, a learning-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CALCIUM-MODULATED PROTEINS; EF-HAND; CIRCULAR-DICHROISM; KINASE-C; MOLECULAR MECHANISMS; STRUCTURE PREDICTION; POTASSIUM CHANNELS; ESCHERICHIA-COLI; MEMORY STORAGE	Calexcitin/cp20 is a low molecular weight GTP- and Ca2+-binding protein, which is phosphorylated by protein kinase C during associative learning, and reproduces many of the cellular effects of learning, such as the reduction of potassium currents in neurons, Here, the secondary structure of cloned squid calexcitin was determined by circular dichroism in aqueous solution and by Fourier transform infrared spectroscopy both in solution and on dried films, The results obtained with the two techniques are in agreement with each other and coincide with the secondary structure computed from the amino acid sequence, In solution, calexcitin is one-third in alpha-helix and one-fifth in beta-sheet. The conformation of the protein in solid state depends on the concentration of the starting solution, suggesting the occurrence of surface aggregation. The secondary structure also depends on the binding of calcium, which causes an increase in alpha-helix and a decrease in beta-sheet, as estimated by circular dichroism, The conformation of calexcitin is independent of ionic strength, and the calcium-induced structural transition is slightly inhibited by Mg2+ and low pH, while favored by high pH. The switch of calexcitin's secondary structure upon calcium binding, which was confirmed by intrinsic fluorescence spectroscopy and nondenaturing gel electrophoresis, is reversible and occurs in a physiologically meaningful range of Ca2+ concentration. The calcium-bound form is more globular than the apoprotein, Unlike other EF-hand proteins, calexcitin's overall lipophilicity is not affected by calcium binding, as assessed by hydrophobic liquid chromatography. Preliminary results from patch-clamp experiments indicated that calcium is necessary for calexcitin to inhibit potassium channels and thus to increase membrane excitability, Therefore the calcium-dependent conformational equilibrium of calexcitin could serve as a molecular switch for the short term modulation of neuronal activity following associative conditioning.	UNIV PISA,DIPARTIMENTO CHIM & CHIM IND,CNR,CTR STUDIO MACROMOL STEREORDINATE & OTTICAMENTE,I-56126 PISA,ITALY; CNR,INST INSTRUMENTAL ANALYT CHEM,I-56126 PISA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Pisa; Consiglio Nazionale delle Ricerche (CNR)	Ascoli, GA (corresponding author), NINCDS,LAS,NIH,BLDG 36,RM 4A24,35 CONVENT DR MSC 4124,BETHESDA,MD 20892, USA.		Olds, James L./P-4917-2019; Olds, James/D-2867-2011; Bramanti, Emilia/E-1114-2011; Bramanti, Emilia/AAQ-9425-2021	Olds, James L./0000-0003-3214-946X; Bramanti, Emilia/0000-0001-8478-7370; Raffaelli, Andrea/0000-0002-6094-835X				ALKON DL, 1989, SCI AM, V261, P42, DOI 10.1038/scientificamerican0789-42; ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; ALKON DL, 1990, FASEB J, V4, P1567, DOI 10.1096/fasebj.4.6.2108074; ALKON DL, 1990, P NATL ACAD SCI USA, V87, P1611, DOI 10.1073/pnas.87.4.1611; ALKON DL, 1995, BEHAV BRAIN RES, V66, P151, DOI 10.1016/0166-4328(94)00142-3; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; AURELL L, 1977, THROMB RES, V11, P595, DOI 10.1016/0049-3848(77)90018-4; BRAMANTI E, 1994, J CHEMOMETR, V8, P409, DOI 10.1002/cem.1180080606; Bramanti E, 1996, BIOPOLYMERS, V38, P639, DOI 10.1002/(SICI)1097-0282(199605)38:5<639::AID-BIP8>3.0.CO;2-T; BRAMANTI E, 1997, IN PRESS BIOPOLYMERS, V41; COSTANTINO HR, 1995, BBA-PROTEIN STRUCT M, V1253, P69, DOI 10.1016/0167-4838(95)00156-O; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DUDAI Y, 1985, FEBS LETT, V191, P165, DOI 10.1016/0014-5793(85)80001-6; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; FU FN, 1994, APPL SPECTROSC, V48, P1432, DOI 10.1366/0003702944028065; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; HADDEN JM, 1995, BBA-PROTEIN STRUCT M, V1248, P115, DOI 10.1016/0167-4838(95)00010-R; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HENNESSEY JP, 1987, BIOPOLYMERS, V26, P561, DOI 10.1002/bip.360260409; IKURA M, 1996, TRENDS BIOCHEM SCI, V21, P6; JENG AY, 1987, BIOCHEM BIOPH RES CO, V145, P782, DOI 10.1016/0006-291X(87)91033-3; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSON WC, 1992, METHOD ENZYMOL, V210, P426; KIM CS, 1995, P NATL ACAD SCI USA, V92, P3060, DOI 10.1073/pnas.92.7.3060; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; LU GH, 1994, PLANT CELL, V6, P501, DOI 10.1105/tpc.6.4.501; MANNING MC, 1989, J PHARMACEUT BIOMED, V7, P1103, DOI 10.1016/0731-7085(89)80049-4; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MOSHIACH S, 1993, BRAIN RES, V605, P298, DOI 10.1016/0006-8993(93)91754-G; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; NEARY JT, 1981, NATURE, V293, P658, DOI 10.1038/293658a0; Nelson TJ, 1996, P NATL ACAD SCI USA, V93, P13808, DOI 10.1073/pnas.93.24.13808; NELSON TJ, 1990, SCIENCE, V247, P1479, DOI 10.1126/science.2108498; NELSON TJ, 1991, MOL NEUROBIOL, V5, P315, DOI 10.1007/BF02935554; NELSON TJ, 1994, P NATL ACAD SCI USA, V91, P9287, DOI 10.1073/pnas.91.20.9287; NELSON TJ, 1995, J NEUROCHEM, V65, P2350; NELSON TJ, 1994, J NEUROCHEM, V57, P2065; OLDS JL, 1989, SCIENCE, V245, P866, DOI 10.1126/science.2772638; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SAKAKIBARA M, 1986, BIOPHYS J, V50, P319, DOI 10.1016/S0006-3495(86)83465-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ JH, 1987, ANNU REV NEUROSCI, V10, P459; SHETERLINE P, 1995, PROTEIN PROFILE, V2, P305; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TRAVE G, 1995, EUR J BIOCHEM, V227, P35, DOI 10.1111/j.1432-1033.1995.tb20357.x; WEBER C, 1994, J BIOL CHEM, V269, P15795	53	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24771	24779		10.1074/jbc.272.40.24771	http://dx.doi.org/10.1074/jbc.272.40.24771			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312073	hybrid			2022-12-27	WOS:A1997XY97000012
J	Ault, BH; Schmidt, BZ; Fowler, NL; Kashtan, CE; Ahmed, AE; Vogt, BA; Colten, HR				Ault, BH; Schmidt, BZ; Fowler, NL; Kashtan, CE; Ahmed, AE; Vogt, BA; Colten, HR			Human factor H deficiency - Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; NASCENT POLYPEPTIDE-CHAINS; HOMOZYGOUS FACTOR-H; REGULATORY PROTEINS; MENINGOCOCCAL DISEASE; HUMAN GENES; B-SUBUNIT; DEGRADATION; COMPONENTS; SEQUENCE	The synthesis and secretion of factor H, a regulatory protein of the complement system, were studied in skin fibroblasts from an H-deficient child who has chronic hypocomplementemic renal disease, In normal fibro blasts, factor H transcripts of 4.3 and 1.8 kilobase pairs (kb) encode a 155-kDa protein containing short consensus repeat (SCR) domains 1-20 and a 45-kDa protein which contains SCRs 1-7, respectively. The patient's fibroblasts expressed normal amounts of the 4.3- and 1.8-kb messages constitutively and after tumor necrosis factor-alpha/interferon-gamma stimulation. Lysates of [S-35]methionine-labeled fibroblasts from the patient contained the 155- and 45-kDa H polypeptides, but secretion of the 155-kDa protein was blocked; the 45-kDa protein was secreted with normal kinetics, The patient's plasma lacked the 155-kDa protein but contained the small form of H. Moreover, in fibroblasts the retained 155-kDa factor H protein was not degraded, even after 12 h, Immunoflourescent staining and confocal microscopic imaging of the patient's fibroblasts indicated that factor H was retained in the endoplasmic reticulum, Sequence analysis of reverse transcription-polymerase chain reaction products (the entire coding region) and genomic DNA revealed a T1679C substitution on one allele and a G2949A substitution on the other (C518R mutation in SCR 9 and C991Y mutation in SCR 16, respectively), Both mutations affect conserved cysteine residues characteristic of SCR modules and therefore predict pro found changes in the higher order structure of the 155-kDa factor H protein, These data provide the first description of a molecular mechanism for factor H deficiency and yield important insights into the normal secretory pathway for this and other plasma proteins with SCR motifs.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; UNIV MINNESOTA,DEPT PEDIAT,MINNEAPOLIS,MN 55455; SPECIALTY LABS INC,SANTA MONICA,CA 90404	Washington University (WUSTL); University of Minnesota System; University of Minnesota Twin Cities				Schmidt, Bela Z/0000-0003-1085-9372				BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRAI M, 1988, J CLIN IMMUNOL, V8, P50, DOI 10.1007/BF00915156; BROOIMANS RA, 1989, J IMMUNOL, V142, P2024; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLTEN HR, 1992, ANNU REV IMMUNOL, V10, P809, DOI 10.1146/annurev.iy.10.040192.004113; COLTEN HR, 1995, BLOOD PRINCIPLES PRA, P477; DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588; DECORDOBA SR, 1985, J EXP MED, V161, P1189, DOI 10.1084/jem.161.5.1189; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; ESTALLER C, 1991, EUR J IMMUNOL, V21, P799, DOI 10.1002/eji.1830210337; FELICIELLO I, 1993, ANAL BIOCHEM, V212, P304; FIJEN CAP, 1989, LANCET, V2, P585; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GARNIER G, 1992, J EXP MED, V175, P471, DOI 10.1084/jem.175.2.471; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; HASHIGUCHI T, 1995, J CLIN INVEST, V95, P1002, DOI 10.1172/JCI117744; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KATZ Y, 1988, J IMMUNOL, V141, P559; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; KULICS J, 1994, IMMUNOLOGY, V82, P509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278; LITZ CE, 1988, AM J MED GENET, V30, P821, DOI 10.1002/ajmg.1320300316; LOPEZLARREA C, 1987, BIOCHEM SOC T, V15, P648, DOI 10.1042/bst0150648; MORGAN BP, 1991, IMMUNOL TODAY, V12, P301, DOI 10.1016/0167-5699(91)90003-C; NIELSEN HE, 1989, SCAND J IMMUNOL, V30, P711, DOI 10.1111/j.1365-3083.1989.tb02480.x; NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277; PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; REYCAMPOS J, 1990, GENOMICS, V7, P644, DOI 10.1016/0888-7543(90)90213-E; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; SCHULZ TF, 1986, EUR J IMMUNOL, V16, P1351, DOI 10.1002/eji.1830161107; SCHWAEBLE W, 1991, EUR J BIOCHEM, V198, P399, DOI 10.1111/j.1432-1033.1991.tb16028.x; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SIMSEK S, 1994, BRIT J HAEMATOL, V88, P839, DOI 10.1111/j.1365-2141.1994.tb05125.x; SKERKA C, 1995, IMMUNOGENETICS, V42, P268; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; TAYLOR SAM, 1992, THROMB HAEMOSTASIS, V67, P63; THOMPSON RA, 1981, CLIN EXP IMMUNOL, V46, P110; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; VIK DP, 1989, CURR TOP MICROBIOL I, V153, P147; VOGT BA, 1995, PEDIATR NEPHROL, V9, P11, DOI 10.1007/BF00858956; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	52	121	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25168	25175		10.1074/jbc.272.40.25168	http://dx.doi.org/10.1074/jbc.272.40.25168			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312129	hybrid			2022-12-27	WOS:A1997XY97000068
J	Jackson, DE; Kupcho, KR; Newman, PJ				Jackson, DE; Kupcho, KR; Newman, PJ			Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of platelet endothelial cell adhesion molecule-1 (PECAM-1) that are required for the cellular association and activation of the protein-tyrosine phosphatase, SHP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SH2 DOMAINS; TRANSENDOTHELIAL MIGRATION; PHOSPHOLIPASE-C; BETA-SUBUNIT; SH-PTP2; PHOSPHORYLATION; KINASE; SRC; SYP	Recent studies have shown that the Src homology-2 (SH2) domain containing protein-tyrosine phosphatase, SHP-2, associates with the cytoplasmic domain of PECAM-1 as it becomes tyrosine-phosphorylated during platelet aggregation: a process that can be mimicked in part by small synthetic phosphopeptides corresponding to the cytoplasmic domain of PECAM-1 encompassing tyrosine residues Tyr-663 or Tyr-686. To further examine the molecular requirements for PECAM-1/SHP-2 interactions, we generated human embryonic kidney (HEK)-293 cell lines that stably expressed mutant forms of PECAM-1 harboring tyrosine to phenylalanine (Tyr --> Phe) mutations in the cytoplasmic domain, Y663F and Y686F forms of PECAM-1 were tyrosine-phosphorylated to a somewhat lesser extent than wild-type PECAM-1, and a doubly substituted Y663,686F form of PECAM-1 failed to become tyrosine-phosphorylated, suggesting that the PECAM-1 cytoplasmic domain tyrosine residues 596, 636 and 701 do nob serve as substrates for cellular kinases, Interestingly, SHP-2 binding was lost when either Tyr-663 or Tyr-686 were changed to phenylalanine, indicating that both residues are required for SHP-2/PECAM-1 association, Although PECAM-1 phosphopeptides NSDVQpY(663)TEVQV and DTETVpY(686)SEVRK stimulated the catalytic activity of the phosphatase to a similar extent, surface plasmon resonance studies revealed that the Tyr-663 containing peptide had approximately 10-fold higher affinity for SHP-2 than did the Tyr-686 peptide. Finally, peptido-precipitation analysis showed that the NH2-terminal SH2 domain of SHP-2 reacted preferentially with the Tyr-663 PECAM-1 phosphopeptide, while the Tyr-686 phosphopeptide associated only with the COOH-terminal SH2 domain of the phosphatase, Together, these data provide a molecular model for PECAM-1/SHP-2 interactions that may shed light on the downstream events that follow PECAM-1-mediated interactions of vascular cells.	BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53233 USA; MED COLL WISCONSIN, DEPT PHARMACOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT CELLULAR BIOL, MILWAUKEE, WI 53226 USA	Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44612] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERMAN ME, 1995, J IMMUNOL, V154, P299; Berman ME, 1996, J IMMUNOL, V156, P1515; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASE RD, 1994, J BIOL CHEM, V269, P10467; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GOLDBERGER A, 1994, J BIOL CHEM, V269, P17183; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HUYER G, 1995, BIOCHEMISTRY-US, V34, P1040, DOI 10.1021/bi00003a039; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEAVESLEY DI, 1994, J IMMUNOL, V153, P4673; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Matsumura T, 1997, J IMMUNOL, V158, P3408; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MODDERMAN PW, 1994, BIOCHEM J, V299, P613, DOI 10.1042/bj2990613; MULLER WA, 1992, J EXP MED, V176, P819, DOI 10.1084/jem.176.3.819; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; NEWMAN PJ, 1994, PLATELET DEPENDENT V, P165; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Osawa M, 1997, EUR J CELL BIOL, V72, P229; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENG ZY, 1995, ONCOGENE, V11, P1955; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; ROTIN D, 1992, J BIOL CHEM, V267, P9678; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sagawa K, 1997, J BIOL CHEM, V272, P13412, DOI 10.1074/jbc.272.20.13412; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; Sheibani N, 1997, MOL BIOL CELL, V8, P1329, DOI 10.1091/mbc.8.7.1329; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STONE RL, 1994, J BIOL CHEM, V269, P31323; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Varon D, 1996, TISSUE ANTIGENS, V48, pPL402; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zocchi MR, 1996, EUR J IMMUNOL, V26, P759, DOI 10.1002/eji.1830260406	62	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24868	24875		10.1074/jbc.272.40.24868	http://dx.doi.org/10.1074/jbc.272.40.24868			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312087	hybrid			2022-12-27	WOS:A1997XY97000026
J	Lu, XH; Nemoto, S; Lin, AN				Lu, XH; Nemoto, S; Lin, AN			Identification of c-Jun NH2-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; MAMMALIAN-CELLS; STRESS; PHOSPHORYLATION; EXPRESSION; MEK; RAF; CASCADE; INVITRO	c-Jun NH2-terminal protein kinase (JNK), a distant member of the mitogen-activated protein (MAP) kinase family, regulates gene expression in response to various extracellular stimuli. JNK is activated by JNK-activating kinase 1 (JNKK1), a dual specificity protein kinase that phosphorylates JNK on threonine 183 and tyrosine 185 residues. Here we show that JNKK2, a novel member of the MAP kinase kinase family, was phosphorylated and activated by MEKK1, a MAP kinase kinase kinase in the JNK signaling cascade. JNKK2 activity was also stimulated by constitutively active forms of Pac and Cdc42Hs, members of the Rho small GTP-binding protein family. Unlike JNKK1 that activates both JNK and p38 MAP kinases, JNKK2 stimulated only JNK. Transient transfection assays demonstrated that JNKK2 potentiated the stimulation of c-Jun transcriptional activity by MEKK1. The existence of multiple JNK-activating kinases may contribute to the specificity of the JNK signaling cascade.	UNIV ALABAMA,DEPT PATHOL,DIV MOL & CELLULAR PATHOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R29CA073740] Funding Source: NIH RePORTER; NCI NIH HHS [CA73740] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1992, J BIOL CHEM, V267, P25628; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	40	106	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24751	24754		10.1074/jbc.272.40.24751	http://dx.doi.org/10.1074/jbc.272.40.24751			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312068	hybrid			2022-12-27	WOS:A1997XY97000007
J	Menice, CB; Hulvershorn, J; Adam, LP; Wang, CLA; Morgan, KG				Menice, CB; Hulvershorn, J; Adam, LP; Wang, CLA; Morgan, KG			Calponin and mitogen-activated protein kinase signaling in differentiated vascular smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHORYLATION; ESTER-INDUCED CONTRACTION; MYOSIN PHOSPHORYLATION; INTRACELLULAR CALCIUM; CALDESMON; FORCE; CELLS; CA2+	Contraction of smooth muscle cells is generally assumed to require Ca2+/calmodulin-dependent phosphorylation of the 20-kDa myosin light chains. However, we report here that in the absence of extracellular calcium, phenylephrine induces a contraction of freshly isolated ferret aorta cells in the absence of increases in intracellular ionized calcium or light chain phosphorylation levels but in the presence of activation of mitogen-activated protein kinase. A protein at 36 kDa co-immunoprecipitated with the mitogen-activated protein kinase and was identified as the actin-binding protein, calponin, by immunoblot. An overlay assay further confirmed an interaction between the kinase and calponin, even though the kinase did not phosphorylate calponin in vitro. Calponin also co-immunoprecipitated from smooth muscle cells with protein kinase C-epsilon. High resolution digital confocal studies indicated that calponin redistributes to the cell membrane during phenylephrine stimulation at a time when mitogen-activated protein kinase and protein kinase C-epsilon are targeted to the plasmalemma. These results suggest a role for calponin as a signaling molecule, possibly an adapter protein, linking the targeting of mitogen-activated protein kinase and protein kinase C-epsilon to the surface membrane.	BOSTON BIOMED RES INST,SIGNAL TRANSDUCT GRP,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02215; BETH ISRAEL DEACONESS MED CTR,BOSTON,MA 02215	Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center				Morgan, Kathleen/0000-0003-3300-3630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056035, R01HL031704, R01HL042293] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42293, HL56035, HL31704] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM LP, 1989, J BIOL CHEM, V264, P7698; ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CHATTERJEE M, 1986, AM J PHYSIOL, V251, pC356, DOI 10.1152/ajpcell.1986.251.3.C356; COLLINS EM, 1992, AM J PHYSIOL, V262, pH754, DOI 10.1152/ajpheart.1992.262.3.H754; DANTHULURI NR, 1984, BIOCHEM BIOPH RES CO, V125, P1103, DOI 10.1016/0006-291X(84)91397-4; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; Gerthoffer WT, 1996, J PHYSIOL-LONDON, V495, P597, DOI 10.1113/jphysiol.1996.sp021619; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; Horowitz A, 1996, AM J PHYSIOL-HEART C, V270, pH1858, DOI 10.1152/ajpheart.1996.270.5.H1858; Horowitz A, 1996, AM J PHYSIOL-CELL PH, V271, pC589, DOI 10.1152/ajpcell.1996.271.2.C589; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; ITOH T, 1995, J BIOL CHEM, V270, P20400, DOI 10.1074/jbc.270.35.20400; JIANG MJ, 1987, AM J PHYSIOL, V253, pH1365, DOI 10.1152/ajpheart.1987.253.6.H1365; JIANG MJ, 1989, PFLUG ARCH EUR J PHY, V413, P637, DOI 10.1007/BF00581814; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KHALIL RA, 1993, AM J PHYSIOL, V265, pC406, DOI 10.1152/ajpcell.1993.265.2.C406; KHALIL RA, 1995, CIRC RES, V76, P1101, DOI 10.1161/01.RES.76.6.1101; MABUCHI K, 1996, J MUSCLE RES CELL M, V17, P1; MORGAN JP, 1982, PFLUG ARCH EUR J PHY, V395, P75, DOI 10.1007/BF00584972; PARKER CA, 1994, AM J PHYSIOL-CELL PH, V267, pC1262, DOI 10.1152/ajpcell.1994.267.5.C1262; RASMUSSEN H, 1984, BIOCHEM BIOPH RES CO, V122, P776, DOI 10.1016/S0006-291X(84)80101-1; REMBOLD CM, 1988, AM J PHYSIOL, V255, pC719, DOI 10.1152/ajpcell.1988.255.6.C719; RUZYCKY AL, 1989, BRIT J PHARMACOL, V97, P391, DOI 10.1111/j.1476-5381.1989.tb11966.x; SINGER HA, 1987, J PHARMACOL EXP THER, V243, P814; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	29	110	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25157	25161		10.1074/jbc.272.40.25157	http://dx.doi.org/10.1074/jbc.272.40.25157			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312127	hybrid			2022-12-27	WOS:A1997XY97000066
J	Schaller, MD; Sasaki, T				Schaller, MD; Sasaki, T			Differential signaling by the focal adhesion kinase and cell adhesion kinase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; INTEGRIN-DEPENDENT PHOSPHORYLATION; SWISS 3T3 CELLS; LYSOPHOSPHATIDIC ACID; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; PAXILLIN; ACTIVATION; PP125(FAK); IDENTIFICATION	pp125(FAK) and CAK beta/Pyk2/CadTK/RAFTK are related protein-tyrosine kinases. It is therefore of interest whether CAK beta shares some of the properties of pp125(FAK). Using recombinant glutathione S-transferase fusion proteins, we show that the C-terminal domains of both proteins bind paxillin in vitro. The C-terminal domain of CAK beta was engineered to be autonomously expressed in chicken embryo cells and, like pp125(FAK) and p41/43(FRNK) (the C-terminal noncatalytic domain of pp125(FAK)) was found to localize to cellular focal adhesions. In contrast, full-length CAK beta was generally found diffusely distributed throughout the cell, although a fraction of the cells exhibited focal adhesion localization. Vanadate treatment of pp125(FAK) and CAK beta-overexpressing CE cells induced a dramatic increase in the phosphotyrosine content of a common set of proteins including tensin, paxillin, and p130(Cas), but some of these substrates, particularly p130(Cas), appeared to be differentially phosphorylated by pp125(FAK) and CAK beta. Levels of tyrosine phosphorylation were higher in CAK beta-overexpressing cells, and additional phosphotyrosine-containing species were specifically immunoprecipitated, In addition, vanadate treatment of CE cells overexpressing CAK beta, but not pp125(FAK) overexpressors, induced a profound morphological change, which could be a consequence of the observed differences in substrate phosphorylation.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; SAPPORO MED INST,CANC RES INST,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	University of North Carolina; University of North Carolina Chapel Hill	Schaller, MD (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,534 TAYLOR HALL,CB 7090,CHAPEL HILL,NC 27599, USA.							ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; HUGHES HS, 1987, J VIROL, V62, P3004; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	51	105	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25319	25325		10.1074/jbc.272.40.25319	http://dx.doi.org/10.1074/jbc.272.40.25319			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312150	hybrid			2022-12-27	WOS:A1997XY97000089
J	Yamaguchi, T; Yamamoto, A; Furuno, A; Hatsuzawa, K; Tani, K; Himeno, M; Tagaya, M				Yamaguchi, T; Yamamoto, A; Furuno, A; Hatsuzawa, K; Tani, K; Himeno, M; Tagaya, M			Possible involvement of heterotrimeric G proteins in the organization of the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; ETHYLMALEIMIDE-SENSITIVE FACTOR; GTP-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; COATED VESICLES; ALPHA-SUBUNITS; BREFELDIN-A; HELA-CELLS; MITOTIC FRAGMENTATION; EPITHELIAL-CELLS	Nordihydroguaiaretic acid (NDGA) caused disassembly of the Golgi apparatus of NRK cells in a dose-, time-, and energy-dependent manner but not in a microtubule-dependent manner. In contrast to brefeldin A, NDGA did not cause release of beta-COP, a component of Golgi-derived vesicles. However, NDGA-induced disassembly was blocked by AlF4-, an activator of the heterotrimeric but not the small GTP-binding proteins. In digitonin-permeabilized cells, guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) as well as AlF4- blocked the NDGA-promoted disassembly of the Golgi apparatus, and G beta gamma (beta gamma subunits of heterotrimeric G proteins) reversed this effect. Our present results suggest the possible involvement of heterotrimeric G proteins in the organization of the Golgi apparatus.	TOKYO UNIV PHARM & LIFE SCI, SCH LIFE SCI, HACHIOJI, TOKYO 19203, JAPAN; KYUSHU UNIV, FAC PHARMACEUT SCI, DIV PHYSIOL CHEM, HIGASHI KU, FUKUOKA 81282, JAPAN; KANSAI MED UNIV, DEPT PHYSIOL, MORIGUCHI, OSAKA 570, JAPAN	Tokyo University of Pharmacy & Life Sciences; Kyushu University; Kansai Medical University								ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; ADAM SA, 1991, METHOD CELL BIOL, V35, P469; ASANO T, 1993, J BIOL CHEM, V268, P20512; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DIAZ R, 1989, METHOD CELL BIOL, V31, P25; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Nurnberg B, 1996, FEBS LETT, V389, P61, DOI 10.1016/0014-5793(96)00584-4; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PUSCHEL AW, 1994, FEBS LETT, V347, P55, DOI 10.1016/0014-5793(94)00505-2; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAGAYA M, 1993, FEBS LETT, V324, P201, DOI 10.1016/0014-5793(93)81393-E; Tagaya M, 1996, J BIOCHEM, V119, P863; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; VEIT B, 1993, J CELL BIOL, V122, P1197, DOI 10.1083/jcb.122.6.1197; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	55	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25260	25266		10.1074/jbc.272.40.25260	http://dx.doi.org/10.1074/jbc.272.40.25260			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312142	hybrid			2022-12-27	WOS:A1997XY97000081
J	Fautsch, MP; Perdok, MM; Wieben, ED				Fautsch, MP; Perdok, MM; Wieben, ED			Production of SVP-1/-3/-4 in guinea pig testis - Characterization of novel transcripts containing long 5'-untranslated regions and multiple upstream AUG codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMINAL-VESICLE; MESSENGER-RNA; SECRETORY PROTEIN; HUMAN-SEMEN; GENE; TRANSLATION; SEQUENCES; IDENTIFICATION; SEMENOGELIN; INITIATION	The GP1G gene of the guinea pig codes for three of the four abundant seminal vesicle secretory proteins produced in this species, This gene is expressed at highest efficiency in the seminal vesicle (SV) from a promoter that contains a canonical TATA box and CCAAT box. However, GP1G gene transcripts and proteins have also been identified in other tissues. To investigate the structure of GP1G transcripts produced in the testis, cDNA clones were isolated by screening a testis library. Three unique cDNAs (TSM1-3) were isolated. Each of these clones contained a 3'-untranslated region (UTR) and coding region identical to that of the seminal vesicle transcript. However, the 5'-UTRs of the testis transcripts were significantly longer than that found on the SV mRNA (416-646 nucleotides compared with only 23 nucleotides for the SV). Each of these alternatively spliced 5'-UTRs incorporated the SV promoter elements into transcribed sequence, and each contained multiple upstream AUG codons predicted to abolish translation of the major open reading frame. Nevertheless, each of the testis transcripts was capable of directing the synthesis of GP1G-related proteins in vitro. Analysis of the translation products suggests that the extended 8'-UTR of the testis transcripts regulate both the choice of translation start site and the efficiency of translation in this system. Western blot analysis of testis proteins revealed that the protein products of GP1G are also synthesized by the testis in vivo.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	Mayo Clinic								Aumuller G, 1990, Int Rev Cytol, V121, P127, DOI 10.1016/S0074-7696(08)60660-9; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DODD JG, 1986, MOL CELL ENDOCRINOL, V47, P191, DOI 10.1016/0303-7207(86)90112-7; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; HAGSTROM JE, 1989, MOL ENDOCRINOL, V3, P1797, DOI 10.1210/mend-3-11-1797; Hagstrom JE, 1996, J BIOL CHEM, V271, P21114, DOI 10.1074/jbc.271.35.21114; HARRIS SE, 1990, J BIOL CHEM, V265, P9896; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; JANUSZESKI MM, 1994, ENDOCRINOLOGY, V134, P1859, DOI 10.1210/en.134.4.1859; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1978, J BIOL CHEM, V253, P6568; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lundwall A, 1996, BIOCHEM BIOPH RES CO, V221, P323, DOI 10.1006/bbrc.1996.0594; Lundwall A, 1996, EUR J BIOCHEM, V235, P424, DOI 10.1111/j.1432-1033.1996.00424.x; MEZQUITA J, 1994, GENE, V147, P231, DOI 10.1016/0378-1119(94)90072-8; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; NORVITCH ME, 1988, BIOL REPROD, V38, P1155, DOI 10.1095/biolreprod38.5.1155; NOTIDES AC, 1967, P NATL ACAD SCI USA, V58, P1991, DOI 10.1073/pnas.58.5.1991; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; PLUCKTHUN A, 1987, J BIOL CHEM, V262, P3951; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; ULVSBACK M, 1992, J BIOL CHEM, V267, P18080; VENEZIALE CM, 1976, ANDROLOGIA, V8, P73; WILLIAMS.HG, 1972, P NATL ACAD SCI USA, V69, P2322, DOI 10.1073/pnas.69.8.2322; WILLIAMSASHMAN HG, 1983, CURR TOP CELL REGUL, V22, P201; YOCWARREN H, 1993, J EXP ZOOL, V265, P653; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	34	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24691	24695		10.1074/jbc.272.39.24691	http://dx.doi.org/10.1074/jbc.272.39.24691			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305940	hybrid			2022-12-27	WOS:A1997XY51500091
J	Gudz, TI; Tserng, KY; Hoppel, CL				Gudz, TI; Tserng, KY; Hoppel, CL			Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; LIVER-MITOCHONDRIA; ELECTRON-TRANSFER; CYTOTOXICITY; INVOLVEMENT; REPERFUSION; GENERATION; METABOLISM; MUSCLE	Ceramide is a lipid second messenger that mediates the effects of tumor necrosis factor a! and other agents on cell growth and differentiation, Ceramide is believed to act via activation of protein phosphatase, proline-directed protein kinase, or protein kinase C, Tumor necrosis factor alpha-induced common pathway of apoptosis is associated with am early impairment of mitochondria. Herein, we demonstrate that ceramide earn directly inhibit mitochondrial respiratory chain function, In isolated mitochondria, a rapid decline of mitochondrial oxidative phosphorylation occurs in the presence of N-acetylsphingosine (C-2-ceramide), a synthetic cell-permeable ceramide analog. An investigation of the Bite of ceramide action revealed that tbe activity of respiratory chain complex III is reduced by C-2-ceramide with half-maximum effect al 5-7 PM. in contrast, N-acetylsphinganine (C-2-dihydroceramide), which lacks a functionally critical double bond and is ineffective in cells, did not alter mitochondrial respiration or complex III activity. We suggest that these in vitro observations may set the stage for identifying a novel mechanism of regulation of mitochondrial function in vivo.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT NUTR,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Gudz, TI (corresponding author), VET AFFAIRS MED CTR,MED RES SERV,10701 EAST BLVD,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK036069, R01DK036069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012447] Funding Source: NIH RePORTER; NIA NIH HHS [AG12447] Funding Source: Medline; NIDDK NIH HHS [DK36069] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gudz T, 1997, ARCH BIOCHEM BIOPHYS, V342, P143, DOI 10.1006/abbi.1997.0113; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; Gurevitch J, 1996, J AM COLL CARDIOL, V28, P247, DOI 10.1016/0735-1097(96)00105-2; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOPPEL C, 1979, J BIOL CHEM, V254, P4164; Jia L, 1996, BLOOD, V87, P2401, DOI 10.1182/blood.V87.6.2401.bloodjournal8762401; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; KRAHENBUHL S, 1994, CLIN CHIM ACTA, V230, P177, DOI 10.1016/0009-8981(94)90270-4; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LUI J, 1994, J BIOL CHEM, V269, P3047; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PALMER JW, 1977, J BIOL CHEM, V252, P8731; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROMANI A, 1991, J BIOL CHEM, V266, P24376; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; TAYLOR RW, 1994, J BIOL CHEM, V269, P3523; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211	33	349	353	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24154	24158		10.1074/jbc.272.39.24154	http://dx.doi.org/10.1074/jbc.272.39.24154			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305864	hybrid			2022-12-27	WOS:A1997XY51500015
J	Seyfang, A; Kavanaugh, MP; Landfear, SM				Seyfang, A; Kavanaugh, MP; Landfear, SM			Aspartate 19 and glutamate 121 are critical for transport function of the myo-inositol/H+ symporter from Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENTS; GLUCOSE-TRANSPORTER; ESCHERICHIA-COLI; MELIBIOSE PERMEASE; ACIDIC RESIDUES; EXPRESSION; BINDING; PROMASTIGOTES; MUTAGENESIS; FAMILY	The protozoan flagellate Leishmania donovani has an active myo-inositol/proton symporter (MIT), which is driven by a proton gradient across the parasite membrane. We have used site-directed mutagenesis in combination with functional expression of transporter mutants in Xenopus oocytes and overexpression in Leishmania transfectants to investigate the significance of acidic transmembrane residues for proton relay and inositol transport, MIT has only three charged amino acids within predicted transmembrane domains. Two of these residues, Asp(19) (TM1) and Glu(121) (TM4), appeared to be critical for transport function of MIT, with a reduction of inositol transport to about 2% of wild-type activity when mutated to the uncharged amides D19N or E121Q and 20% (D19E) or 4% (E121D) of wild-type activity for the conservative mutations that retained tare charge. Immunofluorescence microscopy oocyte cryosections showed that MIT mutants were expressed on the oocyte surface at a similar level as MIT wild type, confirming that these mutations that transport function and do not prevent trafficking of the transporter to the plasma membrane, The proton uncouplers carbonylcyanide-4-(trifluor omethoxy)phenylhydrazone and dinitrophenol inhibited inositol transport by 50-70% in the wild-type as well as in E121Q, despite its reduced transport activity. The mutant D19N, however, was stimulated about 4-fold by either protonophore and 2-fold bg cyanide or increase of pH 7.5 to 8.5 but inhibited at pH 6.5. The conservative mutant D19E, ire contrast, showed an inhibition profile similar to MIT wild type. We conclude that Asp(19) and Glu(121) are critical for myo-inositol transport, while the negatively charged carboxylate at Asp(19) may be important for proton coupling of MIT.	OREGON HLTH SCI UNIV, DEPT MOL MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			Seyfang, Andreas/H-2445-2012	Landfear, Scott/0000-0002-1643-6664; Seyfang, Andreas/0000-0001-6231-9955	NIAID NIH HHS [AI01162, AI25920] Funding Source: Medline; NIGMS NIH HHS [GM48709] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALVAR J, 1994, PARASITOL TODAY, V10, P160, DOI 10.1016/0169-4758(94)90270-4; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; DEGORGOLAS M, 1994, NATURE, V372, P734, DOI 10.1038/372734b0; DREW ME, 1995, MOL CELL BIOL, V15, P5508; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FERGUSON MAJ, 1994, PARASITOLOGY, V108, pS45, DOI 10.1017/S0031182000075715; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; Henderson PJF, 1991, CURR OPIN STRUC BIOL, V1, P590, DOI 10.1016/S0959-440X(05)80082-X; HUTCHISON CA, 1991, METHOD ENZYMOL, V202, P356; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; KABACK R, 1992, MOL BIOL RECEPTORS T, P97; KEITHLY JS, 1976, J PROTOZOOL, V23, P244, DOI 10.1111/j.1550-7408.1976.tb03763.x; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; Lachaal M, 1996, J BIOL CHEM, V271, P5225; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; LANGFORD CK, 1992, MOL BIOCHEM PARASIT, V55, P51, DOI 10.1016/0166-6851(92)90126-5; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MANCINI GMS, 1990, J BIOL CHEM, V265, P12380; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; PIPER RC, 1995, J CELL BIOL, V128, P499, DOI 10.1083/jcb.128.4.499; POURCHER T, 1993, J BIOL CHEM, V268, P3209; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TITUS DE, 1991, PROMEGA PROTOCOLS AP, P98; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wu JH, 1996, BIOCHEMISTRY-US, V35, P5213, DOI 10.1021/bi960064f; ZANI ML, 1993, J BIOL CHEM, V268, P3216; Zar JH, 1984, BIOSTAT ANAL, P150; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013	42	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24210	24215		10.1074/jbc.272.39.24210	http://dx.doi.org/10.1074/jbc.272.39.24210			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305873	hybrid			2022-12-27	WOS:A1997XY51500024
J	DeCesare, D; Palazzolo, M; Berthelsen, J; Blasi, F				DeCesare, D; Palazzolo, M; Berthelsen, J; Blasi, F			Characterization of UEF-4, a DNA-binding protein required for transcriptional synergism between two AP-1 sites in the human urokinase enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR GENE; COLONY-STIMULATING FACTOR; PHORBOL ESTER INDUCTION; REGULATORY ELEMENT; RNA-POLYMERASE; C-JUN; EXPRESSION; MOUSE; INTERLEUKIN-3; PROMOTERS	The enhancer of the inducible urokinase gene depends on three essential but not sufficient transactivating elements, an upstream PEA3/AP-1A and a downstream AP-1B site. Enhancer activity also requires the interposed 74-base pair-long cooperation mediator (COM) region that allows transcriptional synergism between the transactivating sites. The 5'-half of COM (uCOM) forms four retarded complexes with HeLa or Hep-G2 nuclear proteins (UEF-1-4). We have identified the binding sequence for UEF-4 and generated uCOM elements uniquely mutated in the UEF-4-binding site or uniquely binding UEF-4. Introduction of these and other mutations in the context of the urokinase enhancer showed that all uCOM sites are important for enhancer activity but that UEF-4 and UEF-1 plus UEF-2/3 can substitute for each other, suggesting functional redundancy of urokinase enhancer factors. UEF-4 was purified from HeLa nuclear extract by affinity chromatography and shown to contain two polypeptides of 105 and 65 kDa, respectively, of which at least the former was endowed with DNA binding activity.	HS RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICROORGANISMI,MILAN,ITALY	University of Milan				Blasi, Francesco/0000-0001-9406-1784				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; BLASI F, 1994, FIBRINOLYSIS, V8, P182, DOI 10.1016/0268-9499(94)90716-1; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DECESARE D, 1995, ONCOGENE, V11, P365; DeCesare D, 1996, ONCOGENE, V13, P2551; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LU QA, 1995, MOL CELL BIOL, V15, P3786; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Sambrook J., 2002, MOL CLONING LAB MANU; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Teesalu T, 1996, MECH DEVELOP, V56, P103, DOI 10.1016/0925-4773(96)00515-1; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WIGLER M, 1976, NATURE, V259, P232, DOI 10.1038/259232a0	33	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23921	23929		10.1074/jbc.272.38.23921	http://dx.doi.org/10.1074/jbc.272.38.23921			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295342	hybrid			2022-12-27	WOS:A1997XX38100067
J	Mitsuda, N; Roses, AD; Vitek, MP				Mitsuda, N; Roses, AD; Vitek, MP			Transcriptional regulation of the mouse presenilin-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; SYNAPSIN-II GENE; APOLIPOPROTEIN-E; DISTINCT PROMOTERS; TYPE-4 ALLELE; MUTATIONS; PROTEIN; EXPRESSION; DIFFERENTIATION; BINDING	The presenilin-1 (PS-1) gene encodes at least three separate mRNA transcripts from its 12 exons, which are spread over 50 kilobase pairs of mouse DNA. The first transcript begins with exon 1A, whereas the other transcripts begin with exon 1B. Different portions of exon 1B are spliced to give long and short mRNAs. The expression of all of these transcripts depends on a single promoter located just upstream of exon 1A. Although this region lacks a TATA box and a number of common initiator sequences, it does contain a CAAT box, a heat-shock responsive element, a polyomavirus enhancer activator-3 site, an Ets 1-3 site, and multiple-Sp1 and multiple-Ap2 binding sites, which are typically found in eukaryotic promoters. We have combined a reporter gene with various portions of this putative PS-1 promoter and measured firefly luciferase activity relative to an internal renilla luciferase standard. We identified a 25-base pair fragment spanning the 5'-transcription start site of exon 1A as containing the core of the promoter activity. The sequences downstream of this region had undetectable promoter activity, suggesting that this core element is the gene's only promoter, and it controls expression of all three transcripts. Although human PS-1 mRNA expression is clearly different from the mouse PS-1 mRNA pattern, the human and mouse core promoters do share limited homology.	DUKE UNIV,MED CTR,DIV NEUROL,DURHAM,NC 27710; GLAXO WELLCOME INC,DEPT MOL PHARMACOL,RES TRIANGLE PK,NC 27709	Duke University; GlaxoSmithKline				Vitek, Michael/0000-0001-8140-8048	NATIONAL INSTITUTE ON AGING [R01AG013839] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG-13839] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBERT VR, 1992, P NATL ACAD SCI USA, V89, P12053, DOI 10.1073/pnas.89.24.12053; *ALZH DIS COLL GRO, 1995, NAT GENET, V11, P219; Boteva K, 1996, LANCET, V347, P130, DOI 10.1016/S0140-6736(96)90261-5; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FISHER RJ, 1991, ONCOGENE, V6, P2249; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; Kamino K, 1996, NEUROSCI LETT, V208, P195, DOI 10.1016/0304-3940(96)12587-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lah JJ, 1997, J NEUROSCI, V17, P1971; LEINGARTNER A, 1994, EUR J NEUROSCI, V6, P1149, DOI 10.1111/j.1460-9568.1994.tb00613.x; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; PerezTur J, 1995, NEUROREPORT, V7, P297; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; Rossor MN, 1996, LANCET, V347, P1560, DOI 10.1016/S0140-6736(96)90715-1; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1995, J BIOL CHEM, V270, P10314, DOI 10.1074/jbc.270.17.10314; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P775, DOI 10.1001/jama.277.10.775; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TENHUNEN J, 1994, EUR J BIOCHEM, V223, P1049, DOI 10.1111/j.1432-1033.1994.tb19083.x; WASCO W, 1995, NAT MED, V1, P848, DOI 10.1038/nm0995-848a	30	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23489	23497		10.1074/jbc.272.38.23489	http://dx.doi.org/10.1074/jbc.272.38.23489			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295283	hybrid			2022-12-27	WOS:A1997XX38100008
J	Poluha, W; Schonhoff, CM; Harrington, KS; Lachyankar, MB; Crosbie, NE; Bulseco, DA; Ross, AH				Poluha, W; Schonhoff, CM; Harrington, KS; Lachyankar, MB; Crosbie, NE; Bulseco, DA; Ross, AH			A novel, nerve growth factor-activated pathway involving nitric oxide, p53, and p21(WAF1) regulates neuronal differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; INDUCED APOPTOSIS; NADPH DIAPHORASE; HUMAN NEUROBLASTOMA; FACTOR INCREASES; GENE-EXPRESSION; CANCER-CELLS; WILD-TYPE; INDUCTION	During development, neuronal differentiation is closely coupled with cessation of proliferation. We use nerve growth factor (NGF)-induced differentiation of PC12 pheochromocytoma cells as a model and find a novel signal transduction pathway that blocks cell proliferation, Treatment of PC12 cells with. NGF leads to induction of nitric oxide synthase (NOS) (Peunova, N., and Enikolopov, G. (1995) Nature 375, 68-73). The result ing nitric oxide (NO) acts as a second messenger, activating the p21(WAF1) promoter and inducing expression of p21(WAF1) cyclin-dependent kinase inhibitor. NO activates the p21(WAF1) promoter by p53-dependent and p53-independent mechanisms. Blocking production of NO with an inhibitor of NOS reduces accumulation of p53, activation of the p21(WAF1) promoter, expression of neuronal markers, and neurite extension. To determine whether p21(WAF1) is required for neurite extension, we prepared a PC12 line with an inducible p21(WAF1) expression vector. Blocking NOS with an inhibitor decreases neurite extension, but induction of p21(WAF1) with isopropyl-1-thio-beta-D-galactopyranoside restored this response, Levels of p21(WAF1) induced by isopropyl-1-thio-beta-D-galactopyranoside were similar to those induced by NGF. Therefore, we have identified a signal transduction pathway that is activated by NGF; proceeds through NOS, p53, and p21(WAF1) to block cell proliferation; and is required for neuronal differentiation by PC12 cells.	WORCESTER FDN EXPT BIOL INC, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028760, R01NS021716] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-07366, NS-28760, NS-21716] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bevington PR, 1992, DATA REDUCTION ERROR; Billon N, 1996, ONCOGENE, V13, P2047; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5404, DOI 10.1073/pnas.82.16.5404; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Flodstrom M, 1996, FEBS LETT, V385, P4, DOI 10.1016/0014-5793(96)00337-7; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; Gotz C, 1996, ONCOGENE, V13, P391; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAINAUT P, 1993, CANCER RES, V53, P4469; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HENDERSON LP, 1994, J NEUROSCI, V14, P1153, DOI 10.1523/JNEUROSCI.14-03-01153.1994; HIRSCH DB, 1993, CURR BIOL, V3, P749, DOI 10.1016/0960-9822(93)90022-G; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Holtzman DM, 1996, NEUROCHEM RES, V21, P861, DOI 10.1007/BF02532310; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; Ientile R, 1996, FEBS LETT, V379, P82, DOI 10.1016/0014-5793(95)01490-X; JIANG HP, 1994, ONCOGENE, V9, P3397; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOGNER P, 1993, CANCER RES, V53, P2044; KOMURO H, 1993, CANCER RES, V53, P5284; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LAASBERG T, 1988, FEBS LETT, V239, P367, DOI 10.1016/0014-5793(88)80953-0; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOPRESTI P, 1992, CELL GROWTH DIFFER, V3, P627; LUCA FC, 1986, P NATL ACAD SCI USA, V83, P1006, DOI 10.1073/pnas.83.4.1006; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, FEBS LETT, V384, P162; Messmer UK, 1996, ARCH BIOCHEM BIOPHYS, V327, P1, DOI 10.1006/abbi.1996.0085; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MESSMER UK, 1994, FEBS LETT, V355, P23; MICHIELI P, 1994, CANCER RES, V54, P3391; MIZUKAWA K, 1989, J COMP NEUROL, V279, P281, DOI 10.1002/cne.902790210; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Ockel M, 1996, DEVELOPMENT, V122, P301; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; TOHYAMA T, 1991, J COMP NEUROL, V310, P285, DOI 10.1002/cne.903100302; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; VOGAN K, 1993, CANCER RES, V53, P5269; WOOD JN, 1995, NEUROSCI LETT, V192, P41, DOI 10.1016/0304-3940(95)11603-T; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE QW, 1994, J BIOL CHEM, V269, P4705; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	79	136	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24002	24007		10.1074/jbc.272.38.24002	http://dx.doi.org/10.1074/jbc.272.38.24002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295352	hybrid			2022-12-27	WOS:A1997XX38100077
J	Wilkinson, JR; Towle, HC				Wilkinson, JR; Towle, HC			Identification and characterization of the AF-1 transactivation domain of thyroid hormone receptor beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION FUNCTIONS; RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; V-ERBA; CO-REPRESSOR; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR	Physiological responses to thyroid hormones are regulated by a set of nuclear receptors (TRs) related to the steroid receptor superfamily of ligand-dependent transcription factors. Although TR isoforms are highly conserved in their DNA binding, ligand binding, and carboxyl-terminal transactivation domains, their aminoterminal regions are completely divergent. We examined the contribution of these amino-terminal sequences to TR beta 1 function. An amino-terminally truncated version of rat TR beta 1 lacking amino acids 4-89 was impaired in hormone-dependent activation in both yeast and mammalian cells. This defect was not due to impairment of DNA binding, because the truncated receptor displayed enhanced homodimer binding on several different TREs, indicating that residues in the amino-terminal domain of TR beta 1 interfere with homodimerization of the receptor. The presence of an autonomous transactivation domain in the amino-terminal region was demonstrated by its ability to activate transcription in a constitutive manner when fused to the GAL4 DNA binding domain, Deletional analyses localized the residues comprising the amino-terminal transactivation region of TR beta 1 to 19 amino acids residing between residues 69 and 89. Thus, the amino-terminal region of TR beta 1 contains an activation domain (AF-1) that call modulate the function of the receptor and may allow for the fine-tuning of receptor activity in various target tissues.	UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007323] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39997] Funding Source: Medline; NIGMS NIH HHS [5T32-GM07323] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1986, MOL CELL BIOL, V6, P3685, DOI 10.1128/MCB.6.11.3685; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; LEE Y, 1993, J BIOL CHEM, V268, P2021; LIN KH, 1990, J BIOL CHEM, V265, P5161; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; OHASHI H, 1991, BIOCHEM BIOPH RES CO, V178, P1167, DOI 10.1016/0006-291X(91)91015-5; ONATE SA, 1995, SCIENCE, V270, P1354; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; QI JS, 1995, MOL CELL BIOL, V15, P1817; Rahman A, 1995, J BIOL CHEM, V270, P31059, DOI 10.1074/jbc.270.52.31059; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; TOMURA H, 1995, P NATL ACAD SCI USA, V92, P5600, DOI 10.1073/pnas.92.12.5600; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	66	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23824	23832		10.1074/jbc.272.38.23824	http://dx.doi.org/10.1074/jbc.272.38.23824			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295330	hybrid			2022-12-27	WOS:A1997XX38100055
J	Nigou, J; Gilleron, M; Cahuzac, B; Bounery, JD; Herold, M; Thurnher, M; Puzo, G				Nigou, J; Gilleron, M; Cahuzac, B; Bounery, JD; Herold, M; Thurnher, M; Puzo, G			The phosphatidyl-myo-inositol anchor of the lipoarabinomannans from Mycobacterium bovis bacillus Calmette Guerin - Heterogeneity, structure, and role in the regulation of cytokine secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MACROPHAGES; TUBERCULOSIS; STRAINS; SPECTROSCOPY; VIRULENT; PROTEINS; BCG; PERSISTENCE	Lipoarabinomannans are major mycobacterial antigens capable of modulating the host immune response; however, the molecular basis underlying the diversity of their immunological properties remain an open question. In this study a new extraction and purification approach was successfully applied to isolate ManLAMs (lipoarabinomannans with mannosyl extensions) from bacillus Calmette Guerin leading to the obtention of two types of ManLAMs namely parietal and cellular, Structurally, they were found to differ by the percentage of mannooligosaccharide caps, 76 and 48%, respectively, and also, thanks to a new analytical method, by the structure of the phasphatidyl-myo-inositol anchor lipid moiety, A novel fatty acid in the mycobacterium genus assigned to a 12-O-(methoxypropanoyl)-12-hydroxystearic acid was the only fatty acid esterifying C-1 of the glycerol residue of the parietal ManLAMs, while the phosphatidyl unit of the cellular ManLAMs showed a large heterogeneity due to a combination of palmitic and tuberculostearic acid. Finally, parietal and cellular ManLAMs were found to differentially affect interleukin-8 and tumor necrosis factor-alpha secretion from human dendritic cells. We show that parietal but not cellular ManLAMs were able to stimulate tumor necrosis factor-alpha secretion from dendritic cells, From these studies we propose that the 1-[12-O-(methoxypropanoyl)-12-hydroxystearoyl]-sn-glycerol part is the major cytokine-regulating component of the ManLAMs, It seems likely that modification of the ManLAM Lipid part, which may occur in hostile environments, could regulate macrophagic mycobacterial survival by altering cytokine stimulation.	CNRS, INST PHARMACOL & BIOL STRUCT, F-31062 TOULOUSE, FRANCE; UNIV INNSBRUCK, DEPT UROL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Innsbruck; University of Innsbruck			Nigou, Jérôme/D-6802-2019; Thurnher, Martin/AAD-5922-2020	Nigou, Jérôme/0000-0002-6233-2487; GILLERON, Martine/0000-0002-2581-3302; Thurnher, Martin/0000-0001-9940-7326				ADAM O, 1995, ANAL BIOCHEM, V225, P321, DOI 10.1006/abio.1995.1161; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Britton Warwick J., 1994, Trends in Microbiology, V2, P284, DOI 10.1016/0966-842X(94)90005-1; BUDZIKIE.H, 1973, Z NATURFORSCH C, VC 28, P499; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DELMAS C, 1997, IN PRESS GLYCOBIOLOG, V7; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; FINE PEM, 1989, REV INFECT DIS, V11, pS353; Gilleron M, 1997, J BIOL CHEM, V272, P117; GLUSHKA J, 1992, BIOCHEMISTRY-US, V31, P10741, DOI 10.1021/bi00159a014; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Guttman A, 1996, ANAL BIOCHEM, V233, P234, DOI 10.1006/abio.1996.0034; HUNTER SW, 1990, J BIOL CHEM, V265, P14065; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MUHLRADT PF, 1977, EUR J BIOCHEM, V81, P193, DOI 10.1111/j.1432-1033.1977.tb11941.x; ROACH TIA, 1993, J IMMUNOL, V150, P1886; ROCHE PW, 1995, TRENDS MICROBIOL, V3, P397, DOI 10.1016/S0966-842X(00)88986-6; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SCHNITGER H, 1959, BIOCHEM Z, V332, P167; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SWEET DP, 1975, CARBOHYD RES, V40, P967; Thurnher M, 1997, INT J CANCER, V70, P128; VENISSE A, 1993, J BIOL CHEM, V268, P12401; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; VENISSE A, 1995, J BIOL CHEM, V270, P15012, DOI 10.1074/jbc.270.25.15012; WANG Y, 1995, ANAL BIOCHEM, V225, P242, DOI 10.1006/abio.1995.1149; ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702	38	110	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23094	23103		10.1074/jbc.272.37.23094	http://dx.doi.org/10.1074/jbc.272.37.23094			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287310	hybrid			2022-12-27	WOS:A1997XV74400021
J	Cotten, JF; Welsh, MJ				Cotten, JF; Welsh, MJ			Covalent modification of the regulatory domain irreversibly stimulates cystic fibrosis transmembrane conductance regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; CYSTEINE SCANNING MUTAGENESIS; NUCLEOTIDE-BINDING DOMAINS; R-DOMAIN; ATP HYDROLYSIS; CL CHANNELS; LACTOSE PERMEASE; ESCHERICHIA-COLI; PHOSPHORYLATION; IDENTIFICATION	The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is regulated by three cytosolic domains, the regulatory domain (R domain) and two nucleotide binding domains, To learn more about how the cytosolic domains regulate channel activity, we used chemical modification to probe their structure. When we applied the sulfhydryl-modifying reagent N-ethylmaleimide (NEM) and other N-substituted maleimides to the cytosolic domains, we found that they rapidly and irreversibly stimulated channel activity, CFTR contains 14 intracellular cysteine residues that might be targets for NEM modification. We identified one, Cys(832), that was essential for the response, Cys(832) is located in the R domain. Single channel studies showed that NEM stimulated CFTR by increasing the duration of bursts of activity and by shortening the closed interval between bursts. At the single channel level, CFTR in which Cys(832) was mutated to alanine behaved identically to wild-type CFTR, except that it failed to respond to NEM, Additional studies showed that NEM modification increased the potency of ATP-mediated stimulation. Previous work has shown that modification of the R domain by phosphorylation, which introduces negative charge, or replacement of multiple serines by negatively charged aspartates stimulates the channel. Our current data show that covalent modification of the R domain with a neutral, hydrophobic adduct at a site that is not phosphorylated can also stimulate CFTR. This finding suggests that an alteration in the conformation of the R domain may be a key feature that regulates channel activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,EMRB 500,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Iowa				Welsh, Michael/0000-0002-1646-6206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385, R37HL029851, R01HL029851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29851, HL42385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Crampton MR., 1974, CHEM THIOL GROUP, P379; DULHANTY AM, 1994, FEBS LETT, V343, P109, DOI 10.1016/0014-5793(94)80300-5; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HWANG TC, 1993, J GEN PHYSIOL, V101, P629, DOI 10.1085/jgp.101.5.629; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; WU JH, 1994, PROTEIN SCI, V3, P2294, DOI 10.1002/pro.5560031214	34	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25617	25622		10.1074/jbc.272.41.25617	http://dx.doi.org/10.1074/jbc.272.41.25617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325282	hybrid			2022-12-27	WOS:A1997YA35800037
J	Yuan, DS; Dancis, A; Klausner, RD				Yuan, DS; Dancis, A; Klausner, RD			Restriction of copper export in Saccharomyces cerevisiae to a late Golgi or post-Golgi compartment in the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; VACUOLAR H+-ATPASE; CLASS-II MOLECULES; MENKES DISEASE; CANDIDATE GENE; IRON-METABOLISM; TRANSPORTING ATPASE; PLASMA-MEMBRANE; YEAST-CELLS; FET3 GENE	The CCC2 gene in the yeast Saccharomyces cerevisiae encodes a P-type ATPase (Ccc2p) required for the export of cytosolic copper to the extracytosolic domain of a copper dependent oxidase, Fet3p. Ccc2p appears to be both a structural and functional homolog of ATPases impaired in two human disorders of intracellular copper transport, Menkes disease and Wilson disease. In the present work, three approaches were used to determine the locus of Ccc2p-dependent copper export within the secretory pathway. First, like ccc2 mutants, sec mutants blocked in the secretory pathway at steps prior to and including the Golgi complex failed to deliver radioactive copper to Fet3p. Second, also like ccc2 mutants, vps33 and certain other mutants with defects in post-Golgi sorting exhibited phenotypes traceable to deficient copper delivery to Fet3p. These findings were sufficient to explain the respiratory deficiency of these mutants. Third, immunofluorescence microscopy revealed that Ccc2p was distributed among several punctate foci within wild-type cells, consistent with late Golgi or post-Golgi localization. Thus, copper export by Ccc2p appears to be restricted to a late or post-Golgi compartment in the secretary pathway.	NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892; UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104; NCI,OFF DIRECTOR,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								[Anonymous], 1995, METABOLIC BASIS INHE; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; ASLANIDIS C, 1990, NUCLEIC ACIDS RES, V18, P6069, DOI 10.1093/nar/18.20.6069; BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Calakos N, 1996, PHYSIOL REV, V76, P1; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; CONIBEAR E, 1995, CELL, V83, P513, DOI 10.1016/0092-8674(95)90088-8; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JONES EW, 1977, GENETICS, V85, P23; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LIN CM, 1993, J GEN MICROBIOL, V139, P1617, DOI 10.1099/00221287-139-7-1617; LINDER MC, 1991, BIOCH COPPER, P4; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P381; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; RAO K, 1983, FEBS LETT, V160, P213, DOI 10.1016/0014-5793(83)80969-7; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; ROTHBLATT J, 1994, GUIDEBOOK SECRETORY; SCHOSINSKY KH, 1974, CLIN CHEM, V20, P1556; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TARTOF KD, 1987, FOCUS, V9, P12; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WILSBACH K, 1993, EMBO J, V12, P3049, DOI 10.1002/j.1460-2075.1993.tb05974.x; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404; YAVER DS, 1993, J BIOL CHEM, V268, P10564; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	60	133	137	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25787	25793		10.1074/jbc.272.41.25787	http://dx.doi.org/10.1074/jbc.272.41.25787			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325307	hybrid			2022-12-27	WOS:A1997YA35800062
J	Modrich, P				Modrich, P			Strand-specific mismatch repair in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MICROSATELLITE INSTABILITY; DNA-REPLICATION; TUMOR-CELLS; METHYLATION DAMAGE; COLORECTAL-CANCER; MUTATOR PHENOTYPE; NUCLEAR EXTRACTS; DEFICIENCY; PROTEIN; LINES		DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University	Modrich, P (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.			Modrich, Paul/0000-0001-8708-9885				Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Aebi S, 1996, CANCER RES, V56, P3087; ALLEN DJ, 1997, IN PRESS FASEB J, V16; AQUILINA G, 1995, CANCER RES, V55, P2569; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6063; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Eshleman JR, 1996, ONCOGENE, V12, P1425; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FANG WH, 1993, THESIS DUKE U; FISHEL R, 1994, CANCER RES, V54, P5539; FRIEDMAN HS, 1997, IN PRESS CANC RES, V57; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; HAWN MT, 1995, CANCER RES, V55, P3721; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JOHNSON RE, 1996, J BIOL CHEM, V271, P7255; Kane MF, 1997, CANCER RES, V57, P808; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KATABUCHI H, 1995, CANCER RES, V55, P5556; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOI M, 1994, CANCER RES, V54, P4308; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LOEB LA, 1974, CANCER RES, V34, P2311; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Matic I, 1996, TRENDS MICROBIOL, V4, P69, DOI 10.1016/0966-842X(96)81514-9; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MODRICH P, 1997, ACCOMPLISHMENTS CANC; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	62	198	215	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24727	24730		10.1074/jbc.272.40.24727	http://dx.doi.org/10.1074/jbc.272.40.24727			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312062	hybrid			2022-12-27	WOS:A1997XY97000001
J	Pak, Y; ODowd, BF; George, SR				Pak, Y; ODowd, BF; George, SR			Agonist-induced desensitization of the mu opioid receptor is determined by threonine 394 preceded by acidic amino acids in the COOH-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 3RD INTRACELLULAR LOOP; RHODOPSIN KINASE; PHOSPHORYLATION SITES; IN-VIVO; IDENTIFICATION; MECHANISMS; INVOLVEMENT; EXPRESSION; SUBTYPES	To identify the structural determinants necessary for mu opioid receptor desensitization, we serially ablated potential phosphorylation sites in the carboxyl tail of the receptor and examined their effects on [D-Ala(2),N-Me-Phe(4),Gly-ol(5)]lenkephalin (DAMGO)-induced desensitization, First, we replaced Thr(394) with alanine (T394A) and stably expressed this mutant receptor in Chinese hamster ovary cells, The T394A receptor did not desensitize after 1 h of treatment with DAMGO, indicating that Thr(394) is required for agonist-induced early desensitization, To test whether Thr(394) was the only residue necessary, we investigated the importance of 7 potential phosphorylation sites between residues 363 and 383, which were all replaced by alanines with the Thr(394) maintained, This mutant (AT) showed partial loss of desensitization (30%), which was attributable to the Ala mutation at Thr(383), since complete desensitization was achieved by restoring Thr(383) (ATT), These results suggest that Thr(394) is the primary recognition site for G protein-coupled receptor kinases, but Thr(383) is also required for complete agonist-induced desensitization. The specificity of Thr(394) as the primary initiation site appears to be dependent on the preceding acidic amino acid stretch, because in a mutant in which glutamic acid residues at 388, 391, and 393 were replaced by glutamines (EQ), agonist-induced desensitization was completely abolished, identical to the T394A mutant.	UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A8,CANADA; ADDICT RES FDN,TORONTO,ON M5S 2S1,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada			George, Susan/W-7494-2019; George, Susan R/P-9669-2018					BARTON AC, 1990, MOL PHARMACOL, V38, P531; BARTON AC, 1991, MOL PHARMACOL, V39, P650; BATES MD, 1991, MOL PHARMACOL, V39, P55; BLAXALL HS, 1994, MOL PHARMACOL, V45, P176; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CHEN Y, 1994, J BIOL CHEM, V269, P7839; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; FUKUSHIMA N, 1994, NEUROSCI LETT, V176, P55, DOI 10.1016/0304-3940(94)90870-2; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; KOOB G, 1992, SCIENCE, V242, P715; KOOB GF, 1992, TRENDS NEUROSCI, V15, P186, DOI 10.1016/0166-2236(92)90171-4; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEI G, 1995, MOL PHARMACOL, V48, P173; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PULLEN N, 1994, BIOCHEMISTRY-US, V33, P14536, DOI 10.1021/bi00252a021; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMON EJ, 1991, MED RES REV, V11, P357, DOI 10.1002/med.2610110402; TAKANO T, 1994, J BIOL CHEM, V269, P22453; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	36	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24961	24965		10.1074/jbc.272.40.24961	http://dx.doi.org/10.1074/jbc.272.40.24961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312100	hybrid			2022-12-27	WOS:A1997XY97000039
J	Badola, P; Sanders, CR				Badola, P; Sanders, CR			Escherichia coli diacylglycerol kinase is an evolutionarily optimized membrane enzyme and catalyzes direct phosphoryl transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SN-1,2-DIACYLGLYCEROL KINASE; ADENYLATE KINASES; PROTEIN-KINASES; INHIBITORS; DEPENDENCE; MOVEMENTS; DIFFUSION	Pn this contribution the kinetic mechanism and substrate specificity of Escherichia coli diacylglycerol kinase were examined. Steady state kinetic studies were carried out under mixed micellar conditions using a novel continuous coupled assay system. The kinetic data were consistent with a random equilibrium mechanism, implying that diacylglycerol kinase catalyzes direct phosphoryl transfer from MgATP to diacylglycerol, This was supported by failure to detect an enzyme-phosphate covalent intermediate and by the observation that the bisubstrate analog adenosine 5'-tetraphosphoryl-3-O-(1,2-dihexanoyl)-sn-glycerol inhibits the enzyme (K-i much less than K-m,K-DAG). While diacylglycerol kinase's k(cat)/K-m is modest compared with the efficiency of many water-soluble enzymes, the enzyme nevertheless appears to be all evolutionarily optimized biocatalyst in the sense that its chemical reaction rate approaches the substrate diffusion-controlled limit, The fit vitro rate-limiting step of DAGK's reaction appears to be, in part, the transbilayer diffusion of diacylglycerol from the outer leaflet to the inner leaflet of the cytoplasmic membrane where DAGK's active site is located, DAGK was observed to maintain a high nucleotide substrate specificity, with most of this specificity being expressed in the form of reductions in K-cat for ATP analogs.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University					NIGMS NIH HHS [GM47485] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047485, R01GM047485] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERY WJ, 1977, ANGEW CHEM INT EDIT, V16, P285, DOI 10.1002/anie.197702851; ALLAN D, 1978, NATURE, V276, P289, DOI 10.1038/276289a0; ANDERSSON CM, 1979, SCIENCE, V235, P569; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BOHNENBERGER E, 1988, EUR J BIOCHEM, V132, P645; BROOM AD, 1989, J MED CHEM, V32, P2, DOI 10.1021/jm00121a001; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CRONAN JE, 1996, ESCHERICHIA COLI SAL, V1, P612; FELDHAUS P, 1975, EUR J BIOCHEM, V57, P197, DOI 10.1111/j.1432-1033.1975.tb02291.x; Fersht A., 1985, ENZYME STRUCTURE MEC; GENNIS RB, 1989, BIOMEMBRANES MOL STR, P182; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GOLDFINE H, 1982, CURR TOP MEMBR TRANS, V17, P1; HAMILTON JA, 1991, J BIOL CHEM, V266, P1177; Hammes G.G., 1970, ENZYMES, V2, P67; IKEDA S, 1986, J BIOL CHEM, V261, P5836; KENNEDY EP, 1996, ESCHERICHIA COLI SAL, V1, P1064; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P88, DOI 10.1083/jcb.102.1.88; MEDZIHRADSZKY D, 1994, J AM CHEM SOC, V116, P9413, DOI 10.1021/ja00100a001; MERCHANTE R, 1995, J BACTERIOL, V177, P6176, DOI 10.1128/jb.177.21.6176-6183.1995; PREISS J, 1986, J BIOL CHEM, V261, P8597; PURICH DL, 1972, BIOCHIM BIOPHYS ACTA, V276, P563, DOI 10.1016/0005-2744(72)91021-2; RAETZ CRH, 1979, J BACTERIOL, V137, P860, DOI 10.1128/JB.137.2.860-868.1979; RHOADS DG, 1968, J BIOL CHEM, V243, P3963; RUSS E, 1988, EUR J BIOCHEM, V171, P335, DOI 10.1111/j.1432-1033.1988.tb13795.x; SANDERS CR, 1993, BIOPHYS J, V65, P1207, DOI 10.1016/S0006-3495(93)81158-5; Sanders CR, 1996, BIOCHEMISTRY-US, V35, P8610, DOI 10.1021/bi9604892; SANDERS CR, 1994, CHEM PHYS LIPIDS, V72, P41, DOI 10.1016/0009-3084(94)90016-7; SCHAAP D, 1994, BIOCHEM J, V304, P661, DOI 10.1042/bj3040661; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; Segel I. H., 1975, ENZYME KINETICS, P273; SHIBUYA I, 1992, PROG LIPID RES, V31, P245, DOI 10.1016/0163-7827(92)90010-G; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; SMITH RL, 1994, J BACTERIOL, V176, P5459, DOI 10.1128/JB.176.17.5459-5465.1994; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VINOGRADOVA O, 1996, BIOPHYS J, V72, P2688; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WALSH JP, 1990, J BIOL CHEM, V265, P4374; WALSH JP, 1992, METHOD ENZYMOL, V209, P153; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WALSH JP, 1986, J BIOL CHEM, V261, P1021; Wen JA, 1996, NAT STRUCT BIOL, V3, P141, DOI 10.1038/nsb0296-141; YAMASHITA Y, 1993, J BACTERIOL, V175, P6220, DOI 10.1128/JB.175.19.6220-6228.1993; YAN H, 1991, BIOCHEMISTRY-US, V31, P6806	47	71	72	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24176	24182		10.1074/jbc.272.39.24176	http://dx.doi.org/10.1074/jbc.272.39.24176			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305868	hybrid			2022-12-27	WOS:A1997XY51500019
J	Hinderlich, S; Stasche, R; Zeitler, R; Reutter, W				Hinderlich, S; Stasche, R; Zeitler, R; Reutter, W			A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver - Purification and characterization of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; TRIPHOSPHATE; MECHANISM; SIALURIA; BINDING	Biosynthesis of N-acetylneuraminic acid (Neu5Ac), a prominent component of glycoconjugates, is initiated by the action of UDP-N-acetylglucosamine a-epimerase (UDP-GlcNAc a-epimerase, EC 5.1.3.14) and N-acetylmannosamine kinase (ManNAc kinase, EC 2.7.1.60), We demonstrate for the first time that the two activities are parts of one bifunctional enzyme in rat liver, The enzyme was purified to homogeneity from rat liver cytosol using salmine sulfate precipitation and chromatography on phenyl-Sepharose, ATP-agarose, and Mono Q. The purification resulted in one polypeptide with an apparent molecular mass of 75 kDa, Immunoprecipitation with a polyclonal antibody against the polypeptide reduced both enzyme activities in equal amounts, Gel filtration analysis of purified UDP-GlcNAc 2-epimerase/ManNAc kinase showed that the polypeptide self-associates as a dimer and as a hexamer with apparent molecular masses of 150 and 450 kDa, respectively, The hexamer was fully active for both enzyme activities, whereas the dimer catalyzed only the phosphorylation of N-acetylmannosamine (ManNAc), Incubation of the dimer with UDP-N-acetylglucosamine led to reassembly of the fully active hexamer; maximal quantities of the hexamer were produced after incubation for 3 h. Kinetic analysis of purified hexameric and dimeric enzyme revealed significantly lower Michaelis constants (93 +/- 3 to 121 +/- 15 mu M for ManNAc and 1.18 +/- 0.13 to 1.67 +/- 0.20 mm for ATP) and higher cooperativity (Hill coefficients of 1.42 +/- 0.16 to 1.17 +/- 0.06 for ManNAc and 1.30 +/- 0.09 to 1.05 +/- 0.14 for ATP) for the hexamer for both substrates of ManNAc kinase, The Michaelis constant of UDP-GlcNAc a-epimerase for its substrate was 11 +/- 2 mu M. The Hill coefficient of 0.45 +/- 0,07 represents strongly negative cooperativity in substrate binding, UDP-GlcNAc a-epimerase was feedback inhibited by CMP-Neu5Ac. Complete inhibition was achieved with 60 mu M CMP-Neu5Ac, and highly positive cooperativity (Hill coefficient of 4.1) was found for inhibitor binding.	FREE UNIV BERLIN,INST MOL BIOL & BIOCHEM,D-14195 BERLIN,GERMANY	Free University of Berlin								BOULARD C, 1982, J IMMUNOL METHODS, V50, P221, DOI 10.1016/0022-1759(82)90228-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brockhausen I., 1997, GLYCOSCIENCES STATUS, P79; COMB DG, 1958, BIOCHIM BIOPHYS ACTA, V29, P653, DOI 10.1016/0006-3002(58)90031-3; DATTA A, 1970, BIOCHEMISTRY-US, V9, P3363, DOI 10.1021/bi00819a011; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Fritsch M, 1996, J CHROMATOGR A, V727, P223, DOI 10.1016/0021-9673(95)01157-9; GOSH S, 1961, P NATL ACAD SCI USA, V47, P955; HARMS E, 1973, EUR J BIOCHEM, V32, P254, DOI 10.1111/j.1432-1033.1973.tb02605.x; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; KIKUCHI K, 1973, BIOCHIM BIOPHYS ACTA, V327, P193, DOI 10.1016/0005-2744(73)90117-4; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; KUNDIG W, 1966, J BIOL CHEM, V241, P5619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1969, P NATL ACAD SCI USA, V62, P1121, DOI 10.1073/pnas.62.4.1121; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; SEPPALA R, 1991, J BIOL CHEM, V266, P7456; SOMMAR KM, 1972, BIOCHIM BIOPHYS ACTA, V269, P581; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; VANRINSUM J, 1983, BIOCHEM J, V210, P21, DOI 10.1042/bj2100021; WARREN L, 1972, GLYCOPROTEINS, P1097; WEISS P, 1989, J BIOL CHEM, V264, P17635; YABLONSKI MJ, 1996, J BIOL CHEM, V270, P10704; ZEITLER R, 1992, BIOMETALS, V5, P103, DOI 10.1007/BF01062221	27	228	237	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24313	24318		10.1074/jbc.272.39.24313	http://dx.doi.org/10.1074/jbc.272.39.24313			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305887	hybrid			2022-12-27	WOS:A1997XY51500038
J	Jagath, JR; Sharma, B; Rao, NA; Savithri, HS				Jagath, JR; Sharma, B; Rao, NA; Savithri, HS			The role of His-134, -147, and -150 residues in subunit assembly, cofactor binding, and catalysis of sheep liver cytosolic serine hydroxymethyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVE-SITE; ASPARTATE-AMINOTRANSFERASE; EVOLUTIONARY RELATIONSHIPS; TRYPTOPHAN SYNTHASE; NUCLEOTIDE-SEQUENCE; CDNA CLONING; GLYA GENE; IDENTIFICATION; MITOCHONDRIAL	In an attempt to unravel the role of conserved histidine residues in the structure-function of sheep liver cytosolic serine hydroxymethyltransferase (SHMT), three site-specific mutants (H134N, H147N, and H150N) were constructed and expressed, H134N and H147N SHMTs had K-m values for L-serine, L-allo-threonine and beta-phenylserine similar to that of wild type enzyme, although the k(cat) values were markedly decreased, H134N SHMT was obtained in a dimeric form with only 6% of bound pyridoxal 5'-phosphate (PLP) compared with the wild type enzyme, Increasing concentrations of PLP (up to 500 mu M) enhanced the enzyme activity without changing its oligomeric structure, indicating that His-134 may be involved in dimer-dimer interactions, H147N SHMT was obtained in a tetrameric form but with very little PLP (3%) bound to it, suggesting that this residue was probably involved in cofactor binding, Unlike the wild type enzyme, the cofactor could be easily removed by dialysis from H147N SHMT, and the apoenzyme thus formed was present predominantly in the dimeric form, indicating that PLP binding is at the dimer-dimer interface, H150N SHMT was obtained in a tetrameric form with bound PLP, However, the mutant had very little enzyme activity (<2%). The k(cat)/K-m values for L-serine, L-allo-threonine and beta-phenylserine were 80-, 56-, and SS-fold less compared with wild type enzyme, Unlike the wild type enzyme, it failed to form the characteristic quinonoid intermediate and was unable to carry out the exchange of 2-S proton from glycine in the presence of H-4-folate. However, it could form an external aldimine with serine and glycine, The wild type and the mutant enzyme had similar K-d values for serine and glycine, These results suggest that His-150 may be the base that abstracts the alpha-proton of the substrate, leading to formation of the quinonoid intermediate in the reaction catalyzed by SHMT.	INDIAN INST SCI, DEPT BIOCHEM, BANGALORE 560012, KARNATAKA, INDIA	Indian Institute of Science (IISC) - Bangalore			Junutula, Jagath Reddy/ABD-4753-2020; Sharma, Balasubramanya/ABA-9152-2021	Junutula, Jagath Reddy/0000-0002-5942-4428; Sharma, Balasubramanya/0000-0002-9923-5699				ALEXANDER DC, 1987, METHOD ENZYMOL, V154, P41; ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ATSURO M, 1993, EUR J BIOCHEM, V212, P745; BHATIA MB, 1993, J BIOL CHEM, V268, P6932; BLAKLEY RL, 1955, BIOCHEM J, V61, P315, DOI 10.1042/bj0610315; Brahatheeswaran B, 1996, ARCH BIOCHEM BIOPHYS, V330, P363, DOI 10.1006/abbi.1996.0263; BYRNE PC, 1992, BIOCHEM J, V286, P117, DOI 10.1042/bj2860117; CHAN VL, 1991, GENE, V101, P51, DOI 10.1016/0378-1119(91)90223-X; CHEN MS, 1973, J BIOL CHEM, V248, P3631; CIOTTI MM, 1957, METHOD ENZYMOL, V3, P890, DOI 10.1016/S0076-6879(57)03472-2; GARROW TA, 1993, J BIOL CHEM, V268, P11910; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; HATEFI Y, 1960, BIOCHEM PREP, V7, P89; HAYASHI H, 1990, BIOCHEM BIOPH RES CO, V167, P407, DOI 10.1016/0006-291X(90)92037-Z; Jagath JR, 1997, EUR J BIOCHEM, V247, P372, DOI 10.1111/j.1432-1033.1997.00372.x; JAGATHREDDY J, 1995, EUR J BIOCHEM, V230, P533, DOI 10.1111/j.1432-1033.1995.0533h.x; JagathReddy J, 1996, CURR SCI INDIA, V71, P710; KURAMITSU S, 1990, P 8 INT S VIT B6 CAR, P179; LU ZC, 1993, J BIOL CHEM, V268, P8727; MALKIN LI, 1964, BIOCHIM BIOPHYS ACTA, V85, P117, DOI 10.1016/0926-6569(64)90172-5; MALTHOUSE JPG, 1991, BIOCHEM J, V274, P807, DOI 10.1042/bj2740807; MANOHAR R, 1982, J BIOSCIENCES, V4, P31, DOI 10.1007/BF02702579; MANOHAR R, 1984, BIOCHEM J, V224, P703, DOI 10.1042/bj2240703; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MARTINI F, 1989, J BIOL CHEM, V264, P8509; MCCLUNG CR, 1992, MOL CELL BIOL, V12, P1412, DOI 10.1128/MCB.12.4.1412; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; MIYAZAKI SS, 1987, EUR J BIOCHEM, V162, P533, DOI 10.1111/j.1432-1033.1987.tb10672.x; PASCARELLA S, 1993, FEBS LETT, V331, P145, DOI 10.1016/0014-5793(93)80314-K; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; PLAMANN MD, 1983, NUCLEIC ACIDS RES, V11, P2065, DOI 10.1093/nar/11.7.2065; RAO NA, 1987, J SCI IND RES INDIA, V46, P248; ROSSBACH S, 1991, MOL MICROBIOL, V5, P39, DOI 10.1111/j.1365-2958.1991.tb01824.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRCH D, 1993, J BIOL CHEM, V268, P23132; SCHIRCH L, 1964, J BIOL CHEM, V239, P3801; SCHIRCH L, 1964, J BIOL CHEM, V239, P3797; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH LV, 1971, J BIOL CHEM, V246, P3961; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; SNELL K, 1989, FALK SYMP, V51, P375; SNELL K, 1988, BRIT J CANCER, V57, P87, DOI 10.1038/bjc.1988.15; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAYLOR RT, 1965, ANAL BIOCHEM, V13, P80, DOI 10.1016/0003-2697(65)90120-X; TONEY MD, 1992, PROTEIN SCI, V1, P109; TURNER SR, 1992, J BIOL CHEM, V267, P13528; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5355, DOI 10.1021/bi00643a029; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5342, DOI 10.1021/bi00643a027; URBANOWSKI ML, 1984, GENE, V27, P47, DOI 10.1016/0378-1119(84)90237-3; USHA R, 1994, BBA-PROTEIN STRUCT M, V1204, P75, DOI 10.1016/0167-4838(94)90035-3; USHA R, 1992, THESIS INDIAN I SCI; WEBB HK, 1995, J BIOL CHEM, V270, P17204, DOI 10.1074/jbc.270.29.17204; ZIAK M, 1993, EUR J BIOCHEM, V211, P475, DOI 10.1111/j.1432-1033.1993.tb17573.x	55	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24355	24362		10.1074/jbc.272.39.24355	http://dx.doi.org/10.1074/jbc.272.39.24355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305893	hybrid			2022-12-27	WOS:A1997XY51500044
J	Stuhlmeier, KM; Kao, JJ; Bach, FH				Stuhlmeier, KM; Kao, JJ; Bach, FH			Arachidonic acid influences proinflammatory gene induction by stabilizing the inhibitor-kappa B alpha/nuclear factor-kappa B (NF-kappa B) complex, thus suppressing the nuclear translocation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL ACTIVATION; NECROSIS-FACTOR-ALPHA; INDUCED PHOSPHORYLATION; FATTY-ACIDS; EXPRESSION; TRANSCRIPTION; PROTEIN; PROTEOLYSIS; SIGNAL	Arachidonic acid (AA), through its myriad metabolites, is involved in inflammation in a number of ways. AA is produced and released by several cell types, including endothelial cells (EC), and acts on a variety of cells. EC activation plays a key role in inflammation presumably by modulating the immune response through up-or down-regulation of several genes. We have previously shown that AA and its nonmetabolizable analogue, 5,8,11,14-eicosatetraynoic acid (ETYA), inhibit up-regulation of proinflammatory genes in EC. In the present study we identify a mechanism to explain the inhibitory effects: AA and ETYA both inhibit the translocation of nuclear factor-kappa B (NF-kappa B) to the nucleus by blocking the degradation of the inhibitor of NF-kappa B (I kappa B) and thus stabilizing the I kappa B/NF-kappa B complex. To investigate the mechanism whereby AA inhibits upregulation of genes encoding proinflammatory mediators, we examined the ability of ETYA to inhibit tumor necrosis factor-alpha (TNF-alpha) mediated phosphorylation and degradation of I kappa B alpha. Western blot analysis revealed that preincubation of EC with ETYA for 40 min prior to stimulation with TNF-alpha inhibits the phosphorylation and degradation of I kappa B alpha. These findings establish a mechanism by which AA inhibits nuclear translocation of NF-kappa B and thereby explaining its modulatory role in the induction of proinflammatory genes.			Stuhlmeier, KM (corresponding author), HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,SANDOZ CTR IMMUNOBIOL,99 BROOKLINE AVE,BOSTON,MA 02215, USA.							BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BUCKLEY BJ, 1995, AM J PHYSIOL-CELL PH, V38, pC1489; Camandola S, 1996, BIOCHEM BIOPH RES CO, V229, P643, DOI 10.1006/bbrc.1996.1857; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DOWING DT, 1972, BIOCHIM BIOPHYS ACTA, V280, P343; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; GOEBELER M, 1995, J IMMUNOL, V155, P2459; Hennig B, 1996, AM J CLIN NUTR, V63, P322, DOI 10.1093/ajcn/63.3.322; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P192; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LANIADOSCHWARTZMAN M, 1994, J BIOL CHEM, V269, P24321; LAPOSATA M, 1987, PROSTAGLANDINS, V33, P603, DOI 10.1016/0090-6980(87)90284-X; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pierce JW, 1996, J IMMUNOL, V156, P3961; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RIZZO MT, 1995, BLOOD, V86, P2967, DOI 10.1182/blood.V86.8.2967.bloodjournal8682967; SCHERER D, 1995, P NATL ACAD SCI USA, V92, P259; Stuhlmeier KM, 1996, EUR J IMMUNOL, V26, P1417, DOI 10.1002/eji.1830260703; STUHLMEIER KM, 1994, EUR J IMMUNOL, V24, P2186, DOI 10.1002/eji.1830240938; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDERHOEK JY, 1973, BIOCHIM BIOPHYS ACTA, V296, P374, DOI 10.1016/0005-2760(73)90095-7; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	31	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24679	24683		10.1074/jbc.272.39.24679	http://dx.doi.org/10.1074/jbc.272.39.24679			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305938	hybrid			2022-12-27	WOS:A1997XY51500089
J	Alevizopoulos, A; Dusserre, Y; Ruegg, U; Mermod, N				Alevizopoulos, A; Dusserre, Y; Ruegg, U; Mermod, N			Regulation of the transforming growth factor beta-responsive transcription factor CTF-1 by calcineurin and calcium/calmodulin-dependent protein kinase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NUCLEAR FACTOR-I; TGF-BETA; CYCLOSPORINE-A; MAD PROTEINS; HISTONE H3; CTF/NF-I; CALCIUM; ACTIVATION; RECEPTOR	Transforming growth factor beta (TGF-beta) is a pluripotent peptide hormone that regulates various cellular activities, including growth, differentiation, and extracellular matrix protein gene expression, We previously showed that TGF-beta induces the transcriptional activation domain (TAD) of CTF-1, the prototypic member of the CTF/NF-I family of transcription factors. This induction correlates with the proposed role of CTF/NF-I binding sites in collagen gene induction by TGF-beta. However, the mechanisms of TGF-beta signal transduction remain poorly understood. Here, we analyzed the role of free calcium signaling in the induction of CTF-1 transcriptional activity by TGF-beta, We found that TGF-beta stimulates calcium influx and mediates an increase of the cytoplasmic calcium concentration in NIH3T3 cells. TGF-beta induction of CTF-1 is inhibited in cells pretreated with thapsigargin, which depletes the endoplasmic reticulum calcium stores, thus further arguing for the potential relevance of calcium mobilization in TGF-beta action. Consistent with this possibility, expression of a constitutively active form of the calcium/calmodulin-dependent phosphatase calcineurin or of the calcium/calmodulin-dependent kinase IV (Delta CaMKIV) specifically induces the CTF-1 TAD and the endogenous mouse CTF/NF-I proteins, Both calcineurin- and Delta CaMKIV-mediated induction require the previously identified TGF-beta responsive domain of CTF-1. The immunosuppressants cyclosporin A and FK506 abolish calcineurin-mediated induction of CTF-1 activity, However, TGF-beta still induces the CTF-1 TAD in cells treated with these compounds or in cells overexpressing both calcineurin and Delta CaMKIV, suggesting that other calcium-sensitive enzymes might mediate TGF-beta action. These results identify CTF/NF-I as a novel calcium signaling pathway-responsive transcription factor and further suggest multiple molecular mechanisms for the induction of CTF/NF-I transcriptional activity by growth factors.	ECOLE POLYTECH FED LAUSANNE,INST GENIE CHIM,DC,LAB MOL BIOTECHNOL,CTR BIOTECHNOL,UNIL,CH-1015 LAUSANNE,SWITZERLAND; UNIV LAUSANNE,SCH PHARM,PHARMACOL GRP,CH-1015 LAUSANNE,SWITZERLAND	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne				RUEGG, Urs/0000-0001-6078-8280				Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BORDER WA, 1995, NAT MED, V1, P1000, DOI 10.1038/nm1095-1000; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; Ishiyama N, 1996, MOL CELL ENDOCRINOL, V117, P1, DOI 10.1016/0303-7207(95)03726-8; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LoRusso A, 1996, BRIT J PHARMACOL, V118, P885; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MULDOON LL, 1988, J BIOL CHEM, V263, P18834; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	38	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23597	23605		10.1074/jbc.272.38.23597	http://dx.doi.org/10.1074/jbc.272.38.23597			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295299	hybrid			2022-12-27	WOS:A1997XX38100024
J	FloresDiaz, M; AlapeGiron, A; Persson, B; Pollesello, P; Moos, M; vonEichelStreiber, C; Thelestam, M; Florin, I				FloresDiaz, M; AlapeGiron, A; Persson, B; Pollesello, P; Moos, M; vonEichelStreiber, C; Thelestam, M; Florin, I			Cellular UDP-glucose deficiency caused by a single point mutation in the UDP-glucose pyrophosphorylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLC-GLYCOPROTEIN GLUCOSYLTRANSFERASE; GLYCOGEN PHOSPHORYLASE-B; GTP-BINDING PROTEINS; DIFFICILE TOXIN-B; CLOSTRIDIUM-DIFFICILE; ETHYL METHANESULFONATE; TRANSGENIC MICE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE	We previously isolated a mutant cell that is the only mammalian cell reported to have a persistently low level of UDP-glucose. In this work we obtained a spontaneous revertant whose UDP-glucose level lies between those found in the wild type and the mutant cell, The activity of UDP-glucose pyrophosphorylase (UDPG:PP), the enzyme that catalyzes the formation of UDP-glucose, was in the mutant 4% and in the revertant 56% of the activity found in the wild type cell. Sequence analysis of UDPG:PP cDNAs from the mutant cell showed one missense mutation, which changes amino acid residue 115 hom glycine to aspartic acid. The substituted glycine is located within the largest stretch of strictly conserved residues among eukaryotic UDPG:PPs. The analysis of the cDNAs from the revertant cell indicated the presence of an equimolar mixture of the wild type and the mutated mRNAs, suggesting that the mutation has reverted in only one of the alleles. In summary, we demonstrate that the G115D substitution in the Chinese hamster UDPG:PP dramatically impairs its enzymatic activity, thereby causing cellular UDP-glucose deficiency.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; UNIV COSTA RICA,FAC MED,DEPT BIOQUIM,SAN JOSE,COSTA RICA; UNIV COSTA RICA,FAC MICROBIOL,INST CLODOMIRO PICADO,SAN JOSE,COSTA RICA; ORION PHAMACEUT CO,R&D,DRUG DESIGN UNIT,NMR LAB,FIN-02101 ESPOO,FINLAND; UNIV MAINZ,INST MED MICROBIOL & HYG,VERFUGUNGSGEBAUDE FORSCH & ENTWICKLUNG,D-55101 MAINZ,GERMANY	Karolinska Institutet; Karolinska Institutet; Universidad Costa Rica; Universidad Costa Rica; Orion Corporation; Johannes Gutenberg University of Mainz			Pollesello, Piero/I-6884-2019	Pollesello, Piero/0000-0001-6994-768X; Alape-Giron, Alberto/0000-0003-3934-8496				ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; ASHMAN CR, 1987, SOMAT CELL MOLEC GEN, V13, P563, DOI 10.1007/BF01534497; AW TY, 1984, BIOCHEM J, V219, P707, DOI 10.1042/bj2190707; AW TY, 1982, ANAL BIOCHEM, V127, P32, DOI 10.1016/0003-2697(82)90140-3; BETTE P, 1989, INFECT IMMUN, V57, P2507, DOI 10.1128/IAI.57.8.2507-2513.1989; Bork P, 1996, CURR OPIN STRUC BIOL, V6, P366, DOI 10.1016/S0959-440X(96)80057-1; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COROMINAS J, 1992, FEBS LETT, V310, P182, DOI 10.1016/0014-5793(92)81325-G; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; DESMOND GH, 1996, METHOD ENZYMOL, V266, P383; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; Eimert K, 1996, GENE, V170, P227, DOI 10.1016/0378-1119(95)00873-X; Fernandez F, 1996, EMBO J, V15, P705, DOI 10.1002/j.1460-2075.1996.tb00406.x; FLORIN I, 1991, MICROB PATHOGENESIS, V11, P337, DOI 10.1016/0882-4010(91)90019-7; Franks SE, 1996, ANTICANCER RES, V16, P1365; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HAJDU J, 1987, EMBO J, V6, P539, DOI 10.1002/j.1460-2075.1987.tb04786.x; HAMES BD, 1976, ANAL BIOCHEM, V73, P215, DOI 10.1016/0003-2697(76)90157-3; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hellerstein MK, 1997, AM J PHYSIOL-ENDOC M, V272, pE155, DOI 10.1152/ajpendo.1997.272.1.E155; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; INGLE CA, 1989, MUTAT RES, V220, P133, DOI 10.1016/0165-1110(89)90019-5; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KATSUBE T, 1991, BIOCHEMISTRY-US, V30, P8546, DOI 10.1021/bi00099a008; KONISHI Y, 1993, J BIOCHEM-TOKYO, V114, P61, DOI 10.1093/oxfordjournals.jbchem.a124141; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABRIOLA C, 1995, J CELL BIOL, V130, P771, DOI 10.1083/jcb.130.4.771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBKOWSKI JS, 1986, MOL CELL BIOL, V6, P1838, DOI 10.1128/MCB.6.5.1838; LOWIK CWGM, 1993, ANAL BIOCHEM, V213, P426, DOI 10.1006/abio.1993.1442; LUNN JE, 1990, BIOCHEM J, V267, P739, DOI 10.1042/bj2670739; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; MOLLBY R, 1974, J MEMBRANE BIOL, V16, P313, DOI 10.1007/BF01872421; MPOLLESELLO P, 1995, NMR BIOMED, V8, P190; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P528, DOI 10.1093/oxfordjournals.jbchem.a122886; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; RAGHEB JA, 1987, NUCLEIC ACIDS RES, V15, P3891, DOI 10.1093/nar/15.9.3891; REN JM, 1993, J BIOL CHEM, V268, P16113; ROACH PJ, 1975, BIOCHEMISTRY-US, V14, P5445, DOI 10.1021/bi00696a010; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROTH J, 1995, GLYCOPROTEINS, P287; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SANDHOFF K, 1992, BIOCHEM SOC T, V20, P695, DOI 10.1042/bst0200695; SASSON S, 1986, J BIOL CHEM, V261, P6827; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHEED SF, 1993, NMR BIOMED, V6, P254; SHOSHAN MC, 1990, EUR J CELL BIOL, V53, P357; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; SOCHOR M, 1991, DIABETES, V40, P1467, DOI 10.2337/diabetes.40.11.1467; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SPIRO MJ, 1984, DIABETOLOGIA, V26, P70; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Tyagi RK, 1996, MAGN RESON MED, V35, P194, DOI 10.1002/mrm.1910350210; ULLREY DB, 1979, ANAL BIOCHEM, V95, P245, DOI 10.1016/0003-2697(79)90212-4; VANZEELAND AA, 1995, TOXICOL LETT, V77, P49, DOI 10.1016/0378-4274(95)03271-1; VERBERT A, 1995, GLYCOPROTEINS, P145; VIHINEN M, 1994, PROTEINS, V19, P141, DOI 10.1002/prot.340190207; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Watson KA, 1997, EMBO J, V16, P1, DOI 10.1093/emboj/16.1.1; WICE BM, 1985, J BIOL CHEM, V260, P139; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	73	71	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23784	23791		10.1074/jbc.272.38.23784	http://dx.doi.org/10.1074/jbc.272.38.23784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295324	hybrid			2022-12-27	WOS:A1997XX38100049
J	Shin, JH; Ji, CH; Casinghino, S; McCarthy, TL; Centrella, M				Shin, JH; Ji, CH; Casinghino, S; McCarthy, TL; Centrella, M			Parathyroid hormone-related protein enhances insulin-like growth factor-I expression by fetal rat dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-ENRICHED CULTURES; SQUAMOUS-CELL CARCINOMA; RECEPTOR MESSENGER-RNA; PROSTAGLANDIN E(2); HUMAN-SKIN; HUMAN KERATINOCYTES; RESPONSE ELEMENT; GENE-EXPRESSION; FACTOR-BETA; BONE-CELLS	Interactions between cells of differing embryonic origins comprise a common theme during tissue development and repair. Often, communication between them can be mediated by soluble growth mediators and in some cases is restricted in focus. That is, some cells respond to, but do not produce, mediators expressed by other cells within the tissue. Because keratinocytes respond to but do not express insulin-like growth factor I (IGF-I), another skin cell population, the dermal fibroblast, may supply this factor. However, keratinocytes express, but do not respond to parathyroid hormone related protein (PTHrp), which increases cAMP production by dermal fibroblasts. Based on earlier results where inducers of cAMP increase local IGF-I expression in skeletal tissue, we postulated that PTHrp might induce local IGF-I by dermal fibroblasts and provide a source of this factor for keratinocyte activity. Our studies reveal that IGF-I mRNA and protein levels increase in response to PTHrp in vitro, and that this effect is replicated by inducers of cAMP, but not be activators of protein kinase C. Consequently, these factors appear to comprise a paracrine loop within the skin, permitting focused but restricted IGF-I expression to support skin growth, remodeling, or repair.			Shin, JH (corresponding author), YALE UNIV,SCH MED,DEPT SURG,SECT PLAST SURG,333 CEDAR ST,POB 208401,NEW HAVEN,CT 06520, USA.				NIAMS NIH HHS [AR41942] Funding Source: Medline; NIDDK NIH HHS [DK47421] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1991, INSULIN LIKE GROWTH; BARRECA A, 1992, J CELL PHYSIOL, V151, P262, DOI 10.1002/jcp.1041510207; BHORA FY, 1995, J SURG RES, V59, P236, DOI 10.1006/jsre.1995.1160; BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CENTRELLA M, 1993, ANN PLAS SURG, V31, P434, DOI 10.1097/00000637-199311000-00008; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; Dunbar ME, 1996, AM J MED SCI, V312, P287, DOI 10.1097/00000441-199612000-00007; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOLDRING SR, 1979, J CLIN ENDOCR METAB, V48, P655, DOI 10.1210/jcem-48-4-655; HANAFIN NM, 1995, J INVEST DERMATOL, V105, P133, DOI 10.1111/1523-1747.ep12313466; HOEKMAN K, 1990, CANCER RES, V50, P3589; INSOGNA KL, 1989, J CLIN INVEST, V83, P1057, DOI 10.1172/JCI113947; INSOGNA KL, 1989, ANN NY ACAD SCI, V548, P146; JYUNG RW, 1994, SURGERY, V115, P233; KAMALATI T, 1989, DEVELOPMENT, V106, P283; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; McCarthy TL, 1996, J BIOL CHEM, V271, P6666, DOI 10.1074/jbc.271.12.6666; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1994, J CELL PHYSIOL, V160, P163, DOI 10.1002/jcp.1041600119; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; NEELY EK, 1991, J INVEST DERMATOL, V96, P104, DOI 10.1111/1523-1747.ep12515914; ORLOFF JJ, 1995, ENDOCRINOLOGY, V136, P3016, DOI 10.1210/en.136.7.3016; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; Reiser K, 1996, AM J PHYSIOL-REG I, V271, pR696, DOI 10.1152/ajpregu.1996.271.3.R696; RIZZOLI R, 1994, J ENDOCRINOL, V143, P333, DOI 10.1677/joe.0.1430333; SILVE C, 1985, J CLIN ENDOCR METAB, V60, P1144, DOI 10.1210/jcem-60-6-1144; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; WU TL, 1987, J CLIN ENDOCR METAB, V65, P105, DOI 10.1210/jcem-65-1-105; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133	40	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23498	23502		10.1074/jbc.272.38.23498	http://dx.doi.org/10.1074/jbc.272.38.23498			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295284	hybrid			2022-12-27	WOS:A1997XX38100009
J	Sun, ZY; Jiang, YP; Ma, Z; Wu, H; Liu, BF; Xu, YM; Tang, W; Chen, YH; Li, CZ; Zhu, DX; Gurewich, V; Liu, JN				Sun, ZY; Jiang, YP; Ma, Z; Wu, H; Liu, BF; Xu, YM; Tang, W; Chen, YH; Li, CZ; Zhu, DX; Gurewich, V; Liu, JN			Identification of a flexible loop region (297-313) of urokinase-type plasminogen activator, which helps determine its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; PRO-UROKINASE; INTRINSIC ACTIVITY; CRYSTAL-STRUCTURE; GLU-PLASMINOGEN; PROUROKINASE; FIBRIN; LOCALIZATION; FRAGMENT-E-2; PROMOTION	Pro-urokinase has a much higher intrinsic catalytic activity than other zymogens of the serine protease family. Lys(300(c143)) in an apparent ''flexible loop'' region (297-313) was previously shown to be an important determinant of this intrinsic catalytic activity. This was related to the loop allowing the positive charge of Lys(300(c143)) to transiently interact with Asp(355(c194)), thereby inducing an active conformation of the protease domain (Liu, J. N., Tang, W., Sun, Z., Kung, W., Pannell, R., Sarmientos, P., and Gurewich, V. (1996) Biochemistry 35, 14070-14076). To further test this hypothesis, the charge at position 300(c143) and the flexibility of the loop were altered using site-directed mutagenesis designed according to a computer model to affect the interaction between Lys(300(c143)) and Asp(355(c194)). When the charge at Lys(300(c143)) but not Lys(313(c156)) was reduced, a significant reduction in the intrinsic catalytic activity occurred. Similarly, when the flexibility (wobbliness) of the loop was enhanced reducing the size of side chain, the intrinsic catalytic activity was also reduced. By contrast, when the loop was made less flexible, the intrinsic catalytic activity was increased, These findings were consistent with the hypothesis. The effects of these mutations on two-chain activity were less and often discordant with the intrinsic catalytic activity, indicating that they can be modulated independently. This structure-function disparity can he exploited to create a more zymogenic pro-urokinase (lower intrinsic catalytic activity) with a high catalytic activity, as exemplified by two of the mutants. The changes in intrinsic catalytic activity and tyro-chain activity induced by the mutations were due to changes in k(cat) rather than K-m. Some significant structure-function differences between prourokinase and its highly homologous counterpart, tissue plasminogen activator, were also found.	HARVARD UNIV,SCH MED,BETH ISRAEL DEACONESS MED CTR,INST PREVENT CARDIOVASC DIS,VASC RES LAB,BOSTON,MA 02215; NANJING UNIV,DEPT BIOCHEM,STATE KEY LAB PHARMACEUT BIOTECHNOL,NANJING 210008,PEOPLES R CHINA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Nanjing University				Jiang, Yongping/0000-0001-6024-4187				Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; GUREWICH V, 1989, J CLIN INVEST, V82, P1956; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; Liu JN, 1996, BIOCHEMISTRY-US, V35, P14070, DOI 10.1021/bi9605393; LIU JN, 1993, BLOOD, V81, P980; LIU JN, 1995, J BIOL CHEM, V270, P8408, DOI 10.1074/jbc.270.15.8408; LIU JN, 1992, J BIOL CHEM, V267, P15289; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; ORINI G, 1991, EUR J BIOCHEM, V195, P691; PANNELL R, 1986, BLOOD, V67, P1215; PANNELL R, 1987, BLOOD, V69, P22; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PETERSEN LC, 1990, BIOCHEMISTRY-US, V29, P3451, DOI 10.1021/bi00466a005; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; Tachias K, 1997, J BIOL CHEM, V272, P28; Tachias K, 1996, J BIOL CHEM, V271, P28749, DOI 10.1074/jbc.271.46.28749; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; VALINSKY JE, 1981, CELL, V25, P471, DOI 10.1016/0092-8674(81)90065-9; VOSKUILEN M, 1987, J BIOL CHEM, V262, P5944; WINKLER ME, 1986, BIOCHEMISTRY-US, V25, P4041, DOI 10.1021/bi00362a008	30	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23818	23823		10.1074/jbc.272.38.23818	http://dx.doi.org/10.1074/jbc.272.38.23818			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295329	hybrid			2022-12-27	WOS:A1997XX38100054
J	Whitman, SP; Civoli, F; Daniel, LW				Whitman, SP; Civoli, F; Daniel, LW			Protein kinase C beta II activation by 1-beta-D-arabinofuranosylcytosine is antagonistic to stimulation of apoptosis and Bcl-2 alpha down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID-LEUKEMIA CELLS; JUN GENE-EXPRESSION; ETHER LIPID ANALOGS; HL-60 CELLS; BCL-2; INHIBITION; DEATH; CERAMIDE; DIFFERENTIATION; PATHWAY	1-beta-D-Arabinofuranosylcytosine (ara-C) stimulates the formation of both diglyceride and ceramide in the acute myelogenous leukemia cell line HL-60 (Strum, J. C., Small, G. W., Pauig, S. B., and Daniel, L. W. (1994) J. Biol. Chem 269, 15493-15497). ara-C also causes apoptosis in HL-60 cells which can be mimicked by exogenous ceramide. However, the signaling role for ara-C-induced diacylglycerol (DAG) is not defined. We found that Bcl-2 levels were increased by treatment of HL-60 cells with exogenous DAG or 12-O-tetradecanoylphorbol-13-acetate (TPA). In contrast, exogenous ceramide treatment caused a decrease in cellular Bcl-2 levels. Thus, ara-C stimulates the synthesis of two second messengers with opposing effects on Bcl-2. Since the effects of ara-C-induced DAG could be due to protein kinase C (PKC) activation, we determined the effects of ara-C on PKC isozymes. ara-C caused an increase in membrane-bound PKC beta II (but not PKC alpha or PKC delta). ara-C or TPA-induced translocation of PKC beta II was inhibited by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3), and ara-C-induced apoptosis was stimulated by pretreatment of the cells with ET-18-OCH3. ET-18-OCH3 also inhibited stimulation of Bcl-2 by TPA and enhanced the decrease in Bcl-2 observed in ara-C-treated cells. These data indicate that ara-C-induced apoptosis is limited by ara-C-stimulated PKC beta II through effects on Bcl-2. To further determine the role of PKC, we used antisense oligonucleotides directed toward PKC beta II. The antisense, but not the sense, oligonucleotide inhibited PKC beta II activation and enhanced ara-C-induced apoptosis. These data demonstrate that the stimulation of apoptosis by ara-C is self-limiting and can be enhanced by inhibition of PKC.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NCI NIH HHS [CA43297, CA48995, CA67717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA067717, R01CA048995, R01CA043297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BERGGREN MI, 1993, CANCER RES, V53, P4297; BLUMBERG PM, 1994, CANC METASTASIS REV, V13, P411; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BURNS D, 1992, ADV EXP MED BIOL, V318, P275; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CHEN M, 1995, CANCER RES, V55, P991; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DANIEL LW, 1987, LIPIDS, V22, P851, DOI 10.1007/BF02535543; DANIEL LW, 1991, CANC CHEMOTHERAPY, P2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DIOMEDE L, 1997, J CANC, V53, P124; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; HASHIMOTO K, 1990, FEBS LETT, V263, P31, DOI 10.1016/0014-5793(90)80698-I; HELFMAN DM, 1983, CANCER RES, V43, P2955; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOFFMAN DR, 1992, BIOCHIM BIOPHYS ACTA, V1127, P74, DOI 10.1016/0005-2760(92)90203-8; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KEITH FJ, 1995, LEUKEMIA, V9, P131; KHARBANDA S, 1991, BIOCHEMISTRY-US, V30, P7947, DOI 10.1021/bi00246a011; KHARBANDA S, 1994, MOL PHARMACOL, V46, P67; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUCERA GL, 1992, CANCER RES, V52, P3886; Lohmeyer Matthias, 1994, Drugs of the Future, V19, P1021; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MOLINEDO F, 1997, CANCER RES, V57, P1320; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; PRINCIPE P, 1992, CANCER RES, V52, P2509; RAY S, 1994, CANCER CHEMOTH PHARM, V34, P365, DOI 10.1007/s002800050156; SEEWALD MJ, 1990, CANCER RES, V50, P4458; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; WHITMAN SP, 1996, THESIS WAKE FOREST U; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4	44	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23481	23484		10.1074/jbc.272.38.23481	http://dx.doi.org/10.1074/jbc.272.38.23481			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295281	hybrid			2022-12-27	WOS:A1997XX38100006
J	Han, M; Lou, JH; Nakanishi, K; Sakmar, TP; Smith, SO				Han, M; Lou, JH; Nakanishi, K; Sakmar, TP; Smith, SO			Partial agonist activity of 11-cis-retinal in rhodopsin mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE RHODOPSIN; ROD PHOTORECEPTORS; MOLECULAR-ORIGIN; INVERSE AGONISTS; DARK NOISE; ACTIVATION; CHROMOPHORE; OPSIN; REPLACEMENTS; TRANSDUCTION	Rhodopsin, the photoreceptor molecule of the vertebrate rod cell, is a G protein-coupled receptor. Rhodopsin consists of the opsin apoprotein and its 11-cis-retinal chromophore, which is covalently bound to a specific lysine residue by a stable protonated Schiff base linkage, Rhodopsin activation occurs when light causes photoisomerization of the 11-cis chromophore to its all-trans form. The all-trans chromophore is the receptor agonist. The 11-cis-retinylidene chromophore is analogous pharmacologically to a potent inverse agonist of the receptor, We report here that replacement of a highly conserved glycine residue (Gly(121)) causes 11-cis-retinal to become a pharmacologic partial agonist, Although the mutant apoproteins do not display constitutive activity, they are active in the dark when bound to an 11-cis-retinylidene chromophore, or to a ''locked'' chromophore analogue, Ret-7, The degree of partial agonism is directly related to the size of the amino acid replacement at position 121, and it can be reversed by a specific second-site replacement of Phe(261), Thus, mutation of Gly(121) in rhodopsin causes 11-cis-retinal to act as a partial agonist rather than an inverse agonist, allowing the mutant pigment to activate transducin in the dark.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021; COLUMBIA UNIV,DEPT CHEM,NEW YORK,NY 10027; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Columbia University; Yale University			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953	NIGMS NIH HHS [GM 36564, GM 41412] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036564, R01GM041412] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA H, 1980, J AM CHEM SOC, V102, P6370, DOI 10.1021/ja00540a047; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; BARLOW RB, 1993, NATURE, V366, P64, DOI 10.1038/366064a0; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BLACK JW, 1995, NATURE, V374, P214, DOI 10.1038/374214a0; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; Cho W, 1996, MOL PHARMACOL, V50, P1338; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; CORSON DW, 1990, P NATL ACAD SCI USA, V87, P6823, DOI 10.1073/pnas.87.17.6823; CROUCH R, 1984, INVEST OPHTH VIS SCI, V25, P419; DONNER K, 1994, VISION RES, V32, P853; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; Han M, 1996, J BIOL CHEM, V271, P32330, DOI 10.1074/jbc.271.50.32330; Han M, 1996, J BIOL CHEM, V271, P32337, DOI 10.1074/jbc.271.50.32337; Hecht S, 1942, J GEN PHYSIOL, V25, P819, DOI 10.1085/jgp.25.6.819; HU SH, 1994, BIOCHEMISTRY-US, V33, P408, DOI 10.1021/bi00168a004; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; MIN KC, 1993, J BIOL CHEM, V268, P9400; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; OLSON KD, 1995, P NATL ACAD SCI USA, V92, P3185, DOI 10.1073/pnas.92.8.3185; PEPPERBERG DR, 1976, SCIENCE, V191, P394, DOI 10.1126/science.1246621; Rieke F, 1996, BIOPHYS J, V71, P2553, DOI 10.1016/S0006-3495(96)79448-1; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; STRADER CD, 1989, J BIOL CHEM, V264, P16470; ZANKEL T, 1990, J AM CHEM SOC, V112, P5387, DOI 10.1021/ja00169a077; ZHANG HZ, 1994, J AM CHEM SOC, V116, P10165, DOI 10.1021/ja00101a040	33	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23081	23085		10.1074/jbc.272.37.23081	http://dx.doi.org/10.1074/jbc.272.37.23081			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287308	hybrid			2022-12-27	WOS:A1997XV74400019
J	Michel, C; vanEchtenDeckert, G; Rother, J; Sandhoff, K; Wang, E; Merrill, AH				Michel, C; vanEchtenDeckert, G; Rother, J; Sandhoff, K; Wang, E; Merrill, AH			Characterization of ceramide synthesis - A dihydroceramide desaturase introduces the 4,5-trans-double bond of sphingosine at the level of dihydroceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO SPHINGOLIPID BIOSYNTHESIS; SPHINGANINE N-ACYLTRANSFERASE; RAT-LIVER; GOLGI-APPARATUS; DE-NOVO; MEDIATED BIOLOGY; FATTY-ACIDS; CELL-DEATH; SPHINGOMYELIN; CULTURE	Ceramide (N-acylsphingosine) biosynthesis has been proposed to involve introduction of the 4,5-trans-double bond of sphingosine after synthesis of dihydroceramide (i.e. N-acylsphinganine). For the first time, the in vitro conversion of dihydroceramide to ceramide has been demonstrated using rat liver microsomes and N-[1-C-14]octanoyl-D-erythro-sphinganine (st-H,Cer) and either NADH or NADPH as co-substrate; the apparent K-m values for st-H,Cer and NADH were 340 and 120 mu M, respectively. Molecular oxygen is required for enzymatic activity, and cyanide, divalent copper, as well as antibodies raised against cytochrome b(5) are inhibitory, which suggests that this enzyme should be named dihydroceramide desaturase based on these similarities with the mechanism of Delta(9)-desaturase (stearoyl-CoA desaturase). Factors that influenced the activity of dihydroceramide desaturase include the alkyl chain length of the sphingoid base (in the order C-18 > C-12 > C-8) and fatty acid (C-8 > C-18); the stereochemistry of the sphingoid base (D-erythro- > L-threo-dihydroceramides); the nature of the headgroup, with the highest activity with dihydroceramide, but some (similar to 20%) activity with dihydrosphingomyelin (activity was not detected with dihydroglucosylceramide, however); and the ability to utilize alternative reductants (ascorbic acid could substitute for a reduced pyridine nucleotide, but was inhibitory at higher concentrations). Dihydroceramide desaturase was inhibited by dithiothreitol, which suggests that it might be possible to alter ceramide synthesis by varying the thiol status of hepatocytes, Consistent with this hypothesis, when rat hepatocytes were cultured in varying concentrations of N-acetylcysteine (5 and 10 mM), there was a decrease in the relative incorporation of [C-14]serine into [C-14]ceramide. These studies have conclusively established the pathway of ceramide synthesis via desaturation of dihydroceramide and have uncovered several properties of this reaction that warrant further consideration for their relevance to both sphingolipid metabolism and signaling.	UNIV BONN, KEKULE INST ORGAN CHEM & BIOCHEM, D-53121 BONN, GERMANY; EMORY UNIV, DEPT BIOCHEM, ATLANTA, GA 30322 USA	University of Bonn; Emory University				Merrill, Alfred/0000-0002-6673-968X				BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN PE, 1970, J BIOL CHEM, V245, P335; CHIGORNO V, 1994, EUR J BIOCHEM, V221, P1095, DOI 10.1111/j.1432-1033.1994.tb18829.x; DUVAL DL, 1995, ARCH BIOCHEM BIOPHYS, V316, P699, DOI 10.1006/abbi.1995.1093; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Jeffcoat R, 1979, Essays Biochem, V15, P1; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; LARRAURI A, 1987, Molecular Toxicology, V1, P301; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MERRILL AH, 1995, J BIOL CHEM, V270, P13834, DOI 10.1074/jbc.270.23.13834; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MESSMER TO, 1989, J NUTR, V119, P534, DOI 10.1093/jn/119.4.534; NAKAGAWA Y, 1994, EUR J PHARM-ENVIRON, V270, P341, DOI 10.1016/0926-6917(94)90010-8; ONG DE, 1973, J BIOL CHEM, V248, P3884; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; PALTAUF F, 1974, J BIOL CHEM, V249, P2661; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; SREEKRISHNA K, 1980, BIOCHIM BIOPHYS ACTA, V619, P267, DOI 10.1016/0005-2760(80)90075-2; STOFFEL W, 1974, H-S Z PHYSIOL CHEM, V355, P911, DOI 10.1515/bchm2.1974.355.2.911; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WANG E, 1991, J BIOL CHEM, V266, P14486; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; YOKOYAMA K, 1995, FEBS LETT, V368, P477, DOI 10.1016/0014-5793(95)00714-K	35	237	250	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22432	22437		10.1074/jbc.272.36.22432	http://dx.doi.org/10.1074/jbc.272.36.22432			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9312549	hybrid			2022-12-27	WOS:A1997XV49200013
J	Baek, SH; Choi, KS; Yoo, YJ; Cho, JM; Baker, RT; Tanaka, K; Chung, CH				Baek, SH; Choi, KS; Yoo, YJ; Cho, JM; Baker, RT; Tanaka, K; Chung, CH			Molecular cloning of a novel ubiquitin-specific protease, UBP41, with isopeptidase activity in chick skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HYDROLASES; DEUBIQUITINATING ENZYME; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; GENE; DEGRADATION; PROTEINS; PROTEOLYSIS; PRECURSOR; ONCOGENE	A cDNA encoding a new ubiquitin-specific protease, UBP41, in chick skeletal muscle was cloned using an Escherichia coli-based in vivo screening method. Nucleotide sequence analysis of the cDNA containing an open reading frame of 1,071 base pairs revealed that the protease consists of 357 residues with a calculated molecular mass of 40,847 Da, and is related to members of the UBP family containing highly conserved Cys and His domains. Chick UBP41 was expressed in E. coli and purified from the cells to apparent homogeneity, using I-125-labeled ubiquitin-alpha NH-MHISPPEPESEEEEEHYC as a substrate. The purified enzyme behaved as an approximately 43-kDa protein under both denaturing and nondenaturing conditions, suggesting that it consists of a single polypeptide chain. Like other deubiquitinating enzymes, it was sensitive to inhibition by ubiquitin-aldehyde and sulfhydryl blocking agents, such as N-ethylmaleimide. The UBP41 protease cleaved at the C terminus of the ubiquitin moiety in natural and engineered fusions irrespective of their sizes; thus, it is active against ubiquitin-beta-galactosidase as well as ubiquitin C-terminal extension protein of 80 amino acids. UBP41 also released free ubiquitin from poly-His-tagged diubiquitin. Moreover, it converted poly-ubiquitinated lysozyme conjugates to mono-ubiquitinated forms of about 24 kDa, although the latter molecules were not further degraded to free ubiquitin and lysozyme. These results suggest that UBP41 may play an important role in the recycling of ubiquitin by hydrolysis of branched poly-ubiquitin chains generated by the action of 26 S proteasome on poly-ubiquitinated protein substrates, as well as in the production of free ubiquitin from linear poly-ubiquitin chains and of certain ribosomal proteins from ubiquitin fusion proteins.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MOL BIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL NAT SCI, RES CTR CELL DIFFERENTIAT, SEOUL 151742, SOUTH KOREA; LG BIOTECH LTD, TAEJON 305380, SOUTH KOREA; AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, MOL GENET GRP, CANBERRA, ACT 2601, AUSTRALIA; JAPAN SCI & TECHNOL CORP, CREST, METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN	Seoul National University (SNU); Seoul National University (SNU); Australian National University; John Curtin School of Medical Research; Japan Science & Technology Agency (JST)			Yoo, Yung Joon/AAH-5002-2020					Ausubel FM, 1988, MOL REPROD DEV; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Baek SH, 1997, BIOCHEM J, V325, P325, DOI 10.1042/bj3250325; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BOND U, 1986, MOL CELL BIOL, V6, P4602, DOI 10.1128/MCB.6.12.4602; Chung CH, 1996, ADV EXP MED BIOL, V389, P203; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FALQUET L, 1995, FEBS LETT, V376, P233, DOI 10.1016/0014-5793(95)01287-7; FALQUET L, 1995, FEBS LETT, V359, P73, DOI 10.1016/0014-5793(94)01451-6; FINLEY D, 1989, NATURE, V338, P414; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOUGH R, 1986, J BIOL CHEM, V261, P2391; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LUND PK, 1985, J BIOL CHEM, V260, P7609; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; NAKAMURA T, 1992, ONCOGENE, V7, P733; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEIN RL, 1995, BIOCHEMISTRY-US, V34, P12616, DOI 10.1021/bi00039a017; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WILKINSON KD, 1992, BIOCHEM SOC T, V20, P631, DOI 10.1042/bst0200631; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Woo SK, 1997, J BIOCHEM-TOKYO, V121, P684; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766; YOO Y, 1989, J BIOL CHEM, V264, P17078; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	44	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25560	25565		10.1074/jbc.272.41.25560	http://dx.doi.org/10.1074/jbc.272.41.25560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325273	hybrid			2022-12-27	WOS:A1997YA35800028
J	Bowie, AG; Moynagh, PN; ONeill, LAJ				Bowie, AG; Moynagh, PN; ONeill, LAJ			Lipid peroxidation is involved in the activation of NF-kappa B by tumor necrosis factor but not interleukin-1 in the human endothelial cell line ECV304 - Lack of involvement of H2O2 in NF-kappa B activation by either cytokine in both primary and transformed endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY GENE INDUCTION; HUMAN T-CELL; TRANSCRIPTION FACTOR; ADHESION MOLECULE-1; FACTOR-ALPHA; TISSUE FACTOR; POSTTRANSCRIPTIONAL REGULATION; ATHEROSCLEROTIC LESION; HYDROGEN-PEROXIDE; INTACT-CELLS	It has been proposed that reactive oxygen species, and in particular H2O2, may be involved in the activation of NF-kappa B by diverse stimuli in different cell types, Here we have investigated the effect of a range of putative antioxidants on NF-kappa B activation by interleukin-1 and tumor necrosis factor as well as the ability of H2O2 to activate NF-kappa B in primary human umbilical vein endothelial cells and the transformed human endothelial cell line ECV304. Activation of NF-kappa B and stimulation of I kappa B alpha degradation by H2O2 was only evident in the transformed cells and required much longer contact times than that observed with interleukin-1 or tumor necrosis factor. Furthermore, only H2O2 was sensitive to N-acetyl-L-cysteine, and no increase in H2O2 was detected in response to either cytokine, Pyrrolidine dithiocarbamate has been purported to be a specific antioxidant inhibitor of NF-kappa B that acts independently of activating agent or cell type, However, we found that tumor necrosis factor-but not interleukin-1-driven NF-kappa B activation and I kappa B alpha degradation were sensitive to pyrrolidine dithiocarbamate in transformed cells, while neither pathway was inhibited in primary cells, Phorbol ester-mediated activation was sensitive in both transformed and primary cells, Other antioxidants failed to inhibit either cytokine, while the iron chelators desferrioxamine and 2,2,6,6-tetramethylpiperidine-1-oxyl mimicked the pattern of inhibition seen for the dithiocarbamate, This suggested that pyrrolidine dithiocarbamate was inhibiting NF-kappa B activation in endothelial cells primarily through its iron-chelating properties, Tumor necrosis factor, but not interleukin-1, was found to induce lipid peroxidation in ECV304 cells, This was inhibited by pyrrolidine dithiocarbamate and desferrioxamine, t-Butyl hydroperoxide, which induces lipid peroxidation, activated NF-kappa B, Finally, butylated hydroxyanisole, which inhibits lipid peroxidation but has no iron-chelating properties, inhibited NF-kappa B activation by tumor necrosis factor but not interleukin-1. Taken together, the results argue against a role for H2O2 in NF-kappa B activation by cytokines in endothelial cells, Furthermore, tumor necrosis factor and interleukin-1 activate NF-kappa B through different mechanisms in ECV304 cells, with the tumor necrosis factor pathway involving iron-catalyzed lipid peroxidation.	UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND	Trinity College Dublin; University College Dublin				Moynagh, Paul/0000-0002-4139-3061; Bowie, Andrew/0000-0001-5316-4373				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARRADAS MA, 1989, FEBS LETT, V245, P105, DOI 10.1016/0014-5793(89)80201-7; BARTOLI GM, 1983, FEBS LETT, V164, P371, DOI 10.1016/0014-5793(83)80319-6; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHIAO C, 1995, CANCER RES, V55, P3576; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Fiers W, 1995, BIOL THERAPY CANC, P295; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARPE JD, 1985, J IMMUNOL METHODS, V78, P323; Hennig B, 1996, AM J CLIN NUTR, V63, P322, DOI 10.1093/ajcn/63.3.322; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ISRAEL N, 1992, J IMMUNOL, V149, P3386; Kowaltowski AJ, 1996, J BIOL CHEM, V271, P2929, DOI 10.1074/jbc.271.6.2929; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; ORTHNER CL, 1995, BLOOD, V86, P436, DOI 10.1182/blood.V86.2.436.bloodjournal862436; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PERRIN D, 1978, IUPAC STABILITY CO B, P329; ROSEN GM, 1984, METHOD ENZYMOL, V105, P198; ROYALL JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P686, DOI 10.1016/0003-9861(92)90742-F; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Schoonbroodt S, 1997, BIOCHEM J, V321, P777, DOI 10.1042/bj3210777; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sen CK, 1996, BIOCHEM BIOPH RES CO, V218, P148, DOI 10.1006/bbrc.1996.0026; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; SLATER TF, 1984, METHOD ENZYMOL, V105, P283; SUNDERMAN FW, 1991, ANN CLIN LAB SCI, V21, P70; SUZUKI YJ, 1995, BIOCHEM BIOPH RES CO, V210, P537, DOI 10.1006/bbrc.1995.1693; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; VALENTINE WM, 1992, CHEM RES TOXICOL, V5, P254, DOI 10.1021/tx00026a017; VOEST EE, 1993, FREE RADICAL BIO MED, V15, P589, DOI 10.1016/0891-5849(93)90161-M; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665	64	171	175	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25941	25950		10.1074/jbc.272.41.25941	http://dx.doi.org/10.1074/jbc.272.41.25941			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325328	hybrid, Green Accepted			2022-12-27	WOS:A1997YA35800083
J	Hardwick, JS; Sefton, BM				Hardwick, JS; Sefton, BM			The activated form of the Lck tyrosine protein kinase in cells exposed to hydrogen peroxide is phosphorylated at both Tyr-394 and Tyr-505	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMOLECULAR AUTOPHOSPHORYLATION; FUNCTIONAL DISSECTION; P56LCK; P56(LCK); GENE; PALMITOYLATION; STIMULATION; PP60(C-SRC); MYRISTATE; PROMOTER	Members of the Src family of non-receptor tyrosine protein kinases are known to be inhibited by the intramolecular association between a phosphorylated carboxyl-terminal tyrosine residue and the SH2 domain. We have previously shown that exposure of cells to H2O2 strongly activates Lck, a lymphocyte-specific Src family kinase, by inducing phosphorylation on Tyr-394, an absolutely conserved residue within the activation loop of the catalytic domain. Here we show that Lck that has been activated by H2O2 is simultaneously phosphorylated at both the carboxyl-terminal tyrosine (Tyr-505) and Tyr-394. Thus, dephosphorylation of Tyr-505 is not a prerequisite for either phosphorylation of Lck at Tyr-394 or catalytic activation of the kinase. These results indicate that activation of Lck by phosphorylation of Tyr-394 is dominant over any inhibition induced by phosphorylation of Tyr-505. We propose that these results may be extended to all Src family members.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92037	University of California System; University of California San Diego	Hardwick, JS (corresponding author), SALK INST BIOL STUDIES,MOL BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186, USA.				NCI NIH HHS [CA42350, CA14195] Funding Source: Medline; NIGMS NIH HHS [2T32-GM07240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350, P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Bevan AP, 1995, MOL CELL BIOCHEM, V153, P49, DOI 10.1007/BF01075918; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KAMPS MP, 1988, ONCOGENE, V2, P305; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; LUO K, 1990, ONCOGENE, V5, P921; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914; Yurchak LK, 1996, J BIOL CHEM, V271, P12549, DOI 10.1074/jbc.271.21.12549	44	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25429	25432		10.1074/jbc.272.41.25429	http://dx.doi.org/10.1074/jbc.272.41.25429			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325251	hybrid			2022-12-27	WOS:A1997YA35800006
J	Liochev, SI; Fridovich, I				Liochev, SI; Fridovich, I			A mechanism for complementation of the sodA sodB defect in Escherichia coli by overproduction of the rbo gene product (Desulfoferrodoxin) from Desulfoarculus baarsii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; OXIDATIVE DAMAGE; OXYGEN-TOXICITY; DNA-DAMAGE; IN-VITRO; PURIFICATION; MUTANTS; CELLS; VIVO; IRON	Overexpression of rbo in Escherichia coli prevents the inactivation of the [4Fe-4S]-containing fumarases that otherwise occurs in the sodA sodB strain, It similarly protects against the increased sensitivity toward H2O2, which is imposed by the lack of SOD A and SOD B. These results would be explained on the basis of scavenging of O-2(radical anion) within the cells by RBO. This interpretation was supported by measurements of intracellular scavenging of O-2(radical anion) by the lucigenin luminescence method. Since SOD activity could not be detected in dilute extracts, of the RBO-overexpressing sodA sodB strain, we propose that RBO catalyzes the reduction of O-2(radical anion) at the expense of cellular reductants such as NAD(P)H. A similar mechanism may apply to other instances of complementation of SOD defects by non SOD genes.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University								ARCHIBALD FS, 1986, INFECT IMMUN, V51, P631, DOI 10.1128/IAI.51.2.631-641.1986; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; FAULKNER K, 1993, FREE RADICAL BIO MED, V15, P447, DOI 10.1016/0891-5849(93)90044-U; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Hill RL, 1969, METHOD ENZYMOL, V8, P91, DOI 10.1016/0076-6879(69)13021-9; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lehmann Y, 1996, J BACTERIOL, V178, P7152, DOI 10.1128/jb.178.24.7152-7158.1996; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; Liochev SI, 1997, P NATL ACAD SCI USA, V94, P2891, DOI 10.1073/pnas.94.7.2891; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LIOCHEV SI, 1995, ARCH BIOCHEM BIOPHYS, V321, P271, DOI 10.1006/abbi.1995.1395; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V337, P115, DOI 10.1006/abbi.1997.9766; LIOCHEV SI, 1996, FREE RADICAL RES, V5, P369; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PIANZZOLA MJ, 1996, J BACTERIOL, V178, P3736; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3	26	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25573	25575		10.1074/jbc.272.41.25573	http://dx.doi.org/10.1074/jbc.272.41.25573			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325275	hybrid			2022-12-27	WOS:A1997YA35800030
J	Liu, SC; Hoke, D; Julian, J; Carson, DD				Liu, SC; Hoke, D; Julian, J; Carson, DD			Heparin/heparan sulfate (HP/HS) interacting protein (HIP) supports cell attachment and selective, high affinity binding of HP/HS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN HEPARAN-SULFATE; TUMOR-METASTASIS; MOUSE EMBRYOS; GROWTH-FACTOR; LINE RL95; EXPRESSION; ADHESION	Heparin/heparan sulfate (HP/HS), HS proteoglycans, and their binding proteins play important roles in a variety of biological processes. Previously, we identified a novel cell surface HP/HS interacting protein (HIP) from human uterine epithelia and a variety of other human epithelial and endothelial cells and cell lines (Liu, S., Smith, S. E., Julian, J., Rohde, L. H., Karin, N. J., and Carson, D. D. (1996) J. Biol. Chem. 271, 11817-11823; Rohde, L. H., Julian, J., Babaknia, A., and Carson, D. D. (1996) J. Biol. Chem. 271, 11824-11830). In the current studies, we have purified and characterized HIP from HEC cells, a human uterine epithelial cell line, as well as recombinant HIP from a bacterial expression system. HIP supports attachment of the human trophoblastic cell line, JAR, in a HS-dependent fashion. Predigestion of JAR cells with a mixture of heparitinases, but not chondroitinase AC, abolished cell attachment to HIP. In addition, JAR cell attachment to HIP is highly sensitive to HP inhibition and much more selective for HP/HS than other glycosaminoglycans. Dermatan sulfate displays partial inhibitory activity as well, consistent with the observation that chondroitinase ABC digestion partially reduces JAR cell attachment to HIP. Solid-phase binding assays indicate HIP binds [H-3]HP with high affinity (apparent K-D = 8 nM). Furthermore, HIP bound cell surface/extracellular matrix-associated HS, expressed by RL95 cells, a human uterine epithelial cell line. Anti-HIP antibody generated against a synthetic peptide derived from a putative HP/HS-binding motif resident within HIP inhibited about half of [H-3]HP binding to HIP, indicating that this domain is a functional HP-binding domain of HIP. Similarly, this same synthetic peptide motif of HIP could block about 50% of [H-3]HP binding to HIP; however, this peptide almost completely inhibited cell attachment to HIP, suggesting a critical role, in this regard. Collectively, these results suggest that HIP can function as a HP/HS-binding cell-cell/cell-matrix adhesion molecule.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025235, R01HD025235] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25235] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CARSON DD, 1992, CELL SURFACE CARBOHY, P257; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEGREN V, 1984, J IMMUNOL METHODS, V67, P377; Liu SC, 1996, J BIOL CHEM, V271, P11817, DOI 10.1074/jbc.271.20.11817; Liu SC, 1997, P NATL ACAD SCI USA, V94, P1739, DOI 10.1073/pnas.94.5.1739; Marchetti D, 1997, J BIOL CHEM, V272, P15891, DOI 10.1074/jbc.272.25.15891; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; PATTILLO RA, 1971, ANN NY ACAD SCI, V172, P288, DOI 10.1111/j.1749-6632.1971.tb34942.x; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RABOUDI N, 1992, J BIOL CHEM, V267, P11930; ROHDE LH, 1993, J CELL PHYSIOL, V155, P185, DOI 10.1002/jcp.1041550124; Rohde LH, 1996, J BIOL CHEM, V271, P11824, DOI 10.1074/jbc.271.20.11824; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; VLODAVSKY I, 1988, ISRAEL J MED SCI, V24, P464; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888	26	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25856	25862		10.1074/jbc.272.41.25856	http://dx.doi.org/10.1074/jbc.272.41.25856			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325317	hybrid			2022-12-27	WOS:A1997YA35800072
J	Pace, P; Taylor, J; Suntharalingam, S; Coombes, RC; Ali, S				Pace, P; Taylor, J; Suntharalingam, S; Coombes, RC; Ali, S			Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ACTIVATION; GLUCOCORTICOID RECEPTORS; PROGESTERONE RECEPTORS; IN-VITRO; SUPERFAMILY; DOMAINS; GENE; MOUSE; ANTIESTROGENS; REGIONS	The cloning of a novel estrogen receptor beta (denoted ER beta) has recently been described (Kuiper, G. G. J. M., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafsson, J-A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5925-5930 and Mosselman, S., Polman, J., and Dijkema, R. (1996) FEBS Lett. 392, 49-53). ER beta is highly homologous to the ''classical'' estrogen receptor alpha (here referred to as ER alpha), has been shown to bind estrogens with an affinity similar to that of ER alpha; and activates expression of reporter genes containing estrogen response elements in an estrogen-dependent manner. Here we describe functional studies comparing the DNA binding abilities of human ER alpha and beta in gel shift assays. We show that DNA binding by ER alpha and beta are similarly affected by elevated temperature in the absence of ligand or in the presence of 17 beta-estradiol and the partial estrogen agonist 4-hydroxy-tamoxifen. In the absence of ligand, DNA binding by ER alpha and beta is rapidly lost at 37 degrees C, while in the presence of 17 beta-estradiol and 4-hydroxy-tamoxifen the loss in DNA binding at elevated temperature is much more gradual. We show that the loss in DNA binding is not due to degradation of the receptor proteins. However, while the complete antagonist ICI 182,780 does not ''protect'' human ER alpha (hER alpha) from loss of DNA binding at elevated temperature in vitro, it does appear to protect human ER beta (hER beta), suggestive of differences in the way ICI 182,780 acts on hER alpha and beta. We further report that ER alpha and beta can dimerize with each other, the DNA binding domain of hER alpha being sufficient for dimerization with hER beta. Cell and promoter-specific transcription activation by ER alpha has been shown to be dependent on the differential action of the N- and C-terminal transcription activation functions AF-1 and AF-2, respectively. The existence of a second estrogen receptor gene and the dimerization of ER alpha and beta add greater levels of complexity to transcription activation in response to estrogens.	IMPERIAL COLL MED,DEPT MED ONCOL,LONDON W6 8RF,ENGLAND	Imperial College London			Pace, Paul E/A-3104-2012; Ali, Simak/M-6912-2018	Pace, Paul E/0000-0003-1855-5760; Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816				ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V89, P1218; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIBSON MK, 1991, ENDOCRINOLOGY, V129, P2000, DOI 10.1210/endo-129-4-2000; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREEN S, 1987, NATURE, V325, P754; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; KNIPER GGJ, 1996, P NATL ACAD SCI USA, V93, P5925; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x	41	247	257	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25832	25838		10.1074/jbc.272.41.25832	http://dx.doi.org/10.1074/jbc.272.41.25832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325313	hybrid			2022-12-27	WOS:A1997YA35800068
J	Torigoe, K; Ushio, S; Okura, T; Kobayashi, S; Taniai, M; Kunikata, T; Murakami, T; Sanou, O; Kojima, H; Fujii, M; Ohta, T; Ikeda, M; Ikegami, H; Kurimoto, M				Torigoe, K; Ushio, S; Okura, T; Kobayashi, S; Taniai, M; Kunikata, T; Murakami, T; Sanou, O; Kojima, H; Fujii, M; Ohta, T; Ikeda, M; Ikegami, H; Kurimoto, M			Purification and characterization of the human interleukin-18 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA PRODUCTION; T-CELLS; CLONING; PROTEIN; EXPRESSION; CYTOKINE; T1/ST2	Interleukin (IL)-18 was identified as a molecule that induces IFN-gamma production and enhances NK cell cytotoxicity. In this paper, we report upon the purification and characterization of human IL-18 receptor (hIL-18R). We selected the Hodgkin's disease cell line, L428, as the most strongly hIL-18R-expressing cell line based on the results of binding assays. This binding was inhibited by IL-18 but not by IL-1 beta. The dissociation constant (K-d) of I-125-IL-18 binding to L428 cells was about 18.5 nM, with 18,000 binding sites/cell. After immunizing mice with L428 cells and cloning, a single monoclonal antibody (mAb) against hIL-18R was obtained (mAb 117-10C). Sequentially, hIL-18R was purified from 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid (CHAPS)-extracted L428 cells by wheat germ lectin-Sepharose 4B chromatography and mAb 117-10C-Sepharose chromatography. The internal amino acid sequences of hIL-18R all matched those of human IL-1 receptor-related protein (IL-1Rrp), the ligand of which was unknown to date. When expressed in COS-1 cells, the cDNA of IL-1Rrp conferred IL-18 binding properties on the cells and the capacity for signal transduction. From these results, we conclude that a functional IL-18 receptor component is IL-1Rrp.	HAYASHIBARA BIOCHEM LABS INC,FUJISAKI INST,OKAYAMA 702,JAPAN	Hayashibara Biochemical Laboratories, Inc.								Bazan JF, 1996, NATURE, V379, P591, DOI 10.1038/379591a0; CALDERON J, 1988, P NATL ACAD SCI USA, V85, P4837, DOI 10.1073/pnas.85.13.4837; DESAIYAJINIK V, 1995, MOL CELL BIOL, V15, P1817; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Kohno K, 1997, J IMMUNOL, V158, P1541; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsumoto S, 1997, BIOCHEM BIOPH RES CO, V234, P454, DOI 10.1006/bbrc.1997.6665; Micallef MJ, 1996, EUR J IMMUNOL, V26, P1647, DOI 10.1002/eji.1830260736; MORI T, 1994, GENE, V144, P289; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Parnet P, 1996, J BIOL CHEM, V271, P3967; UCHIYAMA T, 1981, J IMMUNOL, V126, P1387; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Ushio S, 1996, J IMMUNOL, V156, P4274; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U	20	423	458	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25737	25742		10.1074/jbc.272.41.25737	http://dx.doi.org/10.1074/jbc.272.41.25737			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325300	hybrid			2022-12-27	WOS:A1997YA35800055
J	Gaffet, P; Jones, AT; Clague, MJ				Gaffet, P; Jones, AT; Clague, MJ			Inhibition of calcium-independent mannose 6-phosphate receptor incorporation into trans-Golgi network-derived clathrin-coated vesicles by Wortmannin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; ENDOCYTIC VESICLES; LYSOSOMAL-ENZYMES; KINASE-ACTIVITY; PROTEIN-KINASE; YEAST; CELLS; INTERNALIZATION; TRAFFICKING; COMPLEX	The transport of pro-catepsin D from the trans-Golgi network (TGN) to the endosomal pathway is dependent on binding to the calcium-independent mannose 6-phosphate receptor (ci-M6PR), which is incorporated into TGN-derived clathrin-coated transport vesicles (CCVs). Inhibition of this transport step by wortmannin has led to the proposal that it is dependent upon a phosphoinositide 3-kinase activity necessary for ci-M6PR recruitment into TGM-derived CCVs or in the formation of those vesicles (Brown, W., J,, DeWald, D, B,, Emr, S. D,, Plutner, H., and Balch, W, E, (1995) J. Cell Biol. 130, 781-796; Davidson, H, W. (1995) J. Cell Biol. 130, 781-796), In this study we have addressed the effect of wortmannin on the TGN step of the ci-M6PR, cycle, CCVs from H562 cells, pretreated or not with 250 nM wortmannin, were purified on equilibrium density gradients. Quantification of TGN-derived CCVs, assessed by gamma-adaptin content in purified vesicle fractions, showed that the formation of the vesicles was only marginally decreased after 20 min of treatment with the drug, while for the same wortmannin treatment, the drug of ci-M6PR recruited into those vesicles was decreased by 70% compared with control, At a later time point (2 h), a reduction in the amount of gamma-adaptin in CCV fractions was also observed, These findings demonstrate that inhibition of ci-M6PR recruitment into CCVs but not of vesicle formation is the primary reason for the observed defect in cathepsin D transport following wortmannin treatment.	UNIV LIVERPOOL,PHYSIOL LAB,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Clague, Michael J/A-7199-2008; Jones, Arwyn/ABE-8709-2020; Jones, Arwyn T/E-4787-2010	Clague, Michael J/0000-0003-3355-9479; Jones, Arwyn/0000-0003-2781-8905; Jones, Arwyn T/0000-0003-2781-8905	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CLAGUE MJ, 1995, FEBS LETT, V367, P272, DOI 10.1016/0014-5793(95)00576-U; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DELBRUCK R, 1994, EUR J CELL BIOL, V64, P7; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HASILIK A, 1980, J BIOL CHEM, V255, P4937; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; JIN M, 1989, J BIOL CHEM, V264, P7675; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; Nakajima Y, 1997, MOL BIOL CELL, V8, P577, DOI 10.1091/mbc.8.4.577; Panaretou C, 1997, J BIOL CHEM, V272, P2477; PEARSE BMF, 1983, METHOD ENZYMOL, V98, P320; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Sato SB, 1996, J BIOCHEM, V119, P887; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STEPHENS L, 1995, BIOCHEM SOC T, V23, P207, DOI 10.1042/bst0230207; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WOODMAN PG, 1991, J CELL BIOL, V112, P1133, DOI 10.1083/jcb.112.6.1133; WOODMAN PG, 1992, METHOD ENZYMOL, V219, P251; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	39	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24170	24175		10.1074/jbc.272.39.24170	http://dx.doi.org/10.1074/jbc.272.39.24170			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305867	hybrid			2022-12-27	WOS:A1997XY51500018
J	Gordon, DF; Lewis, SR; Haugen, BR; James, RA; McDermott, MT; Wood, WM; Ridgway, EC				Gordon, DF; Lewis, SR; Haugen, BR; James, RA; McDermott, MT; Wood, WM; Ridgway, EC			Pit-1 and GATA-2 interact and functionally cooperate to activate the thyrotropin beta-subunit promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-2; COMPOSITE RESPONSE ELEMENT; GENE-EXPRESSION; PITUITARY-GLAND; GROWTH-HORMONE; POU-DOMAIN; MURINE THYROTROPIN; ANTERIOR-PITUITARY; FACTOR PIT-1/GHF-1; HOMEODOMAIN FACTOR	The molecular determinants governing cell-specific expression of the thyrotropin (TSH) beta-subunit gene in pituitary thyrotropes are not well understood, The P1 region of the mouse TSH beta promoter (-133 to -88) region interacts with Pit-1 and an additional 50-kDa factor at an adjacent site that resembles a consensus GATA binding site. Northern and Western blot assays demonstrated the presence of GATA-2 transcripts and protein in TtT-97 thyrotropic tumors, In electrophoretic mobility shift assays, a comigrating complex was observed with both TtT-97 nuclear extracts and GATA-2 expressed in COS cells, The complex demonstrated binding specificity to the P1 region DNA probe and could be disrupted by a GATA-2 antibody, When both Pit-1 and GATA-2 were combined, a slower migrating complex, indicative of a ternary protein-DNA interaction was observed. Cotransfection of both Pit-1 and GATA-2 into CV-1 cells synergistically stimulated mouse TSH beta promoter activity 8.5-fold, while each factor alone had a minimal effect, Mutations that abrogated this functional stimulatory effect mapped to the P1 region. Finally, we show that GATA-2 directly interacts with Pit-1 in solution, In summary, these data demonstrate functional synergy and physical interaction between homeobox and zinc finger factors and provide insights into the transcriptional mechanisms of thyrotrope-specific gene expression.	UNIV COLORADO,HLTH SCI CTR,DIV ENDOCRINOL DIABET & METAB,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036843, K08DK002331] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NIDDK NIH HHS [DK36843, DK02331] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERBLOM IE, 1990, MOL ENDOCRINOL, V4, P589, DOI 10.1210/mend-4-4-589; ALEXANDER LM, 1989, MOL ENDOCRINOL, V3, P1037, DOI 10.1210/mend-3-7-1037; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; Chang W, 1996, J BIOL CHEM, V271, P17733, DOI 10.1074/jbc.271.30.17733; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GORDON DF, 1990, MOL CELL ENDOCRINOL, V71, P93, DOI 10.1016/0303-7207(90)90246-5; GORDON DF, 1993, MOL CELL ENDOCRINOL, V96, P75, DOI 10.1016/0303-7207(93)90097-4; GORDON DF, 1988, DNA-J MOLEC CELL BIO, V7, P17, DOI 10.1089/dna.1988.7.17; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAUGEN BR, 1994, MOL ENDOCRINOL, V8, P1574, DOI 10.1210/me.8.11.1574; Haugen BR, 1996, J BIOL CHEM, V271, P385, DOI 10.1074/jbc.271.1.385; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; KENDALL SK, 1994, MOL ENDOCRINOL, V8, P1420, DOI 10.1210/me.8.10.1420; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; LIN SC, 1994, DEVELOPMENT, V120, P515; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Mink S, 1996, MOL CELL BIOL, V16, P1316; NAGAI T, 1994, BLOOD, V84, P1074, DOI 10.1182/blood.V84.4.1074.bloodjournal8441074; OCRAN KW, 1990, MOL ENDOCRINOL, V4, P766, DOI 10.1210/mend-4-5-766; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSS DS, 1983, ENDOCRINOLOGY, V112, P2050, DOI 10.1210/endo-112-6-2050; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schaufele F, 1996, J BIOL CHEM, V271, P21484, DOI 10.1074/jbc.271.35.21484; SHUPNIK MA, 1992, MOL ENDOCRINOL, V6, P43, DOI 10.1210/me.6.1.43; SHUPNIK MA, 1989, ENDOCR REV, V10, P459, DOI 10.1210/edrv-10-4-459; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WOOD WM, 1990, MOL ENDOCRINOL, V4, P1897, DOI 10.1210/mend-4-12-1897; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	77	110	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24339	24347		10.1074/jbc.272.39.24339	http://dx.doi.org/10.1074/jbc.272.39.24339			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305891	hybrid			2022-12-27	WOS:A1997XY51500042
J	Liu, XL; DeMoss, JA				Liu, XL; DeMoss, JA			Characterization of NarJ, a system-specific chaperone required for nitrate reductase biogenesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-B; GENE-PRODUCT; OPERON; SEQUENCE; PROTEINS; SUBUNIT; IDENTIFICATION; ASSOCIATION; INVOLVEMENT; EXPRESSION	The narGHJI operon encodes the three subunits, alpha, beta, and gamma, of the respiratory nitrate reductase complex in Escherichia coli, A fourth open reading frame of the operon encodes a putative protein, NarJ, which is not present in purified nitrate reductase, bat is required for biogenesis of the membrane-bound complex. NarJ was identified with a T7 expression system and was produced at significantly less than stoichiometric levels relative to the three enzyme subunits. A functional His-tagged NarJ fusion protein was overexpressed di om a multicopy plasmid, purified by Ni2+ affinity chromatography, and characterized. Western blot analysis with antibodies raised against the fusion protein demonstrated that NarJ remained in the cytosol after assembly of the active membrane complex, The cytosolic alpha beta complex accumulated in a nard insertion mutant was rapidly degraded after induction, but was stabilized by NarJ expressed from a multicopy plasmid. Overproduction of the His-tagged NarJ fusion protein in the same mutant led to the formation of an alpha beta NarJ complex, which was resolved by Ni2+ affinity chromatography, The NarJ protein therefore has the properties of a system-specific (private) chaperone that reacts directly with and modifies the properties of the cytosolic alpha beta subunit complex, but remains in the cytoplasm after the assembly of the active alpha beta gamma complex in the membrane.	UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77030 USA	University of Texas System								ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; BERKS BC, 1995, MOL MICROBIOL, V15, P319, DOI 10.1111/j.1365-2958.1995.tb02246.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; BLASCO F, 1992, MOL MICROBIOL, V6, P221, DOI 10.1111/j.1365-2958.1992.tb02003.x; CHAUDHRY GR, 1983, J BIOL CHEM, V258, P5819; DUBOURDIEU M, 1992, J BACTERIOL, V174, P867, DOI 10.1128/jb.174.3.867-872.1992; EDWARDS ES, 1983, J BACTERIOL, V153, P1513, DOI 10.1128/JB.153.3.1513-1520.1983; Edwards RA, 1996, J BACTERIOL, V178, P3426, DOI 10.1128/jb.178.12.3426-3433.1996; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ENOCH HG, 1974, BIOCHEM BIOPH RES CO, V61, P1234, DOI 10.1016/S0006-291X(74)80416-X; GLASER JH, 1972, MOL GEN GENET, V116, P1, DOI 10.1007/BF00334254; HOBSON AH, 1993, P NATL ACAD SCI USA, V90, P5682, DOI 10.1073/pnas.90.12.5682; HOFFMANN T, 1995, FEMS MICROBIOL LETT, V131, P219, DOI 10.1111/j.1574-6968.1995.tb07780.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND K, 1976, J BIOL CHEM, V251, P2207; MACGREGOR CH, 1974, J BIOL CHEM, V249, P5321; MORPETH FF, 1985, BIOCHEMISTRY-US, V24, P40, DOI 10.1021/bi00322a007; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; SCHUMPERLI D, 1982, CELL, V30, P865, DOI 10.1016/0092-8674(82)90291-4; SODERGREN EJ, 1988, J BACTERIOL, V170, P1721, DOI 10.1128/jb.170.4.1721-1729.1988; SODERGREN EJ, 1988, J BIOL CHEM, V263, P16156; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; STEWART V, 1988, MICROBIOL REV, V52, P190, DOI 10.1128/MMBR.52.2.190-232.1988; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074	29	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24266	24271		10.1074/jbc.272.39.24266	http://dx.doi.org/10.1074/jbc.272.39.24266			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305880	hybrid			2022-12-27	WOS:A1997XY51500031
J	Stasche, R; Hinderlich, S; Weise, C; Effertz, K; Lucka, L; Moormann, P; Reutter, W				Stasche, R; Hinderlich, S; Weise, C; Effertz, K; Lucka, L; Moormann, P; Reutter, W			A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver - Molecular cloning and functional expression of UDP-N-acetyl-glucosamine 2-epimerase/N-acetylmannosamine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID; PROTEINS; TUMOR; OLIGOSACCHARIDES; RECOGNITION; 2-EPIMERASE; MUTANTS; BINDING; KIDNEY	N-Acetylneuraminic acid (Neu5Ac) is the precursor of sialic acids, a group of important molecules in biological recognition systems, Biosynthesis of Neu5Ac is initiated and regulated by its key enzyme, UDP-N-acetylglucosamine a-epimerase (UDP-GlcNAc a-epimerase, EC 5.1.3.14)/N-acetylmannosamine kinase (ManNAc kinase, EC 2.7.1.60) in rat liver (Hinderlich, S., Stasche, R., Zeitler, R., and Reutter, W. (1997) J. Biol. Chen. 272, 24313-24318), In the present paper we report the isolation and characterization of a cDNA clone encoding this bifunctional enzyme. An open reading frame of 2166 base pairs encodes 722 amino acids with a predicted molecular mass of 79 kDa. The deduced amino acid sequence contains exact matches of the sequences of five peptides derived from tryptic cleavage of the enzyme, The recombinant bifunctional enzyme was expressed in COS7 cells, where it displayed both epimerase and kinase activity. Distribution of UDP-GlcNAc 2-epimerase/ManNAc kinase in the cytosol of several rat tissues was investigated by determining both specific enzyme activities. Secreting organs (liver, salivary glands, and intestinal mucosa) showed high specific activities of UDP-GlcNAc 2-epimerase/ManNAc kinase, whereas significant levels of these activities were absent from other organs (lung, kidney, spleen, brain, heart, skeletal muscle, and testis). Northern blot analysis revealed no UDP-GlcNAc 2-epimerase/ManNAc kinase mRNA in the non-secreting tissues.	FREE UNIV BERLIN, INST MOL BIOL & BIOCHEM, D-14195 BERLIN, GERMANY; FREE UNIV BERLIN, INST BIOCHEM, D-14195 BERLIN, GERMANY	Free University of Berlin; Free University of Berlin								ALLEN MB, 1980, BIOCHEM J, V185, P577, DOI 10.1042/bj1850577; BASU S, 1995, BIOL SIALIC ACIDS, P7; BHAVANANDAN V P, 1991, Glycobiology, V1, P493, DOI 10.1093/glycob/1.5.493; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BOULARD C, 1982, J IMMUNOL METHODS, V50, P221, DOI 10.1016/0022-1759(82)90228-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTA A, 1970, BIOCHEMISTRY-US, V9, P3363, DOI 10.1021/bi00819a011; DENNIS JW, 1986, EUR J BIOCHEM, V161, P359, DOI 10.1111/j.1432-1033.1986.tb10455.x; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; Maru I, 1996, J BIOL CHEM, V271, P16294, DOI 10.1074/jbc.271.27.16294; NUCK R, 1990, GLYCOCONJUGATE J, V7, P279, DOI 10.1007/BF01073372; PESSINO A, 1991, J BIOL CHEM, V266, P20213; PIRIESHEPHERD SR, 1995, J BIOL CHEM, V270, P5877, DOI 10.1074/jbc.270.11.5877; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; Reuter G, 1996, BIOL CHEM H-S, V377, P325; Reutter, 1997, GLYCOSCIENCES STATUS, P245; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; SAITO M, 1995, BIOL SIALIC ACIDS, P7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA R, 1994, J BIOL CHEM, V269, P1425; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; VANRINSUM J, 1983, BIOCHEM J, V210, P21, DOI 10.1042/bj2100021; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WARREN L, 1972, GLYCOPROTEINS, P1097; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YANG PF, 1994, J BIOL CHEM, V269, P23039	39	150	158	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24319	24324		10.1074/jbc.272.39.24319	http://dx.doi.org/10.1074/jbc.272.39.24319			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305888	hybrid			2022-12-27	WOS:A1997XY51500039
J	Zha, JP; Harada, H; Osipov, K; Jockel, J; Waksman, G; Korsmeyer, SJ				Zha, JP; Harada, H; Osipov, K; Jockel, J; Waksman, G; Korsmeyer, SJ			BH3 domain of BAD is required for heterodimerization with BCL-X-L and pro-apoptotic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-X(L); PROTEIN; INHIBITION; INTERACTS; DISTINCT; SEQUENCE; SURVIVAL	BAD interacts with anti-apoptotic molecules BCL-2 and BCL-X-L and promotes apoptosis. BAD is phosphorylated on serine residues in response to a survival factor, interleukin-3. Phosphorylated BAD cannot bind to BCL-X-L or BCL-2 at membrane sites and is found in the cytosol bound to 14-3-3. We report here that deletion mapping and site-directed mutagenesis identified a BH3 domain within BAD that proved necessary for both its heterodimerization with BCL-X-L and its death agonist activity. Substitution of the conserved Leu(151) with Ala in the BH3 amphipathic alpha-helix abrogated both functions. The BAD Leu(151) mutant was predominantly in the cytosol bound to 14-3-3. The BH3 domain of BCL-2 also proved important for BCL-2/BAD interaction. These results establish a critical role for a BH3 domain within BAD and provide evidence that BAD may function as a death ligand whose pro-apoptotic activity requires heterodimerization with BCL-X-L.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)	Zha, JP (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED & PATHOL,ST LOUIS,MO 63110, USA.							BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Han J, 1996, MOL CELL BIOL, V16, P5857; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	18	257	284	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24101	24104		10.1074/jbc.272.39.24101	http://dx.doi.org/10.1074/jbc.272.39.24101			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305851	hybrid			2022-12-27	WOS:A1997XY51500002
J	Chen, Y; Sharp, ZD; Lee, WH				Chen, Y; Sharp, ZD; Lee, WH			HEC binds to the seventh regulatory subunit of the 26 S proteasome and modulates the proteolysis of mitotic cyclins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-MEDIATED TRANSACTIVATION; ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE; RETINOBLASTOMA PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; ATPASE ACTIVITY; GENE; IDENTIFICATION; YEAST	A newly identified nuclear protein rich in leucine heptad repeats called HEC is important for mitosis. To elucidate its mechanism of action, the region containing leucine heptad repeats was used to identify cellular proteins that potentially interact with HEC. Complementary DNAs encoding several proteins including MSS1, p45, Nek2, and Smc1/Smc2, known to be important for G(2)/M progression, were identified. The interaction be tween HEC and MSS1, the seventh regulatory subunit of the 26 S proteasome, was further demonstrated by in vitro GST pull-down assays. HEC is not a part of the 26 S proteasome and interacts with MSS1 only when it is dissociated from the complex during M phase. Purified MSS1 specifically hydrolyzes ATP, an activity inhibited by HEC. In addition, HEC inhibits the proteolysis of mitotic cyclin B in vitro. Consistent with this biochemical activity, ectopic expression of HEC inhibits the degradation of mitotic cyclins after telophase, resulting eventually in cell death. These results show that HEC is a negative regulator of MSS1 and suggest that it may modulate M phase progression, in part, through the regulation of proteasome mediated degradation of cell cycle regulatory proteins.	UNIV TEXAS,HLTH SCI CTR,DEPT MOL MED,SAN ANTONIO,TX 78245; UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio					NATIONAL CANCER INSTITUTE [R01CA058318] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER; NCI NIH HHS [CA58318] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN Y, 1997, IN PRESS MOL CELL BI, V17; Chen YM, 1996, CANCER RES, V56, P3168; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; He D, 1995, INT REV CYTOL, V162B, P1; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; IRIE K, 1991, CELL, V65, P785, DOI 10.1016/0092-8674(91)90386-D; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; LU KP, 1994, J BIOL CHEM, V269, P6603; LUCERO HA, 1995, J BIOL CHEM, V270, P9178, DOI 10.1074/jbc.270.16.9178; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; ROCQUES PJ, 1995, HUM MOL GENET, V4, P243, DOI 10.1093/hmg/4.2.243; ROY R, 1994, J BIOL CHEM, V269, P9826; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	40	40	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24081	24087		10.1074/jbc.272.38.24081	http://dx.doi.org/10.1074/jbc.272.38.24081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295362	hybrid			2022-12-27	WOS:A1997XX38100087
J	ZernikKobak, M; Vasunia, K; Connelly, M; Anderson, CW; Dixon, K				ZernikKobak, M; Vasunia, K; Connelly, M; Anderson, CW; Dixon, K			Sites of UV-induced phosphorylation of the p34 subunit of replication protein A from HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; NUCLEOTIDE EXCISION-REPAIR; BINDING-PROTEIN; A PHOSPHORYLATION; PURIFIED PROTEINS; POLYMERASE-ALPHA; SV40 ORIGIN; T-ANTIGEN; IN-VITRO; CYCLIN-A	Exposure of mammalian cells to UV radiation alters gene expression and cell cycle progression; some of these responses may ensure survival or serve as mutation-avoidance mechanisms, lessening the consequences of UV-induced DNA damage, We showed previously that UV irradiation increases phosphorylation of the p34 subunit of human replication protein A (RPA) and that this hyperphosphorylation correlated with loss of activity of the DNA replication complex. To characterize further the role of RPA hyperphosphorylation in the cellular response to UV irradiation and to determine which protein kinases might be involved, we identified by phosphopeptide analysis the sites phosphorylated in the p34 subunit of RPA (RPA-p34) from HeLa cells before and after exposure to 30 J/m(2) UV light. In unirradiated HeLa cells, RPA-p34 is phosphorylated primarily at Ser-23 and Ser-29. At least four of the eight serines and one threonine in the N-terminal 33 residues of RPA-p34 can become phosphorylated after UV irradiation, Two of these sites (Ser-23 and Ser-29) ape known to be sites phosphorylated by Cdc2 kinase; two others (Thr-21 and Ser-33) are consensus sites for the DNA-dependent protein kinase (DNA-PK); the fifth site (Ser-11, -12, or -13) does not correspond to the (Ser/Thr)-Gln DNA-PK consensus, All five can be phosphorylated in vitro by incubating purified RPA with purified DNA-PK. Two additional sites, probably Ser-4 and Ser-8, are phosphorylated in vivo after UV irradiation and in vitro by purified DNA-PK. The capacity of purified DNA-PK to phosphorylate many of these same sites on RPA-p34 in vitro implicates DNA-PK or a kinase with similar specificity in the UV-induced hyperphosphorylation of RPA in vivo.	BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	ZernikKobak, M (corresponding author), UNIV CINCINNATI, MED CTR, SCH MED, DEPT ENVIRONM HLTH, CINCINNATI, OH 45267 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052825] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05400, P30 ES06096] Funding Source: Medline; NIGMS NIH HHS [GM52825] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BENOREPARSONS M, 1989, ARCH BIOCHEM BIOPHYS, V272, P274, DOI 10.1016/0003-9861(89)90220-8; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1993, J CELL SCI, V106, P983; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; Henricksen LA, 1996, NUCLEIC ACIDS RES, V24, P3107, DOI 10.1093/nar/24.15.3107; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI L, 1995, MOL CELL BIOL, V15, P5396; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SCHELLENBERGER V, 1994, BIOCHEMISTRY-US, V33, P4251, DOI 10.1021/bi00180a020; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	51	110	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23896	23904		10.1074/jbc.272.38.23896	http://dx.doi.org/10.1074/jbc.272.38.23896			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295339	hybrid			2022-12-27	WOS:A1997XX38100064
J	Maucuer, A; Ozon, S; Manceau, V; Gavet, O; Lawler, S; Curmi, P; Sobel, A				Maucuer, A; Ozon, S; Manceau, V; Gavet, O; Lawler, S; Curmi, P; Sobel, A			KIS is a protein kinase with an RNA recognition motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNAL-TRANSDUCTION; TRANSLATION INITIATION; DISTINCT PATTERNS; ESCHERICHIA-COLI; PHOSPHORYLATION; STATHMIN; CELLS; IDENTIFICATION; ONCOPROTEIN-18; GENE	Protein phosphorylation is involved at multiple steps of RNA processing and in the regulation of protein expression, We present here the first identification of a serine/threonine kinase that possesses an RNP-type RNA recognition motif: KIS. We originally isolated KIS in a two-hybrid screen through its interaction with stathmin, a small phosphoprotein proposed to play a general role in the relay and integration of diverse intracellular signaling pathways. Determination of the primary sequence of KIS shows that it is formed by the juxtaposition of a kinase core with little homology to known kinases and a C-terminal domain that contains a characteristic RNA recognition motif with an intriguing homology to the C-terminal motif of the splicing factor U2AF, KIS produced in bacteria has an autophosphorylating activity and phosphorylates stathmin on serine residues. It also phosphorylates in vitro other classical substrates such as myelin basic protein and synapsin but not histones that inhibit its autophosphorylating activity, Immunofluorescence and biochemical analyses indicate that KIS overexpressed in HEK293 fibroblastic cells is partly targetted to the nucleus. Altogether, these results suggest the implication of KIS in the control of trafficking and/or splicing of RNAs probably through phosphorylation of associated factors.			Maucuer, A (corresponding author), INSERM, U440, 17 RUE FER A MOULIN, F-75005 PARIS, FRANCE.		CURMI, Patrick/G-4036-2013; Maucuer, Alexandre/B-1069-2019	Maucuer, Alexandre/0000-0003-2947-6654; CURMI, Patrick A./0000-0001-5045-8501				Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BERETTA L, 1989, ENDOCRINOLOGY, V125, P1358, DOI 10.1210/endo-125-3-1358; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHNEIWEISS H, 1992, J NEUROCHEM, V58, P282, DOI 10.1111/j.1471-4159.1992.tb09308.x; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOYE V, 1990, J BIOL CHEM, V265, P11650; FRITSCH EF, 1989, MOL CHANGE LAB MANUA; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILBERG MS, 1994, FASEB J, V8, P13, DOI 10.1096/fasebj.8.1.8299885; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; OZON S, 1997, IN PRESS EUR J BIOCH; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POTASHKIN J, 1993, SCIENCE, V262, P573, DOI 10.1126/science.8211184; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; SAWADA S, 1991, MOL CELL BIOL, V11, P5506, DOI 10.1128/MCB.11.11.5506; SCHUBART UK, 1982, J BIOL CHEM, V257, P2231; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK SA, 1995, MOL CELL BIOL, V15, P4497; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	45	43	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23151	23156		10.1074/jbc.272.37.23151	http://dx.doi.org/10.1074/jbc.272.37.23151			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287318	hybrid			2022-12-27	WOS:A1997XV74400029
J	Barth, A; Kreutz, W; Mantele, W				Barth, A; Kreutz, W; Mantele, W			Ca2+ release from the phosphorylated and the unphosphorylated sarcoplasmic reticulum Ca2+ ATPase results in parallel structural changes - An infrared spectroscopic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-ATPASE; RECONSTITUTED PROTEOLIPOSOMES; DIFFERENCE SPECTROSCOPY; CATALYTIC CYCLE; BINDING-SITES; CAGED-ATP; CA2+-ATPASE; CA-2+; H+; PROTON	Structural changes of the sarcoplasmic reticulum Ca2+-ATPase occurring in the reaction step involving phosphoenzyme conversion and Ca2+ release (Ca2E1-P --> E-2-P) were followed using time-resolved infrared spectroscopy in H2O and (H2O)-H-2. The difference spectra measured between 1800 and 1500 cm(-1) were almost identical to those of Ca2+ release from the unphosphorylated ATPase (Ca2E1 --> E), implying that parallel structural changes occur in both steps, This suggests that characteristic structural features of the high affinity Ca2+ binding sites of Ca2E1 are still present in the ADP-sensitive phosphoenzyme Ca2E1-P. In both Ca2+ release steps at least two carboxyl groups become protonated, each of them experiencing the same strength of hydrogen bonding irrespective of whether or not the Ca2+ free ATPase is phosphorylated, This suggests that the same amino acid residues are involved and that they are most likely those that participate in high affinity Ca2+ binding and H+ countertransport, We propose that during Ca2+ release from the phosphoenzyme protons from the lumenal side have access to these residues, Our results are consistent with only one pair of Ca2+ binding sites on the ATPase that serves both Ca2+ translocation and H+ countertransport.	UNIV FREIBURG,INST BIOPHYS & STRAHLENBIOL,D-79104 FREIBURG,GERMANY	University of Freiburg			Barth, Andreas/N-8872-2013	Barth, Andreas/0000-0001-5784-7673				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; Barth A, 1996, J BIOL CHEM, V271, P30637, DOI 10.1074/jbc.271.48.30637; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; BARTH A, 1990, FEBS LETT, V277, P147, DOI 10.1016/0014-5793(90)80830-C; BUCHET R, 1992, BIOCHIM BIOPHYS ACTA, V1104, P207, DOI 10.1016/0005-2736(92)90152-C; BUCHET R, 1991, BIOCHIM BIOPHYS ACTA, V1069, P209, DOI 10.1016/0005-2736(91)90126-S; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; DACOSTA AG, 1994, BBA-BIOMEMBRANES, V1189, P181, DOI 10.1016/0005-2736(94)90064-7; DEACON GB, 1980, COORDIN CHEM REV, V33, P227, DOI 10.1016/S0010-8545(00)80455-5; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4253; FORGE V, 1993, J BIOL CHEM, V268, P10953; FORGE V, 1993, J BIOL CHEM, V268, P10961; GEORG H, 1994, BBA-BIOENERGETICS, V1188, P139, DOI 10.1016/0005-2728(94)90032-9; HENDERSON IMJ, 1994, BIOCHEM J, V297, P615, DOI 10.1042/bj2970615; INESI G, 1983, BIOPHYS J, V44, P271, DOI 10.1016/S0006-3495(83)84299-4; INESI G, 1984, J BIOL CHEM, V259, P996; Inesi G, 1995, BIOSCIENCE REP, V15, P327, DOI 10.1007/BF01788365; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; LEVY D, 1990, J BIOL CHEM, V265, P19524; MADEIRA VMC, 1979, ARCH BIOCHEM BIOPHYS, V193, P22, DOI 10.1016/0003-9861(79)90003-1; MARTIN RB, 1992, FEBS LETT, V308, P59, DOI 10.1016/0014-5793(92)81050-V; Martonosi AN, 1996, BBA-BIOENERGETICS, V1275, P111, DOI 10.1016/0005-2728(96)00059-X; Martonosi AN, 1995, BIOSCIENCE REP, V15, P263, DOI 10.1007/BF01788359; Mintz E, 1995, BIOSCIENCE REP, V15, P377, DOI 10.1007/BF01788369; MYUNG J, 1991, FEBS LETT, V278, P35, DOI 10.1016/0014-5793(91)80077-G; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; NARA M, 1994, FEBS LETT, V349, P84, DOI 10.1016/0014-5793(94)00645-8; PICK U, 1979, BIOCHEMISTRY-US, V18, P108, DOI 10.1021/bi00568a017; POLVANI C, 1989, J BIOL CHEM, V264, P17854; STEINER M, 1988, CLIN CHIM ACTA, V177, P107, DOI 10.1016/0009-8981(88)90313-0; TACKETT JE, 1989, APPL SPECTROSC, V43, P483, DOI 10.1366/0003702894202931; Troullier A, 1996, BIOPHYS J, V71, P2970, DOI 10.1016/S0006-3495(96)79537-1; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; YAMAGUCHI M, 1984, J BIOL CHEM, V259, P9526; YU X, 1993, BIOPHYS J, V64, P1232, DOI 10.1016/S0006-3495(93)81489-9; YU X, 1994, J BIOL CHEM, V269, P16656	41	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25507	25510		10.1074/jbc.272.41.25507	http://dx.doi.org/10.1074/jbc.272.41.25507			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325264	hybrid			2022-12-27	WOS:A1997YA35800019
J	Gill, ZP; Perks, CM; Newcomb, PV; Holly, JMP				Gill, ZP; Perks, CM; Newcomb, PV; Holly, JMP			Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; CERAMIDE; INHIBITION; RECEPTORS; INDUCTION; P53	Insulin-like growth factor (IGF) -independent growth inhibition of human breast cancer cells, Hs578T, by IGF-binding protein-3 (IGFBP-3) has previously been demonstrated. Cell growth is a balance between proliferation and programmed cell death (apoptosis), We have investigated whether IGFBP-3 can affect apoptosis of Hs578T cells. As no induction of apoptosis was found, we also investigated its effect on the response to ceramide, an intracellular second messenger that mediates the signal for apoptosis. Using the cell permeable ceramide analogue, C2, induction of apoptosis was established by 3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide) assay, trypan blue uptake, morphological criteria, and flow cytometry, Incubation of cells with non-glycosylated IGFBP-3 (ngIGFBP-3; 0.5-100 ng/ml) resulted in no growth inhibition or increase in apoptosis; whereas, C2 (1-30 mu M) resulted in a dose-dependent induction of apoptosis. Addition of IGFs to the cells, alone or with C2, elicited no response in terms of proliferation or survival, respectively. When the cells were preincubated with ngIGFBP-3 before addition of C2 (2-5 mu M), apoptosis was accentuated in a dose-dependent manner (at 100 ng/ml IGFBP-3, apoptosis increased from 11 to 88%). In conclusion, we found that IGFBP-3 had no direct inhibitory effect on Hs578T cells but could accentuate apoptosis induced by the physiological trigger ceramide in an IGF-independent manner.	BRISTOL ROYAL INFIRM & GEN HOSP,DEPT HOSP MED,DIV SURG,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary								Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P3259, DOI 10.1210/endo-129-6-3259; COULSON VJ, 1991, GROWTH REGULAT, V1, P119; CWYFANHUGHES SC, 1995, J ENDOCRINOL, V147, P517; DELBE J, 1990, J CELL PHYSIOL, V142, P359, DOI 10.1002/jcp.1041420219; DELEON DD, 1990, J CLIN ENDOCR METAB, V71, P530, DOI 10.1210/jcem-71-2-530; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lalou C, 1996, ENDOCRINOLOGY, V137, P3206, DOI 10.1210/en.137.8.3206; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LILLIE RD, 1977, HJ CONNS BIOL STAINS, P605; NEELY EK, 1992, ENDOCRINOLOGY, V130, P985, DOI 10.1210/en.130.2.985; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; RESNICOFF M, 1995, CANCER RES, V55, P2463; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; Witty JP, 1996, ENDOCRINOLOGY, V137, P5269, DOI 10.1210/en.137.12.5269	27	195	205	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25602	25607		10.1074/jbc.272.41.25602	http://dx.doi.org/10.1074/jbc.272.41.25602			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325280	hybrid			2022-12-27	WOS:A1997YA35800035
J	Kaburagi, Y; Satoh, S; Tamemoto, H; YamamotoHonda, R; Tobe, K; Veki, K; Yamauchi, T; KonoSugita, E; Sekihara, H; Aizawa, S; Cushman, SW; Akanuma, Y; Yazaki, Y; Kadowaki, T				Kaburagi, Y; Satoh, S; Tamemoto, H; YamamotoHonda, R; Tobe, K; Veki, K; Yamauchi, T; KonoSugita, E; Sekihara, H; Aizawa, S; Cushman, SW; Akanuma, Y; Yazaki, Y; Kadowaki, T			Role of insulin receptor substrate-1 and pp60 in the regulation of insulin-induced glucose transport and GLUT4 translocation in primary adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; TYROSINE-PHOSPHORYLATED PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; HEPATOMA-CELLS; ACTIVATING PROTEIN; PLASMA-MEMBRANE; 3T3-L1 CELLS; KINASE; IRS-1; MICE	In muscle and fat, glucose transport occurs through the translocation of GLUT4 from an intracellular pool to the cell surface. Phosphatidylinositol (PI) 3-kinase has been shown to be required in this process. Insulin is thought to activate this enzyme by stimulating its association with tyrosine-phosphorylated proteins such as insulin receptor substrate (IRS)-1, IRS-2, Grb2-associated binder-1, and pp60. To study the role of these endogenous substrates in glucose transport, we analyzed adipocytes from IRS-1 null mice that we previously generated (Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S., Sekihara, H., Yoshioka, S., Horikoshi, H., Furuta, Y., Ikawa, Y., Kasuga, M., Yazaki Y., and Aizawa S. (1994) Nature 372, 182-186). In adipocytes from these mice, we showed that: 1) insulin-induced PI 3-kinase activity in the antiphosphotyrosine immunoprecipitates was 54% of wild-type; 2) pp60 was the major tyrosine-phosphorylated protein that associated with PI 3-kinase, whereas tyrosine phosphorylaion of IRS-2 as well as its association with this enzyme was almost undetectable; and 3) glucose transport and GLUT4 translocation at maximal insulin stimulation were decreased to 52 and 68% of those from wild-type. These data suggest that both IRS-1 and pp60 play a major role in insulin-induced glucose transport in adipocytes, and that pp60 is predominantly involved in regulating this process in the absence of IRS-1.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED 3,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; INST DIABET CARE & RES,ASAHI LIFE FDN,CHIYODA KU,TOKYO 100,JAPAN; NIDDK,EXPT DIABET METAB & NUTR SECT,DIABET BRANCH,NIH,BETHESDA,MD 20892; KUMAMOTO UNIV,SCH MED,IMEG,LAB MORPHOGENESIS,KUMAMOTO 860,JAPAN	University of Tokyo; Yokohama City University; Asahi Life Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Kumamoto University								ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; GLIEMANN J, 1984, BIOCHIM BIOPHYS ACTA, V804, P68, DOI 10.1016/0167-4889(84)90100-9; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HOLGATOMADRUGA M, 1995, NATURE, V379, P560; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KELLY KL, 1993, J BIOL CHEM, V268, P4391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P11439; MILARSKI KL, 1995, BIOCHEM J, V308, P579, DOI 10.1042/bj3080579; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; OGAWA W, 1995, ENDOCRINOLOGY, V136, P476, DOI 10.1210/en.136.2.476; OKADA T, 1994, J BIOL CHEM, V269, P3568; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; SATOH S, 1993, J BIOL CHEM, V268, P17820; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; SUNG CK, 1994, J BIOL CHEM, V269, P12503; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; WEBER TM, 1988, INSULIN RECEPTOR, V2, P171; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921; ZhangSun G, 1996, ENDOCRINOLOGY, V137, P2649, DOI 10.1210/en.137.7.2649	42	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25839	25844		10.1074/jbc.272.41.25839	http://dx.doi.org/10.1074/jbc.272.41.25839			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325314	hybrid			2022-12-27	WOS:A1997YA35800069
J	Kimura, M; Ishiguro, A; Ishihama, A				Kimura, M; Ishiguro, A; Ishihama, A			RNA polymerase II subunits 2, 3, and 11 form a core subassembly with DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL ASSEMBLY DOMAIN; SCHIZOSACCHAROMYCES-POMBE; SEQUENCE DETERMINATION; ALPHA-SUBUNIT; YEAST; DROSOPHILA; SITE; GENE; IDENTIFICATION; TRANSCRIPTION	RNA polymerase II purified from the fission yeast Schizosaccharomyces pombe consists of 10 species of subunit polypeptide. We introduced a histidine cluster tag sequence into the chromosomal rpb1 and rpb3 genes, which encode subunit 1 (Rpb1) and subunit 3 (Rpb3), respectively, and purified the RNA polymerase by Ni2+ affinity chromatography. After stepwise dissociation of the Rpb1- and Rpb3-tagged RNA polymerases fixed on Ni2+-resin by increasing concentrations of urea or guanidium hydrochloride, Rpb2-Rpb3-Rpb11 or Rpb2-Rpb3-Rpb11-Rpb10 complexes were obtained. Since the complex consisting of Rpb2, Rpb3, and Rpb11 cannot be dissociated even after treatment with 6 M urea buffer, we propose that this complex represents a core subassembly of the RNA polymerase II, analogous to the alpha(2) beta complex in the assembly of Escherichia coli RNA polymerase. Both the Rpb2-Rpb3-Rpb11 complex and the free Rpb1 protein showed DNA binding activity, although the affinity was weaker compared with the intact RNA polymerase.	NATL INST GENET,DEPT MOL GENET,MISHIMA,SHIZUOKA 411,JAPAN; GRAD UNIV ADV STUDIES,SCH LIFE SCI,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan				Kimura, Makoto/0000-0003-0868-5334; Ishiguro, Akira/0000-0003-1867-3134				AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; AZUMA Y, 1991, NUCLEIC ACIDS RES, V19, P461, DOI 10.1093/nar/19.3.461; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; CARROLL SB, 1983, J MOL BIOL, V170, P777, DOI 10.1016/S0022-2836(83)80131-4; CHUANG RY, 1987, BIOCHEM BIOPH RES CO, V145, P73, DOI 10.1016/0006-291X(87)91289-7; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; GUNDELFINGER ED, 1983, FEBS LETT, V157, P133, DOI 10.1016/0014-5793(83)81131-4; HORIKOSHI M, 1983, J BIOCHEM-TOKYO, V94, P1761, DOI 10.1093/oxfordjournals.jbchem.a134527; Ishihama A, 1981, Adv Biophys, V14, P1; KAWAGISHI M, 1993, NUCLEIC ACIDS RES, V21, P469, DOI 10.1093/nar/21.3.469; KIMURA M, 1995, J MOL BIOL, V248, P756, DOI 10.1006/jmbi.1995.0258; KIMURA M, 1994, J MOL BIOL, V242, P107, DOI 10.1006/jmbi.1994.1562; Kimura M, 1996, GENES CELLS, V1, P517, DOI 10.1046/j.1365-2443.1996.d01-258.x; KIMURA M, 1995, J MOL BIOL, V248, P710; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; KONTERMANN RE, 1993, PROTEIN SCI, V2, P223; KONTERMANN RE, 1994, FEBS LETT, V344, P166, DOI 10.1016/0014-5793(94)00380-7; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Larkin RM, 1997, J BIOL CHEM, V272, P12824, DOI 10.1074/jbc.272.19.12824; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; MIYAO T, 1996, GENES CELLS, V1, P843; RIVA M, 1990, J BIOL CHEM, V265, P16498; RIVA M, 1987, J BIOL CHEM, V262, P14377; Sakurai H, 1996, GENE, V180, P63, DOI 10.1016/S0378-1119(96)00406-4; SAKURAI H, 1997, IN PRESS GENE AMST; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; SHPAKOVSKI GV, 1992, YEAST, V8, P15; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; Woychik Nancy A., 1993, Gene Expression, V3, P77; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	33	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25851	25855		10.1074/jbc.272.41.25851	http://dx.doi.org/10.1074/jbc.272.41.25851			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325316	hybrid			2022-12-27	WOS:A1997YA35800071
J	Boice, JA; Hightower, LE				Boice, JA; Hightower, LE			A mutational study of the peptide-binding domain of Hsc70 guided by secondary structure prediction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE HSC70; SHOCK COGNATE PROTEIN; UNCOATING PROTEIN; UNFOLDED PROTEINS; COATED VESICLES; ATPASE; HSP70; FRAGMENT; CLATHRIN; IDENTIFICATION	The abundant, cytoplasmic molecular chaperones of eukaryotic cells, of which mammalian Hsc70 is a member, have central roles in protein folding pathways in cells, Although substantial information is now available on substrate interactions and ATPase activity, neither the crystal structure of the intact Hsc70 molecule nor its isolated peptide-binding domain is known, Recently, the crystal structure of the isolated peptide-binding domain of an evolutionary relative of mammalian Hsc70, the DnaK protein of Escherichia coli, was solved, We have generated several rat Hsc70 mutants using site directed and cassette mutagenesis guided by secondary structure predictions to test the hypothesis that the peptide-binding domains of mammalian Hsc70 and DnaK have similar molecular structures, Biochemical properties along with the ATPase and peptide binding activities of the resulting recombinant proteins were determined, Biochemical analyses included one-and two-dimensional gel electrophoresis, electrospray mass spectrometry, and N-terminal amino acid sequencing, The results of our study suggest that the DnaH molecular structure is a useful working model for the mammalian Hsc70 peptide-binding domain, Evidence is provided that (i) small additions to the N terminus of Hsc70 alter the function of the peptide-binding domain, (ii) alterations in the C-terminal tetrapeptide EEVD result in dramatic increases in basal ATPase activity, (iii) polyalanine substitution of a helical connector segment compensates for changes at the C terminus to restore near-normal function, (iv) specific side chain interactions involving this connector segment are not required for peptide-stimulated ATPase activity, and (v) disruption of the cap homologue region inhibits peptide binding by Hsc70.	UNIV CONNECTICUT,DEPT MOL & CELL BIOL,STORRS,CT 06269	University of Connecticut								Benaroudj N, 1997, J BIOL CHEM, V272, P8744, DOI 10.1074/jbc.272.13.8744; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; GREENE LE, 1990, J BIOL CHEM, V265, P6682; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hu SM, 1996, ARCH BIOCHEM BIOPHYS, V332, P163, DOI 10.1006/abbi.1996.0328; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SADIS S, 1990, CURRENT RES PROTEIN, P339; TACK BF, 1980, J BIOL CHEM, V255, P8842; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WANG TF, 1993, J BIOL CHEM, V268, P26049; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; ZHANG XJ, 1992, PROTEIN SCI, V1, P761, DOI 10.1002/pro.5560010608; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	31	18	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24825	24831		10.1074/jbc.272.40.24825	http://dx.doi.org/10.1074/jbc.272.40.24825			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312080	hybrid			2022-12-27	WOS:A1997XY97000019
J	Miyazaki, H; Fukumoto, S; Okada, M; Hasegawa, T; Furukawa, K; Furukawa, K				Miyazaki, H; Fukumoto, S; Okada, M; Hasegawa, T; Furukawa, K; Furukawa, K			Expression cloning of rat cDNA encoding UDP-galactose:G(D2) beta 1,3-galactosyltransferase that determines the expression of G(D1b)/G(M1)/G(A1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE (BETA-1-4)GALACTOSYLTRANSFERASE; GANGLIOSIDE-MEDIATED MODULATION; GM1 GANGLIOSIDE; ALPHA-1,3 GALACTOSYLTRANSFERASE; MONOCLONAL-ANTIBODIES; GOLGI VESICLES; SYNTHASE GENE; CELL-GROWTH; MICE; RECEPTOR	Using an anti-G(D1b) monoclonal antibody, expression cloning of a cDNA for the beta 1,3-galactosyltransferase gene (EC 2.4.1.62) was performed, KF4C, mouse melanoma B16 transfected with polyoma T antigen gene, and G(M2)/G(D2) synthase cDNA was used as a recipient cell line for the cDNA library transfection. A cDNA clone of G(D3) synthase, pD3T-31 was co-transfected with a cDNA library prepared from rat brain RNA using the pcDNAI expression vector. The isolated cDNA clone pM1T-9 predicted a type II membrane protein with 4 amino acids of cytoplasmic domain, 21 amino acids of transmembrane region, and a large catalytic domain with 346 amino acids, Introduction of the cDNA clone into a mouse melanoma line B16 previously transfected with a G(M2)/G(D2) synthase gene resulted in the neo synthesis of G(M1). Co-transfection of the cell line with pM1T-9 and a G(D3) synthase cDNA resulted in the expression of G(D1b) as well as G(M1). Moreover, introduction of pM1T-9 into L cell (lacking G(M3) synthase), previously transfected with G(M2)/G(D2) synthase gene, resulted in the definite expression of asialo-G(M1). These results indicated that G(D1b)/G(M1)/G(A1) synthases mere identical, as previously suggested based on enzymological analysis. In Northern blots of the beta 1,3-galactosyltransferase gene with total RNA from various rat tissues, a 1.6-kilobase mRNA was strongly expressed in spleen, thymus, kidney, and testis, However, the expression level of the gene in the adult brain tissue was not especially high, On the other hand, this gene was expressed at high levels in the rat brain of embryonal day 12, and reached a peak at around birth, then fell to low level in the adult brain.	NAGOYA UNIV,SCH MED,DEPT BIOCHEM 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH DENT,DEPT PEDIAT DENT,NAGASAKI 852,JAPAN; MIE UNIV,SCH MED,DEPT BIOCHEM,TSU,MIE 514,JAPAN	Nagoya University; Nagasaki University; Nagasaki University; Mie University				Fukumoto, Satoshi/0000-0002-5046-6891				BOUVIER JD, 1989, J NEUROCHEM, V52, P460, DOI 10.1111/j.1471-4159.1989.tb09143.x; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; DAVIS LG, 1986, BASIC METHODS MOL BI, P285; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; DEERAUSQUIN GA, 1990, P NATL ACAD SCI USA, V87, P8017, DOI 10.1073/pnas.87.20.8017; FACCI L, 1984, J NEUROCHEM, V42, P299, DOI 10.1111/j.1471-4159.1984.tb02678.x; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520; IBER H, 1989, FEBS LETT, V248, P18, DOI 10.1016/0014-5793(89)80423-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; IKEMATSU S, 1993, GLYCOBIOLOGY, V3, P575, DOI 10.1093/glycob/3.6.575; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; Karpiak S E, 1984, Adv Exp Med Biol, V174, P489; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; ROISEN FJ, 1981, GANGLIOSIDES NEUROLO, P135; RUAN S, 1992, CANCER RES, V52, P5725; RUAN ST, 1995, ARCH BIOCHEM BIOPHYS, V323, P11, DOI 10.1006/abbi.1995.0003; SABEL BA, 1984, SCIENCE, V225, P340, DOI 10.1126/science.6740316; SCHAAL H, 1985, J NEUROCHEM, V45, P544, DOI 10.1111/j.1471-4159.1985.tb04022.x; SCHNEIDER JS, 1992, SCIENCE, V256, P843, DOI 10.1126/science.1350379; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; Seifert W., 1981, GANGLIOSIDES NEUROLO, P99; STAHL N, 1994, J NEUROSCI RES, V38, P234, DOI 10.1002/jnr.490380214; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; SUZUKI K, 1965, J NEUROCHEM, V12, P969, DOI 10.1111/j.1471-4159.1965.tb10256.x; SVENNERHOLM L, 1994, LIFE SCI, V55, P2125, DOI 10.1016/0024-3205(94)00393-9; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; UEJIMA T, 1992, CANCER RES, V52, P6158; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YAMASHIRO S, 1993, CANCER RES, V53, P5395	54	84	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24794	24799		10.1074/jbc.272.40.24794	http://dx.doi.org/10.1074/jbc.272.40.24794			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312075	hybrid			2022-12-27	WOS:A1997XY97000014
J	Satin, B; Norais, N; Telford, J; Rappuoli, R; Murgia, M; Montecucco, C; Papini, E				Satin, B; Norais, N; Telford, J; Rappuoli, R; Murgia, M; Montecucco, C; Papini, E			Effect of Helicobacter pylori vacuolating toxin on maturation and extracellular release of procathepsin D and on epidermal growth factor degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; LYSOSOMAL-ENZYMES; DIPHTHERIA-TOXIN; CATHEPSIN-D; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOCYTIC VESICLES; MOLECULAR-WEIGHT; MAMMALIAN-CELLS; HELA-CELLS; CYTOTOXIN	The effect of vacuolating toxin (VacA) from Helicobacter pylori on endosomal and lysosomal functions was studied by following procathepsin D maturation and epidermal growth factor (EGF) degradation in HeLa cells exposed to the toxin, VacA inhibited the conversion of procathepsin D (53 kDa) into both the intermediate (47 kDa) and the mature (31 kDa) form, Nonprocessed cathepsin D was partly retained inside cells and partly secreted in the extracellular medium via the constitutive secretion pathway, Intracellular degradation of EGF was also inhibited by VacA with a similar dose-response curve, VacA did not alter endocytosis, cell surface recycling, and retrograde transport from plasma membrane to trans-Golgi network and endoplasmic reticulum, as estimated by using transferrin, diphtheria toxin, and ricin as tracers, Subcellular fractionation of intoxicated cells showed that procathepsin D and non-degraded EGF accumulate in lysosomes, Measurements of intracellular acidification with fluorescein isothiocyanate-dextran revealed a partial neutralization of the lumen of endosomes and lysosomes, sufficient to account for both mistargeting of procathepsin D outside the cell and the decreased activity of lysosomal proteases.	UNIV PADUA, DIPARTIMENTO SCI BIOMED, I-35121 PADUA, ITALY; UNIV PADUA, CNR, CTR BIOMEMBRANE, I-35121 PADUA, ITALY; IRIS, I-53100 SIENA, ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Novartis			Papini, Emanuele/AAE-6961-2022; Telford, John Laird/ABG-8144-2020	Papini, Emanuele/0000-0001-6033-4473; 				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; CATRENICH CE, 1992, J MED MICROBIOL, V37, P389, DOI 10.1099/00222615-37-6-389; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; COVER TL, 1993, INFECT IMMUN, V61, P1427, DOI 10.1128/IAI.61.4.1427-1431.1993; COVER TL, 1992, J BIOL CHEM, V267, P10570; COVER TL, 1994, J BIOL CHEM, V269, P10566; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; DELBRUCK R, 1994, EUR J CELL BIOL, V64, P7; FORMAN D, 1993, LANCET, V341, P1359; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN LB, 1993, FEBS LETT, V319, P54, DOI 10.1016/0014-5793(93)80036-T; Lemichez E, 1997, MOL MICROBIOL, V23, P445, DOI 10.1111/j.1365-2958.1997.tb02669.x; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Papini E, 1996, J MED MICROBIOL, V45, P84, DOI 10.1099/00222615-45-2-84; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; PAPINI E, 1993, J BIOL CHEM, V268, P1567; PAPINI E, 1993, FEMS MICROBIOL LETT, V113, P155, DOI 10.1016/0378-1097(93)90262-Z; PAPINI E, 1993, MOL MICROBIOL, V7, P323, DOI 10.1111/j.1365-2958.1993.tb01123.x; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; RAPAK A, 1997, IN PRESS P NATL ACAD; RAPPUOLI R, 1983, J CHROMATOGR, V268, P543, DOI 10.1016/S0021-9673(01)95457-3; RENFREW CA, 1991, J BIOL CHEM, V266, P4348; RICHO G, 1991, ADV EXP MED BIOL, V306, P289; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; TELFORD JL, 1994, TRENDS BIOTECHNOL, V12, P420, DOI 10.1016/0167-7799(94)90031-0; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; TOMPKINS LS, 1995, SCIENCE, V267, P1621, DOI 10.1126/science.7886448; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WARREN JR, 1983, LANCET, V1, P1273	63	106	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25022	25028		10.1074/jbc.272.40.25022	http://dx.doi.org/10.1074/jbc.272.40.25022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312109	hybrid			2022-12-27	WOS:A1997XY97000048
J	Yang, WN; Cerione, RA				Yang, WN; Cerione, RA			Cloning and characterization of a novel Cdc42-associated tyrosine kinase, ACK-2, from bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; WISKOTT-ALDRICH SYNDROME; RHO-FAMILY GTPASES; SACCHAROMYCES-CEREVISIAE; SIGNALING PATHWAY; BINDING PROTEIN; CDC42 GTPASES; RAC1; IDENTIFICATION; EFFECTOR	Cdc42 plays an important role in intracellular signaling pathways that influence cell morphology and motility and stimulate DNA synthesis. In attempts to determine whether nonreceptor tyrosine kinases play a fundamental role in Cdc42 signaling, we have cloned and biochemically characterized a new Cdc42-associated tyrosine kinase (ACK) hom bovine brain. This tyrosine kinase, named ACK-2, has a calculated molecular mass of 83 kDa and shares a number of primary structural domains with the 120-kDa ACK (ACK-1), The main differences between the primary structures of ACK-2 and ACK-1 occur in the amino-and carboxyl-terminal regions, Like ACK-1, ACK-2 binds exclusively to activated (GTP-bound) Cdc42 and does not bind to its closest homologs, e.g. activated Rac. ACK-2 could not be activated by addition of glutathione S-transferase (GST)-Cdc42(Q61L), a GTPase-defective mutant, or by GTP gamma S-loaded GST-Cdc42 in in vitro kinase assays. However, ACK-2 was activated when cotransfected with mild type Cdc42 or Cdc42(Q61L) and stably associated with Cdc42(Q61L) in vivo, indicating that ACK-2 interacts with active Cdc42 in cells, Furthermore, the tyrosine kinase activity of ACK-2 was stimulated both by epidermal growth factor and bradykinin, suggesting that ACK-2 may play a role in the signaling actions of both receptor tyrosine kinases or heterotrimeric G-protein-coupled receptors.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University					NIGMS NIH HHS [GM40654, GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458, R01GM040654] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brill S, 1996, MOL CELL BIOL, V16, P4869; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hoehn GT, 1996, ONCOGENE, V12, P903; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	36	92	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24819	24824		10.1074/jbc.272.40.24819	http://dx.doi.org/10.1074/jbc.272.40.24819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312079	hybrid			2022-12-27	WOS:A1997XY97000018
J	Gary, R; Ludwig, DL; Cornelius, HL; MacInnes, MA; Park, MS				Gary, R; Ludwig, DL; Cornelius, HL; MacInnes, MA; Park, MS			The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL REGION; POLYMERASE-DELTA; RAD PROTEINS; REPLICATION; BACTERIOPHAGE-T4; DOMAINS; GENE; CDK; COMPLEMENTATION	Proliferating cell nuclear antigen (PCNA) is a DNA polymerase accessory factor that is required for DNA replication during S phase of the cell cycle and for resynthesis during nucleotide excision repair of damaged DNA, PCNA binds to flap endonuclease 1 (FEN-1), a structure-specific endonuclease involved in DNA replication. Here we report the direct physical interaction of PCNA with xeroderma pigmentosum (XP) G, a structure-specific repair endonuclease that is homologous to FEN-1, We have identified a 28-amino acid region of human FEN-1 (residues 328-355) and a 29-amino acid region of human XPG (residues 981-1009) that contains the PCNA binding activity, These regions share key hydrophobic residues with the PCNA-binding domain of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1), and all three competed with one another for binding to PCNA. A conserved arginine in FEN-1 (Arg(339)) and XPG (Arg(992)) was found to be crucial for PCNA binding activity, R992A and R992E mutant forms of XPG failed to fully reconstitute nucleotide excision repair in an in vivo complementation assay, These results raise the possibility of a mechanistic linkage between excision and repair synthesis that is mediated by PCNA.	LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	United States Department of Energy (DOE); Los Alamos National Laboratory			Park, Min Sung/HCH-2207-2022; Gary, Ronald K/A-8650-2008	Gary, Ronald K/0000-0001-5079-1953	NATIONAL CANCER INSTITUTE [R29CA071630] Funding Source: NIH RePORTER; NCI NIH HHS [CA71630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Ball KL, 1996, EUR J BIOCHEM, V237, P854, DOI 10.1111/j.1432-1033.1996.0854p.x; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEIN K, 1992, MOL CELL BIOL, V12, P155; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Knauf JA, 1996, MUTAT RES-DNA REPAIR, V363, P67, DOI 10.1016/0921-8777(95)00062-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LIU M, 1995, ONCOGENE, V10, P1955; Ludwig DL, 1996, MAMM GENOME, V7, P644, DOI 10.1007/s003359900198; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; McDonald E, 1996, CANCER RES, V56, P2250; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; Petrocelli T, 1996, ONCOGENE, V12, P1387; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	43	196	206	12	99	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24522	24529		10.1074/jbc.272.39.24522	http://dx.doi.org/10.1074/jbc.272.39.24522			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305916	hybrid			2022-12-27	WOS:A1997XY51500067
J	Wise, A; Milligan, G				Wise, A; Milligan, G			Rescue of functional interactions between the alpha(2A)-adrenoreceptor and acylation-resistant forms of G(i1)alpha by expressing the proteins from chimeric open reading frames	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; ALPHA-SUBUNIT; MEMBRANE ATTACHMENT; LIPID MODIFICATIONS; ADENYLATE-CYCLASE; AMINO-TERMINUS; G-BETA; RECEPTOR; PALMITOYLATION; BINDING	Co-expression of the alpha(2A)-adrenoreceptor with a pertussis toxin-resistant (C351G), but not with an also palmitoylation resistant (C3S/C351G), form of the a subunit of G(il) resulted in agonist-induced, pertussis toxin-independent, GTP hydrolysis. Construction and expression of a chimeric fusion protein between the receptor and G351G G(il)alpha generated a membrane protein in which the G protein element was activated by receptor agonist. An equivalent fusion protein containing C3S/G351G G(il)alpha rescued the ability of receptor agonist to activate this mutant. Fusion proteins of a palmitoylation-resistant (C442A) alpha(2A)-adrenoreceptor and either C351G or C3S/C351G G(il)alpha also responded effectively to agonist. Myristoylation resistant (G2A/G351G) and combined acylation resistant (G2A/C3S/C351G) mutants of G(il)alpha are cytosolic proteins. Expression of these as chimeric alpha(2A)-adrenoreceptor-G protein fusions restored membrane localization and activation of the G protein by receptor agonist. These studies demonstrate the general utility of generating chimeric fusion proteins to examine receptor regulation of G protein function and that the lack of functional activation of acylation-negative G proteins by a co-expressed receptor is related to deficiencies in cellular targeting and location rather than an inherent incapacity to produce appropriate protein-protein interactions and signal transmission.	UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOL BIOL,MOL PHARMACOL GRP,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow			Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GEORGOUSSI Z, 1995, BIOCHEM J, V306, P71, DOI 10.1042/bj3060071; Gillard NP, 1996, BRIT J PHARMACOL, V117, pP298; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN A, 1990, J BIOL CHEM, V265, P5206; GUYER CA, 1990, J BIOL CHEM, V265, P17307; HUNT TW, 1994, J BIOL CHEM, V269, P29565; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KOSKI G, 1981, P NATL ACAD SCI-BIOL, V78, P4185, DOI 10.1073/pnas.78.7.4185; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; RICHARDSON A, 1992, P NATL ACAD SCI USA, V89, P10198, DOI 10.1073/pnas.89.21.10198; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Taylor JM, 1996, J BIOL CHEM, V271, P3336; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; TIAN WN, 1994, MOL PHARMACOL, V45, P524; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wise A, 1997, BIOCHEM J, V321, P721, DOI 10.1042/bj3210721; Wise A, 1997, BIOCHEM J, V325, P17, DOI 10.1042/bj3250017; WISE A, 1997, IN PRESS BIOCHEMISTR	36	52	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24673	24678		10.1074/jbc.272.39.24673	http://dx.doi.org/10.1074/jbc.272.39.24673			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305937	hybrid			2022-12-27	WOS:A1997XY51500088
J	Raman, B; Rao, CM				Raman, B; Rao, CM			Chaperone-like activity and temperature structural changes of alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; B-CRYSTALLIN; QUATERNARY STRUCTURE; MOLECULAR CHAPERONE; THERMAL-STABILITY; MOLTEN-GLOBULE; POSTTRANSLATIONAL MODIFICATIONS; NONLENTICULAR TISSUES; CARBONIC-ANHYDRASE; GAMMA-CRYSTALLIN	alpha-Crystallin is known to exhibit chaperone-like activity, We have studied its chaperone-like activity toward the aggregation of beta(L)-crystallin upon refolding of this protein from its unfolded state in guanidinium chloride, The chaperone-like activity of alpha-crystallin is less pronounced below 30 degrees C and is enhanced above this temperature, The plot of percentage protection as a function of temperature shows two transitions; one at 30 degrees C and another at around 55 degrees C. We have performed steady state fluorescence, fluorescence polarization, fluorescence quenching, circular dichroism, sedimentation analysis, and gel filtration chromatography to probe the temperature-induced structural changes of alpha-crystallin. Our results show that at above 50 degrees C, alpha-crystallin undergoes a transition to a multimeric molten globule-like state. Above 30 degrees C, a minor but detectable perturbation in its tertiary structure occurs that might lead to the observed exposure of its hydrophobic surfaces, These results support our earlier hypothesis that alpha-crystallin prevents the aggregation of other proteins by providing appropriately placed hydrophobic surfaces; a structural transition above 30 degrees C involving enhanced or reorganized hydrophobic surfaces of alpha-crystallin is important for its chaperone like activity, It is possible that a structural alteration induced by temperature forms a part of the general mechanism of chaperone function, because they are required to function more effectively at non-permissible temperatures.	CTR CELLULAR & MOL BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GANEA E, 1995, EUR J BIOCHEM, V231, P181, DOI 10.1111/j.1432-1033.1995.0181f.x; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HARTL MKH, 1996, EMBO J, V15, P6111; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KELLEY MJ, 1993, J BIOL CHEM, V268, P18844; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MAYER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1089, P141, DOI 10.1016/0167-4781(91)90002-4; MERCK KB, 1993, J BIOL CHEM, V268, P1046; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Ptitsyn Oleg B., 1992, P243; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; RAO CM, 1994, INVEST OPHTH VIS SCI, V35, P1905; RAO CM, 1993, INVEST OPHTH VIS SCI, V34, P988; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SHIH P, 1995, PROTEIN SCI, V4, P2050, DOI 10.1002/pro.5560041010; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; Singh N, 1996, BIOPHYS CHEM, V63, P27, DOI 10.1016/S0301-4622(96)02192-8; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1983, EXP EYE RES, V37, P367, DOI 10.1016/0014-4835(83)90173-2; vanBoekel MAM, 1996, OPHTHALMIC RES, V28, P32, DOI 10.1159/000267940; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641	48	124	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23559	23564		10.1074/jbc.272.38.23559	http://dx.doi.org/10.1074/jbc.272.38.23559			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295293	hybrid			2022-12-27	WOS:A1997XX38100018
J	Zhu, XY; Volz, K; Matsumura, P				Zhu, XY; Volz, K; Matsumura, P			The CheZ-binding surface of CheY overlaps the CheA- and FliM-binding surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC RESPONSE REGULATOR; PHOSPHORYLATION-DEPENDENT BINDING; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; FLAGELLAR SWITCH; PROTEIN CHEY; PHOSPHATASE-ACTIVITY; GENE-PRODUCTS; MUTANTS	CheY, the response regulator of bacterial chemotaxis, plays a pivotal role in signal transduction in bacterial chemotaxis and interacts with at least three proteins: CheA, FliM, and CheZ, CheA receives signals from chemoreceptors and then transfers the signal to CheY by a phosphotransfer reaction. Phosphorylated CheY binds to FliM, one of the switch proteins, resulting in a change in flagellar rotation from counterclockwise to clockwise, Phosphorylated CheY is dephosphorylated by its intrinsic autophosphatase activity and by CheZ. The CheA- and FliM-binding surfaces of CheY have been well studied, but characterization of She CheZ-binding surface of CheY is incomplete, We have analyzed the effect of CheZ on the dephosphorylation rates of 14 mutants of CheY, Nine mutant CheY proteins showed more resistance to CheZ phosphatase activity than did wild-type CheY, These nine mutant CheY proteins could be divided into two groups: one with altered CheZ binding and the other with normal CheZ binding The mutations causing reduced CheZ binding altered residues an the same surface of CheY, a region consisting of the beta(5)-alpha(5) loop, the alpha(1)-helix, and part of the alpha(5)-helix. Mutations rendering CheY resistant to CheZ, isolated by Sanna et al, (Sanna, M. G., Swanson, R. V., Bourret, R. B., and Simon, M. I, (1995) Mol. Microbiol; 15, 1069-1079), were also found to affect this surface, The mutations ill the CheY protein that affect CheZ activity but not CheZ binding-are located in the beta(4)-alpha(4) loop, which appears to be involved in the; catalytic activity of CheZ, Finally, our results indicate that the CheY surfaces that bind CheA, FliM, and CheZ overlap, but are not completely identical.	UNIV ILLINOIS,DEPT IMMUNOL & MICROBIOL,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047522] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18985] Funding Source: Medline; NIGMS NIH HHS [GM47522] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSLER CD, 1993, J BACTERIOL, V175, P6238, DOI 10.1128/JB.175.19.6238-6244.1993; Amsler CD., 1995, 2 COMPONENT SIGNAL T, P89; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; Blat Y, 1996, J BIOL CHEM, V271, P1232, DOI 10.1074/jbc.271.2.1232; Blat Y, 1996, J BIOL CHEM, V271, P1226, DOI 10.1074/jbc.271.2.1226; Blat Y, 1996, BIOCHEMISTRY-US, V35, P5679, DOI 10.1021/bi9530447; BLOCK SM, 1982, CELL, V31, P215, DOI 10.1016/0092-8674(82)90421-4; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; Eisenbach M, 1996, MOL MICROBIOL, V20, P903, DOI 10.1111/j.1365-2958.1996.tb02531.x; GANGULI S, 1995, J BIOL CHEM, V270, P17386, DOI 10.1074/jbc.270.29.17386; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; HUANG CX, 1993, BIOCHIM BIOPHYS ACTA, V1202, P297, DOI 10.1016/0167-4838(93)90019-N; KUO SC, 1989, J BACTERIOL, V171, P6279, DOI 10.1128/jb.171.11.6279-6287.1989; KUO SC, 1987, J BACTERIOL, V169, P1307, DOI 10.1128/jb.169.3.1307-1314.1987; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MORRISON TB, 1994, BIOTECHNIQUES, V17, P922; MORRISON TB, 1994, P NATL ACAD SCI USA, V91, P5495; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PARKINSON JS, 1976, J BACTERIOL, V126, P758, DOI 10.1128/JB.126.2.758-770.1976; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PARKINSON JS, 1979, P NATL ACAD SCI USA, V76, P2390, DOI 10.1073/pnas.76.5.2390; RAVID S, 1986, P NATL ACAD SCI USA, V83, P7157, DOI 10.1073/pnas.83.19.7157; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; Sanna MG, 1996, J BIOL CHEM, V271, P7357, DOI 10.1074/jbc.271.13.7357; SANNA MG, 1995, MOL MICROBIOL, V15, P1069, DOI 10.1111/j.1365-2958.1995.tb02282.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SHUKLA D, 1995, J BIOL CHEM, V270, P24414, DOI 10.1074/jbc.270.41.24414; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SWANSON RV, 1995, NAT STRUCT BIOL, V2, P906, DOI 10.1038/nsb1095-906; VOLZ K, 1991, J BIOL CHEM, V266, P15511; Wang H, 1996, MOL MICROBIOL, V19, P695, DOI 10.1046/j.1365-2958.1996.393934.x; WARRICK HM, 1977, J BACTERIOL, V130, P223, DOI 10.1128/JB.130.1.223-231.1977; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	49	44	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23758	23764		10.1074/jbc.272.38.23758	http://dx.doi.org/10.1074/jbc.272.38.23758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295320	hybrid			2022-12-27	WOS:A1997XX38100045
J	Lopez, MJ; Garbers, DL; Kuhn, M				Lopez, MJ; Garbers, DL; Kuhn, M			The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; MICE LACKING; A RECEPTOR; ATRIAL; RATS; RELAXATION; ARTERIES; FAMILY	A genetic model of salt-resistant hypertension has been developed recently through disruption of the guanylyl cyclase-A (GC-A) natriuretic peptide receptor gene (Lopez, M. J., Wong, S. K., Kishimoto, I., Dubois, S., Mach, V., Friesen, J., Garbers, D. L., and Beuve, A. (1995) Nature 378, 65-68). These genetically altered mice were used to determine which of the natural peptides with natriuretic peptide-like structures regulate blood pressure through the GC-A receptor. Atrial natriuretic peptide (ANP) or B-type natriuretic peptide (BNP) half-maximally relaxed precontracted aortic rings in wild-type mice at about 24 nM, but failed to relax such aortas in GC-A null mice, even at micromolar concentrations. C-type natriuretic peptide (CNP), in contrast, caused half-maximal relaxation at concentrations of 335 and 146 nM in aortas from either wild-type or null mice, respectively, suggesting that this peptide acted through a receptor other than GC-A. Since the in vitro results with aortic smooth muscle do not necessarily reflect the physiology of the smaller blood vessels important in blood pressure regulation, the blood pressures of conscious mice infused with the various peptides were determined. ANP caused decreases in blood pressure when infused at rates of 500 ng/kg/min, a rate which resulted in a plasma concentration of 0.8 nM. In the null mice, in contrast, ANP failed to lower blood pressure even at infusion rates of 50 mu g/kg/min. Much higher infusion rates for CNP (50 mu g/kg/min), which yielded final plasma concentrations of 18.3 nM, were required to lower blood pressure in wild-type mice, but the effects of CNP were not altered in GC-A null mice. Thus, two natriuretic peptides (ANP, BNP) act through GC-A whereas another (CNP) acts through another receptor to regulate blood pressure.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, HHMI, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [1-K08-HL03604-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003604] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALKJAER C, 1985, BRIT J PHARMACOL, V86, P447, DOI 10.1111/j.1476-5381.1985.tb08914.x; ALLEN DE, 1987, AM J PHYSIOL, V252, pR610, DOI 10.1152/ajpregu.1987.252.3.R610; BUDZIK GP, 1987, BIOCHEM BIOPH RES CO, V144, P422, DOI 10.1016/S0006-291X(87)80527-2; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; Charles CJ, 1996, AM J PHYSIOL-REG I, V270, pR1324, DOI 10.1152/ajpregu.1996.270.6.R1324; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CLAVELL AL, 1993, AM J PHYSIOL, V264, pR290, DOI 10.1152/ajpregu.1993.264.2.R290; DREWETT JG, 1995, J BIOL CHEM, V270, P4668, DOI 10.1074/jbc.270.9.4668; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Huang PL, 1996, J MOL MED-JMM, V74, P415, DOI 10.1007/s001090050043; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Ikeda T, 1996, HYPERTENSION, V27, P833, DOI 10.1161/01.HYP.27.3.833; John SWM, 1996, AM J PHYSIOL-REG I, V271, pR109, DOI 10.1152/ajpregu.1996.271.1.R109; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; Komatsu Y, 1996, J HYPERTENS, V14, P585, DOI 10.1097/00004872-199605000-00007; KUWAHARA M, 1991, EXP ANIM TOKYO, V40, P331, DOI 10.1538/expanim1978.40.3_331; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Maack T, 1992, HDB PHYSL RENAL PHYS, P1577; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Snedecor G.W., 1967, STAT METHODS, P258; STINGO AJ, 1992, AM J PHYSIOL, V263, pH1318, DOI 10.1152/ajpheart.1992.263.4.H1318; STINGO AJ, 1992, AM J PHYSIOL, V262, pH308, DOI 10.1152/ajpheart.1992.262.1.H308; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; TANIMOTO K, 1994, J BIOL CHEM, V269, P31334; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; WEI CM, 1994, BIOCHEM BIOPH RES CO, V205, P765, DOI 10.1006/bbrc.1994.2731; WEI CM, 1993, AM J PHYSIOL, V264, pH71, DOI 10.1152/ajpheart.1993.264.1.H71; WEI CM, 1994, HYPERTENSION, V23, P903, DOI 10.1161/01.HYP.23.6.903; WILKINS MR, 1992, BRIT J PHARMACOL, V107, P50, DOI 10.1111/j.1476-5381.1992.tb14462.x; WINQUIST RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7661, DOI 10.1073/pnas.81.23.7661; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; ZAR JH, 1984, BIOSTAT ANAL, P165	42	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23064	23068		10.1074/jbc.272.37.23064	http://dx.doi.org/10.1074/jbc.272.37.23064			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287305	hybrid			2022-12-27	WOS:A1997XV74400016
J	Omura, T; Miyazawa, K; Ostman, A; Heldin, CH				Omura, T; Miyazawa, K; Ostman, A; Heldin, CH			Identification of a 190-kDa vascular endothelial growth factor 165 cell surface binding protein on a human glioma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; FACTOR RECEPTORS; VEGF RECEPTORS; EXPRESSION; INTERNALIZATION; ACTIVATION; VEGF(121); MITOGEN; FAMILY; AGENT	Vascular endothelial growth factor (VEGF) is an angiogenesis factor for which two signaling protein tyrosine kinase receptors, Flt1 and KDR, have been identified. We describe here a 190-kDa component present on a human glioma cell line that binds VEGF(165) with high affinity. In contrast, VEGF(121) is bound only with low affinity, suggesting that the C-terminal part of VEGF(165) is important for interaction with the 190-kDa component. No internalization or stimulation of tyrosine phosphorylation was recorded after ligand binding to the 190-kDa component, suggesting that it may not be directly involved in signaling; its function may be to present ligand or stabilize ligand binding to signaling receptors.	LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research			MIYAZAWA, KEIJI/I-9713-2014					BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Mascarelli F, 1991, GROWTH FACTORS, V4, P81, DOI 10.3109/08977199109000260; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; NISTER M, 1991, J BIOL CHEM, V266, P16755; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; RONNSTRAND L, 1987, J BIOL CHEM, V262, P2929; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHIBUYA M, 1990, ONCOGENE, V5, P519; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	29	13	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23317	23322		10.1074/jbc.272.37.23317	http://dx.doi.org/10.1074/jbc.272.37.23317			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287342	hybrid			2022-12-27	WOS:A1997XV74400053
J	Radic, Z; Kirchhoff, PD; Quinn, DM; McCammon, JA; Taylor, P				Radic, Z; Kirchhoff, PD; Quinn, DM; McCammon, JA; Taylor, P			Electrostatic influence on the kinetics of ligand binding to acetylcholinesterase - Distinctions between active center ligands and fasciculin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWNIAN DYNAMICS PROGRAM; RATE CONSTANTS; CRYSTAL-STRUCTURE; IONIC-STRENGTH; CHARGE; SITE; TRANSITION; SPECIFICITY; SIMULATIONS; COMPLEX	To explore the role that surface and active center charges play in electrostatic attraction of ligands to the active center gorge of acetylcholinesterase (AChE), and the influence of charge on the reactive orientation of the ligand, we have studied the kinetics of association of cationic and neutral ligands with the active center and peripheral site of AChE, Electrostatic influences were reduced by sequential mutations of six surface anionic residues outside of the active center gorge (Glu-84, Glu-91, Asp-280, Asp-283, Glu-292, and Asp-372) and three residues within the active center gorge (Asp-74 at the rim and Glu-202 and Glu-450 at the base), The peripheral site ligand, fasciculin 2 (FAS2), a peptide of 6.5 kDa with a net charge of +4, shows a marked enhancement of rate of association with reduction in ionic strength, and this ionic strength dependence can be markedly reduced by progressive neutralization of surface and active center gorge anionic residues, By contrast, neutralization of surface residues only has a modest influence on the rate of cationic m-trimethylammoniotrifluoroacetophenone (TFK+) association with the active serine, whereas neutralization of residues in the active center gorge has a marked influence on the rate but with little change in the ionic strength dependence, Brownian dynamics calculations for approach of a small cationic ligand to the entrance of the gorge show the influence of individual charges to be in quantitative accord with that found for the surface residues, Anionic residues in the gorge may help to orient the ligand for reaction or to trap the ligand. Bound FAS2 on AChE not only reduces the rate of TFK+ reaction with the active center but inverts the ionic strength dependence for the cationic TFK+ association with AChE, Hence it appears that TFK+ must traverse an electrostatic barrier at the gorge entry imparted by the bound FAS2 with its net charge of +4.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV IOWA,DEPT CHEM,IOWA CITY,IA 52242	University of California System; University of California San Diego; University of Iowa	Radic, Z (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.		McCammon, J. Andrew/AAG-1832-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031749, R01GM018360, R37GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021334] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31749, GM18360] Funding Source: Medline; NINDS NIH HHS [NS21334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antosiewicz J, 1996, BIOCHEMISTRY-US, V35, P7819, DOI 10.1021/bi9601565; Antosiewicz J, 1996, J COMPUT CHEM, V17, P1633, DOI 10.1002/(SICI)1096-987X(19961115)17:14<1633::AID-JCC5>3.0.CO;2-M; ANTOSIEWICZ J, 1995, BIOPHYS J, V68, P62, DOI 10.1016/S0006-3495(95)80159-1; Antosiewicz J, 1996, BIOPOLYMERS, V39, P85, DOI 10.1002/(SICI)1097-0282(199607)39:1<85::AID-BIP9>3.0.CO;2-R; ANTOSIEWICZ J, 1995, BIOCHEMISTRY-US, V34, P4211, DOI 10.1021/bi00013a009; ANTOSIEWICZ J, 1994, ISR J CHEM, V34, P151; BARAK D, 1995, BIOCHEMISTRY-US, V34, P15444, DOI 10.1021/bi00047a008; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; EPSTEIN DJ, 1979, BIOCHEMISTRY-US, V18, P4749, DOI 10.1021/bi00588a040; ERMAK DL, 1978, J CHEM PHYS, V69, P1352, DOI 10.1063/1.436761; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; GLASSTONE S, 1941, THEORY RATE PROCESSE; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1996, J AM CHEM SOC, V118, P230; Hosea NA, 1996, BIOCHEMISTRY-US, V35, P10995, DOI 10.1021/bi9611220; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; MACKERELL AD, 1995, CHARMM 22 PARAMETER; MADURA JD, 1994, REV COMP CH, V5, P229, DOI 10.1002/9780470125823.ch4; MADURA JD, 1995, COMPUT PHYS COMMUN, V91, P57, DOI 10.1016/0010-4655(95)00043-F; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; MCCAMMON JA, 1986, J PHYS CHEM-US, V90, P3901, DOI 10.1021/j100408a015; NAIR HK, 1993, BIOORG MED CHEM LETT, V3, P2619, DOI 10.1016/S0960-894X(01)80727-7; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; NOLTE HJ, 1980, BIOCHEMISTRY-US, V19, P3705, DOI 10.1021/bi00557a011; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; Porschke D, 1996, BIOPHYS J, V70, P1603, DOI 10.1016/S0006-3495(96)79759-X; QUINN DM, 1995, ENZYMES OF THE CHOLINESTERASE FAMILY, P203; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; Rosenberry TL, 1996, BIOCHEMISTRY-US, V35, P685, DOI 10.1021/bi952431d; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SHAFFERMAN A, 1994, EMBO J, V13, P3448, DOI 10.1002/j.1460-2075.1994.tb06650.x; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAN RC, 1993, BIOCHEMISTRY-US, V32, P401, DOI 10.1021/bi00053a003; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TOUGU V, 1987, FEBS LETT, V225, P77, DOI 10.1016/0014-5793(87)81134-1; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0	46	177	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23265	23277		10.1074/jbc.272.37.23265	http://dx.doi.org/10.1074/jbc.272.37.23265			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287336	hybrid			2022-12-27	WOS:A1997XV74400047
J	Zhang, LL; Tschantz, WR; Casey, PJ				Zhang, LL; Tschantz, WR; Casey, PJ			Isolation and characterization of a prenylcysteine lyase from bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVIN-CONTAINING MONOOXYGENASE; NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL-PROTEIN THIOESTERASE; P-GLYCOPROTEIN; S-OXYGENATION; FARNESYLCYSTEINE; TRANSPORTER; MEMBRANES; CLEAVAGE; CELLS	Prenylated proteins contain one of two isoprenoid lipids, either the 15-carbon farnesyl or the 20-carbon geranylgeranyl, covalently attached to cysteine residues at or near their C terminus. The cellular abundance of prenylated proteins, which can comprise up to 2% of total cellular protein, raises the question of how cells dispose of prenylcysteines produced during the normal turnover of prenylated proteins. We have identified and characterized a novel enzyme, which we term prenylcysteine lyase, that is capable of cleaving the thioether bond of prenylcysteines. The enzyme was isolated from bovine brain membranes and exhibits an apparent molecular mass of 63 kDa. The enzyme did not require NADPH as cofactor for prenylcysteine degradation, thus distinguishing it from cytochrome P450- and flavin-containing monooxygenases that catalyze S-oxidation of thioethers. Purified prenylcysteine lyase shows similar kinetics in utilization of both farnesylcysteine and geranylgeranylcysteine as substrates, although V-max is 2-fold higher with the former compound. Interaction of prenylcysteine substrates with the enzyme requires that they possess a free amino group; N-acetylated prenylcysteines and prenyl peptides are not substrates. These findings suggest that prenylcysteine lyase is a specific enzyme involved in prenylcysteine metabolism in mammalian cells, most likely comprising the final step ill the degradation of prenylated proteins.	DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM46372, F32 GM18069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372, F32GM018069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CASHMAN JR, 1990, CHEM RES TOXICOL, V3, P344, DOI 10.1021/tx00016a012; DEKANT W, 1989, DRUG METAB REV, V20, P43, DOI 10.3109/03602538908994144; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MA YT, 1994, BIOCHEMISTRY-US, V33, P5414, DOI 10.1021/bi00184a009; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; PARK SB, 1994, CHEM RES TOXICOL, V7, P191, DOI 10.1021/tx00038a012; PARK SB, 1992, CHEM RES TOXICOL, V5, P193, DOI 10.1021/tx00026a008; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; ROWELL CA, 1997, J BIOL CHEM, V272, P14903; SAUSEN PJ, 1990, J BIOL CHEM, V265, P6139; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHANG L, 1994, J BIOL CHEM, V269, P15973; ZHANG LL, 1995, J BIOL CHEM, V270, P22859, DOI 10.1074/jbc.270.39.22859	26	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23354	23359		10.1074/jbc.272.37.23354	http://dx.doi.org/10.1074/jbc.272.37.23354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287348	hybrid			2022-12-27	WOS:A1997XV74400059
J	Liao, JF; Hodge, C; Meyer, D; Ho, PS; Rosenspire, K; Schwartz, J				Liao, JF; Hodge, C; Meyer, D; Ho, PS; Rosenspire, K; Schwartz, J			Growth hormone regulates ternary complex factors and serum response factor associated with the c-fos serum response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JAK2 TYROSINE KINASE; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; TERMINAL PHOSPHORYLATION; 3T3-F442A PREADIPOCYTES; GENE-EXPRESSION; INDUCE BINDING; FACTOR P62TCF; RECEPTOR	For insight into the mechanisms of gene regulation by growth hormone (GH), the regulation of transcription factors associated with the serum response element (SRE) located upstream of c-fos was examined, The SRE can mediate induction of reporter expression in response to GH. For insight into the mechanism by which GH regulates transcription factors, regulation of SRE-associated proteins by GH was examined, In nuclear extracts from 3T3-F442A fibroblasts, several SRE-binding complexes were identified by electrophoretic mobility shift assay, GH treatment for 2-10 min transiently increased binding of two complexes; binding returned to control values within 30 min, The two GH-stimulated complexes were supershifted by antibodies against the serum response factor (SRF), indicating that they contained SRF or an antigenically related protein, One of the GH-stimulated complexes was supershifted by antibody against Elk-1, suggesting that it contains a ternary complex factor (TCF) such as Elk-1 in addition to SRF, Induction of binding by GH was lost when the SRF binding site in the SRE was mutated, and mutation of either the SRF or TCF binding site altered the pattern of protein binding to the SRE, Mutation of the SRF or TCF binding site in SRE-luciferase plasmids inhibited the ability of GH to stimulate reporter expression, supporting a role for both SRF and TCF in GH-induced transcription of c-fos via the SRE, The TCF family member Elk-1 is capable of mediating GH-stimulated transcription, since GH-stimulated reporter expression was mediated by the transcriptional activation domain of Elk-1, Consistent with this stimulation, GH rapidly and transiently stimulated the serine phosphorylation of Elk-1. The increase was evident within 10 min and subsided after 30 min, Taken together, these data indicate that SRF and TCF contribute to GH-promoted transcription of c-fos via the SRE and are consistent with GH-promoted phosphorylation of Elk-1 contributing to GH-promoted transcriptional activation via the SRE.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,MOL & CELLULAR BIOL PROGRAM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046072, F32DK009293] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46072, DK 09293] Funding Source: Medline; NIGMS NIH HHS [GM 07315] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BENSON BA, 1994, J IMMUNOL, V153, P3862; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CM, 1995, ENDOCRINOLOGY, V136, P4505, DOI 10.1210/en.136.10.4505; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; COX AD, 1994, J BIOL CHEM, V269, P19203; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JANKNECHT R, 1993, EUR J BIOCHEM, V216, P469, DOI 10.1111/j.1432-1033.1993.tb18165.x; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Legraverend C, 1996, MOL ENDOCRINOL, V10, P1507, DOI 10.1210/me.10.12.1507; LIU SH, 1993, J BIOL CHEM, V268, P21147; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SLIVA D, 1994, J BIOL CHEM, V269, P26208; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUMANTRAN VN, 1992, ENDOCRINOLOGY, V130, P2016, DOI 10.1210/en.130.4.2016; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Waxman DJ, 1996, J BIOL CHEM, V271, P29978, DOI 10.1074/jbc.271.47.29978; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	60	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25951	25958		10.1074/jbc.272.41.25951	http://dx.doi.org/10.1074/jbc.272.41.25951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325329	hybrid			2022-12-27	WOS:A1997YA35800084
J	Rehemtulla, A; Hamilton, CA; Chinnaiyan, AM; Dixit, VM				Rehemtulla, A; Hamilton, CA; Chinnaiyan, AM; Dixit, VM			Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; DEATH DOMAIN; FAS; RECEPTORS; SIGNAL; LIGHT; GENE	Exposure to ultraviolet light (UV) can induce apoptosis in mammalian cells. The mechanism by which UV radiation engages the suicide apparatus is unclear. Here we demonstrate that UV radiation can activate the Fas pathway via receptor aggregation and subsequent recruitment of the death adaptor molecule FADD/MORT1. UV radiation-induced apoptosis was inhibited by both a dominant negative version of FADD (FADD-DN) and the caspase inhibitor CrmA. Thus, activation of the Fas pathway represents a physiologic mechanism by which UV-damaged cells are eliminated.	UNIV MICHIGAN,SCH MED,MED CTR,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT RADIAT ONCOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIGMS NIH HHS [NIGMS T32] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HUANG RP, 1995, ONCOGENE, V10, P467; JAATTELA M, 1995, ONCOGENE, V10, P2297; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255	13	264	271	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25783	25786		10.1074/jbc.272.41.25783	http://dx.doi.org/10.1074/jbc.272.41.25783			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325306				2022-12-27	WOS:A1997YA35800061
J	Sievert, MK; Ruoho, AE				Sievert, MK; Ruoho, AE			Peptide mapping of the [I-125]iodoazidoketanserin and [I-125]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR AMINE TRANSPORTER; CHROMAFFIN GRANULE MEMBRANES; CATECHOLAMINE TRANSPORTER; RESERPINE BINDING; STORAGE-VESICLES; ESCHERICHIA-COLI; LAC PERMEASE; HUMAN-BRAIN; SENSITIVITY; SUBSTRATE	The full-length cDNA for the rat recombinant synaptic vesicle monoamine transporter (rVMAT2) containing a COOH-terminal polyhistidine epitope was engineered into baculovirus DNA for expression in Spodoptera frugiperda (Sf9) cells. Using this recombinant baculovirus and cultured Sf9 cells, rVMAT2 has been expressed to high levels and purified to >95% homogeneity using immobilized Ni2+-affinity chromatography followed by lectin (concanavalin A) chromatography. Purified transporter was photolabeled using [I-125]-7-azido-8-iodoketanserin ([I-125]AZIK) and [I-125]2-N-[(3'-iodo-4'-azido-phenyl)propionyl]tetrabenazine ([I-125]TBZ-AIPP). Both [I-125]AZIK [I-125]TBZ-AIPP photoaffinity labeling of purified rVMAT2 were protectable by 10 mu M tetrabenazine (TBZ), 10 mu M 7-aminoketanserin, and 1 mM concentrations of the transporter substrates dopamine, norepinephrine, and serotonin. Radiolabeled peptides were generated using enzymatic and chemical methods, purified using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and NH2-terminal microsequenced. Radiosequencing of [I-125]AZIK-labeled rVMAT2 indicated derivatization of Lys-20 in the NH2 terminus, just prior to putative transmembrane domain 1 (TMD1). [I-125]TBZ-AIPP derivatized a segment of rVMAT2 between Gly-408 and Cys-431 in TMD10 and 11. These data implicate juxtaposition of TMD1 and 10/11.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NINDS NIH HHS [NS33650-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033650] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APPS DK, 1980, FEBS LETT, V111, P386, DOI 10.1016/0014-5793(80)80833-7; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CESURA AM, 1990, EUR J PHARMACOL, V186, P95, DOI 10.1016/0014-2999(90)94064-5; DANIELS AJ, 1988, J BIOL CHEM, V263, P5034; DARCHEN F, 1988, MOL PHARMACOL, V33, P672; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; GASNIER B, 1986, MOL PHARMACOL, V29, P275; Gros E., 1967, METHOD ENZYMOL, V11, P238; HENRY JP, 1989, BIOCHEM PHARMACOL, V38, P2395, DOI 10.1016/0006-2952(89)90082-8; Hockerman GH, 1996, MOL PHARMACOL, V49, P1021; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; ISAMBERT MF, 1989, BIOCHEMISTRY-US, V28, P2265, DOI 10.1021/bi00431a044; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; KABACK HR, 1990, TRENDS BIOCHEM SCI, V15, P309; KNOTH J, 1981, BIOCHEMISTRY-US, V20, P6625, DOI 10.1021/bi00526a016; KREJCI E, 1993, FEBS LETT, V335, P27, DOI 10.1016/0014-5793(93)80432-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; NEAR JA, 1983, FEBS LETT, V158, P31, DOI 10.1016/0014-5793(83)80670-X; NEAR JA, 1986, MOL PHARMACOL, V30, P252; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; PETER D, 1993, GENOMICS, V18, P720, DOI 10.1016/S0888-7543(05)80383-0; PETER D, 1994, J BIOL CHEM, V269, P7231; RUOHO AE, 1984, RECEPTOR BIOCH METHO, V1, P119; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERMAN D, 1988, EUR J PHARMACOL, V146, P359, DOI 10.1016/0014-2999(88)90317-2; SCHERMAN D, 1988, J NEUROCHEM, V50, P1131, DOI 10.1111/j.1471-4159.1988.tb10583.x; SCHERMAN D, 1980, BIOCHIM BIOPHYS ACTA, V601, P664, DOI 10.1016/0005-2736(80)90567-2; SCHERMAN D, 1988, MOL PHARMACOL, V33, P72; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHERMAN D, 1983, P NATL ACAD SCI-BIOL, V80, P584, DOI 10.1073/pnas.80.2.584; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; VAILLANCOURT RR, 1995, BIOCHEM J, V311, P987, DOI 10.1042/bj3110987	44	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26049	26055		10.1074/jbc.272.41.26049	http://dx.doi.org/10.1074/jbc.272.41.26049			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325342	hybrid			2022-12-27	WOS:A1997YA35800097
J	deAos, I; Metzger, MH; Exley, M; Dahl, CE; Misra, S; Zheng, DX; Varticovski, L; Terhorst, C; Sancho, J				deAos, I; Metzger, MH; Exley, M; Dahl, CE; Misra, S; Zheng, DX; Varticovski, L; Terhorst, C; Sancho, J			Tyrosine phosphorylation of the CD3-epsilon subunit of the T cell antigen receptor mediates enhanced association with phosphatidylinositol 3-kinase in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM SH2 DOMAINS; SIGNAL-TRANSDUCTION; ACTIVATION MOTIFS; PDGF RECEPTOR; ZETA-CHAIN; BINDING-SPECIFICITY; REGULATORY SUBUNIT; KINASE P56LCK; CD3 COMPLEX; ZAP-70 BIND	T cell receptor signaling results both in T cell. proliferation and apoptosis. A key enzyme at the intersection of these downstream pathways is phosphatidylinositol 3'-kinase (PIS-kinase). In a previous report, we showed that the p85 alpha subunit of the PI 3-kinase preferentially associated with the CD3-zeta membrane-proximal immuno-receptor tyrosine-based activation motif of the zeta chain (zeta A-ITAM) (Exley, M., Varticovski, L., Peter, M., Sancho, J., and Terhorst, C. (1994) J. Biol. Chem. 269, 15140-15146). Here, we demonstrate that tyrosine phosphoryl ation of CD3-epsilon can recruit the PI 3-kinase enzyme in a T cell activation-dependent manner. In vivo studies with Jurkat cells stably transfected with a CD8-CD3-epsilon chimera (termed CD8-epsilon) shows that ligation of endogenous CD3-epsilon or CD8-epsilon by specific antibodies induces tyrosine phosphorylation of CD3-epsilon or CD8-epsilon, respectively. Increased tyrosine phosphorylation correlates with increased binding of p85 alpha PI S-kinase and recruitment of PI S-kinase enzymatic activity to CD3-epsilon or CD8-epsilon proteins. Mutagenesis studies in COS-7 cells, transiently transfected with CD8-epsilon, p85 alpha, and Fyn cDNAs in various combinations, show that both Tyr(170) and Tyr(181) within the CD3-epsilon-ITAM are required for efficient binding of p85 alpha PI 3-kinase. Thus, replacement of Tyr(170) by Phe (Y170F), or Tyr(181) by Phe (Y181F) significantly reduces binding of p85 alpha PI 3-kinase, whereas it does not affect binding of Fyn. Further in vitro experiments suggest that a direct binding of the tandem SH2 domains of p85 alpha PI 3-kinase to the two phosphorylated tyrosines in a single CD3-epsilon-ITAM may occur, The data also support a model in which a single CD3 subunit can recruit distinct effector molecules by means of TCR-mediated differential ITAM phosphorylation.	CSIC, INST PARASITOL & BIOMED, GRANADA 18001, SPAIN; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DIV IMMUNOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02215 USA; CHINESE ACAD MED SCI, INST BASIC MED SCI, DEPT BIOCHEM & MOL BIOL, BEIJING 10005, PEOPLES R CHINA; TUFTS UNIV, ST ELIZABETHS HOSP, SCH MED, DEPT BIOMED RES, BOSTON, MA 02135 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Chinese Academy of Medical Sciences - Peking Union Medical College; Tufts University			Sancho, Jaime/O-3228-2013; Sancho, Jaime/K-5989-2019	Sancho, Jaime/0000-0003-3852-7951; Sancho, Jaime/0000-0003-3852-7951; Varticovski, Lyuba/0000-0002-5105-9008; Exley, Mark/0000-0002-5088-1032	NCI NIH HHS [CA 53094] Funding Source: Medline; NIAID NIH HHS [AI-15066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053094, R01CA053094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI015066, R01AI015066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATHERTON E, 1975, J AM CHEM SOC, V97, P6584, DOI 10.1021/ja00855a053; AUSUBEL FM, 1995, CURRENT PROTOCOLS S, V17, P16131; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CAMBIER JC, 1995, IMMUNOL LETT, V44, P77, DOI 10.1016/0165-2478(94)00196-X; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; EXLEY M, 1994, J BIOL CHEM, V269, P15140; Exley M, 1991, Semin Immunol, V3, P283; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HOWARD FD, 1992, J EXP MED, V176, P139, DOI 10.1084/jem.176.1.139; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; SUSA M, 1992, J BIOL CHEM, V267, P22951; TIMSONGAUEN LK, 1994, MOL CELL BIOL, V14, P3729; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YOAKIM M, 1994, MOL CELL BIOL, V14, P5929, DOI 10.1128/MCB.14.9.5929; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25310	25318		10.1074/jbc.272.40.25310	http://dx.doi.org/10.1074/jbc.272.40.25310			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312149	hybrid			2022-12-27	WOS:A1997XY97000088
J	Kato, Y; Matsui, T; Tanaka, N; Muneyuki, E; Hisabori, T; Yoshida, M				Kato, Y; Matsui, T; Tanaka, N; Muneyuki, E; Hisabori, T; Yoshida, M			Thermophilic F-1-ATPase is activated without dissociation of an endogenous inhibitor, epsilon subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; APPARENT NEGATIVE COOPERATIVITY; COUPLING FACTOR-I; ADENOSINE-TRIPHOSPHATASE; ATP SYNTHASE; CATALYTIC SITE; GAMMA-SUBUNIT; DELTA-SUBUNIT; BACTERIUM PS3; BETA-SUBUNIT	Subunit complexes (alpha(3) beta(3) gamma, alpha(3) beta(3) gamma delta, alpha(3) beta(3) gamma epsilon, and alpha(3) beta(3) gamma delta epsilon) of thermophilic F-1-ATPase were prepared, and their catalytic properties were compared to know the role of delta and epsilon subunits in catalysis. The presence of delta subunit in the complexes had slight inhibitory effect on the ATPase activity, The effect of epsilon subunit was more profound, The (-epsilon) complexes, alpha(3) beta(3) gamma and alpha(3) beta(3) gamma delta, initiated ATP hydrolysis without a lag. In contrast, the (+epsilon) complexes, alpha(3) beta(3) gamma epsilon and alpha(3) beta(3) gamma delta epsilon, started hydrolysis of ATP (<700 mu M) with a lag phase that was gradually activated during catalytic turnover. As ATP concentration increased, the lag phase of the (+epsilon) complexes became shorter, and it was not observed above 1 mM ATP, Analysis of binding and hydrolysis of the ATP analog, 2',3'-O-(2,4,6-trinitrophenyl) ATP, suggested that the (+epsilon) complexes bound substrate only slowly. Differing from Escherichia coli F-1-ATPase, the activation of the (+epsilon) complexes from the lag phase was not due to dissociation of epsilon subunit since the re-isolated activated complex retained epsilon subunit. This indicates that there are two alternative forms of the (+epsilon) complex, inhibited form and activated form, and the inhibited one is converted to the activated one during catalytic turnover.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 226, JAPAN	Tokyo Institute of Technology			Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1990, BIOCHEMISTRY-US, V29, P4335, DOI 10.1021/bi00470a011; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HASHIMOTO T, 1996, SEIKAGAKU, V68, pP775; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; NALIN CM, 1984, J BIOL CHEM, V259, P7275; NELSON N, 1972, J BIOL CHEM, V247, P7657; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SAIKA K, 1995, FEBS LETT, V368, P207, DOI 10.1016/0014-5793(95)00644-O; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; SOTEROPOULOS P, 1994, J BIOL CHEM, V269, P19810; SRERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526; Stiggall D L, 1979, Methods Enzymol, V55, P308; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TOZAWA K, 1992, J BIOL CHEM, V267, P16484; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; XIAO R, 1994, J BIOL CHEM, V269, P19232; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOHDA M, 1987, J BIOCHEM-TOKYO, V102, P875, DOI 10.1093/oxfordjournals.jbchem.a122128; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1977, P NATL ACAD SCI USA, V74, P936, DOI 10.1073/pnas.74.3.936; YOSHIDA M, 1979, J BIOL CHEM, V254, P9525; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	65	58	59	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24906	24912		10.1074/jbc.272.40.24906	http://dx.doi.org/10.1074/jbc.272.40.24906			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312092	hybrid			2022-12-27	WOS:A1997XY97000031
J	Little, SP; Dixon, EP; Norris, F; Buckley, W; Becker, GW; Johnson, M; Dobbins, JR; Wyrick, T; Miller, JR; MacKellar, W; Hepburn, D; Corvalan, J; McClure, D; Liu, XD; Stephenson, D; Clemens, J; Johnstone, EM				Little, SP; Dixon, EP; Norris, F; Buckley, W; Becker, GW; Johnson, M; Dobbins, JR; Wyrick, T; Miller, JR; MacKellar, W; Hepburn, D; Corvalan, J; McClure, D; Liu, XD; Stephenson, D; Clemens, J; Johnstone, EM			Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE SPECIFIC ANTIGEN; BETA-PROTEIN; PRECURSOR PROTEIN; KALLIKREIN GENES; N-TERMINUS; RAT-BRAIN; PEPTIDE; IDENTIFICATION; DNA; GENERATION	The deposition of the beta amyloid peptide in neuritic plaques and cerebral blood vessels is a hallmark of Alzheimer's disease (AD) pathology, The major component of the amyloid deposit is a 4.2-kDa polypeptide termed amyloid beta-protein of 39-43 residues, which is derived from processing of a larger amyloid precursor protein (APP). It is hypothesized that a chymotrypsin-like enzyme is involved in the processing of APP. We have discovered a new serine protease from the AD brain by polymerase chain reaction amplification of DNA sequences representing active site homologous regions of chymotrypsin-like enzymes, A cDNA clone was identified as one out of one million that encodes Zyme, a serine protease, Messenger RNA encoding Zyme can be detected in some mammalian species but not in mice, rats, or hamster, Zyme is expressed predominantly in brain, kidney, and salivary gland, Zyme mRNA cannot be detected in fetal brain but is seen in adult brain, The Zyme gene maps to chromosome 19q13.3, a region which shows genetic linkage with late onset familial Alzheimer's disease. When Zyme cDNA is co expressed with the APP cDNA in 293 (human embryonic kidney) cells, amyloidogenic fragments are detected using C-terminal antibody to APP, These co-transfected cells release an abundance of truncated amyloid beta-protein peptide and shows a reduction of residues 17-42 of A beta (P3) peptide, Zyme is immunolocalized to perivascular cells in monkey cortex and the AD brain, In addition, Zyme is localized to microglial cells in our AD brain sample, The amyloidogenic potential and localization in brain may indicate a role for this protease in amyloid precursor processing and AD.	LILLY RES LABS,TECHNOL CORE RES,INDIANAPOLIS,IN 46285; LILLY RES LABS,CANC RES,INDIANAPOLIS,IN 46285; LILLY RES LABS,ENDOCRINE RES,INDIANAPOLIS,IN 46285	Eli Lilly; Eli Lilly; Eli Lilly	Little, SP (corresponding author), LILLY RES LABS,CENT NERVOUS SYST RES,INDIANAPOLIS,IN 46285, USA.							ABRAHAM CR, 1991, BIOCHEM BIOPH RES CO, V174, P790, DOI 10.1016/0006-291X(91)91487-W; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P561; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Gerard G.F., 1989, FOCUS, V11, P66; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOWING E, 1994, J BIOL CHEM, V269, P10987; HENTTU P, 1989, BIOCHEM BIOPH RES CO, V160, P903, DOI 10.1016/0006-291X(89)92520-5; Higgins LS, 1996, AM J PATHOL, V149, P585; JOHNSTONE EM, 1994, NEUROSCI LETT, V180, P151, DOI 10.1016/0304-3940(94)90509-6; KANG J, 1992, GENE, V110, P181, DOI 10.1016/0378-1119(92)90646-7; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LITTLE SP, 1995, J CELL BIOCH B S, V21, P105; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; NELSON RB, 1990, J BIOL CHEM, V265, P3836; NELSON RB, 1993, J NEUROCHEM, V61, P567; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; RICHARDS RI, 1991, GENOMICS, V11, P77, DOI 10.1016/0888-7543(91)90103-L; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAHASRABUDHE SR, 1993, J BIOL CHEM, V268, P16699; Sambrook J., 2002, MOL CLONING LAB MANU; SCHENK DB, 1995, J MED CHEM, V38, P4141, DOI 10.1021/jm00021a001; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; WISNIEWSKI HM, 1993, ACTA NEUROPATHOL, V85, P586, DOI 10.1007/BF00334667; YU CE, 1994, AM J HUM GENET, V54, P631	36	146	157	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25135	25142		10.1074/jbc.272.40.25135	http://dx.doi.org/10.1074/jbc.272.40.25135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312124	hybrid			2022-12-27	WOS:A1997XY97000063
J	Reidlinger, J; Pike, AM; Savory, PJ; Murray, RZ; Rivett, AJ				Reidlinger, J; Pike, AM; Savory, PJ; Murray, RZ; Rivett, AJ			Catalytic properties of 26 S and 20 S proteasomes and radiolabeling of MB1, LMP7, and C7 subunits associated with trypsin-like and chymotrypsin-like activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; PEPTIDE-HYDROLYZING ACTIVITY; UBIQUITIN-LIGATED PROTEINS; YEAST PROTEASOME; RAT-LIVER; POLYACRYLAMIDE GELS; BRANCHED-CHAIN; COMPONENTS; PROTEOLYSIS; DEGRADATION	20 and 26 S proteasomes were isolated from rat liver, The procedure developed for the 26 S proteasome resulted in greatly improved yields compared with previously published methods, A comparison of the kinetic properties of 20 and 26 S proteasomes showed significant differences in the kinetic characteristics with certain substrates and differences in the effects of a protein substrate on peptidase activity, Observed differences in the kinetics of peptidylglutamyl peptide hydrolase activity suggest that the 26 S complex cannot undergo the conformational changes of 20 S proteasomes at high concentrations of the substrate benzyloxycarbonyl (Z)-Leu-Leu-Glu-beta-naphthylamide. Various inhibitors that differentially affect the trypsin-like and chymotrypsin-like activities have been identified, Ala-Ala-Phe-chloromethyl (CH2Cl) inhibits chymotrypsin-like activity assayed with succinyl (Suc)-Leu-Leu-Val-Tyr-AMC, but surprisingly not hydrolysis of Ala-Ala-Phe-7-amido-4-methylcoumarin (AMC), Tyr-Gly-Arg-CH2Cl inhibits Suc-Leu-Leu-Val-Tyr-AMC hydrolysis as well as trypsinlike activity measured with t-butoxycarbonyl (Boc)-Leu-Ser-Thr-Arg-AMC, while Z-Phe-Gly-Tyr-diazo-methyl (CHN2) was found to inhibit only the two chymotrypsin-like activities, Radiolabeled forms of peptidyl chloromethane and peptidyl diazomethane inhibitors, [H-3]acetyl-Ala-Ala-Phe-CH2Cl, [H-3]acetyl- and radioiodinated Tyr Gly-Arg-CH2Cl, and Z-Phe-Gly-Tyr-(I-125-CHN2), have been used to identify catalytic components associated with each of the three peptidase activities, In each case, incorporation of the label could be blocked by prior treatment of the proteasomes with known active site-directed inhibitors, calpain inhibitor 1 or 3,4-dichloroisocoumarin. Subunits of labeled proteasomes were separated either by reverse phase-HPLC and SDS-polyacrylamide gel electrophoresis or by two-dimensional polyacrylamide gel electrophoresis followed by autoradiography/fluorography and immunoblotting with subunit-specific antibodies, In each case, label was found to be incorporated into subunits C7, MB1, and LMP7 but in different relative amounts depending on the inhibitor used, consistent with the observed effects on the different peptidase activities, The results strongly suggest a relationship between trypsin-like activity and chymotrypsin-like activity, They also help to relate the different subunits of the complex to the assayed multicatalytic endopeptidase activities.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol			Murray, Rachael/J-1370-2012	Murray, Rachael/0000-0002-4935-7794	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardozo C, 1996, ARCH BIOCHEM BIOPHYS, V334, P113, DOI 10.1006/abbi.1996.0436; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DICK LR, 1992, BIOCHEMISTRY-US, V31, P7347, DOI 10.1021/bi00147a020; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DJABALLAH H, 1993, BIOCHEM J, V292, P857, DOI 10.1042/bj2920857; DJABALLAH H, 1992, EUR J BIOCHEM, V209, P629, DOI 10.1111/j.1432-1033.1992.tb17329.x; DJABALLAH H, 1992, BIOCHEMISTRY-US, V31, P4133, DOI 10.1021/bi00131a033; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; DUNCAN R, 1984, ANAL BIOCHEM, V138, P144, DOI 10.1016/0003-2697(84)90783-8; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1995, ARCH BIOCHEM BIOPHYS, V317, P69, DOI 10.1006/abbi.1995.1137; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HILT W, 1993, J BIOL CHEM, V268, P3479; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; KRISTENSEN P, 1994, BIOCHEM BIOPH RES CO, V205, P1785, DOI 10.1006/bbrc.1994.2876; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1994, TRENDS BIOCHEM SCI, V19, P533, DOI 10.1016/0968-0004(94)90054-X; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; RAUBER P, 1988, ANAL BIOCHEM, V168, P259, DOI 10.1016/0003-2697(88)90316-8; RAWLINGS ND, 1990, COMPUT APPL BIOSCI, V6, P118; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RIVETT AJ, 1991, BIOCHEM J, V278, P171, DOI 10.1042/bj2780171; RIVETT AJ, 1995, MOL BIOL REP, V21, P35, DOI 10.1007/BF00990968; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SAVORY PJ, 1993, BIOCHEM J, V296, P601, DOI 10.1042/bj2960601; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SIBILLE C, 1995, CURR BIOL, V5, P923, DOI 10.1016/S0960-9822(95)00182-5; Tanaka K, 1997, ADV IMMUNOL, V64, P1, DOI 10.1016/S0065-2776(08)60885-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; VINITSKY A, 1994, J BIOL CHEM, V269, P29860	54	58	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24899	24905		10.1074/jbc.272.40.24899	http://dx.doi.org/10.1074/jbc.272.40.24899			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312091	Green Published, hybrid			2022-12-27	WOS:A1997XY97000030
J	Shimozaki, K; Nakajima, K; Hirano, T; Nagata, S				Shimozaki, K; Nakajima, K; Hirano, T; Nagata, S			Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; NUCLEOTIDE-SEQUENCE; CYTOPLASMIC REGION; GROWTH-FACTORS; ACTIVATION; PROLIFERATION; SUPPRESSION; APOPTOSIS	Granulocyte colony-stimulating factor (G-CSF) stimulates proliferation and differentiation of the progenitor cells of neutrophilic granulocytes. The binding of G-CSF to its receptor specifically activates JAK1 and JAK2 kinases as well as STAT3, a signal transducer and activator of transcription (STAT), To examine the role of STAT3 in G-CSF receptor-mediated signal transduction, two different forms of the dominant negative STAT3 were introduced into a mouse myeloid cell line that exogenously expresses the mouse G-CSF receptor, In response to G-CSF, the parental myeloid cells grew for about 4 days, and then they stopped dividing and differentiated into cells with lobulated nuclei, During this period, the expression of the myeloperoxidase (MPO) gene was induced, while c-myc gene expression was down-regulated. In contrast, in the cells expressing the dominant negative STAT3, G-CSF could induce neither growth arrest nor morphological change, However, the induction of the MPO gene by G-CSF was not affected by the dominant negative STAT3, These results indicate that STAT3 activation is responsible for part of the G-CSF-induced differentiation of neutrophils but that another pathway, involving the expression of the MPO gene, that does not utilize the activated STAT3, is also required to fully differentiate the cells.	OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV MOL ONCOL,SUITA,OSAKA 565,JAPAN; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Hirano, Toshio/C-8194-2009; Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRY JL, 1987, SCIENCE, V236, P1229; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; deKoning JP, 1996, BLOOD, V87, P132; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FEGAN CD, 1995, BRIT J HAEMATOL, V90, P486, DOI 10.1111/j.1365-2141.1995.tb05183.x; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; LIESCHKE GJ, 1994, BLOOD, V84, P1737; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAGATA S, 1994, CYTOKINE HDB, P371; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rodel JE, 1996, BLOOD, V87, P858, DOI 10.1182/blood.V87.3.858.bloodjournal873858; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TIAN SS, 1994, BLOOD, V84, P1760; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VENTURELLI D, 1989, NUCLEIC ACIDS RES, V17, P5852, DOI 10.1093/nar/17.14.5852; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	47	150	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25184	25189		10.1074/jbc.272.40.25184	http://dx.doi.org/10.1074/jbc.272.40.25184			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312131	hybrid			2022-12-27	WOS:A1997XY97000070
J	Suske, WA; Held, M; Schmid, A; Fleischmann, T; Wubbolts, MG; Kohler, HPE				Suske, WA; Held, M; Schmid, A; Fleischmann, T; Wubbolts, MG; Kohler, HPE			Purification and characterization of 2-hydroxybiphenyl 3-monooxygenase, a novel NADH-dependent, FAD-containing aromatic hydroxylase from Pseudomonas azelaica HBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-HYDROXYBENZOATE HYDROXYLASE; SP STRAIN HBP1; 2,4-DICHLOROPHENOL HYDROXYLASE; ORTHO-PHENYLPHENOL; FLUORESCENS; DIBENZOTHIOPHENE; METABOLISM; CLEAVAGE; SEQUENCE; DESULFURIZATION	2-Hydroxybiphenyl 3-monooxygenase (HbpA), the first enzyme of a-hydroxybiphenyl degradation in Pseudomonas azelaica HBP1, was purified 26-fold with a yield of 8% from strain HBP1 grown on a-hydroxybiphenyl, The enzyme was also purified from a recombinant of Escherichia coli JM109, which efficiently expressed the hbpA gene, Computer densitometry of scanned slab gels revealed a purity of over 99% for both enzyme preparations, Gel filtration, subunit cross-linking, and SDS-polyacrylamide gel electrophoresis showed that the enzyme was a homotetramer with a molecular mass of 256 kDa, Each subunit had a molecular mass of 60 kDa containing one molecule of noncovalently bound FAD, The monooxygenase had a pi of 6.3, It catalyzed the NADH-dependent ortho-hydroxylation of 2-hydroxybiphenyl to 2,3-dihydroxybiphenyl. Molecular oxygen was the source of the additional oxygen of the product, The enzyme hydroxylated various phenols with a hydrophobic side chain adjacent to the hydroxy group, All substrates effected partial uncoupling of NADH oxidation from hydroxylation with the concomitant formation of hydrogen peroxide, 2,3-Dihydroxybiphenyl, the product of the reaction with a-hydroxybiphenyl, was a non-substrate effector that strongly facilitated NADH oxidation and hydrogen peroxide formation without being hydroxylated and also was an inhibitor, The apparent K-m, values (30 degrees C, pH 7.5) were 2.8 mu m for 2-hydroxybiphenyl, 26.8 mu m for NADH, and 29.2 mu m for oxygen, The enzyme was inactivated by p-hydroxymercuribenzoate, a cysteine-blocking reagent, In the presence of a-hydroxybiphenyl, the enzyme was partly protected against the inactivation, which was reversed by the addition of an excess of dithiothreitol, The NH2-terminal amino acid sequence of the enzyme contained the consensus sequence GXGXXG, indicative of the beta alpha beta-fold of the flavin binding site and shared homologies with that of phenol a-hydroxylase from Pseudomonas strain EST1001 as well as with that of 2,4-dichlorophenol 6-hydroxylase from Ralstonia eutropha.	EAWAG,DEPT MICROBIOL,CH-8600 DUBENDORF,SWITZERLAND; ETH ZURICH,INST BIOTECHNOL,CH-8093 ZURICH,SWITZERLAND; UNIV STUTTGART,DEPT BIOL WASTE AIR PURIFICAT,D-70569 STUTTGART,GERMANY	Swiss Federal Institute of Aquatic Science & Technology (EAWAG); ETH Zurich; University of Stuttgart			Kohler, Hans-Peter/C-1456-2015	Kohler, Hans-Peter/0000-0001-7667-0762				BEADLE CA, 1982, EUR J BIOCHEM, V123, P323, DOI 10.1111/j.1432-1033.1982.tb19771.x; BEINERT H, 1960, ENZYMES, V2, P339; CATELANI D, 1974, BIOCHEM J, V143, P431, DOI 10.1042/bj1430431; Copeland R. A., 1994, METHODS PROTEIN ANAL, P59; DENOME SA, 1993, APPL ENVIRON MICROB, V59, P2837, DOI 10.1128/AEM.59.9.2837-2843.1993; DETMER F, 1984, CHEM BIOCH FLAVOENZY, V259, P12125; Eckert J.W., 1977, ANTIFUNGAL COMPOUNDS, VFirst, P269; ENGESSER KH, 1989, FEMS MICROBIOL LETT, V65, P205; FORTNAGEL P, 1990, APPL ENVIRON MICROB, V56, P1148, DOI 10.1128/AEM.56.4.1148-1156.1990; GALLAGHER JR, 1993, FEMS MICROBIOL LETT, V107, P31, DOI 10.1111/j.1574-6968.1993.tb05999.x; GIBSON DT, 1973, BIOCHEM BIOPH RES CO, V50, P211, DOI 10.1016/0006-291X(73)90828-0; GRIFFITH IP, 1972, BIOCHEM J, V126, P553, DOI 10.1042/bj1260553; HOFSTEENGE J, 1983, EUR J BIOCHEM, V133, P91, DOI 10.1111/j.1432-1033.1983.tb07433.x; KOHLER HPE, 1988, APPL ENVIRON MICROB, V54, P2683, DOI 10.1128/AEM.54.11.2683-2688.1988; KOHLER HPE, 1993, APPL ENVIRON MICROB, V59, P860, DOI 10.1128/AEM.59.3.860-866.1993; KOHLER HPE, 1993, J BACTERIOL, V175, P1621, DOI 10.1128/JB.175.6.1621-1628.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU T, 1984, FEBS LETT, V173, P314, DOI 10.1016/0014-5793(84)80797-8; Maarel M. J. E. C. van der, 1993, Biodegradation, V4, P81, DOI 10.1007/BF00702324; MASSEY V, 1975, ENZYMES, V12, P191; Mullis K B, 1991, PCR Methods Appl, V1, P1; NAKAGAWA Y, 1989, XENOBIOTICA, V19, P499, DOI 10.3109/00498258909042289; NAKAGAWA Y, 1995, LIFE SCI, V57, P1433, DOI 10.1016/0024-3205(95)02106-S; NEUJAHR HY, 1978, J BIOL CHEM, V253, P8835; NEUJAHR HY, 1991, CHEM BIOCH FLAVOENZY, V2, P65; NURK A, 1991, GENE, V102, P13, DOI 10.1016/0378-1119(91)90531-F; Ohshiro T, 1996, J FERMENT BIOENG, V81, P121, DOI 10.1016/0922-338X(96)87588-X; OMORI T, 1992, APPL ENVIRON MICROB, V58, P911, DOI 10.1128/AEM.58.3.911-915.1992; PERKINS EJ, 1990, J BACTERIOL, V172, P2351, DOI 10.1128/jb.172.5.2351-2359.1990; Ratkowsky D., 1983, NONLINEAR REGRESSION; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID A, 1997, THESIS U STUTTGART; SCHREUDER HA, 1991, CHEM BIOCH FLAVOENZY, V2, P31; SPECTOR T, 1972, J BIOL CHEM, V247, P4679; STRICKLAND S, 1973, J BIOL CHEM, V248, P2944; STRUBEL V, 1991, J BACTERIOL, V173, P1932, DOI 10.1128/jb.173.6.1932-1937.1991; TAYAMA S, 1994, MUTAT RES, V324, P121, DOI 10.1016/0165-7992(94)90056-6; van Berkel W.J.H., 1991, CHEM BIOCH FLAVOENZY, P1; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1991, EUR J BIOCHEM, V201, P585; VANBERKEL WJH, 1984, EUR J BIOCHEM, V145, P245; VANDERBOLT FJT, 1994, PROTEIN ENG, V7, P801, DOI 10.1093/protein/7.6.801; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324	44	64	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24257	24265		10.1074/jbc.272.39.24257	http://dx.doi.org/10.1074/jbc.272.39.24257			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305879	hybrid, Green Published			2022-12-27	WOS:A1997XY51500030
J	McCormick, SPA; Ng, JK; Cham, CM; Taylor, S; Marcovina, SM; Segrest, JP; Hammer, RE; Young, SG				McCormick, SPA; Ng, JK; Cham, CM; Taylor, S; Marcovina, SM; Segrest, JP; Hammer, RE; Young, SG			Transgenic mice expressing human apoB95 and apoB97	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-B; MONOCLONAL-ANTIBODY; YEAST; DNA; PLASMINOGEN; PLASMA; MUTAGENESIS; REPLACEMENT; EVOLUTION	The structural features of apolipoprotein (apo) B that are important for its covalent linkage to apo(a) to form lipoprotein(a) (Lp(a)) are incompletely understood. Although apoB100 cysteine 4326 is required for the disulfide linkage with apo(a), other structural features, aside from a single free cysteine residue, must be important for apoB's initial interaction with apo(a) and far facilitating the formation of the disulfide bond, To determine if sequences carboxyl-terminal to cysteine 4326 affect the efficiency of Lp(a) formation, we used ''pop-in, pop out'' gene targeting in a human apoB yeast artificial chromosome to introduce nonsense mutations into exon 29 of the apoB gene, The mutant yeast artificial chromosomes, which coded for the truncated versions of human apoB, apoB95, and apoB97, were then used to express these mutant forms of apoB in transgenic mice, As judged by in vitro assays of Ly(a) formation, apoB95 (4330 amino acids) formed a small amount of Lp(a) but did so slowly. In contrast, apoB97 (4397 amino acids) formed Ep(a) rapidly, although not quite as rapidly as the full-length apoB100 (4536 amino acids). These results were supported by an analysis of double-transgenic mice expressing both human apo(a) and either-apoB95 or apoB97. Iu mice expressing bath apoB95 and apo(a), there was only a trace amount of Lp(a) in the plasma, and most of the apo(a) was free, whereas in mice expressing both apoB97 and apo(a), virtually all of the apo(a) was bound to apoB97 in the farm of Lp(a), These results show that sequences carboxyl-terminal to apoB95 (amino acids 4331-4536) are not absolutely required for Lp(a) formation, but this segment of the apoB molecule, particularly residues 4331-4397, is necessary for the efficient assembly of LP(a).	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA; UNIV WASHINGTON, DEPT MED, NW LIPID RES LABS, SEATTLE, WA 98103 USA; UNIV ALABAMA, MED CTR, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Hammer, Robert E./0000-0001-5487-7551; McCormick, Sally/0000-0001-9857-0703; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; CHIESA G, 1992, J BIOL CHEM, V267, P24369; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; KARADI I, 1988, BIOCHIM BIOPHYS ACTA, V960, P91, DOI 10.1016/0005-2760(88)90013-6; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KRUL ES, 1988, J LIPID RES, V29, P937; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LAWN RM, 1995, J BIOL CHEM, V270, P24004, DOI 10.1074/jbc.270.41.24004; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MAKINO K, 1989, ATHEROSCLEROSIS, V78, P81, DOI 10.1016/0021-9150(89)90161-5; MANCINI FP, 1995, ARTERIOSCL THROM VAS, V15, P1911, DOI 10.1161/01.ATV.15.11.1911; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; MCCORMICK SPA, 1995, P NATL ACAD SCI USA, V92, P10147, DOI 10.1073/pnas.92.22.10147; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; McCormick SPA, 1996, TRENDS CARDIOVAS MED, V6, P16, DOI 10.1016/1050-1738(95)00125-5; MCCORMICK SPA, 1994, GENET ANAL-BIOMOL E, V11, P158, DOI 10.1016/1050-3862(94)90036-1; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, CURR OPIN LIPIDOL, V2, P253; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WU TP, 1991, BIOCHEMISTRY-US, V30, P10589, DOI 10.1021/bi00107a030; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1994, J LIPID RES, V35, P399	33	19	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23616	23622		10.1074/jbc.272.38.23616	http://dx.doi.org/10.1074/jbc.272.38.23616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295301	hybrid			2022-12-27	WOS:A1997XX38100026
J	Noti, JD				Noti, JD			Sp3 mediates transcriptional activation of the leukocyte integrin genes CD11C and CD11B and cooperates with c-Jun to activate CD11C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; MYELOID CELLS; ZINC-FINGER; SP1-MEDIATED TRANSCRIPTION; NEGATIVE REGULATION; MOLECULAR-CLONING; PROMOTER ACTIVITY; RB PROTEIN; EXPRESSION; PRODUCT	The leukocyte integrin genes CD11c and CD11b are expressed predominately in myelomonocytic cells. In previous experiments, the -70 to -65 and -121 to -103 regions of the CD11c promoter and the -66 to -59 region of the CD11b promoter were shown to be essential for Sp1-mediated activation of these genes. In vivo genomic footprinting had also revealed cell-specific binding of protein, presumably Sp1, to these regions. In this study, electrophoretic mobility shift analysis showed that the Sp1-related factor, Sp3, also binds at or near these same regions, Cotransfection of Sp3 along with CD11c promoter-luciferase constructs into Sp-deficient Drosophila Schneider 2 cells showed that Sp3 could activate the CD11c promoter, Deletion of both the -70 to -65 and -121 to -103 regions of the CD11c promoter resulted in the loss of activation by Sp3. Both sites showed activation by Sp3; however, the -70 to -65 region was more responsive to Sp3 than to Sp1. Similar transfection analysis of the -66 to -59 region of the CD11b promoter showed Sp3-dependent expression. Further, cotransfection analysis in Drosophila cells showed that Sp3, as was previously shown for Sp1, also synergizes with c-Jun to activate CD11c. Antisense experiments that knocked out endogenous Sp3 expression in the myelomocytic cell line, HL60, revealed that Sp3 participates in activation of the CD11c and CD11b promoters in vivo.			Noti, JD (corresponding author), GUTHRIE RES INST,SAYRE,PA 18840, USA.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN XR, 1994, ONCOGENE, V9, P3179; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HROMAS R, 1991, J BIOL CHEM, V266, P14183; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524; LopezRodriguez C, 1996, J IMMUNOL, V156, P3780; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Noti JD, 1996, MOL IMMUNOL, V33, P115, DOI 10.1016/0161-5890(95)00140-9; NOTI JD, 1992, DNA CELL BIOL, V11, P123, DOI 10.1089/dna.1992.11.123; NOTI JD, 1995, MOL IMMUNOL, V32, P361, DOI 10.1016/0161-5890(94)00164-V; Noti JD, 1996, MOL CELL BIOL, V16, P2940; OHYASHIKI JH, 1995, BLOOD, V85, P3713, DOI 10.1182/blood.V85.12.3713.bloodjournal85123713; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSMARIN AG, 1989, BLOOD, V73, P131; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1986, J IMMUNOL, V136, P230; Sturrock A, 1996, J BIOL CHEM, V271, P32392, DOI 10.1074/jbc.271.50.32392; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; Williams CL, 1996, BIOCHEM PHARMACOL, V51, P707, DOI 10.1016/S0006-2952(95)02393-3; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282; YU DH, 1992, J BIOL CHEM, V267, P10203; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	54	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24038	24045		10.1074/jbc.272.38.24038	http://dx.doi.org/10.1074/jbc.272.38.24038			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295357	hybrid			2022-12-27	WOS:A1997XX38100082
J	Ollinger, K; Roberg, K				Ollinger, K; Roberg, K			Nutrient deprivation of cultured rat hepatocytes increases the desferrioxamine-available iron pool and augments the sensitivity to hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT IRON; OXIDATIVE STRESS; FERRIC IRON; LIQUID-CHROMATOGRAPHY; RADICAL FORMATION; INSULINOMA CELLS; ASCORBIC-ACID; MODEL SYSTEM; SUPEROXIDE; INJURY	Primary cultures of rat hepatocytes were subjected to amino acid and serum deprivation for 4 h, This treatment augmented the sensitivity to ensuing hydrogen peroxide exposure for 30 min, The by nutrient deprivation-increased autophagocytosis was confirmed by transmission electron microscopy and uptake of the lysosomotropic weak base acridine orange within the intracellular acidic vacuolar apparatus, The desferrioxamine-available pool of iron increased 2.5-fold during deprivation, compared with control cells, Furthermore, amino acid deprivation increased the cellular protein turnover, measured by radioactive labeling with [H-3]Leu, Exposure to 40 mu M ascorbic acid specifically decreased the turnover of ferritin, as estimated by enzyme-linked immunosorbent assay, and prevented an increase of the desferrioxamine available iron pool, resulting in protection against hydrogen peroxide-induced cell killing. Thus, hepatocytes with nutrient deprivation-enhanced autophagocytosis contain a larger pool of catalytically active iron than control cells, This iron pool is mainly derived from the turnover (autophagocytosis) of cytosolic ferritin and is probably situated in the lysosomes. Furthermore, nutrient deprived cells show augmented sensitivity to hydrogen peroxide-induced oxidative stress, since the enhanced availability of iron in low molecular weight form results in an increased potential of intralysosomal Fenton chemistry, that may cause lysosomal rupture with release of potent hydrolytic enzymes.			Ollinger, K (corresponding author), LINKOPING UNIV, FAC HLTH SCI, DEPT PATHOL 2, S-58185 LINKOPING, SWEDEN.							ABOK K, 1988, APMIS, V96, P589, DOI 10.1111/j.1699-0463.1988.tb00915.x; AUST SD, 1993, TOXICOL APPL PHARM, V120, P168, DOI 10.1006/taap.1993.1100; BALLA G, 1992, J BIOL CHEM, V267, P18148; BANDO Y, 1990, BIOCHEM BIOPH RES CO, V168, P389, DOI 10.1016/0006-291X(90)92333-U; BOLANN BJ, 1990, EUR J BIOCHEM, V193, P899, DOI 10.1111/j.1432-1033.1990.tb19415.x; BRIDGES KR, 1986, J BIOL CHEM, V261, P14273; BRIDGES KR, 1987, J BIOL CHEM, V262, P14773; BRUN A, 1970, J HISTOCHEM CYTOCHEM, V18, P820, DOI 10.1177/18.11.820; BRUNK UT, 1995, REDOX REP, V1, P267, DOI 10.1080/13510002.1995.11746997; CRAMER SM, 1984, J CHROMATOGR, V295, P405, DOI 10.1016/S0021-9673(01)87642-1; FLOYD RA, 1983, BIOCHEMISTRY-US, V22, P2645, DOI 10.1021/bi00280a008; GOWER JD, 1989, ANAL BIOCHEM, V180, P126, DOI 10.1016/0003-2697(89)90099-7; GRAF E, 1984, J BIOL CHEM, V259, P3620; GREEN CJ, 1989, FREE RADICAL RES COM, V7, P255, DOI 10.3109/10715768909087950; HONEGGER CG, 1989, J CHROMATOGR-BIOMED, V487, P463, DOI 10.1016/S0378-4347(00)83056-X; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; KREBERLE H, 1964, ANN NY ACAD SCI, V119, P758; LATOUR I, 1992, ARCH TOXICOL, V66, P743, DOI 10.1007/BF01972625; LINDER CM, 1983, STRUCTURE FUNCTIONS, P465; LLOYD JB, 1991, BIOCHEM PHARMACOL, V41, P1361, DOI 10.1016/0006-2952(91)90109-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARZABADI MR, 1988, MECH AGEING DEV, V46, P145, DOI 10.1016/0047-6374(88)90122-4; MYERS BM, 1991, J CLIN INVEST, V88, P1207, DOI 10.1172/JCI115423; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; OZAKI M, 1994, TRANSPLANT P, V26, P918; PERTOFT H, 1987, CELL SEPARATION METH, V4, P1; REDEGELD FAM, 1992, EUR J PHARM-ENVIRON, V228, P229, DOI 10.1016/0926-6917(92)90034-A; REIF DW, 1992, FREE RADICAL BIO MED, V12, P417, DOI 10.1016/0891-5849(92)90091-T; RUBIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P450, DOI 10.1016/0003-9861(84)90010-9; RUNDQUIST I, 1984, ACTA PATH MICRO IM A, V92, P303; SAKAIDA I, 1990, MOL PHARMACOL, V37, P435; SCHELLENS JPM, 1991, HISTOCHEM J, V23, P460, DOI 10.1007/BF01041376; SCHRAUFSTATTER IU, 1987, B EUR PHYSIOPATH RES, V23, P297; STARKE PE, 1985, BIOCHEM BIOPH RES CO, V133, P371, DOI 10.1016/0006-291X(85)90916-7; STARKE PE, 1985, J BIOL CHEM, V260, P99; VOOGD A, 1992, J CLIN INVEST, V90, P2050, DOI 10.1172/JCI116086; ZHANG H, 1993, DIABETOLOGIA, V36, P707, DOI 10.1007/BF00401140; Zhang H, 1996, REDOX REP, V2, P235, DOI 10.1080/13510002.1996.11747056; ZHANG H, 1995, DIABETOLOGIA, V38, P635, DOI 10.1007/BF00401832	41	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23707	23711		10.1074/jbc.272.38.23707	http://dx.doi.org/10.1074/jbc.272.38.23707			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295314	hybrid			2022-12-27	WOS:A1997XX38100039
J	Zhang, QM; Berggren, PO; Tally, M				Zhang, QM; Berggren, PO; Tally, M			Glucose increases both the plasma membrane number and phosphorylation of insulin-like growth factor II mannose 6-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-LINE; BINDING; EXPRESSION	We have investigated the effect of glucose on insulinlike growth factor II (IGF-II) binding to, and intracellular phosphorylation of, the IGF-II/mannose B-phosphate (M6P) receptor in the insulin-secreting cell line RINm5F. Glucose, at a concentration of 3 mM, significantly increased binding of IGF-II to the cells. A further increase of the binding was observed at a glucose concentration of 10 mM. Scatchard analysis showed that the increased binding was caused by an increased number of the receptors rather than changes in affinity. This effect of glucose was also demonstrated in another insulin-secreting cell line HIT as well as in the human erythroleukemia cell line K562. Affinity cross-linking of the RLNm5F cells, using I-125-IGF-II, revealed increased binding to the IGF-II/M6P receptor induced by glucose. The effect of glucose on IGF-II binding was mimicked by fructose (10 mm), but not by 3-O-methylglucose (10 mM), and was abolished by the protein kinase C (PKC) inhibitor calphostin C, or down-regulation of PKC, but not by the protein phosphatase inhibitor, okadaic acid, Glucose dose dependently stimulated phosphorylation of the IGF-II/M6P receptor, an effect that was inhibited by down-regulation of PKC activity. This study suggests that the distribution of the IGF-II/M6P receptor in insulin-secreting cells can be regulated by glucose-induced phosphorylation, a mechanism mediated by PKC.			Zhang, QM (corresponding author), KAROLINSKA INST,ROLF LUFT CTR DIABET RES,DEPT MOL MED,ENDOCRINE & DIABET UNIT,S-17176 STOCKHOLM,SWEDEN.			Berggren, Per-Olof/0000-0001-8991-413X				ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BRAULKE T, 1992, J BIOL CHEM, V267, P17347; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; CORVERA S, 1988, BIOCHEM J, V250, P47, DOI 10.1042/bj2500047; CORVERA S, 1988, J BIOL CHEM, V263, P3116; HU KQ, 1990, J BIOL CHEM, V265, P13864; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAURENZI MA, 1995, NEUROSCI RES COMMUN, V16, P37; OH Y, 1993, GROWTH REGULAT, V3, P113; OKA Y, 1985, J BIOL CHEM, V260, P9435; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PILCH PF, 1979, J BIOL CHEM, V254, P3375; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; Roth R A, 1994, Growth Regul, V4 Suppl 1, P31; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; Zhang QM, 1997, P NATL ACAD SCI USA, V94, P6232, DOI 10.1073/pnas.94.12.6232; Zhang QM, 1996, MOL CELL BIOCHEM, V154, P47	21	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23703	23706		10.1074/jbc.272.38.23703	http://dx.doi.org/10.1074/jbc.272.38.23703			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295313	hybrid			2022-12-27	WOS:A1997XX38100038
J	Muller, JN; Krauss, B; Kaltschmidt, C; Baeuerle, PA; Rupec, RA				Muller, JN; Krauss, B; Kaltschmidt, C; Baeuerle, PA; Rupec, RA			Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SERUM RESPONSE ELEMENT; DNA-BINDING ACTIVITY; TERNARY COMPLEX; GENE-EXPRESSION; OXIDATIVE STRESS; HUMAN-BREAST; TUMOR-CELLS; AP-1; ELK-1	Hypoxia is a pathophysiological condition that occurs during injury, ischemia, and stroke. It is characterized by a decrease of reactive oxygen intermediates and a change of the intracellular redox level. In tumors hypoxia is regarded as a trigger for enhanced growth and metastasis. Here we report that in HeLa cells, hypoxic conditions induce the transcriptional activation of c-fos transcription via the serum response element. Mutations in the binding site for the ternary complex factor Elk-1 and the serum response factor abolished this induction, indicating that a ternary complex at the serum response element is necessary for the induction of the c-fos gene under hypoxia, The transcription factor Elk-1 was covalently modified by phosphorylation in response to hypoxia. Furthermore this hyperphosphorylation of Elk-1, the activation of mitogen-activated protein kinase (MAPK), and the induction of c-fos transcripts were blocked by PD98059, a specific inhibitor of mitogen activated protein kinase kinase/extracellular signal-regulated protein kinase kinase 1. An in vitro kinase assay with Elk-1 as substrate showed that MAPK is activated under hypoxia, The activation of MAPK corresponds temporally with the phosphorylation and activation of Elk-1, Thus, a decrease of the intracellular reactive oxygen intermediate level by hypoxia induces c-fos via the MAPK pathway. These results suggest that the intracellular redox levels may be directly coupled to tumor growth, invasion, and metastasis via Elk-1-dependent induction of c-Fos controlled genes.	UNIV FREIBURG, INST BIOCHEM & MOL BIOL, D-79104 FREIBURG, GERMANY	University of Freiburg								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANSEL PK, 1994, FOS JUN FAMILIES TRA; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BERGELSON S, 1994, ONCOGENE, V9, P565; BIUNNO I, 1988, BRIT J CANCER, V57, P464, DOI 10.1038/bjc.1988.108; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN CN, 1988, J CLIN ONCOL, V6, P709, DOI 10.1200/JCO.1988.6.4.709; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HONOKI K, 1992, MOL CARCINOGEN, V6, P122, DOI 10.1002/mc.2940060207; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KENNEDY KA, 1980, BIOCHEM PHARMACOL, V29, P1, DOI 10.1016/0006-2952(80)90235-X; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; POMBO CM, 1994, J BIOL CHEM, V269, P26546; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; RUTHER U, 1989, ONCOGENE, V4, P861; SAKATA K, 1991, BRIT J CANCER, V64, P809, DOI 10.1038/bjc.1991.405; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; SILVA CM, 1989, J BIOL CHEM, V264, P6638; TANNOCK I, 1981, BRIT J CANCER, V43, P245, DOI 10.1038/bjc.1981.37; TEICHER BA, 1990, CANCER RES, V52, P4372; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; URABE A, 1992, J PATHOL, V168, P281, DOI 10.1002/path.1711680307; WALKER RA, 1991, J PATHOL, V163, P323, DOI 10.1002/path.1711630409; Wang GL, 1996, REDOX REP, V2, P89, DOI 10.1080/13510002.1996.11747034; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	57	131	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23435	23439		10.1074/jbc.272.37.23435	http://dx.doi.org/10.1074/jbc.272.37.23435			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287359	hybrid			2022-12-27	WOS:A1997XV74400070
J	Aguado, F; Gombau, L; Majo, G; Marsal, J; Blanco, J; Blasi, J				Aguado, F; Gombau, L; Majo, G; Marsal, J; Blanco, J; Blasi, J			Regulated secretion is impaired in AtT-20 endocrine cells stably transfected with botulinum neurotoxin type A light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; ALPHA-LATROTOXIN; CLOSTRIDIAL NEUROTOXINS; BINDING; PROTEIN; RELEASE; FUSION; EXOCYTOSIS; SNAP-25; TOXIN	Botulinum neurotoxin type A (BoNT/A) inhibits neurotransmitter release by specific cleavage of SNAP-25, a synaptosome-associated protein also expressed in the ACTH secretory cell line AtT-20. Expression of light chain BoNT/A (L-BoNT/A) gene transfected into AtT-20 cells resulted in a cleaved form of SNAP-25 indistinguishable from that generated by bona fide BoNT/A. LBoNT/A-transfected cells showed no difference in replication rate, viability, or phenotype, compared with control AtT-20 cells. In contrast, L-BoNT/A-transfected cells could not be induced to secrete ACTH upon stimulation by 8-bromo-cAMP or KCl. In addition, alpha-latrotoxin induced ACTH release from control cells, but not from L-BoNT/A-transfected cells. These experiments suggest an important role for SNAP-25 in regulated secretion from AtT-20 cells and underline the usefulness of this cell system as a tool for the study of the molecular mechanism of peptide hormone secretion.	UNIV BARCELONA,DEPT BIOL CELLULAR & ANAT PATOL,LHOSPITALET LLOBR 08907,SPAIN; INST RECERCA ONCOL,DEPT CELLULAR BIOL,BARCELONA,SPAIN; CSIC,BARCELONA,SPAIN	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC)			Blasi, Juan/K-7943-2014; Blanco, Jeronimo/H-2764-2015	Blasi, Juan/0000-0002-0482-9444; Blanco, Jeronimo/0000-0003-3765-0640				Aguado F, 1996, EUR J CELL BIOL, V69, P351; AHNERTHILGER G, 1993, NEUROSCIENCE, V53, P547, DOI 10.1016/0306-4522(93)90219-6; Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BIGALKE H, 1978, N-S ARCH PHARMACOL, V303, P133, DOI 10.1007/BF00508058; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOYD RS, 1995, J BIOL CHEM, V270, P18216, DOI 10.1074/jbc.270.31.18216; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V260, P177, DOI 10.1113/jphysiol.1976.sp011510; DASGUPTA BR, 1984, TOXICON, V22, P415, DOI 10.1016/0041-0101(84)90085-0; DAYANITHI G, 1990, NEUROSCIENCE, V39, P711, DOI 10.1016/0306-4522(90)90254-2; Duchen L.W., 1992, GREENFIELDS NEUROPAT, P1; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; KUROKAWA Y, 1987, J GEN MICROBIOL, V133, P2647; LUINI A, 1985, P NATL ACAD SCI USA, V82, P8034, DOI 10.1073/pnas.82.23.8034; MATSUUCHI L, 1988, J CELL BIOL, V106, P239, DOI 10.1083/jcb.106.2.239; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOCHIDA S, 1990, P NATL ACAD SCI USA, V87, P7844, DOI 10.1073/pnas.87.20.7844; NGSEE JK, 1993, MOL BIOL CELL, V4, P747, DOI 10.1091/mbc.4.7.747; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OsenSand A, 1996, J COMP NEUROL, V367, P222, DOI 10.1002/(SICI)1096-9861(19960401)367:2<222::AID-CNE5>3.0.CO;2-7; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; RAFF H, 1989, CLIN CHEM, V35, P596; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; ROTH D, 1994, FEBS LETT, V351, P207, DOI 10.1016/0014-5793(94)00833-7; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SIMPSON LL, 1989, BOTULINUM TOXIN TETA; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TOOZE J, 1989, EUR J CELL BIOL, V49, P259; WATERMAN SA, 1995, NEUROSCIENCE, V69, P977, DOI 10.1016/0306-4522(95)00317-C; WILLIAMS RS, 1983, EUR J BIOCHEM, V131, P437, DOI 10.1111/j.1432-1033.1983.tb07282.x	37	15	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26005	26008		10.1074/jbc.272.41.26005	http://dx.doi.org/10.1074/jbc.272.41.26005			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325336	hybrid, Green Published			2022-12-27	WOS:A1997YA35800091
J	CorthesyTheulaz, IE; Bergonzelli, GE; Henry, H; Bachmann, D; Schorderet, DF; Blum, AL; Ornston, LN				CorthesyTheulaz, IE; Bergonzelli, GE; Henry, H; Bachmann, D; Schorderet, DF; Blum, AL; Ornston, LN			Cloning and characterization of Helicobacter pylori succinyl CoA:acetoacetate CoA-transferase, a novel prokaryotic member of the CoA-transferase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A-TRANSFERASE; CLOSTRIDIUM-ACETOBUTYLICUM ATCC-824; ESCHERICHIA-COLI; ACINETOBACTER-CALCOACETICUS; PSEUDOMONAS-PUTIDA; BETA-KETOADIPATE; GASTRIC-CANCER; PURIFICATION; GENES; EXPRESSION	Sequencing of a fragment of Helicobacter pylori genome led to the identification of two open reading frames showing striking homology with Coenzyme A (CoA) transferases, enzymes catalyzing the reversible transfer of CoA from one carboxylic acid to another. The genes were present in all H. pylori strains tested by polymerase chain reaction or slot blotting but not in Campylobacter jejuni. Genes for the putative A and B subunits of H. pylori CoA-transferase were introduced into the bacterial expression vector pKK223-3 and expressed in Escherichia coli JM105 cells. Amino acid sequence comparisons, combined with measurements of enzyme activities using different CoA donors and accepters, identified the H. pylori CoA-transferase as a succinyl CoA:acetoacetate CoA-transferase. This activity was consistently observed in different H. pylori strains, Antibodies raised against either recombinant A or B subunits recognized two distinct subunits of M-r similar to 26,000 and 24,000 that are both necessary for H. pylori CoA transferase function. The lack of alpha-ketoglutarate dehydrogenase and of succinyl CoA synthetase activities indicates that the generation of succinyl CoA is not mediated by the tricarboxylic acid cycle in H. pylori. We postulate the existence of an alternative pathway where the CoA-transferase is essential for energy metabolism.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,CENT LAB CLIN CHEM,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,DIV MED GENET,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,MOL GENET UNIT,CH-1011 LAUSANNE,SWITZERLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Yale University	CorthesyTheulaz, IE (corresponding author), CHU VAUDOIS,DIV GASTROENTEROL,BH-19N-624,CH-1011 LAUSANNE,SWITZERLAND.							BARKER HA, 1978, J BIOL CHEM, V253, P1219; BLAIR JB, 1969, J BIOL CHEM, V244, P951; BRIDGER WA, 1969, METHOD ENZYMOL, V13, P70; BUCKEL W, 1981, EUR J BIOCHEM, V118, P315, DOI 10.1111/j.1432-1033.1981.tb06404.x; CARRINGTON J M, 1981, Biochemical Society Transactions, V9, P55; CARY JW, 1990, APPL ENVIRON MICROB, V56, P1576, DOI 10.1128/AEM.56.6.1576-1583.1990; CHALK PA, 1994, MICROBIOL-UK, V140, P2085, DOI 10.1099/13500872-140-8-2085; Clayton C. L., 1995, Gut, V37, pA67; De Koster E, 1994, Eur J Cancer Prev, V3, P247; DOTEN RC, 1987, J BACTERIOL, V169, P3168, DOI 10.1128/jb.169.7.3168-3174.1987; FENSELAU A, 1974, LIFE SCI, V15, P811, DOI 10.1016/0024-3205(74)90519-0; FENSELAU A, 1974, BIOCHEMISTRY-US, V13, P3884, DOI 10.1021/bi00716a010; FORMAN D, 1994, LANCET, V343, P243, DOI 10.1016/S0140-6736(94)91034-0; GIBSON GE, 1988, ARCH NEUROL-CHICAGO, V45, P836, DOI 10.1001/archneur.1988.00520320022009; HANSON PJ, 1981, BIOCHEM J, V200, P349, DOI 10.1042/bj2000349; HERSH LB, 1967, J BIOL CHEM, V242, P339; HOWARD JB, 1986, J BIOL CHEM, V261, P60; Hua J, 1996, HELICOBACTER PYLORI, P121; HUGHES EJ, 1988, J GEN MICROBIOL, V134, P2877; JENKINS LS, 1987, J BACTERIOL, V169, P42, DOI 10.1128/jb.169.1.42-52.1987; KassovskaBratinova S, 1996, AM J HUM GENET, V59, P519; KOWALCHUK GA, 1994, GENE, V146, P23, DOI 10.1016/0378-1119(94)90829-X; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; LIN TW, 1992, J BIOL CHEM, V267, P975; LOGAN RPH, 1994, LANCET, V344, P1078, DOI 10.1016/S0140-6736(94)91729-9; MARSHALL BJ, 1995, JAMA-J AM MED ASSOC, V274, P1064, DOI 10.1001/jama.274.13.1064; MENDZ GL, 1995, BBA-GEN SUBJECTS, V1244, P269, DOI 10.1016/0304-4165(95)00018-7; MENDZ GL, 1995, ARCH BIOCHEM BIOPHYS, V321, P153, DOI 10.1006/abbi.1995.1380; PARALES RE, 1992, J BACTERIOL, V174, P4657, DOI 10.1128/JB.174.14.4657-4666.1992; REEVES HC, 1971, METHODS MICROBIOLO A, V6, P446; ROCHET JC, 1994, PROTEIN SCI, V3, P975; RUSSELL JJ, 1982, J NEUROCHEM, V38, P1446, DOI 10.1111/j.1471-4159.1982.tb07924.x; SAUDUBRAY JM, 1987, ENZYME, V38, P80, DOI 10.1159/000469194; SCHERF U, 1991, APPL ENVIRON MICROB, V57, P2699, DOI 10.1128/AEM.57.9.2699-2702.1991; SHARP JA, 1978, BIOCHEM J, V173, P759, DOI 10.1042/bj1730759; SRAMEK SJ, 1975, ARCH BIOCHEM BIOPHYS, V171, P14, DOI 10.1016/0003-9861(75)90002-8; STEWART PR, 1966, J BIOL CHEM, V241, P1222; TUNG KK, 1975, J BACTERIOL, V124, P1462, DOI 10.1128/JB.124.3.1462-1474.1975; WHITE H, 1976, J BIOL CHEM, V251, P1688; WHITE H, 1976, J BIOL CHEM, V251, P1708; WIESENBORN DP, 1989, APPL ENVIRON MICROB, V55, P323, DOI 10.1128/AEM.55.2.323-329.1989; YEH WK, 1981, J BIOL CHEM, V256, P1565; ZHU KY, 1995, BIOTECHNIQUES, V18, P222	43	44	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25659	25667		10.1074/jbc.272.41.25659	http://dx.doi.org/10.1074/jbc.272.41.25659			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325289	hybrid			2022-12-27	WOS:A1997YA35800044
J	Realini, C; Jensen, CC; Zhang, ZG; Johnston, SC; Knowlton, JR; Hill, CP; Rechsteiner, M				Realini, C; Jensen, CC; Zhang, ZG; Johnston, SC; Knowlton, JR; Hill, CP; Rechsteiner, M			Characterization of recombinant REG alpha, REG beta, and REG gamma proteasome activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; PEPTIDE-HYDROLYZING ACTIVITY; ATP-DEPENDENT PROTEASE; INTERFERON-GAMMA; 20S PROTEASOME; IN-VIVO; MOLECULAR-CLONING; YEAST PROTEASOME; THERMOPLASMA-ACIDOPHILUM; PROTEOLYTIC ACTIVITIES	Full-length cDNAs for three human proteasome activator subunits, called REG alpha, REG beta, and REG gamma, have been expressed in Escherichia coli, and the purified recombinant proteins have been characterized. Recombinant alpha or gamma subunits form heptameric species; recombinant beta subunits are found largely as monomers or small multimers. Each recombinant REG stimulates cleavage of fluorogenic peptides by human red cell proteasomes. The pattern of activated peptide hydrolysis is virtually identical for REG alpha and REG beta. These two subunits, alone or in combination, stimulate cleavage after basic, acidic, and most hydrophobic residues in many peptides. Recombinant alpha and beta subunits bind each other with high affinity, and the REG alpha/beta heteromeric complex activates hydrolysis of LLVY-methylcoumaryl-7-amide (LLVY-MCA) and LLE-beta-nitroanilide (LLE-beta NA) more than REG alpha or REG beta alone. Using filter binding and gel filtration assays, recombinant REG gamma subunits were shown to bind themselves but not alpha or beta subunits. REG gamma differs from REG alpha and REG beta in that it markedly stimulates hydrolysis of peptides with basic residues in the P1 position but only modestly activates cleavage of LLVY-MCA or LLE-beta NA by the proteasome. REG gamma binds the proteasome with higher affinity than REG alpha or REG beta yet with lower affinity than complexes containing both REG alpha and REG beta. In summary, each of the three REG homologs is a proteasome activator with unique biochemical properties.			Realini, C (corresponding author), UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132, USA.				NIGMS NIH HHS [GM 37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HILT W, 1993, J BIOL CHEM, V268, P3479; Hisamatsu H, 1996, J EXP MED, V183, P1807, DOI 10.1084/jem.183.4.1807; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Hoffman L, 1996, CURR TOP CELL REGUL, V34, P1, DOI 10.1016/S0070-2137(96)80001-X; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1986, J BIOL CHEM, V261, P2391; KOPP F, 1995, J MOL BIOL, V248, P264; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; Kuehn L, 1996, ARCH BIOCHEM BIOPHYS, V329, P87, DOI 10.1006/abbi.1996.0195; Kuehn L, 1996, FEBS LETT, V394, P183, DOI 10.1016/0014-5793(96)00946-5; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1992, J BIOL CHEM, V267, P10515; MAHAFFEY D, 1993, J BIOL CHEM, V268, P21205; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1994, J BIOL CHEM, V269, P20727; REALINI C, 1995, J BIOL CHEM, V270, P29664; Realini CA, 1996, ADV EXP MED BIOL, V389, P51; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; SEN GC, 1992, J BIOL CHEM, V267, P5017; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Stohwasser R, 1996, FEBS LETT, V383, P109, DOI 10.1016/0014-5793(96)00110-X; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; USTRELL V, 1995, FEBS LETT, V376, P155, DOI 10.1016/0014-5793(95)01257-9; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; YOO Y, 1989, J BIOL CHEM, V264, P17078	64	142	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25483	25492		10.1074/jbc.272.41.25483	http://dx.doi.org/10.1074/jbc.272.41.25483			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325261	hybrid			2022-12-27	WOS:A1997YA35800016
J	Shaywitz, DA; Espenshade, PJ; Gimeno, RE; Kaiser, CA				Shaywitz, DA; Espenshade, PJ; Gimeno, RE; Kaiser, CA			COPII subunit interactions in the assembly of the vesicle coat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; SHUTTLE VECTORS; TRANSPORT; SEC23P; SYSTEM; COMPLEX; ENCODES; BINDING	In vitro analysis of COPII vesicle formation in the yeast Saccharomyces cerevisiae has demonstrated the requirement for three cytosolic factors: Sec31p-Sec13p, Sec23p-Sec24p, and Sar1p. Convergent evidence suggests that the peripheral endoplasmic reticulum (ER) membrane protein Sec16p also represents an important component of the vesicle assembly apparatus: SEC16 interacts genetically with all five COPII genes; Sec16p binds to Sec23p and Sec24p, is found on ER-derived transport vesicles, and is required in vitro for the efficient release of ER-derived vesicle cargo, In this report, we demonstrate an important functional interaction between Sec16p and Sec31p. First, we map onto Sec31p binding regions for Sec16p, Sec23p, Sec24p, and Sec13p. Second, we show that a truncation mutant of Sec31p specifically defective for Sec16p binding is unable to complement a sec31 Delta mutant and cannot rescue the secretion defect of a temperature-sensitive sec31 mutant at nonpermissive temperatures, We propose that Sec16p organizes the assembly of a coat that is stabilized both by the interaction of Sec31p with Sec23p and Sec24p and by the interaction of these three components with Sec16p.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIMENO RE, 1995, J CELL BIOL, V131, P325, DOI 10.1083/jcb.131.2.325; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; Kaiser C., 1994, METHODS YEAST GENETI; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; Miller J. H, 1972, EXPT MOL GENETICS; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PRYER NK, 1993, J CELL BIOL, V120, P867; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Saxena K, 1996, BIOCHEMISTRY-US, V35, P15215, DOI 10.1021/bi961616x; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHAYWITZ DA, 1995, J CELL BIOL, V128, P679; SIKORSKI RS, 1989, GENETICS, V122, P19; SWAROOP A, 1994, HUM MOL GENET, V3, P1281, DOI 10.1093/hmg/3.8.1281; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	34	120	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25413	25416		10.1074/jbc.272.41.25413	http://dx.doi.org/10.1074/jbc.272.41.25413			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325247	hybrid			2022-12-27	WOS:A1997YA35800002
J	Watkins, LM; Mahoney, HJ; McCulloch, JK; Raushel, FM				Watkins, LM; Mahoney, HJ; McCulloch, JK; Raushel, FM			Augmented hydrolysis of diisopropyl fluorophosphate in engineered mutants of phosphotriesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BINUCLEAR METAL CENTER; CARBONIC-ANHYDRASE-II; ZINC-BINDING-SITE; PSEUDOMONAS-DIMINUTA; BACTERIAL PHOSPHOTRIESTERASE; 3-DIMENSIONAL STRUCTURE; HALOALKANE DEHALOGENASE; CATALYTIC ACTIVITY; HYDROGEN-BOND	The phosphotriesterase from Pseudomonas diminuta hydrolyzes a wide variety of organophosphate insecticides and acetylcholinesterase inhibitors. The rate of hydrolysis depends on the substrate and can range from 6000 s(-1) for paraoxon to 0.03 s(-1) for the slower substrates such as diethylphenylphosphate. Increases in the reactivity of phosphotriesterase toward the slower substrates were attempted by the placement of a potential proton donor group at the active site. Distances from active site residues in the wild type protein to a bound substrate analog were measured, and Trp(131), Phe(132), and Phe(306) were found to be located within 5.0 Angstrom of the oxygen atom of the leaving group, Eleven mutants were created using site-directed mutagenesis and purified to homogeneity. Phe(132) and Phe(306) were replaced by tyrosine and/or histidine to generate all combinations of single and double mutants at these two sites. The single mutants W131K, F306K, and F306E were also constructed. Kinetic constants were measured for all of the mutants with the substrates paraoxon, diethylphenylphosphate, acephate, and diisopropylfluorophosphate. V-max values for the mutant enzymes with the substrate paraoxon varied from near wild type values to a 4-order of magnitude decrease for the W131K mutant, There were significant increases in the K-m for paraoxon for all mutants except F132H. V-max values measured using diethylphenylphosphate decreased for all mutants except for F132H and F132Y, whereas K-m values ranged from near wild type levels to increases of 25-fold, V-max values for acephate hydrolysis ranged from near wild type values to a 10(3)-fold decrease for W131R, K-m values for acephate ranged from near wild type to a 5-fold increase. V-max values for the mutants tested with the substrate diisopropylfluorophosphate showed an increase in all cases except for the W131K, F306K, and F306E mutants. The V-max value for the F132H/F306H mutant was increased to 3100 s(-1). These studies demonstrated for the first time that it is possible to significantly enhance the ability of the native phosphotriesterase to hydrolyze phosphorus-fluorine bonds at rates that rival the hydrolysis of paraoxon.	TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station			Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIGMS NIH HHS [T32 GM 08523, GM 33894] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033894, T32GM008523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNING MM, 1995, BIOCHEMISTRY-US, V34, P7973, DOI 10.1021/bi00025a002; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; CHAE MY, 1994, BIOORG MED CHEM LETT, V4, P1473, DOI 10.1016/S0960-894X(01)80516-3; DONARSKI WJ, 1989, BIOCHEMISTRY-US, V28, P4650, DOI 10.1021/bi00437a021; Dufour E, 1995, BIOCHEMISTRY-US, V34, P16382, DOI 10.1021/bi00050a019; DUMAS DP, 1989, BIOTECHNOL APPL BIOC, V11, P235; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; DUMAS DP, 1990, ARCH BIOCHEM BIOPHYS, V277, P155, DOI 10.1016/0003-9861(90)90564-F; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; HEDSTROM L, 1994, CURR OPIN STRUC BIOL, V4, P608, DOI 10.1016/S0959-440X(94)90225-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hong SB, 1996, BIOCHEMISTRY-US, V35, P10904, DOI 10.1021/bi960663m; Huang CC, 1996, BIOCHEMISTRY-US, V35, P3439, DOI 10.1021/bi9526692; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; JONSSON BM, 1993, FEBS LETT, V322, P186, DOI 10.1016/0014-5793(93)81565-H; KENNES C, 1995, EUR J BIOCHEM, V228, P403; Kuo JM, 1997, BIOCHEMISTRY-US, V36, P1982, DOI 10.1021/bi962099l; KUO JM, 1994, BIOCHEMISTRY-US, V33, P4265, DOI 10.1021/bi00180a022; LESBURG CA, 1995, J AM CHEM SOC, V117, P6838, DOI 10.1021/ja00131a005; LEWIS VE, 1988, BIOCHEMISTRY-US, V27, P1591, DOI 10.1021/bi00405a030; Maniatis T., 1982, MOL CLONING; OMBURO GA, 1992, J BIOL CHEM, V267, P13278; Park IS, 1996, BIOCHEMISTRY-US, V35, P10464, DOI 10.1021/bi9603128; RHEINNECKER M, 1994, BIOCHEMISTRY-US, V33, P221, DOI 10.1021/bi00167a029; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vanhooke JL, 1996, BIOCHEMISTRY-US, V35, P6020, DOI 10.1021/bi960325l; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; WANG ZY, 1993, BIOCHEMISTRY-US, V32, P2125, DOI 10.1021/bi00060a001; WATKINS LM, 1997, IN PRESS PROTEINS ST	31	57	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25596	25601		10.1074/jbc.272.41.25596	http://dx.doi.org/10.1074/jbc.272.41.25596			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325279	hybrid			2022-12-27	WOS:A1997YA35800034
J	Chang, MS; McNinch, J; Elias, C; Manthey, CL; Grosshans, D; Meng, T; Boone, T; Andrew, DP				Chang, MS; McNinch, J; Elias, C; Manthey, CL; Grosshans, D; Meng, T; Boone, T; Andrew, DP			Molecular cloning and functional characterization of a novel CC chemokine, stimulated T cell chemotactic protein (STCP-1) that specifically acts on activated T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; MONOCYTE CHEMOATTRACTANT PROTEIN-1; MONOCLONAL-ANTIBODY; LUNG INJURY; IN-VITRO; INTERLEUKIN-8; RECEPTOR; RECRUITMENT; MIP-1-ALPHA; EXPRESSION	A novel human chemokine STCP-1 (stimulated T cell chemotactic protein) was isolated from an activated macrophage cDNA Library. The chemokine has four cysteines positioned in a manner that identifies STCP-1 as a member of the CC chemokine family. The amino acid sequence shows 34% identity with RANTES. The gene consists of 3 exons and 2 introns with the position of intron/exon boundaries similar to that of RANTES. The gene is expressed as a 3.4-kilobase transcript on lymph node, thymus, and appendix. STCP-1 induces Ca2+ mobilization in a small percentage of primary activated T lymphocytes, but on repeated stimulation the percentage of T lymphocytes that respond to STCP-1 increases, The chemokine STCP-1 does not induce Ca2+ mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes, Similarly, STCP-1, while acting as a mild chemoattractant for primary activated T lymphocytes, is a potent chemoattractant for chronically activated T lymphocytes but has no chemoattractant activity for monocytes, neutrophils, eosinophils, and resting T lymphocytes. As STCP-1 acts specifically on activated T lymphocytes, it may play a role in the trafficking of activated/effector T lympho- cytes to inflammatory sites and other aspects of activated T lymphocyte physiology.			Chang, MS (corresponding author), AMGEN INC, DEPT COMPUTAT BIOL, M-S 14-1-D, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bradley LM, 1996, CURR OPIN IMMUNOL, V8, P312, DOI 10.1016/S0952-7915(96)80118-X; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; DAMLE NK, 1993, J IMMUNOL, V151, P2368; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009; FUENTES ME, 1995, J IMMUNOL, V155, P5769; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; KARPUS WJ, 1995, J IMMUNOL, V155, P5003; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; LARSEN CG, 1995, J IMMUNOL, V155, P2151; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUKACS NW, 1995, EUR J IMMUNOL, V25, P245, DOI 10.1002/eji.1830250140; Mackay CR, 1996, J EXP MED, V184, P799, DOI 10.1084/jem.184.3.799; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; Napolitano M, 1996, J IMMUNOL, V157, P2759; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; Rossi DL, 1997, J IMMUNOL, V158, P1033; Roth SJ, 1995, EUR J IMMUNOL, V25, P3482, DOI 10.1002/eji.1830251241; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SHANLEY TP, 1995, J IMMUNOL, V154, P4793; SMITH DE, 1994, J EXP MED, V179, P1400; STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515; SUNDERPLASSMANN R, 1996, BLOOD, V12, P5179; Taub D D, 1994, Ther Immunol, V1, P229; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; Taub DD, 1996, J IMMUNOL, V156, P2095; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; ZHOU Z, 1993, J IMMUNOL, V151, P4333	40	86	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25229	25237		10.1074/jbc.272.40.25229	http://dx.doi.org/10.1074/jbc.272.40.25229			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312138	hybrid			2022-12-27	WOS:A1997XY97000077
J	Ikezu, T; Okamoto, T; Yonezawa, K; Tompkins, RG; Martyn, JAJ				Ikezu, T; Okamoto, T; Yonezawa, K; Tompkins, RG; Martyn, JAJ			Analysis of thermal injury-induced insulin resistance in rodents - Implication of postreceptor mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; SKELETAL-MUSCLE; RECEPTOR SUBSTRATE-1; BURN INJURY; TNF-ALPHA; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; PROTEIN-SYNTHESIS	Burn injury is associated with insulin resistance. The molecular basis of this resistance was investigated by examining insulin receptor signaling in rats after thermal injury. The impaired insulin-stimulated transport of [H-3]2-deoxyglucose into soleus muscle strips confirmed the insulin resistance following burns. In vivo insulin-stimulated phosphoinositide 3-kinase activity, pivotal, in translocation of GLUT4, was decreased in burns when assessed by its insulin receptor substrate-1 (IRS-1)-associated activity. Insulin-induced tyrosine kinase activity of insulin receptor (IR) and tyrosine phosphorylation of IRS-I were also attenuated, Immunoprecipitated IR, however, appeared to have normal insulin-responsive kinase activity. Finally, immunoprecipitated IRS-I was tested for its effect on partially purified recombinant IR and was found to inhibit its kinase activity. This inhibitory effect of IRS-1 was abolished by prior treatment of IRS-1 with alkaline phosphatase, indicating that burn injury-related hyperphosphorylation of IRS-1 is similar to that observed in TNF alpha-induced inhibition of LR signaling All of these changes were observed in the absence of quantitative changes in IR, IRS-1, and phosphoinositide 3-kinase. Alterations in postreceptor insulin signaling, therefore, may be responsible for the insulin resistance after thermal injury.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,SHRINERS BURNS INST,DEPT ANESTHESIOL,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,SHRINERS BURNS INST,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,SHRINERS BURNS INST,DEPT SURG,BOSTON,MA 02114; KOBE UNIV,BIOSIGNAL RES CTR,KOBE,HYOGO 657,JAPAN	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Kobe University				Ikezu, Tsuneya/0000-0002-3979-8596	NIGMS NIH HHS [GM 55032-01, GM 31569-15] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031569, R23GM031569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BURKE JF, 1979, ANN SURG, V190, P274, DOI 10.1097/00000658-197909000-00002; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARK AS, 1984, J CLIN INVEST, V74, P888, DOI 10.1172/JCI111506; CLAUSEN JO, 1995, LANCET, V346, P397, DOI 10.1016/S0140-6736(95)92779-4; COSTELLI P, 1995, J CLIN INVEST, V95, P2367, DOI 10.1172/JCI117929; DEITCH EA, 1990, NEW ENGL J MED, V323, P1249; DEMLING RH, 1985, NEW ENGL J MED, V313, P1389, DOI 10.1056/NEJM198511283132205; ENDO S, 1993, BURNS, V19, P124, DOI 10.1016/0305-4179(93)90033-5; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HERNDON DN, 1988, ANN SURG, V208, P484, DOI 10.1097/00000658-198810000-00010; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HONEYCUTT D, 1992, Journal of Burn Care and Rehabilitation, V13, P181, DOI 10.1097/00004630-199203000-00001; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; JAHOOR F, 1989, AM J PHYSIOL, V257, pE323, DOI 10.1152/ajpendo.1989.257.3.E323; JURASINSKI C, 1995, METABOLISM, V44, P1130, DOI 10.1016/0026-0495(95)90005-5; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEMARCHANDBRUSTEL Y, 1978, AM J PHYSIOL, V234, pE348, DOI 10.1152/ajpendo.1978.234.4.E348; Long SD, 1996, BIOCHEM BIOPH RES CO, V220, P949, DOI 10.1006/bbrc.1996.0512; MARANO MA, 1990, SURG GYNECOL OBSTET, V170, P32; MOLLOY RG, 1993, J IMMUNOL, V151, P2142; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MULLER MJ, 1994, LANCET, V343, P216, DOI 10.1016/S0140-6736(94)90995-4; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NELSON KM, 1982, JPEN-PARENTER ENTER, V6, P3, DOI 10.1177/014860718200600103; OKADA T, 1994, J BIOL CHEM, V269, P3568; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; THOMAS R, 1979, SURGERY, V86, P742; VARY TC, 1995, SHOCK, V3, P403; VEGA G L, 1991, Journal of Burn Care and Rehabilitation, V12, P463, DOI 10.1097/00004630-199109000-00013; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1990, PEPTIDE HORMONE ACTI; WILLMORE DW, 1991, NEW ENGL J MED, V325, P695; WOLFE RR, 1987, NEW ENGL J MED, V317, P403, DOI 10.1056/NEJM198708133170702; WOLFE RR, 1993, SEMIN NEPHROL, V13, P382; YANG YT, 1989, BIOCHEM J, V261, P1; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; YU CC, 1989, BURNS, V15, P145; ZELLER WP, 1991, BIOCHEM BIOPH RES CO, V176, P535, DOI 10.1016/0006-291X(91)90958-A	50	77	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25289	25295		10.1074/jbc.272.40.25289	http://dx.doi.org/10.1074/jbc.272.40.25289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312146	hybrid			2022-12-27	WOS:A1997XY97000085
J	Trinh, K; Minassian, C; Lange, AJ; ODoherty, RM; Newgard, CB				Trinh, K; Minassian, C; Lange, AJ; ODoherty, RM; Newgard, CB			Adenovirus-mediated expression of the catalytic subunit of glucose-6-phosphatase in INS-1 cells - Effects on glucose cycling, glucose usage, and insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; PANCREATIC-ISLETS; MICROSOMAL GLUCOSE-6-PHOSPHATASE; RECOMBINANT ADENOVIRUS; ENZYME-DEFICIENT; GENE-EXPRESSION; HEXOKINASE-I; METABOLISM; LIVER; RAT	Glucose-6-phosphatase (Glu-6-Pase) catalyzes the terminal step of gluconeogenesis, the conversion of glucose 6-phosphate (Glu-6-P) to free glucose, This enzyme activity is thought to be conferred by a complex of proteins residing in the endoplasmic reticulum (ER), including a Glu-6-P translocase that transports Glu-6-P into the lumen of the ER, a phosphohydrolase catalytic subunit residing in the lumen, and putative glucose and inorganic phosphate transporters that allow exit of the products of the reaction, In this study, we have investigated the effect of adenovirus-mediated overexpression of the Glu-6-Pase catalytic subunit on glucose metabolism and insulin secretion, using a well differentiated insulinoma cell line, INS-1, We found that the overexpressed Glu-6-Pase catalytic subunit was normally glycosylated, correctly sorted to the ER, and caused a 10-fold increase in Glu-6-Pase enzymatic activity in in vitro assays, Consistent with these findings, a 4.2-fold increase in (H2O)-H-3 incorporation into glucose was observed in INS-1 cells treated with the recombinant adenovirus containing the Glu-6-Pase catalytic subunit cDNA (AdCMV-Glu-6-Pase). 3-[H-3]Glucose usage was decreased by 32% in AdCMV-Glu-6-Pase-treated cells relative to controls, resulting in a proportional 30% decrease in glucose-stimulated insulin secretion, Our findings indicate that overexpression of the Glu-6-Pase catalytic subunit significantly impacts glucose metabolism and insulin secretion in islet beta-cells. However, INS-1 cells treated with AdCMV-Glu-6-Pase do not exhibit the severe alterations of beta-cell function and metabolism associated with islets from rodent models of obesity and non-insulin-dependent diabetes mellitus, suggesting the involvement of genes in addition to the catalytic subunit of Glu-6-Pase in the etiology of such beta-cell dysfunction.	UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046492] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46492] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARION WJ, 1980, J BIOL CHEM, V255, P396; ASAFARI M, 1992, ENDOCRINOLOGY, V130, P167; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; IVANOVA V, 1994, PREP BIOCHEM, V24, P83, DOI 10.1080/10826069408010084; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KHAN A, 1990, ENDOCRINOLOGY, V126, P2413, DOI 10.1210/endo-126-5-2413; KHAN A, 1989, J BIOL CHEM, V264, P9732; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1994, J CLIN INVEST, V93, P1994, DOI 10.1172/JCI117192; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; MARIE S, 1993, J BIOL CHEM, V268, P23881; MASSAGUE J, 1978, BIOCHIM BIOPHYS ACTA, V543, P269, DOI 10.1016/0304-4165(78)90073-9; McCrory W.J., 1988, VIROLOGY, V163, P614; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Newgard CB, 1996, DIABETES REV, V4, P191; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; PERALES MA, 1991, MOL CELL BIOCHEM, V101, P67; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; TALJEDAL IB, 1969, BIOCHEM J, V114, P387; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; WADDELL ID, 1988, BIOCHEM J, V255, P471, DOI 10.1042/bj2550471; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173	32	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24837	24842		10.1074/jbc.272.40.24837	http://dx.doi.org/10.1074/jbc.272.40.24837			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312082	hybrid			2022-12-27	WOS:A1997XY97000021
J	Jonca, F; Ortega, N; Gleizes, PE; Bertrand, N; Plouet, J				Jonca, F; Ortega, N; Gleizes, PE; Bertrand, N; Plouet, J			Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; TYROSINE KINASE; BINDING-SITES; TUMOR-CELLS; RECEPTOR; IDENTIFICATION; VASCULOTROPIN; HEPARIN; MITOGEN; KDR	Vascular endothelial growth factor (VEGF) is a potent angiogenic factor which is synthesized and secreted by many differentiated cells in response to various stimuli including hypoxia and growth factor exposure, Alternative splicing of vascular endothelial growth factor mRNA results in three distinct molecular forms: V189 and V165 or V121 which lack the exons 6 or 6 and 7, respectively, To clarify the functions of the 24-amino acid insertion, the biological activity of V165 was com pared with that exerted by purified recombinant V189 and a synthetic peptide designed on the sequence encoded by exon 6 (Ex6P), V189 and Ex6P, but not V165, induced cell proliferation on corneal endothelial cells cultured in vitro. These effects were due to the release of fibroblast growth factor 2 (FGF2) stored in the extracellular matrix but not to direct interactions with FGF receptors since V189 was inefficient on heparan sulfate-deficient cells expressing constitutively FGF-R1. Moreover corneas incubated ex vivo with Ex6P solubilized 10-fold more FGF2 than a isocationic peptide containing a scrambled sequence. Ex6P elicited an angiogenic response in a corneal pocket assay which was totally inhibited by addition of anti-FGF2 IgG. Moreover the angiogenic response to V189, but not to V165, was inhibited by FGF2 immunoneutralization. These findings demonstrate that the presence of the exon g-encoded sequence confers VEGF with the ability to exert its biological effects through FGF2 signaling pathways.	CNRS UPR 9006,LAB BIOL MOL EUCARYOTE,F-31062 TOULOUSE,FRANCE; HOP PURPAN,DEPT UROL,F-31052 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse			Gleizes, Pierre-Emmanuel/H-3821-2014; Ortega, Nathalie/C-3382-2019; Gleizes, Pierre-Emmanuel/ABB-9653-2021	Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Gleizes, Pierre-Emmanuel/0000-0003-0830-7341				BEDNARZ J, 1995, CORNEA, V14, P372, DOI 10.1097/00003226-199507000-00005; Berard M, 1997, AM J PATHOL, V150, P1315; BETSHOLTZ C, 1990, NATURE, V344, P299, DOI 10.1038/344299a0; BOENSCH C, 1995, J BIOL CHEM, V270, P1807, DOI 10.1074/jbc.270.4.1807; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FAVARD C, 1991, BIOL CELL, V73, P1, DOI 10.1016/0248-4900(91)90002-5; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V127, P121, DOI 10.1002/jcp.1041270116; GOTO F, 1993, LAB INVEST, V69, P508; GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P7478; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; PLOUET J, 1990, BIOCHIMIE, V72, P51, DOI 10.1016/0300-9084(90)90172-D; PLOUET J, 1990, EXP EYE RES, V51, P519, DOI 10.1016/0014-4835(90)90082-6; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; PRALORAN V, 1991, CR ACAD SCI III-VIE, V313, P21; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	40	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24203	24209		10.1074/jbc.272.39.24203	http://dx.doi.org/10.1074/jbc.272.39.24203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305872	hybrid			2022-12-27	WOS:A1997XY51500023
J	Algenstaedt, PM; Antonetti, DA; Yaffe, MB; Kahn, CR				Algenstaedt, PM; Antonetti, DA; Yaffe, MB; Kahn, CR			Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca2+-ATPases in muscle and heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CA-2+ TRANSPORT; PHOSPHATASE; IRS-1; SH2; DOMAIN; ATPASE; STIMULATION	Following phosphorylation by the insulin receptor kinase, the insulin receptor substrates (IRS)-1 and IRS-2 bind to and activate several Src homology 2 (SH2) domain proteins. To identify novel proteins that interact with IRS proteins in muscle, a human skeletal muscle cDNA expression library was created in the lambda EXLox system and probed with baculovirus-produced and tyrosine-phosphorylated human IRS-I. One clone of the 10 clones which was positive through three rounds of screening represented the C terminus of the human homologue of the adult fast twitch skeletal muscle Ca2+ ATPase (SERCA1) including the cytoplasmic tail and part of transmembrane region 10. Western blot analysis of extracts of rat muscle demonstrated co-immunoprecipitation of both IRS-1 and IRS-2 with the skeletal muscle Ca2+-ATPase (SERCA1) and the cardiac muscle isoform (SERCA2). In both cases, injection of insulin stimulated a 2- to 6-fold increase in association of which was maximal within 5 min. In primary cultures of aortic smooth muscle cells and C2C12 cells, the insulin-stimulated interaction between IRS proteins and SERCA1 and -2 was dose-dependent with a maximum induction at 100 nM insulin. This interaction was confirmed in a ''pull down'' experiment using a glutathione S-transferase fusion protein containing the C terminus of the human SERCA. isoform and phosphorylated IRS-I in vitro and could be blocked by a FLVRES-like domain peptide present in the human SERCA sequence. Affinity chromatography of phosphopeptide libraries using the glutathione S-transferase fusion protein of the C terminus of SERCA1 indicated a consensus sequence for binding of XpYGSS; this is identical to potential tyrosine phosphorylation sites at position 431 of human IRS-1 and at position 500 of human IRS-2. In streptozotocin diabetic rats the interaction between IRS proteins and SERCA1 in skeletal muscle and SERCA2 in cardiac muscle was significantly reduced. Taken together, these results indicate that the IRS proteins bind to the Ca2+-ATPase of the sarcoplasmic reticulin in an insulin-regulated fashion, thus creating a potential link between the tyrosine phosphorylation cascade and effects of insulin on calcium.	JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DEPT CELL BIOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; antonetti, david/0000-0003-1130-6577	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33201, P30 DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BORDA E, 1988, CAN J CARDIOL, V4, P97; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; EIBSCHUTZ B, 1984, RES COMMUN CHEM PATH, V45, P301; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; FOLLI F, 1992, J BIOL CHEM, V267, P22171; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KAELIN, 1993, CELL, V64, P521; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAHN CR, 1995, NEW HORIZONS DIABETE, P46; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAKINO N, 1987, AM J PHYSIOL, V253, pE202, DOI 10.1152/ajpendo.1987.253.2.E202; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAIRA Y, 1991, AM J PHYSIOL, V260, pE626, DOI 10.1152/ajpendo.1991.260.4.E626; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	73	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23696	23702		10.1074/jbc.272.38.23696	http://dx.doi.org/10.1074/jbc.272.38.23696			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295312	hybrid			2022-12-27	WOS:A1997XX38100037
J	Kostenis, E; Gomeza, J; Lerche, C; Wess, J				Kostenis, E; Gomeza, J; Lerche, C; Wess, J			Genetic analysis of receptor-G alpha(q) coupling selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; G-PROTEIN; MOLECULAR-CLONING; ADRENERGIC-RECEPTORS; TERMINAL MUTATIONS; SYNTHETIC PEPTIDES; LIGAND-BINDING; ALPHA-SUBUNIT; AMINO-ACID; ACTIVATION	Many different G protein-linked receptors are preferentially coupled to G proteins of the G(q/11) family, To elucidate the molecular basis underlying this selectivity, different G(q/11)-coupled receptors (m3 muscarinic, V1a vasopressin, and gastrin-releasing peptide receptor) were coexpressed (in COS-7 cells) with mutant alpha(s) subunits in which residues present at the C terminus of alpha(s) were replaced with the corresponding alpha(q/11), residues, Remarkably, whereas none of the receptors was able to interact with wild type alpha(s) to a significant extent, all three receptors gained the ability to productively couple to a mutant alpha(s) subunit containing a single Glu --> Asn point mutation at position -3, Moreover, the m3 muscarinic and the Via vasopressin receptors but not the GRP receptor also gained the ability to interact with a mutant alpha(s) subunit containing a single Gln --> Glu point mutation at position -5, indicating that the alpha(q/11) residues present in these mutant G protein constructs play key roles in determining the selectivity of receptor recognition. To identify the site(s) on G(q/11)-coupled receptors that can functionally interact with the C terminus of alpha(q/11) subunits, we next analyzed the ability of a series of hybrid m2/m3 muscarinic receptors to interact with a mutant alpha(s) subunit (sq5) in which the last five amino acids of alpha(s) were replaced with the corresponding alpha(q/11) sequence, Similar to the wild type m2 and m3 muscarinic receptors, none of the investigated hybrid receptors was able to efficiently interact with wild type alpha(s). Interestingly, however, three mutant m2 receptors in which different segments of the second and third intracellular loops were replaced with the corresponding m3 receptor sequences were identified, which, in contrast to the G(i/o)-coupled wild type m2 receptor, gained the ability to efficiently activate the sq5 subunit, This observation suggests that multiple intracellular receptor domains form a binding pocket for the C terminus of G protein alpha(q/11) subunits.	NIDDK,BIOORGAN CHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BLUML K, 1994, J BIOL CHEM, V269, P402; BLUML K, 1994, J BIOL CHEM, V269, P11537; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON S, 1994, G PROTEIN LINKED REC, P1; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WESS J, 1990, MOL PHARMACOL, V38, P872; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	46	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23675	23681		10.1074/jbc.272.38.23675	http://dx.doi.org/10.1074/jbc.272.38.23675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295309	hybrid			2022-12-27	WOS:A1997XX38100034
J	Oppert, B; Kramer, KJ; Beeman, RW; Johnson, D; McGaughey, WH				Oppert, B; Kramer, KJ; Beeman, RW; Johnson, D; McGaughey, WH			Proteinase-mediated insect resistance to Bacillus thuringiensis toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIOTHIS-VIRESCENS; PLUTELLA-XYLOSTELLA; PLODIA-INTERPUNCTELLA; CRYSTAL PROTEINS; BINDING; LEPIDOPTERA; ENDOTOXINS; RECEPTOR; PROTOXIN; STRAINS	Two Bacillus thuringiensis (Bt)-resistant strains of the Indianmeal moth, Plodia interpunctella, lack a major gut proteinase that activates Bt protoxins. The absence of this enzyme is genetically linked to larval survival on Bt-treated diets. When considered with previous data supporting the existence of receptor-mediated insect resistance to Bt, these results provide evidence that insect adaptation to these toxins occurs through multiple physiological mechanisms, which complicate efforts to prevent or manage resistance to Bt toxins in insect control programs.			Oppert, B (corresponding author), USDA ARS, N CENT REG, US GRAIN MKT RES LAB, 1515 COLL AVE, MANHATTAN, KS 66502 USA.							Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P247, DOI 10.1016/0022-2011(92)90005-O; ESCRICHE B, 1995, BIOCHEM BIOPH RES CO, V212, P388, DOI 10.1006/bbrc.1995.1982; Estruch JJ, 1997, NAT BIOTECHNOL, V15, P137, DOI 10.1038/nbt0297-137; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; Forcada C, 1996, ARCH INSECT BIOCHEM, V31, P257, DOI 10.1002/(SICI)1520-6327(1996)31:3&lt;257::AID-ARCH2&gt;3.0.CO;2-V; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; GOULD F, 1992, P NATL ACAD SCI USA, V89, P7986, DOI 10.1073/pnas.89.17.7986; HOFTE H, 1989, MICROBIOL REV, V53, P242; Keller M, 1996, INSECT BIOCHEM MOLEC, V26, P365, DOI 10.1016/0965-1748(95)00102-6; LEE MK, 1995, APPL ENVIRON MICROB, V61, P3836, DOI 10.1128/AEM.61.11.3836-3842.1995; Luo K, 1997, APPL ENVIRON MICROB, V63, P1024, DOI 10.1128/AEM.63.3.1024-1027.1997; MACINTOSH SC, 1991, P NATL ACAD SCI USA, V88, P8930, DOI 10.1073/pnas.88.20.8930; MASSON L, 1995, J BIOL CHEM, V270, P1; MCGAUGHEY WH, 1992, J ECON ENTOMOL, V85, P1594, DOI 10.1093/jee/85.5.1594; MCGAUGHEY WH, 1992, SCIENCE, V258, P1451, DOI 10.1126/science.258.5087.1451; MOAR WJ, 1995, APPL ENVIRON MICROB, V61, P2086, DOI 10.1128/AEM.61.6.2086-2092.1995; MOUCHES C, 1986, SCIENCE, V233, P778, DOI 10.1126/science.3755546; NICKERSON KW, 1974, APPL MICROBIOL, V28, P129, DOI 10.1128/AEM.28.1.129-132.1974; OPPERT B, 1994, BIOCHEM BIOPH RES CO, V198, P940, DOI 10.1006/bbrc.1994.1134; Oppert B, 1996, INSECT BIOCHEM MOLEC, V26, P571, DOI 10.1016/S0965-1748(96)00013-6; PASTEUR N, 1988, PRACTICAL ISOZYME GE, P42; TABASHNIK BE, 1994, P NATL ACAD SCI USA, V91, P4120, DOI 10.1073/pnas.91.10.4120; Tang JD, 1996, APPL ENVIRON MICROB, V62, P564, DOI 10.1128/AEM.62.2.564-569.1996; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593	26	214	239	3	31	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23473	23476		10.1074/jbc.272.38.23473	http://dx.doi.org/10.1074/jbc.272.38.23473			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295279	hybrid			2022-12-27	WOS:A1997XX38100004
J	Wang, XS; Diener, K; Manthey, CL; Wang, SW; Rosenzweig, B; Bray, J; Delaney, J; Cole, CN; ChanHui, PY; Mantlo, N; Lichenstein, HS; Zukowski, M; Yao, ZB				Wang, XS; Diener, K; Manthey, CL; Wang, SW; Rosenzweig, B; Bray, J; Delaney, J; Cole, CN; ChanHui, PY; Mantlo, N; Lichenstein, HS; Zukowski, M; Yao, ZB			Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; C-JUN; GENE-EXPRESSION; MAMMALIAN-CELLS; PHOSPHORYLATION; STRESS; IDENTIFICATION; CASCADE; DOMAIN	The p38 mitogen-activated protein kinases (MAPK) are activated by cellular stresses and play an important role in regulating gene expression. We have isolated a cDNA encoding a novel protein kinase that has significant homology (57% amino acid identity) to human p38 alpha/CSBP. The novel kinase, p38 delta, has a nucleotide sequence encoding a protein of 365 amino acids with a putative TGY dual phosphorylation motif. Dot-blot analysis of p38 delta mRNA in 50 human tissues revealed a distribution profile of p38 delta that differs from p38 alpha. p38 delta is highly expressed in salivary gland, pituitary gland, and adrenal gland, whereas p38 alpha is highly expressed in placenta, cerebellum, bone marrow, thyroid gland, peripheral leukocytes, liver, and spleen. Like p38 alpha, p38 delta is activated by cellular stress and proinflammatory cytokines. p38 delta phosphorylates AFT-2 and PHAS-I, but not MAPK-activated protein kinase-2 and -3, known in vivo and in vitro substrates of p38 alpha. We also observed that p38 delta was strongly activated by MKK3 and MKK6, while p38 alpha was preferentially activated by MKK6. Other experiments showed that a potent p38 alpha kinase inhibitor AMG 2372 minimally inhibited the kinase activity of p38 delta. Taken together, these data indicate that p38 delta is a new member of the p38 MAPK family and that p38 delta likely has functions distinct from that of p38 alpha.	AMGEN INC,BOULDER,CO 80801; AMGEN INC,THOUSAND OAKS,CA 91320	Amgen; Amgen			Cole, Charles/GRR-1551-2022					BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	46	289	325	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23668	23674		10.1074/jbc.272.38.23668	http://dx.doi.org/10.1074/jbc.272.38.23668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295308	hybrid			2022-12-27	WOS:A1997XX38100033
J	Shang, F; Gong, X; Taylor, A				Shang, F; Gong, X; Taylor, A			Activity of ubiquitin-dependent pathway in response to oxidative stress - Ubiquitin-activating enzyme is transiently up-regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS EPITHELIAL-CELLS; KAPPA-B-ALPHA; SITE-SPECIFIC PHOSPHORYLATION; PROTEIN LIGASE SYSTEM; HYDROGEN-PEROXIDE; PROTEASOME PATHWAY; CONJUGATING ENZYME; RADIOISOTOPIC DETERMINATION; AFFINITY PURIFICATION; CATARACT FORMATION	Relations between the ubiquitin pathway and cellular stress have been noted, but data regarding responses of the ubiquitin pathway to oxidative stress are scanty. This paper documents the response of this pathway to oxidative stress in lens cells. A brief exposure of lens epithelial cells to physiologically relevant levels of H2O2 induces a transient increase in activity of the ubiquitin-dependent pathway. Ubiquitin conjugation activity was maximal and increased 3.5-9.2-fold over the activity noted in untreated cells by 4 h after removal of H2O2. By 24 h after removal of H2O2, ubiquitin conjugation activity returned to the level noted in untreated cells. In parallel to the changes in ubiquitin conjugation activity, the activity of ubiquitin-activating enzyme (E1), as determined by thiol ester formation, increased 2-6.7-fold during recovery from oxidation, Addition of exogenous E1 resulted in an increase in ubiquitin conjugation activity and in the levels of ubiquitin carrier protein (E2)-ubiquitin thiol esters in both the untreated cells and the H2O2-treated cells, These data suggest that E1 is the rate-limiting enzyme in the ubiquitin conjugation process and. that the increases in ubiquitin conjugation activity which are induced upon recovery from oxidation are primarily due to increased E1. activity. The oxidation-and recovery-induced up-regulation of E1 activity is primarily due to post-synthetic events, Substrate availability and up-regulation of E2 activities also appear to be related to the enhancement in ubiquitinylation upon recovery from oxidative stress, The oxidation-induced increases in ubiquitin conjugation activity were associated with an increase in intracellular proteolysis, suggesting that the transient increase in ubiquitinylation noted upon recovery from oxidative stress may play a role in removal of damaged proteins from the cells.	TUFTS UNIV, USDA, JEAN MAYER HUMAN NUTR RES CTR AGING, LAB NUTR & VIS RES, BOSTON, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA)								ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; BARCHOWSKY A, 1994, FREE RADICAL BIO MED, V16, P771, DOI 10.1016/0891-5849(94)90192-9; BLONDIN J, 1987, MECH AGEING DEV, V41, P39, DOI 10.1016/0047-6374(87)90052-2; BLONDIN J, 1986, Journal of Free Radicals in Biology and Medicine, V2, P275; BRAWN MK, 1995, FREE RADICAL RES, V22, P23, DOI 10.3109/10715769509147525; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BRUNK UT, 1995, FREE RADICAL BIO MED, V19, P813, DOI 10.1016/0891-5849(95)02001-Q; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; COOK JC, 1995, P NATL ACAD SCI USA, V92, P3454, DOI 10.1073/pnas.92.8.3454; DEVAMANOHARAN PS, 1991, CURR EYE RES, V10, P831, DOI 10.3109/02713689109013879; DEVAMANOHARAN PS, 1995, OPHTHALMIC RES, V27, P39, DOI 10.1159/000267837; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GIBLIN FJ, 1984, EXP EYE RES, V38, P87, DOI 10.1016/0014-4835(84)90142-8; GIBLIN FJ, 1990, EXP EYE RES, V50, P795, DOI 10.1016/0014-4835(90)90130-M; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOEBL MG, 1994, MOL CELL BIOL, V14, P3022, DOI 10.1128/MCB.14.5.3022; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1979, P NATL ACAD SCI USA, V76, P3107, DOI 10.1073/pnas.76.7.3107; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HONDERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280, DOI 10.1016/0006-291X(92)91555-5; HUANG LL, 1993, BIOCHIM BIOPHYS ACTA, V1175, P181, DOI 10.1016/0167-4889(93)90021-G; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K; Jahngen-Hodge J., 1996, Investigative Ophthalmology and Visual Science, V37, pS799; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KONG SK, 1992, J BIOL CHEM, V267, P14189; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Maki CG, 1996, CANCER RES, V56, P2649; MULLER S, 1995, BIOESSAYS, V17, P677, DOI 10.1002/bies.950170804; NAGAI Y, 1995, J CELL SCI, V108, P2145; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REDDAN JR, 1993, EXP EYE RES, V56, P543, DOI 10.1006/exer.1993.1068; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; SPECTOR A, 1989, EXP EYE RES, V49, P685, DOI 10.1016/S0014-4835(89)80063-6; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Stephen AG, 1996, J BIOL CHEM, V271, P15608, DOI 10.1074/jbc.271.26.15608; TAYLOR A, 1993, TOXICOL IND HEALTH, V9, P349, DOI 10.1177/0748233793009001-226; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; VARMA SD, 1984, CURR EYE RES, V3, P35, DOI 10.3109/02713688408997186; WHISLER RL, 1994, LYMPHOKINE CYTOK RES, V13, P399	73	200	202	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23086	23093		10.1074/jbc.272.37.23086	http://dx.doi.org/10.1074/jbc.272.37.23086			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287309	hybrid			2022-12-27	WOS:A1997XV74400020
J	Tsubaki, M; Nakayama, M; Okuyama, E; Ichikawa, Y; Hori, H				Tsubaki, M; Nakayama, M; Okuyama, E; Ichikawa, Y; Hori, H			Existence of two heme B centers in cytochrome b(561) from bovine adrenal chromaffin vesicles as revealed by a new purification procedure and EPR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANES; PROTEIN; COMPLEX; POLYPEPTIDE; SYSTEM; B561	We have established a new purification procedure of cytochrome b(561) from bovine adrenomedullary chromaffin vesicles, The heme content analysis of the purified sample indicated the presence of 1.7 molecules of heme B/cytochrome b(561), molecule. EPR spectroscopy of the purified enzyme in oxidized state showed that there were three types of law spill heme species. Two of them showed usual EPR signals at g(z) = 3.14 and g(z) = 2.84 arising from the same heme and were interconvertible depending on pH. The other species showed a highly anisotropic low spin signal at g(z) = 3.70, with a lower redox potential than the others, and a temperature-sensitive character, These properties are very similar to low potential cytochrome b (b(L) or b(566)) of the mitochondrial complex III, indicating that the g(z) = 3.70 species is derived from a heme component different from the one that shows the usual low spin EPR signals. Based on our new structural model, these two heme B prosthetic groups are likely to be located on both sides of the membranes in close contact with the ascorbic acid- and semi-dehydroascorbic acid-binding sites, respectively, to facilitate the electron transfer across the membranes, This molecular architecture may provide a structural basis for the transmembrane electron transfer catalyzed by this hemoprotein.	KAGAWA MED UNIV,DEPT BIOCHEM,MIKI,KAGAWA 76107,JAPAN; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	Kagawa University; Osaka University	Tsubaki, M (corresponding author), HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN.							APPS DK, 1984, BIOCHIM BIOPHYS ACTA, V764, P8, DOI 10.1016/0005-2728(84)90134-8; APPS DK, 1980, NEUROSCIENCE, V5, P2279, DOI 10.1016/0306-4522(80)90143-8; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; Bartlett S F, 1974, Methods Enzymol, V31, P379; BERGSTROM J, 1983, FEBS LETT, V164, P71, DOI 10.1016/0014-5793(83)80021-0; BURBAEV DS, 1991, FEBS LETT, V283, P97, DOI 10.1016/0014-5793(91)80562-H; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DUONG LT, 1982, J BIOL CHEM, V257, P8561; FLATMARK T, 1971, BIOCHIM BIOPHYS ACTA, V253, P487, DOI 10.1016/0005-2728(71)90052-1; Fuhrhop J.-H., 1975, PORPHYRINS METLLOPOR, P755; IKEDA M, 1974, BIOCHIM BIOPHYS ACTA, V336, P15, DOI 10.1016/0005-2795(74)90378-X; Markwell M A, 1981, Methods Enzymol, V72, P296; NJUS D, 1993, BIOCHIM BIOPHYS ACTA, V1144, P235, DOI 10.1016/0005-2728(93)90108-R; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; ORMEJOHN.NR, 1971, BIOCHEM BIOPH RES CO, V45, P871, DOI 10.1016/0006-291X(71)90419-0; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; QUINN R, 1982, J AM CHEM SOC, V104, P2588, DOI 10.1021/ja00373a042; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; SILSAND T, 1974, BIOCHIM BIOPHYS ACTA, V359, P257, DOI 10.1016/0005-2795(74)90223-2; SRIVASTAVA M, 1994, BIOCHEM J, V303, P915, DOI 10.1042/bj3030915; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; WAKEFIELD LM, 1984, J BIOCHEM BIOPH METH, V9, P331, DOI 10.1016/0165-022X(84)90017-4; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7	23	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23206	23210		10.1074/jbc.272.37.23206	http://dx.doi.org/10.1074/jbc.272.37.23206			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287327	hybrid			2022-12-27	WOS:A1997XV74400038
J	Paterno, GD; Li, Y; Luchman, HA; Ryan, PJ; Gillespie, LL				Paterno, GD; Li, Y; Luchman, HA; Ryan, PJ; Gillespie, LL			cDNA cloning of a novel, developmentally regulated immediate early gene activated by fibroblast growth factor and encoding a nuclear protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY XENOPUS-EMBRYOS; MESODERM INDUCTION; EXPRESSION; CELLS; ADENOCARCINOMA; TRANSCRIPTION; RECEPTORS; SEQUENCE; DOMAINS; LAEVIS	We have utilized the polymerase chain reaction (PCR)-based differential display methodology (Liang, P., and Pardee, A. B. (1992) Science 257, 967-969) to identify a novel transcript whose expression levels increased in Xenopus embryo explants during mesoderm induction by fibroblast growth factor, The PCR product was used to clone a 2.3-kilobase pair cDNA representing this transcript, which we have named er1 (early response 1), The er1 cDNA contained a single open reading frame predicted to encode a protein of 493 amino acid residues, A data base homology search revealed that the predicted ER1 amino acid sequence contains three regions of similarity to the rat and human proteins encoded by the metastasis-associated gene, mta1, and two regions of similarity to the Caenorhabditis elegans sequence that is similar to mta1. The fibroblast growth factor-induced increase in er1 steady-state levels was not dependent on de novo protein synthesis, demonstrating that er1 is an immediate early gene, Northern blot analysis revealed a single 2.8-kilobase pair mRNA that was observed predominantly during the initial cleavage and blastula stages of Xenopus development, with little or no detectable mRNA during subsequent development, Quantitative PCR analysis of early developmental stages showed that er1 peaked during late blastula, Computer-assisted analysis of the predicted ER1 amino acid sequence revealed two putative nuclear localization signals, four highly acidic regions clustered at the N terminus and a proline rich region located near the C terminus, Subcellular localization by immunocytochemistry revealed that the ER1 protein was targeted exclusively to the nucleus, Transactivation assays using various regions of ER1 fused to the DNA binding domain of GAL4 demonstrated that the N-terminal acidic region is a potent transactivator. These data suggest that ER1 may function as a transcription factor.	MEM UNIV NEWFOUNDLAND, FAC MED, DIV BASIC MED SCI, TERRY FOX CANC RES LABS, St John, NF A1B 3V6, CANADA	Memorial University Newfoundland			Ryan, Patrick/HDO-1133-2022					BAIRD A, 1991, FIBROBLAST GROWTH FA; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; Clemens M, 1984, TRANSCRIPTION TRANSL, P231; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; GILLESPIE LL, 1992, MECH DEVELOP, V38, P99, DOI 10.1016/0925-4773(92)90002-2; GILLESPIE LL, 1995, J BIOL CHEM, V270, P22758, DOI 10.1074/jbc.270.39.22758; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; HARTLEY RS, 1994, DEV BIOL, V163, P521, DOI 10.1006/dbio.1994.1168; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PATHAK S, 1979, J NATL CANCER I, V62, P263; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Reynolds JN, 1996, MOL BRAIN RES, V35, P11, DOI 10.1016/0169-328X(95)00172-O; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RYAN PJ, 1994, DEV BIOL, V166, P101, DOI 10.1006/dbio.1994.1299; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; TOH Y, 1994, J BIOL CHEM, V269, P22958; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355	29	35	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25591	25595		10.1074/jbc.272.41.25591	http://dx.doi.org/10.1074/jbc.272.41.25591			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325278	hybrid			2022-12-27	WOS:A1997YA35800033
J	Zhu, YJ; Qi, C; Jain, S; Rao, MS; Reddy, JK				Zhu, YJ; Qi, C; Jain, S; Rao, MS; Reddy, JK			Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; PPAR-GAMMA; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL EXPRESSION; NUCLEAR RECEPTORS; CO-REPRESSOR; FATTY-ACIDS; RAT; SUPERFAMILY; FAMILY	In an attempt to identify cofactors that could possibly influence the transcriptional activity of peroxisome proliferator-activated receptors (PPARs), we used a yeast two-hybrid system with Gal4-PPAR gamma as bait to screen a mouse liver cDNA library and have identified steroid receptor coactivator-l (SRC-1) as a PPAR transcriptional coactivator. We now report the isolation of a cDNA encoding a 165-kDa PPAR gamma-binding protein, designated PBP which also serves as a coactivator. PBP also binds to PPAR alpha, RAR alpha RXR, and TR beta 1, and this binding is increased in the presence of specific ligands. Deletion of the last 12 amino acids from the carboxyl terminus of PPAR gamma results in the abolition of interaction between PBP and PPAR gamma. PBP modestly increased the transcriptional activity of PPAR gamma, and a truncated form of PBP (amino acids 487-735) acted as a dominant-negative repressor, suggesting that PBP is a genuine coactivator for PPAR. In addition, PBP contains two LXXLL signature motifs considered necessary and sufficient for the binding of several coactivators to nuclear receptors. In situ hybridization and Northern analysis showed that PBP is expressed in many tissues of adult mice, including the germinal epithelium of testis, where it appeared most abundant, and during ontogeny, suggesting a possible role for this cofactor in cellular proliferation and differentiation.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA	Northwestern University				jain, sanjay/0000-0003-2804-127X	NIGMS NIH HHS [R37 GM23750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvares K, 1996, CARCINOGENESIS, V17, P311, DOI 10.1093/carcin/17.2.311; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHU RY, 1995, J BIOL CHEM, V270, P29636; Chu RY, 1996, J BIOL CHEM, V271, P27670, DOI 10.1074/jbc.271.44.27670; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUANG Q, 1995, INT J ONCOL, V6, P307; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; ONATE SA, 1995, SCIENCE, V270, P1354; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	52	288	311	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25500	25506		10.1074/jbc.272.41.25500	http://dx.doi.org/10.1074/jbc.272.41.25500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325263	hybrid			2022-12-27	WOS:A1997YA35800018
J	deFerra, F; Rodriguez, F; Tortora, O; Tosi, C; Grandi, G				deFerra, F; Rodriguez, F; Tortora, O; Tosi, C; Grandi, G			Engineering of peptide synthetases - Key role of the thioesterase-like domain for efficient production of recombinant peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; BACILLUS-SUBTILIS; RATIONAL DESIGN; BIOSYNTHESIS; SYNTHASE; GENES; TEMPLATES; BACTERIAL; CLEAVAGE; PROTEINS	Peptide synthetases are large enzymatic complexes that catalyze the synthesis of biologically active peptides in microorganisms and fungi and typically have an unusual structure and sequence, Peptide synthetases have recently been engineered to modify the substrate specificity to produce peptides of a new sequence, In this study we show that surfactin synthetase can also be modified by moving the carboxyl-terminal intrinsic thioesterase region to the end of the internal amino acid binding domains, thus generating strains that produce new truncated peptides of the predicted sequence. Omission of the thioesterase domain results in nonproducing strains, thus showing the essential role of this region and the possibility of obtaining peptides of different lengths by genetic engineering. Secretion of the peptides depends on the presence of a functional sfp gene.			deFerra, F (corresponding author), ENIRICERCHE SPA,ENVIRONM TECHNOL,GENET ENGN & MICROBIOL LABS,VIA F MARITANO 26,I-20097 SAN DONATO MILANE,ITALY.			Grandi, Guido/0000-0001-9724-2185				AHARONOWITZ Y, 1993, BIO-TECHNOL, V11, P807, DOI 10.1038/nbt0793-807; BORCHERT S, 1994, J BACTERIOL, V176, P2458, DOI 10.1128/JB.176.8.2458-2462.1994; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; GALLI G, 1994, BBA-PROTEIN STRUCT M, V1205, P19, DOI 10.1016/0167-4838(94)90087-6; GROSSMAN TH, 1993, J BACTERIOL, V175, P6203, DOI 10.1128/JB.175.19.6203-6211.1993; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; RAZAFINDRALAMBO H, 1993, J CHROMATOGR, V639, P81, DOI 10.1016/0021-9673(93)83091-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1111/j.1574-6968.1995.tb07328.x; STACHELHAUS T, 1995, SCIENCE, V269, P69, DOI 10.1126/science.7604280; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; STEIN T, 1994, FEBS LETT, V340, P39, DOI 10.1016/0014-5793(94)80169-X; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; TOGNONI A, 1995, MICROBIOL-UK, V141, P645, DOI 10.1099/13500872-141-3-645; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798	27	57	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25304	25309		10.1074/jbc.272.40.25304	http://dx.doi.org/10.1074/jbc.272.40.25304			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312148	hybrid			2022-12-27	WOS:A1997XY97000087
J	Turnbull, AP; Baker, PJ; Rice, DW				Turnbull, AP; Baker, PJ; Rice, DW			Analysis of the quaternary structure, substrate specificity, and catalytic mechanism of valine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRANCHED-CHAIN AMINO; LEUCINE DEHYDROGENASE; GLUTAMATE-DEHYDROGENASE; STREPTOMYCES-FRADIAE; THERMOACTINOMYCES-INTERMEDIUS; PHENYLALANINE DEHYDROGENASE; BACILLUS-SPHAERICUS; PROTEIN STRUCTURES; GENE CLONING; PURIFICATION	The solution of the three-dimensional structure of Bacillus sphaericus leucine dehydrogenase has enabled us to undertake a homology-based modeling exercise on the sequence differences between the families of leucine (LeuDH) and valine (ValDH) dehydrogenases. This analysis indicates that the secondary structure elements in the core of the two domains of a single subunit of these enzymes are conserved, as are residues directly implicated in the recognition of the nucleotide cofactor and in catalysis. Comparison of the sequences indicates that the residues in the pocket accommodating the side chain of the amino acid substrate are conserved be tween these two enzymes, suggesting that the small differences in specificity arise from minor changes in molecular structure, possibly associated with shifts of the main chain rather than mutation of residues in the pocket itself, While B. sphaericus LeuDH is an octamer, both Streptomyces cinnamonensis and Streptomyces coelicolor ValDHs are dimers, The differences in quaternary structure can be understood in terms of the deletion in the latter of a C terminal loop, which forms important interactions around the four-fold axis in LeuDH.	UNIV SHEFFIELD, KREBS INST BIOMOLEC RES, DEPT MOL BIOL & BIOTECHNOL, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND	University of Sheffield				Baker, Patrick/0000-0003-1995-5643				BAKER PJ, 1995, STRUCTURE, V3, P693, DOI 10.1016/S0969-2126(01)00204-0; BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BRITTON KL, 1993, J MOL BIOL, V234, P938, DOI 10.1006/jmbi.1993.1647; BRITTON KL, 1992, EUR J BIOCHEM, V209, P851, DOI 10.1111/j.1432-1033.1992.tb17357.x; DOOLEY KC, 1992, CLIN BIOCHEM, V25, P271, DOI 10.1016/0009-9120(92)80032-C; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FISHER HF, 1992, BIOCHIM BIOPHYS ACTA, V1119, P52, DOI 10.1016/0167-4838(92)90233-4; HANSON RL, 1990, BIOORG CHEM, V18, P116, DOI 10.1016/0045-2068(90)90033-2; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leiser A, 1996, GENE, V177, P217, DOI 10.1016/0378-1119(96)00305-8; LIVESEY G, 1988, METHOD ENZYMOL, V166, P3; MISONO H, 1990, AGR BIOL CHEM TOKYO, V54, P1491, DOI 10.1080/00021369.1990.10870153; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; Nagata S, 1995, APPL MICROBIOL BIOT, V44, P432; NAGATA S, 1988, BIOCHEMISTRY-US, V27, P9056, DOI 10.1021/bi00425a026; NAVARRETE RM, 1990, J GEN MICROBIOL, V136, P273, DOI 10.1099/00221287-136-2-273; OHSHIMA T, 1993, BIOCHIM BIOPHYS ACTA, V1162, P221, DOI 10.1016/0167-4838(93)90151-G; OHSHIMA T, 1978, J BIOL CHEM, V253, P5719; OHSHIMA T, 1994, EUR J BIOCHEM, V222, P305, DOI 10.1111/j.1432-1033.1994.tb18869.x; OMURA S, 1983, J ANTIBIOT, V36, P1792, DOI 10.7164/antibiotics.36.1792; PATCHETT AA, 1980, NATURE, V288, P280, DOI 10.1038/288280a0; PRIESTLEY ND, 1989, BIOCHEM J, V261, P853, DOI 10.1042/bj2610853; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SCHUTTE H, 1985, APPL MICROBIOL BIOT, V22, P306, DOI 10.1007/BF00582413; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; STILLMAN TJ, 1993, J MOL BIOL, V234, P1131, DOI 10.1006/jmbi.1993.1665; TAKADA H, 1991, J BIOCHEM-TOKYO, V109, P371, DOI 10.1093/oxfordjournals.jbchem.a123388; TANG L, 1993, J BACTERIOL, V175, P4176, DOI 10.1128/JB.175.13.4176-4185.1993; TANG L, 1994, J BACTERIOL, V176, P6107, DOI 10.1128/jb.176.19.6107-6119.1994; TELLER JK, 1992, EUR J BIOCHEM, V206, P151, DOI 10.1111/j.1432-1033.1992.tb16912.x; TURNBULL AP, 1994, J MOL BIOL, V236, P663, DOI 10.1006/jmbi.1994.1176; VANCURA A, 1988, J GEN MICROBIOL, V134, P3213; VANCUROVA I, 1988, J BACTERIOL, V170, P5192, DOI 10.1128/jb.170.11.5192-5196.1988; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; YAMAGUCHI A, 1992, SCREENING, V1, P49	39	21	22	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25105	25111		10.1074/jbc.272.40.25105	http://dx.doi.org/10.1074/jbc.272.40.25105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312120	hybrid			2022-12-27	WOS:A1997XY97000059
J	Horsten, U; MullerNewen, G; Gerhartz, C; Wollmer, A; Wijdenes, J; Heinrich, PC; Grotzinger, J				Horsten, U; MullerNewen, G; Gerhartz, C; Wollmer, A; Wijdenes, J; Heinrich, PC; Grotzinger, J			Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6)center dot IL-6 receptor center dot gp130 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; ACUTE-PHASE RESPONSE; TRANSCRIPTION FACTOR APRF; HUMAN IL-6 RECEPTOR; ESCHERICHIA-COLI; GROWTH-HORMONE; EXPRESSION; ACTIVATION; BINDING; PURIFICATION	The transmembrane protein gp130 is involved in many cytokine-mediated cellular responses and acts therein as the signal-transducing subunit, In the case of interleukin-6 (IL-6), the signal-transducing complex is composed of the ligand IL-6, the IL-6 receptor (IL-6R, gp80, CD126), and at least two gp130 (CD130) molecules, The extracellular part of the signal transducer gp130 consists of sis fibronectin type III-like domains, It has recently been shown that the three membrane distal domains bind to the IL-6.IL-6R complex. A structural model of the IL-6.IL-6R gp130 complex enabled us to propose amino acid residues in these domains of gp130 interacting with IL-6 bound to its receptor. The proposed amino acid residues located in the B'C' loop (Val(252)) and in the F'G' loop (Gly(306), Lys(307)) of domain 3 and in the hinge region (Tyr(21S)) connecting domains 2 and 3 of gp130 were mutated to disturb ternary complex formation, Binding of wild type and mutants of the extracellular region of gp130 was studied by use of a co-precipitation assay and Scatchard analysis, All mutants showed decreased binding to the IL-6.IL-6R complex, Biological function of the membrane bound gp130 mutants was studied by STAT (signal transducer and activator of transcription) activation in COS-7 cells and by proliferation of stably transfected Ba/F3 cells. Reduced binding of the mutants was accompanied by decreased biological activity, The combined approach of molecular modeling and site-directed mutagenesis has led to the identification of amino acid residues in gp130 required for complex formation with IL-6 and its receptor.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; DIACLONE,F-25020 BESANCON,FRANCE	RWTH Aachen University								ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P946; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EHLERS M, 1994, J IMMUNOL, V153, P1744; EHLERS M, 1995, J BIOL CHEM, V270, P8158, DOI 10.1074/jbc.270.14.8158; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GRAEVE L, 1989, J CELL BIOL, V265, P1216; Grotzinger J, 1997, PROTEINS, V27, P96; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; Kalai M, 1996, EUR J BIOCHEM, V238, P714, DOI 10.1111/j.1432-1033.1996.0714w.x; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Sambrook J., 2002, MOL CLONING LAB MANU; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; WELLS JA, 1995, BIO-TECHNOL, V13, P647, DOI 10.1038/nbt0795-647; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	37	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23748	23757		10.1074/jbc.272.38.23748	http://dx.doi.org/10.1074/jbc.272.38.23748			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295319	hybrid			2022-12-27	WOS:A1997XX38100044
J	Maeda, M; Firtel, RA				Maeda, M; Firtel, RA			Activation of the mitogen-activated protein kinase ERK2 by the chemoattractant folic acid in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLATE CHEMOTACTIC RECEPTORS; MAP KINASE; MULTICELLULAR DEVELOPMENT; CAENORHABDITIS-ELEGANS; CELL-DIFFERENTIATION; SIGNALING PATHWAYS; ADENYLYL-CYCLASE; VULVAR INDUCTION; BETA-SUBUNIT; DISCOIDEUM	The Dictyostelium MAP kinase ERK2 is activated by extracellular cAMP in aggregation-competent cells and is required far receptor activation of adenylyl cyclase (Maeda, M., Aubry, L., Insall, R., Gaskins, C., Devreotes, P. N., and Firtel, R.A. (1996) J. Biol. Chem, 271, 3351-3354; Segall, J., Kuspa, A., Shaulsky, G., Ecke, M., Maeda, M., Gaskins, C., Firtel, R., and Loomis, W. (1995) J. Cell Biol. 128, 405-413). This cAMP-dependent activation of ERK2 is mediated by the serpentine, G protein-coupled cAMP receptors. However, ERK2 activation by cAMP is at least partially heterotrimeric G protein-independent, with a level of activation in cells lacking the sole G beta subunit or the G protein-coupled cAMP receptors-coupled G alpha 2, subunit that is similar to 50% that of wild-type cells (Maeda, M., Aubry, L., Insall, R., Gaskins, C., Devreotes, P. N., and Firtel, R. A. (1996) J. Biol. Chem, 271, 3351-3354; Segall, J., Kuspa, A., Shaulsky, G., Ecke, M., Maeda, M., Gaskins, C., Firtel, R., and Loomis, W. (1995) J. Cell Biol. 128, 405-413). Folic acid, a chemoattractant in the vegetative cells that enables amoebae to find bacteria in the wild, also triggers the activation of adenylyl cyclase, which is impaired in the vegetative cells lacking the G alpha protein subunit G alpha 4 (Hadwiger, J., Lee, S,, and Firtel, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10566-10570). In this study, we show that folic acid activates ERK2 in developmentally regulated manner and is required far ERK2 stimulation of adenylyl cyclase activity. Maximum levels of folate-stimulated ERK2 activity occur in cells from very early in development, prior to aggregation, and again at the tipped aggregate stages, corresponding to the stages in which folate receptors and the coupled G alpha subunit G alpha 4 are maximally expressed. During the activation by folic acid, ERK2 is phosphorylated on tyrosine residue(s) and contemporaneously shows a mobility shift on SDS-PAGE. Interestingly, this activation is not elicited in the absence of GP subunits, in contrast to the response to cAMP. This response also requires the G alpha 4 subunit known to be required for other folic acid-mediated responses (Hadwiger, J., Lee, S., and Firtel, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10566-10570). Furthermore, we show that the activation of ERK2 by cAMP is independent of the G alpha 4 subunit, while the activation of ERK2 by folate is independent of G alpha 2. Taken together, these data indicate that there are at least two pathways of ERK2 activation, heteroaromatic G protein-dependent and -independent pathways.	UNIV CALIF SAN DIEGO,CTR MOL GENET,DEPT BIOL,SAN DIEGO,CA 92093; OSAKA UNIV,GRAD SCH SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN	University of California System; University of California San Diego; Osaka University								Aubry L, 1997, J BIOL CHEM, V272, P3883, DOI 10.1074/jbc.272.7.3883; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; CHURCH DL, 1995, DEVELOPMENT, V121, P2525; DEWIT RJW, 1986, BIOCHIM BIOPHYS ACTA, V886, P88, DOI 10.1016/0167-4889(86)90214-4; DEWIT RJW, 1985, FEBS LETT, V179, P257, DOI 10.1016/0014-5793(85)80530-5; DEWIT RJW, 1986, DIFFERENTIATION, V32, P192, DOI 10.1111/j.1432-0436.1986.tb00573.x; DEWIT RJW, 1983, CELL DIFFER DEV, V12, P205, DOI 10.1016/0045-6039(83)90029-5; DEWIT RJW, 1985, BIOCHIM BIOPHYS ACTA, V814, P214, DOI 10.1016/0005-2736(85)90439-0; DEWIT RJW, 1986, BIOCHIM BIOPHYS ACTA, V886, P76, DOI 10.1016/0167-4889(86)90213-2; DHARMAWARDHANE S, 1994, DEVELOPMENT, V120, P3549; Gaskins C, 1996, GENE DEV, V10, P118, DOI 10.1101/gad.10.1.118; GASKINS C, 1994, MOL CELL BIOL, V14, P996; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; Hadwiger JA, 1996, DEVELOPMENT, V122, P1215; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HADWIGER JA, 1994, P NATL ACAD SCI USA, V91, P10566, DOI 10.1073/pnas.91.22.10566; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; HOPPER NA, 1993, DEVELOPMENT, V119, P147; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; Knetsch MLW, 1996, EMBO J, V15, P3361, DOI 10.1002/j.1460-2075.1996.tb00701.x; KORNFELD K, 1995, GENE DEV, V9, P756, DOI 10.1101/gad.9.6.756; KUBOHARA Y, 1993, EXP CELL RES, V207, P107, DOI 10.1006/excr.1993.1168; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; MA H, 1997, IN PRESS EMBO J, V16; Maeda M, 1996, J BIOL CHEM, V271, P3351; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MANN SKO, 1991, MECH DEVELOP, V35, P89, DOI 10.1016/0925-4773(91)90060-J; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OKAICHI K, 1992, MOL BIOL CELL, V3, P735, DOI 10.1091/mbc.3.7.735; PAN P, 1972, NATURE-NEW BIOL, V237, P181, DOI 10.1038/newbio237181a0; SEGALL JE, 1988, J CELL SCI, V91, P479; SEGALL JE, 1995, J CELL BIOL, V128, P405, DOI 10.1083/jcb.128.3.405; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; TILLINGHAST HS, 1987, J CELL SCI, V87, P45; WU L, 1994, HDB EXPT PHARM, V108, P335; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; WU Y, 1995, GENE DEV, V9, P742, DOI 10.1101/gad.9.6.742; WURSTER B, 1979, CELL DIFFER DEV, V8, P235, DOI 10.1016/0045-6039(79)90050-2	51	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23690	23695		10.1074/jbc.272.38.23690	http://dx.doi.org/10.1074/jbc.272.38.23690			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295311	hybrid			2022-12-27	WOS:A1997XX38100036
J	Clark, KD; Pech, LL; Strand, MR				Clark, KD; Pech, LL; Strand, MR			Isolation and identification of a plasmatocyte-spreading peptide from the hemolymph of the lepidopteran insect Pseudoplusia includens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-BLOCKING PEPTIDE; MONOCLONAL-ANTIBODIES; MANDUCA-SEXTA; LARVAL DEVELOPMENT; FOREIGN TARGETS; IN-VITRO; HEMOCYTES; ENCAPSULATION; NOCTUIDAE; INFLAMMATION	Insect blood cells (hemocytes) play an essential role in defense against parasites and other pathogenic organisms that infect insects. A key class of hemocytes involved in insect cellular immunity is plasmatocytes. Here we describe the isolation and identification of a peptide from the moth Pseudoplusia includens that mediates the spreading of plasmatocytes to foreign surfaces. This peptide, designated plasmatocyte-spreading peptide (PSP1), contains 23 amino acid residues in the following sequence: H-ENFNGGCLAGYMRTADGRCKPTF-OH. In vitro assays using the synthetic peptide at concentrations greater than or equal to 2 nM induced plasmatocytes from P. includens to spread an the surface of culture dishes. Injection of this peptide into P. includens larvae caused a transient depletion of plasmatocytes from circulation, Labeling studies indicated that this peptide induced 75% of plasmatocytes that were double-labeled by the monoclonal antibodies 49G3A3 and 43E9A8 to spread, whereas plasma induced significantly more plasmatocytes to spread, This suggests that only a certain subpopulation of plasmatocytes responds to the peptide and that other peptidyl factors mediate plasmatocyte adhesion responses.	UNIV WISCONSIN,DEPT ENTOMOL,RUSSELL LABS 237,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Clark, Kevin/GQA-9811-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032917] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32917] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAINES D, 1992, ARCH INSECT BIOCHEM, V21, P303, DOI 10.1002/arch.940210407; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CHADWICK JS, 1992, IMMUNOLOGY INSECTS O, P348; CHAIN BM, 1983, J INSECT PHYSIOL, V29, P1, DOI 10.1016/0022-1910(83)90099-9; CHAIN BM, 1992, J CELL SCI, V103, P1261; CHERBAS L, 1973, J INSECT PHYSIOL, V19, P2011, DOI 10.1016/0022-1910(73)90195-9; DAVIES DH, 1988, DEV COMP IMMUNOL, V12, P241, DOI 10.1016/0145-305X(88)90001-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DiehlJones WL, 1996, J INSECT PHYSIOL, V42, P13, DOI 10.1016/0022-1910(95)00078-X; GENG CX, 1989, DEV COMP IMMUNOL, V13, P17, DOI 10.1016/0145-305X(89)90012-8; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Habicht Gail S., 1994, P159; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HAYAKAWA Y, 1995, FEBS LETT, V376, P185, DOI 10.1016/0014-5793(95)01273-7; KINCADE PW, 1993, NATURE, V361, P15, DOI 10.1038/361015a0; MEAD G P, 1986, J INSECT PHYSL, V25, P795; NOGUCHI H, 1995, INSECT BIOCHEM MOLEC, V25, P197, DOI 10.1016/0965-1748(94)00054-L; Ohnishi A, 1995, INSECT BIOCHEM MOLEC, V25, P1121, DOI 10.1016/0965-1748(95)00054-2; PECH LL, 1995, J INSECT PHYSIOL, V41, P801, DOI 10.1016/0022-1910(95)00023-N; PECH LL, 1995, J INSECT PHYSIOL, V41, P481, DOI 10.1016/0022-1910(94)00136-5; Pech LL, 1996, J CELL SCI, V109, P2053; PECH LL, 1994, CELL TISSUE RES, V277, P159, DOI 10.1007/BF00303092; Pringle JWS, 1938, J EXP BIOL, V15, P101; RATCLIFFE NA, 1985, INT REV CYTOL, V97, P186; RATCLIFFE NA, 1993, PARASITES PATHOGENS, V1, P267; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SKINNER WS, 1991, J BIOL CHEM, V266, P12873; STANLEYSAMUELSON DW, 1994, J INSECT PHYSIOL, V40, P3, DOI 10.1016/0022-1910(94)90106-6; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; STRAND MR, 1990, ANN ENTOMOL SOC AM, V83, P538, DOI 10.1093/aesa/83.3.538; Strand MR, 1996, J INSECT PHYSIOL, V42, P21, DOI 10.1016/0022-1910(95)00079-8; STRAND MR, 1991, J INSECT PHYSIOL, V37, P839, DOI 10.1016/0022-1910(91)90080-J; WILLOTT E, 1994, EUR J CELL BIOL, V65, P417	33	146	165	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23440	23447		10.1074/jbc.272.37.23440	http://dx.doi.org/10.1074/jbc.272.37.23440			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287360	hybrid			2022-12-27	WOS:A1997XV74400071
J	Mathur, A; Zhong, DG; Sabharwal, AK; Smith, KJ; Bajaj, SP				Mathur, A; Zhong, DG; Sabharwal, AK; Smith, KJ; Bajaj, SP			Interaction of factor IXa with factor VIIIa - Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-IX; GAMMA-CARBOXYGLUTAMIC ACID; AFFINITY CA2+-BINDING SITE; BLOOD-COAGULATION; TISSUE FACTOR; ACTIVE-SITE; CALCIUM-BINDING; PROTHROMBINASE COMPLEX; HEMOPHILIA-B; HEAVY-CHAIN	We previously identified a high affinity Ca2+ binding site in the protease domain of factor IXa involving Glu(235) (Glu(70) in chymotrypsinogen numbering; hereafter, the numbers in brackets refer to the chymotrypsin equivalents) and Glu(245)[80] as putative ligands. To delineate the function of this Ca2+ binding site, we expressed IXwild type (IXWT), IXE235K, and IXE245V in 293 kidney cells and compared their properties with those of factor IX isolated from normal plasma (IXNP); each protein had the same M-r and gamma-carboxyglutamic acid content. Activation of each factor IX protein by factor VIIa . Ca2+. tissue factor was normal as analyzed by sodium dodecyl sulfate-gel electrophoresis. The coagulant activity of IXa(WT) was similar to 93%, of IXa(E235K) was similar to 27%, and of IXa(E245V) was similar to 4% compared with that of IXa(NP). In contrast, activation by factor XIa . Ca2+ led to proteolysis at Arg(318)-Ser(319)[150-151] in the protease domain autolysis loop of IXa(E245V) with a concomitant loss of coagulant activity; this proteolysis was moderate in IXa(E235K) and minimal in IXa(WT) or IXa(NP). Interaction of each activated mutant with an active site probe, p-aminobenzamidine, was also examined; the K-d of interaction in the absence and presence (in parentheses) of Ca2+ was: IXa(NP) or IXa(WT) 230 mu M (78 mu M), IXa(E235K) 150 mu M (145 mu M), IXa(E245V) 225 mu M (240 mu M), and autolysis loop cleaved IXa(E245V) 330 mu M (350 mu M). Next, we evaluated the apparent K-d (K-d,K-app) of interaction of each activated mutant with factor Villa. We first investigated the EC50 of interaction of IXa(NP) as well as of IXa(WT) with factor VIIIa in the presence and absence of phospholipid (PL) and varying concentrations of factor X. At each factor X concentration and constant factor VIIIa, EC50 was the free IXa(NP) or IXa(WT) concentration that yielded a half-maximal rate of factor Xa generation. EC50 values for IXa(NP) and IXa(WT) were similar and are as follows: PL-minus/X-minus (extrapolated), 2.8 mu M; PL-minus/X-saturating, 0.25 mu M; PL-plus/X-minus, 1.6 nM; and PL-plus/X-saturating, 0.09 nM. Further, K-d,K-app of binding of active site-blocked factor IXa to factor VIIIa was calculated from its ability to inhibit IXa(WT) in the Tenase assay. K-d,K-app values in the absence and presence (in parentheses) of PL were: IXa(NP) or IXa(WT), 0.19 mu M (0.07 nM); IXa(E235K), 0.68 mu M (0.26 nM); IXa(E245V), 2.5 mu M (1.35 nM); and autolysis loop-cleaved IXa(E245V), 15.6 mu M (14.3 nM). We conclude that (a) PL increases the apparent affinity of factor IXa for factor VIIIa similar to 2,000-fold, and the substrate, factor X, increases this affinity similar to 10-15-fold; (b) the protease domain Ca2+ binding site increases this affinity similar to 15-fold, and lysine at position 235 only partly substitutes for Ca2+; (c) Ca2+ binding to the protease domain increases the S1 reactivity similar to 3-fold and prevents proteolysis in the autolysis loop; and (d) proteolysis in the autolysis loop leads to a loss of catalytic efficiency with retention of S1 binding site and a further similar to 8-fold reduction in affinity of factor IXa for factor VIIIa.	ST LOUIS UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63104; ST LOUIS UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; EMORY UNIV,SCH MED,DEPT HEMATOL,ATLANTA,GA 30322	Saint Louis University; Saint Louis University; Saint Louis University; Emory University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL036365, R55HL036365, R01HL036365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWALA KL, 1994, BIOCHEMISTRY-US, V33, P5167, DOI 10.1021/bi00183a021; ASTERMARK J, 1994, J BIOL CHEM, V269, P3682; Bajaj MS, 1994, ANTICOAGULANTS PHYSL, P41; BAJAJ SP, 1993, METHOD ENZYMOL, V222, P96; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BAJAJ SP, 1975, J BIOL CHEM, V250, P2150; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BYLUND DB, 1993, AM J PHYSIOL, V265, pL421, DOI 10.1152/ajplung.1993.265.5.L421; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CRAIG DA, 1993, TRENDS PHARMACOL SCI, V6, P68; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; Halfman C J, 1981, Methods Enzymol, V74 Pt C, P481; HAMAGUCHI N, 1994, BLOOD, V84, P1837, DOI 10.1182/blood.V84.6.1837.bloodjournal8461837; HAMAGUCHI N, 1994, THROMB HAEMOSTASIS, V72, P856; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KISIEL W, 1985, BLOOD, V66, P1302; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LIN SW, 1990, J BIOL CHEM, V265, P144; LINK RP, 1982, ARCH BIOCHEM BIOPHYS, V215, P215, DOI 10.1016/0003-9861(82)90297-1; LUDWIG M, 1992, BLOOD, V79, P1225; MANN KG, 1990, BLOOD, V76, P1; MATHUR A, 1996, CIRCULATION S1, V94, P268; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; MONROE DM, 1985, THROMB HAEMOSTASIS, V54, P149; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; NISHIMURA H, 1989, J BIOL CHEM, V264, P20320; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rosenberg I.M., 1996, PROTEIN ANAL PURIFIC, V1996, P153; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; SPITZER SG, 1990, BLOOD, V151, P1530; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WARNCRAMER BJ, 1986, BIOCHEM J, V239, P757, DOI 10.1042/bj2390757; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; YE J, 1995, BIOCHEMISTRY-US, V34, P6448, DOI 10.1021/bi00019a026; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHONG D, 1994, THESIS ST LOUIS U ST; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574	58	66	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23418	23426		10.1074/jbc.272.37.23418	http://dx.doi.org/10.1074/jbc.272.37.23418			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287357	hybrid			2022-12-27	WOS:A1997XV74400068
J	Merilainen, J; Lehto, VP; Wasenius, VM				Merilainen, J; Lehto, VP; Wasenius, VM			FAP52, a novel, SH3 domain-containing focal adhesion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PROLINE-RICH PEPTIDES; SECONDARY STRUCTURE; MICROFILAMENT BUNDLES; EXTRACELLULAR-MATRIX; EMBRYO FIBROBLASTS; ADHERENS JUNCTIONS; NEURAL NETWORKS; KINASE-C; TYROSINE	Src-homology 3 (SH3) domain is a 60-70-amino acid motif present in a large variety of signal transduction and cytoskeletal proteins. We used reverse transcriptase-polymerase chain reaction with degenerate and specific primers and chicken brain mRNA to clone a cDNA that codes for a novel SH3 domain-containing protein. The sequence predicts a 448-amino acid polypeptide with a molecular mass of 51,971 daltons, In the amino terminus, it shows a very high propensity for alpha-helicity, suggesting coiled-coil and possibly a higher order oligomeric arrangement, In the carboxyl terminus, there is a unique SH3 sequence. In Northern blotting, a major 3.7-kilobase and a minor 7,2-kilobase transcript was detected in most chicken tissues, In immunofluorescence microscopy and immunoelectron microscopy on cultured chicken fibroblasts, the protein was localized to focal adhesions in which it showed a distinct codistribution with the focal adhesion proteins vinculin, talin, and paxillin. Phosphoamino acid analysis showed that in cultured chicken heart fibroblasts, the protein contains phosphoserine, but no phosphothreonine or phosphotyrosine, and that the phosphorylation is not dependent oil fibronectin. We propose this protein the name FAP52, for Focal Adhesion Protein of 52 kDa, and suggest that it farms part of the multimolecular complex constituting focal adhesion sites.	UNIV OULU, BIOCTR OULU, FIN-90220 OULU, FINLAND; UNIV OULU, DEPT PATHOL, FIN-90220 OULU, FINLAND; HELSINKI UNIV HOSP, DEPT RADIOTHERAPY & ONCOL, FIN-00290 HELSINKI, FINLAND	University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital								BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; Burridge K., 1992, Current Biology, V2, P537, DOI 10.1016/0960-9822(92)90020-B; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN WT, 1984, J CELL BIOL, V98, P1546, DOI 10.1083/jcb.98.4.1546; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CORNISHBOWDEN A, 1985, EUR J BIOCHEM, V150, P1; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; FROSCH PM, 1993, MOL BIOCHEM PARASIT, V58, P301, DOI 10.1016/0166-6851(93)90052-Y; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HOLZMAN DA, 1993, J CELL BIOL, V122, P635; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; Sormunen R, 1995, EUR J CELL BIOL, V68, P387; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1989, J CELL BIOL, V109, P2905, DOI 10.1083/jcb.109.6.2905; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VIELKIND U, 1989, HISTOCHEMISTRY, V91, P81, DOI 10.1007/BF00501916; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	59	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23278	23284		10.1074/jbc.272.37.23278	http://dx.doi.org/10.1074/jbc.272.37.23278			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287337	hybrid			2022-12-27	WOS:A1997XV74400048
J	AttmaneElakeb, A; Boulanger, H; Vernimmen, C; Bichara, M				AttmaneElakeb, A; Boulanger, H; Vernimmen, C; Bichara, M			Apical location and inhibition by arginine vasopressin of K+/H+ antiport of the medullary thick ascending limb of rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	29th Annual Meeting of the American-Society-of-Nephrology	NOV 03-06, 1996	NEW ORLEANS, LA	Amer Soc Nephrol			PLASMA-MEMBRANE VESICLES; BRUSH-BORDER MEMBRANES; FUNCTIONAL-PROPERTIES; BASOLATERAL MEMBRANE; TRANSPORT PATHWAYS; INTRACELLULAR PH; EXCHANGER NHE-2; NH4+ TRANSPORT; NA/H EXCHANGER; RABBIT KIDNEY	To characterize and localize a K+/H+ antiport mechanism in the renal medullary thick ascending limb (MTAL), membrane vesicles were isolated from a rat MTAL homogenate. K+/H+ antiport (in > out H+ gradient-stimulated Rb-86(+) uptake) was abolished by barium and verapamil (apparent K-i of 55 mu M) but unaffected by other K+ channel blockers such as quinidine and high amiloride concentrations, SCH 28080, a H+/K+-ATPase blocker, did not affect K+/H+ antiport. K+/H+ antiport activity was correlated positively with the enrichment factor of the membranes in the apical marker enzyme alkaline phosphatase (r = 0.875, p < 0.01) and negatively correlated with the enrichment factor in basolateral Na+/H+-ATPase (r = -0.665, p < 0.05). Moreover, a functional interaction occurred with Na+/H+ exchange (NBE) consistent with colocation of K+/H+ antiport and apical NHE-3, not basolateral NHE-1. K+/H+ antiport was shown by intracellular pH measurements to be inhibited by arginine vasopressin and 8-bromo-cAMP through cAMP-dependent protein kinase (protein kinase A) activation, These results demonstrate the presence of a K+/H+ antiport mechanism, which is inhibited by arginine vasopressin via protein kinase A, in the apical membrane of the MTAL.	UNIV PARIS 06,INSERM,U356,F-75270 PARIS 06,FRANCE; HOP BROUSSAIS,F-75270 PARIS 06,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite								AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Amlal H, 1996, AM J PHYSIOL-CELL PH, V271, pC455, DOI 10.1152/ajpcell.1996.271.2.C455; AMLAL H, 1994, J BIOL CHEM, V269, P21962; AMLAL H, 1994, AM J PHYSIOL-CELL PH, V267, pC1607, DOI 10.1152/ajpcell.1994.267.6.C1607; Attmane-Elakeb A., 1996, Journal of the American Society of Nephrology, V7, P1251; AttmaneElakeb A, 1996, KIDNEY INT, V50, P1051, DOI 10.1038/ki.1996.408; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; BICHARA M, 1995, J AM SOC NEPHROL, V6, P332; BLEICH M, 1990, PFLUG ARCH EUR J PHY, V415, P449, DOI 10.1007/BF00373623; BORENSZTEIN P, 1995, AM J PHYSIOL-RENAL, V268, pF1224, DOI 10.1152/ajprenal.1995.268.6.F1224; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DESIR GV, 1991, BIOCHIM BIOPHYS ACTA, V1067, P38, DOI 10.1016/0005-2736(91)90023-2; DISCALA F, 1992, BRIT J PHARMACOL, V107, P532, DOI 10.1111/j.1476-5381.1992.tb12779.x; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; FROISSART M, 1992, AM J PHYSIOL, V262, pC963, DOI 10.1152/ajpcell.1992.262.4.C963; GARVIN J L, 1988, American Journal of Physiology, V255, pF57; GOOD DW, 1985, AM J PHYSIOL, V248, pF459, DOI 10.1152/ajprenal.1985.248.4.F459; GOOD DW, 1990, J CLIN INVEST, V85, P1006, DOI 10.1172/JCI114530; Good DW, 1995, P NATL ACAD SCI USA, V92, P12525, DOI 10.1073/pnas.92.26.12525; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HONDA T, 1993, BIOCHIM BIOPHYS ACTA, V1150, P199, DOI 10.1016/0005-2736(93)90090-M; KIKERI D, 1992, J GEN PHYSIOL, V99, P435, DOI 10.1085/jgp.99.3.435; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; KINNE R, 1986, J MEMBRANE BIOL, V94, P279, DOI 10.1007/BF01869723; KINNE R, 1992, HDB PHYSL RENAL PHYS, V2, P2083; LEVIEL F, 1992, J CLIN INVEST, V90, P869, DOI 10.1172/JCI115962; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; MURER H, 1986, KIDNEY INT, V30, P171, DOI 10.1038/ki.1986.169; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PFALLER W, 1980, INT J BIOCHEM, V12, P17, DOI 10.1016/0020-711X(80)90035-X; REEVES WB, 1988, AM J PHYSIOL, V255, pF1138, DOI 10.1152/ajprenal.1988.255.6.F1138; SABOLIC I, 1984, BIOCHIM BIOPHYS ACTA, V772, P140, DOI 10.1016/0005-2736(84)90037-3; Sun A. M., 1996, Journal of the American Society of Nephrology, V7, P1261; TSURUOKA S, 1993, J CLIN INVEST, V92, P1881, DOI 10.1172/JCI116780; WATTS BA, 1994, J GEN PHYSIOL, V103, P917, DOI 10.1085/jgp.103.5.917; YOUNESIBRAHIM M, 1995, AM J PHYSIOL-RENAL, V268, pF1141, DOI 10.1152/ajprenal.1995.268.6.F1141; YU FH, 1993, J BIOL CHEM, V268, P25536	39	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25668	25677		10.1074/jbc.272.41.25668	http://dx.doi.org/10.1074/jbc.272.41.25668			10	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325290	hybrid			2022-12-27	WOS:A1997YA35800045
J	Bigger, CB; Melnikova, IN; Gardner, PD				Bigger, CB; Melnikova, IN; Gardner, PD			Sp1 and Sp3 regulate expression of the neuronal nicotinic acetylcholine receptor beta 4 subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; BOX-BINDING-PROTEINS; TATA-LESS PROMOTER; TRANSCRIPTION FACTOR; ACTIVATION DOMAINS; ALPHA-3 GENE; POU DOMAIN; FAMILY; BRAIN; MEMBERS	Neuronal nicotinic acetylcholine receptors play important roles in signal transduction within the nervous system. The receptors exist in a variety of functionally distinct subtypes that are determined by their subunit structures. The subunits are encoded by 11 genes, alpha 2-alpha 9 and beta 2-beta 4. Three of the genes, alpha 3, alpha 5, and beta 4, are tightly clustered, and their encoded proteins make up the predominant receptor subtype in the peripheral nervous system. The tight linkage of the genes suggests there may be a common regulatory mechanism underlying their expression. However, although their expression patterns significantly overlap, they are not identical, indicating that independent regulatory mechanisms must also exist. Our studies have focused upon the gene encoding the beta 4 subunit for which we have identified several transcriptional regulatory elements. One of these elements, E2, specifically interacts with the general transcription factor Sp1. Here we show that another member of the Sp family of factors, Sp3, can specifically interact with E2 whereas two other members, Sp2 and Sp4, cannot. Co-transfection experiments indicate that Sp3 can transactivate a beta 4 promoter/reporter gene construct and, furthermore, that Sp1 and Sp3 can transactivate the beta 4 reporter construct synergistically. The transactivation is dependent upon an intact E2 and may involve direct interactions between Sp1 and Sp3.	UNIV TEXAS, HLTH SCI CTR, INST BIOTECHNOL, DEPT MOL MED, SAN ANTONIO, TX 78245 USA	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030243] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS030243, NS30243] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMADOR M, 1995, J NEUROSCI, V15, P4525; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1996, J BIOL CHEM, V271, P32842, DOI 10.1074/jbc.271.51.32842; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Boyd RT, 1996, NEUROSCI LETT, V208, P73, DOI 10.1016/0304-3940(96)12561-1; BOYD RT, 1994, J NEUROBIOL, V25, P960, DOI 10.1002/neu.480250806; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAUBAS P, 1993, P NATL ACAD SCI USA, V90, P2237, DOI 10.1073/pnas.90.6.2237; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M; HEINEMANN S, 1990, PROG BRAIN RES, V86, P195; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; HESS N, 1994, FEBS LETT, V346, P135, DOI 10.1016/0014-5793(94)00443-9; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HU MJ, 1995, J BIOL CHEM, V270, P4497, DOI 10.1074/jbc.270.19.11619; HU MJ, 1994, J NEUROCHEM, V62, P392; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MATTER JM, 1995, J NEUROSCI, V15, P5919; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; McDonough J, 1997, J NEUROSCI, V17, P2273; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; Milton NGN, 1996, BIOCHEM J, V317, P419, DOI 10.1042/bj3170419; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; Parks CL, 1996, J BIOL CHEM, V271, P4417; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PATRICK J, 1993, PROG BRAIN RES, V98, P113; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; Yang XD, 1997, J NEUROBIOL, V32, P311, DOI 10.1002/(SICI)1097-4695(199703)32:3<311::AID-NEU5>3.0.CO;2-A; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	56	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25976	25982		10.1074/jbc.272.41.25976	http://dx.doi.org/10.1074/jbc.272.41.25976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325332	hybrid			2022-12-27	WOS:A1997YA35800087
J	Dragani, B; Stenberg, G; Melino, S; Petruzzelli, R; Mannervik, B; Aceto, A				Dragani, B; Stenberg, G; Melino, S; Petruzzelli, R; Mannervik, B; Aceto, A			The conserved N-capping box in the hydrophobic core of glutathione S-transferase P1-1 is essential for refolding - Identification of a buried and conserved hydrogen bond important for protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL STRUCTURE; ISOENZYMES; RESOLUTION; RESIDUES; COMPLEX; SIGNALS; MOTIF; ROLES; DNA	The second domain of cytosolic glutathione S-transferases (GSTs) contains a strictly conserved N-capping box motif (Ser/Thr-Xaa-Xaa-Asp) at the beginning of alpha(6)-helix in the hydrophobic core of the molecule. Considering the specific function attributed to capping box residues in the helix nucleation, we decided to investigate, by site-directed mutagenesis, the role that this moth could have in the folding and stability of human GSTP1-1. Both capping box mutants, S150A and D153A, were significantly more thermolabile than wild-type GSTP1-1, indicating that the local destabilization of the alpha(6)-helix determined by a single capping residue mutation affects the overall stability of the protein. The results also show that, in addition to capping interactions, an important role in the stability of the final structure of the protein is played by a buried and conserved hydrogen bond formed between the side chain of Asp-153 and the amide NH of Ile-144 located in the long loop preceding alpha(6)-helix. Reactivation experiments in vitro indicate that the N-capping box is essential for refolding of the denatured protein at a physiological temperature. The results suggest that during folding this buried and conserved moth, making a definite set of native-like contacts, determines the formation of a specific folding nucleus that probably represents a transition state of the folding process.	UNIV G DANNUNZIO,DIPARTIMENTO SCI BIOMED,I-66100 CHIETI,ITALY; UNIV UPPSALA,CTR BIOMED,DEPT BIOCHEM,S-75123 UPPSALA,SWEDEN	G d'Annunzio University of Chieti-Pescara; Uppsala University				MELINO, SONIA/0000-0001-7694-5279				ACETO A, 1990, CARCINOGENESIS, V11, P2267, DOI 10.1093/carcin/11.12.2267; Aceto A, 1997, BIOCHEM J, V322, P229, DOI 10.1042/bj3220229; ACETO A, 1992, BIOCHEM J, V285, P241, DOI 10.1042/bj2850241; AWASTHI YC, 1985, COMP BIOCH PHYSL, V828, P17; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; DASGUPTA S, 1993, INT J PEPT PROT RES, V41, P499; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1988, GLUTATHIONE CONJUGAT, P316; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; Ketterer B., 1988, P73; KOLM RH, 1995, PROTEIN EXPRES PURIF, V6, P265, DOI 10.1006/prep.1995.1034; KONG KH, 1993, PROTEIN ENG, V6, P93, DOI 10.1093/protein/6.1.93; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; LAMOUREUX GL, 1989, GLUTATHIONE CHEM B B, P153; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MUNOZ V, 1995, STRUCT BOL, V5, P380; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; Ptitsyn OB, 1996, FASEB J, V10, P3, DOI 10.1096/fasebj.10.1.8566544; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; WANG RW, 1992, J BIOL CHEM, V267, P19866; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	30	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25518	25523		10.1074/jbc.272.41.25518	http://dx.doi.org/10.1074/jbc.272.41.25518			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325266	hybrid			2022-12-27	WOS:A1997YA35800021
J	Kominato, Y; Tsuchiya, T; Hata, N; Takizawa, H; Yamamoto, F				Kominato, Y; Tsuchiya, T; Hata, N; Takizawa, H; Yamamoto, F			Transcription of human ABO histo-blood group genes is dependent upon binding of transcription factor CBF/NF-Y to minisatellite sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES SUSCEPTIBILITY LOCUS; HRAS1 MINISATELLITE; DNA-REPLICATION; INSULIN GENE; EXPRESSION; ACTIVATION; ANTIGENS; PROMOTER; PROTEINS; LUNG	We have studied the transcriptional regulatory mechanism of the human histo-blood group ABO genes, and identified DNA cis-elements and trans-activating protein that control the expression of these genes which are important in blood transfusion and organ transplantation. We introduced the 5'-upstream sequence of ABO genes into the promoterless reporter vector and characterized the promoter activity of deletion constructs using transient transfection assays with gastric cancer cell line KATO III cells. The sequence just upstream of the transcription start site (cap site), and an enhancer element, which is located further upstream (between -3899 and -3618 base pairs (bp) from the transcription initiation site) and contains 4 tandem copies of a 43-bp repeat unit, were shown in gastric cancer cells to be responsible for the transcriptional activity of the ABO genes. DNA binding studies have demonstrated that a transcription factor, CBF/NF-Y, bound to the 43-bp repeat unit in the minisatellite. Functional importance of these CBF/NF-Y-binding sites in enhancer activity was confirmed by transfection experiments using reporter plasmids with mutated binding sites. Thus, transcriptional regulation of the human ABO genes is dependent upon binding of CBF/NF-Y to the minisatellite.	TOKYO MED & DENT UNIV, MED RES INST, TOKYO 113, JAPAN; BURNHAM INST, LA JOLLA, CA 92037 USA	Tokyo Medical & Dental University (TMDU); Sanford Burnham Prebys Medical Discovery Institute	Kominato, Y (corresponding author), TOYAMA MED & PHARMACEUT UNIV, FAC MED, DEPT LEGAL MED, 2630 SUGITANI, TOYAMA 93001, JAPAN.		Yamamoto, Fumiichiro/F-1478-2016	Yamamoto, Fumiichiro/0000-0001-9690-7034				BEVILACQUA MA, 1995, BIOCHEM J, V311, P769, DOI 10.1042/bj3110769; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COHEN JB, 1987, J CELL PHYSIOL, P75; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DABELSTEEN E, 1982, J INVEST DERMATOL, V79, P3, DOI 10.1111/1523-1747.ep12510411; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GINSBURG V, 1972, ADV ENZYMOL RAMB, V36, P131; GREEN M, 1993, GENOMICS, V17, P429, DOI 10.1006/geno.1993.1343; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KABAT EA, 1973, ADV CHEM SER, P334; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; Landsteiner K., 1900, ZBL BAKT, V27, P357; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; MADDOX J, 1994, NATURE, V368, P685, DOI 10.1038/368685a0; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Mandel JL, 1997, NATURE, V386, P767, DOI 10.1038/386767a0; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MATSUMOTO H, 1993, CANCER-AM CANCER SOC, V72, P75, DOI 10.1002/1097-0142(19930701)72:1<75::AID-CNCR2820720116>3.0.CO;2-Z; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; MORGAN WTJ, 1969, BRIT MED BULL, V25, P30, DOI 10.1093/oxfordjournals.bmb.a070666; Orntoft TF, 1996, CANCER RES, V56, P1031; OWERBACH D, 1993, DIABETES, V42, P1708, DOI 10.2337/diabetes.42.12.1708; ROY B, 1995, MOL CELL BIOL, V15, P2263; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SPANDIDOS DA, 1987, FEBS LETT, V218, P41, DOI 10.1016/0014-5793(87)81014-1; TEUMER J, 1994, KERATINOCYTE HDB, P235; TREPICCHIO WL, 1992, NUCLEIC ACIDS RES, V20, P2427, DOI 10.1093/nar/20.10.2427; TREPICCHIO WL, 1993, NUCLEIC ACIDS RES, V21, P977, DOI 10.1093/nar/21.4.977; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51	41	64	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25890	25898		10.1074/jbc.272.41.25890	http://dx.doi.org/10.1074/jbc.272.41.25890			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325321	hybrid			2022-12-27	WOS:A1997YA35800076
J	Wilkinson, CRM; Wallace, M; Seeger, M; Dubiel, W; Gordon, C				Wilkinson, CRM; Wallace, M; Seeger, M; Dubiel, W; Gordon, C			Mts4, a non-ATPase subunit of the 26 S protease in fission yeast is essential for mitosis and interacts directly with the ATPase subunit Mts2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; REGULATORY SUBUNIT; BINDING-PROTEIN; CDNA CLONING; THERMOPLASMA-ACIDOPHILUM; ANAPHASE TRANSITION; FUNCTIONAL-ANALYSIS	We have isolated a fission yeast gene, mts4(+), by complementation of a temperature-sensitive mutation and show that it encodes subunit 2 (S2) of the 19 S regulatory complex of the 26 S protease. mts4(+) is an essential gene, and we show that loss of this subunit causes cells to arrest in metaphase, illustrating the importance of S2 for mitosis. The Mts4 protein is 48% identical to S2 of the human 26 S protease, and the lethal phenotype of the null mts4 allele can be rescued by the human cDNA encoding S2. We provide genetic and physical evidence to suggest that the Mts4 protein interacts with the product of the mts2(+) gene, an ATPase which has previously been shown to be subunit 4 of the 26 S protease.	HUMBOLDT UNIV BERLIN, FAC MED, INST BIOCHEM, D-10117 BERLIN, GERMANY	Humboldt University of Berlin	Wilkinson, CRM (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.			Dubiel, Wolfgang/0000-0002-3393-0701				BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARINI DJ, 1995, MOL CELL BIOL, V15, P6311; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; Fujiwara T, 1996, FEBS LETT, V387, P184, DOI 10.1016/0014-5793(96)00489-9; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAGAN IM, 1988, J CELL SCI, V89, P343; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V14, P2620; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SAZER S, 1990, J CELL SCI, V97, P509; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; TODA T, 1981, J CELL SCI, V52, P271; Tsurumi C, 1996, EUR J BIOCHEM, V239, P912, DOI 10.1111/j.1432-1033.1996.0912u.x; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WOODS A, 1989, J CELL SCI, V93, P491; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Yokota K, 1996, MOL BIOL CELL, V7, P853, DOI 10.1091/mbc.7.6.853; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	59	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25768	25777		10.1074/jbc.272.41.25768	http://dx.doi.org/10.1074/jbc.272.41.25768			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325304	hybrid			2022-12-27	WOS:A1997YA35800059
J	Feyzi, E; Trybala, E; Bergstrom, T; Lindahl, U; Spillmann, D				Feyzi, E; Trybala, E; Bergstrom, T; Lindahl, U; Spillmann, D			Structural requirement of heparan sulfate for interaction with herpes simplex virus type 1 virions and isolated glycoprotein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; BINDING; CELLS; OLIGOSACCHARIDES; DEPOLYMERIZATION; PROTEOGLYCANS; INFECTIONS; ADSORPTION; SEQUENCE	Cell surface heparan sulfates mediate primary attach ment of herpes simplex virus type 1, the first step in virus invasion of the cells, Removal of the host cell hepa ran sulfate results in a significantly diminished susceptibility of the cell to virus infection. On the virus envelope, glycoprotein C has been identified as the major binding site for heparan sulfate in the primary attachment of the virus to host cells, Using selectively desulfated heparins and metabolically labeled host cell heparan sulfate, we have analyzed the structural requirements of heparan sulfate to provide binding sites for glycoprotein C and the whole virus, Employing glycoprotein C affinity chromatography and a virus binding assay, we subfractionated oligosaccharides derived from heparan sulfate and partially desulfated heparin into selectively bound and unbound pools, These were chemically depolymerized and analyzed at the disaccharide level, The shortest glycoprotein C-binding fragment consisted of 10-12 monosaccharide units containing at least one 2-O- and one 6-O-sulfate group that have to be localized in a sequence-specific way, based on the finding that bound and unbound HS fragments do not differ in charge or composition, The binding sequence is found within N-sulfated blocks of heparan sulfate, although several N-acetyl groups can be tolerated within the minimal binding sequence. These minimal requirements for herpes simplex virus type 1 binding to heparan sulfate are clearly distinct from other identified protein binding sites.	UNIV UPPSALA, CTR BIOMED, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN; GOTHENBURG UNIV, DEPT CLIN VIROL, S-41346 GOTHENBURG, SWEDEN	Uppsala University; University of Gothenburg				Trybala, Edward/0000-0003-2384-2123; Bergstrom, Tomas/0000-0002-9257-6757				BERGSTROM T, 1992, MOL CELL PROBE, V6, P41, DOI 10.1016/0890-8508(92)90070-E; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; DANISHEF.V, 1965, BIOCHIM BIOPHYS ACTA, V101, P37; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211; HEROLD BC, 1995, VIROLOGY, V206, P1108, DOI 10.1006/viro.1995.1034; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; HOLLAND TC, 1983, J VIROL, V45, P672, DOI 10.1128/JVI.45.2.672-682.1983; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; OLOFSSON S, 1983, J GEN VIROL, V64, P2735, DOI 10.1099/0022-1317-64-12-2735; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; PEJLER G, 1987, J BIOL CHEM, V262, P11413; Rostand KS, 1997, INFECT IMMUN, V65, P1; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; TRYBALA E, 1994, J GEN VIROL, V75, P743, DOI 10.1099/0022-1317-75-4-743; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989	35	109	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24850	24857		10.1074/jbc.272.40.24850	http://dx.doi.org/10.1074/jbc.272.40.24850			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312084	hybrid			2022-12-27	WOS:A1997XY97000023
J	Qin, WN; Khuchua, Z; Klein, SC; Strauss, AW				Qin, WN; Khuchua, Z; Klein, SC; Strauss, AW			Elements regulating cardiomyocyte expression of the human sarcomeric mitochondrial creatine kinase gene in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC EXPRESSION; BOX TRANSCRIPTION FACTORS; ENHANCER-BINDING-FACTOR; RAT MYOCARDIAL-CELLS; LOOP-HELIX PROTEINS; CARDIAC ACTIN GENE; SKELETAL-MUSCLE; DEVELOPING HEART; DROSOPHILA; PROMOTER	Sarcomeric mitochondrial creatine kinase (sMtCK) is one component of a multiprotein, high energy channeling complex consisting of porin, mitochondrial creatine kinase, and adenine nucleotide translocase. To study the transcriptional mechanisms specifying sMtCK gene expression to the heart, transgenic mice were created carrying the 5'-flanking sequences of the human sMtCK gene ligated upstream of the human growth hormone (hGH) reporter gene, RNA blot hybridization demonstrated that the human sMtCK sequence, -485 to +6 base pair (bp), did not activate reporter gene expression to a detectable level, However, the human sMtCK se quence, -921 to +6 bp, expressed the hGH reporter gene at a high level in heart and skeletal muscle and at a very low level in esophagus and kidney, and it did not express the hGH gene in other organs tested (brain, lung, liver, spleen, bladder, uterus, and stomach). In situ hybridization revealed that reporter gene transcription was specified to cardiac and skeletal myocytes, recapitulating precisely the expression pattern of the endogenous gene, Sequence analysis identified several consensus binding sites between -921 and -757 bp, including four GATT motifs, one E box, and one MEF2 site, Further analysis of a third transgenic mouse strain demonstrated that the human sMtCK sequence, -757 to +6 bp, did not direct detectable expression of the hGH reporter gene, We conclude that this 160-bp genomic sequence, from -921 to -757 bp, is necessary in specifying expression of the human sMtCK gene to the oxidative and highly metabolically active heart tissue.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Khuchua, Zaza/J-6536-2016	Khuchua, Zaza/0000-0003-3582-5670	NHLBI NIH HHS [HL52350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAHIC M, 1992, IN SITU HYBRIDIZATIO; CHIEN KR, 1985, J CLIN INVEST, V75, P1770, DOI 10.1172/JCI111889; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; DEVLIN BH, 1989, J BIOL CHEM, V264, P13896; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P1; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KELLEY C, 1993, DEVELOPMENT, V118, P817; KLEIN SC, 1991, J BIOL CHEM, V266, P18058; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS GE, 1991, DEVELOPMENT, V113, P1017; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Ranganayakulu G, 1996, DEV BIOL, V176, P143, DOI 10.1006/dbio.1996.9987; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; TAMURA S, 1993, P NATL ACAD SCI USA, V90, P10876, DOI 10.1073/pnas.90.22.10876; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WELLER PA, 1986, MOL CELL BIOL, V6, P4539, DOI 10.1128/MCB.6.12.4539; WU XS, 1995, DEV BIOL, V169, P619, DOI 10.1006/dbio.1995.1174; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	50	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25210	25216		10.1074/jbc.272.40.25210	http://dx.doi.org/10.1074/jbc.272.40.25210			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312135	hybrid			2022-12-27	WOS:A1997XY97000074
J	Small, FJ; Ensign, SA				Small, FJ; Ensign, SA			Alkene monooxygenase from Xanthobacter strain Py2 - Purification and characterization of a four-component system central to the bacterial metabolism of aliphatic alkenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS BATH; SOLUBLE METHANE MONOOXYGENASE; IRON-SULFUR PROTEIN; MONO-OXYGENASE; NAPHTHALENE DIOXYGENASE; PSEUDOMONAS-OLEOVORANS; PROPENE MONOOXYGENASE; HYDROXYLASE COMPONENT; CHLORINATED ALKENES; REDUCTASE COMPONENT	Alkene monooxygenase from Xanthobacter strain Py2 is an inducible enzyme that catalyzes the O-2- and NADH-dependent epoxidation of short chain (C-2 to C-6) alkenes to their corresponding epoxides as the initial step in the utilization of aliphatic alkenes as carbon and energy sources, In the present study, alkene monooxygenase has been resolved from the soluble fraction of cell-free extracts into four components, each of which has been purified to homogeneity, that are obligately required for alkene epoxidation activity. The four required components are 1) a monomeric 35.5-kDa protein containing 1 mol of FAD and a probable 2Fe-2S center; 2) a 13.3-kDa ferredoxin containing a Rieske-type 2Fe-2S cluster; 3) an 11-kDa monomeric protein that contains no detectable cofactors; and 4) a 212-kDa alpha(2) beta(2) gamma(2) multimeric protein containing four atoms of nonheme iron, The 35.5-kDa protein has been characterized as an NADH reductase, The physiological electron acceptor for the reductase was the Rieske-type ferredoxin, which is proposed to be an intermediate electron carrier between the reductase and terminal catalytic component of the system, The 212-kDa protein was specifically inactivated in cell-free extracts by the mechanism-based inactivator propyne, suggesting that it is the catalytic component and contains the active site(s) for O-2 activation and alkene epoxidation. The subunit structure and metal analysis of this component suggest that it contains two diiron centers, one for each alpha beta gamma protomeric unit, No specific enzymatic activities could be assigned for the 11-kDa protein, but this component was obligately required for steady state alkene epoxidation, The alkene monooxygenase components were expressed during growth of Xanthobacter Py2 on aliphatic alkenes or epoxides and repressed during growth on other carbon sources, The electron transfer components of alkene monooxygenase were highly specific: other reductase activities present in Xanthobacter were incapable of transferring electrons to the Rieske-type ferredoxin or substituting for the reductase in the alkene monooxygenase complex, Likewise, other bacterial and plant ferredoxins were unable to substitute for the Rieske-type ferredoxin in mediating electron transfer to the oxygenase, The biochemical properties of alkene monooxygenase described in this study suggest that this enzyme combines elements of both the well-characterized aromatic dioxygenase (two-component electron transfer scheme) and methane monooxygenase (small regulatory protein and diiron oxygenase) multicomponent enzyme systems.	UTAH STATE UNIV,DEPT CHEM & BIOCHEM,LOGAN,UT 84322	Utah System of Higher Education; Utah State University					NIGMS NIH HHS [GM51805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051805, R01GM051805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JR, 1996, J BACTERIOL, V178, P1469, DOI 10.1128/jb.178.5.1469-1472.1996; BATIE CJ, 1987, J BIOL CHEM, V262, P1510; CHROMY V, 1974, CLIN CHEM, V20, P1362; COLBY J, 1979, BIOCHEM J, V177, P903, DOI 10.1042/bj1770903; COLBY J, 1977, BIOCHEM J, V165, P395, DOI 10.1042/bj1650395; DESMET MJ, 1983, ENZYME MICROB TECHNO, V5, P352; ENSIGN SA, 1992, APPL ENVIRON MICROB, V58, P3038, DOI 10.1128/AEM.58.9.3038-3046.1992; Ensign SA, 1996, APPL ENVIRON MICROB, V62, P61, DOI 10.1128/AEM.62.1.61-66.1996; FEE JA, 1984, J BIOL CHEM, V259, P124; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1989, J BIOL CHEM, V264, P10023; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; GEARY PJ, 1984, BIOCHEM J, V217, P667, DOI 10.1042/bj2170667; GREEN J, 1985, J BIOL CHEM, V260, P5795; HADDOCK JD, 1995, J BACTERIOL, V177, P5834, DOI 10.1128/jb.177.20.5834-5839.1995; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HAIGLER BE, 1990, J BACTERIOL, V172, P465, DOI 10.1128/JB.172.1.465-468.1990; HARTMANS S, 1991, J GEN MICROBIOL, V137, P2555, DOI 10.1099/00221287-137-11-2555; HARTMANS S, 1989, FEMS MICROBIOL LETT, V63, P235, DOI 10.1016/0168-6445(89)90034-X; HYMAN MR, 1985, BIOCHEM J, V227, P719, DOI 10.1042/bj2270719; IWASAKI T, 1995, J BACTERIOL, V177, P2576, DOI 10.1128/jb.177.9.2576-2582.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Latimer MT, 1996, J BIOL CHEM, V271, P24023, DOI 10.1074/jbc.271.39.24023; Link TA, 1996, BIOCHEMISTRY-US, V35, P7546, DOI 10.1021/bi960004+; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P358; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; MAY SW, 1973, J BIOL CHEM, V248, P1725; MCKENNA EJ, 1970, J BIOL CHEM, V245, P3882; MIURA A, 1995, BIOSCI BIOTECH BIOCH, V59, P853, DOI 10.1271/bbb.59.853; MURRELL JC, 1990, METHOD ENZYMOL, V188, P27; NEWMAN LM, 1995, BIOCHEMISTRY-US, V34, P14066, DOI 10.1021/bi00043a012; Pikus JD, 1996, BIOCHEMISTRY-US, V35, P9106, DOI 10.1021/bi960456m; PRIOR SD, 1985, FEMS MICROBIOL LETT, V29, P105; ROMANOV V, 1994, J BACTERIOL, V176, P3368, DOI 10.1128/jb.176.11.3368-3374.1994; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P9424, DOI 10.1021/bi9608572; SMALL FJ, 1995, J BACTERIOL, V177, P6170, DOI 10.1128/jb.177.21.6170-6175.1995; SMALL FJ, 1995, APPL ENVIRON MICROB, V61, P1507, DOI 10.1128/AEM.61.4.1507-1513.1995; SUBRAMANIAN V, 1985, J BIOL CHEM, V260, P2355; VANGINKEL CG, 1987, APPL ENVIRON MICROB, V53, P2903, DOI 10.1128/AEM.53.12.2903-2907.1987; VANGINKEL CG, 1986, ARCH MICROBIOL, V145, P403, DOI 10.1007/BF00470879; VESTAL JR, 1969, J BACTERIOL, V99, P216, DOI 10.1128/JB.99.1.216-221.1969; WEBER FJ, 1992, J BACTERIOL, V174, P3275, DOI 10.1128/jb.174.10.3275-3281.1992; WEIJERS CAGM, 1988, ENZYME MICROB TECH, V10, P214, DOI 10.1016/0141-0229(88)90069-5; WOODLAND MP, 1995, ARCH MICROBIOL, V163, P231; WOODS NR, 1989, J GEN MICROBIOL, V135, P2335; Zhou NY, 1996, APPL MICROBIOL BIOT, V44, P582, DOI 10.1007/BF00172489	46	100	110	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24913	24920		10.1074/jbc.272.40.24913	http://dx.doi.org/10.1074/jbc.272.40.24913			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312093	hybrid			2022-12-27	WOS:A1997XY97000032
J	Yegneswaran, S; Wood, GM; Esmon, CT; Johnson, AE				Yegneswaran, S; Wood, GM; Esmon, CT; Johnson, AE			Protein S alters the active site location of activated protein C above the membrane surface - A fluorescence resonance energy transfer study of topography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VA INACTIVATION; COAGULATION FACTOR VIIA; PEPTIDE-BOND CLEAVAGES; BOUND IMMUNOGLOBULIN-E; BLOOD-COAGULATION; FACTOR-XA; PROTHROMBINASE COMPLEX; PHOSPHOLIPID SURFACE; TISSUE-FACTOR; FACTOR-IXA	The location of the active site of membrane-bound activated protein C (APC) relative to the phospholipid surface was determined both in the presence and absence of its cofactor, protein S, using fluorescence resonance energy transfer (FRET). APC was chemically modified to create the FRET donor species, Fl-FPR-APC, with a fluorescein dye (Fl) covalently attached to the active site via a D-Phe-Pro-Arg (FPR) tether and located in the active site near S-4. FRET was observed when Fl-FPR-APC was titrated in the presence of Ca2+ ions with phosphatidylcholine/phosphatidylserine (4:1) vesicles containing the FRET acceptor, octadecylrhodamine (OR). Assuming a random orientation of transition dipoles (kappa(2) = 2/3), the average distance of closest approach between the fluorescein in the active site of the membrane-bound APC and the OR at the membrane surface is 94 Angstrom. The same calcium-dependent distance was obtained for both small and large unilamellar vesicles and for vesicles that contained phosphatidylethanolamine. The active site of membrane-bound APC is therefore located far above the phospholipid surface. Upon addition of protein S, the efficiency of Fl-FPR-APC to OR energy transfer increased due to a protein S-dependent rotational and/or translational movement of the APC protease domain relative to the surface. If this movement were solely translational, then the average height of the fluorescein in the membrane-bound APC protein S complex would be 84 Angstrom above the surface. The extent of Fl-FPR-APC to OR energy transfer was unaltered by the addition of thrombin-inactivated protein S, The protein S effect was also specific for APC, since the addition of protein S to similarly-labeled derivatives of factor Xa, factor Ma, or factor VIIa did not alter the locations of their active sites, This direct measurement demonstrates that the binding of the protein S cofactor to its cognate enzyme elicits a relocation of the active site of APC relative to the membrane surface and thereby provides a structural explanation for the recently observed protein S-dependent change in the site of factor Va cleavage by APC.	TEXAS A&M UNIV, COLL MED, HLTH SCI CTR, DEPT MED BIOCHEM & GENET, COLLEGE STN, TX 77843 USA; UNIV WISCONSIN PARKSIDE, DEPT CHEM, KENOSHA, WI 53141 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT PATHOL, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, OKLAHOMA CITY, OK 73190 USA; HOWARD HUGHES MED INST, OKLAHOMA CITY, OK 73104 USA; TEXAS A&M UNIV, DEPT CHEM, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Wisconsin System; University of Wisconsin Parkside; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station			Johnson, Arthur E/G-3457-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029807, R37HL030340, R01HL032934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 29807, R01 HL 32934, R37 HL 30340] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BAIRD B, 1985, BIOCHEMISTRY-US, V24, P6252, DOI 10.1021/bi00343a032; BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; Chen Q, 1997, BIOCHEMISTRY-US, V36, P4701, DOI 10.1021/bi961441r; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; DHARMAWARDANA K, 1994, THESIS U OKLAHOMA NO; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1977, CHEM BIOL THROMBIN, P403; ESMON CT, 1995, HEMATOLOGY BASIC PRI, V2, P1597; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; GUINTO ER, 1982, J BIOL CHEM, V257, P38; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; HEEB MJ, 1994, P NATL ACAD SCI USA, V91, P2728, DOI 10.1073/pnas.91.7.2728; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4893, DOI 10.1021/bi00667a022; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KURACHI K, 1976, BIOCHEMISTRY-US, V15, P368, DOI 10.1021/bi00647a020; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LU RL, 1989, J BIOL CHEM, V264, P12956; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; OWEN WG, 1974, J BIOL CHEM, V249, P594; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SUGO T, 1986, J BIOL CHEM, V261, P5116; TANS G, 1991, BLOOD, V77, P2641; THOMPSON AR, 1977, ARCH BIOCHEM BIOPHYS, V178, P356, DOI 10.1016/0003-9861(77)90204-1; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1984, J BIOL CHEM, V259, P335; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1992, P SOC EXP BIOL MED, V200, P285; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027; YE J, 1991, J BIOL CHEM, V266, P23016	70	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25013	25021		10.1074/jbc.272.40.25013	http://dx.doi.org/10.1074/jbc.272.40.25013			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312108	hybrid			2022-12-27	WOS:A1997XY97000047
J	Jezek, P; Costa, ADT; Vercesi, AE				Jezek, P; Costa, ADT; Vercesi, AE			Reconstituted plant uncoupling mitochondrial protein allows for proton translocation via fatty acid cycling mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE OXIDASE; 5-DOXYL-STEARIC ACID; EPR SPECTROSCOPY; ADP/ATP CARRIER; ANION CHANNEL; TRANSPORT; CONDUCTANCE; SENESCENCE; MEMBRANES; LIPOSOMES	Potato and tomato plant uncoupling mitochondrial protein (PUMP) was reconstituted into liposomes, and K+ or H+ fluxes associated with fatty acid (FA)-induced ion movement were measured using fluorescent ion indicators potassium binding benzofuraneisophthalate and 6-methoxy-N-(3-sulfopropyl)-quinolinium. We suggest that PUMP, like its mammalian counterpart, the uncoupling protein of brown adipose tissue mitochondria (Garlid, K. D., Orosz, D. E., Modriansky, M., Vassanelli, S,, and Jezek, P, (1996), J, Biol, Chem, 271, 2615-2702), allows for H+ translocation via a FA cycling mechanism. Reconstituted PUMP translocated anionic linoleic: and heptylbenzoic acids, undecanesulfonate, and hexanesulfonate, but not phenylvaleric and abscisic acids or Cl-. Transport was inhibited by ATP and GDP. Internal acidification of protein-free liposomes by linoleic or heptylbenzoic acid indicated that H+ translocation occurs by FA flip-flopping across the lipid bilayer. However, addition of valinomycin after FA-initiated GDP-sensitive H+ efflux solely in proteoliposomes, indicating that influx of anionic: FA via PUMP precedes a return of protonated FA carrying, H+, Phenylvaleric acid, unable to flip-flop, was without effect, Kinetics of FA and undecanesulfonate uniport; suggested the existence of an internal anion binding site. Exponential flux-voltage characteristics were also studied, We suggest that regulated uncoupling in plant mitochondria may be important during-fruit ripening senescence, and seed dormancy.	UNIV ESTADUAL CAMPINAS,FAC CIENCIAS MED,DEPT PATOL CLIN,SAO PAULO,BRAZIL	Universidade Estadual de Campinas	Jezek, P (corresponding author), ACAD SCI CZECH REPUBL,INST PHYSIOL,DEPT MEMBRANE TRANSPORT BIOPHYS,VIDENSKA 1083,DEPT 375,CR-14220 PRAGUE 4,CZECH REPUBLIC.		Costa, Alexandre Augusto da/HCJ-0140-2022; Jezek, Petr/B-9264-2012; Vercesi, Aníbal E/C-8767-2012	Costa, Alexandre Augusto da/0000-0001-7558-5435; Jezek, Petr/0000-0002-2720-9395; Dias Tavares Costa, Alexandre/0000-0001-8434-2152; Vercesi, Anibal Eugenio/0000-0001-6671-7125				ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; CRUZHERNANDEZ A, 1995, PLANTA, V197, P569, DOI 10.1007/BF00191562; DAY DA, 1995, J BIOENERG BIOMEMBR, V27, P379, DOI 10.1007/BF02110000; Eyring H., 1963, MODERN CHEM KINETICS; Freisleben HJ, 1995, CHEM PHYS LIPIDS, V78, P137, DOI 10.1016/0009-3084(95)02491-Z; GARDESTROM P, 1995, J BIOENERG BIOMEMBR, V27, P415, DOI 10.1007/BF02110004; GARLID KD, 1989, BIOCHIM BIOPHYS ACTA, V976, P109, DOI 10.1016/S0005-2728(89)80219-1; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P141; HULME AC, BIOCH FRUITS THEIR P; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; JEZEK P, 1990, J BIOL CHEM, V265, P19303; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; JEZEK P, 1990, J BIOL CHEM, V265, P10522; JEZEK P, 1995, FEBS LETT, V361, P303, DOI 10.1016/0014-5793(95)00201-J; JEZEK P, 1994, FEBS LETT, V343, P22, DOI 10.1016/0014-5793(94)80599-7; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KIDD F, 1925, 27 GREAT BRIT DEP SC; KRAB K, 1995, J BIOENERG BIOMEMBR, V27, P387, DOI 10.1007/BF02110001; KRISHNAMOORTHY G, 1984, BIOCHEMISTRY-US, V23, P1640, DOI 10.1021/bi00303a009; LAUGER P, 1970, BIOCHIM BIOPHYS ACTA, V211, P458, DOI 10.1016/0005-2736(70)90251-8; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; OROSZ DE, 1993, ANAL BIOCHEM, V150, P97; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; Ruzicka M, 1996, FEBS LETT, V382, P239, DOI 10.1016/0014-5793(96)00161-5; Schonfeld P, 1996, EUR J BIOCHEM, V240, P387, DOI 10.1111/j.1432-1033.1996.0387h.x; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SMART CM, 1994, NEW PHYTOL, V126, P419, DOI 10.1111/j.1469-8137.1994.tb04243.x; SOOLE KL, 1995, J BIOENERG BIOMEMBR, V27, P397, DOI 10.1007/BF02110002; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0	36	68	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24272	24278		10.1074/jbc.272.39.24272	http://dx.doi.org/10.1074/jbc.272.39.24272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305881	hybrid			2022-12-27	WOS:A1997XY51500032
J	Ji, ZS; Hadac, EM; Henne, RM; Patel, SA; Lybrand, TP; Miller, LJ				Ji, ZS; Hadac, EM; Henne, RM; Patel, SA; Lybrand, TP; Miller, LJ			Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTAGONIST BINDING DOMAINS; PROTEIN-COUPLED RECEPTORS; P NK-1 RECEPTOR; ADRENERGIC-RECEPTOR; AMINO-ACID; TRANSMEMBRANE DOMAIN; CCK RECEPTORS; SHORT PROBES; SUBSTANCE-P; B RECEPTOR	Mechanisms of ligand binding and activation of G protein-coupled receptors are particularly important, due to their ubiquitous expression and potential as drug targets, Molecular interactions between ligands and these receptors are best defined for small molecule ligands that bind within the transmembrane helices, Extracellular domains seem to be more important for peptide ligands, based largely on effects of receptor mutagenesis, where interference with binding or activity can reflect allosteric as well as direct effects, We now take the more direct approach of photoaffinity labeling the active site of the cholecystokinin (CCK) receptor, using a photolabile analogue of CCK having a blocked amino terminus, This probe, I-125-desaminotyrosyl-Gly-[Nle(28,31),pNO(2)-Phe(33)]CCK-(26-33), binds specifically, saturably, and with high affinity (K-i = 3.3 nM) and has full agonist activity, This makes likely its being sited in a natural position within the receptor, As substrate, we used CHO-CCK receptor cells overexpressing functional recombinant rat type A CCK receptor, Covalent labeling of the appropriate M-r = 85,000-95,000 plasma membrane glycoprotein with core of M-r = 42,000 was established by SDS-polyacrylamide gel electrophoresis and autoradiography, A single domain adjacent to transmembrane 1 was labeled, as established by cyanogen bromide cleavage and separation by gel and/or high pressure liquid chromatography, The site of interaction was further defined by additional proteolysis with trypsin, with purification of the labeled fragment, followed by manual Edman degradation and radiochemical sequencing, This demonstrated that Trp(39) was specifically labeled and likely resides proximate to the carboxyl-terminal pNO(2)-Phe(33) residue of the probe. A model of this ligand-bound receptor has been constructed and will be used to plan future experiments to refine our understanding of this interaction.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905; UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195	Mayo Clinic; University of Washington; University of Washington Seattle					NIDDK NIH HHS [DK32878] Funding Source: Medline; NINDS NIH HHS [NS33290] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033290] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BLUML K, 1994, J BIOL CHEM, V269, P18870; BODANSZKY M, 1980, INT J PEPT PROT RES, V16, P402; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; FONG TM, 1992, J BIOL CHEM, V267, P25664; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUANG SC, 1989, PEPTIDES, V10, P785, DOI 10.1016/0196-9781(89)90114-9; JAGERSCHMIDT A, 1995, MOL PHARMACOL, V48, P783; JI H, 1994, J BIOL CHEM, V269, P16533; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KENNEDY K, 1995, BIOCHEM BIOPH RES CO, V213, P845, DOI 10.1006/bbrc.1995.2206; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; KLUEPPELBERG UG, 1989, BIOCHEMISTRY-US, V28, P3463, DOI 10.1021/bi00434a047; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; Kontoyianni M, 1996, J MED CHEM, V39, P4406, DOI 10.1021/jm960241a; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABBEJULLIE C, 1995, MOL PHARMACOL, V47, P1050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MAMMI S, 1986, INT J PEPT PROT RES, V27, P145; MANTAMADIOTIS T, 1994, BIOCHEM BIOPH RES CO, V201, P1382, DOI 10.1006/bbrc.1994.1856; MORLEY JS, 1968, PROC R SOC SER B-BIO, V170, P97, DOI 10.1098/rspb.1968.0028; MUTT V, 1980, GASTROINTESTINAL HOR, P169; ONDETTI MA, 1970, AM J DIG DIS, V15, P149, DOI 10.1007/BF02235646; PEARLMAN DA, 1991, AMBER VERSION 4 1; PEARSON RK, 1987, BIOCHEM BIOPH RES CO, V147, P346, DOI 10.1016/S0006-291X(87)80128-6; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; PEARSON RK, 1987, J BIOL CHEM, V262, P869; POWERS SP, 1991, BIOCHEMISTRY-US, V30, P676, DOI 10.1021/bi00217a013; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; POWERS SP, 1988, J BIOL CHEM, V263, P5295; ROSENZWEIG SA, 1983, J CELL BIOL, V96, P1288, DOI 10.1083/jcb.96.5.1288; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Silvente-Poirot S, 1996, J BIOL CHEM, V271, P14698, DOI 10.1074/jbc.271.25.14698; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; SWANSON E, 1995, PSSHOW SILICON GRAPH; TAKASUKA T, 1994, J BIOL CHEM, V269, P7509; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VINAYEK R, 1987, AM J PHYSIOL, V252, pG178, DOI 10.1152/ajpgi.1987.252.2.G178; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1988, J BIOL CHEM, V263, P7925	50	103	105	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24393	24401		10.1074/jbc.272.39.24393	http://dx.doi.org/10.1074/jbc.272.39.24393			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305898	hybrid			2022-12-27	WOS:A1997XY51500049
J	Accili, EA; Kiehn, J; Yang, Q; Wang, ZG; Brown, AM; Wible, BA				Accili, EA; Kiehn, J; Yang, Q; Wang, ZG; Brown, AM; Wible, BA			Separable Kv beta subunit domains alter expression and gating of potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; ALPHA-SUBUNITS; INACTIVATION; BINDING; BRAIN; BLOCK	Kv beta subunits have been shown to affect kinetic properties of voltage-gated K+ channel Kv1 alpha subunits and increase the number of cell surface dendrotoxin-binding sites when coexpressed with Kv1.2. Here, we show that Kv beta 1.2 alters both current expression and gating of Kv alpha 1 channels and that each effect is mediated by a distinct Kv beta 1.2 domain. The Kv beta 1.2 N terminus or Kv alpha 1-blocking domain introduced steady state current block, an apparent negative shift in steady state activation, and a slowing of deactivation along with a dramatic reduction in single channel open probability, N-terminal deletions of Kv beta 1.2 no longer altered channel kinetics but promoted dramatic increases in Kv1.2 current. The conserved Kv beta 1 C terminus or Kv alpha 1 expression domain alone was sufficient to increase the number of functional channels. The same effect was observed with the normally noninactivating subunit, Kv beta 2. By contrast, Kv1.5 currents were reduced when coexpressed with either the Kv beta 1 C terminus or Kv beta 2, indicating that the Kv alpha 1 expression domain has Kv alpha 1 isoform-specific effects. Our results demonstrate that Kv beta subunits consist of two domains that are separable on the basis of both primary structure and functional modulation of voltage-gated K+ channels.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOCHEM,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,RAMMELKAMP CTR RES,CLEVELAND,OH 44109	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; MetroHealth System			Wang, Zhiguo/GRS-4339-2022	Wang, Zhiguo/0000-0002-0811-2045	NHLBI NIH HHS [HL-36930, HL55404] Funding Source: Medline; NINDS NIH HHS [NS-23877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930, R01HL055404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; DeBiasi M, 1997, AM J PHYSIOL-HEART C, V272, pH2932, DOI 10.1152/ajpheart.1997.272.6.H2932; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X; Wang ZG, 1996, J BIOL CHEM, V271, P28311, DOI 10.1074/jbc.271.45.28311; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	21	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25824	25831		10.1074/jbc.272.41.25824	http://dx.doi.org/10.1074/jbc.272.41.25824			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325312	hybrid			2022-12-27	WOS:A1997YA35800067
J	Magalon, A; LemesleMeunier, D; Rothery, RA; Frixon, C; Weiner, JH; Blasco, F				Magalon, A; LemesleMeunier, D; Rothery, RA; Frixon, C; Weiner, JH; Blasco, F			Heme axial ligation by the highly conserved His residues in helix II of cytochrome b (NarI) of Escherichia coli nitrate reductase A (NarGHI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; BACILLUS-SUBTILIS SUCCINATE; SITE-DIRECTED MUTAGENESIS; TERMINAL OXIDASE COMPLEX; BETA-SUBUNIT; UBIQUINONE OXIDOREDUCTASE; PARACOCCUS-DENITRIFICANS; EPR CHARACTERIZATION; ALPHA-SUBUNIT; SEQUENCE	Optical spectroscopy and EPR studies confirm the existence of two b-type hemes in the NarI subunit (cytochrome b(nr)) of the membrane-bound nitrate reductase (NarGHI) of Escherichia coli. Replacement of His-56 by Arg and His-66 by Tyr results in the loss of the high-potential heme and of the low-potential heme, respectively. These data support the assignment of the axial ligands to the low-potential heme (His-66 and His-187) and to the high-potential heme (His-56 and His-205). This pairing is consistent with the model proposed for NarI of the nitrate reductase of Thiosphaera pantotropha (Berks, B. C., Page, M. D., Richardson, D. J., Reilly, A., Cavill, A., Outen, F., and Ferguson, S. J. (1995) Mol. Microbiol. 15, 319-331) in which the two bis-histidine ligated hemes are coordinated by conserved His residues of helix II and V. EPR and optical studies suggest that the low-potential heme (E-m,E-7 = +17 mV) and the high-potential heme (E-m,E-7 = +122 mV) are located near the periplasmic side and the cytoplasmic side of the membrane, respectively. Moreover, correct insertion of both hemes into NarI requires anchoring to NarGH.	CNRS,IBSM,CHIM BACTERIENNE LAB,F-13402 MARSEILLE 8,FRANCE; CNRS,IBSM,LAB BIOENERGET & INGN PROT,F-13402 MARSEILLE,FRANCE; UNIV ALBERTA,DEPT BIOCHEM,MRC,GRP MOL BIOL MEMBRANES,EDMONTON,AB T6G 2H7,CANADA	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Alberta				Magalon, Axel/0000-0002-3375-738X; Rothery, Richard/0000-0003-3265-1783				AUGIER V, 1993, BIOCHEMISTRY-US, V32, P2013, DOI 10.1021/bi00059a018; BALLARD AL, 1988, EUR J BIOCHEM, V174, P207, DOI 10.1111/j.1432-1033.1988.tb14083.x; Banci L, 1996, J BIOL INORG CHEM, V1, P364, DOI 10.1007/s007750050066; BERKS BC, 1995, MOL MICROBIOL, V15, P319, DOI 10.1111/j.1365-2958.1995.tb02246.x; BLASCO F, 1992, MOL MICROBIOL, V6, P209, DOI 10.1111/j.1365-2958.1992.tb02002.x; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; Buc J, 1995, EUR J BIOCHEM, V234, P766, DOI 10.1111/j.1432-1033.1995.766_a.x; CAMMACK R, 1990, BIOCHEMISTRY-US, V29, P8410, DOI 10.1021/bi00488a030; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CRASKE A, 1986, EUR J BIOCHEM, V158, P429, DOI 10.1111/j.1432-1033.1986.tb09771.x; CROUSE BR, 1995, FEBS LETT, V367, P1, DOI 10.1016/0014-5793(95)00522-B; DEGLIESPOSTI M, 1989, BIOCHIM BIOPHYS ACTA, V977, P249; DERVARTANIAN DV, 1975, BIOCHIM BIOPHYS ACTA, V379, P74, DOI 10.1016/0005-2795(75)90009-4; FRIDEN H, 1990, BIOCHIM BIOPHYS ACTA, V1041, P207, DOI 10.1016/0167-4838(90)90067-P; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GUIGLIARELLI B, 1992, EUR J BIOCHEM, V207, P61, DOI 10.1111/j.1432-1033.1992.tb17020.x; Guigliarelli B, 1996, BIOCHEMISTRY-US, V35, P4828, DOI 10.1021/bi952459p; HACKETT NR, 1982, FEMS MICROBIOL LETT, V13, P213; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; HEDERSTEDT L, 1986, J BACTERIOL, V167, P735, DOI 10.1128/jb.167.2.735-739.1986; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES RW, 1980, BIOCHEM J, V190, P79, DOI 10.1042/bj1900079; JONES RW, 1977, BIOCHEM J, V164, P199, DOI 10.1042/bj1640199; Magalon A, 1997, J BACTERIOL, V179, P5037, DOI 10.1128/jb.179.16.5037-5045.1997; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; MORPETH FF, 1985, BIOCHEMISTRY-US, V24, P40, DOI 10.1021/bi00322a007; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; NEWTON G, 1991, BIOCHIM BIOPHYS ACTA, V1089, P8, DOI 10.1016/0167-4781(91)90077-Y; PALMER G, 1985, BIOCHEM SOC T, V13, P548, DOI 10.1042/bst0130548; PASCAL MC, 1982, MOL GEN GENET, V188, P103, DOI 10.1007/BF00333001; PETERSON J, 1994, FEBS LETT, V355, P155, DOI 10.1016/0014-5793(94)01189-3; SALERNO JC, 1983, FEBS LETT, V162, P257, DOI 10.1016/0014-5793(83)80767-4; SALERNO JC, 1984, J AM CHEM SOC, V106, P2156, DOI 10.1021/ja00319a041; SASARMAN A, 1968, J BACTERIOL, V96, P1882; vanderOost J, 1996, MOL MICROBIOL, V22, P193; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8	39	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25652	25658		10.1074/jbc.272.41.25652	http://dx.doi.org/10.1074/jbc.272.41.25652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325288	hybrid			2022-12-27	WOS:A1997YA35800043
J	Chilov, D; Kukk, E; Taira, S; Jeltsch, M; Kaukonen, J; Palotie, A; Joukov, V; Alitalo, K				Chilov, D; Kukk, E; Taira, S; Jeltsch, M; Kaukonen, J; Palotie, A; Joukov, V; Alitalo, K			Genomic organization of human and mouse genes for vascular endothelial growth factor C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTERCHAIN DISULFIDE BONDS; RECEPTOR TYROSINE KINASES; TRANSCRIPTIONAL UNIT; MESSENGER-RNAS; VEGF-C; CELLS; ANGIOGENESIS; HYPOXIA; PROTEIN	We report here the cloning and characterization of human and mouse genes for vascular endothelial growth factor C (VEGF-C), a newly isolated member of the vascular endothelial growth factor/platelet-derived growth factor (VEGF/PDGF) family, Both VEGF-C genes comprise over 40 kilobase pairs of genomic DNA and consist of seven exons, all containing coding sequences, The VEGF homology domain of VEGF-C is encoded by exons 3 and 4, Exons 5 and 7 encode cysteine-rich motifs of the type C6C10CRC, and exon 6 encodes additional C10CXCXC motifs typical of a silk protein, A putative alternatively spliced rare RNA form lacking exon 4 was identified in human fibrosarcoma cells, and a major transcription start site was located in the human VEGF-C gene 523 base pairs upstream of the translation initiation codon, The upstream promoter sequences contain conserved putative binding sites for Sp-1, AP-2, and NF-kappa B transcription factors but no TATA box, and they show promoter activity when transfected into cells, The VEGF-C gene structure is thus assembled from exons encoding propeptides and distinct cysteine-rich domains in addition to the VEGF homology domain, and it shows both similarities and distinct differences in comparison with other members of the VEGF/PDGF gene family.	UNIV HELSINKI,HAARTMAN INST,MOL CANC BIOL LAB,FIN-00014 HELSINKI,FINLAND	University of Helsinki			Jeltsch, Michael/I-5340-2012; Alitalo, Kari K/J-5013-2014; Joukov, Vladimir/K-3525-2019	Jeltsch, Michael/0000-0003-2890-7790; Alitalo, Kari K/0000-0002-7331-0902; Palotie, Aarno/0000-0002-2527-5874; chilov, dmitri/0000-0002-2279-0854				ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BONTHRON D, 1988, EUR J BIOCHEM, V171, P51, DOI 10.1111/j.1432-1033.1988.tb13757.x; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; Hu JS, 1997, FASEB J, V11, P498, DOI 10.1096/fasebj.11.6.9194531; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lagercrantz J, 1996, BIOCHEM BIOPH RES CO, V220, P147, DOI 10.1006/bbrc.1996.0372; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MAGLIONE D, 1993, ONCOGENE, V8, P925; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Paavonen K, 1996, CIRCULATION, V93, P1079, DOI 10.1161/01.CIR.93.6.1079; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; RISAU W, 1988, DEVELOPMENT, V102, P471; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	53	153	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25176	25183		10.1074/jbc.272.40.25176	http://dx.doi.org/10.1074/jbc.272.40.25176			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312130	hybrid			2022-12-27	WOS:A1997XY97000069
J	JugeAubry, C; Pernin, A; Favez, T; Burger, AG; Wahli, W; Meier, CA; Desvergne, B				JugeAubry, C; Pernin, A; Favez, T; Burger, AG; Wahli, W; Meier, CA; Desvergne, B			DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements - Importance of the 5'-flanking region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTOR; BETA-OXIDATION PATHWAY; COA OXIDASE GENE; FATTY-ACIDS; GENOMIC ORGANIZATION; ENZYME GENE; PPAR-ALPHA; RAT; EXPRESSION; HETERODIMER	The three subtypes of the peroxisome proliferator-activated receptors (PPAR alpha, beta/delta, and gamma) form heterodimers with the 9-cis-retinoic acid receptor (RXR) and bind to a common consensus response element, which consists of a direct repeat of two hexanucleotides spaced by one nucleotide (DR1), As a first step toward understanding the molecular mechanisms determining PPAR subtype specificity, we evaluated by electrophoretic mobility shift assays the binding properties of the three PPAR subtypes, in association with either RXR alpha or RXR gamma, on 16 natural PPAR response elements (PPREs). The main results are as follows, (i) PPAR gamma in combination with either RXR alpha or RXR gamma binds more strongly than PPAR alpha or PPAR beta to all natural PPREs tested. (ii) The binding of PPAR to sarong elements is reinforced if the heterodimerization partner is RXR gamma. In contrast, weak elements favor RXR alpha as heterodimerization partner, (iii) The ordering of the 16 natural PPREs from strong to weak elements does not depend on the core DR1 sequence, which has a relatively uniform degree of conservation, but correlates with the number of identities of the 5'-flanking nucleotides with respect to a consensus element, This 5'-flanking sequence is essential for PPAR alpha binding and thus contributes to subtype specificity, As a demonstration of this, the PPAR gamma-specific element ARE6 PPRE is able to bind PPAR alpha only if its 5'-flanking region is exchanged with that of the more promiscuous HMG PPRE.	HOP CANTONAL UNIV GENEVA,THYROID UNIT,CH-1211 GENEVA 14,SWITZERLAND; HOP CANTONAL UNIV GENEVA,MED CLIN 2,DEPT MED,CH-1211 GENEVA 14,SWITZERLAND; UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	University of Geneva; University of Geneva; University of Lausanne			Wahli, Walter/I-3194-2019; Wahli, Walter/B-1398-2009; Desvergne, Beatrice/C-8892-2016	Wahli, Walter/0000-0002-5966-9089; Desvergne, Beatrice/0000-0001-5483-288X				ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; KREY G, 1993, J STEROID BIOCHEM, V47, P65, DOI 10.1016/0960-0760(93)90058-5; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; SIMONSON GD, 1995, GENE, V154, P243, DOI 10.1016/0378-1119(94)00824-C; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	37	301	308	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25252	25259		10.1074/jbc.272.40.25252	http://dx.doi.org/10.1074/jbc.272.40.25252			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312141	hybrid			2022-12-27	WOS:A1997XY97000080
J	Miller, S; Douglas, RM; Carter, P; Booth, IR				Miller, S; Douglas, RM; Carter, P; Booth, IR			Mutations in the glutathione-gated KefC K+ efflux system of Escherichia coli that cause constitutive activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SEQUENCE; CLONING; METHYLGLYOXAL; TRANSPORT; BINDING; REGION; RNA	The kefC gene of Escherichia coli encodes a potassium efflux system that is gated by glutathione (GSH) and by GSH adducts, Independently isolated kefC mutations that result in spontaneous activation of the efflux system have been analyzed, Three mutations affect residues located adjacent to the conserved Rossman fold in the carboxyl-terminal domain, Two mutations lie in a sequence predicted to form a cytoplasmically located loop in the membrane domain of KefC, All of the mutants retain normal regulation by the YabF protein and by GSH adducts, A mutation in the Rossman fold, R416S, alters the normal regulation of KefC by GSH. In contrast to the wild-type protein, which is inactive in the presence of GSH, the R416S mutant is only active in the presence of GSH or its analogue, ophthalmic acid, Other mutations in this region or elsewhere in the protein have their spontaneous activity augmented by depletion of the GSH pool, These data identify a specific role for the carboxyl-terminal domain of KefC in regulating KefC activity and are discussed in the light of recent data that suggest that GSH adducts can bind within a Rossman fold.	UNIV ABERDEEN, INST MED SCI, DEPT MOL & CELL BIOL, FORESTERHILL AB25 2ZD, ABERDEEN, SCOTLAND; UNIV ABERDEEN, DEPT MED MICROBIOL, FORESTERHILL AB25 2ZD, ABERDEEN, SCOTLAND	University of Aberdeen; University of Aberdeen				Miller, Samantha/0000-0002-8223-9693	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKKER EP, 1987, J BACTERIOL, V169, P3743, DOI 10.1128/jb.169.8.3743-3749.1987; BIESECKER G, 1977, NATURE, V266, P328, DOI 10.1038/266328a0; Booth I. R., 1996, HDB BIOL PHYS, V2, P693; DOUGLAS RM, 1994, MOL MEMBR BIOL, V11, P55, DOI 10.3109/09687689409161030; ELMORE MJ, 1990, MOL MICROBIOL, V4, P405, DOI 10.1111/j.1365-2958.1990.tb00607.x; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; FERGUSON GP, 1995, MOL MICROBIOL, V17, P1025, DOI 10.1111/j.1365-2958.1995.mmi_17061025.x; FERGUSON GP, 1993, MOL MICROBIOL, V9, P1297, DOI 10.1111/j.1365-2958.1993.tb01259.x; Ferguson GP, 1996, J BACTERIOL, V178, P3957, DOI 10.1128/jb.178.13.3957-3961.1996; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MEURY J, 1982, EMBO J, V1, P339, DOI 10.1002/j.1460-2075.1982.tb01171.x; MEURY J, 1980, EUR J BIOCHEM, V113, P33; MEURY J, 1985, EUR J BIOCHEM, V148, P113, DOI 10.1111/j.1432-1033.1985.tb08814.x; MUNRO AW, 1991, MOL MICROBIOL, V5, P607, DOI 10.1111/j.1365-2958.1991.tb00731.x; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; PONGS O, 1993, J MEMBRANE BIOL, V136, P1; Puder M, 1997, J BIOL CHEM, V272, P10936; ROWLAND GC, 1984, FEBS LETT, V173, P295, DOI 10.1016/0014-5793(84)80794-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLOSSER A, 1993, MOL MICROBIOL, V9, P533, DOI 10.1111/j.1365-2958.1993.tb01714.x; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305	24	27	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24942	24947		10.1074/jbc.272.40.24942	http://dx.doi.org/10.1074/jbc.272.40.24942			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312097	hybrid			2022-12-27	WOS:A1997XY97000036
J	Moyano, JV; Carnemolla, B; DominguezJimenez, C; GarciaGila, M; Albar, JP; SanchezAparicio, P; Leprini, A; Querze, G; Zardi, L; GarciaPardo, A				Moyano, JV; Carnemolla, B; DominguezJimenez, C; GarciaGila, M; Albar, JP; SanchezAparicio, P; Leprini, A; Querze, G; Zardi, L; GarciaPardo, A			Fibronectin type III5 repeat contains a novel cell adhesion sequence, KLDAPT, which binds activated alpha 4 beta 1 and alpha 4 beta 7 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; HEPARIN-BINDING; DNA-BINDING; MONOCLONAL-ANTIBODIES; CONNECTING SEGMENT; SYNTHETIC PEPTIDE; DOMAIN; SITE; REGION; IDENTIFICATION	The region of fibronectin encompassing type III repeats 4-6 contains a low affinity heparin binding domain, but its physiological significance is not clear, We have studied whether this domain is able to interact with cells as already shown for other heparin binding domains of fibronectin, A computer search based on homologies with known active sites in fibronectin revealed the sequence KLDAPT located in FN-III5, A synthetic peptide containing this sequence induced lymphoid cell adhesion upon treatment with the activating anti-beta 1 monoclonal antibody (mAb) TS2/16 or with Mn2+ indicating that KLDAPT was binding to an integrin, A recombinant fragment containing repeat III5 (FN-III5) also mediated adhesion of TS2/16/Mn2+-treated cells while the FN-III6 fragment did not, Soluble KLDAPT peptide inhibited cell adhesion to FN-III5 as well as to a 38-kDa fibronectin fragment and VCAM-1, two previously known ligands for alpha 4 beta 1 integrin, KLDAPT also competed with the binding of soluble alkaline phosphatase-coupled VCAM-Ig to Mn2+-treated alpha 4 beta 1. Furthermore, mAbs anti-alpha 4 and anti-alpha 4 beta 7, but not mAbs to other integrins, inhibited cell adhesion to FN-III5 and KLDAPT, These results therefore establish a cell adhesive function for the FN-III5 repeat and show that KLDAPT is a novel fibronectin ligand for activated alpha 4 integrins.	CSIC,CTR INVEST BIOL,DEPT INMUNOL,E-28006 MADRID,SPAIN; IST NAZL RIC CANC,CELL BIOL LAB,I-16132 GENOA,ITALY; CSIC,CTR NACL BIOTECNOL,DEPT INMUNOL & ONCOL,E-28049 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Genoa; IRCCS AOU San Martino IST; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Garcia Pardo, Angeles/G-5987-2015	Garcia Pardo, Angeles/0000-0001-5577-2954				BORSI L, 1987, J CELL BIOL, V104, P595, DOI 10.1083/jcb.104.3.595; CALAYCAY J, 1985, J BIOL CHEM, V260, P2136; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; DominguezJimenez C, 1996, CELL ADHES COMMUN, V4, P251, DOI 10.3109/15419069609010770; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; ERLE DJ, 1994, J IMMUNOL, V153, P517; GARCIAPARDO A, 1989, EXP CELL RES, V181, P420, DOI 10.1016/0014-4827(89)90099-2; GARCIAPARDO A, 1987, BIOCHEM J, V241, P923, DOI 10.1042/bj2410923; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; Jongewaard IN, 1996, CELL ADHES COMMUN, V3, P487, DOI 10.3109/15419069609081025; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; PANDE H, 1985, J BIOL CHEM, V260, P2301; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; POSTIGO AA, 1993, J IMMUNOL, V151, P2471; SANCHEZAPARICIO P, 1994, J CELL BIOL, V126, P271, DOI 10.1083/jcb.126.1.271; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V154, P15, DOI 10.1111/j.1432-1033.1986.tb09353.x; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284	30	57	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24832	24836		10.1074/jbc.272.40.24832	http://dx.doi.org/10.1074/jbc.272.40.24832			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312081	hybrid, Green Published			2022-12-27	WOS:A1997XY97000020
J	Papineni, RVL; Pedersen, SE				Papineni, RVL; Pedersen, SE			Interaction of d-tubocurarine analogs with the mouse nicotinic acetylcholine receptor - Ligand orientation at the binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; MOLECULAR DISSECTION; TORPEDO-MARMORATA; DELTA-SUBUNIT; MUSCLE-CELLS; RESIDUES; IDENTIFICATION; INTERFACES; SELECTIVITY; STOICHIOMETRY	The binding of d-tubocurarine and several of its analogs to the mouse nicotinic acetylcholine receptor (AChR) was measured by competition against the initial rate I-125-alpha-bungarotoxin binding to BC3H-1 cells. The changes in affinity due to methylation or halogenation at various functional groups on d-tubocurarine was measured to both the high affinity (alpha gamma-site) and the low affinity site (alpha delta-site). We show that quaternization by methylation of the 2'-N ammonium group enhances the affinity for both the acetylcholine binding sites of mouse AChR, whereas this change does not affect affinity for the Torpedo AChR sites. The effect of N-methylation suggests the presence of interactions with the ammonium moiety that cannot be readily attributed to the known conserved residues thought to stabilize this functional group. Methylation of both the 7'- and 12'-phenols produced net affinity changes at both sites. The changes resulted from contributions at both the 7'- and the 12'-positions; however, these effects were dependent on whether the ammoniums were also methylated Substitution of bromine or iodine at the 13'-position decreased the affinity considerably to the high affinity alpha gamma-site of mouse AChR, whereas the affinity for the Torpedo alpha gamma-site was slightly increased. Furthermore, binding to the mouse AChR was unaffected by the conformational state, whereas these ligands strongly preferred the desensitized conformation of the Torpedo AChR. Comparison of binding changes upon 13'-halogenation to the changes in amino acid residues at the ACh binding sites of the mouse and Torpedo AChR shows mouse residue Ile-gamma 116 as likely to be involved in interacting with the 13'-position of d-tubocurarine. It is predicted that this residue is involved in the conformational equilibrium between the resting and desensitized conformations.	BAYLOR COLL MED, DEPT MOL PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA	Baylor College of Medicine				Pedersen, Steen E./0000-0001-8755-8899	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028879, K04NS001618, R01NS035212] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28879, NS01618, NS35212] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHATURVEDI V, 1993, BIOCHEMISTRY-US, V32, P9570, DOI 10.1021/bi00088a008; CHIARA D C, 1992, Biophysical Journal, V61, pA106; CHIARA DC, 1997, THESIS WASHINGTON U; Cohen J. B., 1986, MOL CELLULAR MECHANI, P111; COHEN JB, 1991, J BIOL CHEM, V266, P23354; DAMLE VN, 1978, BIOCHEMISTRY-US, V17, P2039, DOI 10.1021/bi00604a002; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; GROEBE DR, 1994, J BIOL CHEM, V269, P8885; KAO PN, 1984, J BIOL CHEM, V259, P1662; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; OSWALD RE, 1983, BIOCHEMISTRY-US, V22, P3128, DOI 10.1021/bi00282a015; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; Pedersen SE, 1995, J BIOL CHEM, V270, P31141, DOI 10.1074/jbc.270.52.31141; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1982, J BIOL CHEM, V257, P8106; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1981, J BIOL CHEM, V256, P6692; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Sugiyama N, 1996, J BIOL CHEM, V271, P26575, DOI 10.1074/jbc.271.43.26575; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; WOLOSIN JM, 1980, EUR J BIOCHEM, V109, P495, DOI 10.1111/j.1432-1033.1980.tb04821.x; Xie Y., 1995, Biophysical Journal, V68, pA406	31	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24891	24898		10.1074/jbc.272.40.24891	http://dx.doi.org/10.1074/jbc.272.40.24891			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312090	hybrid			2022-12-27	WOS:A1997XY97000029
J	Althoefer, H; EversoleCire, P; Simon, MI				Althoefer, H; EversoleCire, P; Simon, MI			Constitutively active G alpha q and G alpha 13 trigger apoptosis through different pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; CELL-DEATH; GENE FAMILY; ACTIVATION; SUBUNITS; RECEPTOR; RAS; OVEREXPRESSION; INVOLVEMENT	We investigated the effect of expression of constitutively active G alpha mutants on cell survival, Transfection of constitutively active G alpha q and G alpha 13 in two different cell lines caused condensation of genomic DNA and nuclear fragmentation. Endonuclease cleavage of genomic DNA was followed by labeling the DNA fragments and subsequent flow cytometric analysis. The observed cellular phenotype was identical to the phenotype displayed by cells undergoing apoptosis. To distinguish between the apoptosis-inducing ability of the two G alpha-subunits, the signaling pathways involved in this cellular function were investigated Whereas G alpha q induced apoptosis via a protein kinaseC-dependent pathway, G alpha 13 caused programmed cell death through a pathway involving the activation of the small G-protein Rho, Both of the pathways leading to apoptosis were blocked by overexpression of bcl-2, In contrast to other apoptosis-inducing systems, expression of constitutively active G alpha q and G alpha 13 triggered apoptosis in high serum as well as in defined medium.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology					NIGMS NIH HHS [GM 34236] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; FOIXGOMEZ AM, 1992, P NATL ACAD SCI USA, V267, P25129; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JIMENEZ B, 1995, ONCOGENE, V10, P811; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Krieger C, 1996, TRENDS PHARMACOL SCI, V17, P114, DOI 10.1016/0165-6147(96)10004-3; LEE CH, 1992, J BIOL CHEM, V267, P16044; MCKENNA JP, 1993, BIOCHEM PHARMACOL, V46, P583, DOI 10.1016/0006-2952(93)90541-4; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; OHKUSU K, 1995, EUR J IMMUNOL, V25, P3180, DOI 10.1002/eji.1830251129; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; ORRENIUS S, 1994, J NEURAL TRANSM-SUPP, P1; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOJYO Y, 1990, BIOCHEM PHARMACOL, V39, P1775; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watson S., 1994, G PROTEIN LINKED REC; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349	41	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24380	24386		10.1074/jbc.272.39.24380	http://dx.doi.org/10.1074/jbc.272.39.24380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305896	hybrid, Green Submitted			2022-12-27	WOS:A1997XY51500047
J	Chen, SRW; Li, XL; Ebisawa, K; Zhang, L				Chen, SRW; Li, XL; Ebisawa, K; Zhang, L			Functional characterization of the recombinant type 3 Ca2+ release channel (ryanodine receptor) expressed in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; MUSCLE SARCOPLASMIC-RETICULUM; MAMMALIAN SKELETAL-MUSCLES; MYOMETRIAL SMOOTH-MUSCLE; CALCIUM-RELEASE; PROTEIN ISOFORMS; MICE LACKING; MALIGNANT HYPERTHERMIA; ADENINE-NUCLEOTIDE; CARDIAC-MUSCLE	To investigate the channel properties of the mammalian type 3 ryanodine receptor (RyR3), we have cloned the RyR3 cDNA from rabbit uterus by reverse transcriptase-polymerase chain reaction and expressed! the cDNA inn HEK293 cells, Immunoblotting studies showed that the cloned RyR3 was indistinguishable from the native mammalian RyR3 in molecular size and immunoreactivity. Ca2+ release measurements using the fluorescence Ca2+ indicator fluo 3 revealed that the cloned RyR3 functioned as a caffeine-and ryanodine-sensitive Ca2+ release channel in HEK293 cells, Functional properties of the cloned RyR3 were further characterized by using single channel recordings in lipid bilayers. The cloned RyR3 channel exhibited a K+ conductance of 777 picosiemens in 250 mM KCl and a Ca2+ conductance of 137 picosiemens inn 250 mM CaCl2 and displayed a pCa(2+)/pK(+) ratio of 6.3 and an open time constant of about 1.16 ms, The response of the cloned RyR3 to cytoplasmic Ca2+ concentrations was biphasic. The channel was activated by Ca2+ at about 100 nM and inactivated at about 10 mM. Ca2+ alone was able to activate the cloned RyR3 fully, Calmodulin activated the cloned RyR3 at low Ca2(+) concentrations but inhibited the channel at low Ca2+ concentrations. The cloned RyR3 was activated by ATP, caffeine, and perchlorate, inhibited by Mg2+ and ruthenium red, and modified by ryanodine, cyclic ADP-ribose did not seem to affect single channel activity of the cloned RyR3. The most prominent differences of the cloned RyR3 from the rabbit skeletal muscle ryanodine receptor were in the gating kinetics, extent of maximal activation by Ca2+, and sensitivity to Ca2+ inactivation. Results of the present study provide initial insights into the single channel properties of the mammalian RyR3.			Chen, SRW (corresponding author), UNIV CALGARY,DEPT MED BIOCHEM,CARDIOVASC RES GRP,3330 HOSP DR NW,CALGARY,AB T2N 4N1,CANADA.							AIREY JA, 1990, J BIOL CHEM, V265, P14187; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1996, BIOPHYS J, V70, P390; CHEN SRW, 1997, IN PRESS BIOPHYS J, V73; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU A, 1993, J MEMBRANE BIOL, V135, P49; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; FRUEN BR, 1994, AM J PHYSIOL, V266, pC1729, DOI 10.1152/ajpcell.1994.266.6.C1729; FUTATSUGI A, 1995, BIOCHEM J, V305, P373, DOI 10.1042/bj3050373; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALLANT EM, 1993, AM J PHYSIOL, V264, pC559, DOI 10.1152/ajpcell.1993.264.3.C559; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GONZALEZ A, 1993, J GEN PHYSIOL, V102, P373, DOI 10.1085/jgp.102.3.373; GYORKE S, 1992, J PHYSIOL-LONDON, V456, P443; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LYNN S, 1993, FEBS LETT, V330, P227, DOI 10.1016/0014-5793(93)80279-4; LYNN S, 1995, FEBS LETT, V372, P6, DOI 10.1016/0014-5793(95)00924-X; MA J, 1993, J GEN PHYSIOL, V102, P423, DOI 10.1085/jgp.102.3.423; Marziah G, 1996, FEBS LETT, V394, P76, DOI 10.1016/0014-5793(96)00944-1; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MINTA A, 1989, J BIOL CHEM, V264, P8171; Miyatake R, 1996, FEBS LETT, V395, P123, DOI 10.1016/0014-5793(96)01022-8; Moore DD, 1995, GLOB MOB SURV; MORRISSETTE J, 1993, FEBS LETT, V330, P270, DOI 10.1016/0014-5793(93)80886-Y; MURAYAMA R, 1997, BIOPHYS J, V72, P169; Murayama T, 1996, J BIOL CHEM, V271, P5079; OBRIEN J, 1995, BIOPHYS J, V68, P471, DOI 10.1016/S0006-3495(95)80208-0; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OTSU K, 1994, J BIOL CHEM, V269, P9413; Ottini L, 1996, BIOCHEM J, V315, P207, DOI 10.1042/bj3150207; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; PHILLIPS M, 1996, GENOMICS, V33, P24; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; TANAKA Y, 1995, P NATL ACAD SCI USA, V92, P3244, DOI 10.1073/pnas.92.8.3244; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVES S, 1994, BIOCHEM J, V301, P661, DOI 10.1042/bj3010661; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; XU L, 1994, P NATL ACAD SCI USA, V91, P3294, DOI 10.1073/pnas.91.8.3294; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; ZORZATO F, 1994, BIOCHEM BIOPH RES CO, V203, P1725, DOI 10.1006/bbrc.1994.2385	67	146	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24234	24246		10.1074/jbc.272.39.24234	http://dx.doi.org/10.1074/jbc.272.39.24234			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305876	hybrid			2022-12-27	WOS:A1997XY51500027
J	Ihn, H; LeRoy, EC; Trojanowska, M				Ihn, H; LeRoy, EC; Trojanowska, M			Oncostatin M stimulates transcription of the human alpha 2(I) collagen gene via the Sp1/Sp3-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; LEUKEMIA-INHIBITORY FACTOR; NECROSIS-FACTOR-ALPHA; I COLLAGEN; DERMAL FIBROBLASTS; INTERFERON-GAMMA; EXPRESSION; ACTIVATION; CELLS; INTERLEUKIN-6	Oncostatin M (OSM), a member of the hematopoietic cytokine family, has been implicated in excessive bone growth and in the process of fibrosis, As part of an ongoing study of the molecular mechanisms of fibrosis, we have investigated the transcriptional regulation of the alpha 2(I) collagen gene by OSM in human fibroblasts, An OSM response element was mapped by deletional analysis between base pairs (bp) -148 and -108 in the alpha(I) collagen promoter, Further functional analysis of the alpha 2(I) collagen promoter containing various substitution mutations revealed that both the basal activity and OSM stimulation of this promoter are mediated by a TCCTCC motif located between bp -128 and -123. Futhermore, three copies of the 12-bp synthetic alpha 2(I) collagen promoter fragment containing the ''TCC'' motif conferred OSM inducibility to the otherwise unresponsive thymidine kinase promoter, Electrophoretic mobility shift assays demonstrated that the TCCTCC motif constitutes a novel binding site far the transcription factors Spl and Sp3. No differences have been observed in in vitro gel shift binding assays between unstimulated and OSM-stimulated fibroblasts, However, subtle conformational changes were detected in the region of the promoter surrounding TCC repeats after OSM stimulation using in vivo footprint analysis. In conclusion, this study characterized a dual-function response element that mediates the basal activity and OSM stimulation of the human alpha 2(I) collagen promoter.	MED UNIV S CAROLINA,DEPT MED,DIV RHEUMATOL & IMMUNOL,CHARLESTON,SC 29425	Medical University of South Carolina				Trojanowska, Maria/0000-0001-9550-7178	NIAMS NIH HHS [AR42334] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042334] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALEVIZOPOULOS A, 1996, J BIOL CHEM, V271, P29872; AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DUNCAN MR, 1995, J INVEST DERMATOL, V104, P128, DOI 10.1111/1523-1747.ep12613623; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; HAMILTON JA, 1991, BIOCHEM BIOPH RES CO, V180, P652, DOI 10.1016/S0006-291X(05)81115-5; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; Ichiki Y, 1997, J RHEUMATOL, V24, P90; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; ISHIKAWA O, 1990, BIOCHEM BIOPH RES CO, V169, P232, DOI 10.1016/0006-291X(90)91458-5; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KIKUCHI K, 1992, BIOCHEM BIOPH RES CO, V187, P45, DOI 10.1016/S0006-291X(05)81456-1; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; MALIK N, 1995, MOL CELL BIOL, V15, P2349; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; REITAMO S, 1994, J CLIN INVEST, V94, P2489, DOI 10.1172/JCI117618; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHINDLER R, 1995, ANN REV BIOCH, V64, P621; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; TJIAN R, 1991, GENE DEV, V5, P1646; TRUTER S, 1992, J BIOL CHEM, V267, P25389; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YAMAKAGE A, 1992, J EXP MED, V175, P1227, DOI 10.1084/jem.175.5.1227; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	41	131	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24666	24672		10.1074/jbc.272.39.24666	http://dx.doi.org/10.1074/jbc.272.39.24666			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305936	hybrid			2022-12-27	WOS:A1997XY51500087
J	Muta, T; Kang, D; Kitajima, S; Fujiwara, T; Hamasaki, N				Muta, T; Kang, D; Kitajima, S; Fujiwara, T; Hamasaki, N			p32 protein, a splicing factor 2-associated protein, is localized in mitochondrial matrix and is functionally important in maintaining oxidative phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 TAT TRANSACTIVATOR; IN-VITRO INTERACTION; LAMIN-B RECEPTOR; SACCHAROMYCES-CEREVISIAE; CELLULAR PROTEIN; BINDING-PROTEIN; HEAT-SHOCK; YEAST MITOCHONDRIA; MOLECULAR-CLONING; ACTIVATION DOMAIN	Human p32, originally cloned as a splicing factor 2-associated protein, has been reported to interact with a variety of molecules including human immunodeficiency virus Tat and complement Iq (Clq). p32 protein is supposed to be in the nucleus and on the plasma membrane for the association with human immunodeficiency virus Tat and Clq, respectively. None of the interactions, however, is proven to have a physiological role. To investigate the physiological function of p32, we determined the intracellular localization of p32. The fractionation of cells, fluorescent immunocytochemistry, and electron microscopic immunostaining show that p32 is exclusively localized in the mitochondrial matrix. We cloned a Saccharomyces cerevisiae homologue of human p32 gene, referred to yeast p30 gene. The yeast p30 protein is also localized in the mitochondrial matrix. The disruption of the p30 gene caused the growth retardation of yeast cells in a glycerol medium but not in a glucose medium, i.e. the impairment of the mitochondrial ATP synthesis. The growth impairment was restored by the introduction of the human p32 cDNA, indicating that p30 is a functional yeast counterpart of human p32. Taken together, both p32 and p30 reside in mitochondrial matrix and play an important role in maintaining mitochondrial oxidative phosphorylation.	KYUSHU UNIV, FAC MED, DEPT CLIN CHEM & LAB MED, HIGASHI KU, FUKUOKA 81282, JAPAN; TOKYO MED & DENT UNIV, INST MED RES, DEPT BIOCHEM GENET, TOKYO 113, JAPAN; FUKUOKA UNIV, SCH MED, DEPT BIOCHEM, FUKUOKA 81401, JAPAN	Kyushu University; Tokyo Medical & Dental University (TMDU); Fukuoka University			Muta, Tsuyoshi/AAR-2162-2021					BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Becker A, 1996, ANAL BIOCHEM, V237, P204, DOI 10.1006/abio.1996.0230; Bergmeyer H.U., 1965, METHODS ENZYMATIC AN, P736, DOI [10.1016/b978-0-12-395630-9.50134-1, DOI 10.1016/B978-0-12-395630-9.50134-1]; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; DESAI K, 1991, P NATL ACAD SCI USA, V88, P8875, DOI 10.1073/pnas.88.20.8875; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; GELLERA C, 1990, NEUROLOGY, V40, P495, DOI 10.1212/WNL.40.3_Part_1.495; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HONORE B, 1993, GENE, V134, P283, DOI 10.1016/0378-1119(93)90108-F; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C., 1994, METHODS YEAST GENETI; Kamura T, 1997, J BIOL CHEM, V272, P11361; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KONDO K, 1991, J BIOL CHEM, V266, P17537; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lim BL, 1996, J BIOL CHEM, V271, P26739, DOI 10.1074/jbc.271.43.26739; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; MACHO A, 1995, BLOOD, V86, P2481; MASTERS BSS, 1965, J BIOL CHEM, V240, P921; MCKEE EE, 1984, J BIOL CHEM, V259, P9320; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; Seebacher T, 1996, ELECTROPHORESIS, V17, P1573, DOI 10.1002/elps.1150171013; SIMOS G, 1994, FEBS LETT, V346, P225, DOI 10.1016/0014-5793(94)00479-X; SINGH B, 1990, BIOCHEM BIOPH RES CO, V169, P391, DOI 10.1016/0006-291X(90)90344-M; SMILEY JK, 1992, NUCLEIC ACIDS RES, V20, P4913, DOI 10.1093/nar/20.18.4913; TANAKA K, 1988, EMBO J, V7, P495, DOI 10.1002/j.1460-2075.1988.tb02837.x; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; Yamazaki S, 1997, J BIOCHEM, V121, P8; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995	43	183	189	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24363	24370		10.1074/jbc.272.39.24363	http://dx.doi.org/10.1074/jbc.272.39.24363			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305894	hybrid			2022-12-27	WOS:A1997XY51500045
J	OgierDenis, E; Petiot, A; Bauvy, C; Codogno, P				OgierDenis, E; Petiot, A; Bauvy, C; Codogno, P			Control of the expression and activity of the G(alpha)-interacting protein (GAIP) in human intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS AUTOPHAGIC SEQUESTRATION; GTPASE-ACTIVATING PROTEINS; ISOLATED RAT HEPATOCYTES; N-LINKED GLYCOPROTEINS; COLON CANCER-CELLS; LINE HT-29; ENTEROCYTIC DIFFERENTIATION; ADENYLYL-CYCLASE; ADP-RIBOSYLATION; ALPHA-SUBUNITS	The G(alpha)-interacting protein (GAIP) is known to interact with the G(alpha i3) protein, It has been suggested that, depending on its expression, GAIP can be a regulator of trimeric G(i) protein signaling pathways, In the present study we show that the GAIP mRNA content declines during the enterocytic differentiation of two cell lines derived from human colon adenocarcinomas: HT-29 and Caco-2. In undifferentiated HT-29 cells, when the GDP/GTP cycle on the trimeric G(i3) protein is interrupted by either pertussis toxin treatment or by the transfection of a mutant of the G(alpha i3) protein with no GTPase activity (Q204L), we observed a decrease in the GAIP mRNA content, As these conditions are known to impair the G(i3)-dependent lysosomal-autophagic pathway existing in undifferentiated HT-29 cells, we have investigated the role of G;AIP in controling the lysosomal-autophagic pathway, Overexpression of GAIP stimulated protein degradation along the macroautophagic pathway, In contrast, overexpression of GAIP did not modify the low rate of macroautophagy in cells expressing the Q204L mutant of the G(alpha i3) protein, These results show that GAIP regulates a major catabolic pathway and that the expression of GAIP is dependent upon the activity of the G(alpha i3) protein and the state of enterocytic differentiation of cells.	UNIV PARIS 07,INSERM,U410,F-75018 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Codogno, Patrice/G-1384-2013; Ogier-Denis, Eric/E-5030-2016	Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593				Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Codogno P, 1997, CELL SIGNAL, V9, P125, DOI 10.1016/S0898-6568(96)00130-1; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; HUNT TW, 1994, J BIOL CHEM, V269, P29565; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LEFKOWITZ RJ, 1993, GTPASES BIOL, V2, P33; LESUFFLEUR T, 1991, INT J CANCER, V49, P721, DOI 10.1002/ijc.2910490516; MIOTTO G, 1994, J BIOL CHEM, V269, P25348; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; OGIERDENIS E, 1994, J BIOL CHEM, V269, P4285; PINTO M, 1983, BIOL CELL, V47, P323; PINTO M, 1982, BIOL CELL, V44, P193; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WICE BM, 1985, J BIOL CHEM, V260, P139; WICE BM, 1992, J CELL BIOL, V116, P405, DOI 10.1083/jcb.116.2.405; ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105	36	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24599	24603		10.1074/jbc.272.39.24599	http://dx.doi.org/10.1074/jbc.272.39.24599			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305927	hybrid			2022-12-27	WOS:A1997XY51500078
J	Rao, MN; Ghosh, P; Lakshman, MR				Rao, MN; Ghosh, P; Lakshman, MR			Purification and partial characterization of a cellular carotenoid-binding protein from ferret liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	FASEB Meeting	APR 14-17, 1996	WASHINGTON, DC	FASEB			TRANS-BETA-CAROTENE; CAROTENOPROTEIN; CRUSTACYANIN; ASTAXANTHIN; COMPLEX; RETINOL; TISSUES; MODEL	A cellular carotenoid-binding protein was purified to homogeneity from beta-carotene-fed ferret liver utilizing the following steps: ammonium sulfate precipitation, ion exchange, gel filtration, and affinity chromatography. The final purification was 607-fold. [C-14]beta-Carotene co-purified with the binding protein throughout the purification procedures. SDS-PAGE of the purified protein showed a single band with an apparent molecular mass of 67 kDa. Scatchard analysis of the specific binding of the purified protein to beta-carotene showed two classes of binding sites, a high affinity site with an apparent Kd Of 56 x 10(-9) M and a low affinity site with a K-d of 32 x 10(-6) M. The B-max for beta-carotene binding to the high affinity site was 1 mol/mol, while that for the low affinity site was 145 mol/mol. The absorption spectrum of the complex showed a 32-nm bathochromic shift in lambda(max) with minor peaks at 460 and 516 nm. Except for alpha-carotene and cryptoxanthin, none of the model carotenoids or retinol competed with beta-carotene binding to the protein. Thus, a specific carotenoid-binding protein of 67 kDa has been characterized in mammalian liver with a high degree of specificity for binding only carotenoids with at least one unsubstituted beta-ionone ring.	VET ADM MED CTR,LIPID RES LAB,WASHINGTON,DC 20422; GEORGE WASHINGTON UNIV,DEPT MED,WASHINGTON,DC 20037	US Department of Veterans Affairs; Veterans Health Administration (VHA); George Washington University					NCI NIH HHS [CA39999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ALPH TOC BET CART, 1994, NEW ENGL J MED, V330, pS1029; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLERJAHN GS, 1986, J BACTERIOL, V167, P396, DOI 10.1128/jb.167.1.396-399.1986; CHEN CH, 1982, J LIPID RES, V23, P680; CHYTIL F, 1984, RETINOIDS, P90; FOX JG, 1988, BIOL DIS FERRET; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; Jouni ZE, 1996, J BIOL CHEM, V271, P14722, DOI 10.1074/jbc.271.25.14722; KEEN JN, 1991, EUR J BIOCHEM, V202, P31, DOI 10.1111/j.1432-1033.1991.tb16340.x; KRINSKY NI, 1958, ARCH BIOCHEM BIOPHYS, V73, P233, DOI 10.1016/0003-9861(58)90259-5; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAKSHMAN MR, 1989, P NATL ACAD SCI USA, V86, P9124, DOI 10.1073/pnas.86.23.9124; MATHEWSROTH MM, 1993, ANN NY ACAD SCI, V691, P127, DOI 10.1111/j.1749-6632.1993.tb26164.x; Nielsen T B, 1978, Methods Enzymol, V48, P3; OKOH C, 1993, J NUTR BIOCHEM, V4, P569, DOI 10.1016/0955-2863(93)90025-R; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; ONG DE, 1982, J BIOL CHEM, V257, P13385; RIBAYAMERCADO JD, 1992, J NUTR, V122, P1898, DOI 10.1093/jn/122.9.1898; RIBAYAMERCADO JD, 1989, J NUTR, V119, P665, DOI 10.1093/jn/119.4.665; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; SUBBARAYAN C, 1966, INDIAN J BIOCHEM, V3, P225; TRABER MG, 1994, LIPIDS, V29, P665, DOI 10.1007/BF02538909; WHITE WS, 1993, J NUTR, V123, P1129; ZAGALSKY PF, 1991, BIOCHEM J, V274, P79, DOI 10.1042/bj2740079; ZHOU JR, 1994, J AGR FOOD CHEM, V42, P2386, DOI 10.1021/jf00047a005; ZIEGLER RG, 1992, CANCER RES, V52, pS2060	27	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24455	24460		10.1074/jbc.272.39.24455	http://dx.doi.org/10.1074/jbc.272.39.24455			6	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305906	hybrid			2022-12-27	WOS:A1997XY51500057
J	Asano, K; Merrick, WC; Hershey, JWB				Asano, K; Merrick, WC; Hershey, JWB			The translation initiation factor eIF3-p48 subunit is encoded by int-6, a site of frequent integration by the mouse mammary tumor virus genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA 5' CAP; MALIGNANT TRANSFORMATION; HELA-CELLS; PROTEIN; BINDING	Translation initiation factor eIF3 is a large, multisubunit protein complex that plays a central role in the pathway of initiation by promoting the binding of both methionyl-tRNA(i) and mRNA to the 40S ribosomal subunit. As part of a broad effort to elucidate the structure of eIF3, we have cloned and sequenced the human cDNA encoding the 48-kDa subunit, eIF3-p48. The recombinant protein comigrates with the authentic p48 subunit in purified eIF3 and coprecipitates with affinity-purified antibodies to the p170 subunit of eIF3. A search of the data base indicates that the mouse gene encoding eIF3 p48 had previously been identified and characterized by others as int-6. The int-6 gene is the site of frequent integration of mouse mammary tumor virus DNA into chromosomes, implicating the gene in the regulation of cell proliferation. In addition, it was shown elsewhere that the homologous human int-6 gene product binds to the human T-cell leukemia virus type I Tax protein, leading to the translocation of Int-6 to the cytoplasm. We discuss how the cytosolic function of eIF3-p48 (Int-6) in protein synthesis may account for oncogenesis caused by these two viruses.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	University of California System; University of California Davis; Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, R01GM026796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26796, GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; HERSHEY JWB, 1997, BIOCHIMIE, V78, P903; JOHNSON KR, 1997, J BIOL CHEM, V272, P7016; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; Sambrook J., 2002, MOL CLONING LAB MANU; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; VARMUS HE, 1982, CANCER SURV, V1, P309	20	129	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23477	23480		10.1074/jbc.272.38.23477	http://dx.doi.org/10.1074/jbc.272.38.23477			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295280	hybrid			2022-12-27	WOS:A1997XX38100005
J	James, PF; Zoeller, RA				James, PF; Zoeller, RA			Isolation of animal cell mutants defective in long-chain fatty aldehyde dehydrogenase - Sensitivity to fatty aldehydes and Schiff's base modification of phospholipids: Implications for Sjogren-Larsson syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED FIBROBLASTS; ALCOHOL OXIDATION; METABOLISM; DEFICIENT; OXIDOREDUCTASE; CYCLE	Using tritium suicide, we have isolated a variant of the Chinese hamster ovary cell line, CHO-K1, that is deficient in long-chain fatty alcohol:NAD(+) oxidoreductase (FAO; FC 1.1.1.192), Specifically, it was the fatty aldehyde dehydrogenase component that was affected, The enzymatic deficiency found in this mutant strain, designated FAA.K1A, was similar to that displayed by fibroblasts from patients with Sjogren-Larsson syndrome (SLS), an inheritable neurocutaneaus disorder. Complementation analyses suggested that the deficiency in fatty alcohol oxidation in the FAA.K1A cells and the SLS fibroblasts is a result of lesions in homologous genes, The FAA.K1A cells were usable to convert long chain fatty aldehydes to the corresponding fatty acids, This resulted in a hypersensitivity of the FAA.K1A cells to the cytotoxic effects of long chain fatty aldehydes. The difference between the mutant and wild-type cans was most obvious when using fatty aldehydes between 14 and 20 carbons, with the greatest difference between wild-type and mutant cells found when using octadecanal, Fibroblasts from a patient with SLS also displayed the hypersensitivity phenotype when compared with FA1dDH(+) human fibroblasts. In both CHO and human FA1dDH(-) cell lines, addition of long chain fatty aldehydes to the medium caused a dramatic increase in aldehyde-modified phosphatidylethanolamine, presumably through Schiffs base addition to the primary amine of the ethanolamine head group, When 25 mu M hexadecanal was added to the growth medium, approximately 10% of the phosphatidylethanolamine was found in the fatty aldehyde-modified form in FAA.K1A, although this was not observed in wild-type cells, Modified phosphatidylethanolamine could be detected in FA1dDH(-) cells even when exogenous fatty aldehydes were not added to the medium, We propose a possible role for fatty aldehydes, or other aldehydic species, in mediating some of the symptoms associated with Sjogren-Larsson syndrome.	BOSTON UNIV,SCH MED,DEPT BIOPHYS,CTR ADV BIOMED RES,BOSTON,MA 02118	Boston University				Zoeller, Raphael/0000-0002-6560-0993	NIGMS NIH HHS [GM 50571] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050571] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; BORG J, 1987, FEBS LETT, V213, P406, DOI 10.1016/0014-5793(87)81531-4; CHIARPOTTO E, 1995, BIOCHEM BIOPH RES CO, V207, P477, DOI 10.1006/bbrc.1995.1213; COREY EJ, 1975, TETRAHEDRON LETT, V31, P2647; DAVIS PA, 1981, ARCH BIOCHEM BIOPHYS, V211, P20, DOI 10.1016/0003-9861(81)90424-0; DeLaurenzi V, 1996, NAT GENET, V12, P52; DOWNING DT, 1968, J CHROMATOGR, V38, P91, DOI 10.1016/0021-9673(68)85011-3; FERRELL WJ, 1969, LIPIDS, V4, P278, DOI 10.1007/BF02533186; HEIJER A, 1965, ARCH DERMATOL, V92, P545, DOI 10.1001/archderm.92.5.545; HOGAN M, 1992, J CLIN INVEST, V90, P1110, DOI 10.1172/JCI115928; ICHIHARA K, 1986, BIOCHIM BIOPHYS ACTA, V878, P412, DOI 10.1016/0005-2760(86)90250-X; JAGELL S, 1981, CLIN GENET, V19, P233; JAGELL S, 1980, ACTA OPHTHALMOL, V58, P321; James PF, 1997, J BIOL CHEM, V272, P23540, DOI 10.1074/jbc.272.38.23540; JAMES PF, 1989, P NATL ACAD SCI USA, V87, P6102; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; Kennett R H, 1979, Methods Enzymol, V58, P345; KUCHERLAPATI RS, 1975, CYTOGENET CELL GENET, V14, P362, DOI 10.1159/000130384; LIN RC, 1995, ALCOHOL CLIN EXP RES, V19, P314, DOI 10.1111/j.1530-0277.1995.tb01508.x; LINDAHL R, 1984, J BIOL CHEM, V259, P1986; LITTLEFIELD JW, 1964, SCIENCE, V129, P838; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MECHANIC GL, 1974, BIOCHEM BIOPH RES CO, V56, P923, DOI 10.1016/S0006-291X(74)80276-7; MOSLEY ST, 1981, P NATL ACAD SCI-BIOL, V78, P5717, DOI 10.1073/pnas.78.9.5717; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; PAGE RC, 1968, BIOCHEM BIOPH RES CO, V33, P752, DOI 10.1016/0006-291X(68)90223-4; Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054; PRINGLE MJ, 1981, MOL PHARMACOL, V19, P49; RIZZO WB, 1989, J PEDIATR-US, V115, P228, DOI 10.1016/S0022-3476(89)80070-8; RIZZO WB, 1993, SEMIN DERMATOL, V12, P210; RIZZO WB, 1993, BIOCHEM MED METAB B, V50, P93, DOI 10.1006/bmmb.1993.1050; RIZZO WB, 1988, J CLIN INVEST, V81, P738, DOI 10.1172/JCI113379; RIZZO WB, 1991, J CLIN INVEST, V88, P1643, DOI 10.1172/JCI115478; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; SELMANOWITZ VJ, 1967, AM J MED, V42, P412, DOI 10.1016/0002-9343(67)90269-0; Sjogren T, 1957, ACTA PSYCHIAT NEUROL, V32, P1; THEILE U, 1974, HUMANGENETIK, V22, P91; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170	39	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23532	23539		10.1074/jbc.272.38.23532	http://dx.doi.org/10.1074/jbc.272.38.23532			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295289	hybrid			2022-12-27	WOS:A1997XX38100014
J	Kakizawa, T; Miyamoto, T; Kaneko, A; Yajima, H; Ichikawa, K; Hashizume, K				Kakizawa, T; Miyamoto, T; Kaneko, A; Yajima, H; Ichikawa, K; Hashizume, K			Ligand-dependent heterodimerization of thyroid hormone receptor and retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; RESPONSE ELEMENTS; NUCLEAR RECEPTOR; ESCHERICHIA-COLI; ACID RECEPTORS; LEUCINE-ZIPPER; HUMAN TESTIS; C-ERB; BINDING; DNA	The thyroid hormone receptors (TR) bind to cis-acting DNA elements as heterodimers with the retinoid X receptors (RXR), These heterodimers display distinct specificities in mediating the hormonal response to target gene transcription, We characterized the interaction between TR alpha 1 and RXR alpha via their ligand binding domains (LBDs) and the effect of ligands on the interaction using a yeast two-hybrid system, The DNA binding domain (ED) of yeast Gal4 fusion to the LED of TR alpha 1 had no transcriptional activity on its own, but when it was coexpressed with the activation domain (AD) of yeast Gal4 fusion to LED of RXR alpha conferred activation to a reporter gene harboring a Gal4 binding site, indicating that LBDs of TR alpha 1 and RXR alpha interact with each other in solution, Furthermore, T-3 and 9-cis-RA increased the reporter activity, and an additive effect was observed when both ligands were added, indicating that the TR alpha 1.RXR alpha heterodimerization is augmented by their respective ligands in vivo, Using an in vitro pull down experiment, we confirmed the ligand dependent interaction observed in the yeast system, Matrix-bound glutathione S-transferase-RXR alpha specifically coprecipitated the S-35-labeled TR alpha 1 above the control, and associated S-35-labeled TR alpha 1 was increased by the addition of T-3 and 9-cis-RA. These results imply a complex, sensitive crosstalk in vivo among nuclear receptors and their respective ligands through distinct hormonal signaling pathways.	SHINSHU UNIV,SCH MED,DEPT GERIATR ENDOCRINOL & METAB,MATSUMOTO,NAGANO 390,JAPAN	Shinshu University								BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; ICHIKAWA K, 1988, J ENDOCRINOL, V119, P431, DOI 10.1677/joe.0.1190431; ICHIKAWA K, 1990, MOL CELL ENDOCRINOL, V70, P175; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Miller J.H., 1972, EXPT MOL GENETICS; MIYAMOTO T, 1991, ENDOCRINOLOGY, V129, P3027, DOI 10.1210/endo-129-6-3027; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NAKAI A, 1988, P NATL ACAD SCI USA, V85, P2781, DOI 10.1073/pnas.85.8.2781; OPPENHEIMER JH, 1985, ANN INTERN MED, V102, P374, DOI 10.7326/0003-4819-102-3-374; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SAKURAI A, 1990, MOL ENDOCRINOL, V4, P1988, DOI 10.1210/mend-4-12-1988; SCHUELER PA, 1990, MOL ENDOCRINOL, V4, P227, DOI 10.1210/mend-4-2-227; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	36	26	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23799	23804		10.1074/jbc.272.38.23799	http://dx.doi.org/10.1074/jbc.272.38.23799			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295326	hybrid			2022-12-27	WOS:A1997XX38100051
J	LewisCarl, S; Kirley, TL				LewisCarl, S; Kirley, TL			Immunolocalization of the ecto-ATPase and ecto-apyrase in chicken gizzard and stomach - Purification and N-terminal sequence of the stomach ecto-apyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE HYDROLASE; SMOOTH-MUSCLE; TOXOPLASMA-GONDII; CELL ACTIVATION; PROTEIN ASSAY; MG-ATPASE; DIPHOSPHOHYDROLASE; IDENTIFICATION; CD39	We have examined the in vivo localization of extracellular ecto-ATPase and ecto-apyrase (ATPDase) in adult chicken gizzard and stomach by immunofluorescence and laser scanning confocal microscopy. In chicken gizzard, the ecto-ATPase was distributed in discrete clusters restricted to the sarcolemma of the smooth muscle cells, Anti-ecto-apyrase antibody detected a single 80-kDa band (putative apyrase) in Western blots of both chicken gizzard membrane extracts and partially purified anion exchange fractions, but the antibody did not detect ecto-apyrase in immunolabeled gizzard cryosections. In adult chicken stomach, the ecto-apyrase was observed at the apical membrane of the glandular oxyntico-peptic cells as described in previous immunoperoxidase studies (Stout, J. G., R. S. Strobel, and T. L. Kirley (1995) Biochem, Mol. Biol, Int. 36, 529-535). However, ecto-ATPase was clustered in the sarcolemma of the organized layer of circular smooth muscle and in smooth muscle cells of the septa surrounding the glandular tissue, but not in the glandular cells containing the ecto-apyrase, The findings indicate compartmentalization of the two related extracellular nucleotide hydrolyzing enzymes and suggest differential functions that are specialized for different regions of the chicken stomach, We also partially purified the ecto apyrase of chicken stomach, an 80 kDa membrane glycoprotein. Chicken stomach membranes were solubilized in digitonin, glycoproteins were separated from solubilized proteins by lectin chromatography, and nucleotide-binding glycoproteins were selected by immobilized Cibacron blue chromatography, Further purification by size exclusion and anion exchange chromatography yielded purification of 94-fold, The ATPase specific activity of the purified stomach ecto-apyrase was 75,000 mu mol of P-i/mg of protein/h, and the purified preparation consisted of a major band (55% of total protein) at 80 kDa, The purified enzyme could be deglycosylated with peptide N-glycosidase-F to a core molecular mass of 54 kDa. The N-terminal sequence of the 80-kDa stomach ecto-apyrase band (which reacted with anti-ecto-ATPDase antibodies) was determined to be: MEYKGKVVAGLLTATWV. Immunological cross-reactivity data indicate that the stomach 80-kDa protein isolated is an ecto apyrase and is related to both the chicken liver and oviduct ecto-ATPDase enzymes characterized earlier, as well as to the human lymphoid cell activation antigen, CD39.	UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati				Kirley, Terence/0000-0002-6211-1414				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BURNSTOCK G, 1988, TRENDS PHARMACOL SCI, V9, P116, DOI 10.1016/0165-6147(88)90185-X; Burnstock G, 1996, LANCET, V347, P1604, DOI 10.1016/S0140-6736(96)91082-X; Candinas D, 1996, THROMB HAEMOSTASIS, V76, P807; CORR L, 1991, BRIT J PHARMACOL, V104, P337, DOI 10.1111/j.1476-5381.1991.tb12432.x; CUNNINGHAM HB, 1993, ARCH BIOCHEM BIOPHYS, V303, P32, DOI 10.1006/abbi.1993.1252; DUBYAK GR, 1990, ANN NY ACAD SCI, V603, P1; EDWARDS FA, 1993, FEBS LETT, V325, P86, DOI 10.1016/0014-5793(93)81419-Z; Fiske CH, 1925, J BIOL CHEM, V66, P375; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Kirley TL, 1997, ECTO-ATPASES, P111; Kirley TL, 1997, J BIOL CHEM, V272, P1076, DOI 10.1074/jbc.272.2.1076; KIRLEY TL, 1988, J BIOL CHEM, V263, P12682; KITTEL A, 1994, CELL BIOL INT, V18, P875, DOI 10.1006/cbir.1994.1124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PLESNER L, 1995, INT REV CYTOL, V158, P141; PLESNER L, 1997, ECTOATPASES RECENT P; Robson SC, 1996, TRANSPLANT P, V28, P536; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; STOSCHECK CM, 1990, ANAL BIOCHEM, V184, P111, DOI 10.1016/0003-2697(90)90021-Z; STOSCHECK CM, 1987, ANAL BIOCHEM, V160, P301, DOI 10.1016/0003-2697(87)90051-0; STOUT JG, 1994, J BIOCHEM BIOPH METH, V29, P61, DOI 10.1016/0165-022X(94)90057-4; STOUT JG, 1995, J BIOL CHEM, V270, P11845, DOI 10.1074/jbc.270.20.11845; Stout JG, 1995, BIOCHEM MOL BIOL INT, V36, P529; STROBEL R, 1993, ANN NY ACAD SCI, V671, P487; Strobel RS, 1996, J BIOL CHEM, V271, P16323, DOI 10.1074/jbc.271.27.16323; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; TREUHEIT MJ, 1992, J BIOL CHEM, V267, P11777; Vasconcelos EG, 1996, J BIOL CHEM, V271, P22139, DOI 10.1074/jbc.271.36.22139; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	37	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23645	23652		10.1074/jbc.272.38.23645	http://dx.doi.org/10.1074/jbc.272.38.23645			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295305	hybrid			2022-12-27	WOS:A1997XX38100030
J	Sine, SM				Sine, SM			Identification of equivalent residues in the gamma, delta, and epsilon subunits of the nicotinic receptor that contribute to alpha-bungarotoxin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ACETYLCHOLINE-RECEPTOR; MOLECULAR DISSECTION; TORPEDO-CALIFORNICA; LIGAND-BINDING; SELECTIVITY; INTERFACES; MARMORATA; AFFINITY; PEPTIDE; SITES	Cysteine was introduced from residues 116 to 121 of the gamma subunit of the fetal mouse acetylcholine receptor, and the mutant receptors were treated with methanethiosulfonate reagents and examined for changes in ligand binding properties, Of the 18 combinations of mutant and reagent, only receptors harboring gamma L119C treated with the quaternary ammonium reagent MTSET (trimethylammonium-ethyl methanethiosulfonate) show a decreased number of alpha-bungarotoxin (alpha-btx) sites, The decrease of 50% suggests that alpha-btx binding to the site harboring gamma L119C is blocked, Analysis of binding of the site-selective ligands dimethyl-d-tubocurarine (DMT) and alpha-conotoxin M1 (CTX) confirm specificity of modification for the site harboring gamma L119C, Cysteines placed at equivalent positions of the delta and epsilon subunits also lead to selective loss of alpha-btx binding following MTSET treatment, gamma L119C receptors treated with the primary amine reagent MTSEA (aminoethyl methanethiosulfonate) retain alpha-btx binding to both sites but show reduced affinity for DMT and CTX at the modified site, Lysine mutagenesis of Leu(gamma 119), Leu(delta 121), and Leu(epsilon 119) mimics MTSEA treatment, whereas mutagenesis of Thr(alpha 119) and Gln(beta 119) is without effect, demonstrating subunit and residue specificity of MTSEA modification, MTSET modification of nearby gamma Y117C does not block alpha-btx binding but markedly diminishes affinity for DMT and CTX, The overall findings indicate a localized point of interaction between alpha-btx and the modified gamma L119C, delta L121C, and epsilon L119C.			Sine, SM (corresponding author), MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,RECEPTOR BIOL LAB,ROCHESTER,MN 55905, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031744, R01NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BLOUNT P, 1991, J BIOL CHEM, V266, P14692; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; FU DX, 1994, J BIOL CHEM, V269, P26152; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LENTZ TL, 1988, INT REV NEUROBIOL, V29, P117, DOI 10.1016/S0074-7742(08)60085-9; MACHOLD J, 1995, EUR J BIOCHEM, V234, P427, DOI 10.1111/j.1432-1033.1995.427_b.x; MAELICKE A, 1977, J BIOL CHEM, V252, P4811; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P3008, DOI 10.1073/pnas.83.9.3008; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; TZARTOS SJ, 1983, EMBO J, V2, P381, DOI 10.1002/j.1460-2075.1983.tb01434.x	21	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23521	23527		10.1074/jbc.272.38.23521	http://dx.doi.org/10.1074/jbc.272.38.23521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295287	hybrid			2022-12-27	WOS:A1997XX38100012
J	Tian, H; Yu, L; Mather, MW; Yu, CA				Tian, H; Yu, L; Mather, MW; Yu, CA			The involvement of serine 175 and alanine 185 of cytochrome b of Rhodobacter sphaeroides cytochrome bc(1) complex in interaction with iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTONMOTIVE Q-CYCLE; SUBUNIT-IV; UBIQUINONE; SITE; MUTAGENESIS; BINDING; CHAIN; IDENTIFICATION; PURIFICATION; INHIBITORS	An approach involving cysteine replacement of potentially noncritical amino acid residues, followed by chemical modification studies, was used to investigate structure-function of the ''cd helix'' of cytochrome b from Rhodobacter sphaeroides. Three amino acid residues, Ser-155, Ser-175, and Ala-185, which span this region of cytochrome b, were selected for this study, The S155C substitution yields cells unable to support photosynthetic growth, indicating that Ser-155 is a critical amino acid residue, Further mutational studies of Ser-155 indicate that the size of the amino acid side chain at this position is critical for photosynthetical growth of R. sphaeroides. On the other hand, the S175C and A185C substitutions yield cells with photosynthetic growth rates and enzyme kinetics of the bc(1) complexes very similar to those of the unmutated complex, indicating that Ser-175 and Ala-185 are noncritical residues, Thus, engineered cysteines at these two positions of cytochrome b are suitable far membrane topology and domain/subunit interaction studies. Cys-185 does not react with a sulfhydryl-modifying reagent, N-ethylmaleimide (NEM), either in sealed, inside-out chromatophores or in detergent-disrupted chromatophores, indicating that position 175 of cytochrome b if inaccessible from both sides of the membrane and is probably buried within the protein complex. Cys-185 reacts with NEM only after detergent disruption of the sealed, inside-out chromatophores, indicating that this position of cytochrome b is accessible on the outer (periplasmic) surface of the membrane. These results place the cd helix of cytochrome b on the periplasmic side of the chromatophore membrane, When purified A185C-substituted bc(1) complex was treated with NEM, about 87% of the activity was abolished due to NEM modification of Cys-185. The signature of the Rieske iron-sulfur center is broadened upon NEM modification of A185C, with the g(x) signal shifting from g = 1.80 to g = 1.75, suggesting that Ala-185 of cytochrome b interacts with the iron-sulfur protein. When purified S175C-substituted bc(1) complex is treated with NEM, no change in the activity is observed, since Cys-175 is inaccessible to NEM. However, when the iron-sulfur protein is removed from the S175C-substituted bc(1) complex. Cys-175 becomes accessible to NEM, indicating that Ser-175 of cytochrome b is shielded by the iron-sulfur protein in the bc(1) complex.	OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOL BIOL,STILLWATER,OK 74078	Oklahoma State University System; Oklahoma State University - Stillwater				Mather, Michael/0000-0002-1062-0137	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; CANNON WR, 1995, PROTEIN SCI, V4, P387; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; Ding H, 1995, BIOCHEMISTRY-US, V34, P15997, DOI 10.1021/bi00049a013; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; DU ZJ, 1993, METHOD ENZYMOL, V218, P104; GABELLINI N, 1982, EUR J BIOCHEM, V126, P105, DOI 10.1111/j.1432-1033.1982.tb06753.x; GRAY KA, 1992, BIOCHEMISTRY-US, V31, P11864, DOI 10.1021/bi00162a027; HE DY, 1994, J BIOL CHEM, V269, P2292; HUNTER CN, 1988, BIOCHEMISTRY-US, V27, P3459, DOI 10.1021/bi00409a050; KHOSRAVI M, 1990, PLASMID, V23, P138, DOI 10.1016/0147-619X(90)90032-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWENDON A, 1990, BIOCHEMISTRY-US, V29, P2075, DOI 10.1021/bi00460a016; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; PADDOCK ML, 1995, BIOCHEMISTRY-US, V34, P15742, DOI 10.1021/bi00048a019; *PROM CORP, 1996, ALT SIT IN VITR MUT; PURVIS DJ, 1990, J BIOL CHEM, V265, P1208; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; SUWANTO A, 1992, J BACTERIOL, V174, P1124, DOI 10.1128/jb.174.4.1124-1134.1992; SZCZEPANIAK A, 1991, EMBO J, V10, P2757, DOI 10.1002/j.1460-2075.1991.tb07824.x; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU L, 1984, J BIOL CHEM, V259, P5752; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1987, BIOCHEMISTRY-US, V26, P3658, DOI 10.1021/bi00386a060; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23722	23728		10.1074/jbc.272.38.23722	http://dx.doi.org/10.1074/jbc.272.38.23722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295316	hybrid			2022-12-27	WOS:A1997XX38100041
J	Chang, CH; Luse, DS				Chang, CH; Luse, DS			The H3/H4 tetramer blocks transcript elongation by RNA polymerase II in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE OCTAMER; NUCLEOSOMAL TEMPLATES; HUMAN RAP74; MAJOR LATE; IN-VITRO; INVITRO; DNA; INITIATION; CHROMATIN; BINDING	We have investigated transcript elongation efficiency by RNA polymerase II on chromatin templates in vitro. Circular plasmid DNAs bearing purified RNA polymerase II transcription complexes were assembled into nucleosomes using purified histones and transient exposure to high salt, followed by dilution and dialysis. This approach resulted in nucleosome assembly beginning immediately downstream of the transcription complexes, RNA polymerases on these nucleosomal templates could extend their 15- or 35-nucleotide nascent RNAs by only about 10 nucleotides in 15 min, even in the presence of elongation factors TFIIF and SII, Efficient transcript elongation did occur upon dissociation of nucleosomes with 1% sarkosyl, indicating that the RNA polymerases were not damaged by the high salt reconstitution procedure. Since the elongation complexes were released by sarkosyl but not by SII, these complexes apparently did not enter the arrested conformation when they encountered nucleosomes. Surprisingly, elongation was no more efficient on nucleosomal templates reconstituted only with H3/H4 tetramers, even in the presence of elongation factors and/or competitor DNA at high concentration, Thus, in a purified system lacking nucleosome remodeling factors, not only the core histone octamer but also the H3/H4 tetramer provide an nearly absolute block to transcript elongation by RNA polymerase II, even in the presence of elongation factors.	CLEVELAND CLIN FDN, DEPT MOL BIOL, LERNER RES INST, NC20, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NIGMS NIH HHS [GM 29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; CAI H, 1987, J BIOL CHEM, V262, P298; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KIROV N, 1992, EMBO J, V11, P1941, DOI 10.1002/j.1460-2075.1992.tb05247.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LUSE DS, 1987, J BIOL CHEM, V262, P289; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; ONEILL TE, 1993, P NATL ACAD SCI USA, V90, P6203, DOI 10.1073/pnas.90.13.6203; PATTERTON HG, 1993, J MOL BIOL, V229, P623, DOI 10.1006/jmbi.1993.1068; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; PFAFFLE P, 1990, J BIOL CHEM, V265, P16821; Protacio RU, 1996, J MOL BIOL, V256, P458, DOI 10.1006/jmbi.1996.0101; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RHODES D, 1989, METHOD ENZYMOL, V170, P575; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; SHIMAMURA A, 1989, J BIOL CHEM, V264, P14524; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; STEIN A, 1989, METHOD ENZYMOL, V170, P585; Sternglanz R, 1996, TRENDS BIOCHEM SCI, V21, P357, DOI 10.1016/S0968-0004(96)90120-6; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Studitsky VM, 1996, METHOD ENZYMOL, V274, P246; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; Yankulov KY, 1996, MOL CELL BIOL, V16, P3291; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	57	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23427	23434		10.1074/jbc.272.37.23427	http://dx.doi.org/10.1074/jbc.272.37.23427			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287358	hybrid			2022-12-27	WOS:A1997XV74400069
J	Shi, XO; Bernhardt, TG; Wang, SM; Gershon, PD				Shi, XO; Bernhardt, TG; Wang, SM; Gershon, PD			The surface region of the bifunctional vaccinia RNA modifying protein VP39 that interfaces with Poly(A) polymerase is remote from the RNA binding cleft used for its mRNA 5' cap methylation function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY ACTIVITIES; VIRUS; POLYADENYLATION; PURIFICATION; CLEAVAGE; SUBUNIT; TAIL; ENDS	VP39 is a single-domain, bifunctional viral protein, which acts at both ends of nascent mRNA, At the 3' end, it acts as a cap-specific 2'-O-methyltransferase, At the 3' end, it acts as a poly(A) polymerase processivity factor, requiring its direct association with poly(A) polymerase, Although crystallographic and biochemical data show the catalytic center and associated binding sites for VP39's methyltransferase function to be juxtaposed around a superficial cleft on the protein surface, surface regions required for VP39's mRNA 3' end, modifying functions are not known. Here, we identify a surface region that interfaces directly with poly(A) polymerase, taking three independent approaches: (i) development of a direct in vitro dimerization assay, which is applied to numerous VP39 point mutants; (ii) identification of sites within VP39 that become protected from protease cleavage upon dimerization and further mutagenesis based upon these data; (iii) site-specific photo-crosslinking of VP39 to VP55. We find that the dimerization interface lies on a surface region remote from the methyltransferase cleft and contains a 3-5-residue ''hot-spot,'' which is very sensitive to amino acid substitutions. Various other sites within VP39 consistently became hypersensitive to protease cleavage upon interaction with VP55, indicating the occurrence of extensive conformational changes.	TEXAS A&M UNIV,ALBERT B ALKEK INST BIOSCI & TECHNOL,HOUSTON,TX 77030	Texas A&M University System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051953] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 R01 GM51953-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBOSA E, 1978, J BIOL CHEM, V253, P7698; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ELBRIGHT YW, 1996, BIOCONJUGATE CHEM, V7, P380; Gershon P, 1996, METHOD ENZYMOL, V275, P208; GERSHON PD, 1995, J IMMUNOL METHODS, V183, P65, DOI 10.1016/0022-1759(95)00032-6; GERSHON PD, 1993, J BIOL CHEM, V268, P2203; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1992, GENE DEV, V6, P1575, DOI 10.1101/gad.6.8.1575; Gros E., 1967, METHOD ENZYMOL, V11, P238; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; Hodel AE, 1997, NAT STRUCT BIOL, V4, P350, DOI 10.1038/nsb0597-350; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Miller A, 1997, SCIENCE, V275, P1655, DOI 10.1126/science.275.5306.1655; MOSS B, 1975, J BIOL CHEM, V250, P4722; NEVINS JR, 1977, J BIOL CHEM, V252, P6939; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SCHNIERLE BS, 1994, J BIOL CHEM, V269, P20700; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; Shi XN, 1996, RNA, V2, P88; THOMSON JG, 1995, BIOTECHNIQUES, V19, P416	25	22	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23292	23302		10.1074/jbc.272.37.23292	http://dx.doi.org/10.1074/jbc.272.37.23292			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287339	hybrid			2022-12-27	WOS:A1997XV74400050
J	Zheng, LM; Eckerdal, J; Dimitrijevic, I; Andersson, T				Zheng, LM; Eckerdal, J; Dimitrijevic, I; Andersson, T			Chemotactic peptide-induced activation of Ras in human neutrophils is associated with inhibition of p120-GAP activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; PLECKSTRIN HOMOLOGY DOMAINS; VAV PROTOONCOGENE PRODUCT; SHC ADAPTER PROTEIN; T-CELL ACTIVATION; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; MAP KINASE; CHEMOATTRACTANT RECEPTORS	The monomeric G-protein Ras is now considered to function as an initial regulator of multiple signaling pathways in both normal and transformed cell types, Adhesion and chemoattractant receptors are known to trigger activation of Ras in human neutrophils, but the signaling mechanism that, activates Ras has only been partially elucidated, The present results show that in neutrophils, a time-and dose-dependent f-Met-Leu-Phe (FMLP)-induced activation of Ras is mediated by G(i2)-proteins, because such activation is inhibited by pertussis toxin and because direct stimulation of heterotrimeric G-proteins with AlF4- is sufficient to activate Ras. Pretreatment of neutrophils with tyrosine kinase inhibitors, i.e. genistein or erbstatin that completely block FMLP-stimulated protein tyrosine phosphorylations, did not affect; the FMLP-induced activation of Ras. Moreover, FMLP did not induce any detectable translocation of Grb2 and Sos to the plasma membrane of neutrophils. Other signaling molecules, such as protein kinase C, phosphatidylinositol 3-kinase and Ca2+, do not appear to be involved in the FMLP-induced Pas activation. Instead, stimulation of neutrophils with FMLP or C5a, the latter of which also activates G(i2)-proteins, resulted ill transient inhibition of the activity of Ras GTPase-activating proteins (GAP) with kinetics that correlated well with the kinetics of Ras activation. Moreover, decreased Ras-GAP activity was found in p120-GAP but not in neurofibromin immunoprecipitates of FMLP-stimulated cells. These results suggest that tyrosine kinase-dependent Ras exchange factors do not contribute to the FMLP-induced activation of Ras but that such activation is mediated via inhibition of p120-GAP in neutrophils.			Zheng, LM (corresponding author), LUND UNIV,WALLENBERG LAB,DEPT LAB MED,DIV EXPT PATHOL,FLOOR 4,U-MAS,S-20502 MALMO,SWEDEN.		zheng, limin/HGB-2510-2022	Andersson, Tommy/0000-0003-4032-5769; Zheng, Limin/0000-0002-8281-1450				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BOGUSKI MS, 1993, NATURE, V366, P648; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CRAMER EB, 1992, INFLAMMATION BASIC P, P341; Downey GP, 1996, J BIOL CHEM, V271, P21005, DOI 10.1074/jbc.271.35.21005; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Dusi S, 1996, FEBS LETT, V383, P181, DOI 10.1016/0014-5793(96)00248-7; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GRAVES JD, 1991, J IMMUNOL, V146, P3709; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; Gulbins E, 1995, BIOCHEM BIOPH RES CO, V217, P876, DOI 10.1006/bbrc.1995.2853; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULHINS E, 1994, MOL CELL BIOL, V14, P4749; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hellberg C, 1996, BIOCHEM J, V317, P403, DOI 10.1042/bj3170403; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Katagiri K, 1996, BLOOD, V87, P4276, DOI 10.1182/blood.V87.10.4276.bloodjournal87104276; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFGREN R, 1993, J CELL BIOL, V123, P1597, DOI 10.1083/jcb.123.6.1597; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RIDELY AJ, 1992, CELL, V40, P401; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sarndahl E, 1996, J BIOL CHEM, V271, P15267; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TORRES M, 1993, J IMMUNOL, V150, P1563; Torres M, 1996, J BIOL CHEM, V271, P13244, DOI 10.1074/jbc.271.22.13244; TORTI M, 1992, J BIOL CHEM, V267, P8293; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; ZHENG L, 1995, J IMMUNOL, V155, P776; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	58	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23448	23454		10.1074/jbc.272.37.23448	http://dx.doi.org/10.1074/jbc.272.37.23448			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287361	hybrid			2022-12-27	WOS:A1997XV74400072
J	Lindesmith, L; McIlvain, JM; Argon, Y; Sheetz, MP				Lindesmith, L; McIlvain, JM; Argon, Y; Sheetz, MP			Phosphotransferases associated with the regulation of kinesin motor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE TRANSPORT; OKADAIC ACID; HEAVY-CHAIN; PHOSPHORYLATION; BINDING; PROTEIN; MOTILITY; FORMS; CELLS	Kinesin, a plus-end-directed microtubule motor protein, functions in concert with accessory factors that have been shown to regulate enzyme activity and may also provide cargo specificity. This report identifies the 79-kDa kinesin-associated phosphoprotein as a phosphoisoform of kinesin light chain. Increased phosphorylation of this light chain isoform is sufficient to account for the increase in kinesin-mediated microtubule-gliding activity. Additionally, it was found that the degree of phosphorylation of this isoform is regulated by a 100-kDa kinase and 150-kDa type 1 phosphatase. Both the kinesin light chain kinase and phosphatase co-purify with the kinesin heavy chain, suggesting that kinesin exists in a large complex capable of self-regulation.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	Duke University; University of Chicago								ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; BRAUTIGAN DL, 1989, ARCH BIOCHEM BIOPHYS, V275, P44, DOI 10.1016/0003-9861(89)90348-2; BURKHARDT JK, 1993, J CELL SCI, V104, P151; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Thaler C D, 1996, Int Rev Cytol, V164, P269; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YU H, 1992, J BIOL CHEM, V267, P20457	22	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22929	22933		10.1074/jbc.272.36.22929	http://dx.doi.org/10.1074/jbc.272.36.22929			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9312551	hybrid			2022-12-27	WOS:A1997XV49200078
J	DiSepio, D; Malhotra, M; Chandraratna, RAS; Nagpal, S				DiSepio, D; Malhotra, M; Chandraratna, RAS; Nagpal, S			Retinoic acid receptor-nuclear factor-interleukin 6 antagonism - A novel mechanism of retinoid-dependent inhibition of a keratinocyte hyperproliferative differentiation marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; RESPONSE ELEMENT; PSORIATIC SKIN; TRANSACTIVATION; IDENTIFICATION; EXPRESSION; DOMAIN; CELLS; PROLIFERATION; TRANSCRIPTION	Retinoids inhibit the expression of migration inhibitory factor-related protein-8 (MRP-8), a marker of hyperproliferative or abnormal keratinocyte differentiation, in a retinoic acid receptor (RAR)-dependent manner in various cell culture systems. MRP-8 expression is also down-regulated in vivo in psoriatic lesions after topical application of an anti-psoriatic RAR beta/gamma-selective synthetic retinoid, tazarotene. We demonstrate that an MRP-8 promoter linked to a chloramphenicol acetyltransferase reporter (MRP8CAT) faithfully replicates the differentiation-specific regulation of the endogenous keratinocyte MRP-8 gene. Further, interferon gamma and serum-induced expression of MRP8CAT is inhibited by retinoid receptors in a ligand-dependent manner, We also show that NF-IL6 acts as a transcriptional enhancer of MRP-8, and that RARs inhibit MRP8CAT by inhibiting the enhancer action of nuclear factor-interleukin-6 (NF-IL6), The NF-IL6 antagonism function of RAR is a complex of the core of the DNA binding domain and the hydrophobic zipper region. This manuscript identifies NF-IL6 as another transcription factor, in addition to API, whose activity is inhibited by RAR in a ligand-dependent manner, The interdiction of NF-IL6-dependent signal transduction pathway by RARs may explain some of the therapeutic effects of retinoids in inflammatory and proliferative diseases.	ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT BIOL, IRVINE, CA 92612 USA; ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT CHEM, IRVINE, CA 92612 USA	AbbVie; Allergan; AbbVie; Allergan								ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ANDREATTAVANLEYEN S, 1994, J CELL PHYSIOL, V160, P265, DOI 10.1002/jcp.1041600208; BARTHE C, 1991, BIOCHIM BIOPHYS ACTA, V1096, P175, DOI 10.1016/0925-4439(91)90057-G; Boehm MF., 1995, EXPERT OPIN INV DRUG, V4, P593, DOI DOI 10.1517/13543784.4.7.593; BRASIER AR, 1994, J BIOL CHEM, V269, P10341; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; KRUEGER GG, 1994, J INVEST DERMATOL, V102, pS14, DOI 10.1111/1523-1747.ep12386079; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; Nagpal S, 1996, CELL GROWTH DIFFER, V7, P1783; Nagpal S, 1996, J INVEST DERMATOL, V106, P269, DOI 10.1111/1523-1747.ep12340668; Nagpal S, 1997, MOL CELL BIOL, V17, P4159, DOI 10.1128/MCB.17.7.4159; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nagpal S, 1996, CURR PHARM DESIGN, V2, P295; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; WILKINSON MM, 1988, J CELL SCI, V91, P221	26	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25555	25559		10.1074/jbc.272.41.25555	http://dx.doi.org/10.1074/jbc.272.41.25555			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325272	hybrid			2022-12-27	WOS:A1997YA35800027
J	Piotrowicz, RS; Levin, EG				Piotrowicz, RS; Levin, EG			Basolateral membrane-associated 27-kDa heat shock protein and microfilament polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID-PHASE PINOCYTOSIS; ACTIN POLYMERIZATION; POLYMORPHONUCLEAR LEUKOCYTES; CELLULAR THERMORESISTANCE; ENDOTHELIAL-CELLS; MAPKAP KINASE-2; ALPHA-ACTININ; F-ACTIN; PHOSPHORYLATION; ORGANIZATION	The in vivo activity of the 27-kDa heat shock protein, a barbed-end microfilament capping protein, may be localized to the plasma membrane. To investigate this putative association, bovine endothelial cells expressing the human wild type or a mutant nonphosphorylatable 27-kDa heat shock protein were subjected to subcellular fractionation and immunoblot analysis. The 25-kDa endogenous bovine homolog and both exogenous gene products partitioned with cytosolic or plasma membrane components, indicating that phosphorylation is not required for membrane association. Phorbol ester treatment resulted in phosphorylation of only membrane-associated 25-kDa and wild type 27-kDa heat shock protein and did not induce redistribution. In a second fractionation protocol, streptavidin-agarose precipitation of extracts prepared from cells biotinylated at either the apical or basal surface localized membrane 25- and 27-kDa heat shock protein exclusively to the basolateral surface. Stimulation of transfectants expressing the wild type 27-kDa heat shock protein resulted in its phosphorylation and a doubling in the amount of membrane-associated F-actin precipitated, whereas the mutant protein decreased the amount of F-actin precipitated. These data suggest that membrane-associated 25- and 27-kDa heat shock proteins inhibit the generation of basolateral microfilaments and that phosphorylation releases this inhibition.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040435] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40435] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLERS A, 1994, MOL PHARMACOL, V46, P1077; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; ELLIS JA, 1992, BIOCHEM J, V283, P553, DOI 10.1042/bj2830553; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; GAZITT Y, 1981, CANCER RES, V41, P1064; GLOCK GE, 1953, BIOCHEM J, V55, P400, DOI 10.1042/bj0550400; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GOTLIEB AI, 1990, TOXICOL PATHOL, V18, P603; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HOGEBOOM GH, 1950, J BIOL CHEM, V186, P417; HUOT J, 1995, EUR J BIOCHEM, V227, P418; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LEVIN EG, 1991, J IMMUNOL, V146, P3772; Li S, 1996, AM J PHYSIOL-CELL PH, V271, pC994, DOI 10.1152/ajpcell.1996.271.3.C994; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; PIOTROWICZ RS, 1995, FASEB J, V9, P1079, DOI 10.1096/fasebj.9.11.7649407; PODLUBNAYA ZA, 1975, J MOL BIOL, V92, P357, DOI 10.1016/0022-2836(75)90234-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1994, ADV EXP MED BIOL, V358, P133; WATTS RG, 1992, CELL MOTIL CYTOSKEL, V21, P25, DOI 10.1002/cm.970210104; WATTS RG, 1994, CELL MOTIL CYTOSKEL, V28, P155, DOI 10.1002/cm.970280207	33	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25920	25927		10.1074/jbc.272.41.25920	http://dx.doi.org/10.1074/jbc.272.41.25920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325325	Green Published, hybrid			2022-12-27	WOS:A1997YA35800080
J	Jin, SF; Kharbanda, S; Mayer, B; Kufe, D; Weaver, DT				Jin, SF; Kharbanda, S; Mayer, B; Kufe, D; Weaver, DT			Binding of Ku and c-Abl at the kinase homology region of DNA-dependent protein kinase catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; V(D)J RECOMBINATION; TYROSINE KINASE; END; PHOSPHORYLATION; AUTOANTIGEN; DEFECTS; DOMAINS; COMPLEX; CELLS	The DNA-dependent protein kinase (DNA-PK) con trols the repair of double-stranded DNA breaks in mammalian cells. The protein kinase subunit of DNA-PK (DNA-PKcs) is targeted to DNA breaks by association with the Hu DNA-binding heterodimer. Here we show that a Ku association site is present at the carboxyl terminus of DNA-PKcs (amino acids 3002-3850) near the protein kinase domain. Correspondingly, the nuclear c-Abl tyrosine kinase that associates with DNA-PK also binds to the kinase homology domain. The c-Abl SH3 domain binds to amino acids 3414-3850 of DNA-PKcs. c-Abl phosphorylates C-terminal fragments of DNA-PKcs, particularly amino acids 3414-3850. c-Abl phosphorylation of DNA-PKcs disassociates the DNA-PKcs.Ku complex. Thus, Ku and c-Abl provide opposing functions with regard to DNA-PK activity.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)					NATIONAL CANCER INSTITUTE [R01CA054326] Funding Source: NIH RePORTER; NCI NIH HHS [CA54326] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; Jin SF, 1997, CANCER SURV, V29, P221; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0	28	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24763	24766		10.1074/jbc.272.40.24763	http://dx.doi.org/10.1074/jbc.272.40.24763			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312071	hybrid			2022-12-27	WOS:A1997XY97000010
J	Mitchell, C; Blaho, JA; McCormick, AL; Roizmann, B				Mitchell, C; Blaho, JA; McCormick, AL; Roizmann, B			The nucleotidylylation of herpes simplex virus 1 regulatory protein alpha 22 by human casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GENE-EXPRESSION; WILD-TYPE; MACROMOLECULAR-SYNTHESIS; VIRAL POLYPEPTIDES; DELETION MUTANTS; TRANSCRIPTION; SUBUNIT; CELLS; DNA	The products of the alpha genes of herpes simplex virus 1, the infected cells proteins (ICP) 0, 4, 22, and 27 perform regulatory functions, are nucleotidylylated, and share the signaling or recognition sequence (RR(A/T)(P/S)R) that correctly predicted the nucleotidylylation of viral proteins encoded by U(L)21, U(L)31, U(L)49, and U(L)47 genes expressed later in infection. Extracts from uninfected HeLa cells or casein kinase II purified from sea star nucleotidylylated the ICP22 moiety of a glutathione S-transferase-ICP22 (GST22P) fusion protein with [(alpha-P-32]ATP or [2-H-3]ATP, We report that: (i) Purified HeLa cell casein kinase II specifically labeled a glutathione S-transferase fusion protein containing the aminoterminal 151 amino acids of ICP22 with [2-H-3]ATP, (ii) Nucleotidylylation of GST-ICP22 by purified enzyme exhibited positive cooperativity (Hill coefficient of 2 and a K' of 3.7 mu M) and a K-m = 37.7 mu m for ATP, (iii) Nucleotidylylation was inhibited by heparin, casein, or ATP alpha S but not by ATP gamma S, (iv) Mutation of the signaling sequence from RRAPRR to LKAPEK abolished nucleotidylylation, We conclude that nucleotidylylation of proteins by casein kinase II requires the presence of the signaling or recognition sequence, involves the cleavage of the phosphodiester bond between the alpha and beta phosphate, and need not be preceded by phosphorylation.	UNIV CHICAGO, MARJORIE B KOVLER VIRAL ONCOL LABS, CHICAGO, IL 60637 USA	University of Chicago					NCI NIH HHS [CA47451] Funding Source: Medline; NIAID NIH HHS [AI124009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI124009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLAHO JA, 1993, J VIROL, V67, P3891, DOI 10.1128/JVI.67.7.3891-3900.1993; BLAHO JA, 1994, J BIOL CHEM, V269, P17401; BLAHO JA, 1991, J VIROL, V65, P3759, DOI 10.1128/JVI.65.7.3759-3769.1991; BLAHO JA, 1992, J VIROL, V66, P6393; CAMPBELL MEM, 1984, J MOL BIOL, V180, P1, DOI 10.1016/0022-2836(84)90427-3; DELUCA NA, 1985, MOL CELL BIOL, V5, P1997, DOI 10.1128/MCB.5.8.1997; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P19; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; EVERETT RD, 1984, EMBO J, V3, P3135, DOI 10.1002/j.1460-2075.1984.tb02270.x; HIBBARD MK, 1995, J VIROL, V69, P4656, DOI 10.1128/JVI.69.8.4656-4667.1995; HONESS RW, 1975, P NATL ACAD SCI USA, V72, P1276, DOI 10.1073/pnas.72.4.1276; HONESS RW, 1974, J VIROL, V14, P8, DOI 10.1128/JVI.14.1.8-19.1974; HU E, 1990, J BIOL CHEM, V265, P20609; KRECK W, 1992, J CELL BIOL, V116, P43; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MITCHELL C, 1994, P NATL ACAD SCI USA, V91, P11864, DOI 10.1073/pnas.91.25.11864; PANAGIOTIDIS CA, 1995, GENE, V164, P45, DOI 10.1016/0378-1119(95)00417-5; PRESTON CM, 1979, J VIROL, V29, P275, DOI 10.1128/JVI.29.1.275-284.1979; PRESTON CM, 1983, VIROLOGY, V131, P492, DOI 10.1016/0042-6822(83)90515-9; PURVES FC, 1992, P NATL ACAD SCI USA, V89, P7310, DOI 10.1073/pnas.89.16.7310; PURVES FC, 1993, P NATL ACAD SCI USA, V90, P6701, DOI 10.1073/pnas.90.14.6701; RICE SA, 1988, J VIROL, V62, P3814, DOI 10.1128/JVI.62.10.3814-3823.1988; Roizman B, 1996, FIELDS VIROLOGY, P2231; SACKS WR, 1987, J VIROL, V61, P829, DOI 10.1128/JVI.61.3.829-839.1987; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGHERA JS, 1992, BIOCHEM J, V283, P829, DOI 10.1042/bj2830829; SEARS AE, 1985, J VIROL, V55, P338, DOI 10.1128/JVI.55.2.338-346.1985; SMITH IL, 1992, VIROLOGY, V186, P74, DOI 10.1016/0042-6822(92)90062-T; STEVELY WS, 1985, J GEN VIROL, V66, P661, DOI 10.1099/0022-1317-66-4-661; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TRAUGH JA, 1990, ADV SEC MESS PHOSPH, V24, P224; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; WILCOX KW, 1980, J VIROL, V33, P167, DOI 10.1128/JVI.33.1.167-182.1980	36	23	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25394	25400		10.1074/jbc.272.40.25394	http://dx.doi.org/10.1074/jbc.272.40.25394			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312161	hybrid			2022-12-27	WOS:A1997XY97000100
J	Wang, H; Yoshizumi, M; Lai, KH; Tsai, JC; Perrella, MA; Haber, E; Lee, ME				Wang, H; Yoshizumi, M; Lai, KH; Tsai, JC; Perrella, MA; Haber, E; Lee, ME			Inhibition of growth and p21(ras) methylation in vascular endothelial cells by homocysteine but not cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; PLASMA HOMOCYST(E)INE; CARBOXYL METHYLATION; MAP KINASES; PROTEIN; ACTIVATION; ARTERIAL; ATHEROSCLEROSIS; BINDING; RISK	Although hyperhomocysteinemia has been recognized recently as a prevalent risk factor for myocardial infarction and stroke, the mechanisms by which it accelerates arteriosclerosis have not been elucidated, mostly because the biological effects of homocysteine can only be demonstrated at very high concentrations and can be mimicked by cysteine, which indicates a lack of specificity, We found that 10-50 mu m of homocysteine (a range that overlaps levels observed clinically) but not cysteine inhibited DNA synthesis in vascular endothelial cells (VEC) and arrested their growth at the G(1) phase of the cell cycle. Homocysteine in this same range had no effect on the growth of vascular smooth muscle cells (VSMC) or fibroblasts, Homocysteine decreased carboxyl methylation of p21(ras) (a G(1) regulator whose activity is regulated by prenylation and methylation in addition to GTP-GDP exchange) by 50% in VEC but not VSMC, a difference that may be explained by the ability of homocysteine to dramatically increase levels of S-adenosylhomocysteine, a potent inhibitor of methyltransferase, in VEC but not VSMC. Moreover, homocysteine-induced hypomethylation in VEC was associated with a 66% reduction in membrane-associated p21(ras) and a 67% reduc- tion in extracellular signal-regulated kinase 1/2, which is a member of the mitogen-activated protein (MAP) kinase family, Because the MAP kinases have been implicated in cell growth, the p21(ras)-MAP kinase pathway may represent one of the mechanisms that mediates homocysteine's effect on VEC growth, VEC damage is a hallmark of arteriosclerosis. Homocysteine-induced inhibition of VEC growth may play an important role in this disease process.	HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03194] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER JR, 1984, J BIOL CHEM, V259, P7115; BERGMANN S, 1994, J IMMUNOL, V153, P1736; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; Croteau S., 1994, Zygote, V2, P47; DUDMAN NPB, 1991, ATHEROSCLEROSIS, V91, P77, DOI 10.1016/0021-9150(91)90189-A; FORTIN LJ, 1995, CLIN BIOCHEM, V28, P155, DOI 10.1016/0009-9120(94)00073-5; GORMAND F, 1990, LIFE SCI, V47, P1793, DOI 10.1016/0024-3205(90)90281-U; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HARKER LA, 1993, ARTERIOSCLER THROMB, V13, P512; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; Lai KH, 1996, J CLIN INVEST, V98, P1560, DOI 10.1172/JCI118949; LENTZ SR, 1993, BLOOD, V81, P683; MALINOW MR, 1995, CLIN CHEM, V41, P173; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; OLSZEWSKI AJ, 1993, FREE RADICAL BIO MED, V14, P683, DOI 10.1016/0891-5849(93)90151-J; Paik W K, 1980, Adv Enzyme Regul, V19, P471; PAIK WK, 1980, PROTEIN METHYLATION, P82; PARISH CA, 1994, BIOCHEMISTRY-US, V33, P9986, DOI 10.1021/bi00199a023; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PHILIPS MR, 1995, P NATL ACAD SCI USA, V92, P2283, DOI 10.1073/pnas.92.6.2283; RODGERS GM, 1990, BLOOD, V75, P895; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SOBOTKABRINER C, 1992, J BIOL CHEM, V267, P12116; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; STAMPFER MJ, 1993, JAMA-J AM MED ASSOC, V270, P2726, DOI 10.1001/jama.270.22.2726; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAN EW, 1991, J BIOL CHEM, V266, P10719; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Vizirianakis IS, 1995, BIOCHEM PHARMACOL, V50, P1807, DOI 10.1016/0006-2952(95)02056-X; XIE HY, 1994, J BIOL CHEM, V269, P1981	45	212	225	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25380	25385		10.1074/jbc.272.40.25380	http://dx.doi.org/10.1074/jbc.272.40.25380			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312159	hybrid			2022-12-27	WOS:A1997XY97000098
J	BenMamoun, C; Beckerich, JM; Gaillardin, C				BenMamoun, C; Beckerich, JM; Gaillardin, C			Yarrowia lipolytica TSR1 gene product - A novel endoplasmic reticulum membrane component involved in the signal recognition particle-dependent translocation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; YEAST; COMPLEX; TRANSPORT; RNA	The tsr1-1 mutation has been initially identified as an extragenic suppressor of the scr2.II-13 mutation that alters the 7SL RNA component of the signal recognition particle (SRP) and results in severe defects in protein translocation and SRP stability. We showed previously that the TSR1 gene was essential and that the tsr1-1 mutation allowed complete recovery of scr2.II-13-associated secretory defects. We show here that the tsr1-1 mutation also restores SRP stability in an scr2.II-13 context. The TSR1 gene product (Tsr1p) is stably associated with rapidly sedimenting material and cofractionates with the lumenal protein Kar2p of the endoplasmic reticulum; it behaves in protease protection assays as a transmembrane component. Coimmunoprecipitation experiments revealed a physical interaction with Kar2p and with ribosomal components associated to the 5.8S rRNA as well as with SRP components like Sec65p and 7SL RNA. We propose that Tsr1p is an important component of the endoplasmic reticulum membrane, interacting both with the SRP-ribosome complex in the cytosol and with Kar2p in the lumen of the endoplasmic reticulum.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA; INRA, INST NATL AGRON PARIS GRIGNON, LAB GENET MOL & CELLULAIRE,CTR BIOTECHNOL AGROIND, CNRS, F-78850 THIVERVAL GRIGNON, FRANCE	Howard Hughes Medical Institute; Washington University (WUSTL); AgroParisTech; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay	BenMamoun, C (corresponding author), WASHINGTON UNIV, SCH MED,HOWARD HUGHES MED INST,DEPT MOL MICROBIOL, 660 S EUCLID AVE, BOX 8230, ST LOUIS, MO 63110 USA.							AGAPHONOV MO, 1994, YEAST, V10, P509, DOI 10.1002/yea.320100410; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BENMAMOUN C, 1996, J BIOL CHEM, V27, P23895; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; HE F, 1992, J BIOL CHEM, V267, P1932; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Maniatis T., 1982, MOL CLONING; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; RUOHOLA H, 1987, P NATL ACAD SCI USA, V84, P8468, DOI 10.1073/pnas.84.23.8468; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; VANHEERIKHUIZEN H, 1985, GENE, V39, P213, DOI 10.1016/0378-1119(85)90315-4; WALWORTH NC, 1989, METHOD CELL BIOL, V31, P335; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848	24	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24594	24598		10.1074/jbc.272.39.24594	http://dx.doi.org/10.1074/jbc.272.39.24594			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305926	hybrid, Green Published			2022-12-27	WOS:A1997XY51500077
J	Jisaka, M; Kim, RB; Boeglin, WE; Nanney, LB; Brash, AR				Jisaka, M; Kim, RB; Boeglin, WE; Nanney, LB; Brash, AR			Molecular cloning and functional expression of a phorbol ester-inducible 8S-lipoxygenase from mouse skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; CDNA CLONING; LINOLEIC-ACID; LIPOXYGENASE; SENCAR; GENE; 5-LIPOXYGENASE; 8-LIPOXYGENASE; CHROMATOGRAPHY; LOCALIZATION	One of the effects of topical application of phorbol ester to mouse skin is the induction of all 8S-lipoxygenase in association with the inflammatory response, Here we report the molecular cloning and characterization of this enzyme. The cDNA was isolated by polymerase chain reaction from mouse epidermis and subsequently from a mouse epidermal cDNA library, The cDNA encodes a protein of 677 amino acids with a calculated molecular mass of 76 kDa, The amino acid sequence has 78% identity to a 15S-lipoxygenase cloned recently from human skin and approximately 40% identity to other mammalian lipoxygenases. When expressed in vaccinia virus-infected Hela cells, the mouse enzyme converts arachidonic acid exclusively to 8S-hydroperoxyeicosatetraenoic acid while linoleic acid is converted to 9S-hydroperoxy-linoleic acid in lower efficiency, Phorbol ester treatment of mouse skin is associated with strong induction of 8S-lipoxygenase mRNA and protein, Ey Northern analysis, expression of 8S-Lipoxygenase mRNA was also detected in brain. Immunohistochemical analysis of phorbol ester-treated mouse skill showed the strongest reaction to 8S-lipoxygenase in the differentiated epidermal layer, the stratum granulosum. The inducibility may be a characteristic feature of the mouse 8S-lipoxygenase and its human 15S-lipoxygenase homologue.	VANDERBILT UNIV, DEPT PHARMACOL, SCH MED, DIV CLIN PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT PLAST SURG & CELL BIOL, SCH MED, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University			Kim, Richard/D-6971-2011	Kim, Richard/0000-0001-8148-1632	NIEHS NIH HHS [ES000267] Funding Source: Medline; NIGMS NIH HHS [GM-53638, GM-49502] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053638, R01GM049502] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; BRASH AR, 1990, METHOD ENZYMOL, V187, P187; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; FISCHER SM, 1988, CANCER RES, V48, P658; FISCHER SM, 1987, CANCER RES, V47, P3174; FISCHER SM, 1987, CARCINOGENESIS, V8, P421, DOI 10.1093/carcin/8.3.421; Funk CD, 1996, J BIOL CHEM, V271, P23338, DOI 10.1074/jbc.271.38.23338; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; HAMBERG M, 1980, BIOCHIM BIOPHYS ACTA, V617, P545, DOI 10.1016/0005-2760(80)90022-3; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; LEHMANN WD, 1992, ANAL BIOCHEM, V204, P158, DOI 10.1016/0003-2697(92)90156-2; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; NUGTEREN DH, 1987, BIOCHIM BIOPHYS ACTA, V921, P135, DOI 10.1016/0005-2760(87)90179-2; Oesterling JE, 1996, PROSTATE, P67; SUN D, 1996, J BIOL CHEM, V271, P20455; VANDIJK KW, 1995, BBA-LIPID LIPID MET, V1259, P4, DOI 10.1016/0005-2760(95)00158-9; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZIBOH VA, 1988, PROG LIPID RES, V27, P81, DOI 10.1016/0163-7827(88)90006-9	26	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24410	24416		10.1074/jbc.272.39.24410	http://dx.doi.org/10.1074/jbc.272.39.24410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305900	hybrid			2022-12-27	WOS:A1997XY51500051
J	Kurosu, H; Maehama, T; Okada, T; Yamamoto, T; Hoshino, S; Fukui, Y; Ui, M; Hazeki, O; Katada, T				Kurosu, H; Maehama, T; Okada, T; Yamamoto, T; Hoshino, S; Fukui, Y; Ui, M; Hazeki, O; Katada, T			Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110 beta is synergistically activated by the beta gamma subunits of G proteins and phosphotyrosyl peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHOSPHATIDYLINOSITOL 3-KINASE; MYELOID-DERIVED CELLS; GTP-BINDING PROTEINS; BOVINE BRAIN; RAT-LIVER; KINASE; IDENTIFICATION; CLONING; 3'-KINASE; ALPHA	Phosphoinositide 3-kinase (PI 3-kinase) is a key signaling enzyme implicated in variety of receptor-stimulated cell responses, Receptors with intrinsic or associated tyrosine kinase activity recruit heterodimeric PI 3-kinases consisting of a 110-kDa catalytic subunit (p110) and an 85-kDa regulatory subunit (p85). We separated a PI 3-kinase that could be stimulated by the beta gamma subunits of G protein (G beta gamma) from rack liver, The G beta gamma-sensitive PI 3-kinase appeared to be a heterodimer consisting of p110 beta and p85 (or their related subunits), The stimulation by G beta gamma was inhibited by the GDP-bound alpha subunit of the inhibitory GTP-binding protein, Moreover, the stimulatory action of G beta gamma was markedly enhanced by the simultaneous addition of a phosphotyrosyl peptide synthesized according to the amino acid sequence of the insulin receptor substrate-1, Such enzymic properties could be observed with a recombinant p110 beta/p85 alpha expressed in COS-7 cells with their cDNAs, In contrast, another heterodimeric PI 3-kinase consisting of p110 alpha and p85 in the same rat liver, together with a recombinant p110 alpha/p85 alpha, was mot activated by G beta gamma, although their activities were stimulated by the phosphotyrosyl peptide. These results indicate khat p110 beta/p85 PI 3-kinase may be regulated in a cooperative manner by two different types of membrane receptors, one possessing tyrosine kinase activity and the other activating GTP-binding proteins.	UNIV TOKYO,GRAD SCH PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC AGR,DEPT AGR CHEM,LAB BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,UI LAB,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; University of Tokyo; RIKEN			Maehama, Tomohiko/HGB-4896-2022; Maehama, Tomohiko/AAX-8926-2020	Maehama, Tomohiko/0000-0002-9685-2317; Hoshino, Shinichi/0000-0001-6135-7896				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KONTANI K, 1992, ARCH BIOCHEM BIOPHYS, V294, P527, DOI 10.1016/0003-9861(92)90720-H; KUROSU H, 1995, BIOCHEM BIOPH RES CO, V216, P655, DOI 10.1006/bbrc.1995.2672; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; NISHINA H, 1995, J BIOCHEM-TOKYO, V118, P1083, DOI 10.1093/jb/118.5.1083; Okada T, 1996, BIOCHEM J, V317, P475, DOI 10.1042/bj3170475; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOKER A, 1994, J BIOL CHEM, V269, P32358; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589	30	227	231	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24252	24256		10.1074/jbc.272.39.24252	http://dx.doi.org/10.1074/jbc.272.39.24252			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305878	hybrid			2022-12-27	WOS:A1997XY51500029
J	Marfatia, SM; MoraisCabral, JH; Kim, AC; Byron, O; Chishti, AH				Marfatia, SM; MoraisCabral, JH; Kim, AC; Byron, O; Chishti, AH			The PDZ domain of human erythrocyte p55 mediates its binding to the cytoplasmic carboxyl terminus of glycophorin C - Analysis of the binding interface by in vitro mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NITRIC-OXIDE SYNTHASE; RED-BLOOD-CELLS; MEMBRANE SIALOGLYCOPROTEINS; MONOCLONAL-ANTIBODIES; GUANYLATE KINASES; MOLECULAR-BASIS; HUMAN HOMOLOG; IDENTIFICATION; ORGANIZATION	The PDZ domain, also known as the GLGF repeat/DHR domain, is an similar to 90-amino acid motif discovered in a recently identified family of proteins termed MAGUKs (membrane-associated guanylate kinase homologues), Sequence comparison analysis has since identified PDZ domains in over 50 proteins, Like SH2 and SH3 domains, the PDZ domains mediate specific protein protein interactions, whose specificities appear to be dictated by the primary structure of the PDZ domain as well as its binding target, Using recombinant fusion proteins and a blot overlay assay, we show that a single copy of the PDZ domain in human erythrocyte p55 binds to the carboxyl terminus of the cytoplasmic domain of human erythroid glycophorin C. Deletion mutagenesis of 21 amino acids at the amino terminus of the p55 PDZ domain completely abrogates its binding activity for glycophorin C. Using an alanine scan and surface plasmon resonance technique, we identify residues in the cytoplasmic domain of glycophorin C that are critical for its interaction with the PDZ domain, The recognition specificity of the p55 PDZ domain appears to be unique, since the three PDZ domains of hDlg (human lymphocyte homologue of the Drosophila discs large tumor suppressor) do not bind the cytoplasmic domain of glycophorin C. Taken together with our previous studies, these results complete the identification of interacting domains in the ternary complex between p55, glycophorin C, and protein 4.1, Implications of these findings are discussed in terms of binding specificity and the regulation of cytoskeleton-membrane interactions.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV INFECT & IMMUN,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Leicester; University of Glasgow	Marfatia, SM (corresponding author), TUFTS UNIV,ACH 4 BMR,ST ELIZABETHS MED CTR,SCH MED,LAB TUMOR CELL BIOL,736 CAMBRIDGE ST,BOSTON,MA 02135, USA.		Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716; Byron, Olwyn/0000-0001-7857-4520	NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL051445, P01HL037462, R01HL051445] Funding Source: NIH RePORTER; NCI NIH HHS [CA66263] Funding Source: Medline; NHLBI NIH HHS [HL37462, HL51445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; ANSTEE DJ, 1986, BRIT J HAEMATOL, V64, P211, DOI 10.1111/j.1365-2141.1986.tb04113.x; ANSTEE DJ, 1984, BIOCHEM J, V218, P615, DOI 10.1042/bj2180615; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHANG S, 1991, BLOOD, V77, P644; CHASIS JA, 1992, BLOOD, V80, P1869; Chishti AH, 1996, BLOOD, V87, P3462, DOI 10.1182/blood.V87.8.3462.bloodjournal8783462; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; DISCHER D, 1993, J BIOL CHEM, V268, P7186; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Hata Y, 1996, J NEUROSCI, V16, P2488; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; Hoskins R, 1996, DEVELOPMENT, V122, P97; Kim AC, 1996, GENOMICS, V31, P223, DOI 10.1006/geno.1996.0035; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KING MJ, 1995, BRIT J HAEMATOL, V89, P440, DOI 10.1111/j.1365-2141.1995.tb08347.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamm O., 1929, ARK MAT ASTR FYS, V21B, P1; LOIRAT MJ, 1994, TRANSFUSION MED, V4, P147, DOI 10.1111/j.1365-3148.1994.tb00256.x; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MAZOYER S, 1995, GENOMICS, V28, P25, DOI 10.1006/geno.1995.1101; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; REID ME, 1987, BLOOD, V69, P1068; REID ME, 1990, BLOOD, V75, P2229; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; SMYTHE J, 1994, BLOOD, V83, P1668; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TELEN MJ, 1991, BLOOD, V78, P1603; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	46	82	84	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24191	24197		10.1074/jbc.272.39.24191	http://dx.doi.org/10.1074/jbc.272.39.24191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305870	hybrid			2022-12-27	WOS:A1997XY51500021
J	Hipfner, DR; Almquist, KC; Leslie, EM; Gerlach, JH; Grant, CE; Deeley, RG; Cole, SPC				Hipfner, DR; Almquist, KC; Leslie, EM; Gerlach, JH; Grant, CE; Deeley, RG; Cole, SPC			Membrane topology of the multidrug resistance protein (MRP) - A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; AFFINITY SULFONYLUREA RECEPTOR; BINDING CASSETTE TRANSPORTER; HUMAN TUMOR-CELLS; P-GLYCOPROTEIN; CONDUCTANCE REGULATOR; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; LEUKOTRIENE C-4	Multidrug resistance protein, MRP, is a 190-kDa integral membrane phosphoglycoprotein that belongs to the ATP-binding cassette superfamily of transport proteins and is capable of conferring resistance to multiple chemotherapeutic agents. Previous studies have indicated that MRP consists of two membrane spanning domains (MSD) each followed by a nucleotide binding domain, plus an additional extremely hydrophobic NH2-terminal MSD, Computer-assisted hydropathy analyses and multiple sequence alignments suggest several topological models for MRP. To aid in determining the topology most likely to be correct, we have identified which of the 14 N-glycosylation sequons in this protein are utilized. Limited proteolysis of MRP-enriched membranes and deglycosylation of intact MRP and its tryptic fragments with PNGase F was carried out followed by immunoblotting with antibodies known to react with specific regions of MRP. The results obtained indicated that the sequon at Asn(354) in the middle MSD is not utilized and suggested approximate sites of N-glycosylation, Subsequent site-directed mutagenesis studies established that Asn(19) and Asn(23) in the NH2-terminal MSD and Asn(1006) in the COOH-terminal MSD are the only sites in MRP that are modified with N-linked oligosaccharides. N-Glycosylation of Asn(19) and Asn(23) provides the first direct experimental evidence that MRP has an extracytosolic NH2 terminus. This finding, together with those of previous studies, strongly suggests that the NH2-terminal MSD of MRP contains an odd number of transmembrane helices. These results may have important implications for the further understanding of the interaction of drugs with MRP.	QUEENS UNIV, CANC RES LABS, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PHARMACOL & TOXICOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada			Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Leslie, Elaine/0000-0003-1825-348X				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ALMQUIST KC, 1995, CANCER RES, V55, P102; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; BEJA O, 1995, J BIOL CHEM, V270, P12351; BOLES E, 1995, CURR GENET, V28, P197, DOI 10.1007/BF00315788; CHANG XB, 1994, J BIOL CHEM, V269, P18572; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLE SPC, 1996, DRUG RESISTANCE, P89; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GRANT CE, 1994, CANCER RES, V54, P357; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; HOE MH, 1992, J BIOL CHEM, V267, P4916; Jedlitschky G, 1996, CANCER RES, V56, P988; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nelson DA, 1996, BIOCHEMISTRY-US, V35, P14793, DOI 10.1021/bi960777y; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; Shapiro AB, 1996, INT J CANCER, V67, P256, DOI 10.1002/(SICI)1097-0215(19960717)67:2<256::AID-IJC17>3.0.CO;2-9; SKACH WR, 1993, J BIOL CHEM, V268, P6903; Stride BD, 1996, MOL PHARMACOL, V49, P962; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; vanKuijck MA, 1996, P NATL ACAD SCI USA, V93, P5401, DOI 10.1073/pnas.93.11.5401; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s	49	195	201	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23623	23630		10.1074/jbc.272.38.23623	http://dx.doi.org/10.1074/jbc.272.38.23623			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295302	hybrid			2022-12-27	WOS:A1997XX38100027
J	Lindvall, MK; Pihko, PM; Koskinen, AMP				Lindvall, MK; Pihko, PM; Koskinen, AMP			The binding mode of calyculin A to protein phosphatase-1 - A novel spiroketal vector model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT	The catalytic subunits of serine/threonine protein phosphatases 1 and 2A are subject to inhibition by various toxins such as the microcyst ins, the nodularins, okadaic acid, tautomycin, and the calyculins. A recent paper (Bagu, J. R., Sykes, B. D, Craig, M. M., and Holmes, C. F. B. (1997) J. Biol. Chem. 272, 5087-5097) reported the successful docking of the crystal structure of calyculin A to the crystal structure of protein phosphatase-1. Unfortunately, the model presented there is based on the structure of the unnatural enantiomer of calyculin A and must therefore be incorrect. We have developed a spiroketal vector model which appears to account for the spatial orientation of the hydrophobic and basic chains extending from the spiroketal-phosphate core of calyculin A. The model also clearly demonstrates why the unnatural enantiomer of calyculin A does not fit properly into the pocket of the active site. Based on our model, we present a possible open binding mode for calyculin A in the enzyme, This open structure is conceptually similar to the predicted binding mode of the peptide inhibitor DARPP-32 to the enzyme; the hydrophobic, metal-binding, and electrostatic interactions are all retained in this model.	UNIV OULU,DEPT CHEM,FIN-90570 OULU,FINLAND	University of Oulu			Koskinen, Ari M.P./B-2230-2010; Koskinen, Ari M P/D-2593-2015	Koskinen, Ari M P/0000-0002-5325-2899				Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; Chu YF, 1996, J BIOL CHEM, V271, P2574, DOI 10.1074/jbc.271.5.2574; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HAMADA Y, 1991, TETRAHEDRON LETT, V32, P5605; HOLMES CFB, 1993, CURR OPIN STRUC BIOL, V3, P934, DOI 10.1016/0959-440X(93)90159-I; HOOPS SC, 1991, J AM CHEM SOC, V113, P8262, DOI 10.1021/ja00022a010; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KATO Y, 1986, J AM CHEM SOC, V108, P2780, DOI 10.1021/ja00270a061; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017	12	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23312	23316		10.1074/jbc.272.37.23312	http://dx.doi.org/10.1074/jbc.272.37.23312			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287341	hybrid			2022-12-27	WOS:A1997XV74400052
J	Parry, RJ; Li, WY				Parry, RJ; Li, WY			An NADPH:FAD oxidoreductase from the valanimycin producer, Streptomyces viridifaciens - Cloning, analysis, and overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIBRIO-HARVEYI; BIOSYNTHESIS; PURIFICATION; ENZYME; GENES; NITRILOTRIACETATE; IDENTIFICATION; MONOOXYGENASE; ANTIBIOTICS; ATCC-29600	The valanimycin producer Streptomyces uilidifaciens contains a two-component enzyme system that catalyzes the oxidation of isobutylamine to isobutylhydroxylamine, One component of this enzyme system is isobutylamine hydroxylase, and the other component is a flavin reductase, The gene (vlmR) encoding the flavin reductase required by isobutylamine hydroxylase has been cloned from S. viridifaciens by chromosome walking, The gene codes for a protein of 194 amino acids with a calculated mass of 21,265 Da and a calculated pI of 10.2, Overexpression of the vlmR gene in Escherichia coli as an N-terminal His-tag derivative yielded a soluble protein that was purified to homogeneity. Removal of the N-terminal His-tag from the overexpressed protein by thrombin cleavage also produced a soluble protein, Both forms of the protein exhibited a high degree of flavin reductase activity, and the thrombin-cleaved form functioned in combination with isobutylamine hydroxylase to catalyze the conversion of isobutylamine to isobutylhydroxylamine, Kinetic data indicate that the overexpressed protein utilizes FAD and NADPH in preference to FMN, riboflavin, and NADH. The deduced amino acid sequence of the VlmR protein exhibited similarity to several other flavin reductases that may constitute a new family of flavin reductases.			Parry, RJ (corresponding author), RICE UNIV, DEPT CHEM, 6100 MAIN ST, MS-60, HOUSTON, TX 77005 USA.				NIGMS NIH HHS [GM53818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053818] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRIO JR, 1973, P NATL ACAD SCI USA, V70, P941, DOI 10.1073/pnas.70.3.941; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chater K. F., 1993, P83; DOLGANOV N, 1993, J BACTERIOL, V175, P7644, DOI 10.1128/JB.175.23.7644-7651.1993; IMAMURA N, 1989, J ANTIBIOT, V42, P156, DOI 10.7164/antibiotics.42.156; IZUMOTO Y, 1994, BBA-BIOENERGETICS, V1185, P243, DOI 10.1016/0005-2728(94)90216-X; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; Knobel HR, 1996, J BACTERIOL, V178, P6123, DOI 10.1128/jb.178.21.6123-6132.1996; KORSCH BH, 1964, TETRAHEDRON LETT, P523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY BW, 1951, CHEM IND-LONDON, P75; LARUE TA, 1977, LLOYDIA, V40, P307; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; LYTHGOE B, 1949, J CHEM SOC, P2716, DOI 10.1039/jr9490002716; PARRY RJ, 1994, J CHEM SOC CHEM COMM, P995, DOI 10.1039/c39940000995; Parry RJ, 1997, J BACTERIOL, V179, P409, DOI 10.1128/jb.179.2.409-416.1997; PARRY RJ, 1992, J AM CHEM SOC, V114, P10062, DOI 10.1021/ja00051a049; Parry RJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P47, DOI 10.1006/abbi.1996.9857; PRIETO MA, 1994, J BIOL CHEM, V269, P22823; RIGGS NV, 1956, CHEM IND-LONDON, P926; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; STEVENS CL, 1958, J AM CHEM SOC, V80, P6088, DOI 10.1021/ja01555a048; STEVENS CL, 1959, J AM CHEM SOC, V81, P1435, DOI 10.1021/ja01515a037; STEVENS CL, 1956, J AM CHEM SOC, V78, P3229, DOI 10.1021/ja01594a078; TAKAHASHI Y, 1989, J ANTIBIOT, V42, P1541, DOI 10.7164/antibiotics.42.1541; UETZ T, 1992, J BACTERIOL, V174, P1179, DOI 10.1128/jb.174.4.1179-1188.1992; Worthington V, 1993, WORTHINGTON ENZYME M, P293; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; Xu YR, 1997, J BACTERIOL, V179, P1112, DOI 10.1128/jb.179.4.1112-1116.1997; YAMATO M, 1986, J ANTIBIOT, V39, P184; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994	34	74	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23303	23311		10.1074/jbc.272.37.23303	http://dx.doi.org/10.1074/jbc.272.37.23303			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287340	hybrid			2022-12-27	WOS:A1997XV74400051
J	Croteau, DL; Bohr, VA				Croteau, DL; Bohr, VA			Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HAMSTER OVARY CELLS; ESCHERICHIA-COLI; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; COCKAYNE-SYNDROME; ENDONUCLEASE-III; BASE DAMAGE; PYRIMIDINE DIMERS; THYMINE GLYCOL; RINR-38 CELLS				Croteau, DL (corresponding author), NIA,GENET MOL LAB,NIH,BALTIMORE,MD 21224, USA.		Bohr, Vilhelm/AAP-5931-2020; Croteau, Deb/AAP-5933-2020	Croteau, Deborah/0000-0002-6094-4084				Aburatani H, 1997, CANCER RES, V57, P2151; AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; Beckman K B, 1996, Methods Enzymol, V264, P442, DOI 10.1016/S0076-6879(96)64040-3; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Bohr VA, 1995, CARCINOGENESIS, V16, P2885, DOI 10.1093/carcin/16.12.2885; CHUNG MH, 1991, BIOCHEM BIOPH RES CO, V178, P1472, DOI 10.1016/0006-291X(91)91059-L; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; CROTEAU DL, 1997, IN PRESS J BIOL CHEM, V2725; CUNNINGHAM RP, 1985, P NATL ACAD SCI USA, V82, P474, DOI 10.1073/pnas.82.2.474; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEOLIVEIRA R, 1994, NUCLEIC ACIDS RES, V22, P3760, DOI 10.1093/nar/22.18.3760; DIZDAROGLU M, 1993, DNA FREE RADICALS, P18; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Driggers WJ, 1996, CANCER RES, V56, P1262; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HARING M, 1994, NUCLEIC ACIDS RES, V22, P2010, DOI 10.1093/nar/22.11.2010; HIGUCHI Y, 1995, J BIOL CHEM, V270, P7950, DOI 10.1074/jbc.270.14.7950; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; IDE H, 1994, BIOCHEMISTRY-US, V33, P7842, DOI 10.1021/bi00191a011; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; KANG D, 1995, J BIOL CHEM, V270, P14659, DOI 10.1074/jbc.270.24.14659; KOW YW, 1990, MUTAT RES, V235, P147, DOI 10.1016/0921-8777(90)90068-G; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MALINS DC, 1991, CANCER RES, V51, P5430; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; MULLENDERS LHF, 1986, CARCINOGENESIS, V7, P995, DOI 10.1093/carcin/7.6.995; NAHS HM, 1996, CURR BIOL, V6, P968; NOCENTINI S, 1992, MUTAT RES, V284, P275, DOI 10.1016/0027-5107(92)90012-Q; OLINSKI R, 1992, FEBS LETT, V309, P193, DOI 10.1016/0014-5793(92)81093-2; Parshad R, 1996, P NATL ACAD SCI USA, V93, P5146, DOI 10.1073/pnas.93.10.5146; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; PETTEPHER CC, 1991, J BIOL CHEM, V266, P3113; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; RUNGER TM, 1995, J INVEST DERMATOL, V104, P68, DOI 10.1111/1523-1747.ep12613504; Ryoji M, 1996, NUCLEIC ACIDS RES, V24, P4057, DOI 10.1093/nar/24.20.4057; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; SCUDIERO DA, 1986, MUTAT RES, V159, P125, DOI 10.1016/0027-5107(86)90121-1; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Weaver DT, 1996, CRIT REV EUKAR GENE, V6, P345, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.20; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514	76	388	399	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25409	25412		10.1074/jbc.272.41.25409	http://dx.doi.org/10.1074/jbc.272.41.25409			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325246	hybrid			2022-12-27	WOS:A1997YA35800001
J	Kelley, JA; Knight, KL				Kelley, JA; Knight, KL			Allosteric regulation of RecA protein function is mediated by Gln(194)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PHAGE-LAMBDA-REPRESSOR; P-LOOP MOTIF; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DIRECTED CLEAVAGE; MOTOR DOMAIN; BINDING; RECOMBINATION; RESIDUES	Binding of ATP to the RecA protein induces a high affinity DNA binding required for activation of enzyme function. Screens for in vivo recombination and repressor cleavage activities show Gln(194) to be intolerant of all substitutions. Analyses of three mutant proteins (Q194N, Q194E, and Q194A) show that although basal enzyme function is maintained, each protein no longer displays an ATP-induced increase in DNA binding affinity. High salt activation of RecA function is also disrupted by these mutations. In contrast, ATP-induced changes in the oligomeric structure of Reck are maintained in the mutant proteins. These results demonstrate that Gln(194) is a critical ''allosteric switch'' for ATP-induced activation of Reck function but is not the exclusive mediator of ATP-induced changes in RecA.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOL BIOL, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044772] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44772] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DICAPUA E, 1990, J STRUCT BIOL, V104, P91, DOI 10.1016/1047-8477(90)90062-H; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; KONOLA JT, 1995, J BIOL CHEM, V270, P8411, DOI 10.1074/jbc.270.15.8411; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; Logan KM, 1997, J MOL BIOL, V266, P306, DOI 10.1006/jmbi.1996.0751; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NASTRI HG, 1994, J BIOL CHEM, V269, P26311; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PUGH BF, 1988, J BIOL CHEM, V263, P76; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; RUIGROK RWH, 1991, BIOCHIMIE, V73, P191, DOI 10.1016/0300-9084(91)90202-C; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; SKIBA MC, 1994, J BIOL CHEM, V269, P3823; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WILSON DH, 1990, J BIOL CHEM, V265, P7351; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	39	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25778	25782		10.1074/jbc.272.41.25778	http://dx.doi.org/10.1074/jbc.272.41.25778			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325305	hybrid			2022-12-27	WOS:A1997YA35800060
J	MacFarlane, M; Ahmad, M; Srinivasula, SM; FernandesAlnemri, T; Cohen, GM; Alnemri, ES				MacFarlane, M; Ahmad, M; Srinivasula, SM; FernandesAlnemri, T; Cohen, GM; Alnemri, ES			Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN; SIGNALING COMPLEX; CELL-DEATH; APOPTOSIS; PROTEASE; FADD; ACTIVATION; INTERACTS; CD95	A human receptor for the cytotoxic ligand TRAIL (TRAIL receptor-1, designated DR4) was identified recently as a member of the tumor necrosis factor receptor family. In this report we describe the identification of two additional human TRAIL receptors, TRAIL receptor-2 and TRAIL receptor-3, that belong to the tumor necrosis factor receptor family. Interestingly, TRAIL receptor-g but not TRAIL receptor-3 contains a cytoplasmic ''death domain'' necessary for induction of apoptosis and is hence designated death receptor-5 (DR5). Like DR4, DR5 engages the apoptotic pathway independent of the adaptor molecule FADD/MORT1. Because of its lack of a death domain, TRAIL receptor-3 is not capable of inducing apoptosis. However, by competing for TRAIL, it is capable of inhibiting TRAIL-induced apoptosis. Thus, TRAIL receptor-3 may function as an antagonistic decoy receptor to attenuate the cytotoxic effect of TRAIL in most tissues that are TRAIL(+), DR4(+), and DR5(+).	THOMAS JEFFERSON UNIV,KIMMEL CANC INST,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107; UNIV LEICESTER,MRC,TOXICOL UNIT,LEICESTER LE1 9HN,LEICS,ENGLAND	Jefferson University; Jefferson University; University of Leicester			Alnemri, Emad S/B-4526-2010; Cohen, Gerald M/A-1687-2008		NIA NIH HHS [AG 13487] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsang TC, 1997, BIOTECHNIQUES, V22, P68, DOI 10.2144/97221bm13; Wallach D, 1997, NATURE, V388, P123, DOI 10.1038/40516; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	22	484	546	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25417	25420		10.1074/jbc.272.41.25417	http://dx.doi.org/10.1074/jbc.272.41.25417			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325248	hybrid			2022-12-27	WOS:A1997YA35800003
J	Blostein, R; Wilczynska, A; Karlish, SJD; Arguello, JM; Lingrel, JB				Blostein, R; Wilczynska, A; Karlish, SJD; Arguello, JM; Lingrel, JB			Evidence that Ser(775) in the alpha subunit of Na,K-ATPase is a residue in the cation binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; 4TH TRANSMEMBRANE SEGMENT; SITE-DIRECTED MUTAGENESIS; FUNCTIONAL CONSEQUENCES; POTASSIUM-IONS; CATALYTIC SUBUNIT; ACTIVE-TRANSPORT; SODIUM-PUMP; SUBSTITUTIONS; AFFINITY	Substitution of alanine for Ser(775) in a ouabain-resistant alpha 1 sheep isoform causes a 30-fold decrease in apparent affinity for K+ as an activator of the Na,K-ATPase, as well as an increase in apparent affinity for ATP (Arguello, J. M., and Lingrel, J. B (1995) J. Biol. Chem. 270, 22764-22771). This study was carried out to determine whether Ser(775) is a direct cation-ligating residue or whether the change in apparent affinity for K+ is secondary to a conformational alteration as evidenced in the change in ATP affinity, with the following results, Kinetics of K+ (Rb+) influx into intact cells show that the change is due to a change in K+ interaction at the extracellular surface, The K+ dependence of formation of K+-occluded enzyme (E-2(K)) and of the rate of formation of deoccluded enzyme from E-2(K) indicate that the Ser(775) --> Ala mutation results in a marked increase (greater than or equal to 30-fold) in rate of release of K+ from E-2(K), The high affinity Na+-like competitive antagonist 1,3-dibromo-2,4,6-tris-(methylisothiouronium)benzene (Br2TITU), which interacts with the E-1 conformation and blocks cytoplasmic cation binding (Hoving, S., Bar-Shimon, M., Tijmes, J. J., Tal, D. M., and Karlish, S. J. D. (1995) J. Biol. Chem, 270, 29788-29793), inhibits Na+-ATPase of the mutant less than the control enzyme, With intact cells, Br2TITU acts as a competitive inhibitor of extracellular K+ activation of both the mutant and control enzymes, In this case, the mutant was more sensitive to inhibition, With vanadate as a probe of conformation, a difference in conformational equilibrium between the mutant and control enzymes could not be detected under turnover conditions (Na+-ATPase) in the absence of K+, These results indicate that the increase in apparent affinity for ATP effected by the Ser(775) --> Ala mutation is secondary to a change in intrinsic cation affinity/selectivity. The large change in affinity for extracellular K+ compared with cytoplasmic Na+ and to Br2TITU binding supports the conclusion that the serine hydroxyl is either part of the K+-gate structure or a direct cation-ligating residue that is shared by at least one Na+ ion, albeit with less consequence on rate constants for Na+ binding or release compared with K+.	MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL; UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	McGill University; Weizmann Institute of Science; University System of Ohio; University of Cincinnati			Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NHLBI NIH HHS [HL 28573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; BEAUGE LA, 1979, J PHYSIOL-LONDON, V289, P17, DOI 10.1113/jphysiol.1979.sp012722; DALY SE, 1994, J BIOL CHEM, V269, P23944; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DALY SE, 1997, IN PRESS ANN NY ACAD; EISNER DA, 1981, J PHYSIOL-LONDON, V319, P403, DOI 10.1113/jphysiol.1981.sp013917; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; GLYNN IM, 1987, J PHYSIOL-LONDON, V383, P477; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HOVING S, 1995, J BIOL CHEM, V270, P29788; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KAPLAN JH, 1982, J GEN PHYSIOL, V80, P915, DOI 10.1085/jgp.80.6.915; KARLISH SJD, 1997, IN PRESS ANN NY ACAD; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LEE KH, 1980, NATURE, V285, P338, DOI 10.1038/285338a0; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; POST RL, 1972, J BIOL CHEM, V247, P6530; Post RL, 1967, METHOD ENZYMOL, V10, P773; SACHS JR, 1980, J PHYSIOL-LONDON, V302, P219; TAL DM, 1995, TETRAHEDRON, V51, P3823, DOI 10.1016/0040-4020(95)00105-H; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70	35	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24987	24993		10.1074/jbc.272.40.24987	http://dx.doi.org/10.1074/jbc.272.40.24987			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312104	hybrid			2022-12-27	WOS:A1997XY97000043
J	Haniu, M; Montestruque, S; Bures, EJ; Talvenheimo, J; Toso, R; LewisSandy, S; Welcher, AK; Rohde, MF				Haniu, M; Montestruque, S; Bures, EJ; Talvenheimo, J; Toso, R; LewisSandy, S; Welcher, AK; Rohde, MF			Interactions between brain-derived neurotrophic factor and the TRKB receptor - Identification of two ligand binding domains in soluble TRKB by affinity separation and chemical cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; IMMUNOGLOBULIN-LIKE DOMAIN; LEUCINE-RICH MOTIF; EXTRACELLULAR DOMAIN; GLYCOSYLATION SITES; MONOCLONAL-ANTIBODY; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; FACTOR FAMILY	The extracellular domain of the human neurotrophin TRKB receptor expressed in Chinese hamster ovary cells is a highly glycosylated protein, possessing binding ability for brain-derived neurotrophic factor (BDNF). Two distinct ligand binding domains of TRKB were isolated from proteolytic digests of the receptor by affinity separation on immobilized BDNF, One of these domains consists of amino acid residues 103-181 and contains both the third leucine-rich motif and the second cysteine cluster domain, The second domain is close to the second immunoglobulin-like domain (amino acid residues 342-394). Each of these two domains can bind BDNF independently, Disulfide linkages present in the first domain are necessary for BDNF binding, probably because of preservation of the native conformation, To study the second domain in greater detail, a truncated form of TRKB containing the second immunoglobulinlike domain (residues 248-398) was expressed in Escherichia coli, This domain was cross-linked to BDNF through a 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide coupling reaction. Several synthetic peptides corresponding to amino acid residues 343-379 were able to bind immobilized BDNF, Amino acid substitution and cross-linking analysis indicated that amino acids Phe(347), Asp(354), and Tyr(361) are intimately involved in BDNF binding, These results, obtained from a variety of experimental techniques, highlight the importance of two distinct regions of the extracellular domain of the TRKB receptor in binding BDNF.	AMGEN INC, DEPT PROT CHEM, THOUSAND OAKS, CA 91320 USA; AMGEN INC, DEPT IMMUNOL, THOUSAND OAKS, CA 91320 USA	Amgen; Amgen	Haniu, M (corresponding author), AMGEN INC, DEPT PROT STRUCT, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.							Barbacid Mariano, 1993, P123; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; CANAS B, 1993, ANAL BIOCHEM, V211, P179, DOI 10.1006/abio.1993.1253; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Fairlie WD, 1996, EUR J BIOCHEM, V240, P622, DOI 10.1111/j.1432-1033.1996.0622h.x; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANIU M, 1995, ARCH BIOCHEM BIOPHYS, V322, P256, DOI 10.1006/abbi.1995.1460; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LESAUTEUR L, 1995, J BIOL CHEM, V270, P6564, DOI 10.1074/jbc.270.12.6564; MALMBORG A, 1992, J IMMUNOL, V36, P643; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Parker CE, 1996, J IMMUNOL, V157, P198; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; PHILO J, 1994, J BIOL CHEM, V269, P27840; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Weiergraber O, 1996, FEBS LETT, V379, P122, DOI 10.1016/0014-5793(95)01482-9; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348; ZHAO YM, 1994, ANAL CHEM, V66, P3723, DOI 10.1021/ac00093a029	40	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25296	25303		10.1074/jbc.272.40.25296	http://dx.doi.org/10.1074/jbc.272.40.25296			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312147	hybrid			2022-12-27	WOS:A1997XY97000086
J	Heinemeyer, W; Fischer, M; Krimmer, T; Stachon, U; Wolf, DH				Heinemeyer, W; Fischer, M; Krimmer, T; Stachon, U; Wolf, DH			The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; PEPTIDE-HYDROLYZING ACTIVITY; YEAST PROTEASOME; THERMOPLASMA-ACIDOPHILUM; SACCHAROMYCES-CEREVISIAE; INTERFERON-GAMMA; MULTIFUNCTIONAL PROTEINASE; PROTEOLYTIC ACTIVITIES; ANTIGENIC PEPTIDES; ENCODED SUBUNITS	The 26 S proteasome is the central protease involved in ubiquitin-mediated protein degradation and fulfills vital regulatory functions in eukaryotes, The proteolytic core of the complex is the 20 S proteasome, a cylindrical particle with two outer rings each made of 7 different alpha-type subunits and two inner rings made of 7 different beta-type subunits, In the archaebacterial 20 S proteasome ancestor proteolytically active sites reside in the 14 uniform beta-subunits. Their N-terminal threonine residues, released by precursor processing, perform the nucleophilic attack for peptide bond hydrolysis. By directed mutational analysis of 20 S proteasomal beta-type proteins of Saccharomyces cerevisiae, we identified three active site-carrying subunits responsible for different peptidolytic activities as follows: Pre3 for post-glutamyl hydrolyzing, Pup1 for trypsin-like, and Pre2 for chymotrypsin-like activity, Double mutants harboring only trypsin-like or chymotrypsin-like activity were viable, Mutation of two potentially active site threonine residues in the Pre4 subunit excluded its catalytic involvement in any of the three peptidase activities, The generation of different, incompletely processed forms of the Pre4 precursor in active site mutants suggested that maturation of non-active proteasomal beta-type subunits is exerted by active subunits and occurs in the fully assembled particle, This trans-acting proteolytic activity might also account for processing intermediates of the active site mutated Pre2 subunit, which was unable to undergo autocatalytic maturation.	UNIV STUTTGART,INST BIOCHEM,D-70569 STUTTGART,GERMANY	University of Stuttgart								ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DICK LR, 1994, J IMMUNOL, V152, P3884; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FISCHER M, 1994, FEBS LETT, V355, P69, DOI 10.1016/0014-5793(94)01177-X; FRIEDMAN H, 1994, P NATL ACAD SCI USA, V91, P2031, DOI 10.1073/pnas.91.6.2031; FRIEDMAN H, 1992, GENE, V122, P203, DOI 10.1016/0378-1119(92)90051-P; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HAFFTER P, 1991, NUCLEIC ACIDS RES, V19, P5075, DOI 10.1093/nar/19.18.5075; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 1993, J BIOL CHEM, V268, P3479; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KLEINSCHMIDT JA, 1988, FEBS LETT, V239, P35, DOI 10.1016/0014-5793(88)80540-4; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; KOPP F, 1995, J MOL BIOL, V248, P264; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHAUER TM, 1993, J STRUCT BIOL, V111, P135, DOI 10.1006/jsbi.1993.1044; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SIKORSKI RS, 1989, GENETICS, V122, P19; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	59	389	395	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25200	25209		10.1074/jbc.272.40.25200	http://dx.doi.org/10.1074/jbc.272.40.25200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312134	hybrid			2022-12-27	WOS:A1997XY97000073
J	Ogihara, T; Isobe, T; Ichimura, T; Taoka, M; Funaki, M; Sakoda, H; Onishi, Y; Inukai, K; Anai, M; Fukushima, Y; Kikuchi, M; Yazaki, Y; Oka, Y; Asano, T				Ogihara, T; Isobe, T; Ichimura, T; Taoka, M; Funaki, M; Sakoda, H; Onishi, Y; Inukai, K; Anai, M; Fukushima, Y; Kikuchi, M; Yazaki, Y; Oka, Y; Asano, T			14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-DEPENDENT ACTIVATOR; PHOSPHATIDYLINOSITOL 3-KINASE; TRYPTOPHAN HYDROXYLASES; REGULATORY SUBUNIT; IRS-1; TYROSINE; PHOSPHORYLATION; 14-3-3-PROTEIN; DISTINCT; ASSOCIATION	Insulin binding to its receptor induces the phosphorylation of cytosolic substrates, insulin receptor substrate (IRS)-1 and IRS-2, which associate with several Src homology-a domain-containing proteins. To identify unique IRS-1-binding proteins, we screened a human heart cDNA library with P-32-labeled recombinant IRS-I and obtained two isoforms (epsilon and zeta) of the 14-3-3 protein family. 14-3-3 protein has been shown to associate with IRS-I in L6 myotubes, HepG2 hepatoma cells, Chinese hamster ovary cells, and bovine brain tissue. IRS-2, a protein structurally similar to IRS-1, was also shown to form a complex with 14-3-3 protein using a baculovirus expression system. The amount of 14-3-3 protein associated with IRS-I was not affected by insulin stimulation but was increased significantly by treatment with okadaic acid, a potent serine/threonine phosphatase inhibitor. Peptide inhibition experiments using phosphoserine-containing peptides of IFS-I revealed that IRS-1 contains three putative binding sites for 14-3-3 protein (Ser-270, Ser-374, and Ser-641). Among these three, the motif around Ser-270 is located in the phosphotyrosine binding domain of IRS-I, which is responsible for the interaction with the insulin receptor. Indeed, a truncated mutant of IRS-1 consisting of only the phosphotyrosine binding domain retained the capacity to bind to 14-3-3 protein in vivo. Finally, the effect of 14-3-3 protein binding on the insulin-induced phosphorylation of IRS-1 was investigated. Phosphoamino acid analysis revealed that IRS-1 coimmunoprecipitated with anti-14-3-3 antibody to be weakly phosphorylated after insulin stimulation, on tyrosine as well as serine residues, compared with IRS-l immunoprecipitated with anti-IRS-l antibody. Thus, the association with 14-3-3 protein may play a role in the regulation of insulin sensitivity by interrupting the association between the insulin receptor and IRS-1.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; ASAHI LIFE FDN, INST ADULT DIS, SHINJUKU KU, TOKYO 160, JAPAN; YAMAGUCHI UNIV, SCH MED, DEPT INTERNAL MED 3, UBE, YAMAGUCHI 755, JAPAN; TOKYO METROPOLITAN UNIV, FAC SCI, DEPT CHEM, HACHIOJI, TOKYO 19203, JAPAN; NIIGATA UNIV, SCH MED, DEPT CHEM, NIIGATA 951, JAPAN	University of Tokyo; Asahi Life Foundation; Yamaguchi University; Tokyo Metropolitan University; Niigata University			Isobe, Toshiaki/Q-9279-2017	Taoka, Masato/0000-0001-5554-4951				AITKEN A, 1990, NATURE, V344, P594; Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; Bachmann M, 1996, FEBS LETT, V398, P26, DOI 10.1016/S0014-5793(96)01188-X; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PONS S, 1995, MOL CELL BIOL, V15, P4453; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANTI JF, 1994, J BIOL CHEM, V269, P6051; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	37	134	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25267	25274		10.1074/jbc.272.40.25267	http://dx.doi.org/10.1074/jbc.272.40.25267			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312143	hybrid			2022-12-27	WOS:A1997XY97000082
J	Schoenwaelder, SM; Kulkarni, S; Salem, HH; ImajohOhmi, S; YamaoHarigaya, W; Saido, TC; Jackson, SP				Schoenwaelder, SM; Kulkarni, S; Salem, HH; ImajohOhmi, S; YamaoHarigaya, W; Saido, TC; Jackson, SP			Distinct substrate specificities and functional roles for the 78- and 76-kDa forms of mu-calpain in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; HUMAN BLOOD-PLATELETS; PROCOAGULANT ACTIVITY; MICROPARTICLE FORMATION; MEMBRANE SKELETON; PLASMA-MEMBRANE; CLEAVAGE; AUTOLYSIS; PLASMINOGEN	The intracellular thiol protease mu-calpain exists as a heterodimeric proenzyme, consisting of a large 80-kDa catalytic subunit and a smaller 30 kDa regulatory subunit, Activation of mu-calpain requires calcium influx across the plasma membrane and the subsequent autoproteolytic conversion of the 80-kDa large subunit to a 78-kDa ''intermediate'' and a 76-kDa fully autolyzed form, Currently, there is Limited information on the substrate specificities and functional roles of these distinct active forms of mu-calpain within the cell, Using antibodies that can distinguish among the 80-, 78, and 76-kDa forms of mu-calpain, we have demonstrated a close correlation between the autolytic generation of the 78 kDa enzyme and the proteolysis of the non-receptor tyrosine phosphatase, PTP-1B, in ionophore A23187-stimulated platelets, Time course studies revealed that pp60(c-src) proteolysis lagged well behind that of PTP-1B and correlated closely with the generation of the fully proteolyzed form of mu-calpain (76 kDa), In citro proteolysis experiments with purified mu-calpain and immunoprecipitated PTP-1B or pp60(c-src) confirmed selective proteolysis of pp60(c-src) by the 76-kDa enzyme, whereas PTP-1B cleavage was mediated by both the 76- and 78-kDa forms of mu-calpain. Studies using selective pharmacological inhibitors against the different autolytic forms of mu-calpain have demonstrated that the initial conversion of the mu-calpain large subunit to the 78-kDa form is responsible for the reduction in platelet-mediated clot retraction, whereas complete proteolytic activation of mu-calpain (76 kDa) is responsible for the shedding of procoagulant-rich membrane vesicles from the cell surface, These studies demonstrate the existence of multiple active forms of mu-calpain within the cell, that have unique substrate specificities and distinct functional roles.	BOX HILL HOSP, DEPT PATHOL, BOX HILL, VIC 3128, AUSTRALIA; AUSTRALIAN CTR BLOOD DIS, MONASH MED SCH, DEPT MED, BOX HILL, VIC 3128, AUSTRALIA; TOKYO METROPOLITAN INST MED SCI, TOKYO 113, JAPAN; UNIV TOKYO, INST MED SCI, TOKYO 108, JAPAN	Box Hill Hospital; Monash University; Tokyo Metropolitan Institute of Medical Science; University of Tokyo			Jackson, Shaun P/E-9633-2011; Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Schoenwaelder, Simone/E-9506-2011	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Jackson, Shaun/0000-0002-4750-1991; Schoenwaelder, Simone/0000-0003-0465-5840				ARIYOSHI H, 1995, PLATELETS, V6, P185, DOI 10.3109/09537109509078452; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; BASSE F, 1994, BBA-BIOMEMBRANES, V1190, P217, DOI 10.1016/0005-2736(94)90077-9; BECKERLE MC, 1986, J CELL BIOCHEM, V30, P259, DOI 10.1002/jcb.240300307; CARILLO S, 1994, ONCOGENE, V9, P1679; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DacharyPrigent J, 1996, SEMIN THROMB HEMOST, V22, P157, DOI 10.1055/s-2007-999004; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Goll DE, 1990, INTRACELLULAR CALCIU, P3; HATHAWAY DR, 1982, J BIOL CHEM, V257, P9072; HAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1094, P249, DOI 10.1016/0167-4889(91)90083-A; IMAJOH S, 1986, J BIOCHEM-TOKYO, V99, P1281, DOI 10.1093/oxfordjournals.jbchem.a135593; INOMATA M, 1988, J BIOL CHEM, V263, P19783; INOMATA M, 1985, J BIOCHEM-TOKYO, V98, P407, DOI 10.1093/oxfordjournals.jbchem.a135295; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; KUNITADA S, 1992, BLOOD, V79, P1420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; ODA A, 1993, J BIOL CHEM, V268, P12603; Pasquet JM, 1996, THROMB RES, V82, P509, DOI 10.1016/0049-3848(96)00101-6; Pasquet JM, 1996, EUR J BIOCHEM, V239, P647, DOI 10.1111/j.1432-1033.1996.0647u.x; SABOVIC M, 1989, THROMB HAEMOSTASIS, V62, P1083; SABOVIC M, 1990, THROMB HAEMOSTASIS, V64, P450; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; Tompa P, 1996, J BIOL CHEM, V271, P33161, DOI 10.1074/jbc.271.52.33161; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJINAKA T, 1983, BIOCHEM INT, V6, P71; YAMAMOTO K, 1986, THROMB RES, V43, P41, DOI 10.1016/0049-3848(86)90043-5; YANO Y, 1993, THROMB RES, V71, P385, DOI 10.1016/0049-3848(93)90163-I; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	46	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24876	24884		10.1074/jbc.272.40.24876	http://dx.doi.org/10.1074/jbc.272.40.24876			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312088	hybrid			2022-12-27	WOS:A1997XY97000027
J	Sun, LZ; Chen, CG				Sun, LZ; Chen, CG			Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; TGF-BETA; PROTEOGLYCAN BETAGLYCAN; DISEASE PROGRESSION; ENDOTHELIAL-CELLS; PROSTATE-CANCER; TUMOR-GROWTH; C-MYC; FACTOR-BETA-1; GROWTH-FACTOR-BETA-1	Transforming growth factor beta (TGF-beta) promotes tumor progression in some model systems including human breast cancer cells. In this study, we report that human breast cancer cell lines express reduced amounts of TGF-beta type III receptor (RIII) when compared with untransformed human mammary epithelial cells. Consequently, me examined whether expression of RIII in human breast cancer MDA-MB-231 cells could reduce TGF-beta's tumor promoting activity by sequestering active TGF-beta isoforms produced by the cells. A tetracycline-repressible human RIII expression vector was stably transfected into the cell line. RIII expression in a pool of transfected clones and a single clone was found to be reversibly repressed by tetracycline treatment. Expression of RIII reduced the amount of active TGF-beta(1) and TGF-beta(2) in the conditioned medium. The medium conditioned by control cells showed a significantly higher growth inhibitory effect than that conditioned by RIII-transfected cells on the growth of the mink lung epithelial CCL64 cells. A conditioned medium collected from RIII-transfected cells treated with tetracycline significantly increased its growth inhibitory activity to that of control cells. Expression of RIII also reduced tumor incidence and growth rate in two separate experiments when the cells were inoculated in athymic nude mice. Treatment of the mice with tetracycline repressed RIII expression in the tumors generated by RIII-transfected cells and increased tumor incidence and growth rate. These results suggest that TGF-beta RIII can reduce tumorigenicity of MDA-MB-231 cells apparently by sequestering TGF-beta isoforms produced by these cells.	UNIV KENTUCKY,COLL MED,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536	University of Kentucky	Sun, LZ (corresponding author), UNIV KENTUCKY,MED CTR,DEPT PHARMACOL,MS 311,800 ROSE ST,LEXINGTON,KY 40536, USA.		, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R29CA063480, R01CA075253] Funding Source: NIH RePORTER; NCI NIH HHS [CA75253, CA63480] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1991, J BIOL CHEM, V266, P23282; ANDRES JL, 1992, J BIOL CHEM, V267, P5927; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ARRICK BA, 1990, CANCER RES, V50, P299; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1988, CANCER RES, V48, P3898; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; BARRETTLEE P, 1990, BRIT J CANCER, V61, P612, DOI 10.1038/bjc.1990.136; Bottinger EP, 1996, P NATL ACAD SCI USA, V93, P5877, DOI 10.1073/pnas.93.12.5877; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHANG HL, 1993, CANCER RES, V53, P4391; CHEIFETZ S, 1988, J BIOL CHEM, V263, P10783; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOMBES RC, 1990, J STEROID BIOCHEM, V37, P833, DOI 10.1016/0960-0760(90)90428-N; DALY RJ, 1990, J CELL BIOCHEM, V43, P199, DOI 10.1002/jcb.240430302; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GORSCH SM, 1992, CANCER RES, V52, P6949; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; Kim IY, 1996, CLIN CANCER RES, V2, P1255; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; MIYAMOTO H, 1995, CANCER, V75, P2565, DOI 10.1002/1097-0142(19950515)75:10<2565::AID-CNCR2820751025>3.0.CO;2-M; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SOSROSENO W, 1995, BRIT J BIOMED SCI, V52, P142; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; STEINER MS, 1994, ENDOCRINOLOGY, V135, P2240, DOI 10.1210/en.135.5.2240; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SUN LZ, 1994, EXP CELL RES, V214, P215, DOI 10.1006/excr.1994.1251; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583; UEKI N, 1992, BIOCHIM BIOPHYS ACTA, V1137, P189; VanBelle P, 1996, AM J PATHOL, V148, P1887; WALKER RA, 1992, EUR J CANCER, V28A, P641, DOI 10.1016/S0959-8049(05)80116-9; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	77	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25367	25372		10.1074/jbc.272.40.25367	http://dx.doi.org/10.1074/jbc.272.40.25367			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312157	hybrid			2022-12-27	WOS:A1997XY97000096
J	Xie, W; Jiang, HP; Wu, DQ				Xie, W; Jiang, HP; Wu, DQ			Two basic amino acids in the second inner loop of the interleukin-8 receptor are essential for G alpha 16 coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; FORMYL PEPTIDE RECEPTOR; G-PROTEIN ACTIVATION; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; SIGNAL-TRANSDUCTION; BINDING-SITES; SPECIFICITY; SEQUENCES; DOMAINS	The involvement of basic residues of interleukin (IL)-8 receptors in coupling to the Gi and G16 proteins was investigated by using a series of IL-8 receptor mutants, Substitution of the basic amino acids in the third inner loop of the receptor does not alter the abilities of the receptor mutants to activate recombinant G alpha 16 or phosphoinositide-specific phospholipase C (PLC) beta 2 expressed in COS-7 cells. However, an IL-8 receptor mutant with double mutations at residues Lys(158) and Arg(159) of the second inner loop loses its abilities to activate G alpha 16 but retains its ability to activate PLC beta 2. The activation of PLC beta 2 by an IL-8 receptor that is sensitive to pertussis toxin has been previously demonstrated to be mediated through G beta gamma. Surprisingly, the IL-8 receptor mutants with substitution of Ala for either residue Lys(158) or Arg(159) can still activate G alpha 16, which suggests that either of the two basic residues in the second inner loop of the IL-8 receptor is sufficient for G alpha 16 coupling.	UNIV ROCHESTER,DEPT PHARMACOL PHYSIOL & ONCOL,ROCHESTER,NY 14642	University of Rochester					NIGMS NIH HHS [GM 53162, GM 54597] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054597, R29GM053162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Damaj BB, 1996, FASEB J, V10, P1426, DOI 10.1096/fasebj.10.12.8903513; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	24	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24948	24951		10.1074/jbc.272.40.24948	http://dx.doi.org/10.1074/jbc.272.40.24948			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312098	hybrid			2022-12-27	WOS:A1997XY97000037
J	Chu, G				Chu, G			Double strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DEPENDENT PROTEIN-KINASE; END BINDING-ACTIVITY; X-RAY RESISTANCE; RNA-POLYMERASE-I; V(D)J RECOMBINATION; KU AUTOANTIGEN; DNA-REPAIR; MAMMALIAN-CELLS; SCID MUTATION; CATALYTIC SUBUNIT		STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University; Stanford University								ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; Beall EL, 1996, GENE DEV, V10, P921, DOI 10.1101/gad.10.8.921; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; CHEN DJ, 1994, GENOMICS, V21, P423, DOI 10.1006/geno.1994.1287; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; DANSKA J, 1996, MOL CELL BIOL, V10, P6472; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FALZON M, 1993, J BIOL CHEM, V268, P10546; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P555; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GFACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRZESIUK E, 1987, NUCLEIC ACIDS RES, V15, P971, DOI 10.1093/nar/15.3.971; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; He DM, 1996, MUTAT RES-DNA REPAIR, V363, P43, DOI 10.1016/0921-8777(95)00060-7; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; JEONGYU SJ, 1992, MOL CELL BIOL, V12, P112, DOI 10.1128/MCB.12.1.112; JOHNSON A, 1996, MUTAT RES, V3642, P103; King JS, 1996, J BIOL CHEM, V271, P20450, DOI 10.1074/jbc.271.34.20450; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liang F, 1996, J BIOL CHEM, V271, P14405, DOI 10.1074/jbc.271.24.14405; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LUKACSOVICH T, 1994, NUCLEIC ACIDS RES, V22, P5649, DOI 10.1093/nar/22.25.5649; Mason RM, 1996, NUCLEIC ACIDS RES, V24, P4946, DOI 10.1093/nar/24.24.4946; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Rathmell WK, 1997, CANCER RES, V57, P68; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Shakespeare William, 1998, JULIUS CAESAR; Siede W, 1996, GENETICS, V142, P91; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; THOMPSON D, 1995, FEM PSYCHOL, V5, P531, DOI 10.1177/0959353595054012; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	73	208	211	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24097	24100		10.1074/jbc.272.39.24097	http://dx.doi.org/10.1074/jbc.272.39.24097			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305850	hybrid			2022-12-27	WOS:A1997XY51500001
J	Filoteo, AG; Elwess, NL; Enyedi, A; Caride, A; Aung, HH; Penniston, JT				Filoteo, AG; Elwess, NL; Enyedi, A; Caride, A; Aung, HH; Penniston, JT			Plasma membrane Ca2+ pump in rat brain - Patterns of alternative splices seen by isoform-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAINS; CALCIUM-PUMP; MESSENGER-RNAS; CA2+-ATPASE; EXPRESSION; REGION; 4B	The expression at the protein level of plasma membrane calcium pump (PMCA) isoforms in rat brain was detected by new antibodies that distinguished the four gene products and their alternatively spliced variants. All four gene products were distributed throughout hippocampus, cortex, and cerebellum, but the alternate splices showed more distinct distribution patterns. The b splice of isoform 1 was not detectable in any of the brain regions, which makes it unlikely that this isoform performs an essential housekeeping role as is frequently proposed. The b splices of isoforms 3 and 4, although expressed in all three regions, showed evidence of proteolysis, which removed a portion of the carboxyl terminus, In contrast, isoform 2b retained its full length, indicating that PMCA2b is more resistant to proteolysis than the other b forms, Whereas substantial amounts of isoforms 1a, 2a, and 3a were expressed in all regions, 4a was found only in frontal cortex. The distinct patterns of expression of the PMCA isoforms in brain suggest that some of them play a special role in intracellular Ca regulation.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; NATL INST HAEMATOL & IMMUNOL,H-1113 BUDAPEST,HUNGARY	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDT P, 1992, J NEUROCHEM, V59, P1566, DOI 10.1111/j.1471-4159.1992.tb08476.x; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; EAKIN TJ, 1995, MOL BRAIN RES, V29, P71, DOI 10.1016/0169-328X(94)00231-3; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FLECHA FLG, 1993, BIOCHEM J, V293, P369; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; KEETON TP, 1993, J BIOL CHEM, V268, P2740; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK DJ, 1987, J IMMUNOL, V139, P2615; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Varadi A, 1996, BIOCHEM J, V314, P663, DOI 10.1042/bj3140663; Verma AK, 1996, J BIOL CHEM, V271, P3714; VERMA AK, 1994, J BIOL CHEM, V269, P1687; WANG KKW, 1991, J BIOL CHEM, V266, P9078; ZACHARIAS DA, 1995, MOL BRAIN RES, V28, P263, DOI 10.1016/0169-328X(94)00215-Z	19	129	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23741	23747		10.1074/jbc.272.38.23741	http://dx.doi.org/10.1074/jbc.272.38.23741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295318	hybrid			2022-12-27	WOS:A1997XX38100043
J	Lin, ECK; Ratnikov, BI; Tsai, PM; Carron, CP; Myers, DM; Barbas, CF; Smith, JW				Lin, ECK; Ratnikov, BI; Tsai, PM; Carron, CP; Myers, DM; Barbas, CF; Smith, JW			Identification of a region in the integrin beta 3 subunit that confers ligand binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; VITRONECTIN RECEPTOR; ENDOTHELIAL-CELLS; BETA(3) SUBUNIT; CROSS-LINKING; IIB-IIIA; SITE; FIBRINOGEN; RECOGNITION; FIBRONECTIN	Many integrin adhesion receptors bind ligands containing the Arg-Gly-Asp (RGD) peptide motif, Most integrins exhibit considerable specificity for particular ligands and can distinguish among the many conformations of RGD. In this study we identify the domain of the integrin beta subunit involved in determining ligand binding specificity, Chimeras of beta 3 and beta 5, the most homologous integrin beta subunits, were expressed with alpha v on the surface of human 293 cells, The ligand binding phenotype of each chimera was assessed using the ligands Fab-9 and fibrinogen, both of which have a binding preference for alpha v beta 3. The results of the study show that when exons C and D of the beta 3 subunit (residues 95-233) are substituted into beta 5, the chimera gained the ability to bind Fab-9 with an affinity close to that of wild-type alpha v beta 3. This chimera was able to mediate cell adhesion to fibrinogen. Furthermore, the swap of only a 39-residue segment of this larger domain, beta 3 residues 164-202, into the backbone of beta 5 enabled the chimeric integrin to bind soluble Fab-9. This small domain is highly divergent among the integrin beta subunits, suggesting that it may play a role in determining ligand selection by all integrins.	LA JOLLA CANC RES CTR, BURNHAM INST, PROGRAM CELL ADHES & EXTRACELLULAR MATRIX, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; MONSANTO CO, GD SEARLE RES & DEV, ST LOUIS, MO 63198 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute; Monsanto					NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NCI NIH HHS [CA56483] Funding Source: Medline; NIAMS NIH HHS [AR42750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Alemany M, 1996, BLOOD, V87, P592, DOI 10.1182/blood.V87.2.592.bloodjournal872592; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Brooks PC, 1996, CANCER METAST REV, V15, P187, DOI 10.1007/BF00437471; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1995, P SOC EXP BIOL MED, V208, P346; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; Filardo EJ, 1996, J CELL SCI, V109, P1615; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GRINNELL F, 1992, J CELL SCI, V101, P1; HORTON MA, 1989, J BONE MINER RES, V4, P803; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P243; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LANZA F, 1990, J BIOL CHEM, V265, P18098; LIAW L, 1995, CIRC RES, V77, P665, DOI 10.1161/01.RES.77.4.665; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RECHLER MM, 1977, J BIOL CHEM, V252, P3898; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schulz G.E., 1979, PRINCIPLES PROTEIN S, P28; SEGEL IH, 1976, BIOCH CALCULATIONS, P152; Smith J.W., 1994, INTEGRINS MOL BIOL R, P1; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1994, J BIOL CHEM, V269, P960; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; WEINACKER A, 1994, J BIOL CHEM, V269, P6940	55	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23912	23920		10.1074/jbc.272.38.23912	http://dx.doi.org/10.1074/jbc.272.38.23912			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295341	hybrid			2022-12-27	WOS:A1997XX38100066
J	Norris, FA; Atkins, RC; Majerus, PW				Norris, FA; Atkins, RC; Majerus, PW			The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II - Evidence for conserved alternative splicing in the 4-phosphatase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACTIVATION; HYDROLYSIS; 3-KINASE; INTEGRIN; AKT	Inositol polyphosphate 4-phosphatase (4-phosphatase) is a Mg2+-independent enzyme that catalyzes the hydrolysis of the 4-position phosphate of phosphatidylinositol 3,4-bisphosphate, inositol 1,3,4-trisphosphate, and inositol 3,4-bisphosphate. We have isolated cDNA encoding a 105,257-Da protein that is 37% identical to the previously cloned 4-phosphatase, Recombinant protein was expressed in Escherichia coli and shown to hydrolyze all three 4-phosphatase substrates with enzymatic properties similar to the original enzyme. We designate the original 4-phosphatase and the new isozyme as inositol polyphosphate 4-phosphatase types I and II, respectively. 4-Phosphatase II is highly conserved with the human and rat enzymes having 90% amino acid identity, A conserved motif between 4-phosphatase I and II is the sequence CKSAKDRT that contains the Cys-Xaa(5)-Arg active site consensus sequence identified for other Mg2+-independent phosphatases. Northern blot analysis indicated that 4-phosphatase II is widely expressed with the highest levels occurring in the skeletal muscle and heart. In addition, cDNA encoding alternatively spliced forms of human 4-phosphatase I (107,309 Da) and rat 4-phosphatase II (106,497 Da) were also isolated that encode proteins with a putative transmembrane domain near their C termini. These alternatively spliced forms were expressed as recombinant proteins in E. coli and SF9 insect cells and found to possess no detectable enzymatic activity suggesting that additional factors and/or processing may be required for these alternatively spliced isozymes.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,DIV HEMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOPHYS,DIV HEMATOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	Norris, FA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL 16634, HL 55672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016634, R01HL055672, R01HL016634] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANSAL VS, 1991, J BIOL CHEM, V265, P1806; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; NORRIS FA, 1995, J BIOL CHEM, V270, P16128, DOI 10.1074/jbc.270.27.16128; Norris FA, 1997, J BIOL CHEM, V272, P10987; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; SULTAN C, 1991, J BIOL CHEM, V266, P23554; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	19	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23859	23864		10.1074/jbc.272.38.23859	http://dx.doi.org/10.1074/jbc.272.38.23859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295334	hybrid			2022-12-27	WOS:A1997XX38100059
J	Orita, T; Shimozaki, K; Murakami, H; Nagata, S				Orita, T; Shimozaki, K; Murakami, H; Nagata, S			Binding of NF-Y transcription factor to one of the cis-elements in the myeloperoxidase gene promoter that responds to granulocyte colony-stimulating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-RECEPTOR; DNA-BINDING; CCAAT BINDING; MYELOID DIFFERENTIATION; MURINE MYELOPEROXIDASE; SIGNAL-TRANSDUCTION; MESSENGER-RNA; CDNA CLONING; CLASS-II; EXPRESSION	The expression of the myeloperoxidase (MPO) gene is restricted to cells of the myeloid cell lineage and is induced by granulocyte colony stimulating factor (G-CSF). In this study, a series of deletion mutations was introduced in the promoter of the human MPO gene, which was then fused to the chloramphenicol acetyltransferase gene. The G-CSF-induced promoter activity was examined in mouse myeloid precursor FDC-P1 transformants that constitutively express the G-CSF receptor. A G-CSF-responsive element (GRE) in the MPO gene was found approximately 800 base pairs upstream from the transcription initiation site. When the 5'-flanking region of the human MPO gene contained this element, it yielded promoter activity in cells cultured with G-CSF but not in cells cultured with interleukin 3. Gel shift assays with the element showed that a specific nuclear factor(s) (NF/G-CSF) binds to the element. The NF/G-CSF was purified by affinity chromatography using an oligonucleotide of GRE. Protein sequence analysis of the purified NF/G-CSF indicated that NF/G-CSF is a ubiquitous transcription factor, NF-Y, which is composed of three subunits. The recombinant, NF-Y was then shown to bind to GRE in a combination of the three subunits.	OSAKA UNIV, SCH MED, DEPT GENET, SUITA, OSAKA 565, JAPAN; OSAKA BIOSCI INST, SUITA, OSAKA 565, JAPAN	Osaka University			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASAKURA A, 1993, MOL CELL BIOL, V13, P7153, DOI 10.1128/MCB.13.11.7153; CHANG KS, 1991, LEUKEMIA, V5, P205; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EDGAR S, 1989, NUCLEIC ACIDS RES, V17, P6419; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; ITOH N, 1993, J IMMUNOL, V151, P621; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JOHNSON K, 1989, NUCLEIC ACIDS RES, V17, P7985, DOI 10.1093/nar/17.19.7985; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; JORGENSON KF, 1991, BLOOD, V77, P159; KAWAGUCHI H, 1989, NUCLEIC ACIDS RES, V17, P6229, DOI 10.1093/nar/17.15.6229; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KUN SC, 1986, BLOOD, V68, P1411; LIWEBER M, 1994, J IMMUNOL, V153, P4122; LUBBERT M, 1991, BLOOD, V78, P345; Lubbert M, 1996, BLOOD, V87, P447, DOI 10.1182/blood.V87.2.447.bloodjournal872447; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; NAGATA S, 1994, CYTOKINE HDB, P371; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; SACS L, 1982, J CELL PHYSIOL, V1, P151; SCHEOMECLER C, 1995, BLOOD, V11, P4115; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TOBLER A, 1988, J CELL PHYSIOL, V136, P215, DOI 10.1002/jcp.1041360203; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WEIL SC, 1987, P NATL ACAD SCI USA, V84, P2057, DOI 10.1073/pnas.84.7.2057; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; YAMADA M, 1993, J BIOL CHEM, V268, P13479; YAMADA M, 1987, ARCH BIOCHEM BIOPHYS, V255, P147, DOI 10.1016/0003-9861(87)90304-3; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x	51	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23216	23223		10.1074/jbc.272.37.23216	http://dx.doi.org/10.1074/jbc.272.37.23216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287329	hybrid			2022-12-27	WOS:A1997XV74400040
J	Szabo, K; Bakos, E; Welker, E; Muller, M; Goodfellow, HR; Higgins, CF; Varadi, A; Sarkadi, B				Szabo, K; Bakos, E; Welker, E; Muller, M; Goodfellow, HR; Higgins, CF; Varadi, A; Sarkadi, B			Phosphorylation site mutations in the human multidrug transporter modulate its drug-stimulated ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RESISTANCE P-GLYCOPROTEIN; HAMSTER OVARY CELLS; FUNCTIONAL RECONSTITUTION; MEDIATED PHOSPHORYLATION; VINBLASTINE RESISTANCE; HYDROPHOBIC PEPTIDES; CHLORIDE CHANNELS; GENE-EXPRESSION; INSECT CELLS	In the human multidrug transporter (MDR1), three serine residues located in the ''linker'' region of the protein are targets of in vivo phosphorylation. These three serines, or all eight serines and threonines in the linker, were substituted by alanines (mutants 3A and 8A) or with glutamic acids (mutants 3E and 8E). The wild-type and mutant proteins were expressed in baculovirus-infected Spodoptera frugiperda (Sf9) ovarian insect cells, and the vanadate-sensitive, drug-stimulated ATPase activity was measured in isolated membrane preparations. The maximum drug-stimulated MDR1-ATPase activity was similar for the wild-type and the mutant proteins, However, wild-type MDR1, which is known to be phosphorylated in Sf9 membranes, and the 3E and 8E mutants, which mimic the charge of phosphorylation, achieved half-maximum activation of MDR1-ATPase activity at lower verapamil, vinblastine, or rhodamine 123 concentrations than the nonphosphorylatable 3A and 8A variants. For some other drugs (e.g. valinomycin or calcein acetoxymethylester) activation of the MDR1-ATPase for any of the mutants was indistinguishable from that of the wild-type protein. Kinetic analysis of the data obtained for the 3A and 8A MDR1 variants indicated the presence of more than one drug interaction site, exhibiting an apparent negative cooperativity. This phenomenon was not observed for the wild-type or the 3E and 8E MDR1 proteins. The dependence of the MDR1-ATPase activity on ATP concentration was identical in the wild-type and the mutant proteins, and Hill plots indicated the presence of more than one functional ATP-binding site. These results suggest that phosphorylation of the linker region modulates the interaction of certain drugs with MDR1, especially at low concentrations, although phosphorylation does not alter the maximum level of MDR1-ATPase activity or its dependence on ATP concentration.	HUNGARIAN ACAD SCI, NATL INST HAEMATOL & IMMUNOL, RES GRP, H-1113 BUDAPEST, HUNGARY; HUNGARIAN ACAD SCI, BIOL RES CTR, INST ENZYMOL, H-1113 BUDAPEST, HUNGARY; UNIV OXFORD, NUFFIELD DEPT CLIN BIOCHEM, OXFORD OX3 9DS, ENGLAND; UNIV OXFORD, INST MOL MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DS, ENGLAND	Hungarian Academy of Sciences; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; University of Oxford; Cancer Research UK; University of Oxford			Welker, Ervin/AAC-6493-2022; Sarkadi, Balazs/I-5024-2013; Varadi, Andras/A-2055-2012					AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; AMBUDKAR SV, 1995, J BIOENERG BIOMEMBR, V27, P23, DOI 10.1007/BF02110327; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; Ayesh S, 1996, BBA-MOL BASIS DIS, V1316, P8, DOI 10.1016/0925-4439(96)00008-7; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; Borgnia MJ, 1996, J BIOL CHEM, V271, P3163, DOI 10.1074/jbc.271.6.3163; CARLSEN SA, 1977, BIOCHIM BIOPHYS ACTA, V467, P238, DOI 10.1016/0005-2736(77)90199-7; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1995, BIOCHEMISTRY-US, V34, P14156, DOI 10.1021/bi00043a021; CHAMBERS TC, 1994, BIOCHEM J, V299, P309, DOI 10.1042/bj2990309; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; Childs S, 1994, Important Adv Oncol, P21; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; FERRY DR, 1992, BIOCHEM BIOPH RES CO, V188, P440, DOI 10.1016/0006-291X(92)92404-L; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GERMANN UA, 1995, J BIOENERG BIOMEMBR, V27, P53, DOI 10.1007/BF02110331; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GERMANN UA, 1993, CYTOTECHNOLOGY, V12, P33, DOI 10.1007/BF00744657; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GLAZER RI, 1994, PROTEIN KINASE C, P171; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Homolya L, 1996, BRIT J CANCER, V73, P849, DOI 10.1038/bjc.1996.151; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KIM SH, 1993, CANCER LETT, V74, P37, DOI 10.1016/0304-3835(93)90041-7; MIYAMOTO KI, 1992, CANCER LETT, V64, P177, DOI 10.1016/0304-3835(92)90079-B; Muller M, 1996, J BIOL CHEM, V271, P1877; Orlowski S, 1996, BIOCHEM J, V317, P515, DOI 10.1042/bj3170515; RAO US, 1995, J BIOL CHEM, V270, P6686; SAMPSON KE, 1993, CANCER LETT, V68, P7, DOI 10.1016/0304-3835(93)90213-S; SARKADI B, 1994, FASEB J, V8, P766, DOI 10.1096/fasebj.8.10.7914178; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; SCARBOROUGH GA, 1995, J BIOENERG BIOMEMBR, V27, P37, DOI 10.1007/BF02110329; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHAROM FJ, 1995, J BIOENERG BIOMEMBR, V27, P15, DOI 10.1007/BF02110326; SPOELSTRA EC, 1994, EUR J BIOCHEM, V221, P363, DOI 10.1111/j.1432-1033.1994.tb18748.x; SPOELSTRA EC, 1992, EUR J BIOCHEM, V207, P567, DOI 10.1111/j.1432-1033.1992.tb17083.x; TAMAI I, 1991, J BIOL CHEM, V266, P16796; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; UCHIUMI T, 1993, FEBS LETT, V326, P11, DOI 10.1016/0014-5793(93)81750-T; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WAKUSAWA S, 1992, MOL PHARMACOL, V41, P1034; WELKER E, 1995, BIOCHEM BIOPH RES CO, V166, P180	61	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23165	23171		10.1074/jbc.272.37.23165	http://dx.doi.org/10.1074/jbc.272.37.23165			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287320	hybrid			2022-12-27	WOS:A1997XV74400031
J	Jackson, DD; Stevens, TH				Jackson, DD; Stevens, TH			VMA12 encodes a yeast endoplasmic reticulum protein required for vacuolar H+-ATPase assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; CYCLOPHILIN HOMOLOG NINAA; AMINO-ACID PERMEASES; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; GENE ENCODES; SECRETORY PATHWAY; TRANSPORT VESICLES; SHUTTLE VECTORS; SUBUNIT VPH1P	The Saccharomyces cerevisiae vacuolar membrane proton-translocating ATPase (V-ATPase) can be divided into a peripheral membrane complex (V-1) containing at least eight polypeptides of 69, 60, 54, 42, 32, 27, 14, and 13 kDa, and an integral membrane complex (V-0) containing at least five polypeptides of 100, 36, 23, 17, and 16 kDa. Other yeast genes have been identified that are required for V-ATPase assembly but whose protein products do not co-purify with the enzyme complex. One such gene, VMA12, encodes a 25-kDa protein (Vma12p) that is predicted to contain two membrane-spanning domains. Biochemical analysis has revealed that Vma12p behaves as an integral membrane protein with both the N and C termini oriented toward the cytosol, and this protein immunolocalizes to the endoplasmic reticulum (ER). In cells lacking Vma12p (vma12 Delta), the 100-kDa subunit of the V-0 complex (which contains six to eight putative membrane-spanning domains) was rapidly degraded (t(1/2) similar to 30 min). Protease protection assays revealed that the 100-kDa subunit was inserted/translocated correctly into the ER membrane of vma12 Delta cells. These data indicate that Vma12p functions in the ER after the insertion of V-0 subunits into the ER membrane. We propose that Vma12p functions directly in the assembly of the V-0 subunits into a complex in the ER, and that assembly is required for the stability of the V-0 subunits and their transport as a complex out of this compartment.	UNIV OREGON, INST MOL BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOLF DH, 1975, J BACTERIOL, V123, P1150, DOI 10.1128/JB.123.3.1150-1156.1975; Xie XS, 1996, J BIOL CHEM, V271, P30980; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	55	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25928	25934		10.1074/jbc.272.41.25928	http://dx.doi.org/10.1074/jbc.272.41.25928			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325326	hybrid			2022-12-27	WOS:A1997YA35800081
J	Nguyen, T; Sudhof, TC				Nguyen, T; Sudhof, TC			Binding properties of neuroligin 1 and neurexin 1 beta reveal function as heterophilic cell adhesion molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-NERVE BARRIER; DROSOPHILA-MELANOGASTER; PROTEIN; DOMAIN; MEMBRANE; LAMININ; HOMOLOGY; CADHERIN; ALPHA	beta-Neurexins and neuroligins are plasma membrane proteins that are displayed on the neuronal cell surface. We have now investigated the interaction of neurexin 1 beta with neuroligin 1 to evaluate their potential to function as heterophilic cell adhesion molecules. Using detergent-solubilized neuroligins and secreted neurexin 1 beta-IgG fusion protein, we observed binding of these proteins to each other only in the presence of Ca2+ and in no other divalent cation tested. Only neurexin 1 beta lacking an insert in splice site 4 bound neuroligins, whereas neurexin 1 beta containing an insert was inactive. Half-maximal binding required 1-3 mu M free Ca2+, which probably acts by binding to neuroligin 1 but not to neurexin 1 beta. To determine if neurexin 1 beta and neuroligin 1 can also interact with each other when present in a native membrane environment on the cell surface, we generated transfected cell lines expressing neuroligin 1 and neurexin 1 beta. Upon mixing different cell populations, we found that cells aggregate only if cells expressing neurexin 1 beta are mixed with cells expressing neuroligin 1. Aggregation was dependent on Ca2+ and was inhibited by the addition of soluble neurexin 1 beta lacking an insert in splice site 4 but not by the addition of neurexin 1 beta containing an insert in splice site 4. We conclude that neurexin 1 beta and neuroligin 1 (and, by extension, other beta-neurexins and neuroligins) function as heterophilic cell adhesion molecules in a Ca2+-dependent reaction that is regulated by alternative splicing of beta-neurexins.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; Baumgartner S, 1996, CELL, V87, P1059, DOI 10.1016/S0092-8674(00)81800-0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; DARBOUX I, 1996, EMBO J, V15, P4853; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GEPPERT M, 1992, COLD SPRING HARB SYM, V57, P483, DOI 10.1101/SQB.1992.057.01.053; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hata Y, 1996, J NEUROSCI, V16, P2488; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MURPHYERDOSH C, 1995, J CELL BIOL, V129, P1379, DOI 10.1083/jcb.129.5.1379; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Petrenko AG, 1996, J NEUROSCI, V16, P4360; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; USHKARYOV YA, 1994, J BIOL CHEM, V269, P1197; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314	28	173	179	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26032	26039		10.1074/jbc.272.41.26032	http://dx.doi.org/10.1074/jbc.272.41.26032			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325340	hybrid			2022-12-27	WOS:A1997YA35800095
J	Srikrishna, G; Varki, NM; Newell, PC; Varki, A; Freeze, HH				Srikrishna, G; Varki, NM; Newell, PC; Varki, A; Freeze, HH			An IgG monoclonal antibody against Dictyostelium discoideum glycoproteins specifically recognizes Fuc alpha 1,6GlcNAc beta in the core of N-linked glycans - Localized expression of core-fucosylated glycoconjugates in human tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEINS; HIGH-MANNOSE-TYPE; ALPHA-FETOPROTEIN; HEPATOCELLULAR-CARCINOMA; DEVELOPMENTAL REGULATION; HUMAN LACTOTRANSFERRIN; CARBOHYDRATE EPITOPE; H-1-NMR SPECTROSCOPY; HUMAN-SKIN; LECTINS	Core fucosylation of N-linked oligosaccharides (GlcNAc beta 1,4(Fuc alpha 1,6)GlcNAc beta 1-Asn) is a common modification in animal glycans, but little is known about the distribution of core-fucosylated glycoproteins in mammalian tissues, Two monoclonal antibodies, CAB2 and CAB4, previously raised against carbohydrate epitopes of Dictyostelium discoideum glycoproteins (Crandall, I, E, and Newell, P, C, (1989) Development 107, 87-94), specifically recognize fucose residues in alpha 1,6-linkage to the asparagine-bound GlcNAc of N-linked oligosaccharides. These IgG3 antibodies do not cross-react with glycoproteins containing alpha-fucoses in other linkages commonly seen in N- or O-linked sugar chains, CAB4 recognizes core alpha 1,6 fucose regardless of terminal sugars, branching pattern, sialic acid linkage, or polylactosamine substitution, This contrasts to lentil and pea lectins that recognize a similar epitope in only a subset of these structures, Additional GlcNAc residues found in the core of N-glycans from dominant Chinese hamster ovary cell mutants LEC14 and LEC18 progressively decrease binding, These antibodies show that many proteins in human tissues are core-fucosylated, but their expression is localized to skin keratinocytes, vascular and visceral smooth muscle cells, epithelia, and some extracellular matrix-like material surrounding subpopulations of lymphocytes. The availability of these antibodies now allows for an extended investigation of; core fucose epitope expression in development and malignancy and in genetically manipulated mice.	BURNHAM INST,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,CTR CANC,DEPT MED,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of Oxford				Freeze, Hudson/0000-0001-6316-0501	NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032485] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 38701] Funding Source: Medline; NIGMS NIH HHS [R01-GM 32485] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAGI Y, 1993, CANCER-AM CANCER SOC, V72, P615, DOI 10.1002/1097-0142(19930715)72:2<615::AID-CNCR2820720246>3.0.CO;2-T; AOYAGI Y, 1985, BIOCHIM BIOPHYS ACTA, V830, P217, DOI 10.1016/0167-4838(85)90277-8; AOYAGI Y, 1988, CANCER-AM CANCER SOC, V61, P769, DOI 10.1002/1097-0142(19880215)61:4<769::AID-CNCR2820610422>3.0.CO;2-M; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BELL CM, 1984, BRIT J DERMATOL, V111, P517, DOI 10.1111/j.1365-2133.1984.tb06620.x; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BHAT NR, 1988, J NEUROCHEM, V50, P375, DOI 10.1111/j.1471-4159.1988.tb02922.x; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; CAPALDI MJ, 1985, HISTOCHEM J, V17, P81, DOI 10.1007/BF01003405; CRANDALL IE, 1989, DEVELOPMENT, V107, P87; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; DAMJANOV I, 1987, LAB INVEST, V57, P5; DANGUY A, 1994, HISTOL HISTOPATHOL, V9, P155; DASILVA MLC, 1994, ARCH BIOCHEM BIOPHYS, V312, P151, DOI 10.1006/abbi.1994.1293; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; DINTER A, 1995, ADV EXP MED BIOL, V376, P53; Endo T, 1996, EUR J BIOCHEM, V236, P579, DOI 10.1111/j.1432-1033.1996.t01-1-00579.x; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FREEZE HH, 1992, CELL SURFACE CARBOHY, P285; GEORGE ST, 1986, J BIOL CHEM, V261, P6559; GOODARZI MT, 1995, CLIN CHIM ACTA, V236, P161, DOI 10.1016/0009-8981(95)06049-J; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HASLAM SM, 1994, GLYCOBIOLOGY, V4, P105, DOI 10.1093/glycob/4.2.105; ISHIHARA H, 1979, J BIOL CHEM, V254, P715; ISHII S, 1992, DEV NEUROSCI-BASEL, V14, P221, DOI 10.1159/000111666; IVATT RL, 1984, CELL, V38, P561, DOI 10.1016/0092-8674(84)90510-5; Kamath VP, 1996, GLYCOCONJUGATE J, V13, P315, DOI 10.1007/BF00731506; KATZ F, 1988, EMBO J, V7, P3471, DOI 10.1002/j.1460-2075.1988.tb03222.x; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LEMIEUX RU, 1981, BIOCHEMISTRY-US, V20, P199, DOI 10.1021/bi00504a033; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; NAKAGAWA F, 1986, CELL TISSUE RES, V245, P579; NEMANIC MK, 1983, J HISTOCHEM CYTOCHEM, V31, P887, DOI 10.1177/31.7.6854004; PEREIRA MEA, 1978, ARCH BIOCHEM BIOPHYS, V185, P108, DOI 10.1016/0003-9861(78)90149-2; Raju TS, 1996, J BIOL CHEM, V271, P7484, DOI 10.1074/jbc.271.13.7484; Raju TS, 1995, J BIOL CHEM, V270, P30294, DOI 10.1074/jbc.270.51.30294; REGAN CM, 1991, INT J BIOCHEM, V23, P513; RICE KG, 1992, ANAL BIOCHEM, V206, P278, DOI 10.1016/0003-2697(92)90367-G; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; SAWUTZ DG, 1987, MOL PHARMACOL, V32, P565; SHARKEY DJ, 1991, J BIOL CHEM, V266, P18485; SHIRAKAWA O, 1983, BIOCHEM BIOPH RES CO, V115, P814, DOI 10.1016/S0006-291X(83)80007-2; SPICER SS, 1992, J HISTOCHEM CYTOCHEM, V40, P1, DOI 10.1177/40.1.1370305; SPIK G, 1982, EUR J BIOCHEM, V121, P413, DOI 10.1111/j.1432-1033.1982.tb05803.x; Stubbs HJ, 1996, BIOCHEMISTRY-US, V35, P937, DOI 10.1021/bi9513719; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; TAI T, 1975, J BIOL CHEM, V250, P8569; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TRUONG LD, 1988, HISTOCHEMISTRY, V90, P51, DOI 10.1007/BF00495707; Uozumi N, 1996, J BIOL CHEM, V271, P27810, DOI 10.1074/jbc.271.44.27810; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki Ajit, 1995, Seminars in Developmental Biology, V6, P127, DOI 10.1016/S1044-5781(06)80022-8; VOYNOW JA, 1991, J BIOL CHEM, V266, P21572; WALKER RA, 1985, J PATHOL, V146, P123, DOI 10.1002/path.1711460207; WALKER RA, 1989, PATHOL RES PRACT, V185, P826, DOI 10.1016/S0344-0338(89)80282-1; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476; ZACHARIAH B, 1991, INDIAN J BIOCHEM BIO, V28, P412	65	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25743	25752		10.1074/jbc.272.41.25743	http://dx.doi.org/10.1074/jbc.272.41.25743			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325301	hybrid			2022-12-27	WOS:A1997YA35800056
J	Szabo, I; Bathori, G; Tombola, F; Brini, M; Coppola, A; Zoratti, M				Szabo, I; Bathori, G; Tombola, F; Brini, M; Coppola, A; Zoratti, M			DNA translocation across planar bilayers containing Bacillus subtilis ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-SENSITIVE CHANNEL; ESCHERICHIA-COLI-CELLS; NUCLEAR-PORE COMPLEX; OUTER-MEMBRANE; PATCH-CLAMP; MECHANOSENSITIVE CHANNELS; CONDUCTING CHANNELS; ACTIVATED CHANNELS; TRANSPORT PROTEIN; CATIONIC CHANNEL	The mechanisms by which genetic material crosses prokaryotic membranes are incompletely understood. We have developed a new methodology to study the translocation of genetic material via pores in a reconstituted system, using techniques from electrophysiology and molecular biology. We report here that planar bilayer membranes become permeable to double-stranded DNA (kilobase range) if Bacillus subtilis membrane vesicles containing high conductance channels have been fused into them. The translocation is an electrophoretic process, since it does not occur if a transmembrane electrical field opposing the movement of DNA, a polyanion, is applied. It is not an aspecific permeation through the phospholipid bilayer, since it does not take place if no proteins have been incorporated into the membrane. The transport is also not due simply to the presence of polypeptides in the membrane, since it does not occur if the latter contains gramicidin A or a eukaryotic, multiprotein vesicle fraction exhibiting 30-picosiemens anion-selective channel activity, The presence of DNA alters the behavior of the bacterial channels, indicating that it interacts with the pores and may travel through their lumen, These results support the idea that DNA translocation may lake place through proteic pores and suggest that some of the high conductance bacterial channels observed in electrophysiological experiments may be constituents of the DNA translocating machinery in these organisms.	UNIV PADUA,DEPT BIOMED SCI,UNIT STUDY BIOMEMBRANES,CNR,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua			Tombola, Francesco/C-7311-2011; Brini, Marisa/K-5189-2016; Szabo, Ildiko/AAW-5972-2021; Tombola, Francesco/ABA-6002-2020; Padova, Ildiko/K-5344-2016	Szabo, Ildiko/0000-0002-3637-3947; Tombola, Francesco/0000-0002-9315-0352; Brini, Marisa/0000-0001-5141-0243	Telethon [A.059] Funding Source: Medline	Telethon(Fondazione Telethon)		ALCAYAGA C, 1992, FEBS LETT, V311, P246, DOI 10.1016/0014-5793(92)81112-Y; Alvarez O., 1986, ION CHANNEL RECONSTI, P115; BENZ R, 1993, ZBL BAKT-INT J MED M, V278, P187, DOI 10.1016/S0934-8840(11)80836-4; BERRIER C, 1993, J MEMBRANE BIOL, V133, P119; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOULANGER P, 1992, J BIOL CHEM, V267, P3168; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BUECHNER M, 1990, BIOCHIM BIOPHYS ACTA, V1024, P111, DOI 10.1016/0005-2736(90)90214-9; BUSATH DD, 1993, ANNU REV PHYSIOL, V55, P473; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P253; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P239; CITOVSKY V, 1993, ANNU REV MICROBIOL, V47, P167, DOI 10.1146/annurev.mi.47.100193.001123; CUI C, 1995, J MEMBRANE BIOL, V144, P31; DREISEIKELMANN B, 1994, MICROBIOL REV, V58, P293, DOI 10.1128/MMBR.58.3.293-316.1994; DUBNAU D, 1991, MICROBIOL REV, V55, P395, DOI 10.1128/MMBR.55.3.395-424.1991; Evans CH, 1990, BIOCH LANTHANIDES, P85; FEUCHT A, 1990, J BIOL CHEM, V265, P18561; GLASERWUTTKE G, 1989, BIOCHIM BIOPHYS ACTA, V985, P239, DOI 10.1016/0005-2736(89)90408-2; GUIHARD G, 1992, J BIOL CHEM, V267, P3173; HIGGINS NP, 1992, TRENDS BIOCHEM SCI, V17, P207, DOI 10.1016/0968-0004(92)90376-K; JUIN P, 1995, BIOCHEM BIOPH RES CO, V211, P92, DOI 10.1006/bbrc.1995.1782; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1113, P391; KILLMANN H, 1993, EMBO J, V12, P3007, DOI 10.1002/j.1460-2075.1993.tb05969.x; KORCHEV YE, 1995, J MEMBRANE BIOL, V147, P233; KUBALSKI A, 1993, J MEMBRANE BIOL, V131, P151, DOI 10.1007/BF02260105; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; LORENZ MG, 1994, MICROBIOL REV, V58, P563, DOI 10.1128/MMBR.58.3.563-602.1994; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; MAYNARDSMITH J, 1991, NATURE, V349, P29; PAWLAK M, 1994, BIOCHEMISTRY-US, V33, P283, DOI 10.1021/bi00167a037; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; ROESSNER CA, 1986, J BIOL CHEM, V261, P386; RUTZ JM, 1992, SCIENCE, V258, P471, DOI 10.1126/science.1411544; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Sukharev Sergei I., 1996, Biophysical Journal, V70, pA366; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; SZABO I, 1992, BIOCHIM BIOPHYS ACTA, V1112, P29, DOI 10.1016/0005-2736(92)90250-P; SZABO I, 1993, J MEMBRANE BIOL, V131, P203, DOI 10.1007/BF02260109; SZABO I, 1990, BIOCHEM BIOPH RES CO, V171, P280, DOI 10.1016/0006-291X(90)91389-A; THIEFFRY M, 1992, BIOPHYS J, V63, P333, DOI 10.1016/S0006-3495(92)81626-0; VALLETTE FM, 1994, J BIOL CHEM, V269, P13367; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X; ZORATTI M, 1990, BIOCHEM BIOPH RES CO, V168, P443, DOI 10.1016/0006-291X(90)92341-V	59	60	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25275	25282		10.1074/jbc.272.40.25275	http://dx.doi.org/10.1074/jbc.272.40.25275			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312144	hybrid			2022-12-27	WOS:A1997XY97000083
J	Yanagawa, SI; Lee, JS; Haruna, T; Oda, H; Uemura, T; Takeichi, M; Ishimoto, A				Yanagawa, SI; Lee, JS; Haruna, T; Oda, H; Uemura, T; Takeichi, M; Ishimoto, A			Accumulation of armadillo induced by Wingless, Dishevelled, and dominant-negative Zeste-white 3 leads to elevated DE-cadherin in Drosophila clone 8 wing disc cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT-POLARITY GENE; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; XENOPUS EMBRYOS; SIGNALING PATHWAY; INT-1 PROTOONCOGENE; CYTOPLASMIC DOMAIN; ADHERENS JUNCTION; LIMB DEVELOPMENT	Drosophila genetic studies suggest that in the Wingless (Wg) signaling pathway, the segment polarity gene products, Dishevelled (Dsh), Zeste-white 3 (ZW-3), and Armadillo (Arm), work sequentially; wg and dsh negatively regulate zw-3, which in turn down-regulates arm. To biochemically analyze interactions between the Wg pathway and Drosophila E-cadherin (DE-cadherin) which bind to Arm, we overexpressed Dsh, ZW-3, and Arm, in the Drosophila wing disc cell Line, clone 8, which responds to Wg signal. Dsh overexpression led to accumulation of Arm primarily in the cytosol and elevation of DE-cadherin at cell junctions. Overexpression of wildtype and dominant-negative forms of ZW-3 decreased and increased Arm levels, respectively, indicating that modulation in zw-3 activity negatively regulates Arm levels. Overexpression of an Arm mutant with an aminoterminal deletion elevated DE-cadherin levels, suggesting that Dsh-induced DE-cadherin elevation is caused by the Arm accumulation induced by Dsh. Moreover, the Dsh-, dominant-negative ZW-3-, and truncated Arm-induced accumulation of DE-cadherin protein was accompanied by a marked increase in the steady-state levels of DE-cadherin mRNA, suggesting that transcription of DE-cadherin is activated by Wg signaling. In addition, overexpression of DE-cadherin elevated Arm levels by stabilizing Arm at cell-cell junctions.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	Yanagawa, SI (corresponding author), KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN.		Takeichi, Masatoshi/G-5903-2012; Oda, Hiroki/AAC-2559-2019	Takeichi, Masatoshi/0000-0002-9931-3378; UEMURA, Tadashi/0000-0001-7204-3606				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COUSO JP, 1994, DEVELOPMENT, V120, P621; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PEEL DJ, 1992, ROUX ARCH DEV BIOL, V201, P120, DOI 10.1007/BF00420423; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; PIERCE SB, 1995, DEVELOPMENT, V121, P755; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; ROTHBACHER U, 1995, DEV BIOL, V170, P717, DOI 10.1006/dbio.1995.1249; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; THIESEN H, 1994, DEVELOPMENT, V120, P347; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	81	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25243	25251		10.1074/jbc.272.40.25243	http://dx.doi.org/10.1074/jbc.272.40.25243			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312140	hybrid			2022-12-27	WOS:A1997XY97000079
J	Endo, F; Kubo, S; Awata, H; Kiwaki, K; Katoh, H; Kanegae, Y; Saito, I; Miyazaki, J; Yamamoto, T; Jakobs, C; Hattori, S; Matsuda, I				Endo, F; Kubo, S; Awata, H; Kiwaki, K; Katoh, H; Kanegae, Y; Saito, I; Miyazaki, J; Yamamoto, T; Jakobs, C; Hattori, S; Matsuda, I			Complete rescue of lethal albino c(14CoS) mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY TYROSINEMIA; ACID DIOXYGENASE; MURINE MODEL; RECOMBINANT ADENOVIRUS; MOUSE STRAIN; GENE HPD; LIVER; EXPRESSION; ENZYME; HYPERTYROSINEMIA	Hereditary tyrosinemia 1 (HT1) is characterized by progressive liver damage, hom infancy, and by a high risk for hepatocellular carcinoma. HT1 is due to mutations in the fumarylacetoacetate hydrolase gene Fah, encoding the last enzyme in the tyrosine catabolic pathway. Lethal albino deletion c(14CoS) mice and mice with target-disrupted Fah are models for HT1, but they die ill the perinatal period, albeit with a different phenotype from that seen in HT1 in humans, We-first asked whether homozygous null mutation of the 4-hydroxy-phenylpyruvate dioxygenase gene Hpd could rescue the homozygous c(14CoS) mice (c(14CoS)/c(14CoS) or Fah(-/-)), The double mutant Fah(-/-) Hpd(-/-) mice appeared normal, at least until age 18 months, and there was no evidence of liver disease, findings that facilitated examination of the effect of Fah(-/-) on mature and unmodified hepatocytes in vivo. The hepatocytes of Fah(-/-) undergo rapid apoptosis, and acute death follows. Essentially the same phenomena were observed when Fah(-/-) Hpd(-/-) mice were administered homogentisate intraperitoneally. These changes in liver pathology in Fah(-/-) Hpd(-/-) mice after the administration of homogentisate were associated with massive urinary excretion of succinylacetone, These results suggest that accumulation of fumarylacetoacetate, maleylacetoacetate, or succinylacetone seems to trigger the endogenous process of apoptosis in hepatocytes that lack fumarylacetoacetate hydrolase activity. This apoptosis may be related to the development of hepatocellular carcinomas seen in HT1 patients and pharmaceutically treated fumarylacetoacetate hydrolase-deficient mice.	KUMAMOTO UNIV,SCH MED,GRAD SCH MED SCI,DIV MOL PATHOL,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,COLL MED SCI,KUMAMOTO 860,JAPAN; CENT INST EXPT ANIM,DEPT GENET,KAWASAKI,KANAGAWA 216,JAPAN; UNIV TOKYO,INST MED SCI,GENET MOL LAB,MINATO KU,TOKYO 108,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; FREE UNIV AMSTERDAM HOSP,DEPT PEDIAT & CLIN CHEM,NL-1018 HV AMSTERDAM,NETHERLANDS	Kumamoto University; Kumamoto University; University of Tokyo; Tohoku University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Endo, F (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT PEDIAT,HONJO 1-1-1,KUMAMOTO 860,JAPAN.		Miyazaki, Jun-ichi/N-1976-2015; Kubo, Shuji/Q-3868-2019	Miyazaki, Jun-ichi/0000-0003-2475-589X; Kubo, Shuji/0000-0001-7384-4835				AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; ANDREW HW, 1995, CURR OPIN GENE DEV, V5, P97; AWATA H, 1994, GENOMICS, V23, P534, DOI 10.1006/geno.1994.1540; AWATA H, 1994, BBA-MOL BASIS DIS, V1226, P168, DOI 10.1016/0925-4439(94)90025-6; EDWARDS SW, 1956, J BIOL CHEM, V220, P79; ENDO F, 1992, J BIOL CHEM, V267, P24235; ENDO F, 1983, PEDIATR RES, V17, P92, DOI 10.1203/00006450-198302000-00002; ENDO F, 1991, AM J HUM GENET, V48, P704; ENDO F, 1995, GENOMICS, V25, P164, DOI 10.1016/0888-7543(95)80122-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLUECKSOHNWAELSCH S, 1979, CELL, V16, P225, DOI 10.1016/0092-8674(79)90001-1; GROMPE M, 1995, NAT GENET, V10, P453, DOI 10.1038/ng0895-453; GROMPE M, 1993, GENE DEV, V7, P298; JAKOBS C, 1988, CLIN CHIM ACTA, V223, P223; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KASTAN MB, 1993, NAT GENET, V5, P207, DOI 10.1038/ng1193-207; Katoh H., 1991, Mouse Genome, V89, P572; KELSEY G, 1993, GENE DEV, V7, P2285, DOI 10.1101/gad.7.12a.2285; KELSEY G, 1992, J CELL SCI S, V16, P117; Kiwaki K, 1996, HUM GENE THER, V7, P821, DOI 10.1089/hum.1996.7.7-821; KLEBIG ML, 1992, P NATL ACAD SCI USA, V89, P1363, DOI 10.1073/pnas.89.4.1363; Kubo S, 1997, HUM GENE THER, V8, P65, DOI 10.1089/hum.1997.8.1-65; KVITTINGEN EA, 1993, J CLIN INVEST, V91, P1816, DOI 10.1172/JCI116393; La Du BN, 1995, METABOLIC MOL BASES, P1371; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; LINDSTEDT S, 1992, LANCET, V340, P813, DOI 10.1016/0140-6736(92)92685-9; Mitchell G, 1995, METABOLIC MOL BASES, P1077; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; PHANEUF D, 1992, J CLIN INVEST, V90, P1185, DOI 10.1172/JCI115979; RUPPERT S, 1992, GENE DEV, V6, P1430, DOI 10.1101/gad.6.8.1430; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; RUSSO P, 1990, AM J HUM GENET, V47, P317; TONJES RR, 1992, EMBO J, V11, P127, DOI 10.1002/j.1460-2075.1992.tb05035.x	36	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24426	24432		10.1074/jbc.272.39.24426	http://dx.doi.org/10.1074/jbc.272.39.24426			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305902	hybrid			2022-12-27	WOS:A1997XY51500053
J	Kim, KS; Donelson, JE				Kim, KS; Donelson, JE			Co-duplication of a variant surface glycoprotein gene and its promoter to an expression site in African trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-I; VSG GENE; ANTIGENIC VARIATION; BRUCEI-RHODESIENSE; POINT MUTATIONS; METACYCLIC VSG; TRANSCRIPTION; PROVIDES; PARP	Activation of the metacyclic variant antigen type 7 (MVAT7) variant surface glycoprotein (VSG) gene in bloodstream Trypanosoma brucei rhodesiense involves a duplicative transposition of the gene. The DNA transposition unit extends from a site similar to 3.0 kilobases upstream of the VSG gene through the coding region and includes a 73-base pair sequence that possesses promoter activity in transient transfections. This MVAT7 promoter has 80% identity to a previously characterized promoter for the MVAT4 VSG gene. Nuclear run-on assays demonstrate that the MVAT7 promoter is active in MVAT7 bloodstream organisms and that its transcript is synthesized by an RNA polymerase resistant to alpha-amanitin, consistent with previously published reports regarding VSG gene transcription. The transcription start site was identified by primer extension studies and a modified rapid amplification of cDNA ends protocol. Selective mutational analysis of the MVAT7 promoter showed that two conserved trinucleotide regions are important for full promoter function. This study demonstrates that the MVAT7 VSG gene is co duplicated with its promoter and transcribed into a monocistronic precursor RNA.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; Howard Hughes Medical Institute			Donelson, John E/F-5795-2010					ALARCON CM, 1994, MOL CELL BIOL, V14, P5579, DOI 10.1128/MCB.14.8.5579; Borst P, 1996, ARCH MED RES, V27, P379; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CAMPBELL GH, 1979, AM J TROP MED HYG, V28, P974, DOI 10.4269/ajtmh.1979.28.974; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CROWE JS, 1983, NATURE, V306, P389, DOI 10.1038/306389a0; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; ESSER KM, 1982, J IMMUNOL, V129, P1715; GOTTESDIENER K, 1991, MOL CELL BIOL, V11, P2467, DOI 10.1128/MCB.11.5.2467; GRAHAM SV, 1995, MOL CELL BIOL, V15, P5945; Graham VS, 1996, MOL BIOCHEM PARASIT, V79, P35, DOI 10.1016/0166-6851(96)02642-4; Horn D, 1997, MOL BIOCHEM PARASIT, V84, P189, DOI 10.1016/S0166-6851(96)02794-6; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JANZ L, 1994, MOL CELL BIOL, V14, P5804, DOI 10.1128/MCB.14.9.5804; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LENARDO MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6642, DOI 10.1073/pnas.81.21.6642; LU Y, 1994, MOL CELL BIOL, V14, P3971, DOI 10.1128/MCB.14.6.3971; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; LUMSDEN WHR, 1982, SYST PARASITOL, V4, P373, DOI 10.1007/BF00009977; Maniatis T., 1982, MOL CLONING; McCulloch R, 1997, MOL CELL BIOL, V17, P833, DOI 10.1128/MCB.17.2.833; NAGOSHI YL, 1995, MOL BIOCHEM PARASIT, V72, P33, DOI 10.1016/0166-6851(95)00062-6; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEA C, 1987, CELL, V50, P603, DOI 10.1016/0092-8674(87)90033-X; TURNER CMR, 1988, PARASITOLOGY, V97, P269, DOI 10.1017/S0031182000058479; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	36	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24637	24645		10.1074/jbc.272.39.24637	http://dx.doi.org/10.1074/jbc.272.39.24637			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305933	hybrid			2022-12-27	WOS:A1997XY51500084
J	King, AJ; Teertstra, WR; vanderVliet, PC				King, AJ; Teertstra, WR; vanderVliet, PC			Dissociation of the protein primer and DNA polymerase after initiation of adenovirus DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; SLIDING-BACK MECHANISM; TERMINAL PROTEIN; BINDING PROTEIN; LINEAR TEMPLATE; PRECURSOR; DOMAIN; VITRO; NUCLEOTIDE; DISTINCT	Initiation of adenovirus DNA replication occurs by a jumping back mechanism in which the precursor terminal priming protein (pTP) forms a pTP trinucleotide complex (pTP CAT) catalyzed by the viral DNA polymerase (pol), This covalent complex subsequently jumps back 3 bases to permit the start of chain elongation, Before initiation, pTP and pol form a tight heterodimer, We investigated the fate of this pTP pol complex during the various steps in replication, Employing in vitro initiation and elongation on both natural viral templates and synthetic oligonucleotides followed by glycerol gradient separation of the reaction products, we established that pTP and pol are separated during elongation, Whereas pTP.C and pTP.CA were still bound to the polymerase, after the formation of pTP.CAT 60% of the pTP pol complex had dissociated, Dissociation coincides with a change in sensitivity to inhibitors and in K-m for dNTPs, suggesting a conformational change in the polymerase, both in the active site and in the pTP interaction domain, In agreement with this, the polymerase becomes a more efficient enzyme after release of the pTP primer, We also investigated whether the synthesis of a pTP initiation intermediate is confined to three nucleotides. Employing synthetic oligonucleotide templates with a sequence repeat of two nucleotides (GAGAGAGA ... instead of the natural GTAGTA ...) we show that G5 rather than G3 is used to start, leading to a pTP tetranucleotide (CTCT) intermediate that subsequently jumps back, This indicates flexibility in the use of the start site with a preference for the synthesis of three or four nucleotides during initiation rather than two.	UNIV UTRECHT, PHYSIOL CHEM LAB, NL-3508 TA UTRECHT, NETHERLANDS	Utrecht University								ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; CALDENTEY J, 1993, NUCLEIC ACIDS RES, V21, P3725, DOI 10.1093/nar/21.16.3725; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; COENJAERTS FEJ, 1994, NUCLEIC ACIDS RES, V22, P5235, DOI 10.1093/nar/22.24.5235; Coenjaerts FEJ, 1995, METHOD ENZYMOL, V262, P548; Dekker J, 1996, MOL CELL BIOL, V16, P4073; ENOMOTO T, 1981, P NATL ACAD SCI-BIOL, V78, P6779, DOI 10.1073/pnas.78.11.6779; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FREDMAN JN, 1993, J VIROL, V67, P3384, DOI 10.1128/JVI.67.6.3384-3395.1993; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GRIEP MA, 1990, J BIOL CHEM, V265, P20356; HAY RT, 1996, DNA REPLICATION EUKA, P699; King AJ, 1997, NUCLEIC ACIDS RES, V25, P1745, DOI 10.1093/nar/25.9.1745; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; KWANT MM, 1980, NUCLEIC ACIDS RES, V8, P3993, DOI 10.1093/nar/8.17.3993; LICHY JH, 1982, P NATL ACAD SCI-BIOL, V79, P5225, DOI 10.1073/pnas.79.17.5225; LICHY JH, 1981, P NATL ACAD SCI-BIOL, V78, P2678, DOI 10.1073/pnas.78.5.2678; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; Martin AC, 1996, J MOL BIOL, V260, P369, DOI 10.1006/jmbi.1996.0407; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUL YM, 1989, NUCLEIC ACIDS RES, V17, P8917, DOI 10.1093/nar/17.22.8917; MUL YM, 1993, NUCLEIC ACIDS RES, V21, P641, DOI 10.1093/nar/21.3.641; RIJNDERS AWM, 1983, VIROLOGY, V131, P287, DOI 10.1016/0042-6822(83)90497-X; SALAS M, 1996, DNA REPLICATION EUKA, P131; SHINAGAWA M, 1987, GENE, V55, P85; SUSSENBACH JS, 1983, CURR TOP MICROBIOL, V109, P53; Van der Vliet P C, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P1; vanLeeuwen HC, 1997, J BIOL CHEM, V272, P3398, DOI 10.1074/jbc.272.6.3398; WATSON CJ, 1990, NUCLEIC ACIDS RES, V18, P1167, DOI 10.1093/nar/18.5.1167; WEBSTER A, 1994, J VIROL, V68, P7292, DOI 10.1128/JVI.68.11.7292-7300.1994; Webster A, 1997, J VIROL, V71, P539, DOI 10.1128/JVI.71.1.539-547.1997	32	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24617	24623		10.1074/jbc.272.39.24617	http://dx.doi.org/10.1074/jbc.272.39.24617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305930	hybrid			2022-12-27	WOS:A1997XY51500081
J	Spink, J; Evans, T				Spink, J; Evans, T			Binding of the transcription factor interferon regulatory factor-1 to the inducible nitric-oxide synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA-GENE; NF-KAPPA-B; FACTOR-I; VIRUS INDUCTION; RELAXING FACTOR; NUCLEAR FACTOR; FACTOR IRF-1; DNA; ELEMENTS; EXPRESSION	Nitric oxide production in a variety of inflammatory conditions is dependent on the synthesis of the enzyme, inducible nitric-oxide synthase (iNOS). The gene for this enzyme is regulated by a number of inflammatory cytokines, including interferon-gamma. Transcriptional activation of the gene is dependent on the interferon-gamma-induced transcription factor, interferon regulatory factor-1 (IRF-1). Using a 99-base pair segment of the iNOS gene promoter encompassing nucleotides -979 to -881, a region essential for gene activation by cytokines, we show that with increasing concentrations of added IRF-1, a monomeric then a dimeric complex form. Molecular footprinting analysis shows that the factor binds initially to a canonical IRF-1 site as a monomer. The region of binding is then extended both in a 5' and 3' direction on formation of the dimeric complex, with additional contacts in the minor groove of DNA, Binding of the second molecule of IRF-1 is dependent on the presence of the initial bound protein, Sequential binding of IRF-1 to form a dimeric complex has not been described previously, and we show that formation of this dimeric complex is essential for full activation of the iNOS gene by cytokines in vascular smooth muscle cells.	ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND	Imperial College London								BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; LEE LYYH, 1990, MOL CELL BIOL, V10, P3087; LIN RT, 1994, J BIOL CHEM, V269, P17542; LUSTER AD, 1987, MOL CELL BIOL, V7, P3723, DOI 10.1128/MCB.7.10.3723; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; OHNO S, 1983, NUCLEIC ACIDS RES, V11, P5403, DOI 10.1093/nar/11.16.5403; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; UEGAKI K, 1995, FEBS LETT, V359, P184, DOI 10.1016/0014-5793(95)00040-G; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	39	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24417	24425		10.1074/jbc.272.39.24417	http://dx.doi.org/10.1074/jbc.272.39.24417			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305901	hybrid			2022-12-27	WOS:A1997XY51500052
J	Swaroop, M; Moussalli, M; Pipe, SW; Kaufman, RJ				Swaroop, M; Moussalli, M; Pipe, SW; Kaufman, RJ			Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-V; MAMMALIAN-CELLS; EXPRESSION; CDNA; CERULOPLASMIN; DISSOCIATION; SEQUENCE; CLONING	Coagulation factor VIII (FVIII) and factor V are homologous glycoproteins that have a domain structure of A1-A2-B-A3-C1-C2, FVIII is a heterodimer of the heavy chain (domains A1-A2-B) and the light chain (domains A3-C1-C2) in a metal ion-dependent association between the Al-and A3 domains. Previous studies identified a 110-amino acid region within the FVIII Al-domain that inhibits its secretion and contains multiple short peptide sequences that have potential to bind immunoglobulin-binding protein (BiP), FVIII secretion requires high levels of intracellular ATP, consistent with an ATP-dependent release from BiP, Site-directed mutagenesis was used to elucidate the importance of the potential BiP binding sites in FVIII secretion, Mutation of Phe at position 309 to Ser or Ala enhanced the secretion of functional FVIII and reduced its ATP dependence. The F309S FVIII had a specific activity, thrombin activation profile, and heat inactivation properties similar to those of wild-type FVIII, However, F309S FVIII displayed increased sensitivity to EDTA-mediated inactivation that is known to occur through metal ion chelation-induced dissociation of the heavy and light chains of FVIII. The results support that Phe(309) is important in high affinity heavy and light chain interaction, and this correlates with a high affinity BiP-binding site, Introduction of the F309S mutation into other secretion defective FVIII mu mutants rescued their secretion, demonstrating the ability of the this mutation to improve secretion of mutant FVIII proteins retained in the cell.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PEDIAT,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Pipe, Steven W./ABC-3843-2020	Pipe, Steven W./0000-0003-2558-2089; Swaroop, Manju/0000-0002-0576-1664	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173, R01HL053777] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52173, HL53777] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIHOREAU N, 1994, EUR J BIOCHEM, V222, P41, DOI 10.1111/j.1432-1033.1994.tb18839.x; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KAUFMAN RJ, 1989, METHOD ENZYMOL, V135, P537; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; TAGLIAVACCA L, 1997, IN PRESS J BIOL CHEM, V272; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; ZATLOUKAL K, 1994, P NATL ACAD SCI USA, V91, P5148, DOI 10.1073/pnas.91.11.5148	25	82	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24121	24124		10.1074/jbc.272.39.24121	http://dx.doi.org/10.1074/jbc.272.39.24121			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305856	hybrid			2022-12-27	WOS:A1997XY51500007
J	Mounier, C; Chen, WZ; Klautky, SA; Goodridge, AG				Mounier, C; Chen, WZ; Klautky, SA; Goodridge, AG			Cyclic AMP-mediated inhibition of transcription of the malic enzyme gene in chick embryo hepatocytes in culture - Characterization of a cis-acting element far upstream of the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE GENE; THYROID-HORMONE; RESPONSE ELEMENTS; BINDING PROTEIN; MAMMALIAN-CELLS; V-ERBA; CAMP; JUN; FOS; TRIIODOTHYRONINE	Glucagon, acting via cAMP, inhibits transcription of the malic enzyme gene in chick embryo hepatocytes. In transiently transfected hepatocytes, fragments from the 5'-flanking DNA of the malic enzyme gene confer cAMP responsiveness to linked reporter genes, The major inhibitory cAMP response element at -3180/-3114 base pairs (bp) is similar to the consensus binding site for AP1. DNA fragments from -3134/-3115, -1713/-944, and -413/-147 bp also contain inhibitory cAMP response elements. The negative action of cAMP is mimicked by overexpression of the catalytic subunit of protein kinase A, inhibited by overexpression of a specific inhibitor of protein kinase A, and inhibited by overexpression of the T3 receptor; these results indicate involvement of the classical eukaryotic pathway for cAMP action and suggest interaction between the T3 and cAMP pathways. Sequence-specific complexes form between nuclear proteins and a DNA fragment containing -3192/-3158 bp of 5'-flanking DNA. In nuclear extracts prepared from cells treated with chlorophenylthio-cyclic AMP and T3, the complexes have different masses than those formed with extracts from cells treated with T3 alone. Antibodies to c-Fos or ATF-2 inhibit formation of the complex formed by proteins from cells treated with chlorophenylthio-cyclic AMP and T3 but not by those from cells treated with T3 alone. These results suggest an important role for c-Fos and ATF-2 in glucagon-nediated inhibition of transcription of the malic enzyme gene.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Mounier, Catherine/D-3690-2011	Mounier, Catherine/0000-0003-3608-4229	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021594, P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25295, DK 21594] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAILLIE RB, 1992, J NUTR BIOCH, V4, P431; BARBER JR, 1978, MOL CELL BIOL, V77, P2201; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BORRELLI E, 1992, CRIT REV ONCOGEN, V3, P312; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; Carlisle TL, 1996, J LIPID RES, V37, P2088; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DELMAS V, 1994, REV PHYSIOL BIOCH P, V124, P1, DOI 10.1007/BFb0031030; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GOODRIDGE AG, 1968, BIOCHEM J, V108, P663, DOI 10.1042/bj1080663; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROVE JR, 1987, SCIENCE, V238, P530; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; LUCKOW B, 1987, NUCLEIC ACIDS RES, V17, P2365; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MECHTA F, 1989, New Biologist, V1, P297; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RONCERO C, 1992, ARCH BIOCHEM BIOPHYS, V295, P258, DOI 10.1016/0003-9861(92)90516-Y; SALATI LM, 1991, J BIOL CHEM, V266, P4010; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SIKORSKA M, 1988, J BIOL CHEM, V263, P3005; TAMIR A, 1994, J IMMUNOL, V152, P3391; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	41	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23606	23615		10.1074/jbc.272.38.23606	http://dx.doi.org/10.1074/jbc.272.38.23606			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295300	hybrid			2022-12-27	WOS:A1997XX38100025
J	Nakajima, Y; Tsuji, Y; Homma, K; Natori, S				Nakajima, Y; Tsuji, Y; Homma, K; Natori, S			A novel protease in the pupal yellow body of Sarcophaga peregrina (flesh fly) - Its purification and cDNA cloning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							29-KDA HEMOCYTE PROTEINASE; SARCOTOXIN IA; FAT-BODY; MOLECULAR-CLONING; METAMORPHOSIS; EXPRESSION; GENE	We purified a novel serine protease with a molecular mass of 26 kDa from Sarcophaga pupae. This protease appeared almost exclusively in the yellow body, an organ that develops temporarily in the pupae of dipteran insects and expands to form the adult midgut by engulfing the larval midgut. cDNA analysis revealed that this protease consists of 239 amino acid residues and has significant structural similarity with bovine trypsin (about 40% sequence identity). The 26-kDa protease gene was transiently activated in 1-day-old pupae. The protease was found to cross-react immunologically with antibody against sarcotoxin IA, an antibacterial protein produced by this insect. It is suggested that this protease participates in the decomposition of the larval midgut in the yellow body during metamorphosis.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Tsuji, Yumiko/AAV-9817-2020					Bodenstein D., 1950, BIOL DROSOPHILA, P275; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FLYG C, 1987, INSECT BIOCHEM, V17, P153, DOI 10.1016/0020-1790(87)90155-7; KUBO T, 1991, International Journal of Developmental Biology, V35, P83; KURATA S, 1992, DEV BIOL, V153, P115, DOI 10.1016/0012-1606(92)90096-Y; KURATA S, 1992, EUR J BIOCHEM, V204, P911, DOI 10.1111/j.1432-1033.1992.tb16711.x; KURATA S, 1990, INSECT BIOCHEM, V20, P461, DOI 10.1016/0020-1790(90)90027-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCKSHIN RA, 1985, COMPREHENSIVE INSECT, V2, P301; MATSUMOTO N, 1986, BIOCHEM J, V239, P717, DOI 10.1042/bj2390717; NANBU R, 1988, BIOCHEM BIOPH RES CO, V150, P540, DOI 10.1016/0006-291X(88)90427-5; OHTAKI T, 1966, JPN J MED SCI BIOL, V19, P97, DOI 10.7883/yoken1952.19.97; OKADA M, 1983, BIOCHEM J, V211, P727, DOI 10.1042/bj2110727; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TAKAHASHI N, 1993, FEBS LETT, V334, P153, DOI 10.1016/0014-5793(93)81702-2; YAMADA K, 1990, BIOCHEM J, V272, P633, DOI 10.1042/bj2720633; YANO T, 1995, EUR J BIOCHEM, V234, P39, DOI 10.1111/j.1432-1033.1995.039_c.x	19	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23805	23810		10.1074/jbc.272.38.23805	http://dx.doi.org/10.1074/jbc.272.38.23805			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295327	hybrid			2022-12-27	WOS:A1997XX38100052
J	Plummer, NW; McBurney, MW; Meisler, MH				Plummer, NW; McBurney, MW; Meisler, MH			Alternative splicing of the sodium channel SCN8A predicts a truncated two-domain protein in fetal brain and non-neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; GROWTH-FACTOR RECEPTOR; SKELETAL-MUSCLE; ION CHANNELS; GENOMIC ORGANIZATION; ALPHA-SUBUNIT; SECRETED FORM; RAT-BRAIN; GENE; CLONING	The voltage gated sodium channel alpha subunit SCN8A is one of the most abundant sodium channels in neurons from brain and spinal cord. We have identified two alternatively spliced exons, 18N and 18A, that encode transmembrane segments S3 and S4 in domain III. Exon 18N is expressed in fetal brain and non-neuronal tissues. Transcripts with exon 18N have a conserved in-frame stop codon that predicts the synthesis of a truncated, two-domain protein similar to the fetal form of the muscle calcium channel. The proportion of transcripts containing exon 18N is highest in mouse fetal brain between E12.5 and P1.5; at later ages transcripts containing exon 18A predominate. This developmental program is recapitulated in P19 cells during retinoic acid-induced neuronal differentiation. Non-neuronal tissues contain a low level of SCN8A transcripts containing exon 18N. SCN8A thus provides a new model of differentiation specific splicing. Genomic analysis of SCN8A from human, mouse, and fish demonstrated a conserved structure in which exon 18N is located 300-500 bp upstream of exon 18A. Duplication of exon 18 thus preceded the divergence of fish and mammals. The genomic organization, developmental regulation, and coding content of exons 18N and 18A closely resemble the previously described alternate exons 5N and 5A of the neuronal sodium channel genes. Our proposal that the evolutionary origin of exons 18N and 18A was by duplication of exons 5N and 5A is consistent with other evidence that the four-domain cation channels arose by two rounds of duplication from a single-domain ancestral channel.	UNIV OTTAWA,DEPT MED,OTTAWA,ON K1H 8M5,CANADA	University of Ottawa	Plummer, NW (corresponding author), UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109, USA.			/0000-0003-2971-814X	NIGMS NIH HHS [T32 GM 07544] Funding Source: Medline; NINDS NIH HHS [NS34509] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARREOLA J, 1993, J PHYSIOL-LONDON, V472, P289, DOI 10.1113/jphysiol.1993.sp019947; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BELCHER SM, 1995, P NATL ACAD SCI USA, V92, P11034, DOI 10.1073/pnas.92.24.11034; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHEUN JE, 1991, INT J DEV NEUROSCI, V9, P391, DOI 10.1016/0736-5748(91)90061-P; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; GEORGE AL, 1993, GENOMICS, V15, P598, DOI 10.1006/geno.1993.1113; GUSTAFSON TA, 1993, J BIOL CHEM, V268, P18648; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HARRIS JB, 1986, J NEUROL SCI, V76, P239, DOI 10.1016/0022-510X(86)90172-3; HILLE B, 1992, ION CHANNELS EXCITAB, P538; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kohrman DC, 1996, J NEUROSCI, V16, P5993; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; Kozak CA, 1996, MAMM GENOME, V7, P787, DOI 10.1007/s003359900235; KUBO Y, 1989, J PHYSIOL-LONDON, V409, P497, DOI 10.1113/jphysiol.1989.sp017510; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MAGNUSON DSK, 1995, DEV BRAIN RES, V84, P130, DOI 10.1016/0165-3806(94)00166-W; MALOUF NN, 1992, NEURON, V8, P899, DOI 10.1016/0896-6273(92)90204-Q; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; MORASSUTTI DJ, 1994, NEUROSCIENCE, V58, P753, DOI 10.1016/0306-4522(94)90452-9; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Peixoto AA, 1997, GENETICS, V145, P1003; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SARAO R, 1991, NUCLEIC ACIDS RES, V19, P5673, DOI 10.1093/nar/19.20.5673; SCHALLER KL, 1992, J NEUROSCI, V12, P1370; SCHALLER KL, 1995, J NEUROSCI, V15, P3231; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STRONG M, 1993, MOL BIOL EVOL, V10, P221; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SWAROOP A, 1993, CYTOGENET CELL GENET, V64, P292, DOI 10.1159/000133595; THACKERAY JR, 1995, GENETICS, V141, P203; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236	47	125	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24008	24015		10.1074/jbc.272.38.24008	http://dx.doi.org/10.1074/jbc.272.38.24008			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295353	hybrid			2022-12-27	WOS:A1997XX38100078
J	West, AP; Bjorkman, PJ; Dougherty, DA; Lester, HA				West, AP; Bjorkman, PJ; Dougherty, DA; Lester, HA			Expression and circular dichroism studies of the extracellular domain of the alpha subunit of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; T-CELL RECEPTOR; MOLECULAR-BASIS; ION-CHANNEL; CRYSTAL-STRUCTURE; BINDING SITE; FC RECEPTOR; COMPLEX; FORM; AGGREGATION	To provide material suitable for structural studies of the nicotinic acetylcholine receptor, we have expressed and purified the NH2-terminal extracellular domain of the mouse muscle alpha subunit. Several constructs were initially investigated using Xenopus oocytes as a convenient small scale expression system. A fusion protein (alpha 210GPI) consisting of the 210 NH2-terminal amino acids of the alpha subunit and a glycosylphosphatidylinositol anchorage sequence conferred surface alpha-bungarotoxin binding in oocytes. Coexpression of alpha 210GPI with an analogous construct made from the delta subunit showed no evidence of heterodimer formation. The alpha 210GPI protein was chosen for large scale expression in transfected Chinese hamster ovary cells. The alpha 210GPI protein was cleaved from these cells and purified on an immunoaffinity column. Gel and column chromatography show that the purified protein is processed as expected and exists as a monomer. The purified protein also retains the two distinct, conformation-specific binding sites expected for the correctly folded alpha subunit. Circular dichroism studies of alpha 210GPI suggest that this region of the receptor includes considerable beta-sheet secondary structure, with a small proportion of alpha-helix.	CALTECH,DIV BIOL,PASADENA,CA 91125; CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125; CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125	California Institute of Technology; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS034407, R01NS034407, R01NS011756] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-34407, NS-11756] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1993, FEBS LETT, V327, P241, DOI 10.1016/0014-5793(93)80177-V; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, CURR TOP MEMBR, V39, P277; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GRIFFIN WG, 1993, J CHEM SOC FARADAY T, V89, P3395, DOI 10.1039/ft9938903395; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; MIELKE DL, 1988, J BIOL CHEM, V263, P3177; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; PERCZEL A, 1992, PROTEINS, V13, P57, DOI 10.1002/prot.340130106; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; Sambrook J., 2002, MOL CLONING LAB MANU; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUMIKAWA K, 1994, MOL BRAIN RES, V25, P257, DOI 10.1016/0169-328X(94)90161-9; Unwin N, 1996, J MOL BIOL, V257, P586, DOI 10.1006/jmbi.1996.0187; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WANG WC, 1993, J BIOL CHEM, V268, P1448; Wang ZZ, 1996, J CELL BIOL, V135, P809, DOI 10.1083/jcb.135.3.809; WHITE SH, 1994, MEMBRANE PROTEIN STR; WHITING PJ, 1986, BIOCHEMISTRY-US, V25, P2082, DOI 10.1021/bi00356a037; WU CSC, 1990, J PROTEIN CHEM, V9, P119, DOI 10.1007/BF01024993	39	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25468	25473		10.1074/jbc.272.41.25468	http://dx.doi.org/10.1074/jbc.272.41.25468			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325259	hybrid, Green Accepted			2022-12-27	WOS:A1997YA35800014
J	Daigle, DM; McKay, GA; Wright, GD				Daigle, DM; McKay, GA; Wright, GD			Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE ANALYSIS; ENTEROCOCCUS; SELECTIVITY; MECHANISM	Bacterial resistance to the aminoglycoside antibiotics is manifested primarily through the expression of enzymes which covalently modify these drugs, One important mechanism of aminoglycoside modification is through ATP-dependent O-phosphorylation, catalyzed by a family of aminoglycoside kinases, The structure of one of these kinases, APH(3')-IIIa has recently been determined by x-ray crystallography, and the general fold is strikingly similar to eukaryotic protein kinases (Hon, W. C., McKay, G. A. Thompson, P. R., Sweet, R. M., Yang, D. S. C., Wright, G. D., and Berghuis, A. M. (1997) Cell 89, 887-895), Based on this similarity, we have examined the effect of known inhibitors of eukaryotic protein kinases on two aminoglycoside kinases, APH(3')-IIIa and the enzyme AAC(6')-APH(2 '') which also exhibits acetyl-CoA-dependent aminoglycoside modification activity, We report that several known protein kinase inhibitors are also good inhibitors of aminoglycoside kinases, Compounds belonging to the isoquinolinesulfonamide group are especially effective in this regard, giving competitive inhibition in the micromolar range with respect to ATP and noncompetitive inhibition versus the aminoglycoside substrate, This study provides the basis for future aminoglycoside kinase inhibitor design and for the development of compounds which could reverse antibiotic resistance in the clinic.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University			Wright, G/ABB-7666-2021	Wright, Gerard/0000-0002-9129-7131				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; *AM SOC MICR, 1995, REPO ASM TASK FORC A; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; COLE PA, 1995, J BIOL CHEM, V270, P22105, DOI 10.1074/jbc.270.38.22105; COLEMAN K, 1994, J ANTIMICROB CHEMOTH, V33, P1091, DOI 10.1093/jac/33.6.1091; Davies J, 1997, TRENDS MICROBIOL, V5, P234, DOI 10.1016/S0966-842X(97)01033-0; DAVIS BD, 1987, MICROBIOL REV, V51, P341, DOI 10.1128/MMBR.51.3.341-350.1987; EDSON RS, 1991, MAYO CLIN PROC, V66, P1158, DOI 10.1016/S0025-6196(12)65798-X; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; FERRETTI JJ, 1986, J BACTERIOL, V167, P631, DOI 10.1128/jb.167.2.631-638.1986; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIDAKA H, 1993, PROTEIN PHOSPHORYLAT, P87; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; LEATHERBARROW RJ, 1992, GRAFIT 3 0 ED; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; ROUCH DA, 1987, J GEN MICROBIOL, V133, P3039; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Thompson PR, 1996, CHEM BIOL, V3, P747, DOI 10.1016/S1074-5521(96)90251-3; Xu RM, 1996, P NATL ACAD SCI USA, V93, P6308, DOI 10.1073/pnas.93.13.6308	23	83	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24755	24758		10.1074/jbc.272.40.24755	http://dx.doi.org/10.1074/jbc.272.40.24755			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312069	hybrid			2022-12-27	WOS:A1997XY97000008
J	Gallagher, MJ; Huang, H; Grant, ER; Lynch, DR				Gallagher, MJ; Huang, H; Grant, ER; Lynch, DR			The NR2B-specific interactions of polyamines and protons with the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CORTICAL-NEURONS; GLYCINE-BINDING-SITE; H-3 MK-801 BINDING; PROTEIN-KINASE-C; NMDA RECEPTOR; AMINO-ACID; RAT-BRAIN; PHARMACOLOGICAL CHARACTERIZATION; MOLECULAR CHARACTERIZATION; HIPPOCAMPAL-NEURONS	Many compounds exhibit NR2B-specific modulation of the N-methyl-D-aspartate receptor, although their mechanism(s) of action are largely unknown. Using chimeric NR2A/NR2B subunits, we have located a region of NR2B (amino acids 138-238) which regulated glycine-independent polyamine stimulation. Mutation of glutamate 201 in this region affected stimulation by polyamines in the order E201D < E201A < E201N < E201R. The relief of proton inhibition of the N-methyl-D-aspartate-induced currents mediated by these mutant receptors correlated with the reduction in glycine-independent polyamine stimulation. Electrophysiological evidence with a triple mutant of NR2A further supports the hypothesis that polyamine stimulation may be linked to the relief of tonic inhibition by protons and demonstrates the crucial role of amino acids 200 and 201 in polyamine stimulation. Polyamines and protons, therefore, share common NR2B determinants.	UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE ON DRUG ABUSE [F32DA005675] Funding Source: NIH RePORTER; NIDA NIH HHS [1F32-DAO5675, DAO7130] Funding Source: Medline; NINDS NIH HHS [CIDA NS01789-01] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; BROSE N, 1993, J BIOL CHEM, V268, P22663; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FAGE D, 1992, J NEUROCHEM, V58, P2170, DOI 10.1111/j.1471-4159.1992.tb10960.x; FAGG GE, 1987, NEUROSCI LETT, V76, P221, DOI 10.1016/0304-3940(87)90719-1; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FLETCHER EJ, 1993, EUR J PHARMACOL, V235, P291, DOI 10.1016/0014-2999(93)90148-B; Gallagher MJ, 1996, J BIOL CHEM, V271, P9603, DOI 10.1074/jbc.271.16.9603; HARMAN RJ, 1981, BRIT J PHARMACOL, V73, P165, DOI 10.1111/j.1476-5381.1981.tb16786.x; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; ISHII T, 1993, J BIOL CHEM, V268, P2836; Johnson TD, 1996, TRENDS PHARMACOL SCI, V17, P22, DOI 10.1016/0165-6147(96)81566-5; Kashiwagi K, 1996, MOL PHARMACOL, V49, P1131; KLOOG Y, 1988, BIOCHEMISTRY-US, V27, P843, DOI 10.1021/bi00403a001; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; LYNCH DR, 1995, J NEUROCHEM, V64, P1462; Lynch DR, 1996, J PHARMACOL EXP THER, V279, P154; LYNCH DR, 1996, PHARM RECOMBINANT NM, P325; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PAOLETTI P, 1995, NEURON, V15, P1109, DOI 10.1016/0896-6273(95)90099-3; PARSONS CG, 1995, NEUROPHARMACOLOGY, V34, P1239, DOI 10.1016/0028-3908(95)00092-K; PASCHEN W, 1992, CEREBROVAS BRAIN MET, V4, P59; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS GP, 1994, J NEUROL SCI, V125, P46, DOI 10.1016/0022-510X(94)90240-2; ROCK DM, 1992, MOL PHARMACOL, V42, P157; ROCK DM, 1992, MOL PHARMACOL, V41, P83; SACAAN AI, 1989, MOL PHARMACOL, V36, P836; SAKURAI SY, 1993, J NEUROCHEM, V60, P1344, DOI 10.1111/j.1471-4159.1993.tb03295.x; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; WAFFORD KA, 1995, MOL PHARMACOL, V47, P374; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4; Williams K, 1995, MOL PHARMACOL, V48, P1087; WILLIAMS K, 1994, MOL PHARMACOL, V45, P803; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; WILLIAMS K, 1995, POLYAMINES REGULATIO, P129; ZHENG X, 1994, NEURON, V12, P811; ZHONG J, 1994, MOL PHARMACOL, V45, P846	51	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24971	24979		10.1074/jbc.272.40.24971	http://dx.doi.org/10.1074/jbc.272.40.24971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312102	hybrid			2022-12-27	WOS:A1997XY97000041
J	Lokuta, AJ; Meyers, MB; Sander, PR; Fishman, GI; Valdivia, HH				Lokuta, AJ; Meyers, MB; Sander, PR; Fishman, GI; Valdivia, HH			Modulation of cardiac ryanodine receptors by sorcin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; FEET STRUCTURES; PROTEIN; PHOSPHORYLATION; RECONSTITUTION; PURIFICATION; ACTIVATION; CALMODULIN	Sorcin is a widely expressed, 22-kDa Ca2+-binding protein initially identified in multidrug-resistant cells, In the heart, sorcin localizes to the dyadic junctions of transverse tubules and sarcoplasmic reticulum and coimmunoprecipitates with the Ca2+ release channel/ryanodine receptor (RyR) (Meyers, M.B., Pickel, V. M., Sheu, S.-S., Sharma, V. K., Scotto, K. W., and Fishman, G. I. (1995) J. Biol. Chem. 270, 26411-26418), We have investigated a possible functional interaction between sorcin and cardiac RyR using purified recombinant sorcin in [H-3]ryanodine binding experiments and single channel recordings of RyR, The open probability of single RyR was decreased significantly by the addition of sorcin to the cytoplasmic side of the channel (IC(50)similar to 480 nM), In addition, sorcin completely inhibited [H-3]ryanodine binding with an IC(50)similar to 700 nM. Inhibition occurred over a wide range of [Ca2+], and sorcin-modulated RyR remained Ca2+-dependent. Furthermore, caffeine-activated RyRs were also inhibited by sorcin at low [Ca2+] (pCa 7), suggesting that Ca2+ is not an obligatory factor for sorcin inhibition of RyR, Comparisons of these inhibitory effects with those of calmodulin and calpain, proteins structurally related to sorcin, suggested that the interaction of sorcin with cardiac RyR was distinct from and independent of either of these modulatory proteins, Phosphorylation of sorcin with the catalytic subunit of protein kinase A significantly decreased the ability of sorcin to modulate RyR, These results suggest that sorcin may modulate RyR function in a normal cell environment and that the level of modulation is in turn influenced by signaling pathways that increase protein kinase A activity.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,SECT MOL CARDIOL,BRONX,NY 10461; UNIV WISCONSIN,SCH MED,DEPT PHYSIOL,MADISON,WI 53706	Yeshiva University; Albert Einstein College of Medicine; University of Wisconsin System; University of Wisconsin Madison				Fishman, Glenn/0000-0002-2366-8527	NHLBI NIH HHS [HL55438] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055438] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERS DM, 1991, EXCITATION CONTRACTI; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; FABIATO A, 1981, J GEN PHYSIOL, V78, P457, DOI 10.1085/jgp.78.5.457; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FUENTES O, 1994, CELL CALCIUM, V15, P305, DOI 10.1016/0143-4160(94)90070-1; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20857; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; LOKUTA AJ, 1997, BIOPHYS J, V72, P333; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, ANN REV PHYSL, V56, P484; Meyers M. B., 1991, NOVEL CALCIUM BINDIN, P385, DOI 10.1007/978-3-642-76150-8_22; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MEYERS MB, 1990, STIMULUS RESPONSE CO, P159; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; SHOSHANBARMATZ V, 1994, J MEMBRANE BIOL, V142, P281; STERN MD, 1992, FASEB J, V6, P3092, DOI 10.1096/fasebj.6.12.1325933; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037	29	126	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25333	25338		10.1074/jbc.272.40.25333	http://dx.doi.org/10.1074/jbc.272.40.25333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312152	hybrid			2022-12-27	WOS:A1997XY97000091
J	Modriansky, M; MurdzaInglis, DL; Patel, HV; Freemann, KB; Garlid, KD				Modriansky, M; MurdzaInglis, DL; Patel, HV; Freemann, KB; Garlid, KD			Identification by site-directed mutagenesis of three arginines in uncoupling protein that are essential for nucleotide binding and inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; FAT MITOCHONDRIA; PROTON TRANSPORT; ANION UNIPORT; H+-TRANSPORT; MECHANISM; RECONSTITUTION; MEMBRANE; PROBES; YEAST	Primary regulation of uncoupling protein is mediated by purine nucleotides, which bind to the protein and allosterically inhibit fatty acid-induced proton transport. To gain increased understanding of nucleotide regulation, we evaluated the role of basic amino acid residues using site-directed mutagenesis. Mutant and wildtype proteins were expressed in yeast, purified, and reconstituted into liposomes. We studied nucleotide binding as well as inhibition of fatty acid-induced proton transport in wild-type and six mutant uncoupling proteins. None of the mutations interfered with proton transport. Two lysine mutants and a histidine mutant had no effect on nucleotide binding or inhibition, Arg(83) and Arg(182) mutants completely lost both the ability to bind nucleotides and nucleotide inhibition. Surprisingly, the Arg(276) mutant exhibited normal nucleotide binding, but completely lost nucleotide inhibition. To account for this dissociation between binding and inhibition, Foe propose a three-stage binding-conformational change model of nucleotide regulation of uncoupling protein. We have now identified three nucleotides by site-directed mutagenesis that are essential for nucleotide interaction with uncoupling protein.	OREGON GRAD INST,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97291; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	McMaster University			Modriansky, Martin/A-6338-2008	Modriansky, Martin/0000-0001-7692-0338; Garlid, Keith/0000-0002-6777-1235	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P151, DOI 10.1016/0005-2728(90)90237-X; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; GASSER SM, 1983, METHOD ENZYMOL, V97, P329; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; HUANG SG, 1995, BIOCHEMISTRY-US, V34, P349, DOI 10.1021/bi00001a043; Huang SG, 1996, BIOCHEMISTRY-US, V35, P7846, DOI 10.1021/bi960244p; JEZEK P, 1994, J BIOL CHEM, V269, P26184; JEZEK P, 1990, J BIOL CHEM, V265, P19296; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KATIYAR SS, 1989, P NATL ACAD SCI USA, V86, P2559, DOI 10.1073/pnas.86.8.2559; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; KLINGENBERG M, 1986, METHOD ENZYMOL, V126, P498; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN CS, 1982, BIOCHEMISTRY-US, V21, P2950, DOI 10.1021/bi00541a023; MAYINGER P, 1992, BIOCHEMISTRY-US, V31, P10536, DOI 10.1021/bi00158a017; MIROUX B, 1993, EMBO J, V12, P3739, DOI 10.1002/j.1460-2075.1993.tb06051.x; MURDZAINGLIS DL, 1994, J BIOL CHEM, V269, P7435; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; MURDZAINGLIS DL, 1995, THESIS MCMASTER U HA; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; OROSZ DE, 1993, ANAL BIOCHEM, V210, P7, DOI 10.1006/abio.1993.1143; RAFAEL J, 1994, EUR J BIOCHEM, V223, P971, DOI 10.1111/j.1432-1033.1994.tb19075.x; WINKLER E, 1992, EUR J BIOCHEM, V203, P295, DOI 10.1111/j.1432-1033.1992.tb19859.x; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x; [No title captured]	29	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24759	24762		10.1074/jbc.272.40.24759	http://dx.doi.org/10.1074/jbc.272.40.24759			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312070	hybrid			2022-12-27	WOS:A1997XY97000009
J	Schwalbe, RA; Bianchi, L; Brown, AM				Schwalbe, RA; Bianchi, L; Brown, AM			Mapping the kidney potassium channel ROMK1 - Glycosylation of the pore signature sequence and the COOH terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; RECTIFIER K+ CHANNEL; RECTIFICATION; MUTATIONS; PHOSPHORYLATION; GLYCOPROTEINS; SPERMINE; MEMBRANE; REGION; BLOCK	ROMK1, also known as Kir 1.1, is an inwardly rectifying K+ channel and is the prototypical member of the large Kir gene family. The accepted model of Kir topology predicts intracellular NH2 and COOH termini, and two membrane-spanning segments, M1 and M2, connected by an intramembranous pore-forming segment, H5. The sequence of H5 is similar in voltage-dependent K+ channels and features a strictly conserved GY/FG in its mid-region, which has been proposed as the selectivity filter of the pore. We have been using N-glycosylation substitution mutants to map the extracellular topology of ROMK1 biochemically and have described several loci in H5 that were glycosylated. We now report glycosylation at loci Tyr(144) and Phe(146), which indicates that the signature GYG sequence (143-145) rather than being intramembranous is extracellular, The COOH terminus was predicted to begin at position 178, but contrary to the model, we observed that position 257 was glycosylated and surrounding positions at 199, 222, and 298 were unglycosylated. N-Glycosylation sequon substitution at the latter three positions abolished K+/Na+ selectivity. Our results suggest a major revision of the topology of ROMK1 with H5 and the pore signature sequence now completely extracellular. The COOH terminus appears to form two additional membrane-spanning segments and to contribute to the ion conduction pathway.			Schwalbe, RA (corresponding author), CASE WESTERN RESERVE UNIV, RAMMELKAMP CTR EDUC & RES, METROHLTH CAMPUS, 2500 METROHLTS DR, CLEVELAND, OH 44109 USA.				NHLBI NIH HHS [HL36930, HL55404] Funding Source: Medline; NIDDK NIH HHS [DK52990] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055404, R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052990] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; Doi T, 1996, J BIOL CHEM, V271, P17261, DOI 10.1074/jbc.271.29.17261; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; FENG WJ, 1995, ENDOCRINOLOGY, V136, P52, DOI 10.1210/en.136.1.52; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GIEBISCH G, 1995, KIDNEY INT, V48, P1004, DOI 10.1038/ki.1995.382; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEBERT SC, 1995, KIDNEY INT, V48, P1010, DOI 10.1038/ki.1995.383; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Karolyi L, 1997, HUM MOL GENET, V6, P17; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Possee RD., 1992, BACULOVIRUS EXPRESSI; Schwalbe RA, 1996, J BIOL CHEM, V271, P24201, DOI 10.1074/jbc.271.39.24201; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TAGLIALATELA M, 1994, NEWS PHYSIOL SCI, V9, P169; VIDAL S, 1989, J VIROL, V63, P892, DOI 10.1128/JVI.63.2.892-900.1989; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809; Zhou H, 1996, AM J PHYSIOL-CELL PH, V271, pC1949, DOI 10.1152/ajpcell.1996.271.6.C1949	38	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25217	25223		10.1074/jbc.272.40.25217	http://dx.doi.org/10.1074/jbc.272.40.25217			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312136	hybrid			2022-12-27	WOS:A1997XY97000075
J	Stapulionis, R; Kolli, S; Deutscher, MP				Stapulionis, R; Kolli, S; Deutscher, MP			Efficient mammalian protein synthesis requires an intact F-Actin system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR 1-ALPHA; MESSENGER-RNA; CYTOSKELETAL FRAMEWORK; CYTOCHALASIN-D; SYNTHETASE; ASSOCIATION; BINDING; CELLS; ORGANIZATION	The mammalian protein synthesizing system is highly organized in vivo, and its substrate, tRNA, is channeled throughout the translation process, However, the cellular components responsible for this organization are not known. To examine this question a series of studies was carried out using intact and permeabilized Chinese hamster ovary cells, We show that cold shock dramatically reduces the protein synthetic capacity of these cells by as much as 95%, The loss of activity can be reversed by a short recovery period under conditions that allow energy metabolism to occur; transcription and translation during the recovery period are not needed, While individual components of the translation apparatus are not inactivated by the cold shock, the supramolecular organization of the system appears to be altered and F-actin levels are found to decrease, Resumption of protein synthesis during the recovery period coincides closely with the restoration of F-actin to normal levels. Moreover, disruption of actin filaments, but not microtubules, also leads to a major reduction in translation. These data support the conclusion that the cellular microfilament network plays an important role in the structure and function of the translation system and that perturbations of this network can have profound effects on protein synthesis.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOL BIOL, MIAMI, FL 33101 USA; UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA	University of Miami; University of Connecticut					NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBARESE E, 1995, J CELL SCI, V108, P2781; Bassell G J, 1994, Adv Exp Med Biol, V358, P183; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; BASSELL GJ, 1994, NEURON, V12, P571, DOI 10.1016/0896-6273(94)90213-5; BEKTAS M, 1994, FEBS LETT, V356, P89, DOI 10.1016/0014-5793(94)01239-3; BIEGEL D, 1992, J CELL BIOCHEM, V48, P98, DOI 10.1002/jcb.240480114; CANO ML, 1992, CELL MOTIL CYTOSKEL, V21, P147, DOI 10.1002/cm.970210208; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DANG CV, 1983, J CELL BIOL, V96, P1138, DOI 10.1083/jcb.96.4.1138; DEUTSCHER MP, 1984, J CELL BIOL, V99, P373, DOI 10.1083/jcb.99.2.373; Ganoza MC, 1996, BIOCHIMIE, V78, P51, DOI 10.1016/0300-9084(96)81329-0; Glotzer JB, 1996, SEMIN CELL DEV BIOL, V7, P357, DOI 10.1006/scdb.1996.0045; GOUY M, 1980, FEBS LETT, V115, P151, DOI 10.1016/0014-5793(80)81155-0; GRAF H, 1976, BIOCHIM BIOPHYS ACTA, V425, P175, DOI 10.1016/0005-2787(76)90023-X; Hesketh JE, 1996, EXP CELL RES, V225, P219, DOI 10.1006/excr.1996.0172; HESKETH JE, 1988, FEBS LETT, V231, P62, DOI 10.1016/0014-5793(88)80703-8; HITCHCOCK SE, 1980, J BIOL CHEM, V255, P5668; HOWE JG, 1984, CELL, V37, P85; IRVIN JD, 1972, BIOCHEMISTRY-US, V11, P1915, DOI 10.1021/bi00760a028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu G, 1996, TRENDS CELL BIOL, V6, P168, DOI 10.1016/0962-8924(96)20013-3; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1985, EXP CELL RES, V156, P91, DOI 10.1016/0014-4827(85)90264-2; MORRIS A, 1980, NATURE, V287, P637, DOI 10.1038/287637a0; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; NEGRUTSKII BS, 1992, P NATL ACAD SCI USA, V89, P3601, DOI 10.1073/pnas.89.8.3601; Negrutskii BS, 1996, FEBS LETT, V382, P18, DOI 10.1016/0014-5793(96)00128-7; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; ORNELLES DA, 1986, MOL CELL BIOL, V6, P1650, DOI 10.1128/MCB.6.5.1650; REED VS, 1994, J BIOL CHEM, V269, P32932; RYAZANOV AG, 1987, BIOSYSTEMS, V20, P275, DOI 10.1016/0303-2647(87)90035-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHESTAKOVA EA, 1993, CELL BIOL INT, V17, P417, DOI 10.1006/cbir.1993.1080; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; SUPRENANT KA, 1993, CELL MOTIL CYTOSKEL, V25, P1, DOI 10.1002/cm.970250102; UYEDA TQP, 1986, EXP CELL RES, V165, P461, DOI 10.1016/0014-4827(86)90599-9; WEISENBERG RC, 1972, SCIENCE, V177, P1104, DOI 10.1126/science.177.4054.1104; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; ZAMBETTI G, 1990, EXP CELL RES, V191, P246, DOI 10.1016/0014-4827(90)90011-X	42	91	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24980	24986		10.1074/jbc.272.40.24980	http://dx.doi.org/10.1074/jbc.272.40.24980			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312103	hybrid			2022-12-27	WOS:A1997XY97000042
J	Wong, BR; Rho, JR; Arron, J; Robinson, E; Orlinick, J; Chao, M; Kalachikov, S; Cayani, E; Bartlett, FS; Frankel, WN; Lee, SY; Choi, YW				Wong, BR; Rho, JR; Arron, J; Robinson, E; Orlinick, J; Chao, M; Kalachikov, S; Cayani, E; Bartlett, FS; Frankel, WN; Lee, SY; Choi, YW			TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; DENDRITIC CELLS; VIRAL-PROTEINS; FACTOR-ALPHA; KAPPA-B; APOPTOSIS; DEATH; CD40; IDENTIFICATION; EXPRESSION	A novel member of the tumor necrosis factor (TNF) cytokine family, designated TRANCE, was cloned during a search for apoptosis-regulatory genes using a somatic cell genetic approach in T cell hybridomas. The TRANCE gene encodes a type II membrane protein of 316 amino acids with a predicted molecular mass of 35 kDa. Its extracellular domain is most closely related to TRAIL, FasL, and TNF. TRANCE is an immediate early gene up-regulated by TCR stimulation and is controlled by calcineurin-regulated transcription factors. TRANCE is most highly expressed in thymus and lymph nodes but not in nonlymphoid tissues and is abundantly expressed in T cells but not in B cells. Cross hybridization of the mouse cDNA to a human thymus library yielded the human homolog, which encodes a protein 83% identical to the mouse ectodomain. Human TRANCE was mapped to chromosome 13q14 while mouse TRANCE was located to the portion of mouse chromosome 14 syntenic with human chromosome 13q14. A recombinant soluble form of TRANCE composed of the entire ectodomain induced c-Jun N-terminal kinase (JNK) activation in T cells but not in splenic B cells or in bone marrow-derived dendritic cells. These results suggest a role for this TNF-related ligand in the regulation of the T cell-dependent immune response.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; CORNELL UNIV,DEPT CELL BIOL & ANAT,COLL MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021; COLUMBIA PRESBYTERIAN MED CTR,COLL PHYS & SURG,COLUMBIA GENOME CTR,NEW YORK,NY 10032; JACKSON LAB,BAR HARBOR,ME 04609	Howard Hughes Medical Institute; Rockefeller University; Cornell University; Columbia University; NewYork-Presbyterian Hospital; Jackson Laboratory				Rho, Jaerang/0000-0002-0019-4939; Arron, Joseph/0000-0001-7677-9979	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NCI NIH HHS [CA56490] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; NINDS NIH HHS [NS3336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; deLecea L, 1997, GENOMICS, V42, P499, DOI 10.1006/geno.1997.4763; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; JOHNSON KR, 1994, MAMM GENOME, V5, P670, DOI 10.1007/BF00426073; KEHRL JH, 1987, SCIENCE, V238, P1144, DOI 10.1126/science.3500512; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Rozzo SJ, 1996, P NATL ACAD SCI USA, V93, P15164, DOI 10.1073/pnas.93.26.15164; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Sutherland CL, 1996, J IMMUNOL, V157, P3381; VANLINT J, 1992, J BIOL CHEM, V267, P25916; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong B, 1997, Semin Immunol, V9, P7, DOI 10.1006/smim.1996.0051; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	34	847	935	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25190	25194		10.1074/jbc.272.40.25190	http://dx.doi.org/10.1074/jbc.272.40.25190			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312132	hybrid			2022-12-27	WOS:A1997XY97000071
J	Corbley, MJ				Corbley, MJ			Transformation by ras suppresses expression of the neurotrophic growth factor pleiotrophin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE HB-GAM; VIRUS PHOSPHORYLATES TYROSINE; FACTOR SIGNAL-TRANSDUCTION; SARCOMA-VIRUS; CELL-PROLIFERATION; EPITHELIAL-CELLS; DEVELOPING BRAIN; BINDING-PROTEIN; MESSENGER-RNA; HUMAN CANCER	An 18-kDa protein (p18) was detected in lysates and conditioned medium from contact-arrested NIH 3T3 fibroblasts, but was not detected when the cells mere transformed by the oncogene ras. Analysis of transformation-defective cell clones generated after mutagenesis of the ras-retroviral vector used to transduce the ras gene showed an inverse correlation between p18 expression and the degree of transformation. p18 expression was high in non-transformed clones, intermediate in a partially transformed clone, undetectable in fully transformed clones, and detectable only at the non-permissive temperature in a clone which was cold-sensitive for ras transformation. In non-transformed cells, p18 expression varied with the degree of confluence, It was almost undetectable in medium from sparse, proliferating cells, but increased as the cells approached confluence and peaked 2-4 days after confluence, Microsequencing of partially purified pig identified it as the developmentally regulated neurotrophic factor pleiotrophin, In further experiments, pleiotrophin was undetectable or almost undetectable in medium from fully transformed cells expressing the oncogenes v-src, truncated c-raf, activated c-fms, or polyomavirus middle tumor antigen; it was low but easily detectable in medium from SV40 large tumor antigen-expressing cells, which form soft agar colonies but not foci. Thus, pleiotrophin expression in NIH 3T3 cells is associated with quiescence, and suppression of pleiotrophin is related to oncogenic transformation.			Corbley, MJ (corresponding author), DANA FARBER CANC INST,DEPT CANC BIOL,DIV CELLULAR & MOL BIOL,44 BINNEY ST,BOSTON,MA 02115, USA.							BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; CORBLEY MJ, 1994, BIOTECHNIQUES, V17, P1102; CORBLEY MJ, 1988, THESIS HARVARD U ANN; COURTY J, 1991, BIOCHEM BIOPH RES CO, V180, P145, DOI 10.1016/S0006-291X(05)81267-7; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FINKEL T, 1984, CELL, V37, P151, DOI 10.1016/0092-8674(84)90310-6; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; GRAND RJ, 1991, BIOCHEM J, V279, P165; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HERTZOG PJ, 1994, MOL REPROD DEV, V39, P226; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOHNSON TC, 1994, PHARMACOL THERAPEUT, V62, P247, DOI 10.1016/0163-7258(94)90013-2; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KOVESDI I, 1990, BIOCHEM BIOPH RES CO, V172, P850, DOI 10.1016/0006-291X(90)90753-A; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINSON AD, 1980, J BIOL CHEM, V255, P1973; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LI YS, 1992, BIOCHEM BIOPH RES CO, V184, P427, DOI 10.1016/0006-291X(92)91211-8; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MAILLEUX P, 1992, NEUROSCI LETT, V142, P31, DOI 10.1016/0304-3940(92)90613-C; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MERENMIES J, 1992, FEBS LETT, V307, P297, DOI 10.1016/0014-5793(92)80699-H; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; OLESZAK E, 1988, EXP CELL RES, V179, P575, DOI 10.1016/0014-4827(88)90295-9; PARKER BW, 1993, J NATL CANCER I, V85, P1068, DOI 10.1093/jnci/85.13.1068; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; RAPP UR, 1991, ONCOGENE, V6, P495; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1989, BIOSCIENCE REP, V9, P1, DOI 10.1007/BF01117507; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SANANTONIO JD, 1992, J CELL PHYSIOL, V150, P8; SCHAFFHAUSEN B, 1982, CRC CR REV BIOCH MOL, V13, P215, DOI 10.3109/10409238209114230; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; Szabat E, 1996, DEV BIOL, V178, P77, DOI 10.1006/dbio.1996.0199; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; VANDERWINDEN JM, 1992, ANAT EMBRYOL, V186, P387; WANAKA A, 1993, DEV BRAIN RES, V72, P133, DOI 10.1016/0165-3806(93)90166-8; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WRIGHT TC, 1987, J CELL PHYSIOL, V132, P255, DOI 10.1002/jcp.1041320209; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	65	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24696	24702		10.1074/jbc.272.39.24696	http://dx.doi.org/10.1074/jbc.272.39.24696			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305941	hybrid			2022-12-27	WOS:A1997XY51500092
J	Jiang, M; TsengCrank, J; Tseng, GN				Jiang, M; TsengCrank, J; Tseng, GN			Suppression of slow delayed rectifier current by a truncated isoform of KvLQT1 cloned from normal human heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; I-KS; VENTRICULAR MUSCLE; CLONING; EXPRESSION; MUTATIONS; K(V)LQT1; PROTEINS; DOMAIN; FORM	It has been suggested that the cardiac slow delayed rectifier channel is formed by the association of two subunits: IsK (also called minK) and KvLQT1. N-terminal splice variants of the human KvLQT1 gene have been identified, but the functional roles of different KvLQT1 isoforms are not clear, Using the nested 5'-rapid amplification of cDNA ends technique, we obtained a truncated isoform of KvLQT1 (termed tKvLQT1) that lacks the N-terminal cytoplasmic domain and the initial one-third of the first transmembrane domain, The function of tKvLQT1 was tested by oocyte expression, alone or together with the full-length KvLQT1 or a human IsK clone (hIsK). tKvLQT1 alone did not generate functional channels, However, it suppressed the KvLQT1 current when coexpressed with the full-length isoform, It also suppressed the slow delayed rectifier current induced by hIsK, probably by competing with the KvLQT1 subunit endogenous to Xenopus oocytes in coassembly with the hIsK subunit, On the other hand, tKvLQT1 did not suppress the expression of Kv1.4, Kv4.3, or hERG, Using the reverse transcription-polymerase chain reaction technique, we further show that the truncated and full-length isoforms are coexpressed in different regions of human heart, Therefore, tKvLQT1 may modulate the function of IKs in human cardiac myocytes.	WYETH AYERST RES,PRINCETON,NJ 08543	Pfizer	Jiang, M (corresponding author), COLUMBIA UNIV,DEPT PHARMACOL,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046451, P01HL030557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30557, HL46451] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIU DW, 1995, CIRC RES, V76, P351, DOI 10.1161/01.RES.76.3.351; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Russell MW, 1996, HUM MOL GENET, V5, P1319, DOI 10.1093/hmg/5.9.1319; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SICOURI S, 1993, J CARDIOVASC ELECTR, V4, P48, DOI 10.1111/j.1540-8167.1993.tb01211.x; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tanaka T, 1997, CIRCULATION, V95, P565, DOI 10.1161/01.CIR.95.3.565; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; TSENGCRANK J, 1993, J GEN PHYSIOL, V102, P1057, DOI 10.1085/jgp.102.6.1057; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017	20	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24109	24112		10.1074/jbc.272.39.24109	http://dx.doi.org/10.1074/jbc.272.39.24109			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305853	hybrid			2022-12-27	WOS:A1997XY51500004
J	Mitchelhill, KI; Michell, BJ; House, CM; Stapleton, D; Dyck, J; Gamble, J; Ullrich, C; Witters, LA; Kemp, BE				Mitchelhill, KI; Michell, BJ; House, CM; Stapleton, D; Dyck, J; Gamble, J; Ullrich, C; Witters, LA; Kemp, BE			Posttranslational modifications of the 5'-AMP-activated protein kinase beta(1) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; RAT-LIVER; MEMBRANE PHOSPHOLIPIDS; ATP DEPLETION; FATTY-ACID; PHOSPHORYLATION; ACTIVATION; MYRISTOYLATION; MYRISTYLATION; PURIFICATION	The AMP-activated protein kinase (AMPK) consists of catalytic Lu and noncatalytic beta and gamma subunits and is responsible for acting as a metabolic sensor for AMP levels, There are multiple genes for each subunit and the rat liver AMPK alpha(1) and alpha(2), catalytic subunits are associated with beta(1) and gamma(1) noncatalytic subunits. We find that the isolated gamma(1) subunit is N-terminally acetylated with no other posttranslational modification, The isolated beta(1) subunit is N-terminally myristoylated, Transfection of COS cells with AMPK subunit cDNAs containing a non-myristoylatable beta(1) reduces, but does not eliminate, membrane binding of AMPK heterotrimer, The isolated beta(1) subunit is partially phosphorylated at three sites, Ser(24/25), Ser(182), and Ser(108). The Ser(24/25) and Ser(108) sites are substoichiometrically phosphorylated and can be autophosphorylated in vitro. The Ser-Pro site in the se quence LSSS(182)PPGP is stoichiometrically phosphorylated, and no additional phosphate is incorporated into this site with autophosphorylation, Based on labeling studies in transfected cells, we conclude that alpha(1) Thr(172) is a major, although not exclusive, site of both basal and stimulated alpha(1) phosphorylation by an upstream AMPK kinase.	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; DARTMOUTH COLL SCH MED,DEPT MED,ENDOCRINE METAB DIV,HANOVER,NH 03755; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	St. Vincent's Institute of Medical Research; Dartmouth College; Dartmouth College			Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Dyck, Jason/0000-0002-7045-2884	NIDDK NIH HHS [DK35712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1992, LIPID MODIFICATION P, P3; BERI RK, 1994, FEBS LETT, V356, P117, DOI 10.1016/0014-5793(94)01247-4; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DESJARDINS PR, 1972, CAN J BIOCHEM CELL B, V50, P1249, DOI 10.1139/o72-170; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; Stapleton D, 1997, FEBS LETT, V409, P452, DOI 10.1016/S0014-5793(97)00569-3; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; WANG JH, 1976, J BIOL CHEM, V251, P4521; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831	32	120	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24475	24479		10.1074/jbc.272.39.24475	http://dx.doi.org/10.1074/jbc.272.39.24475			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305909	hybrid			2022-12-27	WOS:A1997XY51500060
J	Saras, J; Franzen, P; Aspenstrom, P; Hellman, U; Gonez, LJ; Heldin, CH				Saras, J; Franzen, P; Aspenstrom, P; Hellman, U; Gonez, LJ; Heldin, CH			A novel GTPase-activating protein for Rho interacts with a PDZ domain of the protein-tyrosine phosphatase PTPL1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; ACTIN STRESS FIBERS; KINASE-C; SIGNAL-TRANSDUCTION; GUANYLATE KINASES; FAMILY GTPASES; CLONING; RAC; CHIMAERIN; BAND-4.1	PTPL1 is an intracellular protein-tyrosine phosphatase that contains five PDZ domains. Here, we present the cloning of a novel 150-kDa protein, the four most C-terminal amino acid residues of which specifically interact with the fourth PDZ domain of PTPL1. The molecule contains a GTPase-activating protein (GAP) domain, a cysteine-rich, putative Zn2+- and diacylglycerol-binding domain, and a region of sequence homology to the product of the Caenorhabditis elegans gene ZK669.1a. The GAP domain is active on Rho, Pac, and Cdc42 in vitro but with a clear preference for Rho; we refer to the molecule as PTPL1-associated RhoGAP 1, PARG1, Rho is inactivated by GAPs, and protein-tyrosine phosphorylation has been implicated in Rho signaling. Therefore, a complex between PTPL1 and PARG1 may function as a powerful negative regulator of Rho signaling, acting both on Rho itself and on tyrosine phosphorylated components in the Rho signal transduction pathway.			Saras, J (corresponding author), LUDWIG INST CANC RES,CTR BIOMED,BOX 595,S-75124 UPPSALA,SWEDEN.							AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Sambrook J., 2002, MOL CLONING LAB MANU; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	39	101	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24333	24338		10.1074/jbc.272.39.24333	http://dx.doi.org/10.1074/jbc.272.39.24333			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305890	hybrid			2022-12-27	WOS:A1997XY51500041
J	Sun, GS; Alexson, SEH; Harrison, EH				Sun, GS; Alexson, SEH; Harrison, EH			Purification and characterization of a neutral, bile salt-independent retinyl ester hydrolase from rat liver microsomes - Relationship to rat carboxylesterase ES-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM CARBOXYLESTERASE; ENDOPLASMIC-RETICULUM; PALMITATE HYDROLYSIS; NUCLEOTIDE-SEQUENCE; MEMBRANE; PROTEIN; ACID; IDENTIFICATION; METABOLISM; EXPRESSION	A neutral, bile salt-independent retinyl ester hydrolase (NREH) has been purified from a rat liver microsomal fraction, The purification procedure involved detergent extraction, DEAE-Sepharose ion exchange, Phenyl-Sepharose hydrophobic interaction, Sephadex G-100 and Sephacryl S-200 gel filtration chromatographies, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The isolated enzyme has an apparent molecular mass of approximately 66 kDa under denaturing conditions on SDS-PAGE, Analysis of the amino acid sequences of four peptides isolated after proteolytic digestion revealed that the enzyme is highly homologous with other rat liver carboxylesterases, In particular, the sequences of the four peptides of the NREH (60 amino acids total) were identical to those of a rat carboxylesterase expressed in the liver (Alexson, S. E. H., Finlay, T. H., Hellman, U., Svensson, L. T., Diczfalusy, U., and Eggertsen, G. (1994) J. Biol. Chem. 269, 17118-17124), Antibodies against this enzyme also react with the purified NREH, Purified NREH shows a substrate preference for retinyl palmitate over triolein and did not catalyze the hydrolysis of cholesteryl oleate, With retinyl palmitate as substrate, the enzyme had a pH optimum of 7 and showed apparent saturation kinetics, with half-maximal activity achieved at substrate concentrations (K-m) of approximately 70 mu M.	ALLEGHENY UNIV HLTH SCI,MED COLL PENN HAHNEMANN SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19129; HUDDINGE UNIV HOSP,KAROLINSKA INST,DIV CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Drexel University; Karolinska Institutet			Harrison, Earl H/AAN-5378-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044498] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07443] Funding Source: Medline; NIDDK NIH HHS [R01 DK044498, DK44498] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXSON SEH, 1993, EUR J BIOCHEM, V214, P719, DOI 10.1111/j.1432-1033.1993.tb17973.x; ALEXSON SEH, 1994, J BIOL CHEM, V269, P17118; AMARCOSTESEC A, 1974, J CELL BIOL, V61, P201, DOI 10.1083/jcb.61.1.201; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; ERLANSON C, 1968, BIOCHIM BIOPHYS ACTA, V167, P629, DOI 10.1016/0005-2744(68)90059-4; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; GAD MZ, 1991, J LIPID RES, V32, P685; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; HARRISON EH, 1993, BIOCHIM BIOPHYS ACTA, V1170, P99, DOI 10.1016/0005-2760(93)90058-H; HARRISON EH, 1995, J LIPID RES, V36, P1498; HARRISON EH, 1989, J BIOL CHEM, V264, P17142; KADNER SS, 1992, ARCH BIOCHEM BIOPHYS, V296, P435, DOI 10.1016/0003-9861(92)90594-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDO D, 1980, BIOCHIM BIOPHYS ACTA, V611, P147, DOI 10.1016/0005-2744(80)90050-9; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MENTLEIN R, 1987, BIOCHEM J, V245, P863, DOI 10.1042/bj2450863; NAPOLI JL, 1984, ARCH BIOCHEM BIOPHYS, V230, P194, DOI 10.1016/0003-9861(84)90100-0; NAPOLI JL, 1989, ARCH BIOCHEM BIOPHYS, V274, P192, DOI 10.1016/0003-9861(89)90430-X; PRYSTOWSKY JH, 1981, J BIOL CHEM, V256, P4498; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151; YAN BF, 1995, J BIOL CHEM, V270, P19128, DOI 10.1074/jbc.270.32.19128	26	31	33	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24488	24493		10.1074/jbc.272.39.24488	http://dx.doi.org/10.1074/jbc.272.39.24488			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305911	hybrid			2022-12-27	WOS:A1997XY51500062
J	Winkler, DG; Johnson, JC; Cooper, JA; Vojtek, AB				Winkler, DG; Johnson, JC; Cooper, JA; Vojtek, AB			Identification and characterization of mutations in Ha-Ras that selectively decrease binding to cRaf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; PHOSPHOTYROSINE-CONTAINING PROTEINS; GTPASE-ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-TRANSFORMATION; SIGNAL TRANSDUCTION; KINASE ACTIVATION; CRYSTAL-STRUCTURE; FOCAL ADHESIONS; R-RAS	The oncoprotein Ras transforms cells by binding to one or more effector proteins, Effector proteins have been identified by their ability to bind to Bas in the GTP but not GDP form, and by their requirement for the Ras effector domain for binding, The best understood Ras effectors are serine/threonine kinases of the Raf family, but other candidate Ras effecters, including a Ral guanine nucleotide dissociation stimulator and phosphatidylinositol 3-kinase (PI3 kinase) have also been identified, To investigate the mechanism of binding of cRaf-1 to Ras, and to investigate the roles of other candidate Ras effectors in transformation, we have isolated and characterized mutants of activated Ras with decreased binding to cRaf-1 relative to other candidate effecters, Examination of these mutants indicates that surface-exposed residues of Res outside the minimal effector domain interact differentially with cRaf-1 and other Ras-binding proteins, and that fibroblast transformation correlates with cRaf-1 binding and mitogen-activated protein (MAP) kinase activation, Furthermore, activation of PI3 kinase can occur in the absence of significant MAP kinase activation, suggesting that PI3 kinase activation is a primary effect of Ras.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98109	Fred Hutchinson Cancer Center					NCI NIH HHS [CA54786, CA66281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054786, F32CA066281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Leung DW, 1989, TECHNIQUE, V1, P11; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P2850; Masuelli L, 1996, MOL CELL BIOL, V16, P5466; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SHIROUZU M, 1992, ONCOGENE, V7, P475; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STONE JC, 1993, MOL CELL BIOL, V13, P7311, DOI 10.1128/MCB.13.12.7311; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	71	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24402	24409		10.1074/jbc.272.39.24402	http://dx.doi.org/10.1074/jbc.272.39.24402			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305899	hybrid			2022-12-27	WOS:A1997XY51500050
J	Chen, DN; Patrick, JW				Chen, DN; Patrick, JW			The alpha-bungarotoxin-binding nicotinic acetylcholine receptor from rat brain contains only the alpha 7 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; PHARMACOLOGICAL PROPERTIES; H-3 ACETYLCHOLINE; CELL-LINE; CHANNEL; PROTEIN; PURIFICATION; EXPRESSION; SITES; SUBTYPES	When expressed in Xenopus oocytes, the rat alpha 7 subunit forms homo-oligomeric nicotinic acetylcholine receptors, which are blocked by alpha-bungarotoxin. Since the pharmacological and physiological properties of the alpha 7 receptor expressed in oocytes are similar to those of the alpha-bungarotoxin-sensitive nicotinic currents recorded from neuronal preparations and the distribution patterns of alpha 7 mRNA and alpha-bungarotoxin-binding sites in the rat brain are very similar, alpha 7 is thought to be the main component of the alpha-bungarotoxin-binding nicotinic receptor in the mammalian brain. However, while alpha 7 is found in purified alpha-bungarotoxin-binding complexes from rat brain or PC12 cells, other proteins copurify with it. Therefore, the question whether alpha 7 forms a homo-oligomeric alpha-bungarotoxin-binding nicotinic receptor in the mammalian brain remains. We have developed and characterized affinity-purified polyclonal antibodies and used these antibodies in Western blot analyses of alpha-bungarotoxin-binding proteins purified from rat brains. We report here that our experimental data support the current working hypothesis that the alpha-bungarotoxin-binding nicotinic receptor is a homo-oligomer of alpha 7 subunits in the rat brain.	BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine					NIDA NIH HHS [DA04077] Funding Source: Medline; NINDS NIH HHS [NS13546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004077, R37DA004077] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBUQUERQUE EX, 1995, ANN NY ACAD SCI, V757, P48, DOI 10.1111/j.1749-6632.1995.tb17464.x; ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; BROIDE RS, 1995, NEUROSCIENCE, V67, P83, DOI 10.1016/0306-4522(94)00623-D; Chen D., 1993, Society for Neuroscience Abstracts, V19, P466; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P1046, DOI 10.1021/bi00456a029; CONTITRONCONI BM, 1985, P NATL ACAD SCI USA, V82, P5208, DOI 10.1073/pnas.82.15.5208; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FUCHS JL, 1989, BRAIN RES, V501, P223, DOI 10.1016/0006-8993(89)90640-9; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; GOTTI C, 1989, NEUROSCIENCE, V32, P759, DOI 10.1016/0306-4522(89)90296-0; GOTTI C, 1995, EUR J NEUROSCI, V7, P2083, DOI 10.1111/j.1460-9568.1995.tb00630.x; GOTTI C, 1994, EUR J NEUROSCI, V6, P1281, DOI 10.1111/j.1460-9568.1994.tb00318.x; GOTTI C, 1992, NEUROSCIENCE, V50, P117, DOI 10.1016/0306-4522(92)90386-G; GOTTI C, 1991, P NATL ACAD SCI USA, V88, P3258, DOI 10.1073/pnas.88.8.3258; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; KELLIS JT, 1991, BIO-TECHNOL, V9, P994, DOI 10.1038/nbt1091-994; KEMP G, 1985, BRAIN RES, V347, P274, DOI 10.1016/0006-8993(85)90187-8; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LUKAS RJ, 1990, J PHARMACOL EXP THER, V253, P51; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; NEFF S, 1995, J NEUROCHEM, V64, P332; PATRICK J, 1977, J BIOL CHEM, V252, P8629; PATRICK J, 1977, P NATL ACAD SCI USA, V74, P4689, DOI 10.1073/pnas.74.10.4689; Radcliffe K. A., 1996, Society for Neuroscience Abstracts, V22, P1264; ROGERS SW, 1992, J NEUROSCI, V12, P4611; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SEGUELA P, 1993, J NEUROSCI, V13, P596; SINE SM, 1981, J BIOL CHEM, V256, P6692; STALLCUP WB, 1979, J PHYSIOL-LONDON, V286, P525, DOI 10.1113/jphysiol.1979.sp012635; TZARTOS SJ, 1991, MOL NEUROBIOL, V5, P1, DOI 10.1007/BF02935610; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WHITING P, 1987, P NATL ACAD SCI USA, V84, P595, DOI 10.1073/pnas.84.2.595; WHITING PJ, 1987, NATURE, V327, P515, DOI 10.1038/327515a0; WONNACOTT S, 1986, J NEUROCHEM, V47, P1706, DOI 10.1111/j.1471-4159.1986.tb13078.x	40	185	188	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24024	24029		10.1074/jbc.272.38.24024	http://dx.doi.org/10.1074/jbc.272.38.24024			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295355	hybrid			2022-12-27	WOS:A1997XX38100080
J	MacPhee, IJ; Barker, PA				MacPhee, IJ; Barker, PA			Brain-derived neurotrophic factor binding to the p75 neurotrophin receptor reduces TrkA signaling while increasing serine phosphorylation in the TrkA intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; INDUCED TYROSINE PHOSPHORYLATION; INSULIN-RECEPTOR; TARGETED DISRUPTION; KINASE-ACTIVITY; CELLS; GENE; NGF; SUBSTRATE-1; DIFFERENTIATION	We have examined whether the low affinity neurotrophin receptor p75NTR modulates TrkA function by intracellular signaling. Using ligands that selectively bind p75NTR or TrkA, we found that a p75NTR-derived signal reduces TrkA activation. Short term treatment of PC12 cells with ceramide analogues also resulted in reduced NGF-stimulated TrkA activation, suggesting that p75-mediated increases in sphingomyelinase activity may contribute to this modulatory effect. Phosphoamino acid analysis was performed to determine if brain derived neurotrophic factor- or ceramide-mediated phosphorylation of the TrkA intracellular domain correlated with a reduction in its ligand-induced activation. A specific increase in TrkA phosphoserine content was observed in response to both C-2-ceramide and brain-derived neurotrophic factor. These results suggest that ligand binding of p75NTR can activate a signaling cascade that results in reduced TrkA activity through phosphorylation of its intracellular domain.	MCGILL UNIV,MONTREAL NEUROL INST,CTR NEURONAL SURVIVAL,MONTREAL,PQ H3A 2B4,CANADA	McGill University								BARKER PA, 1993, J BIOL CHEM, V268, P15150; BARKER PA, 1994, J BIOL CHEM, V269, P30645; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BracciLaudiero L, 1996, NEUROREPORT, V7, P485, DOI 10.1097/00001756-199601310-00026; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; OLSON JE, 1990, J BIOL CHEM, V265, P1847; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; TANTI JF, 1994, J BIOL CHEM, V269, P6051; THEROUX SJ, 1992, J BIOL CHEM, V267, P16620; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1	38	78	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23547	23551		10.1074/jbc.272.38.23547	http://dx.doi.org/10.1074/jbc.272.38.23547			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295291	hybrid			2022-12-27	WOS:A1997XX38100016
J	Quinn, KA; Grimsley, PG; Dai, YP; Tapner, M; Chesterman, CN; Owensby, DA				Quinn, KA; Grimsley, PG; Dai, YP; Tapner, M; Chesterman, CN; Owensby, DA			Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCANS; PLASMINOGEN-ACTIVATOR; ALPHA-2-MACROGLOBULIN RECEPTOR; BINDING-PROTEIN; IDENTIFICATION; LINE; PURIFICATION; COMPARTMENT; CATABOLISM; EXPRESSION	Our studies have identified a soluble molecule in normal human plasma and serum with the characteristics of the alpha-chain of the low density lipoprotein receptor-related protein (LRP). LRP is a large multifunctional receptor mediating the clearance of diverse ligands, including selected lipoproteins, various protease inhibitor complexes, and thrombospondin. A soluble molecule (sLRP) has been isolated from plasma using an affinity matrix coupled with methylamine-activated alpha(2)-macroglobulin, the ligand uniquely recognized by LRP, and eluted with EDTA. This eluate contains a protein that co-migrates on SDS-polyacrylamide gel electrophoresis with authentic human placental LRP alpha-chain, is recognized by anti-LRP alpha-chain monoclonal antibodies, and binds the 39-kDa receptor-associated protein (RAP) and tissue plasminogen activator-inhibitor complexes. A similar RAP-binding molecule was detected in medium conditioned for 24 h by primary cultures of rat hepatocytes, suggesting that the liver may be the in vivo source of sLRP. In contrast, immunoprecipitation experiments failed to detect, the production of sLRP by cultured HepG2 hepatoma and primary human fibroblast cells. Addition of a soluble form of LRP to cultured HepG2 cells resulted in a significant inhibition of capacity of these cells to degrade tPA, a process that has been demonstrated to be mediated by cell surface LRP. Preliminary data indicate that the concentration of sLRP is altered in the plasma of patients with liver disease. Increased levels of sLRP may antagonize the clearance of ligands by cell bound LRP perturbing diverse processes including lipid metabolism, cell migration and extracellular proteinase activity.	UNIV NEW S WALES,SCH PATHOL,CTR THROMBOSIS & VASC RES,KENSINGTON,NSW 2052,AUSTRALIA; UNIV SYDNEY,WESTMEAD HOSP,DEPT MED,STORR LIVER UNIT,WESTMEAD,NSW 2145,AUSTRALIA; ILLAWARRA REG HOSP,WOLLONGONG,NSW 2500,AUSTRALIA	University of New South Wales Sydney; University of Sydney								ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; Goodwin B, 1996, BIOCHEM PHARMACOL, V52, P219, DOI 10.1016/0006-2952(96)00179-7; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; OWENSBY DA, 1989, J BIOL CHEM, V264, P18180; REBECK GW, 1993, NEURON, V11, P575; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; RUTLEDGE EA, 1994, J BIOL CHEM, V269, P31864; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SCHEUTZ EG, 1988, J CELL PHYSL, V134, P309; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401	31	114	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23946	23951		10.1074/jbc.272.38.23946	http://dx.doi.org/10.1074/jbc.272.38.23946			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295345				2022-12-27	WOS:A1997XX38100070
J	Wood, RD				Wood, RD			Nucleotide excision repair in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSCRIPTION-COUPLED REPAIR; RNA-POLYMERASE-II; DNA-REPAIR; COCKAYNE-SYNDROME; FACTOR TFIIH; DAMAGED DNA; PROTEIN; MUTATIONS; GENES; ENDONUCLEASE				Wood, RD (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Ariza RR, 1996, NUCLEIC ACIDS RES, V24, P433, DOI 10.1093/nar/24.3.433; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; LEHMANN AR, 1994, MUTAT RES, V315, P41, DOI 10.1016/0921-8777(94)90026-4; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; McDonald E, 1996, CANCER RES, V56, P2250; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1997, J BIOL CHEM, V272, P7570, DOI 10.1074/jbc.272.12.7570; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Savio M, 1996, ONCOGENE, V13, P1591; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Smith ML, 1996, ONCOGENE, V13, P2255; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Sweder KS, 1996, GENETICS, V143, P1127; VANGOOL AJ, 1997, EMBO J, V116, P4155; vanOosterwijk MF, 1996, MOL CELL BIOL, V16, P4436; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491	50	358	371	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23465	23468		10.1074/jbc.272.38.23465	http://dx.doi.org/10.1074/jbc.272.38.23465			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295277	hybrid			2022-12-27	WOS:A1997XX38100002
J	Yuan, ZM; Utsugisawa, T; Huang, YY; Ishiko, T; Nakada, S; Kharbanda, S; Weichselbaum, R; Kufe, D				Yuan, ZM; Utsugisawa, T; Huang, YY; Ishiko, T; Nakada, S; Kharbanda, S; Weichselbaum, R; Kufe, D			Inhibition of phosphatidylinositol 3-kinase by c-Abl in the genotoxic stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; IONIZING-RADIATION; SH3 DOMAINS; DNA-DAMAGE; GROWTH; CELLS; PHOSPHORYLATION; RECOMBINATION; PROTOONCOGENE	Activation of phosphatidylinositol (PI) 3-kinase by growth factors results in phosphorylation of phosphatidylinositol lipids at the D3 position. Although PI 3-kinase is essential to cell survival, little is known about mechanisms that negatively regulate this activity. Here we show that the c-Abl tyrosine kinase interacts directly with the p85 subunit of PI 3-kinase. Activation of c-Abl by ionizing radiation exposure is associated with c-Abl-dependent phosphorylation of PI 3-kinase. We also show that phosphorylation of p85 by c-Abl inhibits PI 3-kinase activity in vitro and in irradiated cells. These findings indicate that c-Abl negatively regulates PI 3-kinase in the stress response to DNA damage.	UNIV CHICAGO, DEPT RADIAT & CELLULAR ONCOL, CHICAGO, IL 60637 USA	University of Chicago	Yuan, ZM (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, 44 BINNEY ST, BOSTON, MA 02115 USA.		Utsugisawa, Taiju/ABD-7059-2021					Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	43	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23485	23488		10.1074/jbc.272.38.23485	http://dx.doi.org/10.1074/jbc.272.38.23485			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295282	hybrid			2022-12-27	WOS:A1997XX38100007
J	Racke, FK; Lewandowska, K; Goueli, S; Goldfarb, AN				Racke, FK; Lewandowska, K; Goueli, S; Goldfarb, AN			Sustained activation of the extracellular signal-regulated kinase mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; INTEGRIN GENE; C ISOTYPES; MAP; CASCADE; TRANSFORMATION; PROLIFERATION; SPECIFICITY	The extracellular signal-regulated kinase (ERK), originally identified as a participant in mitogenic signaling, has recently been implicated in the signaling of cellular differentiation. To examine the role of the ERK/MAP kinase pathway in megakaryocytic differentiation of K562 cells, the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) and bryostatin on ERK activation were determined. Both TPA and bryostatin are known to activate PBC but paradoxically have opposing effects on megakaryocytic differentiation, TPA, a differentiation inducer, caused sustained activation of ERK (>24 h), whereas bryostatin, a differentiation blocker, only transiently activated ERK (similar to 6 h) and attenuated the activation of ERK by TPA, To confirm a requirement for sustained ERK activation for megakaryocytic differentiation, PD098059, a synthetic inhibitor of the MAP kinase kinase 1 (MEK1) was employed. Introduction of PD098059 at any time during the first 18 h of TPA treatment completely abrogated megakaryocytic differentiation of K562 cells, After 24 h of TPA treatment, introduction of PD098059 failed to block differentiation. Differentiation blockade by PD098059 occurred via inhibition of MEK because transfection of a constitutively active mutant of MEK2 could override the PD098059 blockade. Experiments with conditioned media suggested that sustained activation of the ERK/MAP kinase pathway promoted the autocrine secretion of megakaryocytic lineage determination factors.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,INST PATHOL,CLEVELAND,OH 44106; PROMEGA CORP,SIGNAL TRANSDUCT DIV,MADISON,WI 53711	Case Western Reserve University; Promega Corporation								ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FONG AM, 1994, J BIOL CHEM, V269, P18441; GOLDFARB AN, 1992, BLOOD, V80, P2858; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOCEVAR BA, 1992, J CELL SCI, V101, P671; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; TABILIO A, 1983, CANCER RES, V43, P4569; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VILLAGARCIA M, 1994, BLOOD, V83, P668, DOI 10.1182/blood.V83.3.668.bloodjournal833668	22	162	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23366	23370		10.1074/jbc.272.37.23366	http://dx.doi.org/10.1074/jbc.272.37.23366			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287350	hybrid			2022-12-27	WOS:A1997XV74400061
J	Chen, H; Srinivasan, G; Thompson, EB				Chen, H; Srinivasan, G; Thompson, EB			Protein-protein interactions are implied in glucocorticoid receptor mutant 465*-mediated cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; FUNCTIONAL ANTAGONISM; HORMONE RECEPTOR; C-JUN; GENE; APOPTOSIS; DOMAINS; LINE	Previously we have shown that ICR-27, a clone of glucocorticoid-resistant human leukemic T cells, showed rapid cell loss upon transient transfection with plas mids expressing certain fragments of the human glucocorticoid receptor lacking the ligand binding domain, An extreme example was the frameshift GR mutant 465*, mutated after amino acid 465. This generated a novel al-amino acid ''tail,'' beginning within the second zinc finger of the human glucocorticoid receptor DNA binding domain, a region required for ICR-27 cell death caused by hologlucocorticoid receptor plus hormone, The cell loss mediated by 465* was faster but quantitatively equivalent to that caused by hologlucocorticoid receptor plus hormone, We are therefore investigating the mechanism of action of 465*. We overexpressed 465* with or without a glutathione S-transferase tag fused to its N terminus and tested its ability to affect glucocorticoid response element (GRE)-driven reactions in vitro, Partially purified 465* showed little binding to a consensus GRE, caused virtually no stimulation of transcription from a GRE, and failed to inhibit GR-driven transcription, However, GST-465* ''trapped'' several proteins from ICR-27 cell extracts, including c-Jun; recombinant c-Jun also was bound in vitro, In co-transfection assays of CV-1 cells, 465* expression reduced phorbol ester (12-O-tetradecanoylphorbol-13-acetate) transcriptional activation from a promoter containing multiple AP-1 sites. Further studies proved the repressive activity of 465* was c-Jun-specific and not due to squelching artifacts, The data suggest that interaction of 465* with other proteins, such as c-Jun, might be responsible for its cell killing function.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA 41407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041407] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HARBOUR DV, 1990, J STEROID BIOCHEM, V35, P1, DOI 10.1016/0022-4731(90)90137-H; HARMON JM, 1981, MOL CELL BIOL, V1, P512, DOI 10.1128/MCB.1.6.512; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; IMAI E, 1988, NATURE, V332, P87; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LATCHMAN DS, 1998, TRANSCRIPTION FACTOR, P77; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nazareth LV, 1996, LEUKEMIA, V10, P1789; NAZARETH LV, 1991, J BIOL CHEM, V266, P12976; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NORMAN MR, 1977, CANCER RES, V37, P3785; PALMER LA, 1992, CANCER RES, V52, P6612; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; RYFFEL GU, 1989, NUCLEIC ACIDS RES, V17, P939, DOI 10.1093/nar/17.3.939; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIMONS SS, 1994, VITAM HORM, V48, P49; Srinivasan G, 1997, J STEROID BIOCHEM, V60, P1, DOI 10.1016/S0960-0760(96)00182-3; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; THULASI R, 1993, J BIOL CHEM, V268, P18306; TSAI SY, 1990, J BIOL CHEM, V265, P17055; WARRIAR N, 1994, J BIOL CHEM, V269, P29010; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YUH YS, 1989, J BIOL CHEM, V264, P10904; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	53	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25873	25880		10.1074/jbc.272.41.25873	http://dx.doi.org/10.1074/jbc.272.41.25873			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325319	hybrid			2022-12-27	WOS:A1997YA35800074
J	Hemati, N; Ross, SE; Erickson, RL; Groblewski, GE; MacDougald, OA				Hemati, N; Ross, SE; Erickson, RL; Groblewski, GE; MacDougald, OA			Signaling pathways through which insulin regulates CCAAT/enhancer binding protein alpha (C/EBP alpha) phosphorylation and gene expression in 3T3-L1 adipocytes - Correlation with GLUT4 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; TRANSCRIPTIONAL ACTIVATOR PROTEIN; WHITE ADIPOSE-TISSUE; MESSENGER-RNA; CELL LINE; MAMMALIAN PROTEIN; HEPATOMA-CELLS; DIFFERENTIATION; PREADIPOCYTES; PROMOTER	Treatment of 3T3-L1 adipocytes with insulin (IC50 similar to 200 pM insulin) or insulin-like growth factor-1 (IC50 similar to 200 pM IGF-1) stimulates dephosphorylation of CCAAT/enhancer binding protein alpha (C/EBP alpha), a transcription factor involved in preadipocyte differentiation. As assessed by immunoblot analysis of one-and two-dimensional PAGE, insulin appears to dephosphorylate one site within p30C/EBP alpha and an additional site within p42C/EBP alpha. Consistent with insulin causing dephosphorylation of C/EBP alpha through activation of phosphatidylinositol 3-kinase, addition of phosphatidylinositol 3-kinase inhibitors (e.g. wortmannin) blocks insulin-stimulated dephosphorylation of C/EBP alpha. In the absence of insulin, wortmannin or LY294002 enhance C/EBP alpha phosphorylation. Similarly, blocking the activity of FKBP-rapamycin-associated protein with rapamycin increases phosphorylation of C/EBP alpha in the absence of insulin, Dephosphorylation of C/EBP alpha by insulin is partially blocked by rapamycin, consistent with a model in which activation of FKBP-rapamycin-associated protein by phosphatidylinositol 3-kinase results in dephosphorylation of C/EBP alpha. The dephosphorylation of C/EBP alpha by insulin, in conjunction with the insulin-dependent decline in C/EBP alpha mRNA and protein, has been hypothesized to play a role in repression of GLUT4 transcription by insulin, Consistent with this hypothesis, the decline of GLUT4 mRNA following exposure of adipocytes to insulin correlates with dephosphorylation of C/EBP alpha. However, the repression of C/EBP alpha mRNA and protein levels by insulin is blocked with an inhibitor of the mitogen-activated protein kinase pathway without blocking the repression of GLUT4 mRNA, thus dissociating the regulation of C/EBP alpha and GLUT4 mRNAs by insulin, A decline in C/EBP alpha mRNA and protein may not be required to suppress GLUT4 transcription because insulin also induces expression of the dominant-negative form of C/EBP beta (liver inhibitory protein), which blocks transactivation by C/EBP transcription factors.	UNIV MICHIGAN, MED CTR, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan			Ross, Sarah/HII-3018-2022; Erickson, Robin/AAV-3405-2020	Erickson, Robin/0000-0002-3945-6158; MacDougald, Ormond/0000-0001-6907-7960	NIDDK NIH HHS [R01-DK51562] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051562] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; COOPER JA, 1991, METHOD ENZYMOL, V201, P251; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, CURR BIOL, V5, P618, DOI 10.1016/S0960-9822(95)00125-4; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MACKALL JC, 1977, BIOCHEM BIOPH RES CO, V79, P720, DOI 10.1016/0006-291X(77)91171-8; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; POTTER JJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P360, DOI 10.1016/0003-9861(92)90529-6; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676	51	142	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25913	25919		10.1074/jbc.272.41.25913	http://dx.doi.org/10.1074/jbc.272.41.25913			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325324	hybrid			2022-12-27	WOS:A1997YA35800079
J	Raffy, S; Teissie, J				Raffy, S; Teissie, J			Electroinsertion of glycophorin A in interdigitation-fusion giant unilamellar lipid vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-CELL MEMBRANE; ELECTRIC-FIELD; ERYTHROCYTE-MEMBRANE; BILAYER-MEMBRANES; MAMMALIAN-CELLS; LIPOSOMES; ELECTROPERMEABILIZATION; INSERTION; BREAKDOWN; PROTEIN	Previously we demonstrated that transmembrane back insertion of glycophorin A, a solubilizable intrinsic protein, can be obtained in dipalmitoylphosphatidylcholine multilamellar vesicles, MLVs, by electropulsation (Raffy, S., and Teissie, J. (1995) Eur. J. Biochem. 230, 722-732). Here we report that transmembrane back insertion of protein is obtained by electropulsion of unilamellar giant vesicles, termed interdigitation-fusion vesicles (IFVs), which are better membrane models than MLVs due to their unilamellarity. Electropulsation promotes a field-dependent local permeabilization of the lipid layer, as shown by the associated leakage of entrapped calcein, Glycophorin insertion is assayed by immunofluorescence. Electroinsertion is obtained by pulsing the vesicle/protein mixture. Glycophorin insertion is observed under more drastic electrical conditions than needed for permeabilization, Direct observation of glycophorin insertion in the vesicles under a microscope shows a localized process in agreement with the theoretical prediction. A quantitative evaluation of the immunofluorescence pattern shows that insertion was higher on one side of the vesicle than on the other. This suggests that an electrophoretic movement of the solubilized glycophorin could take place during electropulsation, Insertion of glycophorin, a prefolded intrinsic protein, is then obtained in the lipid bilayer brought transiently to the electropermeabilized state.	CNRS, INST PHARMACOL & BIOL STRUCT, F-31062 TOULOUSE, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			Teissie, Justin/AAA-5697-2019	Teissie, Justin/0000-0002-7588-8062				ABIDOR IG, 1979, BIOELECTROCH BIOENER, V6, P37; AHL PL, 1994, BBA-BIOMEMBRANES, V1195, P237, DOI 10.1016/0005-2736(94)90262-3; ANTANAVAGE J, 1978, BIOPHYS J, V21, pA1224; ARMITAGE IM, 1977, BIOCHEMISTRY-US, V16, P1317, DOI 10.1021/bi00626a012; BANGHAM AD, 1972, ANNU REV BIOCHEM, V41, P753, DOI 10.1146/annurev.bi.41.070172.003541; BENZ R, 1980, BIOCHIM BIOPHYS ACTA, V597, P637, DOI 10.1016/0005-2736(80)90236-9; BENZ R, 1981, BIOCHIM BIOPHYS ACTA, V640, P169, DOI 10.1016/0005-2736(81)90542-3; Bochkareva E, 1996, J BIOL CHEM, V271, P22256, DOI 10.1074/jbc.271.36.22256; BUSCHL R, 1982, FEBS LETT, V150, P38, DOI 10.1016/0014-5793(82)81300-8; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V902, P360, DOI 10.1016/0005-2736(87)90204-5; CHERNOMORDIK LV, 1990, BIOCHIM BIOPHYS ACTA, V1024, P179, DOI 10.1016/0005-2736(90)90222-A; DEKRUIJFF B, 1991, MEMBRANE FUSION, P209; ELMASHAK EM, 1985, BIOCHEMISTRY-US, V24, P2884, DOI 10.1021/bi00333a010; ELOUAGARI K, 1993, BIOCHIM BIOPHYS ACTA, V1151, P105, DOI 10.1016/0005-2736(93)90077-D; ELOUAGARI K, 1995, J BIOL CHEM, V270, P26970; ELOUAGARI K, 1994, EUR J BIOCHEM, V219, P1031; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GABRIEL B, 1991, METHOD ENZYMOL, V198, P480; HARBICH W, 1979, Z NATURFORSCH A, V34, P1063; HARGREAVES WR, 1978, BIOCHEMISTRY-US, V17, P3759, DOI 10.1021/bi00611a014; Helfrich W., 1974, Physics Letters A, V50A, P115, DOI 10.1016/0375-9601(74)90899-8; HUB HH, 1982, FEBS LETT, V140, P254, DOI 10.1016/0014-5793(82)80907-1; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V906, P33, DOI 10.1016/0304-4157(87)90004-9; LOPEZ A, 1988, BIOCHEMISTRY-US, V27, P1222, DOI 10.1021/bi00404a023; MEHRLE W, 1985, FEBS LETT, V185, P89, DOI 10.1016/0014-5793(85)80746-8; MELIKYAN GB, 1989, ELECTROPORATION ELEC, P181; MOUNEIMNE Y, 1989, BIOCHEM BIOPH RES CO, V159, P34, DOI 10.1016/0006-291X(89)92400-5; MOUNEIMNE Y, 1991, BIOCHIM BIOPHYS ACTA, V1066, P83, DOI 10.1016/0005-2736(91)90254-6; MOUNEIMNE Y, 1990, BIOCHIM BIOPHYS ACTA, V1027, P53, DOI 10.1016/0005-2736(90)90047-R; NEEDHAM D, 1989, BIOPHYS J, V55, P1001, DOI 10.1016/S0006-3495(89)82898-X; NEUMANN E, 1989, ELECTROPORATION ELEC, P61; OKU N, 1983, BIOCHIM BIOPHYS ACTA, V734, P54, DOI 10.1016/0005-2736(83)90074-3; PERKINS WR, 1993, CHEM PHYS LIPIDS, V64, P197, DOI 10.1016/0009-3084(93)90066-C; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; RAFFY S, 1995, EUR J BIOCHEM, V230, P722; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROBELLO M, 1989, BIOCHIM BIOPHYS ACTA, V982, P173, DOI 10.1016/0005-2736(89)90189-2; ROLS MP, 1990, BIOPHYS J, V58, P1089, DOI 10.1016/S0006-3495(90)82451-6; ROLS MP, 1992, BIOCHIM BIOPHYS ACTA, V1111, P45, DOI 10.1016/0005-2736(92)90272-N; SCHULTE TH, 1979, BIOCHEMISTRY-US, V18, P275, DOI 10.1021/bi00569a006; SELTZER SE, 1995, RADIOLOGY, V194, P775, DOI 10.1148/radiology.194.3.7862978; SEN K, 1990, P NATL ACAD SCI USA, V87, P743, DOI 10.1073/pnas.87.2.743; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SIXOU S, 1990, BIOCHIM BIOPHYS ACTA, V1028, P154, DOI 10.1016/0005-2736(90)90149-I; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Sowers A. E., 1992, GUIDE ELECTROPORATIO, P29, DOI DOI 10.1016/B978-0-08-091727-6.50006-X; SPRINGER GF, 1966, BIOCHEMISTRY-US, V5, P3254, DOI 10.1021/bi00874a028; STOICHEVA NG, 1994, BBA-BIOMEMBRANES, V1195, P31, DOI 10.1016/0005-2736(94)90005-1; STULEN G, 1981, BIOCHIM BIOPHYS ACTA, V640, P621, DOI 10.1016/0005-2736(81)90092-4; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TEISSIE J, 1981, BIOCHEMISTRY-US, V20, P1548, DOI 10.1021/bi00509a022; TEISSIE J, 1993, BIOPHYS J, V65, P409, DOI 10.1016/S0006-3495(93)81052-X; TEISSIE J, 1987, BIOCHEMISTRY-US, V26, P840, DOI 10.1021/bi00377a027; TEISSIE J, 1989, ELECTROPORATION ELEC, P203; TEISSIE J, 1990, NATO ASI SER H, V47, P149; WEAVER JC, 1984, BIOELECTROCH BIOENER, V12, P393, DOI 10.1016/0302-4598(84)87018-X; WOLF H, 1994, BIOPHYS J, V66, P524, DOI 10.1016/S0006-3495(94)80805-7; ZEIRA M, 1991, P NATL ACAD SCI USA, V88, P4409, DOI 10.1073/pnas.88.10.4409	59	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25524	25530		10.1074/jbc.272.41.25524	http://dx.doi.org/10.1074/jbc.272.41.25524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325267	hybrid			2022-12-27	WOS:A1997YA35800022
J	Wang, HY; Iynedjian, PB				Wang, HY; Iynedjian, PB			Acute glucose intolerance iu insulinoma cells with unbalanced overexpression of glucokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLETS; GENE-EXPRESSION; RAT-LIVER; SPECTROSCOPY	The INS-r3-GK27 insulinoma cells are endowed with artificially inducible glucokinase under control of the reverse tetracycline-dependent transcriptional activator. Moderate induction of glucokinase has been shown to result in proportionate increases in glycolytic flux and in potentiation of glucose effects on insulin secretion and pyruvate kinase gene expression, In cells with 20-fold overexpression of glucokinase, however, glucose activation of secretion and gene expression was severely impaired, Measurements of the glycolytic flux in cells with 7- and 21-fold increases in glucokinase activity and determination of the flux control coefficient of this enzyme showed that control of glycolysis at the glucokinase step was lost in the cells at the higher level of overexpression. Challenging the cells with glucose above 6 nM resulted in massive accumulation of glucose 6-phosphate and caused a rapid and sustained depletion of cellular ATP, in contrast with the glucose-induced rise in ATP in cells with wild-type glucokinase levels, Loss of cell viability ensued upon prolonged culture in high glucose. In summary, in insulinoma beta cells strongly overexpressing glucokinase, an imbalance between glucose phosphorylation and turnover of glucose 6-phosphate resulted in acute glucose intolerance due to trapping of cellular orthophosphate in dead-end product and severe paralysis of energy metabolism.	UNIV GENEVA,SCH MED,DIV CLIN BIOCHEM & DIABET RES,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva								ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Cardenas ML, 1997, BIOCHEM SOC T, V25, P131, DOI 10.1042/bst0250131; COORE HG, 1964, BIOCHEM J, V93, P66, DOI 10.1042/bj0930066; DOYLE TC, 1993, YEAST, V9, P867, DOI 10.1002/yea.320090807; Fell D., 1997, UNDERSTANDING CONTRO; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GITZELMANN R, 1995, METABOLIC MOL BASES, P905; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRODSKY GM, 1963, AM J PHYSIOL, V205, P638, DOI 10.1152/ajplegacy.1963.205.4.638; ILES RA, 1985, BIOCHEM J, V229, P141, DOI 10.1042/bj2290141; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; KACSER H, 1995, BIOCHEM SOC T, V23, P341, DOI 10.1042/bst0230341; MARIE S, 1993, J BIOL CHEM, V268, P23881; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; SMALL JR, 1993, EUR J BIOCHEM, V213, P613, DOI 10.1111/j.1432-1033.1993.tb17801.x; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; Sweet IR, 1996, AM J PHYSIOL-ENDOC M, V271, pE606, DOI 10.1152/ajpendo.1996.271.3.E606; TAL M, 1992, J BIOL CHEM, V267, P17241; VISCHER U, 1987, BIOCHEM J, V241, P249, DOI 10.1042/bj2410249; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372	24	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25731	25736		10.1074/jbc.272.41.25731	http://dx.doi.org/10.1074/jbc.272.41.25731			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325299	hybrid			2022-12-27	WOS:A1997YA35800054
J	Wang, Q; Mullah, B; Hansen, C; Asundi, J; Robishaw, JD				Wang, Q; Mullah, B; Hansen, C; Asundi, J; Robishaw, JD			Ribozyme-mediated suppression of the G protein gamma(7) subunit suggests a role in hormone regulation of adenylylcyclase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; BETA-SUBUNIT; ALPHA-SUBUNIT; SPECIFICITY; EXPRESSION; CLONING; DOMAIN; BRAIN; ASSOCIATION; RECEPTORS	Human HEK 293 cells present a simple and tractable system to directly test the hypothesis that the G protein gamma subunits contribute to the specificity of receptor signaling pathways in vivo. To begin to elucidate the functions of the individual gamma subunits in these cells, a ribozyme strategy was used to specifically inactivate the mRNA encoding the gamma(7) subunit. A phosphorothioated DNA-RNA chimeric hammerhead ribozyme was constructed and analyzed for specificity toward the targeted gamma(7) subunit. In vitro cleavage analysis of this ribozyme revealed a highly efficient cleavage activity directed exclusively toward the gamma(7) RNA transcript. In particular, this ribozyme did not result in cleavage of the gamma(12) RNA transcript, which is 75% identical to the gamma(7) RNA transcript. Using a transient transfection assay, in vivo analysis of this ribozyme showed a specific reduction in both the mRNA and protein expression of the gamma(7) subunit in HEK 293 cells. Coincident with this loss in gamma(7) subunit, there was a specific reduction in the protein expression of the beta(1) subunit, suggesting that the beta(1) and gamma(7) subunits may functionally interact to form a beta gamma dimer in vivo. Functional analysis of the consequences of ribozyme-mediated suppression of the gamma(7) subunit expression indicated that it was associated with significant attenuation of isoproterenol-, but not prostaglandin E-1-, stimulated adenylylcyclase activity. Suppression of the gamma(7) subunit expression had no effect on carbachol- and ATP-mediated stimulation of phosphatidylinositol turnover. Taken together, these results not only indicate the feasibility of using the ribozyme technology to determine the roles of individual gamma subunits in receptor-G protein-effector pathways in vivo, but they point to a specific role of the gamma(7) subunit in the regulation of adenylylcyclase activity in response to isoproterenol.	PENN STATE UNIV, COLL MED, HENRY HOOD MD RES PROGRAM, DANVILLE, PA 17822 USA; APPL BIOSYST INC, FOSTER CITY, CA 94404 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Thermo Fisher Scientific; Applied Biosystems								Barr AJ, 1997, J BIOL CHEM, V272, P2223; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CHANG PS, 1990, CLIN BIOTECHNOL, V2, P23; ERICKSON R, 1992, GENE REGULATION BIOL, P163; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Figler RA, 1996, MOL PHARMACOL, V50, P1587; FOSTER KA, 1991, MOL CELL BIOCHEM, V104, P63; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GU JL, 1995, CIRC RES, V77, P14, DOI 10.1161/01.RES.77.1.14; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KVAPIL P, 1994, EUR J BIOCHEM, V226, P193, DOI 10.1111/j.1432-1033.1994.tb20041.x; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; Mullah B, 1996, NUCLEOS NUCLEOT, V15, P419, DOI 10.1080/07328319608002395; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1994, GENE, V149, P337, DOI 10.1016/0378-1119(94)90172-4; Ray K, 1996, TRENDS CARDIOVAS MED, V6, P115, DOI 10.1016/1050-1738(96)00021-7; ROBISHAW JD, 1994, METHOD ENZYMOL, V237, P498; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SARGUEIL B, 1995, BIOCHEMISTRY-US, V34, P7739, DOI 10.1021/bi00023a021; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WATSON JB, 1994, J NEUROSCI RES, V39, P108, DOI 10.1002/jnr.490390113; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189; ZHU BT, 1993, J PHARMACOL TOXICOL, V29, P85, DOI 10.1016/1056-8719(93)90055-J	39	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26040	26048		10.1074/jbc.272.41.26040	http://dx.doi.org/10.1074/jbc.272.41.26040			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325341	hybrid			2022-12-27	WOS:A1997YA35800096
J	Wen, LP; Fahrni, JA; Troie, S; Guan, JL; Orth, K; Rosen, GD				Wen, LP; Fahrni, JA; Troie, S; Guan, JL; Orth, K; Rosen, GD			Cleavage of focal adhesion kinase by caspases during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FAS-MEDIATED APOPTOSIS; ENZYME-LIKE PROTEASE; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; LAMIN-A; V-SRC; PP125(FAK); ICE; ASSOCIATION	Apoptotic cells undergo characteristic morphological changes that include detachment of cell attachment from the substratum and loss of cell-cell interactions. Attachment of cells to the extracellular matrix and to other cells is mediated by integrins. The interactions of integrins with the extracellular matrix activates focal adhesion kinase (FAK) and suppresses apoptosis in diverse cell types. Members of the tumor necrosis family such as Fas and Apo-2L, also known as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), induce apoptosis in both suspension and adherent cells through the activation of caspases. These caspases, when activated, cleave substrates that are important for the maintenance of nuclear and membrane integrity. In this study, we show that FAK is sequentially cleaved into two different fragments early in Apo-2L-induced apoptosis. We also demonstrate that FAK cleavage is mediated by caspases and that FAK shows unique sensitivity to different caspases. Our results suggest that disruption of FAK may contribute to the morphological changes observed in apoptotic suspension and adherent cells.	STANFORD UNIV, MED CTR, DEPT PULM & CRIT CARE MED, STANFORD, CA 94305 USA; CORNELL UNIV, COLL VET MED, DEPT PATHOL, CANC BIOL LABS, ITHACA, NY 14853 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	Stanford University; Cornell University; University of Michigan System; University of Michigan			Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620; Wen, Longping/0000-0003-0384-4578; Rosen, Glenn/0000-0001-8281-5446	NIGMS NIH HHS [GM52890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Cary LA, 1996, J CELL SCI, V109, P1787; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Crouch DH, 1996, ONCOGENE, V12, P2689; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; Dixit VM, 1996, ADV EXP MED BIOL, V406, P113; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; OWENS LV, 1995, CANCER RES, V55, P2752; PFEFFER KD, 1994, J IMMUNOL, V153, P1789; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413	51	300	305	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26056	26061		10.1074/jbc.272.41.26056	http://dx.doi.org/10.1074/jbc.272.41.26056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325343	hybrid			2022-12-27	WOS:A1997YA35800098
J	Coletta, M; Costa, H; DeSanctis, G; Neri, F; Smulevich, G; Turner, DL; Santos, H				Coletta, M; Costa, H; DeSanctis, G; Neri, F; Smulevich, G; Turner, DL; Santos, H			pH dependence of structural and functional properties of oxidized cytochrome c'' from Methylophilus methylotrophus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXIAL HISTIDINE; A-STATE; MECHANISM; RESONANCE; ELECTRON; PROTEINS; DITHIONITE	Cytochrome c '' from Methylophilus methylotrophus is an unusual monoheme protein that undergoes a major redox-linked change in the heme arrangement: one of the two axial histidines bound to the iron in the oxidized form is detached upon reduction and a proton is taken up. The kinetics of reduction by sodium dithionite and the spectroscopic properties of the oxidized cytochrome c '' have been investigated over the pH range between 1.4 and 10.0, The rate of reduction displays proton-linked transitions of pK(a) congruent to 5.5 and 2.4, and a spectroscopic transition with a pK(a) congruent to 2.4 is also observed. The protein displays a complete reversibility after exposure to low pH, and both electronic absorption and resonance Raman spectroscopic properties suggest that the transition at lower pH brings about a drastic change in the heme coordination geometry, Circular dichroism spectra indicate that over the same proton-linked transition, the pro tein undergoes a marked decrease (similar to 60%) of the alpha-helical content toward a random coil arrangement, which is recovered upon increasing the ionic strength, The structural change at low pH is Linked to a concerted two-proton transition, suggesting the detachment and protonation of axial histidine(s), Such kinetic and spectroscopic features along with the remarkable capacity of this protein to recover its native structure after exposure to extremely low pH values makes it a promising model for studying folding processes and stability in heme proteins.	UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI ALESSANDRO ROSSI FANELLI,I-00185 ROME,ITALY; UNIV NOVA LISBOA,INST TECNOL QUIM & BIOL,P-2780 OEIRAS,PORTUGAL; UNIV CAMERINO,DEPT MOL CELLULAR & ANIM BIOL,I-62032 CAMERINO,MC,ITALY; UNIV FLORENCE,DEPT CHEM,I-52100 FLORENCE,ITALY; UNIV SOUTHAMPTON,DEPT CHEM,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	Sapienza University Rome; Universidade Nova de Lisboa; University of Camerino; University of Florence; University of Southampton	Coletta, M (corresponding author), UNIV ROMA TOR VERGATA,DEPT EXPT MED & BIOCHEM SCI,VIA TOR VERGATA 135,I-00133 ROME,ITALY.		Costa, Helena Soares/D-7058-2013; Santos, Helena/B-9141-2011; Coletta, Massimo/N-9049-2015; Turner, David L/B-9061-2011; Coletta, Massimiliano/GSN-5927-2022; smulevich, giulietta/A-6510-2008; Turner, David/B-8267-2009	Costa, Helena Soares/0000-0001-8168-3963; Santos, Helena/0000-0002-8050-9485; Turner, David L/0000-0002-3754-6459; Smulevich, Giulietta/0000-0003-3021-8919; COLETTA, Massimiliano/0000-0002-5489-9467				BARAKAT R, 1982, BIOCHIM BIOPHYS ACTA, V679, P393, DOI 10.1016/0005-2728(82)90159-1; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; COSTA HS, 1992, EUR J BIOCHEM, V208, P427, DOI 10.1111/j.1432-1033.1992.tb17204.x; COSTA HS, 1993, EUR J BIOCHEM, V215, P817, DOI 10.1111/j.1432-1033.1993.tb18097.x; GOTO Y, 1993, BIOCHEMISTRY-US, V32, P11878, DOI 10.1021/bi00095a017; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; HAGIHARA Y, 1994, J MOL BIOL, V237, P336, DOI 10.1006/jmbi.1994.1234; JACKSON JT, 1983, J BIOL CHEM, V258, P1799; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; JORDAN T, 1995, PROTEIN SCI, V4, P716; LAMBETH DO, 1973, J BIOL CHEM, V248, P6095; LEITCH FA, 1984, BIOCHEMISTRY-US, V23, P1831, DOI 10.1021/bi00303a039; LOMMEN A, 1990, EUR J BIOCHEM, V192, P653, DOI 10.1111/j.1432-1033.1990.tb19272.x; MARMORINO JL, 1995, BIOCHEMISTRY-US, V34, P3140, DOI 10.1021/bi00010a002; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; MOORE GR, 1980, BIOCHIM BIOPHYS ACTA, V590, P261, DOI 10.1016/0005-2728(80)90030-4; SAFO MK, 1991, J AM CHEM SOC, V113, P5497, DOI 10.1021/ja00015a001; SANTOS H, 1988, BIOCHIM BIOPHYS ACTA, V954, P276	18	18	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24800	24804		10.1074/jbc.272.40.24800	http://dx.doi.org/10.1074/jbc.272.40.24800			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312076	hybrid			2022-12-27	WOS:A1997XY97000015
J	Hong, M; Chen, DCR; Klein, PS; Lee, VMY				Hong, M; Chen, DCR; Klein, PS; Lee, VMY			Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; RABBIT SKELETAL-MUSCLE; CHICK SENSORY NEURONS; ALZHEIMERS-DISEASE; INOSITOL MONOPHOSPHATASE; NEUROFIBRILLARY TANGLES; XENOPUS EMBRYOS; NERVOUS-SYSTEM; SENILE PLAQUES; ALPHA-TUBULIN	Lithium is one of the most widely used drugs for treating bipolar (manic-depressive) disorder. Despite its efficacy, the molecular mechanism underlying its action has not been elucidated, One recent study has proposed that lithium inhibits glycogen synthase kinase-3 and thereby affects multiple cellular functions, Because glycogen synthase kinase-3 regulates the phosphorylation of tau (microtubule binding protein that forms paired helical filaments in neurons of the Alzheimer's disease brain), we hypothesized that lithium could affect tau phosphorylation by inhibiting glycogen synthase kinase-3. Using cultured human NT2N neurons, we demonstrate that lithium reduces the phosphorylation of tau, enhances the binding of tau to microtubules, and promotes microtubule assembly through direct and reversible inhibition of glycogen synthase kinase-3. These results provide new insights into how Lithium mediates its effects in the central nervous system, and these findings could be exploited to develop a novel intervention for Alzheimer's disease.	UNIV PENN,SCH MED,CTR NEURODEGENERAT DIS RES,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED HEMATOL ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,INST AGING,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania				Chen, Daniel/0000-0001-6672-6814				ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; ATACK JR, 1994, J PHARMACOL EXP THER, V270, P70; AUER IA, 1995, ACTA NEUROPATHOL, V90, P547; BARRA HS, 1974, BIOCHEM BIOPH RES CO, V60, P1384, DOI 10.1016/0006-291X(74)90351-9; BENNETT GS, 1991, J NEUROCHEM, V57, P120, DOI 10.1111/j.1471-4159.1991.tb02106.x; BENNETT GS, 1991, J NEUROCHEM, V57, P130, DOI 10.1111/j.1471-4159.1991.tb02107.x; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BOSCH F, 1986, J BIOL CHEM, V261, P6927; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BURSTEIN DE, 1985, J CELL BIOL, V101, P862, DOI 10.1083/jcb.101.3.862; COHEN P, 1982, EUR J BIOCHEM, V124, P21, DOI 10.1111/j.1432-1033.1982.tb05902.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GUNDERSEN GG, 1987, J CELL BIOL, V105, P251, DOI 10.1083/jcb.105.1.251; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; HOLLANDER BA, 1991, J NEUROSCI RES, V28, P332, DOI 10.1002/jnr.490280304; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1986, J NEUROSCI, V6, P514; MANJI HK, 1995, ARCH GEN PSYCHIAT, V52, P531; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MawalDewan M, 1996, J NEUROPATH EXP NEUR, V55, P1051, DOI 10.1097/00005072-199655100-00005; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pierce SB, 1996, DEV BIOL, V175, P256, DOI 10.1006/dbio.1996.0113; PIERCE SB, 1995, DEVELOPMENT, V121, P755; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; Schmidt ML, 1996, J NEUROPATH EXP NEUR, V55, P534, DOI 10.1097/00005072-199605000-00006; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; YASUMOTO T, 1984, SEAFOOD TOXINS, P207; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	63	391	414	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25326	25332		10.1074/jbc.272.40.25326	http://dx.doi.org/10.1074/jbc.272.40.25326			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312151	hybrid			2022-12-27	WOS:A1997XY97000090
J	Elangovan, B; Chinnadurai, G				Elangovan, B; Chinnadurai, G			Functional dissection of the pro-apoptotic protein Bik - Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 HOMOLOG BAK; E1B 19K; ENZYME; INHIBITION; INTERACTS; DISTINCT; DOMAIN; SYSTEM; GENE; BH1	Bik is a potent pro-apoptotic protein, which complexes with various anti-apoptotic proteins such as Bcl-2, Bcl-x(L), 19-kDa adenovirus E1B, and EBV-BHRF1, The mechanism by which Bik promotes cell death is not known, It shares a conserved domain, BH3, with other pro-apoptotic proteins, Bar, Bah, Bid, and Hrk, and certain anti-apoptosis proteins such as Bcl-2 and Bcl-x(L). Mutations within the BH3 domain of Bik abrogate its ability to induce cell death and to complex with anti-apoptosis proteins, This result is consistent with the hypothesis that Bik may promote cell death by complexing with and antagonizing the activity of endogenous cellular anti-apoptosis proteins such as Bcl-2 and Bcl-x(L). To elucidate the relationship between protein complex formation and induction of cell death, we have identified the minimal sequences of Bik, from a library of N-terminal and C-terminal deletion mutants, required for interaction with Bcl-2 and Bcl-x, and for inducing efficient cell death, Two-hybrid analysis ill yeast and immunoprecipitation analysis of proteins expressed in mammalian cells indicate that a 52-amino acid region (amino acids 43-94) of Bik, encompassing the BH3 domain, is sufficient for efficient heterodimerization with Bcl-2 and Bcl-x(L) Protein interaction studies further reveal that an 18-amino acid region, encompassing the BH3 domain (residues 57-74), constitutes the core heterodimerization domain. Functional analysis indicates that a Bik deletion mutant expressing residues 43-120, which efficiently heterodimerizes with the anti-apoptosis proteins Bcl-2 and Bel-x(L), is defective in eliciting cell death. In contrast, a mutant expressing additional C-terminal sequences (amino acids 43-134) interacts with the survival proteins and elicits efficient cell death. Our results suggest that for Bik-mediated cell death, the heterodimerization activity encoded by the BH3 domain alone is insufficient and raise the possibility-that Bik may induce cell death autonomous of heterodimerization with survival proteins such as Bcl-2 and Bcl-x(L).	ST LOUIS UNIV,MED CTR,INST MOL VIROL,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, R01 CA033616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Han J, 1996, MOL CELL BIOL, V16, P5857; INOHARA N, 1997, EMBO J, V16, P1638; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1995, J CELL BIOL, V124, P1; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	24	58	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24494	24498		10.1074/jbc.272.39.24494	http://dx.doi.org/10.1074/jbc.272.39.24494			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305912	hybrid			2022-12-27	WOS:A1997XY51500063
J	Jenkins, TD; Nakagawa, H; Rustgi, AK				Jenkins, TD; Nakagawa, H; Rustgi, AK			The keratinocyte-specific Epstein-Barr virus ED-L2 promoter is regulated by phorbol 12-myristate 13-acetate through two cis-regulatory elements containing E-box and Kruppel-like factor motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN PROMOTER; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR USF; TERMINAL DIFFERENTIATION; GENE-EXPRESSION; GROWTH-FACTOR; KINASE-C; MOUSE KERATINOCYTES; EPITHELIAL-CELLS; MULTIGENE FAMILY	We previously employed 782 base pairs of the Epstein-Barr virus ED-LP early lytic cycle promoter in a transgenic mouse model to target cyclin D1 to the stratified squamous epithelium of the tongue and esophagus, This promoter is located 5' to the transcriptional start site of a short open reading frame BNLF-2A and is immediately 3' to the BNLF-1 (LMP-1 oncogene) open reading frame. We studied transcriptional regulation of the ED-LB promoter by phorbol 12-myristate 13-acetate (PMA) as a means of understanding the tissue specificity of this promoter. The transcriptional activity of the ED-LS promoter was stimulated 40-fold by PMA and could be blocked with the compound H7 through antagonism of protein kinase C. 5' deletion analysis of the 782-base pair promoter demonstrated that the sequences necessary for PMA-stimulated trans-activation were located in two separate cis-regulatory regions of the promoter: -187 to -164 and -144 to -114 base pairs from the transcription start site of BNLF-2A. Importantly, mutation of critical base pairs in each region was sufficient to abolish PMA-stimulated trans-activation in the native ED-L2 promoter. Region -187 to -164 contains a CACACCC (E-box) motif, and region -144 to -114 contains a CACACCC motif. Both of these motifs are necessary for trans-activation by PMA. These regions do not, however, demonstrate enhancer characteristics when tested in a heterologous minimal promoter system. Variations of the CACACCC motif are found in other keratinocyte-specific promoters, as well as in the DNA binding motifs of the Kruppel-like family of transcription factors. Electrophoretic mobility shift assays with specific competitors and factor-specific antibody supershift assays demon strated that one complex binding the -187 to -164 region containing the CACCTG nucleotides has characteristics of the helix loop-helix protein upstream stimulatory factor, whereas a factor binding the CACACCC motif may be a member of the Kruppel-like family, These experiments show how ubiquitous and tissue-specific transcription factors induced by PMA regulate the ED-LP promoter in squamous epithelial cells.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NIDDK NIH HHS [DK43351, DK40561, 5 T32 DK07191 D22] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P30DK040561, T32DK007191] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BLUMBERG PM, 1981, CRC CR REV TOXICOL, V8, P199, DOI 10.3109/10408448109109658; BYRNE C, 1993, DEVELOPMENT, V94, P2369; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHAMBERLAIN SH, 1993, J CELL BIOCHEM, V52, P337, DOI 10.1002/jcb.240520310; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; COHEN JI, 1993, ANN INTERN MED, V118, P45; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FARRELL PJ, 1983, EMBO J, V2, P1331, DOI 10.1002/j.1460-2075.1983.tb01588.x; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Jenkins TD, 1996, ONCOGENE, V13, P1809; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kieff E, 1996, VIROLOGY, P2343; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LIN Q, 1994, J BIOL CHEM, V269, P23894; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; Nakagawa H, 1997, J BIOL CHEM, V272, P16688, DOI 10.1074/jbc.272.26.16688; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; OKAN I, 1995, ONCOGENE, V11, P1027; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RIEGER E, 1994, J INVEST DERMATOL, V103, P341, DOI 10.1111/1523-1747.ep12394888; Rutberg SE, 1996, ONCOGENE, V13, P167; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHOSHAN MC, 1994, J CELL BIOCHEM, V55, P496, DOI 10.1002/jcb.240550409; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SNOEK GT, 1987, EXP CELL RES, V172, P146, DOI 10.1016/0014-4827(87)90101-7; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; Stanwell C, 1996, CARCINOGENESIS, V17, P1259, DOI 10.1093/carcin/17.6.1259; STENLUND A, 1990, GENE DEV, V4, P123, DOI 10.1101/gad.4.1.123; TSENG H, 1994, J CELL BIOL, V126, P495, DOI 10.1083/jcb.126.2.495; TSENG H, 1992, P NATL ACAD SCI USA, V89, P10311, DOI 10.1073/pnas.89.21.10311; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang S, 1996, CANCER RES, V56, P4610; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WU RL, 1994, J BIOL CHEM, V269, P28450; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	62	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24433	24442		10.1074/jbc.272.39.24433	http://dx.doi.org/10.1074/jbc.272.39.24433			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305903	hybrid			2022-12-27	WOS:A1997XY51500054
J	Jho, EH; Malbon, CC				Jho, EH; Malbon, CC			G alpha(12) and G alpha(13) mediate differentiation of P19 mouse embryonal carcinoma cells in response to retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA+/H+ EXCHANGER; ALPHA-SUBUNITS; NEURONAL DIFFERENTIATION; GENE; TRANSFORMATION; MUTANT; OLIGODEOXYNUCLEOTIDES; TRANSCRIPTION; FIBROBLASTS	P19 mouse embryonal carcinoma cells can be stimulated to differentiate into endodermal-like, mesodermal-like, and neuronal-like phenotypes in response to specific morphogens. At low concentrations, retinoic acid stimulates P19 embryonal cells to differentiate to cells displaying an endodermal phenotype, whereas at higher concentrations it stimulates differentiation to neuroectoderm, The G alpha(12) and G alpha(13) subunits of heterotrimeric G-proteins are expressed in the embryonal P19 cells and stimulated in response to retinoic acid as the cells differentiate to endodermal or neuroectodermal phenotypes, Suppression of the expression of either G alpha(12) or G alpha(13) by antisense RNA is shown to promote cell detachment from substratum and apoptosis, Expression of the constitutively active, mutant form of Ga-12 (Q229L), in contrast, stimulates loss of the embryonal phenotype, Expression of the constitutively active form of G alpha(13) (Q226L) stimulates differentiation of the cells from embryonal to endodermal, in the absence of retinoic acid. Thus, both Ga-12 and Ga-13 are essential to stimulation of cell differentiation by retinoic acid, Deficiency of either G alpha(12) or G alpha(13) increases programmed cell death.	SUNY STONY BROOK,MED CTR,DEPT MOL PHARMACOL,SCH MED,DIABET & METAB DIS RES CTR,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020	Jho, Eek-hoon/0000-0003-2414-6234	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; DYCK JRB, 1995, J BIOL CHEM, V270, P10420, DOI 10.1074/jbc.270.18.10420; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HORIE S, 1992, P NATL ACAD SCI USA, V89, P5236, DOI 10.1073/pnas.89.12.5236; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; KOLYADA AY, 1994, BBA-GENE STRUCT EXPR, V1217, P54; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Sambrook J., 2002, MOL CLONING LAB MANU; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAPSCOTT SJ, 1981, NATURE, V292, P836, DOI 10.1038/292836a0; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Zhang YH, 1996, ONCOGENE, V12, P2377	36	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24461	24467		10.1074/jbc.272.39.24461	http://dx.doi.org/10.1074/jbc.272.39.24461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305907	hybrid			2022-12-27	WOS:A1997XY51500058
J	KallooHosein, HE; Whitehead, JP; Soos, M; Tavare, JM; Siddle, K; ORahilly, S				KallooHosein, HE; Whitehead, JP; Soos, M; Tavare, JM; Siddle, K; ORahilly, S			Differential signaling to glycogen synthesis by the intracellular domain of the insulin versus the insulin-like growth factor-1 receptor - Evidence from studies of TrkC-chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3'-KINASE; MONOCLONAL-ANTIBODY; SYNTHASE KINASE-3; MITOGENIC SIGNAL; TERMINAL DOMAIN; BINDING; IRS-1; SHC	Insulin and insulin-like growth factor-1 (IGF-1) have similar cell-surface receptors yet subserve different physiological functions, To examine whether these differences relate to intrinsic signaling properties of the intracellular domains of their respective receptors, chimeric receptors were constructed using the extracellular domain of the neurotrophin-3 (NT-3) receptor, TrkC, and the intracellular domain of either the insulin receptor or the IGF-1 receptor, TrkC-IR (TIR) and TrkC-IGF-1R (TIGR) were stably expressed in 3T3-L1 cells, While TIR and TIGR cell lines expressing similar numbers of chimeric receptors showed a similar dose-response relationship in NT-3 stimulated DNA synthesis, NT-3 stimulated glycogen synthesis was greater in TIR than in TIGR cells (maximum TIGR response was 35% of maximum TIR response), Additionally, the concentration of NT-3 at which significant stimulation of glycogen synthesis was seen was 0.1 ng/ml in TIR and 1 ng/ml in TIGR cells, Basal levels of thymidine incorporation but not glycogen synthesis were consistently higher in TIR than in TIGR expressing cells, No detectable basal autophosphorylation of chimeric receptors was seen in any of the cell lines, However, exposure of cell lines to the phosphatase inhibitor bisperoxovanadate resulted in greater basal autophosphorylation of the TIR and endogenous murine IR than the TIGR and endogenous murine IGF-1R. Thus, in this system, the intracellular domain of the IR appears to couple more effectively to glycogen synthesis than that of the IGF-1R, whereas the intracellular domains of both receptors have a similar capacity to stimulate DNA synthesis.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QR, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, CAMBRIDGE CB2 2QR, ENGLAND; UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Bristol			Whitehead, Jonathan/F-5022-2014; O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Whitehead, Jonathan/0000-0003-3978-3148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMO M, 1992, BIOFACTORS, V3, P151; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUANG L, 1990, P NATL ACAD SCI USA, V90, P5172; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; GUITON M, 1994, J BIOL CHEM, V269, P30370; GUITON M, 1995, J BIOL CHEM, V270, P20384, DOI 10.1074/jbc.270.35.20384; Hansen BF, 1996, BIOCHEM J, V315, P271; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAHN CR, 1985, ANNU REV MED, V36, P429; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; MAMOUNAS M, 1989, P NATL ACAD SCI USA, V86, P9294, DOI 10.1073/pnas.86.23.9294; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MOTHE I, 1995, EUR J BIOCHEM, V228, P842, DOI 10.1111/j.1432-1033.1995.0842m.x; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OSTEROP APRM, 1994, BIOCHEMISTRY-US, V33, P7453, DOI 10.1021/bi00189a053; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POGGI C, 1979, ENDOCRINOLOGY, V105, P723, DOI 10.1210/endo-105-3-723; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RANDAZZO PA, 1990, EXP CELL RES, V190, P31, DOI 10.1016/0014-4827(90)90140-6; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAHAL D, 1988, ARCH BIOCHEM BIOPHYS, V260, P416, DOI 10.1016/0003-9861(88)90465-1; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; TARTARE S, 1994, J BIOL CHEM, V269, P11449; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VERSPOHL EJ, 1984, J CLIN INVEST, V74, P1436, DOI 10.1172/JCI111555; WHITE MF, 1994, J BIOL CHEM, V269, P1; XU B, 1995, J BIOL CHEM, V270, P29825; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	50	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24325	24332		10.1074/jbc.272.39.24325	http://dx.doi.org/10.1074/jbc.272.39.24325			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305889	hybrid			2022-12-27	WOS:A1997XY51500040
J	Lopez, F; Esteve, JP; Buscail, L; Delesque, N; SaintLaurent, N; Theveniau, M; Nahmias, C; Vaysse, N; Susini, C				Lopez, F; Esteve, JP; Buscail, L; Delesque, N; SaintLaurent, N; Theveniau, M; Nahmias, C; Vaysse, N; Susini, C			The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; HUMAN TUMOR-CELLS; PHOSPHOTYROSINE PHOSPHATASE; SH2 DOMAIN; G-PROTEIN; MOLECULAR-CLONING; PANCREATIC-CANCER; MOTH-EATEN; PHOSPHORYLATION	Activation of the somatostatin receptor sst2, a member of the G(i) protein-coupled receptor family, results in the stimulation of a protein-tyrosine phosphatase activity involved in the sstZ-mediated growth inhibitory signal, Here, we report that SHP-1, a cytoplasmic protein-tyrosine phosphatase containing two Src homology 2 domains constitutively associated with sst2 as evidence by coprecipitation of SHP-1 pro-rein with sst2, in Chinese hamster ovary cells coexpressing sst2 and SHP-1. Activation of sst2 by somatostatin resulted in a rapid dissociation of SHP-1 from sst2 accompanied by an increase of SHP-1 activity, SHP-1 was phosphorylated on tyrosine in control cells and somatostatin induced a rapid and transient dephosphorylation on tyrosine residues of She enzyme. Stimulation of SIIP-I activity by somatostatin was abolished by pertussis toxin pretreatment of cells, G(i alpha 3) was specifically immunoprecipitated by anti-sst2 and anti-SHP-1 antibodies, and somatostatin induced a rapid dissociation of G(i alpha 3) from sst2, suggesting that G(i alpha 3) may be involved in the sst2-SHP-1 complexes, Finally, somatostatin inhibited the proliferation of cells coexpressing sst2 and SHP-1, and this effect was suppressed in cells coexpressing sst2 and the catalytic inactive SHP-1 (C453S mutant). Our data identify SHP-1 as the tyrosine phosphatase associated with sst2 and demonstrate that this enzyme may be an initial key transducer of the antimitogenic signaling mediated by sst2.	CHU RANGUEIL,INST LOUIS BUGNARD,INSERM UNITE 151,F-31403 TOULOUSE,FRANCE; LAB GENET & PHYSIOL DEV,LUMINY CASE 907,F-13288 MARSEILLE 9,FRANCE; INST COCHIN GENET MOL,F-75014 PARIS,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Theveniau-Ruissy, Magali/N-3563-2018	Theveniau-Ruissy, Magali/0000-0002-7346-7096				Barr AJ, 1997, J BIOL CHEM, V272, P2223; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CAMBILLAU C, 1995, ENDOCRINOLOGY, V136, P5476, DOI 10.1210/en.136.12.5476; COLAS B, 1992, EUR J BIOCHEM, V207, P1017, DOI 10.1111/j.1432-1033.1992.tb17138.x; COSTA T, 1992, MOL PHARMACOL, V41, P549; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Florio T, 1996, J BIOL CHEM, V271, P6129, DOI 10.1074/jbc.271.11.6129; FLORIO T, 1994, MOL ENDOCRINOL, V8, P1289, DOI 10.1210/me.8.10.1289; Gaits F, 1996, J BIOL CHEM, V271, P20151; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBERTS SWJ, 1991, ENDOCR REV, V12, P450, DOI 10.1210/edrv-12-4-450; LAW SF, 1993, J BIOL CHEM, V268, P10721; LEWIN MJM, 1992, ANNU REV PHYSIOL, V54, P455, DOI 10.1146/annurev.physiol.54.1.455; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NAHMIAS C, 1995, BIOCHEM J, V306, P87, DOI 10.1042/bj3060087; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Reardon DB, 1996, BIOCHEM J, V314, P401, DOI 10.1042/bj3140401; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; THEVENIAU MA, 1994, J NEUROCHEM, V63, P447; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VIDAL C, 1994, MOL PHARMACOL, V45, P97; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Yamada T, 1989, HDB PHYSL 6, P431; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YASUDA K, 1992, J BIOL CHEM, V267, P20422; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZEGGARI M, 1994, BIOCHEM J, V303, P441, DOI 10.1042/bj3030441	51	143	144	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24448	24454		10.1074/jbc.272.39.24448	http://dx.doi.org/10.1074/jbc.272.39.24448			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305905	hybrid			2022-12-27	WOS:A1997XY51500056
J	Servent, D; WincklerDietrich, V; Hu, HY; Kessler, P; Drevet, P; Bertrand, D; Menez, A				Servent, D; WincklerDietrich, V; Hu, HY; Kessler, P; Drevet, P; Bertrand, D; Menez, A			Only snake curaremimetic toxins with a fifth disulfide bond have high affinity for the neuronal alpha 7 nicotinic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CHICK OPTIC LOBE; ACETYLCHOLINE-RECEPTORS; SKELETAL-MUSCLE; 3-DIMENSIONAL STRUCTURE; BUNGAROTOXIN; BINDING; NEUROTOXIN; VENOM; METHYLLYCACONITINE	Long chain and short chain curaremimetic toxins from snakes possess 66-74 residues with five disulfide bonds and 60-62 residues with four disulfide bonds, respectively, Despite their structural differences all of these toxins bind with high affinity to the peripheral nicotinic acetylcholine receptors (AChR), Binding experiments have now revealed that long chain toxins only, like the neuronal K-bungarotoxin, have a high affinity for a chimeric form of the neuronal alpha 7 receptor, with K-d values ranging from about 1 to 12 nM, In contrast, all other toxins bind to the chimeric alpha 7 receptor with a low affinity, with K-d values ranging between 3 and 22 mu M. These results are supported by electrophysiological recordings on both the wild-type and chimeric alpha 7 receptors. Amino acid sequence analyses have suggested that high affinities for the neuronal receptor are associated with the presence of the fifth disulfide at the tip of the toxin second loop, In agreement with this conclusion, we show that a long chain toxin whose fifth disulfide is reduced and then dithiopyridylated has a low affinity (K-d = 12 mu M) for the neuronal alpha 7 receptor, whereas it retains a high affinity (K-d = 0.35 nM) for the peripheral AChR, Thus, a long chain curaremimetic toxin having a reduced fifth disulfide bond behaves like a short chain toxin toward both the peripheral and neuronal AChR, Therefore, functional classification of toxins that bind to AChRs should probably be done by considering their activities on both peripheral and neuronal receptors.	CTR MED UNIV GENEVA, DEPT PHYSIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva	Servent, D (corresponding author), CEA SACLAY, DEPT INGN & ETUD PROT, F-91191 GIF SUR YVETTE, FRANCE.			Servent, Denis/0000-0002-0774-1691				ALBUQUERQUE EX, 1979, HDB EXP PHARM, V52, P377; ALKONDON M, 1992, MOL PHARMACOL, V41, P802; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chiappinelli V., 1991, SNAKE TOXINS, P223; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DREVET P, 1997, IN PRESS PROT EXP PU, V10; Ducancel F., 1991, P385; EAKER DL, 1967, JPN J MICROBIOL, V11, P353, DOI 10.1111/j.1348-0421.1967.tb00356.x; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; ENDO T, 1991, SNAKE TOXINS, P259; FIORDALISI JJ, 1994, TECHNIQUES PROTEIN C, V5, P269; GOTTI C, 1994, EUR J NEUROSCI, V6, P1281, DOI 10.1111/j.1460-9568.1994.tb00318.x; ISHIKAWA Y, 1977, TOXICON, V15, P477, DOI 10.1016/0041-0101(77)90098-8; ISHIKAWA Y, 1985, BRAIN RES, V346, P82, DOI 10.1016/0006-8993(85)91097-2; JERUSALINSKY D, 1994, TRENDS PHARMACOL SCI, V15, P424, DOI 10.1016/0165-6147(94)90092-2; KIM HS, 1982, BIOCHEM J, V207, P215, DOI 10.1042/bj2070215; Lamthanh H, 1995, PEPTIDE RES, V8, P316; LEE CY, 1972, ANNU REV PHARMACOL, V12, P84; LORING RH, 1986, BRAIN RES, V385, P30, DOI 10.1016/0006-8993(86)91543-X; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; LUKAS RJ, 1981, BIOCHEMISTRY-US, V20, P7373, DOI 10.1021/bi00529a008; MARTIN BM, 1983, J BIOL CHEM, V258, P8714; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; PENG X, 1994, MOL PHARMACOL, V45, P546; PILLET L, 1993, J BIOL CHEM, V268, P909; ROSENTHAL JA, 1994, J BIOL CHEM, V269, P11178; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; TSERNOGLOU D, 1977, P NATL ACAD SCI USA, V74, P971, DOI 10.1073/pnas.74.3.971; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WARD JM, 1990, FEBS LETT, V270, P45, DOI 10.1016/0014-5793(90)81231-C; WEBER M, 1974, MOL PHARMACOL, V10, P1; WOLF KM, 1988, BRAIN RES, V439, P249, DOI 10.1016/0006-8993(88)91481-3; Wonnacott S., 1993, METHODS NEUROSCI, P263; Zamudio F, 1996, BIOCHEMISTRY-US, V35, P7910, DOI 10.1021/bi9600761; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	41	133	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24279	24286		10.1074/jbc.272.39.24279	http://dx.doi.org/10.1074/jbc.272.39.24279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305882	hybrid			2022-12-27	WOS:A1997XY51500033
J	Statuto, M; Audebet, C; Tonoli, H; SelmiRuby, S; Rousset, B; MunariSilem, Y				Statuto, M; Audebet, C; Tonoli, H; SelmiRuby, S; Rousset, B; MunariSilem, Y			Restoration of cell-to-cell communication in thyroid cell lines by transfection with and stable expression of the connexin-32 gene - Impact on cell proliferation and tissue-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION PROTEIN; C6 GLIOMA-CELLS; EPITHELIAL-CELLS; TRANSFORMED-CELLS; GROWTH-CONTROL; FACTOR-I; CDNA; DNA; TRANSCRIPTION; SEQUENCE	Normal thyroid epithelial cells coexpress connexin-32 and connexin-43, which form distinct gap functions. In primary culture, connexin-43 is expressed by thyrocytes in monolayers or reorganized into follicles, whereas the, expression of eonnexin-32 is dependent upon the reconstitution of follicles, To study the functional impact of connexin-32 gap junctions in thyroid cells, we transfected connexin-32 cDNA in two thyroid-derived communication-deficient cell lines, FRT and FRTL-5. The selected clones, which stably expressed connexin-32 at high levels and exhibited high gap junction-mediated dye-coupling, presented a reduced proliferation rate as compared with that of the corresponding wild-type FRT and FRTL-5 cells; the mean population doubling time was increased by similar to 35%, The proliferation of connexin-32-transfected FRTL-5 cells remained thyrotropin-dependent; the range of thyrotropin concentrations that stimulated growth was the same in transfected and control cells, The expression of connexin-32 led to an increase of thyroglobulin gene expression in FRTL-5 cells, The expression of two other tissue-specific proteins, thyroid transcription factor-1 and Pax-8, was unchanged, These findings provide evidence that connexin-32 gap junction-mediated cell-to-cell communication participates in the control of growth and differentiation of thyroid cells.	FAC MED LYON,RTH LAENNEC,INSERM,U369,F-69372 LYON 08,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			RUBY, Samia/T-1131-2019; selmi-ruby, Samia/L-3509-2016	RUBY, Samia/0000-0001-9491-9285; 				AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; BRADSHAW SL, 1993, GROWTH REGULAT, V3, P26; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVITAREALE D, 1994, BIOCHEM J, V304, P981, DOI 10.1042/bj3040981; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; DERMIETZEL R, 1990, ANAT EMBRYOL, V182, P517; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; FROMAGET C, 1990, J MOL CELL CARDIOL, V22, P1245, DOI 10.1016/0022-2828(90)90061-6; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; GUERRIER A, 1995, J CELL SCI, V108, P2609; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MESNIL M, 1995, CANCER RES, V55, P629; MUNARISILEM Y, 1991, ENDOCRINOLOGY, V128, P3299, DOI 10.1210/endo-128-6-3299; MunariSilem Y, 1996, EUR J ENDOCRINOL, V135, P251, DOI 10.1530/eje.0.1350251; MUNARISILEM Y, 1994, ENDOCRINOLOGY, V135, P724, DOI 10.1210/en.135.2.724; NAUS CCG, 1992, CANCER RES, V52, P4208; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; STEWART WW, 1978, CELL, V14, P741, DOI 10.1016/0092-8674(78)90256-8; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; VOZZI C, 1995, J CELL BIOL, V131, P1561, DOI 10.1083/jcb.131.6.1561; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	41	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24710	24716		10.1074/jbc.272.39.24710	http://dx.doi.org/10.1074/jbc.272.39.24710			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305943	hybrid			2022-12-27	WOS:A1997XY51500094
J	McDonough, PM; Hanford, DS; Sprenkle, AB; Mellon, NR; Glembotski, CC				McDonough, PM; Hanford, DS; Sprenkle, AB; Mellon, NR; Glembotski, CC			Collaborative roles for c-Jun N-terminal kinase, c-Jun, serum response factor, and Sp1 in calcium-regulated myocardial gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NEONATAL CARDIAC MYOCYTES; ATRIAL-NATRIURETIC-FACTOR; CULTURED VENTRICULAR MYOCYTES; RAT SYMPATHETIC NEURONS; ALPHA-ACTIN PROMOTER; BOX-BINDING-PROTEINS; GROWTH-FACTOR; MEMBRANE DEPOLARIZATION; DNA-BINDING	Electrical stimulation of contractions (pacing) of primary neonatal rat ventricular myocytes increases intracellular calcium and activates a hypertrophic growth program that includes expression of the cardiac-specific gene, atrial natriuretic factor (ANF). To investigate the mechanism whereby pacing increases ANF, pacing was tested for its ability to regulate mitogen-activated protein kinase family members, ANF promoter activity, and the trans-activation domain of the transcription factor, Sp1. Pacing and the calcium channel agonist BAYK 8644 activated c-Jun N-terminal kinase (JNK) but not extracellular signal-regulated kinase. Pacing stimulated ANF-promoter activity approximately 10-fold. Furthermore, transfection with an expression vector for c-Jun, a substrate for JNK, also activated the ANF promoter, and the combination of pacing and c-Jun was synergystic, consistent with roles for JNK and c-Jun in calcium-activated ANF expression. Proximal serum response factor and Sp1 binding sites were required for the effects of pacing or c-Jun on the ANF promoter. Pacing and c-Jun activated a GAL4-Sp1 fusion protein by 3- and 12-fold, respectively, whereas the two stimuli together activated GAL4-Sp1 synergistically, similar to their effect on the ANF promoter. Transfection with an expression vector for c-Fos inhibited the effects of c-Jun, suggesting that c-Jun acts independently of AP-1. These results demonstrate an interaction between c-Jun and Sp1 and are consistent with a novel mechanism of calcium-mediated transcriptional activation involving the collaborative actions of JNK, c-Jun, serum response factor, and Sp1.	SAN DIEGO STATE UNIV, INST MOL BIOL, SAN DIEGO, CA 92182 USA; UNIV VIRGINIA, HLTH SCI CTR, CHARLOTTESVILLE, VA 22908 USA	California State University System; San Diego State University; University of Virginia	McDonough, PM (corresponding author), SAN DIEGO STATE UNIV, DEPT BIOL, 5300 CAMPANILE DR, SAN DIEGO, CA 92182 USA.				NHLBI NIH HHS [HL-56861, HL-54030] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054030, R01HL056861] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; BARRY WH, 1993, CIRCULATION, V87, P1806, DOI 10.1161/01.CIR.87.6.1806; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BRAND T, 1993, J MOL CELL CARDIOL, V25, P1325, DOI 10.1006/jmcc.1993.1145; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; DESNOS C, 1990, DEV BRAIN RES, V52, P161, DOI 10.1016/0165-3806(90)90231-M; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; IVESTER CT, 1993, AM J PHYSIOL, V265, pH666; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; KovacicMilivojevic B, 1996, ENDOCRINOLOGY, V137, P1108, DOI 10.1210/en.137.3.1108; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIU F, 1993, J BIOL CHEM, V268, P6714; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MCDERMOTT P, 1985, AM J PHYSIOL, V249, pH763, DOI 10.1152/ajpheart.1985.249.4.H763; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; POLAK KA, 1991, J NEUROSCI, V11, P534; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHIELDS PP, 1988, J BIOL CHEM, V263, P12619; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; SPIEGEL K, 1989, MOL BRAIN RES, V5, P23, DOI 10.1016/0169-328X(89)90014-4; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VANBILSEN M, 1993, CARDIOVASC RES, V27, P1140; VANNGUYEN T, 1990, J NEUROSCI, V10, P2825; WIER WG, 1995, CIBA F SYMP, V188, P146; WU RL, 1994, J BIOL CHEM, V269, P28450; Xia Y, 1996, J BIOL CHEM, V271, P12082, DOI 10.1074/jbc.271.20.12082; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; Zheng JS, 1996, CIRC RES, V78, P525, DOI 10.1161/01.RES.78.4.525; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	76	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24046	24053		10.1074/jbc.272.38.24046	http://dx.doi.org/10.1074/jbc.272.38.24046			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295358	hybrid			2022-12-27	WOS:A1997XX38100083
J	Piotrowski, J; Beal, R; Hoffman, L; Wilkinson, KD; Cohen, RE; Pickart, CM				Piotrowski, J; Beal, R; Hoffman, L; Wilkinson, KD; Cohen, RE; Pickart, CM			Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN CARRIER PROTEINS; MULTIUBIQUITIN-CHAIN; PROTEOLYTIC PATHWAY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ALPHA-GLOBIN; DEGRADATION; ENZYME; PURIFICATION; RESOLUTION	Ubiquitin is a covalent signal that targets cellular proteins to the 26 S proteasome. Multiple ubiquitins can be ligated together through the formation of isopeptide bonds between Lys(48) and Gly(76) of successive ubiquitins. Such a polyubiquitin chain constitutes a highly effective proteolytic targeting signal, but its made of interaction with the proteasome is not well understood. Experiments to address this issue have been limited by difficulties in preparing useful quantities of polyubiquitin chains of uniform length. We report a simple method for large scale synthesis of Lys(48)-linked polyubiquitin chains of defined length. In the first round of synthesis, two ubiquitin derivatives (K48C-ubiquitin and Asp(77)-ubiquitin) were eased as substrates for the well characterized ubiquitin-conjugating enzyme E2-25K. Diubiquitin blocked at the nascent proximal and distal chain. termini was obtained in qualitative yield. Appropriately deblocked chains were then combined to synthesize higher order chains (tetramer and octamer in the present study). Deblocking was achieved either enzymatically (proximal terminus) or by chemical alkylation (distal terminus), Chains synthesized by this method were used to obtain the Fu st quantitative information concerning the influence of polyubiquitin chain length on binding to the 26 S proteasome; this was done through comparison of different length (unanchored) polyubiquitin chains as inhibitors of ubiquitin-conjugate degradation. K-0.5 was found to decrease similar to 90-fold, from 430 to 4.8 mu M, as the chain was lengthened from two to eight ubiquitins. The implications of these results for the molecular basis of chain recognition are discussed.	JOHNS HOPKINS UNIV, DEPT BIOCHEM, SCH PUBL HLTH, BALTIMORE, MD 21205 USA; SUNY BUFFALO, DEPT BIOCHEM, SCH MED, BUFFALO, NY 14214 USA; UNIV UTAH, SCH MED, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Utah System of Higher Education; University of Utah; Emory University; University of Iowa					NIDDK NIH HHS [DK46984] Funding Source: Medline; NIGMS NIH HHS [GM30308, GM37666] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308, R01GM037666] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cole R.D., 1967, METHOD ENZYMOL, V11, P315; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; COX MJ, 1986, ARCH BIOCHEM BIOPHYS, V250, P400, DOI 10.1016/0003-9861(86)90742-3; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HALDEMAN MT, 1997, IN PRESS BIOCHEMISTR, V36; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P1619, DOI 10.1073/pnas.81.6.1619; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MILLER HI, 1989, BIO-TECHNOL, V7, P698, DOI 10.1038/nbt0789-698; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; SHAEFFER JR, 1994, J BIOL CHEM, V269, P29530; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TANAKA K, 1986, J BIOL CHEM, V261, P5197; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; WEFES I, 1995, GENE, V163, P321, DOI 10.1016/0378-1119(95)00374-F	54	176	177	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23712	23721		10.1074/jbc.272.38.23712	http://dx.doi.org/10.1074/jbc.272.38.23712			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295315	hybrid			2022-12-27	WOS:A1997XX38100040
J	Chen, JP; Spector, MS; Kunos, G; Gao, B				Chen, JP; Spector, MS; Kunos, G; Gao, B			Sp1-mediated transcriptional activation from the dominant promoter of the rat alpha(1B) adrenergic receptor gene in DDT1MF-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DNA-BINDING; SYNERGISTIC ACTIVATION; PROTEIN-KINASE; SP1; EXPRESSION; LIVER; PURIFICATION; MECHANISMS; ALPHA-1B	In the rat liver, NF1 and CP1 bind to the major P2 promoter of the alpha(1B) adrenergic receptor gene to generate footprint II. Here we show that, in DDT1MF-2 smooth muscle cells, the major protein bound to footprint II is not NFI but Sp1, which binds to the 5'-portion of the footprint II sequence (footprint IIb), Mutational analyses demonstrate that the CCCGCG sequence in footprint IIb is critical for Sp1 binding and P2 promoter activity. a second GC box in the P2 promoter also binds the Sp1 protein and contributes to the P2 promoter activity. Gel shift assays indicate that footprint II can bind Sp1, NF1, and CP1, and that the binding of these 3 proteins is mutually exclusive. This is also indicated by the results of functional cotransfection experiments, whare transient overexpression of NF1 and Sp1 together caused a similar increase in the activity of a P2/CAT reporter construct as overexpression of either Sp1 or NF1 alone, indicating lack of additivity. The preferential interaction of footprint II with Sp1 in DDT1MF-2 cells and NF1 in Liver appears to be due to low levels of NF1 expression in DDT1MF-2 cells and low levels of Sp1 in liver. These observations suggest. that NF1 and Sp1 are the major transcription factors involved in controlling the P2 promoter in liver versus DDT1MF-2 cells, respectively, which may be one of the mechanisms responsible for the complex tissue-specific regulation of the expression of the alpha(1B) adrenergic receptor gene.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA	Virginia Commonwealth University								ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESBENSHADE TA, 1994, MOL PHARMACOL, V45, P591; GAO B, 1995, J BIOL CHEM, V270, P5614, DOI 10.1074/jbc.270.10.5614; Gao B, 1996, MOL CELL BIOL, V16, P5997; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; GAO B, 1994, J BIOL CHEM, V269, P15762; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; HU ZW, 1993, J BIOL CHEM, V268, P3610; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAJIYAMA Y, 1994, BIOCHEM J, V303, P313, DOI 10.1042/bj3030313; KUNOS G, 1995, ANN NY ACAD SCI, V757, P261, DOI 10.1111/j.1749-6632.1995.tb17483.x; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; LANS MS, 1994, J BIOL CHEM, V269, P14170; LAZARWESLEY E, 1991, ENDOCRINOLOGY, V129, P1116, DOI 10.1210/endo-129-2-1116; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MCGEHEE RE, 1990, MOL CELL ENDOCRINOL, V74, P1, DOI 10.1016/0303-7207(90)90200-R; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Seo SJ, 1996, GENE, V178, P177, DOI 10.1016/0378-1119(96)00383-6; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978	39	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23144	23150		10.1074/jbc.272.37.23144	http://dx.doi.org/10.1074/jbc.272.37.23144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287317	hybrid			2022-12-27	WOS:A1997XV74400028
J	Stenberg, Y; Linse, S; Drakenberg, T; Stenflo, J				Stenberg, Y; Linse, S; Drakenberg, T; Stenflo, J			The high affinity calcium-binding sites in the epidermal growth factor module region of vitamin K-dependent protein S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE DOMAINS; BETA-HYDROXYASPARTIC ACID; EGF-LIKE DOMAIN; HUMAN FACTOR-IX; FACTOR-X; HUMAN FIBRILLIN-1; FACTOR PRECURSOR; MARFAN-SYNDROME; CALBINDIN D9K; ION-BINDING	Vitamin K-dependent protein S, a cofactor of the anticoagulant enzyme-activated protein C, has four epidermal growth factor (EGF)-like modules, all of which have one partially hydroxylated Asp (EGF 1; beta-hydroxyaspartic acid) or Asn (EGF 2, 3, and 4; beta-hydroxyasparagine) residue, The three C-terminal modules have a typical Ca2+ binding sequence motif that is usually present in EGF modules with hydroxylated Asp/Asn residues, Using the chromophoric Ca2+ chelators Quin 2 and 5,5'-Br(2)BAPTA, we have now determined the Ca2+ affinity of recombinant fragments containing EGF modules 1-3, 1-4, 2-3, and 2-4. EGF modules 1-4 and 2-4 each contains two very high affinity Ca2+-binding sites, i.e. with dissociation constants ranging from 10(-10) to 10(-8) M in the absence of salt and from 10(-8) to 10(-6) M in the presence of 0.15 M NaCl. In contrast, in EGF 13 and EGF 2-3, the Ca2+ affinity is 2-4 orders of magnitude lower, EGF 4 thus appears to have the highest Ca2+ affinity, and furthermore it seems to influence the Ca2+ affinity of its immediate N-terminal neighbor EGF 3 by a factor of approximately 230, In addition, EGF 4 seems to influence the Ca2+ affinity of EGF 2 by a factor of approximately 25, The Ca2+ affinity of the binding sites in EGF modules 3 and 4 in fragments EGF 1-4 and EGF 2-4 is 10(3)-10(5)-fold higher than in the corresponding isolated modules, implying important contributions to the Ca2+ affinity of each module from interactions with neighboring modules, This difference is much higher than the approximately 10-fold difference previously found in similar comparisons of EGF modules from fibrillin. However, the modules studied in protein S and fibrillin appear to have the similar Ca2+ ligands, The structural basis for the difference in Ca2+ affinity is not yet understood.	LUND UNIV,DEPT CLIN CHEM,S-20502 MALMO,SWEDEN; LUND UNIV,CTR CHEM,DEPT PHYS CHEM 2,S-22100 LUND,SWEDEN	Lund University; Lund University				Linse, Sara/0000-0001-9629-7109				APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BRYANT DTW, 1985, BIOCHEM J, V226, P613, DOI 10.1042/bj2260613; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; DAHLBACK D, 1994, HAEMOSTASIS THROMBOS, V1, P671; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; GERSHAGEN S, 1987, FEBS LETT, V220, P129, DOI 10.1016/0014-5793(87)80890-6; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HE XH, 1995, EUR J BIOCHEM, V227, P433, DOI 10.1111/j.1432-1033.1995.tb20406.x; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; LINSE S, 1991, BIOCHEMISTRY-US, V30, P154, DOI 10.1021/bi00215a023; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; LINSE S, 1991, J BIOL CHEM, V266, P8050; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; LINSE S, 1988, NATURE, V335, P651, DOI 10.1038/335651a0; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; OHLIN AK, 1987, J BIOL CHEM, V262, P13798; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1988, J BIOL CHEM, V263, P21; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; Stenflo J., 1994, MOL BASIS BLOOD DIS, P565; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; VALCARCE C, 1993, J BIOL CHEM, V268, P26673; WU YS, 1995, CHEM BIOL, V2, P91, DOI 10.1016/1074-5521(95)90281-3; [No title captured]	39	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23255	23260		10.1074/jbc.272.37.23255	http://dx.doi.org/10.1074/jbc.272.37.23255			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287334	hybrid			2022-12-27	WOS:A1997XV74400045
J	Potter, D; Miziorko, HM				Potter, D; Miziorko, HM			Identification of catalytic residues in human mevalonate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI PHOSPHOFRUCTOKINASE; SACCHAROMYCES-CEREVISIAE; ACTIVE-SITE; RAT-LIVER; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; BINDING-SITE; ERG12 GENE; PEROXISOMES	cDNA encoding human mevalonate kinase has been overexpressed and the recombinant enzyme isolated, This stable enzyme is a dimer of 42-kDa subunits and exhibits a V-m = 37 units/mg, K-m(ATP) = 74 mu M, and Km(DL-MVA) = 24 mu M. The sensitivity of enzyme to water-soluble carbodiimide modification of carboxyl groups prompted evaluation of four invariant acidic amino acids (Glu-19, Glu-193, Asp-204, and Glu-296) by site-directed mutagenesis, Elimination of Glu-19's carboxyl group (E19A, E19Q) destabilizes the enzyme, whereas E19D is stable but exhibits only similar to 2-fold changes in V-m and K-m values, E296Q is a stable enzyme, which exhibits kinetic parameters comparable to those measured for wild-type enzyme, E193A is a labile protein, whereas E193Q is stable, exhibiting >50-fold diminution in V-m and elevated K-m values for ATP (similar to 20-fold) and mevalonate (similar to 40-fold). Such effects would be compatible with a role for Glu-193 in interacting with the cation of the MgATP substrate. D204A and D204N are stable enzymes lacking substantial mevalonate kinase activity, The active sites of these Asp-204 mutants are intact, based on their ability to bind a spin-labeled ATP analog with stoichiometries and equilibrium binding constants that are comparable to those determined for wild-type enzyme, Competitive displacement experiments demonstrate that the Asp-204 mutants can bind ATP with K-d values that are comparable to estimates for wild-type enzyme, The >40,000 fold diminution in k(cat) for the Asp-204 mutants and the demonstration that they contain an otherwise intact active site support assignment of a crucial catalytic role to Asp-204. The assignment of Asp-204 as the catalytic base that facilitates deprotonation of the C-5 hydroxyl of mevalonic acid would be compatible with the experimental observations.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin					NCRR NIH HHS [RR-01008] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BERGER SA, 1992, BIOCHEMISTRY-US, V31, P9237, DOI 10.1021/bi00153a017; BEYTIA E, 1970, J BIOL CHEM, V245, P5450; BIARDI L, 1994, J BIOL CHEM, V269, P1197; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUENGER E, 1988, ANAL BIOCHEM, V173, P321, DOI 10.1016/0003-2697(88)90196-0; CHARLIER HA, 1994, BIOCHEMISTRY-US, V33, P9343, DOI 10.1021/bi00197a039; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; GIBSON KM, 1988, EUR J PEDIATR, V148, P250, DOI 10.1007/BF00441413; GIBSON KM, 1989, ENZYME, V41, P47, DOI 10.1159/000469050; GRAY JC, 1972, BIOCHIM BIOPHYS ACTA, V279, P290, DOI 10.1016/0304-4165(72)90145-6; GREEN PC, 1993, J BIOL CHEM, V268, P5085; HARWOOD HJ, 1982, J LIPID RES, V23, P754; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; HELLINGA HW, 1987, NATURE, V327, P437, DOI 10.1038/327437a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; KOTEICHE HA, 1995, BIOCHEMISTRY-US, V34, P15068, DOI 10.1021/bi00046a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEE CS, 1983, BIOCHIM BIOPHYS ACTA, V747, P215, DOI 10.1016/0167-4838(83)90100-0; MILDVAN AS, 1965, J BIOL CHEM, V240, P238; OULMOUDEN A, 1991, CURR GENET, V19, P9, DOI 10.1007/BF00362081; OULMOUDEN A, 1990, GENE, V88, P253, DOI 10.1016/0378-1119(90)90039-T; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; RIDER MH, 1994, BIOCHEM J, V300, P111, DOI 10.1042/bj3000111; RIOU C, 1994, GENE, V148, P293, DOI 10.1016/0378-1119(94)90701-3; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; Schneider D. J., 1989, BIOL MAGN RESON, V8, P1; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SOLER M, 1979, INT J BIOCHEM, V10, P931, DOI 10.1016/0020-711X(79)90126-5; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; TCHEN TT, 1958, J BIOL CHEM, V233, P1100; TSAY YH, 1991, MOL CELL BIOL, V11, P620, DOI 10.1128/MCB.11.2.620; Wanders RJA, 1996, J INHERIT METAB DIS, V19, P193, DOI 10.1007/BF01799427	40	65	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25449	25454		10.1074/jbc.272.41.25449	http://dx.doi.org/10.1074/jbc.272.41.25449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325256	hybrid			2022-12-27	WOS:A1997YA35800011
J	Arai, H; Monteclaro, FS; Tsou, CL; Franci, C; Charo, IF				Arai, H; Monteclaro, FS; Tsou, CL; Franci, C; Charo, IF			Dissociation of chemotaxis from agonist-induced receptor internalization in a lymphocyte cell line transfected with CCR2B - Evidence that directed migration does not require rapid modulation of signaling at the receptor level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT PROTEIN-1 RECEPTOR; CHEMOKINE; BETA; TAIL; TRANSDUCTION; SPECIFICITY; MECHANISM; BIOLOGY	To investigate the role of the carboxyl-terminal region (52 amino acids) of the monocyte chemoattractant protein 1 receptor (CCR2B) in chemotaxis, we created a series of mutants and expressed them in a murine pre-B lymphocyte cell Line. Truncation of the cytoplasmic carboxyl tail to 20 amino acids had little or no effect on chemotaxis or signal transduction, but further truncation resulted in marked functional defects. Upon incubation with monocyte chemoattractant protein 1, CCR2B underwent rapid and extensive internalization, and this was impaired progressively as the carboxyl tail was truncated from 52 to 8 amino acids. Mutation of all of the serine and threonine residues in the carboxyl tail to alanine also resulted in markedly impaired receptor internalization but did not affect signaling or chemotaxis. We conclude that the membrane-proximal portion of the cytoplasmic carboxyl tail of CCR2B is critically involved in chemotaxis and signal transduction, but neither phosphorylation of carboxyl serines or threonines nor internalization of the receptor is required for robust chemotaxis.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849	NHLBI NIH HHS [HL52773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Arai H, 1996, MOL PHARMACOL, V50, P522; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Franci C, 1996, J IMMUNOL, V157, P5606; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; SCHALL TJ, 1994, CYTOKINE HDB, P419; Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	24	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25037	25042		10.1074/jbc.272.40.25037	http://dx.doi.org/10.1074/jbc.272.40.25037			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312111	hybrid			2022-12-27	WOS:A1997XY97000050
J	Giglione, C; Parrini, MC; Baouz, S; Bernardi, A; Parmeggiani, A				Giglione, C; Parrini, MC; Baouz, S; Bernardi, A; Parmeggiani, A			A new function of p120-GTPase-activating protein - Prevention of the guanine nucleotide exchange factor-stimulated nucleotide exchange on the active form of Ha-Ras p21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SWITCH-II REGION; SDC25 C-DOMAIN; SACCHAROMYCES-CEREVISIAE; EFFECTOR INTERACTIONS; CATALYTIC DOMAIN; TERMINAL DOMAIN; BINDING DOMAIN; IN-VITRO; GDP	This work studies the coordination of the action of GTPase-activating protein (GAP) and guanine nucleotide exchange factor (GEF) on activated human c-Ha-Ras p21, Purified human p120-GAP was obtained with a new efficient procedure. To distinguish the GTPase-activating effect of p120-GAP from other effects dependent on the interaction with activated Ha-Has, the nonhydrolyzable GTP analogue guanosine 5'-O-(thiotriphosphate) (GTP gamma S) was used, The results showed that the GTP gamma S/GTP gamma S exchange enhanced by the C-terminal catalytic domain of the yeast GEF Sdc25p (C-Sdc25p) is prevented by p120-GAP, This effect is strictly specific for the activated form of Ha-Ras, the target of GAP; no effect on Ha Ras GDP was detectable. The GAP catalytic domain also inhibited C-Sdc25p but to a lower extent, The interfering effect by p120-GAP was also evident in a homologous mammalian system, using full length mouse RasGEF, its C terminal half-molecule, or C-terminal cat alytic domain, As a consequence of this inhibition, presence of p120-GAP enhanced the regeneration of Ha-Ras.GTP gamma S by GEF at a GDP:GTP gamma S ratio mimicking the in vice GDP:GTP ratio, Our work describes a novel function of p120-GAP and suggests a mechanism by which GAP protects Ha-Ras.GTP in vivo against unproductive exchanges, This constrain is likely involved in the regulation of the physiological GDP/GTP cycle of Ras and in the action of p120-GAP as downstream effector of Ras. Helix alpha 3 is proposed as a Ras element playing a key-role in the interference between GAP and GEF on Ras.	ECOLE POLYTECH,EQUIPE 2,GRP BIOPHYS,F-91128 PALAISEAU,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,F-75251 PARIS,FRANCE	Institut Polytechnique de Paris; UDICE-French Research Universities; Universite Paris Cite			Parrini, Maria Carla/J-5390-2016	Parrini, Maria Carla/0000-0002-7082-9792; Giglione, Carmela/0000-0002-7475-1558				ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; CRECHET JB, 1993, J BIOL CHEM, V268, P14836; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HOWE LR, 1993, ONCOGENE, V8, P2583; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; NUREKAMAL MSA, 1992, MOL BIOL CELL, V3, P1437, DOI 10.1091/mbc.3.12.1437; PAI EF, 1990, EMBO J, V9, P23512; PARRINI MC, 1995, BIOCHEMISTRY-US, V34, P13776, DOI 10.1021/bi00042a008; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; Sermon BA, 1996, J BIOL CHEM, V271, P1566, DOI 10.1074/jbc.271.3.1566; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; TORTI M, 1992, J BIOL CHEM, V267, P8293; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEIJLAND A, 1992, MOL MICROBIOL, V6, P683, DOI 10.1111/j.1365-2958.1992.tb01516.x; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; WOOD DR, 1994, J BIOL CHEM, V269, P5322; YODERHILL J, 1995, J BIOL CHEM, V270, P27615, DOI 10.1074/jbc.270.46.27615; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25128	25134		10.1074/jbc.272.40.25128	http://dx.doi.org/10.1074/jbc.272.40.25128			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312123	hybrid			2022-12-27	WOS:A1997XY97000062
J	Pezet, A; Ferrag, F; Kelly, PA; Edery, M				Pezet, A; Ferrag, F; Kelly, PA; Edery, M			Tyrosine docking sites of the rat prolactin receptor required for association and activation of Stat5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; GAMMA SIGNAL-TRANSDUCTION; COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR; INTRACELLULAR DOMAIN; DIFFERENTIAL ACTIVATION; FUNCTIONAL-ANALYSIS; CYTOKINE RECEPTORS; CYTOPLASMIC DOMAIN; JAK3 EXPRESSION	Prolactin (PRL) interacts with a single chain prolactin-specific receptor of the cytokine receptor superfamily. PRL triggers activation of Jak2 kinase which phosphorylates the PRL receptor itself and the mammary gland factor, Stat5, a member of the family of signal transducers and activators of transcription (Stat). Selection of the particular substrate (Stat 5), that is characterized by transcriptional responses to PRL, has been shown to be determined by specific tyrosine-based motifs common to many cytokine receptors. PRL-induced activation of Stat5 was abolished in 293 fibroblasts expressing PRL receptor mutants lacking all intracellular tyrosines. We have identified tyrosine phosphorylation sites of the PRL receptor (residues 580, 479, and 473) necessary for maximal Stat5 activation and subsequent Stat5-dependent gene transcription. Moreover, we have shown that none of the tyrosine residues of the PRL receptor are implicated in activation of Jak2. This study demonstrates that only specific tyrosines in the PRL receptor are phosphorylated and are in fact utilized differentially for Stat5-mediated transcriptional signaling.	UNIV PARIS 05, INSERM, U344, F-75730 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Kelly, Paul/A-7951-2008					BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Gao J, 1996, MOL ENDOCRINOL, V10, P847, DOI 10.1210/me.10.7.847; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Jabbour HN, 1996, MOL CELL ENDOCRINOL, V123, P17, DOI 10.1016/0303-7207(96)03892-0; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pezet A, 1997, MOL CELL ENDOCRINOL, V129, P199, DOI 10.1016/S0303-7207(97)00063-4; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RUI H, 1994, J BIOL CHEM, V269, P5364; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Sotiropoulos A, 1996, MOL ENDOCRINOL, V10, P998, DOI 10.1210/me.10.8.998; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORTOLANI PJ, 1995, J IMMUNOL, V155, P5220; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang XZ, 1996, MOL ENDOCRINOL, V10, P1249, DOI 10.1210/me.10.10.1249; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Xu BXC, 1996, J BIOL CHEM, V271, P19768, DOI 10.1074/jbc.271.33.19768; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	72	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25043	25050		10.1074/jbc.272.40.25043	http://dx.doi.org/10.1074/jbc.272.40.25043			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312112	hybrid			2022-12-27	WOS:A1997XY97000051
J	Ollagnier, S; Mulliez, E; Schmidt, PP; Eliasson, R; Gaillard, J; Deronzier, C; Bergman, T; Graslund, A; Reichard, P; Fontecave, M				Ollagnier, S; Mulliez, E; Schmidt, PP; Eliasson, R; Gaillard, J; Deronzier, C; Bergman, T; Graslund, A; Reichard, P; Fontecave, M			Activation of the anaerobic ribonucleotide reductase from Escherichia coli - The essential role of the iron-sulfur center for S-adenosylmethionine reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME; SUBUNIT; SPECTROSCOPY; MECHANISM; CLUSTERS; PROTEIN; FORMATE; BINDING; SYSTEM; MODEL	The anaerobic ribonucleotide reductase of Escherichia coli catalyzes the synthesis of the deoxyribonucleotides required for anaerobic DNA synthesis. The enzyme is an alpha(2) beta(2) heterotetramer. in its active form, the large cu,subunit contains are oxygen-sensitive glycyl radical, whereas the beta(2) small protein harbors a [4Fe-4S] cluster that joins its two polypeptide chains, Formation of the glycyl radical in the inactive enzyme requires S-adenosylmethionine (AdoMet), dithiothreitol, K+, and either an enzymatic (reduced flavodoxin) or chemical (dithionite or 5-deazaflavin plus light) reducing system. Here, eve demonstrate that AdoMet is directly reduced by the Fe-S center of beta(2) during the activation of the enzyme, resulting in methionine and glycyl radical formation, Direct binding experiments showed that AdoMet binds to beta(2) with a K-d of 10 mu M and a 1:1 stoichiometry Binding was confirmed by EPR spectroscopy that demonstrated the formation of a complex between AdoMet and the [4Fe-4S] center of beta 2. Dithiothreitol triggered the cleavage of AdoMet, leading to an EPR-silent form of beta(2) and, in the case of alpha(2) beta(2), to glycyl radical formation, In both instances, 3 methionines were formed per mol of protein, Our results indicate that the Fe-S center of beta(2) is directly involved in the reductive cleavage of AdoMet and suggest a mew biological function for an iron-sulfur center, i.e redox catalysis, as recently proposed by others (Staples, R, C,, Ameyibor, E., Fu, W., Gardet-Salvi, L,, Stritt-Etter, A. L,, Schurmann, P,, Knaff D, B,, and Johnson, M, K, (1996) Biochemistry 35, 11425-11434).	UNIV GRENOBLE 1, ETUD DYNAM & STRUCT SELECT LAB, CNRS UMR 5616, F-38041 GRENOBLE 09, FRANCE; KAROLINSKA INST, MBB, MED NOBEL INST, DEPT BIOCHEM 1, S-17177 STOCKHOLM, SWEDEN; UNIV STOCKHOLM, DEPT MOL BIOL & BIOPHYS, S-10691 STOCKHOLM, SWEDEN; CEA, DEPT RECH FONDAMENTALE MAT CONDENSEE, SESAM, SCPM, F-38054 GRENOBLE 09, FRANCE; KAROLINSKA INST, DEPT CHEM 1, MBB, S-17177 STOCKHOLM, SWEDEN	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Karolinska Institutet; Stockholm University; CEA; Karolinska Institutet				Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; ELIASSON R, 1994, J BIOL CHEM, V269, P26116; ELIASSON R, 1995, BIOCHEM BIOPH RES CO, V214, P28, DOI 10.1006/bbrc.1995.2252; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FONTECAVE M, 1989, P NATL ACAD SCI USA, V86, P2147, DOI 10.1073/pnas.86.7.2147; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; FREY M, 1994, J BIOL CHEM, V269, P12432; GEORGIADIS MM, 1992, SCIENCE, V92, P2499; Grimshaw J., 1981, CHEM SULPHONIUM GROU, P141; HARDER J, 1992, J BIOL CHEM, V267, P25548; Johnson DA, 1996, BIOCHEMISTRY-US, V35, P15846, DOI 10.1021/bi961370w; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MOSS ML, 1990, J BIOL CHEM, V265, P18112; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SODERMAN K, 1986, ANAL BIOCHEM, V152, P89, DOI 10.1016/0003-2697(86)90124-7; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577	32	131	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24216	24223		10.1074/jbc.272.39.24216	http://dx.doi.org/10.1074/jbc.272.39.24216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305874	hybrid			2022-12-27	WOS:A1997XY51500025
J	Benoist, F; Lau, P; McDonnell, M; Doelle, H; Milne, R; McPherson, R				Benoist, F; Lau, P; McDonnell, M; Doelle, H; Milne, R; McPherson, R			Cholesteryl ester transfer protein mediates selective uptake of high density lipoprotein cholesteryl esters by human adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOCYTE PLASMA-MEMBRANES; HUMAN FAT-CELLS; APOPROTEIN-A-I; SCAVENGER RECEPTOR; SR-BI; MONOCLONAL-ANTIBODIES; REGIONAL VARIATION; ADRENAL-CELLS; MESSENGER-RNA; RAT	We have determined the role of cholesteryl ester transfer protein (CETP) in selective uptake of high density lipoprotein (HDL)-derived cholesteryl esters (CE) by human adipose tissue, using organ culture or collagenase-digested adipocytes, Incubation of the fresh tissue fragments with HDL containing [H-3]CE or I-125-apoprotein (apo) A-I resulted in significant uptake of HDL-CE-derived label. Addition of recombinant CETP (rCETP) increased CE uptake in a dose-response fashion, In contrast, little association of I-125-apoA-I with adipose tissue was noted, and addition of rCETP did not alter apoA-I uptake or degradation. Incubation of adipose tissue with TP2, an anti-CETP monoclonal antibody, which inhibits neutral lipid transfer, markedly reduced selective uptake of HDL-CE. Studies using human adipocytes isolated by collagenase digestion also demonstrated selective uptake of HDL-CE and enhancement of this process by rCETP. To confirm that the association of HDL-CE-derived radioactivity with adipose tissue was not due to neutral lipid exchange between adipocytes and HDL, we measured changes in HDL composition following incubation of HDL and rCETP with isolated adipocytes. A decreases in HDL-CE concentration in the medium was observed, an effect which was markedly attenuated when incubations were carried out in the presence of monoclonal antibody TP2. Furthermore, the decrease in HDL-CE was accompanied by an increase in HDL free cholesterol, likely representing efflux of adipocyte cholesterol to HDL. There were no significant changes in phospholipid, apoA-I, or apoA-II in the medium following incubation with adipocytes. These data demonstrate a novel and important role for CETP in selective uptake of HDL-cholesteryl esters by human adipocytes and suggest that this pathway may be of quantitative physiological significance in HDL remodeling and adipocyte cholesterol accumulation.	UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; University of Ottawa Heart Institute								Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANGEL A, 1979, CAN J BIOCHEM CELL B, V57, P578, DOI 10.1139/o79-073; ANGEL A, 1987, RECENT ADV OBES RES, P222; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BONIFACINO JS, 1987, CURRENT PROTOCOLS MO, V3; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; DESPRES JP, 1988, AM J PHYSIOL, V254, pE667, DOI 10.1152/ajpendo.1988.254.5.E667; DESPRES JP, 1987, AM J PHYSIOL, V252, pE654, DOI 10.1152/ajpendo.1987.252.5.E654; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; FOLCH J, 1957, J BIOL CHEM, V226, P497; FONG BS, 1985, J CLIN INVEST, V75, P1804, DOI 10.1172/JCI111893; FONG BS, 1989, BIOCHIM BIOPHYS ACTA, V1004, P53, DOI 10.1016/0005-2760(89)90212-9; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDBERG DI, 1991, J CLIN INVEST, V87, P331, DOI 10.1172/JCI114991; HESLER CB, 1988, J BIOL CHEM, V263, P5020; JIANG XC, 1991, J BIOL CHEM, V266, P4631; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KRAEMER FB, 1994, J LIPID RES, V35, P1760; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LEITERSDORF E, 1984, BIOCHIM BIOPHYS ACTA, V796, P72, DOI 10.1016/0005-2760(84)90240-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACALA LJ, 1983, J LIPID RES, V24, P1243; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MISRA KB, 1994, J BIOL CHEM, V269, P23838; Niemeier A, 1996, J LIPID RES, V37, P1733; PARKES JG, 1989, BIOCH CELL BIOL, V68, P870; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Radeau T, 1995, J LIPID RES, V36, P2552; RAJAN VP, 1988, BIOCHIM BIOPHYS ACTA, V959, P206, DOI 10.1016/0005-2760(88)90192-0; RINNINGER F, 1989, J BIOL CHEM, V264, P6111; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; Roy P, 1996, J LIPID RES, V37, P22; SALTER AM, 1987, EUR J CLIN INVEST, V17, P16, DOI 10.1111/j.1365-2362.1987.tb01220.x; Shen G. X., 1994, International Journal of Obesity, V18, P50; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Woollett LA, 1997, J CLIN INVEST, V99, P1704, DOI 10.1172/JCI119334; ZECHNER R, 1991, J BIOL CHEM, V266, P10583	44	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23572	23577		10.1074/jbc.272.38.23572	http://dx.doi.org/10.1074/jbc.272.38.23572			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295295	hybrid			2022-12-27	WOS:A1997XX38100020
J	Malkov, VA; Biswas, I; CameriniOtero, RD; Hsieh, P				Malkov, VA; Biswas, I; CameriniOtero, RD; Hsieh, P			Photocross-linking of the NH2-terminal region of Taq MutS protein to the major groove of a heteroduplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; ESCHERICHIA-COLI; MISMATCH REPAIR; MUTATION; HOMOLOG; IDENTIFICATION; CONTACT; RNA	The MutS DNA mismatch repair protein recognizes heteroduplex DNAs containing mispaired or unpaired bases, To identify regions of MutS protein in close proximity to the heteroduplex DNA, we have utilized the photoactivated cross-linking moiety 5-iododeoxyuridine (5-IdUrd), Nucleoprotein complexes of Thermus aquaticus MutS protein bound to monosubstituted 5-IdUrd-containing heteroduplex DNAs were cross-linked with long-wavelength ultraviolet light, Positioning of the 5-IdUrd moiety at one of three positions within the DNA bulge, two nucleotides upstream or three nucleotides downstream of the unpaired base, resulted in an identical subset of cross-linked peptides as determined by proteolytic fingerprinting, The tryptic peptide cross linked to an unpaired 5-IdUrd residue was determined by peptide sequencing to correspond to a highly conserved region spanning residues 25-49. Cross-linking to the bulge nucleotide occurred at Phe-39, indicating that this residue contacts, or is in close proximity to, the unpaired base of a heteroduplex DNA. Site-directed mutagenesis resulting in the substitution of Ala for Phe-39 reduced the affinity of the mutant protein for heteroduplex DNA by roughly 3 orders of magnitude, but had no apparent effect on its ability to dimerize, its thermostability, or its ATPase activity, These results implicate the region in the vicinity of Phe-39 as being crucial for heteroduplex DNA binding by Tag MutS protein.	NIDDK,GENET & BIOCHEM BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Biswas I, 1996, J BIOL CHEM, V271, P5040; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P311; CHODOSH LA, 1996, CURRENT PROTOCOLS MO, V12; Drapeau G R, 1976, Methods Enzymol, V45, P469; HICKE BJ, 1994, BIOCHEMISTRY-US, V33, P3364, DOI 10.1021/bi00177a030; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P2675, DOI 10.1093/nar/17.7.2675; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SU SS, 1988, J BIOL CHEM, V263, P6829; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; WILLIS MC, 1994, NUCLEIC ACIDS RES, V22, P4947, DOI 10.1093/nar/22.23.4947; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369	21	86	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23811	23817		10.1074/jbc.272.38.23811	http://dx.doi.org/10.1074/jbc.272.38.23811			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295328	hybrid			2022-12-27	WOS:A1997XX38100053
J	Misumi, Y; Sohda, M; Yano, A; Fujiwara, T; Ikehara, Y				Misumi, Y; Sohda, M; Yano, A; Fujiwara, T; Ikehara, Y			Molecular characterization of GCP170, a 170-kDa protein associated with the cytoplasmic face of the Golgi membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; BREFELDIN-A; SECRETORY PROTEINS; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GUANINE-NUCLEOTIDE; COATED VESICLES; COMPLEX; FUSION; CELLS	We have isolated a cDNA clone encoding a protein (designated GCP170) of 1530 amino acid residues with a calculated molecular mass of 170 kDa that is localized to the Golgi complex, Hydropathy analysis shows that GCP170 contains no NH2-terminal signal sequence nor a hydrophobic domain sufficient for participating in membrane localization. It is also predicted that GCP170 has characteristic secondary structures including an extremely long alpha-helical domain that likely forms a coiled-coil between non-coil domains at the NH2 and COOH termini, suggesting that the protein is organized as a globular head, a stalk, and a tail. Immunocytochemical observations revealed that GCP170 was localized to the Golgi complex and the cytoplasm, consistent with biochemical data indicating that the protein exits as a membrane-associated form and a soluble form. GCP170 was dissociated from the Golgi membrane in response to brefeldin A as rapidly as a coat protein complex of non-clathrin-coated vesicles (beta-COP, a subunit of coatomer), but did not co-localize with beta-COP on the Golgi membrane when examined by immunoelectron microscopy. The protein was detected as phosphorylated and unphosphorylated forms, of which the unphosphorylated form was more tightly associated with the Golgi membrane, When cells were extracted with 1% Triton X-100 under microtubule-stabilizing conditions, GCP170 remained in the cells in association with the Golgi complex. These results indicate that GCP170 is a peripheral membrane protein with a long coiled-coil domain that may be involved in the structural organization or stabilization of the Golgi complex.	FUKUOKA UNIV,SCH MED,DEPT BIOCHEM,JONAN KU,FUKUOKA 81480,JAPAN	Fukuoka University								ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DEALMEIDA JB, 1993, J CELL SCI, V106, P1239; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Fritzler MJ, 1995, J BIOL CHEM, V270, P31262, DOI 10.1074/jbc.270.52.31262; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; Funaki T, 1996, CELL STRUCT FUNCT, V21, P63, DOI 10.1247/csf.21.63; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MISUMI Y, 1990, J BIOCHEM-TOKYO, V108, P230, DOI 10.1093/oxfordjournals.jbchem.a123185; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MISUMI Y, 1988, BIOCHEM J, V249, P661, DOI 10.1042/bj2490661; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	49	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23851	23858		10.1074/jbc.272.38.23851	http://dx.doi.org/10.1074/jbc.272.38.23851			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295333	hybrid			2022-12-27	WOS:A1997XX38100058
J	Pregel, MJ; Storer, AC				Pregel, MJ; Storer, AC			Active site titration of the tyrosine phosphatases SHP-1 and PTP1B using aromatic disulfides - Reaction with the essential cysteine residue in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-2 DOMAINS; PHENYLARSINE OXIDE; SULFHYDRYL-GROUPS; PROTEIN; PURIFICATION; THIOL; PHOSPHORYLATION; INACTIVATION; EXCHANGE	Aromatic disulfides were found to inactivate truncated forms of the SHP-1 and PTP1B phosphatases by reaction with the essential active site cysteine residue. For truncated SHP-1 at pH 5.0, the reaction proceeded through an initial burst phase followed by a slower secondary phase. Our experiments demonstrated that the burst phase corresponded to the reaction of the aromatic disulfide with the active site cysteine. The magnitude of the burst phase was found to measure the active enzyme concentration, and the rate of the burst reflected the reactivity of the active site cysteine. The data were consistent with a mechanism in which an intramolecular disulfide is formed between the active site cysteine and a proximal cysteine during the burst reaction. Aromatic disulfides were found to react with the active site cysteines of full-length SHP-1 and truncated PTP1B also. Using vanadate to mask the active site cysteine, the active enzyme concentration could be assayed by comparing product yields for the reaction with aromatic disulfides in the presence and absence of vanadate at pH 8.0. These findings demonstrate the utility of aromatic disulfides as active site titrants and reactivity probes or tyrosine phosphatases.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,PHARMACEUT BIOTECHNOL SECTOR,MONTREAL,PQ H4P 2R2,CANADA	National Research Council Canada								BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Brocklehurst K., 1987, HYDROLYTIC ENZYMES, P39; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CASELLI A, 1994, J BIOL CHEM, V269, P24878; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; FERSHT A, 1985, ENZYME STRUCTURE MEC, P143; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLASHNER M, 1972, J BIOL CHEM, V247, P8114; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; JOSHI S, 1981, J BIOL CHEM, V256, P1112; KORODI I, 1986, BIOCHEMISTRY-US, V25, P6895, DOI 10.1021/bi00370a024; KUSSMANN M, 1995, METHOD ENZYMOL, V251, P430, DOI 10.1016/0076-6879(95)51146-6; LAU KHW, 1993, CRIT REV ONCOGENESIS, V4, P451; LI B, 1994, BIOCHEMISTRY-US, V33, P8594, DOI 10.1021/bi00194a026; LI J, 1995, BIOCHEMISTRY-US, V34, P15829, DOI 10.1021/bi00048a028; LOGAN TM, 1994, BIOCHEMISTRY-US, V33, P11087, DOI 10.1021/bi00203a005; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1991, J BIOL CHEM, V266, P19688; Pregel MJ, 1995, PROTEIN ENG, V8, P1309, DOI 10.1093/protein/8.12.1309; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RIPPA M, 1978, ARCH BIOCHEM BIOPHYS, V186, P406, DOI 10.1016/0003-9861(78)90452-6; SEEHRA JS, 1981, EUR J BIOCHEM, V114, P263, DOI 10.1111/j.1432-1033.1981.tb05145.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Singh R, 1993, CHEM SULPHUR CONTAIN, P633; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TSOU C, 1962, SCI SINICA, V11, P1535; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	38	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23552	23558		10.1074/jbc.272.38.23552	http://dx.doi.org/10.1074/jbc.272.38.23552			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295292	hybrid			2022-12-27	WOS:A1997XX38100017
J	Canovas, D; Vargas, C; IglesiasGuerra, F; Csonka, LN; Rhodes, D; Ventosa, A; Nieto, JJ				Canovas, D; Vargas, C; IglesiasGuerra, F; Csonka, LN; Rhodes, D; Ventosa, A; Nieto, JJ			Isolation and characterization of salt-sensitive mutants of the moderate halophile Halomonas elongata and cloning of the ectoine synthesis genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPOSON MUTAGENESIS; AMINO-ACID; EUBACTERIA; PLASMID; BACTERIA; SYSTEM; GENUS; OSMOLYTE	The moderate halophile Halomonas elongata Deustche Sammlung fur Mikroorganismen 3043 accumulated ectoine, hydroxyectoine, glutamate, and glutamine in response to osmotic stress (3 M NaCl), Two Tn1732-induced mutants, CHR62 and CHR63, that were severely affected in their salt tolerance were isolated, Mutant CHR62 could not grow above 0.75 at NaCl, and CHR63 did not grow above 1.5 M NaCl. These mutants did not synthesize ectoine but accumulated ectoine precursors, as shown by C-13 NMR and mass spectroscopy, Mutant CHR62 accumulated low levels of diaminobutyric acid, and mutant CHR63 accumulated high concentrations of N-gamma-acetyl-diaminobutyric acid, These results suggest that strain CHR62 could be defective in the gene for diaminobutyric acid acetyltransferase (ectB), and strain CHR63 could be defective in the gene for the ectoine synthase (ectC), Salt sensitivity of the mutants at 1.5-2.5 M NaCl could be partially corrected by cytoplasmic extracts of the wild-type strain, containing ectoine, and salt sensitivity of strain CHR62 could be partially repaired by the addition of extracts of strain CHR63, which contained N-gamma-acetyldiaminobutyric acid, This is the first evidence for the role of N-gamma-acetyldiaminobutyric acid as osmoprotectant, Finally, a cosmid from the H, elongata genomic library was isolated which complemented the Ect(-) phenotype of both mutants, indicating that it carried at least the genes ectB and ectC of the biosynthetic pathway of ectoine.	UNIV SEVILLE,FAC PHARM,DEPT MICROBIOL & PARASITOL,E-41012 SEVILLE,SPAIN; UNIV SEVILLE,FAC PHARM,DEPT ORGAN CHEM & PHARMACEUT CHEM,E-41012 SEVILLE,SPAIN; PURDUE UNIV,DEPT HORT,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	University of Sevilla; University of Sevilla; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Ventosa, Antonio/K-8239-2017; /AAA-4450-2019; Gutiérrez, Joaquín José Nieto/K-9974-2014; Vargas, Carmen/A-6283-2018; Cánovas, David/L-7628-2014	Ventosa, Antonio/0000-0002-7573-0556; /0000-0002-7203-5777; Gutiérrez, Joaquín José Nieto/0000-0001-8879-819X; Vargas, Carmen/0000-0002-4094-4319; Cánovas, David/0000-0002-7293-7332				Ausubel FM, 1988, MOL REPROD DEV; BENTOSA A, 1994, BACTERIAL DIVERSITY, P231; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Canovas D, 1996, J BACTERIOL, V178, P7221, DOI 10.1128/jb.178.24.7221-7226.1996; Clarke L, 1979, Methods Enzymol, V68, P396; COHEN G N, 1956, Ann Inst Pasteur (Paris), V91, P693; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; Davis R., 1980, ADV BACTERIAL GENETI; FERNANDEZCASTILLO R, 1992, J GEN MICROBIOL, V138, P1133, DOI 10.1099/00221287-138-6-1133; FernandezLinares L, 1996, LETT APPL MICROBIOL, V22, P169, DOI 10.1111/j.1472-765X.1996.tb01135.x; FOWDEN L, 1972, PHYTOCHEMISTRY, V11, P2271, DOI 10.1016/S0031-9422(00)88389-2; Galinski E A, 1995, Adv Microb Physiol, V37, P272, DOI 10.1016/S0065-2911(08)60148-4; GALINSKI EA, 1985, EUR J BIOCHEM, V149, P135, DOI 10.1111/j.1432-1033.1985.tb08903.x; KESSLER B, 1992, MOL GEN GENET, V233, P293, DOI 10.1007/BF00587591; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; KUNTE HJ, 1995, FEMS MICROBIOL LETT, V128, P293; Kushner D.J., 1988, HALOPHILIC BACTERIA, V1, P109; LISS I, 1962, PHYTOCHEMISTRY, V1, P87, DOI 10.1016/S0031-9422(00)88005-X; MELLADO E, 1995, J BACTERIOL, V177, P3443, DOI 10.1128/jb.177.12.3443-3450.1995; NIETO JJ, 1989, APPL ENVIRON MICROB, V55, P2385, DOI 10.1128/AEM.55.9.2385-2390.1989; PETERS P, 1990, FEMS MICROBIOL LETT, V71, P157; RHODES D, 1987, PLANT PHYSIOL, V84, P775, DOI 10.1104/pp.84.3.775; Sambrook J., 2002, MOL CLONING LAB MANU; SEVERIN J, 1992, J GEN MICROBIOL, V138, P1629, DOI 10.1099/00221287-138-8-1629; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; UBBEN D, 1986, GENE, V41, P145, DOI 10.1016/0378-1119(86)90093-4; VARGAS C, 1995, MOL GEN GENET, V246, P411, DOI 10.1007/BF00290444; Vargas C, 1997, SYST APPL MICROBIOL, V20, P173, DOI 10.1016/S0723-2020(97)80063-X; VENTOSA A, 1995, WORLD J MICROB BIOT, V11, P85, DOI 10.1007/BF00339138; VREELAND RH, 1980, INT J SYST BACTERIOL, V30, P485, DOI 10.1099/00207713-30-2-485; WOHLFARTH A, 1990, J GEN MICROBIOL, V136, P705, DOI 10.1099/00221287-136-4-705; WOHLFARTH A, 1993, APPL MICROBIOL BIOT, V39, P568, DOI 10.1007/BF00205053	32	67	76	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25794	25801		10.1074/jbc.272.41.25794	http://dx.doi.org/10.1074/jbc.272.41.25794			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325308	Green Published, hybrid			2022-12-27	WOS:A1997YA35800063
J	Higashi, S; Matsumoto, N; Iwanaga, S				Higashi, S; Matsumoto, N; Iwanaga, S			Conformation of factor VIIa stabilized by a labile disulfide bond (Cys-310-Cys-329) in the protease domain is essential for interaction with tissue factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-VII; CARBOXYGLUTAMIC ACID DOMAIN; FACTOR-BINDING; EXTRINSIC PATHWAY; CATALYTIC DOMAIN; CRYSTAL-STRUCTURE; COMPLEX; IDENTIFICATION; ACTIVATION; PURIFICATION	Unlike other trypsin-type serine proteases, zymogen-to-enzyme transition of conformation of factor VII apparently requires not only conversion of the zymogen to active form factor VIIa (VIIa) but also interaction of VIIa with tissue factor (TF), To determine the region of interaction that correlates with maturation of the Wa active site, we modified intramolecular disulfide bonds in VIIa and examined the interaction of the modified VIIa with soluble TF (sTF). We found that partial reduction and S-carboxamidomethylation of disulfide bonds in VIIa led to losses of amidolytic activity and the binding ability to sTF. To determine the sites of modification that associate with the loss of functions, partially S-carboxamidomethylated Ma was separated on a column of immobilized sTF, Each of the sTF-bound and sTF-unbound fractions and native VIIa was then digested by trypsin, and the digest was analyzed by reversed-phase high performance liquid chromatography, We found that reduction and S-carboxamidomethylation of a disulfide bond between Cys-310 and Cys-329 in the protease domain of VIIa led to loss of the binding ability with sTF, and the modification of a disulfide bond between Cys-340 and Cys-368 of VIIa led to loss of the amidolytic activity. In the three-dimensional structures of trypsinogen and trypsin, the disulfide bonds corresponding to Cys-340-Cys-368 and Cys-310-Cys-329 of Ma are, respectively, in and adjacent to the activation domain, which has flexible conformation in trypsinogen but not in trypsin. Furthermore, the crystal structure of human VIIa TF complex indicates that the region next to Cys-310-Cys-329 is in contact with sTF, We speculate that a regional flexibility, reflected by the labile nature of disulfide bonds of Cys-310-Cys-329 and Cys-340-Cys-368 in the protease domain, contributes to the inability of VIIa to attain the active conformation. Interaction of TF with this flexible region may stabilize the structure in a conformation similar to that of the active state of VIIa.	KYUSHU UNIV 33, FAC SCI, DEPT BIOL, FUKUOKA 81281, JAPAN; KYUSHU UNIV 33, GRAD SCH MED SCI, DEPT MOL BIOL, FUKUOKA 81281, JAPAN	Kyushu University; Kyushu University								Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BERNARDI F, 1994, BRIT J HAEMATOL, V86, P610, DOI 10.1111/j.1365-2141.1994.tb04793.x; Bhardwaj D, 1996, J BIOL CHEM, V271, P30685, DOI 10.1074/jbc.271.48.30685; BODE W, 1976, J MOL BIOL, V106, P325, DOI 10.1016/0022-2836(76)90089-9; CHANG JY, 1995, BIOCHEMISTRY-US, V34, P12227, DOI 10.1021/bi00038a017; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; HIGASHI S, 1990, J BIOCHEM-TOKYO, V108, P654, DOI 10.1093/oxfordjournals.jbchem.a123258; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; MORRISSEY JH, 1993, BLOOD, V81, P734; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OBRIEN DP, 1991, BLOOD, V78, P132; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TAKAYENOKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1145, DOI 10.1016/0006-291X(91)92058-R; TAKEYA H, 1988, J BIOL CHEM, V263, P14868; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; Varallyay V, 1997, BIOCHEM BIOPH RES CO, V230, P592, DOI 10.1006/bbrc.1996.6009; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	35	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25724	25730		10.1074/jbc.272.41.25724	http://dx.doi.org/10.1074/jbc.272.41.25724			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325298	hybrid			2022-12-27	WOS:A1997YA35800053
J	Sienaert, I; Missiaen, L; DeSmedt, H; Parys, JB; Sipma, H; Casteels, R				Sienaert, I; Missiaen, L; DeSmedt, H; Parys, JB; Sipma, H; Casteels, R			Molecular and functional evidence for multiple Ca2+-binding domains in the type 1 inositol 1,4,5,-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE; INDUCED CALCIUM-RELEASE; LIGAND-BINDING SITE; LUMINAL CA2+; TRISPHOSPHATE RECEPTOR; CYTOSOLIC CA2+; CEREBELLAR MICROSOMES; POSSIBLE MECHANISM; SMOOTH-MUSCLE; CELLS	Structural and functional analyses were used to investigate the regulation of the inositol 1,4,5-trisphosphate (InsP(3)) receptor (InsP(3)R) by Ca2+. To define the structural determinants for Ca2+ binding, cDNAs encoding GST fusion proteins that covered the complete linear cytosolic sequence of the InsP(3)R-1 were expressed in bacteria, The fusion proteins were screened for Ca2+ and ruthenium red binding through the use of Ca-45(2+) and ruthenium red overlay procedures, Six new cytosolic Ca2+-binding regions were detected on the InsP(3)R in addition to the one described earlier (Sienaert, I., De Smedt, H., Parys, J. B., Missiaen, L., Vanlingen, S., Sipma, H., and Casteels, R. (1996) J, Biol, Chem. 271, 27005-27012), Strong Ca-45(2+) and ruthenium red binding domains were localized in the N-terminal region of the InsP(3)R as follows: two Ca2+-binding domains were located within the InsP(3)-binding domain, and three Ca2+ binding stretches were localized in a 500-amino acid region just downstream of the InsP(3)-binding domain, A sixth Ca2+-binding stretch was detected in the proximity of the calmodulin-binding domain, Evidence for the involvement of multiple Ca2+-binding sites in the regulation of the InsP(3)R was obtained from functional studies on permeabilized A7r5 cells, in which we characterized the effects of Ca2+ and Sr2+ on the EC50 and cooperativity of the InsP(3)-induced Ca2+ release, The activation by cytosolic Ca2+ was due to a shift in EC50 toward lower InsP(3) concentrations, and this effect was mimicked by Sr2+. The inhibition by cytosolic Ca2+ was caused by a decrease in cooperativity and by a shift in EC50 toward higher InsP(3) concentrations, The effect on the cooperativity occurred at lower Ca2+ concentrations than the inhibitory effect on the EC50. In addition, Sr2+ mimicked the effect of Ca2+ on the cooperativity but not the inhibitory effect on the EC50. The different [Ca2+] and [Sr2+] dependencies suggest that three different cytosolic interaction sites were involved, Luminal Ca2+ stimulated the release without affecting the Hill coefficient or the EC50, excluding the involvement of one of the cytosolic Ca2+-binding sites. We conclude that multiple Ca2+-binding sites are localized on the InsP(3)R-1 and that at least four different Ca2+-interaction sites may be involved in the complex feedback regulation of the release by Ca2+.			Sienaert, I (corresponding author), KATHOLIEKE UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG O-N, HERESTR 49, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				BENEVOLENSKY D, 1994, BIOCHEM J, V299, P631, DOI 10.1042/bj2990631; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CARDY TJA, 1997, J PHYSIOL-LONDON, V449, pP2; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; DeSmedt H, 1997, BIOCHEM J, V322, P575; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Dufour JF, 1997, J BIOL CHEM, V272, P2675, DOI 10.1074/jbc.272.5.2675; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GAMBERUCCI A, 1995, CELL CALCIUM, V17, P431, DOI 10.1016/0143-4160(95)90089-6; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HANNAERTMERAH Z, 1995, CELL CALCIUM, V18, P390, DOI 10.1016/0143-4160(95)90054-3; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Missiaen L, 1997, BIOCHEM J, V325, P661, DOI 10.1042/bj3250661; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; Missiaen L, 1996, J BIOL CHEM, V271, P12287, DOI 10.1074/jbc.271.21.12287; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; Niki I, 1996, J BIOCHEM, V120, P685; NUNN DL, 1992, MOL PHARMACOL, V41, P115; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1993, J BIOL CHEM, V268, P25206; PIETRI F, 1990, J BIOL CHEM, V265, P17478; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; SUGIYAMA T, 1995, AM J PHYSIOL-CELL PH, V269, pC813, DOI 10.1152/ajpcell.1995.269.3.C813; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; TAYLOR CW, 1995, J MEMBRANE BIOL, V145, P109; VANDELDEN C, 1993, J BIOL CHEM, V268, P12443; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	63	115	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25899	25906		10.1074/jbc.272.41.25899	http://dx.doi.org/10.1074/jbc.272.41.25899			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325322	hybrid			2022-12-27	WOS:A1997YA35800077
J	Bodi, I; Yamaguchi, H; Hara, M; He, M; Schwartz, A; Varadi, G				Bodi, I; Yamaguchi, H; Hara, M; He, M; Schwartz, A; Varadi, G			Molecular studies on the voltage dependence of dihydropyridine action on L-type Ca2+ channels - Critical involvement of tyrosine residues in motif IIIS6 and IVS6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; ALPHA-1 SUBUNIT; FUNCTIONAL EXPRESSION; 1,4-DIHYDROPYRIDINE SENSITIVITY; BINDING DOMAINS; CHARGE MOVEMENT; BETA-SUBUNIT; IDENTIFICATION; DETERMINANTS; RECEPTOR	The interaction site(s) of dihydropyridine (DHP) antagonists and agonists have been identified by site-directed mutagenesis and localized on motifs IIIS5, IIIS6, and IVS6 of L-type voltage gated calcium channels, In this study, we investigated the voltage-dependent action of DHPs with mutants of the IIIS6 and IVS6 segments of a cardiac calcium channel, Tyrosine residues in both motifs (Tyr(1178) and Tyr(1489)) strongly contributed to the action of DHP agonists and antagonists. When these two sites mere mutated, the communication between the voltage sensor and the DHP interaction site(s) was substantially impaired. In contrast, mutants of a nearby Ile (Ile(1182)) had much less influence on DHP agonist and antagonist interaction, and the voltage dependence of DHP antagonists was very similar to that of the wild type. The effect of a mutating of Ile(1182), on agonist or antagonist action, however, depended strongly on the type of amino acid change, When Ile(1182) was substituted with alanine, small changes were noted for DHP agonist and antagonist action, Changing this site into phenylalanine, however, significantly decreased the action of the DHP antagonist. These data show that Ile(1182) can preferentially interact with DHP antagonists, but has a lesser contribution in agonist interaction. Thus, even though the agonist and antagonist interaction sites for DHPs with L-type calcium channels may overlap, some amino acids in this site may exhibit a preference for either DHP enantiomers.	UNIV CINCINNATI,COLL MED,INST MOL PHARMACOL & BIOPHYS,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL043231, P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [5R37-HL43231-08, P01 HL22619-19] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BROWN AM, 1986, J PHYSIOL-LONDON, V379, P495, DOI 10.1113/jphysiol.1986.sp016266; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hille B., 1992, IONIC CHANNELS EXCIT; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; KALASZ H, 1993, FEBS LETT, V331, P177, DOI 10.1016/0014-5793(93)80321-K; KAMP TJ, 1989, CIRC RES, V64, P338, DOI 10.1161/01.RES.64.2.338; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; LANGS DA, 1990, J COMPUT AID MOL DES, V4, P215, DOI 10.1007/BF00125011; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; SANGUINETTI MC, 1986, J GEN PHYSIOL, V88, P369, DOI 10.1085/jgp.88.3.369; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SLISH DF, 1989, FEBS LETT, V250, P509, DOI 10.1016/0014-5793(89)80786-0; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; Strube C, 1996, BIOPHYS J, V71, P2531, DOI 10.1016/S0006-3495(96)79446-8; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; WATANABE T, 1993, FEBS LETT, V334, P261, DOI 10.1016/0014-5793(93)80690-V; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	42	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24952	24960		10.1074/jbc.272.40.24952	http://dx.doi.org/10.1074/jbc.272.40.24952			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312099	hybrid			2022-12-27	WOS:A1997XY97000038
J	Chuang, PI; Young, BA; Thiagarajan, RR; Cornejo, C; Winn, RK; Harlan, JM				Chuang, PI; Young, BA; Thiagarajan, RR; Cornejo, C; Winn, RK; Harlan, JM			Cytoplasmic domain of E-selectin contains a non-tyrosine endocytosis signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION MOLECULE-1; HUMAN ENDOTHELIAL-CELLS; DI-LEUCINE MOTIF; LYSOSOMAL ACID-PHOSPHATASE; PLASMA-MEMBRANE; INTERNALIZATION SIGNAL; P-SELECTIN; TRANSFERRIN RECEPTOR; SORTING SIGNALS; EXPRESSION	E-selectin is an activation-dependent, endothelial cell-restricted adhesion molecule that is internalized and degraded rapidly once expressed on the cell surface. Tyrosine-containing structural motifs play an important role in the internalization of a number of integral proteins, and the membrane-proximal E-selectin cytoplasmic tyrosine residue (Tyr(582)) conforms to the endocytosis motif proposed previously, To determine the endocytosis motif in E-selectin, we selectively introduced truncation, substitution and deletion mutations to the cytoplasmic tail of E-selectin. We analyzed the internalization kinetics of surface-expressed wild-type and mutant E-selectin constructs in transiently transfected Chinese hamster ovary cells using I-125-labeled E-selectin monoclonal antibody (I-126-P6E2) in an acid elution assay. Interestingly, truncation immediately membrane proximal to Tyr(582) (Delta DGS construct) did not alter internalization kinetics significantly (Delta DGS versus wild-type, mean surface half-life = 42 versus 45 min, respectively). Thus, it appears that the tyrosine residues are not required for internalization of E-selectin. Additional analyses indicated that Ser(581) was necessary but alone was insufficient for surface E-selectin endocytosis. Thus, we conclude that there exists a novel non-tyrosine-containing endocytosis signal in the cytoplasmic tail which in volves Ser(581) and residues membrane-proximal to it.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chuang, PI (corresponding author), UNIV WASHINGTON,DIV PULM & CRIT CARE MED,DEPT MED,BOX 356522,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542, P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645, HL30542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBASSI O, 1993, J CLIN INVEST, V92, P2719, DOI 10.1172/JCI116889; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CARTWRIGHT JE, 1995, EXP CELL RES, V217, P329, DOI 10.1006/excr.1995.1094; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISSEKUTZ AC, 1993, IMMUNOLOGY, V79, P600; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; Kansas GS, 1996, J IMMUNOL, V157, P321; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUIJPERS TW, 1994, J IMMUNOL, V152, P5060; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LAWRENCE MB, 1993, J IMMUNOL, V151, P6338; LECA G, 1995, J IMMUNOL, V154, P1069; LEEUWENBERG JFM, 1990, J IMMUNOL, V145, P2110; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NORRIS P, 1991, J INVEST DERMATOL, V96, P763, DOI 10.1111/1523-1747.ep12471720; OGATA S, 1994, J BIOL CHEM, V269, P5210; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; OLOFSSON AM, 1994, BLOOD, V84, P2749, DOI 10.1182/blood.V84.8.2749.bloodjournal8482749; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; ROST B, 1995, PROTEINS, V23, P295, DOI 10.1002/prot.340230304; SETIADI H, 1995, J BIOL CHEM, V270, P26818, DOI 10.1074/jbc.270.45.26818; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; SMEETS EF, 1993, EUR J IMMUNOL, V23, P147, DOI 10.1002/eji.1830230124; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; SPERTINI O, 1991, LEUKEMIA, V5, P300; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TROWBRIDGE IS, 1992, J INORG BIOCHEM, V47, P209, DOI 10.1016/0162-0134(92)84066-V; VERREY F, 1990, CELL REGUL, V1, P471, DOI 10.1091/mbc.1.6.471; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; VONASMUTH EJU, 1992, EUR J IMMUNOL, V22, P2519, DOI 10.1002/eji.1830221009; WILDE A, 1994, J BIOL CHEM, V269, P7131; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445	57	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24813	24818		10.1074/jbc.272.40.24813	http://dx.doi.org/10.1074/jbc.272.40.24813			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312078	hybrid			2022-12-27	WOS:A1997XY97000017
J	Corbett, SA; Lee, L; Wilson, CL; Schwarzbauer, JE				Corbett, SA; Lee, L; Wilson, CL; Schwarzbauer, JE			Covalent cross-linking of fibronectin to fibrin is required for maximal cell adhesion to a fibronectin-fibrin matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA FACTOR-XIIIA; COLD-INSOLUBLE GLOBULIN; COAGULATION FACTOR-XIII; PIG LIVER-ENZYME; STRUCTURAL FEATURES; BLOOD-COAGULATION; STABILIZING FACTOR; DOMAIN-STRUCTURE; TRANSGLUTAMINASES; BINDING	In a blood clot, fibrin and plasma fibronectin (pFN) are covalently cross linked by activated factor XIII (factor XIIIa) to form pFN-fibrin multimers, To determine the functional significance of covalent pFN-fibrin interactions, we have developed an in vitro model which allows the incorporation of recombinant FN (recFN) molecules into a covalently cross-linked recFN-fibrin matrix, Using the baculovirus expression system, we have expressed recFN monomers composed of the amino-terminal 70-kDa region and the first 11 type III repeats (WT) with mutations in the glutamines at positions 3 and 4 (Q2) or at 3, 4, and 16 (Q3), Examination of the covalent incorporation of these recFNs into fibrin clots confirms that glutamines 3 and 4 are major participants in FN-fibrin cross-linking as the mutation of these sites reduces cross-linking efficiency by 65%. Additional mutation of the glutamine at position 16, however, eliminates >99% of cross-linking suggesting that it also may be factor XIIIa reactive, When the Q3 recFN-fibrin clots were used as substrates for cell adhesion, there was a decrease in both cell attachment and spreading when compared with the WT recFN-fibrin clots, These data demonstrate that for maximal cell attachment to a FN-fibrin clot, FN must be cross-linked to fibrin by factor XIIIa.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT SURG,NEW BRUNSWICK,NJ 08703; WASHINGTON UNIV,SCH MED,DIV DERMATOL,ST LOUIS,MO 63110	Princeton University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Washington University (WUSTL)				Schwarzbauer, Jean/0000-0003-1012-7593	NCI NIH HHS [CA-44627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044627] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; Chen R, 1971, Biochemistry, V10, P4487; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Clark RAF, 1989, CURR OPIN CELL BIOL, V1, P1000, DOI 10.1016/0955-0674(89)90072-0; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; Corbett SA, 1996, BLOOD, V88, P158; Dalton BA, 1996, BIOTECHNIQUES, V21, P298; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; ERICKSON HP, 1983, J BIOL CHEM, V258, P4539; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRINNELL F, 1980, CELL, V19, P517, DOI 10.1016/0092-8674(80)90526-7; HAYASHI M, 1983, J BIOL CHEM, V258, P3332; Hynes RO, 1990, FIBRONECTINS; KESKIOJA J, 1976, CELL, V9, P29, DOI 10.1016/0092-8674(76)90049-0; KNOX P, 1986, J CELL BIOL, V102, P2318, DOI 10.1083/jcb.102.6.2318; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUKA YV, 1994, J BIOL CHEM, V269, P9539; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; MORTENSEN SB, 1981, FEBS LETT, V129, P314, DOI 10.1016/0014-5793(81)80191-3; MOSESSON M W, 1992, Seminars in Hematology, V29, P177; MOSHER DF, 1976, J BIOL CHEM, V251, P1639; Mosher DF, 1989, FIBRONECTIN; ODERMATT E, 1989, FIBRONECTIN, P25; POTTS JR, 1994, CURR OPIN CELL BIOL, V6, P648, DOI 10.1016/0955-0674(94)90090-6; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SEKIGUCHI K, 1983, J BIOL CHEM, V258, P3967; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAMAKI T, 1982, J BIOL CHEM, V257, P4767; TRAN H, 1995, J BIOL CHEM, V270, P19458, DOI 10.1074/jbc.270.33.19458; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WILSON CL, 1992, J CELL BIOL, V119, P923, DOI 10.1083/jcb.119.4.923	42	103	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24999	25005		10.1074/jbc.272.40.24999	http://dx.doi.org/10.1074/jbc.272.40.24999			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312106	hybrid			2022-12-27	WOS:A1997XY97000045
J	Gardner, PR; Costantino, G; Szabo, C; Salzman, AL				Gardner, PR; Costantino, G; Szabo, C; Salzman, AL			Nitric oxide sensitivity of the aconitases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-RESONANCE CHARACTERIZATION; ACTIVE-SITE RESIDUES; ESCHERICHIA-COLI; MAMMALIAN-CELLS; 4FE-4S CLUSTER; IRON; SUPEROXIDE; BINDING; PEROXYNITRITE; GLUTATHIONE	Aconitases are important cellular targets of nitric oxide (NO.) toxicity, and NO.-derived species, rather than NO. per se, have been proposed to mediate their inactivation, NO.-mediated inactivation of the Escherichia coli aconitase and the porcine mitochondrial aconitase was investigated. In E. coli, aconitase activity decreased by similar to 70% during a 2-h exposure to an atmosphere containing 120 ppm NO. in N-2. The NO.-inactivated aconitase reactivated poorly in E. coli under anaerobic or aerobic conditions, Elevated superoxide dismutase activity did not affect the aerobic inactivation of aconitase by NO., thus indicating a limited role of the NO.- and superoxide-derived species peroxynitrite. Glutathione-deficient and glutathione-containing E. coli were comparably sensitive to NO.-mediated aconitase inactivation, thus excluding the participation of S-nitrosoglutathione or more oxidizing NO.-derived species, NO. progressively decreased aconitase activity in extracts in the presence of substrates, and inactivation was greatest at an acidic pH with cis-aconitate. The porcine mitochondrial aconitase was sensitive to NO. when exposed at pH 6.5, but not at pH 7.5, and irreversible inactivation occurred during catalysis, The requirement of an acidic pH or substrates for sensitivity may explain the reported resistance of aconitases to NO. in vitro (Castro, L., Rodriguez, M., and Radi, R. (1994) J. Biol. Chem. 269, 29409-29415; Hausladen, A., and Fridovich, I, (1994) J. Biol, Chem. 269, 29405-29408), An S-nitrosation of the aconitase [4Fe-4S] center catalyzed by the solvent-exposed electron withdrawing iron atom (Fe-a) is proposed.	CHILDRENS HOSP, MED CTR, DIV CRIT CARE, CINCINNATI, OH 45229 USA	Cincinnati Children's Hospital Medical Center			Szabo, Csaba/ABG-2644-2021; Szabo, Csaba/D-1882-2013	Gardner, Paul/0000-0001-8189-0903				APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P1, DOI 10.1016/0304-4165(75)90205-6; BENNETT B, 1995, EUR J BIOCHEM, V233, P317, DOI 10.1111/j.1432-1033.1995.317_1.x; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CZAPSKI G, 1995, FREE RADICAL BIO MED, V19, P785, DOI 10.1016/0891-5849(95)00081-8; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, P162; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; Drapier JC, 1996, METHOD ENZYMOL, V269, P26; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; DRAPIER JC, 1994, J IMMUNOL, V14, P2829; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1993, J BIOL CHEM, V268, P12958; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GORETSKI J, 1990, J BIOL CHEM, V265, P11535; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; Hobbs AJ, 1996, METHOD ENZYMOL, V269, P134; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; JI XB, 1988, BIOCHEM BIOPH RES CO, V157, P106, DOI 10.1016/S0006-291X(88)80018-4; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Maniatis T., 1982, MOL CLONING; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROSE IA, 1967, J BIOL CHEM, V242, P1870; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SALZMAN AL, 1994, AM J PHYSIOL, V266, pG633, DOI 10.1152/ajpgi.1994.266.4.G633; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; STADLER J, 1991, ARCH SURG-CHICAGO, V126, P186; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TELSER J, 1986, J BIOL CHEM, V261, P4840; VANDENBROEK PJ, 1989, REV INFECT DIS, V11, P213; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; ZHENG L, 1992, J BIOL CHEM, V267, P7895	50	200	204	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25071	25076		10.1074/jbc.272.40.25071	http://dx.doi.org/10.1074/jbc.272.40.25071			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312115	hybrid			2022-12-27	WOS:A1997XY97000054
J	Osuga, Y; Hayashi, M; Kudo, M; Conti, M; Kobilka, B; Hsueh, AJW				Osuga, Y; Hayashi, M; Kudo, M; Conti, M; Kobilka, B; Hsueh, AJW			Co-expression of defective luteinizing hormone receptor fragments partially reconstitutes ligand-induced signal generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN CHORIOGONADOTROPIN RECEPTOR; FOLLICLE-STIMULATING-HORMONE; PROTEIN-COUPLED RECEPTORS; MOLECULAR-CLONING; CHORIONIC-GONADOTROPIN; THYROTROPIN RECEPTOR; ADRENERGIC-RECEPTORS; GRANULOSA-CELLS; HIGH-AFFINITY; ACTIVATION	Gonadotropin receptors are unique members of the seven-transmembrane (TM), G protein-coupled receptor family with a large extracellular (EC) sequence forming the high-affinity ligand binding domain. In a patient with Leydig cell hypoplasia, we identified a mutant LH receptor that is truncated at TM5. This protein retains limited ligand binding ability but cannot mediate cAMP responses, To study interactions between receptor fragments defective in either ligand binding or signal transduction, we co-expressed this truncated receptor together with a chimeric receptor containing the EC region of the FSH receptor and the TM region of the LH receptor. Although the chimeric receptor could not respond to human chorionic gonadotropin in producing cAMP, co-expression with the truncated LH receptor allowed partial restoration of ligand signaling through intermolecular interactions, In addition, co-expression of the same truncated LH receptor with an N-terminally truncated LH receptor that lacked the EC ligand binding domain also partially restored ligand signaling, Further shortening of the TM region in the mutant receptor found in the patient indicated that the EC domain and TM1 were sufficient for interactions with the N terminally truncated receptor. In contrast, co-expression of the N terminally truncated receptor together with cell-associated or soluble EC region of the LH receptor did not allow ligand signaling, Unlike thrombin receptors, co-expression of the anchored EC region of the LH receptor together with the N-terminally truncated receptor did not allow ligand signaling despite moderate levels of human chorionic gonadotropin binding in transfected cells, These studies demonstrate that the co-expression of binding (+)/signaling (-) and binding (-)/signaling (+) receptor fragments partially restores ligand-induced signal generation and indicate the importance of TM1 of the LH receptor in the proper orientation of the EC ligand binding domain.	STANFORD UNIV, SCH MED, DEPT OBSTET & GYNECOL, DIV REPROD BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NICHD NIH HHS [HD-23273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD023273, R01HD023273] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Bousfield George R., 1994, P1749; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN J, 1994, J BIOL CHEM, V269, P16041; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HSUEH AJW, 1992, TRENDS ENDOCRIN MET, V3, P164, DOI 10.1016/1043-2760(92)90166-X; HSUEH AJW, 1989, RECENT PROG HORM RES, V45, P209; HUANG KS, 1981, J BIOL CHEM, V256, P3802; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1993, J BIOL CHEM, V268, P22971; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; LAUE L, 1995, HUM MOL GENET, V4, P1429, DOI 10.1093/hmg/4.8.1429; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MIYACHI Y, 1972, J CLIN ENDOCR METAB, V34, P23, DOI 10.1210/jcem-34-1-23; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ryu KS, 1996, MOL CELL ENDOCRINOL, V125, P93, DOI 10.1016/S0303-7207(96)03951-2; SALESSE R, 1991, BIOCHIMIE, V73, P109, DOI 10.1016/0300-9084(91)90083-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WONG SKF, 1990, J BIOL CHEM, V265, P6219; XIE YB, 1990, J BIOL CHEM, V265, P21411	46	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25006	25012		10.1074/jbc.272.40.25006	http://dx.doi.org/10.1074/jbc.272.40.25006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312107	hybrid			2022-12-27	WOS:A1997XY97000046
J	Cuisset, L; Tichonicky, L; Jaffray, P; Delpech, M				Cuisset, L; Tichonicky, L; Jaffray, P; Delpech, M			The effects of sodium butyrate on transcription are mediated through activation of a protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIA CELLS; FLOW CYTOMETRIC DETECTION; OKADAIC ACID; HISTONE H1-DEGREES; MESSENGER-RNA; ANNEXIN-V; PHOSPHATIDYLSERINE EXPRESSION; CULTURED-CELLS; HEPATOMA-CELLS; TUMOR-CELLS	In this study we have investigated the molecular mechanism by which sodium butyrate modulates gene expression when added to cultured cells, As a model system we used hepatoma tissue culture cells in which sodium butyrate treatment increases histone H1 degrees mRNA level and decreases c-myc mRNA level. Because we observed that stimulation of histone H1 degrees gene expression could take place in the absence of protein neosynthesis, we hypothesized that sodium butyrate induced a posttranslational modification of a factor involved in the transcription process. Using different types Of well known kinase and phosphatase inhibitors, we studied the implication of kinase or phosphatase activity in this pathway. Interestingly, cell treatment with patent serine-threonine-phosphatase inhibitors, calyculin A or okadaic acid, prevented the regulation of both histone H1 degrees and c-myc gene expressions by sodium butyrate, On the other hand, the tyrosine phosphatase inhibitor, vanadate, or the protein kinase C inhibitor, staurosporine, did not significantly modify sodium butyrate effects. Using protein phosphatase I and 2A for in vitro assays, we found a 45% increase of phosphatase activity after cell treatment by sodium butyrate, possibly due to a protein phosphatase I-type protein phosphatase. These data strongly suggest that signaling pathway(s) triggered by sodium butyrate to modulate gene expression involve(s) a serine-threonine-phosphatase activity.	UNIV PARIS 05, ICGM,EA 1501,FAC MED COCHIN PORT ROYAL, LAB BIOL MOL CELLULES EUCARYOTES, F-75014 PARIS, FRANCE; HOP COCHIN, BIOCHIM LAB A, F-75014 PARIS, FRANCE	UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite								ALONSO A, 1988, EMBO J, V7, P3003, DOI 10.1002/j.1460-2075.1988.tb03163.x; BOHAN C, 1987, BIOCHEM BIOPH RES CO, V148, P899, DOI 10.1016/S0006-291X(87)80217-6; BOIX J, 1992, EXP CELL RES, V201, P531, DOI 10.1016/0014-4827(92)90306-S; BROCARD MP, 1994, EUR J BIOCHEM, V221, P421, DOI 10.1111/j.1432-1033.1994.tb18754.x; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DEXTER DL, 1981, DIFFERENTIATION, V18, P115, DOI 10.1111/j.1432-0436.1981.tb01111.x; DYSON JED, 1992, BRIT J CANCER, V65, P803, DOI 10.1038/bjc.1992.172; FRIEND C, 1987, CANCER RES, V47, P378; GIRARDOT V, 1994, EUR J BIOCHEM, V224, P885, DOI 10.1111/j.1432-1033.1994.00885.x; GOLUB EI, 1991, AIDS, V5, P663, DOI 10.1097/00002030-199106000-00004; GOPE R, 1993, CELL MOL BIOL, V39, P589; GORKA C, 1995, EXP CELL RES, V217, P528, DOI 10.1006/excr.1995.1118; GUPTA S, 1994, GROWTH FACTORS, V10, P171, DOI 10.3109/08977199409000235; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HENNEBERRY RC, 1976, EXP CELL RES, V103, P55, DOI 10.1016/0014-4827(76)90240-8; HERSHKO A, 1971, J BIOL CHEM, V246, P710; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; HERZ F, 1990, EXP CELL RES, V188, P50, DOI 10.1016/0014-4827(90)90276-G; HOCHHUTH C, 1990, DIFFERENTIATION, V43, P212, DOI 10.1111/j.1432-0436.1990.tb00448.x; HOCHHUTH C, 1992, J CELL BIOCHEM, V50, P316, DOI 10.1002/jcb.240500312; HOMBURG CHE, 1995, BLOOD, V85, P532; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KHOCHBIN S, 1993, GENE, V128, P173, DOI 10.1016/0378-1119(93)90560-P; KLUMPP S, 1990, EMBO J, V9, P685, DOI 10.1002/j.1460-2075.1990.tb08160.x; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KRESS H, 1986, NUCLEIC ACIDS RES, V14, P7189, DOI 10.1093/nar/14.18.7189; Kruh J., 1995, P275; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LEIBOVITCH MP, 1979, BIOCHEM BIOPH RES CO, V87, P896, DOI 10.1016/0006-291X(79)92042-4; MULLINS TD, 1991, PANCREAS, V6, P578, DOI 10.1097/00006676-199109000-00012; PANYIM S, 1969, BIOCHEM BIOPH RES CO, V37, P1042, DOI 10.1016/0006-291X(69)90237-X; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; ROUSSEAU D, 1992, EUR J BIOCHEM, V208, P775, DOI 10.1111/j.1432-1033.1992.tb17247.x; SADAIE MR, 1994, VIROLOGY, V202, P513, DOI 10.1006/viro.1994.1372; SAEMUNDSEN AK, 1980, VIROLOGY, V107, P557, DOI 10.1016/0042-6822(80)90326-8; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; THOMPSON EB, 1966, P NATL ACAD SCI USA, V56, P296, DOI 10.1073/pnas.56.1.296; TICHONICKY L, 1990, BIOL CELL, V69, P65, DOI 10.1016/0248-4900(90)90329-2; TOSCANI A, 1988, ONCOGENE RES, V3, P223; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VANWIJK R, 1981, IN VITRO CELL DEV B, V17, P859; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WRIGHT JA, 1973, EXP CELL RES, V78, P456, DOI 10.1016/0014-4827(73)90091-8; WRIGHT PS, 1986, ARCH BIOCHEM BIOPHYS, V248, P243, DOI 10.1016/0003-9861(86)90422-4; ZLATANOVA J, 1994, FASEB J, V8, P1260, DOI 10.1096/fasebj.8.15.8001738	50	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24148	24153		10.1074/jbc.272.39.24148	http://dx.doi.org/10.1074/jbc.272.39.24148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305863	hybrid			2022-12-27	WOS:A1997XY51500014
J	Gavva, NR; Gavva, R; Ermekova, K; Sudol, M; Shen, CKJ				Gavva, NR; Gavva, R; Ermekova, K; Sudol, M; Shen, CKJ			Interaction of WW domains with hematopoietic transcription factor p45/NF-E2 and RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN GENE-EXPRESSION; PORPHOBILINOGEN DEAMINASE GENE; LOCUS-CONTROL REGION; FACTOR NF-E2; CHROMATIN STRUCTURE; ERYTHROID PROMOTER; IN-VIVO; PROTEIN; CELLS; PURIFICATION	NF-E2 is an erythroid-specific transcription factor required for expression of several erythroid-specific genes. By Far-Western blotting and yeast two-hybrid assay, we demonstrate that p45, the large subunit of NF-ES, is capable of binding to a specific set of WW domain containing proteins, including the ubiquitin ligase hRPF1. This binding is mediated through the interaction between the WW domains and a PY motif located within the amino-terminal region of p45. Interestingly, the carboxyl-terminal domain of mammalian RNA polymerase II binds a similar set of WW domains to which p45 interacts with. We discuss the data in terms of possible new pathways through which the processes of transcriptional regulation by NF-EB could be regulated in erythroid and megakaryote cells.	UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN	University of California System; University of California Davis; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Academia Sinica - Taiwan					NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER; NCI NIH HHS [CA01605, CA45757] Funding Source: Medline; NIDDK NIH HHS [DK29800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; ZHANG QY, 1995, J BIOL CHEM, V270, P8501, DOI 10.1074/jbc.270.15.8501; [No title captured]	42	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24105	24108		10.1074/jbc.272.39.24105	http://dx.doi.org/10.1074/jbc.272.39.24105			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305852	hybrid			2022-12-27	WOS:A1997XY51500003
J	Jho, EH; Davis, RJ; Malbon, CC				Jho, EH; Davis, RJ; Malbon, CC			c-Jun amino-terminal kinase is regulated by G alpha(12)/G alpha(13) and obligate for differentiation of P19 embryonal carcinoma cells by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; SIGNAL-TRANSDUCTION PATHWAY; MAMMALIAN-CELLS; DROSOPHILA; APOPTOSIS; JNK; TRANSFORMATION; MORPHOGENESIS; G-ALPHA(12); CASCADE	Retinoic acid induces P19 mouse embryonal carcinoma cells to differentiate to endoderm and increases expression of the heterotrimeric G-protein subunits G alpha(12) and G alpha(13). Retinoic acid was found to induce differentiation and sustained activation of c-Jun amino-terminal kinase, but not of ERK1,S or of p38 mitogen-activated protein kinases. Much like retinoic acid, expression of constitutively active forms of G alpha(12) and G alpha(13) induced differentiation and constitutive activation of c-Jun amino-terminal kinase. Expression of the dominant negative form of c-Jun amino-terminal kinase 1 blocked both the activation of c-Jun amino-terminal kinase and the induction of endodermal differentiation in the presence of retinoic acid. These data implicate c-Jun amino-terminal kinase as a downstream element of activation of G alpha(12) or G alpha(13) obligate for re0inoie acid-induced differentiation.	SUNY STONY BROOK, MED CTR,DEPT MOL PHARMACOL,SCH MED, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA; UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, WORCESTER, MA 01605 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			malbon, craig/ABF-3604-2020	Jho, Eek-hoon/0000-0003-2414-6234	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30111] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; GRAHAM CF, 1978, NATURE, V272, P355; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; Heasley LE, 1996, MOL CELL BIOL, V16, P648; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malbon CC, 1997, BIOCHEM PHARMACOL, V53, P1, DOI 10.1016/S0006-2952(96)00662-4; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RINCON M, 1997, GENES FUNCT, V1, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	47	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24468	24474		10.1074/jbc.272.39.24468	http://dx.doi.org/10.1074/jbc.272.39.24468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305908	hybrid			2022-12-27	WOS:A1997XY51500059
J	Lin, BZ; Pilch, PF; Kandror, KV				Lin, BZ; Pilch, PF; Kandror, KV			Sortilin is a major protein component of Glut4-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED PROTEIN; GLUCOSE-TRANSPORT; 3T3-L1 PREADIPOCYTES; CELL-SURFACE; AMINOPEPTIDASE; TRAFFICKING; COMPARTMENT; EXPRESSION; INDUCTION; TISSUES	In fat and skeletal muscle cells, glucose transporter isoform 4 (Glut4) is translocated to the cell surface in response to insulin via a system of specialized recycling vesicles, Besides Glut4, these vesicles include the novel insulin-regulatable aminopeptidase, receptors for insulin-like growth factor-II/Man-6-phosphate and transferrin, and a glycoprotein with the molecular mass of 110 kDa. We report here by the criteria of the partial protein sequencing and subsequent cDNA cloning that glycoprotein 110, the last unidentified major protein component of Glut4-containing vesicles, is sortilin, a novel type I receptor-like protein recently cloned from human brain (Petersen, C, M,, Nielsen, M. S., Nykjar, A., Jacobsen, L,, Tommerup, N,, Rasmussen, H, H,, Roigaard, H,, Gliemann, J,, Madsen, P,, and Moestrup, S. K, (1997) J, Biol, Chen, 272, 3599-3605), This protein is highly expressed in fat, brain, and lung and is dramatically up-regulated during differentiation of adipocytes in vitro.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Pilch, Paul/0000-0003-1997-0499; Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036424, R01DK030425] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30425, R29DK52057, DK 36424] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; Kandror KV, 1996, SEMIN CELL DEV BIOL, V7, P269, DOI 10.1006/scdb.1996.0035; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	21	99	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24145	24147		10.1074/jbc.272.39.24145	http://dx.doi.org/10.1074/jbc.272.39.24145			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305862	hybrid			2022-12-27	WOS:A1997XY51500013
J	Schechter, NM; Plotnick, M; Selwood, T; Walter, M; Rubin, H				Schechter, NM; Plotnick, M; Selwood, T; Walter, M; Rubin, H			Diverse effects of pH on the inhibition of human chymase by serpins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; PLASMA PROTEINASE-INHIBITORS; 2-STEP REACTION-MECHANISM; ALPHA-1-PROTEINASE INHIBITOR; NEUTROPHIL ELASTASE; ALPHA-CHYMOTRYPSIN; ANTITHROMBIN-III; CENTER LOOP; THROMBIN; HEPARIN	Inhibition of human chymase by the serpins alpha(1)-antichymotrypsin (ACT) and alpha(1)-proteinase inhibitor (PI) at pH 8.0 produces a complex stable to dissociation by SDS/dithiothreitol and a second product, hydrolyzed/inactivated serpin, The first product is the presumed trapped acyl-enzyme complex typical of serpin inhibition, and the second is the result of a concurrent substrate-like reaction, As a result of the hydrolytic reaction, stoichiometries of inhibition (SI) appear greater than 1; values of 4 and 6.0 are observed for the chymase-ACT and -PI reactions, In this study the effect of pH on the inhibition rate constant (k(inh)) and the SI of each reaction were evaluated to better define the rate-limiting steps of the inhibitory and hydrolytic reaction pathways associated with chymase inhibition, Reactions were evaluated over a pH range to correlate k(inh) and SI with the ionizations (pK values of 7 and 9) that typically regulate serine protease catalytic activity, The results show that the effects of pH on SI and k(?inh), differ for each inhibitor, On reducing the pH from 8.0 to 5.5, the chymase-ACT reaction exhibited a decrease in SI (to about 1) and little change in k(inh) whereas the chymase PI reaction revealed an increase in SI and a marked decrease in k(inh). On increasing the pH from 8.0 to 10.0, the chymase-ACT reaction exhibited little change in SI and a marked decrease in k(inh) whereas the chymase-PI reaction revealed a decrease in SI and a marked increase in k(inh). Chymase catalytic properties determined for a peptide substrate were atypical over the high pH range exhibiting increases for k(cat)/K-m and k(cat) and decreases for K-m. This behavior suggests the presence of a high pH enzyme form with enhanced hydrolytic activity. From these results and others involving analyses of ACT/PI reactive loop chimeras and ACT point variants exhibiting a range of SI values, we suggest that the diverse pH effects on k(inh) and SI are caused largely by a difference in the abilities of ACT and PI to interact with low (catalytically inactive) and high (catalytically enhanced) pH forms of chymase, The constancy of k(inh) for the chymase-ACT reaction over the low pH range suggests that the rate-limiting step for inhibition is pH insensitive and not reflective of diminished chymase hydrolytic activity, Low pH did not appear to affect the rate of SDS-stable complex formation as complex accumulation, assessed qualitatively by SDS-PAGE, correlated with the loss of chymase enzymatic activity.	UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Schechter, NM (corresponding author), UNIV PENN,DEPT DERMATOL,CLIN RES BLDG,415 CURIE BLVD,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL50523] Funding Source: Medline; NIAMS NIH HHS [AR42931] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042931] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BJORK I, 1982, J BIOL CHEM, V257, P9487; BOSWELL DR, 1983, BIOCHIM BIOPHYS ACTA, V744, P212, DOI 10.1016/0167-4838(83)90093-6; BRUCH M, 1989, BIOCHEM J, V259, P929, DOI 10.1042/bj2590929; Carrell RW, 1996, BIOL CHEM H-S, V377, P1; CARRELL RW, 1986, RES MONOGRAPHS CELL, V12, P403; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; ELLIOT PR, 1996, NAT STRUCT BIOL, V8, P676; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P33; KNIGHT CG, 1986, RES MONOGR CELL TISS, V12, P23; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIJNEN HR, 1991, J BIOL CHEM, V266, P4041; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MCCONN J, 1969, J MOL BIOL, V39, P551, DOI 10.1016/0022-2836(69)90145-4; MORII M, 1979, J BIOCHEM, V86, P915, DOI 10.1093/oxfordjournals.jbchem.a132623; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; OLSON ST, 1995, J BIOL CHEM, V270, P30007; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; POLGAR L, 1989, MECHANISMS PROTEASE, P87; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SCHECHTER NM, 1995, CL ALLER IM, V6, P47; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; Stone SR, 1997, J MOL BIOL, V265, P344, DOI 10.1006/jmbi.1996.0727; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WANG ZM, 1995, BIOL CHEM H-S, V376, P681; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652	44	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24499	24507		10.1074/jbc.272.39.24499	http://dx.doi.org/10.1074/jbc.272.39.24499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305913	hybrid			2022-12-27	WOS:A1997XY51500064
J	Modarress, KJ; Opoku, J; Xu, M; Sarlis, NJ; Simons, SS				Modarress, KJ; Opoku, J; Xu, M; Sarlis, NJ; Simons, SS			Steroid-induced conformational changes at ends of the hormone-binding domain in the rat glucocorticoid receptor are independent of agonist versus antagonist activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; RETINOIC ACID RECEPTOR; LONG TERMINAL REPEAT; HEPATOMA-CELL LINES; ESTROGEN-RECEPTOR; DEXAMETHASONE 21-MESYLATE; NUCLEAR RECEPTORS; GENE-EXPRESSION; MODULATORY ELEMENT; FUNCTIONAL-GROUP	The underlying molecular mechanism for the expression of agonist versus antagonist activity for a given receptor-steroid complex is still not known. One attractive hypothesis, based on data from progesterone receptors, is that agonist versus antagonist binding induces unique conformations at the C terminus of receptors, which can be detected by the different fragments produced by partial proteolysis. We now report that the determinants of glucocorticoid receptor (GR)-antagonist complex activity are more complex, Steroid binding did cause a conformational change in the GR that was detected by partial trypsin digestion, as described previously (Simons, S. S., Jr., Sistare, F. D., and Chakraborti, P. K. (1989) J. Biol. Chem. 264, 14493-14497). However, there was no uniformity in the digestion patterns of unactivated or activated receptors bound by a series of six structurally different antagonists including the affinity labeling antiglucocorticoid dexamethasone 21-mesylate, A total of four resistant bands were observed on SDS-polyacrylamide gels in the range of 30-27 kDa. Using a series of point mutations and epitope-specific antibodies, it was determined that the 30-kDa species represented the entire C-terminal sequence of amino acids 518-795, whereas the other bands arose from additional N-terminal and/or C-terminal cleavages, Bioassays with GRs containing various point and deletion mutations failed to reveal any C-terminal alterations that could convert antagonists into biologically active agonists, Thus, the presence or absence of C-terminal amino acids of the GR did not uniquely determine either the appearance of smaller trypsin-resistant fragments or the nature of the biological response of receptor-bound antisteroids. When compared with the current model of the ligand-binding domain, which is based on the x-ray structures of the comparable region of thyroid and retinoic acid receptors, the present results suggest that sequences outside of the model structure are relevant for the binding and biological activity of GRs.	NIDDK,STEROID HORMONES SECT,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Sarlis, Nicholas/AAN-9444-2020					ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Allan GF, 1996, MOL ENDOCRINOL, V10, P1206, DOI 10.1210/me.10.10.1206; Arnold SF, 1996, SCIENCE, V272, P1489, DOI 10.1126/science.272.5267.1489; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BOEQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; Collier CD, 1996, MOL ENDOCRINOL, V10, P463, DOI 10.1210/me.10.5.463; DECASTRO M, 1996, MOL MED, V2, P567; DELABRE K, 1993, P NATL ACAD SCI USA, V90, P4421, DOI 10.1073/pnas.90.10.4421; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FLACH H, 1992, J STEROID BIOCHEM, V42, P467, DOI 10.1016/0960-0760(92)90258-K; GRAVANIS A, 1985, J CLIN ENDOCR METAB, V60, P156, DOI 10.1210/jcem-60-1-156; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; HOECK W, 1989, J BIOL CHEM, V264, P14396; KASPER CB, 1975, MOL BIOL BIOCH BIOPH, V8, P114; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; LAMONTAGNE N, 1984, ENDOCRINOLOGY, V114, P2252, DOI 10.1210/endo-114-6-2252; Lamour FPY, 1996, MOL CELL BIOL, V16, P5386; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Martinez E, 1997, NUCLEIC ACIDS RES, V25, P163, DOI 10.1093/nar/25.1.163; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MERCIER L, 1983, ENDOCRINOLOGY, V112, P601, DOI 10.1210/endo-112-2-601; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MILLER PA, 1988, ENDOCRINOLOGY, V122, P2990, DOI 10.1210/endo-122-6-2990; MILLER PA, 1984, BIOCHEMISTRY-US, V23, P6883, DOI 10.1021/bi00321a093; MODARRESS KJ, 1994, J BIOL CHEM, V269, P25621; Newling DWW, 1996, BRIT J UROL, V77, P776, DOI 10.1046/j.1464-410X.1996.00052.x; OJASOO T, 1988, J MED CHEM, V31, P1160, DOI 10.1021/jm00401a015; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; Parczyk K, 1996, J CANCER RES CLIN, V122, P383, DOI 10.1007/BF01212877; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; PRATT WB, 1997, IN PRESS ENDOCR REV; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RICHARDFOY H, 1987, MOL ENDOCRINOL, V1, P659, DOI 10.1210/mend-1-9-659; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1979, BIOCHEM BIOPH RES CO, V86, P793, DOI 10.1016/0006-291X(79)91782-0; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; Simons SS, 1996, SCIENCE, V272, P1451, DOI 10.1126/science.272.5267.1451; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SIMONS SS, 1987, STEROID STEROL HORMO, P251; SIMONS SS, 1997, IN PRESS MOL BIOL ST; SIMONS SS, 1994, VITAM HORM, V48, P49; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SUNDSTROM SA, 1990, ENDOCRINOLOGY, V126, P1449, DOI 10.1210/endo-126-3-1449; SVEC F, 1989, ENDOCRINOLOGY, V125, P3103, DOI 10.1210/endo-125-6-3103; Szapary D, 1996, J BIOL CHEM, V271, P30576, DOI 10.1074/jbc.271.48.30576; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; TRAPP T, 1995, BIOCHEM BIOPH RES CO, V215, P286, DOI 10.1006/bbrc.1995.2464; TUNG L, 1993, MOL ENDOCRINOL, V7, P1257; URDA LA, 1989, MOL ENDOCRINOL, V3, P251, DOI 10.1210/mend-3-2-251; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Wagner BL, 1996, P NATL ACAD SCI USA, V93, P8739, DOI 10.1073/pnas.93.16.8739; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; WEAVER CA, 1988, MOL ENDOCRINOL, V2, P936, DOI 10.1210/mend-2-10-936; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P1585, DOI 10.1210/me.6.10.1585; WILSON JD, 1996, GOODMAN GILMANS PHAR, P1441; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; ZENG ZM, 1994, ENDOCRINOLOGY, V135, P248, DOI 10.1210/en.135.1.248; Zhang SM, 1996, MOL ENDOCRINOL, V10, P24, DOI 10.1210/me.10.1.24	74	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23986	23994		10.1074/jbc.272.38.23986	http://dx.doi.org/10.1074/jbc.272.38.23986			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295350	hybrid			2022-12-27	WOS:A1997XX38100075
J	Thyagarajan, B; Campbell, C				Thyagarajan, B; Campbell, C			Elevated homologous recombination activity in Fanconi anemia fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L-CELLS; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; DNA-REPAIR; PLASMID RECOMBINATION; RAD51 PROTEIN; SOMATIC-CELLS; CROSS-LINKS; COMPLEMENTATION	It is widely believed that Fanconi anemia cells possess a reduced ability to repair inter-strand DNA cross-links. While the mechanism through which inter-strand DNA cross-links are removed from mammalian chromosomes is unknown, these lesions ape repaired via homologous recombination in lower eukaryotes and bacteria. Based on the hypothesis that a similar mechanism of DNA repair functions in mammalian somatic cells, we measured homologous recombination activity in diploid fibroblasts from healthy donors, and Fanconi anemia patients. Somewhat surprisingly, homologous recombination levels in nuclear protein extracts prepared from Fanconi anemia cells were nearly 100-fold higher than in extracts prepared from control cells. We observed a similar increase in the activity of a 100-kDa homologous DNA pairing protein in extracts from Fanconi anemia cells. Transfection studies confirmed that plasmid homologous recombination levels in intact Fanconi anemia cells were substantially elevated, compared with control cells. These results suggest that inappropriately elevated levels of homologous recombination activity may contribute to the genomic instability and cancer predisposition that characterize Fanconi anemia.	UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL CANCER INSTITUTE [R29CA061906] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61906] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1970, J VIROL, V6, P470, DOI 10.1128/JVI.6.4.470-475.1970; AARONSON SA, 1968, VIROLOGY, V36, P253; ABE H, 1994, ANTICANCER RES, V14, P1807; AKHMEDOV AT, 1995, P NATL ACAD SCI USA, V92, P1729, DOI 10.1073/pnas.92.5.1729; AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; AUERBACH AD, 1976, NATURE, V261, P494, DOI 10.1038/261494a0; BENDIXEN C, 1994, GENOMICS, V23, P300, DOI 10.1006/geno.1994.1503; BERTRAND P, 1993, NUCLEIC ACIDS RES, V21, P3653, DOI 10.1093/nar/21.16.3653; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EMERIT I, 1995, HUM GENET, V96, P14, DOI 10.1007/BF00214180; *FANC AN BREAST CA, 1996, NAT GENET, V14, P324; FINN GK, 1989, MOL CELL BIOL, V9, P4009, DOI 10.1128/MCB.9.9.4009; GLANZ A, 1982, J MED GENET, V19, P412, DOI 10.1136/jmg.19.6.412; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HANG B, 1993, NUCLEIC ACIDS RES, V21, P4187, DOI 10.1093/nar/21.18.4187; HELLGREN D, 1992, MUTAT RES, V284, P37, DOI 10.1016/0027-5107(92)90023-U; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; JEONGYU SJ, 1992, MOL CELL BIOL, V12, P112, DOI 10.1128/MCB.12.1.112; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; JOENJE H, 1995, BLOOD, V86, P2156, DOI 10.1182/blood.V86.6.2156.bloodjournal8662156; Johnson BL, 1996, MUTAT RES-DNA REPAIR, V363, P179, DOI 10.1016/0921-8777(96)00007-9; KEOWN W, 1989, METHOD ENZYMOL, V185, P527; KUCHERLAPATI R, 1988, BIOCH ASPECTS HOMOLO, P575; KUCHERLAPATI RS, 1984, P NATL ACAD SCI-BIOL, V81, P3153, DOI 10.1073/pnas.81.10.3153; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LIN FLM, 1990, MOL CELL BIOL, V10, P113, DOI 10.1128/MCB.10.1.113; Liu JM, 1996, BIOCHEM BIOPH RES CO, V223, P685, DOI 10.1006/bbrc.1996.0956; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; McANulty MM, 1996, MUTAT RES-DNA REPAIR, V362, P75, DOI 10.1016/0921-8777(95)00037-2; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PAPADOPOULO D, 1987, MUTAT RES, V184, P271, DOI 10.1016/0167-8817(87)90026-5; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RAUTH S, 1986, P NATL ACAD SCI USA, V83, P5587, DOI 10.1073/pnas.83.15.5587; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; ROUSSET S, 1990, CANCER RES, V50, P2443; SALLES B, 1994, TOXICOLOGY, V93, P235, DOI 10.1016/0300-483X(94)90081-7; SEIDMAN MM, 1987, MOL CELL BIOL, V7, P3561, DOI 10.1128/MCB.7.10.3561; SHEN ZY, 1995, GENOMICS, V25, P199, DOI 10.1016/0888-7543(95)80126-7; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SINDEN RR, 1978, P NATL ACAD SCI USA, V75, P2373, DOI 10.1073/pnas.75.5.2373; SINDEN RR, 1978, J BACTERIOL, V136, P538, DOI 10.1128/JB.136.2.538-547.1978; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SYMINGTON LS, 1983, CELL, V35, P805, DOI 10.1016/0092-8674(83)90113-7; Thyagarajan B, 1996, NUCLEIC ACIDS RES, V24, P4084, DOI 10.1093/nar/24.20.4084; Thyagarajan B, 1996, J BIOL CHEM, V271, P27536, DOI 10.1074/jbc.271.44.27536; Thyagarajan B, 1996, SOMAT CELL MOLEC GEN, V22, P31, DOI 10.1007/BF02374374; TIMME TL, 1989, PLASMID, V22, P1, DOI 10.1016/0147-619X(89)90030-9; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; YOUNG D, 1971, LANCET, V1, P294	55	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23328	23333		10.1074/jbc.272.37.23328	http://dx.doi.org/10.1074/jbc.272.37.23328			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287344	hybrid			2022-12-27	WOS:A1997XV74400055
J	FtouhiPaquin, N; Hauer, CR; Stack, RF; Tarentino, AL; Plummer, TH				FtouhiPaquin, N; Hauer, CR; Stack, RF; Tarentino, AL; Plummer, TH			Molecular cloning, primary structure, and properties of a new glycoamidase from the fungus Aspergillus tubigensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-N-4-(N-ACETYL-BETA-D-GLUCOSAMINYL)ASPARAGINE AMIDASE-F; ASPARAGINE-LINKED GLYCANS; POLYMERASE CHAIN-REACTION; AMINO-ACID-SEQUENCE; N-GLYCOSIDASE-F; FLAVOBACTERIUM-MENINGOSEPTICUM; PEPTIDE; DEGLYCOSYLATION; GLYCOSYLASPARAGINASE; CARBOXYPEPTIDASE	A new glycoamidase, peptide-N-4-(N-acetyl-beta-D-glucosaminyl)asparagine amidase (PNGase) At, was discovered in the eukaryote Aspergillus tubigensis. The enzyme was purified to homogeneity, and the DNA sequence was determined by cloning in Escherichia coli. Over 80% of the deduced amino acid sequence was verified independently by Edman analysis and/or electrospray ionization-mass spectrometry of protease fragments of native PNGase At. This glycoamidase contains 12 potential asparagine-linked glycosylation sites, of which at least 9 sites are occupied with typical high mannose oligosaccharides. PNGase At consists of two non-identical glycosylated subunits that are derived from a single polypeptide gene precursor, Evidence is presented suggesting that autocatalysis is involved in subunit formation, PNGase At is an important new tool for analysis of asparagine-linked glycans; it can hydrolyze a broad range of glycopeptides, including those with core-linked alpha 1-->6 or alpha 1-->3 fucose, under conditions not favorable with existing glycoamidases.	SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	FtouhiPaquin, N (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DIV MOL MED,ALBANY,NY 12201, USA.			Hauer, Christoph/0000-0001-8704-2198	PHS HHS [30471] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; Aronson NN, 1996, GLYCOBIOLOGY, V6, P669, DOI 10.1093/glycob/6.7.669; BLOOMQUIST BT, 1992, DNA CELL BIOL, V11, P791, DOI 10.1089/dna.1992.11.791; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUR SJ, 1987, STRUCTURE ORG FILAME, P93; KUHN P, 1994, BIOCHEMISTRY-US, V33, P11699, DOI 10.1021/bi00205a005; KUHN P, 1995, J BIOL CHEM, V270, P29493, DOI 10.1074/jbc.270.49.29493; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; PLUMMER TH, 1978, J BIOL CHEM, V253, P3907; Plummer TH, 1996, ANAL BIOCHEM, V235, P98; PLUMMER TH, 1987, EUR J BIOCHEM, V163, P167, DOI 10.1111/j.1432-1033.1987.tb10751.x; PLUMMER TH, 1981, J BIOL CHEM, V256, P243; SCHAEFER BC, 1995, ANAL BIOCHEM, V227, P255, DOI 10.1006/abio.1995.1279; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P779; TAKAHASHI N, 1978, J BIOCHEM-TOKYO, V84, P1467, DOI 10.1093/oxfordjournals.jbchem.a132270; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P183; TAPUHI Y, 1981, ANAL BIOCHEM, V115, P123, DOI 10.1016/0003-2697(81)90534-0; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VANDENHOMBERGH JPTW, 1994, GENE, V151, P73, DOI 10.1016/0378-1119(94)90634-3; Weitzhandler M, 1996, ANAL BIOCHEM, V241, P128, DOI 10.1006/abio.1996.0386	26	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1997	272	36					22960	22965		10.1074/jbc.272.36.22960	http://dx.doi.org/10.1074/jbc.272.36.22960			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV492	9312552	hybrid			2022-12-27	WOS:A1997XV49200083
J	Pang, P; Meathrel, K; Ko, KT				Pang, P; Meathrel, K; Ko, KT			A component of the chloroplast protein import apparatus functions in bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SECA-PROTEIN; PRECURSOR PROTEIN; THYLAKOID MEMBRANE; PEA-CHLOROPLASTS; CDNA CLONE; TRANSPORT; IDENTIFICATION; HOMOLOG; TRANSLOCATION	Toc36 is a family of 44-kDa envelope polypeptides previously identified as components of the chloroplast protein import apparatus by virtue of their close physical proximity to translocating proteins. An indication of their function thus remains at large. A heterologous in vivo approach for studying the function of Toc36 was developed in this study by introducing a member of Toc36 into E. coli to assess its effect on bacterial protein translocation. The presence of Toc36 enhances the translocation of two bacterial periplasmic proteins in a manner resembling the chloroplast system. Translocation of the two bacterial periplasmic proteins was less sensitive to sodium azide, resembling more the azide-insensitive nature of the chloroplast protein import process. Mutated Toc36 proteins were not capable of causing the same effect as that observed for unaltered Toc36. Toc36 was also capable of complementing bacterial strains with temperature-sensitive secA mutations that affected protein translocation. The combined results provide evidence that Toc36 plays a central role in the chloroplast protein translocation process.	QUEENS UNIV, DEPT BIOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada								CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; GUTTERIDGE S, 1995, PLANT CELL, V7, P809, DOI 10.1105/tpc.7.7.809; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003-2697(78)90260-9; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIM YJ, 1994, CELL, V78, P845; KIM YJ, 1994, FEBS LETT, V339, P175, DOI 10.1016/0014-5793(94)80410-9; KNOTT TG, 1994, J BIOL CHEM, V269, P7843; KO K, 1995, J BIOL CHEM, V270, P28601, DOI 10.1074/jbc.270.48.28601; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LEVY SB, 1984, ANTIMICROBIAL DRUG R, P191; NAKAI M, 1994, J BIOL CHEM, V269, P31338; NOHARA T, 1995, FEBS LETT, V364, P305, DOI 10.1016/0014-5793(95)00415-6; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; REITH M, 1993, PLANT CELL, V5, P465, DOI 10.1105/tpc.5.4.465; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNELL DJ, 1995, CELL, V83, P521, DOI 10.1016/0092-8674(95)90090-X; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; WU CB, 1993, J BIOL CHEM, V268, P19384; WU CB, 1994, J BIOL CHEM, V269, P32264; YAMATO I, 1975, J BIOCHEM, V77, P705, DOI 10.1093/oxfordjournals.jbchem.a130774; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	28	23	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25623	25627		10.1074/jbc.272.41.25623	http://dx.doi.org/10.1074/jbc.272.41.25623			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325283	hybrid			2022-12-27	WOS:A1997YA35800038
J	He, SM; Withers, SG				He, SM; Withers, SG			Assignment of sweet almond beta-glucosidase as a family 1 glycosidase and identification of its active site nucleophile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GLYCOSYL HYDROLASES; CLASSIFICATION; INHIBITORS; MECHANISM; SIMILARITIES; INTERMEDIATE; PROBES	Sweet almond P-glucosidase is a well studied glycosidase, having been subjected to numerous kinetic analyses and inhibition studies. However, it is not known to which glycosidase family it belongs, nor is the identity of the active site nucleophile known with certainty, It can be inactivated using the specific, mechanism-based enzyme inactivator 2-deoxy-2-fluoro-beta-D-glucopyranosyl fluoride, which functions by forming a stable 2-deoxy-2-fluoro-alpha-D-glucopyranosyl-enzyme intermediate. The glycosylated peptide present in a peptic digest of this trapped glycosyl-enzyme intermediate was identified by use of neutral loss scans on an electrospray ionization triple quadrupole mass spectrometer, Comparative liquid chromatographic/mass spectrometric analysis of peptic digests of labeled and unlabeled enzyme samples confirmed the unique presence of this peptide of m/z = 1011 in the labeled sample, The sequence of this peptide was determined to be Ile-Thr-Glu-Gln-Gly-Val-Asp-Glu by further tandem mass spectrometric analysis in the daughter ion scan mode in conjunction with Edman degradation of the purified peptide. The identity of the labeled side chain was determined by further tandem mass spectrometric analysis in the daughter ion scan mode of a partially purified sample of the labeled peptide subjected to methyl esterification, the fragmentation pattern being consistent only with the first Glu in the sequence being labeled. The sequence around this residue is identical to that surrounding the catalytic nucleophile in many members of glycosidase Family 1, confirming the assignment of this enzyme to that family, The residue labeled is, however, different from that (Asp) identified previously in the enzyme from bitter almonds by use of conduritol epoxide affinity labels, although apparently close in the primary sequence.	PROT ENGN NETWORK CTR EXCELLENCE CANADA,VANCOUVER,BC V6T 1Z1,CANADA; UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z1,CANADA	University of British Columbia								ADAMSON J, 1970, CARBOHYD RES, V15, P351, DOI 10.1016/S0008-6215(00)80451-6; BARRETT T, 1995, STRUCTURE, V3, P951, DOI 10.1016/S0969-2126(01)00229-5; DALE MP, 1986, BIOCHEMISTRY-US, V25, P2522, DOI 10.1021/bi00357a036; DALE MP, 1985, BIOCHEMISTRY-US, V24, P3530, DOI 10.1021/bi00335a022; EVELEIGH DE, 1969, CARBOHYD RES, P87; Febbraio F, 1997, BIOCHEMISTRY-US, V36, P3068, DOI 10.1021/bi962496w; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GROVER AK, 1977, BIOCHIM BIOPHYS ACTA, V482, P98, DOI 10.1016/0005-2744(77)90358-8; HALL LD, 1971, CAN J CHEMISTRY, V49, P118, DOI 10.1139/v71-017; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; LEGLER G, 1970, H-S Z PHYSIOL CHEM, V351, P25, DOI 10.1515/bchm2.1970.351.1.25; LEGLER G, 1978, BIOCHIM BIOPHYS ACTA, V524, P102, DOI 10.1016/0005-2744(78)90108-0; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; Mackenzie LF, 1997, BIOCHEMISTRY-US, V36, P5893, DOI 10.1021/bi962962h; Mackenzie LF, 1997, J BIOL CHEM, V272, P3161, DOI 10.1074/jbc.272.6.3161; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MIAO SC, 1994, J BIOL CHEM, V269, P10975; SHULMAN ML, 1976, BIOCHIM BIOPHYS ACTA, V445, P169, DOI 10.1016/0005-2744(76)90170-4; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STREET IP, 1986, BIOCHEMISTRY-US, V25, P6021, DOI 10.1021/bi00368a028; TULL D, 1995, ANAL BIOCHEM, V224, P509, DOI 10.1006/abio.1995.1080; WEBER JP, 1980, J BIOL CHEM, V255, P9030; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WITHERS SG, 1988, J AM CHEM SOC, V110, P8551, DOI 10.1021/ja00233a045; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WITHERS SG, 1987, J AM CHEM SOC, V109, P7530, DOI 10.1021/ja00258a047; WITHERS SG, 1995, PROTEIN SCI, V4, P361	29	56	57	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24864	24867		10.1074/jbc.272.40.24864	http://dx.doi.org/10.1074/jbc.272.40.24864			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312086	hybrid			2022-12-27	WOS:A1997XY97000025
J	Hettasch, JM; Peoples, KA; Greenberg, CS				Hettasch, JM; Peoples, KA; Greenberg, CS			Analysis of factor XIII substrate specificity using recombinant human factor XIII and tissue transglutaminase chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XIII; FIBRIN-STABILIZING FACTOR; PLASMA FACTOR-XIIIA; PIG LIVER-ENZYME; AMINE-DONOR LYSINE; CROSS-LINKING; ALPHA-2-PLASMIN INHIBITOR; STRUCTURAL FEATURES; CATALYTIC ACTIVITY; BLOOD-PLASMA	Human factor XIII (FXIII) and tissue transglutaminase (tTG) are homologous proteins, FXIII requires thrombin for activation and cross-links the gamma chains of fibrin(ogen) more efficiently than the A alpha chains, On the other hand, tTG is thrombin-independent and forms predominantly A alpha and A alpha-gamma chain complexes, Previous work from this laboratory demonstrated that amino acid residues within exon 7 of FXIII were important for catalysis (Hettasch, J. M., and Greenberg, C. S. (1994) J. Biol. Chem. 269, 28309-28313), To determine to what extent the primary amino acid sequence within exon 7 defines substrate specificity, exon 7 of FXIII was replaced with the corresponding exon of tTG using gene splicing by overlap extension, Other work from this laboratory (Achyuthan, K.E., Slaughter, T.F., Santiago, M. A. Enghild, J. J., and Greenberg, C. S. (1993) J. Biol. Chem, 268, 21284-21292) using synthetic peptides identified two other domains that might play a role in substrate recognition (located in exons 3 and 5), Therefore, recombinant chimeras of FXIII/tTG were also created in which these two exons were exchanged, FXIII, tTG, and chimeras 3, 5, and 7 were expressed in Escherichia coli, purified, and the nature of the fibrin cross-linking pattern of these five proteins was determined by immunoblot analysis, FXIII preferentially formed the gamma-gamma dimer, whereas tTG formed A alpha-gamma complexes, Chimera 7 formed A alpha-gamma complexes that resembled the cross-linking pattern of tTG, This finding demonstrates that the primary amino acid sequence of exon 7 of tTG confers some of the specificity for the A alpha and A alpha-gamma cross-link pattern characteristic of tTG. Chimera 5 exhibited reduced crosslinking activity (50% of FXIII activity) but still retained preference for formation of the gamma-gamma dimer, whereas chimera 3 was not active, In conclusion, exchanging the primary amino acid sequence of the active site exon of human FXIII with that of human tTG modifies the enzyme such that the fibrin cross-linking pattern more closely resembles that of tTG (A alpha and A alpha-gamma complexes) instead of FXIII (gamma-gamma dimers).	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University					NHLBI NIH HHS [HL28391, HL38245, HL26309] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P60HL028391, P50HL026309] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1993, J BIOL CHEM, V268, P21284; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BLOMBACK B, 1958, ARK KEMI, V12, P173; Chen R, 1971, Biochemistry, V10, P4487; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; DOOLITTLE RF, 1983, ANN NY ACAD SCI, V408, P13, DOI 10.1111/j.1749-6632.1983.tb23231.x; DOOLITTLE RF, 1971, BIOCHEM BIOPH RES CO, V44, P94, DOI 10.1016/S0006-291X(71)80163-8; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FRANCIS CW, 1988, BLOOD, V71, P1361; GAFFNEY PJ, 1979, THROMB RES, V14, P85, DOI 10.1016/0049-3848(79)90027-6; GORMAN JJ, 1984, J BIOL CHEM, V259, P9007; GORMAN JJ, 1980, J BIOL CHEM, V255, P419; GORMAN JJ, 1981, J BIOL CHEM, V256, P2712; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GROENEN PJTA, 1994, EUR J BIOCHEM, V220, P795, DOI 10.1111/j.1432-1033.1994.tb18681.x; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; GROSS M, 1977, J BIOL CHEM, V252, P3752; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HERMANS J, 1982, SEMIN THROMB HEMOST, V8, P11, DOI 10.1055/s-2007-1005039; Hettasch JM, 1996, LAB INVEST, V75, P637; HETTASCH JM, 1994, J BIOL CHEM, V269, P28309; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KIM SY, 1994, J BIOL CHEM, V269, P27979; KUROCHKIN IV, 1995, J MOL BIOL, V248, P414, DOI 10.1016/S0022-2836(95)80060-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI TS, 1994, J BIOL CHEM, V269, P24596; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; LORAND L, 1972, ANN NY ACAD SCI, V202, P6, DOI 10.1111/j.1749-6632.1972.tb16319.x; LORAND L, 1964, ARCH BIOCHEM BIOPHYS, V105, P58, DOI 10.1016/0003-9861(64)90235-8; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MCKEE PA, 1970, P NATL ACAD SCI USA, V66, P738, DOI 10.1073/pnas.66.3.738; MICANOVIC R, 1994, J BIOL CHEM, V269, P9190; MOSESSON MW, 1989, P NATL ACAD SCI USA, V86, P1113, DOI 10.1073/pnas.86.4.1113; Mosher D F, 1978, Ann N Y Acad Sci, V312, P38, DOI 10.1111/j.1749-6632.1978.tb16791.x; MURTHY SNP, 1990, P NATL ACAD SCI USA, V87, P9679, DOI 10.1073/pnas.87.24.9679; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKATA Y, 1984, BLOOD, V63, P1393; SAKATA Y, 1982, J CLIN INVEST, V69, P536, DOI 10.1172/JCI110479; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODE J, 1979, J BIOL CHEM, V254, P653; SCHWARTZ ML, 1973, J BIOL CHEM, V248, P1395; Shainoff J R, 1990, Blood Coagul Fibrinolysis, V1, P499, DOI 10.1097/00001721-199010000-00025; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; SIEBENLIST KR, 1992, BIOCHEMISTRY-US, V31, P936, DOI 10.1021/bi00118a040; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; TAMAKI T, 1981, BIOCHIM BIOPHYS ACTA, V661, P280, DOI 10.1016/0005-2744(81)90016-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENZUELA R, 1992, AM J PATHOL, V141, P861; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	54	15	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25149	25156		10.1074/jbc.272.40.25149	http://dx.doi.org/10.1074/jbc.272.40.25149			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312126	hybrid			2022-12-27	WOS:A1997XY97000065
J	Inoue, D; Santiago, P; Horne, WC; Baron, R				Inoue, D; Santiago, P; Horne, WC; Baron, R			Identification of an osteoclast transcription factor that binds to the human T cell leukemia virus type I-long terminal repeat enhancer element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-RESPONSIVE ELEMENT; HTLV-I; C-FOS; CYCLIC-AMP; INTERLEUKIN-2 RECEPTOR; BONE-RESORPTION; TRANSGENIC MICE; DNA-BINDING; TAX; PROTEIN	Transgenic mice expressing human T cell leukemia virus type I (HTLV-I)-tax under the control of HTLV-I-long terminal repeat (LTR) promoter develop skeletal abnormalities with high bone turnover and myelofibrosis, In these animals, Tax is highly expressed in bone with a pattern of expression restricted to osteoclasts and spindle-shaped cells within the endosteal myelofibrosis, To test the hypothesis that lineage-specific transcription factors promote transgene expression from the HTLV-I-LTR in osteoclasts, we first examined tax expression in transgenic bone marrow cultures, Expression was dependent on 1 alpha,25-dihydroxycholecalciferol and coincided with tartrate-resistant acid phosphatase (TRAP) expression, a marker of osteoclast differentiation, Furthermore, Tax was expressed in vitronectin receptor positive mononuclear precursors as well as in mature osteoclast-libe cells (OCLs), Consistent with our hypothesis, electrophoretic mobility shift assays revealed the presence of an OCL nuclear factor (NFOC-1) that binds to the LTR 21-base pair direct repeat, a region critical for the promoter activity, This binding is further enhanced by Tax. Since NFOC-1 is absent in macro phages and conserved in osteoclasts among species including human, such a factor may play a role in lineage determination and/or in expression of the differentiated osteoclast phenotype.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT ORTHOPAED,NEW HAVEN,CT 06510	Yale University; Yale University								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BURGER EH, 1982, J EXP MED, V156, P1604, DOI 10.1084/jem.156.6.1604; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; DAVID JP, 1996, J BONE MINER RES  S1, V11, pS111; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GALIEN GM, 1994, RES VIROLOGY, V145, P361; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; GREENE WC, 1986, ANN INTERN MED, V105, P560, DOI 10.7326/0003-4819-105-4-560; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HOGAN B, 1994, MANIPULATING MOUSE E, P291; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LASKY SR, 1995, J BIOL CHEM, V270, P19676, DOI 10.1074/jbc.270.34.19676; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARUYAMA M, 1987, CELL, V48, P493; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OHSAKI Y, 1992, ENDOCRINOLOGY, V131, P2229, DOI 10.1210/en.131.5.2229; OSAME M, 1986, LANCET, V1, P1031; RUDDLE NH, 1993, VIROLOGY, V197, P196, DOI 10.1006/viro.1993.1580; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; TUGORES A, 1992, J IMMUNOL, V148, P2300; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	47	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25386	25393		10.1074/jbc.272.40.25386	http://dx.doi.org/10.1074/jbc.272.40.25386			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312160	hybrid			2022-12-27	WOS:A1997XY97000099
J	Kozawa, O; Suzuki, A; Kaida, T; Tokuda, H; Uematsu, T				Kozawa, O; Suzuki, A; Kaida, T; Tokuda, H; Uematsu, T			Tumor necrosis factor-alpha autoregulates interleukin-6 synthesis via activation of protein kinase C - Function of sphingosine 1-phosphate and phosphatidylcholine-specific phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; SWISS 3T3 CELLS; BONE-RESORPTION; INOSITOL TRISPHOSPHATE; GROWTH-FACTOR; DIFFERENTIATION; HYDROLYSIS; BREAKDOWN; CERAMIDE; TNF	We investigated the mechanism of interleukin-6 (IL-6) synthesis induced by tumor necrosis factor-alpha (TNF) in osteoblast-like MC3T3-E1 cells. TNF stimulated the synthesis of IL-6 dose dependently in the range between 1 and 30 ng/ml. Staurosporine and calphostin C, inhibitors of protein kinase C (PKC), significantly enhanced the TNF-induced synthesis of IL-6. 1-Oleoyl-2-acetylglycerol, a specific activator of PKC, inhibited the TNF-induced IL-6 synthesis. The stimulative effect of TNF was markedly increased in the PKC down-regulated cells, TNF produced diacylglycerol. TNF had little effect on the formation of inositol phosphates and choline, On the contrary, TNF significantly stimulated the formation of phosphocholine dose dependently. D-609, an inhibitor of phosphatidylcholine-specific phospholipase C, suppressed the TNF-induced diacylglycerol production, The TNF-induced IL-6 synthesis was significantly enhanced by D-609, TNF induced sphingomyelin hydrolysis. Neither C-2-ceramide nor sphingosine but sphingosine 1-phosphate significantly stimulated the synthesis of IL-6. PKC down-regulation amplified the IL-6 synthesis by sphingosine 1-phosphate. These results strongly suggest that sphingosine 1-phosphate may act as a second messenger for TNF-induced IL-6 synthesis and that TNF autoregulates IL-6 synthesis due to PKC activation via phosphatidylcholine-specific phospholipase C in osteoblast-like cells.	NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 1, NAGOYA, AICHI 466, JAPAN; CHUBA NATL HOSP, NATL INST LONGEV SCI, DEPT INTERNAL MED, AICHI 474, JAPAN	Nagoya University	Kozawa, O (corresponding author), GIFU UNIV, SCH MED, DEPT PHARMACOL, GIFU 500, JAPAN.							AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; AMEMIYA Y, 1988, NATURE, V336, P89, DOI 10.1038/336089a0; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EXTON JH, 1990, J BIOL CHEM, V265, P1; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; FRANCHIMONT N, 1995, ENDOCRINOLOGY, V136, P5469, DOI 10.1210/en.136.12.5469; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLE M, 1988, EUR J IMMUNOL, V18, P957, DOI 10.1002/eji.1830180619; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PAPPU AS, 1983, NEUROCHEM RES, V8, P1565, DOI 10.1007/BF00964158; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROODMAN GD, 1992, J BONE MINER RES, V7, P475, DOI 10.1002/jbmr.5650070502; SAKAI T, 1992, CELL CALCIUM, V13, P329, DOI 10.1016/0143-4160(92)90068-4; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SHINODA J, 1995, AM J PHYSIOL-ENDOC M, V269, pE524, DOI 10.1152/ajpendo.1995.269.3.E524; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Suzuki A, 1996, J CELL PHYSIOL, V168, P209, DOI 10.1002/(SICI)1097-4652(199607)168:1<209::AID-JCP25>3.0.CO;2-0; Suzuki A, 1996, J CELL BIOCHEM, V63, P491, DOI 10.1002/(SICI)1097-4644(19961215)63:4<491::AID-JCB10>3.0.CO;2-H; SUZUKI A, 1994, J CELL BIOCHEM, V54, P487, DOI 10.1002/jcb.240540416; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMSON BM, 1987, J IMMUNOL, V138, P775; THOMSON BM, 1986, J EXP MED, V164, P104, DOI 10.1084/jem.164.1.104; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689	39	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25099	25104		10.1074/jbc.272.40.25099	http://dx.doi.org/10.1074/jbc.272.40.25099			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312119	hybrid			2022-12-27	WOS:A1997XY97000058
J	Maundrell, K; Antonsson, B; Magnenat, E; Camps, M; Muda, M; Chabert, C; Gillieron, C; Boschert, U; VialKnecht, E; Martinou, JC; Arkinstall, S				Maundrell, K; Antonsson, B; Magnenat, E; Camps, M; Muda, M; Chabert, C; Gillieron, C; Boschert, U; VialKnecht, E; Martinou, JC; Arkinstall, S			Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INDUCED APOPTOSIS; PROTOONCOGENE; SPECIFICITY; PATHWAY; JNK; INACTIVATION; PHOSPHATASE; SURVIVAL; FAMILY	We have studied the phosphorylation of the Bcl-2 family of proteins by different mitogen-activated protein (MAP) kinases. Purified Bcl-2 was found to be phosphorylated by the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) p54-SAPK beta, and this is specific insofar as the extracellular signal-regulated kinase 1 (ERK1) and p38/RK/CSBP (p38) catalyzed only weak modification. Bcl-2 undergoes similar phosphorylation in COS-7 when coexpressed together with p54-SAPK beta and the constitutive Rac1 mutant G12V, This is seen by both (PO4)-P-32 labeling and the appearance of five discrete Bcl-2 bands with reduced gel mobility. As anticipated, both intracellular p54-SAPK beta activation and Bcl-2 phosphorylation are blocked by co-transfection with the MAP kinase specific phosphatase MKP3/PYST1. MAP kinase specificity is also seen in COS-7 cells as Bcl-2 undergoes only weak phosphorylation when co-expressed with enzymatically activated ERK1 or p38, Four critical residues undergoing phosphorylation in COS-7 cells were identified by expression of the quadruple Bcl-2 point mutant T56A, S70A, T74A, S87A. Sequencing phosphopeptides derived from tryptic digests of Bcl-2 indicates that purified GST-p54-SAPK beta phosphorylates identical sites in vitro. This is the first report of Bcl-2 phosphorylation by the JNK/SAPK class of MAP kinases and could indicate a key modification allowing control of Bcl-2 function by cell surface receptors, Rho family GTPases, and/or cellular stresses.	GLAXO WELLCOME RES & DEV SA,GENEVA BIOMED RES INST,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND	GlaxoSmithKline				martinou, Jean-claude/0000-0002-9847-2051; Camps, Montserrat/0000-0002-9849-8657				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COHEN P, 1997, IN PRESS TRENDS CELL; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shu CH, 1996, APOPTOSIS, V1, P141, DOI 10.1007/BF01321020; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	38	349	363	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25238	25242		10.1074/jbc.272.40.25238	http://dx.doi.org/10.1074/jbc.272.40.25238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312139	hybrid			2022-12-27	WOS:A1997XY97000078
J	Sun, C; Woolford, JL				Sun, C; Woolford, JL			The yeast nucleolar protein Nop4p contains four RNA recognition motifs necessary for ribosome biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; HETERONUCLEAR MAGNETIC-RESONANCE; BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; A-PROTEIN; HNRNP A1; CONSENSUS SEQUENCE; STRUCTURAL DOMAINS; CRYSTAL-STRUCTURE; SPLICING FACTORS	The Saccharomyces cerevisiae nucleolar protein Nop4p is necessary for processing of rRNA and assembly of 60 S ribosomal subunits, Nop4p is unusual in that it contains four RNA recognition motifs (RRMs) including one noncanonical RRM, as well as several auxiliary motifs, two acidic regions between the RRMs, and a carboxyl-terminal domain rich in lysines and arginines. To examine the functional importance of these motifs, we isolated random and site-directed mutations in NOP4 and assayed Nop4p function in vivo. Our results indicate that each RRM is essential for Nop4p function; mutations in conserved aromatic residues of Nop4p cause a temperature-sensitive lethal phenotype and diminished 60 S ribosomal subunit production, The carboxyl-terminal 68 amino acids are important but apparently not essential; carboxyl-terminal truncation of Nop4p causes slow growth, decreased ribosome production, and mislocalization of Nop4p. Deletion of both acidic motifs is lethal but replacement of most of the acidic residues with alanine has no apparent phenotype. These acidic residues may serve as spacers or tethers to separate the RRMs.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University				Woolford, John/0000-0002-7553-7043	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Allmang C, 1996, RNA, V2, P63; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERGES T, 1994, EMBO J, V13, P3136, DOI 10.1002/j.1460-2075.1994.tb06612.x; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P4611, DOI 10.1093/nar/19.17.4611; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; COPELAND CS, 1993, YEAST, V9, P235, DOI 10.1002/yea.320090304; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P82; GARRETT DS, 1994, BIOCHEMISTRY-US, V33, P2852, DOI 10.1021/bi00176a015; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Leung DW, 1989, TECHNIQUE, V1, P11; LIAO XLC, 1993, GENE DEV, V7, P419, DOI 10.1101/gad.7.3.419; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; MCCUSKER JH, 1991, YEAST, V7, P607, DOI 10.1002/yea.320070608; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, RNA, V2, P38; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAGAI K, 1994, RNA PROTEIN INTERACT, P150; NARANDA T, 1994, J BIOL CHEM, V269, P14465; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; RAUE HA, 1995, GENE EXPRESSION, V5, P71; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sherman F., 1986, METHODS YEAST GENETI; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; SUN C, 1994, EMBO J, V13, P3127, DOI 10.1002/j.1460-2075.1994.tb06611.x; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; vanNues RW, 1995, BIOCHEM CELL BIOL, V73, P789, DOI 10.1139/o95-087; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; Xue Zhixiong, 1994, Trends in Cell Biology, V4, P414, DOI 10.1016/0962-8924(94)90095-7; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	65	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25345	25352		10.1074/jbc.272.40.25345	http://dx.doi.org/10.1074/jbc.272.40.25345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312154	hybrid			2022-12-27	WOS:A1997XY97000093
J	Wu, YL; Aghdasi, B; Dou, SJ; Zhang, JZ; Liu, SQ; Hamilton, SL				Wu, YL; Aghdasi, B; Dou, SJ; Zhang, JZ; Liu, SQ; Hamilton, SL			Functional interactions between cytoplasmic domains of the skeletal muscle Ca2+ release channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; RYANODINE RECEPTOR GENE; RAPID CALCIUM RELEASE; MALIGNANT HYPERTHERMIA; CA-2+ RELEASE; REACTIVE OXYGEN; BINDING-SITES; NITRIC-OXIDE; PROTEIN; IDENTIFICATION	The skeletal muscle Ca2+ release channel (RYR1), which plays a critical role in excitation-contraction coupling, is a homotetramer with a subunit molecular mass of 565 kDa, Oxidation of the channel increases its activity and produces intersubunit cross-links within the RYR1 tetramer (Aghdasi, B., Zhang, J., Wu, Y., Reid, M. B., and Hamilton, S. L. (1997) J. Biol. Chem. 272, 3739-3748), Alkylation of hyperreactive sulfhydryls on RYR1 with N-ethylmaleimide (NEM) inhibits channel function and blocks the intersubunit cross-linking, We used calpain and tryptic cleavage, two dimensional SDS polyacrylamide gel electrophoresis, N-terminal sequencing, sequence-specific antibody Western blotting, and [C-14]NEM labeling to identify the domains involved in these effects, Our data are consistent with a model in which 1) diamide, an oxidizing agent, simultaneously produces an intermolecular cross-link between adjacent subunits within the RYR1 tetramer and an intramolecular cross-link within a single subunit; 2) all of the cysteines involved in both cross-links are in either the region between amino acids similar to 2100 and 2843 or the region between amino acids 2844 and 4685; 3) oxidation exposes a new calpain cleavage site in the central domain of the RYR1 (in the region around amino acid 2100); 4) sulfhydryls that react most rapidly with NEM are located in the N-terminal domain (between amino acids 426 and 1396); 5) alkylation of the N-terminal cysteines completely inhibits the formation of both inter- and intra-subunit cross-links, In summary, we present evidence for interactions between the N-terminal region and the putatively cytoplasmic central domains of RYR1 that appear to influence subunit subunit interactions and channel activity.	BAYLOR COLL MED,DEPT MOL PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine				Hamilton, Susan/0000-0003-0241-9369	NIAMS NIH HHS [AR41802] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON JJ, 1983, P NATL ACAD SCI-BIOL, V80, P1526, DOI 10.1073/pnas.80.6.1526; ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750; ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; ABRAMSON JJ, 1988, ARCH BIOCHEM BIOPHYS, V263, P245, DOI 10.1016/0003-9861(88)90633-9; Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; BINDOLI A, 1983, ARCH BIOCHEM BIOPHYS, V221, P458, DOI 10.1016/0003-9861(83)90164-9; BRANDT NR, 1992, J MEMBRANE BIOL, V127, P35; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CHEN SRW, 1994, P NATL ACAD SCI USA, V91, P11953, DOI 10.1073/pnas.91.25.11953; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; DIAZ PT, 1993, J APPL PHYSIOL, V75, P540, DOI 10.1152/jappl.1993.75.2.540; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20857; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; GILLARD EF, 1992, GENOMICS, V13, P1247, DOI 10.1016/0888-7543(92)90042-Q; GRUNWALD R, 1995, J BIOL CHEM, V270, P11338, DOI 10.1074/jbc.270.19.11338; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; PHILLIPS MS, 1994, HUM MOL GENET, V3, P2181, DOI 10.1093/hmg/3.12.2181; QUANE KA, 1993, NAT GENET, V5, P51, DOI 10.1038/ng0993-51; QUANE KA, 1994, HUM MOL GENET, V3, P471, DOI 10.1093/hmg/3.3.471; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; SEILER S, 1984, J BIOL CHEM, V259, P8550; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; WAGENKNECHT T, 1995, BIOPHYS J, V66, pA416; Wang JP, 1996, J BIOL CHEM, V271, P8387, DOI 10.1074/jbc.271.14.8387; WANG K, 1974, J BIOL CHEM, V249, P8005; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; ZHANG YL, 1993, NAT GENET, V5, P46, DOI 10.1038/ng0993-46; ZORZATO F, 1986, J BIOL CHEM, V261, P3252; Zorzato F, 1996, J BIOL CHEM, V271, P22759, DOI 10.1074/jbc.271.37.22759; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	46	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25051	25061		10.1074/jbc.272.40.25051	http://dx.doi.org/10.1074/jbc.272.40.25051			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312113	hybrid			2022-12-27	WOS:A1997XY97000052
J	Li, WQ; Zhang, JC; Bottaro, DP; Li, W; Pierce, JH				Li, WQ; Zhang, JC; Bottaro, DP; Li, W; Pierce, JH			Identification of serine 643 of protein kinase C-delta as an important autophosphorylation site for its enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP BINDING MUTANT; TYROSINE PHOSPHORYLATION; IN-VIVO; ACTIVATION; CELLS; PATHWAY; PKC; DIFFERENTIATION; TRANSFORMATION; STIMULATION	To investigate the role of serine/threonine autophosphorylation of protein kinase C-delta (PMC-delta), we mutated serine 643 of PKC-delta to an alanine residue (PKC-delta S643A). Two different expression vectors containing PKC-delta S643A mutant cDNAs were transfected and expressed in 32D myeloid progenitor cells. In vitro autophosphorylation assays demonstrated 65-83% reduction in autophosphorylation of PKC-delta S643A in comparison to wild type PKC-delta (PKC-delta WT). The enzymatic activity of PKC-delta S643A mutant as measured by phosphorylating the PKC-delta pseudosubstrate region-derived substrate was also reduced more than 70% in comparison to that of PRC-delta WT. In vivo labeling and subsequent two-dimensional phosphopeptide analysis demonstrated that at least one phosphopeptide was absent in PKC-delta S643A when compared with PRC-delta WT, further substantiating that serine 643 is phosphorylated in vivo, Localization and 12-O-tetradecanoylphorbol-13-acetate-dependent translocation and tyrosine phosphorylation of PKC-delta S643A were not altered in comparison to PRC-delta WT, indicating that mutagenesis did not affect the structural integrity of the mutant protein, 12-O-Tetradecanoylphorbol-13-acetate-mediated monocytic differentiation of 32D cells overexpressing PKC-delta S643A mutant protein was impaired in comparison to that of PRC-delta WT transfectant, Taken together, oar results demonstrate that serine 643 of PRC-delta is a major autophosphorylation site, and phosphorylation of this site plays an important role in controlling its enzymatic activity and biological function.	UNIV CHICAGO, BEN MAY INST CANC RES, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	Li, WQ (corresponding author), NCI, MOL & CELLULAR BIOL LAB,NIH,BLDG 37,RM 1E24, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; BORNER C, 1989, J BIOL CHEM, V264, P13902; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HUANG KP, 1986, J BIOL CHEM, V261, P2134; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Li WQ, 1996, ONCOGENE, V13, P731; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOLINA CA, 1991, CANCER RES, V51, P4624; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ORR JW, 1994, J BIOL CHEM, V269, P27715; SMITH H, 1995, P NATL ACAD SCI USA, V92, P9112; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P6130, DOI 10.1073/pnas.90.13.6130	31	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24550	24555		10.1074/jbc.272.39.24550	http://dx.doi.org/10.1074/jbc.272.39.24550			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305920	Green Submitted, hybrid			2022-12-27	WOS:A1997XY51500071
J	Sato, MH; Nakamura, N; Ohsumi, Y; Kouchi, H; Kondo, M; HaraNishimura, I; Nishimura, M; Wada, Y				Sato, MH; Nakamura, N; Ohsumi, Y; Kouchi, H; Kondo, M; HaraNishimura, I; Nishimura, M; Wada, Y			The AtVAM3 encodes a syntaxin-related molecule implicated in the vacuolar assembly in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; YEAST VACUOLE; BARLEY LECTIN; PLANT-CELLS; PROTEIN; MEMBRANE; MORPHOGENESIS; GENES; TRANSFORMATION	The vacuole constitutes a large compartment in plant and fungal cells, The VAM3 gene of Saccharomyces cerevisiae encodes a syntaxin-related protein required far vacuolar assembly, An Arabidopsis thaliana cDNA library, designed for expression iu S. cerevisiae, was screened for cDNAs able to complement defective vacuolar assembly of the Delta vam3 mutation, One cDNA, encoding a 33-kDa protein with structural similarities to the other syntaxins, was identified, The product of AtVAM3 (AtVam3p) was expressed in various tissues including roots, leaves, inflorescence stems, flower buds, and young siliques. The AtVAM3 transcripts were abundant; in undifferentiated cells in the meristematic region, AtVam3p fractionated predominantly to an 8,000 x g pellet fraction where a vacuolar membrane protein H+-translocating inorganic pyrophosphatase (H+-PPase) also fractionated. Immunoelectron microscopy showed that AtVam3p was localized to restricted regions on the vacuolar membranes, The propose that AtVam3p provides the t-SNARE function in the vacuolar assembly in A. thaliana.	UNIV TOKYO,DEPT BIOL,GRAD SCH ARTS & SCI,TOKYO 153,JAPAN; NATL INST AGROBIOL RESOURCES,DEPT APPL PHYSIOL,TSUKUBA,IBARAKI 305,JAPAN; NATL INST BASIC BIOL,DEPT CELL BIOL,OKAZAKI,AICHI 444,JAPAN	University of Tokyo; National Institute of Agrobiological Sciences - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)			Sato, Masa/P-6487-2019; Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166; Nishimura, Mikio/0000-0001-7960-9721; Sato, Masa H./0000-0001-5794-4545				AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BASSHAM DC, 1995, P NATL ACAD SCI USA, V92, P7262, DOI 10.1073/pnas.92.16.7262; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BEDNAREK SY, 1994, PLANT PHYSIOL, V104, P591, DOI 10.1104/pp.104.2.591; BEDNAREK SY, 1990, PLANT CELL, V2, P1145, DOI 10.1105/tpc.2.12.1145; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CONCEICAO AD, 1997, PLANT CELL, V9, P1; DENFERT C, 1992, EMBO J, V11, P4205, DOI 10.1002/j.1460-2075.1992.tb05514.x; DOMBROWSKI JE, 1993, PLANT CELL, V5, P587, DOI 10.1105/tpc.5.5.587; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FEILER HS, 1995, EMBO J, V14, P5626, DOI 10.1002/j.1460-2075.1995.tb00250.x; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HOH B, 1995, J CELL SCI, V108, P299; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOUCHI H, 1993, MOL GEN GENET, V238, P106, DOI 10.1007/BF00279537; LEE HI, 1993, P NATL ACAD SCI USA, V90, P11433, DOI 10.1073/pnas.90.23.11433; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; Maeshima M, 1996, J PLANT RES, V109, P119, DOI 10.1007/BF02344297; MATILE P, 1978, ANNU REV PLANT PHYS, V29, P193, DOI 10.1146/annurev.pp.29.060178.001205; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; Nakamura N, 1997, J BIOL CHEM, V272, P11344; NISHIMURA M, 1993, PROTOPLASMA, V175, P131, DOI 10.1007/BF01385011; Paris N, 1996, CELL, V85, P563, DOI 10.1016/S0092-8674(00)81256-8; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STRZALKA K, 1995, BBA-BIOMEMBRANES, V1239, P103, DOI 10.1016/0005-2736(95)00141-O; TAGUE BW, 1990, PLANT CELL, V2, P533, DOI 10.1105/tpc.2.6.533; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WADA Y, 1992, J BIOL CHEM, V267, P18665; Wada Y, 1996, PROTOPLASMA, V191, P126, DOI 10.1007/BF01281810; WADA Y, 1992, J BIOL CHEM, V267, P18671; Wada Y, 1997, J CELL SCI, V110, P1299; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539	41	102	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24530	24535		10.1074/jbc.272.39.24530	http://dx.doi.org/10.1074/jbc.272.39.24530			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305917	hybrid			2022-12-27	WOS:A1997XY51500068
J	James, PF; Lake, AC; Hajra, AK; Larkins, LK; Buchanan, FG; Zoeller, RA				James, PF; Lake, AC; Hajra, AK; Larkins, LK; Buchanan, FG; Zoeller, RA			An animal cell mutant with a deficiency in acyl/alkyl-dihydroxyacetone-phosphate reductase activity - Effects on the biosynthesis of ether-linked and diacyl glycerolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER PEROXISOMES; PLASMALOGEN BIOSYNTHESIS; ZELLWEGER SYNDROME; PHOSPHATIDYLSERINE; ACYLTRANSFERASE; ENZYMES; KINASE; TRIACYLGLYCEROL; METABOLISM; GROWTH	In the accompanying paper (James, P. F., and Zoeller, R. A. (1997) J. Biol. Chem. 272, 23532-23539), we reported the isolation of st series of mutants from the fibroblast-like cell line, CHO-K1, that are deficient in the incorporation of the long chain fatty alcohol, hexadecanol, into complex lipids. All but one of these mutants, FAA.K1B, were deficient; in long-chain-fatty alcohol oxidase (FAO) activity. We have further characterized this FAO(+) isolate. FAA.K1B cells displayed a 40% decrease in [9,10-H-3]hexadecanol uptake when compared with the parent strain. Although incorporation of hexadacanol into the phospholipid fraction was decreased by 52%, She cells accumulated label in alkylglycerol (20-fold over wild type). The increase in 1-alkylglycerol labeling corresponded to a 4-fold increase in alkylglycerol mass. Short term labeling with P-32(i) showed a 45-50% decrease in overall phospholipid biosynthesis in FAA.K1B. Both diacyl- and ether-linked species were affected, suggesting a general defect in phospholipid biosynthesis. Mutant cells were able to partially compensate for the decreased. biosynthesis by decreasing the turnover of the phospholipid pools. The primary lesion in FAA.K1B was identified as a 95% reduction in acyl/alkyl-dihydroxyacetone-phosphate reductase activity. Whole cell homogenates from FAA.K1B were unable to reduce either acyl-dihydroxyacetone phosphate (DHAP) or alkyl-DHAP, supporting the notion that the reduction of these two compounds is catalyzed by a single enzyme. These data suggest that the biosynthesis of diacyl phospholipids, in Chinese hamster ovary cells, begins with the acylation of dihydroxyacetone phosphate as well as glycero-3-phosphate and that the ''DHAP pathway'' contributes significantly to diacyl glycerolipid biosynthesis. Also, the severe reduction in acyl/alkyl-DHAP reductase activity in FAA.K1B resulted in only a moderate decrease in ether lipid biosynthesis. These latter data together with the observed increase in alkylglycerol levels support the existence of a shunt pathway that is able to partially bypass the enzymatic lesion.	BOSTON UNIV, SCH MED, DEPT BIOPHYS, CTR ADV BIOMED RES, BOSTON, MA 02118 USA; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MENTAL HLTH INST, ANN ARBOR, MI 48109 USA; E TENNESSEE STATE UNIV, JAMES H QUILLEN COLL MED, DEPT BIOCHEM, JOHNSON CITY, TN 37614 USA	Boston University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; East Tennessee State University				Zoeller, Raphael/0000-0002-6560-0993	NCI NIH HHS [CA 59981] Funding Source: Medline; NIGMS NIH HHS [GM 50571] Funding Source: Medline; NINDS NIH HHS [NS 15747] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R15CA059981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015747] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; COREY EJ, 1975, TETRAHEDRON LETT, V31, P2647; DATTA NS, 1984, NEW ENGL J MED, V311, P1080, DOI 10.1056/NEJM198410253111704; DATTA SC, 1990, J BIOL CHEM, V265, P8268; DAVIS PA, 1981, ARCH BIOCHEM BIOPHYS, V211, P20, DOI 10.1016/0003-9861(81)90424-0; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1980, J BIOL CHEM, V255, P4474; FORD DA, 1990, J BIOL CHEM, V265, P12280; GHOSH MK, 1986, ARCH BIOCHEM BIOPHYS, V245, P523, DOI 10.1016/0003-9861(86)90245-6; GREENSPAN MD, 1982, BIOCHIM BIOPHYS ACTA, V710, P15, DOI 10.1016/0005-2760(82)90184-9; HAJRA AK, 1992, METHOD ENZYMOL, V209, P402; Hajra AK, 1995, PROG LIPID RES, V34, P343, DOI 10.1016/0163-7827(95)00013-5; HAJRA AK, 1978, J NEUROCHEM, V31, P125, DOI 10.1111/j.1471-4159.1978.tb12440.x; HAJRA AK, 1983, CHEM PHYS LIPIDS, V33, P179, DOI 10.1016/0009-3084(83)90020-8; HAJRA AK, 1979, J BIOL CHEM, V254, P896; James PF, 1997, J BIOL CHEM, V272, P23532, DOI 10.1074/jbc.272.38.23532; JONES CL, 1980, J BIOL CHEM, V255, P8289; KUGE O, 1991, J BIOL CHEM, V266, P24184; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; LABELLE EF, 1974, J BIOL CHEM, V249, P6936; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING R, 1972, BIOCHEM J, V130, P1003, DOI 10.1042/bj1301003; Martonosi, 1985, ENZYMES BIOL MEMBR, V2, P1; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MOSLEY ST, 1981, P NATL ACAD SCI-BIOL, V78, P5717, DOI 10.1073/pnas.78.9.5717; MYHER JJ, 1989, J CHROMATOGR, V471, P187, DOI 10.1016/S0021-9673(00)94167-0; Nagan N, 1997, P NATL ACAD SCI USA, V94, P4475, DOI 10.1073/pnas.94.9.4475; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; OWENS K, 1966, BIOCHEM J, V100, P354, DOI 10.1042/bj1000354; POLLOCK RJ, 1975, BIOCHIM BIOPHYS ACTA, V380, P421, DOI 10.1016/0005-2760(75)90110-1; POLOKOFF MA, 1981, J BIOL CHEM, V256, P7687; ROCK CO, 1974, J BIOL CHEM, V249, P5382; ROGNSTAD R, 1974, BIOCHEM J, V140, P249, DOI 10.1042/bj1400249; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; WARNE TR, 1995, J BIOL CHEM, V270, P11147, DOI 10.1074/jbc.270.19.11147; WEBBER KO, 1987, ARCH BIOCHEM BIOPHYS, V254, P611, DOI 10.1016/0003-9861(87)90144-5; WYKLE RL, 1970, J BIOL CHEM, V245, P3047; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1992, J BIOL CHEM, V267, P8299	43	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23540	23546		10.1074/jbc.272.38.23540	http://dx.doi.org/10.1074/jbc.272.38.23540			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295290	hybrid			2022-12-27	WOS:A1997XX38100015
J	Richards, OC; Ehrenfeld, E				Richards, OC; Ehrenfeld, E			One of two NTP binding sites in poliovirus RNA polymerase required for RNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; CRYSTAL-STRUCTURE; DNA; IDENTIFICATION; RESOLUTION; MUTATION; RESIDUES; BETA	The poliovirus RNA-dependent RNA polymerase (3D(pol)) has been shown to contain two NTP binding: sites by chemical cross-linking of oxidized nucleotide to the intact protein. Only one site (Lys-61) was shown to be essential for RNA chain elongation activity by purified enzyme; however, a full-length viral RNA, coding for an altered lysine residue (K276L) in the second site, generated virus with a minute plaque phenotype that rapidly reverted to a wild-type phenotype with Arg-276 replacing Leu-276 in 3D. Viruses with lysine to leucine substitutions in other positions of the second binding site of their polymerase proteins grew with wild-type phenotype, To test the significance of the second binding site, poliovirus 3D(pol) was generated with lysine (wild type), leucine, or arginine at residue 276 and tested for NTP cross-linking using P-32-oxidized GTP. Analysis of cyanogen bromide peptides of each 3D preparation showed that the second NTP binding site had severely reduced NTP binding in mu 276(Leu) but not in the revertant mu 276(Arg), despite the reported requirement for lysine in the cross-linking reaction. To eliminate the possibility that P-32-oxidized GTP cross-linked to Arg at residue 276, a model system was designed with unmodified amino acid or acetylated (alpha-amino) amino acid and P-32-oxidized GTP. Cross-linking to lysine, but not leucine or arginine, was observed thus eliminating the possibility that NTP could be cross-linked to residue 276 in 3D, We conclude that NTP binding at the second site in poliovirus 3D is at lysine residues at positions other than 276 (278 or 283), and nucleotide binding at these sites has no bearing on elongation activity or replication of the virus, Nucleotide binding only at the site including Lys-61 is essential for RNA replication.			Richards, OC (corresponding author), UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,3205 BIOL SCI 2,IRVINE,CA 92697, USA.				NIAID NIH HHS [AI17386] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017386, R37AI017386] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; EASTERBROOKSMITH SB, 1976, EUR J BIOCHEM, V62, P125, DOI 10.1111/j.1432-1033.1976.tb10105.x; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; JABLONSKI SA, 1995, J VIROL, V69, P1532, DOI 10.1128/JVI.69.3.1532-1539.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; MORAS D, 1993, NATURE, V364, P572, DOI 10.1038/364572a0; NEUFELD KL, 1991, J BIOL CHEM, V266, P24212; PATA JD, 1995, RNA, V1, P466; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Richards OC, 1996, J VIROL, V70, P8564, DOI 10.1128/JVI.70.12.8564-8570.1996; RICHARDS OC, 1992, J BIOL CHEM, V267, P17141; RICHARDS OC, 1995, BIOCHEMISTRY-US, V34, P6288, DOI 10.1021/bi00019a005; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445	16	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23261	23264		10.1074/jbc.272.37.23261	http://dx.doi.org/10.1074/jbc.272.37.23261			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287335	hybrid			2022-12-27	WOS:A1997XV74400046
J	Sciorati, C; Rovere, P; Ferrarini, M; Heltai, S; Manfredi, AA; Clementi, E				Sciorati, C; Rovere, P; Ferrarini, M; Heltai, S; Manfredi, AA; Clementi, E			Autocrine nitric oxide modulates CD95-induced apoptosis in gamma delta T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; INTRACELLULAR STORES; SIGNAL-TRANSDUCTION; SPHINGOSINE KINASE; CELL-DEATH; ACTIVATION; RECEPTOR; SPHINGOMYELINASE; INHIBITION; TRANSPORT	gamma delta T lymphocytes play an important early role in the defense against pathogens. Their function is terminated by acquisition of susceptibility to CD95-triggered apoptosis. Here we show that the regulation of this process depends on the activity of the endothelial NO synthase expressed by gamma delta T lymphocytes, which is modulated in an activation-dependent way. The effects of nitric oxide thus generated, mediated via cGMP generation, are exerted at at least two sites along the CD95 signaling cascade: one at, or upstream, and the other downstream of ceramide generation. At either site, nitric oxide/cGMP action is sufficient for protection from apoptosis. The effect of NO is selective for apoptosis induced by CD95 cross-linking, since it does not affect apoptotic program triggered by other stimuli. The evidence here reported demonstrates a new physiological role for nitric oxide, acting as a survival factor for T lymphocytes.	SAN RAFFAELE SCI INST,DIPARTIMENTO FARMACOL,DIBIT,I-20132 MILAN,ITALY; SCI INST OSPED SAN RAFFAELE,LAB CANC IMMUNOL,DEPT MED 2,I-88021 CATANZARO,ITALY; UNIV REGGIO CALABRIA,SCH PHARM,DEPT PHARMACOL,CNR,IBAF,I-88021 CATANZARO,ITALY; CNR,CELLULAR & MOL PHARMACOL CTR,I-20132 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Agroambientale e Forestale (IBAF-CNR); Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR)			Heltai, Silvia/AAN-4078-2020; Rovere-Querini, Patrizia/J-2340-2012; Ferrarini, Marina/AAO-1548-2020; Manfredi, Angelo A./C-7018-2014; sciorati, clara/K-4823-2016	Heltai, Silvia/0000-0002-3842-5595; Manfredi, Angelo A./0000-0001-8370-6970; Ferrarini, Marina/0000-0003-1015-9632; sciorati, clara/0000-0003-2030-9366				ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Choi OH, 1996, NATURE, V380, P634; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CIFONE MG, 1993, J EXP MED, V177, P1547; CLEMENTI E, 1995, J BIOL CHEM, V270, P22277, DOI 10.1074/jbc.270.38.22277; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Ferrarini M, 1996, JNCI-J NATL CANCER I, V88, P436, DOI 10.1093/jnci/88.7.436; FERRARINI M, 1995, J IMMUNOL, V154, P3704; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; KIM S, 1995, J BIOL CHEM, V270, P5266, DOI 10.1074/jbc.270.10.5266; Mao CG, 1996, P NATL ACAD SCI USA, V93, P1993, DOI 10.1073/pnas.93.5.1993; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Reiling N, 1996, EUR J IMMUNOL, V26, P511, DOI 10.1002/eji.1830260302; ROONEY E, 1996, J BIOL CHEM, V270, P29304; Rovere P, 1996, J IMMUNOL, V156, P4631; Skowronski EW, 1996, CELL DEATH DIFFER, V3, P171; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509	29	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23211	23215		10.1074/jbc.272.37.23211	http://dx.doi.org/10.1074/jbc.272.37.23211			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287328	hybrid			2022-12-27	WOS:A1997XV74400039
J	Takahashi, K; Sasaki, T; Mammoto, A; Takaishi, K; Kameyama, T; Tsukita, S; Tsukita, S; Takai, Y				Takahashi, K; Sasaki, T; Mammoto, A; Takaishi, K; Kameyama, T; Tsukita, S; Tsukita, S; Takai, Y			Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; DBL ONCOGENE PRODUCT; EXCHANGE PROTEIN; TERMINAL DOMAIN; CD44; PURIFICATION; ASSOCIATION; INVOLVEMENT; FAMILY; P20	The Rho GDP dissociation inhibitor (GDI) forms a complex with the GDP-bound form of the Rho family small G proteins and inhibits their activation. The GDP-bound form complexed with Rho GDI is not activated by the GDP/GTP exchange factor for the Rho family members, suggesting the presence of another factor necessary for this activation. We have reported that the Rho subfamily members regulate the ezrin/radixin/moesin (ERM)-CD44 system, implicated in reorganization of actin filaments. Here we report that Rho GDI directly interacts with ERM, initiating the activation of the Rho subfamily members by reducing the Rho GDI activity. These results suggest that ERM as well as Rho GDI and the Rho GDP/GTP exchange factor are involved in the activation of the Rho subfamily members, which then regulate reorganization of actin filaments through the ERM system.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; KYOTO UNIV,FAC MED,DEPT CELL BIOL,KYOTO 606,JAPAN; KYOTO UNIV,COLL MED TECHNOL,KYOTO 606,JAPAN	Osaka University; Kyoto University; Kyoto University								ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; KURODA S, 1989, BIOCHEM BIOPH RES CO, V163, P674, DOI 10.1016/0006-291X(89)92276-6; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; TANAKA K, 1995, METHOD ENZYMOL, V256, P41; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; UEDA T, 1990, J BIOL CHEM, V265, P9373; UNDERHILL C, 1992, J CELL SCI, V103, P293; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	26	352	364	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23371	23375		10.1074/jbc.272.37.23371	http://dx.doi.org/10.1074/jbc.272.37.23371			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287351	hybrid			2022-12-27	WOS:A1997XV74400062
J	Fang, KC; Raymond, WW; Blount, JL; Caughey, GH				Fang, KC; Raymond, WW; Blount, JL; Caughey, GH			Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe(88)-Gln(89) and Phe(91)-Glu(92) bonds of the catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-3 STROMELYSIN; IV COLLAGENASE; GELATINASE-B; FIBROBLAST COLLAGENASE; 92-KDA GELATINASE; MOLECULAR-CLONING; TUMOR-CELLS; EXPRESSION; PROCOLLAGENASE; TRYPTASE	In prior work we showed that a metallogelatinase is secreted from dog mastocytoma cells and directly activated by exocytosed mast cell alpha-chymase. The current work identifies the protease as a canine homologue of progelatinase B (92-kDa gelatinase, MMP-9), determines the sites cleaved by alpha-chymase, and explores the regulation of gelatinase expression in mastocytoma cells. To obtain a cDNA encoding the complete sequence of mastocytoma gelatinase B, a 2.3-kilobase clone encoding progelatinase was isolated from a BR mastocytoma library. The sequenced cDNA predicts a 704-amino acid protein 80% identical to human progelatinase B. Regions thought to be critical for active site latency, such as the Cys-containing propeptide sequence, PRCGVPD, and the catalytic domain sequence, HEFGHALGLDHSS, are entirely conserved. Cleavage of progelatinase B by purified dog alpha-chymase yielded an similar to 84-kDa product that contained two NH2-terminal amino acid sequences, QTFEGDLKXH and EGDLKXHHND, which correspond to residues 89-98 and 92-101 of the cDNA predicted sequence, respectively. Thus, alpha-chymase cleaves the catalytic domain of gelatinase B at the Phe(88)-Gln(89) and Phe(91)-Glu(92) bonds. Like BR cells, the C2 line of dog mastocytoma cells constitutively secrete progelatinase B which is activated by alpha-chymase. By contrast, non-chymase-producing C1 cells secrete a gelatinase B (which remains in its preform) only in response to 12-O-tetradecanoylphorbol-13-acetate. Whereas 12-O-tetradecanoylphorbol-13-acetate stimulation of BR cells produced a similar to 15-fold increase in gelatinase B mRNA expression, dexamethasone down-regulated its expression by similar to 5-fold. Thus, extracellular stimuli may regulate the amount of mast cell progelatinase B expressed by mast cells. These data further support a role for mast cell alpha-chymase in tissue remodeling involving gelatinase B-mediated degradation of matrix proteins.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Fang, KC (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,BOX 0911,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL-24136, HL-07185, HL-09133] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009133, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benbow U, 1996, J BIOL CHEM, V271, P10715, DOI 10.1074/jbc.271.18.10715; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; CANETESOLER R, 1994, AM J PATHOL, V144, P518; CAUGHEY GH, 1988, BIOCHIM BIOPHYS ACTA, V952, P142, DOI 10.1016/0167-4838(88)90109-4; DENHOLM EM, 1993, AM J PHYSIOL, V265, pL581, DOI 10.1152/ajplung.1993.265.6.L581; DEVINNEY R, 1990, AM J RESP CELL MOL, V3, P413, DOI 10.1165/ajrcmb/3.5.413; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; FINI ME, 1995, INVEST OPHTH VIS SCI, V36, P622; FINI ME, 1994, J BIOL CHEM, V269, P28620; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; GRANT GA, 1987, J BIOL CHEM, V262, P5886; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; HE C, 1989, P NATL ACAD SCI USA, V66, P2632; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; KJELDSEN L, 1993, BLOOD, V82, P3183; KNAUPER V, 1993, BIOCHEM J, V295, P581; LEES M, 1994, EUR J BIOCHEM, V223, P171, DOI 10.1111/j.1432-1033.1994.tb18980.x; LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Maniatis T., 1982, MOL CLONING; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATSUBARA M, 1991, INVEST OPHTH VIS SCI, V32, P3221; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA A, 1995, GENE, V164, P317, DOI 10.1016/0378-1119(95)00447-E; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SALO T, 1994, LAB INVEST, V70, P176; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; SARRET Y, 1992, J INVEST DERMATOL, V99, P836, DOI 10.1111/1523-1747.ep12614800; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; SCHULMAN ES, 1993, CRIT REV IMMUNOL, V13, P35; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; SUZUKI K, 1995, BIOCHEM J, V305, P301, DOI 10.1042/bj3050301; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TANAKA H, 1993, BIOCHEM BIOPH RES CO, V190, P732, DOI 10.1006/bbrc.1993.1110; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; WEEKS BS, 1993, J CELL PHYSIOL, V157, P644, DOI 10.1002/jcp.1041570326; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	47	145	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25628	25635		10.1074/jbc.272.41.25628	http://dx.doi.org/10.1074/jbc.272.41.25628			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325284	hybrid			2022-12-27	WOS:A1997YA35800039
J	Honda, Z; Suzuki, T; Hirose, N; Aihara, M; Shimizu, T; Nada, S; Okada, M; Ra, CS; Morita, Y; Ito, K				Honda, Z; Suzuki, T; Hirose, N; Aihara, M; Shimizu, T; Nada, S; Okada, M; Ra, CS; Morita, Y; Ito, K			Roles of C-terminal Src kinase in the initiation and the termination of the high affinity IgE receptor-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FC-EPSILON-RI; ACTIVATING-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; MAP KINASE; T-CELL; CYTOPLASMIC DOMAINS; IMMUNOGLOBULIN-E; GAMMA-SUBUNITS; FAMILY KINASES	As an attempt to analyze the roles of C-terminal Src kinase (Csk) in the high affinity IgE receptor (Fc epsilon RI)-mediated signaling, we overexpressed Csk, a membrane-targeted form of Csk (mCsk), and a kinase-defective, membrane-targeted form of Csk (mCsk(-)) in rat basophil leukemia (RBL) 2H3 cells. Specific activity of Lyn at the basal state was decreased in Csk-expressing cells, and further decreased in mCsk-expressing cells. In mCsk(-)-expressing cells, basal specific activity of Lyn was increased, thereby indicating that mCsk(-) functioned as a dominant negative molecule. The onset of Fc epsilon RI-mediated Lyn activation was delayed in Csk-expressing cells, and further delayed in mCsk-expressing cells. In mCsk(-)-expressing cells, Lyn activation was rapid and quite long lasting. These findings indicate (i) Csk negatively regulates rapid Fc epsilon RI/Lyn coupling, and (ii) Csk activity is potentially required for its termination. The onsets of the series of events including tyrosyl phosphorylation of Syk, mitogen-activated protein (MAP) kinase activation, elevation of intracellular calcium concentration ([Ca2+](i)), and histamine release were all stepwisely delayed in Csk-expressing cells and in mCsk-expressing cells. The durations of Syk phosphorylation and MAP kinase activation also closely correlated with those of Lyn activation, but [Ca2+](i) elevation and histamine release followed different temporal patterns: the delayed responses in Csk-expressing cells and in mCsk-expressing cells led to sustained [Ca2+](i) oscillation and histamine release, while the prompt responses in parent cells and mCsk(-)-expressing cells rapidly subsided. These findings provide further evidence that the initiations of the Fc epsilon RI-mediated signals are upstreamly regulated by Src family protein tyrosine kinases and revealed that their terminations are regulated by Lyn-dependent (Syk and MAP kinase) and -independent ([Ca2+](i) elevation and histamine release) mechanisms.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,INST PROT RES,DIV PROT METAB,SUITA,OSAKA 565,JAPAN; JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; Osaka University; Juntendo University	Honda, Z (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED & PHYS THERAPY,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							ALBER G, 1991, J BIOL CHEM, V266, P22613; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Jouvin M H, 1995, Semin Immunol, V7, P29, DOI 10.1016/1044-5323(95)90005-5; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MIYAZAKI J, 1989, GENE, V79, P269; Mori M, 1996, J NEUROSCI, V16, P3590; MORITA Y, 1989, INT ARCH ALLER A IMM, V88, P332, DOI 10.1159/000234820; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEET K, 1995, MOL CELL BIOL, V15, P4908; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; TOBE K, 1991, J BIOL CHEM, V266, P24793; Tobe K, 1996, MOL CELL BIOL, V16, P4765; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	59	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25753	25760		10.1074/jbc.272.41.25753	http://dx.doi.org/10.1074/jbc.272.41.25753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325302	hybrid			2022-12-27	WOS:A1997YA35800057
J	Wu, SH; McDowell, MT; Lagarias, JC				Wu, SH; McDowell, MT; Lagarias, JC			Phycocyanobilin is the natural precursor of the phytochrome chromophore in the green alga Mesotaenium caldariorum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN-IX-ALPHA; CYANIDIUM-CALDARIUM; PARTIAL-PURIFICATION; BIOSYNTHESIS; PHYCOBILINS; EXPRESSION; HOLOPHYTOCHROME; ARABIDOPSIS; SEQUENCES; EVOLUTION	Compared with phytochromes isolated from etiolated higher plant tissues and a number of lower plant species, the absorption spectrum of phytochrome isolated from the unicellular green alga Mesotaenium caldariorum is blue-shifted (Kidd, D. G., and Lagarias, J. C. (1990) J. Biol. Chem. 265, 7029-7035). The present studies were undertaken to determine whether this blue shift is due to a chromophore other than phytochromobilin or reflects a different protein environment for the phytochromobilin prosthetic group. Using reversed phase high performance liquid chromatography, we show that soluble protein extracts prepared from algal chloroplasts contain the enzyme activities for ferredoxin-dependent conversions of biliverdin IX alpha to (3Z)-phytochromobilin and (3Z)-phytochromobilin to (3Z)-phycocyanobilin. In vitro assembly of recombinant algal apophytochrome was undertaken with (3E)-phytochromobilin and (3E)-phycocyanobilin. The difference spectrum of the (3E)-phycocyanobilin adduct was indistinguishable from that of phytochrome isolated from dark-adapted algal cells, while the (3E)-phytochromobilin adduct displayed red-shifted absorption maxima relative to purified algal phytochrome. These studies indicate that phycocyanobilin is the immediate precursor of the green algal phytochrome chromophore and that phytochromobilin is an intermediate in its biosynthesis in Mesotaenium.	UNIV CALIF DAVIS,SECT MOL & CELL BIOL,DAVIS,CA 95616	University of California System; University of California Davis			Lagarias, John Clark/L-3139-2013; Wu, Shu-Hsing/B-4317-2009	Lagarias, John Clark/0000-0002-2093-0403; Wu, Shu-Hsing/0000-0002-7179-3138				BEALE SI, 1983, PLANT PHYSIOL, V71, P263, DOI 10.1104/pp.71.2.263; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLACK T, 1994, PLANT MOL BIOL, V25, P413, DOI 10.1007/BF00043870; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; CORDONNIER MM, 1986, BIOCHEMISTRY-US, V25, P7657, DOI 10.1021/bi00371a057; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; ELICH TD, 1989, J BIOL CHEM, V264, P12902; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KIDD DG, 1990, J BIOL CHEM, V265, P7029; Koornneef Maarten, 1994, P601; Lamparter T, 1995, J PLANT PHYSIOL, V147, P426, DOI 10.1016/S0176-1617(11)82178-4; LI LM, 1992, J BIOL CHEM, V267, P19204; LINDEMANN P, 1989, PLANTA, V178, P436, DOI 10.1007/BF00963812; MACHEMER C, 1964, THESIS HASRVARD U CA; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; OYAMA H, 1990, PLANT CELL PHYSIOL, V31, P1229; PRATT LH, 1995, PHOTOCHEM PHOTOBIOL, V61, P10, DOI 10.1111/j.1751-1097.1995.tb09238.x; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; RHIE GE, 1992, J BIOL CHEM, V267, P16088; SAGER R, 1953, ANN NY ACAD SCI, V56, P831, DOI 10.1111/j.1749-6632.1953.tb30261.x; SHARROCK RA, 1989, GENE DEV, V3, P1745, DOI 10.1101/gad.3.11.1745; TAYLOR AO, 1967, PLANT PHYSIOL, V42, P762, DOI 10.1104/pp.42.6.762; TERRY MJ, 1995, J BIOL CHEM, V270, P11111, DOI 10.1074/jbc.270.19.11111; TERRY MJ, 1993, J BIOL CHEM, V268, P26099; Terry MJ, 1997, PLANT CELL ENVIRON, V20, P740, DOI 10.1046/j.1365-3040.1997.d01-102.x; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; TOHUHISA JG, 1987, PLANTA, V172, P371; VIERSTRA RD, 1982, PLANTA, V156, P158, DOI 10.1007/BF00395430; WADA M, 1989, ANNU REV PLANT PHYS, V40, P169; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439; Wu SH, 1996, P NATL ACAD SCI USA, V93, P8989, DOI 10.1073/pnas.93.17.8989	36	55	61	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25700	25705		10.1074/jbc.272.41.25700	http://dx.doi.org/10.1074/jbc.272.41.25700			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325294	hybrid			2022-12-27	WOS:A1997YA35800049
J	Allen, RG; Keogh, BP; Tresini, M; Gerhard, GS; Volker, C; Pignolo, RJ; Horton, J; Cristofalo, VJ				Allen, RG; Keogh, BP; Tresini, M; Gerhard, GS; Volker, C; Pignolo, RJ; Horton, J; Cristofalo, VJ			Development and age-associated differences in electron transport potential and consequences for oxidant generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; DISMUTASE INDUCES DIFFERENTIATION; MITOCHONDRIAL GENE-EXPRESSION; HYDROGEN-PEROXIDE PRODUCTION; RAT-HEART MITOCHONDRIA; ACETYL-L-CARNITINE; SUPEROXIDE-DISMUTASE; CYTOCHROME-OXIDASE; RESPIRATORY-CHAIN; PHOSPHATE CARRIER	We determined the activities of NADH dehydrogenase (ND), succinate dehydrogenase, and cytochrome c oxidase (COX) in 29 skin fibroblast lines established from donors ranging in age from 12 gestational weeks to 94 years. The results of this study demonstrate that all three of the enzyme activities examined are greater in adult-derived fibroblasts than in the fetal cell lines, The ratio of enzyme activities that control electron entry into and exit from the electron transport chain varied directly with lucigenin detected chemiluminescence (an indicator of O-.(2)- generation) and inversely with H2O2 generation, These results indicate a clear difference in the predominant oxidant species generated during fetal and adult stages of life. We also examined the mRNA abundances of different components of the electron transport chain complexes. We observed higher abundances of mitochondrial encoded mRNAs (COX 1 and ND 4) in cell lines established from adults than in fetal cells. No differences in the mRNA abundances of the nuclear encoded sequences (COX 4 and ND 51) were observed in fetal and postnatal-derived Lines. Succinate dehydrogenase mRNA abundance was greater in cell Lines established from postnatal donors than in fetal cell lines. No significant differences between cell Lines established from young and old adults were detected in any of the parameters examined.			Allen, RG (corresponding author), ALLEGHENY UNIV,CTR GERONTOL RES,2900 QUEEN LA,PHILADELPHIA,PA 19129, USA.			Tresini, Maria/0000-0001-7711-3204	NIA NIH HHS [AG00378, AG00131, AG00523] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AITKEN RJ, 1992, J CELL PHYSIOL, V151, P466, DOI 10.1002/jcp.1041510305; ALLEN RG, 1983, BIOCHEM J, V216, P503, DOI 10.1042/bj2160503; ALLEN RG, 1995, J CELL PHYSIOL, V165, P576; ALLEN RG, 1988, J CLIN INVEST, V82, P731, DOI 10.1172/JCI113654; ALLEN RG, 1988, ARCH BIOCHEM BIOPHYS, V261, P205, DOI 10.1016/0003-9861(88)90119-1; ALLEN RG, 1989, FREE RADICAL BIO MED, V6, P631, DOI 10.1016/0891-5849(89)90071-3; ALLEN RG, 1991, P SOC EXP BIOL MED, V196, P117; ATTARDI G, 1990, BIOCHEM SOC T, V18, P509, DOI 10.1042/bst0180509; AU HC, 1995, GENE, V159, P249, DOI 10.1016/0378-1119(95)00162-Y; BASS DA, 1983, J IMMUNOL, V130, P1910; BECKMAN BS, 1989, J CELL PHYSIOL, V139, P370, DOI 10.1002/jcp.1041390220; BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; Boffoli D, 1996, BBA-MOL BASIS DIS, V1315, P66, DOI 10.1016/0925-4439(95)00107-7; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P16; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cristofalo VJ, 1980, J TISSUE CULTURE MET, V6, P117; Djouadi F, 1996, BIOCHEM J, V315, P555, DOI 10.1042/bj3150555; DOGGETT DL, 1992, MECH AGEING DEV, V65, P239, DOI 10.1016/0047-6374(92)90039-G; FARMER KJ, 1989, FREE RADICAL BIO MED, V7, P23, DOI 10.1016/0891-5849(89)90096-8; FAULKNER K, 1993, FREE RADICAL BIO MED, V15, P447, DOI 10.1016/0891-5849(93)90044-U; FOREMAN HJ, 1981, OXYGEN LIVING PROCES, P65; FOREMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; Galante Y M, 1978, Methods Enzymol, V53, P15; Halliwell B, 1981, AGE PIGMENTS, P1; Hatefi Y, 1978, Methods Enzymol, V53, P21; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; Hatefi Y, 1978, Methods Enzymol, V53, P27; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HEGNER D, 1980, MECH AGEING DEV, V14, P101, DOI 10.1016/0047-6374(80)90109-8; HODGSON EK, 1973, PHOTOCHEM PHOTOBIOL, V18, P451, DOI 10.1111/j.1751-1097.1973.tb06449.x; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Keogh BP, 1996, J CELL PHYSIOL, V167, P512, DOI 10.1002/(SICI)1097-4652(199606)167:3<512::AID-JCP15>3.3.CO;2-L; KODAMA S, 1995, EXP CELL RES, V219, P82, DOI 10.1006/excr.1995.1207; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LANG CA, 1992, J LAB CLIN MED, V120, P720; LIOCHEV SI, 1997, ARCH BIOCHEM BIOPHYS, V337, P155; MADDEN EA, 1987, ANAL BIOCHEM, V163, P350, DOI 10.1016/0003-2697(87)90235-1; MARINGARCIA J, 1994, J MOL CELL CARDIOL, V26, P1029, DOI 10.1006/jmcc.1994.1123; Matsuo M., 1993, FREE RADICALS AGING, P143; MUTVEI A, 1989, ARCH BIOCHEM BIOPHYS, V268, P215, DOI 10.1016/0003-9861(89)90582-1; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; NOHL H, 1986, FREE RADICALS AGING, P79; NOY N, 1985, MECH AGEING DEV, V29, P63, DOI 10.1016/0047-6374(85)90047-8; Ostronoff LK, 1996, BIOCHEM J, V316, P183, DOI 10.1042/bj3160183; PARADIES G, 1991, ARCH BIOCHEM BIOPHYS, V284, P332, DOI 10.1016/0003-9861(91)90304-2; PARADIES G, 1992, BIOCHIM BIOPHYS ACTA, V1103, P324, DOI 10.1016/0005-2736(92)90103-S; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; PARADIES G, 1992, INT J BIOCHEM, V24, P783, DOI 10.1016/0020-711X(92)90012-P; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Rafael J, 1983, METHOD ENZYMAT AN, P266; RAGAN CI, 1990, BIOCHEM SOC T, V18, P515, DOI 10.1042/bst0180515; REMBISH SJ, 1994, FREE RADICAL BIO MED, V17, P117, DOI 10.1016/0891-5849(94)90109-0; RIKANS LE, 1988, BIOCHIM BIOPHYS ACTA, V966, P269, DOI 10.1016/0304-4165(88)90076-1; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; ROTHE G, 1994, METHOD ENZYMOL, V233, P539; SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I; SOHAL RS, 1990, FREE RADICAL BIO MED, V9, P495, DOI 10.1016/0891-5849(90)90127-5; SOHAL RS, 1990, MECH AGEING DEV, V53, P217, DOI 10.1016/0047-6374(90)90040-M; SOHAL RS, 1993, FREE RADICAL BIO MED, V14, P583, DOI 10.1016/0891-5849(93)90139-L; SOHAL RS, 1991, MECH AGEING DEV, V57, P187, DOI 10.1016/0047-6374(91)90034-W; SOHAL RS, 1989, MECH AGEING DEV, V49, P129, DOI 10.1016/0047-6374(89)90096-1; SOHAL RS, 1983, MECH AGEING DEV, V24, P185; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; SUGIYAMA S, 1993, BIOCHEM MOL BIOL INT, V30, P937; SUN AS, 1975, ARCH BIOCHEM BIOPHYS, V170, P1, DOI 10.1016/0003-9861(75)90092-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TURRENS JF, 1990, FREE RADICALS LIPOPR, P203; VANDENBOGERT C, 1993, BIOCHIM BIOPHYS ACTA, V1144, P177, DOI 10.1016/0005-2728(93)90170-K; VasquezVivar J, 1997, FEBS LETT, V403, P127, DOI 10.1016/S0014-5793(97)00036-7; VORBECK ML, 1982, ARCH BIOCHEM BIOPHYS, V217, P351, DOI 10.1016/0003-9861(82)90511-2; WIELBURSKI A, 1984, FEBS LETT, V177, P291, DOI 10.1016/0014-5793(84)81302-2; WIELBURSKI A, 1982, BIOCHEM J, V204, P239, DOI 10.1042/bj2040239; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919	80	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24805	24812		10.1074/jbc.272.40.24805	http://dx.doi.org/10.1074/jbc.272.40.24805			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312077	hybrid			2022-12-27	WOS:A1997XY97000016
J	Freemantle, SJ; Moran, RG				Freemantle, SJ; Moran, RG			Transcription of the human folylpoly-gamma-glutamate synthetase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CHINESE-HAMSTER CELLS; B-LINEAGE; METHOTREXATE POLYGLUTAMATES; EXPRESSION; ACCUMULATION; ORGANIZATION; RESISTANCE; MUTANTS; CLONING	In mammals, folylpoly-gamma-glutamate synthetase (FPGS) activity is found in any cell undergoing sustained proliferative phases, but this enzyme also displays a tissue-specific pattern of expression in differentiated tissues, It is now reported that the steady state levels of FPGS mRNA in normal and neoplastic cells reflect these patterns, supporting the concept that the control mechanisms underlying this distribution are transcriptional. To initiate an understanding of these interacting levels of control, me have determined the position and properties of the minimal FPGS promoter controlling transcription of the FPGS gene in human CEM leukemia cells, a line which expresses high levels of this enzyme and its mRNA The TATA-less region immediately upstream of the major transcriptional start site previously mapped in human tumor cells, which includes several GC- and Y-boxes, functioned as a remarkably efficient promoter when used to drive expression of a luciferase reporter in transient expression studies in CEM cells, The minimal region of the FPGS promoter required for maximal transcriptional activation in CEM cells included the 80 base pairs over which the multiple transcriptional start sites were located, and the 43 base pairs immediately upstream. DNase I footprint analysis detected the binding of Sp1 at all seven of the consensus sites within the probe used, two of which are contained within the minimal promoter region. The several Sp1 sites immediately upstream of the first major transcriptional start activated transcription in Drosophila cells when cotransfected with an Sp1 construct, including those in the region which functioned as a minimal promoter in CEM cells, An additional region of the minimal promoter, situated between the two translational start codons of the FPGS gene, was bound by protein(s) from HeLa cell nuclear extracts. We conclude that transcription of the FPGS gene in CEM cells involves transactivation events over a limited upstream DNA sequence and that the FPGS promoter used in proliferating hu- man leukemic cells has strong similarity to other TATA-less promoters that utilize tandem, closely spaced Sp1 sites to initiate transcription.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, MASSEY CANC CTR, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL CANCER INSTITUTE [R01CA027605, R01CA039687] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27605, CA 39687] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARREDO J, 1992, MOL PHARMACOL, V42, P687; BARREDO JC, 1994, BLOOD, V84, P564; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EGAN MG, 1995, J BIOL CHEM, V270, P5462, DOI 10.1074/jbc.270.10.5462; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FORT DW, 1993, BRIT J HAEMATOL, V84, P595, DOI 10.1111/j.1365-2141.1993.tb03133.x; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; LANS MS, 1994, J BIOL CHEM, V269, P14170; LI WW, 1992, CANCER RES, V52, P3908; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MORAN RG, 1984, ANAL BIOCHEM, V140, P326, DOI 10.1016/0003-2697(84)90174-X; PIZZORNO G, 1988, CANCER RES, V48, P2149; Roy K, 1997, J BIOL CHEM, V272, P5587, DOI 10.1074/jbc.272.9.5587; ROY K, 1995, J BIOL CHEM, V270, P26918, DOI 10.1074/jbc.270.45.26918; RUMBERGER BG, 1990, CANCER RES, V50, P4639; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Spinella MJ, 1996, BBA-GENE STRUCT EXPR, V1305, P11, DOI 10.1016/0167-4781(95)00193-X; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TAYLOR SM, 1995, CANCER RES, V55, P6030; Tse Archie, 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P304; WHITEHEAD VM, 1992, BLOOD, V80, P1316; WHITEHEAD VM, 1990, BLOOD, V76, P44	30	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25373	25379		10.1074/jbc.272.40.25373	http://dx.doi.org/10.1074/jbc.272.40.25373			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312158	hybrid			2022-12-27	WOS:A1997XY97000097
J	Orford, K; Crockett, C; Jensen, JP; Weissman, AM; Byers, SW				Orford, K; Crockett, C; Jensen, JP; Weissman, AM; Byers, SW			Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR PROTEIN; SIGNAL-TRANSDUCTION; XENOPUS EMBRYOS; CELL-ADHESION; ARMADILLO; PATHWAY; STABILITY; COMPLEX; INSULIN	Several lines of evidence suggest that accumulation of cytoplasmic beta-catenin transduces an oncogenic signal We show that beta-catenin is ubiquitinated and degraded by the proteosome and that beta-catenin stability is regulated by a diacylglycerol-independent protein kinase C-like kinase activity, which is required for beta-catenin ubiquitination. We also define a sis-amino acid sequence found in both beta-catenin and the NF-kappa B regulatory protein I kappa B alpha, which, upon phosphorylation, targets both proteins for ubiquitination. Mutation of a single serine within the ubiquitination targeting sequence prevents ubiquitination of beta-catenin. Mutations within the ubiquitination targeting sequence of beta-catenin may be oncogenic.	GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; NCI,DCBD,NIH,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Byers S, 1996, ENDOCRINOLOGY, V137, P3265, DOI 10.1210/en.137.8.3265; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GOODE N, 1992, J BIOL CHEM, V267, P16878; Gumbiner B, 1997, CURR OPIN CELL BIOL, V7, P634; HOU D, 1994, J BIOL CHEM, V269, P14244; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; MANJI HK, 1995, ARCH GEN PSYCHIAT, V52, P531; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SOMMERS CL, 1994, CANCER RES, V54, P3544; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; WOODGETT JR, 1993, BIOCHEM SOC T, V21, P905, DOI 10.1042/bst0210905; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	29	615	639	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24735	24738		10.1074/jbc.272.40.24735	http://dx.doi.org/10.1074/jbc.272.40.24735			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312064	hybrid			2022-12-27	WOS:A1997XY97000003
J	Doubeikovski, A; Uzan, G; Doubeikovski, Z; Prandini, MH; Porteu, F; Gisselbrecht, S; DusanterFourt, I				Doubeikovski, A; Uzan, G; Doubeikovski, Z; Prandini, MH; Porteu, F; Gisselbrecht, S; DusanterFourt, I			Thrombopoietin-induced expression of the glycoprotein IIb gene involves the transcription factor PU.1/Spi-1 in UT7-Mpl cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MEGAKARYOCYTIC FEATURES; ACTIVATION PROPERTIES; PLATELET ACTIVATION; HEMATOPOIETIC-CELLS; 5'-FLANKING REGION; RECEPTOR MPL; ETS ONCOGENE; FACTOR PU.1; GPIIB GENE	Thrombopoietin (TPO) is the major regulator of proliferation and differentiation of megakaryocytes and their progenitors. These actions can be reproduced in the human megakaryoblastic cell line UT7 into which the murine TPO receptor, c-Mpl, was introduced, In these cells, TPO enhanced the expression of the specific megakaryocytic marker integrin glycoprotein (GP) IIb-IIIa while decreasing the expression of erythroid genes (Porteu, F,, Rouyez, M.-C., Cocault, L,, Benit, L,, Charon, M., Picard, F., Gisselbrecht, S,, Souyri, M., and Dusanter-Fourt I, (1996) Mol Cell. Biol 16, 2473-2482. We have now analyzed the effect of TPO on the transcriptional activity of the GPIIb promoter in these cells, Using transient transfection assays of a series of human GPIIb promoter fragments, we delineated a TPO-responsive element within the previously reported enhancer region of the promoter. Although this enhancer included GATA- and Ets-binding sites (EBSs), we found that only EBS -514 was important for TPO response, We identified PU.1/Spi-1 as the endogenous Ets transcription factor that strongly and preferentially interacted with this enhancer EBS. This factor did not interact with other proximal EBSs in the GPIIb promoter. We next showed that TPO) induced a strong and selective increase of PU.1/Spi-1 expression and DNA binding activity in UT7-Mpl cells, in contrast, TPO did not affect the expression of Ets-1/2 while weakly increasing the levels of Fli-1. Overexpression of PU.1/Spi-1 was further shown to enhance GPIIb promoter activity in the absence and presence of TPO. Overall, our data indicated that, in UT7-Mpl cells, TPO increased the transcriptional activity of a GPIIb gene in part due to an enhanced expression of an unexpected transcription factor, the Eb family PU.1/Spi-1 factor, To our knowledge, this is the first evidence of a role for the PU.1/Spi-1 factor in the regulation of megakaryocytic genes.	HOP COCHIN, INSERM U363, INST COCHIN GENET MOL, F-75014 PARIS, FRANCE; HOP PAUL BROUSSE, INSERM U268, F-94807 VILLEJUIF, FRANCE; CEA, F-38054 GRENOBLE 9, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA			PORTEU, Françoise/I-8445-2016; Dusanter-Fourt, Isabelle/P-4558-2017; Uzan, Georges/M-8199-2018	PORTEU, Françoise/0000-0002-2403-4163; Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Uzan, Georges/0000-0002-0178-5386				Athanasiou M, 1996, CELL GROWTH DIFFER, V7, P1525; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BLOCK KL, 1994, BLOOD, V84, P3385; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; CarverMoore K, 1996, BLOOD, V88, P803; CHEN JC, 1995, BLOOD, V86, P4054, DOI 10.1182/blood.V86.11.4054.bloodjournal86114054; DELGADO MD, 1994, ONCOGENE, V9, P1723; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; FONG AM, 1994, J BIOL CHEM, V269, P18441; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GEGONNE A, 1992, NEW BIOL, V4, P512; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; HROMAS R, 1993, BLOOD, V82, P2998; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMATSU N, 1991, CANCER RES, V51, P341; LANZA F, 1993, J BIOL CHEM, V268, P20801; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MARTIN F, 1993, J BIOL CHEM, V268, P21606; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PAOLETTI F, 1995, BLOOD, V86, P2624; Porteu F, 1996, MOL CELL BIOL, V16, P2473; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TRONIKLEROUX D, 1995, J EXP MED, V181, P2141, DOI 10.1084/jem.181.6.2141; UZAN G, 1991, J BIOL CHEM, V266, P8932; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZUTTER MM, 1995, BLOOD, V86, P3006	43	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24300	24307		10.1074/jbc.272.39.24300	http://dx.doi.org/10.1074/jbc.272.39.24300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305885	hybrid			2022-12-27	WOS:A1997XY51500036
J	Engfelt, WH; Shackelford, JE; Aboushadi, N; Jessani, N; Masuda, K; Paton, VG; Keller, GA; Krisans, SK				Engfelt, WH; Shackelford, JE; Aboushadi, N; Jessani, N; Masuda, K; Paton, VG; Keller, GA; Krisans, SK			Characterization of UT2 cells - The induction of peroxisomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; RAT-LIVER PEROXISOMES; MEVALONATE-DERIVED PRODUCT; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; IMMUNOELECTRON MICROSCOPY; SACCHAROMYCES-CEREVISIAE; REGULATED DEGRADATION; MEMBRANE DOMAIN	In the liver 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is present not only in the endoplasmic reticulum but also in the peroxisomes, However, to date no information is available regarding the function of the peroxisomal HMG-CoA reductase in cholesterol/isoprenoid metabolism, and the structure of the peroxisomal HMG-CoA reductase has yet to be determined. We have identified a mammalian cell line that expresses only one HMG-CoA reductase protein and that is localized exclusively to peroxisomes, This cell line was obtained by growing UT2 cells (which lack the en doplasmic reticulum HMG-CoA reductase) in the absence of mevalonate. The cells exhibited a marked increase in a 90-kDa HMG-CoA reductase that was localized exclusively to peroxisomes, The wild type Chinese hamster ovary cells contain two HMG-CoA reductase proteins, the well characterized 97-kDa protein, localized in the endoplasmic reticulum, and a 90-kDa protein localized in peroxisomes. The UT2 cells grown in the absence of mevalonate containing the up-regulated peroxisomal HMG-CoA reductase are designated UT2*. A detailed characterization and analysis of this cell line is presented in this study.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; GENENTECH INC,DEPT PRECLIN PHARMACOL,S SAN FRANCISCO,CA 94080	California State University System; San Diego State University; Roche Holding; Genentech					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032852] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32852] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELKVIST EL, 1989, EUR J BIOCHEM, V185, P503, DOI 10.1111/j.1432-1033.1989.tb15142.x; BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BIARDI L, 1994, J BIOL CHEM, V269, P1197; BURMESTER A, 1994, EUR J BIOCHEM, V220, P403, DOI 10.1111/j.1432-1033.1994.tb18637.x; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P7704, DOI 10.1073/pnas.79.24.7704; CHOI D, 1992, PLANT CELL, V4, P1333, DOI 10.1105/tpc.4.10.1333; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHYE ML, 1992, PLANT MOL BIOL, V19, P473, DOI 10.1007/BF00023395; DANPURE CJ, 1995, TRENDS CELL BIOL, V5, P230, DOI 10.1016/S0962-8924(00)89016-9; DIMSTERDENK D, 1994, MOL BIOL CELL, V5, P655, DOI 10.1091/mbc.5.6.655; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; EDWARDS PA, 1979, J LIPID RES, V20, P40; ENJUTO M, 1994, P NATL ACAD SCI USA, V91, P927, DOI 10.1073/pnas.91.3.927; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; Hampton R, 1996, TRENDS BIOCHEM SCI, V21, P140, DOI 10.1016/S0968-0004(96)80168-X; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; LISCUM L, 1983, J BIOL CHEM, V258, P8450; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NARITA JO, 1989, PLANT CELL, V1, P181, DOI 10.1105/tpc.1.2.181; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PARKER RA, 1993, J BIOL CHEM, V268, P11230; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PEFFLEY DM, 1992, SOMAT CELL MOLEC GEN, V18, P19, DOI 10.1007/BF01233446; RAMHARACK R, 1990, DNA CELL BIOL, V9, P677, DOI 10.1089/dna.1990.9.677; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; RUSNAK N, 1987, BIOCHEM BIOPH RES CO, V148, P890, DOI 10.1016/0006-291X(87)90959-4; SHAPIRO DJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P369, DOI 10.1016/0005-2744(74)90098-9; STERMER BA, 1994, J LIPID RES, V35, P1133; STRAKA MS, 1995, ARCH BIOCHEM BIOPHYS, V317, P235, DOI 10.1006/abbi.1995.1158; TANAKA RD, 1983, J BIOL CHEM, V258, P3331; VOLKL A, 1986, JPN SOC CELL BIOL, V289, P13	42	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24579	24587		10.1074/jbc.272.39.24579	http://dx.doi.org/10.1074/jbc.272.39.24579			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305924	hybrid			2022-12-27	WOS:A1997XY51500075
J	Gho, YS; Chae, CB				Gho, YS; Chae, CB			Anti-angiogenin activity of the peptides complementary to the receptor-binding site of angiogenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; TUMOR-GROWTH; PROTEIN; RIBONUCLEASE; RECOGNITION; FIBRONECTIN; SEQUENCE; ADHESION; INHIBIT	Angiogenesis promotes growth and metastasis of tumor cells, In this study, we have developed two peptide antagonists of human angiogenin by deducing the codes from the antisense RNA sequence. corresponding to the receptor-binding site of angiogenin in either 5' --> 3' (chANG) or 3' --> 5' (chGNA) direction. chANG and chGNA peptides bind to angiogenin with specificity and high affinity (K-d approximate to 44 nM) and inhibit the interaction of angiogenin with actin, which is regarded as the angiogenin-binding protein on the surface of endothelial cells. The peptides inhibit the neovascularization induced by angiogenin in the chick chorioallantoic membrane assay. The anti angiogenic activity of the peptides is specific for angiogenin, and the peptides do not have any apparent effect on embryonic angiogenesis or the preexisting blood vessels. chANG and chGNA also inhibit She angiogenesis induced by the angiogenin-secreting PC 3 human prostate adenocarcinoma cells and have no direct effect on the proliferation as well as the adhesion of PC 3 cells to angiogenin. Therefore, the inhibition of the tumor-induced angiogenesis by the peptides is most likely caused by neutralization of the extracellular angiogenin secreted by PC 3 cells, Based on our results, chANG and chGNA peptides may be effective for treatment of various human tumors which secrete angiogenin.	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27514	Pohang University of Science & Technology (POSTECH); University of North Carolina; University of North Carolina Chapel Hill								ACHARYA KR, 1995, P NATL ACAD SCI USA, V92, P2949, DOI 10.1073/pnas.92.7.2949; ACHARYA KR, 1994, P NATL ACAD SCI USA, V91, P2915, DOI 10.1073/pnas.91.8.2915; BADET J, 1989, P NATL ACAD SCI USA, V86, P8427, DOI 10.1073/pnas.86.21.8427; BARSHAVIT R, 1991, J CELL BIOL, V12, P335; BEINTEMA JJ, 1984, ANAL BIOCHEM, V136, P48, DOI 10.1016/0003-2697(84)90306-3; BICKNELL R, 1989, P NATL ACAD SCI USA, V86, P1573, DOI 10.1073/pnas.86.5.1573; BICKNELL R, 1988, P NATL ACAD SCI USA, V85, P5961, DOI 10.1073/pnas.85.16.5961; BLALOCK JE, 1984, BIOCHEM BIOPH RES CO, V121, P203, DOI 10.1016/0006-291X(84)90707-1; BOST KL, 1985, P NATL ACAD SCI USA, V82, P1372, DOI 10.1073/pnas.82.5.1372; BRENTANI RR, 1988, P NATL ACAD SCI USA, V85, P364, DOI 10.1073/pnas.85.2.364; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Folkman J, 1976, Int Rev Exp Pathol, V16, P207; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; HALLAHAN TW, 1991, P NATL ACAD SCI USA, V88, P2222, DOI 10.1073/pnas.88.6.2222; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; KNUTSON VP, 1988, J BIOL CHEM, V263, P14146; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOENNER M, 1994, EUR J BIOCHEM, V226, P483, DOI 10.1111/j.1432-1033.1994.tb20073.x; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; OLSON KA, 1994, CANCER RES, V54, P4576; OLSON KA, 1995, P NATL ACAD SCI USA, V92, P442, DOI 10.1073/pnas.92.2.442; PASQUALINI R, 1989, J BIOL CHEM, V264, P14566; RAINES RT, 1995, J BIOL CHEM, V270, P17180, DOI 10.1074/jbc.270.29.17180; RYBAK SM, 1989, BIOCHEM BIOPH RES CO, V162, P535, DOI 10.1016/0006-291X(89)92030-5; SHAI Y, 1987, BIOCHEMISTRY-US, V26, P669, DOI 10.1021/bi00377a002; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; SONCIN F, 1992, P NATL ACAD SCI USA, V89, P2232, DOI 10.1073/pnas.89.6.2232; SONCIN F, 1994, J BIOL CHEM, V269, P8999	33	37	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24294	24299		10.1074/jbc.272.39.24294	http://dx.doi.org/10.1074/jbc.272.39.24294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305884	hybrid			2022-12-27	WOS:A1997XY51500035
J	Guttridge, DC; Lau, A; Tran, L; Cunningham, DD				Guttridge, DC; Lau, A; Tran, L; Cunningham, DD			Thrombin causes a marked delay in skeletal myogenesis that correlates with the delayed expression of myogenin and p21(CIP1/WAF1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE WITHDRAWAL; PROTEASE NEXIN-I; RECEPTOR ACTIVATION; PLASMINOGEN ACTIVATORS; MUSCLE DIFFERENTIATION; NEUROMUSCULAR SYSTEM; MOLECULAR-CLONING; NERVOUS-SYSTEM; INHIBITOR; BINDING	Thrombin is a multifunctional serine protease whose activity is regulated in the extravasculature by an extracellular inhibitor, protease nexin-l. Because protease nexin-l expression has been shown to be regulated during skeletal muscle cell differentiation, we reasoned that thrombin inactivation may be an important requirement for this developmental process, To test this hypothesis, we examined the effects of thrombin on differentiating C2C12 myoblasts. We report here that myogenesis, as scored by myotube formation, is considerably delayed by thrombin, This regulation correlated with delayed expression of myogenin and p21(CIP1/WAF1), both considered critical components of the skeletal muscle cell differentiation program, Regulation occurred at the RNA level, indicating that the effect of thrombin is either transcriptional or post-transcriptional. Further more, we present evidence suggesting that this regulation is mediated by the thrombin receptor. Although thrombin is mitogenic for certain cell types, we found that delay of myogenesis in C2C12 cells did not involve a mitogenic signal, Taken together, these results imply that inhibition of the serine protease thrombin may be required for proper progression through the myogenic differentiation program, The data point to potentially important roles that thrombin and protease nexin-l may play during skeletal muscle development.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOL GENET,IRVINE,CA 92697	University of California System; University of California Irvine				Guttridge, Denis/0000-0002-7276-6609	NIA NIH HHS [AG 10598, AG 00538] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG000538, R01AG010598] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; CARNEY DH, 1978, J CELL PHYSIOL, V95, P13, DOI 10.1002/jcp.1040950103; CHEN J, 1994, J BIOL CHEM, V269, P16041; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FESTOFF BW, 1991, J CELL PHYSIOL, V147, P76, DOI 10.1002/jcp.1041470111; FESTOFF BW, 1990, J CELL PHYSIOL, V144, P272, DOI 10.1002/jcp.1041440213; GLOOR S, 1986, CELL, V47, P687; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; GUTTRIDGE DC, 1993, J BIOL CHEM, V268, P18966; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HOUENOU LJ, 1995, P NATL ACAD SCI USA, V92, P895, DOI 10.1073/pnas.92.3.895; HUPPI K, 1994, ONCOGENE, V9, P3017; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; MANSUY IM, 1993, DEVELOPMENT, V119, P1119; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PERRAUD F, 1987, INT J DEV NEUROSCI, V5, P181, DOI 10.1016/0736-5748(87)90028-1; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; VAUGHAN PJ, 1994, BRAIN RES, V668, P160, DOI 10.1016/0006-8993(94)90521-5; VerdiereSahuque M, 1996, EXP CELL RES, V222, P70, DOI 10.1006/excr.1996.0009; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WAGNER SL, 1989, J BIOL CHEM, V264, P611; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	31	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24117	24120		10.1074/jbc.272.39.24117	http://dx.doi.org/10.1074/jbc.272.39.24117			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305855	hybrid			2022-12-27	WOS:A1997XY51500006
J	Harrington, C; Lan, Y; Akman, SA				Harrington, C; Lan, Y; Akman, SA			The identification and characterization of a G4-DNA resolvase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TELOMERE-BINDING-PROTEIN; QUADRUPLEX NUCLEIC-ACIDS; G-QUARTET FORMATION; YEAST GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; TOPOISOMERASE-II; MAMMALIAN-CELLS; BETA-SUBUNIT; GENOMIC RNA; DNA	There is increasing evidence that four-stranded Hoogsteen-bonded DNA structures, G4-DNA, play an important role in cellular processes such as meiosis and recombination. The Hoogsteen-bonded G4-DNA is thermodynamically more stable than duplex DNA, and many guanine-rich genomic DNA sequences with the ability to form G4-DNA have been identified. A protein-dependent activity that resolves G4-DNA into single-stranded DNA has been identified in human placental tissue. The resolvase activity was purified from any apparent nuclease activity and is dependent on NTP hydrolysis and MgCl2. Resolvase activity is optimal with 5 mM MgCl2. The V-max/K-m of ATP is 0.055%/min/mu M, higher than the V-max/K-m of the other dNTPs. The products of the resolvase reaction are unmodified single-stranded DNA. The resolvase is not a duplex DNA helicase or a topoisomerase II activity and does not unwind Hoogsteen-bonded tripler DNA. Resolvase is a novel activity that unwinds stable G4-DNA structures using a dNTP-dependent mechanism producing unmodified single-stranded DNA. Potential in vivo roles for this G4-DNA resolvase activity are discussed.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT CANC BIOL, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, CTR COMPREHENS CANC, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [CA-12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKMAN SA, 1991, BIOCHEMISTRY-US, V30, P8648, DOI 10.1021/bi00099a022; AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHUNG IK, 1992, NUCLEIC ACIDS RES, V20, P1973, DOI 10.1093/nar/20.8.1973; FANG GW, 1993, BIOCHEMISTRY-US, V32, P11646, DOI 10.1021/bi00094a022; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRANTZ JD, 1995, J BIOL CHEM, V270, P9413, DOI 10.1074/jbc.270.16.9413; FRANTZ JD, 1995, J BIOL CHEM, V270, P20692, DOI 10.1074/jbc.270.35.20692; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KIM JM, 1990, GENETICS, V126, P799; KORNBERG A, 1992, DNA REPLICATION, P379; LU M, 1993, BIOCHEMISTRY-US, V32, P598, DOI 10.1021/bi00053a027; Lui Z., 1993, P NATL ACAD SCI USA, V90, P3157; LUI Z, 1994, CELL, V77, P1083; MAINE IP, 1994, BIOCHEM BIOPH RES CO, V204, P1119, DOI 10.1006/bbrc.1994.2578; MORAES EC, 1990, CARCINOGENESIS, V11, P283, DOI 10.1093/carcin/11.2.283; PELEG M, 1995, NUCLEIC ACIDS RES, V23, P1292, DOI 10.1093/nar/23.8.1292; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIERER T, 1994, BIOCHEMISTRY-US, V33, P2240, DOI 10.1021/bi00174a034; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHIMIZU A, 1984, CELL, V36, P801, DOI 10.1016/0092-8674(84)90029-1; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SMITH SS, 1989, BIOCHEM BIOPH RES CO, V160, P1397, DOI 10.1016/S0006-291X(89)80159-7; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WALSH K, 1992, J BIOL CHEM, V267, P13714; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; WANG Y, 1993, J MOL BIOL, V234, P1171, DOI 10.1006/jmbi.1993.1668; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WEISMANSHOMER P, 1994, BIOCHEM BIOPH RES CO, V205, P305, DOI 10.1006/bbrc.1994.2665; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	36	51	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24631	24636		10.1074/jbc.272.39.24631	http://dx.doi.org/10.1074/jbc.272.39.24631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305932	hybrid			2022-12-27	WOS:A1997XY51500083
J	Ratovitski, T; Slunt, HH; Thinakaran, G; Price, DL; Sisodia, SS; Borchelt, DR				Ratovitski, T; Slunt, HH; Thinakaran, G; Price, DL; Sisodia, SS; Borchelt, DR			Endoproteolytic processing and stabilization of wild-type and mutant presenilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; CAENORHABDITIS-ELEGANS; MISSENSE MUTATIONS; IN-VIVO; GENE; CELLS	Presenilin 1 (PS1), mutated in pedigrees of early-onset familial Alzheimer's disease, is a polytopic integral membrane protein that is endoproteolytically cleaved into 27-kDa N-terminal and 17-kDa C-terminal fragments, Although these fragments are the principal PSI species found in normal mammalian brain, the role of endoproteolysis in the maturation of PS1 has been unclear. The present study, which uses stably transfected mouse neuroblastoma N2a cells, demonstrates that full-length polypeptides, derived from either wild-type or A246E FAD-mutant human (hu) PSII, are relatively short-lived (t(1/2), 1.5 h) proteins that give rise to the N- and C-terminal PS1 fragments, which are more stable (t(1/2) similar to 24 h), N-terminal fragments, generated artificially by engineering a stop codon at amino acid 306 (PS1-306) of wild-type huPS1, were short-lived, whereas an FAD-linked variant that lacked exon 9 (Delta E9) and was not endoproteolytically cleaved exhibited a long half-life. These observations suggest that endoproteolytic cleavage and stability are not linked, leading us to propose a model ill which wild-type full-length huPS1 molecules are first stabilized then subsequently endoproteolytically cleaved to generate the N- and C-terminal fragments, These fragments appear to represent the mature and functional Terms of wild-type huPS1.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV NEUROPATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NIA NIH HHS [AG05146, AG07914] Funding Source: Medline; NINDS NIH HHS [NS10580] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005146, R35AG007914] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; LO ACY, 1994, J BIOL CHEM, V269, P30966; LO ACY, 1995, J BIOL CHEM, V270, P12641, DOI 10.1074/jbc.270.21.12641; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SLUNT HH, 1995, AMYLOID, V2, P188, DOI 10.3109/13506129509036925; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652	24	192	196	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24536	24541		10.1074/jbc.272.39.24536	http://dx.doi.org/10.1074/jbc.272.39.24536			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305918	hybrid			2022-12-27	WOS:A1997XY51500069
J	Jervis, EJ; Haynes, CA; Kilburn, DG				Jervis, EJ; Haynes, CA; Kilburn, DG			Surface diffusion of cellulases and their isolated binding domains on cellulose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE PHOTOBLEACHING RECOVERY; CRYSTALLINE CELLULOSE; BACTERIAL CELLULASE; MEMBRANE-PROTEINS; FIMI; EXOGLUCANASE; ADSORPTION; RESIDUES; MOBILITY; CENA	The surface diffusion rate of bacterial cellulases from Cellulomonas fimi on cellulose was quantified using fluorescence recovery after photobleaching analysis. Studies were performed on an exo-beta-1-4-glycanase (Cex), an endo-beta-1-4-glucanase (CenA), and their respective isolated cellulose-binding domains (CBDs). Although these cellulose-binding domains hind irreversibly to microcrystalline cellulose, greater than 70% of bound molecules are mobile on the cellulose surface. Surface diffusion rates are dependent on surface coverage and range from a low of 2 x 10(-11) to a maximum of 1.2 x 10(-10) cm(2)/s. The fraction of mobile molecules increases only slightly with increasing fractional surface coverage density. Results demonstrate that the packing of C. fimi cellulases and their isolated binding domains onto the cellulose surface is a dynamic process. This suggests that the exclusion of potential CBD binding sites on the cellulose due to steric effects of neighboring bound CBDs may not fully explain the apparent negative cooperativity exhibited in CBD adsorption isotherms. Comparison with the kinetics of cellulase hydrolysis of crystalline substrate suggests that surface diffusion rates do not limit cellulase activity.	UNIV BRITISH COLUMBIA, BIOTECHNOL LAB, PROT ENGN NETWORK CTR EXCELLENCE, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT CHEM ENGN, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia; University of British Columbia; University of British Columbia								ABNEY JR, 1989, BIOPHYS J, V55, P817, DOI 10.1016/S0006-3495(89)82882-6; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BLONK JCG, 1993, J MICROSC-OXFORD, V169, P363, DOI 10.1111/j.1365-2818.1993.tb03312.x; BRINKLEY M, 1993, PERSPECTIVES BIOCONJ, P59; Creagh AL, 1996, P NATL ACAD SCI USA, V93, P12229, DOI 10.1073/pnas.93.22.12229; DAMUDE HG, 1995, BIOCHEMISTRY-US, V34, P2220, DOI 10.1021/bi00007a016; DIN N, 1991, BIO-TECHNOL, V9, P1096, DOI 10.1038/nbt1191-1096; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; GARDNER KH, 1974, BIOPOLYMERS, V13, P1975, DOI 10.1002/bip.1974.360131005; GASPERS PB, 1994, LANGMUIR, V10, P2699, DOI 10.1021/la00020a032; GILKES NR, 1992, J BIOL CHEM, V267, P6743; GILKES NR, 1993, INT J BIOL MACROMOL, V15, P347, DOI 10.1016/0141-8130(93)90052-N; GREENWOOD JM, 1994, BIOTECHNOL BIOENG, V44, P1295, DOI 10.1002/bit.260441105; HENIS YI, 1988, BIOPOLYMERS, V27, P123, DOI 10.1002/bip.360270110; KATCHALSKIKATZIR E, 1985, BIOPOLYMERS, V24, P257, DOI 10.1002/bip.360240120; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEINKE A, 1993, J BACTERIOL, V175, P1910, DOI 10.1128/JB.175.7.1910-1918.1993; MINTON AP, 1989, BIOPHYS J, V55, P805, DOI 10.1016/S0006-3495(89)82880-2; ONG E, 1993, BIOTECHNOL BIOENG, V42, P401, DOI 10.1002/bit.260420402; ONG E, 1991, ENZYME MICROB TECH, V13, P59, DOI 10.1016/0141-0229(91)90189-H; PETERS R, 1974, BIOCHIM BIOPHYS ACTA, V367, P282, DOI 10.1016/0005-2736(74)90085-6; Revol JF, 1982, CARBOHYD POLYM, V2, P123; SCALETTAR BA, 1988, P NATL ACAD SCI USA, V85, P6726, DOI 10.1073/pnas.85.18.6726; STOUT AL, 1995, PHOTOCHEM PHOTOBIOL, V62, P239, DOI 10.1111/j.1751-1097.1995.tb05264.x; TILTON RD, 1990, BIOPHYS J, V58, P1321, DOI 10.1016/S0006-3495(90)82473-5; Tomme P, 1995, ACS SYM SER, V618, P142; TOMME P, 1995, J BACTERIOL, V177, P4356, DOI 10.1128/jb.177.15.4356-4363.1995; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	28	164	168	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24016	24023		10.1074/jbc.272.38.24016	http://dx.doi.org/10.1074/jbc.272.38.24016			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295354	hybrid			2022-12-27	WOS:A1997XX38100079
J	PalsRylaarsdam, R; Gurevich, VV; Lee, KB; Ptasienski, JA; Benovic, JL; Hosey, MM				PalsRylaarsdam, R; Gurevich, VV; Lee, KB; Ptasienski, JA; Benovic, JL; Hosey, MM			Internalization of the m2 muscarinic acetylcholine receptor - Arrestin-independent and -dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; CHOLINERGIC RECEPTORS; PROTEIN; AGONIST; DYNAMIN; CELLS; DESENSITIZATION; IDENTIFICATION; ENDOCYTOSIS; MECHANISMS	Recent studies have identified agonist-dependent phosphorylation as a critical event in the rapid uncoupling of the m2 muscarinic cholinergic receptors (mAChR) rom G-proteins and sequestration of the receptors away hom the cell surface, However, mutant m2 mAChRs were identified that were phosphorylated but unable to desensitize in adenylyl cyclase assays, while they internalized like wild type (WT) mAChRs, Ne have tested whether these properties might stem from differences in the abilities of the WT and mutant mAChR to bind arrestins, proteins implicated in both receptor-/G-protein uncoupling and internalization, We have de determined that arresting binding requires phosphorylation at a cluster of Ser/Thr residues ia amino acids 307-311 in the m2 mAChR, A strong correlation was found between the ability of WT and mutant receptors to bind arrestins in vitro or in vivo and to desensitize in adenylyl cyclase assays, However, the phosphorylation dependent internalization of the m2 mAChR in HEK-tsA201 cells did not require arrestins and did not proceed via clathrin-mediated endocytosis, While the m2 mAChR was able to enter a clathrin-and arrestin-dependent pathway when arrestin 2 or arrestin 3 was significantly overexpressed, the preferred pathway al internalization of WT and certain mutant m2 mAChR in HEK-tsA201 cells did not involve participation of arrestins. The results suggest that the phosphorylation-mediated regulation of the m2 mAChR may involve arrestin-dependent and -independent events.	NORTHWESTERN UNIV,SCH MED,DEPT MOL PHARMACOL & BIOL CHEM,CHICAGO,IL 60614; SUN HLTH RES INST,SUN CITY,AZ 85372; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107	Northwestern University; Banner Research; Banner Health; Banner Sun Health Research Institute; Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER; NEI NIH HHS [EY11500] Funding Source: Medline; NHLBI NIH HHS [HL50121] Funding Source: Medline; NIGMS NIH HHS [GM4494] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; Bogatkewitsch GS, 1996, MOL PHARMACOL, V50, P424; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUAN XM, 1992, J BIOL CHEM, V267, P21995; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LIGGETT SB, 1994, REGULATION SIGNAL TR, P25; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MORO O, 1993, J BIOL CHEM, V268, P6862; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SCHERER NM, 1990, BIOCHEMISTRY-US, V29, P8475, DOI 10.1021/bi00488a039; SINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Tolbert LM, 1996, J BIOL CHEM, V271, P17335, DOI 10.1074/jbc.271.29.17335; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	28	151	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23682	23689		10.1074/jbc.272.38.23682	http://dx.doi.org/10.1074/jbc.272.38.23682			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295310	hybrid			2022-12-27	WOS:A1997XX38100035
J	Arteaga, CL; Ramsey, TT; Shawver, LK; Guyer, CA				Arteaga, CL; Ramsey, TT; Shawver, LK; Guyer, CA			Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EGF-RECEPTOR; SIGNAL-TRANSDUCTION; POINT MUTATION; TRANSMEMBRANE DOMAIN; CARCINOMA-CELLS; NUCLEOTIDE-BINDING; INDUCED ACTIVATION; MEMBRANE-VESICLES; EXTERNAL DOMAIN	Receptor dimerization is critical for signaling by the epidermal growth factor receptor (EGFR) tyrosine kinase, This occurs after binding of the receptor's extracellular domain by ligand or bivalent antibodies, The role of other receptor domains in dimerization is less clear, and there are no examples of dimers induced by direct perturbation of the EGFR kinase domain, Submicromolar concentrations of AG-1478 and AG-1517, quinazolines specific for inhibition of the EGFR kinase, induced reversible receptor dimerization in vitro and in intact A431 cells, Consistent with the inhibitory effect of quinazolines on receptor kinase activity, the dimers formed lacked a detectable Tyr(P) signal. Quinazoline-induced EGFR dimerization was abrogated in vitro by ATP and the ATP analog adenyl-5'-yl imidodiphosphate, Receptors with a single-point mutation in the ATP binding site as well as wild-type EGFR with a covalent modification of the ATP site failed to dimerize in response to AG-1478 and AG-1517, These data suggest that EGFR dimerization can be induced by the interaction of quinazolines at the ATP site in the absence of receptor ligand binding, In SKBR-3 cells, the quinazolines induced the formation of inactive EGFR/ ErbB-2 heterodimers, potentially sequestering ErbB-2 from interacting with other coreceptors of the ErbB family, Structural studies of the quinazoline interaction with the EGFR tyrosine kinase domain should allow for an analysis of receptor-specific chemical features required for binding to the ATP site and disruption of signaling, a strategy that can be perhaps applied to other tumor cell receptor systems.	VANDERBILT UNIV,SCH MED,VANDERBILT CANC CTR,DEPT CELL BIOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232; SUGEN INC,REDWOOD CITY,CA 94063; VANDERBILT UNIV,DEPT MOL BIOL,NASHVILLE,TN 37235	Vanderbilt University; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), VANDERBILT UNIV,SCH MED,DIV MED ONCOL,VANDERBILT CANC CTR,DEP MED,1161 22ND AVE S,1956 TVC,NASHVILLE,TN 37232, USA.				NATIONAL CANCER INSTITUTE [R55CA065943, R01CA062212] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA62212, R55 CA65943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALIMANDI M, 1995, ONCOGENE, V10, P1813; ARTEAGA CL, 1994, CANCER RES, V54, P4703; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASU M, 1986, J BIOL CHEM, V261, P2879; BUHROW SA, 1982, J BIOL CHEM, V257, P4019; BUHROW SA, 1983, J BIOL CHEM, V258, P7824; CARPENTER CD, 1991, J BIOL CHEM, V266, P5750; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1993, FORUM, V3, P616; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Cheng KR, 1996, J BIOL CHEM, V271, P311, DOI 10.1074/jbc.271.1.311; COCHET C, 1988, J BIOL CHEM, V263, P3290; COHEN S, 1982, J BIOL CHEM, V257, P1523; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1994, J BIOL CHEM, V269, P27595; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; GUYER CA, 1994, ARCH BIOCHEM BIOPHYS, V312, P573, DOI 10.1006/abbi.1994.1347; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; IMAI Y, 1982, CANCER RES, V42, P4394; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; KWATRA MM, 1992, BIOCHIM BIOPHYS ACTA, V1134, P178, DOI 10.1016/0167-4889(92)90042-A; LANGTON BC, 1991, CANCER RES, V51, P2593; LAX I, 1991, J BIOL CHEM, V266, P13828; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; QIAN XL, 1994, ONCOGENE, V9, P1507; RUSSO MW, 1985, J BIOL CHEM, V260, P5205; SELVA E, 1993, J BIOL CHEM, V268, P2250; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STOSCHECK CM, 1983, ARCH BIOCHEM BIOPHYS, V227, P457, DOI 10.1016/0003-9861(83)90476-9; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Zhang K, 1996, J BIOL CHEM, V271, P3884	61	125	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23247	23254		10.1074/jbc.272.37.23247	http://dx.doi.org/10.1074/jbc.272.37.23247			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287333	hybrid			2022-12-27	WOS:A1997XV74400044
J	Bailly, V; Lauder, S; Prakash, S; Prakash, L				Bailly, V; Lauder, S; Prakash, S; Prakash, L			Yeast DNA repair proteins Rad6 and Rad18 form a heterodimer that has ubiquitin conjugating, DNA binding, and ATP hydrolytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MUTAGENESIS; SEQUENCE; UV; MUTATIONS; ENCODES; ENZYME	The RAD6 and RAD18 genes of Saccharomyces cerevisiae are required far postreplicative bypass of ultraviolet (UV)-damaged DNA and for UV mutagenesis. The RAD6 encoded protein is a ubiquitin conjugating enzyme, and RAD18 encodes a protein containing a RING finger motif and a nucleotide binding motif, Rad18 can be co-immunoprecipitated with Rad6, indicating that the two proteins exist in a complex in vivo. Here, we co-overproduce the two proteins using a yeast multicopy plasmid, purify the Rad6-Rad18 complex to near homogeneity, and show that the complex is heterodimeric. The Rad6-Rad18 heterodimer has ubiquitin conjugating activity, binds single-stranded DNA, and possesses single-stranded DNA-dependent ATPase activity. The Rad6-Rad18 complex provides the first example wherein a ubiquitin conjugating activity is physically associated with DNA binding and ATPase activities provided by an associated protein factor, The co-existence of these activities should provide the complex with the ability to recognize single-stranded DNA resulting from stalling of the replication machinery at DNA damage sites and to recognize the components of the DNA replication machinery for ubiquitination by Rad6.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019261] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19261] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG JD, 1994, MUTAT RES-DNA REPAIR, V315, P281, DOI 10.1016/0921-8777(94)90039-6; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; FRIEDBERG EC, 1995, DNA REPAIR; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAWRENCE CW, 1982, ADV GENET, V21, P173, DOI 10.1016/S0065-2660(08)60299-0; LAWRENCE CW, 1985, MOL GEN GENET, V200, P86, DOI 10.1007/BF00383317; LEMONTT JF, 1970, GENETICS, V68, P21; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023	22	245	253	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23360	23365		10.1074/jbc.272.37.23360	http://dx.doi.org/10.1074/jbc.272.37.23360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287349	hybrid			2022-12-27	WOS:A1997XV74400060
J	Macrez, N; Morel, JL; Kalkbrenner, F; Viard, P; Schultz, G; Mironneau, J				Macrez, N; Morel, JL; Kalkbrenner, F; Viard, P; Schultz, G; Mironneau, J			A beta gamma dimer derived from G(13) transduces the angiotensin AT(1) receptor signal to stimulation of Ca2+ channels in rat portal vein myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HETEROTRIMERIC G-PROTEINS; PANCREATIC ACINAR-CELLS; CALCIUM CHANNELS; INTRACELLULAR STORES; SYNTHETIC PEPTIDES; ADENYLYL-CYCLASE; SMOOTH-MUSCLE; ACTIVATION; SUBUNITS	A G protein composed of alpha(13), beta(1) and gamma(3) subunits selectively couples the angiotensin AT(1A) receptors to increase cytoplasmic Ca2+ concentration ([Ca2+](i)) in rat portal vein myocytes (Macrez-Lepretre, N., Kalkbrenner, F., Morel, J. L., Schultz, G., and Mironneau, J. (1997) J. Biol. Chem. 272, 10095-10102). We show here that G beta gamma transduces the signal leading to stimulation of L-type Ca2+ channels, Intracellular dialysis through the patch pipette of a carboxyl-terminal anti-beta(com) antibody and a peptide corresponding to the G beta gamma binding region of She beta-adrenergic receptor kinase 1 inhibited the stimulation of Ca2+ channels and the increase in [Ca2+](i) evoked by angiotensin II. The G beta gamma binding peptide did not prevent the dissociation of the heterotrimeric G protein into its subunits, as it did not block activation of phospholipase C-beta by G alpha(q) in response to stimulation of alpha(1)-adrenoreceptors. Transient overexpression of the beta-adrenergic receptor kinase 1 fragment and of G alpha subunits also inhibited the angiotensin II-induced increase in [Ca2+](i). Both anti-alpha(13) antibody and carboxyl-terminal alpha(13) peptide abrogated the angiotensin II-induced stimulation of Ca2+ channels, We conclude that activation of angiotensin AT(1) receptors requires all three alpha, beta, and gamma subunits of G(13) for receptor-G protein interaction, whereas the transduction of the signal to L-type Ca2+ channels is mediated by G beta gamma.	UNIV BORDEAUX 2,LAB PHYSIOL CELLULAIRE & PHARMACOL MOL,CNRS,ESA 5017,F-33076 BORDEAUX,FRANCE; FREE UNIV BERLIN,INST PHARMAKOL,D-14195 BERLIN,GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Free University of Berlin			Morel, Jean-Luc/AAY-9235-2020	morel, jean-luc/0000-0001-8079-6851; MACREZ, Nathalie/0000-0002-3844-4403				ARKINSTALL S, 1995, FEBS LETT, V364, P45, DOI 10.1016/0014-5793(95)00351-9; Arnaudeau S, 1996, BIOCHEM BIOPH RES CO, V222, P809, DOI 10.1006/bbrc.1996.0808; BARNETT RL, 1993, AM J PHYSIOL, V265, pC1100, DOI 10.1152/ajpcell.1993.265.4.C1100; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Coso OA, 1996, J BIOL CHEM, V271, P3963; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dolphin AC, 1996, TRENDS NEUROSCI, V19, P35, DOI 10.1016/0166-2236(96)81865-0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GANITKEVICH VY, 1990, J PHYSIOL-LONDON, V426, P19, DOI 10.1113/jphysiol.1990.sp018125; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; GUTIERREZ LM, 1994, BIOCHEM BIOPH RES CO, V202, P857, DOI 10.1006/bbrc.1994.2009; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HELL JW, 1993, J BIOL CHEM, V268, P19451; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LASSEGUE B, 1993, BIOCHEM J, V292, P509, DOI 10.1042/bj2920509; LEPRETRE N, 1994, J PHARMACOL EXP THER, V268, P167; LEPRETRE N, 1994, PFLUG ARCH EUR J PHY, V429, P253, DOI 10.1007/BF00374320; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MACREZLEPRETRE N, 1995, PFLUG ARCH EUR J PHY, V430, P590, DOI 10.1007/BF00373897; MacrezLepretre N, 1996, J PHARMACOL EXP THER, V278, P468; MacrezLepretre N, 1997, J BIOL CHEM, V272, P5261, DOI 10.1074/jbc.272.8.5261; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Morel JL, 1996, BRIT J PHARMACOL, V118, P73, DOI 10.1111/j.1476-5381.1996.tb15368.x; Murthy KS, 1996, J BIOL CHEM, V271, P23458, DOI 10.1074/jbc.271.38.23458; NAIR LA, 1995, CIRC RES, V76, P832, DOI 10.1161/01.RES.76.5.832; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; PELET C, 1995, EUR J PHARMACOL, V279, P15, DOI 10.1016/0014-2999(95)00125-5; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR JM, 1994, CELL SIGNAL, V6, P841, DOI 10.1016/0898-6568(94)90017-5; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG J, 1993, J BIOL CHEM, V268, P22251	45	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23180	23185		10.1074/jbc.272.37.23180	http://dx.doi.org/10.1074/jbc.272.37.23180			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287322	hybrid			2022-12-27	WOS:A1997XV74400033
J	Monteclaro, FS; Charo, IF				Monteclaro, FS; Charo, IF			The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1 - Receptor activation by a pseudo-tethered ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; EXTRACELLULAR DOMAIN; CHEMOKINE RECEPTORS; HIV-1 ENTRY; SIGNAL-TRANSDUCTION; MUTAGENESIS; CELLS; MECHANISM; COFACTOR	High affinity binding of monocyte chemoattractant protein 1 (MCP-1) requires the presence of the amino-terminal domain of CCR2, the MCP-1 receptor. Here we report that the 35 amino-terminal residues of CCR2, expressed as a membrane-bound fusion protein, bound MCP-1 with an affinity similar to that of the intact, wildtype receptor, Furthermore, the amino-terminal fusion protein enhanced, in trans, agonist-dependent activation of a CCR2 variant that was engineered to lacks the high affinity binding sites for MCP-1. Mutation of highly conserved cysteines in the amino-terminal domain and third extracellular loop of CCR2, but not in the fusion protein, resulted in a dramatic loss of MCP-1 binding, suggesting the existence of a critical intramolecular disulfide bond that positions the amino-terminal protein for ligand interaction. These data indicate that the amino-terminal region of CCR2 is both necessary and sufficient for the high affinity binding of MCP-1 and provide the first direct evidence for activation of a chemokine receptor by a pseudo-tethered ligand. In this model, high affinity binding by the relatively short amino-terminal domain of CCR2 serves to tether MCP-1 and enhance low affinity interactions with distal regions of the receptor.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHEN J, 1994, J BIOL CHEM, V269, P16041; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; Herzig MCS, 1996, J BIOL CHEM, V271, P29746, DOI 10.1074/jbc.271.47.29746; ISHII K, 1993, J BIOL CHEM, V268, P9780; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; SCHALL TJ, 1994, CYTOKINE HDB, P419; SEETHARAMAIAH GS, 1994, ENDOCRINOLOGY, V134, P549, DOI 10.1210/en.134.2.549; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	31	87	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23186	23190		10.1074/jbc.272.37.23186	http://dx.doi.org/10.1074/jbc.272.37.23186			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287323	hybrid			2022-12-27	WOS:A1997XV74400034
J	Panneerselvam, K; Etchison, JR; Freeze, HH				Panneerselvam, K; Etchison, JR; Freeze, HH			Human fibroblasts prefer mannose over glucose as a source of mannose for N-glycosylation - Evidence for the functional importance of transported mannose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT GLYCOPROTEIN SYNDROME; LINKED OLIGOSACCHARIDE BIOSYNTHESIS; HAMSTER OVARY CELLS; SERUM GLYCOPROTEINS; MAMMALIAN-CELLS; STARVATION; 1-DEOXYMANNOJIRIMYCIN; DIFFERENTIATION; ELECTROPHORESIS; CHROMATOGRAPHY	Mannose in N-linked oligosaccharides is assumed to be derived primarily from glucose through phosphomannose isomerase (PMI), The discovery of mammalian mannose-specific transporters that function at physio logical concentrations suggested that mannose might directly contribute to oligosaccharide synthesis, To determine the relative contribution of glucose and mannose, human fibroblasts were labeled with either [2-H-3]mannose or [1,5,6-H-3]glucose at the same specific activity, and the N-linked chains were released by PN-Gase F digestion, Most of the trichloroacetic acid-precipitable [H-3]mannose label was released by this digestion, but only about 10% of the trichloroacetic acid precipitable material was released from cells labeled with [1,5,6-H-3]glucose. Both sugars labeled a similar array of oligosaccharides, and acid hydrolysis of these chains showed that [2-H-3]mannose contributed 65-75% of the [H-3]mannose in cells labeled for 1 h, despite the 100-fold higher concentration of exogenous glucose, Mannose consumption and [2-H-3]mannose utilization were within the range of rates expected for mannose transport via the mannose-specific transporter. About 7-14% of the [2-H-3]mannose is used for glycosylation, while the rest (86-93%) is catabolized to (H2O)-H-3 via PMI, Increasing the exogenous mannose concentration beyond mannose transporter saturation results in the conversion of >99% of [2-H-3]mannose into (H2O)-H-3. Long term labeling of cells with [2-H-3]mannose showed that the specific activity of mannose in glycoproteins reached 77% of the specific activity of [2-H-3]mannose added to the medium, These results show that when fibroblasts are provided with physiological concentrations of mannose, they use the mannose-specific transporter to supply the majority of mannose needed for glycoprotein synthesis, PMI may normally be used to catabolize excess mannose rather than to primarily supply Man-6-P for glycoprotein synthesis.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute			Chen, Tianren/AAS-6018-2021	Freeze, Hudson/0000-0001-6316-0501	NIGMS NIH HHS [GM RO1 49096] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049096] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAZAWA S, 1986, J CLIN ENDOCR METAB, V62, P984, DOI 10.1210/jcem-62-5-984; ALVARES K, 1982, BIOCHIM BIOPHYS ACTA, V708, P124, DOI 10.1016/0167-4838(82)90212-6; ASIKIN N, 1979, BIOCHEM BIOPH RES CO, V89, P279, DOI 10.1016/0006-291X(79)90975-6; BAUMANN H, 1983, J BIOL CHEM, V258, P3942; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; DAVIDSON SK, 1985, J GEN VIROL, V66, P1457, DOI 10.1099/0022-1317-66-7-1457; DEREPENTIGNY L, 1983, J CLIN MICROBIOL, V17, P1166, DOI 10.1128/JCM.17.6.1166-1169.1983; Etchison JR, 1997, CLIN CHEM, V43, P533; GERSHMAN H, 1981, J BIOL CHEM, V256, P7774; GHOSH AK, 1972, J NEUROCHEM, V19, P1279, DOI 10.1111/j.1471-4159.1972.tb01453.x; GOOCHEE CF, 1992, DEV BIOLOGICALS, V76, P95; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GRACY RW, 1968, J BIOL CHEM, V243, P3161; Gravel P, 1996, BIOCHEM BIOPH RES CO, V220, P78, DOI 10.1006/bbrc.1996.0360; HAGBERG BA, 1993, PEDIATR NEUROL, V9, P255, DOI 10.1016/0887-8994(93)90060-P; HARRIS RA, 1992, TXB BIOCH CLIN CORRE, P261; HARRISON HH, 1992, CLIN CHEM, V38, P1390; Jaeken J, 1991, Acta Paediatr Scand Suppl, V375, P1; JAEKEN J, 1993, GLYCOBIOLOGY, V3, P423, DOI 10.1093/glycob/3.5.423; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANDBERG E, 1995, BIOCHEM BIOPH RES CO, V210, P267, DOI 10.1006/bbrc.1995.1656; MENDICINO J, 1975, EUR J BIOCHEM, V51, P547, DOI 10.1111/j.1432-1033.1975.tb03955.x; MENON AK, 1994, METHOD ENZYMOL, V230, P418; NIEWIAROWSKA A, 1987, J BIOL CHEM, V262, P14815; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; OGIERDENIS E, 1990, J BIOL CHEM, V265, P5366; OGIERDENIS E, 1994, J BIOL CHEM, V269, P4285; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; Panneerselvam K, 1996, J BIOL CHEM, V271, P9417, DOI 10.1074/jbc.271.16.9417; PAYTON MA, 1991, J BACTERIOL, V173, P2006, DOI 10.1128/jb.173.6.2006-2010.1991; PITKANEN E, 1994, BIOL MASS SPECTROM, V23, P590, DOI 10.1002/bms.1200230909; POWELL LD, 1994, J CLIN INVEST, V94, P1901, DOI 10.1172/JCI117540; REARICK JI, 1981, J BIOL CHEM, V256, P6255; RUDERMAN NB, 1974, BIOCHEM J, V138, P1; RUSH JS, 1995, ANAL BIOCHEM, V224, P494, DOI 10.1006/abio.1995.1078; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHWARTZ NB, 1992, TXB BIOCH CLIN CORRE, P329; SHUI RPB, 1977, P NATL ACAD SCI USA, V74, P3840; SOYAMA K, 1984, CLIN CHEM, V30, P293; SPIRO RG, 1983, J BIOL CHEM, V258, P9469; STARK NJ, 1979, ARCH BIOCHEM BIOPHYS, V192, P599, DOI 10.1016/0003-9861(79)90131-0; TACHIBANA H, 1994, CYTOTECHNOLOGY, V16, P151, DOI 10.1007/BF00749902; TACHIBANA H, 1994, TRENDS GLYCOSCI GLYC, V6, P465; TOMITA K, 1990, ANN NY ACAD SCI, V613, P421, DOI 10.1111/j.1749-6632.1990.tb18191.x; TURCO SJ, 1982, J BIOL CHEM, V257, P8674; TURCO SJ, 1982, ARCH BIOCHEM BIOPHYS, V205, P330; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1994, METHOD ENZYMOL, V230, P16; WOOD FC, 1963, J CLIN INVEST, V42, P1300, DOI 10.1172/JCI104814; YUASA I, 1995, BRAIN DEV-JPN, V17, P13, DOI 10.1016/0387-7604(94)00099-J	51	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23123	23129		10.1074/jbc.272.37.23123	http://dx.doi.org/10.1074/jbc.272.37.23123			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287314	hybrid			2022-12-27	WOS:A1997XV74400025
J	Aghdasi, B; Reid, MB; Hamilton, SL				Aghdasi, B; Reid, MB; Hamilton, SL			Nitric oxide protects the skeletal muscle Ca2+ release channel from oxidation induced activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; REACTIVE OXYGEN; CALCIUM-RELEASE; MEMBRANES	Reactive oxygen intermediates and nitric oxide modulate the contractile function of skeletal muscle fibers, possibly via direct interaction with the Ca2+ release channel, Oxidants produce disulfide bonds between subunits of the Ca2+ release channel tetramer, and this is accompanied by an increase in channel activity, The sulfhydryl alkylating agent N-ethylmaleimide has three distinct effects on Ca2+ release channel activity: first, channel activity is decreased (phase 1); then with continued exposure the activity is dramatically increased (phase 2); and finally, the channel is again inhibited (phase 3) (Aghdasi, B., Zhang, J. Z., Wu, Y., Reid, M. B., and Hamilton, S. L., (1997) J. Biol. Chem. 272, 3739-3749). Both H2O2 and nitric oxide (NO) block the phase 1 inhibitory effect of N-ethylmaleimide. NO donors, at concentrations that have no detectable effect on channel activity, block intersubunit cross-linking and prevent activation of the channel by the disulfide inducing agent, diamide, These findings support a model in which NO modulates the activity of the Ca2+ release channel by preventing oxidation of regulatory sulfhydryls. However, higher concentrations of NO donors activate the channel and produce intersubunit cross-links, supporting a bifunctional effect of NO on channel activity, Low NO concentrations prevent oxidation of the Ca2+ release channel whereas higher concentrations oxidize it.	BAYLOR COLL MED,DEPT MOL PHYSIOL & BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Hamilton, Susan/0000-0003-0241-9369	NHLBI NIH HHS [HL45721] Funding Source: Medline; NIAMS NIH HHS [AR41802] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; AGHDASI B, 1996, BIOPHYS J, V70, pA147; BORASO A, 1994, AM J PHYSIOL, V267, pH1010, DOI 10.1152/ajpheart.1994.267.3.H1010; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20857; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LIU GH, 1994, MOL PHARMACOL, V45, P189; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Meszaros LG, 1996, FEBS LETT, V380, P49, DOI 10.1016/0014-5793(96)00003-8; MESZAROS LG, 1996, BIOPHYS J, V70, pA1453; RARDON DP, 1990, CIRC RES, V67, P84, DOI 10.1161/01.RES.67.1.84; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; ROSEMBLATT M, 1981, J BIOL CHEM, V256, P8140; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; STOYANOVSKY TD, 1996, BIOPHYS J, V70, pA257	21	106	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25462	25467		10.1074/jbc.272.41.25462	http://dx.doi.org/10.1074/jbc.272.41.25462			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325258	hybrid			2022-12-27	WOS:A1997YA35800013
J	DelNery, E; Juliano, MA; Lima, APCA; Scharfstein, J; Juliano, L				DelNery, E; Juliano, MA; Lima, APCA; Scharfstein, J; Juliano, L			Kininogenase activity by the major cysteinyl proteinase (Cruzipain) from Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-CELL INVASION; PORPHYROMONAS-GINGIVALIS; MAMMALIAN-CELLS; INHIBITORS; GP57/51; PROTEASE; IDENTIFICATION; EPIMASTIGOTES; PURIFICATION; SPECIFICITY	The major isoform of Trypanosona cruzi cysteinyl proteinase (cruzipain) has generated Lys-bradykinin (Lys-BK or kallidin), a proinflammatory peptide, by proteolysis of kininogen. The releasing of this peptide was demonstrated by mass spectrometry, radioimmunoassay, and ileum contractile responses, The kinin-releasing activity was immunoabsorbed selectively by monoclonal antibodies to the characteristic COOH-terminal domain of cruzipain. To determine the hydrolysis steps that account for the kininogenase activity of cruzipain, we synthesized a fluorogenic peptide (o-aminobenzoyl-Leu-Gly-Met-Ile-Ser-Leu-Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg(389)-Ser(390)-Ser-Arg-Ile-NH2) based on the sequence Leu(373) to Ile(393) of the human high molecular weight kininogen, The hydrolysis products from this peptide were isolated by high performance liquid chromatography, and Lys-BK was characterized as the major released kinin by mass spectrometry. Intramolecularly quenched fluorogenic peptides spanning the Met(379)-Lys(380) and Arg(389)-Ser(390) bradykinin-flanking sequences were then used to assess the substrate specificity re requirements of the parasite-derived protease compared with two COOH-terminal truncated recombinant isoforms (cruzain and cruzipain 2). In contrast to the high catalytic efficiency of parasite-derived cruzipain, the recombinant proteinases cleaved the bradykinin-flanking sites at markedly different rates. In addition, we also demonstrated that cruzipain activates plasmatic prekallikrein, which would be a second and indirect way of the parasite protease to release bradykinin.	UNIV FED SAO PAULO, ESCOLA PAULISTA MED, DEPT BIOPHYS, BR-04044020 SAO PAULO, BRAZIL; UNIV FED RIO DE JANEIRO, INST BIOFIS CARLOS CHAGAS FILHO, LAB MOL IMMUNOL, BR-21949 RIO DE JANEIRO, BRAZIL	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal do Rio de Janeiro			Lima, Ana Paula CA/G-4122-2012; Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822; LIMA, ANA PAULA C. A./0000-0003-4631-2694				ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ASLUND L, 1991, MOL BIOCHEM PARASIT, V33, P33; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BONALDO MC, 1991, PARASITOL RES, V77, P567, DOI 10.1007/BF00931014; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P349; CAMPETELLA O, 1990, FEMS MICROBIOL LETT, V67, P145, DOI 10.1111/j.1574-6968.1990.tb13852.x; CAMPETELLA O, 1992, MOL BIOCHEM PARASIT, V50, P225, DOI 10.1016/0166-6851(92)90219-A; CAZZULO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33, DOI 10.1016/0166-6851(89)90039-X; CHAGAS JR, 1995, BIOCHEM J, V306, P63, DOI 10.1042/bj3060063; CIBOROWSKI P, 1994, J BACTERIOL, V176, P4549, DOI 10.1128/JB.176.15.4549-4557.1994; DELNERY E, 1995, BIOCHEM J, V312, P233, DOI 10.1042/bj3120233; DelNery E, 1997, BIOCHEM J, V323, P427, DOI 10.1042/bj3230427; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; HARTH G, 1993, MOL BIOCHEM PARASIT, V58, P17, DOI 10.1016/0166-6851(93)90086-D; HERRERA EM, 1994, MOL BIOCHEM PARASIT, V65, P73, DOI 10.1016/0166-6851(94)90116-3; Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LIMA APCA, 1992, MOL BIOCHEM PARASIT, V56, P335, DOI 10.1016/0166-6851(92)90183-K; LIMA APCD, 1994, MOL BIOCHEM PARASIT, V67, P333, DOI 10.1016/0166-6851(94)00144-8; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; MCKERROW JH, 1995, PARASITOL TODAY, V11, P279, DOI 10.1016/0169-4758(95)80039-5; MEIRELLES MNL, 1992, MOL BIOCHEM PARASIT, V52, P175, DOI 10.1016/0166-6851(92)90050-T; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; Morrot A, 1997, INT IMMUNOL, V9, P825, DOI 10.1093/intimm/9.6.825; MURTA ACM, 1990, MOL BIOCHEM PARASIT, V43, P27, DOI 10.1016/0166-6851(90)90127-8; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; SCHARFSTEIN J, 1986, J IMMUNOL, V137, P1336; SCHARFSTEIN J, 1995, J IMMUNOL METHODS, V182, P63, DOI 10.1016/0022-1759(95)00023-4; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; Serveau C, 1996, BIOCHEM J, V313, P951, DOI 10.1042/bj3130951; SHIMAMOTO K, 1978, J LAB CLIN MED, V91, P721; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; STOKA V, 1995, FEBS LETT, V370, P101, DOI 10.1016/0014-5793(95)00798-E; TARDIEUX I, 1994, J EXP MED, V179, P1017, DOI 10.1084/jem.179.3.1017; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213; WEBSTER ME, 1970, METHOD ENZYMOL, V19, P681; [No title captured]	43	97	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25713	25718		10.1074/jbc.272.41.25713	http://dx.doi.org/10.1074/jbc.272.41.25713			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325296	hybrid			2022-12-27	WOS:A1997YA35800051
J	Manes, S; Mira, E; Barbacid, MD; Cipres, A; FernandezResa, P; Buesa, JM; Merida, I; Aracil, M; Marquez, G; Martinez, C				Manes, S; Mira, E; Barbacid, MD; Cipres, A; FernandezResa, P; Buesa, JM; Merida, I; Aracil, M; Marquez, G; Martinez, C			Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; IGF-I; MATRIX METALLOPROTEINASES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; MOUSE STROMELYSIN-3; BIOLOGICAL ACTIONS; CELLS; TUMOR	To elucidate the physiological role of human stromelysin-3 (hST-3) in tumor progression and/or wound healing, insulin-like growth factor-binding protein-1 (IGFBP-1) was analyzed as a potential physiological substrate. hST-3 proteolysis generates two fragments of 16 and 9 kDa that react with IGFBP-1 monoclonal antibody, although they do not bind insulin-like growth factor-I (IGF-I) in ligand blot. N-terminal sequencing shows that hST-3 cleaves IGFBP-1 at the His(140)-Val(141) bond located in the IGFBP-1 midregion. We show that IGFBP-1 inhibits IGF-I-induced survival and proliferation of BAF/3 cells, as well as IGF-I-mediated activation of phosphatidylinositol 3-kinase (PI 3-K). Co-incubation of the IGF-I . IGFBP-1 complex with hST-3 restores IGF-I-induced proliferation and PI 3-K kinase activity in these cells. BAF/3 proliferation is significantly increased with the hST-3-treated IGF-I . IGFBP-1 complex compared with that obtained using IGF-I alone. To produce this enhanced proliferation, IGF-I must bind to IGFBP-1 before hST-3 proteolysis, demonstrated using an IGF-I variant that does not bind IGFBP. IGFBP-1 also inhibits IGF-I-induced proliferation of the MCF-7 breast adenocarcinoma, and this inhibition was not seen in hST-3-transfected MCF-7 cells. Such proteolysis may thus play a role in in vivo tumor progression. These results indicate that hST-3 may regulate IGF-I bioavailability by proteolyzing IGFBP, thus favoring cell survival and proliferation.			Manes, S (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,DEPT IMMUNOL & ONCOL,CAMPUS CANTOBLANCO,E-28049 MADRID,SPAIN.		Merida, Isabel/A-9713-2014; Ciprés, Ángel/ABH-6863-2020; Manes, Santos/E-4725-2011; MIRA, EMILIA/K-2456-2014	Merida, Isabel/0000-0003-2762-6241; MIRA, EMILIA/0000-0002-4226-1829; Manes, Santos/0000-0001-8023-957X; Cipres, Angel/0000-0001-7086-2704				ADASHI EY, 1992, J CLIN INVEST, V90, P15933; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BLAT C, 1994, J CLIN INVEST, V93, P2286, DOI 10.1172/JCI117229; CAMACHOHUBNER C, 1991, J CELL PHYSIOL, V148, P281, DOI 10.1002/jcp.1041480214; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; CLEMMONS DR, 1993, ANN NY ACAD SCI, V692, P10; CLEMMONS DR, 1992, INSULIN LIKE GROWTH; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHEN P, 1994, J ENDOCRINOL, V142, P407, DOI 10.1677/joe.0.1420407; CONOVER CA, 1995, J CLIN ENDOCR METAB, V80, P987, DOI 10.1210/jc.80.3.987; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; deTuriso JAL, 1996, J BIOTECHNOL, V46, P235, DOI 10.1016/0168-1656(96)00002-8; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; ENGEL G, 1994, INT J CANCER, V58, P830, DOI 10.1002/ijc.2910580614; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; FIELDER PJ, 1994, GROWTH REGULAT, V1, P164; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Galiano RD, 1996, J CLIN INVEST, V98, P2462, DOI 10.1172/JCI119064; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Lalou C, 1996, ENDOCRINOLOGY, V137, P3206, DOI 10.1210/en.137.8.3206; LAMSON G, 1993, GROWTH REGULAT, V3, P91; Manes S, 1997, ENDOCRINOLOGY, V138, P905, DOI 10.1210/en.138.3.905; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MERIDA I, 1991, J IMMUNOL, V147, P2202; MURPHY G, 1993, J BIOL CHEM, V268, P15435; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; OH Y, 1993, J BIOL CHEM, V268, P26045; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Quesada AR, 1997, CLIN EXP METASTAS, V15, P26; Rajah R, 1996, ENDOCRINOLOGY, V137, P2676, DOI 10.1210/en.137.7.2676; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHIMASAKI S, 1991, PROG GROWTH FACTOR R, V51, P5107; SINGH P, 1994, CANCER RES, V54, P6563; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WOFSY L, 1983, METHOD ENZYMOL, V92, P472; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; YAMAMOTO K, 1992, J BIOL CHEM, V267, P11337	56	158	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25706	25712		10.1074/jbc.272.41.25706	http://dx.doi.org/10.1074/jbc.272.41.25706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325295	hybrid			2022-12-27	WOS:A1997YA35800050
J	Solanes, G; VidalPuig, A; Grujic, D; Flier, JS; Lowell, BB				Solanes, G; VidalPuig, A; Grujic, D; Flier, JS; Lowell, BB			The human uncoupling protein-3 gene - Genomic structure, chromosomal localization, and genetic basis for short and long form transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; MULTIFACTORIAL MOUSE MODEL; SKELETAL-MUSCLE; OBESITY; THERMOGENESIS; FAT; EPINEPHRINE; EXPRESSION; MECHANISM; EVOLUTION	Uncoupling protein-3 (UCP3) is a recently identified candidate mediator of adaptive thermogenesis in humans. Unlike UCP1 and UCP2, UCP3 is expressed preferentially and at high levels in human skeletal muscle and exists as short and long form transcripts, UCP3(S) and UCP3(L). UCP3(S) is predicted to encode a protein which lacks the last 37 C-terminal residues of UCP3(L). In the present study, we have defined the intron-exon structure for the human UCP3 gene and determined that UCP3(S) is generated when a cleavage and polyadenylation signal (AATAAA) located in the last intron prematurely terminates message elongation. In addition we have mapped UCP3 to the distal segment of human chromosome 11q13 (between framework markers D11S916 and D11S911), adjacent to UCP2. Of note, UCP2 and UCP3 in both mice and humans colocalize in P1 and BAC genomic clones indicating that these two UCPs are located within 75-150 kilobases of each other and most likely resulted from a gene duplication event. Previous studies have noted that mouse UCP2 maps to a region of chromosome 7 which is coincident with three independently mapped quantitative trait loci for obesity. Our study shows that UCP3 is also coincident with these quantitative trait loci raising the possibility that abnormalities in UCP3 are responsible for obesity in these models.	BETH ISRAEL DEACONESS MED CTR,DIV ENDOCRINOL,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Flier, jeffrey/AAG-6223-2019	Vidal-Puig, Antonio/0000-0003-4220-9577	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049569, K08DK002119, R37DK053477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49569, DK02119, R37 DK053477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASTRUP A, 1985, AM J PHYSIOL, V248, pE507, DOI 10.1152/ajpendo.1985.248.5.E507; ASTRUP A, 1989, AM J PHYSIOL, V257, pE340, DOI 10.1152/ajpendo.1989.257.3.E340; Beales PL, 1997, J MED GENET, V34, P92, DOI 10.1136/jmg.34.2.92; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; Bruford EA, 1997, GENOMICS, V41, P93, DOI 10.1006/geno.1997.4613; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LEPPERT M, 1994, NAT GENET, V7, P108, DOI 10.1038/ng0594-108; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MICHELSON AM, 1983, J BIOL CHEM, V258, P5245; MURDZAINGLIS DL, 1994, J BIOL CHEM, V269, P7435; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; RAVUSSIN E, 1996, DIABETES REV, V4, P403; SELDIN MF, 1994, J CLIN INVEST, V94, P269, DOI 10.1172/JCI117317; SIMONSEN L, 1992, AM J PHYSIOL, V263, pE850, DOI 10.1152/ajpendo.1992.263.5.E850; SPRAUL M, 1993, J CLIN INVEST, V92, P1730, DOI 10.1172/JCI116760; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; VidalPuig A, 1996, J CLIN INVEST, V97, P2553, DOI 10.1172/JCI118703; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WARDEN CH, 1993, J CLIN INVEST, V92, P773, DOI 10.1172/JCI116649; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; WHITE PC, 1992, J CLIN ENDOCR METAB, V74, P6, DOI 10.1210/jc.74.1.6; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	34	176	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25433	25436		10.1074/jbc.272.41.25433	http://dx.doi.org/10.1074/jbc.272.41.25433			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325252	hybrid			2022-12-27	WOS:A1997YA35800007
J	Langlois, MF; Zanger, K; Monden, T; Safer, JD; Hollenberg, AN; Wondisford, FE				Langlois, MF; Zanger, K; Monden, T; Safer, JD; Hollenberg, AN; Wondisford, FE			A unique role of the beta-2 thyroid hormone receptor isoform in negative regulation by thyroid hormone - Mapping of a novel amino-terminal domain important for ligand-independent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE PROMOTER ACTIVITY; RESPONSE ELEMENTS; SUBUNIT GENE; CO-REPRESSOR; TRANSCRIPTIONAL ACTIVATION; STRUCTURAL-ANALYSIS; VARIANT ALPHA-2; BINDING-SITES; RETINOIC ACID; HALF-SITE	Negative regulation by thyroid hormone is mediated by nuclear thyroid hormone receptors (TRs) acting on thyroid hormone response elements (TREs). We examine here the role of human TR-beta 2, a TR isoform with central nervous system-restricted expression, in the regulation of target genes whose expression are decreased by tri-iodothyronine (T-3), Using transient transfection studies, we found that TR-beta 2 achieved significantly greater ligand-independent activation on the thyrotropin-releasing hormone (TRH) and common glycoprotein alpha-subunit genes than either TR-beta 1 or TR-alpha 1. A chimeric TR-beta isoform containing the TR-beta 2 amino terminus linked to the TR-beta 2 DNA-and ligand-binding domains functioned like the TR-beta 2 isoform on these promoters, confirming that the amino terminus of TR-beta 2 was both necessary and sufficient to mediate this effect. By constructing deletion mutants of the TR-beta 2 amino terminus, we demonstrate that amino acids 89-116 mediate this function. This domain, important in ligand-independent activation on negative TREs, is discrete from a previously described activation domain in the amino-terminal portion of TR-beta 2. We conclude that the central nervous system-restricted TR-beta 2 isoform has a unique effect on negative regulation by T-3 that can be mapped to amino acids 89-116 of the amino terminus of the human TR-beta 2.	BETH ISRAEL DEACONESS MED CTR, THYROID UNIT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002354, R29DK043653] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43653, DK-02354] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7119, DOI 10.1093/nar/11.20.7119; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COHEN O, 1995, J BIOL CHEM, V270, P13899, DOI 10.1074/jbc.270.23.13899; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FENG P, 1994, BIOCHEM BIOPH RES CO, V200, P171, DOI 10.1006/bbrc.1994.1430; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATZ D, 1993, J BIOL CHEM, V268, P20904; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KRISHNA V, 1991, J CLIN INVEST, V87, P1977, DOI 10.1172/JCI115225; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LECHAN RM, 1994, ENDOCRINOLOGY, V135, P92, DOI 10.1210/en.135.1.92; LECHAN RM, 1993, ENDOCRINOLOGY, V132, P2461, DOI 10.1210/en.132.6.2461; Li M, 1996, ENDOCRINOLOGY, V137, P1272, DOI 10.1210/en.137.4.1272; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; Maia AL, 1996, THYROID, V6, P325, DOI 10.1089/thy.1996.6.325; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NG L, 1995, MOL ENDOCRINOL, V9, P1202, DOI 10.1210/me.9.9.1202; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; ONATE SA, 1995, SCIENCE, V270, P1354; RINDT H, 1995, P NATL ACAD SCI USA, V92, P1540, DOI 10.1073/pnas.92.5.1540; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Safer JD, 1997, MOL ENDOCRINOL, V11, P16, DOI 10.1210/me.11.1.16; SAKURAI A, 1990, MOL CELL ENDOCRINOL, V71, P83; SAKURAI A, 1989, MOL ENDOCRINOL, V3, P392, DOI 10.1210/mend-3-2-392; Satoh T, 1996, J BIOL CHEM, V271, P27919, DOI 10.1074/jbc.271.44.27919; SCHWARTZ HL, 1994, J BIOL CHEM, V269, P24777; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SURKS MI, 1973, J BIOL CHEM, V248, P7066; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YEN PM, 1991, ENDOCRINOLOGY, V129, P3331, DOI 10.1210/endo-129-6-3331; Zavacki AM, 1996, ENDOCRINOLOGY, V137, P1438, DOI 10.1210/en.137.4.1438	52	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24927	24933		10.1074/jbc.272.40.24927	http://dx.doi.org/10.1074/jbc.272.40.24927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312095	hybrid			2022-12-27	WOS:A1997XY97000034
J	Murata, T; Takase, K; Yamato, I; Igarashi, K; Kakinuma, Y				Murata, T; Takase, K; Yamato, I; Igarashi, K; Kakinuma, Y			Purification and reconstitution of Na+-translocating vacuolar ATPase from Enterococcus hirae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-FAECALIS; H+-ATPASE; EVOLUTION; SUBUNIT; GENE; COMPONENT; TRANSPORT; SEQUENCE; ARCHAEON; CELLS	Vacuolar ATPases make up a family of proton pumps distributed widely from bacteria to higher organisms. An unusual member of this family, a sodium-translocating ATPase, has been found in the eubacterium Enterococcus hirae. We report here the purification of enterococcal Na+-ATPase from the plasma membrane of cells, whose ATPase content was highly amplified by expression of the cloned ntp operon that encodes this Na+-ATPase (ntpFIKECGABDHJ). The purified enzyme appears to consist of nine Ntp polypeptides, all the above except for the ntpH and ntpJ gene products. ATPase activity was strictly dependent on the presence of Na+ or Li+ ions and was inhibited by nitrate, N-ethylmaleimide, and the peptide antibiotic destruxin B. When the purified ATPase was reconstituted into liposomes prepared from Enterococcus faecalis phospholipids, ATP-driven Na+ uptake was observed; uptake was blocked by nitrate, destruxin B, and monensin, but it accelerated by carbonyl cyanide m-chlorophenylhydrazone and valinomycin. These data demonstrate that E. hirae Na+-ATPase is an electrogenic sodium pump of the vacuolar type. This is a promising system for research on the fundamental molecular structure and mechanism of vacuolar ATPase.	CHIBA UNIV,FAC PHARMACEUT SCI,INAGE KU,CHIBA 263,JAPAN; SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,INAGE KU,NODA,CHIBA 278,JAPAN	Chiba University; Tokyo University of Science			Murata, Takeshi/F-6114-2011; Murata, Takeshi/J-6181-2017	Murata, Takeshi/0000-0002-5748-4670; Igarashi, Kazuei/0000-0003-3751-3187				ABRAMS A, 1985, ENZYMES BIOL MEMBR, V4, P177; ANRAKU Y, 1996, HDB BIOL PHYSICS, P93; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HANADA K, 1988, J BIOL CHEM, V263, P7181; HARVEY WR, 1992, J EXP BIOL, V172, P1; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1989, J BIOENERG BIOMEMBR, V21, P679, DOI 10.1007/BF00762686; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KANE PM, 1989, J BIOL CHEM, V264, P19236; KOBAYASHI H, 1978, J BIOL CHEM, V253, P2085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Murata T, 1996, J BIOL CHEM, V271, P10042, DOI 10.1074/jbc.271.17.10042; Murata T, 1996, J BIOL CHEM, V271, P23661, DOI 10.1074/jbc.271.39.23661; MUROI M, 1994, BIOCHEM BIOPH RES CO, V205, P1358, DOI 10.1006/bbrc.1994.2815; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; PENG SB, 1994, J BIOL CHEM, V269, P11356; SCHAFER G, 1992, ANN NY ACAD SCI, V671, P293, DOI 10.1111/j.1749-6632.1992.tb43804.x; SOLIOZ M, 1990, BIOCHIMIE, V72, P279, DOI 10.1016/0300-9084(90)90084-T; STEVENS TH, 1992, J EXP BIOL, V172, P47; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Wilms R, 1996, J BIOL CHEM, V271, P18843, DOI 10.1074/jbc.271.31.18843	35	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24885	24890		10.1074/jbc.272.40.24885	http://dx.doi.org/10.1074/jbc.272.40.24885			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312089	hybrid			2022-12-27	WOS:A1997XY97000028
J	Vitale, N; Moss, J; Vaughan, M				Vitale, N; Moss, J; Vaughan, M			Characterization of a GDP dissociation inhibitory region of ADP-ribosylation factor domain protein ARD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEOTIDE-EXCHANGE PROTEIN; GUANINE-NUCLEOTIDE; BREFELDIN-A; CHOLERA-TOXIN; BINDING-PROTEIN; AMINO-TERMINUS; FACTOR ARF; FACTOR-I; GOLGI	ADP-ribosylation factors (ARFs) are similar to 20-kDa guanine nucleotide-binding proteins initially identified by their ability to stimulate cholera toxin ADP ribosyltransferase activity and later recognized as critical components in intracellular vesicular transport and phospholipase D activation, ARF domain protein 1 (ARD1) is a member of the ARF family that differs from other ARFs by the presence of a 46-kDa amino-terminal extension, We previously reported that this extension acts as a GTPase-activating protein for the ARF domain of ARD1 (Vitale, N., Moss, J., and Vaughan, M. (1996) Proc, Natl, Acad, Sci. U. S. A. 93, 1941-1944), Both GTP binding and GTP hydrolysis are necessary for physiological function of guanine nucleotide binding proteins, and the rates of GDP/GTP exchange and GTPase activity are critical in the activation/deactivation cycle. Dissociation of GDP from the ARF domain of ARD1 was faster than from ARD1 itself (both proteins synthesized in Escherichia coli). Using deletion mutations, it was demonstrated that the 15 amino acids directly preceding the ARF domain were responsible for decreasing the rate of GDP dissociation but not guanosine 5-[gamma-thio]triphosphate dissociation, By site specific mutagenesis it was shown that hydrophobic amino acids in this region were particularly important in stabilizing the GDP-bound form of ARD1. It is suggested that, Like the amino-terminal segment of ARF, the equivalent region in ARD1, located between the GTPase activating protein and ARF domains, may act as a GDP dissociation inhibitor.			Vitale, N (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,NIH,RM 5N-307,BLDG 10,10 CTR DR,MSC 1434,BETHESDA,MD 20892, USA.		Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907				Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONG JX, 1995, P NATL ACAD SCI USA, V92, P3056, DOI 10.1073/pnas.92.7.3056; HONG JX, 1994, J BIOL CHEM, V269, P9743; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TSAI SC, 1993, J BIOL CHEM, V268, P10820; Vitale N, 1997, J BIOL CHEM, V272, P3897, DOI 10.1074/jbc.272.7.3897; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	35	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25077	25082		10.1074/jbc.272.40.25077	http://dx.doi.org/10.1074/jbc.272.40.25077			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312116	hybrid			2022-12-27	WOS:A1997XY97000055
J	Erickson, JW; Cerione, RA; Hart, MJ				Erickson, JW; Cerione, RA; Hart, MJ			Identification of an actin cytoskeletal complex that includes IQGAP and the Cdc42 GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RASGAP-RELATED PROTEIN; BINDING PROTEIN; DOMAIN; RHO; PHALLOIDIN; FILOPODIA; EFFECTOR; CELLS; RAC	The Rho subfamily of low molecular weight GTPases have been implicated in a variety of cellular functions that include reorganization of the actin cytoskeleton and stress-induced activation of the c-Jun kinase. The downstream targets that mediate the effects of Cdc42 on the actin cytoskeleton have yet to be fully identified, We have used the transient transfection of COS-7 cells with epitope tagged Cdc42 to identify candidate signaling partners for this GTPase and identified the IQGAP protein as a major in. vivo target for activated Cdc42. Epidermal growth factor stimulation of serum-starved COS-7 cells promoted the formation of a Cdc42-IQGAP complex, indicating that growth factors can increase the pool of activated Cdc42, Activated HA-Cdc42 co-localized with IQGAP or F-actin in vivo, whereas cells transfected with dominant-negative forms of Cdc42 (CdC42(T17N)) showed predominantly dispersed distributions for both HA-Cdc42 and endogenous IQGAP, In detergent lysates from COS-7 cells transiently transfected with different forms of Cdc42, or from stably transfected CHO cells, the induction of actin polymerization by phalloidin resulted in the incorporation of both IQGAP and Cdc42 into actin containing complexes. Taken together, these findings are consistent with a model whereby IQGAP serves as a target for GTP-bound Cdc42 providing a direct link between the activated GTPase and the actin cytoskeleton.	CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853; ONYX PHARMACEUT,RICHMOND,CA 94806	Cornell University				Hart, Matthew/0000-0002-2683-480X	NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Boivin D, 1996, CAN J PHYSIOL PHARM, V74, P801, DOI 10.1139/cjpp-74-7-801; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; ESTES JE, 1981, BIOCHEMISTRY-US, V20, P708, DOI 10.1021/bi00507a006; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; LEBART MC, 1994, J BIOL CHEM, V269, P4279; LEBIHAN T, 1991, BIOCHEM BIOPH RES CO, V181, P542; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WIELAND T, 1986, PHALLOTOXINS, P69; WINDER SJ, 1995, J CELL SCI, V108, P63	20	109	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24443	24447		10.1074/jbc.272.39.24443	http://dx.doi.org/10.1074/jbc.272.39.24443			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305904	hybrid			2022-12-27	WOS:A1997XY51500055
J	Marrero, MB; Schieffer, B; Li, B; Sun, JM; Harp, JB; Ling, BN				Marrero, MB; Schieffer, B; Li, B; Sun, JM; Harp, JB; Ling, BN			Role of Janus kinase signal transducer and activator of transcription and mitogen-activated protein kinase cascades in angiotensin II- and platelet-derived growth factor-induced vascular smooth muscle cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; RECEPTOR; JAK2; PP60(C-SRC); PATHWAY	In vascular smooth muscle cells, the induction of early growth response genes involves the janus kinase (JAK)/signal transducer and activators of transcription (STAT) and the Ras/Raf-1/mitogen-activated protein kinase cascades. In the present study, we found that electroporation of antibodies against MEH1 or ERK1 abolished vascular smooth muscle cell proliferation in response to either platelet-derived growth factor or angiotensin II, However, anti-STAT1 or -STAT3 antibody electroporation abolished proliferative responses only to angiotensin II and not to platelet-derived growth factor, AG-490, a specific inhibitor of the JAK2 tyrosine kinase, prevented proliferation of vascular smooth muscle cells, complex formation between JAK2 and Raf-1, the tyrosine phosphorylation of Raf-1, and the activation of ERK1 in response to either angiotensin II or platelet-derived growth factor. However AG-490 had no effect on angiotensin II- or platelet-derived growth factor-induced Ras/Raf-1 complex formation, Our results indicate that: 1) STAT proteins play an essential role in angiotensin II-induced vascular smooth muscle cell proliferation, 2) JAK2 plays an essential role in the tyrosine phosphorylation of Raf-1, and 3) convergent mitogenic signaling cascades involving the cytosolic kinases JAK2, MEK1, and ERK1 mediate vascular smooth muscle cell proliferation in response to both growth factor and G protein-coupled receptors.	EMORY UNIV,SCH MED,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MED,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DIV RENAL,ATLANTA,GA 30322; VET AFFAIRS MED CTR,ATLANTA,GA 30322; UNIV FREIBURG,MED KLIN 3,D-7800 FREIBURG,GERMANY	Emory University; Emory University; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; University of Freiburg	Marrero, MB (corresponding author), EMORY UNIV,SCH MED,CTR CELL & MOL SIGNALLING,079 PHYSIOL BLDG,1648 PIERCE DR NE,ATLANTA,GA 30322, USA.				NIDDK NIH HHS [DK-02111, P01-DK50268] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050268, K08DK002111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernstein KE, 1996, TRENDS CARDIOVAS MED, V6, P179, DOI 10.1016/S1050-1738(96)00053-9; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DHAR A, 1994, J BIOL CHEM, V269, P9123; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1996, AM J PHYSIOL-CELL PH, V270, pC1834, DOI 10.1152/ajpcell.1996.270.6.C1834; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MARRERO MB, 1996, J MOL MED, V74, P85; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; WANG XY, 1995, J BIOL CHEM, V270, P27999; Wilmer WA, 1997, J BIOL CHEM, V272, P10877; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681	25	203	216	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24684	24690		10.1074/jbc.272.39.24684	http://dx.doi.org/10.1074/jbc.272.39.24684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305939	hybrid			2022-12-27	WOS:A1997XY51500090
J	Oka, T; Yamamoto, R; Futai, M				Oka, T; Yamamoto, R; Futai, M			Three vha genes encode proteolipids of Caenorhabditis elegans vacuolar-type ATPase - Gene structures and preferential expression in an H-shaped excretory cell and rectal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; V-ATPASE; MOLECULAR-CLONING; PLASMA-MEMBRANE; B-SUBUNIT; CDNA; ACIDIFICATION; SEQUENCE; PROTEIN; TRANSPORT	The proteolipids of the vacuolar-type H+-ATPase (V-ATPase) are major components of the integral membrane sector. The vha-l and vha-2 (vacuolar type H+-ATPase) genes in Caenorhabditis elegans encode putative 16-kDa proteolipids and are tandemly localized on chromosome III. The vha-2 gene has three exons, whereas vha-l has no introns, The deduced amino acid sequences of the two genes exhibit about 60% identity with the homologues from yeast, mouse, and cow. The mRNAs of both vha genes are trans-spliced to spliced leaders, suggesting that these genes constitute a polycistronic transcriptional unit. The vha-4 gene consists of four exons and is very similar to the yeast VMA16 gene that codes for the 23-kDa proteolipid. This is the first example of three distinct V-ATPase proteolipids being identified in higher eukaryotes. Northern blot and transgenic analyses show that the three vha genes may be highly expressed in the II-shaped excretory cell, rectum, and a pair of cells posterior to the anus, These results suggest that the V-ATPase activity may be important for exporting toxic compounds or metabolic wastes in this organism.	OSAKA UNIV,INST SCI & IND RES,DIV BIOL SCI,DEPT MOL CELL BIOL,OSAKA 567,JAPAN	Osaka University								ANRAKU Y, 1996, HDB BIOL PHYS, V2, P93; BROEKS A, 1995, EMBO J, V14, P1858, DOI 10.1002/j.1460-2075.1995.tb07178.x; BROWN D, 1992, J EXP BIOL, V172, P231; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Davies SA, 1996, J BIOL CHEM, V271, P30677, DOI 10.1074/jbc.271.48.30677; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1996, HDB BIOL PHYS, V2, P47; GLUCK S, 1992, J EXP BIOL, V172, P29; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HARVEY WR, 1992, J EXP BIOL, V172, P1; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HESEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; KLEIN U, 1992, J EXP BIOL, V172, P345; KLINNSKY DJ, 1992, J EXP BIOL, V172, P83; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MEAGHER L, 1990, NUCLEIC ACIDS RES, V18, P6712, DOI 10.1093/nar/18.22.6712; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Moriyama Y, 1996, BIOL CHEM H-S, V377, P155; NELSON FK, 1984, J EXP ZOOL, V231, P45, DOI 10.1002/jez.1402310107; NELSON FK, 1983, J ULTRA MOL STRUCT R, V82, P156; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J EXP BIOL, V172, P19; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STEVENS TH, 1992, J EXP BIOL, V172, P47; Sulston J., 1988, NEMATODE CAENORHABDI, P587; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	38	57	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24387	24392		10.1074/jbc.272.39.24387	http://dx.doi.org/10.1074/jbc.272.39.24387			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305897	hybrid			2022-12-27	WOS:A1997XY51500048
J	Grenert, JP; Sullivan, WP; Fadden, P; Haystead, TAJ; Clark, J; Mimnaugh, E; Krutzsch, H; Ochel, HJ; Schulte, TW; Sausville, E; Neckers, LM; Toft, DO				Grenert, JP; Sullivan, WP; Fadden, P; Haystead, TAJ; Clark, J; Mimnaugh, E; Krutzsch, H; Ochel, HJ; Schulte, TW; Sausville, E; Neckers, LM; Toft, DO			The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; PROGESTERONE-RECEPTOR; IN-VIVO; GLUCOCORTICOID RECEPTOR; RETICULOCYTE LYSATE; TYROSINE KINASE; COMPLEX; HETEROCOMPLEX; ASSOCIATION; RAF	Many functions of the chaperone, heat shock protein 90 (hsp90), are inhibited by the drug geldanamycin that specifically binds hsp90, We have studied an amino-terminal domain of hsp90 whose crystal structure has recently been solved and determined to contain a geldanamycin binding site. We demonstrate that, in solution, drug binding is exclusive to this domain. This domain also binds ATP linked to Sepharose through the gamma-phosphate. Binding is specific for ATP and ADP and is inhibited by geldanamycin, Mutation of four glycine residues within two proposed ATP binding motifs diminishes both geldanamycin binding and the ATP-dependent conversion of hsp90 to a conformation capable of binding the co-chaperone p23, Since p23 binding requires regions outside the 1-221 domain of hsp90, these results indicate a common site for nucleotides and geldanamycin that regulates the conformation of other hsp90 domains.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; NCI,NIH,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia					NHLBI NIH HHS [HL 19242] Funding Source: Medline; NICHD NIH HHS [HD 09140] Funding Source: Medline; NIDDK NIH HHS [DK 46249] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Chavany C, 1996, J BIOL CHEM, V271, P4974; CSERMELY P, 1991, J BIOL CHEM, V266, P4943; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Gerloff DL, 1997, PROTEINS, V27, P450, DOI 10.1002/(SICI)1097-0134(199703)27:3<450::AID-PROT12>3.3.CO;2-9; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Hartson SD, 1996, BIOCHEMISTRY-US, V35, P13451, DOI 10.1021/bi961332c; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LEHNINGER AL, 1993, PRINCIPLES BIOCH, P371; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; McGuire J, 1995, J BIOL CHEM, V270, P31353, DOI 10.1074/jbc.270.52.31353; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHNUR RC, 1994, J LABELLED COMPD RAD, V34, P529, DOI 10.1002/jlcr.2580340606; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; YAMAMOTO M, 1991, J BIOCHEM-TOKYO, V110, P141, DOI 10.1093/oxfordjournals.jbchem.a123532	57	478	498	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23843	23850		10.1074/jbc.272.38.23843	http://dx.doi.org/10.1074/jbc.272.38.23843			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295332	hybrid			2022-12-27	WOS:A1997XX38100057
J	Murayama, T; Ogawa, Y				Murayama, T; Ogawa, Y			Characterization of type 3 ryanodine receptor (RyR3) of sarcoplasmic reticulum from rabbit skeletal muscles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; BINDING-PROTEIN ISOFORMS; CA2+ RELEASE; MICE LACKING; MOLECULAR-CLONING; FIBER TYPES; BRAIN-TYPE; EXPRESSION; CDNA; CA-2+	We investigated type 3 isoform (RyR3) of ryanodine receptor in rabbit skeletal muscles using an antibody specific for RyR3. By Western blot analysis and by immunoprecipitation, a single polypeptide for RyR3 was detected in sarcoplasmic reticulum vesicles from rabbit diaphragm but not in those from back muscle. The molecular mass was slightly smaller than that of RyR1, the major isoform in skeletal muscles. Each of RyR1 and RyR3 formed a homotetramer in rabbit diaphragm. RyR3 had a single class of [H-3]ryanodine binding sites of high affinity (K-D = 1.6 nM). From the B-max of the binding, the content of RyR3 was estimated to be only 0.6% of RyR1 in rabbit diaphragm, [H-3]Ryanodine binding to RyR3 was biphasically dependent on Ca2+, as is true of RyR1, and was stimulated further by adenine nucleotide, caffeine, or high. salt concentration. Procaine and ruthenium red inhibited the binding. RyR3 was more resistant to Mg2+ inhibition than RyR1. interestingly, RyR3 showed about a 7-fold lower Ca2+ sensitivity for activation than RyR1. Comparison with the counterparts in bullfrog skeletal muscles indicates that the Ca2+ sensitivities of RyR3 homologs are similar to each other, whereas those of RyR1 homologs are species-specific.	JUNTENDO UNIV,SCH MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN	Juntendo University								AIREY JA, 1990, J BIOL CHEM, V265, P14187; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GREEN HJ, 1984, HISTOCHEMISTRY, V81, P67, DOI 10.1007/BF00495403; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARAFUJI H, 1980, J BIOCHEM, V87, P1305, DOI 10.1093/oxfordjournals.jbchem.a132868; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; KILARSKI W, 1990, J ANAT, V168, P13; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; Marziah G, 1996, FEBS LETT, V394, P76, DOI 10.1016/0014-5793(96)00944-1; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Miyatake R, 1996, FEBS LETT, V395, P123, DOI 10.1016/0014-5793(96)01022-8; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MOORE GE, 1985, J MUSCLE RES CELL M, V6, P513, DOI 10.1007/BF00712587; MURAYAMA T, 1994, J BIOCHEM-TOKYO, V116, P1117, DOI 10.1093/oxfordjournals.jbchem.a124636; Murayama T, 1996, FEBS LETT, V380, P267, DOI 10.1016/0014-5793(96)00053-1; Murayama T, 1996, J BIOL CHEM, V271, P5079; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Nucifora FC, 1996, MOL BIOL CELL, V7, P949, DOI 10.1091/mbc.7.6.949; OGAWA Y, 1986, J BIOCHEM-TOKYO, V100, P1305, DOI 10.1093/oxfordjournals.jbchem.a121837; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; OTSU K, 1990, J BIOL CHEM, V265, P13472; OYAMADA H, 1994, J BIOL CHEM, V269, P17206; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; Sorrentino V, 1995, Adv Pharmacol, V33, P67, DOI 10.1016/S1054-3589(08)60666-3; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Takeshima H, 1996, J BIOL CHEM, V271, P19649, DOI 10.1074/jbc.271.33.19649; WEBER A, 1968, J GEN PHYSIOL, V52, P750, DOI 10.1085/jgp.52.5.750; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	45	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24030	24037		10.1074/jbc.272.38.24030	http://dx.doi.org/10.1074/jbc.272.38.24030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295356	hybrid			2022-12-27	WOS:A1997XX38100081
J	Ragolia, L; Cherpalis, B; Srinivasan, M; Begum, N				Ragolia, L; Cherpalis, B; Srinivasan, M; Begum, N			Role of serine/threonine protein phosphatases in insulin regulation of Na+/K+-ATPase activity in cultured rat skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; KINASE-C; PHOSPHOSERINE PHOSPHATASE; CATALYTIC SUBUNIT; PHOSPHORYLATION; NA+,K+-ATPASE; STIMULATION; INHIBITION; IDENTIFICATION; ACTIVATION	In this study, we examined the potential role of serine/threonine protein phosphatase-1 (PP-1) and PP-2A in the mechanism of Na+/K+-ATPase activation by insulin in the rat skeletal muscle cell line L6. Incubation of L6 cells with insulin caused a time-and dose-dependent stimulation of ouabain-sensitive plasma membrane Na+/K+-ATPase activity, Pretreatment with okadaic acid (OA; 0.1-1 mu M) or calyculin A (1 mu M) blocked insulin's effect on Na+/K+-ATPase activation, Low concentrations of OA that specifically inhibit PP-2A were ineffective, Immunoprecipitation of the enzyme from P-32-labeled cells with an antibody directed against the alpha-1 subunit of the enzyme revealed a 60% decrease in 110 kDa protein phosphorylation in insulin-treated cells. The presence of calyculin A blocked insulin-mediated dephosphorylation of Na+/K+-ATPase, whereas low concentrations of OA were ineffective, To further confirm the role of PP-1, we used L6 cell lines that overexpress the glycogen/SR-associated regulatory subunit of PP-1, PP-1(G). Overexpression of PP-1(G) resulted in a 3-fold increase in insulin-stimulated PP-1 catalytic activity. This was accompanied by a 30% increase in basal Na+/K+-ATPase activity and a > 2-fold increase in insulin's effect on pump activity, Inhibition of phosphatidylinositol-3 kinase with wortmannin blocked insulin-stimulated PP-1 activation as well as the dephosphorylation and activation of Na+/K+-ATPase. We conclude that insulin regulates the activity of Na+/K+ ATPase by promoting dephosphorylation of the alpha subunit via an insulin-stimulated PP-1 and that phosphatidylinositol 3 kinase-generated signals may mediate insulin activation of PP-1 and Na+/K+-ATPase.	WINTHROP UNIV HOSP,DIABET RES LAB,MINEOLA,NY 11501; SUNY STONY BROOK,SCH MED,STONY BROOK,NY 11704	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Ragolia, Louis/AAW-2383-2021	Ragolia, Louis/0000-0002-8292-5159				APERIA A, 1991, P NATL ACAD SCI USA, V88, P2798, DOI 10.1073/pnas.88.7.2798; BARNETT RE, 1970, BIOCHEMISTRY-US, V9, P4644, DOI 10.1021/bi00826a004; BEGUM N, 1992, J BIOL CHEM, V267, P5959; BEGUM N, 1991, DIABETES, V40, P1620, DOI 10.2337/diabetes.40.12.1620; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BERTORELLO AM, 1993, AM J PHYSIOL, V265, pF743, DOI 10.1152/ajprenal.1993.265.6.F743; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DRAZNIN B, 1991, EXCERPTA MED INT C S, V980, P225; EWART HS, 1995, AM J PHYSIOL-CELL PH, V269, pC295, DOI 10.1152/ajpcell.1995.269.2.C295; FAVRE B, 1996, J BIOL CHEM, V272, P13856; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISONE G, 1994, J BIOL CHEM, V269, P9368; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI DL, 1995, AM J PHYSIOL-RENAL, V269, pF673, DOI 10.1152/ajprenal.1995.269.5.F673; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MARETTE A, 1993, AM J PHYSIOL, V265, pC1716, DOI 10.1152/ajpcell.1993.265.6.C1716; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MOORE RD, 1983, J PHYSIOL-LONDON, V338, P277, DOI 10.1113/jphysiol.1983.sp014673; NISHIDA K, 1992, METABOLISM, V41, P56, DOI 10.1016/0026-0495(92)90191-C; OGUCHI A, 1993, AM J PHYSIOL, V265, pH1167, DOI 10.1152/ajpheart.1993.265.4.H1167; OHARA T, 1991, DIABETES, V40, P1560, DOI 10.2337/diabetes.40.11.1560; OKADA T, 1994, J BIOL CHEM, V269, P3563; Ragolia L, 1997, ENDOCRINOLOGY, V138, P2398, DOI 10.1210/en.138.6.2398; SAMPSON SR, 1994, AM J PHYSIOL, V266, pC751, DOI 10.1152/ajpcell.1994.266.3.C751; SATOH T, 1992, J CLIN INVEST, V89, P1496, DOI 10.1172/JCI115740; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; XIA P, 1995, J CLIN INVEST, V96, P733, DOI 10.1172/JCI118117	33	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23653	23658		10.1074/jbc.272.38.23653	http://dx.doi.org/10.1074/jbc.272.38.23653			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295306	hybrid			2022-12-27	WOS:A1997XX38100031
J	Ortiz, L; Zannini, M; DiLauro, R; Santisteban, P				Ortiz, L; Zannini, M; DiLauro, R; Santisteban, P			Transcriptional control of the forkhead thyroid transcription factor TTF-2 by thyrotropin, insulin, and insulin-like growth factor I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROGLOBULIN GENE-EXPRESSION; CYCLIC-AMP; DNA-BINDING; THYROPEROXIDASE PROMOTER; HORMONAL-REGULATION; RESPONSIVE ELEMENT; NUCLEAR-PROTEIN; FRTL-5 CELLS; PEROXIDASE; IDENTIFICATION	The hormonal regulation of both thyroglobulin and thyroperoxidase promoter activity in FRTL-5 thyroid cells takes place, at least in part, through a hormone-responsive element to which the thyroid transcription factor TTF-2 binds. The TTF-2 cDNA, encoded by the titf2 locus, has recently been clotted and classified as a member of the forkhead transcription factor family. Here, rye demonstrate that TTF-2 mRNA levels become undetectable in FRTL-5 thyroid cells cultured for 4 days in 0.2% serum and in the absent of thyrotropin (TSH) and insulin. Addition of TSH, insulin or insulin-like growth factor I (IGF-I) to the culture medium increases the levels of this transcription factor in a dose-and time-dependent manner and requires ongoing protein synthesis. The TSH effect is greater than that produced by insulin or IGF-I and is similar to the effect produced by the cAMP analog forskolin. The TSH and insulin effects are additive. In all eases, the mRNA levels increase is accompanied by an increase in transcription rate, as demonstrated by run-off assays, These data demonstrate that the TTF-2 mRNA is under tight hormonal control. This is consistent with an important role for TTF-2 as a mediator of the transcriptional activation of thyroid-specific genes (thyroglobulin and thyroperoxidase) by TSH via cAMP and by insulin through the IGF-I receptor.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN; UNIV NAPLES, DIPARTIMENTO BIOL & PATOL CELLULARE & MOL, I-80131 NAPLES, ITALY; Staz Zool Anton Dohrn, I-80121 NAPLES, ITALY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Naples Federico II; Stazione Zoologica Anton Dohrn di Napoli			Zannini, Mariastella/I-1735-2012; Di Lauro, Roberto/A-2746-2012; Santisteban, Pilar/E-7829-2016	Di Lauro, Roberto/0000-0001-9493-3036; Santisteban, Pilar/0000-0002-2758-796X; Ortiz Hernandez, Lourdes/0000-0001-6084-3411				ABRAMOWICZ MJ, 1992, EUR J BIOCHEM, V203, P467, DOI 10.1111/j.1432-1033.1992.tb16571.x; ABRAMOWICZ MJ, 1990, BIOCHEM BIOPH RES CO, V166, P1257, DOI 10.1016/0006-291X(90)91001-9; ALEXANDER MC, 1988, P NATL ACAD SCI USA, V87, P5273; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; AVVEDIMENTO VE, 1984, BIOCHEM BIOPH RES CO, V122, P472; AZABLANC P, 1993, MOL ENDOCRINOL, V7, P1297, DOI 10.1210/me.7.10.1297; Berg V, 1996, BBA-GENE STRUCT EXPR, V1307, P35, DOI 10.1016/0167-4781(96)00044-9; CHABAUD O, 1988, J ENDOCRINOL, V116, P25, DOI 10.1677/joe.0.1160025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOPHE D, 1989, MOL CELL ENDOCRINOL, V64, P5, DOI 10.1016/0303-7207(89)90060-9; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; DAMANTE G, 1989, ENDOCRINOLOGY, V124, P2889, DOI 10.1210/endo-124-6-2889; DEGROOT LJ, 1977, METABOLISM, V26, P665, DOI 10.1016/0026-0495(77)90088-9; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; GERARD CM, 1988, MOL CELL ENDOCRINOL, V60, P239, DOI 10.1016/0303-7207(88)90184-0; GREENBERG ME, 1994, CURR PROTEIN MOL B S, V26; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; ISOZAKI O, 1989, MOL ENDOCRINOL, V3, P1681, DOI 10.1210/mend-3-11-1681; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; KASTNER KH, 1994, GENOMICS, V20, P377; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEE NT, 1988, J BIOL CHEM, V264, P7523; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Pichon B, 1996, ENDOCRINOLOGY, V137, P4691, DOI 10.1210/en.137.11.4691; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; ROSSI DL, 1995, J BIOL CHEM, V270, P23139, DOI 10.1074/jbc.270.39.23139; SALVATORE G, 1980, THYROID GLAND, P443; SANTISTEBAN P, 1992, MOL ENDOCRINOL, V6, P1310, DOI 10.1210/me.6.8.1310; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; Sato K, 1996, BIOCHEM BIOPH RES CO, V220, P86, DOI 10.1006/bbrc.1996.0361; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SHIMURA Y, 1994, J BIOL CHEM, V269, P31908; SKINNER CA, 1992, MOL CELL ENDOCRINOL, V90, P33, DOI 10.1016/0303-7207(92)90098-Q; TAUROG A, 1976, THYROID FUNDAMENTAL, P47; VANHEUVERSWYN B, 1984, P NATL ACAD SCI-BIOL, V81, P5941; VANHEUVERSWYN B, 1985, FEBS LETT, V188, P192, DOI 10.1016/0014-5793(85)80370-7; VanRenterghem P, 1996, BBA-GENE STRUCT EXPR, V1307, P97, DOI 10.1016/0167-4781(96)00018-8; VANRENTGERHEM P, 1995, MOL CELL ENDOCRINOL, V112, P83; Zannini M, 1997, EMBO J, V16, P3185, DOI 10.1093/emboj/16.11.3185; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZARRILLI R, 1990, MOL ENDOCRINOL, V4, P39, DOI 10.1210/mend-4-1-39	47	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23334	23339		10.1074/jbc.272.37.23334	http://dx.doi.org/10.1074/jbc.272.37.23334			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287345	hybrid			2022-12-27	WOS:A1997XV74400056
J	Aronson, D; Dufresne, SD; Goodyear, LJ				Aronson, D; Dufresne, SD; Goodyear, LJ			Contractile activity stimulates the c-Jun NH2-terminal kinase pathway in rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; CARDIAC MYOCYTES; GENE-EXPRESSION; MECHANICAL-STRESS; GAMMA-RADIATION; JNK ACTIVATION; PHOSPHORYLATION; FOS	Contractile activity plays a critical role in the regulation of gene transcription in skeletal muscle, which in turn determines muscle functional capabilities. However, little is known about the molecular signaling mechanisms that convert contractile activity into gene regulatory responses in skeletal muscle. In the current study we determined the effects of contractile activity in vivo on the c-Jun NH2-terminal kinase (JNK) pathway, a signaling cascade that has been implicated in the regulation of transcription. Electrical stimulation of the sciatic nerve to produce contractions in anaesthetized rats increased JNK activity by up to 7-fold above basal. Maximal enzyme activity occurred at 15 min of contraction and remained elevated at 60 min of contraction. The upstream activators of JNK, the mitogen-activated protein kinase kinase 4 and the mitogen-activated protein kinase kinase kinase 1 followed a similar time course of activation in response to contractile activity. In contrast, contraction induced a rapid and transient activation of the extracellular-regulated kinase pathway, indicating that the regulation of JNK signaling is distinct from that of extracellular-regulated kinase. The activation of the JNK signaling cascade was temporally associated with an increased expression of c-jun mRNA. These results demonstrate that contractile activity regulates JNK activity in skeletal muscle and suggest that activation of JNK may regulate contraction-induced gene expression in skeletal muscle.	BRIGHAM & WOMENS HOSP,DEPT MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Aronson, Doron/F-3390-2010		NIAMS NIH HHS [AR-42238] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR042238, R01AR042238] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1995, CIRC RES, V76, P183, DOI 10.1161/01.RES.76.2.183; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; Aronson D, 1997, J CLIN INVEST, V99, P1251, DOI 10.1172/JCI119282; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WE, 1983, J BIOL CHEM, V258, P4686; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; IWAKI K, 1990, J BIOL CHEM, V265, P13809; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; Williams RS, 1996, HDB PHYSL EXERCISE R, P1124; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; XU O, 1996, J CLIN INVEST, V97, P508; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	40	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25636	25640		10.1074/jbc.272.41.25636	http://dx.doi.org/10.1074/jbc.272.41.25636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325285	hybrid			2022-12-27	WOS:A1997YA35800040
J	Misaki, A; Kakuta, M; Meah, Y; Goldstein, IJ				Misaki, A; Kakuta, M; Meah, Y; Goldstein, IJ			Purification and characterization of the alpha-1,3-mannosylmannose-recognizing lectin of Crocus vernus bulbs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-SPECIFIC LECTINS; OLIGOSACCHARIDES; MANNANS; MOIETY; YEAST	A unique mannose-binding lectin, highly specific for terminal Man(alpha 1,3)Man groups, was isolated from bulbs of crocus (Crocus vernus All.), The lectin failed to bind to a mannose affinity column and was purified by simple gel permeation chromatography (Sephacryl S200). The purified lectin, obtained in crystalline form, had a molecular mass of 44 kDa on gel filtration and showed a single peptide band with a molecular mass of 11 kDa on SDS-polyacrylamide gel electrophoresis, indicating it to be a tetrameric protein composed of four identical subunits, The N-terminal amino acid sequence analysis of the crocus lectin showed essentially no homology with that of other mannose-binding bulb lectins. The crocus lectin selectively interacted with the wild type Saccharomyces cerevisiae and other mannans carrying terminal Man(alpha 1,3)Man but not with those lacking this disaccharide unit, In hapten inhibition studies, methyl alpha-mannopyranoside did not inhibit the mannan-lectin interaction, Of various alpha-mannooligosaccharides, those having the Man(alpha 1,3)Man sequence showed the highest inhibitory potency, confirming the strict requirement of lectin for terminal alpha 1,3-linked mannosylmannose units, An affinity column of immobilized lectin enabled the complete resolution of yeast mannan and glycogen, The immobilized lectin may provide a useful tool for purification and analysis of biologically important polysaccharides and glycoproteins.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Misaki, A (corresponding author), KONAN WOMENS UNIV,6-2-23 MORIKITA MACHI,KOBE,HYOGO 658,JAPAN.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU CE, 1973, J BIOL CHEM, V248, P4667; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; HESTER G, 1995, NAT STRUCT BIOL, V2, P473; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K; KAKU H, 1992, CARBOHYD RES, V229, P347, DOI 10.1016/S0008-6215(00)90580-9; KAKU H, 1992, CARBOHYD RES, V229, P337, DOI 10.1016/S0008-6215(00)90579-2; KAKU H, 1991, CARBOHYD RES, V213, P109, DOI 10.1016/S0008-6215(00)90602-5; KONISI Y, 1976, ANN M JAP AGR CHEM S, P22; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MISAKI A, 1982, CARBOHYD RES, V109, P207, DOI 10.1016/0008-6215(82)84039-1; MISAKI A, 1980, CARBOHYD RES, V84, P273, DOI 10.1016/S0008-6215(00)85557-3; MISAKI A, 1977, J BIOL CHEM, V252, P6995; ODA Y, 1985, EUR J BIOCHEM, V159, P239; OHTANI K, 1980, CARBOHYD RES, V87, P275, DOI 10.1016/S0008-6215(00)85214-3; PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347; SAITO K, 1993, EUR J BIOCHEM, V217, P677, DOI 10.1111/j.1432-1033.1993.tb18293.x; SAITO K, 1997, IN PRESS LGYCOCONJ J, V14; SARKAR AK, 1989, CARBOHYD RES, V190, P181, DOI 10.1016/0008-6215(89)84124-2; SHIBATA N, 1995, J BIOL CHEM, V270, P1113, DOI 10.1074/jbc.270.3.1113; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SO LUCY L., 1967, J BIOL CHEM, V242, P1617; TORGOV VI, 1984, BIOORG KHIM+, V10, P946; VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52, DOI 10.1111/j.1399-3054.1988.tb09192.x	23	10	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25455	25461		10.1074/jbc.272.41.25455	http://dx.doi.org/10.1074/jbc.272.41.25455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325257	hybrid			2022-12-27	WOS:A1997YA35800012
J	Sarkar, AK; Rostand, KS; Jain, RK; Matta, KL; Esko, JD				Sarkar, AK; Rostand, KS; Jain, RK; Matta, KL; Esko, JD			Fucosylation of disaccharide precursors of sialyl Lewis(X) inhibit selectin-mediated cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ATTENUATES REPERFUSION INJURY; N-LINKED OLIGOSACCHARIDES; HAMSTER OVARY CELLS; RAT ADIPOSE-TISSUE; ALPHA-L-FUCOSIDASE; P-SELECTIN; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; RABBIT EAR	We showed previously that HL-60 and F9 mouse embryonal carcinoma cells will take up and deblock peracetylated Gal beta 1-4GlcNAc beta-O-naphthalenemethanol (Gal beta 1-4GlcNAc-NM) and use the disaccharide as a primer of oligosaccharide chains (Sarkar, A. K., Fritz, T. A., Taylor, W. H., and Esko, J. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3323-3327). We now report that another disaccharide, acetylated GlcNAc beta 1-3Gal-naphthalenemethanol (GlcNAc beta 1-3Gal-NM), has even greater potency and that both compounds will inhibit sialyl Lewis(X) (sLe(x))-dependent cell adhesion. When fed to U937 cells, acetylated forms of Galpl-1GrlcNAc-NM and GlcNAc beta 1-3Gal-NM primed oligosaccharides in a dose-dependent manner. Analysis of compounds assembled on Gal beta 1-4GlcNAc-NM showed only one product, namely Gal beta 1-4(Fuc alpha 1-3)GlcNAc-NM. In contrast, Glc-NAc beta 1-3Gal-NM generated Gal beta 1-4GlcNAc beta 1-3Gal-NM, Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal-NM, NeuAc alpha 2-3Gal beta 1-4GlcNAc beta 1-3Gal-NM, and NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3Gal-NM. Both compounds decreased the incorporation of [H-3]fucose into cellular glycoconjugates, without affecting the incorporation of [H-3]mannosamine, a precursor of sialic acid residues. Moreover, the overall extent of sialylation was not affected based on the reactivity of cells to fluorescein isothiocyanate-conjugated Maackia amurensis lectin. Priming inhibited expression of sLe(x) on cell surface glycoconjugates, which reduced E-selectin-dependent cell adhesion to tumor necrosis factor-cu-activated human umbilical vein endothelial cells. GlcNAc beta 1-3Gal-NM and Gal beta 1-4Glc-NAc-NM represent starting points for making enzyme-specific, site-directed inhibitors of glycosyltransferases that could act in living cells.	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093; UNIV ALABAMA,SCH MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294; ROSWELL PK CANC INST,DEPT GYNECOL ONCOL,BUFFALO,NY 14263	University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Roswell Park Cancer Institute					NCI NIH HHS [CA35329, CA46462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035329, R01CA046462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRIGGS JB, 1995, GLYCOBIOLOGY, V5, P583, DOI 10.1093/glycob/5.6.583; BUERKE M, 1994, J CLIN INVEST, V93, P1140, DOI 10.1172/JCI117066; CECCONI O, 1994, J BIOL CHEM, V269, P15060; Chammas R, 1996, MOL BIOL CELL, V7, P1691, DOI 10.1091/mbc.7.11.1691; Clarke JL, 1996, J BIOL CHEM, V271, P10317, DOI 10.1074/jbc.271.17.10317; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Etchison JR, 1996, GLYCOBIOLOGY, V6, P177, DOI 10.1093/glycob/6.2.177; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P300; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; GABRIEL O, 1992, GLYCOBIOLOGY, V2, P427; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; HAN KT, 1995, J IMMUNOL, V155, P4011; HARANO T, 1988, J BIOCHEM-TOKYO, V103, P149, DOI 10.1093/oxfordjournals.jbchem.a122221; Hicke BJ, 1996, J CLIN INVEST, V98, P2688, DOI 10.1172/JCI119092; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HUGHES RC, 1964, BIOCHEMISTRY-US, V3, P1535, DOI 10.1021/bi00898a025; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KAWASHIMA H, 1993, J BIOL CHEM, V268, P27118; KHAN SH, 1993, J BIOL CHEM, V268, P2468; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; KUAN SF, 1989, J BIOL CHEM, V264, P19271; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; LOWARY TL, 1994, CARBOHYD RES, V256, P257, DOI 10.1016/0008-6215(94)84212-4; LOWE JB, 1991, J BIOL CHEM, V266, P17467; Lowe JB, 1997, J CLIN INVEST, V99, P822, DOI 10.1172/JCI119244; MA XL, 1993, CIRCULATION, V88, P649, DOI 10.1161/01.CIR.88.2.649; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MENTLEIN R, 1988, BIOCHIM BIOPHYS ACTA, V964, P319, DOI 10.1016/0304-4165(88)90032-3; MIHELCIC D, 1994, BLOOD, V84, P2322; MULLIGAN MS, 1993, J IMMUNOL, V151, P6410; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MULLIGAN MS, 1993, J EXP MED, V178, P62; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NELSON RM, 1993, BLOOD, V82, P3253; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OConnell D, 1996, P NATL ACAD SCI USA, V93, P5883, DOI 10.1073/pnas.93.12.5883; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1994, PROGR BRAIN RES, P179; Portner A, 1996, GLYCOBIOLOGY, V6, P7, DOI 10.1093/glycob/6.1.7; RAO BNN, 1994, J BIOL CHEM, V269, P19663; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; ROUX L, 1988, J BIOL CHEM, V263, P8879; SANO M, 1992, J BIOL CHEM, V267, P1522; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; TSUJITA T, 1982, BIOCHIM BIOPHYS ACTA, V715, P181, DOI 10.1016/0304-4165(82)90357-9; TSUJITA T, 1988, J BIOCHEM, V103, P327, DOI 10.1093/oxfordjournals.jbchem.a122269; TSUJITA T, 1992, J BIOL CHEM, V267, P23489; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WANG WC, 1988, J BIOL CHEM, V263, P4576; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WINN RK, 1993, J CLIN INVEST, V92, P2042, DOI 10.1172/JCI116799; WOYNAROWSKA B, 1989, CANCER RES, V49, P5598; Woynarowska B, 1996, GLYCOCONJUGATE J, V13, P663, DOI 10.1007/BF00731455; YANO T, 1985, AGR BIOL CHEM TOKYO, V49, P3179, DOI 10.1080/00021369.1985.10867252; ZHUANG D, 1991, Glycobiology, V1, P425, DOI 10.1093/glycob/1.4.425	74	89	93	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25608	25616		10.1074/jbc.272.41.25608	http://dx.doi.org/10.1074/jbc.272.41.25608			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325281	hybrid			2022-12-27	WOS:A1997YA35800036
J	Tjalsma, H; Noback, MA; Bron, S; Venema, G; Yamane, K; vanDijl, JM				Tjalsma, H; Noback, MA; Bron, S; Venema, G; Yamane, K; vanDijl, JM			Bacillus subtilis contains four closely related type I signal peptidases with overlapping substrate specificities - Constitutive and temporally controlled expression of different sip genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI LEADER PEPTIDASE; ESCHERICHIA-COLI; MOLECULAR-CLONING; CATALYTIC MECHANISM; SEQUENCE SIMILARITY; ALPHA-AMYLASE; MEMBRANE; PROTEINS; GENOME; AMYLOLIQUEFACIENS	Most biological membranes contain one or two type I signal peptidases for the removal of signal peptides from secretory precursor proteins. In this respect, the Grampositive bacterium Bacillus subtilis seems to be exceptional, because it contains at least four chromosomally-encoded type I signal peptidases, denoted SipS, SipT, SipU, and SipV. Here, we report the identification of the sipT and sipV genes, and the functional characterization of SipT, SipU, and SipV. The four signal peptidases have similar substrate specificities, as they can all process the same beta-lactamase precursor. Nevertheless, they seem to prefer different pre-proteins, as indicated by studies on the processing of the pre-alpha-amylase of Bacillus amyloliquefaciens in strains lacking SipS, SipT, SipU, or SipV. The sipU and sipV genes are constitutively transcribed at a low level, suggesting that they are required for processing of (pre-)proteins secreted during all growth phases. In contrast, the transcription of sipS and sipT is temporally controlled, in concert with the expression of the genes for most secretory proteins, which suggests that SipS and SipT serve to increase the secretory capacity of B. subtilis. Taken together, our findings suggest that SipS, SipT, SipU, and SipV serve different functions during the exponential and post-exponential growth phase of B. subtilis.	GRONINGEN BIOMOL SCI & BIOTECHNOL INST,DEPT GENET,NL-9751 NN HAREN,NETHERLANDS; UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Groningen; University of Tsukuba			van Dijl, Jan Maarten/G-1205-2013; Tjalsma, Harold/I-7146-2012					Akagawa E, 1995, MICROBIOL-UK, V141, P3241, DOI 10.1099/13500872-141-12-3241; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; BRON S, 1972, MUTAT RES, V15, P1, DOI 10.1016/0027-5107(72)90086-3; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cregg KM, 1996, J BACTERIOL, V178, P5712, DOI 10.1128/jb.178.19.5712-5718.1996; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DALBEY RE, 1994, SIGNAL PEPTIDASES, P5; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferrari Eugenio, 1993, P917; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GAY P, 1983, J BACTERIOL, V153, P1133, DOI 10.1128/JB.153.3.1133-1137.1983; HOANG V, 1995, BBA-MOL CELL RES, V1269, P64, DOI 10.1016/0167-4889(95)00101-W; Klug G, 1997, MOL GEN GENET, V253, P666, DOI 10.1007/s004380050370; KONTINEN VP, 1988, J GEN MICROBIOL, V134, P2333; KUO DW, 1993, ARCH BIOCHEM BIOPHYS, V303, P274, DOI 10.1006/abbi.1993.1283; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; LIVELY MO, 1994, SIGNAL PEPTIDASES, P59; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; Miller J. H., 1982, EXPT MOL GENETICS; Msadek Tarek, 1993, P729; Muller P, 1995, MOL MICROBIOL, V18, P831, DOI 10.1111/j.1365-2958.1995.18050831.x; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; PACKER JCL, 1995, PLANT MOL BIOL, V27, P199, DOI 10.1007/BF00019191; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; Philipp WJ, 1996, P NATL ACAD SCI USA, V93, P3132, DOI 10.1073/pnas.93.7.3132; Pratje E., 1994, SIGNAL PEPTIDASES, P105; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SMITH H, 1987, J BACTERIOL, V169, P3321, DOI 10.1128/jb.169.7.3321-3328.1987; SOROKIN A, 1993, MOL MICROBIOL, V10, P385, DOI 10.1111/j.1365-2958.1993.tb02670.x; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; VANDIJL JM, 1988, MOL GEN GENET, V214, P55; VANSINDEREN D, 1990, MOL GEN GENET, V224, P396, DOI 10.1007/BF00262434; Von Heijne Gunnar, 1994, V22, P1; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WOLFE PB, 1983, J BIOL CHEM, V258, P2073	58	103	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25983	25992		10.1074/jbc.272.41.25983	http://dx.doi.org/10.1074/jbc.272.41.25983			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325333	hybrid			2022-12-27	WOS:A1997YA35800088
J	Yaworsky, PJ; Gardner, DP; Kappen, C				Yaworsky, PJ; Gardner, DP; Kappen, C			Transgenic analyses reveal developmentally regulated neuron- and muscle-specific elements in the murine neurofilament light chain gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-L; TRANSCRIPTION FACTORS; BINDING-FACTOR; POLYOMAVIRUS ENHANCER; NERVOUS-SYSTEM; EXPRESSION; MICE; PROTEINS; SUBUNIT; CELLS	We report here the developmental activity of regula tory elements that reside within 1.7 kilobases of the murine neurofilament light chain (NF-L) gene promoter. NF-L promoter activity is first detected at embryonic day 8.5 in neuroepithelial cells. Neuron specific gene expression is maintained in the spinal cord until embryonic day 12.5 and at later developmental stages in the brain and sensory neuroepithelia. After day 14.5, the promoter becomes active in myogenic cells. Transgene expression in both neurons and muscle is consistent with the detection of endogenous NF-L transcript in both neuronal and myogenic tissues of neonates by reverse transcriptase-polymerase chain reaction. Neuron- and muscle-specific activities of the NF-L promoter decrease and are nearly undetectable after birth. Thus, the 1.7-kilobase NF-L promoter contains regulatory elements for initiation but not maintenance of transcription from the NF-L locus. Deletion analyses reveal that independent regulatory elements control the observed tissue-specific activities and implicate a potential MyoD binding site as the muscle-specific enhancer. Our results demonstrate that the NF-L promoter contains distinct regulatory elements for both neuron-and muscle-specific gene expression and that these activities are temporally separated during embryogenesis.	MAYO CLIN ARIZONA,SAMUEL C JOHNSON MED RES CTR,SCOTTSDALE,AZ 85259	Mayo Clinic; Mayo Clinic Phoenix								ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BEAUDET L, 1993, MOL BRAIN RES, V18, P23, DOI 10.1016/0169-328X(93)90170-T; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; BEGEMANN M, 1990, P NATL ACAD SCI USA, V87, P9042, DOI 10.1073/pnas.87.22.9042; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BYRNE GW, 1989, P NATL ACAD SCI USA, V86, P5473, DOI 10.1073/pnas.86.14.5473; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Charron G, 1995, J BIOL CHEM, V270, P30604, DOI 10.1074/jbc.270.51.30604; COCHARD P, 1984, J NEUROSCI, V4, P2080; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Gardner DP, 1996, TRANSGENIC RES, V5, P37, DOI 10.1007/BF01979920; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HOGAN B, 1986, MANIPULATING MOUSE E, P153; HSU C, 1995, MOL BRAIN RES, V32, P241, DOI 10.1016/0169-328X(95)00082-4; IKENAKA K, 1990, J BIOL CHEM, V265, P19782; IVANOV TR, 1992, J NEUROSCI RES, V32, P149, DOI 10.1002/jnr.490320204; JULIEN JP, 1987, BIOCHIM BIOPHYS ACTA, V909, P10, DOI 10.1016/0167-4781(87)90041-8; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KRISTIE TM, 1984, P NATL ACAD SCI-BIOL, V81, P4065, DOI 10.1073/pnas.81.13.4065; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LECONTE L, 1995, J MOL NEUROSCI, V5, P273; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; LEE VMY, 1992, MOL BRAIN RES, V15, P76, DOI 10.1016/0169-328X(92)90154-4; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; PLEASURE SJ, 1989, J NEUROSCI, V9, P698; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; REEBEN M, 1995, J NEUROSCI RES, V40, P177, DOI 10.1002/jnr.490400206; REEBEN M, 1993, BIOCHEM BIOPH RES CO, V192, P177; ROTH HJ, 1991, MOL CELL BIOL, V11, P1488, DOI 10.1128/MCB.11.3.1488; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1995, J BIOL CHEM, V270, P26364, DOI 10.1074/jbc.270.44.26364; SCHWARTZ ML, 1994, J BIOL CHEM, V269, P13444; SHIRAKATA M, 1988, MOL CELL BIOL, V8, P2581, DOI 10.1128/MCB.8.6.2581; SHNEIDMAN PS, 1992, MOL BRAIN RES, V13, P127, DOI 10.1016/0169-328X(92)90052-D; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAZDANBAKHSH K, 1993, NUCLEIC ACIDS RES, V21, P455, DOI 10.1093/nar/21.3.455; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	55	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25112	25120		10.1074/jbc.272.40.25112	http://dx.doi.org/10.1074/jbc.272.40.25112			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312121	hybrid			2022-12-27	WOS:A1997XY97000060
J	Gong, DW; He, YF; Karas, M; Reitman, M				Gong, DW; He, YF; Karas, M; Reitman, M			Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta 3-adrenergic agonists, and leptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; PROTON TRANSPORT; FAT; EXPRESSION; CLONING; OBESITY; MICE; GENE; MECHANISM; C57BL/6J	Mitochondrial uncoupling proteins (UCPs) are transporters that are important for thermogenesis, The net result of their activity is the exothermic movement of protons through the inner mitochondrial membrane, uncoupled from ATP synthesis, We have cloned a third member of the UCP family, UCP3. UCP3 is expressed at high levels in muscle and rodent brown adipose tissue, Overexpression in yeast reduced the mitochondrial membrane potential, showing that UCP3 is a functional uncoupling protein, UCP3 RNA levels are regulated by hormonal and dietary manipulations, In contrast, levels of UCP2, a widely expressed UCP family member, showed little hormonal regulation, In particular, muscle UCP3 levels were decreased 3-fold in hypothyroid rats and increased B-fold in hyperthyroid rats, Thus UCP3 is a strong candidate to explain the effects of thyroid hormone on thermogenesis. White adipose UCP3 levels were greatly increased by treatment with the beta 3-adrenergic agonist, CL214613, suggesting another pathway for increasing thermogenesis, UCP3 mRNA levels were also regulated by dexamethasone, leptin, and starvation, albeit differently in muscle and brown adipose tissue. Starvation caused increased muscle and decreased BAT UCP3, suggesting that muscle assumes a larger role in thermoregulation during starvation, The UCP3 gene is located close to that encoding UCP2, in a chromosomal region implicated in previous linkage studies as contributing to obesity.			Gong, DW (corresponding author), NIDDK,DIABET BRANCH,NIH,BLDG 10,RM 8N-250,10 CTR DR,MSC 1770,BETHESDA,MD 20892, USA.		Reitman, Marc/B-4448-2013; Gong, Dawei/AAB-4283-2020	Reitman, Marc/0000-0002-0426-9475; 				Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLAUD F, 1985, P NATL ACAD SCI USA, V82, P445, DOI 10.1073/pnas.82.2.445; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; DAWSON AG, 1979, TRENDS BIOCHEM SCI, V4, P171, DOI 10.1016/0968-0004(79)90417-1; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; FREAKE HC, 1995, ANNU REV NUTR, V15, P263, DOI 10.1146/annurev.nu.15.070195.001403; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Lowell BB, 1997, ANNU REV MED, V48, P307; MIROUX B, 1993, EMBO J, V12, P3739, DOI 10.1002/j.1460-2075.1993.tb06051.x; Nagase I, 1996, J CLIN INVEST, V97, P2898, DOI 10.1172/JCI118748; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; SHAPIRO HM, 1994, METHOD CELL BIOL, V41, P121; Silva JE, 1995, THYROID, V5, P481, DOI 10.1089/thy.1995.5.481; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Soloveva V, 1997, MOL ENDOCRINOL, V11, P27, DOI 10.1210/me.11.1.27; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; WESTERTERP KR, 1986, J APPL PHYSIOL, V61, P2162, DOI 10.1152/jappl.1986.61.6.2162; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	36	700	744	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24129	24132		10.1074/jbc.272.39.24129	http://dx.doi.org/10.1074/jbc.272.39.24129			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305858	hybrid			2022-12-27	WOS:A1997XY51500009
J	Isenring, P; Forbush, B				Isenring, P; Forbush, B			Ion and bumetanide binding by the Na-K-Cl cotransporter - Importance of transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CHLORIDE COTRANSPORTER; CYTOPLASMIC DOMAIN; PROTEIN; PHOSPHORYLATION; LOCALIZATION; TRANSPORT; EXCHANGER	The Na-K-CI cotransporter (NKCC) plays a key role in electrolyte secretion and absorption across polarized epithelia, The structure of the Na-R-Cl cotransporter transport protein is not known, but from analysis of the primary amino acid sequence and biochemical studies, it has been inferred that the protein has large cytoplasmic N and C termini and a hydrophobic central domain containing 12 transmembrane helices, Both the central domain and the C-terminal domain are highly conserved within the cation-chloride cotransporter family, This paper examines the role of these three domains in interacting with the transported ions and with the inhibitor bumetanide. We have used a chimera approach, exploiting the functional differences between the structurally similar shark and human secretory Na-R-Cl cotransporters (sNKCC1 and hNKCC1). These transporters are 74% identical to one another and have similar transport and regulatory behaviors; however, sNKCCI differs markedly from hNRCC1 with regard to apparent affinities for the cotransported ions and for bumetanide. We prepared six sNKCC1-hNKCC1 chimeras in which N and C termini were interchanged between species, When transfected in HEK-293 cells, each chimera carried out bumetanide-sensitive Rb-86 influx, demonstrating transporter synthesis and cell surface delivery, Monoclonal antibodies J3 and J7 were used to detect the chimeric proteins, and the epitopes for these antibodies were localized to residues 49-196 and 1050-1168, respectively, in the shark sequence, For each of tyro chimeras that were examined, the time course of activation in low Cl- medium was the same as for the parent proteins; activation was found to proceed through a change in V-max rather than K-m. For the six chimeras, the apparent affinities for Na+, K+, Cl-, and bumetanide segregated exactly according-to whether the large hydrophobic central domain was derived from sNKCCI or hNKCCl, Significantly, the well-conserved C terminus does not appear to contain residues involved in She shark-human affinity differences, These results demonstrate that residues involved with ion translocation and inhibitor binding are within the large central domain that contains the 12 predicted transmembrane helices.			Isenring, P (corresponding author), YALE UNIV,DEPT CELLULAR & MOL PHYSIOL,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47661] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK PJ, 1990, MOL CELL BIOL, V10, P4612, DOI 10.1128/MCB.10.9.4612; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Brill S., 1995, B MT DESERT ISL BIOL, V34, P53; COLLINS JF, 1993, P NATL ACAD SCI USA, V90, P3938, DOI 10.1073/pnas.90.9.3938; DELPIRE E, 1994, J BIOL CHEM, V269, P26677; FISCHBARG J, 1994, MOL CELL BIOCHEM, V140, P147, DOI 10.1007/BF00926753; FORBUSH B, 1995, INT SOC NEPHR AM PHY; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GILLEN CM, 1996, BIOPHYS J, V70, P204; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HEDGE RS, 1992, J MEMBRANE BIOL, V126, P27; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; ISENRING P, 1995, J AM SOC NEPHROL, V6, P341; Isenring Paul, 1996, Journal of the American Society of Nephrology, V7, P1282; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAUF PK, 1984, J MEMBRANE BIOL, V77, P57, DOI 10.1007/BF01871100; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Shainskaya A, 1996, J BIOL CHEM, V271, P10309, DOI 10.1074/jbc.271.17.10309; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	31	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24556	24562		10.1074/jbc.272.39.24556	http://dx.doi.org/10.1074/jbc.272.39.24556			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305921	hybrid			2022-12-27	WOS:A1997XY51500072
J	Ishimi, Y				Ishimi, Y			A DNA helicase activity is associated with an MCM4, -6, and -7 protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; REPLICATION LICENSING SYSTEM; HUMAN NUCLEAR-PROTEIN; S-PHASE; YEAST; XENOPUS; INITIATION; CHROMATIN; COMPONENT; ENZYMES	All six minichromosome maintenance (MCM) proteins have DNA-dependent ATPase motifs in the central domain which is conserved from yeast to mammals. Our group purified MCM protein complexes consisting of MCM2, -4 (Cdc21), -6 (Mis5), and -7 (CDC47) proteins from HeLa cells by using histone-Sepharose column chromatography (Ishimi, Y., Ichinose, S., Omori, A., Sato K., and Kimura, H. (1996) J. Biol. Chem. 271, 24115-24122). The present study revealed that both ATPase activity and DNA helicase activity that displaces oligonucleotides annealed to single-stranded circular DNA are associated with an MCM protein complex, Both ATPase and DNA helicase activities were co-purified with a 600-kDa protein complex that is consisted of equal amounts of MCM4, -6, and -7 proteins, An immunodepletion of the MCM protein complex from the purified fraction using anti-MCM4 antibody resulted in the severe reduction of the DNA helicase activity. Displacement of DNA fragments by the DNA helicase suggested that it migrated along single-stranded DNA in the 3' to 5' direction, and the DNA helicase activity was detected only in the presence of hydrolyzable ATP or bATP. These results suggest that this helicase may be involved in the initiation of DNA replication as a DNA unwinding enzyme.			Ishimi, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.							ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P9642; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DEAN FB, 1992, J BIOL CHEM, V267, P14129; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Fujita M, 1997, J BIOL CHEM, V272, P10928; GOETZ GS, 1988, J BIOL CHEM, V263, P383; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Holthoff HP, 1996, GENOMICS, V37, P131, DOI 10.1006/geno.1996.0530; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Krude T, 1996, J CELL SCI, V109, P309; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MARIORANO D, 1996, EMBO J, V15, P861; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Matson SW, 1995, METHOD ENZYMOL, V262, P389; MATSUMOTO K, 1995, BIOCHEMISTRY-US, V34, P7913, DOI 10.1021/bi00024a016; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; SEKI M, 1995, MOL CELL BIOL, V15, P165, DOI 10.1128/MCB.15.1.165; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; STARBORG M, 1995, J CELL SCI, V108, P927; Su TT, 1996, MOL BIOL CELL, V7, P319, DOI 10.1091/mbc.7.2.319; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; TODOROV IT, 1994, J CELL SCI, V107, P253; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	51	462	472	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24508	24513		10.1074/jbc.272.39.24508	http://dx.doi.org/10.1074/jbc.272.39.24508			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305914	hybrid			2022-12-27	WOS:A1997XY51500065
J	Laudanna, C; Campbell, JJ; Butcher, EC				Laudanna, C; Campbell, JJ; Butcher, EC			Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL ADHERENCE; SIGNALING PATHWAY; CYCLIC-AMP; PROTEIN; ENDOTHELIUM; LYMPHOCYTES; RECEPTORS; INFILTRATION; CHEMOTAXIS; MODULATION	Chemoattractant receptors of the serpentine, heterotrimeric G alpha(i) protein-linked family can activate leukocyte integrins and in this role regulate leukocyte traffic and cell-cell interactions in immune and inflammatory responses. Using a mouse lymphoid cell line transfected with human formyl peptide or interleukin-8 receptors and normal human neutrophils as models, we show that cAMP functions as a gating element on the chemoattractant-induced rho-dependent signaling pathway leading to leukocyte integrin activation and adhesion. cAMP, acting through protein kinase A, inhibits chemoattractant-triggered integrin-dependent leukocyte adhesion. cAMP also prevents guanine nucleotide exchange on RhoA, a small GTP-binding protein of the rho subfamily, which is activated in seconds by chemoattractants. In contrast, chemoattractant-triggered intracellular calcium elevation is unaffected by cAMP, and cAMP has no effect on rho-dependent adhesion and RhoA guanine nucleotide exchange triggered through the independent protein kinase C pathway. These data suggest that cAMP-induced inhibition of rho activation may be responsible for the anti-adhesive effect of cAMP and may contribute to the anti-inflammatory activity of cAMP elevating agonists and drugs, Moreover, the findings extend the concept of cyclic nucleotide gating as a broadly important mechanism in the regulation of intracellular signaling pathways and the cellular activities they control.	STANFORD UNIV,DEPT PATHOL,LAB IMMUNOL & VASC BIOL,STANFORD,CA 94305; STANFORD UNIV,DEPT MED,CTR DIGEST DIS,STANFORD,CA 94305; VET AFFAIRS HLTH CARE SYST,CTR MOL BIOL & MED,PALO ALTO,CA 94304	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Campbell, James/0000-0003-4252-5182	NHLBI NIH HHS [HL48638] Funding Source: Medline; NIAID NIH HHS [AI37832, AI37319] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037832, R01AI037319] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURKEY TH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P312, DOI 10.1016/0167-4889(93)90223-C; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CONDINONETO A, 1991, BRIT J CLIN PHARMACO, V32, P557, DOI 10.1111/j.1365-2125.1991.tb03951.x; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GRISTWOOD RW, 1991, INT ARCH ALLER A IMM, V94, P293, DOI 10.1159/000235388; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARVATH L, 1991, J IMMUNOL, V146, P224; HONDA S, 1994, J IMMUNOL, V152, P4026; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; MATSUMOTO T, 1994, J PHARMACOL EXP THER, V269, P1236; Milligan G, 1995, Adv Pharmacol, V32, P1, DOI 10.1016/S1054-3589(08)61010-8; NIELSON CP, 1990, J ALLERGY CLIN IMMUN, V86, P801, DOI 10.1016/S0091-6749(05)80186-1; OPPENHEIMERMARKS N, 1994, J IMMUNOL, V152, P5703; RAVI L, 1996, SCIENCE, V271, P461; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VALITUTTI S, 1993, EUR J IMMUNOL, V23, P790, DOI 10.1002/eji.1830230403; VANEPPS DE, 1981, INFLAMMATION, V5, P81, DOI 10.1007/BF00910782; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	27	178	180	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24141	24144		10.1074/jbc.272.39.24141	http://dx.doi.org/10.1074/jbc.272.39.24141			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305861	hybrid			2022-12-27	WOS:A1997XY51500012
J	Lazarowski, ER; Homolya, L; Boucher, RC; Harden, TK				Lazarowski, ER; Homolya, L; Boucher, RC; Harden, TK			Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL SELECTIVITY; FUNCTIONAL EXPRESSION; PHOSPHOLIPASE-C; ATP RECEPTOR; CELLS; CLONING; IDENTIFICATION; ASTROCYTES; SIGNAL; PURINE	ATP is released from most cell types and functions as an extracellular signaling molecule through activation of members of the two large families of P2X and P2Y receptors. Although three mammalian P2Y receptors have been cloned that are selectively activated by uridine nucleotides, direct demonstration of the release of cellular UTP has not, been reported, Pharmacological studies of the P2Y, receptor expressed in 1321N1 human astrocytoma cells indicated that this receptor is activated by UTP but mot by ATP. Mechanical stimulation of 1321N1 cells also resulted in release of a molecule that markedly activated the expressed P2Y(4) receptor. This nucleotide was shown to be UTP by two means, First, high performance liquid chromatography analysis of the medium from [P-33]H3PO4-loaded 1321N1 cells illustrated that mechanical stimulation resulted in a large increase in a radioactive species that co-eluted with authentic UTP. This species was degraded by incubation with the nonspecific pyrophosphohydrolase apyrase or with hexokinase and was specifically lost by incubation with the UTP-specific enzyme UDP-glucose pyrophosphorylase. Second, a sensitive assay that quantitates UTP mass at low nanomolar concentrations was devised Based on the nucleotide specificity of UDP-glucose pyrophosphorylase. Using this assay, mechanical stimulation of 1321N1 cells was shown to result in an increase of medium UTP levels from 2.6 to 36.4 pmol/10(6) cells within a min, This increase was paralleled by a similar augmentation of extracellular ATP levels, Pn calcein-based fluorescence quenching method was utilized to confirm that none of the increases in medium nucleotide levels could be accounted for by cell lysis, Taken together, these results directly demonstrate the mechanically induced release of UTP and illustrate the efficient coupling of this release to activation of P2Y(4) receptors.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MED,CHAPEL HILL,NC 27599; HUNGARIAN ACAD SCI,MEMBRANE RES GRP,H-1113 BUDAPEST,HUNGARY	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Hungarian Academy of Sciences			Homolya, Laszlo/N-1154-2016	Homolya, Laszlo/0000-0003-1639-8140	NHLBI NIH HHS [HL32322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbracchio MP, 1996, CIBA F SYMP, V198, P142; ANDERSSON M, 1988, INT J BIOCHEM, V20, P1039, DOI 10.1016/0020-711X(88)90248-0; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Charlton SJ, 1996, BRIT J PHARMACOL, V118, P704, DOI 10.1111/j.1476-5381.1996.tb15457.x; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ENOMOTO K, 1994, PFLUG ARCH EUR J PHY, V427, P533, DOI 10.1007/BF00374271; FREDHOLM BB, 1997, DRUG DEVELOP RES, V39, P461; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HO C, 1995, BRIT J PHARMACOL, V116, P2909, DOI 10.1111/j.1476-5381.1995.tb15944.x; KEPPLER D, 1970, ANAL BIOCHEM, V38, P105, DOI 10.1016/0003-2697(70)90160-0; LAZAROWSKI ER, 1994, J BIOL CHEM, V269, P11830; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; LAZAROWSKI ER, 1995, BRIT J PHARMACOL, V116, P1619, DOI 10.1111/j.1476-5381.1995.tb16382.x; Lazarowski ER, 1997, P NATL ACAD SCI USA, V94, P2599, DOI 10.1073/pnas.94.6.2599; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MILNER P, 1990, BIOCHEM BIOPH RES CO, V170, P649, DOI 10.1016/0006-291X(90)92141-L; Neary JT, 1996, CIBA F SYMP, V198, P130; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PEARCE B, 1994, BRAIN RES, V660, P329, DOI 10.1016/0006-8993(94)91307-2; PLESNER L, 1995, INT REV CYTOL, V158, P141; Saiag B, 1995, ENDOTHELIUM, V2, P279, DOI 10.3109/10623329509024644; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; STEELMAN VS, 1966, BIOCHIM BIOPHYS ACTA, V128, P92, DOI 10.1016/0926-6593(66)90145-7; WATT WC, 1996, PEDIAT PULMONAL S, V13, P26; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I	33	254	257	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24348	24354		10.1074/jbc.272.39.24348	http://dx.doi.org/10.1074/jbc.272.39.24348			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305892	Green Published, hybrid			2022-12-27	WOS:A1997XY51500043
J	Smith, KE; Forray, C; Walker, MW; Jones, KA; Tamm, JA; Bard, J; Branchek, TA; Linemeyer, DL; Gerald, C				Smith, KE; Forray, C; Walker, MW; Jones, KA; Tamm, JA; Bard, J; Branchek, TA; Linemeyer, DL; Gerald, C			Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; XENOPUS OOCYTES; GUINEA-PIG; SEROTONIN RECEPTORS; ANTERIOR-PITUITARY; MOLECULAR-CLONING; CHIMERIC PEPTIDE; NERVE INJURY; SPINAL-CORD; BRAIN	The neuropeptide galanin is widely distributed throughout the central and peripheral nervous systems and participates in the regulation of processes such as nociception, cognition, feeding behavior, and insulin secretion. Multiple galanin receptors are predicted to underlie its physiological effects, We now report the isolation by expression cloning of a rat galanin receptor cDNA distinct from GALR1. The receptor, termed GALR2, was isolated from a Pat hypothalamus cDNA library using a I-125-porcine galanin (I-125-pGAL) binding assay. The GALR2 cDNA encoded a protein of 372 amino acids exhibiting 38% amino acid identity with rat GALR1. Binding of I-125-pGAL to transiently expressed GALR2 receptors was saturable (K-D = 0.15 naa) and displaceable by galanin peptides and analogues in rank order: porcine galanin similar or equal to M32 similar or equal to M35 similar or equal to M40 greater than or equal to galanin-(1-16) similar or equal to M15 similar or equal to [D-Trp(2)]galanin-(1-29) > C7 much greater than galanin-(3-29). This profile resembles that of the rat, GALR1 receptor with the notable exception that [D-Trp(2)]galanin exhibited significant selectivity for GALR2 over GALR1, Activation of GALR2 receptors with porcine galanin and other galanin analogues increased inositol phospholipid turnover and intracellular calcium levels in stably transfected Chinese hamster ovary cells and generated calcium-activated chloride currents in Xenopus oocytes, suggesting that the rat. GALR2 receptor is primarily coupled to the activation of phospholipase C.	SYNAPT PHARMACEUT CORP,DEPT PHARMACOL,PARAMUS,NJ 07652		Smith, KE (corresponding author), SYNAPT PHARMACEUT CORP,DEPT MOL BIOL,215 COLL RD,PARAMUS,NJ 07652, USA.							AHMAD S, 1996, 8 WORLD C PAIN VANC, P134; Ahren B, 1996, BIOCHEM BIOPH RES CO, V221, P89, DOI 10.1006/bbrc.1996.0550; AHREN B, 1992, INT J PANCREATOL, V11, P147; BARD JA, 1993, J BIOL CHEM, V268, P23422; BARTFAI T, 1993, P NATL ACAD SCI USA, V90, P11287, DOI 10.1073/pnas.90.23.11287; BARTFAI T, 1991, P NATL ACAD SCI USA, V88, P10961, DOI 10.1073/pnas.88.23.10961; BARTFAI T, 1993, CRIT REV NEUROBIOL, V7, P229; BAUER FE, 1986, GASTROENTEROLOGY, V91, P877, DOI 10.1016/0016-5085(86)90689-X; BENNET WM, 1991, J ENDOCRINOL, V130, P463, DOI 10.1677/joe.0.1300463; BOYLE MR, 1994, REGUL PEPTIDES, V50, P1, DOI 10.1016/0167-0115(94)90185-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan-Palay V, 1990, Adv Neurol, V51, P253; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; ELFVIN LG, 1994, MICROSC RES TECHNIQ, V29, P131, DOI 10.1002/jemt.1070290210; Forray C., 1996, Society for Neuroscience Abstracts, V22, P1304; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; GREGERSEN S, 1993, EUR J PHARMACOL, V232, P35, DOI 10.1016/0014-2999(93)90725-W; GU ZF, 1995, J PHARMACOL EXP THER, V272, P371; GUNDERSEN CB, 1983, PROC R SOC SER B-BIO, V219, P103, DOI 10.1098/rspb.1983.0062; Gustafson EL, 1996, NEUROREPORT, V7, P953, DOI 10.1097/00001756-199603220-00025; HABERTORTOLI E, 1994, P NATL ACAD SCI USA, V91, P9780, DOI 10.1073/pnas.91.21.9780; HARDWICK JC, 1992, J AUTONOM NERV SYST, V40, P87, DOI 10.1016/0165-1838(92)90019-D; HEDLUND PB, 1992, EUR J PHARMACOL, V224, P203, DOI 10.1016/0014-2999(92)90806-F; Howard AD, 1997, FEBS LETT, V405, P285, DOI 10.1016/S0014-5793(97)00196-8; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KAPLAN LM, 1988, P NATL ACAD SCI USA, V85, P7408, DOI 10.1073/pnas.85.19.7408; Kask K, 1995, CELL MOL NEUROBIOL, V15, P653, DOI 10.1007/BF02071130; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; MERCHENTHALER I, 1993, PROG NEUROBIOL, V40, P711, DOI 10.1016/0301-0082(93)90012-H; Parker EM, 1995, MOL BRAIN RES, V34, P179, DOI 10.1016/0169-328X(95)00159-P; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; QUICK MW, 1994, METH NEUROSCI, V19, P261; SETHI T, 1991, CANCER RES, V51, P1674; SHEN Y, 1993, J BIOL CHEM, V268, P18200; SKOFITSCH G, 1985, PEPTIDES, V6, P509, DOI 10.1016/0196-9781(85)90118-4; TAKAHASHI T, 1987, P NATL ACAD SCI USA, V84, P5063, DOI 10.1073/pnas.84.14.5063; VILLAR MJ, 1989, NEUROSCIENCE, V33, P587, DOI 10.1016/0306-4522(89)90411-9; VRONTAKIS ME, 1987, J BIOL CHEM, V262, P16755; WARDEN D, 1968, J GEN VIROL, V3, P371, DOI 10.1099/0022-1317-3-3-371; Wetzel JM, 1996, RECEPTOR CHANNEL, V4, P165; WIESENFELDHALLIN Z, 1992, P NATL ACAD SCI USA, V89, P3334, DOI 10.1073/pnas.89.8.3334; WYNICK D, 1993, P NATL ACAD SCI USA, V90, P4231, DOI 10.1073/pnas.90.9.4231	43	174	186	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24612	24616		10.1074/jbc.272.39.24612	http://dx.doi.org/10.1074/jbc.272.39.24612			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305929	hybrid			2022-12-27	WOS:A1997XY51500080
J	Choi, HS; Chung, MR; Tzameli, I; Simha, D; Lee, YK; Seol, W; Moore, DD				Choi, HS; Chung, MR; Tzameli, I; Simha, D; Lee, YK; Seol, W; Moore, DD			Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; THYROID-HORMONE; GENE-EXPRESSION; GROWTH-HORMONE; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE ELEMENT; CRYSTAL-STRUCTURE; CONSERVED REGION; X-RECEPTOR	We have identified a new murine orphan member of the nuclear hormone receptor superfamily, termed mCAR, that is closely related to the previously described human orphan MB67, referred to here as hCAR. Like hCAR, mCAR expression is highest in liver, In addition to the most abundant mCAR1 isoform, the mCAR gene expresses a truncated mCAR2 variant that is missing the C-terminal portion of the ligand binding/dimerization domain. The mCAR gene has 8 introns, and this mCAR2 variant is generated by a splicing event that skips the 8th exon. mCAR1, like hCAR, binds as a heterodimer with the retinoid X receptor to the retinoic acid response element from the promoter of the retinoic acid receptor beta 2 isoform, Consistent with its lack of a critical heterodimerization interface, the mCAR2 variant does not bind this site, Both mCAR1 and hCAR are apparently constitutive transcriptional activators, This activity is dependent on the presence of the conserved C terminal AF-2 transcriptional activation motif, As expected from its inability to bind DNA, the mCAR2 variant neither transactivates by itself nor inhibits transactivation by hCAR or mCAR1.	MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital					NIDDK NIH HHS [DK46546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRENT GA, 1989, J BIOL CHEM, V264, P178; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Malik S, 1996, MOL CELL BIOL, V16, P1824; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SMITH DP, 1994, NUCLEIC ACIDS RES, V22, P66, DOI 10.1093/nar/22.1.66; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TONE Y, 1994, J BIOL CHEM, V269, P31157; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	52	232	250	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23565	23571		10.1074/jbc.272.38.23565	http://dx.doi.org/10.1074/jbc.272.38.23565			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295294	hybrid			2022-12-27	WOS:A1997XX38100019
J	Elhabazi, A; Lang, V; Herold, C; Freemann, GJ; Bensussan, A; Boumsell, L; Bismuth, G				Elhabazi, A; Lang, V; Herold, C; Freemann, GJ; Bensussan, A; Boumsell, L; Bismuth, G			The human semaphorin-like leukocyte cell surface molecule CD100 associates with a serine kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH CONE GUIDANCE; HUMAN LYMPHOCYTES-T; SELECTIVE INHIBITOR; TYROSINE PHOSPHORYLATION; AXON GUIDANCE; CD45; ACTIVATION; COMPLEX; FAMILY	CD100 is a 150-kDa homodimeric glycoprotein broadly expressed on the surface of human hematopoietic cells. CD100 has been recently identified as the first lymphoid gene that belongs to the semaphorin gene family. Semaphorins function as chemorepellent molecules in the nervous system, but the function of CD100 remains poorly understood. In lymphoid cells, it has been suggested to play a role in homotypic cell adhesion and in T cell activation. We demonstrate that in T cells and natural killer cells a serine kinase activity is immunoprecipitated with CD100. Distinct epitopes of CD100 have been defined with specific monoclonal antibodies, mediating opposite effects at the functional level, especially in T cells. The kinase activity is retained only with an antibody against a particular epitope of CD100. Additionally, a fusion protein containing the cytoplasmic domain of the molecule retains the kinase activity in cellular lysates, and CD100 itself is presumably a favorite substrate of the kinase, These findings suggest that a serine kinase pathway may participate in the different functional effects triggered through the distinct epitopes of CD100 and is likely involved in the biological effects of this semaphorin-like leukocyte cell surface molecule.	CTR HOSP PITIE SALPETRIERE,CERVI,CNRS,URA 625,LAB IMMUNOL CELLULAIRE,F-75013 PARIS,FRANCE; HARVARD UNIV,SCH MED,DEPT MED,DIV HEMATOL MALIGNANCIES,DANA FARBER CANC INST,BOSTON,MA 02115; FAC MED CRETEIL,IMMUNOL LAB,INSERM,U448,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)			Bensussan, Armand/E-5434-2017	Bensussan, Armand/0000-0002-0409-2497				ALBEROLAILA J, 1993, J IMMUNOL, V151, P4423; BOUGERET C, 1992, J IMMUNOL, V148, P318; BOUMSELL L, 1990, J IMMUNOL, V145, P2797; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CARDINE AM, 1994, EUR J IMMUNOL, V124, P1255; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; DAVID V, 1990, J IMMUNOL, V144, P1; DEANS JP, 1993, J IMMUNOL, V151, P4494; Frearson JA, 1996, IMMUNOL TODAY, V17, P385, DOI 10.1016/0167-5699(96)10026-8; Furuyama T, 1996, J BIOL CHEM, V271, P33376, DOI 10.1074/jbc.271.52.33376; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; HEROLD C, 1995, INT IMMUNOL, V7, P1, DOI 10.1093/intimm/7.1.1; Herold C, 1996, J IMMUNOL, V157, P5262; HEROLD C, 1995, LEUKOCYTE TYPING, V5, P290; HEROLD C, 1995, LEUCOCYTE TYPING, V5, P288; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LOH C, 1994, J BIOL CHEM, V269, P8817; MUSTELIN T, 1995, EUR J IMMUNOL, V25, P942, DOI 10.1002/eji.1830250413; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PINTO A, 1994, LEUKEMIA, V8, P347; PRASAD KVS, 1992, MOL CELL BIOL, V12, P5260, DOI 10.1128/MCB.12.11.5260; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHRAVEN B, 1993, EUR J IMMUNOL, V23, P119, DOI 10.1002/eji.1830230119; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474	41	47	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23515	23520		10.1074/jbc.272.38.23515	http://dx.doi.org/10.1074/jbc.272.38.23515			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295286	hybrid			2022-12-27	WOS:A1997XX38100011
J	Garabedian, EM; Roberts, LJJ; McNevin, MS; Gordon, JI				Garabedian, EM; Roberts, LJJ; McNevin, MS; Gordon, JI			Examining the role of Paneth cells in the small intestine by lineage ablation in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL-INTESTINE; SEGMENTED FILAMENTOUS BACTERIA; GASTROINTESTINAL-TRACT; EPITHELIAL-CELLS; CELLULAR-DIFFERENTIATION; PEPTIDE COMPONENTS; FORCED EXPRESSION; ENHANCING FACTOR; MAJOR MODIFIER; HOST-DEFENSE	The Paneth cell lineage is one of four epithelial lineages derived from the adult mouse small intestine's multipotent stem cell. Mature Paneth cells secrete antimicrobial peptides (cryptdins), growth factors, as well as two gene products, a secreted phospholipase A, and matrilysin, that has been implicated as modifiers of adenoma formation in mice containing a mutation in the tumor suppressor Apc. Immature Paneth cells are located just above and below the cell layer, in intestinal crypts, that has been proposed to contain the multipotent stem cell. Paneth cells differentiate during a downward migration to the crypt base. The location and direction of Paneth cell migration, their high density and long residency time at the crypt base, and the nature of their secreted gene products, suggest that they may influence the structure and/or function of the stem cell niche. Paneth cell ablation can therefore be viewed as an experimental manipulation of the cellular microenvironment that purportedly contains the stem cell and its immediate descendants. Two types of ablation experiments were performed in transgenic mice. Nucleotides -6500 to +34 of the mouse cryptdin-2 gene (CR2) were used to express an attenuated diphtheria toxin A fragment. Light and electron microscopic immunohistochemical analyses of several pedigrees of postnatal day 28 to 180 animals established that ablation of Paneth cells is accompanied by an increase in the proportion of undifferentiated crypt base columnar cells. These cells normally co-exist with Paneth cells. The ablation does not produce a detectable effect on the proliferation or terminal differentiation programs of the other three lineages or on host-microbial interactions. The last conclusion is based on the ability of crypts to remain free of microbes detectable by Gram and Warthin-Starry stains and by retention of the normal crypt-villus distribution of components of the diffuse gut-associated lymphoid tissue. CR2-directed expression of simian virus 40 large T antigen also results in a loss of mature Paneth cells but produces a marked amplification of crypt cells having a morphology intermediate between Paneth and granule goblet cells, EM immunohistochemical analyses suggest that intermediate cells can differentiate to mature goblet cells but not to Paneth cells, as they migrate up the crypt-villus axis. Our findings suggest that (i) stemness in the crypt is not defined by instructive interactions involving the Paneth cell; (ii) expressing a Paneth cell fate may require that precursors migrate to the crypt base; (iii) antimicrobial factors produced by Paneth cells are not required to prevent colonization of small intestinal crypts; and (iv) this lineage does not function to maintain the asymmetric crypt-villus distribution of components of the diffuse gut-associated lymphoid tissue.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIDDK NIH HHS [DK 37960] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037960] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJERKNES M, 1981, AM J ANAT, V160, P51, DOI 10.1002/aja.1001600105; BJERKNES M, 1981, AM J ANAT, V160, P65, DOI 10.1002/aja.1001600106; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; CALVERT R, 1988, ANAT REC, V220, P291, DOI 10.1002/ar.1092200310; CASTRO NM, 1959, LIN ACTA ANAT, V38, P345; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1969, AM J ANAT, V126, P507, DOI 10.1002/aja.1001260409; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; COHN SM, 1984, J BIOL CHEM, V259, P2456; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; DAVIS CP, 1974, INFECT IMMUN, V10, P948, DOI 10.1128/IAI.10.4.948-956.1974; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dove WF, 1997, CANCER RES, V57, P812; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GHOOS Y, 1971, Histochemical Journal, V3, P175, DOI 10.1007/BF01002560; Gould KA, 1996, GENETICS, V144, P1769; Gould KA, 1996, GENETICS, V144, P1777; GUSTAFSSON BE, 1982, SCAND J GASTROENTERO, V17, P117; HALL PA, 1994, J CELL SCI, V107, P3569; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; Hertzog AJ, 1937, AM J PATHOL, V13, P351; Hunyady B, 1996, HISTOCHEM CELL BIOL, V106, P447, DOI 10.1007/BF02473306; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JEPSON MA, 1993, INFECT IMMUN, V61, P4001, DOI 10.1128/IAI.61.9.4001-4004.1993; KLAASEN HLBM, 1991, ARCH MICROBIOL, V156, P148, DOI 10.1007/BF00290989; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; Luna LG, 1968, MANUAL HISTOLOGIC ST, V3; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; MERZEL J, 1969, AM J ANAT, V124, P281, DOI 10.1002/aja.1001240303; MONTERO C, 1978, ANAT REC, V190, P127, DOI 10.1002/ar.1091900111; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; PEETERS T, 1975, GUT, V16, P553, DOI 10.1136/gut.16.7.553; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POULSEN SS, 1986, HISTOCHEMISTRY, V85, P389, DOI 10.1007/BF00982668; Roberts SJ, 1996, P NATL ACAD SCI USA, V93, P11774, DOI 10.1073/pnas.93.21.11774; ROTH KA, 1990, J CELL BIOL, V110, P1791, DOI 10.1083/jcb.110.5.1791; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; SNEL J, 1995, INT J SYST BACTERIOL, V45, P780, DOI 10.1099/00207713-45-4-780; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TAN XD, 1993, AM J PATHOL, V142, P1858; TROUGHTON WD, 1969, J CELL BIOL, V41, P251, DOI 10.1083/jcb.41.1.251; TUCCARI G, 1984, BASIC APPL HISTOCHEM, V28, P177; UMESAKI Y, 1995, MICROBIOL IMMUNOL, V39, P555, DOI 10.1111/j.1348-0421.1995.tb02242.x; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Wyllie A H, 1980, Int Rev Cytol, V68, P251	72	192	204	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23729	23740		10.1074/jbc.272.38.23729	http://dx.doi.org/10.1074/jbc.272.38.23729			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295317	hybrid			2022-12-27	WOS:A1997XX38100042
J	Liang, GS; Hai, T				Liang, GS; Hai, T			Characterization of human activating transcription factor 4, a transcriptional activator that interacts with multiple domains of cAMP-responsive element-binding protein (CREB)-binding protein (CBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; LARGE T-ANTIGEN; COACTIVATOR CBP; ADENOVIRUS E1A; LEUCINE ZIPPER; FACTOR ATF; INDUCED STIMULATION; MOLECULAR-CLONING; NUCLEAR FACTOR; BZIP PROTEIN	We demonstrate that human activating transcription factor 4 (hATF4), a member of the activating transcription factor/cAMP-responsive element-binding protein (ATF/CREB) family of transcription factors, is a potent transcriptional activator in both mammalian cells and yeast. The N-terminal 113 amino acids of hATF4 activate transcription efficiently, and unexpectedly, the C-terminal bZip DNA binding domain of hATF4 also activates transcription, albeit weakly. Our results indicate that hATF4 interacts with several general transcription factors: TATA-binding protein, TFIIB, and the RAP30 subunit of TFIIF. In addition, hATF4 interacts with the coactivator CREB-binding protein (CBP) at four regions: 1) the KIX domain, 2) a region that contains the third zinc finger and the E1A-interacting domain, 3) a C-terminal region that contains the p160/SRC-1-interacting domain, and 4) the recently identified histone acetyltransferase domain. Interestingly, both the N-terminal and C-terminal regions of hATF4 interact with the above general transcription factors and CBP, providing a mechanistic explanation for their ability to activate transcription. Consistent, with its role as a coactivator, CBP potentiates the ability of hATF4 to activate transcription. The potential significance of the interaction between hATF4 and multiple factors is discussed.	OHIO STATE UNIV,BIOCHEM PROGRAM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210; OHIO STATE UNIV,NEUROBIOTECHNOL CTR,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NIGMS NIH HHS [GM46218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BRANDL CJ, 1989, P NATL ACAD SCI USA, V86, P2652, DOI 10.1073/pnas.86.8.2652; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHEN BPC, 1994, GENE, V139, P73, DOI 10.1016/0378-1119(94)90525-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARPER JW, 1993, CELL, V75, P805; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JONES RH, 1989, P NATL ACAD SCI USA, V86, P2176, DOI 10.1073/pnas.86.7.2176; JOSEPH CK, 1993, J BIOL CHEM, V268, P2002; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martin ML, 1996, MOL CELL BIOL, V16, P2110; MIELNICKI LM, 1991, NUCLEIC ACIDS RES, V19, P6332, DOI 10.1093/nar/19.22.6332; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; NOJIMA H, 1994, NUCLEIC ACIDS RES, V22, P5279, DOI 10.1093/nar/22.24.5279; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; Rose MD., 1990, METHODS YEAST GENETI; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; VULLIET R, 1992, J BIOL CHEM, V267, P22570; Willems L, 1991, DNA Seq, V1, P415, DOI 10.3109/10425179109020800; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	77	100	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24088	24095		10.1074/jbc.272.38.24088	http://dx.doi.org/10.1074/jbc.272.38.24088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295363	hybrid			2022-12-27	WOS:A1997XX38100088
J	Spizz, G; Blackshear, PJ				Spizz, G; Blackshear, PJ			Identification and characterization of cathepsin B as the cellular MARCKS cleaving enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SUBSTRATE MARCKS; MEMBRANE ASSOCIATION; MOLECULAR-CLONING; TISSUE DISTRIBUTION; CHROMOSOMAL LOCALIZATION; MEDIATED PHOSPHORYLATION; EPOXYSUCCINYL PEPTIDES; LYSOSOMAL PROTEOLYSIS; MAJOR SUBSTRATE	The importance of regulating the cellular concentrations of the myristoylated alanine-rich C kinase substrate (MARCKS), a major cellular substrate of protein kinase C, is indicated by the fact that mice lacking MARCKS exhibit gross abnormalities of central nervous system development and die shortly after birth, We previously identified a novel means of regulating cellular MARCKS concentrations that involved a specific proteolytic cleavage of the protein and implicated a cysteine protease in this process (Spizz, G., and Blackshear, P. J. (1996) J. Biol. Chem. 271, 553-562). Here we show that p40, the carboxyl-terminal fragment resulting from this cleavage of MARCKS, was associated with the mitochondrial/lysosomal pellet fraction of human diploid fibroblasts and that its generation in cells was sensitive to treatment with NH4Cl. These data suggest the involve ment of lysosomes in the generation and/or stability of p40, The MARCKS-cleaving enzyme (MCE) activity was peripherally associated with a 10,000 x g pellet fraction from bovine liver, and it co-purified with the activity and immunoreactivity of a lysosomal protease, cathepsin B, Cathepsin B catalyzed the generation of p40 from MARCKS in a cell-free system and behaved similarly to the MCE with respect to mutants of MARCKS previously shown to be poor substrates for the MCE, Treatment of fibroblasts with a cell-permeable, specific inhibitor of cathepsin B, CA074-Me, resulted in parallel time-and concentration-dependent inhibition off cathepsin B and MCE activity, Incubation of a synthetic MARCKS phosphorylation site domain peptide with purified cathepsin B resulted in cleavage of the peptide at sites consistent with preferred cathepsin B substrate sites, These data provide evidence for the identity of the MCE as cathepsin B and suggest that this cleavage most likely takes place within lysosomes, perhaps as a result of specific lysosomal targeting sequences within the MARCKS primary sequence, The data also suggest a direct interaction between MARCKS and cathepsin B in cells and leave open the possibility that MARCKS may in some way regulate the protease for which it is a substrate.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL METAB & NUTR,SECT DIABET & METAB,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AGARWAL SK, 1987, BIOCHEM INT, V15, P785; ALDRED AR, 1995, COMP BIOCHEM PHYS B, V111, P1, DOI 10.1016/0305-0491(94)00229-N; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; AMESS B, 1992, FEBS LETT, V297, P285; BACKER JM, 1983, P NATL ACAD SCI-BIOL, V80, P2166, DOI 10.1073/pnas.80.8.2166; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BLACKSHEAR PJ, 1982, BIOCHEM J, V204, P817, DOI 10.1042/bj2040817; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Blackshear PJ, 1997, EXP NEUROL, V145, P46, DOI 10.1006/exnr.1997.6475; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; CARDOZO C, 1992, J LAB CLIN MED, V119, P169; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; COOPER JA, 1983, J BIOL CHEM, V258, P1108; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DEAN RT, 1984, BIOCHEM J, V217, P27, DOI 10.1042/bj2170027; DEVAL C, 1990, BIOCHEM CELL BIOL, V68, P822, DOI 10.1139/o90-121; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HASNAIN S, 1993, J BIOL CHEM, V268, P235; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; JOHNSON GVW, 1993, J NEUROSCI RES, V34, P642, DOI 10.1002/jnr.490340607; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KHOURI HE, 1991, BIOCHEM J, V275, P751, DOI 10.1042/bj2750751; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; KOGA H, 1991, J BIOCHEM-TOKYO, V110, P179, DOI 10.1093/oxfordjournals.jbchem.a123554; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; LINDNER D, 1992, J BIOL CHEM, V267, P24; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MUNGER JS, 1995, BIOCHEM J, V311, P299, DOI 10.1042/bj3110299; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NAKAOKA T, 1995, J BIOL CHEM, V270, P12147, DOI 10.1074/jbc.270.20.12147; OTSUKA M, 1991, BIOCHEM BIOPH RES CO, V178, P494, DOI 10.1016/0006-291X(91)90134-S; PAGE AE, 1992, BIOCHIM BIOPHYS ACTA, V1116, P57, DOI 10.1016/0304-4165(92)90128-H; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; ROWAN AD, 1992, BIOL CHEM H-S, V373, P427, DOI 10.1515/bchm3.1992.373.2.427; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SHI GP, 1994, J BIOL CHEM, V269, P11530; Spizz G, 1996, J BIOL CHEM, V271, P553, DOI 10.1074/jbc.271.1.553; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; TERLECKY SR, 1994, EXPERIENTIA, V50, P1021, DOI 10.1007/BF01923456; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X; TU GF, 1992, AM J PHYSIOL, V263, pR195, DOI 10.1152/ajpregu.1992.263.1.R195; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WOJTASZEK PA, 1993, ONCOGENE, V8, P755; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YASUHARA O, 1993, BRAIN RES, V628, P85, DOI 10.1016/0006-8993(93)90941-F	79	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23833	23842		10.1074/jbc.272.38.23833	http://dx.doi.org/10.1074/jbc.272.38.23833			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295331	hybrid			2022-12-27	WOS:A1997XX38100056
J	Coleman, ST; Tseng, E; MoyeRowley, WS				Coleman, ST; Tseng, E; MoyeRowley, WS			Saccharomyces cerevisiae basic region-leucine zipper protein regulatory networks converge at the ATR1 structural gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; AMINO-ACID CONTROL; TRANSCRIPTIONAL ACTIVATION; TRANSLATIONAL CONTROL; POSITIVE SELECTION; SHUTTLE VECTORS; GCN4 PROTEIN; JUN FAMILY; YEAST; RESISTANCE	Saccharomyces cerevisiae cells express a family of transcription factors belonging to the basic region-leucine zipper family. Two of these proteins, yAP-1 and Gcn4p, are known to be involved in oxidative; stress tolerance and general control of amino acid biosynthesis, respectively. Strains lacking the YAP1 or GCN4 structural gene have very different phenotypes, which have been taken as evidence that these transcriptional regulatory proteins central separate batteries of target genes. In this study, we provide evidence that both yAP-1 and Gcn4p control the expression of a putative integral membrane protein, Atr1p. Both yAP-1 and Gen4p can elevate resistance to 3-amino-1,2,4-triazole and 4-nitroquinoline-N-oxide but only if the ATR1 gene is intact. Expression of ATR1 is enhanced in the presence of constitutively active alleles of YAP1 and GCN4. Regulation of ATR1 transcription by yAP-1 and Gcn4p, occurs through a common DNA element related to the yAP-1 recognition element found upstream of other yAP-1-regulated genes. These data provide the first indication of overlap between the regulatory networks defined by yAP-1 and Gcn4p.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM49825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; GOMPELKLEIN P, 1990, CURR GENET, V18, P93, DOI 10.1007/BF00321122; Grant CM, 1996, MOL MICROBIOL, V22, P739, DOI 10.1046/j.1365-2958.1996.d01-1727.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAASE E, 1992, CURR GENET, V21, P319, DOI 10.1007/BF00351689; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1983, P NATL ACAD SCI-BIOL, V80, P5374, DOI 10.1073/pnas.80.17.5374; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HIRATA D, 1994, MOL GEN GENET, V242, P250, DOI 10.1007/BF00280413; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUEMINFAURE I, 1994, MOL GEN GENET, V244, P519, DOI 10.1007/BF00583903; JANUSKA AP, 1988, GENETIKA+, V24, P773; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLOPOTOW.T, 1965, ARCH BIOCHEM BIOPHYS, V112, P562, DOI 10.1016/0003-9861(65)90096-2; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEPPERT G, 1990, GENETICS, V125, P13; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; MACK M, 1988, MOL GEN GENET, V211, P260, DOI 10.1007/BF00330602; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; THIREOS G, 1984, P NATL ACAD SCI-BIOL, V81, P5096, DOI 10.1073/pnas.81.16.5096; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VINCENT AC, 1992, MOL CELL BIOL, V12, P5394, DOI 10.1128/MCB.12.12.5394; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	49	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23224	23230		10.1074/jbc.272.37.23224	http://dx.doi.org/10.1074/jbc.272.37.23224			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287330	hybrid			2022-12-27	WOS:A1997XV74400041
J	Yoon, SO; Soltoff, SP; Chao, MV				Yoon, SO; Soltoff, SP; Chao, MV			A dominant role of the juxtamembrane region of the TrkA nerve growth factor receptor during neuronal cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE INTERACTION DOMAIN; TYROSINE KINASE-ACTIVITY; PC12 CELLS; EGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITES; MAP KINASE; PHEOCHROMOCYTOMA CELLS; SUSTAINED ACTIVATION; SIGNAL-TRANSDUCTION	All receptor tyrosine kinases share a common intracellular signaling machinery, including ras activation, whereas cellular responses vary from mitogenesis to cell differentiation. To investigate the structural basis for receptor tyrosine kinase action for nerve growth factor, the juxtamembrane region of TrkA was transferred to a corresponding region of the epidermal growth factor (EGF) receptor. The resulting chimeric receptor contains an additional She site, Tyr(490), in the juxtamembrane region. In transfected PC12 cell lines, neuronal differentiation was observed with EGF treatment, as evidenced by increased neurite extension. The action of the chimeric receptor was correlated with prolonged activation of MAP kinases and a 3-4-fold increase in phosphatidylinositol 3-kinase activity. The effect of the juxtamembrane chimera was dependent upon the She site at Tyr(490), because expression of a chimeric receptor containing a Y490F mutation resulted in a complete loss of neuritogenesis by EGF treatment. These findings indicate that the juxtamembrane region of the TrkA receptor serves as a key functional domain that can confer a dominant effect upon neuronal differentiation.	CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; BETH ISRAEL DEACONESS MED CTR,DIV SIGNAL TRANSDUCT,DEPT MED,BOSTON,MA 02115	Cornell University; Harvard University; Beth Israel Deaconess Medical Center			Yoon, Sung Ok/C-5992-2012	Chao, Moses/0000-0002-6969-3744				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BERG MM, 1992, J BIOL CHEM, V267, P13; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; Mandiyan V, 1996, J BIOL CHEM, V271, P4770; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P278; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHONG DG, 1993, BIOTECHNIQUES, V15, P874; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23231	23238		10.1074/jbc.272.37.23231	http://dx.doi.org/10.1074/jbc.272.37.23231			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287331	hybrid			2022-12-27	WOS:A1997XV74400042
J	Zollner, S; Haseloff, RF; Kirilyuk, IA; Blasig, IE; Rubanyi, GM				Zollner, S; Haseloff, RF; Kirilyuk, IA; Blasig, IE; Rubanyi, GM			Nitroxides increase the detectable amount of nitric bride released from endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE MIMICS; HYDROXYL RADICAL PRODUCTION; OXYGEN RADICALS; RELAXING FACTOR; OXIDE; PEROXYNITRITE; KINETICS; IRON; CYTOTOXICITY; DERIVATIVES	Nitroxides are known to exert superoxide dismutase-mimetic properties and to decrease O-2(.-)- and H2O2-mediated cytotoxicity. However, the effect of nitroxides on (NO)-N-. homeostasis has not been studied yet. The present study investigates the effect of nitroxides on the detectable amount of (NO)-N-. released by 3-morpholinosydnonimine (SIN-1) and cultured endothelial cells. Cultured bovine aortic and atrial endothelial cells stimulated with 10 mu m A23187 released a stable flux of (NO)-N-., as detected by (NO)-N-. chemiluminescence. Addition of 100 units/ml SOD or 10 mu M of the nitroxides 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL), 3-carboxy-proxyl, and 3-ethoxycarbonyl-proxyl, increased the chemiluminescence signal. The effect of these nitroxides on the amount of (NO)-N-. released from cell monolayers was dose-dependent, with the highest efficacy between 30 and 100 mu M. EPR spin trapping in SIN-1 solutions revealed the formation of (OH)-O-. adducts from spontaneous dismutation of O-2(.-) and concomitant reaction with H2O2. Both SOD and TEMPOL increased the signal intensity of the (OH)-O-. adduct by accelerating the dismutation of O-2(.-). The results of this study demonstrate that the SOD-mimetic activity of nitroxides increases the amount of bioavailable (NO)-N-. in vitro.	BERLEX BIOSCI,CARDIOVASC DEPT,RICHMOND,CA 94804; INST MOL PHARMACOL,D-10315 BERLIN,GERMANY; RUSSIAN ACAD SCI,INST ORGAN CHEM,NOVOSIBIRSK 630090,RUSSIA	Russian Academy of Sciences; Vorozhtsov Novosibirsk Institute of Organic Chemistry			Kirilyuk, Igor/R-1688-2016; Kirilyuk, Igor/AAR-1400-2021	Kirilyuk, Igor/0000-0001-6033-0368; 				ANKEL EG, 1987, LIFE SCI, V40, P495, DOI 10.1016/0024-3205(87)90116-0; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BEHAR D, 1970, J PHYS CHEM-US, V74, P3209, DOI 10.1021/j100711a009; CHAN PH, 1994, BRAIN PATHOL, V4, P59; COSENTINO F, 1994, HYPERTENSION, V23, P229, DOI 10.1161/01.HYP.23.2.229; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; DEGRAFF WG, 1992, ENVIRON MOL MUTAGEN, V19, P21, DOI 10.1002/em.2850190105; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GADZHEVA V, 1994, FREE RADICAL RES, V21, P177, DOI 10.3109/10715769409056568; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAHN SM, 1994, CANCER RES, V54, pS2006; HALLE W, 1984, PHARMAZIE, V39, P77; HALLIWELL B, 1993, BRIT MED J, V307, P885, DOI 10.1136/bmj.307.6909.885; Haseloff RF, 1997, FREE RADICAL RES, V26, P7, DOI 10.3109/10715769709097780; HASELOFF RF, 1992, J BIOLUM CHEMILUM, V7, P171, DOI 10.1002/bio.1170070303; HASELOFF RF, 1990, FREE RADICAL BIO MED, V9, P111, DOI 10.1016/0891-5849(90)90113-W; JOSEPH J, 1993, BIOCHEM BIOPH RES CO, V192, P926, DOI 10.1006/bbrc.1993.1504; Katusic ZS, 1996, FREE RADICAL BIO MED, V20, P443, DOI 10.1016/0891-5849(96)02116-8; Koppenol W.H., 1981, OXYGEN OXYRADICALS C, P671; Krishna MC, 1996, J BIOL CHEM, V271, P26026, DOI 10.1074/jbc.271.42.26026; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAGANO T, 1989, J BIOL CHEM, V264, P9243; NOACK E, 1989, J CARDIOVASC PHARM, V14, pS1, DOI 10.1097/00005344-198914110-00002; RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199304000-00002; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH815, DOI 10.1152/ajpheart.1986.250.5.H815; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; RUBANYI GM, 1988, FREE RADICAL BIO MED, V4, P107, DOI 10.1016/0891-5849(88)90071-8; RYAN US, 1980, TISSUE CELL, V12, P619, DOI 10.1016/0040-8166(80)90017-8; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1991, FREE RADICAL RES COM, V12-3, P187, DOI 10.3109/10715769109145785; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; SHI XL, 1994, BIOCHEM BIOPH RES CO, V203, P1515, DOI 10.1006/bbrc.1994.2357; SHIMIZU S, 1994, RES COMMUN CHEM PATH, V84, P301; SHUFF ST, 1992, BIOCHEM PHARMACOL, V43, P1601, DOI 10.1016/0006-2952(92)90219-9; SOSNOVSKY G, 1995, J ORG CHEM, V60, P3414, DOI 10.1021/jo00116a029; THOMAS JP, 1993, J LIPID RES, V34, P479; WEISS RH, 1993, J BIOL CHEM, V268, P23049; ZHANG RL, 1994, ARCH BIOCHEM BIOPHYS, V312, P385, DOI 10.1006/abbi.1994.1323	48	43	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23076	23080		10.1074/jbc.272.37.23076	http://dx.doi.org/10.1074/jbc.272.37.23076			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287307	hybrid			2022-12-27	WOS:A1997XV74400018
J	Goltsev, YV; Kovalenko, AV; Arnold, E; Varfolomeev, EE; Brodianskii, VM; Wallach, D				Goltsev, YV; Kovalenko, AV; Arnold, E; Varfolomeev, EE; Brodianskii, VM; Wallach, D			CASH, a novel caspase homologue with death effector domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; CELL-DEATH; CYSTEINE PROTEASE; GENE CED-3; C-ELEGANS; APOPTOSIS; INHIBITION; INTERACTS; ENCODES	CASP-8 and CASP-10, members of a cysteine protease family that participates in apoptosis, interact with MORT1/FADD, an adapter protein in the CD120a (p55 tumor necrosis factor receptor), and CD95 (Fas/Apo-1) death-inducing signaling pathways, through a shared N-terminal sequence motif, the death effector domain. We report cloning of two splice variants of a novel protein, CASH, that contain two N-terminal death effector domains and can bind through them to each other, to MORT1/FADD, to CASP-8, and to CASP-10. The unique C-terminal part of the longer variant shows marked sequence homology to the caspase protease region yet lacks several of the conserved caspase active site residues, suggesting that it is devoid of cysteine protease activity. Overexpression of the short CASH splice variant strongly inhibited cytotoxicity induction by CD120a and CD95. Expression of the longer variant, while inhibiting cytotoxicity in HeLa cells, had a marked cytocidal effect in 293 cells that could be shown to involve its protease homology region. The findings suggest that CASH acts as an attenuator and/or initiator in CD95 and CD120a signaling for cell death.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								Ahmad M, 1997, CANCER RES, V57, P615; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERNANDESALNEMR.T, 1996, P NATL ACAD SCI USA, V93, P7646; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; TEWARI M, 1995, CELL, V81, P1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VanCriekinge W, 1996, J BIOL CHEM, V271, P27245, DOI 10.1074/jbc.271.44.27245; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	32	265	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 8	1997	272	32					19641	19644		10.1074/jbc.272.32.19641	http://dx.doi.org/10.1074/jbc.272.32.19641			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XQ059	9289491	hybrid			2022-12-27	WOS:A1997XQ05900003
J	Fredenburgh, JC; Stafford, AR; Weitz, JI				Fredenburgh, JC; Stafford, AR; Weitz, JI			Evidence for allosteric linkage between exosites 1 and 2 of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; PROTEIN-C ACTIVATION; BLOOD-COAGULATION PROTEINASES; PROTHROMBIN FRAGMENT-2; ACTIVE-SITE; FACTOR-VA; STRUCTURAL-CHANGES; PPACK-THROMBIN; CATALYTIC SITE; BINDING	Investigations to date have demonstrated that ligand binding to exosites 1 or 2 on thrombin produces conformational changes at the active site. In this study, we directly compared the effect of ligand binding to exosites 1 and 2 on the structure and function of the active site of thrombin and investigated functional linkage between the two exosites. Binding studies were performed in solution with fluorescein-Phe-Pro-Arg-CH2Cl (FPR)-thrombin. Hirudin-(54-65) and sF2, a synthetic peptide corresponding to residues 63-116 of prothrombin fragment 2, were used as ligands for exosites 1 and 2 of thrombin, respectively. The two ligands produce diametric changes in the fluorescence of fluorescein-FPR-thrombin and also have opposing effects on the rate of thrombin hydrolysis of a number of chromogenic substrates. These results indicate that sF2 and hirudin-(54-65) differentially affect the conformation of the active site. Experiments then were performed to investigate whether both ligands can bind to thrombin simultaneously. When thrombin-bound fluorescein-sF2 is titrated with hirudin-(54-65), complete displacement of fluorescein-sF2 is observed. Likewise, when thrombin-bound fluorescein-hirudin-(54-65) is titrated with sF2, complete displacement occurs. Additional support for reciprocal binding was obtained in fluorescence experiments where both probes were labeled and in experiments monitoring ligand binding to agarose-immobilized thrombin. This mutually exclusive binding of either ligand can be explained by reciprocal, allosteric modulation of ligand affinity between the two exosites. Thus, not only do the two exosites differentially influence the active site, they also affect the binding properties of the opposing exosite.	HAMILTON CIV HOSP, RES CTR, HAMILTON, ON L8V 1C3, CANADA; MCMASTER UNIV, HAMILTON, ON L8V 1C3, CANADA	McMaster University; McMaster University			Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Bray A M, 1995, J Pept Sci, V1, P80, DOI 10.1002/psc.310010110; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH WR, 1991, J BIOL CHEM, V266, P8384; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DECRISTOFARO R, 1995, J MOL BIOL, V245, P447; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU LW, 1991, J BIOL CHEM, V266, P16977; LIU LW, 1994, J BIOL CHEM, V269, P11807; LIU LW, 1991, J BIOL CHEM, V266, P23632; Mann KG., 1994, HEMOSTASIS THROMBOSI, P184; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NASKI MC, 1990, J BIOL CHEM, V265, P13484; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON TA, 1986, ANN NY ACAD SCI, V485, P96, DOI 10.1111/j.1749-6632.1986.tb34571.x; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER FJ, 1979, J BIOL CHEM, V254, P5618; WEITZ JI, 1991, J CLIN INVEST, V87, P1082, DOI 10.1172/JCI115069; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1994, J BIOL CHEM, V269, P17965	44	92	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25493	25499		10.1074/jbc.272.41.25493	http://dx.doi.org/10.1074/jbc.272.41.25493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325262	hybrid			2022-12-27	WOS:A1997YA35800017
J	Curmi, PA; Andersen, SSL; Lachkar, S; Gavet, O; Karsenti, E; Knossow, M; Sobel, A				Curmi, PA; Andersen, SSL; Lachkar, S; Gavet, O; Karsenti, E; Knossow, M; Sobel, A			The stathmin/tubulin interaction in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STAGE-SPECIFIC EXPRESSION; MICROTUBULE DYNAMICS; PHYLOGENETIC CONSERVATION; DEVELOPMENTAL REGULATION; MAJOR PHOSPHOPROTEIN; LIVER-REGENERATION; MESSENGER-RNA; GENE FAMILY; RAT-BRAIN	Stathmin is a highly conserved ubiquitous cytoplasmic protein, phosphorylated in response to extracellular signals and during the cell cycle, Stathmin has recently been shown to destabilize microtubules, but the molecular mechanisms of this function remained unclear. We show here that stathmin directly interacts with tubulin, We assessed the conditions of this interaction and determined some its quantitative parameters using plasmon resonance, gel filtration chromatography, and analytical ultracentrifugation. The stathmin/tubulin interaction leads to the formation of a 7.7 S complex with a 60-Angstrom Stokes radius, associating one stathmin with two tubulin heterodimer molecules as determined by direct quantification by Western blotting, This interaction is sensitive to pH and ionic environment. Its equilibrium dissociation constant, determined by plasmon resonance measurement of kinetic constants, has an optimum value of 0.5 mu M at pH 6.5. The affinity was lowered with a fully ''pseudophosphorylated'' 4-Glu mutant form of stathmin, suggesting that it is modulated in vivo by stathmin phosphorylation. Finally, analysis of microtubule dynamics by video microscopy shows that, in our conditions, stathmin reduces the growth rate of microtubules with no effect on the catastrophe frequency. Overall, our results suggest that the stathmin destabilizing activity on microtubules is related to tubulin sequestration by stathmin.	EUROPEAN MOL BIOL LAB,CELL BIOL PROGRAM,D-69012 HEIDELBERG,GERMANY; CNRS,LAB ENZYMOL & BIOL STRUCT,UPR 9063,F-91198 GIF SUR YVETTE,FRANCE	European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Curmi, PA (corresponding author), INSERM,U440,17 RUE FER MOULIN,F-75005 PARIS,FRANCE.		CURMI, Patrick/G-4036-2013; Andersen, Søren S. L./O-1915-2017	Andersen, Søren S. L./0000-0002-3625-1640; CURMI, Patrick A./0000-0001-5045-8501				ALLEN RD, 1981, CELL MOTIL CYTOSKEL, V1, P291, DOI 10.1002/cm.970010303; AMAT JA, 1991, DEV BRAIN RES, V60, P205, DOI 10.1016/0165-3806(91)90049-O; ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; Balogh A, 1996, EXP CELL RES, V224, P8, DOI 10.1006/excr.1996.0106; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BERETTA L, 1988, ENDOCRINOLOGY, V122, P40, DOI 10.1210/endo-122-1-40; CHNEIWEISS H, 1992, J NEUROCHEM, V58, P282, DOI 10.1111/j.1471-4159.1992.tb09308.x; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; COOPER HL, 1991, J IMMUNOL, V146, P3689; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; DOYE V, 1992, DIFFERENTIATION, V50, P89, DOI 10.1111/j.1432-0436.1992.tb00489.x; DOYE V, 1990, J BIOL CHEM, V265, P11650; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LEGOUVELLO S, 1991, FEBS LETT, V287, P80, DOI 10.1016/0014-5793(91)80020-4; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; MAUCUER A, 1997, J BIOL CHEM, V272; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; OKAZAKI T, 1993, FEBS LETT, V336, P8, DOI 10.1016/0014-5793(93)81598-T; OZON S, 1997, IN PRESS EUR J BIOCH, V248; PAMPFER S, 1992, REPROD FERT DEVELOP, V4, P205, DOI 10.1071/RD9920205; PASMANTIER R, 1986, ENDOCRINOLOGY, V19, P1229; PESCHANSKI M, 1993, J COMP NEUROL, V337, P655, DOI 10.1002/cne.903370410; PRAKASH V, 1997, J MOL BIOL, V160, P499; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; SCHUBART UK, 1988, J BIOL CHEM, V263, P12156; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; Schubart UK, 1996, J BIOL CHEM, V271, P14062, DOI 10.1074/jbc.271.24.14062; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; [No title captured]	48	186	193	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25029	25036		10.1074/jbc.272.40.25029	http://dx.doi.org/10.1074/jbc.272.40.25029			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312110	hybrid			2022-12-27	WOS:A1997XY97000049
J	Inagaki, N; Goto, H; Ogawara, M; Nishi, Y; Ando, S; Inagaki, M				Inagaki, N; Goto, H; Ogawara, M; Nishi, Y; Ando, S; Inagaki, M			Spatial patterns of Ca2+ signals define intracellular distribution of a signaling by Ca2+/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENTS; INOSITOL TRISPHOSPHATE; ASTROCYTES; VIMENTIN; CELLS; PHOSPHORYLATION; VISUALIZATION; OSCILLATIONS; LOCALIZATION; ACTIVATION	Ca2+ plays a central role in cell signaling, and Ca2+/ calmodulin-dependent protein kinase II (CaMKII) is a major mediator of Ca2+ actions. The spatial distribution of intracellular Ca2+ signaling is not homogenous, rather it is dynamically organized, and it has been speculated that spatial patterns of Ca2+ signals may function as a form of cellular information transmitted to downstream molecules, To address this issue, we studied the intracellular distributions of the signalings by CaMKII and Ca2+ in the same astrocytes. The former was visualized by monitoring site-specific phosphorylation of a cytoskeletal protein vimentin, using site-and phosphorylation-specific antibodies, while the latter was examined by fura-2-based Ca2+ microscopy, Local Ca2+ sig- nals induced vimentin phosphorylation by CaMKII localized in the same area, On the other hand, Ca2+ waves in astrocytes induced global phosphorylation of vimentin by CaMKII, A small population of vimentin filaments highly phosphorylated by CaMKII underwent structural alteration into short filaments at electron microscopic level, These results indicate that CaMKII transmits spatial patterns of Ca2+ signals to vimentin as cellular information, The possibility is discussed that spatial patterns of vimentin phosphorylation may be important for intracellular organization of vimentin filament networks.	TOKYO METROPOLITAN INST GERONTOL, DEPT NEUROPHYSIOL, ITABASHI KU, TOKYO 173, JAPAN; TOKYO METROPOLITAN INST GERONTOL, DEPT MEMBRANE BIOCHEM, ITABASHI KU, TOKYO 173, JAPAN; MIE UNIV, SCH MED, DEPT PEDIAT, TSU, MIE 514, JAPAN	Tokyo Metropolitan Institute of Gerontology; Tokyo Metropolitan Institute of Gerontology; Mie University	Inagaki, N (corresponding author), AICHI CANC CTR, RES INST, BIOCHEM LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN.		Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467; Inagaki, Naoyuki/0000-0002-2664-9196				Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; FEDOROFF S, 1983, DEV BRAIN RES, V7, P303, DOI 10.1016/0165-3806(83)90187-6; FRANKE WW, 1981, COLD SPRING HARB SYM, V46, P431, DOI 10.1101/SQB.1982.046.01.041; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILBERT SH, 1994, J CELL BIOL, V127, P489, DOI 10.1083/jcb.127.2.489; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; INAGAKI N, 1994, GLIA, V11, P102, DOI 10.1002/glia.440110205; INAGAKI N, 1991, P NATL ACAD SCI USA, V88, P4215, DOI 10.1073/pnas.88.10.4215; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; SCHOLZ WK, 1988, J NEUROSCI, V8, P1039; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Takai Y, 1996, SEMIN CELL DEV BIOL, V7, P741, DOI 10.1006/scdb.1996.0091; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TAKEMURA K, 1994, PATHOBIOLOGY, V62, P149, DOI 10.1159/000163895; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1986, TRENDS BIOCHEM SCI, V11, P450, DOI 10.1016/0968-0004(86)90245-8; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; YANO S, 1994, J BIOL CHEM, V269, P5428; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	32	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25195	25199		10.1074/jbc.272.40.25195	http://dx.doi.org/10.1074/jbc.272.40.25195			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312133	hybrid			2022-12-27	WOS:A1997XY97000072
J	Muller, S; Goletz, S; Packer, N; Gooley, A; Lawson, AM; Hanisch, FG				Muller, S; Goletz, S; Packer, N; Gooley, A; Lawson, AM; Hanisch, FG			Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1 - All putative sites within the tandem repeat are glycosylation targets in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; SKIM MILK MUCINS; UDP-GALNAC; LINKED POLYLACTOSAMINOGLYCANS; MASS-SPECTROMETRY; IN-VIVO; SPECIFICITY; PROTEINS; PEPTIDES; CORE	Since there is no consensus sequence directing the initial GalNAc incorporation into mucin peptides, O-glycosylation sites are not reliably predictable. We have developed a mass spectrometric sequencing strategy that allows the identification of in vivo O-glycosylation sites on mucin-derived glycopeptides. Lactation-associated MUC1 was isolated from human milli and partially deglycosylated by trifluoromethanesulfonic acid to the level of core GalNAc residues, The product was fragmented by the Arg-C-specific endopeptidase clostripain to yield tandem repeat icosapeptides starting with the PAP motif, PAP20 glycopeptides were subjected to sequencing by post-source decay matrix-assisted laser desorption ionization mass spectrometry or by solid phase Edman degradation to localize the glycosylation sites, The masses of C- or N-terminal fragments registered for the mono-to pentasubstituted PAP20 indicated that GalNAc was linked to the peptide at Ser(5), Thr(6) (GSTA) and Thr(14) (VTSA) but contrary to previous in vitro glycosylation studies also at Thr(19) and Ser(15) located within the PDTR or VTSA motifs, respectively, Quantitative data from solid phase Edman sequencing revealed no preferential glycosylation of the threonines, These discrepancies between in vivo and in vitro glycosylation patterns may be explained by assuming that O-glycosylation of adjacent peptide positions is a dynamically regulated process that depends on changes of the substrate qualities induced by glycosylation at vicinal sites.	UNIV COLOGNE, FAC MED, INST BIOCHEM, D-50931 COLOGNE, GERMANY; MAX DELBRUCK CTR MOL MED, D-13125 BERLIN, GERMANY; MACQUARIE UNIV, CTR ANALYT BIOTECHNOL, SYDNEY, NSW 2109, AUSTRALIA; NORTHWICK PK HOSP & CLIN RES CTR, IMPERIAL COLL SCH MED, MRC, GLYCOSCI LAB, HARROW HA1 3UJ, MIDDX, ENGLAND	University of Cologne; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Macquarie University; Imperial College London			Goletz, Steffen/AAR-2654-2021; Packer, Nicolle/Q-8929-2019	Goletz, Steffen/0000-0003-1463-5448; Packer, Nicolle/0000-0002-7532-4021				AITKEN A, 1989, PROTEIN SEQUENCING P, P43; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BHAVANANDAN VP, 1993, ANAL BIOCHEM, V213, P438, DOI 10.1006/abio.1993.1445; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Brockhausen I, 1996, GLYCOCONJUGATE J, V13, P849, DOI 10.1007/BF00702349; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; Chaplin MF, 1986, CARBOHYDRATE ANAL PR; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; GERKEN TA, 1992, BIOCHEMISTRY-US, V31, P639, DOI 10.1021/bi00118a002; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GOLETZ S, 1997, IN PRESS GLYCOBIOLOG; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; HANISCH FG, 1995, CANCER RES, V55, P4036; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HANISCH FG, 1985, EUR J BIOCHEM, V149, P323, DOI 10.1111/j.1432-1033.1985.tb08929.x; HANISCH FG, 1990, GLYCOCONJUGATE J, V7, P525, DOI 10.1007/BF01189075; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; JEROME KR, 1991, CANCER RES, V51, P2908; KAUFMANN R, 1994, INT J MASS SPECTROM, V131, P355, DOI 10.1016/0168-1176(93)03876-N; MERKLE RK, 1994, METHOD ENZYMOL, V230, P1; MONSIGNY M, 1988, ANAL BIOCHEM, V175, P525, DOI 10.1016/0003-2697(88)90578-7; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; NISHIMORI I, 1994, CANCER RES, V54, P3738; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OSHANNESSY DJ, 1987, ANAL BIOCHEM, V163, P204, DOI 10.1016/0003-2697(87)90114-X; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PISANO A, 1994, GLYCOBIOLOGY, V4, P837, DOI 10.1093/glycob/4.6.837; PISANO A, 1997, TECHNIQUES GLYCOBIOL, P299; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SHIMIZU M, 1982, J BIOCHEM, V91, P515, DOI 10.1093/oxfordjournals.jbchem.a133724; SOJAR HT, 1987, ARCH BIOCHEM BIOPHYS, V259, P52, DOI 10.1016/0003-9861(87)90469-3; Spencer DIR, 1996, CANCER LETT, V100, P11, DOI 10.1016/0304-3835(95)04055-2; STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x; TAYLORPAPADIMITRIOU J, 1994, TRENDS BIOTECHNOL, V12, P227, DOI 10.1016/0167-7799(94)90121-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728	38	131	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24780	24793		10.1074/jbc.272.40.24780	http://dx.doi.org/10.1074/jbc.272.40.24780			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312074	hybrid			2022-12-27	WOS:A1997XY97000013
J	Haberland, J; Becker, J; Gerke, V				Haberland, J; Becker, J; Gerke, V			The acidic C-terminal domain of rna1p is required for the binding of Ran center dot GTP and for RanGAP activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN IMPORT; LEUCINE-RICH REPEATS; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; ACTIVATING PROTEIN; PORE COMPLEX; SCHIZOSACCHAROMYCES-POMBE; CYTOSOLIC FACTORS; TRANSPORT FACTORS; CRYSTAL-STRUCTURE	The small GTP binding protein Ran is an essential component of the nuclear protein import machinery whose GTPase cycle is regulated by the nuclear guanosine nucleotide exchange factor RCC1 and by the cytosolic GTPase activating protein RanGAP. In the yeasts Schizosaccharomyces pombe and Saccharomyces cerevisiae the RanGAP activity is encoded by the RNA1 genes which are essential for cell viability and nucleocytoplasmic transport in vivo. Although of limited sequence identity the two yeast proteins show a conserved structural organization characterized by an N-terminal domain of eight leucine-rich repeats, motifs implicated in protein-protein interactions, and a C-terminal domain rich in acidic amino acid residues. By analyzing the RanGAP activity of a series of recombinantly expressed rna1p mutant derivatives, we show that the highly acidic sequence in the C-terminal domain of both yeast proteins is indispensable for activating Ran-mediated GTP hydrolysis. Chemical cross-linking reveals that the same sequence in rna1p is required for rnalp.Ran complex formation indicating that the loss of GAP activity in the C-terminally truncated rna1p mutants results from an impaired interaction with Ran. The predominant species stabilized through the covalent cross-link is a rna1p.Ran heterodimer whose formation requires the GTP-bound conformation of Ran. As the acidic C-terminal domain of rna1p is required for establishing the interaction with Ran, the leucine-rich repeats domain in rna1p is potentially available for additional protein interactions perhaps required for directing a fraction of rna1p to the nuclear pore.	UNIV MUNSTER, INST MED BIOCHEM, D-48149 D-48149..MUNSTER, GERMANY; MAX PLANCK INST MOL PHYSIOL, DEPT BIOL STRUCT, D-44139 DORTMUND, GERMANY	University of Munster; Max Planck Society								ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HABERLAND J, 1995, FEBS LETT, V357, P173, DOI 10.1016/0014-5793(94)01353-3; HARTMANN E, 1995, TRENDS CELL BIOL, V5, P192, DOI 10.1016/S0962-8924(00)88992-8; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; JOHN J, 1988, J BIOL CHEM, V263, P11792; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; SAITOH H, 1995, J BIOL CHEM, V270, P10658, DOI 10.1074/jbc.270.18.10658; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; SWEET DJ, 1995, TRENDS CELL BIOL, V5, P444, DOI 10.1016/S0962-8924(00)89108-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24717	24726		10.1074/jbc.272.39.24717	http://dx.doi.org/10.1074/jbc.272.39.24717			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305944	hybrid			2022-12-27	WOS:A1997XY51500095
J	Lambeth, DO; Mehus, JG; Ivey, MA; Milavetz, BI				Lambeth, DO; Mehus, JG; Ivey, MA; Milavetz, BI			Characterization and cloning of a nucleoside-diphosphate kinase targeted to matrix of mitochondria in pigeon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; X-RAY STRUCTURE; SUCCINIC THIOKINASE; CRYSTAL-STRUCTURE; DICTYOSTELIUM-DISCOIDEUM; TUMOR-METASTASIS; NM23 GENE; DROSOPHILA; RESOLUTION; CELLS	Nucleoside-diphosphate kinase (NDP kinase) from the matrix space of mitochondria in pigeon liver was purified to homogeneity, Degenerate oligonucleotide primers to the N-terminal sequence of the purified protein and the region containing the active site histidine were used in reverse transcriptase-polymerase chain reaction to obtain a major portion of the coding sequence for the mature protein, The sequences of the C and N termini of the mature protein, and eight residues in the signal peptide, were obtained by rapid amplification of cDNA end procedures, The entire coding sequence of a cytosolic form of NDP kinase was also determined, Both isoforms, which share 53% sequence identity, possess the characteristically conserved regions of known NDP kinases, The mature mitochondrial NDP kinase protein migrates in molecular sieving columns with an apparent molecular mass of about 66 kDa. It shows very high thermal stability even though it lacks the proline residue in the killer of prune loop, and the Tyr/Glu C termini that are important in stabilizing other NDP kinases, The affinity of the mitochondrial isoform for adenine and guanine nucleotides is much higher than for pyrimidine nucleotides, but the enzyme is especially susceptible to substrate inhibition by GDP. Semi-quantitative reverse transcriptase-polymerase chain reaction showed that the relative levels of expression of the mitochondrial isoform are Liver > kidney much greater than heart = brain > breast muscle, The cytosolic isoform is strongly and approximately equally expressed in these same five tissues, This work is the first characterization of a NDP kinase isoform that is found in the matrix space of mitochondria.			Lambeth, DO (corresponding author), UNIV N DAKOTA,SCH MED & HLTH SCI,DEPT BIOCHEM & MOL BIOL,BOX 9037,GRAND FORKS,ND 58202, USA.				NIGMS NIH HHS [GM54260] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM054260] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMAULA N, 1995, J BACTERIOL, V177, P2524, DOI 10.1128/jb.177.9.2524-2529.1995; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BIONDI RM, 1995, ARCH BIOCHEM BIOPHYS, V323, P187, DOI 10.1006/abbi.1995.0025; Brodbeck M, 1996, EUR J BIOCHEM, V239, P208, DOI 10.1111/j.1432-1033.1996.0208u.x; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; COLOMB MG, 1969, BIOCHEMISTRY-US, V8, P1926, DOI 10.1021/bi00833a024; COLOMB MG, 1972, BIOCHEMISTRY-US, V11, P3370, DOI 10.1021/bi00768a009; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; ERECINSKA M, 1984, J BIOL CHEM, V259, P904; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; Giartosio A, 1996, J BIOL CHEM, V271, P17845, DOI 10.1074/jbc.271.30.17845; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GLEZE RP, 1967, J BIOL CHEM, V242, P2139; GOFFEAU A, 1968, J BIOL CHEM, V243, P1685; GOFFEAU A, 1967, J BIOL CHEM, V242, P1845; HAMILTON ML, 1981, FEBS LETT, V123, P252, DOI 10.1016/0014-5793(81)80300-6; HANSFORD RG, 1973, FEBS LETT, V31, P317, DOI 10.1016/0014-5793(73)80130-9; HELDT HW, 1967, EUR J BIOCHEM, V1, P199, DOI 10.1111/j.1432-1033.1967.tb00064.x; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; ISAYA G, 1995, METHOD ENZYMOL, V248, P556; JACOBUS WE, 1977, J BIOL CHEM, V252, P4232; JI L, 1995, J BIOL CHEM, V270, P13392, DOI 10.1074/jbc.270.22.13392; Karlsson A, 1996, J BIOL CHEM, V271, P19928, DOI 10.1074/jbc.271.33.19928; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LAMBETH DO, 1993, ANAL BIOCHEM, V209, P192, DOI 10.1006/abio.1993.1102; LASCU I, 1992, J BIOL CHEM, V267, P12775; MacDonald NJ, 1996, J BIOL CHEM, V271, P25107, DOI 10.1074/jbc.271.41.25107; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; MUHONEN WW, 1995, COMP BIOCHEM PHYS B, V110, P211, DOI 10.1016/0305-0491(94)00123-C; NAKAMURA H, 1966, J BIOL CHEM, V241, P4917; OTTAWAY JH, 1981, INT J BIOCHEM, V13, P401, DOI 10.1016/0020-711X(81)90111-7; PEDERSEN PL, 1973, J BIOL CHEM, V248, P3956; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SANADI DR, 1954, BIOCHIM BIOPHYS ACTA, V14, P434, DOI 10.1016/0006-3002(54)90205-X; SANADI DR, 1955, J BIOL CHEM, V218, P505; Schaertl S, 1996, FEBS LETT, V394, P316, DOI 10.1016/0014-5793(96)00978-7; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TOKUMITSU Y, 1973, BIOCHIM BIOPHYS ACTA, V292, P310, DOI 10.1016/0005-2728(73)90038-8; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TROLL H, 1993, J BIOL CHEM, V268, P25469; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WADKINS CL, 1963, J BIOL CHEM, V238, P2555; WEAVER RH, 1962, ENZYMES, V6, P151; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673	53	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24604	24611		10.1074/jbc.272.39.24604	http://dx.doi.org/10.1074/jbc.272.39.24604			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305928	hybrid			2022-12-27	WOS:A1997XY51500079
J	Pan, GH; Aso, T; Greenblatt, J				Pan, GH; Aso, T; Greenblatt, J			Interaction of elongation factors TFIIS and Elongin A with a human RNA polymerase II holoenzyme capable of promoter-specific initiation and responsive to transcriptional activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; BASAL TRANSCRIPTION; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; NASCENT TRANSCRIPT; TERMINAL DOMAIN; REPEAT DOMAIN; 3 PROTEINS; FACTOR-SII; COMPLEX	Affinity chromatography on columns containing the immobilized monomeric transcriptional elongation factor TFIIS or the essential large subunit, Elongin A, of the trimeric elongation factor, Elongin, was used to purify a human RNA polymerase II holoenzyme from HeLa whole cell extract. This holoenzyme contained near-stoichiometric amounts of all the general transcription factors, TFIIB, TFIID (TBP + TAF(II)s), TFIIE, TFIIF, and TFIIH, required to accurately initiate transcription in vitro at the adenovirus major late promoter. It behaved as a large complex, slightly smaller than 70 S ribosomes, during gelfiltration chromatography, and contained nearly half the, TFIID that was present in the extract used for the affinity chromatography. It also contained the cyclin-dependent kinase CDK8, a human homologue of the Saccharomyces cerevisiae holoenzyme subunit SRB10, and many other polypeptides. Efficient interaction of holoenzyme with TFIIS or Elongin A required only the amino-terminal region of either protein. These regions are similar in amino acid sequence but dispensable for TFIIS or Elongin to regulate elongation in, vitro by highly purified RNA polymerase II. The transcriptional activators GAL4-VP16 and GAL4-Sp1 activated transcription in vitro by purified holoenzyme in the absence of any additional factors.	UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5G 1L6, CANADA; OKLAHOMA MED RES FDN, PROGRAM MOL & CELL BIOL, OKLAHOMA CITY, OK 73104 USA	University of Toronto; University of Toronto; Oklahoma Medical Research Foundation								AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Blau J, 1996, MOL CELL BIOL, V16, P2044; BURATOWSKI S, 1993, SCIENCE, V260, P37, DOI 10.1126/science.8465198; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAVIES CJ, 1990, NATURE, V345, P298, DOI 10.1038/345298a0; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FENG GH, 1994, J BIOL CHEM, V269, P22282; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; GU WG, 1993, J BIOL CHEM, V268, P25604; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI Y, 1981, FEBS LETT, V130, P69, DOI 10.1016/0014-5793(81)80667-9; NONET ML, 1989, GENETICS, V123, P715; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PAN GH, 1994, J BIOL CHEM, V269, P30101; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SOPTA M, 1985, J BIOL CHEM, V260, P353; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; TAN SY, 1994, J BIOL CHEM, V269, P25684; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	99	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24563	24571		10.1074/jbc.272.39.24563	http://dx.doi.org/10.1074/jbc.272.39.24563			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305922	hybrid			2022-12-27	WOS:A1997XY51500073
J	Merienne, K; Germain, N; ZinnJustin, S; Boulain, JC; Ducancel, F; Menez, A				Merienne, K; Germain, N; ZinnJustin, S; Boulain, JC; Ducancel, F; Menez, A			The functional architecture of an acetylcholine receptor-mimicking antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CROSS-REACTION COMPLEX; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ALKALINE-PHOSPHATASE; CRYSTAL-STRUCTURE; BINDING-SITE; PROTEIN ANTIGENS; FUSION PROTEIN	M alpha 2-3 is a monoclonal antibody that partially mimics the nicotinic acetylcholine receptor (AChR), Its three-dimensional structure has been previously predicted by molecular modeling, suggesting that 29 complementarity determining region (CDR) residues and 2 framework residues are exposed to solvent. To identify the antibody residues that bind to the antigen, i.e. snake toxin that binds specifically to AChR, we (i) produced the scFv form of M alpha 2-3 fused to alkaline phosphatase, in the periplasmic space of Escherichia coli; (ii) submitted approximately 75% of exposed residues of the fused scFv to individual or combined mutations, and (iii) identified the residues whose mutations affect scFv binding to the toxin, using a sensitive enzyme-linked immunosorbent assay. 11 critical residues were identified, including 8 heavy chain residues, 2 framework residues, and 1 light chain residue, They cover a surface of approximately 800 Angstrom(2), with a subset of most critical residues (VHD31, VHY32, and VHG101) and several aromatic residues. This functional architecture not only constitutes a plausible complementary binding surface for the snake toxin but also offers a structural basis to ultimately understand the capacity of the antibody to partially mimic AChR.	CEA, DEPT INGN & ETUD PROT, DIRECT SCI VIVANT, F-91191 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay				Merienne, Karine/0000-0003-2549-2315				AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AMATI V, 1995, PROTEIN ENG, V8, P403, DOI 10.1093/protein/8.4.403; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CARRIER A, 1995, J IMMUNOL METHODS, V181, P177, DOI 10.1016/0022-1759(94)00344-V; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Chanussot C, 1996, J IMMUNOL METHODS, V197, P39, DOI 10.1016/0022-1759(96)00109-3; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DARVEAU RP, 1992, J CLIN IMMUNOASSAY, V15, P25; DAVIES DR, 1993, ACCOUNTS CHEM RES, V26, P421, DOI 10.1021/ar00032a005; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DAVIS SJ, 1992, NATURE, V358, P76, DOI 10.1038/358076a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DORING E, 1994, MOL IMMUNOL, V31, P1059, DOI 10.1016/0161-5890(94)90101-5; DUCANCEL F, 1993, BIO-TECHNOL, V11, P601, DOI 10.1038/nbt0593-601; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GILLET D, 1993, ANAL CHEM, V65, P1779, DOI 10.1021/ac00061a023; GILLET D, 1992, PROTEIN ENG, V5, P273, DOI 10.1093/protein/5.3.273; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JANIN J, 1990, J BIOL CHEM, V265, P16027; JANON K, 1996, THESIS U PARIS 11 PA; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; LESCAR J, 1995, J BIOL CHEM, V270, P18067, DOI 10.1074/jbc.270.30.18067; MALBY RL, 1994, STRUCTURE, V2, P733, DOI 10.1016/S0969-2126(00)00074-5; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PRASAD L, 1993, J BIOL CHEM, V268, P10705; RIECHMANN L, 1995, J BIOMOL NMR, V6, P141, DOI 10.1007/BF00211778; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Tenette C, 1996, PROTEINS, V26, P9, DOI 10.1002/(SICI)1097-0134(199609)26:1<9::AID-PROT2>3.0.CO;2-E; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WHITLOW M, 1994, PROTEIN ENG, V7, P1017, DOI 10.1093/protein/7.8.1017; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Xiang J, 1996, PROTEIN ENG, V9, P539, DOI 10.1093/protein/9.6.539; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	60	22	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23775	23783		10.1074/jbc.272.38.23775	http://dx.doi.org/10.1074/jbc.272.38.23775			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295323	hybrid			2022-12-27	WOS:A1997XX38100048
J	Ali, MS; Sayeski, PP; Dirksen, LB; Hayzer, DJ; Marrero, MB; Bernstein, KE				Ali, MS; Sayeski, PP; Dirksen, LB; Hayzer, DJ; Marrero, MB; Bernstein, KE			Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT(1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; ACTIVATION; BINDING; PROTEIN; TRANSCRIPTION; PATHWAYS; REGION; CELLS	Angiotensin II is the effector molecule of the renin-angiotensin system. Virtually all of its biochemical actions are mediated through a single class of cell-surface receptors called AT(1). These receptors contain the structural features of the seven-transmembrane, G-protein-coupled receptor superfamily. Angiotensin II, acting through the AT(1) receptor, also stimulates the Jak/STAT pathway by inducing ligand-dependent Jak2 tyrosine phosphorylation and activation. Here, we show that a glutathione S-transferase fusion protein containing the carboxyl-terminal 54 amino acids of the rat AT(1A) receptor physically binds to Jak2 in an angiotensin II-dependent manner. Deletional analysis, using both in vitro protocols and cell transfection analysis, showed that this association is dependent on the AT(1A) receptor motif YIPP (amino acids 319-322), The mild-type AT(1A) receptor can induce Jak2 tyrosine phosphorylation, In contrast, an AT(1A) receptor lacking the YIPP motif is unable to induce ligand-dependent phosphorylation of Jak2. Competition experiments with synthetic peptides suggest that each of the YIPP amino acids, including tyrosine 319, is important in Jak2 binding to the AT(1A) receptor. The binding of the AT(1A) receptor to the intracellular tyrosine kinase Jak2 supports the concept that the seven-transmembrane superfamily of receptors can physically associate with enzymatically active intracellular proteins, creating a signaling complex mechanistically similar to that observed with growth factor and cytokine receptors.	EMORY UNIV,DEPT PATHOL & LAB MED,ATLANTA,GA 30322	Emory University				Bernstein, Kenneth/0000-0001-8097-3272	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044280, R01DK039777, R37DK039777, P50DK045215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39777, DK45215, DK44280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Bernstein KE, 1996, TRENDS CARDIOVAS MED, V6, P179, DOI 10.1016/S1050-1738(96)00053-9; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DINERSTEIN H, 1995, MOL ENDOCRINOL, V9, P1701, DOI 10.1210/me.9.12.1701; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Ihle JN, 1996, PHILOS T R SOC B, V351, P159, DOI 10.1098/rstb.1996.0012; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARRERO MB, 1995, CARDIOVASC RES, V30, P530, DOI 10.1016/0008-6363(95)00094-1; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Tian Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE831, DOI 10.1152/ajpendo.1996.270.5.E831; TIMMERMANS PBM, 1993, PHARMACOL REV, V45, P206; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	28	184	190	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23382	23388		10.1074/jbc.272.37.23382	http://dx.doi.org/10.1074/jbc.272.37.23382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287353	hybrid			2022-12-27	WOS:A1997XV74400064
J	Bai, XM; Bame, KJ; Habuchi, H; Kimata, K; Esko, JD				Bai, XM; Bame, KJ; Habuchi, H; Kimata, K; Esko, JD			Turnover of heparan sulfate depends on 2-O-sulfation of uronic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; OVARIAN GRANULOSA-CELLS; INTRACELLULAR DEGRADATIVE PATHWAYS; POLYMER-MODIFICATION REACTIONS; PROTEIN INTERACTIONS; MOUSE MASTOCYTOMA; CORE PROTEIN; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; ENDOGLUCURONIDASE	To study how the pattern of sulfation along a heparan sulfate chain affects its turnover, we examined heparan sulfate catabolism in wild-type Chinese hamster ovary cells and mutant pgsF-17, defective in 2-O-sulfation of uronic acid residues (Bai, X., and Esko, J. D. (1996) J. Biol, Chem. 271, 17711-17717). Heparan sulfate from the mutant contains normal amounts of 6-O-sulfated glucosamine residues and iduronic acid and somewhat higher levels of N-sulfated glucosamine residues but lacks any 2-O-sulfated iduronic or glucuronic acid residues. Pulse-chase experiments showed that both mutant and wild-type cells transport newly synthesized heparan sulfate proteoglycans to the plasma membrane, where they shed into the medium or move into the cell through endocytosis. Internalization of the cell-associated molecules leads to sequential endoglycosidase (heparanase) fragmentation of the chains and eventual lysosomal degradation. In wild-type cells, the chains begin to degrade within 1 h, leading to the accumulation of intermediate (1O-20-kDa) and small (4-7-kDa) oligosaccharides. Mutant cells did not generate these intermediates, although internalization and intracellular trafficking of the heparan sulfate chains appeared normal, and the chains degraded with normal kinetics. This difference was not due to defective heparanase activities in the mutant, since cytoplasmic extracts from mutant cells cleaved wild-type heparan sulfate chains in vitro. instead, the heparan sulfate chains from the mutant ware relatively resistant to degradation by cellular heparanases. These findings suggest that 2-O-sulfated iduronic acid residues in heparan sulfate are important for cleavage by endogenous heparanases but not for the overall catabolism of the chains.	UNIV CALIF SAN DIEGO, CTR CANC, DEPT MED, DIV CELL & MOL BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV MISSOURI, SCH BIOL SCI, DIV MOL BIOL & BIOCHEM, KANSAS CITY, MO 64110 USA; AICHI MED UNIV, INST MOL SCI MED, NAGAKUTE, AICHI 48011, JAPAN	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Missouri System; University of Missouri Kansas City; Aichi Medical University								Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; Bame KJ, 1997, J BIOL CHEM, V272, P2245; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1993, J BIOL CHEM, V268, P19956; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; CZEKAY RP, 1995, J CELL SCI, V108, P1433; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Edgren G, 1997, GLYCOBIOLOGY, V7, P103, DOI 10.1093/glycob/7.1.103; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; ESKO JD, 1986, J BIOL CHEM, V261, P5725; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407; FREEMAN C, 1992, ADV EXP MED BIOL, V313, P121; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HOOK M, 1975, BIOCHEM BIOPH RES CO, V67, P1422, DOI 10.1016/0006-291X(75)90185-0; IOZZO RV, 1987, J BIOL CHEM, V262, P1888; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V73, P569, DOI 10.1016/0006-291X(76)90848-2; KLEIN U, 1979, H-S Z PHYSIOL CHEM, V360, P1465, DOI 10.1515/bchm2.1979.360.2.1465; KLEIN U, 1976, FEBS LETT, V71, P266, DOI 10.1016/0014-5793(76)80947-7; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; OGREN S, 1975, J BIOL CHEM, V250, P2690; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; TAKEUCHI Y, 1992, J BIOL CHEM, V267, P14677; THUNBERG L, 1982, J BIOL CHEM, V257, P278; Tumova S, 1997, J BIOL CHEM, V272, P9078; YANAGISHITA M, 1985, J BIOL CHEM, V260, P1075; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505; YANAGISHITA M, 1985, J BIOL CHEM, V260, P5445; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	48	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23172	23179		10.1074/jbc.272.37.23172	http://dx.doi.org/10.1074/jbc.272.37.23172			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287321	hybrid			2022-12-27	WOS:A1997XV74400032
J	Emoto, H; Tagashira, S; Mattei, MG; Yamasaki, M; Hashimoto, G; Katsumata, T; Negoro, T; Nakatsuka, M; Birnbaum, D; Coulier, F; Itoh, N				Emoto, H; Tagashira, S; Mattei, MG; Yamasaki, M; Hashimoto, G; Katsumata, T; Negoro, T; Nakatsuka, M; Birnbaum, D; Coulier, F; Itoh, N			Structure and expression of human fibroblast growth factor-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; CHROMOSOME; CLONING; MEMBER; REGION; FGF8	We isolated the cDNA encoding a novel member of the human fibroblast growth factor (FGF) family from the lung. The cDNA encodes a protein of 208 amino acids with high sequence homology (95.6%) to rat FGF-10, in dicating that the protein is human FGF-10. Human FGF-10 as well as rat FGF-10 has a hydrophobic amino terminus (similar to 40 amino acids), which may serve as a signal sequence. The apparent evolutionary relationships of human FGFs indicate that FGF-10 is closest to FGF-7. Chromosomal localization of the human FGF-IO gene was examined by in situ hybridization. The gene was found to map to the 5p12-p13 region. Human FGF-10 (amino acids 40 to 208 with a methionine residue at the amino terminus) was produced in Escherichia coli and purified from the cell lysate. Recombinant human FGF-10 (similar to 19 kDa) showed mitogenic activity for fetal rat keratinizing epidermal cells, but essentially no activity for NIH/3T3 cells, fibroblasts. The specificity of mitogenic activity of FGF-10 is similar to that of FGF-7 but distinct from that of bFGF, In structure and biological activity, FGF-10 is similar to FGF-7.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM GENET, SAKYO KU, KYOTO 60601, JAPAN; SUMITOMO PHARMACEUT CO LTD, RES CTR, OSAKA 554, JAPAN; INSERM, U406, F-13385 MARSEILLE, FRANCE; INSERM, U119, F-13009 MARSEILLE, FRANCE	Kyoto University; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773; Yamasaki, Masahiro/0000-0002-5296-4974; Negoro, Takaharu/0000-0002-4159-6352				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; ARAKAWA T, 1989, BIOCHEM BIOPH RES CO, V161, P335, DOI 10.1016/0006-291X(89)91601-X; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; COULIER F, 1991, ANN NY ACAD SCI, V638, P53, DOI 10.1111/j.1749-6632.1991.tb49017.x; DICKSON C, 1991, ANN NY ACAD SCI, V638, P18, DOI 10.1111/j.1749-6632.1991.tb49014.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; JACSKSON A, 1992, P NATL ACAD SCI USA, V89, P10691; LOVEC H, 1997, IN PRESS CYTOGENET C; MATTEI MG, 1995, GENOMICS, V29, P811, DOI 10.1006/geno.1995.9926; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MATTEI MG, 1995, MAMM GENOME, V6, P196, DOI 10.1007/BF00293012; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; PATRY V, 1986, J VET MED B, V33, P609; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TAGASHIRA S, 1997, IN PRESS GENE; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WHITE RA, 1995, GENOMICS, V30, P109, DOI 10.1006/geno.1995.0020; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YOSHIDA T, 1991, ANN NY ACAD SCI, V638, P27, DOI 10.1111/j.1749-6632.1991.tb49015.x	29	101	127	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23191	23194		10.1074/jbc.272.37.23191	http://dx.doi.org/10.1074/jbc.272.37.23191			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287324	hybrid			2022-12-27	WOS:A1997XV74400035
J	Seimiya, M; Kusakabe, T; Suzuki, N				Seimiya, M; Kusakabe, T; Suzuki, N			Primary structure and differential gene expression of three membrane forms of guanylyl cyclase found in the eye of the teleost Oryzias latipes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; HEAT-STABLE ENTEROTOXIN; MOLECULAR-CLONING; RAT LUNG; FUNCTIONAL EXPRESSION; BOVINE LUNG; PROTEIN; SUBUNIT; ATRIAL; HOMOLOGY	Three cDNAs (OlGC3, OlGC4, and OlGC5) encoding membrane guanylyl cyclases were isolated from a medaka (Oryzias latipes) eye cDNA library, An. open reading frame for OlGC3 predicted a protein of 1057 amino acids, and those for OlGC4 and OlGC5, 1134 and 1151, respectively. These proteins consist of an apparent signal peptide (21 residues for OlGC3, 50 residues for OlGC4, and 48 residues for OlGC5) and a single transmembrane domain that divides the protein into an amino-terminal extracellular domain and a carboxyl-terminal intracellular domain that further divides into a kinase-like domain and a cyclase catalytic domain, Phylogenetic analysis with amino acid sequences of OlGC3, OlGC4, and OlGC5, as well as those of other membrane guanylyl cyclases, indicated that OlGC3, OlGC4, and OlGC5 are members of the sensory organ-specific guanylyl cyclase family, Reverse transcription-polymerase chain reaction and Northern blot analyses demonstrated that OlGC3, OlGC4, and OlGC5 transcripts are present in the eye, which contains more cGMP than the other organs, In addition to being expressed in the eye, OlGC3 transcripts are also present in the brain, heart, liver, pancreas, and ovary, while OlGC4 is present in the liver and OlGC5 in the heart. Reverse transcription polymerase chain reaction analysis with RNA from unfertilized eggs and embryos showed that OlGC3 and OlGC5 are expressed both maternally and zygotically, while OlGC4 is expressed only zygotically, and that the zygotic expression of these three genes is differentially activated, These results suggest a structural and functional diversity of sensory organ-specific guanylyl cyclases in vertebrates.	HOKKAIDO UNIV,GRAD SCH SCI,DIV BIOL SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University			Kusakabe, Takehiro/H-7178-2012	Kusakabe, Takehiro/0000-0002-8325-3665				Battey, 1986, BASIC METHODS MOL BI; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHANG M, 1989, NATURE, V341, P68, DOI 10.1038/341068a0; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GIGLIOTTI S, 1993, DEV BIOL, V159, P450, DOI 10.1006/dbio.1993.1255; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; Honkawa H., 1996, Zoological Science (Tokyo), V13, P104; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; IWAMATSU T, 1994, ZOOL SCI, V11, P825; KAMISAKI Y, 1986, J BIOL CHEM, V261, P7236; KATAFUCHI T, 1994, EUR J BIOCHEM, V222, P835, DOI 10.1111/j.1432-1033.1994.tb18930.x; KIMURA M, 1983, NEUTRAL THEORY MOL E, P75; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; KOZAK M, 1983, MICROBIOL REV, V47, P1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MCNEIL L, 1995, J BIOL CHEM, V270, P7189, DOI 10.1074/jbc.270.13.7189; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NARUSE K, 1992, J EXP ZOOL, V262, P81, DOI 10.1002/jez.1402620111; PANDEY KN, 1990, J BIOL CHEM, V265, P12342; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; Shimizu T, 1996, ZOOL SCI, V13, P285, DOI 10.2108/zsj.13.285; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORPE DS, 1989, J BIOL CHEM, V264, P6545; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WADA A, 1994, MICROBIOL IMMUNOL, V38, P535, DOI 10.1111/j.1348-0421.1994.tb01819.x; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	49	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23407	23417		10.1074/jbc.272.37.23407	http://dx.doi.org/10.1074/jbc.272.37.23407			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287356	hybrid			2022-12-27	WOS:A1997XV74400067
J	Conchon, S; Barrault, MB; Miserey, S; Corvol, P; Clauser, E				Conchon, S; Barrault, MB; Miserey, S; Corvol, P; Clauser, E			The C-terminal third intracellular loop of the rat AT(1A) angiotensin receptor plays a key role in G protein coupling specificity and transduction of the mitogenic signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II TYPE-1 RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; TRANSMEMBRANE DOMAIN; AGONIST ACTIVATION; INSULIN-RECEPTOR; PHOSPHOLIPASE-C; MUTATION; IDENTIFICATION; MUTAGENESIS	To identify the role(s) of the third intracellular loop of the angiotensin II (AngII) type 1A (AT(1A)) receptor in G protein coupling specificity and receptor activation, several chimerae were constructed and characterized, The cDNA sequence encoding the C-terminal segment of the third intracellular loop of the AT(1A) receptor (residues 234-240) was replaced with the homologous regions of the alpha(1B) adrenergic (alpha(1B)-AR), the beta(2) adrenergic (beta(2)-AR), and the AngII type 2 (AT(2)) receptors. These chimeric receptors were stably expressed in Chinese hamster ovary cells, and their pharmacological and functional properties were characterized, including AngII-induced inositol phosphate and cyclic AMP (cAMP) productions, [H-3]thymidine incorporation into DNA, and internalization. The affinities of these chimeric receptors for [Sar(1)]AngII, [Sar(1),Ile(8)]AngII, and losartan were essentially normal; however, the affinity of these mutants was increased by a factor of 10-40 for the AT(2)-specific ligand CGP42112A. The functional properties of the alpha(1B)-AR chimera were essentially identical to those of the wild type AT(1A) receptor. On the other hand, replacement with the beta(2)-AR segment produced a partial reduction of the inositol phosphate production, a measurable AngII-induced cAMP accumulation, a reduced internalization, and a total impairment to transduce the mitogenic effect of AngII. The AT(2) chimera presented a normal internalization, but was inactive in all the other functional tests. In conclusion, the distal segment of the third intracellular loop of the rat AT(1A) receptor plays a pivotal role in coupling selectivity and receptor signaling via G protein(s) as well as in the activation of the specific signaling pathways involved in the mitogenic actions of AngII.	COLL FRANCE,INSERM,U36,F-75005 PARIS,FRANCE; CTR ETUD SACLAY,SERV BIOL CELLULAIRE,F-91191 GIF SUR YVETTE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France				Conchon, Sophie/0000-0003-2602-3385				BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BLUML K, 1994, J BIOL CHEM, V269, P18870; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; Clauser E, 1996, EUR J ENDOCRINOL, V134, P403, DOI 10.1530/eje.0.1340403; CONCHON S, 1994, BIOCHEM BIOPH RES CO, V199, P1347, DOI 10.1006/bbrc.1994.1379; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; Eason MG, 1996, J BIOL CHEM, V271, P12826, DOI 10.1074/jbc.271.22.12826; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Gilchrist RL, 1996, J BIOL CHEM, V271, P19283, DOI 10.1074/jbc.271.32.19283; Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; Hayashida W, 1996, J BIOL CHEM, V271, P21985, DOI 10.1074/jbc.271.36.21985; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Hunyady L, 1996, P NATL ACAD SCI USA, V93, P10040, DOI 10.1073/pnas.93.19.10040; IWAI N, 1992, BIOCHEM BIOPH RES CO, V182, P1094, DOI 10.1016/0006-291X(92)91844-G; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LECONTE I, 1994, J BIOL CHEM, V269, P18062; Liu J, 1996, J BIOL CHEM, V271, P6172, DOI 10.1074/jbc.271.11.6172; MARIE J, 1994, J BIOL CHEM, V269, P20815; MARIN P, 1990, EUR J NEUROSCI, V2, P1110, DOI 10.1111/j.1460-9568.1990.tb00022.x; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PARMA J, 1994, MOL CELL ENDOCRINOL, V100, P159, DOI 10.1016/0303-7207(94)90296-8; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Perez DM, 1996, MOL PHARMACOL, V49, P112; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Shibata T, 1996, BIOCHEM BIOPH RES CO, V218, P383, DOI 10.1006/bbrc.1996.0067; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TORRENS Y, 1989, J NEUROCHEM, V52, P1913, DOI 10.1111/j.1471-4159.1989.tb07276.x; TSENG MJ, 1995, J BIOL CHEM, V270, P17884, DOI 10.1074/jbc.270.30.17884; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; Wen YS, 1996, AM J PHYSIOL-CELL PH, V271, pC1212, DOI 10.1152/ajpcell.1996.271.4.C1212; WONG SKF, 1994, J BIOL CHEM, V269, P18968; Zhang JS, 1996, J BIOL CHEM, V271, P15026, DOI 10.1074/jbc.271.25.15026	46	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25566	25572		10.1074/jbc.272.41.25566	http://dx.doi.org/10.1074/jbc.272.41.25566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325274	hybrid			2022-12-27	WOS:A1997YA35800029
J	Huang, JR; Nueda, A; Yoo, S; Dynan, WS				Huang, JR; Nueda, A; Yoo, S; Dynan, WS			Heat shock transcription factor 1 binds selectively in vitro to Ku protein and the catalytic subunit of the DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; COILED-COIL; HSP70 EXPRESSION; ACTIVATION; AUTOANTIGEN; PHOSPHORYLATION; DOMAIN; OLIGOMERIZATION; TRIMERIZATION; TRANSITION	Heat shock transcription factor 1 (HSF1) functions as the master regulator of the heat shock response in eukaryotes, We have previously shown that, in addition to its role as a transcription factor, HSF1 stimulates the activity of the DNA-dependent protein kinase (DNA-PK). DNA-PK is composed of two components: a 460-kDa catalytic subunit and a 70- and 86-kDa heterodimeric regulatory component, also known as the Ku protein. We report here that HSF1 binds specifically to each of the two components of DNA-PK. Binding occurs in the absence of DNA. The complex with the Ku protein is stable and forms at a stoichiometry close to unity between the Ku protein heterodimer and the active HSF1 trimer, The binding is blocked by antibodies against HSF1. Our results show that HSF1 also binds directly, but more weakly, to the catalytic subunit of DNA-PK. Both interactions are dependent on a specific region within the HSF1 regulatory domain, This sequence is necessary but not sufficient for HSF1 stimulation of DNA-PK activity. The ability of HSF1 to interact with both components of DNA-PK provides a potential mechanism for the activation of DNA-PK in response to heat and other forms of stress.	MED COLL GEORGIA,INST MOL MED & GENET,GENE REGULAT PROGRAM,AUGUSTA,GA 30912	University System of Georgia; Augusta University				Dynan, William/0000-0002-4045-5662; Nueda, Arsenio/0000-0001-8373-500X	NIGMS NIH HHS [GM35866] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035866] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; DYNAN WS, 1987, GENETIC ENG PRINCIPL, V9, P75; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KIM J, 1997, IN PRESS J CELL BIOC; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; McConnell K, 1996, CURR OPIN CELL BIOL, V8, P325, DOI 10.1016/S0955-0674(96)80005-6; MIVECHI NF, 1995, CANCER RES, V55, P5512; Newton EM, 1996, MOL CELL BIOL, V16, P839; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Yang SH, 1996, MOL CELL BIOL, V16, P3799, DOI 10.1128/mcb.16.7.3799; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	39	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26009	26016		10.1074/jbc.272.41.26009	http://dx.doi.org/10.1074/jbc.272.41.26009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325337	hybrid			2022-12-27	WOS:A1997YA35800092
J	Jin, DY; Teramoto, H; Giam, CZ; Chun, RF; Gutkind, JS; Jeang, KT				Jin, DY; Teramoto, H; Giam, CZ; Chun, RF; Gutkind, JS; Jeang, KT			A human suppressor of c-Jun N-terminal kinase 1 activation by tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; MAP KINASE; SIGNAL-TRANSDUCTION; HA-RAS; TAX; PATHWAY	Tumor necrosis factor alpha (TNF alpha) has pleiotropic effects on cellular metabolism. One of the signaling paths from the TNF alpha receptor induces a stress-activated protein kinase cascade. Components within this TNF alpha kinase cascade include mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1) and stress-activated protein kinase/extracellular signal-regulated kinase kinase (SEK), which regulate the activity of c-Jun N-terminal kinase 1 (JNK1). Currently, molecules upstream of MEKK1 that link TNF alpha receptor to downstream kinases are not well understood. Besides TNF alpha, many other stimuli including several oncoproteins can activate JNK1. In most cases, the signaling cascade(s) leading from oncoproteins to JNK1 is poorly elucidated. We report here that the human T-cell lymphotrophic virus, type I (HTLV-I) oncoprotein, Tax, can activate JNK1. We isolated a novel human cell factor, G-protein pathway suppressor 2 (GPS2), by its ability to bind the HTLV-I oncoprotein, and we show that this factor can potently suppress Tax activation of JNK1. In trying to understand the mechanism of GPS2 activity, we found that it also suppressed TNF alpha activation of JNK1 but not TNF alpha activation of p38 kinase nor phorbol activation of extracellular signal-regulated kinase 2. Because GPS2 has minimal effect on MEKK1- or SEK-regulated JNK1 activity, it could act at a point between the TNF alpha receptor and MEKK1 in the initial step(s) of this kinase cascade. Alternatively, it is not excluded that GPS2 could work in a parallel pathway that leads from TNF alpha to JNK1. GPS2 represents a new molecule that could contribute important insights toward how cytokine-and oncoprotein-mediated signal transduction might converge.	NIAID, MOL MICROBIOL LAB, MOL VIROL SECT, NIH, BETHESDA, MD 20892 USA; NIDR, CELLULAR DEV & ONCOL LAB, NIH, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT MICROBIOL & IMMUNOL, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Uniformed Services University of the Health Sciences - USA			Chun, Rene/A-9415-2010; Gutkind, J. Silvio/J-1201-2016	Chun, Rene/0000-0002-0190-0807; Gutkind, J. Silvio/0000-0002-5150-4482				BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; ELION EA, 1995, J CELL BIOL, V130, P1283, DOI 10.1083/jcb.130.6.1283; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; Gao MH, 1996, CANCER RES, V56, P4229; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; Kumar S, 1996, J BIOL CHEM, V271, P30864, DOI 10.1074/jbc.271.48.30451; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Liu Delong, 1994, Journal of Biomedical Science, V1, P65, DOI 10.1007/BF02257980; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MIDEN A, 1994, SCIENCE, V266, P1719; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; Spain BH, 1996, MOL CELL BIOL, V16, P6698; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; YAN MH, 1994, NATURE, V372, P798; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	42	90	92	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25816	25823		10.1074/jbc.272.41.25816	http://dx.doi.org/10.1074/jbc.272.41.25816			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325311	hybrid			2022-12-27	WOS:A1997YA35800066
J	Ojaniemi, M; Vuori, K				Ojaniemi, M; Vuori, K			Epidermal growth factor modulates tyrosine phosphorylation of p130(Cas) - Involvement of phosphatidylinositol 3'-kinase and actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MEDIATED CELL-ADHESION; CRK-ASSOCIATED SUBSTRATE; STRESS FIBERS; PHOSPHOINOSITIDE 3-KINASE; EXTRACELLULAR-MATRIX; RECEPTOR MUTANTS; DIRECT BINDING; PROTEIN; SRC	Epidermal growth factor (EGF) treatment of Rat-1 cells expressing human EGF receptor results in the modification of the tyrosine phosphorylation of the p130 Crk-associated substrate (Cas), a novel signaling molecule residing in focal adhesions. At low, mitogenic concentrations (<10 ng/ml), EGF treatment induced a rapid and transient tyrosine phosphorylation of Cas and promoted the formation of a Cas-adapter protein Crk complex in intact cells. The increase in tyrosine phosphorylation of Cas paralleled an increase in the cellular content of actin stress fibers and occurred via a pathway that depended on the integrity of the cytoskeleton. Further, phosphatidylinositol 3'-kinase activity was found to be required for the EGF-stimulated Cas phosphorylation and actin polymerization. At high concentrations (>30 ng/ml), EGF treatment resulted in the tyrosine dephosphorylation of Cas in a time-dependent manner with a concomitant decrease in the length and number of actin stress fibers. Thus, Cas exhibits an unusual bell-shaped dose-response curve in response to EGF stimulation, These results demonstrate a novel signaling role for EGF in inducing changes in tyrosine phosphorylation of Cas and Cas-Crk complex formation and suggest that Cas could be a signaling component in EGF-mediated signal transduction.	LA JOLLA CANC RES CTR, BURNHAM INST, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [K08CA072560] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Astier A, 1997, J BIOL CHEM, V272, P228; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Ishino M, 1995, ONCOGENE, V11, P2331; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Law SF, 1996, MOL CELL BIOL, V16, P3327; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; PATCH LA, 1995, J CELL SCI, V108, P1371; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHRAW W, 1995, BIOCHEMISTRY-US, V34, P13760, DOI 10.1021/bi00042a006; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tobe K, 1996, MOL CELL BIOL, V16, P4765; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YANO H, 1993, J BIOL CHEM, V268, P25846	59	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25993	25998		10.1074/jbc.272.41.25993	http://dx.doi.org/10.1074/jbc.272.41.25993			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325334	hybrid			2022-12-27	WOS:A1997YA35800089
J	Fiedler, K; Rothman, JE				Fiedler, K; Rothman, JE			Sorting determinants in the transmembrane domain of p24 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; COPII-COATED VESICLES; AMINO-ACID PERMEASES; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; GOLGI TRANSPORT; STRUCTURAL REQUIREMENTS; HELICAL INTERACTIONS; RETENTION; LOCALIZATION	Members of the p24 family of putative cargo receptors are proposed to contain retrograde and anterograde trafficking signals in their cytoplasmic domain to facilitate coat protein binding and cycling in the secretory pathway. We have analyzed the role of the transmembrane domain (TMD) of a p24 protein isolated from COPI-coated intra-Golgi transport vesicles. CD8-p24 chimeras were transiently expressed in COS7 cells and analyzed by immunofluorescence and pulse-chase experiments. The localization and transit of the wild-type chimera from the endoplasmic reticulum (ER) through the Golgi complex involved a glutamic acid residue and a conserved glutamine in the TMD. The TMD glutamic acid mediated the localization of the chimeras to the ER in the absence of the conserved glutamine. Efficient ER exit required the TMD glutamine and was further facilitated by a pair of phenylalanine residues in the cytoplasmic bail. TMD residues of p24 proteins may mediate the interaction with integral membrane proteins of the vesicle budding machinery to ensure p24 packaging into transport vesicles.			Fiedler, K (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Fiedler, Klaus/0000-0001-9398-1116				ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Blum R, 1996, J BIOL CHEM, V271, P17183, DOI 10.1074/jbc.271.29.17183; BOEHM J, 1994, EMBO J, V13, P3696, DOI 10.1002/j.1460-2075.1994.tb06679.x; Boehm J, 1997, J CELL SCI, V110, P991; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; Chen LI, 1997, J CELL BIOL, V137, P619, DOI 10.1083/jcb.137.3.619; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; GRAHAM TR, 1995, MOL BIOL CELL, V6, P809, DOI 10.1091/mbc.6.7.809; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; Lazarovits J, 1996, J CELL BIOL, V134, P339, DOI 10.1083/jcb.134.2.339; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Poster JB, 1996, J BIOL CHEM, V271, P3837; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SATO K, 1995, MOL BIOL CELL, V6, P1459, DOI 10.1091/mbc.6.11.1459; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; Stenius K, 1995, J CELL BIOL, V131, P1801, DOI 10.1083/jcb.131.6.1801; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; Tsukada M, 1996, J CELL SCI, V109, P2471; WADA I, 1991, J BIOL CHEM, V266, P19599; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2	61	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24739	24742		10.1074/jbc.272.40.24739	http://dx.doi.org/10.1074/jbc.272.40.24739			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312065	hybrid			2022-12-27	WOS:A1997XY97000004
J	Olivares, M; Alonso, C; Lopez, MC				Olivares, M; Alonso, C; Lopez, MC			The open reading frame 1 of the L1Tc retrotransposon of Trypanosoma cruzi codes for a protein with apurinic-apyrimidinic nuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXONUCLEASE-III; DNA; DROSOPHILA; REPAIR; ENDONUCLEASE; EXPRESSION; ELEMENTS; SEQUENCE; R2BM	The deduced amino acid sequence of the open reading frame 1 (ORF1) of the L1Tc non-site-specific non-long terminal repeat retrotransposon of Trypanosoma cruzi exhibits a significant homology with the consensus sequence of the class II family of the endonuclease apurinic-apyrimidinic (AP) proteins. The analysis of the activity of the 40-kDa recombinant protein, named NL1Tc, obtained from the expression of the L1Tc ORF1 in an Escherichia coli ''in vitro'' expression system revealed that the sequence codes for a protein with endonuclease activity specific for apurinic-apyrimidinic (AP) sites. Data are also presented showing that in vivo expression of the NL1Tc protein conferred viability by complementation to E. coli exonuclease III deletion mutants (BW286 strain), We propose that the biological function of the AP endonuclease activity of the NL1Tc protein may be connected with the introduction into the DNA of free 3' ends that could be used as primers for the integration, along the T. cruzi genome, of the L1Tc element and that the nicking could be a general mechanism for the retrotransposition of non-site specific non-long terminal repeat retrotransposons.	CSIC,INST PARASITOL & BIOMED LOPEZ NEYRA,DEPT MOL BIOL,GRANADA 18001,SPAIN; UNIV AUTONOMA MADRID,CTR BIOL MOL SEVERO OCHOA,CSIC,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Lopez, Manuel/Z-5641-2019	Lopez, Manuel Carlos/0000-0003-0002-3678				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHETON A, 1990, TRENDS GENET, V6, P16, DOI 10.1016/0168-9525(90)90044-7; EICKBUSH TH, 1992, NEW BIOL, V4, P430; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FINNEGAN DJ, 1989, MOBILE DNA, P503; GABRIEL A, 1993, REVERSE TRANSCRIPTAS, P275; LEETON PRJ, 1993, MOL GEN GENET, V237, P97, DOI 10.1007/BF00282789; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MARTIN F, 1995, J MOL BIOL, V247, P49, DOI 10.1006/jmbi.1994.0121; Martin F, 1996, TRENDS BIOCHEM SCI, V21, P283, DOI 10.1016/S0968-0004(96)80130-7; MARTIN F, 1996, J MOL BIOL, V248, P283; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; OYO Y, 1993, INT J BIOCHEM, V25, P359; REQUENA JM, 1994, GENE, V146, P245, DOI 10.1016/0378-1119(94)90300-X; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SCHWARZSOMMER Z, 1987, EMBO J, V6, P3873, DOI 10.1002/j.1460-2075.1987.tb02727.x; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; STUDIER JA, 1988, MOL BIOL EVOL, V5, P729; TAYLOR AF, 1982, J BACTERIOL, V151, P351, DOI 10.1128/JB.151.1.351-357.1982; VANDEPEER Y, 1993, COMPUT APPL BIOSCI, V9, P177; VARMUS H, 1989, MOBILE DNA, P53; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; [No title captured]	27	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25224	25228		10.1074/jbc.272.40.25224	http://dx.doi.org/10.1074/jbc.272.40.25224			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312137	hybrid			2022-12-27	WOS:A1997XY97000076
J	Pentikainen, MO; Lehtonen, EMP; Oorni, K; Lusa, S; Somerharju, P; Jauhiainen, M; Kovanen, PT				Pentikainen, MO; Lehtonen, EMP; Oorni, K; Lusa, S; Somerharju, P; Jauhiainen, M; Kovanen, PT			Human arterial proteoglycans increase the rate of proteolytic fusion of low density lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATHEROSCLEROTIC LESIONS; LIPID DEPOSITS; RABBIT; AORTA; CHOLESTEROL; BINDING; INTIMA; CELLS; ATHEROGENESIS; ACCUMULATION	Low density lipoprotein (LDL) particles can undergo fusion in the arterial intima, where they are bound to proteoglycans. Here we studied the effect of human arterial proteoglycans on proteolytic fusion of LDL in vitro. For this purpose, an assay was devised based on fluorescence resonance energy transfer that allowed continuous monitoring of fusion of proteoglycan-bound LDL particles, We found that addition of human arterial proteoglycans markedly increased the rate of proteolytic fusion of LDL, The glycosaminoglycans isolated from the proteoglycans also increased the rate of fusion, demonstrating that this effect was produced by the negatively charged sulfated polysaccharides In the proteoglycans, Furthermore, heparin, chondroitin 6-sulfate, and dextran sulfate, three commercially available sulfated polysaccharides, also increased the rate of LDL fusion, with heparin and chondroitin g-sulfate being as effective as and dextran sulfate more effective than hu man proteoglycans. The ability of the sulfated polysaccharides to increase the rate of proteolytic fusion of LDL depended critically on their ability to form insoluble complexes with LDL, which, in turn, resulted in an increased rate of LDL proteolysis and, in consequence, in an increased rate of LDL fusion, The results reveal a novel mechanism regulating LDL fusion and point to the potentially important role of arterial proteoglycans in the generation of LDL-derived lipid droplets in the arterial intima during atherogenesis.	WIHURI RES INST, SF-00140 HELSINKI, FINLAND; UNIV HELSINKI, DEPT MED CHEM, INST BIOMED, HELSINKI 00014, FINLAND; NATL PUBL HLTH INST, DEPT BIOCHEM, SF-00300 HELSINKI, FINLAND	Wihuri Research Institute; University of Helsinki; Finland National Institute for Health & Welfare			Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; BERGMEYER HU, 1985, METHOD ENZYMAT AN, V8, P1; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; CAMEJO G, 1991, BIOCHIM BIOPHYS ACTA, V1096, P253, DOI 10.1016/0925-4439(91)90013-Y; CAMEJO G, 1982, ADV LIPID RES, V19, P1; FRANK JS, 1989, J LIPID RES, V30, P967; GUYTON JR, 1992, AM J PATHOL, V141, P925; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; GUYTON JR, 1991, J LIPID RES, V32, P953; GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; KAARTINEN M, 1994, CIRCULATION, V90, P1669, DOI 10.1161/01.CIR.90.4.1669; KAARTINEN M, 1995, ARTERIOSCL THROM VAS, V15, P2047, DOI 10.1161/01.ATV.15.11.2047; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KOKKONEN JO, 1995, MAST CELL PROTEASES, P257; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACEK J, 1987, J CHROMATOGR-BIOMED, V414, P156, DOI 10.1016/0378-4347(87)80034-8; MORA R, 1987, ATHEROSCLEROSIS, V67, P143, DOI 10.1016/0021-9150(87)90274-7; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; OHNISHI T, 1990, J LIPID RES, V31, P397; PAANANEN K, 1995, J BIOL CHEM, V270, P12257, DOI 10.1074/jbc.270.20.12257; PASQUINELLI G, 1989, SCANNING MICROSCOPY, V3, P1151; Pentikainen MO, 1996, J LIPID RES, V37, P2638; PIHA M, 1995, BIOCHEMISTRY-US, V34, P10120, DOI 10.1021/bi00032a004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schwenke DC, 1996, CIRCULATION, V94, P2295; Smith E B, 1974, Adv Lipid Res, V12, P1; SRINIVASAN SR, 1989, BIOCHIM BIOPHYS ACTA, V1006, P159, DOI 10.1016/0005-2760(89)90190-2; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; TIRZIU D, 1995, ATHEROSCLEROSIS, V112, P101, DOI 10.1016/0021-9150(94)05405-8; VIA DP, 1982, J LIPID RES, V23, P570; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	37	21	21	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25283	25288		10.1074/jbc.272.40.25283	http://dx.doi.org/10.1074/jbc.272.40.25283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312145	hybrid			2022-12-27	WOS:A1997XY97000084
J	Duncan, RR; Westwood, PK; Boyd, A; Ashley, RH				Duncan, RR; Westwood, PK; Boyd, A; Ashley, RH			Rat brain p64H1, expression of a new member of the p64 chloride channel protein family in endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; CHROMAFFIN GRANULE MEMBRANES; CALCIUM CHANNELS; SARCOPLASMIC-RETICULUM; SELECTIVE CHANNEL; POTASSIUM CURRENT; ANION CHANNELS; MESSENGER-RNAS; ION CHANNELS; M2 PROTEIN	Many plasma membrane Cl- channels have been cloned, including the cystic fibrosis transmembrane conductance regulator and several members of the voltage-gated ClC family, In contrast, very little is known about the molecular identity of intracellular Cl- channels, me used a polymerase chain reaction-based approach to identify candidate genes in mammalian brain and cloned the cDNA. corresponding to rat brain p64H1. This encoded a microsomal membrane protein of predicted M-r 28,635 homologous to the putative intracellular bovine kidney Cl- channel p64. In situ mRNA hybridization histochemistry showed marked expression in hippocampus and cerebellum, and in vitro expression revealed a large cytoplasmic domain, one membrane-spanning segment, and a small nonglycosylated N-terminal luminal domain. The predicted protein contained consensus phosphorylation sites for protein kinase C and protein kinase A, and protein kinase C-mediated phosphorylation increased the M-r of p64H1 to similar to 43,000, characteristic of the native protein in Western blots. Recombinant p64H1 was immunolocalized to the endoplasmic reticulum of human embryonic kidney 293 and HT-4 cells, and incorporation of human embryonic kidney 293 endoplasmic reticulum vesicles into planar lipid bilayers gave rise to intermediate conductance, outwardly rectifying anion channels. Although p64H1 is the first intracellular Cl- channel component or regulator to be identified in brain, Northern blotting revealed transcripts in many other rat tissues. This suggests that p64H1 may contribute widely to intracellular Cl- transport.	UNIV EDINBURGH,DEPT BIOCHEM,EDINBURGH EH8 9XD,MIDLOTHIAN,SCOTLAND	University of Edinburgh				Duncan, Rory/0000-0003-0693-910X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; ARISPE N, 1992, J MEMBRANE BIOL, V130, P191; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; ASHLEY RH, 1994, EUR BIOPHYS J BIOPHY, V23, P263, DOI 10.1007/BF00213576; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark AG, 1997, BIOPHYS J, V73, P168, DOI 10.1016/S0006-3495(97)78057-3; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HAYMAN KA, 1993, J MEMBRANE BIOL, V136, P181, DOI 10.1007/BF02505762; HODGKIN AL, 1949, J PHYSL, V108, P27; Howell S, 1996, FEBS LETT, V390, P207, DOI 10.1016/0014-5793(96)00676-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; MARTIN C, 1993, CELL CALCIUM, V14, P427, DOI 10.1016/0143-4160(93)90002-N; Miller C., 1984, ION CHANNEL RECONSTI; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; MORIER N, 1994, BIOPHYS J, V67, P590, DOI 10.1016/S0006-3495(94)80519-3; MURUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; RAHAMIMOFF R, 1988, P NATL ACAD SCI USA, V85, P5310, DOI 10.1073/pnas.85.14.5310; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SCHMID A, 1988, J MEMBRANE BIOL, V104, P275, DOI 10.1007/BF01872329; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SUKHAREVA M, 1994, BIOPHYS J, V67, P751, DOI 10.1016/S0006-3495(94)80536-3; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TERASAKI M, 1992, J CELL SCI, V101, P315; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; YOUNG WS, 1986, NEUROSCI LETT, V70, P198	47	97	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23880	23886		10.1074/jbc.272.38.23880	http://dx.doi.org/10.1074/jbc.272.38.23880			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295337	hybrid			2022-12-27	WOS:A1997XX38100062
J	Gerber, HP; Condorelli, F; Park, J; Ferrara, N				Gerber, HP; Condorelli, F; Park, J; Ferrara, N			Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes - Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; LACTATE-DEHYDROGENASE-A; HIPPEL-LINDAU PROTEIN; FACTOR MESSENGER-RNA; INDUCIBLE FACTOR-1; TYROSINE KINASE; NITRIC-OXIDE; FACTOR VEGF; EXPRESSION; CELLS	Vascular endothelial growth factor (VEGF) and its two endothelial cell-specific receptor tyrosine kinases, Flk-1/KDR and Flt-1, play a key role in physiological and pathological angiogenesis. Hypoxia has been shown tee be a major mechanism for up-regulation of VEGF and its receptors in vivo. When we exposed human umbilical vein endothelial cells to hypoxic conditions in vitro, we observed increased levels of Flt-1 expression, In contrast, Flk-1/KDR mRNA levels were unchanged or slightly repressed, These findings suggest a differential transcriptional regulation of the two receptors by hypoxia, To identify regulatory elements involved in the hypoxic response, promoter regions of the mouse Flt-1 and Flk-1/KDR genes were isolated and tested in conjunction with luciferase reporter gene. In transient transfection assays, hypoxia led to strong transcriptional activation of the Flt-1 promoter, whereas Flk-1/KDR transcription was essentially unchanged, Promoter deletion analysis demonstrated a 430-bp region of the Flt-1 promoter to be required for transcriptional activation in response to hypoxia, This region includes a heptamer sequence matching the hypoxia-inducible factor-1 (HIF) consensus binding site previously found in other hypoxia-inducible genes such as the VEGF gene and erythropoietin gene, We further narrowed down the element mediating the hypoxia response to a 40-base pair sequence including the putative HIF binding site, We show that this element acts like an enhancer, since it activated transcription irrespective of its location or orientation in the construct, Furthermore, mutations within the putative HIF consensus binding site lead to impaired transcriptional activation by hypoxia, These findings indicate that, unlike the KDR/Flk-1 gene, the Flt-1 receptor gene is directly up-regulated by hypoxia via a hypoxia-inducible enhancer element located at positions -976 to -937 of the Flt-1 promoter.	GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Condorelli, Fabrizio/J-4726-2016	Condorelli, Fabrizio/0000-0002-9943-0857				Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINNERTY H, 1993, ONCOGENE, V8, P2293; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; FOLKMAN J, 1987, J NATL CANCER I, V82, P4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; IKEDA T, 1996, GROWTH FACTORS, V13, P1151; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MINCHENKO A, 1994, LAB INVEST, V71, P374; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PHILLIPS HS, 1993, INT J ONCOL, V2, P913; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Sambrook J., 2002, MOL CLONING LAB MANU; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; TERMAN BI, 1991, ONCOGENE, V6, P1677; THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647	52	635	666	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23659	23667		10.1074/jbc.272.38.23659	http://dx.doi.org/10.1074/jbc.272.38.23659			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295307	hybrid			2022-12-27	WOS:A1997XX38100032
J	Wandall, HH; Hassan, H; Mirgorodskaya, E; Kristensen, AK; Roepstorff, P; Bennett, EP; Nielsen, PA; Hollingsworth, MA; Burchell, J; TaylorPapadimitriou, J; Clausen, H				Wandall, HH; Hassan, H; Mirgorodskaya, E; Kristensen, AK; Roepstorff, P; Bennett, EP; Nielsen, PA; Hollingsworth, MA; Burchell, J; TaylorPapadimitriou, J; Clausen, H			Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; O-LINKED GLYCOSYLATION; CORE-PROTEIN; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; HUMAN FIBRONECTIN; DONOR SUBSTRATE; CDNA CLONING; IN-VIVO; EXPRESSION	Mucin-type O-glycosylation is initiated by UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferases (GalNAc-transferases). The role each GalNAc-transferase plays in O-glycosylation is unclear, In this report we characterized the specificity and kinetic properties of three purified recombinant GalNAc-transferases. GalNAc-T1, -T2, and -T3 were expressed as soluble proteins in insect cells and purified to near homogeneity, The enzymes have distinct but partly overlapping specificities with short peptide acceptor substrates, Peptides specifically utilized by GalNAc-T2 or -T3, or preferentially by GalNAc-T1 were identified. GalNAc-T1 and -T3 showed strict donor substrate specificities for UDP-GalNAc, whereas GalNAc-T2 also utilized UDP-Gal with one peptide acceptor substrate. Glycosylation of peptides based on MUC1 tandem repeat showed that three of five potential sites in the tandem repeat were glycosylated by all three enzymes when one or five repeat peptides were analyzed, However, analysis of enzyme kinetics by capillary electrophoresis and mass spectrometry demonstrated that the three enzymes react at different rates with individual sites in the MUC1 repeat, The results demonstrate that individual GalNAc-transferases have distinct activities and the initiation of O-glycosylation in a cell is regulated by a repertoire of GalNAc-transferases.	UNIV COPENHAGEN, SCH DENT, DK-2200 COPENHAGEN N, DENMARK; ODENSE UNIV, DEPT MOL BIOL, DK-5230 ODENSE, DENMARK; UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	University of Copenhagen; University of Southern Denmark; University of Nebraska System; University of Nebraska Medical Center; Cancer Research UK			Bennett, Eric/AAG-6120-2020; clausen, henrik/AAD-8016-2021; Burchell, Joy/G-4560-2012	Bennett, Eric/0000-0002-4976-0647; Clausen, Henrik/0000-0002-0915-5055; Burchell, Joy/0000-0003-0413-3823; Wandall, Hans H./0000-0003-0240-9232	NATIONAL CANCER INSTITUTE [R01CA066234] Funding Source: NIH RePORTER; NCI NIH HHS [1 RO1 CA66234] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BENNETT EP, 1995, BIOCHEM BIOPH RES CO, V206, P318, DOI 10.1006/bbrc.1995.1044; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; BURCHELL J, 1987, CANCER RES, V47, P5476; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; ELLIOTT S, 1994, BIOCHEMISTRY-US, V33, P11237, DOI 10.1021/bi00203a020; Finck M, 1996, GLYCOBIOLOGY, V6, P313, DOI 10.1093/glycob/6.3.313; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; GERWIG GJ, 1993, J BIOL CHEM, V268, P26956; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; GREENWELL P, 1986, CARBOHYD RES, V149, P149, DOI 10.1016/S0008-6215(00)90375-6; GRUNNET N, 1994, VOX SANG, V67, P210, DOI 10.1111/j.1423-0410.1994.tb01662.x; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HANSEN JE, 1994, PROTEIN STRUCTURE BY DISTANCE ANALYSIS, P247; HennebicqReig S, 1996, CARBOHYD RES, V280, P121, DOI 10.1016/0008-6215(95)00297-9; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HILL HD, 1977, J BIOL CHEM, V252, P3799; HINDSGAUL O, 1994, ALFRED BENZON SYMP S, V36, P104; HOMA FL, 1993, J BIOL CHEM, V268, P12609; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; MANDEL U, 1992, APMIS, V100, P817, DOI 10.1111/j.1699-0463.1992.tb04005.x; MATSUURA H, 1989, J BIOL CHEM, V264, P10472; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; NISHIMORI I, 1994, CANCER RES, V54, P3738; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; Yamamoto F, 1996, J BIOL CHEM, V271, P10515, DOI 10.1074/jbc.271.18.10515; YATES AD, 1984, BIOCHEM SOC T, V11, P300; Zara J, 1996, BIOCHEM BIOPH RES CO, V228, P38, DOI 10.1006/bbrc.1996.1613	48	255	271	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23503	23514		10.1074/jbc.272.38.23503	http://dx.doi.org/10.1074/jbc.272.38.23503			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295285	hybrid			2022-12-27	WOS:A1997XX38100010
J	Wang, F; Kan, M; McKeehan, K; Jang, JH; Feng, SJ; McKeehan, WL				Wang, F; Kan, M; McKeehan, K; Jang, JH; Feng, SJ; McKeehan, WL			A homeo-interaction sequence in the ectodomain of the fibroblast growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; THANATOPHORIC DYSPLASIA; CONSTITUTIVE ACTIVATION; STRUCTURAL DOMAINS; BINDING; HEPARIN; MUTATIONS; CELLS; IDENTIFICATION; ACHONDROPLASIA	Interaction of fibroblast growth factor receptors (FGFR) sufficient for a trans-phosphorylation event in which one intracellular domain is substrate for the other is essential for signal transduction. By analysis of the direct interaction of recombinant constructions coexpressed in baculoviral-infected insect cells, we identified a 17-amino acid sequence that is required for the stable interaction between ectodomains of FGFR, The sequence (160)ERSPHRPILQAGLPANK(176) (Glu(160)-Lys(176)) connects immunoglobulin modules II and III. In insect cells, the interaction between Glu(160)-Lys(176) domains occurs independently of intact heparin or FGF binding domains, The sequence is not required for the binding of heparin or FGF-1, but is essential for mitogenic activity of the FGFR kinase in mammalian cells. The results support a model in which the homeo-interaction between Glu(160)-Lys(176) in the ectodomain contributes to the interaction between intracellular domains in mammalian cell membranes (Kan, M., Wang, F., Kan, M., To, B., Gabriel, J. L., and McKeehan, W. L. (1996) J. Biol. Chem. 271, 26143-26148), We propose that the Glu(160)-Lys(176) domain plays a pivotal role in restriction of the interaction between kinases by pericellular matrix heparan sulfate proteoglycan and divalent cations. Restrictions are overcome by FGF or constitutively by diverse gain of function mutations which cause skeletal and craniofacial abnormalities.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, CTR CANC BIOL & NUTR, HOUSTON, TX 77030 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, HOUSTON, TX 77030 USA	Texas A&M University System; Texas A&M University System					NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310, R01DK040739] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK35310, DK40739] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bellus GA, 1996, NAT GENET, V14, P174, DOI 10.1038/ng1096-174; Bonaventure J, 1996, AM J MED GENET, V63, P148, DOI 10.1002/(SICI)1096-8628(19960503)63:1<148::AID-AJMG26>3.0.CO;2-N; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Feng SJ, 1996, BBA-MOL CELL RES, V1310, P67, DOI 10.1016/0167-4889(95)00146-8; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOU JZ, 1992, J BIOL CHEM, V267, P17804; HOU JZ, 1993, PROTEIN SCI, V2, P86; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN M, 1988, J BIOL CHEM, V263, P11306; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Luo YD, 1996, J BIOL CHEM, V271, P26876, DOI 10.1074/jbc.271.43.26876; Matsuzaki K, 1996, IN VITRO CELL DEV-AN, V32, P345, DOI 10.1007/BF02722961; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1996, MOL CELL BIOL, V16, P4081; XU JM, 1992, J BIOL CHEM, V267, P17792; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	33	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23887	23895		10.1074/jbc.272.38.23887	http://dx.doi.org/10.1074/jbc.272.38.23887			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295338	hybrid			2022-12-27	WOS:A1997XX38100063
J	Tomura, H; Itoh, H; Sho, K; Sato, K; Nagao, M; Ui, M; Kondo, Y; Okajima, F				Tomura, H; Itoh, H; Sho, K; Sato, K; Nagao, M; Ui, M; Kondo, Y; Okajima, F			beta gamma Subunits of pertussis toxin-sensitive G proteins mediate A(1) adenosine receptor agonist-induced activation of phospholipase C in collaboration with thyrotropin - A novel stimulatory mechanism through the cross-talk of two types of receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRTL-5 THYROID-CELLS; SIGNAL TRANSDUCTION SYSTEMS; NG 108-15 CELLS; ALPHA-SUBUNITS; ADENYLYL-CYCLASE; INOSITOL 1,4,5-TRISPHOSPHATE; PHOSPHOINOSITIDE TURNOVER; ARACHIDONATE RELEASE; BRADYKININ RECEPTORS; CA-2+ MOBILIZATION	COS-7 cells were transiently transfected with human thyrotropin receptor and dog A(1) adenosine receptor cDNAs. An A(1) agonist, N-6-(L-2-phenylisopropyl) adenosine (PIA), which is ineffective alone, enhanced tale thyrotropin (TSH)-induced inositol phosphate production, reflecting phospholipase C (PLC) activation, but inhibited the TSH-induced cAMP accumulation, reflecting adenylyl cyclase inhibition, These PIA-induced actions were completely inhibited by pertussis toxin (PTX) treatment. Moreover, in the cells expressing a PTX-insensitive mutant of G(i)2 alpha or G(i)3 alpha, in which a glycine residue was substituted for a cysteine residue to be ADP-ribosylated by PTX, at the fourth position of the C terminus, PIA effectively exerted both stimulatory and inhibitory effects on the TSH-induced actions although the cells were treated with the toxin. Overexpression of the beta gamma subunits of the G proteins enhanced the TSH-induced inositol phosphate production without any significant effect on the cAMP response; under these conditions, PIA did not further increase the elevated inositol phosphate response to TSH. On the contrary, overexpression of a constitutively active mutant of G(i)2 alpha, in which the guanosine triphosphatase activity is lost, inhibited the TSH-induced cAMP accumulation brat hardly affected the inositol phosphate response; under these conditions, PIA never exerted further inhibitory effects an the cAMP response to TSH. In contrast to the case of the TSH-induced inositol phosphate response, the response to a constitutively active G(11)alpha mutant was not appreciably affected, and that to NaF was rather inhibited by PIA and overexpression of the beta gamma subunits. Taken together, these results suggest that a single type of PTX-sensitive G protein mediates the A(1) adenosine receptor-linked modulation of two signaling pathways in collaboration with an activated thyrotropin receptor; alpha subunits of the PTX-sensitive G proteins mediate the inhibitory action an adenylyl cyclase, and the beta gamma subunits mediate the stimulatory action on PLC, In the case of the latter stimulatory action on PLC, the beta gamma subunits may not directly activate PLC. The possible mechanism by which beta gamma subunits enhance the TSH-induced PLC activation is discussed.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,YOKOHAMA,KANAGAWA 226,JAPAN; TOKYO METROPOLITAN INST MED SCI,TOKYO 113,JAPAN	Tokyo Institute of Technology; Tokyo Metropolitan Institute of Medical Science	Tomura, H (corresponding author), GUNMA UNIV,LAB SIGNAL TRANSDUCT,INST MOL & CELLULAR REGULAT,3-39-15 SHOWA MACHI,MAEBASHI,GUMMA 371,JAPAN.							AKBAR M, 1994, MOL PHARMACOL, V45, P1036; ALI H, 1990, J BIOL CHEM, V265, P745; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; GERWINS P, 1992, P NATL ACAD SCI USA, V89, P7330, DOI 10.1073/pnas.89.16.7330; GERWINS P, 1992, J BIOL CHEM, V267, P16081; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HUNT TW, 1994, J BIOL CHEM, V269, P29565; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; ITOH H, 1988, J BIOL CHEM, V263, P6656; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Laglia G, 1996, ENDOCRINOLOGY, V137, P3170, DOI 10.1210/en.137.8.3170; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; NAZAREA M, 1991, EUR J PHARM-MOLEC PH, V206, P47, DOI 10.1016/0922-4106(91)90145-8; OKAJIMA F, 1990, J BIOL CHEM, V265, P21741; OKAJIMA F, 1995, BIOCHEM J, V306, P709, DOI 10.1042/bj3060709; OKAJIMA F, 1989, FEBS LETT, V248, P145, DOI 10.1016/0014-5793(89)80450-8; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAJIMA F, 1993, BIOCHEM J, V290, P241, DOI 10.1042/bj2900241; OKAJIMA F, 1992, FEBS LETT, V301, P223, DOI 10.1016/0014-5793(92)81252-H; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V281, P298, DOI 10.1016/0003-9861(90)90447-7; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SHO K, 1991, J BIOL CHEM, V266, P12180; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STILES GL, 1992, J BIOL CHEM, V267, P6451; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TOMURA H, 1992, NEUROSCI LETT, V148, P93, DOI 10.1016/0304-3940(92)90812-L; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WATSON S, 1994, G PROTEIN LINKED REC, P296; WEST RE, 1985, J BIOL CHEM, V260, P4428; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; YASUDA K, 1992, J BIOL CHEM, V267, P20422	58	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23130	23137		10.1074/jbc.272.37.23130	http://dx.doi.org/10.1074/jbc.272.37.23130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287315	hybrid			2022-12-27	WOS:A1997XV74400026
J	Natoli, G; Costanzo, A; Moretti, F; Fulco, M; Balsano, C; Levrero, M				Natoli, G; Costanzo, A; Moretti, F; Fulco, M; Balsano, C; Levrero, M			Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2 - Nuclear factor kappa B (NF kappa B)-inducing kinase requirement for activation of activating protein 1 and NF kappa B but not of c-Jun N-terminal kinase/stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; MAP KINASE; TRANSDUCTION PATHWAY; PROLONGED ACTIVATION; INDUCED APOPTOSIS; FACTOR-ALPHA; DOMAIN; PHOSPHORYLATION; TRANSCRIPTION; INTERACTS	Like other members of the tumor necrosis factor (TNF) receptor family, p55 TNF receptor 1 (TNF-R1) lacks intrinsic signaling capacity and transduces signals by recruiting associating molecules, The TNF-R1 associated death domain protein interacts with the p55 TNF-R1 cytoplasmic domain and recruits the Fas-associated death domain protein (which directly activates the apoptotic proteases), the protein kinase receptor interacting protein, and TNF receptor-associated factor 2 (TRAF2), TRAF2 has previously been demonstrated to activate both transcription factor nuclear factor kappa B (NF kappa B) and the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) pathway, which in turn stimulates transcription factor activating protein 1 (AP1) mainly via phosphorylation of the c-Jun component. We have investigated the signaling properties of NF kappa B-inducing kinase (NIK), a TRAF2-associated protein kinase that mediates NF kappa B induction, NM was found to be unable to activate JNK/SAPK, mitogen-activated protein kinase, or p38 kinase, Moreover, NIK was not required for JNK/SAPK activation by TNF-R1, thus representing the first TNF-R1 complex component to dissect the NF kappa B and the JNK/SAPK pathways. Despite being unable to activate JNK/SAPK and mitogen-activated protein kinase, NIK strongly activated AP1 and was required for TNF-R1-induced AP1 activation, Therefore, NIK links TNF-R1 to a novel, JNK/SAPK-independent, AP1 activation pathway.	UNIV ROMA LA SAPIENZA,FDN ANDREA CESALPINO,I-00161 ROME,ITALY; UNIV PALERMO,IST MED INTERNA,I-90100 PALERMO,ITALY; UNIV AQUILA,DIPARTIMENTO MED INTERNA,I-86100 LAQUILA,ITALY	Sapienza University Rome; University of Palermo; University of L'Aquila	Natoli, G (corresponding author), UNIV ROMA LA SAPIENZA,IST CLIN MED 1,POLICLIN UMBERTO I,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018; Costanzo, Antonio/D-3896-2012; Balsano, Clara/AAK-9870-2020; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875; Natoli, Gioacchino/0000-0003-0711-2411				AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Baker SJ, 1996, ONCOGENE, V12, P1; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; TEWARY M, 1996, CURR OPIN GENE DEV, V6, P89; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VIETOR I, 1993, J BIOL CHEM, V268, P18994; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798	41	106	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	1997	272	42					26079	26082		10.1074/jbc.272.42.26079	http://dx.doi.org/10.1074/jbc.272.42.26079			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YB139	9334169	hybrid			2022-12-27	WOS:A1997YB13900003
J	Fu, Y; Shearing, LN; Haynes, S; Crewther, P; Tilley, L; Anders, RF; Foley, M				Fu, Y; Shearing, LN; Haynes, S; Crewther, P; Tilley, L; Anders, RF; Foley, M			Isolation from phage display libraries of single chain variable fragment antibodies that recognize conformational epitopes in the malaria vaccine candidate, apical membrane antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-KNOWLESI; SEQUENCE-ANALYSIS; SURFACE-ANTIGEN; I AMA-1; PROTEIN; EXPRESSION; INHIBIT; FAB; IGG	Phage display of single chain variable fragment (scFv) antibodies is a powerful tool for the selection of important and useful antibody specificities. We have constructed such a library from mice protected from malaria challenge by immunization with recombinant Plasmodium chabaudi DS apical membrane antigen (AMA-1). Panning on refolded AMA-1 enriched a population of scFvs which specifically bound the antigen. The single chain antibodies recognize conformational epitopes on AMA-1 from the P. chabaudi DS strain but not on AMA-1 of the 556KA strain of P. chabaudi. A subset of the antibody fragments recognized AMA-1 from the human malaria parasite Plasmodium falciparum. Nucleotide sequencing revealed that at least four unique scFv genes were selected by the panning procedure. These scFv antibodies are valuable reagents for probing the structure and function of AMA-1 and will be used to test the feasibility of using recombinant antibodies in a passive immunization therapy against malaria.	LA TROBE UNIV,SCH BIOCHEM,BUNDOORA,VIC 3083,AUSTRALIA; WALTER & ELIZA HALL INST MED RES,COOPERAT RES CTR DIAGNOST TECHNOL,MELBOURNE,VIC 3050,AUSTRALIA	La Trobe University; Walter & Eliza Hall Institute			Tilley, Leann/AAU-5281-2020	Foley, Michael/0000-0003-1349-4698; Tilley, Leann/0000-0001-9910-0199; fu, ying/0000-0002-1261-3336; Anders, Robin/0000-0002-0693-4547				ANDERS RF, 1997, MOL IMMUNOLOGICAL CO, P167; ANDERS RF, 1997, IN PRESS VACCINE, V15; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CHENG Q, 1994, MOL BIOCHEM PARASIT, V65, P183, DOI 10.1016/0166-6851(94)90127-9; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; Crewther PE, 1996, INFECT IMMUN, V64, P3310, DOI 10.1128/IAI.64.8.3310-3317.1996; DEANS JA, 1982, CLIN EXP IMMUNOL, V49, P297; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; DUTTA S, 1995, MOL BIOCHEM PARASIT, V73, P267, DOI 10.1016/0166-6851(95)00112-E; ELGAVISH RA, 1993, BIOTECHNIQUES, V15, P1066; Giudicelli V, 1997, NUCLEIC ACIDS RES, V25, P206, DOI 10.1093/nar/25.1.206; Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; MARSHALL VM, 1989, MOL BIOCHEM PARASIT, V37, P281, DOI 10.1016/0166-6851(89)90160-6; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PETERSON MG, 1989, MOL CELL BIOL, V9, P3151, DOI 10.1128/MCB.9.7.3151; PETERSON MG, 1990, MOL BIOCHEM PARASIT, V39, P279, DOI 10.1016/0166-6851(90)90067-V; Samuelsson A, 1996, EUR J IMMUNOL, V26, P3029, DOI 10.1002/eji.1830261231; SAUL A, 1987, PARASITE IMMUNOL, V9, P1, DOI 10.1111/j.1365-3024.1987.tb00483.x; SIEGEL DL, 1994, BLOOD, V83, P2334, DOI 10.1182/blood.V83.8.2334.bloodjournal8382334; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; WATERS AP, 1990, J BIOL CHEM, V265, P17974; WATERS AP, 1991, MOL BIOCHEM PARASIT, V44, P141, DOI 10.1016/0166-6851(91)90230-4; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0	25	18	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25678	25684		10.1074/jbc.272.41.25678	http://dx.doi.org/10.1074/jbc.272.41.25678			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325291	hybrid			2022-12-27	WOS:A1997YA35800046
J	Stennicke, HR; Salvesan, GS				Stennicke, HR; Salvesan, GS			Biochemical characteristics of caspases-3, -6, -7, and -8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; PROTEASE ACTIVATION; CYSTEINE PROTEASE; C-ELEGANS; APOPTOSIS; ACIDIFICATION; EQUILIBRIA; EVENTS; PAPAIN	The observation that the nematode cell, death effector gene product Ced-3 is homologous to human interleukin-1 beta-converting enzyme (caspase-1) has led to the discovery of at least nine other human caspases, many of which are implicated as mediators of apoptosis. Significant interest has been given to aspects of the cell biology and substrate specificity of this family of proteases; however, quantitative descriptions of their biochemical characteristics have lagged behind. We describe the influence of a number of environmental parameters, including pH, ionic strength, detergent, and specific ion concentrations, on the activity and stability of four caspases involved in death receptor-mediated apoptosis. Based on these observations, we recommend the following buffer as optimal for investigation of their characteristics in vitro: 20 mM piperazine-N,N'-bis-(2-ethanesulfonic acid) (PIPES), 100 mM NaCl, 10 mM dithiothreitol, 1 mM EDTA, 0.1% 3-[(3-cholamidopropyl) -dimethylammonio]-2-hydroxy-1-propanesulfonic acid (CHAPS), 10% sucrose, pH 7.2. Caspase activity is not affected by concentrations of Ca2+ below 100 mM, but is abolished by Zn2+ in the submicromolar range, a common characteristic of cysteine proteases. Optimal pH values vary from 6.8 for caspase-8 to 7.4 for caspase-3, and activity of all is relatively stable between 0 and 150 mM NaCl. Consequently, changes in the physiologic pH and ionic strength would not significantly alter the activity of the enzymes, inasmuch as all four caspases are optimally active within the range of these parameters found in the cytosol of living and dying human cells.	BURNHAM INST,PROGRAM APOPTOSIS & CELL DEATH,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BLACK RA, 1989, J BIOL CHEM, V264, P5323; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOND JS, 1989, PROTEOLYTIC ENZYMES, P232; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CERETTI DP, 1992, SCIENCE, V256, P97; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; GODT RE, 1988, AM J PHYSIOL, V254, pC891; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; KERR JFR, 1991, APOPTOSIS MOL BASIS, P321; LEATHERBARROW RJ, 1993, GRAFIT VERSION 3 01; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; MILLER DK, 1996, THERAPEUTIC MODULATI, P143; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SLUYTERMAN LAA, 1976, EUR J BIOCHEM, V71, P383, DOI 10.1111/j.1432-1033.1976.tb11125.x; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1996, J BIOL CHEM, V271, P21853, DOI 10.1074/jbc.271.36.21853; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	40	460	488	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25719	25723		10.1074/jbc.272.41.25719	http://dx.doi.org/10.1074/jbc.272.41.25719			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325297	hybrid			2022-12-27	WOS:A1997YA35800052
J	Roux, P; Delepierre, M; Goldberg, ME; Chaffotte, AF				Roux, P; Delepierre, M; Goldberg, ME; Chaffotte, AF			Kinetics of secondary structure recovery during the refolding of reduced hen egg white lysozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; CYTOCHROME-C; FOLDING PATHWAY; DISULFIDE BONDS; PROTEIN; RENATURATION; H-1-NMR; NMR; SPECTROSCOPY; INTERMEDIATE	We have shown previously that, in less than 4 ms, the unfolded/oxidized hen lysozyme recovered its native secondary structure, while the reduced protein remained fully unfolded, To investigate the role played by disulfide bridges in the acquisition of the secondary structure at later stages of the renaturation/oxidation, the complete refolding of reduced lysozyme was studied, This was done in a renaturation buffer containing 0.5 M guanidinium chloride, 60 mu M oxidized glutathione, and 20 mu M reduced dithiothreitol, in which the aggregation of lysozyme was minimized and where a renaturation yield of 80% was obtained, The refolded protein could not be distinguished from the native lysozyme by activity, compactness, stability, and several spectroscopic measurements, The kinetics of renaturation were then studied by following the reactivation and the changes in fluorescence and circular dichroism signals, When bi- or triphasic sequential models were fitted to the experimental data, the first two phases had the same calculated rate constants for all the signals showing that, within the time resolution of these experiments, the folding/oxidation of hen lysozyme is highly cooperative, with the secondary structure, the tertiary structure, and the integrity of the active site appearing simultaneously.	INST PASTEUR,UNITE BIOCHIM CELLULAIRE,CNRS,URA 1129,F-75724 PARIS 15,FRANCE; INST PASTEUR,LAB RMN,F-75724 PARIS 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ACHARYA AS, 1976, J BIOL CHEM, V251, P6934; ANDERSON WL, 1976, J BIOL CHEM, V251, P3147; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P9694, DOI 10.1021/bi00155a024; CHAFFOTTE AF, 1992, BIOCHEMISTRY-US, V31, P4303, DOI 10.1021/bi00132a022; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; ELOVE GA, 1992, BIOCHEMISTRY-US, V31, P6876, DOI 10.1021/bi00145a003; FISHER WR, 1973, J BIOL CHEM, V248, P3188; FITCH WL, 1994, J ORG CHEM, V59, P7955, DOI 10.1021/jo00105a006; Goldberg, 1995, Fold Des, V1, P21; GOLDBERG ME, 1994, PROTEIN SCI, V3, P883; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GUIJARRO JI, 1995, BIOCHEMISTRY-US, V34, P2998, DOI 10.1021/bi00009a031; HARRISON SC, 1985, P NATL ACAD SCI USA, V82, P4028, DOI 10.1073/pnas.82.12.4028; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KUWAJIMA K, 1991, BIOCHEMISTRY-US, V30, P7693, DOI 10.1021/bi00245a005; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; ORSINI G, 1978, J BIOL CHEM, V253, P3453; PRIVALOV G, 1995, ANAL BIOCHEM, V232, P79, DOI 10.1006/abio.1995.9957; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Raman B, 1996, J BIOL CHEM, V271, P17067, DOI 10.1074/jbc.271.29.17067; REDFIELD C, 1988, BIOCHEMISTRY-US, V27, P122, DOI 10.1021/bi00401a020; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SAWANO H, 1992, FEBS LETT, V303, P11, DOI 10.1016/0014-5793(92)80466-T; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SOPHIANOPOULOS AJ, 1964, BIOCHEMISTRY-US, V3, P1920, DOI 10.1021/bi00900a023; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; VARLEY P, 1993, SCIENCE, V260, P1110, DOI 10.1126/science.8493553	32	45	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24843	24849		10.1074/jbc.272.40.24843	http://dx.doi.org/10.1074/jbc.272.40.24843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312083	hybrid			2022-12-27	WOS:A1997XY97000022
J	Silver, DL; Vorotnikov, AV; Watterson, DM; Shirinsky, VP; Sellers, JR				Silver, DL; Vorotnikov, AV; Watterson, DM; Shirinsky, VP; Sellers, JR			Sites of interaction between kinase-related protein and smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; C-PROTEIN; HEAVY-MEROMYOSIN; SKELETAL-MUSCLE; CARBOXYL-TERMINUS; 10S CONFORMATION; CHICKEN GIZZARD; MYBP-C; BINDING; PHOSPHORYLATION	Kinase-related protein, also known as KRP or telokin, is an independently expressed protein product derived from a gene within the gene for myosin light chain kinase (MLCK). KRP binds to unphosphorylated smooth muscle myosin filaments and stabilizes them against ATP-induced depolymerization in vitro. KRP competes with MLCK for binding to myosin, suggesting that both proteins bind to myosin by the KRP domain (Shirinsky, V. P., Vorotnikov, A. V., Birukov, K. G., Nanaev, A. K., Collinge, M., Lukas, T. J., Sellers, J. R., and Watterson, D. M. (1993) J. Biol. Chem. 268, 16578-16583). In this study, we investigated which regions of myosin and KRP interact in vitro. Using cosedimentation assays, we determined that HRP binds to unphosphorylated myosin with a stoichiometry of 1 mol of KRP/1 mol of myosin and an affinity of 5.5 mu m. KRP slows the rate of proteolytic cleavage of the head-tail junction of heavy meromyosin by papain and chymotrypsin, suggesting it is binding to this region of myosin. In addition, competition experiments, using soluble headless fragments of nonmuscle myosin, confirmed that KRP interacts with the regulatory light chain binding region of myosin. The regions important for KRP's binding to myosin were investigated using bacterially expressed KRP truncation mutants. We determined that the acid-rich sequence between Gly(138) and Asp(151) of KRP is required for high affinity myosin binding, and that the amino terminus and beta-barrel regions weakly interact with myosin. All KRP truncations, at concentrations comparable to their K-D values, exhibited some stabilization of myosin filaments against ATP depolymerization in vitro, suggesting that KRP's ability to stabilize myosin filaments is commensurate with its myosin binding affinity. HRP weakened the K-m but not the V-max of phosphorylation of myosin by MLCK, demonstrating that bound HRP does not prevent MLCK from activating myosin.	NHLBI,MOL CARDIOL LAB,BETHESDA,MD 20892; RUSSIAN ACAD MED SCI,CARDIOL RES CTR,INST EXPT CARDIOL,MOL ENDOCRINOL LAB,MOSCOW 121552,RUSSIA; NORTHWESTERN UNIV,DRUG DISCOVERY PROGRAM,CHICAGO,IL 60611; NORTHWESTERN UNIV,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Medical Research Center of Cardiology; Russian Academy of Medical Sciences; Northwestern University; Northwestern University			Shirinsky, Vladimir/AAN-3938-2020; Vorotnikov, Alexander/A-8392-2014; Vorotnikov, Alexander/AAN-3080-2020	Vorotnikov, Alexander/0000-0002-1460-971X; Vorotnikov, Alexander/0000-0002-1460-971X; Watterson, Daniel/0000-0001-7605-5866; Silver, Debra/0000-0001-9189-844X	NIGMS NIH HHS [GM30861] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030861] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1982, METHOD ENZYMOL, V85, P298; Benian GM, 1996, J CELL BIOL, V132, P835, DOI 10.1083/jcb.132.5.835; COLLINGE M, 1992, MOL CELL BIOL, V12, P2359, DOI 10.1128/MCB.12.5.2359; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Gilbert R, 1996, J CELL SCI, V109, P101; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Godfraind-De Becker A, 1988, Adv Exp Med Biol, V226, P149; GUERRIERO V, 1981, CELL, V27, P449, DOI 10.1016/0092-8674(81)90386-X; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOROWITS R, 1986, NATURE, V323, P160, DOI 10.1038/323160a0; HOROWITZ A, 1994, J CELL BIOL, V126, P1195, DOI 10.1083/jcb.126.5.1195; HOUMEIDA A, 1995, J CELL BIOL, V131, P1471, DOI 10.1083/jcb.131.6.1471; IKEBE M, 1983, BIOCHEMISTRY-US, V22, P4580, DOI 10.1021/bi00288a036; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; ITO M, 1989, J BIOL CHEM, V264, P13971; KATOH T, 1995, J BIOCHEM-TOKYO, V118, P428, DOI 10.1093/oxfordjournals.jbchem.a124925; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; Masato T, 1997, J BIOCHEM, V121, P225; MOOS C, 1975, J MOL BIOL, V97, P1, DOI 10.1016/S0022-2836(75)80017-9; MURPHY RA, 1994, FASEB J, V8, P311, DOI 10.1096/fasebj.8.3.8143937; OKAGAKI T, 1993, J CELL BIOL, V123, P619, DOI 10.1083/jcb.123.3.619; Olney JJ, 1996, J BIOL CHEM, V271, P20375, DOI 10.1074/jbc.271.34.20375; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; ONISHI H, 1984, J BIOCHEM, V95, P899, DOI 10.1093/oxfordjournals.jbchem.a134685; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1984, J BIOL CHEM, V259, P7740; SELLERS JR, 1988, BIOCHEMISTRY-US, V27, P6977, DOI 10.1021/bi00418a046; SELLERS JR, 1987, ENZYMES, P381; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; Silver D. L., 1996, Biophysical Journal, V70, pA52; SOMLYO AV, 1981, NATURE, V294, P567, DOI 10.1038/294567a0; STARR R, 1978, BIOCHEM J, V171, P813, DOI 10.1042/bj1710813; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; TRYBUS KM, 1982, P NATL ACAD SCI-BIOL, V79, P6151, DOI 10.1073/pnas.79.20.6151; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; VOROTNIKOV AV, 1995, BIOPHYS J, V17, pA153	44	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25353	25359		10.1074/jbc.272.40.25353	http://dx.doi.org/10.1074/jbc.272.40.25353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312155	hybrid			2022-12-27	WOS:A1997XY97000094
J	Blanquet, PR; Lamour, Y				Blanquet, PR; Lamour, Y			Brain-derived neurotrophic factor increases Ca2+/calmodulin-dependent protein kinase 2 activity in hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; SYNAPTIC TRANSMISSION; GROWTH-FACTOR; II ACTIVITY; NEURONS; DIFFERENTIATION; MODULATION; ACTIVATION; SIGNALS; CELLS	Here we show that brain-derived neurotrophic factor (BDNF) stimulates both the phosphorylation of the Ca2+/calmodulin-dependent protein kinase 2 (CaMK2) and its kinase activity in rat hippocampal slices. In addition, we find that: (i) the time course of BDNF action is not accompanied by a change in the spectrum of either alpha- and beta-subunits of CaMK2 detected by immunoblotting; (ii) both treatment of solubilized CaMK2 with alkaline phosphatase and treatment of immunoprecipitated CaMK2 with protein phosphatase 1 reverse phosphorylation and activation of the kinase; (iii) phospholipase C inhibitor D609 and intracellular Ca2+ chelation by 1,2-bis-(o-aminophenoxy)ethane-N,N,N '',N',-tetracetic acid tetra(acetoxymethyl) ester or 8-(diethylamino) octyl-3, 4,5-trimethoxybenzoate but not omission of Ca2+ or Ca2+ chelation by EGTA, abolish the stimulatory effect of BDNF on phosphorylation and activation of CaMK2. These results strongly suggest that the conversion of CaMK2 into its active, autophosphorylated form, but not its concentration, is increased by BDNF via stimulation of phospholipase C and subsequent intracellular Ca2+ mobilization.			Blanquet, PR (corresponding author), U161 INSERM,UNITE RECH PHYSIOPHARMACOL SYST NERVEUX,2 RUE ALESIA,F-75014 PARIS,FRANCE.							ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; Aronowski J, 1996, BRAIN RES, V709, P103, DOI 10.1016/0006-8993(95)01311-3; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; BLANQUET PR, 1995, J CELL PHYSIOL, V165, P358, DOI 10.1002/jcp.1041650217; CHARRIAUTMARLANGUE C, 1991, P NATL ACAD SCI USA, V88, P10232, DOI 10.1073/pnas.88.22.10232; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Frenguelli BG, 1996, SEMIN NEUROSCI, V8, P301, DOI 10.1006/smns.1996.0037; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; KANG HJ, 1995, J PHYSIOLOGY-PARIS, V89, P11, DOI 10.1016/0928-4257(96)80547-X; Levine ES, 1996, MOL BRAIN RES, V38, P300, DOI 10.1016/0169-328X(96)00025-3; Marsh HN, 1996, J NEUROCHEM, V67, P952; Miyamoto E, 1996, NEUROSCI RES, V24, P117, DOI 10.1016/0168-0102(95)00991-4; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; SchmidtKastner R, 1996, NEUROSCIENCE, V74, P161, DOI 10.1016/0306-4522(96)00093-0; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; Tan SE, 1996, BRAIN RES, V711, P234, DOI 10.1016/0006-8993(95)01411-X; Tsuda M, 1996, NEUROCHEM INT, V29, P443, DOI 10.1016/0197-0186(96)00014-9; Wu K, 1996, MOL BRAIN RES, V43, P286, DOI 10.1016/S0169-328X(96)00211-2	23	58	59	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24133	24136		10.1074/jbc.272.39.24133	http://dx.doi.org/10.1074/jbc.272.39.24133			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305859	hybrid			2022-12-27	WOS:A1997XY51500010
J	Burdick, MD; Harris, A; Reid, CJ; Iwamura, T; Hollingsworth, MA				Burdick, MD; Harris, A; Reid, CJ; Iwamura, T; Hollingsworth, MA			Oligosaccharides expressed an MUC1 produced by pancreatic and colon tumor cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; MOLECULAR-CLONING; GENE-EXPRESSION; O-GLYCOSYLATION; CARCINOMA; CDNA; SELECTIN; ADHESION; PROTEIN; SIALYL-LEWIS(X)	MUC1 is expressed at the apical surface of ductal epithelia of tissues, including breast, pancreas, airway, and the gastrointestinal tract, where its functions include lubrication and protection of the epithelia, In addition, roles for MUC1 have been suggested in both adhesive and antiadhesive properties of tumor cells, and extensive O-glycosylation of the MUC1 tandem repeat domain may contribute to these functions. Little information is available on the specific O-glycosylation of MUC1. One problem in identifying different MUC1 glycoforms has been that monoclonal antibodies raised against the MUC1 core protein recognize epitopes in the tandem repeat domain, which is often glycosylated to an extent that obscures these epitopes, We developed an epitope-tagged form of MUC1 that allowed the detection of multiple MUC1 glycoforms and established the presence of a number of important blood group and tumor-associated carbohydrate antigens on MUC1 expressed by two pancreatic tumor cell lines (Panc-1 and S2-013) and two colon tumor cell Lines (Caco-2 and HT-29). Antigens detected include sialyl-Lewis(a), sialyl-Lewis(c), sialyl-Lewis(x), and sialyl-Tn.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND; MIYAZAKI MED COLL,DEPT SURG 1,MIYAZAKI 88916,JAPAN	University of Nebraska System; University of Nebraska Medical Center; University of Oxford; University of Miyazaki					NATIONAL CANCER INSTITUTE [R01CA069234, R01CA057362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046589] Funding Source: NIH RePORTER; NCI NIH HHS [CA57362, CA69234] Funding Source: Medline; NIDDK NIH HHS [DK46589] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATRA SK, 1991, J CELL SCI, V100, P841; BATRA SK, 1992, INT J PANCREATOL, V12, P271; BOSHELL M, 1992, BIOCHEM BIOPH RES CO, V185, P1, DOI 10.1016/S0006-291X(05)80946-5; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BYRD JC, 1995, EUR J CANCER, V31A, P1498, DOI 10.1016/0959-8049(95)00248-H; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hanisch FG, 1996, EUR J BIOCHEM, V236, P318, DOI 10.1111/j.1432-1033.1996.00318.x; HANSKI C, 1993, CANCER RES, V53, P4082; HANSKI C, 1995, CANCER RES, V55, P928; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HO JJL, 1995, CANCER RES, V55, P3659; HO SB, 1993, CANCER RES, V53, P641; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; IWAMURA T, 1992, J GASTROEN HEPATOL, V7, P512, DOI 10.1111/j.1440-1746.1992.tb01030.x; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; PANDEY P, 1995, CANCER RES, V55, P4000; Park H, 1996, AM J RESP CELL MOL, V15, P237, DOI 10.1165/ajrcmb.15.2.8703480; PEMBERTON L, 1992, BIOCHEM BIOPH RES CO, V185, P167, DOI 10.1016/S0006-291X(05)80971-4; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA T, 1994, INT J CANCER, V57, P901, DOI 10.1002/ijc.2910570621; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SPICER AP, 1995, MAMM GENOME, V6, P885, DOI 10.1007/BF00292441; TAKADA A, 1993, CANCER RES, V53, P354; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Woynarowska B, 1996, GLYCOCONJUGATE J, V13, P663, DOI 10.1007/BF00731455; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; YONEZAWA S, 1991, BIOCHEM J, V276, P599, DOI 10.1042/bj2760599; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	33	183	188	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24198	24202		10.1074/jbc.272.39.24198	http://dx.doi.org/10.1074/jbc.272.39.24198			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305871	hybrid			2022-12-27	WOS:A1997XY51500022
J	Francisco, JA; Gawlak, SL; Siegall, CB				Francisco, JA; Gawlak, SL; Siegall, CB			Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL LYMPHOMA; ENDOTHELIAL-CELLS; CD40 ANTIGEN; PHASE-I; PSEUDOMONAS EXOTOXIN; CONTINUOUS-INFUSION; BRYONIA-DIOICA; ACTIVATION; CARCINOMAS	The major limitation to the use of immunotoxins in the clinic is the toxicity associated with the toxin moiety, BD1-G28-5 single-chain Fv (sFv) is a single-chain immunotoxin targeted to human CD40 and consists of bryodin 1 (BD1), a plant ribosome-inactivating protein that is 20-30-fold less toxic in animals than commonly used toxins, fused to the sFv region of the anti-CD40 monoclonal antibody G28-5, This immunotoxin was expressed in Escherichia coli and purified from refolded inclusion bodies. BD1-G28-5 sFv retained the full protein synthesis inhibition activity of recombinant BD1 and specifically bound to CD40 with a binding affinity, k(d), of 1.5 nM, within 10-fold of the bivalent parental monoclonal antibody, BD1-G28-5 sFv was potently cytotoxic against CD40-expressing B lineage non-Hodgkin's lymphoma and multiple myeloma cell lines, with EC50 values in the ng/ml range, but not against a CD40-negative T cell line, Interestingly, BD1-G28-5 sFv was not cytotoxic against CD40-expressing carcinoma cell lines that were sensitive to a BD1-based immunotoxin conjugate targeted to the Le(y) carbohydrate antigen, These data represent the first report indicating that BD1 can be used in the construction of potent single-chain immunotoxins, Additionally, although BD1-G28-5 sFv effectively killed CD40-expressing hematologic malignancies, its lack of activity against CD40-expressing carcinomas suggests that CD40-mediated trafficking of BD1 differs in the two cancer types.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL IMMUNOL,SEATTLE,WA 98121	Bristol-Myers Squibb								ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARIANSEN S, 1993, BIOCHEMISTRY-US, V32, P83, DOI 10.1021/bi00052a012; BETTER M, 1995, J BIOL CHEM, V270, P14951, DOI 10.1074/jbc.270.25.14951; BRINKMANN U, 1994, BBA-REV CANCER, V1198, P27, DOI 10.1016/0304-419X(94)90004-3; CASELLAS P, 1984, J BIOL CHEM, V259, P9359; COOK JP, 1993, BIOCONJUGATE CHEM, V4, P440, DOI 10.1021/bc00024a005; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Francisco JA, 1997, BLOOD, V89, P4493, DOI 10.1182/blood.V89.12.4493; FRANCISCO JA, 1995, CANCER RES, V55, P3099; Francisco JA, 1996, J IMMUNOL, V157, P1652; FRANKEL AE, 1995, SEMIN CANCER BIOL, V6, P307, DOI 10.1006/scbi.1995.0039; FRIEDMAN PN, 1993, CANCER RES, V53, P334; Gawlak SL, 1997, BIOCHEMISTRY-US, V36, P3095, DOI 10.1021/bi962474+; GROSSBARD ML, 1993, J CLIN ONCOL, V11, P726, DOI 10.1200/JCO.1993.11.4.726; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; HONJO T, 1968, J BIOL CHEM, V243, P3553; IGLEWSKI BH, 1977, INFECT IMMUN, V15, P138, DOI 10.1128/IAI.15.1.138-144.1977; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OGRADY JT, 1994, AM J PATHOL, V144, P21; Pai LH, 1996, NAT MED, V2, P350, DOI 10.1038/nm0396-350; Pammer J, 1996, AM J PATHOL, V148, P1387; PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23; PELLATDECEUNYNCK C, 1994, BLOOD, V84, P2597, DOI 10.1182/blood.V84.8.2597.bloodjournal8482597; PRESS OW, 1991, BIOTHERAPY, V3, P65, DOI 10.1007/BF02175100; Przepiorka D, 1995, BONE MARROW TRANSPL, V16, P737; RAMAKRISHNAN S, 1984, SCIENCE, V223, P58, DOI 10.1126/science.6318313; SIEGALL CB, 1995, DRUG DEVELOP RES, V34, P210, DOI 10.1002/ddr.430340210; SIEGALL CB, 1994, BIOCONJUGATE CHEM, V5, P423, DOI 10.1021/bc00029a008; SIEGALL CB, 1991, BIOCHEMISTRY-US, V30, P7154, DOI 10.1021/bi00243a016; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STIRPE F, 1986, BIOCHEM J, V240, P659, DOI 10.1042/bj2400659; Stone MJ, 1996, BLOOD, V88, P1188, DOI 10.1182/blood.V88.4.1188.bloodjournal8841188; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Thomas WD, 1996, INT J CANCER, V68, P795, DOI 10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; UCKUN FM, 1990, BLOOD, V76, P2449; VITETTA ES, 1991, CANCER RES, V51, P4052	38	25	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24165	24169		10.1074/jbc.272.39.24165	http://dx.doi.org/10.1074/jbc.272.39.24165			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305866	hybrid			2022-12-27	WOS:A1997XY51500017
J	Salinas, M; Duprat, F; Heurteaux, C; Hugnot, JP; Lazdunski, M				Salinas, M; Duprat, F; Heurteaux, C; Hugnot, JP; Lazdunski, M			New modulatory alpha subunits for mammalian Shab K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELAYED-RECTIFIER PROPERTIES; GATED POTASSIUM CHANNELS; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; XENOPUS-OOCYTES; MESSENGER-RNA; MOUSE-BRAIN; RAT-BRAIN; CATION CHANNEL; GENE	Two novel K+ channel alpha subunits, named Kv9,1 and Kv9,2, have been cloned, The Kv9,2 gene is situated in the 8q22 region of the chromosome, mRNAs for these two subunits are highly and selectively expressed in the nervous system, High levels of expressions are found in the olfactory bulb, cerebral cortex, hippocampal formation, habenula, basolateral amygdaloid nuclei, and cerebellum, Interestingly Kv9.1 and Kv9,2 colocalized with Kv2,1 and/or Kv2,2 alpha subunits in several regions of the brain, Neither Kv9,1 nor Kv9,2 have K+ channel activity by themselves, but both modulate the activity of Kv2,1 and Kv2,2 channels by changing kinetics and levels of expression and by shifting the half-inactivation potential to more polarized values, This report also analyzes the changes in electrophysiological properties of Kv2 subunits induced by Kv5,1 and Kv6,1, two other modulatory subunits, Each modulatory subunit has its own specific properties of regulation of the functional Kv2 subunits, and they can lead to extensive inhibitions, to large changes in kinetics, and/or to large shifts in the voltage dependencies of the inactivation process, The increasing number of modulatory subunits for Kv2,1 and Kv2,2 provides an amazingly new capacity of functional diversity.	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			SALINAS, Miguel/N-6380-2016; HEURTEAUX, Catherine/M-4947-2016; Duprat, Fabrice/D-1221-2013	SALINAS, Miguel/0000-0002-7445-123X; HEURTEAUX, Catherine/0000-0002-9741-9777; Duprat, Fabrice/0000-0001-8774-1220				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATTALI B, 1992, J BIOL CHEM, V267, P8650; ATTALI B, 1993, J BIOL CHEM, V268, P24283; Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Biel M, 1996, J BIOL CHEM, V271, P6349, DOI 10.1074/jbc.271.11.6349; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CHANDY KG, 1995, VOLTAGE GATES K PLUS; Chen ML, 1996, NEURON, V17, P535, DOI 10.1016/S0896-6273(00)80185-3; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; CHRISTIE MJ, 1990, NEURON, V2, P405; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEMIERA EV, 1992, P ROY SOC LOND B BIO, V248, P9, DOI [DOI 10.1098/RSPB.1992.0036, 10.1098/rspb.1992.0036]; DREWE JA, 1992, J NEUROSCI, V12, P538; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEURTEAUX C, 1993, MOL BRAIN RES, V18, P17, DOI 10.1016/0169-328X(93)90169-P; Hille B., 1992, IONIC CHANNELS EXCIT; Hille Bertil, 1994, P75; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; HWANG PM, 1993, NEUROSCIENCE, V55, P613, DOI 10.1016/0306-4522(93)90427-H; HWANG PM, 1992, NEURON, V8, P473, DOI 10.1016/0896-6273(92)90275-I; Jegla T, 1997, J NEUROSCI, V17, P32, DOI 10.1523/JNEUROSCI.17-01-00032.1997; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, EUR J BIOCHEM, V216, P679, DOI 10.1111/j.1432-1033.1993.tb18188.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOPATIN AN, 1993, J PHARMACOL EXP THER, V265, P1011; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; PAK MD, 1991, J NEUROSCI, V11, P869; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; PATIL N, 1995, NAT GENET, V11, P126, DOI 10.1038/ng1095-126; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; PONGS O, 1993, J MEMBRANE BIOL, V136, P1; Post MA, 1996, FEBS LETT, V399, P177, DOI 10.1016/S0014-5793(96)01316-6; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; Salinas M, 1997, J BIOL CHEM, V272, P8774, DOI 10.1074/jbc.272.13.8774; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SHAHIDULLAH M, 1995, FEBS LETT, V371, P307, DOI 10.1016/0014-5793(95)00928-3; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WILSON GG, 1994, PFLUG ARCH EUR J PHY, V428, P186, DOI 10.1007/BF00374857; Wood S, 1993, Cytogenet Cell Genet, V64, P134; ZHAO B, 1994, NEURON, V13, P1205, DOI 10.1016/0896-6273(94)90058-2	56	163	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24371	24379		10.1074/jbc.272.39.24371	http://dx.doi.org/10.1074/jbc.272.39.24371			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305895	hybrid			2022-12-27	WOS:A1997XY51500046
J	January, B; Seibold, A; Whaley, B; Hipkin, RW; Lin, D; Schonbrunn, A; Barber, R; Clark, RB				January, B; Seibold, A; Whaley, B; Hipkin, RW; Lin, D; Schonbrunn, A; Barber, R; Clark, RB			beta(2)-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DEPENDENT PROTEIN-KINASE; ADENYLATE-CYCLASE; HETEROLOGOUS DESENSITIZATION; BETA-2-ADRENERGIC RECEPTOR; S49-LYMPHOMA CELLS; COUPLED RECEPTORS; LYMPHOMA-CELLS; WILD-TYPE; STIMULATION	Previous studies indicated that partial agonists cause less desensitization of the beta(2)-adrenergic receptor (beta AR) than full agonists; however, the molecular basis for this in intact cells has not been investigated, In the present work, we have determined the rates of desensitization, internalization, and phosphorylation caused by a series of beta AR agonists displaying a 95-fold range of coupling efficiencies, These studies were performed with HEK-293 cells overexpressing the beta AR with hemagglutinin and 6-histidine epitopes introduced into the N and C termini, respectively, This modified beta AR behaved identically to the wild type receptor with regard to agonist K-d, coupling efficiency, and desensitization. The coupling efficiencies for beta AR agonist activation of adenylyl cyclase relative to epinephrine (100%) were 4.2% for fenoterol, 4.9% for albuterol, 2.5% for dobutamime, and 1.1% for ephedrine, At concentrations of these agonists yielding >90% receptor occupancy, the rate and extent (0-30 min) of agonist-induced desensitization of beta AR activation of adenylyl cyclase followed the same order as coupling efficiency, i.e. epinephrine greater than or equal to fenoterol > albuterol > dobutamine > ephedrine, The rate of internalization of the beta AR with respect to these agonists also followed the same order as the desensitization and exhibited a slight lag, Like internalization and desensitization, beta AR phosphorylation exhibited a dependence on agonist strength. The two strongest agonists, epinephrine and fenoterol, provoked 11-13-fold increases in the level of beta AR phosphorylation after just 1 min, whereas the weak agonists dobutamine and ephedrine caused only 3-4-fold increases, similar to levels induced by cAMP-dependent protein kinase activation with forskolin. With longer treatment times, the level of beta AR phosphorylation declined with strong agonists, but it progressively increased with the weaker partial agonists, such that after 30 min the -fold elevation with epinephrine (6.2 +/- 0.82) was not appreciably different from ephedrine (5.0 +/- 0.96) and significantly less than that caused by albuterol (10.4 +/- 1.7), In summary, our results demonstrate an excellent proportionality between the agonist strength and agonist-induced desensitization, internalization, and the rapid initial phase of phosphorylation. The data support the hypothesis that increasing agonist-coupling efficiency primarily affects desensitization by increasing the rate of beta ARK phosphorylation of the beta AR.	UNIV TEXAS,SCH MED,DEPT INTEGRAT BIOL PHARMACOL & PHYSIOL,HOUSTON,TX 77225	University of Texas System					NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031208] Funding Source: NIH RePORTER; NCRR NIH HHS [RR07710] Funding Source: Medline; NIGMS NIH HHS [GM31208] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; BAROVSKY K, 1980, J CYCLIC NUCL PROT, V6, P297; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CHEUNG AH, 1988, MOL PHARMACOL, V34, P132; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1986, ADV CYCLIC NUCL PROT, V20, P151; Clark RB, 1996, MOL PHARMACOL, V49, P182; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HOYER D, 1984, MOL PHARMACOL, V25, P209; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Krumins AM, 1997, MOL PHARMACOL, V52, P144, DOI 10.1124/mol.52.1.144; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PROLL MA, 1992, MOL PHARMACOL, V42, P116; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SLOWIEJKO DM, 1994, J NEUROCHEM, V62, P1795; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; SU YF, 1980, J BIOL CHEM, V255, P7410; TOWES ML, 1908, J BIOL CHEM, V259, P2227; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WALDO GL, 1983, J BIOL CHEM, V258, P3900; Whaley B. S., 1995, PHARM COMMUN, V6, P203; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; YU SS, 1993, J BIOL CHEM, V268, P337; YUAN NY, 1994, J BIOL CHEM, V269, P23032	38	133	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23871	23879		10.1074/jbc.272.38.23871	http://dx.doi.org/10.1074/jbc.272.38.23871			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295336	hybrid			2022-12-27	WOS:A1997XX38100061
J	Owczarek, CM; Hwang, SY; Holland, KA; Gulluyan, LM; Tavaria, M; Weaver, B; Reich, NC; Kola, I; Hertzog, PJ				Owczarek, CM; Hwang, SY; Holland, KA; Gulluyan, LM; Tavaria, M; Weaver, B; Reich, NC; Kola, I; Hertzog, PJ			Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA RECEPTOR; BINDING; CELLS; EXPRESSION; SUBUNIT; GENE; RESPONSES; SITE	This report describes the cloning of cDNAs encoding transmembrane and soluble isoforms of a novel chain of the murine type I interferon (IFN) receptor and characterization of its capability to bind ligand and transduce signals, The transmembrane receptor (murine IFNAR 2c) has an extracellular domain of 215 amino acids and an intracellular domain of 250 amino acids, with 48% amino acid and 71% nucleotide identity with human IFNAR 2c, The cDNA for the soluble murine receptor (IFNAR 2a) encodes a 221-amino acid polypeptide identical to the first 210 amino acids of IFNAR 2c plus a novel 11 amino acids, Northern blot analyses show that murine IFNAR 2 is expressed as two transcripts of 4 kilobases encoding the transmembrane isoform and 1.5 kilobases encoding the more abundant soluble isoform, Studies using primary murine cells that lack IFNAR 1 show that IFNAR 2 is expressed, and cells bind type I IFN ligand, but do not transduce signals as detected by electrophoretic mobility shift assays of ISGF3 or GAF complexes binding to their cognate oligonucleotides, These cells show no effects on the ability of IFN gamma to activate these complexes, These studies demonstrate that the IFNAR 2 transmembrane (2c) and soluble (2a) isoforms are conserved between the human and mouse and that IFNAR 2c has intrinsic ligand binding activity, but no intrinsic signal transducing activity as measured in this study.	MONASH UNIV, INST REPROD & DEV, MOL GENET & DEV GRP, CLAYTON, VIC 3168, AUSTRALIA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	Monash University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Kola, Ismail/C-5254-2013; Hertzog, Paul J/I-7053-2013; Hertzog, Paul J/G-6734-2013	Hertzog, Paul J/0000-0002-1373-8472; Hertzog, Paul J/0000-0002-1373-8472	NCI NIH HHS [CA50773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050773, R29CA050773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HAMILTON JA, 1996, J IMMUNOL, V156, P2533; HERTZOG PJ, 1991, CLIN IMMUNOL IMMUNOP, V58, P18, DOI 10.1016/0090-1229(91)90145-Z; HERTZOG PJ, 1994, J BIOL CHEM, V269, P14088; Holland KA, 1997, J BIOL CHEM, V272, P21045, DOI 10.1074/jbc.272.34.21045; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; Hwang SY, 1996, INT J BIOCHEM CELL B, V28, P911, DOI 10.1016/1357-2725(96)00023-4; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; LUTFALLA G, 1995, EMBO J, V14, P101; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MULLERSMAN JE, 1995, J INTERF CYTOK RES, V15, P815, DOI 10.1089/jir.1995.15.815; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; ROBERTS RM, 1991, SERONO SYMP, P235; RUSSELLHARDE D, 1995, J BIOL CHEM, V270, P26033, DOI 10.1074/jbc.270.44.26033; SOH JM, 1994, J BIOL CHEM, V269, P18102; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERFERON CYTOKIN, V25, P3; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4	29	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23865	23870		10.1074/jbc.272.38.23865	http://dx.doi.org/10.1074/jbc.272.38.23865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295335	hybrid			2022-12-27	WOS:A1997XX38100060
J	Roth, A; Kreienkamp, HJ; Meyerhof, W; Richter, D				Roth, A; Kreienkamp, HJ; Meyerhof, W; Richter, D			Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GASTRIN-RELEASING PEPTIDE; BETA-ADRENERGIC-RECEPTOR; CHOLINERGIC RECEPTORS; PITUITARY-CELLS; ARRESTIN; ENDOCYTOSIS; BINDING; PHOSPHATASE; KINASES	Agonist-dependent internalization of the rat somatostatin receptor subtype 3 (SSTR3) requires four hydroxyl amino acids (Ser(341), Ser(346), Ser(351), and Thr(357)) in the receptor C terminus (Roth, A., Kreienkamp, H.-J., Nehring, R., Roostermann, D., Meyerhof, W. and Richter, D. (1997) DNA Cell Biol. 16, 111-119). Here we report on the molecular mechanism responsible for the endocytotic process by analyzing the agonist-dependent phosphorylation of wild-type and mutant receptors expressed in human embryonic kidney cells, Wild-type SSTR3 is phosphorylated in response to agonist treatment, Phosphorylation is markedly reduced in a S341A/S346A/S351A triple mutant and is also reduced, but to a lesser extent, in the T357A point mutant. Internalization of the wild-type receptor is preceded by a functional desensitization of the receptor; in contrast, the triple serine mutant does not desensitize after treatment with agonists as assayed by its ability to inhibit forskolin-stimulated adenylate cyclase activity, After internalization via a clathrin-coated vesicle mediated endocytotic pathway, SSTR3 efficiently recycles to the cell surface, suggesting that agonist mediated endocytosis is necessary for the functional resensitization of a phosphorylated and desensitized receptor.	UNIV HAMBURG,INST ZELLBIOCHEM & KLIN NEUROBIOL,D-20246 HAMBURG,GERMANY; DEUTSCH INST ERNAHRUNGSFORSCH,ABT MOL GENET,D-14558 POTSDAM,GERMANY	University of Hamburg; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)								BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERELOWITZ M, 1995, ENDOCRINOLOGY, V136, P3695, DOI 10.1210/en.136.9.3695; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HIGUCHI R, 1992, PCR PROTOCOLS GUIDE, P177; HOFLAND LJ, 1995, ENDOCRINOLOGY, V136, P3698, DOI 10.1210/en.136.9.3698; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; John M, 1996, GUT, V38, P33, DOI 10.1136/gut.38.1.33; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; MAYOR F, 1987, J BIOL CHEM, V262, P6468; NEHRING RB, 1995, DNA CELL BIOL, V14, P939, DOI 10.1089/dna.1995.14.939; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; PRESKY DH, 1988, J BIOL CHEM, V263, P714; PRESKY DH, 1986, J CELL BIOL, V102, P878, DOI 10.1083/jcb.102.3.878; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; Roth A., 1996, Society for Neuroscience Abstracts, V22, P1298; YASUDA K, 1992, J BIOL CHEM, V267, P20422; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	31	77	82	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23769	23774		10.1074/jbc.272.38.23769	http://dx.doi.org/10.1074/jbc.272.38.23769			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295322	hybrid			2022-12-27	WOS:A1997XX38100047
J	Wang, ZG; Wu, XH; Friedberg, EC				Wang, ZG; Wu, XH; Friedberg, EC			Molecular mechanism of base excision repair of uracil-containing DNA in yeast cell-free extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC ENDONUCLEASE; 5'-TERMINAL DEOXYRIBOSE-PHOSPHATE; ESCHERICHIA-COLI; POLYMERASE-BETA; SACCHAROMYCES-CEREVISIAE; BOVINE TESTIS; HOMOLOG; GENE; PURIFICATION; RESIDUES	Base excision repair (BER) constitutes a ubiquitous excision repair mechanism, which is responsible for the removal of multiple types of damaged and inappropriate bases in DNA. We have employed a yeast cell-free system to examine the biochemical mechanism of the BER pathway in lower eukaryotes. Using uracil-containing DNA as a model substrate, we demonstrate that yeast BER requires Apn1 protein, an Escherichia coli endonuclease IV homolog. In extracts of an apn1 deletion mutant, the 5'-incision at AP (apurinic/apyrimidinic) sites is not detectable, supporting the notion that yeast contains only one major 5'-AP endonuclease. The processing of the 5'-deoxyribose phosphate moieties was found to be a rate-limiting step. During BER of uracil-containing DNA, repair patch sizes of 1-5 nucleotides were detected, with single nucleotide repair patches predominant.	UNIV TEXAS,SW MED CTR,DEPT PATHOL,LAB MOL PATHOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, ZG (corresponding author), UNIV KENTUCKY,GRAD CTR TOXICOL,LEXINGTON,KY 40536, USA.				NATIONAL CANCER INSTITUTE [R55CA067978, R37CA012428, R01CA067978, R01CA012428] Funding Source: NIH RePORTER; NCI NIH HHS [CA67978, CA12428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Budd ME, 1995, METHOD ENZYMOL, V262, P108; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; JOHSON RE, 1995, SCIENCE, V269, P238; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LINDAHL T, 1973, BIOCHEMISTRY-US, V12, P5151, DOI 10.1021/bi00749a020; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Sander M, 1997, BIOCHEMISTRY-US, V36, P6100, DOI 10.1021/bi970048y; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P3694, DOI 10.1021/bi00129a019; Wang Zhigang, 1995, Methods (Orlando), V7, P177, DOI 10.1006/meth.1995.1023	40	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					24064	24071		10.1074/jbc.272.38.24064	http://dx.doi.org/10.1074/jbc.272.38.24064			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295360	hybrid			2022-12-27	WOS:A1997XX38100085
J	Gao, EW; Wang, Y; Alcorn, JL; Mendelson, CR				Gao, EW; Wang, Y; Alcorn, JL; Mendelson, CR			The basic helix-loop-helix-zipper transcription factor USF1 regulates expression of the surfactant protein-A gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR USF; MAJOR LATE PROMOTER; BINDING-PROTEINS; DEVELOPMENTAL REGULATION; PULMONARY SURFACTANT; MULTIPLE FORMS; FETAL LUNG; C-MYC; UPSTREAM; ELEMENTS	Expression of the rabbit pulmonary surfactant protein A (SP-A) gene is lung-specific, occurs primarily in type II cells, and is developmentally regulated. We previously identified two E-box-like enhancers, termed the distal binding element (DBE) and proximal binding element (PBE), in the 5'-flanking region of the rabbit SP-A gene. In the present study, the PBE was used to screen a rabbit fetal lung cDNA expression library; a cDNA insert was isolated which is highly similar in sequence to human upstream stimulatory factor 1 (hUSF1). By use of reverse transcription polymerase chain reaction, two isoforms of rabbit USF1 (rUSF1) mRNAs were identified in fetal rabbit lung and other tissues. The levels of rUSF1 mRNAs reach a peak in fetal rabbit lung at 23 days gestation, in concert with the time of initiation of SP-A gene transcription, Binding complexes of nuclear proteins obtained from fetal rabbit lung tissue and isolated type II cells with the DBE and PBE were supershifted by the addition of anti-rUSF1 IgG. Binding activity was enriched in type II cells compared with lung fibroblasts. Overexpression of rUSF1s in A549 adenocarcinoma cells positively regulated SP-A promoter activity of cotransfected reporter gene constructs, It is suggested that rUSF1s, which bind to two E-box elements in the SP-A gene 5'-flanking-region, may serve a key role in the regulation of SP-A gene expression in pulmonary type II cells.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Mendelson, Carole Ruth/0000-0003-1696-9791	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050022] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL50022] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORN JL, 1993, MOL ENDOCRINOL, V7, P1072, DOI 10.1210/me.7.8.1072; AUTEN RL, 1990, AM J RESP CELL MOL, V3, P491, DOI 10.1165/ajrcmb/3.5.491; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BOGGARAM V, 1988, J BIOL CHEM, V263, P19060; BOGGARAM V, 1988, J BIOL CHEM, V263, P2939; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRESNICK EH, 1994, J BIOL CHEM, V269, P21110; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P937; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GAO E, 1993, J BIOL CHEM, V268, P19697; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Harlow E., 1988, ANTIBODIES LAB MANUA; HAWGOOD S, 1991, ANNU REV PHYSIOL, V53, P375, DOI 10.1146/annurev.ph.53.030191.002111; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; MENDELSON CR, 1993, SEMIN PERINATOL, V17, P223; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MICHAEL LF, 1996, MOL ENDOCRINOL, V10, P8159; Miller J.H., 1972, EXPT MOL GENETICS; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; PATERSON JM, 1995, BIOCHEM J, V310, P401, DOI 10.1042/bj3100401; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; Rose MD, 1988, LAB COURSE MANUAL ME; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIEH BH, 1993, GENOMICS, V16, P266, DOI 10.1006/geno.1993.1174; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH IS, 1994, MOL ENDOCRINOL, V8, P1163, DOI 10.1210/me.8.9.1163; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Young PP, 1997, MOL ENDOCRINOL, V11, P1082, DOI 10.1210/me.11.8.1082	43	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23398	23406		10.1074/jbc.272.37.23398	http://dx.doi.org/10.1074/jbc.272.37.23398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287355	hybrid			2022-12-27	WOS:A1997XV74400066
J	You, M; Zhao, ZZ				You, M; Zhao, ZZ			Positive effects of SH2 domain-containing tyrosine phosphatase SHP-1 on epidermal growth factor- and interferon-gamma-stimulated activation of STAT transcription factors in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; GENE-EXPRESSION; PHOSPHORYLATION; KINASE; PTP1C; PATHWAY; FAMILY; DEPHOSPHORYLATION; ASSOCIATION	SHP-1 (also known as PTP1C, SHPTP-1, SHP, and HCP) is an SH2 domain-containing protein-tyrosine phosphatase. We have stably overexpressed the native form and a catalytically inactive cysteine to serine mutant of the enzyme, SHP-1-(Cys --> Ser), in human cervical carcinoma HeLa cells, Following stimulation of the cells with epidermal growth factor (EGF) and interferon-gamma (INF-gamma), signal transducers and activators of transcription (STAT) activity was analyzed by using two P-32-labeled DNA probes, namely hSIE which is derived from a high affinity mutant form of the serum-inducible element in the c-fos promotor and GAS which resembles the INF-gamma activation site, EGF induced hSIE binding activity only, and the activity was suppressed by similar to 70% when the inactive mutant. form of SHP-1 was expressed but was essentially unaffected by expression of the native enzyme. INF-gamma treatment resulted in appearance of both hSIE and GAS binding activities. While expression of the inactive mutant reduced the activities by 30-50%, the native enzyme caused a 20-30% increase. Consistent with effects on STAT activation, altered SHP-1 expression also affected EGF-induced activation of the mitogen-activated protein kinase pathway; expression of SHP-1-(Cys --> Ser) inhibited activity of MEK by similar to 25%, whereas expression of SHP-1 resulted in a similar to 25% increase. Further studies revealed that overexpression of SHP-1 caused decreased tyrosine phosphorylation of the EGF receptor and that EGF induced phosphorylation and recruitment of SHP-1. Together, the data suggest that SHP-1 is positively involved in EGF-and INF-gamma-induced STAT activation in non-hematopoietic HeLa cells and that, in the EGF signaling system, SHP-1 functions at least partly by modulating tyrosine phosphorylation of EGF receptor.	VANDERBILT UNIV,DEPT VET AFFAIRS MED CTR,DEPT MED,DIV HEMATOL,NASHVILLE,TN 37232	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University			You, Min/I-4973-2012	You, Min/0000-0003-1977-3479				Adachi M, 1996, CELL, V85, P15; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO Z, 1995, ADV PROT PHOSPHATASE, V9, P297; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	36	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23376	23381		10.1074/jbc.272.37.23376	http://dx.doi.org/10.1074/jbc.272.37.23376			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287352	hybrid			2022-12-27	WOS:A1997XV74400063
J	ChapmanSmith, A; Forbes, BE; Wallace, JC; Cronan, JE				ChapmanSmith, A; Forbes, BE; Wallace, JC; Cronan, JE			Covalent modification of an exposed surface turn alters the global conformation of the biotin carrier domain of Escherichia coli acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE MULTIENZYME COMPLEX; YEAST PYRUVATE-CARBOXYLASE; LIPOYL DOMAIN; 3-DIMENSIONAL STRUCTURE; H-PROTEIN; SEQUENCE; SUBUNIT; PURIFICATION; REPRESSOR; COENZYME	We have studied the apo (unbiotinylated) and hole (biotinylated) forms of BCCP87, an 87-residue COOH-terminal peptide comprising the biotin carrier domain of the biotin carboxyl carrier protein subunit of Escherichia coli acetyl-CoA carboxylase. The apo; protein spontaneously formed disulfide-linked dimers and was modified readily by sulfhydryl reagents, whereas the hole protein remained monomeric and was unreactive toward sulfhydryl reagents unless a protein denaturant was present, These data indicated that the single cysteine residue of the domain (Cys-116) was much more reactive in the apo form of the protein. Incubation of apoBCCP87 with biotin ligase for different times, followed by reaction with fluorescein-5-maleimide, clearly showed that the loss of Cys-116 reactivity was the result of modification with biotin, In addition, reaction of Cys-116 with 5,5'-dithiobis(2-nitrobenzoic acid) showed that apoBCCP87 denatured at lower urea concentrations than holoBCCP87. We also found that apoBCCP87 was at least 10-fold more sensitive than the hole form to proteolysis by a range of proteases, Identification of the cleavage sites indicated that the differences in protease sensitivity could not be attributed to shielding of susceptible bonds by the biotin moiety of the hole protein, These data indicate that a conformational change accompanies biotinylation of the biotin domain. Thus, modification of a beta-turn protruding from the protein surface results in alteration of the overall structure of this protein domain.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	ChapmanSmith, A (corresponding author), UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA.		, John/AAP-5150-2020; Cronan, John/V-6626-2019; Forbes, Briony/R-1838-2019	Forbes, Briony/0000-0003-4360-9927	NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P831; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DARDEL F, 1991, EUR J BIOCHEM, V201, P203, DOI 10.1111/j.1432-1033.1991.tb16275.x; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; EISENBERG MA, 1982, J BIOL CHEM, V257, P5167; FALL RR, 1973, J BIOL CHEM, V248, P2078; FALL RR, 1972, J BIOL CHEM, V247, P8005; FONTANA A, 1997, J MOL BIOL, V266, P228; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; LI SJ, 1992, J BIOL CHEM, V267, P855; LIM F, 1988, J BIOL CHEM, V263, P11493; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; NERVI AM, 1971, ARCH BIOCHEM BIOPHYS, V143, P401, DOI 10.1016/0003-9861(71)90227-X; PARES S, 1994, P NATL ACAD SCI USA, V91, P4850, DOI 10.1073/pnas.91.11.4850; REED KE, 1991, J BIOL CHEM, V266, P11425; ROBERTS EL, 1996, THESIS U CAMBRIDGE C; SAMOLS D, 1988, J BIOL CHEM, V263, P6461; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHMID FX, 1989, PROTEIN STRUCTURE PR, P265; SUTTON MR, 1977, J BIOL CHEM, V252, P3934; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; Xu Y, 1995, BIOCHEMISTRY-US, V34, P16624, DOI 10.1021/bi00051a010	29	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					26017	26022		10.1074/jbc.272.41.26017	http://dx.doi.org/10.1074/jbc.272.41.26017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325338	hybrid			2022-12-27	WOS:A1997YA35800093
J	Williams, JA; Shacter, E				Williams, JA; Shacter, E			Regulation of macrophage cytokine production by prostaglandin E-2 - Distinct roles of cyclooxygenase-1 and -2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ENDOPEROXIDE SYNTHASE CYCLOOXYGENASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MATRIX METALLOPROTEINASE PRODUCTION; ARACHIDONIC-ACID METABOLITES; SWISS 3T3 CELLS; INDUCIBLE CYCLOOXYGENASE; MESSENGER-RNA; PERITONEAL-MACROPHAGES; RHEUMATOID-ARTHRITIS	Prostaglandin E-2 (PGE(2)) modulates a variety of physiological processes including the production of inflammatory cytokines. There are two cyclooxygenase (Cox) enzymes, Cox-1 and Cox-2, that are responsible for initiating PGE(2) synthesis. These isozymes catalyze identical biosynthetic reactions but are regulated by different mechanisms in the cell. This report examines differ differences in the roles of Cox-1 and Cox-2 in regulating cytokine synthesis in macrophages. We employed agents that selectively modulate the activity of each isozyme and measured their effects on synthesis of interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha by peritoneal macrophages. Among these three cytokines, only IL-6 synthesis was stimulated by production of endogenous PGE(2). This effect was specifically linked to activation of Cox-2 and not Cox-1. The specificity derives, partly, from the timing of the production of PGE(2) following stimulation of each isozyme and from induction of ancillary signals that control the response to PGE(2). The experimental findings demonstrate that the effects of Cox-1 and Cox-2 activity on macrophage IL-6 synthesis are segregated. This provides a mechanism for IL-6 to be induced selectively during inflammation.	US FDA,CBER,HFM 538,IMMUNOL LAB,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; BHARDWAJ N, 1989, J IMMUNOL, V143, P2153; BRANDWEIN SR, 1986, J BIOL CHEM, V261, P8624; CALLERY MP, 1990, J SURG RES, V48, P523, DOI 10.1016/0022-4804(90)90224-P; CORCORAN ML, 1994, ARCH BIOCHEM BIOPHYS, V310, P481, DOI 10.1006/abbi.1994.1196; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; ERTEL W, 1991, ANN SURG, V214, P141, DOI 10.1097/00000658-199108000-00008; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FIEREN MWJ, 1991, IMMUNOL LETT, V31, P85; FLETCHER JR, 1993, ARCH SURG-CHICAGO, V128, P1192; FU JY, 1990, J BIOL CHEM, V265, P16737; FUTAKI N, 1993, J PHARM PHARMACOL, V45, P753, DOI 10.1111/j.2042-7158.1993.tb07103.x; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GOSS JA, 1993, AM J PHYSIOL, V264, pG601, DOI 10.1152/ajpgi.1993.264.4.G601; GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921; HABIB A, 1993, J BIOL CHEM, V268, P23448; HELLE M, 1988, EUR J IMMUNOL, V18, P1535, DOI 10.1002/eji.1830181010; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hinson RM, 1996, P NATL ACAD SCI USA, V93, P4885, DOI 10.1073/pnas.93.10.4885; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; HUMES JL, 1977, NATURE, V269, P149, DOI 10.1038/269149a0; KARGMAN SL, 1995, CANCER RES, V55, P2556; KASSIS S, 1989, AGENTS ACTIONS, V27, P274, DOI 10.1007/BF01972795; KOMATSU H, 1981, INT J IMMUNOPHARMACO, V13, P1137; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUNKEL SL, 1986, J IMMUNOL, V136, P186; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LEE SH, 1992, J BIOL CHEM, V267, P25934; LEISTEN JC, 1990, CLIN IMMUNOL IMMUNOP, V56, P108, DOI 10.1016/0090-1229(90)90174-O; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MEHINDATE K, 1995, J IMMUNOL, V155, P3570; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OGLE CK, 1994, INFLAMMATION, V18, P175, DOI 10.1007/BF01534558; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PHILLIPS TA, 1993, J LEUKOCYTE BIOL, V53, P411, DOI 10.1002/jlb.53.4.411; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; PRUIMBOOM WM, 1994, IMMUNOL LETT, V41, P255, DOI 10.1016/0165-2478(94)90142-2; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RENZ H, 1988, J IMMUNOL, V141, P2388; Richardson C, 1996, DRUG SAFETY, V15, P249, DOI 10.2165/00002018-199615040-00003; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; Rola-Pleszczynski M, 1992, Mediators Inflamm, V1, P5, DOI 10.1155/S0962935192000024; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; ROTH GJ, 1994, BLOOD, V83, P885; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; SEIBERT K, 1994, RECEPTOR, V4, P17; SHACTER E, 1987, J IMMUNOL METHODS, V99, P259, DOI 10.1016/0022-1759(87)90136-0; SHACTER E, 1993, BLOOD, V82, P2853; SHACTER E, 1988, CARCINOGENESIS, V9, P2297, DOI 10.1093/carcin/9.12.2297; SHACTER E, 1992, BLOOD, V80, P194; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; SPENGLER RN, 1989, J IMMUNOL, V142, P4346; THEISENPOPP P, 1992, INT J IMMUNOPHARMACO, V14, P565, DOI 10.1016/0192-0561(92)90117-4; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	67	157	161	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	1997	272	41					25693	25699		10.1074/jbc.272.41.25693	http://dx.doi.org/10.1074/jbc.272.41.25693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YA358	9325293	hybrid			2022-12-27	WOS:A1997YA35800048
J	Heyeck, SD; Wilcox, HM; Bunnell, SC; Berg, LJ				Heyeck, SD; Wilcox, HM; Bunnell, SC; Berg, LJ			Lck phosphorylates the activation loop tyrosine of the Itk kinase domain and activates Itk kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; ATP-BINDING SITE; TEC FAMILY KINASE; SRC FAMILY; PROTEIN-KINASE; T-CELLS; GENE; IDENTIFICATION; BTK	The Tec family tyrosine kinase Itk has been implicated in T cell receptor (TCR) signaling, yet its precise role and mechanism of activation remain undefined. To investigate these issues, we examined the biochemical response of Itk to TCR stimulation. We found that Itk is tyrosine-phosphorylated after TCR cross-linking and that this phosphorylation depends on the presence of functional Lck. To determine if this Lck dependence results from direct phosphorylation of Itk by Lck, we generated recombinant Itk and Lck using a baculovirus expression system and used these proteins in subsequent biochemical analyses, We found that Lck phosphorylates Itk upon co-expression in insect cells and, further, that this phosphorylation of Itk results in increased Itk in vitro kinase activity. The major site of Lck phosphorylation on Itk was mapped to the conserved tyrosine (Tyr(511)) in the activation loop of the Itk kinase domain. Substitution of this tyrosine with phenylalanine abolishes Itk kinase activity in insect cells, indicating that phosphorylation at this site plays a critical role in regulating Itk function.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University				Bunnell, Stephen/0000-0001-6887-0828	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037584] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37584] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V2; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; Gibson S, 1996, J IMMUNOL, V156, P2716; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; GIBSON S, 1993, BLOOD, V82, P1561; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; King PD, 1997, J IMMUNOL, V158, P580; King PD, 1996, INT IMMUNOL, V8, P1707, DOI 10.1093/intimm/8.11.1707; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Watts JD, 1996, FEBS LETT, V398, P217, DOI 10.1016/S0014-5793(96)01241-0; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x	44	134	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					25401	25408		10.1074/jbc.272.40.25401	http://dx.doi.org/10.1074/jbc.272.40.25401			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312162	hybrid			2022-12-27	WOS:A1997XY97000101
J	Vishnevetsky, M; Ovadis, M; Itzhaki, H; Vainstein, A				Vishnevetsky, M; Ovadis, M; Itzhaki, H; Vainstein, A			CHRC, encoding a chromoplast-specific carotenoid-associated protein, is an early gibberellic acid-responsive gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUCUMIS-SATIVUS COROLLAS; PHYTOENE SYNTHASE; BARLEY ALEURONE; EXPRESSION; PETUNIA; TRANSDUCTION; BIOGENESIS; PROMOTER	CHRC, a corolla-specific carotenoid-associated protein, is a major component of carotenoid-lipoprotein complexes in Cucumis sativus chromoplasts. Using an in vitro flower bud culture system that mimics in vivo flower development, CHRC mRNA levels in corollas were shown to be specifically up regulated by gibberellic acid, The response to gibberellic acid was very rapid (within 20 min) and insensitive to protein synthesis inhibition by cycloheximide. Abscisic acid, known to antagonize gibberellin in many developmental systems, strongly down-regulated CHRC mRNA levels. The gibberellin synthesis inhibitor paclobutrazol exhibited a similar negative effect on CHRC expression. Inclusion of exogenous gibberellic acid into the in. vitro bud culture system with the paclobutrazol not only prevented the CHRC mRNA down-regulation, it up-regulated transcript accumulation to the level of gibberellic acid-treated corollas, CHRC mRNA accumulation in response to gibberellic acid displayed a dose-dependent increase up to 10(-4) M gibberellic acid, The up-regulation could be detected with as little as 10(-7) M gibberellic acid. Based on these data, we suggest that CHRC is the first structural gene identified to date whose expression is regulated by gibberellic acid in a primary fashion, The critical role of the rapid response of CHRC to gibberellic acid in aiding carotenoid sequestration while preserving chromoplast structural organization is discussed.	HEBREW UNIV JERUSALEM,FAC AGR,KENNEDY LEIGH CTR HORT RES,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,FAC AGR,OTTO WARBURG CTR BIOTECHNOL AGR,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem								Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; BARTLEY GE, 1995, PLANT CELL, V7, P1027, DOI 10.1105/tpc.7.7.1027; CHORY J, 1987, PLANT PHYSIOL, V83, P15, DOI 10.1104/pp.83.1.15; FRASER PD, 1995, PLANTA, V196, P321, DOI 10.1007/BF00201391; FRAY RG, 1995, PLANT J, V8, P693, DOI 10.1046/j.1365-313X.1995.08050693.x; GRAY JC, 1987, ADV BOT RES, V14, P25; GUBLER F, 1995, PLANT CELL, V7, P1879, DOI 10.1105/tpc.7.11.1879; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOOLEY R, 1994, PLANT MOL BIOL, V26, P1529, DOI 10.1007/BF00016489; HUTTLY AK, 1995, PHYSIOL PLANTARUM, V95, P310, DOI 10.1111/j.1399-3054.1995.tb00843.x; HUTTLY AK, 1989, EMBO J, V8, P1907, DOI 10.1002/j.1460-2075.1989.tb03593.x; KARVOUNI Z, 1995, PLANT MOL BIOL, V27, P1153, DOI 10.1007/BF00020888; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; LibalWeksler Y, 1997, PLANT PHYSIOL, V113, P59, DOI 10.1104/pp.113.1.59; MUR L, 1995, THESIS VRIJE U AMSTE; Penson SP, 1996, PLANT CELL, V8, P2325, DOI 10.1105/tpc.8.12.2325; RAVEN HP, 1992, BIOL PLANTS, P545; Sambrook J., 2002, MOL CLONING LAB MANU; Schuurink RC, 1996, PLANT PHYSIOL, V111, P371, DOI 10.1104/pp.111.2.371; SMIRRA I, 1993, PLANT PHYSIOL, V102, P491, DOI 10.1104/pp.102.2.491; Swain SM, 1996, PLANT PHYSIOL, V112, P11, DOI 10.1104/pp.112.1.11; VAINSTEIN A, 1993, PHYSIOL PLANTARUM, V89, P192, DOI 10.1111/j.1399-3054.1993.tb01805.x; VAINSTEIN A, 1994, PLANT PHYSIOL, V104, P321, DOI 10.1104/pp.104.2.321; Vishnevetsky M, 1996, PLANT J, V10, P1111, DOI 10.1046/j.1365-313X.1996.10061111.x; WEISS D, 1995, PLANT PHYSIOL, V107, P695, DOI 10.1104/pp.107.3.695	27	16	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	1997	272	40					24747	24750		10.1074/jbc.272.40.24747	http://dx.doi.org/10.1074/jbc.272.40.24747			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY970	9312067	hybrid			2022-12-27	WOS:A1997XY97000006
J	Finco, TS; Westwick, JK; Norris, JL; Beg, AA; Der, CJ; Baldwin, AS				Finco, TS; Westwick, JK; Norris, JL; Beg, AA; Der, CJ; Baldwin, AS			Oncogenic Ha-Ras-induced signaling activates NF-kappa B transcriptional activity, which is required for cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE INHIBITION; KINASE ACTIVATION; INDUCED APOPTOSIS; PROTEIN-KINASES; GENE-EXPRESSION; DNA-BINDING; C-JUN; ALPHA; PHOSPHORYLATION; INDUCTION	Ras proteins function in stimulating cell proliferation and differentiation through the activation of Raf-dependent and Raf independent signal transduction pathways and the subsequent activation of specific transcription factors, The transcription factor NF-kappa B has been widely studied as a regulator of genes involved in immune and inflammatory responses, A variety of stimuli activate NF-kappa B through the induced phosphorylation and degradation of the inhibitor I kappa B followed by nuclear translocation of NF-kappa B. We show here that oncogenic forms of Ha-Ras activate NF-kappa B, not through induced nuclear translocation, but rather through the activation of the transcriptional function of the NF-kappa B RelA/p65 subunit, Importantly, RelA/p65 -/- cells are inefficient in the activation of kappa B-dependent gene expression in response to oncogenic Ras expression, Furthermore, I kappa B alpha expression blocks focus formation in NIH3T3 cells induced by oncogenic Ras, These results demonstrate that NF-kappa B is a critical downstream mediator of Ha-Ras signaling and oncogenic potential.	UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Columbia University				Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA069577, R01CA072771] Funding Source: NIH RePORTER; NCI NIH HHS [CA69577, CA72771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cogswell PC, 1997, J EXP MED, V185, P491, DOI 10.1084/jem.185.3.491; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OLSEN MF, 1995, SCIENCE, V269, P1270; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; ZHANG JD, 1994, ONCOGENE, V9, P1931	38	320	326	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24113	24116		10.1074/jbc.272.39.24113	http://dx.doi.org/10.1074/jbc.272.39.24113			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305854	Green Published, hybrid			2022-12-27	WOS:A1997XY51500005
J	Hristova, K; Selsted, ME; White, SH				Hristova, K; Selsted, ME; White, SH			Critical role of lipid composition in membrane permeabilization by rabbit neutrophil defensins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE CONTENTS; ANTIMICROBIAL PEPTIDES; GRANULOCYTE PEPTIDES; CANDIDA-ALBICANS; FUSION; BILAYERS; MECHANISM; PHOSPHATIDYLETHANOLAMINE; EXTRUSION; KINETICS	We have examined the interactions of the six known rabbit neutrophil defensin antimicrobial peptides with large unilamellar vesicles (LW) made from various lipid mixtures based an the lipid composition of Escherichia coli membranes. We find that the permeabilization of LUV made from E. coli whole lipid extracts differs dramatically from that of single-component LUV made from palmitoyl-oleoyl-phosphatidylglcerol (POPG). Specifically, defensins NP-1, NP-2, NP-3A, NP-3B, and a natural mixture of the six defensins cause fast nonpreferential leakage of high molecular weight dextrans as well as the low molecular weight fluorophore/ quencher pair 8-aminonapthalene-1,3,6 trisulfonic acid (ANTS)/p-xylene-bis-pyridium bromide (DPX) from E. coli whole lipid LUV through large, transient membrane lesions. In contrast, release of ANTS/DPX form POPG LUV induced by the defensins is slow and graded with preference for DPX (Hristova, K., Selstad, M. E., and White, S. H. (1996) Biochemistty 35, 11888-11894). Interestingly, defensins NP-4 and NP-5 alone do not induce leakage from E. Coli whole lipid LUV, whereas only NP-4 is ineffective with POPG LW, Examination of She sequences of the six defensins suggests that the inactivity of NP-4 and NP-5 may be due to their lower net positive charge and/or the substitution of a Thr for the Arg or Lys that follows the fourth Cys residue. We found the presence of three major lipid components of E. coli whole lipid to be essential for creation of the large lesions observed in LUV: phosphatidylethanolamine, phosphatidylglycerol, and cardiolipin, Cardiolipin appears to play a key role because no leakage can be induced when only phosphatidylglycerol, and phosphatidylethanolamine are present. These results indicate the importance of membrane lipid composition in the permeabilization of cell membranes by rabbit defensins.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT PATHOL,IRVINE,CA 92697	University of California System; University of California Irvine; University of California System; University of California Irvine			White, Stephen H/B-1053-2009; Abrams, William R/A-5782-2008; White, Stephen/N-1507-2019	White, Stephen H/0000-0001-8540-7907; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031696, R37AI022931, R01AI022931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046823] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31696, AI-22931] Funding Source: Medline; NIGMS NIH HHS [GM-46823] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; BACH AC, 1987, BIOCHEMISTRY-US, V26, P4389, DOI 10.1021/bi00388a030; BATENBURG AM, 1987, BIOCHIM BIOPHYS ACTA, V903, P142, DOI 10.1016/0005-2736(87)90164-7; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; ELLENS H, 1984, BIOCHEMISTRY-US, V23, P1532, DOI 10.1021/bi00302a029; FUJII G, 1993, PROTEIN SCI, V2, P1301, DOI 10.1002/pro.5560020813; GANZ T, 1990, EUR J HAEMATOL, V44, P1; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hristova K, 1996, BIOCHEMISTRY-US, V35, P11888, DOI 10.1021/bi961100d; Jost W., 1960, DIFFUSION SOLIDS LIQ; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KANEMASA Y, 1967, BIOCHIM BIOPHYS ACTA, V144, P382; KANEMASA Y, 1971, ACTA MED OKAYAMA, V25, P255; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; Ladokhin AS, 1997, METHOD ENZYMOL, V278, P474; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; Ladokhin AS, 1995, BIOPHYS J, V69, P1964, DOI 10.1016/S0006-3495(95)80066-4; LAURENT TC, 1967, BIOCHIM BIOPHYS ACTA, V136, P191, DOI 10.1016/0304-4165(67)90063-3; LEHRER RI, 1985, J VIROL, V54, P467, DOI 10.1128/JVI.54.2.467-472.1985; LEHRER RI, 1985, INFECT IMMUN, V49, P207, DOI 10.1128/IAI.49.1.207-211.1985; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LEHRER RI, 1986, INFECT IMMUN, V52, P902, DOI 10.1128/IAI.52.3.902-904.1986; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; LIU YP, 1993, J AM CHEM SOC, V115, P708, DOI 10.1021/ja00055a047; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MUI BLS, 1993, BIOPHYS J, V64, P443, DOI 10.1016/S0006-3495(93)81385-7; NAGAWA Y, 1991, J AM CHEM SOC, V113, P7237, DOI 10.1021/ja00019a022; NIR S, 1982, BIOCHIM BIOPHYS ACTA, V688, P275, DOI 10.1016/0005-2736(82)90604-6; NIR S, 1980, BIOCHEMISTRY-US, V19, P6030, DOI 10.1021/bi00567a013; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; PARDI A, 1988, J MOL BIOL, V201, P625, DOI 10.1016/0022-2836(88)90643-2; PARDI A, 1992, BIOCHEMISTRY-US, V31, P11357, DOI 10.1021/bi00161a013; RANDLE CL, 1969, BIOCHIM BIOPHYS ACTA, V187, P214, DOI 10.1016/0005-2760(69)90030-7; SCHANCK A, 1993, BIOCHEM BIOPH RES CO, V195, P654, DOI 10.1006/bbrc.1993.2095; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SHIN KH, 1995, BBA-BIOMEMBRANES, V1238, P42, DOI 10.1016/0005-2736(95)00111-F; STRICKLAND KP, 1973, FORM FUNCTION PHOSPH, P9; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TYTLER EM, 1995, BIOCHEMISTRY-US, V34, P4393, DOI 10.1021/bi00013a031; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; WILDE CG, 1989, J BIOL CHEM, V264, P11200; WILSCHUT J, 1980, BIOCHEMISTRY-US, V19, P6011, DOI 10.1021/bi00567a011; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; WIMLEY WC, 1993, ANAL BIOCHEM, V213, P213, DOI 10.1006/abio.1993.1411	45	125	134	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24224	24233		10.1074/jbc.272.39.24224	http://dx.doi.org/10.1074/jbc.272.39.24224			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305875	hybrid			2022-12-27	WOS:A1997XY51500026
J	Leroux, MR; Melki, R; Gordon, B; Batelier, G; Candido, EPM				Leroux, MR; Melki, R; Gordon, B; Batelier, G; Candido, EPM			Structure-function studies on small heat shock protein oligomeric assembly and interaction with unfolded polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BOVINE ALPHA-CRYSTALLIN; CHAPERONE-LIKE ACTIVITY; CAENORHABDITIS-ELEGANS; MOLECULAR CHAPERONES; CITRATE SYNTHASE; IN-VITRO; H-1-NMR SPECTROSCOPY; A-CRYSTALLIN; B-CRYSTALLIN; BETA-TUBULIN	The small heat shock protein (smHSP) and alpha-crystallin genes encode a family of 12-43-kDa proteins which assemble into large multimeric structures, function as chaperones by preventing protein aggregation, and contain a conserved region termed the alpha-crystallin domain, Here we report on the structural and functional characterization of Caenorhabditis elegans HSP16-2, a 16-kDa smRSP produced only under stress conditions. A combination of sedimentation velocity, size exclusion chromatography, and cross-linking analyses on wild-type HSP16-2 and five derivatives demonstrate that the N-terminal domain but not most of the the C-terminal extension which follows the alpha-crystallin domain is essential for the oligomerization of the smHSP into high molecular weight complexes. The N terminus of HSP16-2 is found to be buried within complexes which can accommodate at least an additional 4-kDa of heterologous sequence per subunit. Studies on the interaction of HSP16-2 with fluorescently-labeled and radiolabeled actin and tubulin reveal that this smHSP possesses a high affinity for unfolded intermediates which form early on the aggregation pathway, but has no apparent substrate specificity, Furthermore, both wild-type and C-terminally-truncated HSP16-2 can function as molecular chaperones by suppressing the thermally-induced aggregation of citrate synthase., Taken together our data on HSP16-2 and a unique 12.6-kDa smHSP we have recently characterized demonstrate that multimerization is a prerequisite for the interaction of smHSPs with unfolded protein as well as for chaperone activity.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOL BIOL, VANCOUVER, BC V6T 1Z3, CANADA; CNRS, LAB ENZYMOL & BIOCHIM STRUCT, F-91198 GIF SUR YVETTE, FRANCE	University of British Columbia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BENTLEY NJ, 1992, YEAST, V8, P95, DOI 10.1002/yea.320080204; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CANDIDO EPM, 1989, GENOME, V31, P690, DOI 10.1139/g89-126; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CARVER JA, 1995, FEBS LETT, V369, P305, DOI 10.1016/0014-5793(95)00770-A; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; DETMERS P, 1981, J BIOL CHEM, V256, P99; DIXON DK, 1990, DNA CELL BIOL, V9, P177, DOI 10.1089/dna.1990.9.177; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; Feder ME, 1996, J EXP BIOL, V199, P1837; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; Gesierich U, 1996, FEBS LETT, V393, P151, DOI 10.1016/0014-5793(96)00867-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOCKERTZ MK, 1991, FEBS LETT, V280, P375, DOI 10.1016/0014-5793(91)80335-Z; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Huot J, 1996, CANCER RES, V56, P273; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jones D, 1996, TOXICOLOGY, V109, P119, DOI 10.1016/0300-483X(96)03316-1; JONES D, 1986, J BIOL CHEM, V261, P2006; KATO K, 1994, J BIOL CHEM, V269, P11274; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; KUNTZ ID, 1971, J AM CHEM SOC, V93, P514, DOI 10.1021/ja00731a036; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; LIN TH, 1991, J BIOL CHEM, V266, P1635; Linder B, 1996, J BIOL CHEM, V271, P30158, DOI 10.1074/jbc.271.47.30158; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MEJILLANO MR, 1989, BIOCHEMISTRY-US, V28, P6518, DOI 10.1021/bi00441a053; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1996, BIOCHEMISTRY-US, V35, P10422, DOI 10.1021/bi960788r; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MERCK KB, 1993, J BIOL CHEM, V268, P1046; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Rajaraman K, 1996, J BIOL CHEM, V271, P27595, DOI 10.1074/jbc.271.44.27595; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; RUSSNAK RH, 1983, NUCLEIC ACIDS RES, V11, P3187, DOI 10.1093/nar/11.10.3187; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SIEZEN RJ, 1980, EUR J BIOCHEM, V107, P243, DOI 10.1111/j.1432-1033.1980.tb04644.x; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; SINGH K, 1995, FEBS LETT, V372, P283, DOI 10.1016/0014-5793(95)00980-N; SINGH M, 1970, J BIOL CHEM, V245, P4636; SMULDERS RHPH, 1995, J BIOL CHEM, V270, P13916, DOI 10.1074/jbc.270.23.13916; Smulders RHPH, 1996, J BIOL CHEM, V271, P29060, DOI 10.1074/jbc.271.46.29060; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDENOETELAAR PJM, 1989, BIOCHIM BIOPHYS ACTA, V995, P91, DOI 10.1016/0167-4838(89)90238-0; WANG KY, 1994, J BIOL CHEM, V269, P13601; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; WANG Z, 1992, PROTEIN SCI, V1, P522; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WELCH WJ, 1985, J CELL BIOL, V101, P1198, DOI 10.1083/jcb.101.4.1198; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; YEH KW, 1994, BIOTECHNOL APPL BIOC, V19, P41; [No title captured]	105	191	199	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	1997	272	39					24646	24656		10.1074/jbc.272.39.24646	http://dx.doi.org/10.1074/jbc.272.39.24646			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XY515	9305934	hybrid			2022-12-27	WOS:A1997XY51500085
J	Kuroki, DW; Minden, A; Sanchez, I; Wattenberg, EV				Kuroki, DW; Minden, A; Sanchez, I; Wattenberg, EV			Regulation of a c-Jun amino-terminal kinase stress-activated protein kinase cascade by a sodium-dependent signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR PROMOTER; PALYTOXIN; PHOSPHORYLATION; DOMAIN; ERK; ONCOPROTEIN; CYTOKINES; CLONING; BINDS; MAPKS	Palytoxin is a novel skin tumor promoter that does not activate protein kinase C. Previous studies demonstrated that palytoxin stimulates a sodium-dependent signaling pathway that activates the c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK) in Swiss 3T3 fibroblasts. In this study we show that a JNK kinase known as the stress-activated protein kinase/extracellular signal-regulated kinase-1 (SEK1) plays an important role in the regulation of JNK by palytoxin. We found that palytoxin stimulates the sustained activation of both JNK and SEK1 in COS7 and HeLa cells. Transiently expressed SEK1 isolated from palytoxin-treated cells can phosphorylate and activate JNK, which, in turn, can phosphorylate c-Jun, Furthermore, expression of a dominant negative mutant of SEK1 blocks activation of JNK by palytoxin, Sodium appears to play an important role in the regulation of JNK and SEK1 by palytoxin. Activation of JNK and SEK1 by palytoxin, but not anisomycin, requires extracellular sodium, Complementary studies showed that the sodium ionophore gramicidin can mimic palytoxin by regulating JNK and SEK1 through a sodium-dependent mechanism. Collectively, these results demonstrate that palytoxin stimulates a sodium-dependent signaling pathway that activates the SEK1/JNK/c-Jun protein kinase cascade.	UNIV MINNESOTA,DIV ENVIRONM & OCCUPAT HLTH,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	University of Minnesota System; University of Minnesota Twin Cities; Columbia University; Harvard University					NATIONAL CANCER INSTITUTE [R29CA072498] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72498-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CORPUZ GP, 1995, P INT S CIG MAR NAT, P143; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUBOURDIEU DJ, 1992, TOXICOL APPL PHARM, V116, P47, DOI 10.1016/0041-008X(92)90143-G; EAN J, 1996, J BIOL CHEM, V271, P2886; FUJIKI H, 1986, CARCINOGENESIS, V7, P707, DOI 10.1093/carcin/7.5.707; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HABERMANN E, 1989, TOXICON, V27, P1171, DOI 10.1016/0041-0101(89)90026-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kuroki DW, 1996, CANCER RES, V56, P637; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOORE RE, 1971, SCIENCE, V172, P495, DOI 10.1126/science.172.3982.495; MOORE RE, 1985, PROGR CHEM ORGANIC N, V48, P81; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanghera JS, 1996, J IMMUNOL, V156, P4457; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; WATTENBERG EV, 1987, CANCER RES, V47, P4618; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	40	38	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 19	1997	272	38					23905	23911		10.1074/jbc.272.38.23905	http://dx.doi.org/10.1074/jbc.272.38.23905			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XX381	9295340	hybrid			2022-12-27	WOS:A1997XX38100065
J	McCloskey, P; Fridell, YW; Attar, E; Villa, J; Jin, Y; Varnum, B; Liu, ET				McCloskey, P; Fridell, YW; Attar, E; Villa, J; Jin, Y; Varnum, B; Liu, ET			GAS6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARREST-SPECIFIC GENE-6; PROTEIN-S; HUMAN MONOCYTES; ACTIVATION; DOMAIN; LIGAND; ENCODES; BINDING; MEMBER	Axl is a receptor tyrosine kinase that contains both immunoglobulin and fibronectin III repeats in its extracellular domain reminiscent of cell adhesion molecules. Expression of the receptor tyrosine kinase Axl in the 32D myeloid cell line permits aggregation of cells in response to treatment with the native ligand GAS6; this aggregation was not observed in untreated 32D-Axl cells nor in treated parental cells. This aggregation can be blocked by the addition of excess Axl extracellular domain peptide and does not require intracellular Axl kinase activity. Cell surface binding activity of GAS6 was mapped to distinct plasma membrane interacting domains that are separate from the GAS6 motifs that engage the Axl receptor. This suggests that aggregation is mediated by a heterotypic intercellular mechanism whereby cell-bound GAS6 interacts with Axl receptor on an adjacent cell. This mechanism is supported by our observation that GAS6 binds to 32D parental cells which then permits their aggregation with untreated 32D-Ax1 cells. We have recently demonstrated that the GAS6-Axl interaction does not initiate mitogenesis in 32D cells. When considered with the adhesion results, these data suggest that an important biological function of the Axl-GAS6 interaction is to mediate cell cell binding.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599; AMGEN CORP,THOUSAND OAKS,CA 91320	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Amgen			Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [P50CA058223] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA58223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GOEBELER M, 1993, IMMUNOBIOLOGY, V188, P159, DOI 10.1016/S0171-2985(11)80495-X; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MCCLOSKEY P, 1994, CELL GROWTH DIFFER, V5, P1105; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; SAP J, 1994, MOL CELL BIOL, V1, P1; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; SUGO T, 1986, J BIOL CHEM, V261, P5116; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; WANG J, 1994, CLIN EXP IMMUNOL, V95, P263, DOI 10.1111/j.1440-1681.1994.tb02511.x; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	24	115	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	1997	272	37					23285	23291		10.1074/jbc.272.37.23285	http://dx.doi.org/10.1074/jbc.272.37.23285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	XV744	9287338	hybrid, Green Published			2022-12-27	WOS:A1997XV74400049
